<SEC-DOCUMENT>0001628280-21-003069.txt : 20210224
<SEC-HEADER>0001628280-21-003069.hdr.sgml : 20210224
<ACCEPTANCE-DATETIME>20210224161737
ACCESSION NUMBER:		0001628280-21-003069
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		100
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210224
DATE AS OF CHANGE:		20210224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		21673384

	BUSINESS ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		7000 MARINA BLVD
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sgmo-20201231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:a450ce61-5a63-468d-aea1-980040e585ad,g:3eb33991-981d-4627-a625-d6dd25ee8674,d:24672e5030474c1ba9673ec16c177662--><html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:sgmo="http://www.sangamo.com/20201231" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sgmo-20201231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml80L2ZyYWc6OWU5Yjk0NTEzNjZkNGYzMjkzNDIzN2YwZWQxMjM3ODkvdGFibGU6OTczM2JjMWM0MzA3NGRmMjg2MjM2Yzk4NDAxNmQ4MDgvdGFibGVyYW5nZTo5NzMzYmMxYzQzMDc0ZGYyODYyMzZjOTg0MDE2ZDgwOF83LTEtMS0xLTA_8af205dc-dc55-442b-80cf-c582528bc901">false</ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml80L2ZyYWc6OWU5Yjk0NTEzNjZkNGYzMjkzNDIzN2YwZWQxMjM3ODkvdGFibGU6OTczM2JjMWM0MzA3NGRmMjg2MjM2Yzk4NDAxNmQ4MDgvdGFibGVyYW5nZTo5NzMzYmMxYzQzMDc0ZGYyODYyMzZjOTg0MDE2ZDgwOF85LTEtMS0xLTA_05e2f740-62d8-4c38-b215-b435b80e3d8c">2020</ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml80L2ZyYWc6OWU5Yjk0NTEzNjZkNGYzMjkzNDIzN2YwZWQxMjM3ODkvdGFibGU6OTczM2JjMWM0MzA3NGRmMjg2MjM2Yzk4NDAxNmQ4MDgvdGFibGVyYW5nZTo5NzMzYmMxYzQzMDc0ZGYyODYyMzZjOTg0MDE2ZDgwOF8xMC0xLTEtMS0w_ab750bd7-69cd-4998-b34c-74b83c8313c2">FY</ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml80L2ZyYWc6OWU5Yjk0NTEzNjZkNGYzMjkzNDIzN2YwZWQxMjM3ODkvdGFibGU6OTczM2JjMWM0MzA3NGRmMjg2MjM2Yzk4NDAxNmQ4MDgvdGFibGVyYW5nZTo5NzMzYmMxYzQzMDc0ZGYyODYyMzZjOTg0MDE2ZDgwOF8xMy0xLTEtMS0w_98dbd816-ba57-4d24-b9c8-0a1afe6a8f49">0001001233</ix:nonNumeric><ix:nonNumeric contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMy0wLTEtMS0xNjEyL3RleHRyZWdpb246NzFmN2MwOTg1MThiNDk5OTlkYTc2YjZjNWE1N2ExODRfMzg0ODI5MDY5NzMxNA_3e224bd6-7770-4f80-a1e8-1ea28d8e7eec">us-gaap:AccountingStandardsUpdate201409Member</ix:nonNumeric><ix:nonNumeric contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" name="us-gaap:AccountingStandardsUpdateExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTUtMC0xLTEtMTYwOC90ZXh0cmVnaW9uOjNhOGYyMjhiMzNkMTQzZWM5ZjU0ZmEzZWZjMTM0MGFiXzM4NDgyOTA2OTcyOTg_5213575c-8402-4879-a9de-4af8a6520892">us-gaap:AccountingStandardsUpdate201801Member</ix:nonNumeric><ix:nonNumeric contextRef="ie917e6f491354d9cacd7d16bca15c4ad_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTY1MDM_37296027-8590-4fe0-b3ed-3ef8d7731671">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xNjgwL2ZyYWc6YmQzNjY4Mzk4ZjFjNGJmZWExNTJhODRhYTA1YzMyMGMvdGFibGU6YjRhNDllMjEyYTQwNDAxMjk0YjNmM2FkNTVkOTExYjIvdGFibGVyYW5nZTpiNGE0OWUyMTJhNDA0MDEyOTRiM2YzYWQ1NWQ5MTFiMl8xLTEtMS0xLTIzMDA_625b2d8a-b01c-4c68-8a56-750c0175397a">us-gaap:AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie376e3e497f44b6090164ea2f06721ba_I20201231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzY5Mw_274e8caf-5cf0-4157-9146-6781d7736ff8">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xNjg5L2ZyYWc6M2MxYTRlYWVkNTRjNDZmNjg0YWJmYWFjN2YwYjlkN2MvdGFibGU6OTY1NTI3ZDYzMzM4NDg3OWE5MmJkNTQ4ZWYzM2I2MWQvdGFibGVyYW5nZTo5NjU1MjdkNjMzMzg0ODc5YTkyYmQ1NDhlZjMzYjYxZF8xLTEtMS0xLTIzMjk_5af04a9a-3dee-4a86-8af7-818b6fac7a75">us-gaap:AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i042ac2c793264cb2bd18dd2abe87d7dc_D20200101-20201231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTIvZnJhZzo3YzVhOGI5OGNmOTE0NmQzYjBjYTJlN2E0OWJhMGVmZi90YWJsZTo2ZWY0ZTQ3ZTAzN2U0YmRhOTBlMmQwODg2ZTA1MGY5NC90YWJsZXJhbmdlOjZlZjRlNDdlMDM3ZTRiZGE5MGUyZDA4ODZlMDUwZjk0XzItMS0xLTEtMA_678f73b7-5810-49c3-bc11-d65d0984b088">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i53b6b787aad747bb9826358cf0f80be9_D20200101-20201231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTIvZnJhZzo3YzVhOGI5OGNmOTE0NmQzYjBjYTJlN2E0OWJhMGVmZi90YWJsZTo2ZWY0ZTQ3ZTAzN2U0YmRhOTBlMmQwODg2ZTA1MGY5NC90YWJsZXJhbmdlOjZlZjRlNDdlMDM3ZTRiZGE5MGUyZDA4ODZlMDUwZjk0XzQtMS0xLTEtMA_33a40771-d126-4def-8ef0-42432e54baad">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="icd4d7fedb43e46f1ab4828dbcde9c9f3_D20200101-20201231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTIvZnJhZzo3YzVhOGI5OGNmOTE0NmQzYjBjYTJlN2E0OWJhMGVmZi90YWJsZTo2ZWY0ZTQ3ZTAzN2U0YmRhOTBlMmQwODg2ZTA1MGY5NC90YWJsZXJhbmdlOjZlZjRlNDdlMDM3ZTRiZGE5MGUyZDA4ODZlMDUwZjk0XzYtMS0xLTEtMA_2965c0b7-852b-40ea-9089-32489e68ef7a">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="ic393a32a90e74583a781dcf3a5e9a6ee_D20200101-20201231" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTIvZnJhZzo3YzVhOGI5OGNmOTE0NmQzYjBjYTJlN2E0OWJhMGVmZi90YWJsZTo2ZWY0ZTQ3ZTAzN2U0YmRhOTBlMmQwODg2ZTA1MGY5NC90YWJsZXJhbmdlOjZlZjRlNDdlMDM3ZTRiZGE5MGUyZDA4ODZlMDUwZjk0XzktMS0xLTEtMA_6f761cd8-dd7c-4809-aa21-ddad54b8333e">2.08</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sgmo-20201231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="iee1b756f6c0a4abe92e4664a43ad8035_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i22a6be9ae52e4042a972a3c232e7c320_I20210219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6f46cdcf64446fbb0ec043c3e9bfa14_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b7ca23b9754fce9a17de50c7c8a39a_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202e314c35d9413996c927fa899da1c2_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4b56ade4b50487fb2fbba4e2c124931_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb5b79c99094b17a8f2ce637a6f9a2d_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1099157ecec044679915cbcb253acd13_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief4531bd4090429ab0a53e48c051817f_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22d2afa166f04addaba3df267d7905bc_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d05b39e6b184c809c28b20cda11f744_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d6997ffafa040db837de130bd2c9cc5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb85ed8fe2a4cc9a528a3f2afd5ee04_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79a71c8223434e32990a220f63b9c4bd_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i651b9b252cc242febd5e34ac22fad42d_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d4c9fcbe5f94694af0132cce7457120_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f51a95393aa40d082b4cca44112fce1_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921be278c72e486185352cb920f4347b_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5022310b80e40a9adf07bedacb21665_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabf107dbdd5b48f8903b89e3c7cea36e_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6f7ea91dc8646daa2cc71ca00f38850_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80940087d3b44c008290532496a8063a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddc7094e93e045b7b4aade122a21ba69_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d0c82cbf5e5409490970fcf70c60bb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d79e000a7564936afd32ea6d9c1290e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f5e0542d6f24c119eae1888c0d6a5a8_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21e69f23c33c473daf20855d84a342a2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae1f574b2f8c4344aa08242f7ae98ac4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf0ea9431c824de99c89f4536634ee4b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia724ba89921d4bbfb3ab7f41022dfa7c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if95cd0d324cb450abdb22b5197a92e30_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1627062e2d1a4e6db06f7f2ed164591a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0eae3c26ed10449298243b22f0dc770f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2728c5446992435fa94d6ae800954885_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d1e7cbe14db45d6a003fba4484e6074_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idcd9bdcf4f1749ed855ea52ac19c1e57_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66dc03e15abd412984fd7c2b45d9d856_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3eca6f8c437940cbabb9d377e58e590a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie858b057f0224ebf8778dd6b34548eab_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c141aaf58334fba855db4ee4e38db81_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0ad2d8d5ce840e99dbd93fd64e0439e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8133ce2775074245969bc9f50d4ffa89_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i196e1cc25f284d418cc58737e82a5139_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1555d5279c444f89f02b32de1c4f4c5_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ibe21513e3cbc4ef9b8379cf9af56af7d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2340761cd284f108a1e5d64cc980af8_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30e0b646a8df46a79e760eb6aaef235e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88b6be668e8d446b9d5199171f704f9f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf6e9495caa24ce480ffea19c28f507b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04e7b9f9d96a4feca307fbdfe9824533_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifafcd10a99b94ea9a3cd858f75019057_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae79ca8469af4ddda9eb0ae2461bfda7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib362499858ff441b81abb16c4b161e94_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5af392ecf9040dd85a30262c5b91b6a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21037a15db8240bba2e6a6eacf66d265_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05a8036803764bc19d8b0408d9a6778e_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffb1c905529f4b78895e5ec6a2fb1454_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75abcc855e7c486a8f9453c309984ec6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef75ce3e3d4408195a24cf8317ce59b_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie917e6f491354d9cacd7d16bca15c4ad_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b662a6bf84f48d6baa29804b606526c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>sgmo:segment</xbrli:measure></xbrli:unit><xbrli:context id="if3a7053c82b34112baeacb539acdacee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife4a9b65e8c8453ab64e7777ee2d3100_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i538799473b654234a0fff4940007026d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3382b9ba2d54e45aab7d37fe53c048f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bf0705352c54572bf4f38ac982a31be_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26c02145fa9242f38709a5edc46b448e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa885c5039e145c09f646a2a7f4b8107_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b3adc9c15cd451ba7eaf4b09cd384e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i561ac4ef919945fa872f15ce1139a321_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i031949a99f364927ac232102e610e2ca_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98278431e88f4c0db17846d0b3dbbad8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6465df1f81a4ab5a788482e7565d968_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id92a9f54439349c1a5e6a1bba22a0d23_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1a201eb484d4bd5a0b59012ba2f791d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16d9dab193d54c309786833b5661b693_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5c17352407648038a079be92904f2a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i307cf2a5e93040adbb97545d97da4f9a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8632ee484ed4ce287dd150a59f7e976_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifed10ba46af8409e8b84b8e8186dc592_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8205c80a5c0477aaa06acb0a8e8e7da_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4478684879bc414381bb41ce8b5add16_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e83dea29142486786bea569ac583153_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i638b4338e64c4c0c9035f64c4bda767b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6648a09a42b483cb342868211de9128_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaea9ff66312d4cb985f8cc0115634d45_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bb9617224f949bbaa727b52246f5819_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i290f705cf9df4b7c8d071b425026aec8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaaf320a38a84e55affa256f7f30ad18_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c791708c2b54c489b0564343ced9b29_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd782cef16a4070ae70af4879663f30_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5de38cf429814456bca0ed781cb6c510_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i452c62674a9a4271ba5e89c6c050a050_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cc2751230724e7381a103381d9dfb53_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9ba3950185d4776adff785cc0c2a7d2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b12148036dc4575b8e1a20cf11d14ac_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e9967af55594a0298a27d240144e1ee_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67764fa5748c4450ae52695bab506bb9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4407422f7c044d0fbec953a99a3872a1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bfe2c49f1a646b8b8fc3e3df333620f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa947c04f600459f8abe14c30287d39d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6756c61effe4e938932ae8029a287b7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8674e557d87406d95862eb814aebd8d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7a51c69784164925a1155915e905a9e6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i233261fb4cbb44eda76666923ba0fa00_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecff100e21624aa380f317bd2cc77424_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad5f02563ca4f3a935b0a28075cfc38_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief8529b02bab4938b24e07cedff4a61f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb3348e7e8ad4e5e8f79068e98c38849_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i409228d676604420a5080c8402d96e8f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6e07e12ba97461c86c7911b067139c0_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic469cb9c12c84ba284e53503bcfe990f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89d852320136494288e8326d40cbfdf4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b619f4f00de4396b3df3e86c1308164_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica609585796849f4b3f75e74fd3cd261_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc061743215f46799ca3ad39e4073044_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e0cda171ca943959c35929427e42666_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic88a281a19cc4a8daaf8b3f721602378_I20180720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-07-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7377f8b263024b66ad603bd494ee0f22_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333a5711c7bb4f51917b34946c0b9f23_I20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16391b7df5174ed5b8c2310d931447ad_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibda42ad49ccb40e6a99670b2432a3b0a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40c0c8a181b34eaaa65d8a1d56afba94_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i40f0fb62debc4ccf8d53156b1bc24685_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00900b9889da4cdaa8eb8e2b586dcb12_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i297eba0e37914b6d8ec0577f4ee289d4_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1da1bc0ccada4c6289947f9de2c4b135_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9bff90492d5f446284b8b7c02033b51f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a3f456b9804ec4b6dd169a8bd7f4ba_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibaa6bc7784424a67be7faba1d682b136_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i010cb6bb38804fb49deced19c47e723d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6eb7b715da4cb69e1a51dd18e5bc9d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id11b23041c6d4a04a5f707b52b28660f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33732cfa0f614ab6a16f0a26f36db075_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25b9c44848094c8188cda00e8392c015_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aae7219ce14478f887d9df6f6050a1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f6d62eac76941a9907a1769725bc84f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2fd506f04f5e450699099f18e1a52d5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie054ce2f1c4741c38e021cbc84c88cae_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i166d41c1d13840e79f6069d74eed0581_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i195f8095900e47b59c48f9b46ca9e135_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib59efa220c014139a6c6518f23eb3381_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6edba78934f34526818d49f23b52582d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie90d9c1847f64dc498789d1a25747db7_D20200801-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie25f2c3034b549c1a2403b3c2b59e8be_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08c85ff8ca5b455fa7266f68c7634773_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679870fa4aa947f2b092c683d49e48be_D20200727-20200727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-27</xbrli:startDate><xbrli:endDate>2020-07-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9662bfa60bd435086718d9bfee03841_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41532f5f82c84a95a08ae7d3f428f14a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65e104e30eb7451ebcb1b6d67543ae50_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3b3cfc543ee4dfbb9fa9f54e698bbe0_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09bf3f7bc1bf4ca2aee88d98cbb49c11_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-08</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if650f84ed8e44993a9c4382072ecf061_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecf6454954a34af8a88c9bb4071baf99_D20200501-20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c641a230af14951931f575b265aa8bf_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7101296ba8e4016aee3ac0bd6885981_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i36d7c81806f3497d988a10597afd1494_I20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="product_target"><xbrli:measure>sgmo:product_target</xbrli:measure></xbrli:unit><xbrli:context id="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9997a66b33774bf8874b84e01397ca61_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2433e456bdfb43a4aa95fe4c28d4d208_D20200201-20200229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-02-01</xbrli:startDate><xbrli:endDate>2020-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i336e9bea9e624f2d85ca346d8219bd49_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae50536cbc814ac6a99bb260423fdb2e_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icccc34360eed452f9ad238a715656769_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb0c68923ff146d280fb7f97045dad9b_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dbd4261e96a4a87808a78d8e6b23ba1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4b362953ca94b868a22eeeacdc5d1c8_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i791f1d7d58614b2e92e9f6fca8affadb_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86be779bb370428988a0873a257efbeb_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i622b78d941574e52bc533f27c36c5fe7_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0e221499b664eee8f775e18eb6f11f8_D20180404-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-04</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b05e76cf87f4a609ff6d9a1d6be38e3_D20180404-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-04</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15ca38def7cc4d739746ecdfadfe6b6c_D20180404-20180405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-04</xbrli:startDate><xbrli:endDate>2018-04-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>sgmo:option</xbrli:measure></xbrli:unit><xbrli:context id="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd8eb466e5ab46dcbfe11a464c069eff_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i279331e783974f13b570a80bdae2914d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic99454b17cf8426abe411aa4bfe33b84_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7c5dfd1e85a4c9aa4e84a23484dc176_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bfa78bdc3244b5693d30aa711524848_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd7a58620bca4d85b6783c708b906014_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if07241a21483414fa49f01f2b3ff040d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i160f22e556494a06802b40e3edf5f834_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d31979f09c648999fccb66122fd46ee_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fc50ac5b1034ddcab9f5dc7d229bd83_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42157f7e86b3408ab390ad6b9ce433d2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16e9fd5645c342c6a53a2d4075df3f32_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16d56044bc30409491f4cd99b8ed0162_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i828ebcc51b3447ab9fb4c223a4ed2af9_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:GiroctocogeneFitelparvovecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7ce5c1ee6e64ac5b1260a8a278341bf_D20170501-20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2017-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic844e08373f649f89686b25d4f48e080_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:GiroctocogeneFitelparvovecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3ea3fbe1ff04cd78a9c151aab7fe03c_I20170531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i108f738726ee4d188ea13f5c58559305_D20170501-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:GiroctocogeneFitelparvovecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-05-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>sgmo:product</xbrli:measure></xbrli:unit><xbrli:context id="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="milestone"><xbrli:measure>sgmo:milestone</xbrli:measure></xbrli:unit><xbrli:context id="i56711bf4d33b463384f2cf6fa4b99cdc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:GiroctocogeneFitelparvovecMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iadfc90055252476ea94b6b78e49c2e2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55dfc2b24f4d4413a989e868a6ffeb5d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13a9ae1225e7485bb10275ccee50ca2d_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e6d1ed2be0044ea9cbcaf840d0780e9_D20191201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieae2c1f6faba4e33888460da2e302ddf_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24940a7706ea4d2d978b4613538afbda_D20201001-20201030"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PhaseThreeClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ccabe9bc30f4799a7625faed92a6917_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PhaseThreeClinicalTrialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6100f8c9e8534579a67d80618dd87117_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c0d2ceb04c46e0a6ca01fc7f9e2ee7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22cdf77958324fea8f5137db56d2e321_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i435e100ac21c4e6f970572239a77eda2_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7fb94b0bae17481a87c59979d81ce0ca_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae47e409b4ea42aabf27810d9f1f5f22_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9745d562dd854f4fb6b39832e3c4a5b4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9782c197ba3149bb984663397b6a69d2_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10f82f0783e54af6831a3e260dd85a3a_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e8f31eadadf4aefb75c29f6979d4b3e_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0ee411f36884cd796eb1615539214bc_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i233ad9c6f5b64570a51d2349ba0f80be_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f3fd66a77ca4c298f3fc4272b6044f2_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if4d9b4cf1fe14e8c82e398543c33609d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3baf5d6da95a464d83ca547a1f07fb10_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4c4b9a1b3734f819b23f8fd6c8bebc0_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f62390b2d3a48338361f2876c31e6ab_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee59d8fb45e041e791c0ab5b1d0fec94_D20171201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8179c5be57324f34a1d01a5075b4a59a_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaa9934a0caf4048ad529227a6b3e342_D20171201-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-12-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c9f2942ee064c10a7180d004ca68961_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2d17dcf5e64a158d897e7941665566_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51fd8b7623f54652888d1fbd20802015_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaeb550dc7fee4f0daa6ea8fc7073f7db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2886651fadc8409c8daddb378e4b5b45_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacbb3e15255f4990bd049724d75ef0f1_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f68e79e666471ea1075c8953d1f9ed_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d058778fed0482c9abdb1e80bf3e5f0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf79dd2baa0749b1942c7d86d20c6f21_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1df52988f363438398a2de08f94aa387_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85bea8547944486692a85e6b523ddecd_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="program"><xbrli:measure>sgmo:program</xbrli:measure></xbrli:unit><xbrli:context id="ibe586645e7eb480fa88f004968e69f26_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9122d80b46af45729722b3a5a580fddc_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a8f2c72a0c4b7da4f6fe01645f2fbc_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91c96f778c484ff7b36d40e42b5cef1a_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3117020fd58a4382be68a9dd0e475832_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd4d071a5a1240e899107dc0bc2d0d7f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id81a1acd8821404c8ec43c3bcbc17cf3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i034bd4a542ff4479990ca46381d0f393_D20140101-20140131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6f1610375924f09a443d3568cdc1d68_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a4ecba9c6614c06b7f7c8459b127a96_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dc2cac8272f43ee8e45b5b6bd542b3e_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b1c3dc836d24210b520f3db7f97f9c0_D20190801-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94120f03c5fd4072a8bb3031d5eaff43_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a5217c51de4459902f1b79d64f6c95_D20140101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78bd26e8f611439f93e83caa744593ce_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cd52bb2ae3a4d5e9b83e8bb8f82e121_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aacd04dbe964a6fa6e32e1188460504_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaedf24cb2ecc475bb59fce790b63d4dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0224ad04487349818fda88d3a4f7b06f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i739d766508794dde903e7ea835312bb5_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9bbe06eb17f4e4389ae875bb992beae_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61957911f74047ab839b3929a36f2784_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2fc4f96355416b89ed85d1b3204e27_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6851909816f43d9927a3b74f4eb9ae0_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b192f0b536424dbbf09712a8ca6db3_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a973ce71ad84032872771f13a2ca702_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i764803be26a0446cb2b582d6f52c4848_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7808e1ec9ea64ec3bca436fa6a85404a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i194b83713fb341fbbd2acdc7368d1a8a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64443d1a16cd488f905e7295d699439b_D20120101-20120131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-01-01</xbrli:startDate><xbrli:endDate>2012-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56dfa7a7f694412ca8f155eddda57f6b_D20140101-20141231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2014-01-01</xbrli:startDate><xbrli:endDate>2014-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2161524129470cafb1f5a6567f6cba_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e5077542aaf42a4bb4062f041a4038c_I20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b3feba275324427aa270226c8ff4256_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b3e32e94c384b1e966f84999353cd18_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86082d75aed4dbdb15c659083e9bf9b_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01464b993796404cb11757f956a8a3c7_D20070101-20071231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2007-01-01</xbrli:startDate><xbrli:endDate>2007-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccfbbecbaede42b5845fac46fdce4a09_I20091031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-10-01</xbrli:startDate><xbrli:endDate>2009-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief34bca385d04e8aa286ffe64c5ec431_I20091031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2009-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i706a8d68f1cf40cb9c3132b4ff11e8f2_D20091001-20091031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2009-10-01</xbrli:startDate><xbrli:endDate>2009-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i546676fe6a9d40ddaa72ca93f19fcba8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if616c1c1a07f410682a95cb374ebf65f_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad0d9ea6bdab481590237f5b575dc744_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-01-01</xbrli:startDate><xbrli:endDate>2005-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2df94fee7564a61bb14696381264213_I20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2005-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia280905d8bb74bf892bb6bdb624a87ea_D20050101-20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-01-01</xbrli:startDate><xbrli:endDate>2005-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5fceb7cf1e54c71be44f291df33cab6_D20050101-20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-01-01</xbrli:startDate><xbrli:endDate>2005-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b580b7103874a51aa8d767ed03b3928_D20050101-20051231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2005-01-01</xbrli:startDate><xbrli:endDate>2005-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e7888a0f40541728fa78e28fb8d32b9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13e149c04b9c44ae968ce27839b0ff98_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d636ae7fc074737a7f48065c83c1704_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a7eb33edfe747c3aefde90c4e3c2a60_D20181001-20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02eebe0086a243caa7e9e1bb622faf7a_D20181001-20181123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-01</xbrli:startDate><xbrli:endDate>2018-11-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a6b2a742e264c81a0162eee4479ebde_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i592fbd2441fa41bd9d36900308836ecc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0581803351f54eeebd9c251d33078aec_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6f3f191be824087ad8c554b2a988bfa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5224f1a418c04fb395423371d5cd63de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i796f26491be441f2a96fe82d3903003f_I20181001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i727255e08dff491997abe1595a807416_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib03bf486440e4058b398c99085b2e3bb_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i17ed21c4f31a48f9884d2e5a34a07660_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78b6fc4c001f43229955467cb883d455_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd01b55790404653a8dbf54a898c83e9_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b618149cf52411482e490b4cfbaa70b_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f9736e534b649e19378d63d2cb29bd7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7127032c342b4a9ba46f6b46c2355df9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc0d4241c9514c2bbe8a711b6b6d76c7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7bb97c3073446b9aa8c3f008be817ce_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="ia6609b14089f4212a584aa69b64acfc5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbb078359b94445aa19de4957f01c8a3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9ddad8fdf914a9eb455c759a9202939_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ad9465ba0dc4a299f459f90c677d791_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06474dbe630c4f41836daafffa78c161_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie376e3e497f44b6090164ea2f06721ba_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5adb6c8a5fbe4ae8998f2aaff0f11681_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99562ae603894a8189b5ff099684f86d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68aebf0104924b419a789b0d776a9b5e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:LonzaNetherlandsBVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04133be982284def86006aea3fb52327_I20200629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34bcdc0ce9f64813a8d36f116a1f90eb_D20200401-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77930a25b46346a2979712dac12ee7a0_D20190401-20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30d8dda504854d9ca7d63f9a88cc3816_I20190430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic46aca1e871a400a88bda284834701ce_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0bb49a1111a409c8731842f7bda4df1_I20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i075446115f764740898840df11c14db0_D20200805-20200805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-05</xbrli:startDate><xbrli:endDate>2020-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic740901c064241959e061ee1525d0c94_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a2222cfa49440338b7416d398920ffc_D20180401-20180430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-04-01</xbrli:startDate><xbrli:endDate>2018-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66466b43ef874206b64889bb27cb2d08_I20200531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:Restated2018StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91713b083997409ea11ba55173dcc112_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8715c1886674912998f731a86a14a57_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief4c9ff8ff294f60aa457e9361e9bea3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18bf0cf17b5642529f184871db5ac039_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6aabd68f41804669ac596bb7586ed7bc_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4c94703dab45468283cb739266adc8_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>sgmo:installment</xbrli:measure></xbrli:unit><xbrli:context id="i042ac2c793264cb2bd18dd2abe87d7dc_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53b6b787aad747bb9826358cf0f80be9_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd4d7fedb43e46f1ab4828dbcde9c9f3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic393a32a90e74583a781dcf3a5e9a6ee_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d397545580d4460a2a0fec1fc8ba1a5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6df1c8f3c9a84c598d0ae819a426267c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5cec61b66c8248d2abcb75627ce796b4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i855baf86bae64ff0bd95f564c7fd3fd0_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf94cc35763140c7b88de393e914a63c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f5dfc4d40fd4effae8227da27de4cfc_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7597d30081de44f3921ada32f9dbc896_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i223299de6a284218a780245b2f4e9fb8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a566e45d4414942be208342c5c516a6_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia188228a2f714148b418bbafdff8df68_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f59d4e0ade74a58893ddc753841891e_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i279740780022456087bde23ef4f549fa_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib90a62c3edc44c90a63b7c1744a27bb7_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d3f08aef11f4a318908f591e111b593_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b01dbcc0f74a77aa727c03cc8da109_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd84dea3dd62427db0d47cb010b83133_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc661d039934a93b782c591c4f4b854_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae60b3bb0a244843baf181d3d3f789f8_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc4caf6b9fb443ea9a67e1cd79ff3121_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51512ee82f7c4322a3633294ba2c9a7c_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43e320fb9b704556adf1b2e8fe7699a4_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i311774a19c3b43b292a88509437d6a57_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4f372a7d1ad4108a38bfe05388f5e5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i218e12e36203494ba48b0ba0613475c4_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83b08e5e95284441967eed76e78797ba_D20180101-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b08863acefe4d8ca8e10ed1322fc31b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0470d6b5a9684856b669c0c4cd5d041f_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9b4e0c3f43d4338ab8fc2ce3ffce740_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:MinistryOfTheEconomyFinanceAndIndustryFranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84d0b5985441420eb3dbc496787e07aa_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:FormerExecutiveOfSangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6374baea04443699a67c6e73111ae5d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:FormerExecutiveOfSangamoFranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48f4d381b117429fa8a27a467285b605_D20210101-20210219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001001233</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-02-19</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i24672e5030474c1ba9673ec16c177662_1"></div><div style="min-height:6.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:115%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:115%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">Washington,&#160;D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%">_______________________________________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:17pt;font-weight:700;line-height:115%">Form&#160;<ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8xODE_e43ff816-8248-485b-b791-a861b2669082">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%">_______________________________________________________________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MTg1MzAwZjVhOTFiNDMyOWFiY2Y1OWU3MmU5OGY2ODUvdGFibGVyYW5nZToxODUzMDBmNWE5MWI0MzI5YWJjZjU5ZTcyZTk4ZjY4NV8wLTAtMS0xLTA_f7e5fd6e-d03b-41e5-8cb8-f03127b3e0bd">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the fiscal year ended <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zMDg_0d322f2c-f264-471c-b845-009ce531a935"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zMDg_3d992c01-d9ee-493e-84d3-4efae693811b">December&#160;31</ix:nonNumeric>, 2020</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">or</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.123%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6YTM4OGEzMzJkNjQ1NDM4YTk0ZTczMjJhZjBhYjI5MzYvdGFibGVyYW5nZTphMzg4YTMzMmQ2NDU0MzhhOTRlNzMyMmFmMGFiMjkzNl8wLTAtMS0xLTA_4b79ade3-e803-4690-8db9-334d71f0b4d8">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">Commission file number: <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zOTk_a9c426fc-fa2c-4f81-8616-b94eee56b597">000-30171</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%">_______________________________________________________________________________________________</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:20pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF80OTg_4b896b11-8861-4775-99e7-601c91d3ebea">SANGAMO THERAPEUTICS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%">_______________________________________________________________________________________________</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY18wLTAtMS0xLTA_5cbd6c91-ea0e-4d27-805c-f8433f1779a2">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY18wLTQtMS0xLTA_75e849ae-0bb6-4ce6-8462-1a929d385a9f">68-0359556</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY18zLTAtMS0xLTA_87ca8d34-0a06-4758-8ebe-a62f5099d8e0">7000 Marina Blvd.</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY180LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZTg4YTgwMTI3YzU0YTFhOWI1OTk0M2EyYTMzNWRkMl80_b29b9efc-b122-4897-859c-23085633097a">Brisbane</ix:nonNumeric>, <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY180LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZTg4YTgwMTI3YzU0YTFhOWI1OTk0M2EyYTMzNWRkMl84_1f656e99-551c-475b-894e-acb155577dec">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY180LTQtMS0xLTA_471a7ea5-c96f-4457-b72a-de59fe3ec7e6">94005</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(<ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF82NTU_2af9534e-d08d-4dfd-806a-cdd0a0d98908">510</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF82NTk_181e0517-b531-4e3a-80ca-6b98679d26ec">970-6000</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.968%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6ZGU1MThlYTNjNjlmNDkyMDg0ZjM1NzlkN2JiNDk5YTcvdGFibGVyYW5nZTpkZTUxOGVhM2M2OWY0OTIwODRmMzU3OWQ3YmI0OTlhN18xLTAtMS0xLTA_228a1fc3-343c-4224-9424-bce1e365bc31">Common Stock, par value $0.01&#160;per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6ZGU1MThlYTNjNjlmNDkyMDg0ZjM1NzlkN2JiNDk5YTcvdGFibGVyYW5nZTpkZTUxOGVhM2M2OWY0OTIwODRmMzU3OWQ3YmI0OTlhN18xLTEtMS0xLTA_a8240a3e-4de6-489a-9573-59a48f3e72ed">SGMO</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6ZGU1MThlYTNjNjlmNDkyMDg0ZjM1NzlkN2JiNDk5YTcvdGFibGVyYW5nZTpkZTUxOGVhM2M2OWY0OTIwODRmMzU3OWQ3YmI0OTlhN18xLTItMS0xLTA_db9bddfa-dc52-4d46-900e-ed5de7272d03">Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:700;line-height:115%">______________________________________________________________________________________________</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#160;&#160;<ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODY2_b59025c4-6d22-4a47-9f99-d4fb8271ae48">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act. &#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODY5_a6658fe2-2d04-4b70-8f53-ccd26ab1ada6">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#160;&#160;<ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODY3_a6ae2481-c2de-4f31-a55e-a550415686b7">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;<ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODcw_4f9bbdf8-b188-4880-93d2-b3ad3ecba118">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.026%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.027%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6OWJmNWZkZWEzNDI1NGJkZDg1ZWVmYzEzZWZhNDliMmYvdGFibGVyYW5nZTo5YmY1ZmRlYTM0MjU0YmRkODVlZWZjMTNlZmE0OWIyZl8wLTAtMS0xLTA_490bfb17-f222-4c06-8d5d-ffefd1bc0fe7">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6OWJmNWZkZWEzNDI1NGJkZDg1ZWVmYzEzZWZhNDliMmYvdGFibGVyYW5nZTo5YmY1ZmRlYTM0MjU0YmRkODVlZWZjMTNlZmE0OWIyZl8xLTQtMS0xLTA_973c3a0e-b87c-445c-a00c-2a2b0efb6797">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6OWJmNWZkZWEzNDI1NGJkZDg1ZWVmYzEzZWZhNDliMmYvdGFibGVyYW5nZTo5YmY1ZmRlYTM0MjU0YmRkODVlZWZjMTNlZmE0OWIyZl8yLTQtMS0xLTA_19c31e88-92ca-4adc-a7c5-9cb6eaca9121">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#9744;</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160;&#160;&#160;&#160;&#160; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:IcfrAuditorAttestationFlag" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zMjk4NTM0ODg3NTU2_abce3f40-8971-4270-a63c-68f1f8a42df3">&#9746;</ix:nonNumeric></span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act). &#160;&#160;Yes&#160;&#160;<ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODcx_fde17f04-d386-4149-99ec-e2a7a85dc706">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">The aggregate market value of the common stock held by non-affiliates of the registrant based upon the closing sale price of the common stock on June&#160;30, 2020 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), as reported on the Nasdaq Global Select Market was $<ix:nonFraction unitRef="usd" contextRef="iee1b756f6c0a4abe92e4664a43ad8035_I20200630" decimals="0" format="ixt:numdotdecimal" name="dei:EntityPublicFloat" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8xMDk5NTExNjMyMDI0_8b152bf6-69ef-4e68-ad0c-4f272ffb79fc">1,262,431,735</ix:nonFraction>. For purposes of this calculation, directors and executive officers of the registrant have been deemed affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As of February&#160;19, 2021, a total of <ix:nonFraction unitRef="shares" contextRef="i22a6be9ae52e4042a972a3c232e7c320_I20210219" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zMjE5_47645386-8355-485c-be53-7ec4cd9be023">143,251,243</ix:nonFraction> shares of common stock, $0.01 par value per share were outstanding.</span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:115%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:4pt;text-indent:18pt"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODY1_5c0dc9d7-9178-4536-91ea-cc8a92cc7527" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Certain information required by Part III, Items 10-14 of this Form 10-K is incorporated by reference to the registrant&#8217;s definitive Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">.</span></ix:nonNumeric></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:6.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.334%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_13">PART&#160;I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_16">Item&#160;1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_19">Item&#160;1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_19">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_19">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_22">Item&#160;1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_22">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_25">Item&#160;2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_25">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_25">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_28">Item&#160;3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_28">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_28">66</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_31">Item&#160;4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_31">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_31">66</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_34">PART&#160;II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_37">Item&#160;5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_37">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_37">67</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_40">Item&#160;6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_40">Selected Financial Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_40">68</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_43">Item&#160;7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_43">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_43">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_61">Item&#160;7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_61">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_61">77</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_64">Item&#160;8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_64">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_64">79</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_142">Item&#160;9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_142">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_142">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_145">Item&#160;9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_145">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_145">117</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_148">Item&#160;9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_148">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_148">120</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_151">PART&#160;III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_154">Item&#160;10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_154">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_154">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_157">Item&#160;11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_157">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_157">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_160">Item&#160;12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_160">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_160">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_163">Item&#160;13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_163">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_163">120</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_166">Item&#160;14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_166">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_166">121</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_169">PART&#160;IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_172">Item&#160;15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_172">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_172">122</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_175">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_175">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_175">125</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_178">SIGNATURES</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some statements contained in this report are &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. These statements relate to our future events, including our anticipated operations, research, development and commercialization activities, clinical trials, operating results and financial condition. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Forward-looking statements may include, but are not limited to, statements about:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our strategy;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated research and development of product candidates and potential commercialization of any resulting approved products;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, scope, rate of progress, enrollment, anticipated results and timing of our preclinical studies and clinical trials and those of our collaborators or strategic partners;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the therapeutic and commercial potential of technologies used by us in our product candidates, including our zinc finger protein technology platform, zinc finger nucleases and zinc finger protein transcription factors;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected benefits of the acquisition of Sangamo Therapeutics France S.A.S., or Sangamo France;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations and strategic partnerships and realize the expected benefits of such arrangements;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">anticipated revenues from existing and new collaborations and the timing thereof;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the impact of the evolving COVID-19 pandemic on our business and operations and the business and operations of our collaborators, including clinical trials and manufacturing, and our ability to manage such impacts;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our research and development and other expenses;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain adequate preclinical and clinical supplies of our product candidates from current and potential new suppliers and manufacturers;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability of Sangamo and our collaborators and strategic partners to obtain and maintain regulatory approvals for product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to comply with, and the impact of, regulatory requirements, obligations and restrictions on our business and operations;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others, including our ability to obtain rights to the gene transfer technologies required to develop and commercialize our product candidates;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the sufficiency of our cash resources and our expenses, capital requirements and need for additional financing, and our ability to obtain additional financing;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the growth of our business;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected operating and financial performance;</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our operational and legal risks; and</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans, objectives, expectations and intentions and any other statements that are not historical facts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and similar expressions intended to identify forward-looking statements. These statements reflect our current views with respect to future events, are based on assumptions and are subject to risks and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in this Annual Report on Form 10-K. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information or future events or developments. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Annual Report on Form 10-K.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF RISK FACTORS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business involves significant risks. Below is a summary of the material risks that our business faces, which makes an investment in our common stock speculative and risky. This summary does not address all these risks. These risks are more fully described below under the heading &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. Before making investment decisions regarding our common stock, you should carefully consider these risks. The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event, the market price of our common stock could decline, and you could lose all or part of your investment. In addition, there are also additional risks not described below that are either not presently known to us or that we currently deem immaterial, and these additional risks could also materially impair our business, operations or market price of our common stock.</span></div><div><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are a clinical-stage biotechnology company with no approved products or product revenues. Our success depends substantially on clinical trial results demonstrating safety and efficacy of our product candidates to the satisfaction of regulatory authorities. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any product candidates.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Many of our product candidates are based on novel zinc finger protein technologies that have yet to yield any approved commercially viable therapeutic products.  </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant operating losses since inception and anticipate continued losses for the foreseeable future. We may never become profitable.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We require additional capital to fund our operations and continue operating as a viable business. This additional capital may not be available to us on favorable terms or at all.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely heavily on collaborations with larger biopharmaceutical companies to generate revenues and develop, obtain regulatory approvals for and commercialize many of our product candidates. If conflicts arise with our collaborators or if the collaborations terminate for any reason, our revenues and product development efforts would be negatively impacted.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Biotechnology and genomic medicine are highly competitive businesses. Our competitors may develop rival technologies and products that are superior to or are commercialized more quickly than our technologies and product candidates.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing genomic medicines is complex, expensive, highly regulated and risky. We currently rely heavily on third party manufacturers and have limited experience manufacturing products ourselves. Manufacturing challenges may result in unexpected costs, supply interruptions and harm and delay to our product development efforts.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we obtain regulatory approvals for our product candidates, our approved products may not gain market acceptance among physicians and patients and adequate coverage and reimbursement from third-party payors and may not demonstrate commercial viability.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain, maintain and enforce necessary and desirable intellectual property protections for our technologies and product candidates in all desired jurisdictions, which could adversely affect the value of our technologies and our product development efforts and could increase the risks of costly, lengthy and distracting litigation with unpredictable results.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our success depends on hiring, integrating and retaining additional highly qualified skilled employees and retaining current key executives and employees, which may be challenging given that competition for these individuals is intense.  </span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The evolving COVID-19 pandemic could continue to adversely impact our business and operations and the business and operations of our collaborators, manufacturers and other business partners. If such impacts become material, our revenues and product development efforts could be negatively impacted.</span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock has been and will likely continue to be volatile, and you could lose all or part of any investment in our common stock.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="i24672e5030474c1ba9673ec16c177662_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1 &#8211; BUSINESS </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases. We plan to deliver on this mission through (i) development of our clinical and preclinical product candidates, (ii) our novel science and (iii) our in-house manufacturing capabilities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Product Candidates</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical-stage product candidates are:</span></div><div><span><br/></span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Giroctocogene fitelparvovec, also known as SB-525, our lead product candidate, is a gene therapy for the treatment of hemophilia A and is currently being evaluated in the registrational Phase 3 AFFINE (efficAcy and saFety Factor vIii geNe thErapy) clinical trial. We are developing giroctocogene fitelparvovec with our collaborator Pfizer Inc., or Pfizer;</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, is currently being evaluated in our Phase 1/2 STAAR clinical study;</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BIVV003, our cell therapy product candidate for the treatment of sickle cell disease, or SCD, is currently being evaluated in our Phase 1/2 PRECIZN-1 clinical study. We are developing BIVV003 with our collaborator Sanofi S.A., or Sanofi; and</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ST-400, our cell therapy product candidate for the treatment of transfusion dependent beta thalassemia, is currently being evaluated in our Phase 1/2 Thales clinical study. We are developing ST-400 with our collaborator Sanofi.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we expect to initiate clinical studies for two additional product candidates in 2021:</span></div><div><span><br/></span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TX200, our wholly-owned Chimeric Antigen Receptor, or CAR, engineered regulatory T cell, or CAR-Treg, cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection; and</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">KITE-037, our allogeneic anti-CD19 CAR-T cell therapy product candidate for the treatment of cancer. We are developing KITE-037 with our collaborator Kite Pharma Inc., or Kite, a wholly-owned subsidiary of Gilead Sciences, Inc.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we are focusing our preclinical development in emerging areas for us including CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Indications for our other preclinical programs include neurodevelopmental disorders, cancer, inflammatory bowel disease, or IBD, tauopathies such as Alzheimer&#8217;s and neurodegenerative diseases such as amyotrophic lateral sclerosis, or ALS, multiple sclerosis, or MS, and Huntington&#8217;s disease, some of which we are developing with our collaborators Biogen MA, Inc. and Biogen International GmbH, which we refer to together as Biogen, Kite, Novartis Institutes for BioMedical Research, Inc., or Novartis, Pfizer and Takeda Pharmaceutical Company Limited, or Takeda.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple collaborations with biopharmaceutical companies bring us important financial and strategic benefits and reinforce the potential of our research and development efforts and our zinc finger protein, or ZFP, technology platform. They leverage our collaborators&#8217; therapeutic and clinical expertise and commercial resources with the goal to bring our medicines more rapidly to patients. We believe these collaborations reflect the value of our ZFP technology platform and will potentially expand the addressable markets of our product candidates. To date, we have received approximately $815.0 million in upfront licensing fees, milestone payments and proceeds from sale of our common stock to collaborators and have the right to earn up to $7.0 billion in future milestone payments from our collaborations, in addition to potential product royalties.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Novel Science</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a leader in the research and development of ZFPs, which are naturally occurring sequence specific DNA binding proteins found in humans and other species. We have developed a proprietary synthetic ZFP technology platform with potential clinical utility in (i) genome editing and genome regulation, which we refer to together as genome engineering and (ii) gene-edited cell therapy, which we refer to as cell therapy.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to translate our differentiated and versatile ZFP technology platform to product candidates with best- or first-in-class clinical potential. For example, ZFPs can be engineered to make zinc finger nucleases, or ZFNs, which are proteins that can be used to edit genomes by specifically modifying DNA sequences by knocking in or knocking out select genes. ZFPs can also be engineered to make ZFP transcription factors, or ZFP-TFs, which are proteins that can be used to regulate genomes by selectively increasing or decreasing gene expression.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the process of developing these genome engineering technologies, we have additionally accrued significant scientific, manufacturing and development capabilities, as well as related know-how, that are broadly applicable to the field of gene therapy, which we have used to develop our gene therapy product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, we have also leveraged our ZFP technology platform and technologies obtained through acquisitions to become a leader in researching and developing CAR-Treg product candidates for the treatment of autoimmune and inflammatory diseases in broad patient populations, including kidney transplant rejection, MS and IBD. CAR-Tregs are considered to have enhanced suppressive function over polyclonal Tregs due to the antigen-specificity introduced by the CAR. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our In-House Manufacturing</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our current and future in-house manufacturing capacity provides us a competitive advantage. We currently operate an in-house adeno-associated virus, or AAV, manufacturing facility in our Brisbane, California headquarters, and we are building cell therapy manufacturing facilities in Brisbane, California and Valbonne, France, which we expect to be operational by the end of 2021. Our manufacturing strategy is to provide greater flexibility, quality and control by building a balanced and necessary capacity achieved through our in-house manufacturing and contract manufacturing organization, or CMO, partnerships, investing in manufacturing processes and analytics and developing a strong supply chain.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Updates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Giroctocogene Fitelparvovec &#8211;Hemophilia A</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we and Pfizer jointly announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, our investigational gene therapy for the treatment of severe hemophilia A. As of the August 31, 2020 cutoff date, all five patients in the high dose 3e13 vg/kg cohort had at least one year of follow-up, with 85 weeks of follow-up for the longest treated patient. The results showed that all five patients </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">showed sustained factor VIII, or FVIII, activity levels, with a group median FVIII activity of 56.9% and a group geometric mean FVIII activity of 70.4% via chromogenic assay from week nine to 52. Steady-state FVIII activity was achieved for all patients in this high dose cohort within nine weeks of treatment with giroctocogene fitelparvovec, with no bleeding events and no FVIII infusions (beyond three weeks post-infusion) within the first year. More detailed information about FVIII activity levels in the high dose cohort as of the August 31, 2020 cutoff date are presented in the tables below. As of the cutoff date, one patient had one target joint bleed requiring FVIII therapy, occurring after week 52.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Giroctocogene fitelparvovec was generally well tolerated. One patient in the high dose cohort had a treatment-related serious adverse event of hypotension (grade 3) and fever (grade 2), with symptoms of headache and tachycardia, which occurred six hours post-infusion with giroctocogene fitelparvovec, and which fully resolved within 24 hours. No other treatment-related serious adverse events were reported as of the cutoff date. Among the five patients in the high dose cohort, four received corticosteroids for liver enzyme (alanine aminotransferase, or ALT) elevations. Three patients had subsequent ALT elevations that responded to corticosteroids. All episodes of ALT elevations fully resolved with oral corticosteroids, and as of the cutoff date, no participants were on corticosteroids and no corticosteroid use had been initiated after week 52. Pfizer expects to present two-year follow-up data from the Alta study within the next year.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-align:center"><img src="sgmo-20201231_g1.jpg" alt="sgmo-20201231_g1.jpg" style="height:789px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we and Pfizer jointly announced that we dosed the first participant in our registrational Phase 3 AFFINE clinical trial of giroctocogene fitelparvovec. AFFINE is a global Phase 3, open-label, multicenter, single arm trial evaluating the efficacy and safety of a single infusion of giroctocogene fitelparvovec in more than 60 adult (ages 18-64 years) male patients with moderately severe to severe hemophilia A. The primary endpoint is impact on annual bleed rate, or ABR, through 12 months following treatment with giroctocogene fitelparvovec, compared to ABR on FVIII replacement therapy collected in the Phase 3 lead-in study period. Pfizer anticipates a pivotal data readout from this trial in 2022. We received a $30.0 million milestone from Pfizer in connection with the initiation of the AFFINE trial and have the potential to earn up to $245.0 million in future milestone payments plus tiered royalties of 14%-20% on potential future product sales.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ST-920 &#8211;Fabry Disease</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August and September 2020, we dosed the first two patients in our Phase 1/2 STAAR study evaluating our ST-920 gene therapy product candidate to treat Fabry disease, a rare inherited metabolic disease. These first two patients comprise the first of three dose-escalation cohorts in the study. In February 2021, we dosed the first patient in the second cohort. STAAR is an open-label, multicenter, dose-ascending clinical study evaluating the safety and tolerability of ST-920 in adult males with classic Fabry disease. We expect to present initial clinical data from the STAAR study by the end of 2021.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIVV003 &#8211; Sickle Cell Disease &amp; ST-400 &#8211; Transfusion Dependent Beta Thalassemia</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By the end of 2021, we and Sanofi expect to present clinical data from our Phase 1/2 PRECIZN-1 study evaluating our BIVV003 cell therapy product candidate for the treatment of sickle cell disease. We anticipate presenting at the same time follow-up clinical data from our Phase 1/2 Thales study evaluating ST-400, our cell therapy product candidate for the treatment of transfusion dependent beta thalassemia.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TX200 &#8211; HLA-A2 Mismatched Kidney Transplant Rejection</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to seek the regulatory approvals necessary to initiate our Phase 1/2 STEADFAST clinical study evaluating our TX200 CAR-Treg cell therapy product candidate to treat HLA-A2 mismatched kidney transplant rejection. We expect to initiate the study in the second half of 2021. We expect that dosing of the first patient in this study will occur several months after initiation and patient enrollment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genome Engineering &#8211; ALS &amp; FTLD</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are developing genome engineering product candidates with Pfizer that use ZFP-TFs to treat ALS and frontotemporal lobar degeneration, or FTLD, linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. In September 2020, we completed our research obligations under the collaboration, and in November 2020, we received a $5.0 million milestone from Pfizer associated with this program.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genome Engineering &#8211; Prion Disease </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to advance our wholly-owned preclinical genome engineering program in prion disease, a fatal and incurable neurodegenerative disease caused by the misfolding of the prion protein encoded by the gene </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PRNP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTION TO OUR TECHNOLOGY</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategy is to translate our differentiated and versatile ZFP technology platforms to product candidates with best- or first-in-class clinical potential. We believe that the versatility and flexibility of our technology platforms enables us to design therapeutic approaches to resolve the underlying genetic or cellular causes of disease, using whichever technology is best suited to deliver that treatment. Our current emerging areas of focus in preclinical studies include genome regulation with our ZFP technology platform in the central nervous system, or CNS, diseases and CAR-Treg cell therapy for autoimmune diseases.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZFPs: Naturally Occurring Sequence Specific DNA Binding Proteins in Humans</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZFPs are naturally occurring sequence specific DNA binding proteins in humans that recognize and bind to a specific DNA sequence within or near a particular gene and causes expression of that gene to be &#8220;turned on&#8221; (activated) or &#8220;turned off&#8221; (repressed). ZFPs are the most common class of such naturally occurring proteins in a wide range of organisms from yeast to humans. Functional domains may be added to ZFPs that enable genome editing (with enzymes such as nucleases or integrases) or genome regulation (with activators and repressors) at a specific genomic site determined by the ZFP DNA-binding domain.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><img src="sgmo-20201231_g2.jpg" alt="sgmo-20201231_g2.jpg" style="height:326px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure 1:</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schematic of the two-domain structure of a ZFP and its therapeutic functional domain </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with the structure of natural ZFPs, we take a modular approach to the design of the proteins that we engineer. The ZFP portion of our engineered proteins, the DNA-recognition domain, is typically composed of four to six zinc fingers. Each individual finger recognizes and binds to a three or four base pair sequence of DNA and multiple fingers can be linked together to recognize longer stretches of DNA, thereby improving specificity. By modifying the amino acid sequence of a ZFP, we can engineer novel ZFPs capable of recognizing the unique DNA sequences of a chosen genomic target. The engineered ZFP DNA-binding domain is then linked to a functional domain. The ZFP DNA-binding domain brings this functional domain to the target of interest. Our ability to use our highly specific ZFPs to precisely target a DNA sequence to a gene of interest provides us with a range of genome editing and genome regulation functionalities that can be applied to multiple cell types.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our engineered ZFPs can be attached to a cleavage domain of a restriction endonuclease, an enzyme that cuts DNA, creating a ZFN. When a pair of ZFNs binds DNA in the correct orientation and spacing, a cut is introduced into the DNA sequence between the ZFP binding sites. DNA binding by both ZFNs is necessary for cleavage, and the two halves of the endonuclease must be present in the correct orientation to interact with one another in order to mediate DNA cleavage. This break in the DNA triggers a natural process of DNA repair within the cell. This endogenous DNA repair process may be harnessed to achieve one of several outcomes that may be therapeutically useful (Figure 2). If cells are treated with ZFNs alone, the repair process joins the two ends of the broken DNA together and frequently results in the loss (deletion) or addition (insertion) of a small amount of genetic material at the site of the break. These insertions and deletion events are collectively known as &#8220;indels&#8221;. These disrupt the target DNA sequence and result in the expression of a truncated or non-functional protein from the targeted gene, effectively &#8220;knocking out&#8221; the gene function. ZFN-mediated genome editing can be used to disrupt genes that are involved in disease pathology. We are using ZFN-mediated genome editing of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCL11A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> erythroid specific enhancer, or ESE, in hematopoietic stem progenitor cells, or HSPCs, as the basis of a potential long-lasting and once only treatment for beta thalassemia (ST-400) and SCD (BIVV003).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-align:center;text-indent:36pt"><img src="sgmo-20201231_g3.jpg" alt="sgmo-20201231_g3.jpg" style="height:432px;margin-bottom:5pt;vertical-align:text-bottom;width:529px"/></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure 2:</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schematic of ZFP genome editing and genome regulation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In contrast, if cells with a mutation in a particular gene are treated not only with ZFNs, but also with an additional DNA sequence that encodes the correct gene sequence (referred to as a &#8220;donor&#8221; DNA) and with ZFNs that recognize and bind to sequences flanking the mutation, the cell&#8217;s repair machinery can use the donor DNA as a template to correct the mutated gene. This ZFN-mediated gene correction enables the corrected gene to be expressed in its natural chromosomal context and may provide a novel approach for the precise repair of DNA sequence mutations responsible for certain monogenic diseases. In addition to providing a donor sequence that encodes a complete gene, a new copy of a gene can also be precisely added into the genome at a specific location. The ability to precisely place a gene-sized segment of DNA specifically into a pre-determined location in the genome broadens the range of mutations of a gene that can be corrected in a single step. It also reduces the insertional mutagenesis concerns associated with traditional integrating gene replacement approaches such as lentiviruses, in which the insertion of a new corrective copy of the gene typically occurs at random locations in the genome.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also evaluating ZFP-TFs, which have the potential to regulate the expression of a target gene (Figure 2). For instance, attaching an activation domain to a ZFP will cause a target gene to be expressed at increased levels, relative to an untreated cell. Alternatively, a repression domain causes the gene to be downregulated or completely turned off. We have several preclinical programs evaluating the potential of ZFP-TFs that have been designed to down regulate the expression of genes as potential treatments for CNS diseases, including a collaboration agreement with Biogen for Alzheimer&#8217;s disease and Parkinson&#8217;s disease, a collaboration with Takeda for Huntington&#8217;s disease and a collaboration with Pfizer for ALS. We also have a preclinical collaboration with Novartis evaluating the potential of ZFP-TFs to upregulate expression of genes as a potential treatment for autism spectrum disorders and intellectual disability. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ZFPs Provide Opportunity to Develop a New Class of Human Therapeutics</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our ZFP technology provides a unique and proprietary basis for a broad new class of drugs that have differentiated technical advantages over small-molecule drugs, protein pharmaceuticals, RNA-based therapeutics, conventional gene therapy approaches and other gene and genome editing platforms, potentially enabling us to develop therapies that address a broad range of unmet medical needs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can generate highly specific ZFNs for genome editing and ZFP-TFs for genome regulation using a range of proprietary methods. We are developing delivery strategies to administer these therapeutics, including using mRNA, AAV, adenovirus, plasmid, lipid nanoparticles and direct injection into brain tissue or into the cerebrospinal fluid. As more genes and DNA sequences are linked to specific diseases, we believe that the clinical breadth and scope of our ZFP therapeutic reagents will continue to expand.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAR-Tregs Have Potential to Address Autoimmune and Inflammatory Diseases</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tregs are a type of white blood cell and act as the key regulators of the immune system. Their natural role is to maintain immune homeostasis and prevent undesirable immune reactions to autoantigens (autoimmunity) or to antigens that are normally tolerated (food antigens, inhaled antigens, contact antigens and bacterial flora antigens). Tregs play the role of &#8216;peacekeepers&#8217; containing other T cells before they become harmful to the organism, ensuring the immune system does not mistakenly attack healthy organs while still protecting the body from harm, e.g., from viruses and bacteria. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are genetically re-programming Tregs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to add a CAR, to give Tregs the ability to target a specific protein, called an antigen. CAR-Tregs are thus re-programmed to recognize and accumulate in specific tissues where the antigen is being expressed and an immune-mediated disorder is occurring. Our preclinical research shows that CAR-Tregs can inhibit overactive immune cells within the body. Moreover, they have the potential to induce long-term immune tolerance &#8211; a state of non-reactivity by the immune system to a particular auto-antigen. We aim to develop therapies that can induce and restore immune tolerance to address a wide range of inflammatory and autoimmune diseases.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CARs are composed of three main parts (see Figure 3):</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The extracellular section is composed of a single chain variable fragment, or scFv, typically derived from a monoclonal antibody and designed to recognize the target antigen, and a spacer or hinge to add spatial flexibility. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The transmembrane domain anchors the CAR in the plasma membrane.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The intracellular section, made of signaling and co-stimulatory domains, transmits an intracellular signal upon recognition of the antigen by the scFv.</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><img src="sgmo-20201231_g4.jpg" alt="sgmo-20201231_g4.jpg" style="height:248px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure 3:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schematic of CAR-Treg cell recognizing antigen on tissue cell, with detailed CAR structure</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carefully select the CAR target antigen for each autoimmune or inflammatory indication. Our CAR-Treg cells are designed to be active only at the site of inflammation, ensuring specific and selective action. For instance, for a CNS disease such as MS, we want to make sure that the target antigen is localized in the CNS. The target antigen may in some instances be linked to the disease etiology. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A major feature of Tregs is that they can act via multiple mechanisms to mediate suppression. Their mechanism of action can be mediated upon cell contact, through soluble factors, metabolism disruption and/or cytolysis. The proposed mechanism of action for CAR-Tregs is shown in Figure 4. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Following IV administration, CAR-Tregs are expected to migrate toward inflamed tissues due to Tregs&#8217; natural ability to migrate towards inflammatory tissues.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Subsequently, CAR-Treg are expected to bind to their specific antigen, leading to the proliferation and activation of CAR-Treg cells. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">This activation is expected to allow Tregs to exert their natural anti-inflammatory and immuno-suppressive activities, acting through multiple molecular and cellular targets.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="sgmo-20201231_g5.jpg" alt="sgmo-20201231_g5.jpg" style="height:480px;margin-bottom:5pt;vertical-align:text-bottom;width:354px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure 4:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schematic of the proposed mechanism of actions of CAR-Treg cells</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-align:center"><img src="sgmo-20201231_g6.jpg" alt="sgmo-20201231_g6.jpg" style="height:363px;margin-bottom:5pt;vertical-align:text-bottom;width:500px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure 5:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Schematic of our autologous CAR-Treg approach</span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced CAR-Treg product candidate, TX200, is being studied for the prevention of immune-mediated rejection following HLA-A2 mismatched kidney transplantation. TX200 is an autologous CAR-Treg cell therapy product candidate. An autologous cell therapy is made using cells from the same person as the recipient of the cells, as shown on Figure 5. The patient&#8217;s Tregs are collected before transplant, genetically engineered with a CAR, and then injected back into the same patient. As a result of this detailed process, we expect dosing of patients will occur several months after their enrollment. The CAR in TX200 is designed to recognize the HLA-A2 protein present on the transplanted kidney.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to initiate a clinical study in 2021 to evaluate the safety, tolerability, and mechanism of action of TX200 in patients who have received a kidney transplant. Our STEADFAST clinical study will help us understand how CAR-Tregs work in humans and may provide broader proof of concept for genetically modified cell therapy using Tregs. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are convinced of the fundamental impact of our CAR-Treg approach and are initiating the next step with the goal to make approach available to larger group of patients. Accordingly, we are developing ZFN-edited allogeneic Treg therapies. Allogeneic cell therapies are donor derived, made using cells from a different person to the recipient of the cells, as opposed to autologous cell therapies. We believe that allogeneic therapies are the future of cell therapy and will overcome the challenges of autologous approaches such as scale and manufacturing. If we are able to demonstrate proof-of-concept of autologous TX200, we anticipate follow-on allogeneic programs for kidney transplant rejection, IBD such as Crohn&#8217;s disease and MS, all of which are currently in preclinical development. There is tremendous potential from there to go into many other large autoimmune indications such as rheumatoid arthritis or diabetes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gene Therapy Introduces Genes into a Patient&#8217;s Cells to Treat Genetic Diseases</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the process of developing our ZFP technologies, we have refined our understanding of gene therapies. Gene therapy is the treatment of disease by delivery of a new gene into a patient&#8217;s cells to replace an incorrect or damaged gene. Most often, gene therapy works by introducing a corrected copy of a defective gene into the patient&#8217;s cells, without removing or modifying DNA. The goal of gene therapy is to treat, or potentially cure, a genetic disease by adding back a normal copy of the gene responsible for the disease.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In gene therapy, we can deliver a therapeutic gene by engineering a deactivated virus to deliver DNA for a human therapeutic protein rather than viral proteins. One virus that is commonly used in gene therapy is adeno-associated virus, or AAV. AAV is a naturally occurring virus that infects humans but is not known to cause disease. Engineered AAV has been used as a delivery method for gene therapy in many clinical trials in the U.S. and Europe and has been found thus far to be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally well-tolerated without major side effects. A gene encoding a therapeutic protein can be packaged into AAV and delivered to cells in tissues such as the liver, the eye, the brain or the heart. Once inside the cell, the gene is unpacked from the virus coat, or capsid, and can then enable that cell to make the therapeutic protein. AAV can be manufactured at a large enough scale for use as a human therapeutic.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center"><img src="sgmo-20201231_g7.jpg" alt="sgmo-20201231_g7.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Figure 6:</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our gene therapy technology</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">THERAPEUTIC PRODUCT DEVELOPMENT</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases. We plan to deliver on this mission through (i) development of our clinical and preclinical product candidates, (ii) our novel science and (iii) our in-house manufacturing capabilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Product Candidates</span></div><div style="text-align:center"><img src="sgmo-20201231_g8.jpg" alt="sgmo-20201231_g8.jpg" style="height:401px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proprietary Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ST-920 - Fabry Disease </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August and September of 2020, we dosed the first two patients in our open label Phase 1/2 STAAR study evaluating our ST-920 gene therapy product candidate to treat Fabry disease, a rare inherited metabolic disease. These first two patients comprise the first of three dose-escalation cohorts in the study. In February 2021, we dosed the first patient in the second cohort. We are currently evaluating ST-920 in adult males with classic Fabry disease who are on an enzyme replacement therapy, or ERT, regimen; are ERT na&#239;ve; or are ERT pseudo na&#239;ve and have not received ERT treatment in the six months prior to the study. The goal of the study is to abrogate the need for ERT with a recombinant AAV2/6 vector encoding cDNA for human &#945;-Gal A, resulting in long-term expression of &#945;-Gal A. The primary endpoint of the trial is safety and tolerability. The secondary endpoints include pharmacodynamics of &#945; Gal A and the presence of its substrates in plasma over time; impact on ERT administration; impact on renal function; and vector DNA shedding over time. We will also be conducting a long-term follow-up study to monitor patients for an additional four years. We expect to present initial clinical data from the STAAR study by the end of 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a liver-directed gene therapy, ST-920 is designed to be delivered by a one-time IV infusion that does not require any preconditioning regimen for patients. We believe ST-920 has the potential to deliver efficacy with preserved renal function and reduced cardiac morbidity and neuropathy. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TX200 - HLA-A2 Mismatched Kidney Transplant Rejection </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TX200 is our autologous HLA-A2 specific CAR-Treg cell therapy product candidate that we have developed for the prevention of immune mediated rejection following HLA-A2 mismatched renal transplantation. We continue to seek the regulatory approvals necessary to initiate the proof-of-concept Phase 1/2 STEADFAST clinical study and we expect to initiate the study in Europe in the second half of 2021. The STEADFAST study will be critical for our understanding of CAR-Treg pharmacology and biology in patients as well as establishing process development and manufacturing know-how. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TX200 has been developed for patients with end-stage renal disease or ESRD, receiving a kidney transplant, where the recipient of the kidney is HLA-A2 negative and the donor is HLA-A2 positive. A kidney transplant is considered the best </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment option for ESRD, the last stage of chronic kidney disease, when a person&#8217;s kidneys are no longer working. HLA mismatch is the initial and most important barrier to successful transplantation after ABO blood types incompatibility, and approximately 20-25% of transplanted organs are HLA-A2 mismatched. In the case of an HLA-A2 positive kidney transplanted into an HLA-A2 negative patient, the recipient&#8217;s immune system can recognize this mismatch and, without long-term immunosuppressive medication, will attack the new kidney carrying the HLA-A2 protein, leading to graft rejection. A lifetime of immunosuppressive therapy is associated with significant morbidity and mortality, including the development of systemic infection, malignancy and cardiovascular disease, the leading cause of death in this patient population. Therefore, the induction of immunological tolerance defined a stable and acceptable graft function without the need for immunosuppression remains a key priority in this field of medicine.</span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TX200 is composed of autologous Treg cells engineered to express an HLA-A2 CAR, allowing them to localize to the renal graft and activate upon recognition of the HLA-A2 antigen. We believe that TX200 has the potential to prevent kidney rejection by binding to the HLA-A2 positive kidney and inducing immune tolerance. </span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to other genetically engineered cell therapy approaches, patients will undergo a leukapheresis procedure, from which their Treg cells will be isolated and engineered then cryopreserved. The HLA-A2 negative patient will subsequently undergo transplantation surgery to receive a kidney from and HLA-A2 positive living donor. Following a recovery period, the transplant recipient will receive their personalized TX200 drug candidate. As a result of this detailed process, we expect dosing of patients will occur several months after study initiation and patient enrollment.</span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical data supporting the STEADFAST study that we presented in October 2020 showed that the TX200 HLA-A2 CAR-Tregs efficiently prevented rejection in both graft versus host disease and skin transplantation models. They were also shown to be safe and well tolerated in our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is that TX200 establishes the foundation for a portfolio of CAR-Tregs for major autoimmune indications. We believe that allogeneic therapies are the future of cell therapy and will overcome the challenges of autologous approaches such as scale and manufacturing. If we are able to demonstrate proof-of-concept of autologous TX200, we will continue to advance our kidney transplant allogeneic program which is currently in preclinical development. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAR-Treg Cell Therapy - IBD </span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to advance preclinical development of our wholly-owned CAR-Treg program to treat IBD. IBD covers debilitating disorders that involve chronic inflammation of the digestive tract, including ulcerative colitis and Crohn's disease. Our product candidate to treat IBD is composed of allogeneic Treg cells engineered to express a CAR designed to recognize an antigen relevant to IBD, so that it allows resulting CAR-Treg cells to localize and activate in the gut.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">CAR-Treg Cell Therapy - MS </span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to advance preclinical development of our wholly-owned CAR-Treg program to treat MS, an autoimmune disease of the CNS. Similarly to our IBD program, our product candidate to treat MS is composed of allogeneic Treg cells engineered to express a CAR designed to recognize an antigen relevant to MS, so that resulting CAR-Tregs can localize and activate in the CNS.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ST-101 - PKU</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to advance preclinical development of ST-101, our wholly-owned investigational gene therapy product candidate to treat phenylketonuria, or PKU, a rare inherited disorder that originates from a defect in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">PAH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene and results in harmful accumulation of phenylalanine in cells throughout the body.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Partnered Programs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Giroctocogene Fitelparvovec - Hemophilia A</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer continue to develop giroctocogene fitelparvovec, which is currently being evaluated in our registrational Phase 3 AFFINE clinical trial as an investigational gene therapy for severe hemophilia A. Under our collaboration agreement with Pfizer, we conducted the Phase 1/2 clinical study and certain manufacturing activities, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization.</span></div><div style="text-indent:39.6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we initiated the Phase 1/2 Alta study to evaluate the safety and efficacy of giroctocogene fitelparvovec, also known as SB-525, in adults with severe hemophilia A. The Alta study is an open label, ascending dose Phase 1/2 clinical study in 11 male patients with severe hemophilia A. In December 2020, we and Pfizer jointly announced updated follow-up data from the study, which were presented at the 62</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> American Society for Hematology Annual meeting. As of the August 31, 2020 cut-off date, all five patients in the high dose 3e13 vg/kg cohort had at least one year of follow-up, with 85 weeks of follow-up for the longest treated patient, and showed sustained factor VIII, or FVIII, activity levels, with a group median FVIII activity of 56.9% and a group geometric mean FVIII activity of 70.4% via chromogenic assay from week nine to 52. Steady-state FVIII activity was achieved for all patients in the high dose cohort within nine weeks of treatment with giroctocogene fitelparvovec, with no bleeding events and no FVIII infusions (beyond three weeks post-infusion) within the first year. As of the cut-off date, one patient had one target joint bleed requiring FVIII therapy, occurring after week 52. Giroctocogene fitelparvovec was generally well tolerated. As previously reported, one patient in the high dose cohort had a treatment-related serious adverse event of hypotension (grade 3) and fever (grade 2), with symptoms of headache and tachycardia, which occurred six hours post-infusion with giroctocogene fitelparvovec, and which fully resolved within 24 hours. No other treatment-related serious adverse events were reported as of the cutoff date. Among the five patients in the high dose cohort, four received corticosteroids for liver enzyme (alanine aminotransferase, or ALT) elevations. Three patients had subsequent ALT elevations that responded to corticosteroids. All episodes of ALT elevations fully resolved with oral corticosteroids, and as of the cutoff date no participants were on corticosteroids and no corticosteroid use has been initiated after week 52. Pfizer expects to present two-year follow-up data from the Alta study within the next year.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, we and Pfizer jointly announced that we dosed the first participant in the registrational Phase 3 AFFINE clinical trial of giroctocogene fitelparvovec. AFFINE is a global Phase 3, open-label, multicenter, single arm trial evaluating the efficacy and safety of a single infusion of giroctocogene fitelparvovec in more than 60 adult (age 18-64) male patients with moderately severe to severe hemophilia A. The primary endpoint is impact on ABR through 12 months following treatment with giroctocogene fitelparvovec, compared to ABR on FVIII replacement therapy collected in the Phase 3 lead-in study period. Participants will be analyzed throughout the five-year study period following the single infusion to further assess the durability and efficacy. Pfizer expects a pivotal data readout from this trial in 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results from the Alta study, the FDA granted regenerative medicine advanced therapy, or RMAT, designation to giroctocogene fitelparvovec. RMAT designation is granted to regenerative medicine therapies intended to treat, modify, reverse, or cure a serious condition, for which preliminary clinical evidence indicates that the medicine has the potential to address an unmet medical need. The RMAT designation includes all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with the FDA. The FDA also granted giroctocogene fitelparvovec Orphan Drug and Fast Track designation, and the European Medicines Agency, or EMA, granted it Orphan Medicinal Product designation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">BIVV003 &#8211; Sickle Cell Disease &amp; ST-400 &#8211; Transfusion Dependent Beta Thalassemia </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Sanofi continue to develop therapeutics for hemoglobinopathies, focused on SCD and beta thalassemia. We and Sanofi are currently evaluating BIVV003, our cell therapy product candidate for SCD, in the Phase 1/2 PRECIZN-1 study and ST-400, our cell therapy product candidate for transfusion dependent beta thalassemia, in the Phase 1/2 Thales study. Sanofi is responsible for all subsequent development, manufacturing, marketing and commercialization.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BIVV003 and ST-400 are related product candidates using the same technology involving genome editing of a patient&#8217;s own hematopoietic stem progenitor cells using non-viral delivery of our ZFN technology designed to induce the synthesis of fetal hemoglobin. This is achieved by gene-edited knock out of the erythroid specific enhancer of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BCL11a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene, which encodes a strong repressor of the gamma globin gene. In SCD, increased fetal hemoglobin synthesis may provide the patient with functional hemoglobin and help downregulate the abnormal sickle hemoglobin that results in painful sickle cell crises and other disease feature. In beta thalassemia, if fetal hemoglobin is expressed at high enough levels, it may substitute for a patient&#8217;s absent or impaired levels of beta globin. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are conducting the Phase 1/2 Thales study, an open-label, single arm clinical study to evaluate the safety and efficacy of ST-400 in up to six patients with beta thalassemia. We have dosed five patients into the Thales study, and we presented preliminary results in December 2019. Sanofi announced in early 2020 that it had dosed the first patient in the Phase 1/2 PRECIZN-1 study, and that it continues to enroll patients into the study.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Sanofi will present a new analysis of the studies&#8217; data when the two studies have accumulated a sufficient number of patients and follow-up, which we expect to do by the end of 2021. We will not dose any additional patients in the Thales study until the data from both studies has been collected and analyzed.  </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">KITE-037 - Cancer </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Kite continue to develop cell therapies to treat cancer using our research to design ZFNs and viral vectors to disrupt and insert select genes in T cells and natural killer cells, or NK-cells, including the insertion of genes that encode CARs, T cell receptors, or TCRs, and NK-cell receptors, or NKRs, directed to mutually agreed targets. Kite is responsible for all clinical development, manufacturing, marketing and commercialization. Kite anticipates submitting an investigational new drug, or IND, application for KITE-037, our allogeneic anti-CD19 CAR-T cell therapy product candidate, in the first half of 2021, and it expects to initiate a clinical study on KITE-037 by the end of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ST-501 &#8211; Tauopathies &amp; ST-502 - Synucleinopathies </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Biogen continue to develop preclinical genome engineering therapies, including our ST-501 product candidate to treat tauopathies including Alzheimer&#8217;s disease, ST-502 to treat synucleinopathies including Parkinson&#8217;s disease and an additional therapy to treat an undisclosed neuromuscular target. Under our collaboration agreement with Biogen, it has exclusive rights to nominate up to nine additional targets over a target selection period of five years. This collaboration leverages ZFP-TFs to aim to modulate the expression of key genes involved in neurological diseases. Our preclinical studies using AAV vectors to deliver tau-targeted (ST-501) and alpha synuclein-targeted (ST-502) ZFP-TFs have demonstrated highly specific, potent and tunable repression of tau and alpha synuclein.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genome Engineering &#8211; Autism Spectrum Disorder and Neurodevelopmental Disorders</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Novartis continue to develop preclinical genome engineering therapies for three neurodevelopmental targets, including genes linked to autism spectrum disorder and intellectual disability. The collaboration leverages our ZFP-TFs to aim to upregulate the expression of key genes involved in neurodevelopmental disorders. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Genome Engineering &#8211; ALS &amp; FTLD </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer continue to develop preclinical genome engineering product candidates that use ZFP-TFs to treat ALS and FTLD linked to mutations in th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. In September 2020, we completed our research obligations associated with this collaboration, which required us to identify, characterize and preclinically develop ZFP-TFs satisfying pre-agreed criteria. Pfizer is now responsible for subsequent research and development activities as well as subsequent development, manufacturing, marketing and commercialization.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TAK-686 &#8211; Huntington&#8217;s Disease </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Takeda continue to develop a preclinical genome engineering product candidate to treat Huntington&#8217;s Disease that uses a ZFP-TF designed to differentially down regulate the mutated disease-causing huntingtin gene, or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene, while preserving the expression of the normal version of the gene. Takeda continues to advance preclinical IND enabling studies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For more information on the collaborations underlying these partnered programs, see &#8220;&#8212;Collaborations&#8221; below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legacy Clinical Research Programs</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stopped development of the following clinical research programs. We continue to perform the appropriate long-term follow-up and closeout activities of the legacy studies in accordance with the study protocols.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SB-728&#8211; Human Immunodeficiency Virus, or HIV</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recently stopped development in HIV.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SB-728 was one of the first clinical candidates to use an early generation of our ZFN-mediated genome editing technology. We conducted several clinical studies evaluating SB-728, demonstrating the safety of the platform and showing immune responses from a subset of patients, however the studies did not meet our clinical expectations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SB-913 - MPS II</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we announced that we have stopped development of SB-913, our ZFN genome editing product candidate for the treatment of Mucopolysaccharidosis Type II, or MPS II. While the Phase 1/2 CHAMPIONS study evaluating SB-913 demonstrated the first molecular evidence of genome editing, the study did not meet our clinical expectations. Research </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is ongoing to improve the potency and delivery of our ZFNs for genome editing, which we believe will optimize the platform for therapeutic effect. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SB-318 - MPS I &amp; SB-FIX &#8211; Hemophilia B</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have stopped development of SB-318 and SB-FIX, genome editing product candidates for the treatment of MPS I and hemophilia B, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COLLABORATIONS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into strategic collaborations with larger biopharmaceutical companies for several of our therapeutic programs and other partnerships for several non-therapeutic applications of our technology. We will continue to pursue further collaborations when appropriate to fund internal research and development activities and to assist in product development, manufacturing, regulatory approval and commercialization. Decisions to collaborate or not will be based on review of our internal resources, institutional knowledge and commercial considerations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, we entered into a collaboration and license agreement with Novartis for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, we granted to Novartis an exclusive, royalty bearing and worldwide license, under our relevant patents and know-how, to develop, manufacture and commercialize certain of our ZFP-TFs targeted to three undisclosed genes that are associated with neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. We perform early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which are funded by Novartis. Novartis is responsible for additional research activities, IND-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, we are prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of our proprietary AAVs for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Novartis paid us a $75.0 million upfront license fee payment in August 2020. In addition, we are eligible to earn from Novartis up to $420.0 million in development milestones and up to $300.0 million in commercial milestones. We are also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement continues, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, we entered into a global licensing collaboration agreement with Biogen for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases which became effective in April 2020. Our collaboration aims to leverage our proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, we also entered into a stock purchase agreement with Biogen MA, Inc., pursuant to which Biogen MA, Inc. purchased 24,420,157 shares of our common stock, or the Biogen Shares for an aggregate purchase price of $225.0 million.    </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid us an upfront license fee payment of $125.0 million. We are also eligible to earn research, development, regulatory and commercial milestone payments that could total up to approximately $2.37 billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0 million in pre-approval milestone payments and up to $1.45 billion in first commercial sale and other sales-based milestone payments. In addition, we are also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, we granted to Biogen an exclusive, royalty bearing and worldwide license, under our relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, we perform early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary CNS delivery vectors and ZFP-TFs targeting therapeutically relevant genes. Biogen then assumes responsibility and costs for the IND-enabling studies, clinical development, related regulatory interactions, and global commercialization. We are primarily responsible for GMP manufacturing activities for the initial clinical studies for the first three products of the collaboration and plan to leverage our in-house manufacturing capacity. Biogen is responsible for GMP manufacturing activities beyond the first clinical study for each of the first three products. Subject to certain exceptions set forth in the collaboration agreement, we are prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement continues, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, we may terminate the collaboration agreement if Biogen challenges any patents licensed by us to Biogen. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without our prior written and subject to specified conditions and exceptions, directly or indirectly acquire shares of our outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in us. Subject to customary exceptions, such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the Biogen collaboration agreement and the date that Biogen beneficially owns less than 5% of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock purchase agreement also provides that until the first anniversary of the effectiveness of the Biogen collaboration agreement, Biogen must hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen must hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, upon Biogen&#8217;s request, we must register for resale any of the Biogen Shares on a registration statement to be filed with the SEC, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Act during any 90-day period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Biogen has agreed that, excluding specified extraordinary matters, it must vote the Biogen Shares in accordance with our recommendation and has granted us an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the two-year anniversary of the effectiveness of the Biogen collaboration agreement, (ii) the date that Biogen beneficially owns less than 5% of our common stock and (iii) the date the Biogen collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the Biogen collaboration agreement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, we entered into a collaboration and license agreement with Kite, a wholly-owned subsidiary of Gilead, which became effective in April 2018 and was amended and restated in September 2019, for the research, development and commercialization of engineered cell therapies for cancer. Kite is responsible for all clinical development and commercialization of any resulting products. Kite anticipates an IND submission for KITE-037, our allogeneic anti-CD19 CAR-T cell therapy product candidate, in the first half of 2021, and it expects to initiate a clinical study on KITE-037 by the end of 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, we granted Kite an exclusive, royalty-bearing, worldwide, sublicensable license, under our relevant patents and know-how, to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using selected ZFNs and AAVs developed under the research program, to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions, except pursuant to this agreement, we are prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">this agreement, we are prohibited from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a $150.0 million upfront payment from Kite when the agreement became effective in April 2018. In addition, Kite reimburses our direct costs to conduct the joint research program, and Kite is responsible for all subsequent development, manufacturing and commercialization of any licensed products. We are also eligible to earn contingent development- and sales-based milestone payments that could total up to $3.01 billion if all the specified milestones set forth in this agreement are achieved. Of this amount, approximately $1.26 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75 billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels. Each development- and sales-based milestone payment is payable (i) only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii) only for the first 10 times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event. In addition, we are entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kite has the right to terminate this agreement, in its entirety or on a per licensed product or per candidate target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two separate collaboration agreements with Pfizer:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Giroctocogene Fitelparvovec Collaboration</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2017, we entered into an exclusive, global collaboration and license agreement with Pfizer for the research, development and commercialization of giroctocogene fitelparvovec, also known as SB-525, our gene therapy product candidate for hemophilia A, and closely related products, which we amended in December 2019.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, we were responsible for conducting the Phase 1/2 clinical study and certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. We may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received an upfront license fee of $70.0 million, achieved a $25.0 million milestone in December 2019 upon completion of the transfer of the IND for giroctocogene fitelparvovec to Pfizer, and achieved a $30.0 million in October 2020 upon the dosing of the first patient in our pivotal Phase III AFFINE trial. We are eligible to earn further development milestone payments on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in this agreement, is $475.0 million, which includes up to $300.0 million for giroctocogene fitelparvovec and up to $175.0 million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer agreed to pay us royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third party intellectual property.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, we granted Pfizer an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by us for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted us a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture our products that utilize the AAV delivery system. During a specified period, neither we nor Pfizer are permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues, on a per product and per country basis, until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) 15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by us to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products automatically terminate. Upon termination by us for cause or by Pfizer in any country or countries, Pfizer is required to automatically grant us an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat ALS and FTLD linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, we agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received a $12.0 million upfront payment from Pfizer and achieved a $5.0 million in September 2020 associated with the completion of all of our research activities for the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration. We are eligible to earn up to $60.0 million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0 million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay us royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party is responsible for the cost of its performance of the research program. Pfizer is operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, we granted Pfizer an exclusive, worldwide, royalty-bearing, license under our relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither we nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues, on a per licensed product and per country basis, until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) 15 years after the first commercial sale of a licensed product in a major market country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if we are unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by us to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by us for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, we will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by us for Pfizer&#8217;s material breach, either party will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, we entered into an exclusive worldwide collaboration and license agreement with Biogen MA, Inc., who subsequently assigned it to Bioverativ Inc., who was then subsequently acquired by Sanofi to develop therapeutics for hemoglobinopathies. Under the agreement, we are jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, we are responsible for all discovery, research and development activities through the first human clinical study. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of our remaining activities. Furthermore, we have an option to co-promote in the United States any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate us for such co-promotion activities. Subject to the terms of the agreement, we have granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by us for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. We have also granted Sanofi a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, under our interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, we are not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, we received an upfront license fee of $20.0 million, achieved a $6.0 million milestone in August 2019, upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial, achieved a $7.5 million milestone in December 2019 upon dosing of the first subject in the SCD Phase 1 clinical study, and are eligible to earn additional development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is $276.3 million. In addition, we will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by (i) us or Sanofi for the uncured material breach of the other party, (ii) us or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii) Sanofi, upon 180 days&#8217; advance written notice to us and (iv) Sanofi, for certain safety reasons upon written notice to, and after consultation with, us.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2012, we entered into a collaboration and license agreement with Shire International GmbH, a wholly-owned subsidiary of Takeda, which we amended and restated in September 2015, to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on our ZFP technology. We received an upfront license fee of $13.0 million in 2012 and achieved a $1.0 million milestone in 2014. Pursuant to the amended and restated agreement, Takeda has an exclusive, worldwide license to ZFP therapeutics for treating Huntington&#8217;s disease.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended and restated agreement, Takeda has full control over, and full responsibility for the costs of, the Huntington&#8217;s disease program, subject to certain obligations, including the obligation to retain us to perform ZFP design, optimization and assessment services and to reimburse us for the costs of such services. Takeda does not have any milestone payment obligations but is required to pay single digit percentage royalties to us, up to a specified maximum cap, on the commercial sales of ZFP therapeutic products for Huntington&#8217;s disease. During the term of the amended and restated agreement, we are not permitted to research, develop or commercialize, outside of the agreement, certain products that target the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the amended and restated agreement, we have full control over, and full responsibility for the costs of, the hemophilia A and B programs returned to us by Takeda, subject to certain diligence obligations. We also granted Takeda a right of first negotiation to obtain a license to such programs under certain circumstances. We are required to pay single digit percentage royalties to Takeda, up to a specified maximum cap, on commercial sales of therapeutic products from the programs returned to us by Takeda.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amended and restated agreement may be terminated by (i) us or Takeda, in whole or in part, for the uncured material breach of the other party, (ii) us or Takeda for the bankruptcy or other insolvency proceeding of the other party and (iii) Takeda, in its entirety, effective upon at least 90 days&#8217; advance written notice.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Partnerships</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our partnerships for the development of human therapeutic applications, we have also licensed our technology in several other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering. These license partners include Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc. and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents, trade secrets, know-how and licenses are important to our business. Our strategy includes filing and licensing patents and patent applications to protect technology, inventions and improvements to inventions that we consider important for the development and commercialization of our genome editing and genome regulation technologies and our potential products. We have filed numerous patent applications with the U.S. Patent and Trademark Office, or U.S. PTO, and foreign jurisdictions. Our proprietary intellectual property includes methods relating to the design of zinc finger proteins, Transcription Activator-Like Effector, or TALE, proteins and Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR/Cas editing systems, therapeutic applications of genome editing technology, enabling technologies related to our platform and the use of genome editing across a variety of applications. We rely on a combination of patent, copyright, trademark, proprietary know&#8211;how, continuing technological innovations and trade secret laws, as well as confidentiality agreements, materials transfer agreements, research agreements and licensing agreements, to establish and protect our proprietary rights.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">In-Licensed Technology</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exclusively licensed certain intellectual property directed to the design, selection, and use of ZFPs, ZFNs and ZFP-TFs for genome editing and genome regulation from numerous academic institutions. Although no individual in-license is material to our overall protection of our ZFP and ZFN platforms, we believe in combination our in-licenses, in connection with our own knowhow, patent applications and patents protects us from third parties who might try to copy our products.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, with respect to our cell therapy products, our subsidiary, Sangamo France, has a license agreement with the University of British Columbia pursuant to which it exclusively licensed the right to the CAR for use in our TX200 product candidate. This license includes one patent family, which expires in September 2038, absent any patent term adjustment, patent term extension or terminal disclaimers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Intellectual Property</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our in-licensed patent portfolio, we have numerous issued patents and pending patent filings directed to the design, composition and use of ZFPs, ZFNs, ZFP-TFs, TALE proteins and CRISPR/Cas editing systems and other technologies related to our program.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given our two-decade history with zinc finger technology, some of the earliest zinc finger patents in our portfolio began expiring in 2015. However, we have continued to build on this patent portfolio and have been issued additional patents and have applications pending that provide protection for our ZFP technology. Additionally, patents that may be issued from our pending applications will extend the patent exclusivity of our patent estate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our licensed patents and patent applications, as well as our issued patents and pending patent applications, in the aggregate, will provide us with a substantial intellectual property position in our commercial development of our gene therapy, cell therapy and genome engineering programs. In this regard, patents issued to us, applied for by us, or exclusively and non-exclusively licensed to us, cover the following types of inventions, processes and products:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ZFP and ZFN design, engineered nucleases (e.g., CAS), and compositions (four patents issued with expiration dates ranging from 2029 to 2036), absent any PTA, PTE or TD):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes DNA target site selection, zinc finger binding domain design, nuclease domain design, linker design, DNA nickases, ZFP libraries databases and methods of construction, as well as methods to increase zinc finger binding specificity (see, e.g., US9982245, US10066242, US10113207);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">ZFP Therapeutics (three patents issued with expiration dates ranging from 2028 to 2031, absent any PTA, PTE or TD):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Methods relating to activation and inhibition of endogenous genes, identification of accessible regions within chromatin, including treatment of Huntington&#8217;s disease, HIV, cancer therapeutics, modulation of cardiac contractility and methods to regulate the glucocorticoid receptor (see, e.g., US9943565);</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Nuclease Therapeutics (12 patents issued with expiration dates ranging from 2031 to 2036, absent any PTA, PTE or TD):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Treatments for HIV, beta thalassemia and SCD, hemophilia inherited metabolic diseases, genome editing, Parkinson&#8217;s Disease, regulation of the expression of PD1; Immunomodulatory therapeutics; Cystic Fibrosis; CNS disease; Severe combined immunodeficiency, Modified T cells, including HLA knock out and methods of editing stem cells (see, e.g., US9877988, US9963715, US10072066, US10081661, US10143760); and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Non-Therapeutic Applications of ZFPs and Nucleases (seven patents issued with expiration dates ranging from 2028 to 2035, absent any PTA, PTE or TD):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Identification of regulatory sequences, analysis of gene regulation, structure and biological function, methods of agricultural biotechnology, methods of altering cellular differentiation state, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of cell lines for improved protein production, methods of transgenic animal development, engineering of stem cells, methods of genome editing (see, e.g., US9890395).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies, including our patent position, are uncertain and involve complex legal and factual questions for which important legal tenets are largely unresolved and are subject to interpretation and refinement by the court system. Patent applications may not result in the issuance of patents and the coverage claimed in a patent application may be significantly reduced before a patent is issued. Although we have filed for patents on some aspects of our technology, we cannot provide assurances that patents will be issued as a result of these pending applications or that any patent that has been or may be issued will be upheld. The laws of some foreign countries may not protect our proprietary rights to the same extent as do the laws of the United States.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the U.S. PTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The U.S. PTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business. We may not be able to protect our intellectual property rights throughout the world.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, third parties may assert patent, copyright, trademark, and other intellectual property rights to technologies that are important to our business. The outcome following any potential legal assertions of invalidity and unenforceability is unpredictable. Any claims asserting that our products infringe or may infringe proprietary rights of third parties, if determined adversely to us, could significantly harm our business. See &#8220;Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Risks Relating to Our Intellectual Property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITION</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and our biopharmaceutical collaborators, are leaders in the research and development of gene therapies, cell therapies and genome engineering therapies using ZFP DNA-binding proteins.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several other companies focused on other methods for editing genes and regulating gene expression and a limited number of commercial and academic groups pursuing the development of ZFP genome engineering technologies. The fields of gene therapy, cell therapy and genome engineering are highly competitive, and we expect competition to persist and intensify in the future from a number of different sources, including other biopharmaceutical companies; academic and research institutions; and government agencies that will seek to develop ZFPs as well as technologies that will compete with our ZFP technology platform, such as TALE proteins and the CRISPR-Cas editing system.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval or commercializing competitive products before us. If we commence commercial product sales, we may be competing against companies with greater marketing, sales, distribution and manufacturing capabilities, areas in which we have limited or no experience. In addition, any product candidate that we successfully develop may compete with existing products that have long histories of safe and effective use.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are in the clinical development phase of operations and have no current therapeutic product sales, we believe the following companies, products and/or technologies may potentially be competitive with our technology or our product candidates under development:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protein pharmaceuticals under development at pharmaceutical and biotechnology companies such as Pfizer, Bayer AG, Novo Nordisk A/S, Sanofi, Takeda, BioMarin Pharmaceutical Inc., or BioMarin, Biogen, Acceleron Pharma Inc., ArmaGen, Inc., Amicus Therapeutics, Inc., Protalix Biotherapeutics, Inc., F. Hoffman-LaRoche Ltd., Novartis AG, and numerous other biopharmaceutical firms.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gene therapy companies developing gene-based products in clinical trials. Orchard Therapeutics plc&#8217;s Strimvelis&#8482; (acquired from GlaxoSmithKline plc, or GSK) is approved in Europe, Spark Therapeutics, Inc.&#8217;s LUXTURNA&#8482; is approved in the United States and Europe, Novartis Gene Therapies&#8217; Zolgensma</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved in the United States, Europe and additional territories, and bluebird bio&#8217;s ZYNTEGLO&#8482; is approved in Europe. Other competitors in this category may include, but not be limited to, uniQure N.V., BioMarin, REGENXBIO Inc., Ultragenyx Pharmaceutical Inc., Voyager Therapeutics, Inc., Takeda, Pfizer, Freeline Therapeutics, Amicus Therapeutics, Inc., and Novartis AG.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cell therapy companies developing cell-based products. Novartis AG&#8217;s Kymriah&#8482; and Gilead&#8217;s Yescarta&#8482;, gene-modified cell-based therapies, are approved in both the United States and Europe, and Bristol Myers Squibb&#8217;s Breyanzi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved in the United States. Other competitors in this category may include, but not be limited to, Adaptimmune Therapeutics PLC, bluebird bio, Inc., Cellectis S.A., Sana, Lyell, Inc., Kite/Gilead, AvroBio, Inc., Medeor Therapeutics, Inc., CRISPR Therapeutics AG, Intellia Therapeutics, Inc., Casebia Therapeutics, Targazyme, Inc., ZIOPHARM Oncology, Inc., Tmunity Therapeutics, Inc., Caladrius Biosciences, Inc., TRACT Therapeutics, Inc., Cellenkos&#8482;, Inc., Regcell Co., Ltd., Allogene, Fate Therapeutics, NKarta Therapeutics and Bristol Myers Squibb.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Nuclease and base editing technologies under development for therapeutic applications of genome modification including companies such as Editas Medicine, Inc., CRISPR Therapeutics AG, Caribou Biosciences, Inc., Intellia Therapeutics, Inc. and Beam Therapeutics developing the CRISPR/Cas9 editing system, Cellectis S.A. developing TALE nucleases and meganucleases, bluebird bio, Inc. developing Homing Endonucleases and MegaTALs and Precision BioSciences, Inc. developing meganucleases.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Antisense therapeutics and RNA interference technology, including RNAi and microRNA, which are technologies that may compete with us in the development of novel therapeutic products acting through the regulation of gene expression. These technologies are being developed by several companies including Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Moderna, Inc., Sanofi and Regulus Therapeutics Inc.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Small molecules in development from both in-house drug discovery programs of pharmaceutical companies such as Pfizer, GSK, Novartis AG and Merck &amp; Co., Inc., as well as from biotechnology companies with expertise and capabilities in small molecule discovery and development such as Gilead, Sanofi, Bristol Myers Squibb, and Global Blood Therapeutics, Inc., which has an approved small molecule product for SCD.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Monoclonal antibody companies and product candidates from certain biotechnology firms such as Genentech, Inc. and Amgen Inc.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to face intense competition from other companies for collaborative arrangements with biopharmaceutical companies for establishing relationships with academic and research institutions, for licenses to proprietary technology and for subjects in our clinical trials of treatments for rare diseases. These competitors, either alone or with their collaborative partners, may succeed in developing technologies or products that are more effective or less costly than ours.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete successfully will depend, in part, on our ability to:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop safe, efficacious and commercially attractive proprietary products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain access to gene transfer technology on commercially reasonable terms;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain required regulatory approvals;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain reimbursement for our products in approved indications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain qualified scientific and product development personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enter into collaborative and strategic partnerships with others, including our competitors, to develop our technology and product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain and enforce patents, licenses or other proprietary protection for our products and technologies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">formulate, manufacture, market and sell any product that we develop;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop and maintain products that reach the market first and are technologically superior to or are of lower cost than other products in the market; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recruit subjects into our clinical trials in a timely fashion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely heavily on CMOs to produce our preclinical and clinical product candidates in accordance with FDA and EMA mandated regulations, also known as current good manufacturing practices, or cGMPs. We employ a technical operations staff in the areas of process development, analytical development, quality control, quality assurance, project management, and manufacturing to facilitate appropriate oversight of our CMOs, support of our regulatory filings and execution of clinical trials. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that in-house manufacturing capability can provide a competitive advantage. To this end, we have recently completed and brought online an AAV cGMP manufacturing facility in our headquarters building in Brisbane, California designed to manufacture Phase 1/2 clinical study supplies for our gene therapy pipeline. We are also building cell therapy manufacturing facilities in Brisbane, California and in Valbonne, France that we expect to become operational by the end of 2021.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after these in-house facilities are operational, we intend to continue to rely on CMOs for the manufacture of our product candidates for any Phase 3 clinical trials, and if approved, for commercial supply. We believe this balanced approach to manufacturing, investing in internal capacity and capabilities while strengthening our commitment to external capacity, will enable us to meet our anticipated pipeline needs. Additionally, in 2019 we signed an expanded services agreement with Brammer Bio MA, a Thermo Fisher Scientific, Inc. subsidiary, or Brammer, which provided us with access to dedicated AAV manufacturing capacity up to 2000-L bioreactor scale capable of handling large-scale, commercial-grade runs for products such as ST-920, our gene therapy product candidate for Fabry disease. The agreement also allows us to leverage Brammer&#8217;s viral vector manufacturing know-how in our Brisbane manufacturing facility that we believe will provide a seamless transition from early development to late-stage clinical trials and commercial-scale manufacturing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently leverage three distinct manufacturing platforms: AAV vector production for our genome engineering and gene therapy product candidates, HSPC modification for some of our cell therapy product candidates and engineered T cell therapies. We use a commercial scale baculovirus manufacturing platform to manufacture AAV vectors for genome editing and gene therapy, with each AAV vector packaging a different transgene specific to the target indication or ZFN. The manufacturing process for our HSPC cell therapy product candidates utilizes the patient&#8217;s own HSPCs. These HSPCs are transfected using mRNA to produce ZFNs that target specific DNA sites, resulting in modified HSPCs. The third platform utilizes our ZFN technology to transform CAR-Tregs for autologous and allogeneic cell therapies. With the acquisition of Sangamo France, we also added capabilities to manufacture regulatory T cells in therapeutic quantities to be used to treat inflammatory and autoimmune disorders.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate within the heavily regulated biopharmaceutical industry and much of our operations, including nonclinical and clinical trials, development, manufacturing, commercialization, marketing and reimbursement are subject to regulatory approvals. Relevant regulatory authorities include, but are not limited to, the FDA, the EMA, Commission of the European Union, or EU, Member State agencies, including the UK Medicines and Healthcare Products Regulatory Agency, or MHRA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Regulation </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the FDA regulates biologic products including gene therapy and human cellular therapy products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and regulations and guidance implementing these laws. The FDCA, PHSA and their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biologic products. Applications to the FDA are required before conducting human clinical testing of biologic products and in the EU, approval must be obtained from the EMA. FDA approval also must be obtained before marketing of biologic products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to obtain the required regulatory approvals.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accelerated Assessment</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A number of agencies, including the FDA and the EMA, have expedited development programs, including for innovative products and in areas of high unmet medical need, such as PRIME in the EU. These programs require a certain level of evidence demonstrating safety and efficacy in patients from early-stage clinical trials. Entry into one of these expedited programs may result in assistance with the scientific opinion and faster approval timelines. Some of these programs may offer joint approval and reimbursement advice. It is noted that even applications in an expedited development program may be assessed under standard timelines, where the regulatory authority deems that the program may no longer meet the requirements for priority review.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Biologic Products Development Process</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates must be approved by the FDA before they may be legally marketed in the United States. The process required by the FDA before a biologic product candidate may be marketed in the United States generally involves the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of preclinical laboratory tests and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies in accordance with the FDA&#8217;s current Good Laboratory Practice, or GLP, regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an IND application, which allows human clinical trials to begin unless FDA objects within 30 days;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board, or IRB, reviewing each clinical site before each clinical trial may be initiated;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials according to the FDA&#8217;s Good Clinical Practice, or GCP, regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biologic product candidate for its intended use;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation and submission to the FDA of a biologics license application, or BLA, for marketing approval that includes substantial evidence of safety and efficacy from results of nonclinical testing and clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review of the product by an FDA advisory committee, if applicable;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biologic product candidate is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the biologic product candidate&#8217;s identity, safety, strength, quality, potency and purity;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential FDA inspection of the nonclinical and clinical trial sites that generated the data in support of the BLA; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payment of user fees, if applicable, and FDA review and approval, or licensure, of the BLA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before testing any biologic product candidate in humans, including a gene therapy product candidate, the product candidate must undergo preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies to assess the potential safety and activity of the product candidate and to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies usually must complete additional preclinical testing, that may include animal tests of reproductive adverse events and carcinogenicity, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human gene transfer protocols are subject to the FDA&#8217;s oversight and other clinical trial regulations, and oversight at the local level as set forth in National Institutes of Health, or NIH, Guidelines. Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. Compliance with the NIH Guidelines is mandatory for investigators at institutions receiving NIH funds for research involving recombinant DNA. However, many companies and other institutions, not otherwise subject to the NIH Guidelines, voluntarily follow them.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA also may impose clinical holds on a biologic product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical studies to begin, or that, once begun, issues will not arise that suspend or terminate such studies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU Drug Development Process</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States, the EU regulatory framework sets both EU-wide and national, Member State-specific requirements for the development and approval of medicinal products. Article 8(3) of Directive 2001/83/EC sets out the contents of a marketing authorization, or MA, application and all the information that must be submitted for the evaluation of a medicinal product. Certain preclinical (also termed &#8220;non-clinical&#8221;) data is required in order to enable clinical trials and later be used in dossier for a marketing authorization application. All studies should take place in accordance with GLP and all applicable EMA, Commission and European Pharmacopoeia guidelines on preclinical studies, including guidance on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requisite amount of preclinical data enables the design of a clinical trial, from Phase 1 (first-in-human clinical trials) through to Phases 2 and 3, which are safety and efficacy studies. Similar restrictions and requirements apply as in the United States regarding preclinical data to support trials using viral vectors. The preclinical tests should establish parameters such as toxicity, pharmacodynamics and pharmacokinetic properties, as well as the quality of the gene therapy medicinal products. Due to the particular nature of gene therapy medicinal products, it is recognized that it may not always be possible for the non-clinical safety studies to be in conformity with the principles of GLP and a proper justification should be submitted where a pivotal non-clinical safety study has not been conducted under GLP rules.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical studies are crucial to obtaining the required data and the requirements governing the conduct of clinical trials are further analyzed below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All medicinal products and advanced therapy medicinal products, or ATMPs, must be manufactured in accordance with the guidelines on Good Manufacturing Practice, or GMP, and in a GMP licensed facility, which can be subject to GMP inspections.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Human Clinical Trials Under an IND</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the biologic product candidate to patients under the supervision of qualified investigators which generally are physicians not employed by, or under, the control of the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject, or their legal representative, reviews and approves the study protocol, and must monitor the clinical trial until completed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials typically are conducted in three sequential phases that may overlap or be combined:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The biologic product candidate initially is introduced into a small number of human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early understanding of its effectiveness. Phase 1 clinical trials of gene and cell therapies are typically conducted in patients rather than healthy volunteers.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The biologic product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 3 clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a biologic product. In Phase 3 studies, the biologic product candidate is administered to an expanded patient population, generally at multiple geographically dispersed clinical trial sites in adequate and well-controlled clinical trials to generate sufficient data to statistically confirm the efficacy and safety of the product for approval. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. Sometimes approval for a product is conditional upon the completion of post-marketing clinical studies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During all phases of clinical development, regulatory agencies (such as the FDA, the EMA and other comparable regulatory agencies) require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written IND safety reports must be promptly submitted to the FDA and the investigators for: serious and unexpected adverse events; any findings from other trials, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> laboratory tests or </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggest a significant risk for human subjects; or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable safety risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biologic product candidate has been associated with unexpected serious harm to patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA usually recommends that sponsors observe subjects for potential gene therapy-related delayed adverse events for up to a 15-year period.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the EU, clinical trials almost always require approval from a national competent authority of the relevant Member State and an approval from an Ethics Committee. If the medicinal product is considered to be a genetically modified organism, or GMO, then GMO approval must also be obtained. There is no harmonization between Member States regarding the approach to and timelines of GMO approval, which may result in the submission of additional information, which may impact study initiation in a given country.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conduct of clinical trials should follow the approved clinical trial protocol and be in accordance with the principles of GCP. Gene therapy medicinal products are in addition subject to the rules of GCP for ATMPs, which outline specific additional safeguards and requirements. Record retention requirements are increased for ATMPs as there are relevant long-term follow-up and human safety and traceability requirements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with cGMP Requirements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of biologics must comply with applicable current Good Manufacturing Practices, or cGMP, regulations, including quality control and quality assurance and maintenance of records and documentation. Manufacturers and others involved in the manufacture and distribution of such products also must register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Any material changes to the manufacturing equipment, process or location of the approved manufacturing site must be reported to the relevant agency/authority. Establishments may be subject to periodic, unannounced inspections by government authorities (including regulatory agencies) to ensure compliance with cGMP requirements and other laws. Discovery of problems may result in a government entity placing restrictions on a product, manufacturer or holder of an approved BLA, and may extend to requiring withdrawal of the product from the market, issue warning or similar letters or seeking civil, criminal or administrative sanctions against the company. The </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FDA will not approve a BLA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specification.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies develop additional information about the physical and biological characteristics of the product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or of causing other adverse events with the use of biologic products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biologic product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biologic product candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a product candidate that is also a human cellular or tissue product, the FDA also requires compliance with current Good Tissue Practices, or cGTPs. These are FDA regulations that govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissues and cellular and tissue-based products, or HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Review and Approval Processes</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of the preclinical tests and clinical trials, together with detailed information relating to the product&#8217;s Chemistry, Manufacturing and Controls, or CMC, and proposed labeling, among other things, are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for approved biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business or for a product indication for orphan diseases.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews a BLA within 60 days of submission to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In that event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth, substantive review of the BLA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and effective, for its intended use and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the product approval process, the FDA also will determine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the product candidate. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events, and whether the product is a new molecular entity. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product candidate unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product candidate within required specifications. Additionally, before approving a BLA, the FDA typically will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the biologic product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post-marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biologic product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has agreed to specified performance goals in the review of BLAs under the PDUFA. One such goal is to review standard BLAs in 10 months after the FDA accepts the BLA for filing, and priority BLAs in six months, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EU Review and Approval Process</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a medicinal product can be placed on the market in the EU, it must have received an MA. This could either be at national or EU level under a mutual recognition, decentralized or centralized procedure. Our product candidates are innovative treatments, which will bear the classification of ATMP. As such, the appropriate authorization procedure is the centralized procedure, which involves an MA being granted by the European Commission following a positive opinion by the EMA. A centralized MA is simultaneously valid in all EU Member States and the European Economic Area, or EEA, (Iceland, Liechtenstein and Norway). A centralized MA also results in a single set of product information (patient information leaflet, labelling and summary of product characteristics) for all EU Member States.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timeline for the grant of a centralized MA since the time of the application is 210 days for the assessment of the application (including &#8220;clock stops&#8221; for the applicant to prepare answers to the questions from the EMA). The Committee for Medicinal Products for Human Use, or the CHMP, may either provide a positive or negative opinion. Following a positive opinion, the European Commission will usually issue its legally binding MA after 67 days. A negative opinion may be appealed by the applicant who must submit a request for re-examination within 60 days. There is the possibility for accelerated timelines of drug applications for eligible applicants, which can reduce the timeline to 150 days, if the applicant can produce sufficient justification.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the MA application contains less comprehensive than the required standard as at the time of the application, when there are public health grounds and often in the case of orphan medicinal products, the EMA may recommend to the European Commission that it issues a different type of an MA, as follows: (a) a Conditional MA (valid for one year and renewable), when the medicinal product shows a positive benefit-risk balance and targets an unmet medical need and it is expected that the applicant will be able to provide comprehensive data in due course; or (b) an MA under &#8216;exceptional circumstances&#8217;, when it is not expected that the applicant will be able to provide comprehensive efficacy and safety data (often for very rare indications).</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing Regulation in Europe</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various requirements apply to the manufacturing and placing on the EU market of medicinal products. The manufacturing of medicinal products in the EU requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including EU cGMP standards. Similarly, the distribution of medicinal products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU member states. Marketing authorization holders may be subject to civil, criminal or administrative sanctions, including suspension of manufacturing authorization, in case of non-compliance with the EU or EU member states&#8217; requirements applicable to the manufacturing of medicinal products.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-approval Requirements</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rigorous and extensive FDA regulation of biologic products continues after approval, particularly with respect to cGMP requirements. Manufacturers are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post-approval requirements applicable to biologic products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record-keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA, together with a release protocol, showing a summary of the history of manufacture of the lot and the results of all tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biologic products. Failure to comply with the FDA&#8217;s post-approval regulations can result in withdrawal of product approval and licensure.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor also must comply with the FDA&#8217;s or appropriate national authority&#8217;s advertising and promotion requirements, such as the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off-label use&#8221;). Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan and RMAT designation</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products that are intended for treating rare conditions that affect fewer than 200,000 people in the U.S., or that affect more than 200,000 persons but are not expected to recover the costs of developing and marketing a treatment drug, may qualify for orphan designation. In the EU, these rare conditions are defined as having a prevalence of no more than five in every 10,000 people in the EU. Once a medicinal product with orphan designation obtains a marketing approval, it can benefit from a marketing exclusivity period in respect of the specific orphan indication for which the drug has been approved for a period of seven years in the U.S. and for up to 10 years in the EU. If the manufacturer is no longer able to assert that the product meets the orphan designation criteria or is not able to provide sufficient quantities, it may lose the orphan market exclusivity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regenerative medicine advanced therapy, or RMAT, designation is intended to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates the potential to address unmet medical needs for such a disease or condition. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RMAT designation provides potential benefits that include more frequent meetings with the FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review of the related BLA. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. However, RMAT designation does not change the FDA&#8217;s standards for product approval. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Trial Data Disclosure</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many jurisdictions have mandatory clinical trial information obligations on sponsors. In the EU this is under the Transparency Regulation No. 1049/ 2001, EMA Policy 0043, EMA Policy 0070, as well as the new Clinical Trials Regulation No. 536/2014, all of which impose on sponsors the obligation to make publicly available certain information stemming from clinical studies. In the EU, the transparency framework provides for a wide right for (EU-based at the moment) interested parties to submit an access to documents request to the EMA for information included in the marketing authorization application dossier for approved medicinal products. Only very limited information is exempted from disclosure (i.e., commercially confidential information, which is construed increasingly narrowly and protected personal data). It is possible for competitors to access and use this data in their own research and development programs anywhere in the world, once these data are in the public domain.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation of Our Operations</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we currently do not have any products on the market, we may be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal civil and criminal false claims laws, including the federal False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit, among other things, knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by certain healthcare providers, health plans and healthcare clearinghouses, known as covered entities, and individuals and entities that perform services for them that involve individually identifiable health information, known as business associates as well as covered subcontractors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Physician Payments Sunshine Act created under the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, which requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare and Medicaid Services, or CMS, information related to payments and other transfers of value to physicians, currently defined to included doctors, dentists, optometrists, podiatrists and chiropractors, and teaching hospitals, and ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to physician assistants, nurse practitioners, clinical nurse specialists, anesthesiologist assistants, certified registered nurse anesthetists and certified nurse midwives during the previous year;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, require drug manufacturers to report information related to payments and other transfers of value to other healthcare providers and healthcare entities, marketing expenditures; or drug pricing; and/or ensure the registration of sales personnel; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state and foreign laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to significant penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs, imprisonment, suspension or withdrawal of our marketing and commercialization in respect of our commercially approved products, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of which could adversely affect our ability to operate our business and our financial results. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Any such investigation or settlement could increase our costs or otherwise have an adverse effect on our business. See &#8220;Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Our current and future relationships with healthcare providers, customers and third-party payors subject us to applicable anti-kickback, fraud and abuse, privacy, data security and other healthcare laws and regulations. If we fail to comply with such regulations, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare Reform </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. and some foreign jurisdictions are considering enacting or have enacted a number of additional legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our product candidates profitably, if approved. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts, which include major legislative initiatives, such as the ACA, to reduce the cost of care through changes in the healthcare system, including limits on the pricing, coverage, and reimbursement of pharmaceutical and biopharmaceutical products, especially under government-funded health care programs, and increased governmental control of drug pricing. The ACA and its implementing regulations, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including products similar to our product candidates, that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, created a new Patient Centered Outcomes Research Institute, which provides incentives to programs that increase the federal government&#8217;s comparative effectiveness research, established a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D, and created a licensure framework for follow-on biologic products.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There remain legal and political challenges to certain aspects of the ACA, as well as efforts to repeal or replace certain aspects of the ACA. Several bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, included a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. In addition, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated &#8220;Cadillac&#8221; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminates the health insurer tax. In addition, the Bipartisan Budget Act of 2018, or the BBA, among other things, amended the ACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans, commonly referred to as the &#8220;donut hole.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Act. Additionally, on December 18, 2019, the U.S. Court of Appeals for the 5th Circuit upheld the District Court ruling that the individual mandate was unconstitutional and remanded the case back to the District Court to determine whether the remaining provisions of the ACA are invalid as well. The United States Supreme Court is currently reviewing this case, although it is unclear when a decision will be made.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013, and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2029 unless additional Congressional action is taken. However, pursuant to COVID-19 pandemic relief legislation, these Medicare sequester reductions are suspended from May 1, 2020 through March 31, 2021 due to the COVID-19 pandemic. In January 2013, the American Taxpayer Relief Act of 2012, or the ATRA, was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. At the federal level, the Trump administration&#8217;s budget proposal for fiscal year 2021 included a $135 billion allowance to support legislative proposals seeking to reduce drug prices, increase competition, lower out-of-pocket drug costs for patients, and increase patient access to lower-cost generic and biosimilar drugs. On March 10, 2020, the Trump administration sent &#8220;principles&#8221; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary out-of-pocket pharmacy expenses, provide an option to cap Medicare Part D </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">beneficiary monthly out-of-pocket expenses, and place limits on pharmaceutical price increases. Further, the Trump administration released a &#8220;Blueprint&#8221; to lower drug prices and reduce out-of-pocket costs of drugs that contained proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers. On July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result, the FDA released a final rule on September 24, 2020, effective November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, the U.S. Department of Health and Human Services, or HHS, finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. On November 20, 2020, CMS issued an interim final rule implementing President Trump&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. On December 28, 2020, the United States District Court in Northern California issued a nationwide preliminary injunction against implementation of the interim final rule. It is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the EU and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the EU will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pricing, Coverage and Reimbursement</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement of a therapeutic product will largely determine the affordability of the product, and whether the product is prescribed and supplied to patients and private insurance companies may take into account government reimbursement methodologies. Due to these proposed and enacted laws, as well as other actions, significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval, particularly for novel products. In both domestic and foreign markets, sales and reimbursement of any approved products will depend, in part, on the extent to which third-party payors, such as government health programs, commercial insurance and managed healthcare organizations provide coverage, and establish adequate reimbursement levels, for such products. Third-party payors are increasingly challenging the prices charged for medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Additionally, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. If third-party payors do not consider our products to be cost-effective compared to other therapies, these payors may not cover our products after approved as a benefit under their plans or, if they do, the level of reimbursement may not be sufficient to allow us to sell our products on a profitable basis. See &#8220;Risk Factors&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement are the prerogative of Member States. Therefore, the requirements around reimbursement of medicinal products can vary widely. Each Member State can follow its own approach, subject to common rules of transparency, competition, and freedom of trade and movement in the EU. Many Member States, including France, Germany and the United Kingdom, follow a health technology assessment, or HTA, procedure for medicinal products in order to assess the cost-effectiveness of a product which could then be recommended for reimbursement under the national health services. There is increasingly exchange of information concerning HTAs on a voluntary basis among EU Member States. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the United Kingdom, the National Institute for Health and Care Excellence is the body which conducts HTAs and issues guidance to be followed by the regional health bodies called clinical commissioning groups.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environmental Regulation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. federal and state laws regarding safe working conditions, environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act, affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations. We may incur significant costs to comply with such laws and regulations now or in the future. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines. We believe that we are in material compliance with applicable environmental laws and regulations that continued compliance therewith will not have a material effect on our business. We cannot predict, however, how changes in these laws and regulations may affect our future operations.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Privacy Regulation</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are required to comply with privacy and data security laws in the United States and in other foreign jurisdiction in which we operate, such as the EU General Data Protection Regulation, or GDPR, and the California Consumer Privacy Act of 2018, or CCPA, which apply to the collection, use, disclosure, transfer, or other processing of personal data.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection, use, disclosure, transfer or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the GDPR, which became effective on May 25, 2018. The GDPR, which is wide-ranging in scope, imposes several requirements on us relating to, among other things, the control over personal data by individuals to whom the personal data relates; notice we must provide to individuals regarding our processing of their personal data; the documentation we must maintain; the security and confidentiality of the personal data; data breach notification; and the use of third-party processors in connection with the processing of personal data. The GDPR also imposes strict rules on the transfer of personal data out of the EU. The post-Brexit trade and cooperation agreement between the United Kingdom and the EU provides that transfers of personal data from the EU to the United Kingdom will not be treated as restricted transfers to a non-EU country for a period of up to six months from January 1, 2021. However, unless the EU Commission makes an &#8220;adequacy finding&#8221; with respect to the United Kingdom before the end of that transition period, from that date the United Kingdom will be a &#8220;third country&#8221; under the GDPR, and transfers of personal data from the European Economic Area to the United Kingdom will require an &#8220;adequacy mechanism,&#8221; such as the Standard Contractual Clauses. The GDPR authorizes the imposition of large penalties for noncompliance, including the potential for fines of up to &#8364;20 million or 4% of the annual global revenue of the noncompliant company, whichever is greater. The GDPR requirements related to international data transfers apply not only to third-party transactions, but also to transfers of information between us and our subsidiaries such as Sangamo France, including employee information. The GDPR has increased our responsibility and potential liability in relation to personal data that we process compared to prior EU law, particularly in light of our acquisition of Sangamo France, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, which could divert management&#8217;s attention and increase our cost of doing business. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite our ongoing efforts to bring our practices into compliance with the GDPR, we may not be successful either due to various factors within our control or other factors outside our control. It is possible that local data protection authorities may interpret the GDPR in different ways, leading to potential inconsistencies in the requirements we must meet in different EU member states. Any failure or alleged failure (including as a result of deficiencies in our policies, procedures or measures relating to privacy, data security, marketing or communications) by us to comply with laws, regulations, policies, legal or contractual obligations, industry standards or regulatory guidance relating to privacy or data security may result in governmental investigations and enforcement actions, litigation, fines and penalties or adverse publicity. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, California adopted the CCPA, which became effective in January 2020. The CCPA establishes a privacy framework for covered businesses, including an expansive definition of personal information and data privacy rights for California residents. The CCPA includes a framework with potentially severe statutory damages and private rights of action. The CCPA requires covered businesses to provide new disclosures to California consumers (as that word is broadly defined in the CCPA), provide such consumers new ways to opt-out of certain sales of their personal information and allow for a new cause of action for data breaches. It remains unclear how the CCPA will be interpreted, but as currently written, it will likely impact our business activities and exemplifies the vulnerability of our business not only to cyber threats but also to the evolving regulatory environment related to personal data. As we expand our operations, the CCPA may increase our compliance costs and potential liability. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CCPA itself will be expanded substantially effective January 1, 2023, as a result of California voters approving the California Privacy Rights Act of 2020, or CPRA, on the November 2020 ballot, which will, among other things, establish the California Privacy Protection Agency to implement and enforce the new law, as well as impose administrative fines. Some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the United States. Other states are beginning to pass similar laws.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations. Furthermore, the laws are not consistent, and compliance in the event of a widespread data breach is costly. See &#8220;Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;Our current and future relationships with healthcare providers, customers and third-party payors subject us to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations. If we fail to comply with federal, state and foreign laws and regulations, including healthcare, privacy and data security laws and regulations, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HUMAN CAPITAL MANAGEMENT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Mission &amp; Our Employees</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Sangamo, we are committed to translating ground-breaking science into genomic medicines that transform patients&#8217; lives. We are a passionate group of biotechnology professionals based in the United States, France and the United Kingdom with years of experience and technical expertise, committed to developing best-in-class genomic medicines. We embrace collaboration, discipline and efficiency while welcoming fresh ideas and stimulating personal development. We encourage and embrace diversity and believe it enhances our work towards one common goal: to transform the lives of the patients we aim to serve.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We view our employees as one of our most valuable assets in serving our mission. We compete in the highly competitive biotechnology industry, and attracting, retaining and developing a diverse group of talented employees is crucial to our strategy and our ability to compete effectively. We need to grow the size of our organization in order to support our current research, product development, manufacturing and regulatory efforts and our plans for commercializing our wholly-owned product candidates when approved. This growth is critical to our success. There currently is a shortage of skilled individuals with substantial experience discovering, developing and manufacturing genomic medicines, which is likely to continue. As a result, competition for these individuals is intense and the turnover rate can be high. We face substantial competition among numerous biopharmaceutical companies and academic institutions for individuals with these skills. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Values</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe success comes when we and our employees align our core values with our mission to translate our ground-breaking science into genomic medicines that transform patients&#8217; lives. Our core values are:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Patient Centric</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Patient welfare is the rule against which we measure our actions and decisions. Before making decisions affecting patients, we work to understand their needs and experiences. Our focus on patients is a source of competitive advantage: it sharpens our research and development efforts and guides us to develop important medicines.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Teamwork &amp; Accountability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We seek appropriate input across our company to make better decisions and achieve our goals. We treat one another with respect and expect a great deal of each other. We honor our commitments.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Innovation &amp; Excellence</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The bold pursuit of technological advancement and scientific breakthrough is our foundation. We are also a company where individuals can flourish, grow and develop their expertise. We celebrate our successes and the personal and professional accomplishments of our colleagues.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Urgency &amp; Efficiency</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We make decisions quickly and thoughtfully; we decentralize decision making authority appropriately to foster ownership and action. We define our priorities clearly, communicate them and move forward decisively. We commit to achieving or surpassing performance objectives, and we celebrate exceeding the expectations of our colleagues and stakeholders.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Management of Human Capital</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recently hired our first Chief People Officer in September 2020 to lead our human resources function and to expand our programs to recruit, retain and develop our employees. As of December 31, 2020, our global human resources function was comprised of nine full time human resources professionals.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To manage our human resources, we track and report internally on key talent metrics including headcount by business unit and country, historical headcount growth, turnover, new hires and terminations, open roles and employee demographics including gender, race and ethnicity. Our senior executives use these metrics to assist with resource planning, recruitment and retention initiatives and design of compensation and benefits programs. We share these metrics quarterly with the Compensation Committee of our Board of Directors to assist it in fulfilling its duties to (a) establish our enterprise compensation philosophy, (b) administer our compensation and benefit plans, (c) evaluate the performance of our executive officers and key employees and (d) review and monitor management development and succession plans.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had 413 full time employees located in the United States, France and the United Kingdom. Of these employees, 349 are located in the United States, primarily in the San Francisco Bay Area, 57 are located in Valbonne, France and the remaining 7 are located near London, United Kingdom. Of these employees, 185 were primarily engaged in research and development activities, 140 were primarily engaged in technical operations and manufacturing and 88 were primarily engaged in general and administrative activities. We also engage the services of independent contractors and consultants as needed for special or temporary projects or specific expertise.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Commitment to Diversity, Equity &amp; Inclusion</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strongly believe in a diverse workplace where all Sangamo employees can thrive in an inclusive environment free from discrimination, harassment, bias and prejudice. We aim to treat all individuals with respect and dignity and to provide all Sangamo employees with equal opportunity and fair treatment based on merit. By embracing diversity and inclusion, we create an organization committed to working together to develop innovative solutions in support of the Sangamo mission consistent with our values. At Sangamo, we cultivate a culture and environment where different backgrounds and perspectives are not only respected and heard, but embraced and celebrated. Not only is a diverse, equitable and inclusive mindset and culture critical to an engaged and committed workplace, but it is also imperative to understanding and meeting the needs of the patients we seek to help with our medicines.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, with the support of our Board of Directors and Chief Executive Officer, we convened a Diversity, Equity and Inclusion, or DEI, working group comprised of a diverse group of employees tasked with designing and implementing specific initiatives to promote greater diversity, equity and inclusion at Sangamo worldwide, including potential amendments to our company values to reflect our commitment to these ideals and the launch of a corporate social responsibility scorecard tracking our DEI initiatives. We also have engaged an experienced DEI consultant to help survey our employee population and advise us on the design and planning of new DEI initiatives based on this input and external benchmarking. In 2021, we expect to implement these measures, institute new DEI tracking and benchmarking and increase our focus on DEI in recruitment and retention initiatives. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, women accounted for the following approximate percentages of our full-time employees: 51% globally; 48% in the United States; 65% in France and 71% in the United Kingdom. As of December 31, 2020, our employee records indicate that approximately 57% of our full-time U.S. employees identify as non-white.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Compensation &amp; Benefits</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the highly competitive nature of our industry and the importance of recruitment and retention to our success, we strive to furnish our employees with what we believe is a very competitive and comprehensive total rewards package of compensation, benefits and services. This package includes at or above-market pay; healthcare benefits for employees and family members; a health savings account for eligible U.S. employees with above market employer contributions; generous paid time off benefits; family leave; flexible work schedules; contributions to retirement and/or pension plans; mental health benefits and onsite services. In addition, we offer every full-time employee globally the benefit of equity ownership in the company through stock option grants and/or restricted stock units. Our U.S. employees are also eligible to participate in an employee stock purchase plan, which offers the opportunity to purchase our common stock at a discount of at least 15%.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Efforts to Address the COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee safety and wellbeing is of paramount importance to us in any year and was of particular focus in 2020 in light of the evolving COVID-19 pandemic. In response to the pandemic, we have supported our employees and government efforts to curb the COVID-19 pandemic through safety and communication efforts and investments, which include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Creating a COVID-19 task force responsible for establishing COVID-19, safety protocols and regularly communicating updates to all employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A strict working from home policy in the U.S., in which all work that can be done from home, must be done from home;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Decreasing density and increasing physical distancing in our facilities for employees working onsite using scheduling adjustments and flexibility&#894;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Mandatory weekly COVID-19 testing for all onsite employees in our U.S. facilities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Robust cleaning protocols across all locations&#894;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provision of masks to all onsite employees and strict masking requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Rigorous procedures to address actual and suspected COVID-19 cases and potential exposure&#894; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prohibition of all domestic and international non-essential travel for all employees.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, from time to time we have instituted additional programs during the pandemic to support our employees, including monthly subsidies to all employees for home office expenses and upgrades, mental well-being private coaching and therapy services.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks &amp; Tradenames</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SANGAMO&#174;, Better Therapeutics By Design&#174;, ZFP Therapeutic&#174; and Engineering Genetic Cures&#174; are our registered trademarks in the United States and Sangamo Therapeutics&#8482; and Pioneering Genetic Cures&#8482; are our trademarks. All other trademarks or trade names referred to in this Annual Report on Form 10-K are the property of their respective owners.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our website is located at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sangamo.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge on our website as soon as reasonably practicable after we electronically file this material with, or furnish it to, the Securities and Exchange Commission, or SEC. Information found on, or accessible through, our website is not a part of, and is not incorporated into, this Annual Report on Form 10-K. In addition, the SEC maintains a website at www.sec.gov that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i24672e5030474c1ba9673ec16c177662_19"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A &#8211; RISK FACTORS</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business involves significant risks, some of which are described below. Before making investment decisions regarding our common stock, you should carefully consider these risks, as well as the other information in this Annual Report on Form 10-K, including our financial statements and the related notes and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; The occurrence of any of the events or developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price. In such event, the market price of our common stock could decline, and you could lose all or part of your investment. In addition, there are also additional risks not described below that are either not presently known to us or that we currently deem immaterial, and these additional risks could also materially impair our business, operations or market price of our common stock.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Research, Development, Regulatory Approval and Commercialization of Our Product Candidates and Technologies</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends substantially on clinical trial results demonstrating safety and efficacy of our product candidates to the satisfaction of regulatory authorities. We may be unable to obtain positive clinical trial results and regulatory approvals for any of our product candidates. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company with no approved products and no product revenues. We have ongoing clinical trials evaluating product candidates that use</span><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> our platform technologies in gene therapy and cell therapy and we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="background-color:#ffffff;color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">anticipate initiating additional clinical trials in the future on other product candidates.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are substantially dependent on the results of these clinical trials, and there is no guarantee that final results of clinical trials conducted on our product candidates now or in the future will demonstrate the safety and efficacy of any of our product candidates. In addition, none of our product candidates have obtained regulatory approval. Obtaining positive clinical trial results and regulatory approvals is expensive, lengthy, challenging and unpredictable and may never occur for any of our product candidates. If we fail to obtain positive clinical trial results and regulatory approvals for our product candidates, our anticipated revenues from our product candidates and our prospects for profitability would be adversely affected, which would likely cause the market price of our common stock to significantly decline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conducting clinical trials and obtaining regulatory approvals is complex and exposes our business to numerous risks, including potential unexpected costs and delays.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates to the satisfaction of regulatory authorities in order to obtain regulatory approvals necessary for commercialization. We have limited experience in conducting later stage clinical trials and may not possess the necessary resources and expertise to complete such trials. Clinical trials are expensive, lengthy and unpredictable. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage. Events that may prevent successful or timely completion of clinical development and regulatory approval include, among others:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching a consensus with regulatory authorities on clinical trial design;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in reaching agreement on acceptable terms with prospective clinical research organizations, or CROs, and clinical trial sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in opening clinical trial sites or obtaining required institutional review board, or IRB, or independent ethics committee approval at each clinical trial site;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in recruiting and enrolling suitable patients to participate in our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in clinical trial activities due to the evolving COVID-19 global pandemic and the diversion of healthcare resources to fight the pandemic, such as the delays that have previously impacted clinical trial timelines for our Fabry and TX200 programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of clinical holds by regulatory authorities as a result of serious adverse events or after an inspection of clinical trial operations or trial sites;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to perform in accordance with the Good Clinical Practice regulations of the U.S. FDA, or applicable regulatory guidelines in the EU and other countries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions, or as a result of manufacturing or formulation changes to our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in having patients complete participation in a trial or return for post-treatment follow-up;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial sites or patients dropping out of a trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">selections of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrences of serious adverse events or other safety concerns associated with product candidates that are viewed to outweigh their potential benefits, result in approval delays or other regulatory restrictions, or harm our reputation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">occurrences of serious adverse events or other safety concerns in clinical trials of the same class of agents conducted by other sponsors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failures to demonstrate that product candidates are safe and effective for their proposed indication;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected costs and expenses and lack of sufficient funding to develop our product candidates; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">losses of licenses to critical intellectual properties.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not yet reached agreement with regulatory authorities on the complete development pathway for certain product candidates, and such authorities have the ability to change decisions or guidance with respect to approvable endpoints, particularly as the technology continues to develop in these areas. For example, we are aware of another company developing a gene therapy to treat hemophilia A that the FDA recommended complete its Phase 3 study and submit two-year follow-up safety and efficacy data on all study participants notwithstanding the company&#8217;s contention that it and the FDA had previously agreed on the extent of data necessary to support a BLA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the novelty of certain product candidates and their technologies, the endpoints needed to support regulatory approvals will likely be different from those originally anticipated. Any inability to successfully complete preclinical and clinical development of our product candidates, or complete such trials in the time frames anticipated, could result in additional costs to us or impair our ability to generate revenues from product sales or achieve regulatory and commercialization milestones and royalties, or shorten any periods during which we may have exclusivity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product candidate successfully obtains approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. Also, any regulatory approval of our product candidates, once obtained, may be withdrawn. If we are unable to obtain and maintain regulatory approvals for our product candidates in one or more jurisdictions, or if any approval contains significant limitations, we would not be able to generate anticipated revenues and may struggle to become profitable, which would have an adverse effect on our business operations and financial conditions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Success in research and preclinical studies or early clinical trial results may not be indicative of results obtained in later trials. Likewise, preliminary, initial or interim data from clinical trials may be materially different from final data.   </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Results from research and preclinical studies or early clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical trial are not necessarily indicative of final results. Our product candidates may fail to show the desired safety and efficacy in clinical trials despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials or preliminary stages of clinical trials. From time to time, we have and may in the future publish or report preliminary, initial or interim data. Preliminary, initial or interim data from our clinical trials and those of our collaborators may not be indicative of the final results of the trial and are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and/or more patient data become available. In this regard, such data may show initial evidence of clinical benefit, but as patients continue to be followed and more patient data becomes available, there is a risk that any therapeutic effects will not be durable in patients and/or will decrease over time, or cease entirely. Preliminary, initial or interim data also remain subject to audit and verification procedures that may result in the final data being materially different from such preliminary, initial or interim data. As a result, preliminary, initial or interim data should be considered carefully and with caution until the final data are available. For example, there can be no assurance that the steady-state FVIII levels shown in the preliminary follow-up data presented in December 2020 by Pfizer and us from the Phase 1/2 Alta study of giroctocogene fitelparvovec will persist in future follow-up or any other data from the Alta study, or that giroctocogene fitelparvovec will ultimately demonstrate a clinical benefit in the final results of the Alta study or in the Phase 3 AFFINE clinical trial of giroctocogene fitelparvovec.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that any of our pending clinical trials will be successful. Many of our product candidates currently use our ZFP technology platform, including ZFN and ZPT-TF technologies, which has not yet yielded any approved therapeutic products. Moreover, many of our product candidates are preclinical and have never demonstrated any clinical benefit. In addition, our viral delivery systems continue to evolve and have not been used in any approved products. If our product candidates using our ZFP technology platform and viral delivery systems are not able to demonstrate the safe, effective and durable results we are hoping to see in clinical trials, we may be forced to suspend or terminate development of some or all of our product candidates or seek alternative technologies to develop or deliver product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there is a high failure rate for product candidates proceeding through clinical trials. Many companies in the biopharmaceutical industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. Any such setbacks could adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are subject to a lengthy and unpredictable regulatory approval process in each jurisdiction where approval is sought.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A regulatory authority such as the FDA or the EMA must approve any human therapeutic product before it can be marketed in the jurisdiction it governs. The process for receiving regulatory approval is lengthy and unpredictable, and a product candidate may not withstand the rigors of testing under the process. Before commencing clinical trials in humans in the United States, we must submit an IND, to the FDA. Certain countries outside of the United States have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial authorization, or CTA, must be submitted for each clinical protocol to each country&#8217;s national health authority and an independent ethics committee. Only after an IND becomes effective and/or the applicable CTA has been accepted may clinical trials begin. See &#8220;Business&#8212;Government Regulation&#8221; for details regarding the regulatory approval processes applicable to our product candidates. While there is some overlap, the regulatory requirements to conduct clinical trials and seek marketing approval vary by jurisdiction. There is no guarantee that the safety studies and other data generated will be sufficient to permit us to conduct clinical trials in all jurisdictions where planned, or once generated, that such clinical trial data will be sufficient to obtain marketing approval in all jurisdictions in which we intend to seek such approval. If we are not able to obtain the necessary regulatory approvals to conduct our clinical trials and commercialize our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates, or if such approvals are delayed or suspended, our business, prospects and market price of our common stock would be adversely affected. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to identify, qualify and enroll sufficient patients for our clinical trials or complete our clinical trials in a timely manner, which could delay or prevent us from proceeding with the development of our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying, qualifying and enrolling patients in clinical trials of our product candidates, and completing these clinical trials, is critical to our success. Patient enrollment and trial completion is affected by factors including:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">size of the patient population and process for identifying patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design of the trial protocol;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">eligibility and exclusion criteria;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of the product candidate under study;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived risks and benefits of genomic approaches to treatment of diseases;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of competing therapies and clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential delays related to the evolving COVID-19 global pandemic and the diversion of healthcare resources to fight the pandemic;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">severity of the disease under investigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of genetic testing for potential patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">proximity and availability of clinical trial sites for prospective patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">required and desired characteristics of patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to obtain and maintain patient consent;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risk that enrolled patients will drop out before completion of the trial;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">patient referral practices of physicians; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ability to monitor patients adequately during and after treatment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of our clinical trials depends on our ability to recruit patients to participate as well as completion of required follow-up periods. There are also a number of other product candidates in development by our competitors, who compete for the same limited patient populations. If we are not able to enroll the necessary number of patients in a timely manner, we may not be able to complete our clinical trials on our desired timelines or at all. If fewer patients are willing to participate in our clinical trials because of negative publicity from adverse events related to genomic medicines, competitive clinical trials for similar patient populations or for other reasons, the timelines for conducting clinical trials of our product candidates may be delayed. These delays could result in increased costs, limitation or termination of clinical trials, and delays in product development timelines. If we are forced to expand to additional jurisdictions to address these challenges, it could impose additional costs, delays and risks. If we are not successful in conducting our clinical trials as planned, it would have an adverse effect on our business, financial condition, results of operations, prospects and market price of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in advancing product candidates from research programs to preclinical and clinical development.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to advance our product candidates from research programs through preclinical development and to submit new INDs, CTAs and equivalent filings in other jurisdictions necessary to conduct human clinical trials evaluating our product candidates. The preparation and submission of applications to conduct clinical trials requires us to conduct rigorous and time-consuming preclinical testing and studies and prepare documentation relating to, among other things, the toxicity, safety, manufacturing, chemistry and clinical protocols of our product candidates. We may experience unforeseen difficulties that could delay or otherwise prevent us from executing this strategy successfully. For example, we may encounter problems in the manufacturing of a product candidates and may fail to demonstrate consistency in the formulation of a product candidate. Our preclinical tests may produce negative or inconclusive results, which may lead us to decide, or which may lead regulators to require us, to conduct additional preclinical testing. If we cannot obtain positive results in preclinical testing, we may decide to abandon a product candidate altogether. In addition, our ability to complete and submit such applications to conduct clinical trials may depend on the support of our collaborators and the timely performance of their obligations under relevant collaboration agreements. If our collaborators are not able to perform such obligations or if they choose to slow down or delay the development of a product candidate, we may not be able to submit the clinical trial applications on a timely basis or at all. Furthermore, the submission of applications to conduct clinical trials involves significant cost and labor, and we may not have sufficient resources and personnel to complete the filing of all intended applications, which may force us to scale back the number of applications or forego potential applications that we believe are promising. Any delay, suspension or reduction of our efforts to pursue our preclinical and clinical development strategy could have an adverse effect on our business and cause the market price of our common stock to decline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Special regulatory designations, such as RMAT, or orphan drug designations, may not be available for our product candidates or may not lead to a faster development or regulatory review or approval process.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received RMAT, designation for our product candidate to treat severe hemophilia A. Additionally, some of our product candidates, including our product candidate to treat Fabry disease, have also been granted Orphan Drug Designation by the FDA, and some have also been designated Orphan Medicinal Products by the EMA. Regulatory authorities in some jurisdictions, including the United States and the EU, may designate drugs for relatively small patient populations as orphan drugs. For additional information regarding these special regulatory designations, see &#8220;Business&#8212;Government Regulation.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we request such designations for our other current or future product candidates, there can be no assurances that the FDA or the EMA will grant any of our product candidates such designations. Additionally, such designations do not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve, those product candidates, nor does it limit the ability of any regulatory agency to grant such designations to product candidates of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval. Such designations can also be revoked. RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges. Orphan drug exclusivity may be revoked if any regulatory agency determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the approved indications or commercial potential, or result in significant negative consequences following any potential marketing approval.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions, particularly as many of the diseases we are studying have complex comorbidities. If clinical experience indicates that a product candidate has side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results and financial condition.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and additional adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product development efforts are successful and even if the requisite regulatory approvals are obtained, our products may not gain market acceptance among physicians, patients, healthcare payors and the medical community.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the approved product may not gain market acceptance among physicians, healthcare payors, patients or the medical community. Market acceptance of approved products depends on a number of factors, including:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and safety of the product as demonstrated in clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the clinical indications and patient populations for which the product is approved;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance by physicians, treatment centers and patients of the product as a safe and effective treatment;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the adoption of novel genomic therapies by physicians, hospitals and third-party payors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential and perceived advantages of the product over alternative treatments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the safety of the product seen in a broader patient group, including its use outside the approved indications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on product use together with other medications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of market introduction of the product as well as competitive products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the development of manufacturing and distribution processes for the product;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of treatment in relation to alternative treatments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of coverage and adequate reimbursement and the willingness of patients to pay out-of-pocket in the absence of coverage or inadequacy of reimbursement by third-party payors and government authorities;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts and those of our collaborators.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved but fail to achieve market acceptance among physicians, patients, healthcare payors or treatment centers, we will not be able to generate significant revenues from the approved product, which would compromise our ability to become profitable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any approved products, such products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize them, which could harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels, which can affect demand for, or the price of, any approved product. Given the nature of the product candidates that we are developing, some patients may require treatment only one-time (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">., single dose administration), and there is substantial uncertainty about the pricing structure for such products, and the level of coverage and reimbursement that will be available for a shift to single-dose treatment as compared to chronic therapy over a patient&#8217;s lifetime. If other companies establish a new pricing structure or business model, including payment based on demonstration of long-term efficacy, our ability to price or obtain reimbursement for our products may be adversely affected. If such pricing structure or business model do not adequately fund the costs of our research and development, manufacturing and commercialization efforts, our business may be adversely affected.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to uncertainty about the potential pricing structure for certain of our product candidates, cost containment is a recurrent trend in the healthcare industry. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for certain medications. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. If reimbursement is not available or is available only at limited levels, we may be unable to successfully commercialize any product candidate for which we obtain regulatory approval. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for any approved products that we develop could have an adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform initiatives, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. Also, there has been heightened governmental scrutiny recently over biopharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for biopharmaceutical products. At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, have been designed to encourage importation from other countries and bulk purchasing. For a discussion of health reform activity and the current pricing framework, see &#8220;Business&#8212;Government Regulation&#8212;Healthcare Reform&#8221; and &#8220;&#8212;Pricing, Coverage and Reimbursement.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the demand for our product candidates, if we obtain regulatory approval;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of taxes that we are required to pay; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates or impose ongoing requirements for potentially costly post-approval studies, post-market surveillance or patient or drug restrictions. For example, the FDA typically advises that patients treated with gene therapy undergo follow-up observations for potential adverse events for a 15-year period. Additionally, the holder of an approved BLA is required to comply with FDA rules and is subject to FDA review and periodic inspections, in addition to other potentially applicable federal and state laws, to ensure compliance with cGMP and adherence to commitments made in the BLA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. Moreover, product labeling, advertising and promotion for any approved product will be subject to regulatory requirements and continuing regulatory review. Failure to comply with such requirements, when and if applicable, could subject us to a number of actions ranging from warning letters to product seizures or significant fines, among other actions. See &#8220;Business&#8212;Government Regulation&#8212;U.S. Review and Approval Processes&#8221; for more information.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of laws or regulations could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenues.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees or contractors may engage in misconduct or other improper activities, including noncompliance with research, development, manufacturing or regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk of fraud or other misconduct by our employees and contractors, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Misconduct by our employees and contractors could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter such misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, personal imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on other programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited resources and may forego or delay pursuit of certain research programs or product candidates that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities or pursue collaborations rather than retain sole responsibility for development. Our current and future research and development programs for product candidates may not yield any commercially viable products. The evaluation of the commercial potential or target market for a particular product candidate is forward-looking and based upon assumptions involving, for example and not limited to, market evolution, advances in disease </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standard of care, competition and reimbursement. This reliance on assumptions means that, if our assumptions prove to be inaccurate or incomplete, we may pursue opportunities that end up having a number of competitors that are more advanced than our product candidates, or we may relinquish valuable rights to a product candidate through strategic collaboration, licensing or other royalty arrangements in cases where it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. We may also allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration or that does not prove to have viable commercial opportunities. Any failure to use our financial and human resources efficiently could harm our business and operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ZFP technology is novel and has never been used to develop any approved, commercially viable therapeutic products.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ZFP technology is a novel technology which to date has not yielded any approved commercially viable therapeutic products, and there can be no guarantee that our product development efforts using ZFP technology will be fruitful. We have invested heavily in development of this technology, and our failure to develop approved, commercially viable products using ZFP technology would significantly limit our business and prospects and would adversely impact the market value of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to Manufacturing</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building manufacturing facilities for clinical trial supplies. We have limited experience manufacturing biopharmaceutical products, and there can be no assurance that we will be able to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to use both contract manufacturing organizations, or CMOs, and our own facilities to meet our projected needs for clinical trial supply. In 2020, we completed the construction of an AAV manufacturing facility in our Brisbane, California headquarters building to manufacture Phase 1/2 clinical study supplies for our gene therapy product candidates and we are building additional facilities in our headquarters building and in Valbonne, France to manufacture supplies for our cell therapy product candidates. We expect the cell therapy facilities to be operational by the end of 2021. Building these facilities requires us to transition manufacturing processes and know-how of our product candidates from our CMOs to our own facilities. Transferring manufacturing processes and know-how is complex and involves review and incorporation of both documented and undocumented processes that may have evolved over time. In addition, transferring production to different facilities may require utilization of new or different processes to meet the specific requirements of a given facility. Additional studies may also need to be conducted to support the transfer of certain manufacturing processes and process improvements. We cannot be certain that all relevant know-how and data has been adequately incorporated into the manufacturing process until the completion of studies and evaluations intended to demonstrate the comparability of material previously produced by CMOs with that generated by our facilities. Although some of our employees have experience in the manufacturing of biopharmaceutical products from prior employment at other companies, we, as a company, have no prior experience in biopharmaceutical product manufacturing, and operating these facilities will require us to comply with complex regulations and to continue to hire and retain experienced scientific, quality control, quality assurance and manufacturing personnel. Designing and building manufacturing facilities has been and will continue to be time-consuming and expensive, and we may experience delays or cost overruns. In addition, government approvals are required for us to operate manufacturing facilities and are time-consuming to obtain and maintain. As a manufacturer of biopharmaceutical products, we also will be required to demonstrate and maintain cGMP compliance. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Furthermore, establishing manufacturing operations will require a reallocation of other resources, particularly the time and attention of our senior management. Even if we are able to establish our own manufacturing capabilities, we could encounter challenges in operating the manufacturing facilities in compliance with cGMP, regulatory or other applicable requirements, resulting in potential negative consequences, including regulatory actions, which could undermine our ability to use these facilities for our own manufacturing needs. Any failure or delay in the development of our manufacturing capabilities could adversely impact the development of our product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The manufacture, storage and transport of our product candidates is complex, expensive, highly regulated and risky, which could hamper their commercial viability. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are significant risks associated with manufacturing, storing and transporting our product candidates including, among others, cGMP compliance, cost overruns, technical problems with process scale-up, specialized facilities, process reproducibility, stability issues, lot consistency, yields and timely availability of highly specific raw materials. Even though</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> product batches released for use in clinical trials undergo sample testing, some defects may only be identified following release. In addition, process deviations or unanticipated effects of approved process changes may result in these intermediate products </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not complying with stability requirements or specifications. Also, our product candidates must be stored and transported at temperatures within a certain range. If these environmental conditions deviate, our product candidates&#8217; remaining shelf-lives could be impaired or their efficacy and safety could be adversely affected, making them no longer suitable for use. Moreover, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product candidates that are biologics involving complex processes, including the development of cell lines or cell systems to produce the biologic, with the challenge of significant variability. There are difficulties in growing large quantities of such cells, consistently and sufficiently isolating certain types of cells and harvesting and purifying the biologic produced by them. The cost to manufacture biologics is generally far higher than traditional small molecule chemical compounds, and the manufacturing process can be difficult to reproduce.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, manufacturing, storing and transporting our product candidates is subject to strict regulatory standards, which adds additional production risk. Even if efficacy and safety data from our clinical trials would otherwise support regulatory approval of a product candidate, there is no assurance that we or our CMOs will be able to manufacture our product candidates to specifications at levels necessary to support or maintain regulatory approval by the FDA or other regulatory authorities. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus, there is no guarantee we will be successful in establishing a larger-scale commercial manufacturing process for our product candidates or obtaining the needed manufacturing capacity. Due to these manufacturing challenges, there is risk that some of our product candidates could be subject to inventory outages, reputational damage and product liability risks, and result in additional expense and delays to clinical trials and commercialization. Supply interruptions or shortages could result in potential negative impacts to our business, prospects and market price of our common stock. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we use chemical, biological or hazardous materials in a manner that causes injury or violates laws, we may be liable for damages.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals, and various radioactive compounds typically employed in the study of molecular and cellular biology. We routinely use cells in culture and gene delivery vectors, and we employ small amounts of radioisotopes in trace experiments. Although we maintain up-to-date licensing and training programs, we cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling, or disposal of these materials. In the event of contamination or injury, we could be held liable for damages that result, and any liability could exceed our resources. We currently carry insurance covering certain claims arising from our use of these materials. However, if we are unable to maintain our insurance coverage at a reasonable cost and with adequate coverage, our insurance may not cover any liability that may arise. We are subject to federal, state, and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Failure to comply with these laws and regulations could result in fines, penalties and additional liabilities and restrictions on our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently rely on third parties to conduct some or all aspects of manufacturing of our product candidates for preclinical and clinical development. If one of our third-party manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts, to find new suppliers or manufacturers.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have limited experience in clinical-scale manufacturing of our product candidates, and we rely in large part upon third-party CMOs to manufacture and supply drug product for our preclinical studies and clinical trials. Although we are in the process of establishing manufacturing facilities in Brisbane, California and Valbonne, France, these facilities will only manufacture limited quantities of our product candidates for our early-stage clinical trials. We intend to continue to rely on third parties for the manufacture of product candidates for later stage clinical trials, and for commercial-scale manufacturing for any approved product. The manufacture of biopharmaceutical products in compliance with the FDA&#8217;s cGMP requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of biopharmaceutical products often encounter difficulties in production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced cGMP requirements, other federal and state regulatory requirements and foreign regulations. If our manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to conduct later-stage clinical trials could be jeopardized. Any delay or interruption in the supply of clinical trial materials could delay the completion of our clinical trials, increase the costs associated with developing our product candidates and, depending upon the period of delay, require us to commence new clinical trials at significant additional expense or terminate the clinical trials completely.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our CMOs must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. We and our CMOs may be unable to comply with these cGMP requirements and with other FDA, state and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">foreign regulatory requirements. The FDA or similar foreign regulatory agencies may also implement new standards at any time or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. We have limited control over our manufacturers&#8217; compliance with these regulations and standards. Failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall or withdrawal of product approval. If the safety of any product supplied is compromised due to our manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of our product candidates, entail higher costs or impair our reputation.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current agreements with our CMOs do not provide for the entire supply of the drug product necessary for all anticipated clinical trials or for full scale commercialization. If we and our CMOs cannot agree to the terms and conditions for them to provide the drug product necessary for our clinical and commercial supply needs, we may not be able to manufacture the product candidate until a qualified alternative manufacturer is identified, which could also delay the development of, and impair our ability to commercialize our product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of third-party CMOs with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative CMOs, which could have an adverse effect on our business. New manufacturers of any product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and third parties on which we rely may be adversely affected by natural disasters and catastrophic or other events outside of our control, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster or event.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Natural disasters could severely disrupt our operations and our facilities, including our current and planned manufacturing facilities in Brisbane, California and Valbonne, France and the manufacturing facilities of our CMOs, and any disruption would likely have a negative impact on our business, financial condition, results of operations and prospects. If a natural disaster, pandemic or epidemic, including the evolving COVID-19 pandemic, political crisis, power outage or any other event that is out of our control occurred that prevented us or third parties on which we rely from using all or a significant portion of our or their facilities, that damaged critical infrastructure or that otherwise disrupted our or their operations, it may be difficult or, in certain cases, impossible for us to continue our business and operations for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and may not prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have an adverse effect on our business, financial condition, results of operations and prospects. Such disasters or events occurring at facilities of third parties on which we rely could also negatively impact our business and operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Industry</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are based on novel genomic medicine technologies, which makes it difficult to predict the timing and costs of development and of subsequently obtaining regulatory approval.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concentrated our research and development efforts on genomic medicine, consisting of gene therapy, gene-edited cell therapy and genome engineering. The regulatory approval process for novel product candidates such as ours is unclear and may be lengthier and more expensive than the process for other, better-known or more extensively studied product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse developments in clinical trials of genomic medicines conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulatory review committees and advisory groups, and any new guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our current or future product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be harmed. Even if our product candidates are approved, we expect that the FDA will require us to submit follow-up data regarding our clinical trial patients for a number of years after any approval. If this follow-up data shows negative long-term safety or efficacy outcomes for these patients, the FDA may revoke its approval or change the label of our products in a manner that could have an adverse impact on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, adverse developments in clinical trials of genomic medicines conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates. The FDA and EMA have only very recent and limited experience in the approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene therapy products. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our competitors develop, acquire, or market technologies or products that are more effective than ours, our financial condition and ability to successfully market or commercialize our product candidates or be profitable would be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry is highly competitive and subject to significant and rapid technological change. We are aware of several companies focused on other methods for editing cells, editing genes and regulating gene expression and a growing number of commercial and academic groups pursuing the development of genome engineering technology. The field of genomic medicine is highly competitive, and we expect competition to persist and intensify in the future from a number of different sources, including biopharmaceutical companies, academic and research institutions, and government agencies that will seek to develop competing products as well as technologies that will compete with our ZFP technology platform. For example, in genome engineering and gene therapy products, competing proprietary technologies with our product development focus include but are not limited to, recombinant proteins, other gene therapy/cDNAs, antisense, siRNA and microRNA approaches, exon skipping, small molecule drugs, monoclonal antibodies, CRISPR/Cas technology and TALE proteins, meganucleases, and MegaTALs. See &#8220;Business&#8212;Competition&#8221; for more information on the competition we may face. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any products that we or our collaborators or strategic partners develop will enter into highly competitive markets. Even if we are able to generate products that are safe and effective for their intended use, competing technologies may prove to be more effective or less expensive, which, to the extent these competing technologies achieve market acceptance, will limit our revenue opportunities. In some cases, competing technologies have proven to be effective and less expensive. Competing technologies may include other methods of regulating gene expression or modifying genes. ZFNs and ZFP-TFs have broad application in the life sciences industry and compete with a broad array of new technologies and approaches being applied to genetic research by many companies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to possessing competing technologies, our competitors include biopharmaceutical companies with:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantially greater capital resources than ours; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">larger research and development staffs and facilities than ours; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater experience in product development and in obtaining regulatory approvals and patent protection. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These organizations also compete with us to attract qualified personnel, attract parties for acquisitions, joint ventures or other collaborations and license the proprietary technologies of academic and research institutions that are competitive with our technology, which may preclude us from pursuing similar opportunities. Accordingly, our competitors may succeed in obtaining patent protection or commercializing products before us. Even if our product candidate is more effective, it may be disadvantaged if it is not first to market. In addition, any products that we develop may compete with existing products or services that are well established in the marketplace. Further, some of our product candidates in development are designed for use once. Any success in developing single-dose therapeutics could cause us to lose potential recurring revenues from therapeutics that are designed to be taken over a patient&#8217;s lifetime.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:109%">The evolving COVID-19 pandemic could continue to adversely impact our business and operations and the business and operations of our collaborators, manufacturers and other business partners.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2020, the World Health Organization declared the novel coronavirus, or COVID-19, outbreak a pandemic, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and since such time, actions taken around the world to help mitigate the spread of COVID-19 have included varying restrictions on travel, quarantines in certain areas, and forced closures for certain types of public places and businesses, including in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three countries where we have most of our day-to-day operations, the United States, France and the United Kingdom. Our business has been directly impacted by pandemic restrictions aimed at reducing the spread of the disease, including multiple California executive orders, several semi-coordinated San Francisco Bay Area orders, several other state and additional local orders across the country and similar orders outside the United States, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To comply with these orders, we implemented an operating plan to continue business operations during the ongoing COVID-19 pandemic, including enhanced workplace safety protocols and modified working schedules in our laboratories. In the United States, employees who are able to fulfill their job duties working from home are required to work from home, and have been doing so since March 2020. These protocols and modifications have slowed our productivity and disrupted our business to a moderate degree and are likely to continue doing so through 2021. For example, we have experienced periodic short-term disruptions to our onsite laboratory and manufacturing operations while addressing positive cases of COVID-19 by onsite workers, and our laboratory and manufacturing operations could experience longer term disruptions in the future in the event of a significant outbreak of COVID-19 among our onsite workers. Moreover, from time to time, we have been required to reorganize and prioritize our research resources to mitigate moderate COVID-19 impacts arising from travel restrictions, laboratory density restrictions and laboratory supply constraints. If our research programs encounter longer-term disruptions, it could impact our ability to support our biopharmaceutical partners as contemplated in our collaboration agreements and could result in adjustments to our research timelines, although we do not believe that the short-term disruptions to date have resulted in any such impacts.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our Phase 1/2 STAAR clinical study evaluating ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, has experienced delays in its timeline due to COVID-19 impacts and the diversion of healthcare resources to fight the pandemic. For example, the clinical trial site in the UK for this study has not been able to open due to the significant prevalence of COVID-19 in the UK. Additionally, we have experienced delays in recruiting, enrolling and dosing patients for this study at our US trial sites, due in some part to the understandable hesitation of patients to travel by plane to trial sites not within driving distance and to enter medical facilities during the pandemic and in other part to trial sites prioritizing COVID-19 clinical care over research activities such as the STAAR study. Moreover, we have experienced some short-term delays in sourcing the necessary raw materials to manufacture supplies for the STAAR study due to COVID-19 impacts. We estimate that these challenges have set back our STAAR study timelines three to six months. While we currently still expect to share initial clinical study data by the end of 2021, this timeline could be revised if COVID-19 impacts to our enrollment and dosing of patients and to our sourcing of raw materials for this study intensify because of vaccination delays, new COVID-19 variants or unexpected events.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our STEADFAST clinical study evaluating TX200, our wholly-owned CAR-Treg cell therapy product candidate for the treatment of kidney transplant rejection, has experienced delays in its commencement timeline due to COVID-19 impacts related to manufacturing and technology transfer challenges with our CMOs. We estimate that these challenges have set back our commencement timeline by approximately three months. While we currently still expect to initiate this clinical study by the end of 2021, this timeline could be revised if COVID-19 impacts result in additional delays.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our partnered programs, the timelines for the studies and trials managed by our collaborators are also subject to potential delay in the future if these studies and trials experience similar challenges that we have experienced in our STAAR and STEADFAST studies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have been working with our collaborators, clinical trial sites and CMOs to minimize any impact of COVID-19 on clinical trials and research and development operations conducted by us and our collaborators, we do expect that at least some of our programs will nonetheless experience delays and disruptions in the future due to COVID-19 impacts on the operations of us and our business partners. These delays and disruptions have in the past and could in the future relate to clinical site initiation, patient recruitment and enrollment or dosing of patients. Some patients and clinical trial staff may not be able or willing to comply with clinical trial protocols if quarantines impede movement or interrupt healthcare services.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is uncertain when restrictions will be fully lifted, and if so, when we will be able to resume pre-pandemic work routines. Imposition of government orders, including quarantine and shelter-in-place orders related to COVID-19 or other infectious diseases, is expected to continue to impact personnel at our laboratories and our third-party manufacturing facilities in the United States and other countries, for the foreseeable future, and could impact the availability or cost of materials, which would disrupt our supply chain. Many of our third-party manufacturers which we use for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical tests and clinical trials are located in countries heavily affected by the COVID-19 pandemic, and should they experience disruptions in the future, such as temporary closures or suspension of services, we would likely experience delays in advancing these tests and trials.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the potential economic impact brought by, and the duration of, the COVID-19 pandemic may be difficult to assess or predict, it could continue to result in significant disruption of global financial markets, impairing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the COVID-19 pandemic could materially affect our business and the value of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic impacts our business, our clinical development and regulatory efforts will depend on future developments that remain highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration and severity of the pandemic, travel restrictions, quarantines and social distancing requirements in the United States, France, United Kingdom and other countries, business closures or business disruptions and the effectiveness and timeliness of actions taken in the United States, France, United Kingdom and other countries to contain and treat the disease, including the effectiveness and timing of vaccination programs in the United States and worldwide. Accordingly, we do not yet know the full extent of potential delays or impacts on our business, sales of our products, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these effects could have material adverse impacts on our business, financial condition, results of operations and growth prospects.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent the evolving COVID-19 pandemic continues to adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section.</span></div><div style="text-indent:32.39pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Negative public opinion and increased regulatory scrutiny of genomic medicines may damage public perception of the safety of our product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genetically modified products are currently subject to public debate and heightened regulatory scrutiny. Gene therapy remains a novel technology, with only two </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene therapy products approved for a genetic disease to date in the United States and only a few </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene therapy products for genetic diseases approved to date in the EU. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. For example, reports of serious adverse events in a retroviral gene transfer trial for infants with X-linked severe combined immunodeficiency (X-linked SCID) in France and subsequent FDA actions putting related trials on hold in the United States had a significant negative impact on the public perception and stock price of certain companies involved in gene therapy, whether or not the specific company was involved with retroviral gene transfer, or whether the specific company&#8217;s clinical trials were placed on hold in connection with these events. Other adverse events could occur in the field of genomic medicine that could result in increased regulatory scrutiny, potential regulatory delays or negative impact on public perception genomic medicines, which could cause our stock price to decline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the regulatory approval for genetically modified products developed using our technology is obtained, our success will also depend on public acceptance of the use of genetically modified products including medicines, plants and plant products. Claims that genetically modified products are unsafe for consumption or pose a danger to the environment may influence public attitudes. Our genetically modified products may not gain public acceptance. More restrictive government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. For example, earlier gene therapy trials led to several well-publicized adverse events, including cases of leukemia and death seen in other trials using other vectors. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors&#8217; products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved and a decrease in demand for any such product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future relationships with healthcare providers, customers and third-party payors subject us to applicable anti-kickback, fraud and abuse, privacy, data security and other healthcare laws and regulations. If we fail to comply with such regulations, we could face substantial penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a biotechnology company, even though we will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse, transparency, health privacy and security and patients&#8217; rights are and will be applicable to our business. For details regarding the restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate see &#8220;Business&#8212;Government Regulation&#8212;Additional Regulation&#8221;.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Scrutiny has also increased, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Responding to investigations can be time-and resource-consuming and can divert management&#8217;s attention from the business. Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. If our operations or if any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws or applicable regulations, we and they could be subjected to significant civil, criminal and administrative enforcement actions, see &#8220;Business&#8212;Government Regulation&#8212;Additional Regulation&#8221;.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we are required to comply with privacy and data security laws, such as the GDPR and the CCPA, and after January 1, 2023, the California Privacy Rights Act, which apply to the collection, use, disclosure, transfer, or other processing of personal data. For more information regarding these regulations, see &#8220;Business&#8212;Government Regulation&#8212;Privacy Regulation&#8221;. To comply with the GDPR restrictions on the transfer of personal data from Europe, we have relied on Standard Contractual Clauses. However, a July 2020 decision of the EU&#8217;s highest court has called into question this practice, and UK authorities may similarly question the viability of the Standard Contractual Clauses as a mechanism for the lawful transfer of personal data outside of that country. Moreover, there is uncertainty regarding how &#8216;Brexit&#8217; will impact these practices. If we are unable to implement safeguards necessary to ensure that our transfers of personal data from and within Europe are lawful, we will face increased exposure to regulatory actions, substantial fines, and injunctions against processing personal data from Europe, and could be required to increase our data processing capabilities in Europe at significant expense. Restrictions on our ability to transfer personal data from Europe could impact our clinical trial activities in Europe and limit our ability to collaborate with CROs and other third parties subject to European data protection laws. Other countries may adopt restrictions similar to the GDPR, which could further impact our operations.</span></div><div style="text-indent:32.39pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure or alleged failure (including as a result of deficiencies in our policies, procedures or measures relating to privacy, data security, marketing or communications) by us to comply with laws, regulations, policies, legal or contractual obligations, industry standards or regulatory guidance relating to privacy or data security, may result in governmental investigations and enforcement actions, litigation, fines and penalties or adverse publicity. In addition, new regulation, legislative actions or changes in interpretation of existing laws or regulations regarding privacy and data security (together with applicable industry standards) may increase our costs of doing business. In this regard, we expect that there will continue to be new proposed laws, regulations and industry standards relating to privacy and data security in the United States, the EU and other jurisdictions, and we cannot determine the impact such future laws, regulations and standards will have on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face inherent risks of product liability exposure related to the testing of our product candidates in human clinical trials and will face even greater product liability risks if we commercially sell any approved products. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trial sites or entire trial programs;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to clinical trial patients;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diversion of management and scientific resources from our business operations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products that we may develop.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Finances</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have generated operating losses since we began operations in 1995. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have been engaged in developing our ZFP technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from collaboration agreements, other strategic partnerships in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. We expect to continue to incur additional operating losses for the next several years as we continue to develop our product candidates. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to curtail or suspend our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to raise additional capital on favorable terms, if at all, which would harm our ability to develop our technology and product candidates and could delay or terminate some or all of our programs. Future sales and issuances of equity securities could also result in substantial dilution to our stockholders. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure and research and product development activities. While we believe our available cash, cash equivalents and marketable securities as of December 31, 2020, when combined with additional capital raises and expected revenues from collaborations, strategic partners and research grants, will be adequate to fund our currently planned operations through at least the next 12 months from the date the financial statements in this Annual Report on Form 10-K are issued, we will need to raise substantial additional capital to fund the development, manufacturing and potential commercialization of our product candidates. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approvals of our product candidates, a process that could cost in excess of hundreds of millions of dollars per product. We may experience difficulties in accessing the capital markets due to external factors beyond our control, such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. For example, our ability to raise additional capital may be adversely impacted by global economic conditions and disruptions to and volatility in the credit and financial markets in the United States and worldwide, which could be impacted by the evolving COVID-19 pandemic. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will adversely affect our business and our ability to develop our technology and products candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent we raise additional capital by issuing equity securities, including sales pursuant to our at-the-market offering program with Jefferies LLC, our stockholders may experience substantial dilution. We may issue common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. New investors could gain rights superior to our existing stockholders.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use net operating losses to offset future taxable income may be subject to limitations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although a certain amount of our federal net operating loss carryforwards carry forward indefinitely (but are subject to a percentage limitation), a significant amount of our federal and all of our state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2024 and 2029, respectively. The net operating loss carryforwards subject to expiration could expire unused and be unavailable to offset future income tax liabilities. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percentage point change in its equity ownership value over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. We have experienced an ownership change in the past and we may also experience additional ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating loss carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations. In addition, at the state level, there may be periods during which the use of net operating loss carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California has imposed limits on the usability of California state net operating losses to offset California taxable income in tax years beginning after 2019 and before 2023. As a result, if we earn net taxable income, we may be unable to use all or a material portion of our net operating loss carryforwards and other tax attributes, which could potentially result in increased future tax liability to us and adversely affect our future cash flows.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. In the event securities or industry analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Reliance on Third Parties</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If conflicts arise with our contractors, collaborators or other business partners, these conflicts may limit our ability to implement our strategies and may harm our business and prospects.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If conflicts arise with our contractors, collaborators or other business partners, the other party will likely act in its self-interest, which may limit our ability to implement our strategies. For example, some of our collaborators are conducting multiple product development efforts within each area that is the subject of their collaboration with us. Our collaborators may develop, either alone or with others, product candidates in related fields that are competitive with the product candidates that are the subject of their collaborations with us. Competing products, either developed by the collaborators or to which the collaborators or have rights, may result in the withdrawal of their support for our product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaborators could also become our competitors in the future. Our collaborators could develop or invest in competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate or breach their agreements with us unexpectedly or prematurely, or fail to devote sufficient resources to the development and commercialization of product candidates covered by the collaboration.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, conflicts could arise between us and our collaborators resulting from disputes regarding our or our collaborators&#8217; or strategic partners&#8217; performance under the applicable agreement, including disputes arising from alleged breaches of our agreements with our collaborators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these conflicts could harm our product development efforts and otherwise adversely affect our business and prospects.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators control certain aspects of our product development efforts, including certain of our clinical trials, which could result in unanticipated delays and other obstacles in the commercialization of our product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on collaborators to design and conduct certain of our clinical trials for some of our product candidates. As a result, these clinical trials may not be conducted in the manner or on the timeline we desire, which may negatively impact our </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">product development efforts. In addition, if any of these collaborators withdraws support for our product candidates or otherwise impairs their development, our business could be negatively affected.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our lack of control over aspects of product development in our agreements with Novartis, Biogen, Kite, Sanofi, Takeda and Pfizer could cause delays or other difficulties in the development and commercialization of our product candidates, which may prevent us from completing the intended IND filings in a timely fashion and receiving any milestone, royalty payments and other benefits under the agreement. In addition, under their respective agreements, our third-party collaborators have certain rights to terminate the agreements by providing us with advance notices, therefore, the actual milestone payments that we may receive under these agreements may be substantially lower than the full amounts provided for under these agreements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our collaborators licensing our ZFP technologies may decide to adopt alternative technologies or products or may be unable or unwilling to develop commercially viable products with our ZFP technologies, which would negatively impact our revenues and our strategy to develop product candidates using ZFP technologies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Several of our collaborations leverage our ZFP technology platform. These collaborators may elect to adopt alternative technologies in the future, which could decrease the value of our ZFP technology platform and impede the development of product candidates using the platform. Additionally, because many of our collaborators are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so, this would delay our ability to test and develop our ZFP technology platform and would delay or terminate the development of our product candidates using the platform. Further, our collaborators may elect not to develop product candidates arising out of our collaborations or not to devote sufficient resources to the development, manufacturing, marketing or sale of these product candidates. If they terminate the collaborations with us and we wish to continue developing the product candidates, we will be required to seek the support of other collaborators or develop the products ourselves. We may not be able to identify a suitable partner or negotiate a favorable collaboration agreement, and we may not have sufficient resources and expertise internally, to allow us to continue the development of these product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercialization of our technologies will depend, in part, on collaborations with other companies. If we are not able to find collaborators in the future or if our collaborators do not diligently pursue product development efforts, we may not be able to develop our technologies or product candidates, which could slow our growth and decrease the market value of our common stock.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have financial resources ourselves to fully develop, obtain regulatory approval for and commercialize our product candidates. We rely significantly on our collaborations with other biopharmaceutical companies to provide funding for our research and development efforts, including preclinical studies and clinical tests, and expect to rely significantly on such collaborations to provide funding for the lengthy regulatory approval processes required to commercialize our product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, we have collaborations with Novartis to develop product candidates to treat certain neurodevelopment disorders, including autism and intellectual disability; with Biogen to develop product candidates to treat tauopathies including Alzheimer&#8217;s disease, alpha-synuclein related diseases including Parkinson&#8217;s disease and other neurological diseases; with Kite to develop product candidates to treat cancer; with Pfizer to develop product candidates to treat hemophilia A and amyotrophic lateral sclerosis and frontotemporal lobar degeneration linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene; and with Sanofi to develop product candidates to treat beta thalassemia and sickle cell disease.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to secure additional collaborations or if our collaborators are unable or unwilling to diligently advance the development, regulatory approval and commercialization of our product candidates, our growth may slow and adversely affect our ability to generate funding for development of our technologies and product candidates. In addition, our collaborators may sublicense or abandon development programs with little advance notice, or we may have disagreements or disputes with our collaborators, which would cause associated product development to slow or cease. In addition, the business or operations of our collaborators may change significantly through restructurings, acquisitions, other strategic transactions that may negatively impact their ability to advance our programs. The evolving COVID-19 pandemic could similarly impact our ability to realize the expected benefits of our collaborations due to the impacts of the pandemic on our collaborators and their business and operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under typical collaborations, we expect to receive revenue for the research and development of our product candidates based on achievement of specific milestones, as well as royalties based on a percentage of sales of any commercialized products. Achieving these milestones will depend, in part, on the efforts of our collaborators as well as our own efforts. If we or any collaboration partner fails to meet specific milestones, then the collaboration agreement may be terminated, which could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduce our revenues. In addition, if sales of commercialized products fail to meet expectations, we could receive lower royalties than expected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Intellectual Property</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because it is difficult, time consuming and costly to obtain, maintain and enforce patent protections for our technologies and product candidates, and because third parties may have made inventions that are similar to ours, we may not be able to secure optimal patent protections of our technologies and product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success may depend in part on obtaining, maintaining and enforcing patent protection for our technologies and product candidates and successfully defending any of our patents that may be challenged. Obtaining and enforcing biopharmaceutical patents is costly, time consuming and complex, and we may not be able to file and prosecute all necessary or desirable patent applications in all desired jurisdictions, or maintain, enforce and license any patents that may issue from such patent applications, at a reasonable cost or in a timely manner or at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent positions of biopharmaceutical companies can be highly uncertain and can involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims that may issue from any patent applications that we own or license, nor are we able to predict whether any third-party patents might issue with claims that are relevant to our product candidates or technologies. Even if patents do successfully issue and even if such patents cover our technologies and product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Furthermore, if third parties have made similar inventions, there are multiple ways they could impact the coverage of our own applications.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to various license agreements that grant us rights under specified patents and patent applications. We are also party to various license agreements by which we grant third parties rights under specified patents and patent applications. Our current licenses contain performance obligations. If we fail to meet those obligations, the licenses could be terminated. If we are unable to continue to license these technologies on commercially reasonable terms, or at all, we may be forced to delay or terminate aspects of our product development and research activities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to exercise the same degree of control over intellectual property that we license from third parties as we exercise over our internally developed intellectual property. We do not control the prosecution of certain of the patent applications that we license from third parties; therefore, the patent applications may not be prosecuted as we desire or in a timely manner.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors were the first to make the inventions covered by each of our pending patent applications;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our licensors were the first to file patent applications for these inventions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others will not have an adverse effect on our ability to do business;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others will not independently develop similar or alternative technologies or reverse engineer any of our products, processes or technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any of our pending patent applications will result in issued patents;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued or licensed to us, our collaborators or strategic partners will provide a basis for commercially viable products or will provide us with any competitive advantages;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any patents issued or licensed to us will not be challenged and invalidated by third parties;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the laws in the U.S. and foreign countries will not change or be interpreted in a way that modifies our patent rights or impacts our ability to enforce or maintain our patent rights; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we will develop additional products, processes or technologies that are patentable.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Others have filed and in the future are likely to file patent applications that are similar to ours. We are aware that there are academic groups and other companies that are attempting to develop technology that is based on the use of zinc finger, TALE, CRISPR/Cas and other DNA-binding proteins, and that these groups and companies have filed patent applications. Several patents with claims directed to this technology have issued, although we have no current plans to use the claimed inventions. If these or other patent applications issue as patents, it is possible that the holder of any patent or patents granted on these applications may bring an infringement action against us, our collaborators, or strategic partners claiming damages and seeking to enjoin commercial activities relating to the affected products and processes. The costs of litigating the claim could be substantial regardless of outcome. Moreover, we cannot predict whether we, our collaborators, or strategic partners would </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevail in any actions. In addition, if the relevant patent claims were upheld as valid and enforceable and our products or processes were found to infringe a patent or patents, we or our collaborators may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, and we may be prevented from making, using, or selling the relevant product or process unless we or our collaborators could obtain a license or were able to design around the patent claims. We can give no assurance that such a license would be available to us or our collaborators on commercially reasonable terms, or at all, or that we would be able to successfully design around the relevant patent claims. There may be significant litigation in the genomics or cell therapy industry regarding patent and other intellectual property rights, which could subject us to costly, lengthy and distracting litigation with unpredictable results. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secrets to protect technology where we believe patent protection is not appropriate or obtainable. Trade secrets, however, are difficult to protect. While we require employees, academic collaborators and consultants to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other proprietary information or enforce these confidentiality agreements.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaborators, strategic partners, and scientific advisors have rights to publish data and information in which we may have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations and strategic partnerships, then we may not be able to receive patent protection or protect our proprietary information.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time and may vary based on jurisdiction.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date or from the filing date of the corresponding international application. Various extensions may be available. However, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be adversely affected, and our business would be harmed.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, collaborators, partners and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures have been and may in the future be breached, and we may not have adequate remedies for any breach. See also the risk factor titled, &#8220;Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.&#8221; In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, collaborators, partners and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have an adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could adversely affect our business, results of operations and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in obtaining or maintaining necessary rights to product components, platforms and processes for our development pipeline through acquisitions and in-licenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Presently, we believe we have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our gene and cell therapy product candidates. Because our programs may involve additional product candidates, such as TX200 and potential future CAR-Treg therapies that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify on commercially reasonable terms, if at all. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights, including from other companies and academic institutions, that we may consider attractive. Other companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, our business, financial condition and prospects for growth could suffer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist that might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many cases, patent prosecution of our in-licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have an adverse effect on our business, financial condition, results of operations and prospects. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have an adverse effect on our business, financial conditions, results of operations and prospects. As an example, Sangamo France has exclusively licensed the right to the CAR for use in TX200 from the University of British Columbia, or UBC. Should UBC terminate this license agreement, we may have to develop or acquire the appropriate CAR which would extend our anticipated development timeline and add expense, and which could result in our failure to realize the anticipated benefits of the acquisition of Sangamo France.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be involved in patent or intellectual property lawsuits or similar disputes involving patents under our control or patents of third parties claiming infringement, which lawsuits could be expensive, time-consuming and impair or prevent development and commercialization activities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex parte</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> reexaminations, post-grant review and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review proceedings before the U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may assert that we are employing their proprietary technology without authorization, and such parties may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. For example, we are aware of certain patents held by third parties related to certain vector and vector manufacturing methods that are related to certain of our product candidates. We have not yet finalized the commercial scale manufacturing process for any of our product candidates. If our commercial scale manufacturing process utilizes these vector manufacturing methods, and if these third-party patents are valid and in force at the time of commercialization, we may need to challenge these patents, use or develop non-infringing alternatives or seek a license to these patents. In any event, if any third-party patents were held by a court of competent jurisdiction to cover our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block or hinder our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations or processes for manufacture or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license, or until such patents expires. Moreover, because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our product candidates may infringe.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Defense of these claims, regardless of their merit, would involve substantial litigation expense, could expose proprietary information and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may also infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable, in whole or in part, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Moreover, if we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover our product candidate. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have an adverse impact on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by us or declared by the U.S. PTO may be necessary to determine the priority of inventions or other matters of inventorship with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could expose us to significant monetary damages, result in the loss of valuable intellectual property, require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation, interference, derivation or other proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to license gene transfer technologies that we may need to commercialize our ZFP technology and potential products, if approved.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to regulate or modify a gene in a cell, the ZFP must be efficiently delivered to the cell. We have licensed certain gene transfer technologies for our ZFP in research, including AAV and mRNA technology, and we are evaluating these systems and other technologies that may need to be used in the delivery of ZFP into cells for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> applications. We have not developed our own gene transfer technologies, and we rely on our ability to enter into license agreements to provide us with rights to the necessary gene transfer technology. Our approach has been to license appropriate technology as required. For example, we are aware of certain patents held by a third party related to certain vector manufacturing methods that are currently being used in certain of our product candidates. We have not yet finalized the commercial scale manufacturing process for any of our product candidates. If our commercial scale manufacturing process utilizes these vector manufacturing methods, and if these third-party patents are in force at the time of commercialization, we may need to use or develop a non-infringing manufacturing method or seek a license to these patents. However, we may not be able to license the gene transfer technologies on reasonable terms, if at all, required to develop and commercialize our product candidates. The inability to obtain a license to use gene transfer technologies with entities that own such technology on reasonable commercial terms, if at all, could delay or prevent the preclinical evaluation, drug development collaborations, clinical testing and/or commercialization of our therapeutic product candidates.</span></div><div style="text-indent:32.39pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Business Operations</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure to operate our business, which are large and complex. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal data (including personal health information) and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks or our confidential information. Many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the size, complexity, accessibility and distributed nature of our information technology systems, and the large amounts of sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious, internal and external attacks </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on our technology environment. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity. In addition, the effects of the COVID-19 pandemic have intensified our dependence on information technology systems as many of our critical business activities are currently being conducted remotely and our increased reliance on personnel working from home could increase our cybersecurity risk.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant disruptions of our, our third-party vendors&#8217; and/or business partners&#8217; information technology systems or other similar data security incidents could adversely affect our business operations and/or result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial and reputational harm to us. For example, in April 2018, we announced a data security incident involving the compromise of a senior executive&#8217;s company email account. Our investigation of the incident did not reveal any evidence that our systems were otherwise compromised in connection with the incident or that personal data about patients or other individuals besides the executive were accessed or disclosed. However, proprietary, confidential and other sensitive information of ours and that of other entities was accessed and may have been compromised as a result of the incident. Unforeseen developments related to this incident could occur, which could have a further adverse impact on us. Any litigation or regulatory review or investigation arising from this incident could result in significant legal exposure to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our facility, development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are aware of the company email incident described above, there is no way of knowing with certainty whether we have experienced any other data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any delay in the discovery of an attack may result in increased expense and may harm our reputation. Any event, including the company email incident described above, that leads to unauthorized access, use or disclosure of personal data could, among other consequences, disrupt our business, harm our reputation, compel us to comply with applicable federal and/or state data breach notification laws and foreign law equivalents. In addition, failure to maintain effective internal accounting controls related to security breaches and cybersecurity in general could impact our ability to produce timely and accurate financial statements and subject us to regulatory scrutiny. While we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or further security incidents.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have business operations in France and the United Kingdom, which exposes us to additional costs and risks. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business operations in France and the United Kingdom subject us to certain additional costs and risks associated with doing business outside the United States, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the increased complexity and costs inherent in managing international operations in geographically disparate locations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges of complying with diverse regulatory, financial and legal requirements, which are subject to change at any time;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially adverse tax consequences, including changes in applicable tax laws and regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potentially costly trade laws, tariffs, export quotas, custom duties or other trade restrictions, and any changes to them;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">liabilities for activities of, or related to, our international operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">challenges inherent in efficiently managing employees in diverse geographies, including the need to adapt systems, policies, benefits and compliance programs to differing labor and other regulations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of health epidemics, including the evolving COVID-19 pandemic, and the resulting global economic and social impacts;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">workforce uncertainty in countries where labor unrest is more common than in the United States; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing laws and regulations relating to data security and the unauthorized use of, or access to, commercial and personal information.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our international operations in France and the United Kingdom expose us to fluctuations in currency exchange rates between the Euro and the U.S. dollar and between the Pound Sterling and the U.S. dollar. Given the volatility of currency exchange rates, there is no assurance that we will be able to effectively manage currency transaction and/or conversion risks. To date, we have not entered into derivative instruments to offset the impact of foreign exchange fluctuations, which fluctuations could have an adverse effect on our financial condition and results of operations. In any event, difficulties resulting </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from these and other risks related to our operations outside of the United States could expose us to increased expenses, impair our development efforts, adversely affect our financial condition and results of operations and harm our competitive position.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are in the process of growing the size of our organization globally, and we may experience difficulties in hiring, integrating and retaining qualified skilled employees.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need to grow the size of our organization in order to support our research, product development, manufacturing and regulatory efforts, and such growth is critical to our success. We may not be able to hire, integrate and retain a sufficient number of qualified employees with the appropriate levels of experience and skills to accomplish our growth objectives. </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There currently is a shortage of skilled individuals with substantial experience discovering, developing and manufacturing genomic medicines, which is likely to continue. As a result, competition for these individuals is intense and the turnover rate can be high. We may not be able to hire, integrate and retain employees with these skills on acceptable terms given the competition among numerous biopharmaceutical companies and academic institutions for individuals with these skills. In addition, any negative or unexpected results in our preclinical or clinical trials or applications for marketing approval would make it more challenging to hire and retain qualified skilled employees. Moreover, the evolving COVID-19 pandemic has further challenged our ability to hire skilled employees. If we do not achieve our growth objectives, the progress of our research, development, manufacturing and regulatory efforts will slow down, which will adversely impact our business, financial condition, results of operations and prospects. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on certain key members of our executive team and certain of our scientific, clinical development and manufacturing personnel, the loss of whose services may impede the progress of our research, development, manufacturing and regulatory efforts. While we have entered into employment agreements with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#8220;at will&#8221; employees. We do not have &#8220;key person&#8221; insurance on any of our employees. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to discover, license or acquire new potential product candidates </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and may fail to capitalize on product candidates with a greater commercial opportunity or for which there is a greater likelihood of success</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our existing product candidates do not receive regulatory approval or are not successfully commercialized, then the success of our business will depend on our ability to continue to expand our product pipeline through discovery, in-licensing or acquisitions. We may be unable to do so. If we do identify potential product candidates for licensing or acquisition, we may be unable to reach acceptable terms with the licensors or sellers. Further, there may be risks and liabilities associated with the product candidates which our due diligence efforts fail to discover, that are not disclosed to us, that we inadequately assess, or that we are unable to manage effectively. Additionally, we may not realize the anticipated benefits of such licenses or acquisitions for a variety of reasons, including the possibility that the product candidates prove not to be safe or effective in clinical trials, that we are unable to successfully integrate the product candidate into our operations, or that the anticipated benefits will not otherwise be realized within the expected timeframe.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, because we have limited resources, we may forego or delay pursuit of opportunities with certain product candidates or indications that later prove to have greater commercial potential. Our spending on current and future research and development programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, licensing or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration arrangement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Relating to our Common Stock and Corporate Organization</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been volatile and will likely continue to be volatile, which could result in substantial losses for investors, and could be influenced by public perception of genomic medicines and the biotechnology sector.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been volatile and may continue to be volatile, which could cause stockholders to incur substantial losses. An active public market for our common stock may not be sustained, and the market price of our common stock may continue to be volatile. The market price of our common stock has fluctuated significantly in response to various factors, some of which are beyond our control, including but not limited to the following:</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or collaborators providing updates on the progress or development status of product candidates or data from clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation or termination of clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in market valuations of similar companies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">overall market and economic conditions, including the equity markets for emerging biotechnology companies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">deviations in our results of operations from the guidance given by us;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of new or enhanced products or technologies or significant contracts, acquisitions, strategic relationships, joint ventures or capital commitments;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcement of changes in business and operations by our collaborators, or changes to our existing collaboration agreements;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in public opinions of genomic medicines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory developments, including increased regulatory scrutiny of genomic medicines;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes, by one or more of our securities analysts, in recommendations, ratings or coverage of our stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock or other securities by us, officers or directors, liquidation of institutional funds that comprised large holdings of our stock and decreases in our cash balances.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies, including very recently in connection with the evolving COVID-19 pandemic, which has resulted in decreased stock prices for many companies notwithstanding the lack of a fundamental change in their underlying business models or prospects. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, including potentially worsening economic conditions and other adverse effects or developments relating to the evolving COVID-19 pandemic, and political, regulatory and other market conditions, may negatively affect the market price of shares of our common stock, regardless of our actual operating performance.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Actual or potential sales of significant amounts of shares of our common stock into the market could cause the market price of our common stock to fall or prevent it from increasing for numerous reasons.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Our outstanding shares of common stock generally may be freely sold in the public market at any time to the extent permitted by Rules 144 and 701 under the Securities Act of 1933, as amended, or the Securities Act, or to the extent the issuance of such shares has already been registered under the Securities Act and are held by non-affiliates of ours. While Biogen agreed not to sell any of the shares that we issued to Biogen in April 2020 until the first anniversary of the effectiveness of the Biogen collaboration, and to limit resales through the second anniversary, such restrictions are only temporary. Further, we also agreed, subject to certain limitations, to register for resale under the Securities Act any of the shares we issued to Biogen. We have also filed registration statements registering all shares of common stock that we may issue under our equity compensation plans. Such shares can be freely sold in the public market upon issuance, subject to volume limitations and black-out periods applicable to affiliates. Additionally, we are party to a sales agreement with Jefferies LLC which permits us from time to time at our discretion to sell up to $150.0 million of shares of our common stock in the public markets at prevailing market prices. As of February 19, 2021, we have sold 1,034,762 shares of our common stock under the sales agreement for net proceeds of approximately $15.7&#160;million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in accordance with the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and our policies regarding stock transactions, c</span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ertain of our employees, executive officers and directors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> have adopted, and may continue to adopt, stock trading plans pursuant to which they have arranged to sell shares of our common stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Our employees, executive officers, directors and affiliated stockholders also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information. Actual or potential sales of our common stock by such persons could be viewed negatively by other investors and could cause the price of our common stock to fall or prevent it from increasing.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our certificate of incorporation, Delaware law and our bylaws could make an acquisition of our company more difficult and could prevent attempts by our stockholders to remove or replace current management.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anti-takeover provisions of Delaware law and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may issue up to 5,000,000 shares of preferred stock with rights and privileges that might be senior to our common stock, without the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the stockholders, the board of directors would have the authority to determine the price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights of, the holders of common stock. Although the issuance of this preferred stock would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to acquire a majority of our outstanding voting stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, our authorized but unissued common stock is available for future issuance without stockholder approval. Our certificate of incorporation further provides that stockholders may not take action by written consent.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our amended and restated bylaws:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish advance notice requirements for nominations for election to the board of directors or proposing matters that can be acted upon at stockholders&#8217; meetings; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibit stockholders from calling a special meeting of stockholders.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to Section 203 of the General Corporation Law of the State of Delaware, which provides, subject to certain exceptions, that if a person acquires 15% of our voting stock, the person is an &#8220;interested stockholder&#8221; and may not engage in &#8220;business combinations&#8221; with us for a period of three years from the time the person acquired 15% or more or our voting stock. The application of Section 203 may, in some circumstances, deter or prevent a change in control of our company even when such change may be beneficial to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated bylaws designate exclusive forums for the adjudication of certain disputes, which could limit our stockholders&#8217; ability to bring claims in a judicial forum it finds favorable for disputes with us or our directors, officers, or employees.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws provide that a state or federal court located within the State of Delaware is the sole and exclusive forum for:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any derivative action or proceeding brought on our behalf;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee or stockholder of Sangamo to us or our stockholders;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our charter or our bylaws, as to which the General Corporation Law of the State of Delaware confers jurisdiction on the Court of Chancery of the State of Delaware; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any action asserting a claim governed by the internal affairs doctrine.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated bylaws further provide that a federal district court of the United State is the sole and exclusive forum for any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These provisions further provide that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to these provisions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find any of these provisions to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;1B &#8211; UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i24672e5030474c1ba9673ec16c177662_25"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;2 &#8211; PROPERTIES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California, pursuant to a lease that expires in May 2029. We also lease approximately 54,200 square feet of research and office space in Richmond, California, subject to leases that expire in August 2026. We also lease approximately 20,800 square feet of office, research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through March 2028. We believe that our facilities are currently adequate to meet our needs. As we continue to expand our operations, we may need to lease or purchase additional facilities.</span></div><div id="i24672e5030474c1ba9673ec16c177662_28"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;3 &#8211; LEGAL PROCEEDINGS </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not a party to any material pending legal proceeding. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</span></div><div id="i24672e5030474c1ba9673ec16c177662_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;4 &#8211; MINE SAFETY DISCLOSURES </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i24672e5030474c1ba9673ec16c177662_37"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;5 &#8211; MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock trades on the Nasdaq Global Select Market under the symbol &#8220;SGMO.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;19, 2021, there were 53 holders of record of our common stock. This number does not include &#8220;street name,&#8221; or beneficial holders, whose shares are held of record by banks, brokers, financial institutions and other nominees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not paid dividends on our common stock, and currently do not plan to pay any cash dividends in the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Performance Graph</span></div><div style="margin-top:6pt"><img src="sgmo-20201231_g9.jpg" alt="sgmo-20201231_g9.jpg" style="height:568px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The above Stock Performance Graph and related information shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC nor shall such information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, each as amended, except to the extent that the Company specifically incorporates it by reference into such filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6 &#8211; SELECTED FINANCIAL DATA</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following Selected Financial Data should be read in conjunction with &#8220;Item&#160;7 &#8211; Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Item&#160;8 &#8211; Financial Statements and Supplementary Data&#8221; included elsewhere in this Annual Report on Form&#160;10-K. Historical results are not necessarily indicative of future results.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Statement of Operations Data:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,192&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,389&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,728&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,618&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,330&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,744&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,608&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,602&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,928&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,552)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105,180)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,150)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56,361)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,559)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,261&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,777)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,419)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,672)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121,122)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,419)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,889)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,658)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,996)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,186)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,334)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54,568)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,658)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.90)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.85)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.70)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.02)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,449&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,114&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,941&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78,084&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,553&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:37.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2016</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Consolidated Balance Sheet Data:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, marketable securities, and interest receivable</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,988&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400,508&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,759&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">516,121&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335,601&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,010&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203,538&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,289&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637,516&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590,395&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">286,741&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,891&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#185;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">)</span></div></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,396&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,192&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,689&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,738&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(777,981)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(656,985)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(562,696)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(495,479)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(440,911)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">497,366&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432,739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) In 2019, we adopted Accounting Standards Update No. 2016-02 (Topic 842) &#8220;Leases,&#8221; which requires lessees to recognize right-of-use assets and lease liabilities for operating leases with a lease term greater than one year. We adopted Topic 842 using the modified retrospective method. As such, results for reporting periods beginning after January 1, 2019 are presented under Topic 842, while prior period amounts are not adjusted and continue to be reported in accordance with our historical accounting under Topic 840 &#8220;Leases.&#8221;</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Sangamo France was acquired in October 2018 and the results of operations have been included in the selected consolidated financial data since the date of acquisition (see Note 5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"> &#8211; Acquisition of Sangamo France</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> in our Consolidated Financial Statements).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_43"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7 &#8211; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section 27A of the Securities Act, as amended, and Section 21E of the Exchange Act, as amended. These forward-looking statements include, without limitation, statements containing the words &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited to, the &#8220;Risk Factors&#8221; described in Part I, Item 1A of this Annual Report on Form 10-K. You should read the following discussion and analysis along with the &#8220;Selected Financial Data&#8221; and the Consolidated Financial Statements and notes attached to those statements included elsewhere in this report.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the section of this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; generally discusses 2020 and 2019 items and year-to-year comparisons between 2020 and 2019. Discussions of 2018 items and year-to-year comparisons between 2019 and 2018 are not included in this Annual Report on Form 10-K and can be found in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of our </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231.htm">Annual Report on Form 10-K for the fiscal year ended December 31, 201</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231.htm">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, filed with the SEC on February 28, 2020.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases. We plan to deliver on this mission through (i) development of our clinical and preclinical product candidates, (ii) our novel science and (iii) our in-house manufacturing capabilities.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current clinical-stage product candidates are:</span></div><div><span><br/></span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Giroctocogene fitelparvovec, also known as SB-525, our lead product candidate, is a gene therapy for the treatment of hemophilia A and is currently being evaluated in the registrational Phase 3 AFFINE (efficAcy and saFety Factor vIii geNe thErapy) clinical trial. We are developing giroctocogene fitelparvovec with our collaborator Pfizer Inc., or Pfizer;</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, is currently being evaluated in our Phase 1/2 STAAR clinical study;</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">BIVV003, our cell therapy product candidate for the treatment of sickle cell disease, or SCD, is currently being evaluated in our Phase 1/2 PRECIZN-1 clinical study. We are developing BIVV003 with our collaborator Sanofi S.A., or Sanofi; and</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ST-400, our cell therapy product candidate for the treatment of transfusion dependent beta thalassemia, is currently being evaluated in our Phase 1/2 Thales clinical study. We are developing ST-400 with our collaborator Sanofi.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we expect to initiate clinical studies for two additional product candidates in 2021:</span></div><div><span><br/></span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TX200, our wholly-owned Chimeric Antigen Receptor, or CAR, engineered regulatory T cell, or CAR-Treg, cell therapy product candidate for the treatment of HLA-A2 mismatched kidney transplant rejection; and</span></div><div style="padding-left:58.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">KITE-037, our allogeneic anti-CD19 CAR-T cell therapy product candidate for the treatment of cancer. We are developing KITE-037 with our collaborator Kite Pharma Inc., or Kite, a wholly-owned subsidiary of Gilead Sciences, Inc.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we are focusing our preclinical development in emerging areas for us including CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Indications for our other preclinical programs include neurodevelopmental disorders, cancer, inflammatory bowel disease, or IBD, tauopathies such as Alzheimer&#8217;s and neurodegenerative diseases such as amyotrophic lateral sclerosis, or ALS, multiple sclerosis, or MS, and Huntington&#8217;s disease, some of which we are developing with our collaborators Biogen MA, Inc. and Biogen International GmbH, which we refer to together as Biogen, Kite, Novartis Institutes for BioMedical Research, Inc., or Novartis, Pfizer and Takeda Pharmaceutical Company Limited, or Takeda.   </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our multiple collaborations with biopharmaceutical companies bring us important financial and strategic benefits and reinforce the potential of our research and development efforts and our zinc finger protein, or ZFP, technology platform. They leverage our collaborators&#8217; therapeutic and clinical expertise and commercial resources with the goal to bring our medicines more rapidly to patients. We believe these collaborations reflect of the value of our ZFP technology platform and will potentially expand the addressable markets of our product candidates. To date, we have received approximately $815.0 million in upfront licensing fees, milestone payments, and proceeds from sale of our common stock to collaborators and have the right to earn up to $7.0 billion in future milestone payments from our collaborations, in addition to potential product royalties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information regarding our business, see &#8220;Business&#8221; in Part I, Item 1 of this Annual Report on </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Business Highlights</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2020, we and Pfizer jointly announced updated follow-up data from the Phase 1/2 Alta study of giroctocogene fitelparvovec, an investigational gene therapy for the treatment of severe hemophilia A.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2020, we and Pfizer jointly announced that we dosed the first participant in the registrational Phase 3 AFFINE clinical trial of giroctocogene fitelparvovec.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In August and September 2020, we dosed the first two patients in our Phase 1/2 STAAR study evaluating our ST-920 gene therapy product candidate to treat Fabry disease, a rare inherited metabolic disease. In February 2021, we dosed the first patient in the second cohort.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2020, we entered into a collaboration agreement with Novartis to develop and commercialize gene regulation therapies to treat three neurodevelopmental targets, including genes linked to autism spectrum disorder and intellectual disability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In February 2020, we entered into a collaboration agreement with Biogen to develop gene regulation therapies for Alzheimer&#8217;s, Parkinson&#8217;s, neuromuscular and other neurological diseases.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In 2020, we brought in-house AAV manufacturing capabilities online in our Brisbane, California headquarters.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Estimated Impacts of Evolving COVID-19 Pandemic</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the World Health Organization declared the novel coronavirus disease, or COVID-19, outbreak a global pandemic, and since such time, actions taken around the world to help mitigate the spread of COVID-19 have included varying restrictions on travel, quarantines in certain areas, and forced closures for certain types of public places and businesses, including in the three countries where we have most of our day-to-day operations, the United States, France and the United Kingdom. Our business has been directly impacted by pandemic restrictions aimed at reducing the spread of the disease, including multiple California executive orders, several semi-coordinated San Francisco Bay Area orders, several other state and additional local orders across the country and similar orders outside the United States, which, among other things, direct individuals to shelter at their places of residence, direct businesses and governmental agencies to cease non-essential operations at physical locations, prohibit certain non-essential gatherings, and order cessation of non-essential travel. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To comply with these orders, we implemented an operating plan to continue business operations during the ongoing COVID-19 pandemic, including enhanced workplace safety protocols and modified working schedules in our laboratories. Employees who are able to fulfill their job duties working from home are required to work from home, and have been doing so since March 2020. These protocols and modifications have slowed our productivity and disrupted our business to a moderate degree and are likely to continue doing so through 2021. For example, we have experienced periodic short-term disruptions to our onsite laboratory and manufacturing operations while addressing positive cases of COVID-19 by onsite workers, and our laboratory and manufacturing operations could experience longer term disruptions in the future in the event of a significant outbreak of COVID-19 among our onsite workers. Moreover, from time to time, we have been required to reorganize and prioritize our research resources to mitigate moderate COVID-19 impacts arising from travel restrictions, laboratory density restrictions and laboratory supply constraints. If our research programs encounter longer-term disruptions, it could impact our ability to support our biopharmaceutical partners as contemplated in our collaboration agreements and could result in adjustments to our research timelines, although we do not believe that the short-term disruptions to date have resulted in any such impacts.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our Phase 1/2 STAAR clinical study evaluating ST-920, our wholly-owned gene therapy product candidate for the treatment of Fabry disease, has experienced delays in its timeline due to COVID-19 impacts and the diversion of healthcare resources to fight the pandemic. For example, the clinical trial sites in the UK for this study have not been able to open due to the significant prevalence of COVID-19 in the UK. Additionally, we have experienced delays in recruiting, enrolling and dosing patients for this study at our US trial sites, due in some part to the understandable hesitation of patients to travel by plane to trial sites not within driving distance and to enter medical facilities during the pandemic and in other part to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">trial sites prioritizing COVID-19 clinical care over research activities such as the STAAR study. Moreover, we have experienced some short-term delays in sourcing the necessary raw materials to manufacture supplies for the STAAR study due to COVID-19 impacts. We estimate that these challenges have set back our STAAR study timelines three to six months. While we currently still expect to share initial clinical study data by the end of 2021, this timeline could be revised if COVID-19 impacts to our enrollment and dosing of patients and to our sourcing of raw materials for this study intensify because of vaccination delays, new COVID-19 variants or unexpected events.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our STEADFAST clinical study evaluating TX200, our wholly-owned CAR-Treg cell therapy product candidate for the treatment of kidney transplant rejection, has experienced delays in its commencement timeline due to COVID-19 impacts related to manufacturing and technology transfer challenges with our CMOs. We estimate that these challenges have set back our commencement timeline by approximately three months. While we currently still expect to initiate this clinical study by the end of 2021, this timeline could be revised if COVID-19 impacts result in additional delays.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to our partnered programs, the timelines for the studies and trials managed by our collaborators are also subject to potential delay in the future if these studies and trials experience similar challenges that we have experienced in our STAAR and STEADFAST studies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Going forward, we will continue to monitor the impact of COVID-19 on our operations, research commitments and clinical trials and those of our collaborators, clinical trial sites and CMOs. The magnitude of these impacts will depend, in part, on the length and severity of the COVID-19 pandemic and related government orders and restrictions, and how the pandemic limits the ability of us and our business partners to operate business in the ordinary course. Disruptions to these operations, and possibly more severe disruptions in the future that could arise due to the extension of government orders or new government orders applicable in the places we operate or our industry generally or to us and our facilities specifically, could impede our ability to conduct research in a timely manner, comply with our research obligations to our collaborators and advance the development of our therapeutic programs. These delays and disruptions could result in adverse material impacts to our business, operating results and financial condition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not anticipate any material negative impact on our financial condition in 2021 as a result of the COVID-19 pandemic. We believe we are well positioned financially in the near term to execute on our wholly-owned and partnered research and clinical programs. We ended 2020 with $692.0&#160;million in cash, cash equivalents and marketable securities and have raised an additional $15.7&#160;million in cash through February 19, 2021 through sales of our common stock under our at-the-market offering program. Although we believe we are well capitalized currently, the effects of the evolving pandemic could result in disruption of global financial markets, impairing our ability to access capital, which could in the future negatively affect our liquidity. We do not currently anticipate any material impairments to the valuation of the financial assets or goodwill on our balance sheet as a result of COVID-19. We do not believe that the remote workplace arrangements we have implemented for our office-based employees have affected our financial reporting or control systems.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 pandemic will impact our business, operations and financial condition, either directly or indirectly, will depend on future developments that remain highly uncertain at the present time. These developments include the ultimate duration and severity of the pandemic, the impacts of new COVID-19 variants, travel restrictions, quarantines and social distancing requirements in the United States, France, United Kingdom and other countries, business closures or business disruptions and the effectiveness and timeliness of actions taken in the United States, France, United Kingdom and other countries to contain and treat the disease, including the effectiveness and timing of vaccination programs. Although certain government orders and restrictions have eased, and phased re-openings are underway, it is not certain when such restrictions and orders will be fully lifted, and recent resurgences in number and rates of infections and the surge of new variants of the virus may result in the return of prior orders and restrictions or new quarantine and shelter-in-place orders or other restrictions. As our understanding of events evolves and additional information becomes available, we may materially change our guidance relating to our revenues, expenses and timelines for manufacturing, clinical trials and research and development.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See also the section titled &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Annual Report on Form 10-K for additional information on risks and uncertainties related to the evolving COVID-19 pandemic.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certain Components of Results of Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenues have consisted primarily of revenues from upfront licensing fees, reimbursements for research services, milestones achievements and research grant funding. We expect revenues to continue to fluctuate from period to period and there can be no assurance that new collaborations or partner reimbursements will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since inception and expect to incur losses for at least the next several years as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities and revenues from collaborations and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our product candidates from research stage through clinical trials. Pursuant to the terms of our agreements with Biogen, Kite, Novartis, Pfizer and Sanofi, certain expenses related to research and development activities will be reimbursed to us. The reimbursement funds to be received from Biogen, Kite, Novartis, Pfizer and Sanofi will be recognized as revenue as the related costs are incurred and collection is reasonably assured.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expenses, professional fees, allocated facilities expenses, patent prosecution expenses and other general corporate expenses. As we continue to advance our product candidates into and through the clinic, we expect the growth of our business to require increased general and administrative expenses.</span></div><div id="i24672e5030474c1ba9673ec16c177662_46"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying discussion and analysis of our financial condition and results of operations are based upon our Consolidated Financial Statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these Consolidated Financial Statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our Consolidated Financial Statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following policies to be the most critical to an understanding of our financial condition and results of operations because they require us to make estimates, assumptions and judgments about matters that are inherently uncertain.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies and estimates relating to revenue recognition, including the estimated fair value of common shares issued as part of the transaction price and valuation of long-lives assets including goodwill and intangible assets are the more significant estimates and assumptions used in the preparation of our Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a complete description of our significant accounting policies, see Note 1 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Organization and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Annual Report on Form 10-K. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenues from research services generally as services are provided while revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (when there is a stand-ready obligation).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimation of measure of progress is complex, involves significant judgment, and is affected by our estimates of the total costs required to complete the performance obligations including the total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on our revenue recognition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a further description of our revenue recognition, see Note 4 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Major Customers, Partnerships and Strategic Alliances</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the accompanying notes to the Consolidated Financial Statements included in Part II, Item 8, "Financial Statements and Supplementary Data" of this Annual Report on Form 10-K. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Valuation of Long-lived Assets including Goodwill and Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We allocate the fair value of purchase consideration in a business combination to the tangible assets acquired, liabilities assumed, and intangible assets acquired based on their estimated fair values. Any excess of purchase consideration over the fair value of net assets acquired is recorded as goodwill. Such valuations require management to make significant estimates and assumptions, especially with respect to intangible assets. Significant estimates in valuing certain intangible assets include, but are not limited to, future expected cash flows from acquired in-process research and development, or IPR&amp;D, projects. Management&#8217;s estimates of fair value are based upon assumptions believed to be reasonable, but which are inherently uncertain and unpredictable and, as a result, actual results may differ from estimates. Allocation of purchase consideration to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">identifiable assets and liabilities affects our amortization expense, as acquired finite-lived intangible assets are amortized over the useful lives, whereas any indefinite lived intangible assets, including goodwill, are not amortized. During the measurement period, which is not to exceed one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period, any subsequent adjustments are recorded to earnings.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review goodwill and indefinite-lived intangible assets for impairment at least annually or more frequently if events or changes in circumstances would more likely than not reduce the fair value these assets below their carrying values. As of December&#160;31, 2020, no impairment of goodwill or indefinite-lived intangible assets was identified.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for possible impairment whenever events or circumstances indicate that the carrying amount of such assets may not be recoverable. The evaluation is performed at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. Recoverability of these assets is measured by a comparison of the carrying amounts to the future undiscounted cash flows the assets are expected to generate from the use and eventual disposition. If such review indicates that the carrying amount of property and equipment and intangible assets is not recoverable, the carrying amount of such assets is reduced to fair value. We have not recorded any significant impairment charges during the years presented.</span></div><div id="i24672e5030474c1ba9673ec16c177662_49"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Years Ended December&#160;31, 2020, 2019 and 2018</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:23.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,192&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,452&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,976&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues consisted of revenues from collaboration agreements and research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Biogen, Kite, Novartis, Pfizer and Sanofi as we continue to recognize upfront and milestone payments received under such agreements over time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $15.8&#160;million in revenues in 2020 compared to 2019 was primarily due to the recognition of upfront license fees of $21.4&#160;million and $4.1&#160;million under our collaboration agreements with Biogen and Novartis entered into in 2020, respectively. In addition, an increase of $6.2&#160;million in recognition of upfront license fee related to our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collaboration agreement with Pfizer due to advancement of the program.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These increases were partially offset by a decrease of $12.6&#160;million in revenues related to our hemophilia A collaboration agreement with Pfizer due to a decrease in activities following the IND transfer in December 2019, and a decrease of $3.2&#160;million in license revenue from our collaboration agreement with Sanofi primarily due to a change in estimate driven by a change in project scope and related project cost.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:24.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.391%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.539%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.750%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands, except percentage values)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,647&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,922&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247,744&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,608&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,136&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207,608&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161,602&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted primarily of compensation related expenses, including stock-based compensation, laboratory supplies, preclinical and clinical studies, manufacturing clinical supply, contracted research, allocated facilities and information technology expenses.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $34.7&#160;million in research and development expenses in 2020 compared to 2019 was primarily driven by a $20.0&#160;million increase in compensation expense as a result of increased headcount to support our programs, clinical trials and start-up of our internal manufacturing operations, a $14.2&#160;million increase in allocated facility overhead costs as we ramped up our internal manufacturing operations, and a $2.1&#160;million increase in preclinical, clinical, research and manufacturing supply expenses. These increases were partially offset by a decrease of $1.7&#160;million in travel and corporate costs due to COVID-19 travel restrictions. Stock-based compensation expense included in research and development expenses was $13.5&#160;million and $10.1&#160;million for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows research and development expenses related to our clinical and preclinical programs. As shown in the table below, preclinical and research programs contributed $50.7&#160;million of the increase in our research and development expenses primarily due to advancement of our technical platform and our wholly-owned preclinical programs, and our CNS programs partnered with Biogen and Novartis in 2020, offset by a decrease of $16.0&#160;million in our clinical programs in 2020 as compared to 2019, primarily driven by a decrease in activities following the IND transfer for our giroctocogene fitelparvovec program in 2019.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:61.509%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Clinical Programs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inherited metabolic disorders clinical programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,030&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beta thalassemia clinical program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,317&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIV clinical programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Hemophilia clinical programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,805&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,099&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,046&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Preclinical Programs:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wholly-owned programs and early research activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,193&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,018&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CNS programs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oncology programs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,214&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,548&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,876&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,263&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,922&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,866&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required to complete our development programs and our development costs for those programs may be impacted by the scope and timing of enrollment in clinical trials for our product candidates, our decisions to pursue development programs in other therapeutic areas, and whether we pursue development of our product candidates with a partner or collaborator or independently. For example, our product candidates are being developed in multiple therapeutic areas, and we do not yet know-how many of those therapeutic areas we will continue to pursue. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued therapeutic area is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential therapeutic areas that we may elect to pursue, and even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or completion costs associated with our development programs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of any necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected. In addition, clinical trials of our product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $5.4&#160;million in general and administrative expenses in 2020 compared to 2019 was primarily due to an increase of $7.3&#160;million in headcount driven compensation costs, and an increase of $6.3&#160;million in professional fees associated </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with our 2020 business activities. These increases were partially offset by a decrease of $7.4&#160;million in allocated facility overhead costs, and a decrease of $1.1&#160;million in travel related expenses due to COVID-19 travel restrictions. Stock-based compensation expense included in general and administrative expenses was $12.2&#160;million and $9.2&#160;million for the years ended December 31, 2020 and 2019, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interest and other income, net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease of $1.0&#160;million in interest and other income, net in 2020 compared to 2019 was primarily due to a decrease of $5.1&#160;million in interest income reflecting the decline in market interest rates. This decrease was partially offset by an increase of $3.1&#160;million in foreign exchange gains as a result of favorable foreign exchange rates and an increase of $1.1&#160;million in other income.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income tax expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes was $0.3&#160;million, zero, and zero&#160;for 2020, 2019 and 2018, respectively. The income tax expense for 2020 was primarily due to an increase in the long-term liability associated with uncertain tax positions, foreign income taxes and state income taxes. This expense was partially offset by a foreign deferred tax benefit.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had net operating loss carryforwards for federal and state income tax purposes of approximately $622.6&#160;million and $261.7&#160;million, respectively. The federal net operating loss generated before 2018 will begin to expire in 2024 and will keep expiring through 2037, if not utilized. Federal net operating losses generated in 2018 will carry forward indefinitely. If not utilized, the state net operating loss carryforwards will begin to expire in 2029. We also have federal and state research tax credit carryforwards of $21.9&#160;million and $18.3&#160;million, respectively. The federal research credits will begin to expire in 2021, while the state research credits have no expiration date. Utilization of our net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before use. Due to the carryforwards related to the net operating losses and research and development tax credits, we do not expect to pay any U.S. federal taxes related to income in the near future.</span></div><div id="i24672e5030474c1ba9673ec16c177662_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant net losses, and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had cash, cash equivalents and marketable securities totaling $692.0&#160;million compared to $384.3&#160;million as of December 31, 2019 with the increase primarily attributable to our collaboration with and sale of our common stock to Biogen, which became effective and closed in April 2020, and our collaboration with Novartis, which became effective in July 2020 and included an upfront fee. Our most significant use of capital was for employee compensation and external research and development expenses, such as manufacturing, clinical trials and preclinical activity related to our therapeutic programs. Our cash and investment balances are held in a variety of interest-bearing instruments, including commercial paper, money market funds, corporate debt securities, certificates of deposit, asset-backed securities, and U.S. government-sponsored entity debt securities. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the beginning of 2017, we have received significant amounts of capital as upfront payments under our collaboration agreements. In addition, our collaboration agreements provide for the payment of development, regulatory, and commercial milestones. For example, in May 2020, we received an upfront license fee of $125.0 million from Biogen upon the effectiveness of our collaboration and license agreement for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. And in August 2020, we received an upfront license fee of $75.0 million from Novartis upon the effectiveness of our collaboration and license agreement for the development and commercialization of gene regulation therapies for the treatment of neurodevelopment disorders. For more information, see &#8220;Business &#8211; Collaborations&#8221; in Part I, Item 1 of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, we entered into an Open Market Sale Agreement with Jefferies LLC, or Jefferies, providing for the sale of up to $150.0 million of our common stock from time to time in &#8216;at-the-market&#8217; offerings under our existing shelf registration statement. As of February 19, 2021, we have sold 1,034,762 shares of our common stock under the sales agreement for net proceeds of approximately $15.7&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we currently believe that our available cash, cash equivalents and marketable securities, when combined with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional capital raises and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund our currently planned operations through at least the next 12 months from the date the financial statements are issued. During this period of uncertainty and volatility related to the evolving COVID-19 pandemic, we will continue to monitor our liquidity.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$169.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2020 compared to net cash used in operating activities of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$144.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2019. The increase was primarily attributable to favorable changes in working capital of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$325.6&#160;million driven by an increase in deferred revenues of $252.2&#160;million, reflecting the cash received under the Biogen and Novartis collaboration agreements, and a decrease in accounts receivable of $63.9&#160;million. This increase was partially offset by an increase in our net loss of $25.7&#160;million. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $271.6&#160;million&#160;in 2020, and $59.8&#160;million in 2019. The increase was primarily due to a net increase of $217.3&#160;million in the purchase of marketable securities, partially offset by a decrease of $6.0&#160;million in purchases of property and equipment.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $153.1&#160;million&#160;in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2020, and $142.0&#160;million in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2019.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase was primarily attributed to the $145.4&#160;million estimated fair value of the Biogen Shares issued in April 2020, net of $2.9&#160;million of issuance costs, partially offset by $136.3&#160;million received in 2019 related to our April 2019 underwritten public offering.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Capital and Capital Expenditure Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate continuing to incur operating losses for at least the next several years. While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we currently believe that our available cash resources, when combined with additional capital raises and expected revenues from collaborations, strategic partners and research grants, will be adequate to fund our currently planned operations through at least the next 12 months from the date the financial statements are issued. Although we believe we are well capitalized currently, the effects of the ongoing COVID-19 pandemic could result in significant disruption of global financial markets, impairing our ability to access capital, which could in the future negatively affect our liquidity. Future capital requirements beyond the next 12 months will be substantial and we will need to raise substantial additional capital to fund the development, manufacturing and potential commercialization of our product candidates through equity or debt financing. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approvals of our product candidates, a process that could cost in excess of hundreds of millions of dollars per product. We regularly consider fund-raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation. Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to advance our product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities, including sales pursuant to our at-the-market financing offering programs, may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many forward-looking factors, including the following:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome, timing and cost of regulatory approvals;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaboration agreements;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays that may be caused by changing regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of product candidates that we pursue;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and terms of future in-licensing and out-licensing transactions;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of procuring clinical and commercial supplies of our product candidates;</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or invest in businesses, products or technologies, including the costs associated with such acquisitions and investments; and</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of potential disputes and litigation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.</span></div><div id="i24672e5030474c1ba9673ec16c177662_58"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, we had contractual obligations and commercial commitments as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments Due by Period</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Less&#160;Than<br/>1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">1-3<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">4-5<br/>Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">More&#160;Than<br/>5 Years</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,422&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,191&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,607&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,571&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing obligations</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,507&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,605&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,902&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,887&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,974&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,799&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,333&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,781&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases consist of base rents for facilities we occupy in Brisbane, California; Richmond, California; and Valbonne, France.&#160;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License obligations includes an ongoing license maintenance fee associated with cancellable in-licensed patent agreements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing obligations include the following non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,736&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,771&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total manufacturing obligations</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,507&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div id="i24672e5030474c1ba9673ec16c177662_61"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;7A &#8211; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exposure to market risk relates to our cash, cash equivalents and marketable securities. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The securities in our investment portfolio are not leveraged and are classified as available-for-sale. The majority of these available-for-sale securities are short-term in nature and subject to minimal interest rate risk. Our investments currently consist of commercial paper, money market funds, corporate debt securities, certificates of deposit, asset-backed securities and U.S. government-sponsored entity debt securities. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. All investments have a fixed interest rate and are carried at market value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. We do not believe that a change in interest rates would have a material negative impact on the value of our investment portfolio.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operations in the United States as well as in Europe. The functional currency of each foreign subsidiary is the local currency. We are exposed to foreign currency risk, primarily through operations of our subsidiaries in Europe which conduct business primarily in Euros.&#160;We record gains and losses within our stockholders&#8217; equity due to the translation of our subsidiaries&#8217; financial statements into U.S. dollars.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 10% strengthening/(weakening) in the rates used to translate the results of our foreign subsidiaries would have increased/(decreased) net loss for the year ended December 31, 2020 by approximately $2.1&#160;million and would not have materially impacted our operating loss.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we incur foreign currency transaction gains and losses related to the level of activity between the United States and Europe. In 2020, we incurred foreign currency transaction gains of $2.2&#160;million.&#160;A 10% unfavorable change in the Euro and U.S. dollar exchange rate on December&#160;31, 2020 would have had an immaterial impact on foreign currency transaction gains for 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020 and 2019, we maintained cash balances of approximately $16.8&#160;million and $22.6&#160;million, respectively, denominated in a foreign currency in the United States. A hypothetical 10% change in foreign exchange rates would have increased/(decreased) net loss for the year ended December 31, 2020 by approximately $1.7&#160;million and would not have materially impacted our operating loss.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_64"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;8 &#8211; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:92.301%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.499%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_67">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_67">80</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_70">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_70">82</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_73">Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_73">83</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_76">Consolidated Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_76">84</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_79">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_79">85</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_82">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_82">86</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_85">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i24672e5030474c1ba9673ec16c177662_85">87</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Sangamo Therapeutics, Inc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Sangamo Therapeutics, Inc. (the Company) as of December 31, 2020 and 2019, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows for each of the three years in the period ended December 31, 2020, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2020, in conformity with U.S. generally accepted accounting principles.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated February 24, 2021 expressed an unqualified opinion thereon.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div><span><br/></span></div><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.524%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Estimation of Fair value of shares sold to Biogen</span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><br/>Description of the Matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in Note 4 to the consolidated financial statements, in 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. and Biogen International GmbH (together, &#8220;Biogen&#8221;) for the research, development and commercialization of gene regulation therapies for the treatment of neurological diseases. Concurrent with the execution of the Biogen collaboration agreement, the Company entered into a stock purchase agreement pursuant to which Biogen agreed to purchase 24.4 million shares of the Company's common stock for an aggregate purchase price of approximately $225.0 million, a price which exceeded the fair value of the shares at the time of the purchase. Since the purchase price exceeded the fair value of the common shares issued in this transaction, management had to estimate the fair value of these shares using an option pricing model to reflect certain holding period restrictions and other unique terms of the agreement. The fair value of these shares was estimated to be $145.4 million, and the $79.6 million excess consideration was included in the transaction price of the collaboration and license agreement.<br/><br/>Auditing the estimated fair value of the shares issued in this transaction was complex as management had to use significant judgment in selecting the valuation methodology and estimating the significant unobservable inputs used in the valuation model. The use of a different valuation methodology and inputs could significantly affect the fair value assigned to the common shares thereby impacting the total transaction price of the collaboration and license agreement and ultimately the amount of revenue that is recognized under this agreement.<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"><br/>How We Addressed the Matter in Our Audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design and tested the operating effectiveness of controls over the Company&#8217;s accounting for this new collaboration agreement, including management&#8217;s review controls over development of the significant unobservable inputs that affected the determination of the fair value of the common shares issued to Biogen.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the fair value of the common shares, our audit procedures included, among others, evaluating the Company&#8217;s valuation methodology and the significant unobservable inputs and testing the mathematical accuracy of the Company&#8217;s valuation calculations. We involved our valuation specialists to assist us with evaluating the Company&#8217;s valuation methodology and assessing the reasonableness of the inputs by comparing them to information available from third-party sources and market data. We also independently developed fair value estimates with the assistance of our valuation specialists and compared them to the Company&#8217;s valuation results.</span></div></td></tr></table></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;ERNST&#160;&amp; YOUNG LLP</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 1997.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share and per share amounts)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMy0xLTEtMS0w_91a5b4c1-eb5e-4113-8f66-3f1b855c380a">131,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMy0zLTEtMS0w_264fe9d2-ee02-4fbe-9b15-f9552cf039a5">80,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNS0xLTEtMS0w_1a443dfa-5d77-4d1d-b327-85a14bca9b89">510,094</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNS0zLTEtMS0w_cc09bc0b-74c9-42af-ac36-9cef9c09f068">282,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNi0xLTEtMS0w_476177eb-6246-477c-9d26-809af0bb083c">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" name="us-gaap:InterestReceivableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNi0zLTEtMS0w_072a0d9e-1085-437c-a53e-2a471b4f33bc">682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNy0xLTEtMS0w_e3ae44c0-9eea-436d-ad55-a7c15875a6f9">5,224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNy0zLTEtMS0w_63da99ca-92ed-4df6-b535-b7cf4026a6ff">36,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfOC0xLTEtMS0w_5ffdcbcc-5595-4f62-8ccb-bc955f078fcf">11,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfOC0zLTEtMS0w_a372bf15-bf83-46f7-aa39-8e1bdc3f0003">5,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfOS0xLTEtMS0w_6168cacf-076d-47e7-a146-b01cdeeac456">659,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfOS0zLTEtMS0w_8297dc80-ad69-4539-9b56-3a14b9affa10">405,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTAtMS0xLTEtMA_c5c63c5c-1edb-4c49-9db3-ef1972e83c2e">50,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTAtMy0xLTEtMA_ee93bb1d-610a-424c-9306-e3128bc944d6">21,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTEtMS0xLTEtMA_1a464f95-3d54-4064-b04a-649329d2605f">41,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTEtMy0xLTEtMA_e959d7d9-c217-4103-b876-cf9acf262571">29,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTItMS0xLTEtMA_d7df4965-14cd-447d-9bc8-b7e73a16175a">58,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTItMy0xLTEtMA_ad5f3a30-1501-497a-8666-21ec40d80e15">53,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTMtMS0xLTEtMA_26db89a0-e682-4903-9d7a-2f1cd5240bfc">42,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTMtMy0xLTEtMA_5f78b0b9-deb1-4f5a-9115-5a79741f5814">39,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTQtMS0xLTEtMA_15a07be4-de5b-4803-aac8-b9e74349012a">71,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTQtMy0xLTEtMA_7657c3d8-2703-40b8-8bc2-a0fd33489eb3">77,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTUtMS0xLTEtMA_169eba40-1342-4b79-ac1e-29c278c5d6a5">13,557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTUtMy0xLTEtMA_c4c41b28-4fb2-425d-b51e-8993b42d0619">9,067</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTYtMS0xLTEtMA_765a1bcf-58a4-456c-9d85-ef4991c11214">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTYtMy0xLTEtMA_521dedbe-1457-41d5-9d1f-ecdb9dacc18b">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTctMS0xLTEtMA_b1462a66-4949-4a84-a4fd-a87203e0fef2">938,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTctMy0xLTEtMA_a4390181-4d7e-4ff5-854c-2b5181f1cd85">637,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjAtMS0xLTEtMA_05ab8b29-7720-44f2-a454-0e43d9734874">12,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjAtMy0xLTEtMA_b7565d19-95de-4b25-9fbc-74036c61fd41">6,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjEtMS0xLTEtNTM3OA_0285c5d8-475d-497f-823c-c1ffa97ffd8e">18,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjEtMy0xLTEtNTM3OA_267bfd59-c987-4e42-a125-b910d00a9a3c">10,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjEtMS0xLTEtMA_a511be9b-fde9-465f-b83d-436a700e30c5">20,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjEtMy0xLTEtMA_3bf4f646-04f7-4e15-a969-e53e67ee411b">13,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjItMS0xLTEtMA_c44d6ba3-23d7-4552-b131-b7eca356309b">91,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjItMy0xLTEtMA_de35a0b0-7b3c-41c4-be9c-34e2b7a99487">38,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjMtMS0xLTEtMA_ba1fc418-3ebd-4860-8a93-fd2e3d500684">143,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjMtMy0xLTEtMA_e7defcaf-7ad9-41ef-acfa-d5fc0e246eb0">69,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenues, non-current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjQtMS0xLTEtMA_e3692664-00fc-4f5f-a4d0-a3fcd3adcb3a">245,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjQtMy0xLTEtMA_0b655e2f-1cd6-4b98-8bb7-7c28a1f841d9">81,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjUtMS0xLTEtMA_056a18d0-ca52-4e22-9942-3013841477cc">38,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjUtMy0xLTEtMA_639a7630-cb02-49f0-a907-78da77058817">41,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjYtMS0xLTEtMA_9e754358-6be2-4e97-bb2a-a25b48b01793">7,185</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjYtMy0xLTEtMA_3b55164b-8af0-4b02-8833-bdf2d3138104">6,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjctMS0xLTEtMA_81f2438d-c785-42ba-8b43-c7fcc00b1fac">7,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjctMy0xLTEtMA_5fff0711-e4e8-4ebe-a5d8-d92948749f32">5,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjgtMS0xLTEtMA_7bcdc5a5-c3ff-4bbe-8e85-c60242af631c">441,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjgtMy0xLTEtMA_ad11383c-909b-4534-afc3-116fc1235d62">204,777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjktMS0xLTEtMA_06b90adb-6f47-4e0a-b6e2-2b33498f71a7"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjktMy0xLTEtMA_9e9a3cd1-5336-48a5-a061-ad04248a9170"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzIx_15af6f8a-75b8-48ef-a46d-f3051b23963b"><ix:nonFraction unitRef="usdPerShare" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzIx_c74887c3-5672-4eb7-8100-471b83d45a79">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzM1_e585f574-2a12-411a-9290-b72485249bca"><ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzM1_fc009e23-f1cc-41d1-a736-4bed1ae7b42a">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized, and <ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzYw_25576737-2d9b-42f4-9136-534210c4be18"><ix:nonFraction unitRef="shares" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzYw_4cbb366c-d72f-42ae-819b-86fa5763e405"><ix:nonFraction unitRef="shares" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzYw_7932965d-63bd-419c-a4ea-56dac52ddf90"><ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzYw_83fe3a4b-e05f-4609-9383-e7251ca9cbdb">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMS0xLTEtMA_e015b47f-76fa-4eea-a270-4d82b68cde64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMy0xLTEtMA_70ae7de6-b62b-4742-8142-00dc5bdc481a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzE4_503b5833-bbdd-4195-953b-ffcd3b303eec"><ix:nonFraction unitRef="usdPerShare" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzE4_87460c8f-be0e-4df3-87af-aef0f73d500b">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzMy_60eb80f9-81c2-4321-b84f-45d4ff214839"><ix:nonFraction unitRef="shares" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzMy_be5e3c3c-2d7a-46a7-b33b-bc942054ec74">320,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzU0_095446f2-47a4-4440-925e-46f4e557655e"><ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzU0_7a80ebd3-80d8-476c-94d7-e69989724253">142,063,203</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzYx_732cc5c6-f709-4043-9566-330d10d80301"><ix:nonFraction unitRef="shares" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzYx_943bf96e-782b-4a98-98d0-9c1f3802177f">115,972,708</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December 31, 2020 and 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMS0xLTEtMA_b5170ba8-56cb-473c-8817-d0ffaa927368">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMy0xLTEtMA_889d4b25-f50d-4d51-aa9d-11872cd6ccbb">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzMtMS0xLTEtMA_c1a4ad9d-d990-40cf-9308-2fd2b84341d5">1,269,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzMtMy0xLTEtMA_0ee55b8a-3403-4893-8977-edcdc1c5853a">1,090,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzQtMS0xLTEtMA_6fdeebc0-fd3a-4032-8ad5-b2832aadb7fe">777,981</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzQtMy0xLTEtMA_f1342f0e-7bbc-4f38-b519-feb2b7855f5e">656,985</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzUtMS0xLTEtMA_8d2553cd-a63a-4dac-9d09-2f70a2b7a85c">5,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzUtMy0xLTEtMA_f6d2485e-7c5b-4fe0-9b5a-0ad5fe4e54ae">2,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Sangamo Therapeutics, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzYtMS0xLTEtMA_e4206fbe-bc76-4471-bcdd-5dc8e7ffc938">498,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzYtMy0xLTEtMA_bc9eea20-0557-4539-aff5-9cb561bdde28">432,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzctMS0xLTEtMA_862a92b9-a131-48f1-ba4c-eac3a913eebf">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzctMy0xLTEtMA_db136bf7-842a-4eb0-b2ce-4469e99e1808">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzgtMS0xLTEtMA_2aa27cd3-b2ee-44a9-8463-d37a9d64ca8b">497,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzgtMy0xLTEtMA_302a43ff-7ed4-4a53-b948-96f4f323842a">432,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzktMS0xLTEtMA_ff98f1c2-7efc-4f58-a73d-493addbee421">938,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzktMy0xLTEtMA_2718e9e0-4916-4a24-bd53-112e7b6e9d21">637,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except per share amounts) </span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNS0xLTEtMS0w_3a893e17-d559-4fc4-bf62-e0d79b4a771d">118,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNS0zLTEtMS0w_75240a92-4d4c-45bc-a067-bdfd2625593f">102,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNS01LTEtMS0w_83770339-8877-4a29-884a-1f354364e078">84,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNy0xLTEtMS0w_9874b099-d565-4ecc-9c3b-6b2d5400720d">180,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNy0zLTEtMS0w_6c6956e4-9dd2-4d7d-bb26-9d03b15f13ef">145,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNy01LTEtMS0w_cd851e60-7c6f-4e3f-ac50-4ebace1d234f">114,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOC0xLTEtMS0w_34de09c5-3fb7-455a-9841-3a4145bcce83">67,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOC0zLTEtMS0w_2b9d9810-94fb-4dc1-b583-afd1f38f5db1">61,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOC01LTEtMS0w_3b881846-d787-49ec-9a11-6a96b56df684">46,736</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOS0xLTEtMS0w_6fb7bb87-16b4-4604-9ce5-f62973eb0696">247,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOS0zLTEtMS0w_b406ac29-3b36-471f-ae33-235f977681b7">207,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOS01LTEtMS0w_4d99ba5b-ecdd-41dd-a75a-dacb97e30a02">161,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTAtMS0xLTEtMA_8c90aaac-c01b-4139-becc-567f5577f9ef">129,552</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTAtMy0xLTEtMA_e6c04df6-9b55-471a-a7a9-ec626314c775">105,180</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTAtNS0xLTEtMA_c978a024-b522-477b-91cd-522b4ba686a4">77,150</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTEtMS0xLTEtMA_53d8615e-c22f-43b1-968a-1d96f1d879f3">8,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTEtMy0xLTEtMA_a268edaf-e787-4728-b591-b11dc2161539">9,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestAndOtherIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTEtNS0xLTEtMA_ec56b452-9d1e-40a0-a99a-5a189854bfa8">8,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTItMS0xLTEtMA_c46fed7a-df9f-4de3-8313-ba2cc415882d">120,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTItMy0xLTEtMA_fc573cab-6ad8-448b-8821-c0f44cb69507">95,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTItNS0xLTEtMA_627a043e-6407-45f0-bf78-9694bb9fd9d4">68,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTMtMS0xLTEtMA_8f859092-7241-413b-91b4-69b1e8858513">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTMtMy0xLTEtMA_d3cb24c9-6819-4241-b2af-4a1ce092eefe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTMtNS0xLTEtMA_3d48c79e-e7e2-4f2d-9d7e-703b32d37d8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTQtMS0xLTEtMA_f7b1df83-45a7-4786-9495-dfca38964e46">121,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTQtMy0xLTEtMA_8d210a0a-ef9f-40fa-83b3-2cccc9b7286f">95,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTQtNS0xLTEtMA_9d7c7749-89ae-4a44-b9bb-58a3dad07212">68,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTUtMS0xLTEtMA_e4f1e61c-a46d-4ac1-8b42-18a345b242ff">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTUtMy0xLTEtMA_cdc0cb7b-5161-47ca-abb0-715a6b962a77">233</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTUtNS0xLTEtMA_6aa1f7b0-f22e-4248-bce1-527b5bddf590">555</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTYtMS0xLTEtMA_4890a941-955a-46ca-b727-8e11356d1e06">120,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTYtMy0xLTEtMA_c9b1a9b0-6aa7-4429-a667-438bfe694db5">95,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTYtNS0xLTEtMA_17f222bc-8634-4ba2-8a04-0808e3bfca61">68,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTctMS0xLTEtMA_ab60242c-c946-4f0e-ab11-dbdd66ed3c22">0.90</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTctMy0xLTEtMA_a8e0613c-f15c-4711-ba25-e53fd74abb47">0.85</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTctNS0xLTEtMA_67e647ab-8186-47fb-9020-2230168d7f69">0.70</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTgtMS0xLTEtMA_265841b8-93e1-4c66-b714-7e5777b376c4">134,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTgtMy0xLTEtMA_c14912fc-d033-4eb2-b250-f3041c191cfd">112,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTgtNS0xLTEtMA_6115e244-c6b4-4c4b-ae0f-a60a742b299a">96,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_76"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMi0xLTEtMS0w_e4f41ce4-8cad-4206-b448-aa80ad9576ee">121,122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMi0zLTEtMS0w_fed71a00-25cb-4ef9-9f2f-4c4bacd4fce6">95,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMi01LTEtMS0w_c6e7f049-4fdd-4e7a-b8dc-928754ba41c6">68,889</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMy0xLTEtMS0w_3da83126-e61f-43de-815e-4ecc5f67ea06">8,345</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMy0zLTEtMS0w_4696d378-3505-42aa-961d-9b4f9eb688a7">1,573</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMy01LTEtMS0w_03d79088-9152-41d8-80cc-1db5529e1f29">1,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net pension losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNC0xLTEtMS0w_8ddd492c-b9df-4175-99c3-a505e89d0c87">193</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNC0zLTEtMS0w_5b81ae24-1473-455a-b271-45912820bb17">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNC01LTEtMS0w_ba6a99da-f7e8-4337-b20e-5f8605bc685b">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in unrealized (loss) gain on marketable securities, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNS0xLTEtMS0w_bcd70945-d648-460f-a0f5-95cfd5bd30fb">284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNS0zLTEtMS0w_6b29bd4d-ab9d-42c3-9a1f-64c5a5ab057a">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNS01LTEtMS0w_a3176012-5ef4-4358-8c80-ff1bd492c0b8">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNi0xLTEtMS0w_b0900fa7-dd98-4fa7-8c6f-d6aac25d79a7">113,254</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNi0zLTEtMS0w_51417b7b-604e-488b-9c63-17c7c3a37d51">96,428</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNi01LTEtMS0w_6e88c82f-ab89-43c3-9c36-cb07ea1d0969">70,062</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNy0xLTEtMS0w_7550c2ab-d309-44c6-a814-bf9f5769b067">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNy0zLTEtMS0w_0bcbb0f9-1285-43e7-b270-91a68bca287f">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNy01LTEtMS0w_5a79375c-f2b5-4515-a5e0-369e872991ed">574</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfOC0xLTEtMS0w_c5616375-cee3-4460-bf2b-1b5a5959a4fd">113,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfOC0zLTEtMS0w_72fd2a05-491c-48aa-845d-3f57ddf1190a">96,195</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfOC01LTEtMS0w_74042fdb-0635-4f24-ae5a-7201bcf21361">69,488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands, except share amounts)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:29.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.310%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.143%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>Controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Balances at December 31, 2017</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if6f46cdcf64446fbb0ec043c3e9bfa14_I20171231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS0xLTEtMS0w_bb888fb4-cf5f-4932-8b83-da72a4c057ff">85,598,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6f46cdcf64446fbb0ec043c3e9bfa14_I20171231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS0zLTEtMS0w_fac5e6b7-5f82-4fdd-a9e2-9a73eba5524e">856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15b7ca23b9754fce9a17de50c7c8a39a_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS01LTEtMS0w_d1ec945a-cb1c-49b5-9f0c-ec233abd31c8">682,809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i202e314c35d9413996c927fa899da1c2_I20171231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS03LTEtMS0w_64ae72ce-e4e8-4294-bb68-7076411e7647">495,479</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4b56ade4b50487fb2fbba4e2c124931_I20171231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS05LTEtMS0w_eb1daa3f-f57d-4734-adf1-75f77db0c521">286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb5b79c99094b17a8f2ce637a6f9a2d_I20171231" decimals="-3" format="ixt:zerodash" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS0xMS0xLTEtMA_0e11f546-f765-4ddf-8782-ccd84e70843e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1099157ecec044679915cbcb253acd13_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS0xMy0xLTEtMA_22ec992b-1deb-47f3-ae82-2f7ff485e88f">187,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Cumulative-effect adjustment of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMy0wLTEtMS0xNjEyL3RleHRyZWdpb246NzFmN2MwOTg1MThiNDk5OTlkYTc2YjZjNWE1N2ExODRfMzg0ODI5MDY5NzMxNA_3e224bd6-7770-4f80-a1e8-1ea28d8e7eec">ASC Topic 606</span> on January 1, 2018</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4531bd4090429ab0a53e48c051817f_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTAtNy0xLTEtMA_5503780c-9672-4422-95a3-36365315e3f0">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22d2afa166f04addaba3df267d7905bc_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTAtMTMtMS0xLTA_477459bc-25ac-49ed-a422-8898dceefa21">1,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTEtMS0xLTEtMA_3551f207-0305-42d2-8e92-da441b23b5cd">2,103,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTEtMy0xLTEtMA_7788d54e-694e-4183-936e-3ad8e23c6c02">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTEtNS0xLTEtMA_1616916a-f9fb-4766-afb4-4c85a71163d8">14,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTEtMTMtMS0xLTA_7421066e-9de9-4a6e-8707-85422496e454">14,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTItMS0xLTEtMA_86b89ef2-76f4-4c98-bcfb-764ae88cdf24">328,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTItMy0xLTEtMA_438c22ce-f232-4cda-9f64-7c734981bba5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTItNS0xLTEtMA_9547f3ca-f5d6-401a-86c6-894a3d68dfd1">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTItMTMtMS0xLTA_887393cc-5b58-4d34-a61d-f1d2795509ef">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance of common stock under public offering, net of issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTMtMS0xLTEtMA_ceee4359-099c-4b14-bb36-3627e3165e5d">14,156,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTMtMy0xLTEtMA_0aeedfc5-c81c-4acb-9d69-85d8ef6462f3">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTMtNS0xLTEtMA_e9c4128c-2fde-4d62-b74e-06484bc210f9">215,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTMtMTMtMS0xLTA_8b7e9b39-b129-49b1-8515-5d282b686555">215,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTQtNS0xLTEtMA_21dec7f6-c8e8-4112-9511-bb1ba47ea7c1">14,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTQtMTMtMS0xLTA_dc6ebd9c-5fa0-4448-8768-72c010b8bb2d">14,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Additional paid-in capital for acquisition of Sangamo France</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231" decimals="-3" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTUtNS0xLTEtMA_0dfc982c-e025-466a-9272-94cf718c0397">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTUtMTMtMS0xLTA_3598f89f-eb3e-42eb-aebd-3c35b8b4d324">603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Non-controlling interest upon acquisition of Sangamo France</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d05b39e6b184c809c28b20cda11f744_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTYtMTEtMS0xLTA_a212ffa9-ce26-48f4-9f51-b4d45a4bd17c">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTYtMTMtMS0xLTA_e67a26ab-d63e-4f3f-8ca2-5dcbe066383f">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d6997ffafa040db837de130bd2c9cc5_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTctOS0xLTEtMA_8f5e49ed-68e6-48b1-a188-622b8477c3f5">1,129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d05b39e6b184c809c28b20cda11f744_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTctMTEtMS0xLTA_53010239-2b51-4760-8e75-731945a24c74">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTctMTMtMS0xLTA_5800f087-a5f7-482c-b8ca-f1522b60d754">1,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Net pension losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d6997ffafa040db837de130bd2c9cc5_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTgtOS0xLTEtMA_f596cc03-bb20-493d-a127-ebe8404f9a45">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTgtMTMtMS0xLTA_c969dcf1-297e-458b-b6c0-8c2a48b29607">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d6997ffafa040db837de130bd2c9cc5_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTktOS0xLTEtMA_2df7e42d-19b8-47b1-8cc8-793d313dbffe">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTktMTMtMS0xLTA_72b1ad54-566d-45ae-a57f-369b669966b8">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5eb85ed8fe2a4cc9a528a3f2afd5ee04_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjAtNy0xLTEtMA_02dd4d76-8df1-4384-9234-a49f06c36bb5">68,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d05b39e6b184c809c28b20cda11f744_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjAtMTEtMS0xLTA_2fd447c6-b68d-494f-b702-1f1a59bdd5c9">555</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjAtMTMtMS0xLTA_16c6c1b5-199a-4935-90e6-2f7b978de442">68,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Balances at December 31, 2018</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79a71c8223434e32990a220f63b9c4bd_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtMS0xLTEtMA_af66246a-f534-42b0-8cca-27e1bf6a9a74">102,187,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79a71c8223434e32990a220f63b9c4bd_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtMy0xLTEtMA_12c05272-34a6-47c7-b87c-82957ae88680">1,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i651b9b252cc242febd5e34ac22fad42d_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtNS0xLTEtMA_b707baf1-598c-4e7e-b4fd-ba441c44c2a1">929,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d4c9fcbe5f94694af0132cce7457120_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtNy0xLTEtMA_e366d1a4-2442-4079-86fb-9d42e9dddb9c">562,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f51a95393aa40d082b4cca44112fce1_I20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtOS0xLTEtMA_2b6761f9-ff8a-44d7-abdd-67d04f32feae">1,440</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i921be278c72e486185352cb920f4347b_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtMTEtMS0xLTA_c7ba27f4-3630-4fcb-8993-0a6ee43e3f67">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtMTMtMS0xLTA_92282760-398e-4dfc-8be1-a655debfc02b">367,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Cumulative-effect adjustment of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTUtMC0xLTEtMTYwOC90ZXh0cmVnaW9uOjNhOGYyMjhiMzNkMTQzZWM5ZjU0ZmEzZWZjMTM0MGFiXzM4NDgyOTA2OTcyOTg_5213575c-8402-4879-a9de-4af8a6520892">ASC Topic 842</span> on January 1, 2019</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5022310b80e40a9adf07bedacb21665_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjItNy0xLTEtMA_7ec59ddc-fa08-4632-8ec1-60fac6a20edf">897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabf107dbdd5b48f8903b89e3c7cea36e_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjItMTMtMS0xLTA_f29204e4-3fe6-4dae-9159-1a0418348285">897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjMtMS0xLTEtMA_850d9d92-8372-41cd-a1df-502f6a9b3316">885,873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjMtMy0xLTEtMA_596ff1c3-99e1-40f3-869f-bda587aad057">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjMtNS0xLTEtMA_f30aa6ce-c525-45d2-8dfd-5c9b9bfdab4c">3,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjMtMTMtMS0xLTA_847901d1-94ce-4064-b718-ef822459e4c8">3,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjQtMS0xLTEtMA_56cbdbff-625d-491d-82fd-2115c863ff79">249,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjQtMy0xLTEtMA_5c297cea-2470-4faa-bc34-ed6f7804681a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjQtNS0xLTEtMA_eaf960d1-a5a8-4959-9ad5-fb0da1bac788">2,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjQtMTMtMS0xLTA_a6f7f712-ef87-465e-bf77-80172b249a9c">2,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance of common stock under public offering, net of issuance costs</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjUtMS0xLTEtMA_3be46960-4a37-42f4-8115-43803962211b">12,650,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjUtMy0xLTEtMA_a9edb9a7-9a8f-4966-9a4f-73c7b7d069ad">127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjUtNS0xLTEtMA_26b4bc4a-8971-46bb-b7bd-092929a948b6">136,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjUtMTMtMS0xLTA_864c3971-7a0c-4464-8788-819f0ad3b33c">136,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjYtNS0xLTEtMA_7694aafc-ff8c-4d32-87af-80791b83770b">19,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjYtMTMtMS0xLTA_d1572393-07c0-4fa8-b3f7-6a97f582310e">19,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Acquisition of additional shares of Sangamo <br/>     France</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6f7ea91dc8646daa2cc71ca00f38850_D20190101-20191231" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMTEtMS0xLTA_1be1165a-641f-4d24-8ad2-74f66b235b82">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMTMtMS0xLTA_7625b419-8dce-4fec-8e1b-03ea03f30511">321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance costs related to Sangamo France acquisition</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtNS0xLTEtMA_006185b4-99aa-4400-8280-9057d21e3a68">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtMTMtMS0xLTA_2a5465b7-7dc2-440e-aafe-609da7f3fdf3">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80940087d3b44c008290532496a8063a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktOS0xLTEtMA_e39f3371-b339-49ea-82d8-2d52babd63f0">1,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia6f7ea91dc8646daa2cc71ca00f38850_D20190101-20191231" sign="-" xsi:nil="true" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMTEtMS0xLTA_402b2701-f9b6-42a3-8f04-8f4b89338165"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMTMtMS0xLTA_c1a144ae-f8d8-4ead-898c-8f2d9e8a049e">1,573</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Net pension losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i80940087d3b44c008290532496a8063a_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzAtOS0xLTEtMA_a26e341b-c170-4677-82fc-a965fed6e054">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzAtMTMtMS0xLTA_b85afea3-49b5-48dd-a191-6d0037367194">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Net unrealized gain on marketable securities, net of tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80940087d3b44c008290532496a8063a_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzEtOS0xLTEtMA_ebcc4f3f-44fb-4616-b9e6-2ec92cb810dc">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzEtMTMtMS0xLTA_c7cd98d9-61c8-44ed-bcda-4418c48619ea">592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iddc7094e93e045b7b4aade122a21ba69_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItNy0xLTEtMA_16d5f482-13e2-4c57-9c4b-9551c90178ee">95,186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6f7ea91dc8646daa2cc71ca00f38850_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItMTEtMS0xLTA_0e3543a2-f33c-45ae-ac96-df7755bea8ab">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItMTMtMS0xLTA_4dec8ed4-e5a9-4b91-aaf6-d79e8761a3d5">95,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Balances at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4d0c82cbf5e5409490970fcf70c60bb2_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMS0xLTEtMA_3ce3a770-dc82-43d9-aff8-c51a15708a55">115,972,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d0c82cbf5e5409490970fcf70c60bb2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMy0xLTEtMA_12b526c1-5bd4-4b5a-b62f-64d9c9655608">1,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d79e000a7564936afd32ea6d9c1290e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtNS0xLTEtMA_efff0718-f46b-47be-92b6-8963c19f289d">1,090,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f5e0542d6f24c119eae1888c0d6a5a8_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtNy0xLTEtMA_cd098e08-b316-49d5-8015-384074eef343">656,985</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21e69f23c33c473daf20855d84a342a2_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtOS0xLTEtMA_7288612f-2c55-418a-9601-2ba92c037c7b">2,449</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1f574b2f8c4344aa08242f7ae98ac4_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMTEtMS0xLTA_70e330a5-5226-42b8-af59-649b404a6f08">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMTMtMS0xLTA_4f3e08a9-eaa0-4f6a-a940-cba0b5fa64a3">432,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMS0xLTEtMTU2NQ_7fa11a3d-2a18-4393-89c1-cecbaa572b9b">1,395,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMy0xLTEtMTU2NQ_b198344f-9382-4b09-a4d9-8c9d0e552a6f">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctNS0xLTEtMTU2NQ_d66d4cd1-a1e7-4c2e-b984-be1dac548e25">8,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMTMtMS0xLTE1NjU_ecc48d56-8db1-49fa-a3ff-79d6bb84d0c2">8,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance of common stock under employee stock purchase plan</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtMS0xLTEtMTU2NQ_97cb2469-437c-42d3-9b40-ede82300fc5b">274,382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtMy0xLTEtMTU2NQ_26e29698-fd8d-4f17-a35f-8e535b73dc34">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtNS0xLTEtMTU2NQ_686630e5-8bf9-47ff-9895-504e1fb8c8df">2,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtMTMtMS0xLTE1NjU_12b8bff5-835e-40eb-bf76-bc7084877181">2,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMS0xLTEtMTU2NQ_2789ff6d-250c-49ee-9188-e03f2891c4aa">24,420,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMy0xLTEtMTU2NQ_5e05bd9a-567f-4a87-b80e-cd0b76b7ad3a">244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktNS0xLTEtMTU2NQ_127a501c-bed8-4d07-a0dd-272aa7a7b50c">142,282</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMTMtMS0xLTE1NjU_8558fbb5-2912-4b18-ba43-04f0289312c2">142,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzAtNS0xLTEtMTU2NQ_cd56a1aa-6d80-4af4-923e-15d13671fe9b">25,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzAtMTMtMS0xLTE1NjU_585a4ed5-637e-42c5-9ba8-1f8cfd4bc05d">25,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Acquisition of additional shares of Sangamo <br/>     France</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf0ea9431c824de99c89f4536634ee4b_D20200101-20201231" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzEtMTEtMS0xLTE1NjU_09a8793a-96d5-4eea-a1dd-900221102e8f">927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzEtMTMtMS0xLTE1NjU_d3f0c202-db5b-4af4-b295-0891aaf35e1c">927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia724ba89921d4bbfb3ab7f41022dfa7c_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItOS0xLTEtMTU2NQ_e6959866-bb08-4cba-a10c-404ee8c12846">8,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItMTMtMS0xLTE1NjU_3e70ebc0-9194-4f30-b2bb-ba5693bce4ac">8,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Net pension losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia724ba89921d4bbfb3ab7f41022dfa7c_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtOS0xLTEtNTU2MA_d1004658-a4b2-4ea2-8332-8a09e92aaed9">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMTMtMS0xLTU1NjA_360aa1c6-b58a-4cd1-9152-d8827b4a060c">193</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Net unrealized loss on marketable securities, net of tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia724ba89921d4bbfb3ab7f41022dfa7c_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtOS0xLTEtMTU2NQ_85e593d2-250b-4ea9-9418-e4b55266ca51">284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMTMtMS0xLTE1NjU_215a5905-2ffd-4d56-9c5a-0ab2fe4bd551">284</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if95cd0d324cb450abdb22b5197a92e30_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzQtNy0xLTEtMTU2NQ_661e25c2-95ee-4f5e-8810-8ac022f8b4c9">120,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf0ea9431c824de99c89f4536634ee4b_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzQtMTEtMS0xLTE1NjU_2f3526c9-a5b2-4d90-b630-aaacfc1e51d5">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzQtMTMtMS0xLTE1NjU_e89898da-d040-459c-beaf-e6e75904372b">121,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">Balances at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1627062e2d1a4e6db06f7f2ed164591a_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtMS0xLTEtMTU2NQ_66aa6039-16a0-4db0-8fa4-6829591bb5bb">142,063,203</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1627062e2d1a4e6db06f7f2ed164591a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtMy0xLTEtMTU2NQ_1ad68d70-a419-4c06-9c4f-4365f2afdf1a">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0eae3c26ed10449298243b22f0dc770f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtNS0xLTEtMTU2NQ_6fe791c9-e370-4508-9906-b9ce53460216">1,269,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2728c5446992435fa94d6ae800954885_I20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtNy0xLTEtMTU2NQ_9bd15b02-ba2f-4113-a015-a5633798f9ed">777,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1e7cbe14db45d6a003fba4484e6074_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtOS0xLTEtMTU2NQ_502dd295-0b47-403b-9fad-5f5f67f1c322">5,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd9bdcf4f1749ed855ea52ac19c1e57_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtMTEtMS0xLTE1NjU_c4ed8f03-0575-4865-8a5e-1ecd3c259a53">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.4pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtMTMtMS0xLTE1NjU_c8cfc398-ce27-4c71-976e-d56c8c05f432">497,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:700;line-height:100%">Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMy0xLTEtMS0w_5cb4f1ac-5e3f-468c-8d6e-7fb76c32204c">121,122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMy0zLTEtMS0w_91853b78-cc1d-4aa2-bcc3-697ec84e1c50">95,419</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMy01LTEtMS0w_fb88be44-6c40-49e2-95f0-def1d53bc70d">68,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNS0xLTEtMS0w_12b5a665-df89-4b9e-85d4-45722ac04c8d">5,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNS0zLTEtMS0w_73261503-9106-4a7c-a530-2fc76460e13d">3,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNS01LTEtMS0w_bf23cb73-9d7a-4238-9829-ab416e1af18e">2,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Amortization of discount on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNi0xLTEtMS0w_ed10fba4-bfba-4f8b-892c-091a48644afd">825</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNi0zLTEtMS0w_1a80f700-b449-43bd-be87-06831424e2f6">4,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNi01LTEtMS0w_86d637a9-d0fe-4aa7-ad17-12788198f6d9">5,829</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Amortization and other changes in right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNy0xLTEtMS0w_18479a4f-9eb6-4c17-a6f0-d3bd809e8af0">7,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNy0zLTEtMS0w_da504d8a-0197-4a37-bf78-e9cbbc4fee79">5,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="sgmo:AmortizationAndOtherChangesInRightOfUseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNy01LTEtMS0w_f56893d9-b60a-47a2-9225-945bc60739a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Gain on free shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="sgmo:GainOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfOC0xLTEtMS0w_974c6988-f55f-45dc-822e-a9d1db527a23">63</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="sgmo:GainOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfOC0zLTEtMS0w_d7ef6aa1-c63e-4ea2-afeb-7732692c2eeb">488</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="sgmo:GainOnFreeShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfOC01LTEtMS0w_1c5102cb-feaf-41b9-b9a3-b166992f4893">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Net loss on disposal of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTAtMS0xLTEtMA_60b20577-6d93-42e4-b6ef-af5bc5e3db15">222</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTAtMy0xLTEtMA_e86d1894-d32f-4b1c-a8ac-b7d5447b9ea4">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTAtNS0xLTEtMA_b33c5782-47e2-40b8-ab75-adb59ed85b3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTEtMS0xLTEtMA_fb180db5-470e-4d7c-97bd-c33b099c3942">25,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTEtMy0xLTEtMA_2f7f2991-7fd8-4954-a61e-82bd57607f8c">19,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTEtNS0xLTEtMA_2a154522-f8b5-4673-baf3-f9ff6911093e">14,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Net loss on lease termination</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTMtMS0xLTEtMA_7240a97c-e4ed-4407-adac-2cd2b1d1d16b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTMtMy0xLTEtMA_a6b59460-b16c-456f-a1c1-d3b9a2ad4731">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnTerminationOfLease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTMtNS0xLTEtMA_21a28e70-a409-4ff4-b52e-1255c58327df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Build-to-suit leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sgmo:BuildToSuitLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTQtMy0xLTEtMA_40e012a0-ad44-42ca-a371-85658d1338f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="sgmo:BuildToSuitLeases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTQtNS0xLTEtMA_24ab2296-140e-48c9-b391-a4c023d11a05">966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Net changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Interest receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTctMS0xLTEtMA_a163d9e9-05ef-4811-9783-ff1a6d34b81c">353</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTctMy0xLTEtMA_75865483-2ba3-4461-82c1-f51ce8b8e822">307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTctNS0xLTEtMA_2ebcc4e2-7d34-4542-b972-e9e5ebb68e67">135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTgtMS0xLTEtMA_8c298376-3bef-4d52-8f30-072208d32c9d">31,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTgtMy0xLTEtMA_e043bfcf-55f3-41ba-8707-2463a35f85fd">32,236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTgtNS0xLTEtMA_e41dab0e-b75e-4a62-b685-3f23d13da82a">1,330</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTktMS0xLTEtMA_1dff1ad4-b1c7-4d0a-b47c-9ba1a41757a7">10,411</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTktMy0xLTEtMA_8cb7cbe8-a160-4e11-bac8-2eb39d977ac3">6,660</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTktNS0xLTEtMA_926313f9-71be-464a-b2e3-e29713eca93d">2,828</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Accounts payable and other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjEtMS0xLTEtMA_5b3f9046-c4e5-4dbc-98f4-3600c0c16ad9">10,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjEtMy0xLTEtMA_86ffb13f-8011-4f18-b137-6b90cefc3f87">4,192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjEtNS0xLTEtMA_2144b048-3e38-446d-b023-e664b0f27187">6,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Accrued compensation and employee benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjItMS0xLTEtMA_c0bca357-76ef-4f4d-8a77-4981eb6d6d52">6,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjItMy0xLTEtMA_c8fbdd16-a044-455c-ac92-1e3881df2518">4,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjItNS0xLTEtMA_e14e1185-3114-4805-9149-cff9ede0c5db">2,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjMtMS0xLTEtMA_05ff662f-69d2-44df-bfdd-1265cece0960">216,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjMtMy0xLTEtMA_9602ad1f-2695-44d5-95a2-fcc3e462fe0f">35,693</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjMtNS0xLTEtMA_ee901139-1d01-41b9-8edf-0d679ea933e1">99,364</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Long-term portion of lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjQtMS0xLTEtMA_f258d9ab-d63f-4496-b44b-0da784d034b6">3,761</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjQtMy0xLTEtMA_aa0fb39c-06c4-4c5d-a58e-2993a4fea705">1,800</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjQtNS0xLTEtMA_7209b6a0-71cd-4f6a-a6e2-cd912ed5b994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjUtMS0xLTEtMA_83462334-9948-4ac6-bf93-e48d9ac111a0">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjUtMy0xLTEtMA_be50ec1b-1674-440d-b977-29fe0d7ddd98">3,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjUtNS0xLTEtMA_24cb331e-d04b-43c3-8281-e024719f3fbe">1,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjYtMS0xLTEtMA_59b9b011-4e79-4389-bc74-7dadefdbb88b">169,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjYtMy0xLTEtMA_b76a2052-cfda-4bc2-9e3b-e142be1f70b3">144,402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjYtNS0xLTEtMA_396e738d-6055-478b-b4ab-ff9bd57cb5e1">36,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:700;line-height:100%">Investing Activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Acquisition, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjgtMS0xLTEtMA_702d8161-8b64-41e5-8ec0-6d53f772d74d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjgtMy0xLTEtMA_77fd5b27-9648-4fcf-97e2-7bb610aea086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjgtNS0xLTEtMA_7923797a-199c-48f0-9886-b7bd46f1a816">75,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjktMS0xLTEtMA_beb0d48f-00bc-4a2e-a034-637890cb1a28">570,779</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjktMy0xLTEtMA_914e45fe-a512-4d61-8b0e-d644719cc8fe">443,711</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjktNS0xLTEtMA_7ef4f4a6-d5c2-4f77-b2f6-e7970f43ad97">451,239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzAtMS0xLTEtMA_11cf818d-539b-43b9-873a-9f590eff43a8">314,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzAtMy0xLTEtMA_065c20d5-1bba-44fb-a543-e25c635e5412">404,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzAtNS0xLTEtMA_bc3c59d7-9062-4f65-9c89-21cee2270feb">391,845</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzEtMS0xLTEtMA_297defee-ec8b-4879-9126-c30e96e9df37">14,714</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzEtMy0xLTEtMA_2338b794-50b5-4211-968b-e838e48348a6">20,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzEtNS0xLTEtMA_29e0a9cf-a1bc-4014-b971-9eacbb589f34">43,065</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Purchase of additional Sangamo France shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzItMS0xLTEtMA_b7cd90b1-6d99-4efb-9819-f269b788cf45">704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzItMy0xLTEtMA_786ca13a-98d6-48da-abd5-b3f8c5e5b746">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzItNS0xLTEtMA_482af546-270b-40df-bdfd-b062c5e40f70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzUtMS0xLTEtMA_0108d647-dc03-4d9b-b8cc-193920030df3">271,627</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzUtMy0xLTEtMA_eb2860f4-3c52-4456-89c5-82f5e65ca065">59,801</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzUtNS0xLTEtMA_c9cfb309-c7d3-40dd-b2cd-89934d7634ec">178,106</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:700;line-height:100%">Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Proceeds from public offering of common stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzctMS0xLTEtMA_5bcdc003-9f61-4a06-b068-4746ef65038c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzctMy0xLTEtMA_e8a1afe3-81c6-4707-81ec-85117ce58e0d">136,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzctNS0xLTEtMA_2b04692e-de2c-4509-bed7-230055e10f68">215,758</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtMS0xLTEtMzU2NQ_bd3ef52b-cc70-41da-942b-93e06deafb39">142,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtMy0xLTEtMzU2NQ_d86be87a-88a4-4272-9957-369e68d7787d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtNS0xLTEtMzU2NQ_481a3d2f-32ae-40d9-af2d-0c853a6e3905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtMS0xLTEtMA_c5d95e3b-7d7a-45c6-905c-c2aac57b8e43">765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtMy0xLTEtMA_d390188a-f266-499e-adcf-1dc068ad221e">422</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtNS0xLTEtMA_f58f0b8a-ab15-442a-bf1b-a4d2e0d323fc">254</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under employee stock purchase plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzktMS0xLTEtMA_df672156-ab78-431a-9c28-3f89e97d2795">2,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzktMy0xLTEtMA_5dc366bf-9482-485d-87ed-ad598aea6960">2,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzktNS0xLTEtMA_3674a3f9-df37-41af-8400-cc3b5893e6ba">1,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Proceeds from exercise of stock options and restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDAtMS0xLTEtMA_d14ece2c-389d-4ad1-bcdf-330c8bb084fe">9,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDAtMy0xLTEtMA_d5896c87-f2bc-4be3-acc6-a83b9eb1d3d6">4,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDAtNS0xLTEtMA_3002750a-d0c4-468e-9c7a-bcdbcfeb4562">14,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDEtMS0xLTEtMA_e074d325-5a61-4dae-9a02-e19d1a70e825">153,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDEtMy0xLTEtMA_a4ca2ddb-9326-4940-abaf-a9131f0c0f18">142,029</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDEtNS0xLTEtMA_143cfc13-7205-427e-9338-2e31ae4fdcbe">231,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDItMS0xLTEtMA_7e06340e-2989-4b78-9823-79c3b1717723">447</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDItMy0xLTEtMA_b0629036-edd0-462b-a226-80a7b555b065">184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDItNS0xLTEtMA_80700e5c-4127-4aa4-a2e8-ad3705ef8a18">439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDMtMS0xLTEtMA_9bb360d9-c3e5-40a7-ba4d-9a4239f08056">50,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDMtMy0xLTEtMA_c196557e-42b0-4aef-959d-6ff408346b14">61,990</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDMtNS0xLTEtMA_00b0c802-7c2b-4c06-85bd-0251b26f1142">90,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDQtMS0xLTEtMA_3b210d98-79b8-4817-be0f-af39ddbc8e58">81,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDQtMy0xLTEtMA_b75bc04f-645a-4273-a5f7-a2926ce8e52b">143,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1099157ecec044679915cbcb253acd13_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDQtNS0xLTEtMA_79213399-fdb1-4f02-8364-f07de87eba27">53,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDUtMS0xLTEtMA_6fd03223-eacc-4cba-901d-3b01e5d5a3ae">132,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDUtMy0xLTEtMA_d7d52aee-f98e-40a5-9797-bffbdb0d275a">81,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDUtNS0xLTEtMA_e42da688-0be4-4429-b8c0-4d3e742c082d">143,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:700;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Non-controlling interest for acquisition</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDctMS0xLTEtMA_634f2547-7ca1-4ac4-b599-35107a39d072">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDctMy0xLTEtMA_66a755ee-2c78-4693-a0af-b986ae32a712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDctNS0xLTEtMA_3be0ae62-415f-4f95-bcdc-9aa07f94ca63">1,313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Property and equipment included in unpaid liabilities</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66dc03e15abd412984fd7c2b45d9d856_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDgtMS0xLTEtMA_ad458279-5b21-4db0-be38-c0abc897598f">4,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3eca6f8c437940cbabb9d377e58e590a_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDgtMy0xLTEtMA_db924a19-a6ea-4490-b8ac-94217c0c8b9c">2,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie858b057f0224ebf8778dd6b34548eab_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDgtNS0xLTEtMA_95f6e154-23be-40c5-88be-0af9ca95ea9c">4,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Build-to-suit leases included in build-to-suit liabilities</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c141aaf58334fba855db4ee4e38db81_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDktMS0xLTEtMA_0693b4fa-f08d-4ec5-9658-d3e807b2722d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0ad2d8d5ce840e99dbd93fd64e0439e_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDktMy0xLTEtMA_dd7667f3-0edb-4faa-b85c-a3ac99bdb2db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8133ce2775074245969bc9f50d4ffa89_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDktNS0xLTEtMA_503be08b-9fb7-4323-bd6c-d9ae039991d8">2,950</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNTAtMS0xLTEtMA_23317cd5-8c55-4a41-ba9c-36797959e901">1,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNTAtMy0xLTEtMA_ff8d9a9b-86d0-4aae-8e71-7195b8260dd0">31,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.3pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNTAtNS0xLTEtMA_0b515a63-8389-4ff0-a44e-10d282873919">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:15pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SANGAMO THERAPEUTICS, INC.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="i24672e5030474c1ba9673ec16c177662_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTE_933a90b7-3b0c-43a4-b127-f4a2f682ce55" continuedAt="i47a680068afc4945a0dfd608cccc5543" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i47a680068afc4945a0dfd608cccc5543" continuedAt="ic347066555464dee87f32deb06cd4185"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases using its platform technologies in gene therapy, cell therapy and genome engineering. </span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDY_3da82dd7-82b3-4216-8d25-79243c931374" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S.&#160;GAAP&#8221;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of December&#160;31, 2020, when combined with additional capital raises and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next 12&#160;months from the date these Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTI_ca12f965-d6e5-4537-8c55-a54b2278da32" continuedAt="iec3a3b256632494dbae2fbc0eeca67ed" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, including the estimated fair value of common shares issued as part of the transaction price, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#8220;Sanofi&#8221;) and Pfizer Inc. (&#8220;Pfizer&#8221;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $<ix:nonFraction unitRef="usd" contextRef="i196e1cc25f284d418cc58737e82a5139_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTA5OTUxMTY2ODQ4NQ_dabf28c4-1fbf-4cf6-a9d4-674afcbfd3aa">8.9</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="i196e1cc25f284d418cc58737e82a5139_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTA5OTUxMTY2ODQ3MA_c6c465b6-4d3d-4345-b5a9-6d9f7ac35f18">8.9</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i196e1cc25f284d418cc58737e82a5139_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTA5OTUxMTY2ODQ1NQ_56b0b357-c59c-4b05-b6c7-537bb1545923">0.06</ix:nonFraction> for the year ended December&#160;31, 2020.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iec3a3b256632494dbae2fbc0eeca67ed">During the year ended December 31, 2019, the Company recorded adjustments to revenue related to a change in estimate in connection with the giroctocogene fitelparvovec collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;). This change in estimate was driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance.</ix:continuation> These adjustments increased revenue by $<ix:nonFraction unitRef="usd" contextRef="if1555d5279c444f89f02b32de1c4f4c5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfNDYwMw_515304c3-1708-47eb-9a0a-fc36af0df90c">5.7</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="if1555d5279c444f89f02b32de1c4f4c5_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfNDYzNw_e25d9381-a024-4843-908b-7fd0b8ee86ee">5.7</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="if1555d5279c444f89f02b32de1c4f4c5_D20190101-20191231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfNDcwNA_2b2115cf-a3ca-40e4-8553-f129183eac4b">0.05</ix:nonFraction> for the year ended December&#160;31, 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="ic347066555464dee87f32deb06cd4185" continuedAt="i36cc1d952ad5428786d62a4e19932b13"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDc_5d88bee9-bd22-4f66-8b0b-d30092a14c18" continuedAt="ib95b13252bdf4790b4b95b3bff696d44" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDA_b992c75b-354f-456b-ad2c-42d02e1b00dc" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe21513e3cbc4ef9b8379cf9af56af7d_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMi0xLTEtMS0w_c057ec93-713d-4515-a2d3-26093381de4b">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2340761cd284f108a1e5d64cc980af8_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMi0zLTEtMS0w_3838f410-524e-48a2-95a7-e79fbacb1241">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i30e0b646a8df46a79e760eb6aaef235e_D20180101-20181231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMi01LTEtMS0w_33488b64-5b27-4721-9451-ba21fcbfdc47">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i88b6be668e8d446b9d5199171f704f9f_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNC0xLTEtMS0yNjc1_140bef75-1dd3-454c-8af5-626ebe67b727">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf6e9495caa24ce480ffea19c28f507b_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNC0zLTEtMS0yNjc1_06a57c77-1a3a-4698-b9c6-b340d45bb5a3">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i04e7b9f9d96a4feca307fbdfe9824533_D20180101-20181231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNC01LTEtMS0yNjc1_c573c306-1443-4041-9866-501e39ab2238">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifafcd10a99b94ea9a3cd858f75019057_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMy0xLTEtMS0w_f72f67aa-3055-4cff-920c-9f9c015e5c4b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iae79ca8469af4ddda9eb0ae2461bfda7_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMy0zLTEtMS0w_c458bbd3-84b7-448f-b488-a225c9a25113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib362499858ff441b81abb16c4b161e94_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMy01LTEtMS0w_adbcb9d4-8129-4759-b4cc-89cac2dcff16">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi Genzyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id5af392ecf9040dd85a30262c5b91b6a_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS0xLTEtMS0yNDYy_ff7b7105-da4e-47b2-9a07-fdc734a8511d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i21037a15db8240bba2e6a6eacf66d265_D20190101-20191231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS0zLTEtMS0yNDYy_3edf9bbc-8549-46bd-a827-633a3dc321ea">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i05a8036803764bc19d8b0408d9a6778e_D20180101-20181231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS01LTEtMS0yNDYy_7be49b4d-9538-4ccd-ad6e-41bee8aa8530">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffb1c905529f4b78895e5ec6a2fb1454_D20200101-20201231" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS0xLTEtMS0zMTc_43938f2d-194d-4c3c-aee0-e0ba7877448c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75abcc855e7c486a8f9453c309984ec6_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS0zLTEtMS0zMTM_a0fb8d14-f4ef-475a-8fe9-faeed6d8d98c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifef75ce3e3d4408195a24cf8317ce59b_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ConcentrationRiskPercentage1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS01LTEtMS0zMTM_d69ae6d9-aa53-4ccd-bef5-c58a99c95cce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i36cc1d952ad5428786d62a4e19932b13" continuedAt="ie760693171a243ccb9d114335ec1e119"><ix:continuation id="ib95b13252bdf4790b4b95b3bff696d44"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as it fulfills its performance obligations. The Company&#8217;s performance obligations are satisfied over time (i.e., stand ready obligations) or using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div></ix:continuation><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDE_54317c18-add4-4227-b105-752f6b393aaf" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div></ix:nonNumeric><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTA_bf5c5a55-d5f7-46ef-9234-086fabe88fa7" continuedAt="i8698ffdfef3846ef835d9aed174325c9" escape="true">Goodwill and Intangible Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8698ffdfef3846ef835d9aed174325c9">Goodwill represents the excess of the purchase consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.</ix:continuation> As of December&#160;31, 2020, <ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillAndIntangibleAssetImpairment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMzI5ODUzNDk1NTYxNg_69c11715-9813-4604-8a46-f998989f0ffd">no</ix:nonFraction> impairment of goodwill or indefinite-lived intangible assets was identified.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDI_8d6385b6-2de9-4359-bf00-3933eacbe010" continuedAt="i0376eeea5b0a4b0a9af37990075d6491" escape="true">Valuation of Long-Lived Assets</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0376eeea5b0a4b0a9af37990075d6491">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</ix:continuation> As of December&#160;31, 2020, <ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMzI5ODUzNDk1NTYyNw_7b9c29c9-fc33-49f2-ba54-48b2493dce4c">no</ix:nonFraction> impairment of any long-lived assets was identified.</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5MzM_fe726a22-cb90-4d86-9eb7-54071d3f8bc2" escape="true"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.</span></div></ix:nonNumeric><div style="margin-top:15pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5Mzc_60bb82c1-87f0-401a-ae6f-121cb150bbcd" continuedAt="i52fd83e7843542618a785b9bdccc0fe4" escape="true">Cash, Cash Equivalents and Restricted Cash</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="i52fd83e7843542618a785b9bdccc0fe4"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cash, deposits in demand money market accounts, and commercial paper.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Restricted cash consists of a letter of credit for $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTQ2MTk_10c09fc4-fcdc-45b2-9ef2-196ebc826d6f">1.5</ix:nonFraction>&#160;million as a deposit for the Brisbane lease.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="ie760693171a243ccb9d114335ec1e119" continuedAt="i30f9aece0c3c452494ec0d38f8d23349"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5MzQ_fe424033-999b-4832-8740-237921fff118" escape="true"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5Mzg_60a7d7c8-bffa-4ea7-9b8e-cddb808cd6c0" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfMi0xLTEtMS0w_215b51e2-22c3-4698-8da3-df2eb63a1f92">131,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfMi0zLTEtMS0w_e4a42600-24d9-4836-8933-e0bb63143932">80,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfMi01LTEtMS0w_4cdff864-e98f-41aa-91fc-cc63246a9bda">140,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNC0xLTEtMS0w_448b456d-6fd9-4a02-b46a-a2301bb2eb17">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNC0zLTEtMS0w_3db423bf-6e56-4c96-a443-8060f735be60">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNC01LTEtMS0w_ed71f1bb-5476-48bc-bbc2-df249dc7148e">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNS0xLTEtMS0w_3e821767-0878-4c83-9eaf-dbbda6f6c3d1">132,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNS0zLTEtMS0w_72161764-a224-4bad-8a9c-54686d30c102">81,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNS01LTEtMS0w_d4e407c3-255b-4c5c-874f-c8f874b0dfda">143,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTM_c04506f8-edf5-4b55-b624-875ae6cb492c" escape="true"><div style="margin-bottom:3pt;margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Marketable Securities</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMzI5ODUzNDk2MTIwMQ_54337b1c-e0a6-4f47-a801-3132013d373d" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments with high credit ratings which are expected to bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities and issuers of investments to the extent recorded on the Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug (&#8220;IND&#8221;) application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers was interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5MzU_bc55c045-95f4-40cc-a093-61a2405e6ab6" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTY1MDM_37296027-8590-4fe0-b3ed-3ef8d7731671">three</span> to <ix:nonNumeric contextRef="i6b662a6bf84f48d6baa29804b606526c_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTY1MDk_84b802dc-db20-4a10-8005-0d91bfd926b4">five years</ix:nonNumeric>. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDU_be26215e-77c6-4386-8ac6-ac7c10b38aa1" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, materials and supplies and overhead allocations consisting of various support and facility-related costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTg_400296f4-93d2-494b-a88f-eb98e07c10d9" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i30f9aece0c3c452494ec0d38f8d23349" continuedAt="ic320d414f3a649b6b8ca66f9eb2d84ae"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTk_f7da9f06-64f6-43a5-9034-83d1768b3bb0" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#8220;RSUs&#8221;) and employee stock purchases related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDk_938d7fcb-a047-4c72-872b-381f1aec9f3f" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#8217;s Consolidated Financial Statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within other accrued liabilities on its Consolidated Balance Sheets.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMzI5ODUzNDk2NTkzNA_5fb50575-6528-4ff8-8539-603a983e4cb4" escape="true"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on January 1, 2019, using the modified retrospective approach with a cumulative-effect adjustment. The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NjA_f8312a85-7da5-4ba5-b177-aeecaa8889c9" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Foreign Currency Translation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Consolidated Statements of Operations.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="ic320d414f3a649b6b8ca66f9eb2d84ae" continuedAt="i63657d79cd984959be8e11e1e0968de3"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTQ_9532408e-0bb8-428b-a8a5-bbcd6e3f7eab" continuedAt="id2af658637be47b0bafb4fa2847951d5" escape="true"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id2af658637be47b0bafb4fa2847951d5">The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders.</ix:continuation> Stock options and RSUs outstanding and ESPP shares reserved for issuance as of December&#160;31, 2020, 2019 and 2018 were <ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjE1Njc_961eeabb-6560-448c-8da9-2b3c9dac452c">14,237,871</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjE1NzE_d74ebbf5-3b90-434c-987b-466486013541">10,750,550</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjE1Nzk_7f7434d9-9506-47e0-88f5-21eb27c436e4">9,048,793</ix:nonFraction>, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5Mzk_d899d7bf-4bdb-4b63-96e1-4d910390047d" continuedAt="i10c1c6d3f25b473aa2d39e23d0f93f82" escape="true">Segments</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i10c1c6d3f25b473aa2d39e23d0f93f82">The Company operates in <ix:nonFraction unitRef="segment" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjE2MzA_ed30218e-6ff5-485d-b723-88dc65635b07">one</ix:nonFraction> segment. Management uses one measure of profitability and does not segregate its business for internal reporting.</ix:continuation> As of December&#160;31, 2020 and 2019, substantially all of the Company&#8217;s assets were maintained in the United States. For the years ended December&#160;31, 2020, 2019 and 2018, substantially all of the Company&#8217;s revenues and operating expenses were generated and incurred in the United States.</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTc_407117d3-eebb-410f-b1f6-989b5239fea1" continuedAt="ib6019c5f0f964a96a72f9ceeac4a52b2" escape="true"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2018-18&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill Impairment Testing</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2017-04&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December 15, 2019. ASU 2017-04 required the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Credit Losses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326) (&#8220;ASU 2016-13&#8221;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes &#8211; Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). The guidance removes exceptions to the general principles in Income Taxes (Topic 740) for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on the Company's Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i63657d79cd984959be8e11e1e0968de3"><ix:continuation id="ib6019c5f0f964a96a72f9ceeac4a52b2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cloud Computing Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other-Internal Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2018-15&#8221;). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance becomes effective for annual reporting periods beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard on January 1, 2020 using the prospective method. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div id="i24672e5030474c1ba9673ec16c177662_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzk3NQ_11b4a6e2-1e78-4a68-9d50-5bfeabda5d33" continuedAt="i0acf5e90baeb4f27b12b723fde579555" escape="true">FAIR VALUE MEASUREMENT</ix:nonNumeric></span></div><ix:continuation id="i0acf5e90baeb4f27b12b723fde579555" continuedAt="idbf936c4517944c2a11f3e161ab13154"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities and the free shares asset.&#160;The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supported by little or no market activity).</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzk3Ng_50900710-6c33-43de-b0d0-6683c33753b1" continuedAt="i42143a44b36544bd8f6f3749992197a4" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3a7053c82b34112baeacb539acdacee_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNS0xLTEtMS0w_fd3904c9-bf32-4508-9650-6fd18a8757a1">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife4a9b65e8c8453ab64e7777ee2d3100_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNS0zLTEtMS0w_4b12becd-3c5f-42ec-b00b-d044b10ce9d5">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i538799473b654234a0fff4940007026d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNS01LTEtMS0w_f8b6879c-855e-492d-9ce9-0a17cd82a9ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if3382b9ba2d54e45aab7d37fe53c048f_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNS03LTEtMS0w_dda45472-e79e-4951-8bcd-d57231bb6e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf0705352c54572bf4f38ac982a31be_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNy0xLTEtMS0w_17a8de45-92e0-44f1-b354-aa40562604ba">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c02145fa9242f38709a5edc46b448e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNy0zLTEtMS0w_13416993-ebd6-47d9-9553-07a45a50efea">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa885c5039e145c09f646a2a7f4b8107_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNy01LTEtMS0w_6dc93880-3d8a-4619-914c-4af0bfc9cec4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3adc9c15cd451ba7eaf4b09cd384e5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNy03LTEtMS0w_81d74dc0-e910-4705-8cfe-49617fea8567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i561ac4ef919945fa872f15ce1139a321_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfOS0xLTEtMS0w_c0933f27-73f8-4e68-b0cf-5b17395f7484">213,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i031949a99f364927ac232102e610e2ca_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfOS0zLTEtMS0w_d1227494-5a26-4376-984c-43cd1de0bd99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98278431e88f4c0db17846d0b3dbbad8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfOS01LTEtMS0w_6fb39f9c-ea43-4ec2-8352-4536070b64e8">213,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6465df1f81a4ab5a788482e7565d968_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfOS03LTEtMS0w_d4e5a4a2-a534-4e7f-9dd7-108875c6fbef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id92a9f54439349c1a5e6a1bba22a0d23_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTAtMS0xLTEtMA_c73070fc-a047-45be-a08a-50df92492e28">59,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1a201eb484d4bd5a0b59012ba2f791d_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTAtMy0xLTEtMA_38cd0a8b-ce7f-4c6f-a1df-7b79f79f95dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16d9dab193d54c309786833b5661b693_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTAtNS0xLTEtMA_674e930f-7284-4fc3-8288-2b4f8d0fff74">59,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5c17352407648038a079be92904f2a3_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTAtNy0xLTEtMA_383a8b92-ef3c-492c-b749-7917a2fedd4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307cf2a5e93040adbb97545d97da4f9a_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMS0xLTEtNzU0MQ_e7672b94-30f8-4182-b232-ef1a8f4f833e">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8632ee484ed4ce287dd150a59f7e976_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMy0xLTEtNzU0MQ_28b9f7bb-1d7e-4a03-aa00-6eb8302f7765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifed10ba46af8409e8b84b8e8186dc592_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNS0xLTEtNzU0MQ_2e6e0b5d-ecea-4978-b289-39d750dd097d">12,311</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8205c80a5c0477aaa06acb0a8e8e7da_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNy0xLTEtNzU0MQ_bfae44ef-7289-405e-b841-d0bca7c4f4ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4478684879bc414381bb41ce8b5add16_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMS0xLTEtNDcw_3a4ed37c-e492-4efb-a848-37a001cf5b64">17,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e83dea29142486786bea569ac583153_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMy0xLTEtNDcw_736e6ac6-4e81-4bd6-b46b-5d63b10bc0b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i638b4338e64c4c0c9035f64c4bda767b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNS0xLTEtNDcw_7dc5db33-7120-4fdd-8c2f-5a4298a930be">17,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6648a09a42b483cb342868211de9128_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNy0xLTEtNDcw_b7344abc-22ce-4a3d-8009-845d537f3853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea9ff66312d4cb985f8cc0115634d45_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMS0xLTEtMA_9e38a1ae-af95-4a9e-8bec-72f06024587e">257,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bb9617224f949bbaa727b52246f5819_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMy0xLTEtMA_1459cd70-0964-426e-8ae4-4c4898534f66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i290f705cf9df4b7c8d071b425026aec8_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNS0xLTEtMA_eab17e3f-1211-4d96-87c6-35c862989164">257,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaaf320a38a84e55affa256f7f30ad18_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNy0xLTEtMA_0209078c-c521-4229-83d9-1ddf8d924dc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf0705352c54572bf4f38ac982a31be_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTItMS0xLTEtMA_c3b22f3c-2f24-4d32-be4a-9ec0c68c3abb">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c02145fa9242f38709a5edc46b448e_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTItMy0xLTEtMA_358adf1b-3a76-4198-911d-8f8a2a3d02ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa885c5039e145c09f646a2a7f4b8107_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTItNS0xLTEtMA_411969a7-9373-40a0-ab2f-77a78c8da059">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3adc9c15cd451ba7eaf4b09cd384e5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTItNy0xLTEtMA_7b502cff-f3f6-4a32-9bfd-a31969c83ece">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bf0705352c54572bf4f38ac982a31be_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTMtMS0xLTEtMA_f5c371fb-e5b3-4e94-8842-96de207c148d">613,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26c02145fa9242f38709a5edc46b448e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTMtMy0xLTEtMA_96ad94f7-deda-4da6-aa20-766f60d01ab5">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa885c5039e145c09f646a2a7f4b8107_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTMtNS0xLTEtMA_137035eb-5c28-4e7a-a8b6-4d5937b8aefd">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b3adc9c15cd451ba7eaf4b09cd384e5_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTMtNy0xLTEtMA_cb368ec3-287a-47f1-acd9-781fb33ac17d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c791708c2b54c489b0564343ced9b29_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTUtMS0xLTEtMA_d5809cf7-f90b-4a68-9a55-5e71886c1c1a">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd782cef16a4070ae70af4879663f30_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTUtMy0xLTEtMA_e62f60d5-ee07-4d7a-b237-2f4999fcfbaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de38cf429814456bca0ed781cb6c510_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTUtNS0xLTEtMA_1360b414-0867-454a-93bb-96885d1323eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i452c62674a9a4271ba5e89c6c050a050_I20201231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTUtNy0xLTEtMA_85d4a657-0167-4c56-9ff1-bcb4e18deb71">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="idbf936c4517944c2a11f3e161ab13154" continuedAt="ie9ce80305656497fa946ed569552d636"><div><ix:continuation id="i42143a44b36544bd8f6f3749992197a4"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc2751230724e7381a103381d9dfb53_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNS0xLTEtMS0w_5c43032a-c367-4f79-9b17-a864843cb60c">30,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9ba3950185d4776adff785cc0c2a7d2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNS0zLTEtMS0w_bd6af0c9-87a2-4137-8f88-30d125212497">30,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b12148036dc4575b8e1a20cf11d14ac_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNS01LTEtMS0w_e1d8dad9-f525-49cc-b5b6-54b7ee04eac9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e9967af55594a0298a27d240144e1ee_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNS03LTEtMS0w_9c0eb5a8-9336-458a-9ef0-54c41521de11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67764fa5748c4450ae52695bab506bb9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi0xLTEtMS00NjM_3a6fabde-2d03-48b1-9161-711f031ab9c9">2,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4407422f7c044d0fbec953a99a3872a1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi0zLTEtMS00NjM_61826e3a-6f92-4575-ae5e-7bf67bf5a2f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfe2c49f1a646b8b8fc3e3df333620f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi01LTEtMS00NjM_9c01836a-90ff-4097-9fc0-724e37ef931d">2,999</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa947c04f600459f8abe14c30287d39d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi03LTEtMS00NjM_70de8c0a-ffbe-4805-abb9-195b9d7f3626">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6756c61effe4e938932ae8029a287b7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi0xLTEtMS0w_b5eb4eff-7fb1-4930-86bf-9b9ff8e13e0b">33,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8674e557d87406d95862eb814aebd8d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi0zLTEtMS0w_dcde8b49-c846-4f3c-89e4-e4df0347b995">30,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a51c69784164925a1155915e905a9e6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi01LTEtMS0w_17bb5a8a-ba8e-4910-8d51-52cbb052b082">2,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233261fb4cbb44eda76666923ba0fa00_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi03LTEtMS0w_ed8a11ae-6009-4b49-9b8b-5797f14c888b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67764fa5748c4450ae52695bab506bb9_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOC0xLTEtMS0w_9539e4f9-45be-4a99-87e3-85255c5122ff">155,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4407422f7c044d0fbec953a99a3872a1_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOC0zLTEtMS0w_64980128-e485-48f5-b840-6e9b2c9fd506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfe2c49f1a646b8b8fc3e3df333620f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOC01LTEtMS0w_79bf8ed0-73d0-4471-bc8b-9090223b58c1">155,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa947c04f600459f8abe14c30287d39d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOC03LTEtMS0w_210d409b-17f5-4834-bb51-92439febc671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecff100e21624aa380f317bd2cc77424_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOS0xLTEtMS0w_5809c7ac-ce3b-4a12-aa24-4f173b60abe1">95,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad5f02563ca4f3a935b0a28075cfc38_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOS0zLTEtMS0w_77f65813-c1f1-46d1-b819-62a45de73fb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief8529b02bab4938b24e07cedff4a61f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOS01LTEtMS0w_5f715f32-a9b3-405c-970d-66adf937fdab">95,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3348e7e8ad4e5e8f79068e98c38849_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOS03LTEtMS0w_df92dd12-846a-430e-9526-9d6c3bab8786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i409228d676604420a5080c8402d96e8f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTAtMS0xLTEtMA_f1100602-72c8-4868-82ba-256c9c9ce600">53,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e07e12ba97461c86c7911b067139c0_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTAtMy0xLTEtMA_24dec97b-bc2b-45a0-a27c-7876cda318d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic469cb9c12c84ba284e53503bcfe990f_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTAtNS0xLTEtMA_6e9aac05-c188-4084-b2ed-aaf761e66636">53,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89d852320136494288e8326d40cbfdf4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTAtNy0xLTEtMA_112d6f2c-f29e-4d6b-ad88-983f38465ce2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6756c61effe4e938932ae8029a287b7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTEtMS0xLTEtMA_7fd8bd90-3322-40d1-9777-64670dc7cdc2">303,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8674e557d87406d95862eb814aebd8d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTEtMy0xLTEtMA_e900d15d-11be-405e-bd6d-2a7f759619da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a51c69784164925a1155915e905a9e6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTEtNS0xLTEtMA_be2c4fce-803d-4516-885c-a19b87ebf63e">303,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233261fb4cbb44eda76666923ba0fa00_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTEtNy0xLTEtMA_857ba7f1-7975-4410-8f94-9c0341850a89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6756c61effe4e938932ae8029a287b7_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTItMS0xLTEtMA_ea8cbfea-0a91-4074-b6d2-909068eb736b">337,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8674e557d87406d95862eb814aebd8d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTItMy0xLTEtMA_0e5556a8-6735-4bd5-9d8d-a68f99bbf3a7">30,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a51c69784164925a1155915e905a9e6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTItNS0xLTEtMA_b2e2a4d4-0274-4001-a3f6-f42fbe6beddb">306,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i233261fb4cbb44eda76666923ba0fa00_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTItNy0xLTEtMA_83f7dd24-23d1-4e1d-b988-a5b6e0dc1b96">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b619f4f00de4396b3df3e86c1308164_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTQtMS0xLTEtMA_16ed1519-63fc-497f-ae7c-1b930330db8f">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica609585796849f4b3f75e74fd3cd261_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTQtMy0xLTEtMA_4ccf4974-b521-400b-a178-411d5f84f831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc061743215f46799ca3ad39e4073044_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTQtNS0xLTEtMA_096b6dd7-606c-4237-a405-498b8c10d151">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e0cda171ca943959c35929427e42666_I20191231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTQtNy0xLTEtMA_74d711e7-afdb-4015-b297-f58665580fbc">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities and some cash equivalents as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Free Shares Asset</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 5 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Sangamo France</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company entered into arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMjU0Mg_bbffd6fe-c9ba-46d3-a247-5fd5b1b79779">477,000</ix:nonFraction> &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $<ix:nonFraction unitRef="usd" contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMjg0Mg_ecbc5cdf-989c-4df1-917b-8c5633f6b66d">0.2</ix:nonFraction>&#160;million on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#8220;Monte Carlo simulation model&#8221;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Consolidated Statements of Operations. The Company purchased approximately <ix:nonFraction unitRef="shares" contextRef="i7377f8b263024b66ad603bd494ee0f22_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzQzNA_76e2abc3-40cb-406c-9f96-281f04e62773">111,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMjE5OTAyMzI1OTg0Ng_277edf15-9fae-4000-8209-12f610ad1660">322,000</ix:nonFraction> shares during 2019 and 2020 respectively, of the <ix:nonFraction unitRef="shares" contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzQ1MQ_bbffd6fe-c9ba-46d3-a247-5fd5b1b79779">477,000</ix:nonFraction> total free shares for a cash payment of approximately $<ix:nonFraction unitRef="usd" contextRef="i7377f8b263024b66ad603bd494ee0f22_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzUwOA_ef8e351e-d2ef-4da3-9454-b2cd9011bd7f">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMjE5OTAyMzI1OTg5Mg_2f1ee5e7-e8e9-40fe-a317-e9f5fe8012cf">0.7</ix:nonFraction>&#160;million respectively, upon exercise of the put options. As of December&#160;31, 2020, approximately <ix:nonFraction unitRef="shares" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzU2OQ_2a47d0f6-c69e-483e-bcbe-c718bbb874c5">44,000</ix:nonFraction> free shares remain outstanding and subject to purchase by the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the free shares&#8217; asset was approximately $<ix:nonFraction unitRef="usd" contextRef="i333a5711c7bb4f51917b34946c0b9f23_I20181001" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzY4Nw_43c85e38-cf07-4b0d-a8d1-9cac7f4d2b02">0.2</ix:nonFraction>&#160;million at December 31, 2019. The Company recognized a gain due to an increase in the fair value of the free shares of approximately $<ix:nonFraction unitRef="usd" contextRef="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzgxOA_b38aaab6-242f-4851-b838-ff7cee5572aa">0.1</ix:nonFraction>&#160;million for the year ended December&#160;31, 2020, offset by approximately $0.2&#160;million for the shares purchased during the year, resulting in an asset balance of approximately $<ix:nonFraction unitRef="usd" contextRef="i16391b7df5174ed5b8c2310d931447ad_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzk2Mw_fed56b50-c757-441e-aec9-24a817ed020b">0.1</ix:nonFraction>&#160;million at December&#160;31, 2020.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzk3Nw_ecbf34cd-9739-406f-8e1a-1ad1ccd204c5" continuedAt="id4342909c0a8490f9cb7f72197147dee" escape="true"></ix:nonNumeric><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><ix:continuation id="ie9ce80305656497fa946ed569552d636"><ix:continuation id="id4342909c0a8490f9cb7f72197147dee"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:72.684%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free Shares valuation assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibda42ad49ccb40e6a99670b2432a3b0a_I20201231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfMi0xLTEtMS0w_2ca2094e-8a46-4168-b2b7-7a4093d066d3">15.61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i40c0c8a181b34eaaa65d8a1d56afba94_I20191231" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfMi0zLTEtMS0w_19b61492-7970-47bb-9de4-0efd61f9a9c7">8.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="i40f0fb62debc4ccf8d53156b1bc24685_I20201231" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfMy0xLTEtMS0w_b2ad96fd-93d8-4141-9790-0b7440f15522">3.85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eurPerShare" contextRef="i00900b9889da4cdaa8eb8e2b586dcb12_I20191231" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfMy0zLTEtMS0w_5700d7bd-612c-453a-9ac9-74d1c653587a">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR/ USD exchange rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNC0xLTEtMS0w_e437c797-bfd5-4f41-b54b-ab42489bab01">0.82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNC0zLTEtMS0w_e936f58c-78be-4373-80fe-f22b53727e50">0.91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated correlation Sangamo and Sangamo France stock prices</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i297eba0e37914b6d8ec0577f4ee289d4_I20201231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNS0xLTEtMS0w_21b5bcc1-1e88-4845-a18a-6b1e03d00a4f">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1da1bc0ccada4c6289947f9de2c4b135_I20191231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNS0zLTEtMS0w_828ab2f5-a724-4dca-8bab-aa1e98efbccf">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD) volatility estimate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9bff90492d5f446284b8b7c02033b51f_I20201231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNi0xLTEtMS0w_b23556c7-518d-4366-806d-96f6659484ca">88.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie2a3f456b9804ec4b6dd169a8bd7f4ba_I20191231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNi0zLTEtMS0w_fd7b494a-220c-4873-9101-d58b0bfd7352">72.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR) volatility estimate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibaa6bc7784424a67be7faba1d682b136_I20201231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNy0xLTEtMS0w_96fd5768-7ff4-4bd9-9104-dacc013c4c10">88.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i010cb6bb38804fb49deced19c47e723d_I20191231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNy0zLTEtMS0w_8e14ba71-c4f8-4650-8525-2be5cce2005b">72.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR/ USD exchange rate volatility estimate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd6eb7b715da4cb69e1a51dd18e5bc9d_I20201231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfOC0xLTEtMS0w_5cfb4307-f072-45ee-8b22-434c21c498c5">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id11b23041c6d4a04a5f707b52b28660f_I20191231" decimals="INF" name="us-gaap:DerivativeLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfOC0zLTEtMS0w_41f5190d-5428-45b5-8bb1-93108e48c829">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate and cost of debt by expected exercise date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td></tr></table></ix:continuation></ix:continuation></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfNTk4_367d3de7-6eb6-4eda-8724-3f26b303d85d" continuedAt="i5caac89fbf1147f98e5a1282582d2bde" escape="true">CASH EQUIVALENTS AND MARKETABLE SECURITIES</ix:nonNumeric></span></div><ix:continuation id="i5caac89fbf1147f98e5a1282582d2bde"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:MarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfNTk5_39fcba61-2470-4611-9658-5c2340541e33" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33732cfa0f614ab6a16f0a26f36db075_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMy0xLTEtMS0w_6a9407ff-adf1-4d8c-a92b-651119e71991">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33732cfa0f614ab6a16f0a26f36db075_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMy0zLTEtMS0w_896cf895-926b-4f4d-95fe-7dd9585df765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33732cfa0f614ab6a16f0a26f36db075_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMy01LTEtMS0w_92c895f2-94cb-4994-9829-e1f94fc16803">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33732cfa0f614ab6a16f0a26f36db075_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMy03LTEtMS0w_b40fc630-17be-4dd7-8ab5-501e4106bc1c">53,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b9c44848094c8188cda00e8392c015_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNS0xLTEtMS0w_459c1fa4-2ea0-4681-bb24-a67acd1f4d08">53,165</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b9c44848094c8188cda00e8392c015_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNS0zLTEtMS0w_a67fad99-341c-45d1-a9bd-b4bb79a783ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b9c44848094c8188cda00e8392c015_I20201231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNS01LTEtMS0w_9a06c5b9-9e67-41a7-9986-79ed88a56520">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25b9c44848094c8188cda00e8392c015_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNS03LTEtMS0w_5667a7ad-1922-45ae-9216-f9334d91c863">53,165</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aae7219ce14478f887d9df6f6050a1b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNy0xLTEtMS0w_e6182fb2-8fe0-4ea3-881d-c88b6b10d97b">213,500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aae7219ce14478f887d9df6f6050a1b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNy0zLTEtMS0w_b21eeb10-2cd9-4c99-a6b2-10955d1b7d20">41</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7aae7219ce14478f887d9df6f6050a1b_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNy01LTEtMS0w_91403874-ab7e-4830-8412-0b68fa31b472">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aae7219ce14478f887d9df6f6050a1b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNy03LTEtMS0w_9efb97d4-34ca-4868-822e-685292752854">213,533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6d62eac76941a9907a1769725bc84f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOC0xLTEtMS0w_bd62dfa1-f0c5-46d6-9788-f61c363939bf">59,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6d62eac76941a9907a1769725bc84f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOC0zLTEtMS0w_924de231-cdc0-4a72-9567-2fe5c1ec1afa">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3f6d62eac76941a9907a1769725bc84f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOC01LTEtMS0w_e53d8824-b6c0-4e51-baa9-c0b047a4fb0f">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f6d62eac76941a9907a1769725bc84f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOC03LTEtMS0w_e093724c-e535-4184-ab15-2cf2de6b4bf0">59,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd506f04f5e450699099f18e1a52d5b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0xLTEtMS03NTQ2_fe8388b6-6c97-48c7-bc99-d1852f6d6894">12,311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd506f04f5e450699099f18e1a52d5b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0zLTEtMS03NTQ2_2fcb5826-b2ec-4e6e-8bc7-fee4964715ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd506f04f5e450699099f18e1a52d5b_I20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS01LTEtMS03NTQ2_44ecb1b6-8e1c-4c24-b6cc-ce645e438d77">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2fd506f04f5e450699099f18e1a52d5b_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS03LTEtMS03NTQ2_b70c9f69-2f59-4e25-8ac9-58420c6ffa79">12,311</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie054ce2f1c4741c38e021cbc84c88cae_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0xLTEtMS01NjQ_8f267830-a981-494a-ac6b-03edf8d9e07c">17,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie054ce2f1c4741c38e021cbc84c88cae_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0zLTEtMS01NjQ_4f5e491c-181e-47d2-be34-4a271a8a757a">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie054ce2f1c4741c38e021cbc84c88cae_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS01LTEtMS01NjQ_721980c7-b8cd-485a-b318-9049a37359c3">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie054ce2f1c4741c38e021cbc84c88cae_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS03LTEtMS01NjQ_39771141-00a7-4a0c-a86e-b1358ef8299e">17,908</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0xLTEtMS0w_59b46117-a751-4e34-8909-72c5a262b659">257,284</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0zLTEtMS0w_5986dd97-e43e-4468-ae4f-94e2818dec32">19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS01LTEtMS0w_87ca486a-dffe-453e-bead-38f27d3928a5">5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS03LTEtMS0w_6d7260db-5e87-4d83-81cd-1bbc9f2a61c4">257,298</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTAtMS0xLTEtMA_8813fa6c-cd9a-4cb8-82bf-7f55824060f7">560,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTAtMy0xLTEtMA_c5d90aaa-f5d7-42b5-a8d1-bbfda9772184">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTAtNS0xLTEtMA_f4d3972a-9414-462b-81d5-a525450fd97a">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTAtNy0xLTEtMA_e7abaa92-f575-4828-9dba-641f5c4ee60d">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTEtMS0xLTEtMA_e9b6f3c4-5ede-483f-b76a-63adbfc5b7b4">613,740</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTEtMy0xLTEtMA_d3179ff6-e773-471c-8aaa-0fcf8f407ec5">86</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTEtNS0xLTEtMA_cca69f88-9f0a-440b-868e-68abf2ed11f1">37</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTEtNy0xLTEtMA_032896c3-98d3-4496-bb98-ca9088f16bc4">613,789</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166d41c1d13840e79f6069d74eed0581_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTQtMS0xLTEtMA_af35f377-35e5-4bc4-973b-944c4567af8e">30,496</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166d41c1d13840e79f6069d74eed0581_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTQtMy0xLTEtMA_b52631c4-a13e-46d1-afc8-0efc21975118">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166d41c1d13840e79f6069d74eed0581_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTQtNS0xLTEtMA_30adad0c-45ee-42c6-a75d-d7f147c30992">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i166d41c1d13840e79f6069d74eed0581_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTQtNy0xLTEtMA_dc83b739-fa5d-4282-8d1a-0fa7b85788c6">30,496</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctMS0xLTEtNTYw_7e9a0671-cb2e-47e3-947d-d15db5722e6b">2,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctMy0xLTEtNTYw_930c65c3-f351-4329-8546-7e56eaca1445">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctNS0xLTEtNTYw_4ce090ca-d6e9-44d8-b37f-ac05cd895315">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctNy0xLTEtNTYw_5d868edb-8ac8-4e69-8f90-faeffbfa6a5f">2,999</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195f8095900e47b59c48f9b46ca9e135_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTUtMS0xLTEtMA_d860e03d-89fe-423c-9fd3-799c98443d2f">33,494</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195f8095900e47b59c48f9b46ca9e135_I20191231" decimals="-3" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTUtMy0xLTEtMA_e210f2ea-3aa8-4f8e-adeb-bcf5813007a8">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195f8095900e47b59c48f9b46ca9e135_I20191231" decimals="-3" format="ixt:zerodash" name="sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTUtNS0xLTEtMA_48541a24-44b8-457d-bd61-1c868bd8ff9e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i195f8095900e47b59c48f9b46ca9e135_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTUtNy0xLTEtMA_12fd54a2-16e9-4326-9ae5-b3018eebddc6">33,495</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctMS0xLTEtMA_307a4805-1e4b-4558-a287-b24beb0e2364">155,230</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctMy0xLTEtMA_7b335830-938b-42c0-a7d1-51b71fa6ee98">145</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctNS0xLTEtMA_adcb74a0-6b37-42a5-829d-37253d3525e7">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctNy0xLTEtMA_d19eee0a-e560-4fee-9d1c-8dcbf78983da">155,368</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59efa220c014139a6c6518f23eb3381_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTgtMS0xLTEtMA_3b60b78d-1f0d-464a-9c9f-750d610155aa">94,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59efa220c014139a6c6518f23eb3381_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTgtMy0xLTEtMA_f8330c50-676e-4503-8acc-503561014d85">115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib59efa220c014139a6c6518f23eb3381_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTgtNS0xLTEtMA_e0b1f8f6-65b5-4269-93e5-a485a2b9d2ac">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib59efa220c014139a6c6518f23eb3381_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTgtNy0xLTEtMA_ba1ead97-14be-4a91-a3fc-c88da0809c47">95,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edba78934f34526818d49f23b52582d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTktMS0xLTEtMA_e4a3e185-abc9-40d7-a059-d6f2660c7a48">53,411</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edba78934f34526818d49f23b52582d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTktMy0xLTEtMA_7a6a905a-3d51-46b4-89a3-6d7a723b4d4d">91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6edba78934f34526818d49f23b52582d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTktNS0xLTEtMA_bc907e9e-4aad-4ffd-a675-31638a6502f3">9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6edba78934f34526818d49f23b52582d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTktNy0xLTEtMA_caa391f5-954a-4e13-a127-3d053b72cab4">53,493</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjAtMS0xLTEtMA_9bf341df-9027-43cd-b13f-5aeae672991b">303,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjAtMy0xLTEtMA_6f1d1081-3bda-4891-9988-2d4728522c31">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjAtNS0xLTEtMA_ee52e31c-3162-46ff-9ee2-fba336ad867d">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjAtNy0xLTEtMA_80ec471d-526c-4b93-b147-1e3b8d03b27a">303,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjEtMS0xLTEtMA_953d87d4-1ee7-4511-a319-abec5f829783">337,040</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjEtMy0xLTEtMA_2b4d73aa-c9c5-4b5d-9c83-d773eab45f52">352</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" name="sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjEtNS0xLTEtMA_ef6dfbda-00f5-4053-b305-f41b6c173cbe">19</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:CashEquivalentsAndAvailableForSaleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjEtNy0xLTEtMA_57cea4f7-d964-44a4-bac4-1921640499e6">337,373</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfMzI5ODUzNDg4NTI1Ng_5bf07fa7-8303-4e5f-9976-8b35980dd40b" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.969%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfMi0xLTEtMS0w_c92458bd-8f1a-49af-8aef-dffdf9f16103">510,094</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfMi0zLTEtMS0w_566ed2af-6363-4e27-96e4-ac05795c2267">282,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfMy0xLTEtMS0w_3aa5b3d3-6942-463f-b065-ca0a416914be">50,530</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfMy0zLTEtMS0w_837088f8-a24f-4726-9f24-757d50f2a4c0">21,832</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfNC0xLTEtMS0w_494d0d67-ff09-4429-9ae6-27cda758b640">560,624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfNC0zLTEtMS0w_009c1871-80dd-4cfb-95ca-5da787078932">303,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfMjcx_c22bc051-78e1-435e-82f8-054de4b70d19"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfMjcx_d17fb8f4-2053-4c2a-bd65-d64031cf141b"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfMjcx_f93eeb92-576a-45ee-9598-03e6e74399fd">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> realized losses from the sale of marketable securities for the years ended December&#160;31, 2020, 2019 or 2018. <ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:OtherThanTemporarilyImpairedInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfNTI2_5cec25d6-8dbc-4e0f-b7bb-186068869934"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:OtherThanTemporarilyImpairedInvestment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfNTI2_d2710929-9f33-4a4a-a91e-a96ee60b8b33">No</ix:nonFraction></ix:nonFraction> investments were other-than-temporarily impaired at either December&#160;31, 2020 or 2019. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these marketable securities at December&#160;31, 2020.</span></div></ix:continuation><div style="height:0pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI4NQ_effbfc5f-06fe-4473-8a0f-3db10eeb4e93" continuedAt="i0db65b9f5e5147ab927c9a0b26c9cbaf" escape="true">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES</ix:nonNumeric></span></div><ix:continuation id="i0db65b9f5e5147ab927c9a0b26c9cbaf" continuedAt="i2ceafc8ad8cf498da339df96a83831fa"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#8220;ZFP&#8221;) transcription factors (&#8220;ZFP-TFs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company performs early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, investigational new drug-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Novartis paid the Company a $<ix:nonFraction unitRef="usd" contextRef="ie90d9c1847f64dc498789d1a25747db7_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQ1OA_c2940d46-ccbb-453d-8bb7-ed646c94242c">75.0</ix:nonFraction>&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $<ix:nonFraction unitRef="usd" contextRef="ie25f2c3034b549c1a2403b3c2b59e8be_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTI5NA_90436c7b-539f-4820-9336-b44d23feac76">420.0</ix:nonFraction>&#160;million in development milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i08c85ff8ca5b455fa7266f68c7634773_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTM0OA_39e4c1af-aced-4947-b750-ccf27c816034">300.0</ix:nonFraction>&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement, when earned, are non-refundable and non-creditable. The transaction price of $<ix:nonFraction unitRef="usd" contextRef="i679870fa4aa947f2b092c683d49e48be_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQwNg_b76680ff-14d9-4f75-9340-7d842a254756">95.1</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i679870fa4aa947f2b092c683d49e48be_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementLicenseFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTM2Nw_e9ed832f-0f76-4830-8156-a142db04f983">75.0</ix:nonFraction>&#160;million and estimated research costs of $<ix:nonFraction unitRef="usd" contextRef="i679870fa4aa947f2b092c683d49e48be_D20200727-20200727" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTM4Nw_adeda9f5-3c12-4ec7-afef-df28cfacd4b6">20.1</ix:nonFraction>&#160;million for identified research projects over the estimated research period. None of the development and commercial milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic 606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. As of December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ic9662bfa60bd435086718d9bfee03841_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQyNQ_655ef93a-e488-4961-bd02-0e3b70e335a1">70.9</ix:nonFraction>&#160;million related to the upfront license fee received.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i41532f5f82c84a95a08ae7d3f428f14a_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcxMjQxNw_4bf6f572-0ceb-40c2-8871-b8d4f9048cf4">4.1</ix:nonFraction>&#160;million of upfront license fee and $<ix:nonFraction unitRef="usd" contextRef="i65e104e30eb7451ebcb1b6d67543ae50_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcxMjQ1MQ_087b09ee-9854-4069-aacc-04cd020bdf4f">1.1</ix:nonFraction>&#160;million research reimbursement costs as revenue related to the Novartis agreement during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="ic9662bfa60bd435086718d9bfee03841_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQ3Nw_98e12fbb-1127-4f16-ae0e-37dab6f80035">1.5</ix:nonFraction>&#160;million for financial advisory fees related to the Novartis collaboration and license agreement during the year ended December&#160;31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="ib3b3cfc543ee4dfbb9fa9f54e698bbe0_D20201001-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjIzNA_133c2fe7-dc0f-410e-a450-03f13bae3a76">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="ie90d9c1847f64dc498789d1a25747db7_D20200801-20200831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQ5Ng_64264f1e-233c-414a-94a2-25c7ebf93768">75.0</ix:nonFraction>&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized this $<ix:nonFraction unitRef="usd" contextRef="ic9662bfa60bd435086718d9bfee03841_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTUxNA_1a856f3c-0609-4f62-a917-9a3f4a4f142c">1.5</ix:nonFraction>&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic 340, Other Assets and Deferred Costs. The Company amortized $<ix:nonFraction unitRef="usd" contextRef="i09bf3f7bc1bf4ca2aee88d98cbb49c11_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTYwOQ_4aaaef57-3db2-45c6-86be-5aaef87b3d68">0.1</ix:nonFraction>&#160;million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i2ceafc8ad8cf498da339df96a83831fa" continuedAt="i13ad15306fdc4ea7a9002a9be22bb8d4"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulation therapies for the treatment of neurological diseases. The Company and Biogen plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase <ix:nonFraction unitRef="shares" contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDYxMw_1f488b73-ae50-4a9b-a483-49b27f21aa2a">24,420,157</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="if650f84ed8e44993a9c4382072ecf061_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDYyMw_4327490a-c60c-46f8-8d28-2f4c0de6b24c">9.2137</ix:nonFraction>, for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDY0MA_062585dd-a880-4bf3-ac8b-a2a234da661f">225.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $<ix:nonFraction unitRef="usd" contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDY2MA_6532a2bb-f3b7-4082-b6d9-e62e345046b5">225.0</ix:nonFraction>&#160;million for the purchase of the Biogen Shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="iecf6454954a34af8a88c9bb4071baf99_D20200501-20200531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTEyNQ_c6183ecf-6d09-4b5d-94da-fd86157c5250">125.0</ix:nonFraction>&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $<ix:nonFraction unitRef="usd" contextRef="i1c641a230af14951931f575b265aa8bf_I20200229" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDY3OQ_f7bad75b-74f1-4c2c-8175-bbac18fbc042">2.37</ix:nonFraction>&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $<ix:nonFraction unitRef="usd" contextRef="ia7101296ba8e4016aee3ac0bd6885981_I20200229" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDcyMQ_37639100-e4b3-407c-bb19-a741611b8c2c">925.0</ix:nonFraction>&#160;million in pre-approval milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="i36d7c81806f3497d988a10597afd1494_I20200229" decimals="-7" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDcwMQ_8c57d2a2-b1d5-45f8-a168-58f751cfbc92">1.45</ix:nonFraction>&#160;billion in first commercial sale and other sales-based milestone payments. In addition, the Company is also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to <ix:nonFraction unitRef="product_target" contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229" decimals="INF" name="sgmo:CollaborativeArrangementNumberOfProductTargets" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjIzOA_0653acf6-c919-45a2-8595-86e2b4b1eede">12</ix:nonFraction> neurological disease gene targets selected by Biogen. Biogen has already selected <ix:nonFraction unitRef="product_target" contextRef="i1c641a230af14951931f575b265aa8bf_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0MQ_552d0d3b-8c70-4ac1-b6e3-f11265557a0a">three</ix:nonFraction> of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to <ix:nonFraction unitRef="product_target" contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAgreementNumberOfAdditionalProductTargets" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0Mg_368600b2-39c1-452b-82de-6282215cc1e9">nine</ix:nonFraction> additional targets over a target selection period of <ix:nonNumeric contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborationAgreementTargetSelectionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0Mw_00d3f2b5-76e1-47fa-8822-aeacf5613758">five years</ix:nonNumeric>. For each gene target selected by Biogen, the Company performs early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first <ix:nonFraction unitRef="product_target" contextRef="i1c641a230af14951931f575b265aa8bf_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0NA_0085e78f-73a0-4eac-a386-6c4023304d41">three</ix:nonFraction> products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first <ix:nonFraction unitRef="product_target" contextRef="i1c641a230af14951931f575b265aa8bf_I20200229" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborativeArrangementNumberOfProductTargetsSelected" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0NQ_80a56a9b-5db8-4949-9261-715a4cb961bc">three</ix:nonFraction> products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed <ix:nonNumeric contextRef="i9997a66b33774bf8874b84e01397ca61_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborationArrangementResearchPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0Ng_d4376931-b3f0-49a8-8eb7-3da901d1fce5">seven years</ix:nonNumeric> from the effective date of the agreement (i.e., through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to <ix:nonFraction unitRef="product_target" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2NjI5Ng_70921711-44a1-4801-afa2-048d8e9cc0c6">10</ix:nonFraction> targets. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the <ix:nonNumeric contextRef="i2433e456bdfb43a4aa95fe4c28d4d208_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborativeArrangementStandstillRestrictionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2MDY3OA_afba260c-0b2f-4ada-9635-e3e074a7e508">three-year</ix:nonNumeric> anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="i336e9bea9e624f2d85ca346d8219bd49_I20200228" decimals="INF" name="sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI1MA_81889e8b-ccc2-4779-b032-7e32fc9656b8">5</ix:nonFraction>% of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock purchase agreement also provides that until the first anniversary of the effectiveness of the collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least <ix:nonFraction unitRef="number" contextRef="i336e9bea9e624f2d85ca346d8219bd49_I20200228" decimals="INF" name="sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI1NA_cf1df317-c8c5-4eb4-9d44-e98f7639aa4e">50</ix:nonFraction>% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the Securities and Exchange Commission.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the <ix:nonNumeric contextRef="i2433e456bdfb43a4aa95fe4c28d4d208_D20200201-20200229" format="ixt-sec:durwordsen" name="sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI1OA_ee911873-706c-47e3-b60a-edbe07d6151f">two-year</ix:nonNumeric> anniversary of the effectiveness of the collaboration agreement, (ii) the date that Biogen beneficially owns less than <ix:nonFraction unitRef="number" contextRef="i336e9bea9e624f2d85ca346d8219bd49_I20200228" decimals="INF" name="sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI2MA_b38d9153-8a98-4f88-8db3-a56048a33d30">5</ix:nonFraction>% of the Company&#8217;s common stock and (iii) the date the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i13ad15306fdc4ea7a9002a9be22bb8d4" continuedAt="if361162b1ec846c38e780b06296bca28"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic 606 and concluded that Biogen is a customer. As of December&#160;31, 2020, the transaction price includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDkzMQ_0faf2db6-d896-43cf-aa3b-14f872f0dc6b">125.0</ix:nonFraction>&#160;million and the excess consideration from the stock purchase of $<ix:nonFraction unitRef="usd" contextRef="iae50536cbc814ac6a99bb260423fdb2e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDk1MA_c8770666-3cd8-4a14-a2de-a116c8d3af85">79.6</ix:nonFraction>&#160;million, which represents the difference between the $<ix:nonFraction unitRef="usd" contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDk5MA_26cf7cb1-a5e9-4fa6-ad6e-bf922403016e">225.0</ix:nonFraction>&#160;million received for the purchase of the Biogen Shares and the $<ix:nonFraction unitRef="usd" contextRef="icccc34360eed452f9ad238a715656769_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationAgreementEquityIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDk3MA_d8598018-4412-404c-9276-6c18c3baaba6">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of December&#160;31, 2020, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="icccc34360eed452f9ad238a715656769_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTAxMA_2e2d7b9a-23af-4191-96f6-83874ac16960">183.2</ix:nonFraction>&#160;million related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $<ix:nonFraction unitRef="usd" contextRef="icb0c68923ff146d280fb7f97045dad9b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcxMjgzMg_5849a27e-ef57-42ba-96a0-82f21d897437">21.4</ix:nonFraction>&#160;million of upfront license fee and the excess consideration from the stock purchase, and $<ix:nonFraction unitRef="usd" contextRef="i6dbd4261e96a4a87808a78d8e6b23ba1_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcxMjg1MA_8bd1dd8d-41e3-445b-968f-29c17044b18c">6.5</ix:nonFraction>&#160;million research reimbursement costs as revenue related to the Biogen agreement during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $<ix:nonFraction unitRef="usd" contextRef="ie4b362953ca94b868a22eeeacdc5d1c8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTAyOA_94b9426c-2c7c-40bd-85e0-e59b1d18bfa0">7.0</ix:nonFraction>&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to <ix:nonFraction unitRef="number" contextRef="i791f1d7d58614b2e92e9f6fca8affadb_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI2NA_49d1d690-e3e1-4a08-a015-73cebbc5a3c4">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTA0OA_2400410e-1c14-43e9-bd18-5510a782f41f">225.0</ix:nonFraction>&#160;million received for the sale of shares and <ix:nonFraction unitRef="number" contextRef="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI2OA_5eb3283d-ad14-41d8-83b8-bdaceb31e51d">2</ix:nonFraction>% of $<ix:nonFraction unitRef="usd" contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTEwNA_27e102af-f4cd-44bb-a84b-62af755cb7aa">125.0</ix:nonFraction>&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="ie4b362953ca94b868a22eeeacdc5d1c8_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTE0Mw_c9658029-ab94-4155-8acd-95d3c647a226">4.1</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI3Mg_eb04db6d-7165-4bec-8bd0-e494b0bfa2e7">2</ix:nonFraction>% of the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollaborators" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTI1NQ_e6048dfa-8232-4104-9afd-478cadada163">125.0</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="number" contextRef="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI3Ng_9429c472-31c8-4a40-be14-213af42335a0">2</ix:nonFraction>% of the excess consideration from the stock purchase of $<ix:nonFraction unitRef="usd" contextRef="iae50536cbc814ac6a99bb260423fdb2e_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTE2Mg_402c836a-479b-4a79-981a-67669f1c8740">79.6</ix:nonFraction>&#160;million, as a contract asset. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic 340, Other Assets and Deferred Costs. The Company amortized $<ix:nonFraction unitRef="usd" contextRef="i791f1d7d58614b2e92e9f6fca8affadb_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSoldAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTE5Nw_0d33bec9-db39-4013-b5db-4e7d25bfd2fc">0.4</ix:nonFraction>&#160;million during the year ended December&#160;31, 2020. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="i86be779bb370428988a0873a257efbeb_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTIxNQ_2a36b4aa-6aab-4fc0-93f8-21822ab49aef">2.9</ix:nonFraction>&#160;million, which represents <ix:nonFraction unitRef="number" contextRef="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231" decimals="INF" name="sgmo:CollaborativeAgreementPercentOfInitialRecognition" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI4MA_7bc6cb8c-6361-45cb-a008-4efc4e4e9308">2</ix:nonFraction>% of the $<ix:nonFraction unitRef="usd" contextRef="icccc34360eed452f9ad238a715656769_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborationAgreementEquityIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTIzNQ_699350fe-9496-475a-896c-a40d07af316f">145.4</ix:nonFraction>&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as reduction in proceeds during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), which became effective on April 5, 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions, except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="if361162b1ec846c38e780b06296bca28" continuedAt="i56dd343880e34410802d582d06a42d9e"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the effective date, in April 2018, the Company received a $<ix:nonFraction unitRef="usd" contextRef="i622b78d941574e52bc533f27c36c5fe7_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQwNQ_fc534fb2-fb51-48ed-8908-98694384147a">150.0</ix:nonFraction>&#160;million upfront payment from Kite. In addition, Kite will reimburse the Company&#8217;s direct costs to conduct service under the joint research program provisions of the agreement, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $<ix:nonFraction unitRef="usd" contextRef="ic0e221499b664eee8f775e18eb6f11f8_D20180404-20180405" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjgxNw_1f943d02-f1dc-4071-8cbd-acdb13bea104">3.01</ix:nonFraction>&#160;billion if all of the specified milestones in this agreement are achieved.&#160;Of this amount, approximately $<ix:nonFraction unitRef="usd" contextRef="i6b05e76cf87f4a609ff6d9a1d6be38e3_D20180404-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjkxNw_ba1337f8-610e-4551-bd40-474afff3b1a7">1.26</ix:nonFraction>&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $<ix:nonFraction unitRef="usd" contextRef="i15ca38def7cc4d739746ecdfadfe6b6c_D20180404-20180405" decimals="-7" format="ixt:numdotdecimal" name="sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzA1OQ_1c3b5ffb-8386-4383-abee-00f55cacac68">1.75</ix:nonFraction>&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first 10 times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event. In addition, the Company will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term of the agreement is <ix:nonNumeric contextRef="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231" format="ixt-sec:durwordsen" name="sgmo:InitialResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDAzNA_92b2318e-e8a2-49f1-90d9-e01e20f390f7">six years</ix:nonNumeric>. Kite has an option to extend the research term for up to <ix:nonFraction unitRef="option" contextRef="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfOptionsToExtendInitialResearchTerm" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDA5NQ_27623c9f-c788-42e4-9674-f1be9d1d184a">two</ix:nonFraction> additional <ix:nonNumeric contextRef="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231" format="ixt-sec:durwordsen" name="sgmo:ExtendedResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI3NA_1d671f64-7063-45ff-a31f-be15ac1cab8f">one-year</ix:nonNumeric> periods for a separate fee of $<ix:nonFraction unitRef="usd" contextRef="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SeparateUpfrontFee" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDE0Nw_66f60c2a-9042-4efb-abdd-9dafbbd36545">10.0</ix:nonFraction>&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDQ2MQ_08a5cb03-8e5d-4a6c-ad31-9742755146ae">3.4</ix:nonFraction>&#160;million. The Company concluded the transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDUzMw_73523854-dcfc-434d-b2da-8226e780f4f9">189.3</ix:nonFraction>&#160;million and includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDU3Ng_6f4d4f19-ab63-434b-b569-764924553b0a">150.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDU4Mw_49246a7b-429c-4a16-a8e2-3d2c153717ce">39.3</ix:nonFraction>&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. The Company concluded that the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. Kite has the right to terminate this agreement, in its entirety or on a per licensed product or per candidate target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the primary performance obligations within the Kite agreement as: (1) a license to the technology along with the stand-ready obligation to perform research services, and (2) the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2020, and 2019 the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ifd8eb466e5ab46dcbfe11a464c069eff_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNzEyMg_fdab5189-0adc-41bb-8033-b13ad0478676">81.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i279331e783974f13b570a80bdae2914d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNzEyOQ_e54870c5-2d7a-42d3-9ad7-9fd96eb0bab9">106.5</ix:nonFraction>&#160;million, respectively, related to this agreement. </span></div><ix:nonNumeric contextRef="ic99454b17cf8426abe411aa4bfe33b84_D20200101-20201231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3Mzg_172d0686-1621-4a48-bccf-f6719debeaa9" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"></td><td style="width:58.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.004%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7c5dfd1e85a4c9aa4e84a23484dc176_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfMy0xLTEtMS0w_2ad3c177-bef9-4940-953b-d5b75c14fb18">25,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bfa78bdc3244b5693d30aa711524848_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfMy0zLTEtMS0w_4e611650-d812-44db-affd-49d8aa910bf6">24,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd7a58620bca4d85b6783c708b906014_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfMy01LTEtMS0xNDE_59732352-11e3-473f-ab80-dac2492c061e">18,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if07241a21483414fa49f01f2b3ff040d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNC0xLTEtMS0w_7e128333-7943-43b9-acf4-88113fb1bf2b">3,562</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160f22e556494a06802b40e3edf5f834_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNC0zLTEtMS0w_7c8c0c1d-67ac-489f-a831-3a272f83e271">9,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d31979f09c648999fccb66122fd46ee_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNC01LTEtMS0xNDE_69046952-b1cd-433a-a19c-4668f514490c">6,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic99454b17cf8426abe411aa4bfe33b84_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNS0xLTEtMS0w_493e89bc-c181-41a9-a758-1d77a3fb97db">28,608</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc50ac5b1034ddcab9f5dc7d229bd83_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNS0zLTEtMS0w_496cb753-4bc5-4eee-bfb3-d5ef7f931954">34,350</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42157f7e86b3408ab390ad6b9ce433d2_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNS01LTEtMS0xNDE_5e5c32cc-d9f8-4e8a-a03b-c3915077dd5e">25,517</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i56dd343880e34410802d582d06a42d9e" continuedAt="icbd9cd7a8f26496e8c53ea1f63681d5b"><div style="margin-top:15pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company originally received an upfront fee of $<ix:nonFraction unitRef="usd" contextRef="i16e9fd5645c342c6a53a2d4075df3f32_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODA3OQ_32ebba4d-5242-485c-aaf0-fdfbeba3c0c1">70.0</ix:nonFraction>&#160;million and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i16d56044bc30409491f4cd99b8ed0162_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODM2OQ_2bb4a79b-5b1e-4f38-a1b5-ac16d5d0cb60">208.5</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $<ix:nonFraction unitRef="usd" contextRef="i828ebcc51b3447ab9fb4c223a4ed2af9_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODQ5OA_9dca6ef0-ee42-4801-985f-ee286580c352">266.5</ix:nonFraction>&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in the giroctocogene fitelparvovec Pfizer agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="ie7ce5c1ee6e64ac5b1260a8a278341bf_D20170501-20170531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODgyNw_d0d74b94-d0e9-4a6c-a619-2e6cae416ba0">475.0</ix:nonFraction>&#160;million, which includes up to $<ix:nonFraction unitRef="usd" contextRef="ic844e08373f649f89686b25d4f48e080_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODg1Mg_9fb26f26-4874-4358-afde-1ea44a99e8db">300.0</ix:nonFraction>&#160;million for giroctocogene fitelparvovec and up to $<ix:nonFraction unitRef="usd" contextRef="ic3ea3fbe1ff04cd78a9c151aab7fe03c_I20170531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODg3Ng_65f0c4bd-e57d-4c15-b14a-58dc474c3791">175.0</ix:nonFraction>&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement based on an escalating tiered, double-digit percentage of the annual net sales of such product. These royalties are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $<ix:nonFraction unitRef="usd" contextRef="i108f738726ee4d188ea13f5c58559305_D20170501-20200930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTg0Nw_b4c5d2cc-f657-422d-b37e-3b0733494f51">55.0</ix:nonFraction>&#160;million in aggregate have been achieved and paid, however <ix:nonFraction unitRef="product" contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfOTUxMA_3c380c1c-9e87-4ee1-b9e7-4156e510dd91">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i56711bf4d33b463384f2cf6fa4b99cdc_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfOTU1NQ_350e5d00-c7f9-4be3-9af0-8b3d038c31eb">no</ix:nonFraction> royalty fees have been earned under the giroctocogene fitelparvovec Pfizer agreement.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. As of December&#160;31, 2020, the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfOTgyNw_c665db12-f729-4a36-9792-d61323484b4e">134.0</ix:nonFraction>&#160;million, which represents the upfront and research services fees of $<ix:nonFraction unitRef="usd" contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementResearchServiceFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfOTg5MA_9ba564d3-f8b9-4f54-a22e-47e530f818e1">79.0</ix:nonFraction>&#160;million and two unconstrained milestones achieved of an aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="iadfc90055252476ea94b6b78e49c2e2c_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTgxNA_823a220d-34c4-47d8-86f3-dba9fe11a0a1">55.0</ix:nonFraction>&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price, as all such milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;<ix:nonNumeric contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231" format="ixt-sec:duryear" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTE4OTc_58295caa-3947-492e-aad4-3d94fda36ba4">15</ix:nonNumeric> years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified one performance obligation within the giroctocogene fitelparvovec Pfizer agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete, as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="icbd9cd7a8f26496e8c53ea1f63681d5b" continuedAt="ic5dd68fb85294660b00253b5ad2ef27b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services through 2020, the estimated period the Company will perform research services. The estimate of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. The Company satisfied the deliverables and research services responsibilities within the arrangement which were completed in December 2020. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020. As of December&#160;31, 2019, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i55dfc2b24f4d4413a989e868a6ffeb5d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTM1NTU_24a61da4-5f10-4903-acbc-4827fa4ad278">4.0</ix:nonFraction>&#160;million related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into an amendment to the collaboration agreement, pursuant to which the Company transferred the IND for giroctocogene fitelparvovec to Pfizer. Upon this transfer the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="i13a9ae1225e7485bb10275ccee50ca2d_D20191201-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMjcwNA_c418aff5-0430-4cc7-9fd0-c6ecf9b7a987">25.0</ix:nonFraction>&#160;million milestone as the conditions for achieving the milestone were met. The cumulative revenue recognized in connection with this milestone was $<ix:nonFraction unitRef="usd" contextRef="i2e6d1ed2be0044ea9cbcaf840d0780e9_D20191201-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcwNTg1NQ_0479bf30-33f3-429c-b4df-97134f63826a">25.0</ix:nonFraction>&#160;million as of December&#160;31, 2020 and included $<ix:nonFraction unitRef="usd" contextRef="ieae2c1f6faba4e33888460da2e302ddf_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcwNTgzOQ_f1daaab0-c4ed-4ad7-84dd-9215a24f5798">1.3</ix:nonFraction>&#160;million recognized during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company determined that there was a high probability of achievement of a $<ix:nonFraction unitRef="usd" contextRef="i24940a7706ea4d2d978b4613538afbda_D20201001-20201030" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMjkxNQ_8273122b-01a1-410e-b1ba-75b7e6502469">30.0</ix:nonFraction>&#160;million milestone with Pfizer for giroctocogene fitelparvovec. The milestone was subsequently achieved upon dosing of the first subject in a Phase 3 clinical trial in early October 2020. The cumulative revenue recognized in connection with this milestone was $<ix:nonFraction unitRef="usd" contextRef="i9ccabe9bc30f4799a7625faed92a6917_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMjg3Ng_ecd2ddb9-6de7-4046-a5af-2e1b9f12c070">30.0</ix:nonFraction>&#160;million during the year ended December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="i6100f8c9e8534579a67d80618dd87117_D20200101-20201231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3Mzk_44101e2a-7eee-4f9a-a0ae-55bf2b048704" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"></td><td style="width:57.909%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.964%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Pfizer giroctocogene fitelparvovec agreement:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee and research services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c0d2ceb04c46e0a6ca01fc7f9e2ee7_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfMy0xLTEtMS0w_75e1d809-d2c9-457f-9d16-4365dfcd4158">3,111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22cdf77958324fea8f5137db56d2e321_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfMy0zLTEtMS0w_6ab3cccc-9919-4673-bcc4-4176f2178159">15,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i435e100ac21c4e6f970572239a77eda2_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfMy01LTEtMS0w_9ba8ef80-3924-40fe-804a-c104fc1971ae">37,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fb94b0bae17481a87c59979d81ce0ca_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNC0xLTEtMS0w_e87b1152-59ac-4473-96a7-d2c10e11c073">31,338</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae47e409b4ea42aabf27810d9f1f5f22_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNC0zLTEtMS0w_d30aca47-201d-4f22-83ef-69f2a83951a6">23,662</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9745d562dd854f4fb6b39832e3c4a5b4_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNC01LTEtMS0w_57450216-537c-42cf-929c-5623e53ed92a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6100f8c9e8534579a67d80618dd87117_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNS0xLTEtMS0w_957f0dae-2c8b-4252-a575-e1a668c6b705">34,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9782c197ba3149bb984663397b6a69d2_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNS0zLTEtMS0w_10a42aa9-512b-4675-93d4-e2d597af36bc">39,359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10f82f0783e54af6831a3e260dd85a3a_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNS01LTEtMS0w_72489285-582c-4a61-9dbe-169592de1b35">37,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company updated its estimated project cost and related revenues under this program. This adjustment was a direct result of the increase in project scope during the first quarter of 2019 and the corresponding costs, which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon transfer of the IND for giroctocogene fitelparvovec to Pfizer. This adjustment was a direct result of the decrease in project scope during the fourth quarter of 2019 and the corresponding costs, which resulted in an increase in the measure of proportional performance. During the year ended December 31, 2019, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i22cdf77958324fea8f5137db56d2e321_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTUzMTc_b432aecb-57f4-4c2b-b531-b535c618e227">15.7</ix:nonFraction>&#160;million in revenues related to the Pfizer giroctocogene fitelparvovec agreement, which included approximately $<ix:nonFraction unitRef="usd" contextRef="i7e8f31eadadf4aefb75c29f6979d4b3e_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTU0MDE_763f556c-3465-4551-9863-156d627c59ce">8.7</ix:nonFraction>&#160;million acceleration in revenues recorded in the three months ended December 31, 2019 related to the updated estimated project cost, offset by approximately $<ix:nonFraction unitRef="usd" contextRef="ib0ee411f36884cd796eb1615539214bc_D20200101-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTU1NjE_3adffbbd-2c55-4d93-b8c5-1247f48d741d">3.0</ix:nonFraction>&#160;million reduction in revenues recorded in the three months ended March&#160;31, 2019 related to the updated estimated project cost.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the giroctocogene fitelparvovec collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs, after the successful IND transfer of the giroctocogene fitelparvovec product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $<ix:nonFraction unitRef="usd" contextRef="i233ad9c6f5b64570a51d2349ba0f80be_D20200301-20200331" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMzY3MA_4ca54d7e-8cf9-466d-9187-8771345651f6">2.4</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="i233ad9c6f5b64570a51d2349ba0f80be_D20200301-20200331" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMzY5OQ_7892c31e-9a87-4a18-90f9-b0827452b4b3">2.4</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f3fd66a77ca4c298f3fc4272b6044f2_D20200301-20200331" decimals="INF" sign="-" name="sgmo:CollaborativeArrangementNetIncomeLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMzcxMA_5f481ba3-bbe0-4ea6-b809-296236f2f9ff">0.02</ix:nonFraction> for year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal lobar degeneration (&#8220;FTLD&#8221;) linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;<ix:nonNumeric contextRef="if4d9b4cf1fe14e8c82e398543c33609d_D20200101-20201231" format="ixt-sec:duryear" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTkwNjM_5fd15a49-53fc-43bd-ac29-5763a065918e">15</ix:nonNumeric> years after the first commercial sale of a licensed product in a major </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="ic5dd68fb85294660b00253b5ad2ef27b" continuedAt="i96ac10f8d4044e9a9ca879d8b6f3f747"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $<ix:nonFraction unitRef="usd" contextRef="i3baf5d6da95a464d83ca547a1f07fb10_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNTY0MQ_228920e3-ab99-4326-8f99-7c1f17bef630">12.0</ix:nonFraction>&#160;million upfront payment from Pfizer and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ie4c4b9a1b3734f819b23f8fd6c8bebc0_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNTcwNg_9968af45-3c9c-4fb5-a2d9-e10b89b1d8a1">60.0</ix:nonFraction>&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $<ix:nonFraction unitRef="usd" contextRef="i5f62390b2d3a48338361f2876c31e6ab_D20171201-20171231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNTg5Mw_4b6559ff-ca8d-4b49-ba69-fbf62182d0db">90.0</ix:nonFraction>&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $<ix:nonFraction unitRef="usd" contextRef="iee59d8fb45e041e791c0ab5b1d0fec94_D20171201-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzODI2OQ_c0122644-845b-44cb-842f-18a6233b6f9b">5.0</ix:nonFraction>&#160;million has been achieved and paid, however <ix:nonFraction unitRef="milestone" contextRef="iee59d8fb45e041e791c0ab5b1d0fec94_D20171201-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2NjMwMw_502df2bf-2d8f-421d-a014-9add263b0085">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="iee59d8fb45e041e791c0ab5b1d0fec94_D20171201-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2NjMxMQ_78b452fb-bed9-4d39-93bc-ad24e881f596">no</ix:nonFraction> royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $<ix:nonFraction unitRef="usd" contextRef="i8179c5be57324f34a1d01a5075b4a59a_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNzc5Ng_45972014-1787-4859-a15d-4855737da3f5">17.0</ix:nonFraction>&#160;million, which represents the upfront fee of $<ix:nonFraction unitRef="usd" contextRef="ifaa9934a0caf4048ad529227a6b3e342_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNzgwNg_0e391027-0ae0-42dd-a413-8b2b47da2f34">12.0</ix:nonFraction>&#160;million and one unconstrained milestone in the amount of $<ix:nonFraction unitRef="usd" contextRef="i8179c5be57324f34a1d01a5075b4a59a_D20171201-20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNzk0Nw_a9db7fb9-6a19-40e1-8123-d7936d7d5d51">5.0</ix:nonFraction>&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligation within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. The Company satisfied the deliverables and research services responsibilities within the arrangement which were completed in September 2020. As a result, the Company recognized the remaining deferred revenue from the upfront payment in September 2020. As of December&#160;31, 2019, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="i3c9f2942ee064c10a7180d004ca68961_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE1NDk_dab25db8-7c94-48d3-bcc4-f1c8dd073cdb">8.0</ix:nonFraction>&#160;million related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company earned a $<ix:nonFraction unitRef="usd" contextRef="i4e2d17dcf5e64a158d897e7941665566_D20200901-20200930" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyODc1Mg_64f46222-a2ba-40f3-8537-e7a41fa7da62">5.0</ix:nonFraction>&#160;million milestone associated with the completion of the Company&#8217;s research activities in its collaboration with Pfizer to develop genome regulation therapies using ZFP-TFs for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-related ALS and frontotemporal lobar degeneration. This milestone was achieved upon Pfizer&#8217;s notification to the Company of its election to pay the first development milestone payment under the collaboration agreement. This milestone payment is non-refundable, and the Company recognized on a cumulative basis $<ix:nonFraction unitRef="usd" contextRef="i51fd8b7623f54652888d1fbd20802015_D20201001-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyODc3MA_a0b0511c-27f7-41be-957d-9cbc27b64069">5.0</ix:nonFraction>&#160;million for the year ended December&#160;31, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i96ac10f8d4044e9a9ca879d8b6f3f747" continuedAt="i4285ba44fa0641d7873be5df994465d9"><ix:nonNumeric contextRef="if4d9b4cf1fe14e8c82e398543c33609d_D20200101-20201231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3NDE_493084be-df8f-40ee-bcde-54ed2312e11a" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:59.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.659%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Pfizer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> agreement:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeb550dc7fee4f0daa6ea8fc7073f7db_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfMy0xLTEtMS0w_6b64fdb3-2ce0-4993-aba0-8dcd90c750d8">7,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2886651fadc8409c8daddb378e4b5b45_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfMy0zLTEtMS0w_ce2e60eb-c1a1-4811-8b49-b27f20497a28">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacbb3e15255f4990bd049724d75ef0f1_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfMy01LTEtMS0w_64e6dfb2-50a7-453f-b1f6-fa95bb4fed0b">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f68e79e666471ea1075c8953d1f9ed_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNC0xLTEtMS0w_dd73838c-c2ef-4633-801b-97aa4ec4a469">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d058778fed0482c9abdb1e80bf3e5f0_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNC0zLTEtMS0w_ba4fece1-c2cf-4ed7-a1ed-1a3fce6cf3d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf79dd2baa0749b1942c7d86d20c6f21_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNC01LTEtMS0xMzM1_3a123543-9a1f-4430-ba90-b015d23bed77">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d9b4cf1fe14e8c82e398543c33609d_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNS0xLTEtMS0w_f5be605c-429f-4ab4-8359-a01251fdaa72">12,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1df52988f363438398a2de08f94aa387_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNS0zLTEtMS0w_e00d6930-182f-4399-a7b4-6af64fc3d967">1,827</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85bea8547944486692a85e6b523ddecd_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNS01LTEtMS0xMzM1_5a33cce1-e2d3-46e1-829f-9fa1f7d867eb">2,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimate in connection with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collaboration agreement with Pfizer. These adjustments were a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. These adjustments increased revenue by $<ix:nonFraction unitRef="usd" contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMDc4Mg_8b079ba8-7e9d-4be0-bbcd-5ce47f2e72db">8.8</ix:nonFraction>&#160;million, decreased net loss by $<ix:nonFraction unitRef="usd" contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMDgwMQ_11e9ae11-09d4-4569-9313-44eadc10bb95">8.8</ix:nonFraction>&#160;million and decreased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231" decimals="INF" name="sgmo:CollaborativeArrangementNetIncomeLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMDc2Nw_2bbc5eee-ed86-4199-bcd0-ff74f6de077a">0.06</ix:nonFraction> for the year ended December&#160;31, 2020.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Genzyme</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#8220;Sanofi&#8221;)), to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting <ix:nonFraction unitRef="program" contextRef="ibe586645e7eb480fa88f004968e69f26_D20140101-20140131" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfResearchProgram" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjIxNzY_830bf22c-6f0b-4b2e-b6e1-6cebf9ad55f8">two</ix:nonFraction> research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company received an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="ibe586645e7eb480fa88f004968e69f26_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQwMzk_cfbe4299-a081-475e-ae1e-fc3b112c28c8">20.0</ix:nonFraction>&#160;million and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="i9122d80b46af45729722b3a5a580fddc_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQyNjM_420b2cbd-f3d9-47df-848e-2c9aa7459f11">115.8</ix:nonFraction>&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $<ix:nonFraction unitRef="usd" contextRef="i42a8f2c72a0c4b7da4f6fe01645f2fbc_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQzNzc_5a4cdeb5-3622-4376-be34-edb0c3a70c02">160.5</ix:nonFraction>&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $<ix:nonFraction unitRef="usd" contextRef="i91c96f778c484ff7b36d40e42b5cef1a_D20140101-20140131" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQ2MTg_d910fb1e-cb30-48ef-8a5f-34b77bb64a15">276.3</ix:nonFraction>&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $<ix:nonFraction unitRef="usd" contextRef="i3117020fd58a4382be68a9dd0e475832_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQ5Mjc_6a6f0387-5d0b-41c7-adcb-8ab113b1e98e">6.0</ix:nonFraction>&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $<ix:nonFraction unitRef="usd" contextRef="idd4d071a5a1240e899107dc0bc2d0d7f_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjUwMDk_298668c6-dc1a-4d0f-849a-e10be64749de">7.5</ix:nonFraction>&#160;million milestone has been achieved related to SCD, however <ix:nonFraction unitRef="product" contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjUwNjQ_6c857be3-1df4-40c0-bd5d-654b2a828192">no</ix:nonFraction> products have been approved and therefore <ix:nonFraction unitRef="milestone" contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjUxMDk_a98a62a0-e2d2-4591-b4f1-0e3dd6cb4ff9">no</ix:nonFraction> royalty fees have been earned under the Sanofi agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:durday" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjUzOTk_537e664b-063d-4989-9877-6f9263601c6e">180</ix:nonNumeric> days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price as of December&#160;31, 2020 of $<ix:nonFraction unitRef="usd" contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementTransactionPrice" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjU3OTg_ff45bc62-602a-4027-a35c-f3b9b0bc3433">93.3</ix:nonFraction>&#160;million includes the upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjU4Mzc_2e1c8afd-2bab-4600-a719-7cfc22f86c61">20.0</ix:nonFraction>&#160;million, two unconstrained milestones of $<ix:nonFraction unitRef="usd" contextRef="id81a1acd8821404c8ec43c3bcbc17cf3_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjU4NTU_2b6d0ba5-b7ca-4851-80c9-13cbecc025bb">13.5</ix:nonFraction>&#160;million and estimated research costs of $<ix:nonFraction unitRef="usd" contextRef="i034bd4a542ff4479990ca46381d0f393_D20140101-20140131" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMjYxMg_55bd49d9-0103-4ef8-a1c1-194ec33231f2">59.8</ix:nonFraction>&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i4285ba44fa0641d7873be5df994465d9" continuedAt="i2a9f0b3f0e1c4fbcab702c85cd695d9c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the constrained clinical or regulatory milestones have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Sanofi in accordance with ASC Topic 606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the estimated period the Company will perform research services. The estimate of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of December&#160;31, 2020 and 2019, the Company had deferred revenue of $<ix:nonFraction unitRef="usd" contextRef="ic6f1610375924f09a443d3568cdc1d68_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjc4NjA_75cd69e2-f2af-471c-a6c0-49c356e48745">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i1a4ecba9c6614c06b7f7c8459b127a96_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjc4Njc_107e6d4b-824c-4874-b896-6b03ce129a7f">1.7</ix:nonFraction>&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="i4dc2cac8272f43ee8e45b5b6bd542b3e_I20190831" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjc5NTE_15c1f8fc-578d-44a2-a731-0cb6f644792c">6.0</ix:nonFraction> million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $<ix:nonFraction unitRef="usd" contextRef="i9b1c3dc836d24210b520f3db7f97f9c0_D20190801-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjgxMDE_cc4ef05b-34a4-444d-8eff-7302ba0fcf17">5.8</ix:nonFraction>&#160;million as of December&#160;31, 2020 and included $<ix:nonFraction unitRef="usd" contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcwNTcyOQ_759a90fc-15d2-4e22-aea4-df4ff9ac59c2">0.1</ix:nonFraction>&#160;million recognized during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company achieved a $<ix:nonFraction unitRef="usd" contextRef="i94120f03c5fd4072a8bb3031d5eaff43_I20191231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestoneRevenueReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjgyMjY_0bdc46ae-4e11-4a08-b8d8-c55a180cc59c">7.5</ix:nonFraction> million milestone with Sanofi upon dosing of the first subject in the SCD Phase 1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $<ix:nonFraction unitRef="usd" contextRef="ib3a5217c51de4459902f1b79d64f6c95_D20140101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjgzNTY_5fb19d70-aabc-437f-9952-b69a510e65ab">7.2</ix:nonFraction>&#160;million as of December&#160;31, 2020 and included $<ix:nonFraction unitRef="usd" contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcwNTc0OA_fef2d7a6-35ab-474c-a5d6-f51bf3db400d">0.1</ix:nonFraction>&#160;million recognized during the year ended December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3NDI_96879cc7-864f-4ab4-b555-3b7925328485" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78bd26e8f611439f93e83caa744593ce_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfMy0xLTEtMS0w_8d4d4b42-0a32-430c-9c75-92173dcf7782">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cd52bb2ae3a4d5e9b83e8bb8f82e121_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfMy0zLTEtMS0w_0e964408-5a18-4593-963f-c1fd66ede4a7">3,494</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aacd04dbe964a6fa6e32e1188460504_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfMy01LTEtMS0w_65b590ab-78f5-4c53-b235-1b7f8bc4f628">4,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaedf24cb2ecc475bb59fce790b63d4dc_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNC0xLTEtMS0w_767fefba-a66b-4b37-8451-e07c4db83379">4,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0224ad04487349818fda88d3a4f7b06f_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNC0zLTEtMS0w_532a4c61-f8de-4b04-a429-4bed941e997e">6,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739d766508794dde903e7ea835312bb5_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNC01LTEtMS0w_340c8c95-b2c9-4fff-b323-27eaf1288ac5">9,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9bbe06eb17f4e4389ae875bb992beae_D20200101-20201231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNS0xLTEtMS0w_d71a93cc-18ec-4db4-9e51-e899629e07a0">201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61957911f74047ab839b3929a36f2784_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNS0zLTEtMS0w_faec9e20-1a4d-4ad0-b7da-53e6ac6e9fff">12,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2fc4f96355416b89ed85d1b3204e27_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNS01LTEtMS0w_7ee1d78f-9de5-4195-8ba6-66992a8aa1c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNi0xLTEtMS0w_13ee8ad5-098c-44a9-8391-282ed5a24c4b">5,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6851909816f43d9927a3b74f4eb9ae0_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNi0zLTEtMS0w_7ec2e8b7-7d47-4d91-a5e0-0e7d817894b9">22,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b192f0b536424dbbf09712a8ca6db3_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNi01LTEtMS0w_20fbf896-0ae5-469a-9a87-8c463d5530c8">13,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi. This adjustment was a direct result of the decision in March 2020 to increase the project scope and the corresponding costs, both of which resulted in a decrease in the measure of proportional cumulative performance. This adjustment decreased revenue by $<ix:nonFraction unitRef="usd" contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMjU1Nw_667c41c3-ff69-4389-949e-f6e694feedad">2.2</ix:nonFraction>&#160;million, increased net loss by $<ix:nonFraction unitRef="usd" contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231" decimals="-5" sign="-" format="ixt:numdotdecimal" name="sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMjU3NQ_34716a35-a055-4f54-b5a6-ddada6cb1ec0">2.2</ix:nonFraction>&#160;million and increased the Company&#8217;s basic net loss per share by $<ix:nonFraction unitRef="usdPerShare" contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231" decimals="2" sign="-" name="sgmo:CollaborativeArrangementNetIncomeLossPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMjU0Mg_f959e2eb-43a5-469b-add2-d527efaac87c">0.02</ix:nonFraction> for the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Institute for Regenerative Medicine</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $<ix:nonFraction unitRef="usd" contextRef="i6a973ce71ad84032872771f13a2ca702_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:GrantFundingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjkwMzA_27529387-7e69-49da-ba6e-a7ad95b573c3">8.0</ix:nonFraction>&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta&#160;thalassemia. As of December&#160;31, 2020, the Company had received $<ix:nonFraction unitRef="usd" contextRef="i764803be26a0446cb2b582d6f52c4848_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjk0NDI_824ad513-c72e-41dc-91cf-f68b5febba2a">5.2</ix:nonFraction>&#160;million under the award.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these Consolidated Financial Statements. In the event that the Company terminates a CIRM-funded clinical trial, it will be obligated to repay the remaining CIRM funds on hand. As of December&#160;31, 2020 and 2019, $<ix:nonFraction unitRef="usd" contextRef="i7808e1ec9ea64ec3bca436fa6a85404a_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzAxMDA_4a1f5dc9-d027-4b85-a643-8b583e4348c2">6.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i194b83713fb341fbbd2acdc7368d1a8a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzAxMDc_ee0af2e0-ebe6-4cea-a60e-47b009fd7ede">5.7</ix:nonFraction>&#160;million, respectively, including accrued interest, related to this award is recorded as a loan in other non-current liabilities on the Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Collaboration and License Agreement with Takeda</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2012, the Company entered into a collaboration and license agreement with Shire International GmbH, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), to research, develop and commercialize a ZFP therapeutic for treating Huntington&#8217;s disease. The Company received an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i64443d1a16cd488f905e7295d699439b_D20120101-20120131" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzA2NDk_bfca44a1-6332-408c-9e60-346fa2ee0c2b">13.0</ix:nonFraction>&#160;million in 2012 and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i2a9f0b3f0e1c4fbcab702c85cd695d9c" continuedAt="iea1cc703ca4a425ba081916943b7b8e1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized a $<ix:nonFraction unitRef="usd" contextRef="i56dfa7a7f694412ca8f155eddda57f6b_D20140101-20141231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzA2ODM_ad4b5d20-ac89-4927-b440-9d015065b852">1.0</ix:nonFraction>&#160;million milestone payment in 2014. Takeda does not have any milestone payment obligations, but is required to pay single digit percentage royalties to the Company, up to a specified maximum cap, on the commercial sales of therapeutic products for Huntington&#8217;s disease. The Company is required to pay single digit percentage royalties to Takeda, up to a specified maximum cap, on commercial sales of therapeutic products from programs returned under the original agreement (which include blood clotting Factors VIII and IX) that use two zinc fingers.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the Company granted Takeda an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use the Company&#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the huntingtin gene (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene&#8221;). During the term of the agreement, the Company is not permitted to research, develop or commercialize, outside of the agreement, certain products that target the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. The agreement may be terminated by (i)&#160;the Company or Takeda, in whole or in part, for the uncured material breach of the other party, (ii)&#160;the Company or Takeda for the bankruptcy or other insolvency proceeding of the other party and (iii)&#160;Takeda, in its entirety, effective upon at least <ix:nonNumeric contextRef="i7d2161524129470cafb1f5a6567f6cba_D20200101-20201231" format="ixt-sec:durday" name="sgmo:AgreementTerminationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzIwMjM_a9009911-106f-4461-a13b-b96a1a1e0c9a">90</ix:nonNumeric> days&#8217; advance written notice.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Takeda in accordance with ASC Topic 606 and concluded that Takeda is a customer. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Takeda apart from the research services to be performed pursuant to the Takeda agreement. The Company satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. As a result, the Company recognized the remaining $<ix:nonFraction unitRef="usd" contextRef="i8e5077542aaf42a4bb4062f041a4038c_I20171231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI1Nzc_fd4c703e-f59c-4c8b-94a5-a79be9f00d13">2.3</ix:nonFraction>&#160;million of deferred revenue from the upfront payment during the year ended December 31, 2017.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="usd" contextRef="i7b3feba275324427aa270226c8ff4256_D20200101-20201231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI2OA_34ef71a8-6731-43c0-96ae-9c8f87f391e5"><ix:nonFraction unitRef="usd" contextRef="i6b3e32e94c384b1e966f84999353cd18_D20180101-20181231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI2OA_3ef8e925-37fd-42e8-93a4-31af41266c09"><ix:nonFraction unitRef="usd" contextRef="if86082d75aed4dbdb15c659083e9bf9b_D20190101-20191231" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI2OA_4918525d-9f33-4166-950c-e60bbf4035e3">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t recognize any revenues under the Takeda agreement for the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement with Sigma-Aldrich Corporation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2007, Sangamo entered into a license agreement with Sigma-Aldrich Corporation (&#8220;Sigma&#8221;) to provide Sigma with access to Sangamo&#8217;s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC (&#8220;DAS&#8221;), a wholly-owned subsidiary of Dow Chemical Company. Sangamo developed laboratory research reagents using its ZFP technology over a <ix:nonNumeric contextRef="i01464b993796404cb11757f956a8a3c7_D20070101-20071231" format="ixt-sec:durwordsen" name="sgmo:ResearchServicesPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI3NQ_a011e356-d90e-44c1-bd90-02f29c46a887">three-year</ix:nonNumeric> research services period. Sangamo has since transferred the ZFP manufacturing technology to Sigma.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="iccfbbecbaede42b5845fac46fdce4a09_I20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM4Nzg_bdf4f85c-d0de-4029-a941-61489b4a557a">20.0</ix:nonFraction>&#160;million consisting of a $<ix:nonFraction unitRef="usd" contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM4OTc_f448667f-ae10-4d0e-8c6d-e9e35895cfb8">4.9</ix:nonFraction>&#160;million purchase of <ix:nonFraction unitRef="shares" contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM5MTI_870cfbdb-e9f5-44a2-a933-f43dfbd6f99c">636,133</ix:nonFraction> shares of Sangamo common stock, valued at $<ix:nonFraction unitRef="usd" contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM5NTc_08651543-9fdc-48d9-ae00-aab1838510b6">4.9</ix:nonFraction>&#160;million, and a $<ix:nonFraction unitRef="usd" contextRef="ief34bca385d04e8aa286ffe64c5ec431_I20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM5Njc_70ed7f6d-0b66-41e6-a88b-98558392f089">15.1</ix:nonFraction>&#160;million upfront license fee. Sangamo is also eligible to receive commercial license fees of $<ix:nonFraction unitRef="usd" contextRef="i706a8d68f1cf40cb9c3132b4ff11e8f2_D20091001-20091031" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQwNTQ_19991ce4-d41e-4842-82fa-4a6c79a8cdcd">5.0</ix:nonFraction>&#160;million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of <ix:nonFraction unitRef="number" contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031" decimals="3" name="sgmo:ReducedRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQxNjA_4bf0e626-41cf-4fa5-b9cb-a751b89d8c31">10.5</ix:nonFraction>% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones, Sigma will make milestone payments to Sangamo up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031" decimals="-5" format="ixt:numdotdecimal" name="sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQzNDk_92fcbd14-1a2d-4500-8f7c-e48859ddd62d">25.0</ix:nonFraction>&#160;million. Sangamo does not have additional ongoing performance obligations under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement with Sigma for the years ended December&#160;31, 2020, 2019 and 2018, were $<ix:nonFraction unitRef="usd" contextRef="i546676fe6a9d40ddaa72ca93f19fcba8_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQ1MzA_fe3496a0-43ae-4884-a488-dc5ab3fb6dda">0.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="if616c1c1a07f410682a95cb374ebf65f_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQ1MzQ_f2bd62a6-3c7b-4a54-84f2-8d50beb04726">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="iad0d9ea6bdab481590237f5b575dc744_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQ1NDE_9a41d44c-c698-4a08-996b-eb0464c7e1a8">0.5</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement with DAS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2005, Sangamo entered into an exclusive commercial license with DAS, with an initial <ix:nonNumeric contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231" format="ixt-sec:durwordsen" name="sgmo:InitialResearchTermOfAgreement" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI3Ng_1b1187f1-5464-44f0-8f65-7ab9ca569cd6">three-year</ix:nonNumeric> research term. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP-TFs or ZFNs into humans or animals for diagnostic, therapeutic or prophylactic purposes. In 2008, DAS exercised its option and obtained a commercial license to sell products incorporating or derived from plant cells generated using the Company&#8217;s ZFP technology. The exercise of the option triggered a one-time commercial license fee of $<ix:nonFraction unitRef="usd" contextRef="ib2df94fee7564a61bb14696381264213_I20051231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:OneTimeLicenseFeeEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzUzNjU_7c8752fe-6524-42fb-a2d9-ad895cff9e82">6.0</ix:nonFraction>&#160;million, payment of the remaining $<ix:nonFraction unitRef="usd" contextRef="ia280905d8bb74bf892bb6bdb624a87ea_D20050101-20051231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzUzOTQ_f78daf37-b26b-44cf-9252-7c8f3aa1b18c">2.3</ix:nonFraction>&#160;million of the previously agreed upon $<ix:nonFraction unitRef="usd" contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzU0Mjc_12d38765-3018-4d0a-9433-62049f403e63">4.0</ix:nonFraction>&#160;million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#8217;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to <ix:nonFraction unitRef="number" contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231" decimals="2" name="sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzU3MzY_7e63a2c5-0109-4302-87cd-7cd1c07e72f3">25</ix:nonFraction>% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December&#160;31, 2012.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $<ix:nonFraction unitRef="usd" contextRef="id5fceb7cf1e54c71be44f291df33cab6_D20050101-20051231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:AnnualFeesRelatedToAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzYxNDc_82b2a32e-5838-473f-9b31-0edc47f0ded1">0.3</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i8b580b7103874a51aa8d767ed03b3928_D20050101-20051231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:AnnualFeesRelatedToAgreement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzYxNTM_43780b76-ad01-46ed-b82c-8f4368583fec">3.0</ix:nonFraction>&#160;million and total $<ix:nonFraction unitRef="usd" contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:FeeDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzYxNjY_83244560-f71f-4f00-98d6-c8ead0f78ca5">25.3</ix:nonFraction>&#160;million </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="iea1cc703ca4a425ba081916943b7b8e1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over <ix:nonNumeric contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231" format="ixt-sec:duryear" name="sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzYxNzQ_6225d80f-0af0-4adb-a4e1-8f78d499e79a">11</ix:nonNumeric> years. The Company has identified the performance obligation within this arrangement as a license to the technology. In the event of any termination of the agreement, all rights to use the Company&#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo&#8217;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#8217;s ZFP technology.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the agreement with DAS were $<ix:nonFraction unitRef="usd" contextRef="i1e7888a0f40541728fa78e28fb8d32b9_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY2ODk_3e4dd82a-256b-45c7-8221-0953d035e468">3.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i13e149c04b9c44ae968ce27839b0ff98_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY2OTM_444be296-3362-4f1b-9481-a0b07a5c65d2">3.0</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i6d636ae7fc074737a7f48065c83c1704_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3MDE_e9abe9d1-a1f7-45c0-a26d-485dec977a18">3.0</ix:nonFraction>&#160;million during 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div id="i24672e5030474c1ba9673ec16c177662_100"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzM2Nzk_f9bbbce1-8dd0-4b36-beb8-73da7cf5eed0" continuedAt="i034238be9ff44aaeba50ed2c2e5028f9" escape="true">ACQUISITION OF SANGAMO FRANCE</ix:nonNumeric></span></div><ix:continuation id="i034238be9ff44aaeba50ed2c2e5028f9"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;20, 2018, Sangamo entered into various agreements with the goal of eventually acquiring <ix:nonFraction unitRef="number" contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720" decimals="INF" name="sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzE0MA_19270489-694c-47e0-841f-b5b88d0894d6">100</ix:nonFraction>% of Sangamo France&#8217;s share capital. The Company entered into the Sangamo France SPA with certain shareholders of Sangamo France, pursuant to which it acquired <ix:nonFraction unitRef="shares" contextRef="i7a7eb33edfe747c3aefde90c4e3c2a60_D20181001-20181001" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzMwMQ_0a0a1d9e-4261-4e65-a94a-ed16a92a6881">13,519,036</ix:nonFraction> ordinary shares of Sangamo France (&#8220;Ordinary Shares&#8221;) as part of a block transaction that closed on October&#160;1, 2018 (the &#8220;Acquisition Date&#8221;). Additionally, the Company and Sangamo France entered into a Tender Offer Agreement pursuant to which Sangamo agreed to acquire <ix:nonFraction unitRef="shares" contextRef="i02eebe0086a243caa7e9e1bb622faf7a_D20181001-20181123" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzU3Mw_a0609b13-4224-403a-b154-7413eb6fb47c">11,528,635</ix:nonFraction> Ordinary Shares for the same price per share as the Sangamo France SPA via a cash tender offer that closed on November&#160;23, 2018. Following the block transaction, cash tender offer, and other open market purchases of shares, the Company owned <ix:nonFraction unitRef="number" contextRef="i4a6b2a742e264c81a0162eee4479ebde_I20181231" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzgxOA_404203f5-c6d0-4f1c-a48d-87280cfa44de">98.2</ix:nonFraction>% of the Ordinary Shares as of December&#160;31, 2018 (or <ix:nonFraction unitRef="shares" contextRef="i592fbd2441fa41bd9d36900308836ecc_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzg3Mg_2bb5eaf8-a24a-41e0-a235-0603eb9b0e12">25,047,671</ix:nonFraction> Ordinary Shares). In addition to the Sangamo France SPA and the tender offer agreement, the Company also entered into arrangements with the holders of approximately <ix:nonFraction unitRef="shares" contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwNDA_bbffd6fe-c9ba-46d3-a247-5fd5b1b79779">477,000</ix:nonFraction> &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#8220;Free Shares Options&#8221;). During 2019, the Company acquired approximately <ix:nonFraction unitRef="shares" contextRef="i7377f8b263024b66ad603bd494ee0f22_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzE1Mjc_76e2abc3-40cb-406c-9f96-281f04e62773">111,000</ix:nonFraction> vested free shares, increasing its ownership of the Ordinary Shares from <ix:nonFraction unitRef="number" contextRef="i4a6b2a742e264c81a0162eee4479ebde_I20181231" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzIzODA_00adb8f6-0d00-4485-b35e-c7ae49a1c357">98.2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i0581803351f54eeebd9c251d33078aec_I20191231" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzE2MDE_51f33f15-6a2c-407f-820b-aeea6bf31823">98.7</ix:nonFraction>%. During 2020, the Company acquired approximately <ix:nonFraction unitRef="shares" contextRef="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzIzMzY_277edf15-9fae-4000-8209-12f610ad1660">322,000</ix:nonFraction> vested free shares, pursuant to the exercise of the put options for approximately $<ix:nonFraction unitRef="usd" contextRef="if6f3f191be824087ad8c554b2a988bfa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzIzNjk_402f0c91-5043-4a9e-ba42-da3b43fcf32e">0.7</ix:nonFraction>&#160;million of cash, increasing its ownership of the Ordinary Shares to <ix:nonFraction unitRef="number" contextRef="i5224f1a418c04fb395423371d5cd63de_I20201231" decimals="3" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzIzNTQ_ddda84e9-44b8-4f68-8cb9-940592c25457">99.8</ix:nonFraction>% as of December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of $<ix:nonFraction unitRef="usd" contextRef="i333a5711c7bb4f51917b34946c0b9f23_I20181001" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzE3MTY_43c85e38-cf07-4b0d-a8d1-9cac7f4d2b02">0.2</ix:nonFraction>&#160;million. See Note 2 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Free Shares Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding the valuation method. The fair value of the Free Shares Options will vary based on future changes in the Company&#8217;s stock price during the option period. The fair value of the Free Shares Options was estimated to be an asset of $<ix:nonFraction unitRef="usd" contextRef="i16391b7df5174ed5b8c2310d931447ad_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzIwMzk_fed56b50-c757-441e-aec9-24a817ed020b">0.1</ix:nonFraction>&#160;million as of December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for total consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i7a7eb33edfe747c3aefde90c4e3c2a60_D20181001-20181001" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzE4OTI_2ea6aff2-d058-461b-8f69-1841bb771ed2">45.9</ix:nonFraction>&#160;million at the Acquisition Date. The operating results of Sangamo France after the Acquisition Date have been included in the Company&#8217;s Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzI0MTI_3ac73438-1152-42f9-9258-2505c3c0ae59"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzI0MTI_afaf2702-4087-4b33-93fd-36406b7feb96"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzI0MTI_e231650e-0af6-4345-9ded-644391a16c75">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> goodwill impairment during the years ended December&#160;31, 2020, 2019 or 2018 and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of December&#160;31, 2020 and 2019.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the remaining non-controlling interest was determined based on the number of outstanding shares comprising the non-controlling interest and the $<ix:nonFraction unitRef="usdPerShare" contextRef="i796f26491be441f2a96fe82d3903003f_I20181001" decimals="INF" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzI5NzY_74108d9b-f95f-4e4c-adb6-4d959f37a4d7">2.99</ix:nonFraction> acquisition price per share as of the Acquisition Date. The non-controlling interest is presented as a component of stockholders&#8217; equity on the Company&#8217;s Consolidated Balance Sheets.</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="sgmo:ScheduleOfNoncontrollingInterestTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzM2ODE_ea48a9db-01cf-4e12-a57d-3259960851b0" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest as of December&#160;31, 2020 was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae1f574b2f8c4344aa08242f7ae98ac4_I20191231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90YWJsZTo2YWJkOTY5MTQyZjI0MmU4ODcxNzk5MTVkYzVkMzhkNi90YWJsZXJhbmdlOjZhYmQ5NjkxNDJmMjQyZTg4NzE3OTkxNWRjNWQzOGQ2XzctMS0xLTEtMA_a7d64920-fa6e-46b6-9006-3232114eb358">185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of additional shares acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90YWJsZTo2YWJkOTY5MTQyZjI0MmU4ODcxNzk5MTVkYzVkMzhkNi90YWJsZXJhbmdlOjZhYmQ5NjkxNDJmMjQyZTg4NzE3OTkxNWRjNWQzOGQ2XzgtMS0xLTEtMA_a9bfce5b-834d-4ee7-9da7-e46596b6b4ab">927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90YWJsZTo2YWJkOTY5MTQyZjI0MmU4ODcxNzk5MTVkYzVkMzhkNi90YWJsZXJhbmdlOjZhYmQ5NjkxNDJmMjQyZTg4NzE3OTkxNWRjNWQzOGQ2XzktMS0xLTEtMA_8eda3e1e-ac0a-4626-8120-a7b7906f5cde">126</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idcd9bdcf4f1749ed855ea52ac19c1e57_I20201231" decimals="-3" sign="-" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90YWJsZTo2YWJkOTY5MTQyZjI0MmU4ODcxNzk5MTVkYzVkMzhkNi90YWJsZXJhbmdlOjZhYmQ5NjkxNDJmMjQyZTg4NzE3OTkxNWRjNWQzOGQ2XzEwLTEtMS0xLTA_1fe93ccd-590e-4dbf-8286-69ea7d0f9085">868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzQ5NA_43f434c5-3ff2-4786-8cf0-26b38350bc65" continuedAt="if362935d1a2c4adaa4caa09901565fd1" escape="true">OTHER BALANCE SHEET DETAILS</ix:nonNumeric></span></div><ix:continuation id="if362935d1a2c4adaa4caa09901565fd1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzQ5NQ_bd630e41-d73c-4b84-9d93-c2ebdca2c783" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i727255e08dff491997abe1595a807416_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzItMS0xLTEtMA_e24080e0-f8d5-4190-b264-6b07125519db">24,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib03bf486440e4058b398c99085b2e3bb_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzItMy0xLTEtMA_f1833e7b-ccea-4cff-a7e5-6ef7008472b9">17,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17ed21c4f31a48f9884d2e5a34a07660_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzMtMS0xLTEtMA_3197b3eb-9ec1-4475-9ecd-f922f72ac879">4,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b6fc4c001f43229955467cb883d455_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzMtMy0xLTEtMA_617ca324-4bcc-45d5-b8c5-6d70872fbba6">4,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd01b55790404653a8dbf54a898c83e9_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzQtMS0xLTEtMA_d03d21d9-af05-4996-8402-129527032922">15,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b618149cf52411482e490b4cfbaa70b_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzQtMy0xLTEtMA_63101a92-48fd-48dc-934e-73bf8bc5aaac">13,888</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9736e534b649e19378d63d2cb29bd7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzUtMS0xLTEtMzUyMA_e81c86a0-9903-4219-b5e6-537264e041fb">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7127032c342b4a9ba46f6b46c2355df9_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzUtMy0xLTEtMzUyMA_0f49e69c-ab3b-4223-98a5-d03cb6eb92c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc0d4241c9514c2bbe8a711b6b6d76c7_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzYtMS0xLTEtMA_8dbad4ce-766a-4cb6-8f62-2db6b6bad4d7">12,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7bb97c3073446b9aa8c3f008be817ce_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzYtMy0xLTEtMA_1a166fba-ba05-495f-9f06-3e614aa24617">5,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzctMS0xLTEtMA_f6e7567e-e6d4-4784-a734-882798c5a680">58,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzctMy0xLTEtMA_2c57f9db-f700-431e-8a95-01796b1801c4">41,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzgtMS0xLTEtMA_3a97f3bb-19cd-499b-96cf-3f7d4b61f1c4">17,416</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzgtMy0xLTEtMA_7fb1163b-0a4c-4f81-b111-bbce82b3fdd8">11,681</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzktMS0xLTEtMA_5250c44d-2c10-4afb-8454-57578bcbc193">41,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzktMy0xLTEtMA_c053dfe6-1683-4453-a213-ea3025ea377e">29,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzE4Mw_d59990bc-5e84-42d7-996b-7b0a77608d00">5.7</ix:nonFraction>&#160;million in 2020, $<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzE5Mw_625fb359-c61f-4c8a-b8e8-2d06ffdc5a65">3.9</ix:nonFraction>&#160;million in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzIwNg_f4a04b96-17c8-49e2-bd65-b63cf4d36b03">2.4</ix:nonFraction>&#160;million in 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzQ5Ng_fbdcf3e7-b554-4133-a69d-079a3cdcb54b" continuedAt="ice462f18afeb4b7f96cfbafca5c82e06" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in intangible assets were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzItMS0xLTEtMA_894a5164-9e45-46fa-a928-b463e119df61">53,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzItMy0xLTEtMA_9663dfa0-8f1e-4f04-86c5-bd06bfe3dfb0">54,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzQtMS0xLTEtMA_06b1f433-ed0c-4c97-a3b5-6fd71f51aa58">4,972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzQtMy0xLTEtMA_1b268b76-2c74-4821-859c-26123a1380d2">1,087</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzUtMS0xLTEtMA_bcab23dd-3f04-4ad3-a0fb-55efb37830f2">58,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzUtMy0xLTEtMA_6b26a9db-4b27-48ff-88b1-239ee2680186">53,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:continuation id="ice462f18afeb4b7f96cfbafca5c82e06"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in goodwill were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzItMS0xLTEtMA_bf43e516-495c-457c-91d9-a08b56dac9de">39,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzItMy0xLTEtMA_34fd1107-abf0-471f-b61d-e45d5cbcbf94">40,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzQtMS0xLTEtMA_4e63ec2c-950a-44a6-8233-8cb7bb9e854d">3,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzQtMy0xLTEtMA_3a041c98-aec7-4b89-8ee2-2997b5797a16">771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzUtMS0xLTEtMA_605a501b-3c06-46c6-b2af-5b62392e62c5">42,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzUtMy0xLTEtMA_43ec4d62-0ba3-44bb-a266-2782175cf998">39,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Accrued Liabilities</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzQ5Mw_0147f986-59fd-4258-a8f5-801abc52af86" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.372%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer advance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzMtMS0xLTEtNDEyNg_04705276-b38f-4b68-864a-c763b2bef7af">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzMtMy0xLTEtNDEyNg_5d6c3feb-b925-4e24-bc81-ba0d7a01bf56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:AccruedResearchAndDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzMtMS0xLTEtMA_c088d770-bc17-4bd8-8d84-8fa391f16ebc">4,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:AccruedResearchAndDevelopmentExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzMtMy0xLTEtMA_b9bb5614-bcfa-4b42-8d8f-b9ae279d5a44">4,102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liabilities &#8211; current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzQtMS0xLTEtMA_c671bf7e-cb3f-401d-b40c-62c26208c161">3,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzQtMy0xLTEtMA_96798900-b4c6-4417-ac35-8a40b661811f">3,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzUtMS0xLTEtMA_66ec16a2-90bb-4ebe-9262-8aba8ed7cab2">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzUtMy0xLTEtMA_7bfa5176-1a7f-4800-95e8-bb32d19d73f0">1,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzctMS0xLTEtMA_d8f98311-dc45-4880-9896-fe32f06bc748">4,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzctMy0xLTEtMA_aff02bb4-5736-4585-a47a-a236e6c514b6">2,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzgtMS0xLTEtMA_ad8c02f4-81fe-417a-8a88-1932ae4b9170">18,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzgtMy0xLTEtMA_d4aa5d8d-2f54-4568-acc3-574561a6b701">10,885</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div id="i24672e5030474c1ba9673ec16c177662_106"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzQxODA_53a7809c-0f47-4a9d-b648-f05de0ef5dac" continuedAt="i138668062a4f4532b63dfc1e9b9c931d" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i138668062a4f4532b63dfc1e9b9c931d" continuedAt="ied4fb5316fd240fd9327044c6bacf0f3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo occupies approximately <ix:nonFraction unitRef="sqft" contextRef="ia6609b14089f4212a584aa69b64acfc5_I20201231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzgy_2ec0e7fd-c998-49f1-b414-14d18847c129">87,700</ix:nonFraction> square feet of office and research and development laboratory facilities in Brisbane, California pursuant to a lease that expires in May 2029. Sangamo also occupies approximately <ix:nonFraction unitRef="sqft" contextRef="ibbb078359b94445aa19de4957f01c8a3_I20201231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI2NA_14588999-09ff-439c-b645-37ff48c6444c">54,200</ix:nonFraction> square feet of research and office space in Richmond, California, pursuant to leases that expire in August 2026. In addition, the Company </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="ied4fb5316fd240fd9327044c6bacf0f3" continuedAt="i8911fd43912b41cc94003dbe1734e8c1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leases approximately <ix:nonFraction unitRef="sqft" contextRef="ia9ddad8fdf914a9eb455c759a9202939_I20201231" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzQyNQ_336067f5-9612-4900-9a1f-20c8963daf01">20,800</ix:nonFraction> square feet of office, and research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through March 2028.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into an amendment to an existing lease to acquire approximately <ix:nonFraction unitRef="sqft" contextRef="i8ad9465ba0dc4a299f459f90c677d791_I20200531" decimals="-2" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzQ5NDc4MDIzMzE4NTQ_1d5908ac-b92b-45e8-8e21-a894ed2e4ab3">8,500</ix:nonFraction> square feet of research and office space in Richmond, California that expires in August 2026. Total lease payments over the life of this amended lease are approximately $<ix:nonFraction unitRef="usd" contextRef="i8ad9465ba0dc4a299f459f90c677d791_I20200531" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzEwOTk1MTE2MzU3NzI_0df728bb-a583-44a7-8e2d-6877781d7064">1.6</ix:nonFraction>&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The amended lease was effective October 1, 2020, and the Company recorded a lease liability and corresponding ROU asset of $<ix:nonFraction unitRef="usd" contextRef="i06474dbe630c4f41836daafffa78c161_I20201001" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzEwOTk1MTE2MzU3NTM_2aed6bb8-34e7-4ada-ab76-0d16a981f070">1.3</ix:nonFraction>&#160;million upon inception of this amended lease. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzY5Mw_274e8caf-5cf0-4157-9146-6781d7736ff8">five</span> to <ix:nonNumeric contextRef="i5adb6c8a5fbe4ae8998f2aaff0f11681_I20201231" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzM4NDgyOTA3MDUzNTA_fbe34e5e-4385-4abb-8353-62f6f894bc11">10</ix:nonNumeric> years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2020, the Company incurred $<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzE2NjI_4f7431f1-549a-4f44-820b-9daf51a7b217">10.4</ix:nonFraction>&#160;million of lease costs included in operating expenses in the Consolidated Statement of Operations in relation to these operating leases. Variable lease expense was $<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:VariableLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzE4MjE_9ba7ac33-ed3c-460e-bdd6-29a9833cd802">2.3</ix:nonFraction>&#160;million for the year ended December&#160;31, 2020 and was not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December&#160;31, 2020 was $<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzIyOTY_0a45b75c-b3c0-4852-b4f7-fa5e7d43e32b">6.4</ix:nonFraction>&#160;million and was included in net cash provided by operating activities in the Company&#8217;s Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense related to lease agreements was $<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI0NTY_1b976bfd-b481-4ece-a480-62933c956c8e">10.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI0NjA_2ea88c87-4cc3-4d04-adaa-7e27075de15b">7.9</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LeaseAndRentalExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI0Njg_79962c4b-244d-4fe7-b006-7e9f73782132">2.3</ix:nonFraction>&#160;million for 2020, 2019 and 2018, respectively. <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzQxNzk_4d69103f-2dab-42f8-8c3c-c9fb3bc00d0f" continuedAt="i2859f3899bfb45f7b671d691fe40582c" escape="true">Future minimum payments under lease obligations at December&#160;31, 2020 consist of the following (in thousands):</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i2859f3899bfb45f7b671d691fe40582c" continuedAt="i5ef24f6a293445ef9913b1a96288fda6">&#160;</ix:continuation></span></div><div style="margin-bottom:6pt;margin-top:6pt"><ix:continuation id="i5ef24f6a293445ef9913b1a96288fda6"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzEtMS0xLTEtMA_2655289f-2bbc-40a2-8a60-bf6181128a05">6,191</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzItMS0xLTEtMA_ae7fb50c-1286-4c60-8b9c-5aec859a403b">6,756</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzMtMS0xLTEtMA_291b260c-f30f-41f7-9bfe-1aa46f214db3">6,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzQtMS0xLTEtMA_dcc28a91-66cb-4c3a-9218-9f00bb09d17b">6,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzUtMS0xLTEtMA_7ef64c0c-4e04-4682-91a7-a8f77ef50498">7,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzYtMS0xLTEtMA_cdde31b5-159f-4616-9370-9440810d162a">19,571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzctMS0xLTEtMA_16c93c12-d197-4177-8633-6a776bf8bc70">53,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzktMS0xLTEtMA_625c3e26-0954-4ca5-a02c-048e925071f4">11,336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzEwLTEtMS0xLTA_3a5d2b6e-bdac-46c9-8c25-89c730ab251b">42,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as of December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current (included in Other accrued liabilities on the Consolidated Balance Sheet)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzEzLTEtMS0xLTA_59253b85-0768-480b-996f-c85c77be2d63">3,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzE0LTEtMS0xLTA_6bef4d19-ac2a-45f6-91a2-9c700244892d">38,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzE1LTEtMS0xLTA_e944b093-840f-4d56-bfce-1420d1081305">42,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the weighted-average remaining lease term is <ix:nonNumeric contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI2NTc_d29fad78-a295-4eb5-b53c-cebe70b6e02c">7.6</ix:nonNumeric> years and the weighted-average incremental borrowing rate used to determine the operating lease liability was <ix:nonFraction unitRef="number" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI3NzA_3c3b77fe-6499-4b49-8e62-5cad971be752">6.1</ix:nonFraction>% for the Company&#8217;s operating leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any financing leases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Commitments</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:OtherCommitmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzMyOTg1MzQ4OTAxOTY_850fb769-2553-483b-9ba1-f4e9bf405d12" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.221%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.147%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.805%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.322%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total commitments </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99562ae603894a8189b5ff099684f86d_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTowOTdiZDMyY2Y4NGM0MmE0YTAyMTk3NTgyMGZhYzY2MC90YWJsZXJhbmdlOjA5N2JkMzJjZjg0YzQyYTRhMDIxOTc1ODIwZmFjNjYwXzEtMi0xLTEtMjMy_1e40f10d-fcea-44a3-9971-d59a84db36aa">7,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68aebf0104924b419a789b0d776a9b5e_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTowOTdiZDMyY2Y4NGM0MmE0YTAyMTk3NTgyMGZhYzY2MC90YWJsZXJhbmdlOjA5N2JkMzJjZjg0YzQyYTRhMDIxOTc1ODIwZmFjNjYwXzItMi0xLTEtMjMy_9779d0a4-6e51-4235-a2ee-104e29c2faab">13,771</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual commitments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTowOTdiZDMyY2Y4NGM0MmE0YTAyMTk3NTgyMGZhYzY2MC90YWJsZXJhbmdlOjA5N2JkMzJjZjg0YzQyYTRhMDIxOTc1ODIwZmFjNjYwXzMtMi0xLTEtMjMy_93da9c0e-55dc-4ddf-9883-d3a3aa7b8b09">21,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i8911fd43912b41cc94003dbe1734e8c1"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:LicenseObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzM5MzE_f9fefba6-df86-4ede-a136-1c57ca10edc9">1.0</ix:nonFraction>&#160;million of license obligations related to its intellectual property as of December&#160;31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is not party to any material pending legal proceeding. From time to time, Sangamo may be involved in legal proceedings arising in the ordinary course of business.</span></div></ix:continuation><div id="i24672e5030474c1ba9673ec16c177662_109"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzY0OTY_91930e8a-17de-4494-9f21-24f4a08bd336" continuedAt="i94894fcf0bd3443fa83392073ddef309" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="i94894fcf0bd3443fa83392073ddef309" continuedAt="ide94d6b03bfb4b269d579f05d1780f11"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Certificate of Incorporation authorizes the Company to issue up to <ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzY3_c5d95157-2e91-49a7-9f98-e46ea76db273">5,000,000</ix:nonFraction> shares of preferred stock, which may be issued at the discretion of the Company&#8217;s Board of Directors. As of December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM4NDgyOTA3MTE1Mzk_cfed0e93-853b-4bba-a05b-f077c1060a21"><ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM4NDgyOTA3MTE1Mzk_eb5fe95b-00ce-477f-8cb7-54a1e25554ca">no</ix:nonFraction></ix:nonFraction> shares of the Company&#8217;s preferred stock have been issued or are outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Certificate of Incorporation to increase the total number of shares of the Company&#8217;s common stock authorized for issuance from <ix:nonFraction unitRef="shares" contextRef="i04133be982284def86006aea3fb52327_I20200629" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2NDIwNzk_c3db9a82-6a27-48bc-92b8-3c6e379acc5d">160,000,000</ix:nonFraction> shares to <ix:nonFraction unitRef="shares" contextRef="iee1b756f6c0a4abe92e4664a43ad8035_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2NDIwOTM_4bd979e3-08c1-4a63-904e-29c400ac4f8d">320,000,000</ix:nonFraction> shares. As of December 31, 2020, <ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2MzkxOTU_53a9a6bb-8e97-47c2-8a56-3780f17441cd">142,063,203</ix:nonFraction> shares of the Company&#8217;s common stock are outstanding.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the collaboration agreement with BIMA described in Note 4 of these Consolidated Financial Statements, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase the Biogen Shares at a price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="if650f84ed8e44993a9c4382072ecf061_I20200430" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIxOTkwMjMyNjI5MDE_5e11d075-9e8e-4257-8d06-04e0f10d896a">9.2137</ix:nonFraction>, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="i34bcdc0ce9f64813a8d36f116a1f90eb_D20200401-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIxOTkwMjMyNjI4ODc_3e4c3368-3e3e-4b92-9aa1-5cd785f7113e">225.0</ix:nonFraction>&#160;million. The Company closed the sale of the Biogen Shares in April 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company completed an underwritten public offering of its common stock, in which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="i77930a25b46346a2979712dac12ee7a0_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzMyNw_7892b148-6579-4596-ab00-3691de5b04d7">12.7</ix:nonFraction>&#160;million shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i30d8dda504854d9ca7d63f9a88cc3816_I20190430" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM4Nw_ecfe6f0e-7bbd-419e-94c8-97853b431b5d">11.50</ix:nonFraction> per share. The net proceeds to the Company from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="i77930a25b46346a2979712dac12ee7a0_D20190401-20190430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU3NA_f05a7e70-c46c-4735-8eda-2b2b9f372aa6">136.3</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company completed an underwritten public offering of its common stock, in which the Company sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="ic46aca1e871a400a88bda284834701ce_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzcwNg_d665bfa5-14c3-402f-a157-17ea96d64f8c">14.2</ix:nonFraction>&#160;million shares of its common stock at a public offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie0bb49a1111a409c8731842f7bda4df1_I20180430" decimals="INF" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4Xzc2Ng_2592c6e9-fb8c-4c72-99a3-59ff8e4408b0">16.25</ix:nonFraction> per share. The net proceeds to the Company from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $<ix:nonFraction unitRef="usd" contextRef="ic46aca1e871a400a88bda284834701ce_D20180401-20180430" decimals="-5" format="ixt:numdotdecimal" name="sgmo:NetProceedsFromIssuancePublicOffering" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4Xzk1Mw_1e316f1d-68be-4dfc-9a26-cac9d70411df">215.8</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="i075446115f764740898840df11c14db0_D20200805-20200805" decimals="-5" format="ixt:numdotdecimal" name="sgmo:StockOfferingProgramMaximumValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIxOTkwMjMyNjQ4NDE_087f994f-67e6-4e7b-8d68-6a67815fcfe7">150.0</ix:nonFraction>&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. As of December&#160;31, 2020, <ix:nonFraction unitRef="shares" contextRef="ic740901c064241959e061ee1525d0c94_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5NDc4MDIzMzQzNDE_5d474e7c-29c3-48a6-a660-9e7b050c6159">no</ix:nonFraction> shares had been sold under the sales agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company&#8217;s stockholders approved the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;). In connection with the approval of the 2018 Plan, <ix:nonFraction unitRef="shares" contextRef="i1a2222cfa49440338b7416d398920ffc_D20180401-20180430" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzE3MzI_278481c2-925a-4453-818e-094992adf1f7">no</ix:nonFraction> additional equity awards will be granted under the previous 2013 Plan, however all outstanding equity awards under the 2013 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such awards and the terms of the 2013 Plan.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company&#8217;s stockholders approved an amendment and restatement of the 2018 Plan, to, among other things, increase the aggregate number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 Plan by <ix:nonFraction unitRef="shares" contextRef="i66466b43ef874206b64889bb27cb2d08_I20200531" decimals="INF" format="ixt:numdotdecimal" name="sgmo:CommonStockAdditionalCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2Mzc1OTc_af044e3d-7fcf-41e7-9b27-5290d8d3e67e">9,900,000</ix:nonFraction> shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of a stock option granted under the 2018 Plan may not be less than <ix:nonFraction unitRef="number" contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIwODM_714819b6-a940-4b13-8a76-5b5cdcab8cb6">100</ix:nonFraction>% of the fair market value of the Company's common stock subject to the stock option on the date of grant, and the option term will not exceed <ix:nonNumeric contextRef="i91713b083997409ea11ba55173dcc112_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIyMjc_bca04d73-0e77-40d5-be2b-95d468c6bbde">10</ix:nonNumeric> years. If the person to whom the stock option is granted is a <ix:nonFraction unitRef="number" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" name="sgmo:SpecifiedStockholderOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIyODY_8abcb32a-d151-426d-8a7a-ec01bb61c71c">10</ix:nonFraction>% stockholder of the Company, and the stock option granted qualifies as an incentive stock option, then the exercise price per share will not be less than <ix:nonFraction unitRef="number" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI0NDM_8ef4488d-d215-4c0a-ba02-104d892786d2">110</ix:nonFraction>% of the fair market value of the Company&#8217;s common stock on the date of grant, and the option term will not exceed <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:durwordsen" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI1NTk_61cd1364-fb25-4193-9c41-3ea814e5e281">five years</ix:nonNumeric>. Generally, stock options granted under the 2018 Plan vest over <ix:nonNumeric contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI2MjY_5aea839d-a8c9-4388-a533-4a80c0b8bbc8">four years</ix:nonNumeric> at a rate of <ix:nonFraction unitRef="number" contextRef="ib8715c1886674912998f731a86a14a57_D20200101-20201231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI2NDI_acda93b1-91f3-4df2-8315-3d649ad091ce">25</ix:nonFraction>% on the one-year anniversary of the date of grant and 1/48 per month thereafter and expire <ix:nonNumeric contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231" format="ixt-sec:duryear" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI3Mjk_dfb70174-619c-46cb-80b5-e8db052580cb">10</ix:nonNumeric> years after the date of grant, or earlier upon termination of employment or services to the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock reserved for issuance under the 2018 Plan will be reduced: (i)&#160;on a <ix:nonFraction unitRef="number" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" name="sgmo:CommonStockExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI5MzI_3c8902ce-fb1f-4cc8-a8ff-7dd7b63dc25a">1</ix:nonFraction>-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&#160;by a fixed </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="ide94d6b03bfb4b269d579f05d1780f11" continuedAt="i30b1cc096b5d43949e1df8f52bfc655f"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ratio of <ix:nonFraction unitRef="number" contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzMwODI_6369e4ee-3a77-48ab-b9d2-f48267b6b4d6">1.33</ix:nonFraction> shares of common stock for each share of common stock issued pursuant to a full-value award granted under the plan.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares subject to any outstanding stock options or other awards under the 2018 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those stock options or awards will be available for subsequent issuance under the 2018 Plan. Any unvested shares issued under the 2018 Plan that the Company subsequently purchases, pursuant to repurchase rights under the 2018 Plan, will be added back to the number of shares reserved for issuance under the 2018 Plan on a <ix:nonFraction unitRef="number" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" name="sgmo:CommonStockExchangeRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM2ODk_42dbb62a-c6cc-4520-9a77-235810b8c1ad">1</ix:nonFraction>-for-1 basis or a <ix:nonFraction unitRef="number" contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM3MTA_6369e4ee-3a77-48ab-b9d2-f48267b6b4d6">1.33</ix:nonFraction>-for-1 basis (depending on the ratio at which the share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the 2018 Plan.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="ief4c9ff8ff294f60aa457e9361e9bea3_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2NDA4MjI_63e9c407-c57e-4135-98fe-b442d4b1b6a4">10,942,576</ix:nonFraction> shares of the Company&#8217;s common stock reserved for future awards under the Company&#8217;s 2018 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2010 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2018, the Company&#8217;s stockholders approved an amendment and restatement of the Company&#8217;s 2010 Employee Stock Purchase Plan (&#8220;the ESPP&#8221;). As amended, the ESPP provides for a total of <ix:nonFraction unitRef="shares" contextRef="i18bf0cf17b5642529f184871db5ac039_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQwODk_1a645163-a321-4fa4-ad74-73b95c6d6069">4.6</ix:nonFraction>&#160;million&#160;shares of common stock reserved for issuance thereunder. Eligible employees may purchase common stock at <ix:nonFraction unitRef="number" contextRef="i6aabd68f41804669ac596bb7586ed7bc_D20180601-20180630" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQxOTI_76e66e75-4763-44f8-b183-356765de78b1">85</ix:nonFraction>% of the lesser of the fair market value of the Company&#8217;s common stock on the first day of the applicable <ix:nonNumeric contextRef="i6aabd68f41804669ac596bb7586ed7bc_D20180601-20180630" format="ixt-sec:durwordsen" name="sgmo:PurchasePlanOfferingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzMyOTg1MzQ4OTc5MDc_429b7bba-4d95-46be-a1bb-8b7f5c1d0a2c">two-year</ix:nonNumeric> offering period or the last day of the applicable <ix:nonNumeric contextRef="i6aabd68f41804669ac596bb7586ed7bc_D20180601-20180630" format="ixt-sec:durwordsen" name="sgmo:PurchasePlanPurchasePeriod" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzMyOTg1MzQ4OTc5MDg_eee1c8af-8474-474a-8150-c620a549aca6">six-month</ix:nonNumeric> purchase period. As of December&#160;31, 2020, there were <ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2NDEwNjA_c8156773-b558-4b67-a9e3-2b31e52684e8">2,483,218</ix:nonFraction> shares of the Company&#8217;s common stock reserved for future issuance under the ESPP. The ESPP expired on April 30, 2020. The ongoing offering will continue through the end of its 24 months offering period ending on October 29, 2021 at which point the ESPP will be fully terminated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzY0OTU_00e625a2-f053-4ef3-b203-a6c55d23787f" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:47.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise per<br/>Share Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzItMS0xLTEtMA_13404154-b069-41a8-ae98-d689951dce90">9,829,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzItMy0xLTEtMA_44165c34-a3b3-4560-861b-58631b122497">10.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzMtMS0xLTEtMA_1f1bdb01-382d-4826-a78d-d8c28927234c">4,563,425</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzMtMy0xLTEtMA_bb80aaf1-165a-453e-9110-40979b1f63e8">8.09</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzQtMS0xLTEtMA_d5d99526-d4c8-4a7b-97c0-37188555e994">1,162,268</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzQtMy0xLTEtMA_a3a887b5-448b-458a-a946-c3456422d859">8.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzUtMS0xLTEtMA_0fddafb4-115c-4932-a6d3-c452ac003ec4">1,751,746</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzUtMy0xLTEtMA_61f7eef7-1101-4a9d-a5d2-734bb0f834bf">10.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzYtMS0xLTEtMA_fc155af6-3dfe-4b49-8fb0-a29f0e91c168">11,478,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzYtMy0xLTEtMA_84de63b8-2117-4514-8d32-dc8a69cf91db">10.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzYtNS0xLTEtMA_47ae5424-2f58-418d-bee9-a3fc7209d473">7.80</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzYtNy0xLTEtMA_43912fbd-9a32-444d-8c0e-0829fab49594">69,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at December 31, 2020</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzctMS0xLTEtMA_fae265bc-8257-434c-b4e6-b25c7320b080">11,478,698</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzctMy0xLTEtMA_a8ae7442-cfd0-40bd-ac19-492a01d97db0">10.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzctNS0xLTEtMA_2d508bf6-c7fa-479e-a55a-c272881e2284">7.80</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzctNy0xLTEtMA_49c7f9db-6916-424a-bdac-33ba25df4e94">69,616</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzgtMS0xLTEtMA_f81875e2-29f5-48c5-85dd-9772edc72831">5,127,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzgtMy0xLTEtMA_83e11517-c1e5-4731-9ab7-b1a6dca81f89">10.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzgtNS0xLTEtMA_2d8ff22f-75e6-47f8-9dc9-785eee37a586">6.48</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzgtNy0xLTEtMA_24794c84-fd6a-4b42-a094-a5fa975206fb">29,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ2NDM_edefd8a8-d3da-455c-bfa2-53ee12f8abe0">5.4</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ2NDc_6192d4b6-36d3-492a-940b-a4463bd8c927">4.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ2NTQ_683fa230-8c7b-46e9-aac8-1c396af1fbd7">27.0</ix:nonFraction>&#160;million during 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the aggregate intrinsic values of outstanding and exercisable options were $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ3NzU_ec91116e-36c5-4510-85b7-c19de20ed984">69.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ3ODI_c0c03c35-7c7c-4cc0-8061-c1761f173005">29.0</ix:nonFraction> million, respectively. The aggregate intrinsic value of options vested and expected to vest as of December&#160;31, 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ4OTM_989261a3-0e47-4fff-ab07-a8cf445593dc">69.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ4OTc_f44ae4bd-febc-4d39-b42a-394a264b77e7">7.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5MDQ_d752fc96-335b-4998-860f-88f4aae255b8">24.5</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018, the Company awarded <ix:nonFraction unitRef="shares" contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5ODc_7eca0e76-b4ad-4cd7-8206-58445ddc0c5a">2,517,101</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5OTE_73908d6f-55ec-4d37-a4f9-3023685154f4">834,745</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="icc4c94703dab45468283cb739266adc8_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5OTk_01f017d0-420d-4e6b-8126-1cc29734cc4c">346,055</ix:nonFraction> RSUs, respectively. The RSUs awarded in 2020, 2019 and 2018 had an average grant date fair value per award of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUxMDY_ecc79caa-3980-4636-83e2-e5758079583c">8.06</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUxMTA_a41a9b2f-6add-427a-9191-a69a9ba86bd0">9.49</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="icc4c94703dab45468283cb739266adc8_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUxMTc_2ac7962e-4a9e-4394-833e-1f2b13df2919">17.87</ix:nonFraction>, respectively. These awards generally vest in a series of <ix:nonFraction unitRef="installment" contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUxNzg_1cf6988b-6006-4b4e-97ff-bc85e95a1f15">three</ix:nonFraction> successive equal annual installments. The aggregate fair value of RSUs vested during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usd" contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUyODQ_d5e4e488-7ecf-464c-8e6e-c1543645d987">3.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUyODg_ba0272a7-f6d1-4d75-9c31-1eff3a7ac4aa">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icc4c94703dab45468283cb739266adc8_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUyOTU_c788ed28-a7be-4987-a2d6-e3ee22daed9f">0.6</ix:nonFraction>&#160;million, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i30b1cc096b5d43949e1df8f52bfc655f"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzY0OTc_74a5a6d5-a648-46ab-9420-5ed200c7f56c" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.351%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate&#160;Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzItMS0xLTEtMA_fa0d8db3-6226-4c53-b593-d9a5ae55bd51">862,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs awarded</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzMtMS0xLTEtMA_800aaff5-125f-4979-993b-efa83639c0d3">2,517,101</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs released</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzQtMS0xLTEtMA_ef5aa686-3631-487a-a531-821c20f022c9">324,305</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzUtMS0xLTEtMA_d4b40c49-2ec9-42e4-bd85-a7027d04c40d">384,118</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzYtMS0xLTEtMA_e8287dd7-55c1-45dc-9f54-0676f952dbd8">2,671,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzYtMy0xLTEtMA_ae305884-ec40-4e62-abc6-34ef14e4f933">1.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzYtNS0xLTEtMA_b1f87485-b9f8-4340-a6e4-cbc7b15046cd">41,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested and expected to vest at December 31, 2020</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzctMS0xLTEtMA_35e54161-e8c3-4332-a3a0-67e12dc13115">2,671,528</ix:nonFraction>&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:duryear" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzctMy0xLTEtMA_9e85788e-25d2-46dc-8260-ee1862e6b022">1.19</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzctNS0xLTEtMA_6e91dbb9-7667-4de3-93fe-9e9ba542129a">41,689</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs that vested in 2020, 2019 and 2018 were net-share settled such that the Company withheld shares with value equivalent to the employees&#8217; minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately <ix:nonFraction unitRef="shares" contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU2OTA_33b30ce7-0fc7-4afe-ade4-40fe7c8f9121">90,617</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU2OTQ_9db650f5-2d3a-4568-bc71-2dbf9dbd613c">39,160</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="icc4c94703dab45468283cb739266adc8_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU3MDI_56c6d5e7-51b3-415c-a73b-cbebd23ffa60">20,193</ix:nonFraction> for 2020, 2019 and 2018, respectively, and were based on the value of the RSUs on their respective issuance dates as determined by the Company&#8217;s closing stock price. Total payments for the employees&#8217; tax obligations to taxing authorities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU5NDI_c80ba334-aa16-4c75-8a90-f329fa40b6ed">0.8</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU5NDY_05103c87-9c62-4131-b9ca-662a0e301bdc">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU5NTM_7e9d16b1-90ec-4836-8c81-8eab26e39b9f">0.3</ix:nonFraction>&#160;million in 2020, 2019 and 2018, respectively and are reflected as a financing activity within the accompanying Consolidated Statements of Cash Flows.&#160;These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.</span></div></ix:continuation><div id="i24672e5030474c1ba9673ec16c177662_115"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzIxNjI_076aeaa8-8947-441f-affc-d0ac26c8b299" continuedAt="i0a66d76fadf749db8ad9d1da65f2b189" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i0a66d76fadf749db8ad9d1da65f2b189" continuedAt="i892c03b61edf4344a4f2dfb5da4ca7c7"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzIxNjM_8c419ccb-06de-49cc-8292-0960810c00b9" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d397545580d4460a2a0fec1fc8ba1a5_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzItMS0xLTEtMA_4993534e-a7c3-4f8b-b066-d64afd8b63b9">13,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6df1c8f3c9a84c598d0ae819a426267c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzItMy0xLTEtMA_f9a09772-178e-419e-bd30-3cc2636da25a">10,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5cec61b66c8248d2abcb75627ce796b4_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzItNS0xLTEtMA_a5c993b6-6913-49af-a1b9-cdbf6c1527c0">8,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i855baf86bae64ff0bd95f564c7fd3fd0_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzMtMS0xLTEtMA_54602c28-be5e-4eb2-8652-11fe97f7d6ac">12,185</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf94cc35763140c7b88de393e914a63c_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzMtMy0xLTEtMA_98a9b7a9-1036-43aa-84bd-3eb9fecc65dc">9,195</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f5dfc4d40fd4effae8227da27de4cfc_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzMtNS0xLTEtMA_03480567-6127-4f40-9ae5-e2685c47da6e">6,428</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzQtMS0xLTEtMA_9a20e96a-1e3b-48a0-b2eb-b74a0bd7052a">25,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzQtMy0xLTEtMA_3d1d7059-71a8-42f7-ac3a-a2238c7811f7">19,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzQtNS0xLTEtMA_3d15f0af-ffbf-476c-b746-b3506d96ae60">14,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, total stock-based compensation expense to be recognized in future periods related to unvested stock options was $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzMxMw_6a031e3e-92e1-4362-a9df-ad145b7b280d">35.5</ix:nonFraction>&#160;million, which is expected to be expensed over a weighted-average period of <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzM4NA_611a729e-5707-4d3d-922e-fdbc2a220839">2.72</ix:nonNumeric> years. As of December&#160;31, 2020, total stock-based compensation expense to be recognized in future periods related to unvested RSUs was $<ix:nonFraction unitRef="usd" contextRef="i7597d30081de44f3921ada32f9dbc896_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzUwMQ_7e35c84a-199e-48a6-928b-5930370ee860">17.1</ix:nonFraction>&#160;million, which is expected to be expensed over a weighted-average period of <ix:nonNumeric contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzU3Mg_228ed19f-25fc-4dfb-a254-013a505c489d">2.07</ix:nonNumeric> years. There was <ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzU4Ng_1729cb67-4771-49ad-8b2b-c778748ce694"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzU4Ng_32080797-af88-497a-93f1-ed263bd43eb8"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzU4Ng_b9dffc62-b8dc-4514-9c73-0e19546a2fca">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> capitalized stock-based employee compensation expense as of December&#160;31, 2020, 2019 or 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock-based compensation expense was determined using the Black-Scholes option valuation model for stock options and employee share purchases under the ESPP. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its determination of expected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i892c03b61edf4344a4f2dfb5da4ca7c7"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average estimated fair value per share of options granted during 2020, 2019 and 2018 was $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE0Njk_e6e76ddd-67ea-4741-8473-dca778b2bfe6">5.25</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE0NzM_69922504-372d-414c-a01b-0538ea5c9814">6.37</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE0ODE_6dd63d7a-dce6-4434-96d2-d6a15280b7f9">11.39</ix:nonFraction>, respectively, based upon the assumptions used in the Black-Scholes valuation model. <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzIxNjQ_b37d9a31-421a-4d86-aedd-8f61b6a1eea0" continuedAt="ia453f5bec2da4eda9f1b4ed9573f5a81" escape="true">The assumptions used for estimating the fair value of the employee stock options were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><ix:continuation id="ia453f5bec2da4eda9f1b4ed9573f5a81"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:55.058%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i223299de6a284218a780245b2f4e9fb8_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItMS0xLTEtMC90ZXh0cmVnaW9uOjE2NDMxMDU4MjBjOTQ4YjE4NzE1NWY1ZjM4Y2Y4YjY2XzEwOTk1MTE2Mjc3ODA_5f707715-7ca7-4e98-ba67-ccce964b0544">0.34</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i9a566e45d4414942be208342c5c516a6_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItMS0xLTEtMC90ZXh0cmVnaW9uOjE2NDMxMDU4MjBjOTQ4YjE4NzE1NWY1ZjM4Y2Y4YjY2XzEwOTk1MTE2Mjc3ODQ_5e5b1ed1-281c-47f5-b001-b9ffe07b289f">0.61</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia188228a2f714148b418bbafdff8df68_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItMy0xLTEtMC90ZXh0cmVnaW9uOjdhZmEzNDhiZTNhMTRlZTg5OWE5OGYzZmZhZDBmYjJiXzEwOTk1MTE2Mjc3ODg_9961bd02-dea3-419d-b566-ec3df83febf5">1.68</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i3f59d4e0ade74a58893ddc753841891e_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItMy0xLTEtMC90ZXh0cmVnaW9uOjdhZmEzNDhiZTNhMTRlZTg5OWE5OGYzZmZhZDBmYjJiXzEwOTk1MTE2Mjc3OTI_08e3ab66-130c-4e3e-b2b2-9ce1b9b182fb">2.25</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i279740780022456087bde23ef4f549fa_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItNS0xLTEtMC90ZXh0cmVnaW9uOmFhYTljNzU0MmFhNDRhZDE4YmIyN2Q5MmY0NzkwZWY5XzEwOTk1MTE2Mjc3ODA_9794cf60-7d9a-499a-8ce5-3c65af2723f7">2.53</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="ib90a62c3edc44c90a63b7c1744a27bb7_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItNS0xLTEtMC90ZXh0cmVnaW9uOmFhYTljNzU0MmFhNDRhZDE4YmIyN2Q5MmY0NzkwZWY5XzEwOTk1MTE2Mjc3ODQ_75edf83f-6468-4593-8b09-92803d75e8a2">2.96</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i223299de6a284218a780245b2f4e9fb8_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtMS0xLTEtMC90ZXh0cmVnaW9uOmJhOTc1NGU3ODVkNjQ3MmU5OTQwYWYwYTg2MjM1OWI2XzEwOTk1MTE2Mjc3ODA_f781fd8c-98f7-4a06-bf96-34a313ce180a">5.51</ix:nonNumeric>-<ix:nonNumeric contextRef="i9a566e45d4414942be208342c5c516a6_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtMS0xLTEtMC90ZXh0cmVnaW9uOmJhOTc1NGU3ODVkNjQ3MmU5OTQwYWYwYTg2MjM1OWI2XzEwOTk1MTE2Mjc3ODQ_ac547e43-7178-4ccb-a929-423b69d632c8">5.57</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia188228a2f714148b418bbafdff8df68_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtMy0xLTEtMC90ZXh0cmVnaW9uOmE3ZGI1OGY1YzllNzQ4OWViOGNlMWY3MzNkNmFlY2VlXzEwOTk1MTE2Mjc3OTA_e5de1157-dab1-49f4-b2fc-30748d7ade11">5.50</ix:nonNumeric>-<ix:nonNumeric contextRef="i3f59d4e0ade74a58893ddc753841891e_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtMy0xLTEtMC90ZXh0cmVnaW9uOmE3ZGI1OGY1YzllNzQ4OWViOGNlMWY3MzNkNmFlY2VlXzEwOTk1MTE2Mjc3OTQ_e9be15a4-cbdf-4760-840a-79fe4bcb2cec">5.62</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i279740780022456087bde23ef4f549fa_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtNS0xLTEtMC90ZXh0cmVnaW9uOjg4NmVhZDMwYWRlMjRmMjhiNDZkMWFhZDQzZTI3YzAzXzEwOTk1MTE2Mjc3ODA_594a35e2-2574-4587-98d7-1183fa527fca">5.59</ix:nonNumeric>-<ix:nonNumeric contextRef="ib90a62c3edc44c90a63b7c1744a27bb7_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtNS0xLTEtMC90ZXh0cmVnaW9uOjg4NmVhZDMwYWRlMjRmMjhiNDZkMWFhZDQzZTI3YzAzXzEwOTk1MTE2Mjc3ODQ_c994f597-567a-4b39-b334-07ed463e7dd5">5.61</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3d3f08aef11f4a318908f591e111b593_D20200101-20201231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzQtMS0xLTEtMA_17832e59-ef50-4590-8249-f2fc6c590fa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29b01dbcc0f74a77aa727c03cc8da109_D20190101-20191231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzQtMy0xLTEtMA_61656d62-8aac-410d-8bbb-0f2b3449141e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd84dea3dd62427db0d47cb010b83133_D20180101-20181231" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzQtNS0xLTEtMA_1c220b9a-9af6-4fef-ad0a-52c2d70bd4db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i223299de6a284218a780245b2f4e9fb8_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtMS0xLTEtMC90ZXh0cmVnaW9uOmVlNzJhOGUwYTk1MzRkNjRhMDJmOTZhNmFjY2M3NmE4XzEwOTk1MTE2Mjc3ODA_6f0ca2c4-479f-4db4-8ae6-87f28c9dfc7f">77.61</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i9a566e45d4414942be208342c5c516a6_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtMS0xLTEtMC90ZXh0cmVnaW9uOmVlNzJhOGUwYTk1MzRkNjRhMDJmOTZhNmFjY2M3NmE4XzEwOTk1MTE2Mjc3ODQ_37041d8b-9e43-4b56-8424-9a20cd39e155">80.32</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia188228a2f714148b418bbafdff8df68_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjllMjFkMjM4YzMwZjQzMDQ4ZjBhMGJhOTUwMGY0ZGY1XzEwOTk1MTE2Mjc3ODA_4eb9aae5-000e-4d87-82c4-4a1868209750">76.46</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i3f59d4e0ade74a58893ddc753841891e_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjllMjFkMjM4YzMwZjQzMDQ4ZjBhMGJhOTUwMGY0ZGY1XzEwOTk1MTE2Mjc3ODQ_7911d5f5-6f99-4f9f-b410-ea4cd6d09cf2">78.39</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i279740780022456087bde23ef4f549fa_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtNS0xLTEtMC90ZXh0cmVnaW9uOmU2YWI5ZmI3N2Q3YjQ1NDhhMGU0YjliMDVjNmI3NDdhXzEwOTk1MTE2Mjc3ODA_4b2b7b94-63e6-422f-979f-0d3a90605d6d">72.33</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="ib90a62c3edc44c90a63b7c1744a27bb7_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtNS0xLTEtMC90ZXh0cmVnaW9uOmU2YWI5ZmI3N2Q3YjQ1NDhhMGU0YjliMDVjNmI3NDdhXzEwOTk1MTE2Mjc3ODQ_078ecb3d-1b69-4a74-9999-85228f7899dc">75.49</ix:nonFraction>%</span></div></td></tr></table></ix:continuation></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees purchased <ix:nonFraction unitRef="shares" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE2ODk_4067c420-a8c8-45b9-a5d3-5b0ede88fb3a">274,382</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE2OTM_9f439866-4909-4e65-aab9-93183a2a9f3c">249,364</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE3MDA_dbf059bf-2110-4a7d-9fae-458576cc70d2">328,710</ix:nonFraction> shares of common stock through the ESPP at an average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="2" name="sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE3NzU_7fdb4493-97fb-4a7c-8746-100b85bf3bc3">7.34</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="2" name="sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE3Nzk_c6991f39-64d3-4309-8154-7fd2f1e9abd5">8.53</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="2" name="sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE3ODc_90630efb-869f-4cc6-8e73-2aebeb978a8d">4.51</ix:nonFraction> per share during 2020, 2019 and 2018, respectively. The weighted-average estimated fair values of shares purchased under the Company&#8217;s ESPP during 2020, 2019 and 2018 were $<ix:nonFraction unitRef="usdPerShare" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="2" name="sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE5NTA_dabc593e-8f66-4d30-a52a-52d65c1e0f7c">8.02</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="2" name="sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE5NTQ_c1756098-1dc0-4f80-a785-8969e5576116">4.70</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="2" name="sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE5NjE_ae2ed5c5-fc6a-400a-a46c-99807b3145c2">7.07</ix:nonFraction>, respectively, based upon the assumptions used in the Black-Scholes valuation model.</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzIxNjU_0794b4fa-4591-4668-aa06-2292cb6f1a94" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for estimating the fair value of the ESPP purchase rights are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1cc661d039934a93b782c591c4f4b854_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItMS0xLTEtMC90ZXh0cmVnaW9uOmIxMTU1MTljYjk2YzQ3NjRiMWY0MzBmMTYwZGQ1MmQ4XzEwOTk1MTE2Mjc3OTY_da63a44d-5cf0-490c-be5c-3bc13fa0171f">1.53</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="iae60b3bb0a244843baf181d3d3f789f8_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItMS0xLTEtMC90ZXh0cmVnaW9uOmIxMTU1MTljYjk2YzQ3NjRiMWY0MzBmMTYwZGQ1MmQ4XzEwOTk1MTE2Mjc3ODQ_1826fa9b-01ad-4bd6-aff6-b78bf8fa9ca8">2.80</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc4caf6b9fb443ea9a67e1cd79ff3121_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItMy0xLTEtMC90ZXh0cmVnaW9uOmNiMzY0YTk3YTg3NTQ2NzM4MTNlZTk3NTE5MmI0NjY3XzEwOTk1MTE2Mjc3ODA_18c5c7ab-85e4-4da4-915e-a85b36c9158d">1.53</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i51512ee82f7c4322a3633294ba2c9a7c_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItMy0xLTEtMC90ZXh0cmVnaW9uOmNiMzY0YTk3YTg3NTQ2NzM4MTNlZTk3NTE5MmI0NjY3XzEwOTk1MTE2Mjc3ODQ_0edce150-bf24-42b8-82ac-1fd24e462066">2.42</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43e320fb9b704556adf1b2e8fe7699a4_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItNS0xLTEtMC90ZXh0cmVnaW9uOmVlYzA3YWY5ZjFkODQ5M2M4NjFiODk4MmQ5NDNjMzk3XzEwOTk1MTE2Mjc3ODA_a565330c-e9af-4319-912a-f9a505b72954">2.16</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i311774a19c3b43b292a88509437d6a57_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItNS0xLTEtMC90ZXh0cmVnaW9uOmVlYzA3YWY5ZjFkODQ5M2M4NjFiODk4MmQ5NDNjMzk3XzEwOTk1MTE2Mjc3ODQ_9681bce7-8ec9-4444-9160-d0fa0dc2e175">2.80</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1cc661d039934a93b782c591c4f4b854_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjBmNTkyYmY1MmNjNzRiYmE4MmQ4ODI5MjRlM2ZiNGZlXzEwOTk1MTE2Mjc3ODA_fc1fe112-5535-4cde-a074-c46ba7fdcb9e">0.5</ix:nonNumeric>-<ix:nonNumeric contextRef="iae60b3bb0a244843baf181d3d3f789f8_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjBmNTkyYmY1MmNjNzRiYmE4MmQ4ODI5MjRlM2ZiNGZlXzEwOTk1MTE2Mjc3ODQ_97cd78d5-dc28-47c3-8a3e-f5f8f82d000e">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icc4caf6b9fb443ea9a67e1cd79ff3121_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjdjNzkyM2JjNzk5OTRlMjNhZDE4ZDAzM2NkODc0NGYwXzEwOTk1MTE2Mjc3ODA_1ee42d9a-54ba-4c5b-9ce7-2a587fc5071f">0.5</ix:nonNumeric>-<ix:nonNumeric contextRef="i51512ee82f7c4322a3633294ba2c9a7c_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjdjNzkyM2JjNzk5OTRlMjNhZDE4ZDAzM2NkODc0NGYwXzEwOTk1MTE2Mjc3ODQ_ac51641f-2cdf-4f54-b877-e33216079cf9">2.0</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i43e320fb9b704556adf1b2e8fe7699a4_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtNS0xLTEtMC90ZXh0cmVnaW9uOjUwYWYxZjMzMTYyNjRjOTViMzNhYTQxNjRmMGVhNWQxXzEwOTk1MTE2Mjc3ODA_95d45470-0384-42c6-862f-f4faaceca99d">0.5</ix:nonNumeric>-<ix:nonNumeric contextRef="i311774a19c3b43b292a88509437d6a57_D20180101-20181231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtNS0xLTEtMC90ZXh0cmVnaW9uOjUwYWYxZjMzMTYyNjRjOTViMzNhYTQxNjRmMGVhNWQxXzEwOTk1MTE2Mjc3ODQ_f4147d51-a125-4879-9968-bb0776fc7f4c">2.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia4f372a7d1ad4108a38bfe05388f5e5d_D20200101-20201231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzQtMS0xLTEtMA_4459dd14-f16b-4bfc-9494-e58f457d85c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i218e12e36203494ba48b0ba0613475c4_D20190101-20191231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzQtMy0xLTEtMA_641228c8-ae7a-4c7a-9347-bce193f6a675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i83b08e5e95284441967eed76e78797ba_D20180101-20181231" decimals="2" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzQtNS0xLTEtMA_e05ac946-d62a-4425-b791-5e2e38df526b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1cc661d039934a93b782c591c4f4b854_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjhlYmM3NDEzMjE4YTRkYmViOGVmMmRmNzdiMmRmODQ1XzEwOTk1MTE2Mjc4MDM_2d453a5d-9f9c-4607-90a2-2a3c31c27200">51.02</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="iae60b3bb0a244843baf181d3d3f789f8_D20200101-20201231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjhlYmM3NDEzMjE4YTRkYmViOGVmMmRmNzdiMmRmODQ1XzEwOTk1MTE2Mjc3OTU_1561b9f2-8660-42a4-a3b3-31ba1c53ff35">91.96</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icc4caf6b9fb443ea9a67e1cd79ff3121_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtMy0xLTEtMC90ZXh0cmVnaW9uOjgzZTNmM2I5Y2MzMTRjNjZiMjc0Y2ZiZTlmOGMwZmMzXzEwOTk1MTE2Mjc3ODA_962c770f-570d-4248-8f06-fdde1309bbc2">51.02</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i51512ee82f7c4322a3633294ba2c9a7c_D20190101-20191231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtMy0xLTEtMC90ZXh0cmVnaW9uOjgzZTNmM2I5Y2MzMTRjNjZiMjc0Y2ZiZTlmOGMwZmMzXzEwOTk1MTE2Mjc3ODQ_a9144f35-ec3f-4a0f-9cef-e9e3f28e4869">91.96</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43e320fb9b704556adf1b2e8fe7699a4_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtNS0xLTEtMC90ZXh0cmVnaW9uOmRjNzY4NzJiOWUyMTQ4MTdiYTRjOTUxMjI3MWE2ZDViXzEwOTk1MTE2Mjc3ODA_02a5c2f8-5ef7-4ce7-8cb3-aa3cef003238">73.21</ix:nonFraction>-<ix:nonFraction unitRef="number" contextRef="i311774a19c3b43b292a88509437d6a57_D20180101-20181231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtNS0xLTEtMC90ZXh0cmVnaW9uOmRjNzY4NzJiOWUyMTQ4MTdiYTRjOTUxMjI3MWE2ZDViXzEwOTk1MTE2Mjc3ODQ_70d90dc9-f733-4c24-b7ad-718c279fb13d">83.25</ix:nonFraction>%</span></div></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i24672e5030474c1ba9673ec16c177662_121"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzU3OQ_e3441527-7398-45e6-9c32-56801aabfa68" continuedAt="i76a5f74399bf4a39b4b7a5773b513f11" escape="true">EMPLOYEE BENEFIT PLAN</ix:nonNumeric></span></div><ix:continuation id="i76a5f74399bf4a39b4b7a5773b513f11"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code covering all full-time employees (&#8220;Sangamo 401(k) Plan&#8221;). The Sangamo 401(k) Plan is intended to qualify under Section&#160;401 of the Internal Revenue Code.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company matched employee contributions equal to <ix:nonFraction unitRef="number" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzMzMA_918b9c4c-299a-4370-951b-2d5c88a753e0"><ix:nonFraction unitRef="number" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzMzMA_d9b2aab0-558b-4999-a195-fa0d2bfd549a"><ix:nonFraction unitRef="number" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzMzMA_dfdbc9af-c5be-4482-8ff4-b345b39ae4fd">50</ix:nonFraction></ix:nonFraction></ix:nonFraction>% for the first <ix:nonFraction unitRef="number" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM0Nw_4fc6551c-f582-444f-86c7-76a18391044f"><ix:nonFraction unitRef="number" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM0Nw_9fccc3ed-b1f3-4876-b40a-c679ce62de52"><ix:nonFraction unitRef="number" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM0Nw_de5470aa-e38b-45c1-80c6-3c97d5f47faf">8</ix:nonFraction></ix:nonFraction></ix:nonFraction>% in 2020, 2019 and 2018, up to a limit of $<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM4NQ_4b8224ed-f1f6-4532-b13f-ed6665a81aa3"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM4NQ_eca14762-3a6b-4bd6-a794-65917efc7cb0"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM4NQ_f6d3b77e-2657-40d7-add9-953331ce7cf9">4,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> in 2020, 2019 and 2018. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan by the Company were $<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzUxNw_77433917-4320-437c-97c6-c30db38eec17">1.2</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzUyMQ_befed431-0af5-4c46-98b5-6229f491bc0e">0.9</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzUyOQ_47453a15-6c29-4c81-b6b5-f9b6591bfe57">0.8</ix:nonFraction>&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div></ix:continuation><div id="i24672e5030474c1ba9673ec16c177662_124"></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjU_333583a5-1651-4774-b4b5-f55b4299351b" continuedAt="ib29ca372a6a741349d30ed5348580885" escape="true">INCOME TAXES </ix:nonNumeric></span></div><ix:continuation id="ib29ca372a6a741349d30ed5348580885" continuedAt="i79b9c403a04a4255845cc5b0c4ece1ab"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MTk_73907f9f-a92a-4e59-86e0-8d29ee1aa88f" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of loss before income taxes were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzItMS0xLTEtMA_50e70cbf-5e64-4806-b2e3-08267fdf145e">126,624</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzItMy0xLTEtMA_70664c95-9fbf-456e-83b4-13bcc1313438">77,354</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzItNS0xLTEtMA_2149da36-b549-46fa-a99c-9df8e140e047">65,695</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzMtMS0xLTEtMA_f1783f40-214e-449c-99f0-538d2ef1f207">5,847</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzMtMy0xLTEtMA_64b8865a-0268-40c4-8cec-ff19327bae03">18,065</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzMtNS0xLTEtMA_9c857f56-f1e3-46df-9a81-e06b04b0319f">3,194</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzQtMS0xLTEtMA_e61828bb-6fef-4c95-83b5-c9fd506beb50">120,777</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzQtMy0xLTEtMA_d7746092-80da-4d08-9cde-e9a332a0f6d9">95,419</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzQtNS0xLTEtMA_d1993b89-d937-4b90-bc76-a6a08a2cd885">68,889</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="i79b9c403a04a4255845cc5b0c4ece1ab" continuedAt="ia1ccd1577e4e4119b7599917a0df4694"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjA_01a6d1a5-77ad-4310-8685-ebae7fa4d66f" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzQtMS0xLTEtMA_ce34d462-c8e3-4f71-b26f-46b23fc6970d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzQtMy0xLTEtMA_e84651a1-6790-4483-97ec-c13cee5091ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzQtNS0xLTEtMA_18828cc7-c42a-497d-8adf-8a80214a9dea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzUtMS0xLTEtMA_332cfd9d-a390-424c-a1fc-2620fd8f1dd2">133</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzUtMy0xLTEtMA_97e0ddd2-c3f7-4622-a6c9-21edfc4ae2e8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzUtNS0xLTEtMA_3367940f-17e9-4b62-b2ad-326fc747e52b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzYtMS0xLTEtMA_0983db3a-c627-4c36-9d5d-2104703aa758">686</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzYtMy0xLTEtMA_53bb5854-d9c5-49a4-b1b4-448ef73ca708">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzYtNS0xLTEtMA_067fb365-c59a-4da2-b65c-0e2176c01468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzctMS0xLTEtMA_0fa5750e-a986-4fc4-8f43-213c25da4357">819</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzctMy0xLTEtMA_7a28025c-1d92-41e3-a1b5-1987fb64052e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzctNS0xLTEtMA_5aab27af-d4e0-47bc-b31c-f1e91c863346">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzktMS0xLTEtMA_e2533f85-8d35-4c7f-9890-90fbd1c16468">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzktMy0xLTEtMA_343a9d42-6def-4cae-b021-cfdea917836c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzktNS0xLTEtMA_a19dfc0c-dcc2-4473-a7c1-88f3f22616e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEwLTEtMS0xLTA_8a062978-429d-426e-bf1d-697136800361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEwLTMtMS0xLTA_205c7872-af6c-40fa-aca9-e3d917cccbbb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEwLTUtMS0xLTA_a230c2e5-da61-4a64-8eb8-e05cdc72780f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzExLTEtMS0xLTA_bf4927c5-b30a-4eff-9316-10f36c94f989">474</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzExLTMtMS0xLTA_ce7de7ba-9469-469e-9b26-ca63655abb82">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzExLTUtMS0xLTA_b62b3e2b-5145-4835-bea1-524f1d0a131a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEyLTEtMS0xLTA_93463860-0d3a-446f-acfe-584644dcfe3b">474</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEyLTMtMS0xLTA_d78c02c7-2532-473c-a1d7-1a58612e8c10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEyLTUtMS0xLTA_3fc7cfd8-2e8c-4b3e-ba84-66bd35d8292a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEzLTEtMS0xLTA_fa691dbe-687a-4c10-8ddb-9f9f23926b8d">345</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEzLTMtMS0xLTA_a35ac73e-129c-45d8-90c6-1d59712095c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEzLTUtMS0xLTA_21926571-6549-43c4-a87e-e173a094507c">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjE_38b5edb9-7bff-4c21-8188-e31b783d2838" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the income tax expense and the amount computed by applying the federal statutory income tax rate to loss before income taxes is explained as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:61.748%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzItMS0xLTEtMA_421b9277-d787-43fc-9d79-c8d1c3a3928f">25,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzItMy0xLTEtMA_a47ebc70-2322-4cf8-85ea-ab7cc3998889">20,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzItNS0xLTEtMA_a2be099f-9b0e-4425-bef8-3ec06243f90c">14,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzMtMS0xLTEtMA_15518454-4a4c-4b2a-a78b-b842bfb9d645">3,168</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzMtMy0xLTEtMA_c03ddca5-5af9-4094-a807-ced7b8dd3e82">9,597</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzMtNS0xLTEtMA_aec1c04e-3c1d-453a-bacd-9845bb1beb0e">2,849</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtMS0xLTEtMA_dc0b9e49-4701-486f-9dce-d72548fab398">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtMy0xLTEtMA_c22f039e-b508-491d-a372-e25f9c01582b">665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtNS0xLTEtMA_f8384f3e-c3b1-428d-aec8-5f2304664de6">177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Intangible Low-Taxed Income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtMS0xLTEtNzA4OA_4c2f07a1-bc70-44cd-9737-3f47c142169c">1,335</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sgmo:EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtMy0xLTEtNzA4OA_d792dd09-774e-4012-9286-86cb51e1e8da">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="sgmo:EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtNS0xLTEtNzA4OA_9b0ea891-cab5-4693-808d-101c98ae3a58">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzYtMS0xLTEtMA_5484c413-66e7-4955-8eb6-c1d282766bce">4,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzYtMy0xLTEtMA_8a03d310-ef7a-4e3a-bfa5-bb13a2402270">2,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzYtNS0xLTEtMA_4b9840d6-af7d-4dfe-b374-06fe39e53d9d">2,729</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzctMS0xLTEtMA_0968255c-ed0a-4f25-b801-c13f2f51df32">3,657</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzctMy0xLTEtMA_5fd50c54-142b-419e-a5f9-a0372d177803">3,429</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzctNS0xLTEtMA_fd17dc73-1ea3-4b9d-804c-47df6863897a">1,005</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzgtMS0xLTEtMA_e9986ed0-a240-424e-b910-4fb40ec3833d">26,537</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzgtMy0xLTEtMA_ada7ada9-b525-4853-a69e-62ec811718e6">29,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzgtNS0xLTEtMA_df1e4a80-a296-4074-a802-06eea823ada4">20,271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzktMS0xLTEtMA_a5b87491-66fe-4fdf-a72e-714cf0ecd6ed">53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzktMy0xLTEtMA_7889e240-b689-498a-9a2c-8f8b73ba292e">1,257</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzktNS0xLTEtMA_c6ad0e73-00be-4919-83ef-149b09f1617a">956</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzEwLTEtMS0xLTA_63a1377f-9b54-45f6-a9a0-564bc896792a">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzEwLTMtMS0xLTA_7ec7aaed-6ec1-411f-a978-b47f9c87389d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzEwLTUtMS0xLTA_1c4da127-fbdc-4268-a7b7-94087c2b1596">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and December 2020, in response to the COVID-19 pandemic, the CARES Act and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic. The Company does not expect any significant benefit to its income tax provision as a result of this legislation.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="ia1ccd1577e4e4119b7599917a0df4694" continuedAt="ie8ae566c71ad4275b7ab912c40b13c26"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjM_bcd07041-82a2-4985-a98e-d3679773aa08" continuedAt="if198e87d681f402097ed6261611a8326" escape="true">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="if198e87d681f402097ed6261611a8326"><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzQtMS0xLTEtMA_34bcca24-e536-4709-b015-31b2d8cd06c6">164,276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzQtMy0xLTEtMA_093f87c2-0cf4-4d5e-a985-bc45937f6ffb">133,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit carryforwards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzUtMS0xLTEtMA_ff68c2ec-68bd-4b5c-8dd5-b35d633bce65">27,679</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzUtMy0xLTEtMA_9a516a33-9f71-41cd-aa3a-efc557ac1d82">21,459</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzYtMS0xLTEtMA_9a210c0b-e597-4aef-a529-3693aff07ccd">5,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzYtMy0xLTEtMA_326e6e1e-3760-4cd1-8e6e-928e5102b05b">4,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzctMS0xLTEtMA_f6d63be1-536e-4825-82de-a8d7573d6518">20,681</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzctMy0xLTEtMA_9d06e67a-5925-4493-97a0-bda494259bf8">32,171</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzgtMS0xLTEtMA_08a241f4-5d17-4340-8d53-ac27fdfce301">10,525</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzgtMy0xLTEtMA_a657b90c-a221-497c-aa91-728c150fc78d">11,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzktMS0xLTEtMA_e21b2e65-1897-4edf-8fe6-a9b8aa46309b">10,251</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:DeferredTaxAssetsLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzktMy0xLTEtMA_c1a2296f-1b3a-409d-950e-f658e7010184">11,722</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzExLTEtMS0xLTA_97cf7893-36be-438d-938a-100d4dd86375">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzExLTMtMS0xLTA_7491b7bb-59a1-4a5b-8fef-0ab79f95dbc2">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzEyLTEtMS0xLTA_630274fd-2f4d-41ae-b3c0-577298d69162">308</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzEyLTMtMS0xLTA_8f12f6ab-253f-42c0-b945-abb0c8a59344">151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzEzLTEtMS0xLTA_2b312d3f-ce05-443c-9bb3-f1690d7b5624">239,471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzEzLTMtMS0xLTA_594cfe32-3168-4b24-9eea-879adbeed08c">215,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE0LTEtMS0xLTA_0dc19ba9-e340-4034-a617-3ff2b6bc901e">214,351</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE0LTMtMS0xLTA_9b8b4d6b-b839-43b2-bab7-64796743a246">187,724</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE1LTEtMS0xLTA_e50d7d33-fdd0-41f8-bb5c-bfef485a362e">25,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE1LTMtMS0xLTA_13fce361-cab5-4dfc-955b-a17a98d6afee">27,695</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE3LTEtMS0xLTA_549cde03-8140-4800-abf8-c274bf48d6b6">14,321</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE3LTMtMS0xLTA_d3cda8f8-704e-4eb3-8c21-d05040587627">13,609</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE4LTEtMS0xLTA_5564280d-bcec-4ad6-9440-6e5a30875aa4">17,510</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE4LTMtMS0xLTA_76cdd903-4560-497c-849f-3f8a73e1e6ee">20,656</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzIwLTEtMS0xLTA_eb42a51a-1d1a-4190-ba3f-583fe2b03301">31,831</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzIwLTMtMS0xLTA_446ba377-5803-4c7e-94f7-3935103ea0c4">34,265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzIxLTEtMS0xLTA_41befb91-c5c5-43ed-8171-0ff752141332">6,711</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzIxLTMtMS0xLTA_f29e9121-9790-47da-b693-8459bfe3838b">6,570</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax assets and liabilities based on tax jurisdictions are presented on the Consolidated Balance Sheet as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.607%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.183%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other non-current assets on the Consolidated Balance Sheet)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b08863acefe4d8ca8e10ed1322fc31b_I20201231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzItMS0xLTEtNjc3Ng_49ea02ad-d0c5-4231-853c-9acb90455e58">474</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0470d6b5a9684856b669c0c4cd5d041f_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzItMy0xLTEtNjc3Ng_43744302-6bad-4da8-b27f-e177a73421b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzMtMS0xLTEtNjc3Ng_24078e8e-72a6-4167-88cd-0d8ae73cfa2f">7,185</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzMtMy0xLTEtNjc3Ng_d422effc-2cc3-43c2-9214-042d7decad89">6,570</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzQtMS0xLTEtNjc3Ng_38795168-a011-4ebf-82ec-881d15df84e5">6,711</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzQtMy0xLTEtNjc3Ng_894b930e-ddfc-4306-bc0d-c3c6718dad32">6,570</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company acquired Sangamo France. The Company recorded goodwill and intangible assets as part of accounting for the acquisition of Sangamo France. There is no corresponding tax basis for the goodwill or intangible assets. A portion of the intangible assets acquired were for the use in a particular research and development project and are considered indefinite-lived assets with no tax basis.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of the unrealized gain (loss) on marketable securities are recorded as a component of accumulated other comprehensive income (loss), net of a provision for income taxes.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. The Company regularly assesses the need for a valuation allowance against its deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that the Company&#8217;s deferred income tax assets will be realized. In evaluating the Company&#8217;s ability to recover its deferred income tax assets within the jurisdiction from which they arise, the Company considers all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. Accordingly, based upon the Company&#8217;s analysis of these factors the net deferred tax assets have been substantially offset by a valuation allowance. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI0NDQ_9aca500f-b64f-4f35-86e4-48d4ae3cb5ba">26.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI0NDg_013dd1cc-8f96-412d-9428-add07ce5de8c">29.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI0NTU_2a6fd790-ac3e-4dfc-b230-d411ed8bc54e">45.3</ix:nonFraction>&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI2MjI_bb571e16-221a-4131-b583-8d6dbac4d522">622.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI2Mjk_3db99109-9041-42af-9d7e-7200f9244457">261.7</ix:nonFraction>&#160;million, respectively. The federal net operating loss generated before 2018 will begin to expire in 2024 and will keep expiring through 2037, if not utilized. Federal net operating loss generated in 2018 will carry forward indefinitely. If not utilized, the state net operating loss carryforwards will begin to expire in 2029, respectively. The Company&#8217;s French net operating loss carryforward balance is $<ix:nonFraction unitRef="usd" contextRef="ia9b4e0c3f43d4338ab8fc2ce3ffce740_I20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzMwMjk_02da88a5-4911-444a-9137-31e62b12d77e">145.9</ix:nonFraction>&#160;million, which carries over indefinitely. The Company </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><ix:continuation id="ie8ae566c71ad4275b7ab912c40b13c26"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also has federal and state research tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzMxNDI_7039ea4a-dbe9-4bc5-96e2-7bd98a0cd6ce">21.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-5" format="ixt:numdotdecimal" name="sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzMxNDk_55cd5827-4ae5-435d-9436-d20ebde9dbae">18.3</ix:nonFraction>&#160;million, respectively. The federal research credits will begin to expire in 2021, while the state research credits have no expiration date. Utilization of the Company&#8217;s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before utilization.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to reinvest the earnings of its non-U.S. subsidiaries in those operations. The Company does not provide for U.S. taxes on the earnings of foreign subsidiaries because the Company intends to reinvest such earnings offshore indefinitely. However, if these funds were repatriated, the Company would be required to accrue and pay applicable U.S. taxes and withholding taxes. Due to the cumulative losses generated in foreign countries there are no earnings to repatriate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files federal and state income tax returns with varying statutes of limitations. The tax years from 2002 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files United Kingdom and French income tax returns, and the tax years from 2008 and thereafter remain open in the United Kingdom and 2016 and thereafter in France are still subject to examination.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2020, the Company had <ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzYxNDE_0418de03-3ebf-4860-a9c9-edde8626ccd5">no</ix:nonFraction> accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate will not be affected.</span></div><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjQ_5d9656b3-2389-4025-b37a-e1ba7ed669d0" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.631%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzItMS0xLTEtMA_7148699a-7d0e-4815-b332-1b5b3ef5cb16">11,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzItMy0xLTEtMA_5a54184b-ecef-4808-a5c6-39577938edc0">6,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1099157ecec044679915cbcb253acd13_I20171231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzItNS0xLTEtMA_9fc5b329-5a5e-401b-bd75-5c56d140f360">5,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzMtMS0xLTEtMA_ffb43e01-a8db-4b3b-9408-73205c1704dd">2,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzMtMy0xLTEtMA_2d93bb8f-6a1a-4e38-981a-ab82debb69e1">5,393</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzMtNS0xLTEtMA_e6a9a3d9-8a5b-4467-bbd0-cfc3d5609841">636</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzQtMS0xLTEtMA_80e8a4d6-8fac-4a68-85a8-cd4b5a032218">1,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" format="ixt:zerodash" name="sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzQtMy0xLTEtMA_e779faf8-0277-46c0-a711-5d34ae9ecf64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" format="ixt:zerodash" name="sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzQtNS0xLTEtMA_fcbd491a-a465-4c0f-a090-d6968d2c95ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzUtMS0xLTEtMA_1e785925-88ab-40da-bddf-ca34e7a1d8be">3,554</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzUtMy0xLTEtMA_fcd8233d-ca67-4f68-87ab-462e7897bb85">51</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzUtNS0xLTEtMA_31932c24-39a8-48cf-8e59-661def204a6a">7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzYtMS0xLTEtMA_022bf952-5339-4e80-b5bd-8717fa0bc1a2">12,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzYtMy0xLTEtMA_218c468d-63f6-4d0c-9335-b5a17c0bb007">11,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:UnrecognizedTaxBenefits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzYtNS0xLTEtMA_4c445f35-3731-426f-be14-6844910e2f4a">6,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="i24672e5030474c1ba9673ec16c177662_127"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzI1OQ_e1129744-6c26-4649-a65f-4c10d6861e66" continuedAt="id7a3ea5591da4ef089327b0305e011ce" escape="true">RELATED PARTY TRANSACTION</ix:nonNumeric></span></div><div style="margin-bottom:12pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id7a3ea5591da4ef089327b0305e011ce">The Company acquired <ix:nonFraction unitRef="shares" contextRef="i84d0b5985441420eb3dbc496787e07aa_D20200101-20201231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzEwOTk1MTE2MjgwNjM_c9149f70-8898-4e37-901b-64e915f3c868">185,400</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="id6374baea04443699a67c6e73111ae5d_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="sgmo:BusinessAcquisitionNumberOfSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzEwOTk1MTE2MjgyMTU_a1b30433-3af8-4c79-b8e5-5e31790005c1">52,700</ix:nonFraction> vested free shares from a former executive of Sangamo, pursuant to the exercise of the Free Shares Options for approximately $<ix:nonFraction unitRef="usd" contextRef="i84d0b5985441420eb3dbc496787e07aa_D20200101-20201231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzEwOTk1MTE2MjgxMjA_db99e0ab-3ad3-4096-906d-151eff45298b">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id6374baea04443699a67c6e73111ae5d_D20190101-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzEwOTk1MTE2MjgyMzA_eadc2842-0bf8-4b39-8be0-3671718fa2e7">0.1</ix:nonFraction>&#160;million of cash, during the years ended December&#160;31, 2020 and 2019, respectively.</ix:continuation></span></div><div id="i24672e5030474c1ba9673ec16c177662_130"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:QuarterlyFinancialInformationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90ZXh0cmVnaW9uOmE1ODY5NjRiZmFlODQ0NmJhODEyNzVkYWVkMThhMTJlXzUxMg_217bcef7-271b-463e-8c95-374e754848c3" continuedAt="i7547497fbed446618f5d9e2f660f50b2" escape="true">QUARTERLY FINANCIAL DATA (UNAUDITED)</ix:nonNumeric></span></div><ix:continuation id="i7547497fbed446618f5d9e2f660f50b2"><ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90ZXh0cmVnaW9uOmE1ODY5NjRiZmFlODQ0NmJhODEyNzVkYWVkMThhMTJlXzUxMw_e47c3e97-6f47-430e-bea5-888767f4d491" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2020. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:23.164%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.723%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.730%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q4</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMS0xLTEtMA_063cfe4b-3bd1-493e-994a-32713db95f0c">13,076</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMy0xLTEtMA_f2f9af31-5232-498b-abf4-34582c3734c1">21,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItNS0xLTEtMA_f845c80e-4551-49ae-86b5-cdf450574f12">57,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItNy0xLTEtMA_68e3d6b9-3cfc-4192-ba09-7c14ee1386aa">25,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItOS0xLTEtMA_ad191302-0df0-48da-878b-e366a4bb3fc1">8,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMTEtMS0xLTA_a3b32d88-a435-4247-bf85-2071b2e228f4">17,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMTMtMS0xLTA_25574157-54c7-4a48-a165-ade8b89d21dd">21,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMTUtMS0xLTA_f220b52a-6b6a-480e-b80e-d68f69cfa774">54,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMS0xLTEtMA_e8e4dd82-420a-4113-b447-a0d9143dfdea">57,598</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMy0xLTEtMA_f5736fe7-d62b-4513-917e-ca970159a3a8">59,450</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtNS0xLTEtMA_a84d4ca3-e10b-40d1-8efe-b5f670c202d3">61,464</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtNy0xLTEtMA_8eb57bfb-6929-4b37-9a7a-c238c35ebc35">69,232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtOS0xLTEtMA_0bd9d9af-709e-4f2f-b5c2-a149e98dda02">51,968</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMTEtMS0xLTA_c5ab3fdb-cb72-475e-8b4e-6450c09d9438">51,052</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMTMtMS0xLTA_1014b03e-bae6-442b-9d60-d16c688b467b">51,206</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMTUtMS0xLTA_992f4c81-61bc-47e1-a302-1b73203ccec7">53,382</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMS0xLTEtMA_a887488a-060a-42be-a5ce-bd57a66d2d29">42,974</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMy0xLTEtMA_009a219a-b195-488a-909b-5cfff01220e1">35,965</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtNS0xLTEtMA_d9a6aa38-94aa-4ed0-86f1-d758de577866">1,508</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtNy0xLTEtMA_ce4a9f03-7fb8-470c-afdf-4403e7443e75">40,675</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtOS0xLTEtMA_a6818b25-2472-4cea-b673-80cd914b677b">42,203</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMTEtMS0xLTA_2e600102-cf50-42a5-808e-26aaf916a33c">30,356</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMTMtMS0xLTA_88aa08ea-6cb1-4642-91ae-8bb5fb8a3954">27,361</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMTUtMS0xLTA_59d52605-0270-4a26-b7f1-bb2043a60b2c">4,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to non-controlling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMS0xLTEtMA_02e82e90-642c-4272-b65e-87b08aabaf7e">61</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMy0xLTEtMA_215c8add-94aa-441b-82c6-65e501275803">36</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtNS0xLTEtMA_9b26a3a6-e264-48ff-9f76-980944c3679e">42</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtNy0xLTEtMA_92716a50-6086-430d-9269-6dd8ca95923d">71</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtOS0xLTEtMA_928c23e8-4333-4261-8905-f1dd3faab100">53</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMTEtMS0xLTA_43071d34-5133-4093-83bf-3d74e2bb6972">72</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMTMtMS0xLTA_d9e2f4cc-70fe-4d1a-903a-96c8323884a5">54</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMTUtMS0xLTA_bf5df110-f286-4931-bd1b-8cece07208a4">54</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to Sangamo Therapeutics, Inc.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMS0xLTEtMA_6a7d6cbd-3e2e-43f5-b8ed-1fac6c768fdf">42,913</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMy0xLTEtMA_12c5081d-9484-4304-b997-f172131bb7c1">35,929</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtNS0xLTEtMA_13a65313-307e-4427-a5a8-530c76c15e42">1,550</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtNy0xLTEtMA_c718968c-6ab9-43ec-bbbf-5d0cc2271d88">40,604</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtOS0xLTEtMA_c3dd59f4-8286-479d-867b-b3090d1eb2f0">42,150</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMTEtMS0xLTA_dc028808-88d0-458c-bf09-d3bb9e0ef017">30,284</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMTMtMS0xLTA_e16f8809-578a-499a-841d-8eb8826cb9a4">27,307</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMTUtMS0xLTA_993f22f2-46ed-4838-8b57-698b28debd6c">4,555</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMS0xLTEtMA_fd509cf3-2642-4558-ae85-e6eb3d63e7cf">0.37</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMy0xLTEtMA_3b1e1fa2-6c19-44aa-9ef7-32da169eb115">0.26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctNS0xLTEtMA_5cf08e64-62db-4ad3-943a-eebdc2aee4a8">0.01</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctNy0xLTEtMA_3d58f38d-9a4f-4247-a317-aa7675c70d2e">0.29</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctOS0xLTEtMA_e38a4e11-a36f-4d35-b34a-c0af5effa2e0">0.41</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMTEtMS0xLTA_20a36e3b-9399-4d15-a759-8d1a5d01e4f4">0.26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMTMtMS0xLTA_665a54fd-a721-4f55-bb23-f528f4c40012">0.24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231" decimals="2" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMTUtMS0xLTA_3a67972a-ae85-44ee-9647-de912c300f65">0.04</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div><span><br/></span></div><div id="i24672e5030474c1ba9673ec16c177662_133"></div><div style="margin-top:21pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14 &#8211; <ix:nonNumeric contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzMvZnJhZzozOWQzNzA2ZWU3Y2I0YjY1YWY5ZTMzNTQyMzliMmI1MS90ZXh0cmVnaW9uOjM5ZDM3MDZlZTdjYjRiNjVhZjllMzM1NDIzOWIyYjUxXzY0NjA_322984f2-69a9-49bf-a648-58e3e261fd32" continuedAt="ia5ef24beb64549c2bc36f6fdf5b579bf" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia5ef24beb64549c2bc36f6fdf5b579bf">In the first quarter of 2021 through February 19, 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i48f4d381b117429fa8a27a467285b605_D20210101-20210219" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzMvZnJhZzozOWQzNzA2ZWU3Y2I0YjY1YWY5ZTMzNTQyMzliMmI1MS90ZXh0cmVnaW9uOjM5ZDM3MDZlZTdjYjRiNjVhZjllMzM1NDIzOWIyYjUxXzEwOTk1MTE2NDIzNjU_f6bdcf82-5a4c-41f6-b5ad-62b719adc213">1,034,762</ix:nonFraction> shares of its common stock for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i48f4d381b117429fa8a27a467285b605_D20210101-20210219" decimals="-5" format="ixt:numdotdecimal" name="sgmo:SaleOfStockConsiderationReceivedOnTransactionGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzMvZnJhZzozOWQzNzA2ZWU3Y2I0YjY1YWY5ZTMzNTQyMzliMmI1MS90ZXh0cmVnaW9uOjM5ZDM3MDZlZTdjYjRiNjVhZjllMzM1NDIzOWIyYjUxXzEwOTk1MTE2NDIzNzM_9fc63c2d-8c70-4cef-b5fa-8d0b60423178">16.1</ix:nonFraction>&#160;million from an at-the-market offering program under an Open Market Sale Agreement&#8480; with Jefferies dated August 5, 2020. After deducting sales commissions and expenses, net cash proceeds through February 19, 2021 under the at-the-market offering are approximately $<ix:nonFraction unitRef="usd" contextRef="i48f4d381b117429fa8a27a467285b605_D20210101-20210219" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzMvZnJhZzozOWQzNzA2ZWU3Y2I0YjY1YWY5ZTMzNTQyMzliMmI1MS90ZXh0cmVnaW9uOjM5ZDM3MDZlZTdjYjRiNjVhZjllMzM1NDIzOWIyYjUxXzEwOTk1MTE2NDIzODk_742009bc-a9ac-45aa-8ddc-1110017286b5">15.7</ix:nonFraction>&#160;million.</ix:continuation></span></div><div id="i24672e5030474c1ba9673ec16c177662_142"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9 &#8211; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i24672e5030474c1ba9673ec16c177662_145"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9A &#8211; CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the supervision of our principal executive officer and acting principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15&#8364; and 15d-15(e) of the Exchange Act) as of December&#160;31, 2020. Based on that evaluation, as of December&#160;31, 2020, our principal executive officer and acting principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inherent Limitations on Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, including the principal executive officer and acting principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining an adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) for our company. Our management, including our principal executive officer and acting principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework set forth in the &#8220;Internal Control&#8212;Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on an evaluation under that framework, our management concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of our internal control over financial reporting as of December&#160;31, 2020 has been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as stated in their report, which is included herein.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules&#160;13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended December&#160;31, 2020 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:110%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of Sangamo Therapeutics, Inc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Sangamo Therapeutics, Inc.&#8217;s internal control over financial reporting as of December 31, 2020, based on criteria established in Internal Control &#8211; Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Sangamo Therapeutics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2020, based on the COSO criteria. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2020 consolidated financial statements of the Company and our report dated February 24, 2021 expressed an unqualified opinion thereon. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">/s/&#160;ERNST&#160;&amp; YOUNG LLP</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Redwood City, California</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">February&#160;24, 2021</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;9B &#8211; OTHER INFORMATION</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i24672e5030474c1ba9673ec16c177662_151"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information required by Part&#160;III is omitted from this Report on Form&#160;10-K because we intend to file our definitive Proxy Statement for our next Annual Meeting of Stockholders, pursuant to Regulation&#160;14A of the Securities Exchange Act of 1934, as amended, or the 2021 Proxy Statement, no later than April&#160;30, 2021, and certain information to be included in the 2021 Proxy Statement is incorporated herein by reference.</span></div><div id="i24672e5030474c1ba9673ec16c177662_154"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;10 &#8211; DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is to be included in our 2021 Proxy Statement as follows:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The information relating to our directors and nominees for director is to be included in the section entitled &#8220;Election of Directors;&#8221;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The information relating to our executive officers is to be included in the section entitled &#8220;Executive Officers;&#8221;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The information relating to our audit committee and audit committee financial expert is to be included in the section entitled &#8220;Election of Directors &#8211; Audit Committee;&#8221;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The information relating to the procedures by which stockholders may recommend nominees to our Board of Directors is to be included in the section entitled &#8220;Questions and Answers About These Proxy Materials and Voting;&#8221; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The information regarding compliance with Section 16(a) of the Exchange Act is to be included in the section entitled &#8220;Delinquent Section 16(a) Reporting.&#8221;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Such information is incorporated herein by reference to our 2021 Proxy Statement, provided that if the 2021 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div id="i24672e5030474c1ba9673ec16c177662_157"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;11 &#8211; EXECUTIVE COMPENSATION </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is to be included in our 2021 Proxy Statement under the sections entitled &#8220;Executive Compensation,&#8221; &#8220;Director Compensation,&#8221; &#8220;Election of Directors&#8212;Compensation Committee Interlocks and Insider Participation&#8221; and &#8220;Report of the Compensation Committee of the Board of Directors&#8221; and is incorporated herein by reference, provided that if the 2021 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div id="i24672e5030474c1ba9673ec16c177662_160"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;12 &#8211; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item with respect to equity compensation plans is to be included in our 2021 Proxy Statement under the section entitled &#8220;Equity Compensation Plan Information&#8221; and the information required by this item with respect to security ownership of certain beneficial owners and management is to be included in our 2021 Proxy Statement under the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management&#8221; and in each case is incorporated herein by reference, provided that if the 2021 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div id="i24672e5030474c1ba9673ec16c177662_163"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;13 &#8211; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is to be included in our 2021 Proxy Statement under the sections entitled &#8220;Certain Relationships and Related Transactions&#8221; and &#8220;Election of Directors&#8212;Board Independence&#8221; and is incorporated herein by reference, provided that if the 2021 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;14 &#8211; PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is to be included in our 2021 Proxy Statement under the section entitled &#8220;Ratification of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference, provided that if the 2021 Proxy Statement is not filed within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K, the omitted information will be included in an amendment to this Annual Report on Form 10-K filed not later than the end of such 120-day period.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i24672e5030474c1ba9673ec16c177662_172"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM&#160;15 &#8211; EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) The following documents are included as part of this Annual Report on Form 10-K:</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. Financial Statements&#8212;See Index to Consolidated Financial Statements in Item&#160;8.</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Financial Statement Schedules&#8212;Not Applicable.</span></div><div style="margin-top:6pt;padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Exhibits</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518223059/d558251dex21.htm">Share Purchase Agreement dated July 20, 2018 among the Company and the Selling TxCell Shareholders named on the signature page thereto (incorporated by reference to Exhibit 2.1 to the Company&#8217;s Current Report on Form 8-K filed July 23, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518319603/d651511dex22.htm">Amendment Agreement to the Share Purchase Agreement dated October 1, 2018 between the Company and TxCell S.A. (incorporated by reference to Exhibit 2.2 to the Company&#8217;s Current Report on Form 8-K filed November 6, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518223059/d558251dex22.htm">Tender Offer Agreement dated July 20, 2018 between the Company and TxCell S.A. (incorporated by reference to Exhibit 2.2 to the Company&#8217;s Current Report on Form 8-K filed July 23, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312518319603/d651511dex24.htm">Amendment No. 1 to the Tender Offer Agreement dated October 1, 2018 between the Company and TxCell S.A. (incorporated by reference to Exhibit 2.4 to the Company&#8217;s Current Report on Form 8-K filed November&#160;6, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Seventh Amended and Restated Certificate of Incorporation, as </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">amended</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">(incorporated by reference to Exhibit 3.1 to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm"> Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">10</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">-</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm"> filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">August 9</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">17</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex31_651.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex31.htm">Fourth Certificate of Amendment of the Seventh Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed May 22, 2020).</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">Fourth</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm"> Amended and Restated Bylaws (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Current Report on Form 8-K filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">December</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm"> 15, 20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">20</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520318091/d88073dex31.htm">).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="sgmo-20201231xexx41.htm">Description of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="sgmo-20201231xexx41.htm">Capital</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="sgmo-20201231xexx41.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="sgmo-20201231xexx41.htm">Stock.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312517003781/d304900dex41.htm">Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Current Report on Form&#160;8-K filed January 6, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018012641/sgmo-ex102_123.htm">Amended and Restated 2013 Stock Incentive Plan (the &#8220;2013 Plan&#8221;) (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed May 10, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">Amended and Restated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;) (incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm"> to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">Current</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">Report</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm"> on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">8-K</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm"> filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">22,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520150198/d935677dex101.htm">2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm">2018 Equity Incentive Plan French Stock-Options Sub-Plan (the &#8220;French Options Sub-Plan&#8221;) (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Annual Report on Form 10-K</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm">filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex103_614.htm"> March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex104_439.htm">2018 Equity Incentive Plan French Restricted Stock Unit Award Sub-Plan (the &#8220;French RSU Sub-Plan&#8221;) (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000119312520269552/d98696dex991.htm">2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 99.1 to the Company&#8217;s Registration Statement on Form S-8, filed October 15, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex102.htm">Form of Restricted Stock Unit Award Agreement under the 2013 Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex103.htm">Form of Notice of Grant of Stock Option under the 2013 Plan (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex104.htm">Form of Stock Option Agreement under the 2013 Plan (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex105.htm">Form of Notice of Grant of Stock Option &#8211; Director Initial Grant under the 2013 Plan (incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.10(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex106.htm">Form of Notice of Grant of Stock Option &#8211; Director Annual Grant under the 2013 Plan (incorporated by reference to Exhibit&#160;10.6 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.11(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513259487/d554133dex107.htm">Form of Automatic Stock Option Agreement under the 2013 Plan (incorporated by reference to Exhibit&#160;10.7 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.12(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex992_12.htm">Form of Stock Option Grant Notice and Form of Option Agreement (U.S. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.2 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.13(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex993_11.htm">Form of Stock Option Grant Notice and Form of Option Agreement (non-employee directors) under the 2018 Plan (incorporated by reference to Exhibit 99.3 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.14(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex994_10.htm">Form of Stock Option Grant Notice and Form of Option Agreement (U.K. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.4 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.15(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm">Form of Stock Option Grant Notice (French employees) under the 2018 Plan and the French Options Sub-Plan (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Annual Report on Form 10-K </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm">filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1014_438.htm">March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.16(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm">Form of Stock Option Agreement (French Employees) under the 2018 Plan and the French Options Sub-Plan (incorporated by reference to Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm"> filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1015_613.htm">March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.17(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex995_9.htm">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (U.S. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.5 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.18(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex996_7.htm">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (non-employee directors) under the 2018 Plan (incorporated by reference to Exhibit 99.6 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018015648/sgmo-ex997_8.htm">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (U.K. employees) under the 2018 Plan (incorporated by reference to Exhibit 99.7 to the Company&#8217;s Current Report on Form 8-K filed June 15, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.20(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1019_437.htm">Form of Restricted Stock Unit Grant Notice and Form of Restricted Stock Unit Award Agreement (French employees) under the 2018 Plan and the French RSU Sub-Plan. (incorporated by reference to Exhibit 10.19 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1020_436.htm">Amended and Restated Severance Plan (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.22(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018012641/sgmo-ex102_123.htm">Amended and Restated Incentive Compensation Plan (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 10, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.23(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm">Form of </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm">Indemnity</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm"> Agreement (incorporated by reference to Exhibit&#160;10.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm"> to the Company&#8217;s Quarterly Report on Form 10-Q filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm">May</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm">11,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex103.htm">2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.24(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459016022708/sgmo-ex101_285.htm">Employment Agreement between the Company and Alexander (Sandy) Macrae, dated May 17, 2016 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 4, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.25(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1024.htm">Employment Agreement between the Company and Sung Lee effective as of October 31, 2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1024.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1024.htm">(incorporated by reference to Exhibit 10.24 to the Company&#8217;s Annual Report on Form 10-K filed February 28, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.26(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828021000921/leeconsultingagreementfinal.htm">Letter Agreement between the Company and Sung Lee dated as of January 22, 2021 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed January 28, 2021).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.27(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1025.htm">Employment Agreement between the Company and Gary Loeb effective as of June 6, 2019</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1025.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1025.htm">(incorporated by reference to Exhibit 10.25 to the Company&#8217;s Annual Report on Form 10-K filed February 28, 2020)</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.28(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1026.htm">Employment Agreement between the Company and Rolf Andrew (Andy) Ramelmeier effective as of November 1, 2017</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1026.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1026.htm">(incorporated by reference to Exhibit 10.26 to the Company&#8217;s Annual Report on Form 10-K filed February 28, 2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1026.htm">)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1026.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.29(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex102.htm">Letter Agreement Regarding Andrew Ramelmeier Special Bonus (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 5, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.30(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1027_724.htm">Employment Agreement between the Company and St&#233;phane Boissel, effective October 1, 2018 (incorporated by reference to Exhibit 10.27 to the Company&#8217;s Annual Report on Form 10-K</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1027_724.htm"> filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1027_724.htm"> March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.31(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1028_725.htm">Employment Agreement between the Company and Adrian Woolfson, effective January 21</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1028_725.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1028_725.htm"> 2019 (incorporated by reference to Exhibit 10.28 to the Company&#8217;s Annual Report on Form 10-K </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1028_725.htm">filed</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1028_725.htm"> March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex101.htm">Employment Agreement between the Company and Mark McClung effective as of April 13, 2020 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 5, 2020)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex101.htm">.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33(+)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000095014900000384/0000950149-00-000384.txt">Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated May&#160;23, 1997 (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form&#160;S-1 (Reg. No.&#160;333-30314), as amended, filed February 24, 2000).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.34</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000095014905000054/f05860exv10w20.htm">First Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated March&#160;12, 2004 (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Annual Report on Form&#160;10-K filed February 23, 2005).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.35</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513425338/d595389dex101.htm">Second Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated March&#160;15, 2007 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed November 4, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.36</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312513425338/d595389dex102.htm">Third Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated August 1, 2013 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed November 4, 2013).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.37</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1033_728.htm">Fourth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated June 10, 2016 (incorporated by reference to Exhibit 10.33 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.38</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1034_727.htm">Fifth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated July 10, 2017 (incorporated by reference to Exhibit 10.34 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.39</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018020536/sgmo-ex109_61.htm">Sixth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated May 11, 2018 (incorporated by reference to Exhibit 10.9 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed August 8, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex104.htm">Seventh Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated May 20, 2020 (incorporated by reference to Exhibit 10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 5, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex105.htm">Eighth Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated May 29, 2020 (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 5, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.42</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018004163/sgmo-ex1021_830.htm">Lease Agreement between the Company and Marina Boulevard Property, LLC dated November 3, 2017 (incorporated by reference to Exhibit 10.21 to the Company&#8217;s Annual Report on Form 10-K filed March 1, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.43</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459019005808/sgmo-ex1037_729.htm">First Amendment to Lease Agreement between the Company and Marina Boulevard Property, LLC dated January 1, 2019 (incorporated by reference to Exhibit 10.37 to the Company&#8217;s Annual Report on Form 10-K (File No. 000-30171), filed with the SEC on March 1, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.44</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">Open</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">Market</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">Sale</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> Agreement between the Company and </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">Jefferies</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> LLC, dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">5,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">2020</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> (incorporated by reference to Exhibit 1.1 to the Company&#8217;s </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">Quarterly</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> Report on Form </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">10-Q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> filed </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">August</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">5,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020011806/sgmo-20200630xex11.htm">2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.45&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459015009009/sgmo-ex101_99.htm">Amended and Restated Collaboration and License Agreement between the Company and Shire International GmbH, dated September 1, 2015 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed October 30, 2015).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.46&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000119312514187386/d699448dex101.htm">Global Research, Development and Commercialization Collaboration and License Agreement between the Company and Biogen MA Inc. (Bioverativ Inc.), dated January 8, 2014 (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed May 7, 2014).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.47&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459016012882/sgmo-ex1063_373.htm">Letter Amendment to Global Research, Development and Commercialization Collaboration and License Agreement between the Company and Biogen MA Inc. (Bioverativ Inc.), dated December 14, 2015 (incorporated by reference to Exhibit 10.63 to the Company&#8217;s Annual Report on Form 10-K filed February 18, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459016018000/sgmo-ex101_333.htm">Letter Agreement and Waiver between the Company and Biogen MA Inc. (Bioverativ Inc.), dated March 24, 2016 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed May&#160;5, 2016).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459017017005/sgmo-ex101_575.htm">Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 2017 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 9, 2017).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50&#8273;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1045.htm">Letter Amendment, dated December 17, 2019, to the Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 2017</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1045.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020002582/sgmo-20191231xexx1045.htm">(incorporated by reference to Exhibit 10.45 to the Company&#8217;s Annual Report on Form 10-K filed February 28, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000156459018004163/sgmo-ex1040_689.htm">Research Collaboration and License Agreement between the Company and Pfizer Inc., dated December 28, 2017 (incorporated by reference to Exhibit 10.40 to the Company&#8217;s Annual Report on Form 10-K filed March&#160;1, 2018).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000156459019017255/sgmo-ex103_230.htm">Amendment No. 1 to Research Collaboration and License Agreement between the Company and Pfizer Inc., dated March 21, 2019 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 8, 2019).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.53&#8273;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020015504/sgmo-20200930xex103.htm">Amendment No. 2 to Research Collaboration and License Agreement between the Company and Pfizer Inc., dated July </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020015504/sgmo-20200930xex103.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020015504/sgmo-20200930xex103.htm">1, 2020 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed November 4, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.54&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1001233/000162828019013510/sgmo-20190930xex101.htm">Amended and Restated Collaboration and License Agreement between the Company and Kite Pharma, Inc., dated September 11, 2019 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed November 6, 2019).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.55&#8273;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xexfe7.htm">Collaboration and License Agreement among the Company, Biogen MA, Inc. and Biogen International GmbH, dated February 26, 2020 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 11, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020007462/sgmo-20200331xex102.htm">Stock Purchase Agreement between the Company and Biogen MA, Inc., dated February 26, 2020 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 11, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.57&#8273;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1001233/000162828020015504/sgmo-20200930xex102.htm">Collaboration and License Agreement between the Company and Novartis Institutes for BioMedical Research, Inc., dated July 27, 2020 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed November 4, 2020).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20201231xexx211.htm">Subsidiaries of the Company</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20201231xexx231.htm">Consent of Independent Registered Public Accounting Firm.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_178">Power of Attorney (included on signature page).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20201231xex311.htm">Rule&#160;13a-14(a) Certification of Principal Executive Officer.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20201231xex312.htm">Rule&#160;13a-14(a) Certification of Principal Financial Officer.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sgmo-20201231xex321.htm">Certification Pursuant to 18 U.S.C. Section&#160;1350.</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The cover page from Sangamo&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, is formatted in Inline XBRL and it is contained in Exhibit 101</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">________________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Confidential treatment has been granted for certain information contained in this document pursuant to an order of the SEC. Such information has been omitted and filed separately with the SEC.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8273;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">          </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain portions of this exhibit (indicated by &#8220;[*]&#8221;) have been omitted in accordance with 17 CFR &#167; 229.601(b).</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(+)&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan or arrangement.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18 U.S.C. Section</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">1350, as adopted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span></div><div id="i24672e5030474c1ba9673ec16c177662_175"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16 &#8211; FORM 10-K SUMMARY</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><div id="i24672e5030474c1ba9673ec16c177662_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i24672e5030474c1ba9673ec16c177662_7">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on February&#160;24, 2021.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.993%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February 24, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SANGAMO THERAPEUTICS, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> /&#160;&#160;&#160;&#160;A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LEXANDER D.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ACRAE</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alexander D. Macrae</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">President and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alexander D. Macrae and Gary Loeb, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Date</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ S /&#160;&#160;&#160;&#160;ALEXANDER D. MACRAE</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President,&#160;Chief&#160;Executive&#160;Officer<br/>(Principal&#160;Executive Officer) and Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Alexander D. Macrae</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ S /&#160;&#160;&#160;&#160;SUNG H. LEE</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acting Principal&#160;Financial&#160;Officer<br/>&#160;(Principal&#160;Financial Officer)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sung H. Lee</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ S /&#160;&#160;&#160;&#160;PRATHYUSHA DURAIBABU</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vice President, Finance and Principal Accounting Officer (Principal Accounting Officer)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Prathyusha Duraibabu</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ S /&#160;&#160;&#160;&#160;H. STEWART PARKER</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director and Chairwoman of the Board</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">H. Stewart Parker</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ S /&#160;&#160;&#160;ROBERT F. CAREY</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Robert F Carey</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;S&#160;/&#160;&#160;&#160;&#160;KENNETH J. HILLAN,&#160;M.B.,&#160;C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.B.</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Kenneth J. Hillan, M.B., Ch.B.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;S&#160;/&#160;&#160;&#160;&#160;JAMES R. MEYERS</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">James R. Meyers</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;S&#160;/&#160;&#160;&#160;&#160;JOHN MARKELS,&#160;P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.D.</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">John Markels, Ph.D.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/&#160;S&#160;/&#160;&#160;&#160;&#160;SAIRA RAMASASTRY</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Saira Ramasastry</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> /&#160;&#160;&#160;&#160;KAREN SMITH, M.D, P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">H</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.D., M.B.A., L.L.M.</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Karen Smith, M.D., Ph.D., M.B.A., L.L.M.</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/ </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> /&#160;&#160;&#160;&#160;JOSEPH S. ZAKRZEWSKI</span></div></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 24, 2021</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Joseph S. Zakrzewski</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>sgmo-20201231xexx41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ife9314f513ec440784204d1304d5a48a_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:138%">Exhibit 4.1</font></div></div><div style="margin-top:6pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DESCRIPTION OF CAPITAL STOCK</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">References herein to &#8220;Sangamo,&#8221; &#8220;our,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; refer only to Sangamo Therapeutics, Inc. and not to any of our subsidiaries. </font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our seventh amended and restated certificate of incorporation, as amended, or the Restated Certificate, authorizes us to issue 320,000,000 shares of common stock, par value $0.01 per share, and 5,000,000 shares of preferred stock, par value $0.01 per share. </font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary description of our capital stock is based on the provisions of the Restated Certificate, our fourth amended and restated bylaws, or the Bylaws, and the applicable provisions of the General Corporation Law of the State of Delaware, or DGCL. This information may not be complete in all respects and is qualified entirely by reference to the provisions of the Restated Certificate, the Bylaws and the DGCL.  The Restated Certificate and the Bylaws are filed as exhibits to this Annual Report on Form 10-K to which this Description of Capital Stock is an exhibit. </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of our common stock are the only security of the Company registered pursuant to Section 12 of the Securities Exchange Act of 1934, as amended, or the Exchange Act. The holders of common stock are entitled to one vote per share on all matters to be voted on by the stockholders. Stockholders have no cumulative voting rights. Subject to the preferences of any outstanding shares of preferred stock, the holders of common stock are entitled to receive ratably any dividends our board of directors declares out of funds legally available for the payment of dividends. If we are liquidated, dissolved or wound up, the holders of common stock are entitled to share pro rata all assets remaining after payment of liabilities and liquidation preferences of any outstanding shares of preferred stock. Holders of common stock have no preemptive rights or rights to convert their common stock into any other securities. There are no redemption or sinking fund provisions applicable to the common stock. </font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Restated Certificate, our board of directors has the authority, without further action by the stockholders, to issue shares of preferred stock in one or more series. Our board of directors also has the authority to determine or alter the designation, rights, preferences, privileges and restrictions granted to or imposed upon any unissued series of preferred stock, any or all of which may be greater than the rights of the common stock. Our board of directors, without stockholder approval, may issue preferred stock with voting, conversion or other rights that are superior to the voting and other rights of the holders of common stock. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change of control of Sangamo without further action by the stockholders, and may have the effect of delaying or preventing changes in management of Sangamo. In addition, the issuance of preferred stock may have the effect of decreasing the market price of the common stock and may adversely affect the voting power of holders of common stock and reduce the likelihood that common stockholders will receive dividend payments and payments upon liquidation.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Antitakeover Effects of Provisions of our Restated Certificate, Bylaws and Delaware Law</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Restated Certificate and Bylaws</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted above, our board of directors, without stockholder approval, has the authority under our Restated Certificate to issue preferred stock with rights superior to the rights of the holders of common stock. As a result, the issuance of preferred stock may have the effect of delaying, deferring or preventing a change of control of Sangamo without further action by the stockholders and may adversely affect the voting and other rights of the holders of common stock. Our Restated Certificate also requires that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of the stockholders and may not be effected by a consent in writing. Further, our Restated Certificate provides that a special meeting of the stockholders may be called only by our board of directors.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the provisions noted above, our Bylaws further establish advance notice procedures with respect to stockholder proposals and nomination of candidates for election as directors other than nominations made by or at the direction of the board of directors or a committee of the board of directors. Although our stockholders may amend, repeal or alter our Bylaws by a vote of at least a majority of the outstanding shares of our capital stock entitled to vote, our board of directors may also unilaterally adopt, repeal, alter, amend and rescind our Bylaws by a vote of at least a majority of board of directors. Finally, our board of directors has the ability to elect a director to fill a vacancy created by the expansion of the board of directors or due to the resignation or departure of an existing board member.</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may have the effect of delaying, deferring or preventing a change in control and may also delay or prevent changes in management of Sangamo, which could have an adverse effect on the market price of our stock. These and other provisions are intended to enhance the likelihood of continued stability in the composition of our board of directors and to discourage certain types of transactions that may involve an actual or threatened change of control. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, such provisions also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts.</font></div><div style="margin-top:6pt;text-indent:24.45pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Section 203 of the General Corporation Law of the State of Delaware</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to Section 203 of the DGCL which regulates acquisitions of some Delaware corporations. In general, Section 203 prohibits, with some exceptions, a publicly held Delaware corporation such as us from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years following the time that the stockholder became an interested stockholder, unless&#58;</font></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.906%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.894%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">prior to the time the stockholder became an interested stockholder, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the number of shares outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned by (a) persons who are directors and also officers and (b) employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer&#59; or</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">at or subsequent to the time the stockholder became an interested stockholder, the business combination is approved by the board of directors and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8260;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:1.41pt;vertical-align:baseline">3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">% of the outstanding voting stock which is not owned by the interested stockholder.</font></div></td></tr></table></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 203 of the DGCL generally defines a &#8220;business combination&#8221; to include any of the following&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">any merger or consolidation involving the corporation and the interested stockholder&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">any sale, lease, exchange, mortgage, transfer, pledge or other disposition involving the interested stockholder (in one transaction or a series of transactions) of assets of the corporation having an aggregate market value equal to 10% or more of the aggregate market value of either all of the assets of the corporation or its outstanding stock&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder&#59;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">subject to exceptions, any transaction involving the corporation that has the effect, directly or indirectly, of increasing the proportionate share of the stock or any class or series of the corporation beneficially owned by the interested stockholder&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">the receipt by the interested stockholder of the benefit, directly or indirectly (except proportionately as a stockholder of such corporation), of any loans, advances, guarantees, pledges or other financial benefits, other than certain benefits set forth in Section 203, provided by or through the corporation.</font></td></tr></table></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, Section 203 defines an &#8220;interested stockholder&#8221; as an entity or person who, together with the person&#8217;s affiliates and associates, beneficially owns, or within three years prior to the time of determination of interested stockholder status did own, 15% or more of the outstanding voting stock of the corporation.</font></div><div style="margin-top:6pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 203 of the DGCL could depress our stock price and delay, discourage or prohibit transactions not approved in advance by our board of directors, such as takeover attempts that might otherwise involve the payment to our stockholders of a premium over the market price of our common stock.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forum Selection Bylaw</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum for (1) any derivative action or proceeding brought on behalf of Sangamo, (2) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, other employee or stockholder of Sangamo to Sangamo or to our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL, the Restated Certificate, the Bylaws, or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, or (4) any action asserting a claim governed by the internal affairs doctrine shall be a state or federal court located within the state of Delaware.  However, this provision does not apply to actions arising under the Securities Act of 1933, as amended, or the Securities Act, or the Exchange Act, or any claim for which the federal courts have exclusive jurisdiction.</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted by law, the federal district courts of the United States of America shall be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act.</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of Sangamo is deemed to have notice of and consented to the forum selection provisions of the Bylaws.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>3
<FILENAME>sgmo-20201231xexx211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iffa5124707f7415aa3d6e0e83ec0775a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries of the Company</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gendaq Limited (U.K.)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ceregene Inc. (Delaware)</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Sangamo Therapeutics France S.A.S. (France)</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>sgmo-20201231xexx231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i59043d3f7b5c4b638b127ee3e3e877ad_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:6pt;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in the following Registration Statements&#58;</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.458%"></td><td style="width:0.1%"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Registration Statements (Forms S-8 No. 333-166220, 333-189621, 333-206173, 333-221827, 333-225552, 333-241033, and 333-249482) pertaining to the Amended and Restated 2013 Stock Incentive Plan, 2010 Employee Stock Purchase Plan, Amended and Restated 2018 Equity Incentive Plan, and 2020 Employee Stock Purchase Plan of Sangamo Therapeutics, Inc., and</font></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Registration Statements (Form S-3 No. 333-224418) and related prospectuses of Sangamo Therapeutics, Inc.&#59;</font></td></tr></table></div><div style="margin-top:15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our reports dated February&#160;24, 2021, with respect to the consolidated financial statements of Sangamo Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Sangamo Therapeutics, Inc. included in this Annual Report (Form 10-K) of Sangamo Therapeutics, Inc. for the year ended December&#160;31, 2020.</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47;&#160;Ernst&#160;&#38; Young LLP&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Redwood City, California</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2021</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>sgmo-20201231xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6b55af98d96b4f238b98e163a62cee93_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Alexander D. Macrae, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this annual report on Form 10-K of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 24, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>sgmo-20201231xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i6a569ecb59f04251aea43731a042f02d_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">CERTIFICATION</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Sung H. Lee, certify that&#58;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">I have reviewed this annual report on Form 10-K of Sangamo Therapeutics, Inc.&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:46.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-top:6pt;padding-left:108pt;text-indent:-54pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:42.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:74.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.681%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 24, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SUNG H. LEE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sung H. Lee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acting Principal&#160;Financial&#160;Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>sgmo-20201231xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i743ed33215904f40996b296e2d335797_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt"><font><br></font></div></div><div style="margin-top:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Certifications Pursuant to 18 U.S.C. &#167;1350, as Adopted</font></div><div style="margin-top:3pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, Alexander Macrae, President and Chief Executive Officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), and Sung Lee, Acting Principal Financial Officer of the Company, each hereby certifies in such capacity, that, to the best of his knowledge&#58;</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2020, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section 15(d) of the Exchange Act&#59; and</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:79.134%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; ALEXANDER D. MACRAE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alexander D. Macrae</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 24, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; SUNG H. LEE</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sung H. Lee</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acting Principal&#160;Financial&#160;Officer</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; February 24, 2021</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>sgmo-20201231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a450ce61-5a63-468d-aea1-980040e585ad,g:3eb33991-981d-4627-a625-d6dd25ee8674-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sgmo="http://www.sangamo.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:num="http://www.xbrl.org/dtr/type/numeric" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20201231">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20201231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20201231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20201231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20201231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sangamo.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperations" roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>1005006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>1006007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail">
        <link:definition>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails">
        <link:definition>2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurement" roleURI="http://www.sangamo.com/role/FairValueMeasurement">
        <link:definition>2107102 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementTables" roleURI="http://www.sangamo.com/role/FairValueMeasurementTables">
        <link:definition>2308302 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail">
        <link:definition>2409404 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail">
        <link:definition>2410405 - Disclosure - Fair Value Measurement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail">
        <link:definition>2411406 - Disclosure - Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecurities" roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities">
        <link:definition>2112103 - Disclosure - Cash Equivalents and Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesTables" roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables">
        <link:definition>2313303 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
        <link:definition>2414407 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail">
        <link:definition>2415408 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>2416409 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliances" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances">
        <link:definition>2117104 - Disclosure - Major Customers, Partnerships and Strategic Alliances</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesTables" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables">
        <link:definition>2318304 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail">
        <link:definition>2419410 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail">
        <link:definition>2420411 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail">
        <link:definition>2421412 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail" roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail">
        <link:definition>2422413 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with DAS (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofSangamoFrance" roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFrance">
        <link:definition>2123105 - Disclosure - Acquisition of Sangamo France</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofAcquisitionofSangamoFranceTables" roleURI="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables">
        <link:definition>2324305 - Disclosure - Acquisition of Acquisition of Sangamo France (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofSangamoFranceAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail">
        <link:definition>2425414 - Disclosure - Acquisition of Sangamo France - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail">
        <link:definition>2426415 - Disclosure - Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetails" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetails">
        <link:definition>2127106 - Disclosure - Other Balance Sheet Details</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsTables" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables">
        <link:definition>2328306 - Disclosure - Other Balance Sheet Details (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsDetail" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail">
        <link:definition>2429416 - Disclosure - Other Balance Sheet Details (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail">
        <link:definition>2430417 - Disclosure - Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail">
        <link:definition>2431418 - Disclosure - Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.sangamo.com/role/CommitmentsandContingencies">
        <link:definition>2132107 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesTables">
        <link:definition>2333307 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail">
        <link:definition>2434419 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail">
        <link:definition>2435420 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1" roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1">
        <link:definition>2435420 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail" roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail">
        <link:definition>2436421 - Disclosure - Commitments and Contingencies - Non-cancelable Material Contractual Commitments (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.sangamo.com/role/StockholdersEquity">
        <link:definition>2137108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.sangamo.com/role/StockholdersEquityTables">
        <link:definition>2338308 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail">
        <link:definition>2439422 - Disclosure - Stockholders' Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofStockOptionActivityDetail" roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail">
        <link:definition>2440423 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail">
        <link:definition>2441424 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.sangamo.com/role/StockBasedCompensation">
        <link:definition>2142109 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.sangamo.com/role/StockBasedCompensationTables">
        <link:definition>2343309 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetail" roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>2444425 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail">
        <link:definition>2445426 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" roleURI="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail">
        <link:definition>2446427 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" roleURI="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail">
        <link:definition>2447428 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.sangamo.com/role/EmployeeBenefitPlan">
        <link:definition>2148110 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail">
        <link:definition>2449429 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.sangamo.com/role/IncomeTaxes">
        <link:definition>2150111 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.sangamo.com/role/IncomeTaxesTables">
        <link:definition>2351310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail">
        <link:definition>2452430 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail">
        <link:definition>2453431 - Disclosure - Income Taxes - Summary of Benefit for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail">
        <link:definition>2454432 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail">
        <link:definition>2455433 - Disclosure - Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails" roleURI="http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails">
        <link:definition>2456434 - Disclosure - Income Taxes - Deferred Tax Assets &amp; Liabilities, Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail">
        <link:definition>2457435 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail">
        <link:definition>2458436 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosures" roleURI="http://www.sangamo.com/role/RelatedPartyDisclosures">
        <link:definition>2159112 - Disclosure - Related Party Disclosures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyDisclosuresDetail" roleURI="http://www.sangamo.com/role/RelatedPartyDisclosuresDetail">
        <link:definition>2460437 - Disclosure - Related Party Disclosures (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnaudited" roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited">
        <link:definition>2161113 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedTables" roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables">
        <link:definition>2362311 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail">
        <link:definition>2463438 - Disclosure - Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.sangamo.com/role/SubsequentEvents">
        <link:definition>2164114 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.sangamo.com/role/SubsequentEventsDetails">
        <link:definition>2465439 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sgmo_NumberOfOptionsToExtendInitialResearchTerm" abstract="false" name="NumberOfOptionsToExtendInitialResearchTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" abstract="false" name="IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" abstract="true" name="RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_DeferredTaxAssetsLeaseLiability" abstract="false" name="DeferredTaxAssetsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" abstract="false" name="MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" abstract="false" name="MinimumSublicenseAnnualFeesSpecificReckoningPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborationArrangementResearchPeriod" abstract="false" name="CollaborationArrangementResearchPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_MilestoneThreeMember" abstract="true" name="MilestoneThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MilestoneRevenueReceivable" abstract="false" name="MilestoneRevenueReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PreApprovalMilestoneMember" abstract="true" name="PreApprovalMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MilestoneOneMember" abstract="true" name="MilestoneOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" abstract="false" name="NoncashOrPartNoncashNonControllingInterestAcquisition" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneAxis" abstract="true" name="CollaborativeAgreementMilestoneAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_NumberOfResearchProgram" abstract="false" name="NumberOfResearchProgram" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_OfficeAndLaboratoryMember" abstract="true" name="OfficeAndLaboratoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_GainOnFreeShares" abstract="false" name="GainOnFreeShares" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" abstract="true" name="CaliforniaInstituteForRegenerativeMedicineAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" abstract="false" name="NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" abstract="false" name="StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementPercentOfInitialRecognition" abstract="false" name="CollaborativeAgreementPercentOfInitialRecognition" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" abstract="false" name="CollaborativeArrangementMaximumMilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SangamoFranceMember" abstract="true" name="SangamoFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PfizerC9ORF72Member" abstract="true" name="PfizerC9ORF72Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargets" abstract="false" name="CollaborativeArrangementNumberOfProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementReimbursableServiceCosts" abstract="false" name="CollaborativeArrangementReimbursableServiceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AnnualFeesRelatedToAgreement" abstract="false" name="AnnualFeesRelatedToAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfSharesAcquired" abstract="false" name="BusinessAcquisitionNumberOfSharesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_FormerExecutiveOfSangamoFranceMember" abstract="true" name="FormerExecutiveOfSangamoFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" abstract="false" name="CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" abstract="false" name="CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecurities" abstract="false" name="CashEquivalentsAndAvailableForSaleSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PurchasePlanOfferingPeriod" abstract="false" name="PurchasePlanOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" abstract="false" name="CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" abstract="false" name="EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NetProceedsFromIssuancePublicOffering" abstract="false" name="NetProceedsFromIssuancePublicOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" abstract="false" name="CollaborationAgreementNumberOfAdditionalProductTargets" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" abstract="false" name="ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgmo_Restated2018StockIncentivePlanMember" abstract="true" name="Restated2018StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SeparateUpfrontFee" abstract="false" name="SeparateUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" abstract="false" name="CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" abstract="false" name="IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAgreementTargetSelectionPeriod" abstract="false" name="CollaborationAgreementTargetSelectionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_ChangeInCollaborationAgreementScopeMember" abstract="true" name="ChangeInCollaborationAgreementScopeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" abstract="false" name="CollaborativeArrangementNumberOfProductTargetsSelected" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementMember" abstract="true" name="CollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" abstract="false" name="CustomerContractLiabilityMilestonePaymentEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesMilestonesMember" abstract="true" name="AchievementOfSpecifiedSalesMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PfizerGiroctocogeneFitelparvovecMember" abstract="true" name="PfizerGiroctocogeneFitelparvovecMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_KitePharmaIncMember" abstract="true" name="KitePharmaIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" abstract="false" name="CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ManufacturingEquipmentMember" abstract="true" name="ManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" abstract="false" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_SigmaAldrichCorporationMember" abstract="true" name="SigmaAldrichCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BiogenMAIncMember" abstract="true" name="BiogenMAIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" abstract="false" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementResearchServiceFees" abstract="false" name="CollaborativeArrangementResearchServiceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AchievementOfFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BrisbaneCaliforniaMember" abstract="true" name="BrisbaneCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" abstract="true" name="AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PurchasePlanPurchasePeriod" abstract="false" name="PurchasePlanPurchasePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" abstract="false" name="SaleOfStockExcessConsiderationReceivedOnTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborationAgreementEquityIssued" abstract="false" name="CollaborationAgreementEquityIssued" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ExtendedResearchTermOfAgreement" abstract="false" name="ExtendedResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_FeeDue" abstract="false" name="FeeDue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ReducedRoyaltyRate" abstract="false" name="ReducedRoyaltyRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_ValbonneFranceMember" abstract="true" name="ValbonneFranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CommonStockExchangeRatio" abstract="false" name="CommonStockExchangeRatio" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_TwoThousandEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_CNineORFSevenTwoMember" abstract="true" name="CNineORFSevenTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_JefferiesLLCMember" abstract="true" name="JefferiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" abstract="false" name="BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_DowAgroSciencesMember" abstract="true" name="DowAgroSciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AchievementOfCommercialMilestonesMember" abstract="true" name="AchievementOfCommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PfizerMember" abstract="true" name="PfizerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AccruedResearchAndDevelopmentExpenses" abstract="false" name="AccruedResearchAndDevelopmentExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_FreeSharesAssetMember" abstract="true" name="FreeSharesAssetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BuildToSuitLeases" abstract="false" name="BuildToSuitLeases" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_NovartisInstitutesForBioMedicalResearchIncMember" abstract="true" name="NovartisInstitutesForBioMedicalResearchIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeAgreementMilestoneDomain" abstract="true" name="CollaborativeAgreementMilestoneDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_FreeSharesLiabilityMember" abstract="true" name="FreeSharesLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_AmortizationAndOtherChangesInRightOfUseAssets" abstract="false" name="AmortizationAndOtherChangesInRightOfUseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_AtTheMarketOfferingAgreementMember" abstract="true" name="AtTheMarketOfferingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_ShireAgMember" abstract="true" name="ShireAgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" abstract="false" name="BusinessAcquisitionNumberOfFreeSharesHeldByHolders" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_GiroctocogeneFitelparvovecMember" abstract="true" name="GiroctocogeneFitelparvovecMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_ResearchAndOfficeSpaceMember" abstract="true" name="ResearchAndOfficeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" abstract="false" name="CollaborativeArrangementVotingProvisionsExpirationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_OneTimeLicenseFeeEarned" abstract="false" name="OneTimeLicenseFeeEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_AtTheMarketStockOfferingMember" abstract="true" name="AtTheMarketStockOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" abstract="false" name="IncreaseInFairValueOfFreeSharesAssetAndLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" abstract="false" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" abstract="false" name="CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ResearchServicesMember" abstract="true" name="ResearchServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_RichmondCaliforniaMember" abstract="true" name="RichmondCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_InitialResearchTermOfAgreement" abstract="false" name="InitialResearchTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_ResearchServicesPeriod" abstract="false" name="ResearchServicesPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_AgreementTerminationTerm" abstract="false" name="AgreementTerminationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" abstract="true" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_AmendedCollaborationAndLicenseAgreementMember" abstract="true" name="AmendedCollaborationAndLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MilestoneTwoMember" abstract="true" name="MilestoneTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_StockOfferingProgramMaximumValue" abstract="false" name="StockOfferingProgramMaximumValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementLicenseFee" abstract="false" name="CollaborativeArrangementLicenseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" abstract="false" name="BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" abstract="false" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" abstract="false" name="ScheduleOfNoncontrollingInterestTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="sgmo_BuildToSuitLeaseMember" abstract="true" name="BuildToSuitLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_IntangibleAssetsExcludingGoodwillRollForward" abstract="true" name="IntangibleAssetsExcludingGoodwillRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" abstract="false" name="CollaborativeArrangementIncreaseDecreaseInRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementNetIncomeLossPerShare" abstract="false" name="CollaborativeArrangementNetIncomeLossPerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" abstract="false" name="PercentageOfRoyaltiesToBeReceivedFromSublicensing" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" abstract="true" name="SharePurchaseAgreementAndTenderOfferAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_GrantFundingAmount" abstract="false" name="GrantFundingAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_PropertyAndEquipmentMember" abstract="true" name="PropertyAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_LicenseObligations" abstract="false" name="LicenseObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementStandstillRestrictionPeriod" abstract="false" name="CollaborativeArrangementStandstillRestrictionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" abstract="false" name="CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" abstract="true" name="AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" abstract="false" name="BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" abstract="false" name="LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:areaItemType"/>
  <xs:element id="sgmo_SpecifiedStockholderOwnershipPercentage" abstract="false" name="SpecifiedStockholderOwnershipPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" abstract="false" name="EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_OtherThanTemporarilyImpairedInvestment" abstract="false" name="OtherThanTemporarilyImpairedInvestment" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" abstract="false" name="CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="sgmo_PfizerSB525Member" abstract="true" name="PfizerSB525Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MeasurementInputStockPriceCorrelationMember" abstract="true" name="MeasurementInputStockPriceCorrelationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_SanofiMember" abstract="true" name="SanofiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MilestonePaymentsReceived" abstract="false" name="MilestonePaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_SalesBasedMilestoneMember" abstract="true" name="SalesBasedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_LonzaNetherlandsBVMember" abstract="true" name="LonzaNetherlandsBVMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_PhaseThreeClinicalTrialMember" abstract="true" name="PhaseThreeClinicalTrialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_BrammerBioMAMember" abstract="true" name="BrammerBioMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_MilestoneAchievementMember" abstract="true" name="MilestoneAchievementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="sgmo_CollaborativeArrangementTransactionPrice" abstract="false" name="CollaborativeArrangementTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" abstract="false" name="ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>sgmo-20201231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a450ce61-5a63-468d-aea1-980040e585ad,g:3eb33991-981d-4627-a625-d6dd25ee8674-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20201231.xsd#Cover"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_9366bbe7-7022-4216-b1ba-c80c2154ed9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b829a6b0-2a01-4ef1-8167-96c3412e308d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9366bbe7-7022-4216-b1ba-c80c2154ed9a" xlink:to="loc_us-gaap_Liabilities_b829a6b0-2a01-4ef1-8167-96c3412e308d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_f36b56a5-047e-4317-a570-b0329b7c26f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9366bbe7-7022-4216-b1ba-c80c2154ed9a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_f36b56a5-047e-4317-a570-b0329b7c26f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b4249eb1-f8c9-4cc5-ae1a-c89ca69afee2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_9366bbe7-7022-4216-b1ba-c80c2154ed9a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b4249eb1-f8c9-4cc5-ae1a-c89ca69afee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_50dd5810-0fae-4d95-8e29-5c47b8736c8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_29fb88b5-fd07-4a94-96d1-6a49ede4c7e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50dd5810-0fae-4d95-8e29-5c47b8736c8b" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_29fb88b5-fd07-4a94-96d1-6a49ede4c7e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_34c45d72-8186-4ba1-a28a-742816040149" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50dd5810-0fae-4d95-8e29-5c47b8736c8b" xlink:to="loc_us-gaap_CommonStockValue_34c45d72-8186-4ba1-a28a-742816040149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_205b770c-323e-4456-8969-5bdc3b60951e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50dd5810-0fae-4d95-8e29-5c47b8736c8b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_205b770c-323e-4456-8969-5bdc3b60951e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9fc7b59e-ce8f-4cd2-8579-09fe87303a4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50dd5810-0fae-4d95-8e29-5c47b8736c8b" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9fc7b59e-ce8f-4cd2-8579-09fe87303a4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_adb02bd1-4280-47fc-9a6f-06fa7ac0b663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_50dd5810-0fae-4d95-8e29-5c47b8736c8b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_adb02bd1-4280-47fc-9a6f-06fa7ac0b663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_10fa19f6-6495-4ea1-b89f-27c0f10f6ec0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_744ea6fb-d447-4772-827a-761086156365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10fa19f6-6495-4ea1-b89f-27c0f10f6ec0" xlink:to="loc_us-gaap_LiabilitiesCurrent_744ea6fb-d447-4772-827a-761086156365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd57f253-2de3-4a4c-9f8a-242cb736a23d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10fa19f6-6495-4ea1-b89f-27c0f10f6ec0" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_fd57f253-2de3-4a4c-9f8a-242cb736a23d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5ecc7b3-dbe0-4616-b980-a143e4d0117b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10fa19f6-6495-4ea1-b89f-27c0f10f6ec0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c5ecc7b3-dbe0-4616-b980-a143e4d0117b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_61607b81-3091-44e0-8dab-2c395ea34029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10fa19f6-6495-4ea1-b89f-27c0f10f6ec0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_61607b81-3091-44e0-8dab-2c395ea34029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_0e25b0ed-5445-49e3-9e36-020f000074b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_10fa19f6-6495-4ea1-b89f-27c0f10f6ec0" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_0e25b0ed-5445-49e3-9e36-020f000074b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e1960773-cbe5-462c-9dc9-747e2da05439" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eabb87a2-08ba-44fa-bd3b-79adf689025a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1960773-cbe5-462c-9dc9-747e2da05439" xlink:to="loc_us-gaap_AccountsPayableCurrent_eabb87a2-08ba-44fa-bd3b-79adf689025a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_1f782a44-3391-4ce3-ad34-15ef95c16e28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1960773-cbe5-462c-9dc9-747e2da05439" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_1f782a44-3391-4ce3-ad34-15ef95c16e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_adf1b9cf-2355-4d28-9e42-9f58375d056c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1960773-cbe5-462c-9dc9-747e2da05439" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_adf1b9cf-2355-4d28-9e42-9f58375d056c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bb50e6c7-036b-4cb0-9b92-6b3e807d7621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_e1960773-cbe5-462c-9dc9-747e2da05439" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bb50e6c7-036b-4cb0-9b92-6b3e807d7621" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_004c02a9-7c59-48de-b07d-368b18327a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5ed501a1-b147-4c91-97fd-c18a8a31f7a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_004c02a9-7c59-48de-b07d-368b18327a1f" xlink:to="loc_us-gaap_StockholdersEquity_5ed501a1-b147-4c91-97fd-c18a8a31f7a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f9dc3321-a3bd-451a-b3d0-aaa162db1f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_004c02a9-7c59-48de-b07d-368b18327a1f" xlink:to="loc_us-gaap_MinorityInterest_f9dc3321-a3bd-451a-b3d0-aaa162db1f95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_5bd12c2a-c5f9-4f83-b1c4-9c75c052ebb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_327656f2-dcf9-41f3-b540-e60c5ea598d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bd12c2a-c5f9-4f83-b1c4-9c75c052ebb1" xlink:to="loc_us-gaap_AssetsCurrent_327656f2-dcf9-41f3-b540-e60c5ea598d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_508f3419-73b7-436a-aeed-aaa828c7e9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bd12c2a-c5f9-4f83-b1c4-9c75c052ebb1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_508f3419-73b7-436a-aeed-aaa828c7e9fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e6a8c48b-b272-4430-ac1c-464ba3c8b7ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bd12c2a-c5f9-4f83-b1c4-9c75c052ebb1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e6a8c48b-b272-4430-ac1c-464ba3c8b7ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cc2d9099-a65b-4c22-a3b0-d4f2fea64c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bd12c2a-c5f9-4f83-b1c4-9c75c052ebb1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cc2d9099-a65b-4c22-a3b0-d4f2fea64c3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_02d22754-c250-4991-a0d1-3419c48eb7bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bd12c2a-c5f9-4f83-b1c4-9c75c052ebb1" xlink:to="loc_us-gaap_Goodwill_02d22754-c250-4991-a0d1-3419c48eb7bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f60d050a-c53d-4599-aeca-361eb978efa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bd12c2a-c5f9-4f83-b1c4-9c75c052ebb1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f60d050a-c53d-4599-aeca-361eb978efa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_90751d0c-b526-4f56-a8ab-b6be6c1892c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bd12c2a-c5f9-4f83-b1c4-9c75c052ebb1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_90751d0c-b526-4f56-a8ab-b6be6c1892c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d7a1ee7d-cbfe-4868-95c7-3837f31f5b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_5bd12c2a-c5f9-4f83-b1c4-9c75c052ebb1" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d7a1ee7d-cbfe-4868-95c7-3837f31f5b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e9f00418-5fa5-4124-a3cc-858d14f67608" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e20f1d9d-a85e-435d-8f92-b299bc25c89f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9f00418-5fa5-4124-a3cc-858d14f67608" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e20f1d9d-a85e-435d-8f92-b299bc25c89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_df856bd7-20f1-4898-ac5f-ca25bb6cf281" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9f00418-5fa5-4124-a3cc-858d14f67608" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_df856bd7-20f1-4898-ac5f-ca25bb6cf281" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_9044f1e9-42c3-4c57-8244-4a9dfcba2239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9f00418-5fa5-4124-a3cc-858d14f67608" xlink:to="loc_us-gaap_InterestReceivableCurrent_9044f1e9-42c3-4c57-8244-4a9dfcba2239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a5f5b8a9-b2e1-4484-813e-4247f5a0368c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9f00418-5fa5-4124-a3cc-858d14f67608" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a5f5b8a9-b2e1-4484-813e-4247f5a0368c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6bbf55f9-8d19-4444-b453-8772632fe920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_e9f00418-5fa5-4124-a3cc-858d14f67608" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6bbf55f9-8d19-4444-b453-8772632fe920" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3c0c6a48-dfcb-4e4d-9f34-85a939b57ca1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6fe59a64-770b-4584-95dd-4abf9a2d299b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3c0c6a48-dfcb-4e4d-9f34-85a939b57ca1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6fe59a64-770b-4584-95dd-4abf9a2d299b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_58a4be10-3ea0-4d7b-89c3-4e718b765cd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3c0c6a48-dfcb-4e4d-9f34-85a939b57ca1" xlink:to="loc_us-gaap_OperatingExpenses_58a4be10-3ea0-4d7b-89c3-4e718b765cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6e5b4a23-0f7a-4d1d-b439-7be8f740769c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9378c767-9864-4600-8db2-4bb13af3f619" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6e5b4a23-0f7a-4d1d-b439-7be8f740769c" xlink:to="loc_us-gaap_OperatingIncomeLoss_9378c767-9864-4600-8db2-4bb13af3f619" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_92edf407-fb5d-40d3-bca4-93365e635066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6e5b4a23-0f7a-4d1d-b439-7be8f740769c" xlink:to="loc_us-gaap_InterestAndOtherIncome_92edf407-fb5d-40d3-bca4-93365e635066" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0ea1e6b1-aaae-4a36-9c73-a27372a6fd81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6c9c77d3-c4a3-4155-bf2a-545698a457c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0ea1e6b1-aaae-4a36-9c73-a27372a6fd81" xlink:to="loc_us-gaap_ProfitLoss_6c9c77d3-c4a3-4155-bf2a-545698a457c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8a94d666-ad24-4fe8-aaeb-dceb7fbe7a81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_0ea1e6b1-aaae-4a36-9c73-a27372a6fd81" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_8a94d666-ad24-4fe8-aaeb-dceb7fbe7a81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_b285440c-c9c7-430c-aae5-6234abccf05e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2bbea151-f988-4a32-a209-7d0104a26611" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b285440c-c9c7-430c-aae5-6234abccf05e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2bbea151-f988-4a32-a209-7d0104a26611" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_997bcc53-0ba2-4e6f-9131-7bee0b9a33f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_b285440c-c9c7-430c-aae5-6234abccf05e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_997bcc53-0ba2-4e6f-9131-7bee0b9a33f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5c950bef-39da-4354-b94f-9a1bb6951d0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_711dead5-da8b-4708-beb7-2d5a77ca2e25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5c950bef-39da-4354-b94f-9a1bb6951d0b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_711dead5-da8b-4708-beb7-2d5a77ca2e25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_3a814532-f03a-4daa-8961-11d10a1ee0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_5c950bef-39da-4354-b94f-9a1bb6951d0b" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_3a814532-f03a-4daa-8961-11d10a1ee0de" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bd86cd60-3be3-4453-91bb-07294fe45e15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_de981b61-747b-49b3-b5bf-dd9e3b5969ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bd86cd60-3be3-4453-91bb-07294fe45e15" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_de981b61-747b-49b3-b5bf-dd9e3b5969ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6ce8b26f-3d67-41ef-9fb0-b0a0e76f2fb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bd86cd60-3be3-4453-91bb-07294fe45e15" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_6ce8b26f-3d67-41ef-9fb0-b0a0e76f2fb7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_007e2f18-85aa-4a26-877e-af819d166c1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1df4cdfd-6567-4793-9568-8bb4aba845ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_007e2f18-85aa-4a26-877e-af819d166c1d" xlink:to="loc_us-gaap_ProfitLoss_1df4cdfd-6567-4793-9568-8bb4aba845ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_43494189-676d-4a04-ba62-75ebb178e352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_007e2f18-85aa-4a26-877e-af819d166c1d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_43494189-676d-4a04-ba62-75ebb178e352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1b84b86f-3ebe-4945-b393-78eb5534d731" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_007e2f18-85aa-4a26-877e-af819d166c1d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1b84b86f-3ebe-4945-b393-78eb5534d731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3bae756b-b25d-410e-beac-e05059b854f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_007e2f18-85aa-4a26-877e-af819d166c1d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3bae756b-b25d-410e-beac-e05059b854f6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_848cb4d4-e5a0-43f9-9bce-3d5411edbd2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_befd4f2b-2722-4fa0-912d-727ed6b98115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_848cb4d4-e5a0-43f9-9bce-3d5411edbd2a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_befd4f2b-2722-4fa0-912d-727ed6b98115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44fc5b1b-480d-4e08-8c51-43e09603eea7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_848cb4d4-e5a0-43f9-9bce-3d5411edbd2a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_44fc5b1b-480d-4e08-8c51-43e09603eea7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9acdbeed-8532-4df3-a4bb-48833e388551" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_848cb4d4-e5a0-43f9-9bce-3d5411edbd2a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9acdbeed-8532-4df3-a4bb-48833e388551" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1f74af4-3981-4e6e-80f4-ea17a7f6b620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_848cb4d4-e5a0-43f9-9bce-3d5411edbd2a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a1f74af4-3981-4e6e-80f4-ea17a7f6b620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2006adc-85ef-4c57-a2dc-cb911c0e36d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9b055d77-69b8-43d8-aa4a-7dcc9d67f14e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2006adc-85ef-4c57-a2dc-cb911c0e36d7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9b055d77-69b8-43d8-aa4a-7dcc9d67f14e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_043bf7b0-b2be-4e97-969e-174bdda59cae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2006adc-85ef-4c57-a2dc-cb911c0e36d7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_043bf7b0-b2be-4e97-969e-174bdda59cae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d64ba548-b4a7-40aa-a2c7-620dbf089a05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2006adc-85ef-4c57-a2dc-cb911c0e36d7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_d64ba548-b4a7-40aa-a2c7-620dbf089a05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b1828e81-6bfd-4ed6-828d-e7bcbb96cbb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2006adc-85ef-4c57-a2dc-cb911c0e36d7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b1828e81-6bfd-4ed6-828d-e7bcbb96cbb2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_da5b6d9a-fa51-4cc8-b224-8386727b4761" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b2006adc-85ef-4c57-a2dc-cb911c0e36d7" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_da5b6d9a-fa51-4cc8-b224-8386727b4761" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dccf344a-e771-4510-81ad-cc4056db5604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_8f9f6ad8-f93e-46db-b6f7-3c2efb41aa18" xlink:href="sgmo-20201231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dccf344a-e771-4510-81ad-cc4056db5604" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_8f9f6ad8-f93e-46db-b6f7-3c2efb41aa18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_cd02a33d-394f-4d5d-a5fa-e7927c5ca919" xlink:href="sgmo-20201231.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dccf344a-e771-4510-81ad-cc4056db5604" xlink:to="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_cd02a33d-394f-4d5d-a5fa-e7927c5ca919" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_acfc5be7-28f8-462e-8022-aac531a5f884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dccf344a-e771-4510-81ad-cc4056db5604" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_acfc5be7-28f8-462e-8022-aac531a5f884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_06659cb3-a1f7-4bee-93bc-872f2eb59ecb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dccf344a-e771-4510-81ad-cc4056db5604" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_06659cb3-a1f7-4bee-93bc-872f2eb59ecb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bbb8f7b8-724c-46d7-98ed-5bf0df5c705c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_dccf344a-e771-4510-81ad-cc4056db5604" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_bbb8f7b8-724c-46d7-98ed-5bf0df5c705c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_266552fa-af55-45ff-9186-7c2f86340acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_ProfitLoss_266552fa-af55-45ff-9186-7c2f86340acd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_7a386f1d-19f2-469f-8b05-3022eedca97e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_7a386f1d-19f2-469f-8b05-3022eedca97e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2eb8f35f-927f-4486-bf4e-9c191fa81fc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2eb8f35f-927f-4486-bf4e-9c191fa81fc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_ac40a23e-c37b-4b88-b41a-9e29e7e37058" xlink:href="sgmo-20201231.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_ac40a23e-c37b-4b88-b41a-9e29e7e37058" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainOnFreeShares_f441840b-f34b-4ddc-874b-d9640d486770" xlink:href="sgmo-20201231.xsd#sgmo_GainOnFreeShares"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_sgmo_GainOnFreeShares_f441840b-f34b-4ddc-874b-d9640d486770" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1c0e8eb4-06c2-4b04-9839-f8eb411ef00f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1c0e8eb4-06c2-4b04-9839-f8eb411ef00f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_58afd351-4f74-45e1-b7de-98671a0fbad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_ShareBasedCompensation_58afd351-4f74-45e1-b7de-98671a0fbad7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_11f3400a-48b6-4966-a713-0e9801756d43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_11f3400a-48b6-4966-a713-0e9801756d43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeases_5a10318c-3aea-4769-bec7-0c004d2b0a1a" xlink:href="sgmo-20201231.xsd#sgmo_BuildToSuitLeases"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_sgmo_BuildToSuitLeases_5a10318c-3aea-4769-bec7-0c004d2b0a1a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_317068a0-26d1-44da-8f1c-a38467d2c8a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_317068a0-26d1-44da-8f1c-a38467d2c8a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e496eca7-78ee-4fdb-a458-6c621059b8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_e496eca7-78ee-4fdb-a458-6c621059b8d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08d1670b-97bb-40a9-b3ce-c9a418f36dba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_08d1670b-97bb-40a9-b3ce-c9a418f36dba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ac661b2-68c8-48a5-bd0b-92dd90ed206e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7ac661b2-68c8-48a5-bd0b-92dd90ed206e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_b2304001-40ea-4719-b043-d41147c3f941" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_b2304001-40ea-4719-b043-d41147c3f941" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_76c462ef-0a42-466e-b0b2-767f0fb4ad14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_76c462ef-0a42-466e-b0b2-767f0fb4ad14" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_50372d25-fae3-499a-808a-d9f84a11ff2a" xlink:href="sgmo-20201231.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_50372d25-fae3-499a-808a-d9f84a11ff2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3ed0442a-a50e-4237-a74c-d7d20372727f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_65d6b94e-bade-46b8-8693-0b0572f80c7c" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_3ed0442a-a50e-4237-a74c-d7d20372727f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1693851-79ec-4fad-a8c0-3be347597621" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_b9b83dd7-65a5-47a4-92fb-f136742b467c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1693851-79ec-4fad-a8c0-3be347597621" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_b9b83dd7-65a5-47a4-92fb-f136742b467c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8cac1bd3-d99a-444f-9ae2-bd654296fd35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1693851-79ec-4fad-a8c0-3be347597621" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_8cac1bd3-d99a-444f-9ae2-bd654296fd35" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurement"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_847d650c-46fd-4c36-96d7-44af3cb22a95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_24633da6-84fe-4684-83f9-e7039e1ec849" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_847d650c-46fd-4c36-96d7-44af3cb22a95" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_24633da6-84fe-4684-83f9-e7039e1ec849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eff5ab94-9bec-4f00-a312-007444c5f24a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_847d650c-46fd-4c36-96d7-44af3cb22a95" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_eff5ab94-9bec-4f00-a312-007444c5f24a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecurities"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_70963d09-ccbe-4c74-860e-6480e0b6508b" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_a9c50da6-39eb-4993-9282-f3c0373bf504" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_70963d09-ccbe-4c74-860e-6480e0b6508b" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_a9c50da6-39eb-4993-9282-f3c0373bf504" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_d0f0777a-018f-43b9-abc7-e64dcfde4def" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_70963d09-ccbe-4c74-860e-6480e0b6508b" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_d0f0777a-018f-43b9-abc7-e64dcfde4def" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_49db1993-0219-4dc2-8bd4-c999381b6277" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_70963d09-ccbe-4c74-860e-6480e0b6508b" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_49db1993-0219-4dc2-8bd4-c999381b6277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8681a905-6651-4425-9b51-92a38b5c2f64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_3f41fa29-ff19-409b-b865-a9f5a8b39cda" xlink:href="sgmo-20201231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8681a905-6651-4425-9b51-92a38b5c2f64" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_3f41fa29-ff19-409b-b865-a9f5a8b39cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_c2c498a5-e266-47ad-8478-5658fefca833" xlink:href="sgmo-20201231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8681a905-6651-4425-9b51-92a38b5c2f64" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_c2c498a5-e266-47ad-8478-5658fefca833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_58d638ed-f327-4384-bee7-520725f97bfd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8681a905-6651-4425-9b51-92a38b5c2f64" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_58d638ed-f327-4384-bee7-520725f97bfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cdfd07af-949d-497f-9453-2d149f2e15ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2b152102-b720-463a-9747-dac21e0db766" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cdfd07af-949d-497f-9453-2d149f2e15ae" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_2b152102-b720-463a-9747-dac21e0db766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9adf272d-982b-42ae-b8a3-e9df4b2b00b1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cdfd07af-949d-497f-9453-2d149f2e15ae" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9adf272d-982b-42ae-b8a3-e9df4b2b00b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b8fc453-3df2-4a52-bdb4-e6cf0d433239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cdfd07af-949d-497f-9453-2d149f2e15ae" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5b8fc453-3df2-4a52-bdb4-e6cf0d433239" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7bdbf94-1a7f-4864-90b3-4253b3ca1884" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f945fa15-9b0a-4a4f-a446-d2608cdf5fd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7bdbf94-1a7f-4864-90b3-4253b3ca1884" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_f945fa15-9b0a-4a4f-a446-d2608cdf5fd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3c1fed3b-f31a-4621-bd2f-a40e8aa0af7f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f7bdbf94-1a7f-4864-90b3-4253b3ca1884" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_3c1fed3b-f31a-4621-bd2f-a40e8aa0af7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliances"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofSangamoFrance"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofAcquisitionofSangamoFranceTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofSangamoFranceAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_beea0255-6759-4f1b-a91b-e1eb52c0b7c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_f739daaf-b7c0-4e7d-96d8-668124aeccb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_beea0255-6759-4f1b-a91b-e1eb52c0b7c0" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_f739daaf-b7c0-4e7d-96d8-668124aeccb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AccruedResearchAndDevelopmentExpenses_a1c4f587-468b-4556-947b-a1ae4a149fd0" xlink:href="sgmo-20201231.xsd#sgmo_AccruedResearchAndDevelopmentExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_beea0255-6759-4f1b-a91b-e1eb52c0b7c0" xlink:to="loc_sgmo_AccruedResearchAndDevelopmentExpenses_a1c4f587-468b-4556-947b-a1ae4a149fd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_40855fb9-7583-4d1f-9053-a64332b0a6b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_beea0255-6759-4f1b-a91b-e1eb52c0b7c0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_40855fb9-7583-4d1f-9053-a64332b0a6b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5fe498fe-473e-4378-b457-144d4db7f513" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_beea0255-6759-4f1b-a91b-e1eb52c0b7c0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5fe498fe-473e-4378-b457-144d4db7f513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6656b7df-46b9-490a-a4bb-c1cb82001b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_beea0255-6759-4f1b-a91b-e1eb52c0b7c0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_6656b7df-46b9-490a-a4bb-c1cb82001b8b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_015fd181-167d-42da-8e65-c4a5d5dc6fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8f4340a7-71f1-4781-ae95-5bf8dd67d678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_015fd181-167d-42da-8e65-c4a5d5dc6fe0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_8f4340a7-71f1-4781-ae95-5bf8dd67d678" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fee09734-2a99-4866-823b-5b33185996b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_015fd181-167d-42da-8e65-c4a5d5dc6fe0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fee09734-2a99-4866-823b-5b33185996b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_16110857-0dd7-473f-b0a7-9202ba6e4d16" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_015fd181-167d-42da-8e65-c4a5d5dc6fe0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_16110857-0dd7-473f-b0a7-9202ba6e4d16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_288a08ce-9170-470b-9cf0-a4e512e03472" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_015fd181-167d-42da-8e65-c4a5d5dc6fe0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_288a08ce-9170-470b-9cf0-a4e512e03472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f9d14e3c-3b88-4637-b5f7-0fdfd7625ed0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_015fd181-167d-42da-8e65-c4a5d5dc6fe0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_f9d14e3c-3b88-4637-b5f7-0fdfd7625ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_41532622-506d-4c61-b13a-4a05202416f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_015fd181-167d-42da-8e65-c4a5d5dc6fe0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_41532622-506d-4c61-b13a-4a05202416f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a1b65012-5196-49eb-9e69-f51f43fdaaf2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_baf839a8-f600-4830-91a7-5e810b7bb7c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a1b65012-5196-49eb-9e69-f51f43fdaaf2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_baf839a8-f600-4830-91a7-5e810b7bb7c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8000a15c-a8cc-4925-becd-c70e3a718036" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_a1b65012-5196-49eb-9e69-f51f43fdaaf2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8000a15c-a8cc-4925-becd-c70e3a718036" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1dcfcc9f-1bcb-4b4c-ac4a-f9907352b829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_18dd739a-c8d2-43c6-9f13-bf6cf9671be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1dcfcc9f-1bcb-4b4c-ac4a-f9907352b829" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_18dd739a-c8d2-43c6-9f13-bf6cf9671be3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_ef768bad-429b-48e2-8458-f6f0912ec125" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1dcfcc9f-1bcb-4b4c-ac4a-f9907352b829" xlink:to="loc_us-gaap_OperatingLeaseLiability_ef768bad-429b-48e2-8458-f6f0912ec125" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquity" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquitySummaryofStockOptionActivityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensation"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sgmo-20201231.xsd#EmployeeBenefitPlan"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#EmployeeBenefitPlanAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_72be7aea-6bea-4854-9bb6-6a1c739d22f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_efc8dd03-5d63-42ed-8c46-3cc827130351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_72be7aea-6bea-4854-9bb6-6a1c739d22f2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_efc8dd03-5d63-42ed-8c46-3cc827130351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a5330682-d286-4783-ad89-03e052909904" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_72be7aea-6bea-4854-9bb6-6a1c739d22f2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_a5330682-d286-4783-ad89-03e052909904" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_cfb2d0af-ae64-4469-a7f2-e32d2433687d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b999761c-2ff7-44b3-9e97-43268d5aa61b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_cfb2d0af-ae64-4469-a7f2-e32d2433687d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b999761c-2ff7-44b3-9e97-43268d5aa61b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_375dd4fc-ab68-4f47-ae2d-d8610bec5b9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_cfb2d0af-ae64-4469-a7f2-e32d2433687d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_375dd4fc-ab68-4f47-ae2d-d8610bec5b9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_07cd8fcd-d0dc-423a-ac2a-f260f3188009" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_cfb2d0af-ae64-4469-a7f2-e32d2433687d" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_07cd8fcd-d0dc-423a-ac2a-f260f3188009" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_518b1be7-a083-407a-be05-b3ed18f65a44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1406b8ad-4f23-4d38-875d-b589ae2724d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_518b1be7-a083-407a-be05-b3ed18f65a44" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1406b8ad-4f23-4d38-875d-b589ae2724d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6cab3c92-df21-4bbc-85de-58b821574632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_518b1be7-a083-407a-be05-b3ed18f65a44" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_6cab3c92-df21-4bbc-85de-58b821574632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ebad8ce6-6b9b-41fc-ad53-577467400c23" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_518b1be7-a083-407a-be05-b3ed18f65a44" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ebad8ce6-6b9b-41fc-ad53-577467400c23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_178669d3-025d-4c35-bf4c-7f8403f01ea1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_9be991e1-8677-4c03-8cdd-5129fb686bf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_178669d3-025d-4c35-bf4c-7f8403f01ea1" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_9be991e1-8677-4c03-8cdd-5129fb686bf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_4c45b0a9-8e56-4dfe-8186-58ea17eb78eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_178669d3-025d-4c35-bf4c-7f8403f01ea1" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_4c45b0a9-8e56-4dfe-8186-58ea17eb78eb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_371bab59-f27a-4379-b559-14266e6888b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_93356436-15c5-4047-b3a9-76ff79acc0c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_371bab59-f27a-4379-b559-14266e6888b8" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_93356436-15c5-4047-b3a9-76ff79acc0c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_a1f4530a-10b4-4cc1-a47d-ae33aec8c99c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_371bab59-f27a-4379-b559-14266e6888b8" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_a1f4530a-10b4-4cc1-a47d-ae33aec8c99c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2a400eac-ab9a-4f6c-8946-025f6d8d8930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_371bab59-f27a-4379-b559-14266e6888b8" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_2a400eac-ab9a-4f6c-8946-025f6d8d8930" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount_9699a168-70bb-4b08-a599-0a2f4c10d108" xlink:href="sgmo-20201231.xsd#sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_371bab59-f27a-4379-b559-14266e6888b8" xlink:to="loc_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount_9699a168-70bb-4b08-a599-0a2f4c10d108" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_782b4f90-0ac7-441d-a1a2-b239f4e4be7e" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_371bab59-f27a-4379-b559-14266e6888b8" xlink:to="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_782b4f90-0ac7-441d-a1a2-b239f4e4be7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1099e2d7-5222-4fe7-8c3c-067d9bbe1d46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_371bab59-f27a-4379-b559-14266e6888b8" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_1099e2d7-5222-4fe7-8c3c-067d9bbe1d46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2e3548ff-28db-414a-b9d9-019e8b1f1cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_371bab59-f27a-4379-b559-14266e6888b8" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2e3548ff-28db-414a-b9d9-019e8b1f1cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_eaf30582-ffef-45f5-a664-820259b7ea9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_371bab59-f27a-4379-b559-14266e6888b8" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_eaf30582-ffef-45f5-a664-820259b7ea9f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5f44a392-4d09-470a-b43e-fecd816b114d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_35efc313-5b6b-4faf-af3d-9f7728135618" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5f44a392-4d09-470a-b43e-fecd816b114d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_35efc313-5b6b-4faf-af3d-9f7728135618" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b9b57513-90f7-4a7f-a0e1-1684e4427377" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5f44a392-4d09-470a-b43e-fecd816b114d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_b9b57513-90f7-4a7f-a0e1-1684e4427377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d7195e0e-3882-44dc-899e-5dd1c20ab194" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e21d1a51-4de3-4b4d-a9c4-2b99473bce1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d7195e0e-3882-44dc-899e-5dd1c20ab194" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e21d1a51-4de3-4b4d-a9c4-2b99473bce1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_db10e202-a7c3-4703-923a-0dfef82bbd4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d7195e0e-3882-44dc-899e-5dd1c20ab194" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_db10e202-a7c3-4703-923a-0dfef82bbd4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_e94eb4f0-da0f-4a09-8ff1-80fa92176b03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_469f51d5-fcbc-4069-9b46-0f10f9240542" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_e94eb4f0-da0f-4a09-8ff1-80fa92176b03" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_469f51d5-fcbc-4069-9b46-0f10f9240542" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_f07edc56-f532-4558-81c1-f534bf8a264c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_e94eb4f0-da0f-4a09-8ff1-80fa92176b03" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_f07edc56-f532-4558-81c1-f534bf8a264c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_cad63888-c2d1-446b-84ec-7a9470aef93a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_af683c37-76b5-42df-ac84-d587d9c47dbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cad63888-c2d1-446b-84ec-7a9470aef93a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_af683c37-76b5-42df-ac84-d587d9c47dbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60235815-80e1-4ca3-997c-989351550a15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cad63888-c2d1-446b-84ec-7a9470aef93a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60235815-80e1-4ca3-997c-989351550a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_630a8ae5-5d77-4889-aae7-6c4603e1ea92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cad63888-c2d1-446b-84ec-7a9470aef93a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_630a8ae5-5d77-4889-aae7-6c4603e1ea92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3d95ea11-6e53-4e2a-94df-0fba2d87d699" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cad63888-c2d1-446b-84ec-7a9470aef93a" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_3d95ea11-6e53-4e2a-94df-0fba2d87d699" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_0a2d12b1-2d5d-4462-b6ed-6d755d8c798a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cad63888-c2d1-446b-84ec-7a9470aef93a" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_0a2d12b1-2d5d-4462-b6ed-6d755d8c798a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsLeaseLiability_51dbd03f-1a66-4bb0-adee-f409365398b2" xlink:href="sgmo-20201231.xsd#sgmo_DeferredTaxAssetsLeaseLiability"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cad63888-c2d1-446b-84ec-7a9470aef93a" xlink:to="loc_sgmo_DeferredTaxAssetsLeaseLiability_51dbd03f-1a66-4bb0-adee-f409365398b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_7f6eecea-dbc3-485c-92cb-9f8b027cb1d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cad63888-c2d1-446b-84ec-7a9470aef93a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_7f6eecea-dbc3-485c-92cb-9f8b027cb1d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_d85b01d2-3486-4e36-9cc7-51effe91cd39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_cad63888-c2d1-446b-84ec-7a9470aef93a" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_d85b01d2-3486-4e36-9cc7-51effe91cd39" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="sgmo-20201231.xsd#RelatedPartyDisclosures"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosuresDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#RelatedPartyDisclosuresDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosuresDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="sgmo-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgmo-20201231.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#SubsequentEventsDetails"/>
  <link:calculationLink xlink:role="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>sgmo-20201231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a450ce61-5a63-468d-aea1-980040e585ad,g:3eb33991-981d-4627-a625-d6dd25ee8674-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20201231.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended" id="i3bb0a27870ec4beca486f8df4a0eca92_Cover"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="extended" id="i74d71fef367d42919bd87b5fec17c709_ConsolidatedBalanceSheets"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" id="i5a8f718cd9e645258031593136b404e5_ConsolidatedBalanceSheetsParenthetical"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="extended" id="i295a397cc8d6445ea7f7f65b32fa8c06_ConsolidatedStatementsofOperations"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="ie5ac605e4c0446ddb506cec961f58cf7_ConsolidatedStatementsofComprehensiveLoss"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i8c89e2234e52412791ca45a20c000840_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_426fbddc-fff2-4672-81d7-fe59a6956cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_CommonStockSharesIssued_426fbddc-fff2-4672-81d7-fe59a6956cd5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48816d05-50ca-4bce-8359-e99799c83f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48816d05-50ca-4bce-8359-e99799c83f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d9a2fa6-152b-4844-94a9-b2759d69f104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d9a2fa6-152b-4844-94a9-b2759d69f104" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_03750296-56b9-4e3c-9121-53c7955b4b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_03750296-56b9-4e3c-9121-53c7955b4b34" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e5ae7bbc-ab1e-4748-8624-3111c0aba9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e5ae7bbc-ab1e-4748-8624-3111c0aba9fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6f023b44-bd3f-43f7-9319-231b30cd9910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6f023b44-bd3f-43f7-9319-231b30cd9910" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_123663b9-f61b-486e-8826-4420df193dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_123663b9-f61b-486e-8826-4420df193dda" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6dabf219-c9e3-4899-8341-229b13532d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6dabf219-c9e3-4899-8341-229b13532d71" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f3ed9d6-9325-476a-a7b7-c4517f2c24a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f3ed9d6-9325-476a-a7b7-c4517f2c24a0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_d80868e8-e5e4-4ca8-9acc-afea81dad9fb" xlink:href="sgmo-20201231.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_d80868e8-e5e4-4ca8-9acc-afea81dad9fb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_7d251b16-e10f-440b-a511-20eb8e154fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_7d251b16-e10f-440b-a511-20eb8e154fe7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f9a87c74-473f-4e5e-81fa-3df2e2f0e8b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f9a87c74-473f-4e5e-81fa-3df2e2f0e8b2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_66254cc2-ccc7-406c-8756-dc29a6fc69e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_66254cc2-ccc7-406c-8756-dc29a6fc69e3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_95bf7957-827b-4902-8efe-f1f4e1c74e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_95bf7957-827b-4902-8efe-f1f4e1c74e41" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5bb16597-f3e6-4fe3-a5d2-cf774ef2b174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5bb16597-f3e6-4fe3-a5d2-cf774ef2b174" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_238b7354-d7aa-49e6-8687-f0bd81180aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_ProfitLoss_238b7354-d7aa-49e6-8687-f0bd81180aab" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4b4d224f-7cae-4de0-872c-6dd00d20703e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a0f76b3-e411-49df-96b0-a62c33da379c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_2197aac8-8d27-4c38-bb4b-31bb425ed126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_2197aac8-8d27-4c38-bb4b-31bb425ed126" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_13a1e29c-3b10-49c0-9712-a70fa21ebf83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StatementTable_13a1e29c-3b10-49c0-9712-a70fa21ebf83" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_50369298-2cda-449c-93be-bbfbf93d0f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_13a1e29c-3b10-49c0-9712-a70fa21ebf83" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_50369298-2cda-449c-93be-bbfbf93d0f08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_50369298-2cda-449c-93be-bbfbf93d0f08_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_50369298-2cda-449c-93be-bbfbf93d0f08" xlink:to="loc_us-gaap_EquityComponentDomain_50369298-2cda-449c-93be-bbfbf93d0f08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_50369298-2cda-449c-93be-bbfbf93d0f08" xlink:to="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c77908c1-08d2-404d-8b25-c0421a1d577a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_CommonStockMember_c77908c1-08d2-404d-8b25-c0421a1d577a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_edaaec2f-3f35-41ed-b010-5d585d0cd782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_edaaec2f-3f35-41ed-b010-5d585d0cd782" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bb3feebf-f2d9-42c6-93cb-faf08b178f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_RetainedEarningsMember_bb3feebf-f2d9-42c6-93cb-faf08b178f7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a396e630-d415-4e79-a9fd-75114f32bbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a396e630-d415-4e79-a9fd-75114f32bbce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_07827300-ef50-4b1f-9a88-7ef2e70c6813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_07827300-ef50-4b1f-9a88-7ef2e70c6813" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fa9874c4-bed0-4813-af54-511550d420d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_13a1e29c-3b10-49c0-9712-a70fa21ebf83" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fa9874c4-bed0-4813-af54-511550d420d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fa9874c4-bed0-4813-af54-511550d420d8_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fa9874c4-bed0-4813-af54-511550d420d8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_fa9874c4-bed0-4813-af54-511550d420d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e339aa0e-d6de-48ef-b583-f0c1027d11e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fa9874c4-bed0-4813-af54-511550d420d8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e339aa0e-d6de-48ef-b583-f0c1027d11e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_104a328c-87e5-4979-a882-f8c7d185a3bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e339aa0e-d6de-48ef-b583-f0c1027d11e0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_104a328c-87e5-4979-a882-f8c7d185a3bb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended" id="i9951afe236b94c55af7bc2a01148b28f_ConsolidatedStatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_40ac7c7f-d2ee-4da2-a1e2-eb4c9892030f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:to="loc_us-gaap_ProfitLoss_40ac7c7f-d2ee-4da2-a1e2-eb4c9892030f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_51e00365-5c8d-4bfc-a624-acfc53aac7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_51e00365-5c8d-4bfc-a624-acfc53aac7d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9614069b-8f5a-4be5-b72e-c0246fc5167f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9614069b-8f5a-4be5-b72e-c0246fc5167f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_82f89860-b270-45fc-8e19-66d30c8128a9" xlink:href="sgmo-20201231.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_82f89860-b270-45fc-8e19-66d30c8128a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainOnFreeShares_0545270e-7811-48be-91df-21ae4b9c9a2d" xlink:href="sgmo-20201231.xsd#sgmo_GainOnFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_sgmo_GainOnFreeShares_0545270e-7811-48be-91df-21ae4b9c9a2d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3e09199d-038c-485c-ac96-350a120b0b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3e09199d-038c-485c-ac96-350a120b0b1a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_51cef562-311f-4646-98fa-d937781df361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_ShareBasedCompensation_51cef562-311f-4646-98fa-d937781df361" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_a6816eb3-3f64-471d-90ea-91469d8926d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_a6816eb3-3f64-471d-90ea-91469d8926d8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeases_f3625960-4fe3-4bf6-a40e-dffb5ca58ee4" xlink:href="sgmo-20201231.xsd#sgmo_BuildToSuitLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_sgmo_BuildToSuitLeases_f3625960-4fe3-4bf6-a40e-dffb5ca58ee4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_710028c7-4d51-483c-89e2-6c0d4441ec82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_710028c7-4d51-483c-89e2-6c0d4441ec82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_33a3b35e-7b63-4bf9-81ce-6bd44988fd61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_33a3b35e-7b63-4bf9-81ce-6bd44988fd61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_93502b4a-165f-4ddc-88f8-8c1452a6e940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_93502b4a-165f-4ddc-88f8-8c1452a6e940" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f18c5bf8-5e07-4815-b56f-1db1824c6ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f18c5bf8-5e07-4815-b56f-1db1824c6ed3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d0236c0a-7913-4aab-adb7-d0c970eea60d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d0236c0a-7913-4aab-adb7-d0c970eea60d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5dd4c9fb-54f2-4a52-bc59-3efa6481c3bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5dd4c9fb-54f2-4a52-bc59-3efa6481c3bd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_720ec6d1-c700-4520-a487-c73cc2980740" xlink:href="sgmo-20201231.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_720ec6d1-c700-4520-a487-c73cc2980740" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_30e0c1be-e3fb-4210-a0a5-248447714652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_30e0c1be-e3fb-4210-a0a5-248447714652" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_081dca51-c457-41db-97bf-e724d0061c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_081dca51-c457-41db-97bf-e724d0061c1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_32552566-9b95-47d4-bcda-bdde3eb73b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_32552566-9b95-47d4-bcda-bdde3eb73b5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fca92a94-d43d-4f7a-af3a-70dd7a580c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fca92a94-d43d-4f7a-af3a-70dd7a580c7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_51172077-4e30-495c-9d6f-36609e7321c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_51172077-4e30-495c-9d6f-36609e7321c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aae0efa0-105d-4553-b7c0-46cc50810bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aae0efa0-105d-4553-b7c0-46cc50810bdd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_92dd5e5e-35e4-48b0-8297-74a15500363d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_92dd5e5e-35e4-48b0-8297-74a15500363d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_611bd281-7f54-4e64-a20c-4787590846e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_611bd281-7f54-4e64-a20c-4787590846e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_05ad7e75-c295-4ace-af31-856da3dbe540" xlink:href="sgmo-20201231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_05ad7e75-c295-4ace-af31-856da3dbe540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_7169bbc6-0987-4840-a2ea-a31e06fde3f3" xlink:href="sgmo-20201231.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_7169bbc6-0987-4840-a2ea-a31e06fde3f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_778d7435-cbbd-4a90-b064-5aed2164e03c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_778d7435-cbbd-4a90-b064-5aed2164e03c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3a9a0881-94e8-4025-ba9b-02b26dba0ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3a9a0881-94e8-4025-ba9b-02b26dba0ef4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ade1ae6e-a4fc-4db3-88ff-b3f4f53d8383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ade1ae6e-a4fc-4db3-88ff-b3f4f53d8383" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80aef257-008e-43bb-9463-8ff7ec718a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80aef257-008e-43bb-9463-8ff7ec718a85" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_11881325-e594-4799-8b93-a76034ad5da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_11881325-e594-4799-8b93-a76034ad5da4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cbb4742b-67ef-4aca-9bb7-79710c8c94d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cbb4742b-67ef-4aca-9bb7-79710c8c94d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab0627b5-beb2-40f0-8266-fdbec979f57c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab0627b5-beb2-40f0-8266-fdbec979f57c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69306518-88c3-473c-b6a1-5bdde90bdeec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_b4f1ac98-3660-4f05-806f-878825845a9b" xlink:href="sgmo-20201231.xsd#sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:to="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_b4f1ac98-3660-4f05-806f-878825845a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_79f98bf9-352d-45ca-9a02-ca4a6140b850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_79f98bf9-352d-45ca-9a02-ca4a6140b850" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9bb18621-6478-4a19-9bff-43889b1c5486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9bb18621-6478-4a19-9bff-43889b1c5486" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1c859c34-97fb-424b-b797-15c9a1f882f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_StatementTable_1c859c34-97fb-424b-b797-15c9a1f882f4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_c220cba1-6d5c-4942-a230-508c039c9d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1c859c34-97fb-424b-b797-15c9a1f882f4" xlink:to="loc_us-gaap_LeaseContractualTermAxis_c220cba1-6d5c-4942-a230-508c039c9d19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_c220cba1-6d5c-4942-a230-508c039c9d19_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_c220cba1-6d5c-4942-a230-508c039c9d19" xlink:to="loc_us-gaap_LeaseContractualTermDomain_c220cba1-6d5c-4942-a230-508c039c9d19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_a428a85d-a0b8-458c-a125-ac7a6a65fce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_c220cba1-6d5c-4942-a230-508c039c9d19" xlink:to="loc_us-gaap_LeaseContractualTermDomain_a428a85d-a0b8-458c-a125-ac7a6a65fce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseMember_e7ecdd78-43c2-48a2-bb60-43465d928987" xlink:href="sgmo-20201231.xsd#sgmo_BuildToSuitLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_a428a85d-a0b8-458c-a125-ac7a6a65fce0" xlink:to="loc_sgmo_BuildToSuitLeaseMember_e7ecdd78-43c2-48a2-bb60-43465d928987" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33ece32d-eb03-45c1-ad36-7b2f4f7fb77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1c859c34-97fb-424b-b797-15c9a1f882f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33ece32d-eb03-45c1-ad36-7b2f4f7fb77a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33ece32d-eb03-45c1-ad36-7b2f4f7fb77a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33ece32d-eb03-45c1-ad36-7b2f4f7fb77a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33ece32d-eb03-45c1-ad36-7b2f4f7fb77a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19a1203c-757e-4ca3-9497-66e38d7c0661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33ece32d-eb03-45c1-ad36-7b2f4f7fb77a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19a1203c-757e-4ca3-9497-66e38d7c0661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertyAndEquipmentMember_17d9f535-759c-4788-a096-73260277aefe" xlink:href="sgmo-20201231.xsd#sgmo_PropertyAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19a1203c-757e-4ca3-9497-66e38d7c0661" xlink:to="loc_sgmo_PropertyAndEquipmentMember_17d9f535-759c-4788-a096-73260277aefe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i9f24cbcdee2541e0841f1bdba2a2d205_OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ic13463e831094e2c95b1c8323ce25eaf_OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i8137bcab10b547f885c97d3f5515bcd8_OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended" id="ib0b828c851fd43919d07428365d7ecde_OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:href="sgmo-20201231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7513c922-71b7-4cf4-beb3-0fe4b0313b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7513c922-71b7-4cf4-beb3-0fe4b0313b46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_331b3a3c-192d-4e2d-b2f7-d74bc3bb0f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_ProfitLoss_331b3a3c-192d-4e2d-b2f7-d74bc3bb0f6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_50812cb8-d449-4559-a284-202bce9a7ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_EarningsPerShareBasic_50812cb8-d449-4559-a284-202bce9a7ff7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_8d64faa7-f3d8-4034-9564-b29f645a3b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_8d64faa7-f3d8-4034-9564-b29f645a3b46" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_df9e07ec-ff9f-4818-bd6a-d201f5e1e887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_df9e07ec-ff9f-4818-bd6a-d201f5e1e887" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_31063433-5562-4497-9275-b6bd3e6dcbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_31063433-5562-4497-9275-b6bd3e6dcbe3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_86332bbd-757d-46bb-bab8-dc8e1b534a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_86332bbd-757d-46bb-bab8-dc8e1b534a94" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_632b8526-e527-4481-871b-59941d83df74" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_632b8526-e527-4481-871b-59941d83df74" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c715b678-4608-4d83-84e1-b0507c93f44a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c715b678-4608-4d83-84e1-b0507c93f44a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:href="sgmo-20201231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d9e3c23-409b-42fe-864f-e5269e0bf002" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:to="loc_srt_RangeAxis_5d9e3c23-409b-42fe-864f-e5269e0bf002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5d9e3c23-409b-42fe-864f-e5269e0bf002_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5d9e3c23-409b-42fe-864f-e5269e0bf002" xlink:to="loc_srt_RangeMember_5d9e3c23-409b-42fe-864f-e5269e0bf002_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39b8f8cb-4dd5-4428-8e5d-f2053c0a888a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5d9e3c23-409b-42fe-864f-e5269e0bf002" xlink:to="loc_srt_RangeMember_39b8f8cb-4dd5-4428-8e5d-f2053c0a888a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbecbca2-4c20-476d-a200-d1f3fa152d70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39b8f8cb-4dd5-4428-8e5d-f2053c0a888a" xlink:to="loc_srt_MinimumMember_fbecbca2-4c20-476d-a200-d1f3fa152d70" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3211ad63-0da8-4a48-a389-22fdc513d4ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_39b8f8cb-4dd5-4428-8e5d-f2053c0a888a" xlink:to="loc_srt_MaximumMember_3211ad63-0da8-4a48-a389-22fdc513d4ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5f2dc068-68f4-4630-a678-18c8604bf1b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:to="loc_srt_CounterpartyNameAxis_5f2dc068-68f4-4630-a678-18c8604bf1b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f2dc068-68f4-4630-a678-18c8604bf1b1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5f2dc068-68f4-4630-a678-18c8604bf1b1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5f2dc068-68f4-4630-a678-18c8604bf1b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec689e2e-d187-4b95-8408-24500daa91de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5f2dc068-68f4-4630-a678-18c8604bf1b1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec689e2e-d187-4b95-8408-24500daa91de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_07aeb347-0d96-403b-b070-9b62539fbede" xlink:href="sgmo-20201231.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec689e2e-d187-4b95-8408-24500daa91de" xlink:to="loc_sgmo_PfizerSB525Member_07aeb347-0d96-403b-b070-9b62539fbede" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_0460bceb-74ae-4677-869d-676095462577" xlink:href="sgmo-20201231.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec689e2e-d187-4b95-8408-24500daa91de" xlink:to="loc_sgmo_PfizerMember_0460bceb-74ae-4677-869d-676095462577" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f69f2cb7-3c03-4d16-9018-902490081f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f69f2cb7-3c03-4d16-9018-902490081f07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_f69f2cb7-3c03-4d16-9018-902490081f07_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f69f2cb7-3c03-4d16-9018-902490081f07" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_f69f2cb7-3c03-4d16-9018-902490081f07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_7a115781-49a0-470f-b8f2-a7c6819b2223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f69f2cb7-3c03-4d16-9018-902490081f07" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_7a115781-49a0-470f-b8f2-a7c6819b2223" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_a5f5e591-4ab2-4299-bfef-901ba9e72745" xlink:href="sgmo-20201231.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_7a115781-49a0-470f-b8f2-a7c6819b2223" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_a5f5e591-4ab2-4299-bfef-901ba9e72745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bca05c4c-b6b1-4c2a-9bbb-fce398fd46ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bca05c4c-b6b1-4c2a-9bbb-fce398fd46ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca05c4c-b6b1-4c2a-9bbb-fce398fd46ea_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bca05c4c-b6b1-4c2a-9bbb-fce398fd46ea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bca05c4c-b6b1-4c2a-9bbb-fce398fd46ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0aae6dd-4ab1-4196-aa09-5258db3390b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bca05c4c-b6b1-4c2a-9bbb-fce398fd46ea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0aae6dd-4ab1-4196-aa09-5258db3390b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_04ac44f8-b8eb-4057-b495-ebfd10b25dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0aae6dd-4ab1-4196-aa09-5258db3390b4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_04ac44f8-b8eb-4057-b495-ebfd10b25dc5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended" id="i4aa4cbcc61e548f2a2119f1a89a0ac9d_OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_79e0a490-6a05-44b0-9520-d1a579a8a23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5bf4b272-221f-4896-ae10-59804ecb7527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_79e0a490-6a05-44b0-9520-d1a579a8a23f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5bf4b272-221f-4896-ae10-59804ecb7527" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_79e0a490-6a05-44b0-9520-d1a579a8a23f" xlink:to="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a0220cdb-3322-4ffd-a0d3-b8c8d1a6e661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a0220cdb-3322-4ffd-a0d3-b8c8d1a6e661" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a0220cdb-3322-4ffd-a0d3-b8c8d1a6e661_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a0220cdb-3322-4ffd-a0d3-b8c8d1a6e661" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a0220cdb-3322-4ffd-a0d3-b8c8d1a6e661_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cfaeb4-0389-419d-9b72-a52c73d17170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a0220cdb-3322-4ffd-a0d3-b8c8d1a6e661" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cfaeb4-0389-419d-9b72-a52c73d17170" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_a952530d-4ef8-42a9-bd3f-e53da05755c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cfaeb4-0389-419d-9b72-a52c73d17170" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_a952530d-4ef8-42a9-bd3f-e53da05755c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_76902c41-d03e-4ca8-81d5-e0006f621de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_76902c41-d03e-4ca8-81d5-e0006f621de7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_76902c41-d03e-4ca8-81d5-e0006f621de7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_76902c41-d03e-4ca8-81d5-e0006f621de7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_76902c41-d03e-4ca8-81d5-e0006f621de7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3d0d55b0-5112-4eb9-89ed-d0feef28e054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_76902c41-d03e-4ca8-81d5-e0006f621de7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3d0d55b0-5112-4eb9-89ed-d0feef28e054" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_c90e5a4d-7516-4592-89b3-06cabb4137dd" xlink:href="sgmo-20201231.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3d0d55b0-5112-4eb9-89ed-d0feef28e054" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_c90e5a4d-7516-4592-89b3-06cabb4137dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bd885c84-8e70-4a65-818a-fca45c9eea4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:to="loc_srt_CounterpartyNameAxis_bd885c84-8e70-4a65-818a-fca45c9eea4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd885c84-8e70-4a65-818a-fca45c9eea4d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bd885c84-8e70-4a65-818a-fca45c9eea4d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd885c84-8e70-4a65-818a-fca45c9eea4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bd885c84-8e70-4a65-818a-fca45c9eea4d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_fb1f4804-961a-4561-b19c-7a7aa2f290a2" xlink:href="sgmo-20201231.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_PfizerMember_fb1f4804-961a-4561-b19c-7a7aa2f290a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_f0c68b64-827e-4b28-af44-db9d089e9ab3" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_BiogenMAIncMember_f0c68b64-827e-4b28-af44-db9d089e9ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_f63a12e0-2c46-4465-82a6-2a1ebe6f16c8" xlink:href="sgmo-20201231.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_KitePharmaIncMember_f63a12e0-2c46-4465-82a6-2a1ebe6f16c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_8f43954d-0bf1-4765-a972-dab040dd1b9d" xlink:href="sgmo-20201231.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_8f43954d-0bf1-4765-a972-dab040dd1b9d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_9863ff25-67e8-44cb-a350-a00679c53b01" xlink:href="sgmo-20201231.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_SanofiMember_9863ff25-67e8-44cb-a350-a00679c53b01" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="extended" id="ide0abd691ff04beda17c21b0df2c3eeb_OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurement"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="extended" id="ifccef9af275946c3866bebb1836b4300_FairValueMeasurement"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="extended" id="i636a46853657461eb97a2f58760f4727_FairValueMeasurementTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="extended" id="if2265bad94214efeae8e9800af3f599b_FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_44f75733-fe05-4f6d-90b6-6fd8174218f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_44f75733-fe05-4f6d-90b6-6fd8174218f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5351898-b8a9-4118-b26e-25bae39f7498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5351898-b8a9-4118-b26e-25bae39f7498" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4e992e37-1f3c-48fd-9027-08726bcf9011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4e992e37-1f3c-48fd-9027-08726bcf9011" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4c2958ce-869d-4605-8c52-ea4d559823ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4c2958ce-869d-4605-8c52-ea4d559823ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c2958ce-869d-4605-8c52-ea4d559823ce_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4c2958ce-869d-4605-8c52-ea4d559823ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_4c2958ce-869d-4605-8c52-ea4d559823ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf843462-da66-443a-a525-781dbb3c239a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4c2958ce-869d-4605-8c52-ea4d559823ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf843462-da66-443a-a525-781dbb3c239a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_170d6e00-c53d-4c52-85b8-46e46d691852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf843462-da66-443a-a525-781dbb3c239a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_170d6e00-c53d-4c52-85b8-46e46d691852" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1d2a5def-b08d-498c-93e5-bc42318927c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1d2a5def-b08d-498c-93e5-bc42318927c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1d2a5def-b08d-498c-93e5-bc42318927c6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1d2a5def-b08d-498c-93e5-bc42318927c6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1d2a5def-b08d-498c-93e5-bc42318927c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1d2a5def-b08d-498c-93e5-bc42318927c6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8f673753-854d-4258-a5e9-8dc06bf63340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8f673753-854d-4258-a5e9-8dc06bf63340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_926c42d9-0615-48da-b0a6-f861e7a10702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_us-gaap_CertificatesOfDepositMember_926c42d9-0615-48da-b0a6-f861e7a10702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_070c2ec8-66c2-4f7f-ab2e-4e6f00530957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_070c2ec8-66c2-4f7f-ab2e-4e6f00530957" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_fb961b0d-dcd5-415e-ac5a-4fbe701c43b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_fb961b0d-dcd5-415e-ac5a-4fbe701c43b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_bd2407a8-dfa9-468d-82fb-74d98376c39b" xlink:href="sgmo-20201231.xsd#sgmo_FreeSharesAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_sgmo_FreeSharesAssetMember_bd2407a8-dfa9-468d-82fb-74d98376c39b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesLiabilityMember_2895c85d-6287-47d5-9af3-4080c08633aa" xlink:href="sgmo-20201231.xsd#sgmo_FreeSharesLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_sgmo_FreeSharesLiabilityMember_2895c85d-6287-47d5-9af3-4080c08633aa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0d391d2-503a-4ef4-91f7-26b4b3efe018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0d391d2-503a-4ef4-91f7-26b4b3efe018" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0d391d2-503a-4ef4-91f7-26b4b3efe018_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0d391d2-503a-4ef4-91f7-26b4b3efe018" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e0d391d2-503a-4ef4-91f7-26b4b3efe018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0d391d2-503a-4ef4-91f7-26b4b3efe018" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_899e6760-ccae-4475-9949-6f03f5818846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_899e6760-ccae-4475-9949-6f03f5818846" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_194d39eb-0be1-443a-b794-d039939abc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_194d39eb-0be1-443a-b794-d039939abc6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_33c90453-6107-443c-9332-5ac7196f1743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_33c90453-6107-443c-9332-5ac7196f1743" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8343d660-158f-47d2-957f-b949e40af95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:to="loc_us-gaap_InvestmentTypeAxis_8343d660-158f-47d2-957f-b949e40af95a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_8343d660-158f-47d2-957f-b949e40af95a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_8343d660-158f-47d2-957f-b949e40af95a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_8343d660-158f-47d2-957f-b949e40af95a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d06cc675-1163-48f4-930b-a5b224c901aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_8343d660-158f-47d2-957f-b949e40af95a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d06cc675-1163-48f4-930b-a5b224c901aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8504993a-b02f-4a3d-8812-cff60a729d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d06cc675-1163-48f4-930b-a5b224c901aa" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8504993a-b02f-4a3d-8812-cff60a729d8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1e21c079-d467-4b76-a7a7-f037806d949a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d06cc675-1163-48f4-930b-a5b224c901aa" xlink:to="loc_us-gaap_CommercialPaperMember_1e21c079-d467-4b76-a7a7-f037806d949a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="extended" id="i77367885dfbe44d1a0564d57080c6aaf_FairValueMeasurementAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_6907ebb7-991b-40b2-9f38-dfd82067e0bd" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_6907ebb7-991b-40b2-9f38-dfd82067e0bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_bdec24ed-ccc4-41e9-bb7f-eee4f5173ac8" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_bdec24ed-ccc4-41e9-bb7f-eee4f5173ac8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_286326db-9142-4afb-a216-d9e433c30280" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_286326db-9142-4afb-a216-d9e433c30280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_c689bc2c-78ca-4b9a-aa74-5899ea2176b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_c689bc2c-78ca-4b9a-aa74-5899ea2176b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_ad7a717d-b099-43d6-ba7e-a2b99d9b5c27" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_ad7a717d-b099-43d6-ba7e-a2b99d9b5c27" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_d0b4b4fe-ca2a-478b-8635-bac8767ae9d6" xlink:href="sgmo-20201231.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_d0b4b4fe-ca2a-478b-8635-bac8767ae9d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_722bea04-f74b-4a6e-a947-03ae01ea118b" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_722bea04-f74b-4a6e-a947-03ae01ea118b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b994028-7d3d-4b1d-b334-93328c59c292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b994028-7d3d-4b1d-b334-93328c59c292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b994028-7d3d-4b1d-b334-93328c59c292_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b994028-7d3d-4b1d-b334-93328c59c292" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6b994028-7d3d-4b1d-b334-93328c59c292_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4a8ca57-2532-4322-8b96-91e63093f41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b994028-7d3d-4b1d-b334-93328c59c292" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4a8ca57-2532-4322-8b96-91e63093f41d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_2f76b6c5-0a67-4597-91a2-8953a26a4621" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4a8ca57-2532-4322-8b96-91e63093f41d" xlink:to="loc_sgmo_SangamoFranceMember_2f76b6c5-0a67-4597-91a2-8953a26a4621" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1ccaa3b8-dbdc-4572-bf93-556c54960bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1ccaa3b8-dbdc-4572-bf93-556c54960bd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ccaa3b8-dbdc-4572-bf93-556c54960bd0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1ccaa3b8-dbdc-4572-bf93-556c54960bd0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1ccaa3b8-dbdc-4572-bf93-556c54960bd0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f566a5a-8550-47b9-903b-12bc77e02466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1ccaa3b8-dbdc-4572-bf93-556c54960bd0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f566a5a-8550-47b9-903b-12bc77e02466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_e8d9294b-3d3f-40ad-a059-42351a2fbbc3" xlink:href="sgmo-20201231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f566a5a-8550-47b9-903b-12bc77e02466" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_e8d9294b-3d3f-40ad-a059-42351a2fbbc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_10966208-fcb8-46c7-bd99-24b30cab002c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:to="loc_us-gaap_ValuationTechniqueAxis_10966208-fcb8-46c7-bd99-24b30cab002c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_10966208-fcb8-46c7-bd99-24b30cab002c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_10966208-fcb8-46c7-bd99-24b30cab002c" xlink:to="loc_us-gaap_ValuationTechniqueDomain_10966208-fcb8-46c7-bd99-24b30cab002c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_344480cb-218b-43fa-9f24-652ddb3309a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_10966208-fcb8-46c7-bd99-24b30cab002c" xlink:to="loc_us-gaap_ValuationTechniqueDomain_344480cb-218b-43fa-9f24-652ddb3309a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_4bde7117-d6b8-40dc-9ed9-5f3b9fdb8c22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_344480cb-218b-43fa-9f24-652ddb3309a0" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_4bde7117-d6b8-40dc-9ed9-5f3b9fdb8c22" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="extended" id="ife4bd9b2c1d74566b6a6f989129d136c_FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_27d623b3-47bb-4f81-9bec-fd4465ff32aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_SharePrice_27d623b3-47bb-4f81-9bec-fd4465ff32aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_4b263daf-2315-4e2d-a670-9f7fc88ada85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_4b263daf-2315-4e2d-a670-9f7fc88ada85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e70245d4-cad8-4c4b-998b-35b3751a63a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e70245d4-cad8-4c4b-998b-35b3751a63a9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2f83918b-3508-4135-97f6-53c60974fd11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2f83918b-3508-4135-97f6-53c60974fd11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_f87d1955-123a-4fb2-a81d-fcd77e85c10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_f87d1955-123a-4fb2-a81d-fcd77e85c10d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_896d9961-8f8f-4979-8ada-3cca7abee88d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_896d9961-8f8f-4979-8ada-3cca7abee88d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_91804d4a-32fb-4aed-874b-4fe5fa702afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_896d9961-8f8f-4979-8ada-3cca7abee88d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_91804d4a-32fb-4aed-874b-4fe5fa702afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91804d4a-32fb-4aed-874b-4fe5fa702afb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_91804d4a-32fb-4aed-874b-4fe5fa702afb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91804d4a-32fb-4aed-874b-4fe5fa702afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0baa88-c960-4da9-892f-1ee8ea0392a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_91804d4a-32fb-4aed-874b-4fe5fa702afb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0baa88-c960-4da9-892f-1ee8ea0392a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_6619b39e-219d-4d0e-839e-5102d07b0a66" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0baa88-c960-4da9-892f-1ee8ea0392a3" xlink:to="loc_sgmo_SangamoFranceMember_6619b39e-219d-4d0e-839e-5102d07b0a66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_326e794f-d2b4-441a-af01-78ee1bf6f97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_896d9961-8f8f-4979-8ada-3cca7abee88d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_326e794f-d2b4-441a-af01-78ee1bf6f97d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_326e794f-d2b4-441a-af01-78ee1bf6f97d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_326e794f-d2b4-441a-af01-78ee1bf6f97d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_326e794f-d2b4-441a-af01-78ee1bf6f97d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_326e794f-d2b4-441a-af01-78ee1bf6f97d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_548ac720-bb88-4b59-838f-c87f231470aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_548ac720-bb88-4b59-838f-c87f231470aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_b2faec85-8c29-4baa-8bc5-0dbe45129652" xlink:href="sgmo-20201231.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_b2faec85-8c29-4baa-8bc5-0dbe45129652" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_89e02e33-9cee-4ad2-998b-4873e2a73710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_89e02e33-9cee-4ad2-998b-4873e2a73710" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_0449ba7f-2748-4d40-a5a3-e3e458720a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_0449ba7f-2748-4d40-a5a3-e3e458720a61" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecurities"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities" xlink:type="extended" id="i3832274744144df09912b31f2615d835_CashEquivalentsandMarketableSecurities"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="extended" id="i474c78f6e3874473842f1301b267e681_CashEquivalentsandMarketableSecuritiesTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended" id="i4dd987d0f2c14b0fbd50cf45d259e1af_CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c37c3d16-2a14-4bdc-98c2-1c8a8e59b656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c37c3d16-2a14-4bdc-98c2-1c8a8e59b656" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_fb35543b-a396-46fe-961e-00db75618df5" xlink:href="sgmo-20201231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_fb35543b-a396-46fe-961e-00db75618df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_429c0b56-472b-4e1e-b147-d6ca74a09ee8" xlink:href="sgmo-20201231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_429c0b56-472b-4e1e-b147-d6ca74a09ee8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8c415f68-a843-4d38-bfc4-8073c1f89cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8c415f68-a843-4d38-bfc4-8073c1f89cbf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_33cc9ef0-f610-4269-9b05-e9dbb5f02bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_33cc9ef0-f610-4269-9b05-e9dbb5f02bca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d4fd514-971e-404f-9a9c-4642499b7363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d4fd514-971e-404f-9a9c-4642499b7363" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f01ddc8c-6bab-499b-9a2d-5e706ea7bf4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f01ddc8c-6bab-499b-9a2d-5e706ea7bf4f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b44f1987-f222-456c-8b85-779186a0d2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b44f1987-f222-456c-8b85-779186a0d2d6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_de6dc4c3-4c15-420a-8081-d7678b95f49e" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_de6dc4c3-4c15-420a-8081-d7678b95f49e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_cf548017-139a-4590-af63-56ed809d304b" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_cf548017-139a-4590-af63-56ed809d304b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_36a1037f-8ef7-4b9b-8251-3dc82c373d5d" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_36a1037f-8ef7-4b9b-8251-3dc82c373d5d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_b74d87da-58bd-4dd4-a9e0-fbf55a06c309" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_b74d87da-58bd-4dd4-a9e0-fbf55a06c309" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_44ee1cbf-4e82-413a-b12e-bed648350da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_44ee1cbf-4e82-413a-b12e-bed648350da0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d1b01bdd-0c4d-43c1-90d5-617471f3bfb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_44ee1cbf-4e82-413a-b12e-bed648350da0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d1b01bdd-0c4d-43c1-90d5-617471f3bfb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1b01bdd-0c4d-43c1-90d5-617471f3bfb6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d1b01bdd-0c4d-43c1-90d5-617471f3bfb6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d1b01bdd-0c4d-43c1-90d5-617471f3bfb6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d1b01bdd-0c4d-43c1-90d5-617471f3bfb6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d33faa5a-44fb-4178-a2d3-00a7aeaf5620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d33faa5a-44fb-4178-a2d3-00a7aeaf5620" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ce4e09c4-2d6a-4dd9-9ed3-4de33d9fa14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ce4e09c4-2d6a-4dd9-9ed3-4de33d9fa14f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d889dc7b-57d8-4cb7-8164-aef98a9dcb7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d889dc7b-57d8-4cb7-8164-aef98a9dcb7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5c191d27-1dc6-41ef-b4b3-8cba33e23dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5c191d27-1dc6-41ef-b4b3-8cba33e23dc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_377d7a6e-8fb5-49f1-9dfd-d3e5c58f3425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_44ee1cbf-4e82-413a-b12e-bed648350da0" xlink:to="loc_us-gaap_InvestmentTypeAxis_377d7a6e-8fb5-49f1-9dfd-d3e5c58f3425" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_377d7a6e-8fb5-49f1-9dfd-d3e5c58f3425_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_377d7a6e-8fb5-49f1-9dfd-d3e5c58f3425" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_377d7a6e-8fb5-49f1-9dfd-d3e5c58f3425_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_377d7a6e-8fb5-49f1-9dfd-d3e5c58f3425" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4e4f0040-c76e-4323-8ad1-82d1c4de3d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4e4f0040-c76e-4323-8ad1-82d1c4de3d41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d879fed8-ae31-4131-b69d-7fd28c3a8cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:to="loc_us-gaap_CommercialPaperMember_d879fed8-ae31-4131-b69d-7fd28c3a8cb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_51c9e41f-7bda-4dbe-8b20-202472a486be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:to="loc_us-gaap_CashEquivalentsMember_51c9e41f-7bda-4dbe-8b20-202472a486be" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="extended" id="iafa5be997aa3417580e2633e11f2f958_CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended" id="id443c0c0259a4b0a9e5bb30f07712517_CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliances"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="extended" id="i7dcf42d1572647dcb37569f3c7b7e7c0_MajorCustomersPartnershipsandStrategicAlliances"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="extended" id="i28043b7ceace49d3851ae09071cda96d_MajorCustomersPartnershipsandStrategicAlliancesTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_702dfb88-4a47-4982-a950-cc522d2cb60a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3521c64c-094f-4fa7-a618-8ef6b658b1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_702dfb88-4a47-4982-a950-cc522d2cb60a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3521c64c-094f-4fa7-a618-8ef6b658b1b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2694129c-4448-4eb4-992a-6e98378064c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_702dfb88-4a47-4982-a950-cc522d2cb60a" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2694129c-4448-4eb4-992a-6e98378064c1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f30daf6f-20f3-443e-ba69-87dcf472903c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2694129c-4448-4eb4-992a-6e98378064c1" xlink:to="loc_srt_CounterpartyNameAxis_f30daf6f-20f3-443e-ba69-87dcf472903c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f30daf6f-20f3-443e-ba69-87dcf472903c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_f30daf6f-20f3-443e-ba69-87dcf472903c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f30daf6f-20f3-443e-ba69-87dcf472903c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_f30daf6f-20f3-443e-ba69-87dcf472903c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_f6e46044-a5c3-4814-bfb7-aaee7cab8378" xlink:href="sgmo-20201231.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_f6e46044-a5c3-4814-bfb7-aaee7cab8378" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_84189158-9d4d-468a-a1b5-1b62a8b04d97" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_BiogenMAIncMember_84189158-9d4d-468a-a1b5-1b62a8b04d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_22938b8e-50d3-404b-beb5-0499d7fdacce" xlink:href="sgmo-20201231.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_KitePharmaIncMember_22938b8e-50d3-404b-beb5-0499d7fdacce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_1a030fa3-b1a9-4d6f-a662-9db299b74708" xlink:href="sgmo-20201231.xsd#sgmo_PfizerGiroctocogeneFitelparvovecMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_1a030fa3-b1a9-4d6f-a662-9db299b74708" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_33d978ee-ea42-4d8d-bb13-f92b5d260b8a" xlink:href="sgmo-20201231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_PfizerC9ORF72Member_33d978ee-ea42-4d8d-bb13-f92b5d260b8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_8a39d234-92a6-48b1-8f60-fbbc59b5df10" xlink:href="sgmo-20201231.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_SanofiMember_8a39d234-92a6-48b1-8f60-fbbc59b5df10" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="extended" id="i06ddfa4e51834d1790063fa4e8464b87_MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_517ffc5e-7f9c-45c7-b1a5-8989fa2e475d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ProceedsFromCollaborators_517ffc5e-7f9c-45c7-b1a5-8989fa2e475d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_97e723d1-e901-4883-9688-01454a9f423f" xlink:href="sgmo-20201231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_97e723d1-e901-4883-9688-01454a9f423f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_7f27d2ba-46a7-4f13-b8ce-52adebd087d0" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_7f27d2ba-46a7-4f13-b8ce-52adebd087d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_7ae5adab-d732-4ef3-a753-01fdba3c1ef6" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_7ae5adab-d732-4ef3-a753-01fdba3c1ef6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7cadbba5-4cb4-4ba0-b210-e2a428bfa989" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7cadbba5-4cb4-4ba0-b210-e2a428bfa989" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b332d9d0-e898-4d99-af7d-5c9cf417ad67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b332d9d0-e898-4d99-af7d-5c9cf417ad67" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_29fad6b1-3657-4fbc-9210-dc5e4e86c1d3" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_29fad6b1-3657-4fbc-9210-dc5e4e86c1d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_d0b3b036-bb67-4a86-8719-56f835e8137d" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_d0b3b036-bb67-4a86-8719-56f835e8137d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_b4ee62ce-9e15-4ebc-ba0c-d5c0ab2d75e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_b4ee62ce-9e15-4ebc-ba0c-d5c0ab2d75e8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b90c48e-b9cd-4242-9f96-ff21f016a1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b90c48e-b9cd-4242-9f96-ff21f016a1ad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cb8695cf-00fb-4835-9ca8-14407d7f7aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cb8695cf-00fb-4835-9ca8-14407d7f7aa4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_90f119bc-5118-4e38-9377-05c5cfb33f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_90f119bc-5118-4e38-9377-05c5cfb33f72" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_222b85ed-708c-49ec-9ea2-fcfa32484036" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_222b85ed-708c-49ec-9ea2-fcfa32484036" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_47d95211-adff-4f00-895a-e97c013f87ab" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_47d95211-adff-4f00-895a-e97c013f87ab" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_286f7998-7a07-49e5-97c6-ee755f8eed19" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_286f7998-7a07-49e5-97c6-ee755f8eed19" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_2c0c55ad-8302-479a-a40f-4f80afbbb940" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_2c0c55ad-8302-479a-a40f-4f80afbbb940" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_ade37d59-c9a8-43de-9fa4-29dd3a0f203c" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_ade37d59-c9a8-43de-9fa4-29dd3a0f203c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_1321ea3c-3798-4553-919a-50491333d890" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_1321ea3c-3798-4553-919a-50491333d890" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_9ec9e830-07f7-4429-adad-92a3dc79f4a8" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_9ec9e830-07f7-4429-adad-92a3dc79f4a8" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_ab451127-a933-4188-b27b-08ccdaf296cd" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_ab451127-a933-4188-b27b-08ccdaf296cd" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_0e9bc7a0-31eb-41b7-8d13-2aa6e9a3a035" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_0e9bc7a0-31eb-41b7-8d13-2aa6e9a3a035" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_1ee86e8d-eff6-4a26-a494-b53d879e2a60" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_1ee86e8d-eff6-4a26-a494-b53d879e2a60" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_e709c018-e131-49ef-a2d7-d6f33fc8d410" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_e709c018-e131-49ef-a2d7-d6f33fc8d410" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_4870d54e-dd96-4a5f-8ed9-0e5d8254696f" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_4870d54e-dd96-4a5f-8ed9-0e5d8254696f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_cb413fec-7448-4d86-9060-4a557fe73ae7" xlink:href="sgmo-20201231.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_cb413fec-7448-4d86-9060-4a557fe73ae7" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_07a22fe3-96ef-48d9-abf4-b41a9bd991be" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_07a22fe3-96ef-48d9-abf4-b41a9bd991be" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_ad474c94-03aa-4392-81b6-ef1de8597694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_ad474c94-03aa-4392-81b6-ef1de8597694" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_51be2b72-e54b-4db3-ba76-baaf14eb2493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_51be2b72-e54b-4db3-ba76-baaf14eb2493" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_58897af3-48dc-474b-b0e6-d64a2856326a" xlink:href="sgmo-20201231.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_MilestonePaymentsReceived_58897af3-48dc-474b-b0e6-d64a2856326a" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_bd3a3c8d-569e-43ca-9418-0e902660678b" xlink:href="sgmo-20201231.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_bd3a3c8d-569e-43ca-9418-0e902660678b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_623e34b8-2b0f-421e-94e6-1903edeff737" xlink:href="sgmo-20201231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_623e34b8-2b0f-421e-94e6-1903edeff737" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_c2517806-d0fd-475f-ace0-938054b3d8c7" xlink:href="sgmo-20201231.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_c2517806-d0fd-475f-ace0-938054b3d8c7" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_dbc8e523-52b6-4c2d-9a85-b764b53adf93" xlink:href="sgmo-20201231.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_dbc8e523-52b6-4c2d-9a85-b764b53adf93" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_32f329b3-fe67-4afc-8064-be8c17c1e136" xlink:href="sgmo-20201231.xsd#sgmo_SeparateUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_SeparateUpfrontFee_32f329b3-fe67-4afc-8064-be8c17c1e136" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_f1f8bcbc-1fd6-4ed5-b4b7-586c45c98fe7" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_f1f8bcbc-1fd6-4ed5-b4b7-586c45c98fe7" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_748c9a55-c8ec-4ac4-a04e-8802946d5836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_748c9a55-c8ec-4ac4-a04e-8802946d5836" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_a94ffa6f-cd0c-4b58-9636-e0cd2dbf3d48" xlink:href="sgmo-20201231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_a94ffa6f-cd0c-4b58-9636-e0cd2dbf3d48" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_de1f2d45-734c-4f1f-9a4d-4f37132fe5e3" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_MilestoneRevenueReceivable_de1f2d45-734c-4f1f-9a4d-4f37132fe5e3" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_2d6c8011-48f3-4a31-ae5f-d6f003082913" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_2d6c8011-48f3-4a31-ae5f-d6f003082913" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_8cbf2c31-0630-40b2-8ce1-cc4bc583cdb8" xlink:href="sgmo-20201231.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_8cbf2c31-0630-40b2-8ce1-cc4bc583cdb8" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_e21f00dd-b421-4f06-8447-d1a6ed2d2d2c" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_e21f00dd-b421-4f06-8447-d1a6ed2d2d2c" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementReimbursableServiceCosts_0215de15-eb73-43d3-84c3-e9ff9179f6a4" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementReimbursableServiceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementReimbursableServiceCosts_0215de15-eb73-43d3-84c3-e9ff9179f6a4" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_8fe6ab83-4f86-4feb-b650-27b26b8d6c15" xlink:href="sgmo-20201231.xsd#sgmo_AgreementTerminationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_AgreementTerminationTerm_8fe6ab83-4f86-4feb-b650-27b26b8d6c15" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e4d4fd2e-a6f7-4258-8af0-1a7ef57ccec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e4d4fd2e-a6f7-4258-8af0-1a7ef57ccec2" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_163d122f-d5cf-43e3-aaef-c688be865a02" xlink:href="sgmo-20201231.xsd#sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_163d122f-d5cf-43e3-aaef-c688be865a02" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac723909-e447-43bf-8700-2ca5eba29180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac723909-e447-43bf-8700-2ca5eba29180" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_776af207-dd7e-4a24-bda9-c30f135ea2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_776af207-dd7e-4a24-bda9-c30f135ea2f9" xlink:type="arc" order="46"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_c168621d-8e57-4bf6-9274-8fcf20504a82" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_c168621d-8e57-4bf6-9274-8fcf20504a82" xlink:type="arc" order="47"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_f1212418-60d2-42f6-936b-3ba2590ac0d1" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_f1212418-60d2-42f6-936b-3ba2590ac0d1" xlink:type="arc" order="48"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_066b2eee-2b5a-4a70-abb4-fb684c2e9c6d" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementNetIncomeLossPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_066b2eee-2b5a-4a70-abb4-fb684c2e9c6d" xlink:type="arc" order="49"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_dff0afdb-30af-4f23-81c2-822e19ad440b" xlink:href="sgmo-20201231.xsd#sgmo_NumberOfResearchProgram"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_NumberOfResearchProgram_dff0afdb-30af-4f23-81c2-822e19ad440b" xlink:type="arc" order="50"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_3f3de6b0-6ef0-4af7-bce6-7976575d57fc" xlink:href="sgmo-20201231.xsd#sgmo_GrantFundingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_GrantFundingAmount_3f3de6b0-6ef0-4af7-bce6-7976575d57fc" xlink:type="arc" order="51"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d688be01-dbae-4e42-83da-6e32eb59f18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d688be01-dbae-4e42-83da-6e32eb59f18f" xlink:type="arc" order="52"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c105cd73-27b3-4666-853e-9e07f4f294cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_srt_CounterpartyNameAxis_c105cd73-27b3-4666-853e-9e07f4f294cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c105cd73-27b3-4666-853e-9e07f4f294cc_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c105cd73-27b3-4666-853e-9e07f4f294cc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c105cd73-27b3-4666-853e-9e07f4f294cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c105cd73-27b3-4666-853e-9e07f4f294cc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d123c07e-52d3-472f-a63d-106a7469fa1b" xlink:href="sgmo-20201231.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d123c07e-52d3-472f-a63d-106a7469fa1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_e14557ba-21dd-409f-ad96-6afa4d282534" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_BiogenMAIncMember_e14557ba-21dd-409f-ad96-6afa4d282534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_e593538d-7144-4220-b142-a2a5e69480ae" xlink:href="sgmo-20201231.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_KitePharmaIncMember_e593538d-7144-4220-b142-a2a5e69480ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_6ad4adc5-7cd8-4098-a3c7-940e68022e7a" xlink:href="sgmo-20201231.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_PfizerSB525Member_6ad4adc5-7cd8-4098-a3c7-940e68022e7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_87e2c6e9-7c44-4dc9-9927-595539ec4bdc" xlink:href="sgmo-20201231.xsd#sgmo_PfizerGiroctocogeneFitelparvovecMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_87e2c6e9-7c44-4dc9-9927-595539ec4bdc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_2e336c07-09ee-46f7-b213-6ddcc71b3884" xlink:href="sgmo-20201231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_PfizerC9ORF72Member_2e336c07-09ee-46f7-b213-6ddcc71b3884" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_40c105a3-ee07-4f71-87ca-36486c94aef6" xlink:href="sgmo-20201231.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_SanofiMember_40c105a3-ee07-4f71-87ca-36486c94aef6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShireAgMember_d4dbf232-d805-45a3-b35f-d40751e2a79f" xlink:href="sgmo-20201231.xsd#sgmo_ShireAgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_ShireAgMember_d4dbf232-d805-45a3-b35f-d40751e2a79f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_cdbb1323-c2ec-47a8-b935-efd7acd3e2cd" xlink:href="sgmo-20201231.xsd#sgmo_PfizerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_PfizerMember_cdbb1323-c2ec-47a8-b935-efd7acd3e2cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4e2d10ab-b94a-470b-9ce7-61374f958240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4e2d10ab-b94a-470b-9ce7-61374f958240" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4e2d10ab-b94a-470b-9ce7-61374f958240_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4e2d10ab-b94a-470b-9ce7-61374f958240" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4e2d10ab-b94a-470b-9ce7-61374f958240_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4e2d10ab-b94a-470b-9ce7-61374f958240" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_831cc329-d684-4792-ad01-986878a0baf1" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_831cc329-d684-4792-ad01-986878a0baf1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_df069b82-1820-4693-93d4-d0a38f8be1af" xlink:href="sgmo-20201231.xsd#sgmo_AmendedCollaborationAndLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:to="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_df069b82-1820-4693-93d4-d0a38f8be1af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_941caa0e-2910-422f-b31f-2bae774864ca" xlink:href="sgmo-20201231.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:to="loc_sgmo_StockPurchaseAgreementMember_941caa0e-2910-422f-b31f-2bae774864ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_62841589-ec7c-466f-b64d-e58f9481142f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_srt_ProductOrServiceAxis_62841589-ec7c-466f-b64d-e58f9481142f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62841589-ec7c-466f-b64d-e58f9481142f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_62841589-ec7c-466f-b64d-e58f9481142f" xlink:to="loc_srt_ProductsAndServicesDomain_62841589-ec7c-466f-b64d-e58f9481142f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_62841589-ec7c-466f-b64d-e58f9481142f" xlink:to="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_5feb739e-3b1e-4762-af74-aa4620349737" xlink:href="sgmo-20201231.xsd#sgmo_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_sgmo_OtherProductsMember_5feb739e-3b1e-4762-af74-aa4620349737" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_f1e9dde8-1e85-45ad-a39e-59a01ccb055c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_us-gaap_LicenseAndServiceMember_f1e9dde8-1e85-45ad-a39e-59a01ccb055c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_4d8f4029-eabf-4565-b4fd-6f6ab27d2e90" xlink:href="sgmo-20201231.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_sgmo_CNineORFSevenTwoMember_4d8f4029-eabf-4565-b4fd-6f6ab27d2e90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_7d0c2984-20ed-40d9-8472-03b3cb2e0ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_us-gaap_GrantMember_7d0c2984-20ed-40d9-8472-03b3cb2e0ed4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GiroctocogeneFitelparvovecMember_3afc5b40-4a19-4103-a506-84a3eed054b8" xlink:href="sgmo-20201231.xsd#sgmo_GiroctocogeneFitelparvovecMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_sgmo_GiroctocogeneFitelparvovecMember_3afc5b40-4a19-4103-a506-84a3eed054b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_0d925c42-d1fc-430d-8710-d7a63b311d34" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_0d925c42-d1fc-430d-8710-d7a63b311d34" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_0d925c42-d1fc-430d-8710-d7a63b311d34_default" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_0d925c42-d1fc-430d-8710-d7a63b311d34" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_0d925c42-d1fc-430d-8710-d7a63b311d34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_0d925c42-d1fc-430d-8710-d7a63b311d34" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_74ee4d11-74b6-493f-9ce5-60413dd1b48d" xlink:href="sgmo-20201231.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_PreApprovalMilestoneMember_74ee4d11-74b6-493f-9ce5-60413dd1b48d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_5cfb1598-458c-4246-87f3-ace5a4c49fc7" xlink:href="sgmo-20201231.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_SalesBasedMilestoneMember_5cfb1598-458c-4246-87f3-ace5a4c49fc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneOneMember_4e06ba67-0cac-43c2-b1a9-86ddc7174c2d" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_MilestoneOneMember_4e06ba67-0cac-43c2-b1a9-86ddc7174c2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_33b03051-2733-4b0e-891e-c88e798527d4" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_MilestoneTwoMember_33b03051-2733-4b0e-891e-c88e798527d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_50ae3de5-68bc-4294-984f-79eb366e8dcf" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_MilestoneThreeMember_50ae3de5-68bc-4294-984f-79eb366e8dcf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PhaseThreeClinicalTrialMember_f8a64a6a-0bd6-4544-a38e-61154a68f1b1" xlink:href="sgmo-20201231.xsd#sgmo_PhaseThreeClinicalTrialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_PhaseThreeClinicalTrialMember_f8a64a6a-0bd6-4544-a38e-61154a68f1b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_339035fe-6467-4411-8755-555f67f13675" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_srt_RangeAxis_339035fe-6467-4411-8755-555f67f13675" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_339035fe-6467-4411-8755-555f67f13675_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_339035fe-6467-4411-8755-555f67f13675" xlink:to="loc_srt_RangeMember_339035fe-6467-4411-8755-555f67f13675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0075e9aa-8839-4924-bde9-04e7c4de1c51" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_339035fe-6467-4411-8755-555f67f13675" xlink:to="loc_srt_RangeMember_0075e9aa-8839-4924-bde9-04e7c4de1c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_28cccbce-dbab-4ef5-a6c5-8f2088a3f569" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0075e9aa-8839-4924-bde9-04e7c4de1c51" xlink:to="loc_srt_MaximumMember_28cccbce-dbab-4ef5-a6c5-8f2088a3f569" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_500f5431-c1e6-490f-b749-869cbeb9465b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0075e9aa-8839-4924-bde9-04e7c4de1c51" xlink:to="loc_srt_MinimumMember_500f5431-c1e6-490f-b749-869cbeb9465b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_95b2e776-21bb-4f30-aa80-6a6772451b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_95b2e776-21bb-4f30-aa80-6a6772451b17" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_95b2e776-21bb-4f30-aa80-6a6772451b17_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_95b2e776-21bb-4f30-aa80-6a6772451b17" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_95b2e776-21bb-4f30-aa80-6a6772451b17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_95b2e776-21bb-4f30-aa80-6a6772451b17" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_ff450292-8a7d-4ece-bafe-30b1132d3a76" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_ff450292-8a7d-4ece-bafe-30b1132d3a76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_014c7195-00f8-4286-81ce-59bba7ffb162" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_014c7195-00f8-4286-81ce-59bba7ffb162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_0203a82d-3d63-4c1e-8110-76282652f11f" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_0203a82d-3d63-4c1e-8110-76282652f11f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_988a96f1-b4bd-48b8-aa58-5ee93de4caaa" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_988a96f1-b4bd-48b8-aa58-5ee93de4caaa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_2a161883-e739-4524-bc7e-de82af33e711" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_2a161883-e739-4524-bc7e-de82af33e711" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_4481e3d6-e2d7-492a-9a0f-af1178bfd623" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_4481e3d6-e2d7-492a-9a0f-af1178bfd623" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_70e86a80-cc53-43eb-9056-a8be441a6f65" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_70e86a80-cc53-43eb-9056-a8be441a6f65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_72a1c3f3-4754-4291-8a98-b6645772a4ac" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_72a1c3f3-4754-4291-8a98-b6645772a4ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_1f9dd6c4-d9ea-4892-99f3-204d1cf32440" xlink:href="sgmo-20201231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_1f9dd6c4-d9ea-4892-99f3-204d1cf32440" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="extended" id="i7e2d3bcb61c146e0b2444e24a3a218b3_MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ee30b696-6513-41e0-8103-800178b3bf43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e0bfbb14-77f6-4646-a8d5-ab1001eccccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ee30b696-6513-41e0-8103-800178b3bf43" xlink:to="loc_us-gaap_RevenuesAbstract_e0bfbb14-77f6-4646-a8d5-ab1001eccccd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80c5c0ba-320d-445b-bf61-929e758309dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_e0bfbb14-77f6-4646-a8d5-ab1001eccccd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80c5c0ba-320d-445b-bf61-929e758309dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a8228849-4915-4476-b5e5-0959107a7a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ee30b696-6513-41e0-8103-800178b3bf43" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a8228849-4915-4476-b5e5-0959107a7a1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ab97aee8-b6b2-4fc2-ba9b-610f161cba9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a8228849-4915-4476-b5e5-0959107a7a1d" xlink:to="loc_srt_CounterpartyNameAxis_ab97aee8-b6b2-4fc2-ba9b-610f161cba9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab97aee8-b6b2-4fc2-ba9b-610f161cba9a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ab97aee8-b6b2-4fc2-ba9b-610f161cba9a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab97aee8-b6b2-4fc2-ba9b-610f161cba9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ab97aee8-b6b2-4fc2-ba9b-610f161cba9a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_9ff0ee6f-1418-43c0-9198-f6e4a8397ae2" xlink:href="sgmo-20201231.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_9ff0ee6f-1418-43c0-9198-f6e4a8397ae2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_14e7c264-1199-4ba3-9904-f6d6dabc113c" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_BiogenMAIncMember_14e7c264-1199-4ba3-9904-f6d6dabc113c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_adb487ae-cb57-400b-9e24-db557a8f1b64" xlink:href="sgmo-20201231.xsd#sgmo_KitePharmaIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_KitePharmaIncMember_adb487ae-cb57-400b-9e24-db557a8f1b64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_f6e56773-aa06-4bba-8ec8-a1c8e469ef25" xlink:href="sgmo-20201231.xsd#sgmo_PfizerSB525Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_PfizerSB525Member_f6e56773-aa06-4bba-8ec8-a1c8e469ef25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_eabeb159-5ce4-4121-b455-09001385f42d" xlink:href="sgmo-20201231.xsd#sgmo_PfizerGiroctocogeneFitelparvovecMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_eabeb159-5ce4-4121-b455-09001385f42d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_924f348b-a08f-48b4-876e-7d797d3d82a5" xlink:href="sgmo-20201231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_PfizerC9ORF72Member_924f348b-a08f-48b4-876e-7d797d3d82a5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_8e505504-b633-4d0a-a769-7936640ba0a2" xlink:href="sgmo-20201231.xsd#sgmo_SanofiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_SanofiMember_8e505504-b633-4d0a-a769-7936640ba0a2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b368712f-999a-4e39-8153-a4ad85a0cee1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a8228849-4915-4476-b5e5-0959107a7a1d" xlink:to="loc_srt_ProductOrServiceAxis_b368712f-999a-4e39-8153-a4ad85a0cee1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b368712f-999a-4e39-8153-a4ad85a0cee1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b368712f-999a-4e39-8153-a4ad85a0cee1" xlink:to="loc_srt_ProductsAndServicesDomain_b368712f-999a-4e39-8153-a4ad85a0cee1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b368712f-999a-4e39-8153-a4ad85a0cee1" xlink:to="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_19087b5b-ad1e-4b49-b75c-c3f5f01cea9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:to="loc_us-gaap_LicenseAndServiceMember_19087b5b-ad1e-4b49-b75c-c3f5f01cea9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_ae01d857-49ac-4331-8b80-f3a1834660aa" xlink:href="sgmo-20201231.xsd#sgmo_ResearchServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:to="loc_sgmo_ResearchServicesMember_ae01d857-49ac-4331-8b80-f3a1834660aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_10eddd22-9e19-41c2-adc3-145e17812902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_153da7b5-e9f6-4f01-a656-8eff6a12821a" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneAchievementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:to="loc_sgmo_MilestoneAchievementMember_153da7b5-e9f6-4f01-a656-8eff6a12821a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail" xlink:type="extended" id="i5d130de8f42741cd9140ad61888096db_MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesPeriod_feb3b6cd-a077-45cc-b238-f7356d8d4346" xlink:href="sgmo-20201231.xsd#sgmo_ResearchServicesPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_sgmo_ResearchServicesPeriod_feb3b6cd-a077-45cc-b238-f7356d8d4346" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5cbb1df1-7c5f-489c-94a9-75278c04edd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5cbb1df1-7c5f-489c-94a9-75278c04edd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cd8ad6a9-dad3-4057-b33d-bdcfa627a9ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cd8ad6a9-dad3-4057-b33d-bdcfa627a9ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_346705c0-674e-4faa-a990-3a3fa09d552c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_346705c0-674e-4faa-a990-3a3fa09d552c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0ceaed1e-0799-423c-b46d-b1d4e6542665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0ceaed1e-0799-423c-b46d-b1d4e6542665" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ReducedRoyaltyRate_1a28aa15-e552-47f7-bb8c-65fc61a9240a" xlink:href="sgmo-20201231.xsd#sgmo_ReducedRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_sgmo_ReducedRoyaltyRate_1a28aa15-e552-47f7-bb8c-65fc61a9240a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_59c0b7bc-ad5a-4497-91e6-b78d68c58f14" xlink:href="sgmo-20201231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_59c0b7bc-ad5a-4497-91e6-b78d68c58f14" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2f006154-4f62-4d1c-b39c-ffbd702c6a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2f006154-4f62-4d1c-b39c-ffbd702c6a96" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5207e0c4-4901-4fa9-9912-284da5ac6c39" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:to="loc_srt_CounterpartyNameAxis_5207e0c4-4901-4fa9-9912-284da5ac6c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5207e0c4-4901-4fa9-9912-284da5ac6c39_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5207e0c4-4901-4fa9-9912-284da5ac6c39" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5207e0c4-4901-4fa9-9912-284da5ac6c39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5059c750-ab09-4721-852a-ef2bfd2ab850" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5207e0c4-4901-4fa9-9912-284da5ac6c39" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5059c750-ab09-4721-852a-ef2bfd2ab850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SigmaAldrichCorporationMember_39d0bf06-7307-4268-8a88-0eb456c86ed8" xlink:href="sgmo-20201231.xsd#sgmo_SigmaAldrichCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5059c750-ab09-4721-852a-ef2bfd2ab850" xlink:to="loc_sgmo_SigmaAldrichCorporationMember_39d0bf06-7307-4268-8a88-0eb456c86ed8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_95b6ac34-a407-4bc8-9b5e-2f7fd7e16d8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:to="loc_srt_ProductOrServiceAxis_95b6ac34-a407-4bc8-9b5e-2f7fd7e16d8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_95b6ac34-a407-4bc8-9b5e-2f7fd7e16d8c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_95b6ac34-a407-4bc8-9b5e-2f7fd7e16d8c" xlink:to="loc_srt_ProductsAndServicesDomain_95b6ac34-a407-4bc8-9b5e-2f7fd7e16d8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f66844e0-e1a4-4c87-8891-a3464c1ee847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_95b6ac34-a407-4bc8-9b5e-2f7fd7e16d8c" xlink:to="loc_srt_ProductsAndServicesDomain_f66844e0-e1a4-4c87-8891-a3464c1ee847" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_802e00c5-ded3-43c2-b112-d36607991228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f66844e0-e1a4-4c87-8891-a3464c1ee847" xlink:to="loc_us-gaap_LicenseMember_802e00c5-ded3-43c2-b112-d36607991228" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7ba0cc5f-9592-4843-a4b4-0c595d039684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7ba0cc5f-9592-4843-a4b4-0c595d039684" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ba0cc5f-9592-4843-a4b4-0c595d039684_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7ba0cc5f-9592-4843-a4b4-0c595d039684" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_7ba0cc5f-9592-4843-a4b4-0c595d039684_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc8b967-7ded-4d29-8b13-aa8f1d5bd79a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7ba0cc5f-9592-4843-a4b4-0c595d039684" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc8b967-7ded-4d29-8b13-aa8f1d5bd79a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_73866209-0100-4118-a49a-a58c7a884daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc8b967-7ded-4d29-8b13-aa8f1d5bd79a" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_73866209-0100-4118-a49a-a58c7a884daf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail" xlink:type="extended" id="i92c67405906c49caa2fc2afe38ae3ed2_MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_41ce29f8-4cb6-4d2a-a075-db4476bb89df" xlink:href="sgmo-20201231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_41ce29f8-4cb6-4d2a-a075-db4476bb89df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OneTimeLicenseFeeEarned_093d7f1d-88c3-48d1-b96c-8ba26d1700f5" xlink:href="sgmo-20201231.xsd#sgmo_OneTimeLicenseFeeEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_OneTimeLicenseFeeEarned_093d7f1d-88c3-48d1-b96c-8ba26d1700f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99782e05-312a-4480-ac86-d9f3c0a138a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99782e05-312a-4480-ac86-d9f3c0a138a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_18807ceb-c0e8-488f-8d7b-bfb69f07d80b" xlink:href="sgmo-20201231.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_18807ceb-c0e8-488f-8d7b-bfb69f07d80b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_9f7832f2-ed2c-413a-ad44-78982073f866" xlink:href="sgmo-20201231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_9f7832f2-ed2c-413a-ad44-78982073f866" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AnnualFeesRelatedToAgreement_1bf8d731-a394-4368-81d6-7755ed505297" xlink:href="sgmo-20201231.xsd#sgmo_AnnualFeesRelatedToAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_AnnualFeesRelatedToAgreement_1bf8d731-a394-4368-81d6-7755ed505297" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FeeDue_e04594ea-ab20-4e3b-8b1e-0f8e4c5643f1" xlink:href="sgmo-20201231.xsd#sgmo_FeeDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_FeeDue_e04594ea-ab20-4e3b-8b1e-0f8e4c5643f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_63a2ce97-8f1c-4df6-8aed-e9a869b20110" xlink:href="sgmo-20201231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_63a2ce97-8f1c-4df6-8aed-e9a869b20110" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9370514f-0688-4f63-85fd-7f8257cf7162" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:to="loc_srt_CounterpartyNameAxis_9370514f-0688-4f63-85fd-7f8257cf7162" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9370514f-0688-4f63-85fd-7f8257cf7162_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_9370514f-0688-4f63-85fd-7f8257cf7162" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9370514f-0688-4f63-85fd-7f8257cf7162_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_778e180b-9e42-49b3-9d30-34289b0bea5c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_9370514f-0688-4f63-85fd-7f8257cf7162" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_778e180b-9e42-49b3-9d30-34289b0bea5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DowAgroSciencesMember_84cfc43e-2c35-4f2c-8dee-3ee46a06d6de" xlink:href="sgmo-20201231.xsd#sgmo_DowAgroSciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_778e180b-9e42-49b3-9d30-34289b0bea5c" xlink:to="loc_sgmo_DowAgroSciencesMember_84cfc43e-2c35-4f2c-8dee-3ee46a06d6de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_196c62f7-2942-435a-969d-896110dcecb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_196c62f7-2942-435a-969d-896110dcecb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_196c62f7-2942-435a-969d-896110dcecb9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_196c62f7-2942-435a-969d-896110dcecb9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_196c62f7-2942-435a-969d-896110dcecb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8a7d04ce-861a-42e4-805e-1e3b9170fbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_196c62f7-2942-435a-969d-896110dcecb9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8a7d04ce-861a-42e4-805e-1e3b9170fbe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_ff8b156b-59c2-42c3-a7e7-73d8ad03bb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8a7d04ce-861a-42e4-805e-1e3b9170fbe3" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_ff8b156b-59c2-42c3-a7e7-73d8ad03bb49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e7f8524-15d0-4a79-981c-cc130c56991e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:to="loc_srt_ProductOrServiceAxis_1e7f8524-15d0-4a79-981c-cc130c56991e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1e7f8524-15d0-4a79-981c-cc130c56991e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1e7f8524-15d0-4a79-981c-cc130c56991e" xlink:to="loc_srt_ProductsAndServicesDomain_1e7f8524-15d0-4a79-981c-cc130c56991e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_958c8c93-76da-4be3-9dd5-29990ce36da5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1e7f8524-15d0-4a79-981c-cc130c56991e" xlink:to="loc_srt_ProductsAndServicesDomain_958c8c93-76da-4be3-9dd5-29990ce36da5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_556d8a96-e360-4f50-a396-8b7b44fae268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_958c8c93-76da-4be3-9dd5-29990ce36da5" xlink:to="loc_us-gaap_RoyaltyMember_556d8a96-e360-4f50-a396-8b7b44fae268" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d1946e02-617c-4d8a-ae88-026f460d19bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_958c8c93-76da-4be3-9dd5-29990ce36da5" xlink:to="loc_us-gaap_LicenseMember_d1946e02-617c-4d8a-ae88-026f460d19bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17ab1654-0b7d-4df8-9c6b-af93f7691346" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:to="loc_srt_RangeAxis_17ab1654-0b7d-4df8-9c6b-af93f7691346" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17ab1654-0b7d-4df8-9c6b-af93f7691346_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_17ab1654-0b7d-4df8-9c6b-af93f7691346" xlink:to="loc_srt_RangeMember_17ab1654-0b7d-4df8-9c6b-af93f7691346_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f35fbfc3-714f-4723-b1e3-ade194ff159c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_17ab1654-0b7d-4df8-9c6b-af93f7691346" xlink:to="loc_srt_RangeMember_f35fbfc3-714f-4723-b1e3-ade194ff159c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_972baed0-2a47-4218-aedf-772802ac92c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f35fbfc3-714f-4723-b1e3-ade194ff159c" xlink:to="loc_srt_MinimumMember_972baed0-2a47-4218-aedf-772802ac92c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37a8f85d-7aa7-4471-a405-1e190b8dceef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f35fbfc3-714f-4723-b1e3-ade194ff159c" xlink:to="loc_srt_MaximumMember_37a8f85d-7aa7-4471-a405-1e190b8dceef" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofSangamoFrance"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="extended" id="i0139893e63b4480bb9cdb2ff47b200fb_AcquisitionofSangamoFrance"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofAcquisitionofSangamoFranceTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="extended" id="ice3f109b92024064b9f373b548a7b364_AcquisitionofAcquisitionofSangamoFranceTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofSangamoFranceAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="extended" id="i3852f2091022423493bf453fbba0e191_AcquisitionofSangamoFranceAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_5579ff01-0beb-4da5-894c-2ef09c564264" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_5579ff01-0beb-4da5-894c-2ef09c564264" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_64f33a57-0a04-4471-9cef-2bbc6204be42" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_64f33a57-0a04-4471-9cef-2bbc6204be42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0903f26b-53c4-45ab-aa73-5765cbc85eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0903f26b-53c4-45ab-aa73-5765cbc85eea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_77485551-8294-4c48-a04b-b2f5c6d1b19b" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_77485551-8294-4c48-a04b-b2f5c6d1b19b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ef5d3324-d0d9-4248-a838-73f4e6950e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ef5d3324-d0d9-4248-a838-73f4e6950e61" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d854967a-8c4d-4918-b4da-c43ad322c9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d854967a-8c4d-4918-b4da-c43ad322c9b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_5ede7abf-cf05-4845-9de2-5abd61410c07" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_5ede7abf-cf05-4845-9de2-5abd61410c07" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_c5e5fe4b-eadc-4969-a122-b4093c6d2645" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_c5e5fe4b-eadc-4969-a122-b4093c6d2645" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ca9b11d2-79f6-49bd-89a6-fe223f6809ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ca9b11d2-79f6-49bd-89a6-fe223f6809ee" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3c1251be-b482-4c78-b2b0-bf8e77d89478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3c1251be-b482-4c78-b2b0-bf8e77d89478" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_02cdd4f0-7a68-4829-8c57-78833ce45a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_02cdd4f0-7a68-4829-8c57-78833ce45a43" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_55cd8479-7932-42e2-b057-ebd3066bbd73" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:to="loc_srt_OwnershipAxis_55cd8479-7932-42e2-b057-ebd3066bbd73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_55cd8479-7932-42e2-b057-ebd3066bbd73_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_55cd8479-7932-42e2-b057-ebd3066bbd73" xlink:to="loc_srt_OwnershipDomain_55cd8479-7932-42e2-b057-ebd3066bbd73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6d9bfc9f-b42e-4e1b-9a64-2d0b89b25869" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_55cd8479-7932-42e2-b057-ebd3066bbd73" xlink:to="loc_srt_OwnershipDomain_6d9bfc9f-b42e-4e1b-9a64-2d0b89b25869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_b287d96a-e4ef-4c6b-8e00-e6bcad83d6f7" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_6d9bfc9f-b42e-4e1b-9a64-2d0b89b25869" xlink:to="loc_sgmo_SangamoFranceMember_b287d96a-e4ef-4c6b-8e00-e6bcad83d6f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b8f50815-47f8-448b-8d9c-655a9b60ad47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b8f50815-47f8-448b-8d9c-655a9b60ad47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8f50815-47f8-448b-8d9c-655a9b60ad47_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b8f50815-47f8-448b-8d9c-655a9b60ad47" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b8f50815-47f8-448b-8d9c-655a9b60ad47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3eb45fba-b0b2-4b24-9dad-cb68bc38503f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b8f50815-47f8-448b-8d9c-655a9b60ad47" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3eb45fba-b0b2-4b24-9dad-cb68bc38503f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_a27f0575-c03a-4eab-9dbc-39311af6cd8f" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3eb45fba-b0b2-4b24-9dad-cb68bc38503f" xlink:to="loc_sgmo_SangamoFranceMember_a27f0575-c03a-4eab-9dbc-39311af6cd8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f88789d8-6c03-437b-82ca-690cc377e8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f88789d8-6c03-437b-82ca-690cc377e8bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f88789d8-6c03-437b-82ca-690cc377e8bd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f88789d8-6c03-437b-82ca-690cc377e8bd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f88789d8-6c03-437b-82ca-690cc377e8bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99a45392-593f-44d3-8641-8abf5e36ca87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f88789d8-6c03-437b-82ca-690cc377e8bd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99a45392-593f-44d3-8641-8abf5e36ca87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_7ead0e48-35de-4c75-824f-8f82d5bfcb7c" xlink:href="sgmo-20201231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99a45392-593f-44d3-8641-8abf5e36ca87" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_7ead0e48-35de-4c75-824f-8f82d5bfcb7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_140ab130-d60a-4a6f-930d-d42d7cca2ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:to="loc_us-gaap_ValuationTechniqueAxis_140ab130-d60a-4a6f-930d-d42d7cca2ae2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_140ab130-d60a-4a6f-930d-d42d7cca2ae2_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_140ab130-d60a-4a6f-930d-d42d7cca2ae2" xlink:to="loc_us-gaap_ValuationTechniqueDomain_140ab130-d60a-4a6f-930d-d42d7cca2ae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_ef2121f8-8bfa-4362-ac07-680a4edbaadf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_140ab130-d60a-4a6f-930d-d42d7cca2ae2" xlink:to="loc_us-gaap_ValuationTechniqueDomain_ef2121f8-8bfa-4362-ac07-680a4edbaadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_cda3342a-3824-4bb1-ba65-0625210fc294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_ef2121f8-8bfa-4362-ac07-680a4edbaadf" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_cda3342a-3824-4bb1-ba65-0625210fc294" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="extended" id="i049d107e368a4a26a03488682ffb26b9_AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_03cdf41b-53e4-4209-9751-48612d6acc48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestLineItems_03cdf41b-53e4-4209-9751-48612d6acc48" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2a1fac8d-fb5e-4979-87b8-4c3010af051e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:to="loc_us-gaap_MinorityInterest_2a1fac8d-fb5e-4979-87b8-4c3010af051e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_76a808dc-102e-4e1d-82ef-3386b0946ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_76a808dc-102e-4e1d-82ef-3386b0946ce3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a0c43d4-7346-4660-9f84-ebfa9144ae83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a0c43d4-7346-4660-9f84-ebfa9144ae83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_dab5ac81-d859-4d0a-831f-69b8b83ed9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_3bf54ce6-ae58-42e4-a032-1d769e5d7a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_MinorityInterestLineItems_03cdf41b-53e4-4209-9751-48612d6acc48" xlink:to="loc_us-gaap_MinorityInterestTable_3bf54ce6-ae58-42e4-a032-1d769e5d7a89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ddc8fbb5-f9e1-4350-a16e-16b332afdd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_MinorityInterestTable_3bf54ce6-ae58-42e4-a032-1d769e5d7a89" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ddc8fbb5-f9e1-4350-a16e-16b332afdd4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ddc8fbb5-f9e1-4350-a16e-16b332afdd4c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ddc8fbb5-f9e1-4350-a16e-16b332afdd4c" xlink:to="loc_us-gaap_EquityComponentDomain_ddc8fbb5-f9e1-4350-a16e-16b332afdd4c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_058dfcee-6792-4027-895d-69b7a5485b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ddc8fbb5-f9e1-4350-a16e-16b332afdd4c" xlink:to="loc_us-gaap_EquityComponentDomain_058dfcee-6792-4027-895d-69b7a5485b33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1ba26e89-6b74-4b7e-86ad-42e51822bdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_058dfcee-6792-4027-895d-69b7a5485b33" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1ba26e89-6b74-4b7e-86ad-42e51822bdb8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="extended" id="ie24b5adaeb234c88b95176ef95bcb49b_OtherBalanceSheetDetails"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended" id="i9c32ef38fd8f4c51ac0d1ced521638bb_OtherBalanceSheetDetailsTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="extended" id="ieab78167c1234ad39b7d172cf535e53c_OtherBalanceSheetDetailsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_65f0b33b-5385-4c07-802d-57771f2354ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_65f0b33b-5385-4c07-802d-57771f2354ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0463af9b-683a-448a-92bf-a44ae9433fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0463af9b-683a-448a-92bf-a44ae9433fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba52733a-226a-4270-b63b-a61392082baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ba52733a-226a-4270-b63b-a61392082baf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5dc345df-277d-4880-8e58-9f01c49003df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5dc345df-277d-4880-8e58-9f01c49003df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5302336e-f212-420a-8033-6e00bed63ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5302336e-f212-420a-8033-6e00bed63ed4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_845d1ecc-74d8-46c9-a83f-b098d2e01201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5302336e-f212-420a-8033-6e00bed63ed4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_845d1ecc-74d8-46c9-a83f-b098d2e01201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_845d1ecc-74d8-46c9-a83f-b098d2e01201_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_845d1ecc-74d8-46c9-a83f-b098d2e01201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_845d1ecc-74d8-46c9-a83f-b098d2e01201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_845d1ecc-74d8-46c9-a83f-b098d2e01201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LaboratoryEquipmentMember_cf1615f2-8d68-4cfe-b608-3b017e432df6" xlink:href="sgmo-20201231.xsd#sgmo_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_sgmo_LaboratoryEquipmentMember_cf1615f2-8d68-4cfe-b608-3b017e432df6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f11675ca-1d4e-485c-b1a8-aff82e928572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f11675ca-1d4e-485c-b1a8-aff82e928572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2a81b8f5-38a8-486a-90d9-4f0505baf8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2a81b8f5-38a8-486a-90d9-4f0505baf8d9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingEquipmentMember_f6187033-7ebe-4915-96ad-189226a81a10" xlink:href="sgmo-20201231.xsd#sgmo_ManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_sgmo_ManufacturingEquipmentMember_f6187033-7ebe-4915-96ad-189226a81a10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2ac26701-2547-474d-8834-864da1d33ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_us-gaap_ConstructionInProgressMember_2ac26701-2547-474d-8834-864da1d33ebd" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="extended" id="i38dc56169d1b4276b95b0223a8d876c5_OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended" id="i2dc138bc0b334b7cb5af0b49325847c9_OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="extended" id="i1c5a25f197cc4602877d351d066b3b77_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="extended" id="if57f904dc5954726a11a0b19dcd9ec76_CommitmentsandContingenciesTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended" id="iec56406134f74a1599e669ccf4888497_CommitmentsandContingenciesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:href="sgmo-20201231.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_e21a741d-1b5f-4642-b814-01bb89138d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_e21a741d-1b5f-4642-b814-01bb89138d2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_b4580feb-2da8-41bd-94d7-fdc5868a213a" xlink:href="sgmo-20201231.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_b4580feb-2da8-41bd-94d7-fdc5868a213a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_a0327ff3-2e94-48ca-8d75-b1c964286a4b" xlink:href="sgmo-20201231.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_a0327ff3-2e94-48ca-8d75-b1c964286a4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3d895a2d-aaf7-4dee-861a-77bf29293e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3d895a2d-aaf7-4dee-861a-77bf29293e9b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_de1e06d2-c2d2-494a-90b9-5d77d58760b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeaseCost_de1e06d2-c2d2-494a-90b9-5d77d58760b5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_c399543b-420f-4dcd-b50b-ad2fca93b0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_VariableLeaseCost_c399543b-420f-4dcd-b50b-ad2fca93b0b2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_cceb52ea-76b6-4b6a-a06f-267baca8e36a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeasePayments_cceb52ea-76b6-4b6a-a06f-267baca8e36a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_edf1db8b-33ae-455e-bcf9-bdecd3918f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeaseExpense_edf1db8b-33ae-455e-bcf9-bdecd3918f3f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_6a0bc6eb-206d-4b20-9dce-07eca0acabcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_LeaseAndRentalExpense_6a0bc6eb-206d-4b20-9dce-07eca0acabcc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_11f89a41-1a88-4ec6-92ff-f80bf74641b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_11f89a41-1a88-4ec6-92ff-f80bf74641b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c608b0d4-938b-4acd-9236-99d57daa2f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c608b0d4-938b-4acd-9236-99d57daa2f5f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_11134770-fd17-4bfa-9c4d-8e5f9f3e86df" xlink:href="sgmo-20201231.xsd#sgmo_LicenseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_sgmo_LicenseObligations_11134770-fd17-4bfa-9c4d-8e5f9f3e86df" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:href="sgmo-20201231.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd78d22-bfe2-4227-93dd-0d2ad8c8cb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd78d22-bfe2-4227-93dd-0d2ad8c8cb2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0bd78d22-bfe2-4227-93dd-0d2ad8c8cb2c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd78d22-bfe2-4227-93dd-0d2ad8c8cb2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0bd78d22-bfe2-4227-93dd-0d2ad8c8cb2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e6e9d7c-c975-4991-8b41-dd29152a3a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd78d22-bfe2-4227-93dd-0d2ad8c8cb2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e6e9d7c-c975-4991-8b41-dd29152a3a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_1d172c3f-e5b3-435e-86af-fb447a7b3e53" xlink:href="sgmo-20201231.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e6e9d7c-c975-4991-8b41-dd29152a3a08" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_1d172c3f-e5b3-435e-86af-fb447a7b3e53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_e859bfba-c0bc-41b6-b639-ee076538483d" xlink:href="sgmo-20201231.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e6e9d7c-c975-4991-8b41-dd29152a3a08" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_e859bfba-c0bc-41b6-b639-ee076538483d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2ceaa7dd-9cf4-45ff-8131-7d3cf25c4fc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:to="loc_srt_StatementGeographicalAxis_2ceaa7dd-9cf4-45ff-8131-7d3cf25c4fc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2ceaa7dd-9cf4-45ff-8131-7d3cf25c4fc0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2ceaa7dd-9cf4-45ff-8131-7d3cf25c4fc0" xlink:to="loc_srt_SegmentGeographicalDomain_2ceaa7dd-9cf4-45ff-8131-7d3cf25c4fc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2ceaa7dd-9cf4-45ff-8131-7d3cf25c4fc0" xlink:to="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_cba83fe4-e80d-4563-9501-2d58d4633357" xlink:href="sgmo-20201231.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_cba83fe4-e80d-4563-9501-2d58d4633357" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_e686828f-8239-4bb9-a7ff-7ac6ea1a0c25" xlink:href="sgmo-20201231.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:to="loc_sgmo_RichmondCaliforniaMember_e686828f-8239-4bb9-a7ff-7ac6ea1a0c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_99a40cb4-d1fc-4287-a7e6-46ffe8a3fb0e" xlink:href="sgmo-20201231.xsd#sgmo_ValbonneFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:to="loc_sgmo_ValbonneFranceMember_99a40cb4-d1fc-4287-a7e6-46ffe8a3fb0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ebe8392e-13e1-474d-90d1-9017a7af74c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:to="loc_srt_RangeAxis_ebe8392e-13e1-474d-90d1-9017a7af74c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ebe8392e-13e1-474d-90d1-9017a7af74c1_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ebe8392e-13e1-474d-90d1-9017a7af74c1" xlink:to="loc_srt_RangeMember_ebe8392e-13e1-474d-90d1-9017a7af74c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4618cd15-dc61-4c08-b400-ebdbc62d986a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ebe8392e-13e1-474d-90d1-9017a7af74c1" xlink:to="loc_srt_RangeMember_4618cd15-dc61-4c08-b400-ebdbc62d986a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_668f23d8-4c64-4e98-bc2e-502c5929d436" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4618cd15-dc61-4c08-b400-ebdbc62d986a" xlink:to="loc_srt_MinimumMember_668f23d8-4c64-4e98-bc2e-502c5929d436" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cb94499a-4080-40a2-869b-7ef7a1f75a58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4618cd15-dc61-4c08-b400-ebdbc62d986a" xlink:to="loc_srt_MaximumMember_cb94499a-4080-40a2-869b-7ef7a1f75a58" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="extended" id="i74888d64ad964e4b8831d9f2f96987b1_CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail" xlink:type="extended" id="i379f95a6752c453dbdf02a92450a3f16_CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c98b3cc4-030e-47a1-bcbb-da90f408b107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_b744f761-a430-4d51-8fa5-739162bb2a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c98b3cc4-030e-47a1-bcbb-da90f408b107" xlink:to="loc_us-gaap_ContractualObligation_b744f761-a430-4d51-8fa5-739162bb2a98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_089fe74b-3866-4319-a6d2-36c3d2bdc071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c98b3cc4-030e-47a1-bcbb-da90f408b107" xlink:to="loc_us-gaap_OtherCommitmentsTable_089fe74b-3866-4319-a6d2-36c3d2bdc071" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9bd3198-c266-4a1a-b7d8-a254835b75fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_089fe74b-3866-4319-a6d2-36c3d2bdc071" xlink:to="loc_srt_CounterpartyNameAxis_a9bd3198-c266-4a1a-b7d8-a254835b75fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9bd3198-c266-4a1a-b7d8-a254835b75fb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a9bd3198-c266-4a1a-b7d8-a254835b75fb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a9bd3198-c266-4a1a-b7d8-a254835b75fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88bc5dec-29e7-4440-8e43-61b5196628db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a9bd3198-c266-4a1a-b7d8-a254835b75fb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88bc5dec-29e7-4440-8e43-61b5196628db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrammerBioMAMember_b5804942-e7aa-4395-972c-fc649fcfd965" xlink:href="sgmo-20201231.xsd#sgmo_BrammerBioMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88bc5dec-29e7-4440-8e43-61b5196628db" xlink:to="loc_sgmo_BrammerBioMAMember_b5804942-e7aa-4395-972c-fc649fcfd965" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LonzaNetherlandsBVMember_41a32d77-1690-4f60-bfab-5ecbaf3d90f7" xlink:href="sgmo-20201231.xsd#sgmo_LonzaNetherlandsBVMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88bc5dec-29e7-4440-8e43-61b5196628db" xlink:to="loc_sgmo_LonzaNetherlandsBVMember_41a32d77-1690-4f60-bfab-5ecbaf3d90f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquity" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquity" xlink:type="extended" id="ie49906fcab854493ad4a4e96241c7140_StockholdersEquity"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="extended" id="i653a55be56d843e79ea078deccabffd5_StockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended" id="i08aed13b2fcc4de2b1c64c133a806643_StockholdersEquityAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8f351d2f-caac-4928-aec0-8e06809b2d15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8f351d2f-caac-4928-aec0-8e06809b2d15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_391d6991-e1d5-4df8-ae34-2474a698a6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_391d6991-e1d5-4df8-ae34-2474a698a6de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7fca691e-43d4-46a2-8ce8-c84996d80656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7fca691e-43d4-46a2-8ce8-c84996d80656" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b15d1105-08f9-4414-a3f2-ead6f5d7cb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b15d1105-08f9-4414-a3f2-ead6f5d7cb29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_338da8e0-a366-48bd-802b-4134c443d31e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_338da8e0-a366-48bd-802b-4134c443d31e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d567ce90-30ed-4340-82a6-2633d516c825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d567ce90-30ed-4340-82a6-2633d516c825" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dbe6b7d9-b492-44cc-a24c-6f4d78e147f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dbe6b7d9-b492-44cc-a24c-6f4d78e147f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_873e6e5b-4ffe-4b42-8c89-e42158268b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_873e6e5b-4ffe-4b42-8c89-e42158268b36" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_cff06ced-0ff9-4737-a20a-bdfbb8a78be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_cff06ced-0ff9-4737-a20a-bdfbb8a78be6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_8b821b6d-d0bd-4f39-9b8d-f550a5c7cfee" xlink:href="sgmo-20201231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_8b821b6d-d0bd-4f39-9b8d-f550a5c7cfee" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_b2a1caec-6525-4cd0-b5f8-cff9afcf342e" xlink:href="sgmo-20201231.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_b2a1caec-6525-4cd0-b5f8-cff9afcf342e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b1c8bed6-1a53-4be6-be23-70ad5061b3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b1c8bed6-1a53-4be6-be23-70ad5061b3ed" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_f964664f-995a-4684-b001-83b3177fc854" xlink:href="sgmo-20201231.xsd#sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_f964664f-995a-4684-b001-83b3177fc854" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cd956630-5eb2-4814-9526-5d023a837ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cd956630-5eb2-4814-9526-5d023a837ed6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74d218da-1cff-4b57-b184-7e39d6f89e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74d218da-1cff-4b57-b184-7e39d6f89e4e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SpecifiedStockholderOwnershipPercentage_6a17237a-59a3-4ee4-8684-41ff088eb598" xlink:href="sgmo-20201231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_SpecifiedStockholderOwnershipPercentage_6a17237a-59a3-4ee4-8684-41ff088eb598" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_d15052d7-7659-48a3-8947-5e8bab425080" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_d15052d7-7659-48a3-8947-5e8bab425080" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_1c550322-609a-48c7-b7e6-03087a3f9f18" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_1c550322-609a-48c7-b7e6-03087a3f9f18" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fcab35c2-3555-47cd-9fc1-dda0bf08a9c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fcab35c2-3555-47cd-9fc1-dda0bf08a9c2" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fc9e787b-da9b-4c6d-945e-6217ab0badb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fc9e787b-da9b-4c6d-945e-6217ab0badb0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_52142f7c-ba12-4bab-a62c-34614363eaf4" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_52142f7c-ba12-4bab-a62c-34614363eaf4" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonStockExchangeRatio_9b679f5b-b03b-41f1-ba95-0011d1ed0c0a" xlink:href="sgmo-20201231.xsd#sgmo_CommonStockExchangeRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_CommonStockExchangeRatio_9b679f5b-b03b-41f1-ba95-0011d1ed0c0a" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_49f41102-28ed-4206-8696-a70035009485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_49f41102-28ed-4206-8696-a70035009485" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1563c19a-1a27-4caa-969a-9ec40c42e882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1563c19a-1a27-4caa-969a-9ec40c42e882" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanOfferingPeriod_5dcb8a46-d61c-45b7-943a-e4b67c3658a1" xlink:href="sgmo-20201231.xsd#sgmo_PurchasePlanOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_PurchasePlanOfferingPeriod_5dcb8a46-d61c-45b7-943a-e4b67c3658a1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanPurchasePeriod_d69336de-56da-4b04-ba39-7b263fdefe85" xlink:href="sgmo-20201231.xsd#sgmo_PurchasePlanPurchasePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_PurchasePlanPurchasePeriod_d69336de-56da-4b04-ba39-7b263fdefe85" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8c683a5a-7898-4860-bf16-58a86de66bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8c683a5a-7898-4860-bf16-58a86de66bca" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fd72dc51-d826-4c50-95a9-989bead8fda0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fd72dc51-d826-4c50-95a9-989bead8fda0" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f07389d1-5006-4f93-b110-a0cdf115705b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f07389d1-5006-4f93-b110-a0cdf115705b" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1a72c19e-7bbe-4b05-8c88-6f8e6b54a7c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1a72c19e-7bbe-4b05-8c88-6f8e6b54a7c6" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5eedafd2-874c-404e-8896-d680889f45c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5eedafd2-874c-404e-8896-d680889f45c9" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_a8b72b52-6cd7-4cee-9ea5-772ee5053fdb" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_a8b72b52-6cd7-4cee-9ea5-772ee5053fdb" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_610608a6-a268-4a6c-a981-cedda2b75dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_610608a6-a268-4a6c-a981-cedda2b75dc0" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d8c09248-8391-4f8a-a066-a98fbb895ace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d8c09248-8391-4f8a-a066-a98fbb895ace" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0bae2a82-2014-4260-bc59-536aaf41bf33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0bae2a82-2014-4260-bc59-536aaf41bf33" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4d491d4b-516b-4fe3-aee4-5ced62ef293a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4d491d4b-516b-4fe3-aee4-5ced62ef293a" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b88efe6c-51d2-4a72-ac79-faa45e08c17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b88efe6c-51d2-4a72-ac79-faa45e08c17a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b88efe6c-51d2-4a72-ac79-faa45e08c17a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b88efe6c-51d2-4a72-ac79-faa45e08c17a" xlink:to="loc_us-gaap_EquityComponentDomain_b88efe6c-51d2-4a72-ac79-faa45e08c17a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d45aa1ac-e5f4-4d4f-a703-7ec30f8f8295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b88efe6c-51d2-4a72-ac79-faa45e08c17a" xlink:to="loc_us-gaap_EquityComponentDomain_d45aa1ac-e5f4-4d4f-a703-7ec30f8f8295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6c0a7efa-f9a5-4ce8-a3e0-dd739026887a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_d45aa1ac-e5f4-4d4f-a703-7ec30f8f8295" xlink:to="loc_us-gaap_CommonStockMember_6c0a7efa-f9a5-4ce8-a3e0-dd739026887a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3d702d71-f16d-41bf-8a40-ec1a8d97b700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3d702d71-f16d-41bf-8a40-ec1a8d97b700" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d702d71-f16d-41bf-8a40-ec1a8d97b700_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d702d71-f16d-41bf-8a40-ec1a8d97b700" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d702d71-f16d-41bf-8a40-ec1a8d97b700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ec401bd-3341-48c2-92d3-ed5ab05539ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d702d71-f16d-41bf-8a40-ec1a8d97b700" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ec401bd-3341-48c2-92d3-ed5ab05539ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_69010e07-8eda-4bc3-a1d4-8bf18d1f613e" xlink:href="sgmo-20201231.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ec401bd-3341-48c2-92d3-ed5ab05539ee" xlink:to="loc_sgmo_StockPurchaseAgreementMember_69010e07-8eda-4bc3-a1d4-8bf18d1f613e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_adeeee8c-9e58-4815-bd41-ee9bcef2d320" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_srt_CounterpartyNameAxis_adeeee8c-9e58-4815-bd41-ee9bcef2d320" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_adeeee8c-9e58-4815-bd41-ee9bcef2d320_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_adeeee8c-9e58-4815-bd41-ee9bcef2d320" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_adeeee8c-9e58-4815-bd41-ee9bcef2d320_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd76b93c-1c6e-4776-8d89-ad6e71dfc477" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_adeeee8c-9e58-4815-bd41-ee9bcef2d320" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd76b93c-1c6e-4776-8d89-ad6e71dfc477" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_caec44f7-6a9c-4641-b5d0-0b29832f7280" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd76b93c-1c6e-4776-8d89-ad6e71dfc477" xlink:to="loc_sgmo_BiogenMAIncMember_caec44f7-6a9c-4641-b5d0-0b29832f7280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_08c9d2f5-d702-4595-9ce4-3cfa35a13a26" xlink:href="sgmo-20201231.xsd#sgmo_JefferiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd76b93c-1c6e-4776-8d89-ad6e71dfc477" xlink:to="loc_sgmo_JefferiesLLCMember_08c9d2f5-d702-4595-9ce4-3cfa35a13a26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98bb01b4-aba8-4957-af6a-3f1b68966365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98bb01b4-aba8-4957-af6a-3f1b68966365" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98bb01b4-aba8-4957-af6a-3f1b68966365_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98bb01b4-aba8-4957-af6a-3f1b68966365" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_98bb01b4-aba8-4957-af6a-3f1b68966365_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_74a616ec-1849-4c60-9b1f-b2d3b54b9721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98bb01b4-aba8-4957-af6a-3f1b68966365" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_74a616ec-1849-4c60-9b1f-b2d3b54b9721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_a6f2424e-4701-4cdc-bce2-95f8b80b8374" xlink:href="sgmo-20201231.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_74a616ec-1849-4c60-9b1f-b2d3b54b9721" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_a6f2424e-4701-4cdc-bce2-95f8b80b8374" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_53f4455e-7c0c-49c8-8131-c3c987ab7e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_AwardTypeAxis_53f4455e-7c0c-49c8-8131-c3c987ab7e03" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53f4455e-7c0c-49c8-8131-c3c987ab7e03_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_53f4455e-7c0c-49c8-8131-c3c987ab7e03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53f4455e-7c0c-49c8-8131-c3c987ab7e03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5987df4d-1869-49cf-8f8a-f4e8c6471b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_53f4455e-7c0c-49c8-8131-c3c987ab7e03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5987df4d-1869-49cf-8f8a-f4e8c6471b8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eacda993-e871-491d-a5b0-97fab619755a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5987df4d-1869-49cf-8f8a-f4e8c6471b8b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eacda993-e871-491d-a5b0-97fab619755a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c61de8ad-cf8a-436c-a453-ab022975201a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5987df4d-1869-49cf-8f8a-f4e8c6471b8b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c61de8ad-cf8a-436c-a453-ab022975201a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a6070de-48e1-480b-a49b-56a7298dfd6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_srt_RangeAxis_1a6070de-48e1-480b-a49b-56a7298dfd6f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1a6070de-48e1-480b-a49b-56a7298dfd6f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1a6070de-48e1-480b-a49b-56a7298dfd6f" xlink:to="loc_srt_RangeMember_1a6070de-48e1-480b-a49b-56a7298dfd6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0837df3-cbb5-410c-859c-d10a2e57509c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1a6070de-48e1-480b-a49b-56a7298dfd6f" xlink:to="loc_srt_RangeMember_b0837df3-cbb5-410c-859c-d10a2e57509c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_642dc766-c4be-4cf4-974f-39b857133a45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b0837df3-cbb5-410c-859c-d10a2e57509c" xlink:to="loc_srt_MaximumMember_642dc766-c4be-4cf4-974f-39b857133a45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2de5ef28-a80e-443f-b1b2-d2a78ae94a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_PlanNameAxis_2de5ef28-a80e-443f-b1b2-d2a78ae94a62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_2de5ef28-a80e-443f-b1b2-d2a78ae94a62_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_2de5ef28-a80e-443f-b1b2-d2a78ae94a62" xlink:to="loc_us-gaap_PlanNameDomain_2de5ef28-a80e-443f-b1b2-d2a78ae94a62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_2de5ef28-a80e-443f-b1b2-d2a78ae94a62" xlink:to="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember_39651ebd-39b3-499c-8979-ad82fe4085b0" xlink:href="sgmo-20201231.xsd#sgmo_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:to="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember_39651ebd-39b3-499c-8979-ad82fe4085b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember_35f38180-e18e-46b1-98de-3aa87aa65842" xlink:href="sgmo-20201231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:to="loc_sgmo_EmployeeStockPurchasePlanMember_35f38180-e18e-46b1-98de-3aa87aa65842" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_Restated2018StockIncentivePlanMember_0b616e60-7dc3-49ee-91f4-fdaebe7892d0" xlink:href="sgmo-20201231.xsd#sgmo_Restated2018StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:to="loc_sgmo_Restated2018StockIncentivePlanMember_0b616e60-7dc3-49ee-91f4-fdaebe7892d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e624518c-1180-40cf-b83e-a92e2186961d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_VestingAxis_e624518c-1180-40cf-b83e-a92e2186961d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_e624518c-1180-40cf-b83e-a92e2186961d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_e624518c-1180-40cf-b83e-a92e2186961d" xlink:to="loc_us-gaap_VestingDomain_e624518c-1180-40cf-b83e-a92e2186961d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_e624518c-1180-40cf-b83e-a92e2186961d" xlink:to="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8399aa7c-73f9-414b-93cb-912022943203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8399aa7c-73f9-414b-93cb-912022943203" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b489f875-8fea-448b-9ac9-d1f98b3f951f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b489f875-8fea-448b-9ac9-d1f98b3f951f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_af72d033-0e0f-4404-b530-6134e40c71a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_af72d033-0e0f-4404-b530-6134e40c71a1" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquitySummaryofStockOptionActivityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="extended" id="ic0375a1246ff453dae3234f0b45173ee_StockholdersEquitySummaryofStockOptionActivityDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="extended" id="ie0433ce54d0f4dff9b6ae7b68ca218f0_StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensation"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="extended" id="i01fa889404ca421ca441f3834e74bcf8_StockBasedCompensation"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="extended" id="i9966237700234e0a9aab4b9831adaa78_StockBasedCompensationTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended" id="i31826491658f4b798264b860bd1c6bc2_StockBasedCompensationStockBasedCompensationExpenseDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b5083a19-8ca6-4ba5-b938-dd6222b97718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2523c2b0-74fb-4604-81c8-f40bfce5f84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b5083a19-8ca6-4ba5-b938-dd6222b97718" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2523c2b0-74fb-4604-81c8-f40bfce5f84b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f498b5b4-f8ed-4296-b668-500602aaf977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b5083a19-8ca6-4ba5-b938-dd6222b97718" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f498b5b4-f8ed-4296-b668-500602aaf977" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e9d5ecae-bc31-456c-ad34-778f248cc6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f498b5b4-f8ed-4296-b668-500602aaf977" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e9d5ecae-bc31-456c-ad34-778f248cc6e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e9d5ecae-bc31-456c-ad34-778f248cc6e0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e9d5ecae-bc31-456c-ad34-778f248cc6e0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e9d5ecae-bc31-456c-ad34-778f248cc6e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e21d7b38-682c-4ce9-9e8b-11feb5bac866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e9d5ecae-bc31-456c-ad34-778f248cc6e0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e21d7b38-682c-4ce9-9e8b-11feb5bac866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9750b1aa-cb7d-423d-bac1-a44c049f5b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e21d7b38-682c-4ce9-9e8b-11feb5bac866" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9750b1aa-cb7d-423d-bac1-a44c049f5b63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ea02ee29-51fd-488e-922f-e62cec3de3a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e21d7b38-682c-4ce9-9e8b-11feb5bac866" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ea02ee29-51fd-488e-922f-e62cec3de3a4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended" id="i46b4a66485034d209112fcf03ece7941_StockBasedCompensationAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_79731eaf-6dd9-400b-9ba7-d6e9f03b478d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_79731eaf-6dd9-400b-9ba7-d6e9f03b478d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53280104-203e-4075-96a4-43318dba4c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53280104-203e-4075-96a4-43318dba4c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c7493655-b6ce-4c0d-9aa5-50ab968e8559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c7493655-b6ce-4c0d-9aa5-50ab968e8559" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a30d863c-964c-4894-9b18-4ab0fabe473a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a30d863c-964c-4894-9b18-4ab0fabe473a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bfff8279-bf7e-42a5-995c-87ef7e36554d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bfff8279-bf7e-42a5-995c-87ef7e36554d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_07528df0-dcd5-4859-a773-010885d06ba5" xlink:href="sgmo-20201231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_07528df0-dcd5-4859-a773-010885d06ba5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_79807b3f-e75c-4ac3-b78a-c98c4215e95c" xlink:href="sgmo-20201231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_79807b3f-e75c-4ac3-b78a-c98c4215e95c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53764305-ed49-4240-980d-f31094c72f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53764305-ed49-4240-980d-f31094c72f06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3d5c89ea-c30e-4717-9901-b73d51358ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53764305-ed49-4240-980d-f31094c72f06" xlink:to="loc_us-gaap_AwardTypeAxis_3d5c89ea-c30e-4717-9901-b73d51358ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d5c89ea-c30e-4717-9901-b73d51358ea3_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3d5c89ea-c30e-4717-9901-b73d51358ea3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3d5c89ea-c30e-4717-9901-b73d51358ea3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c96b80a5-14f9-4f3d-b655-7d218b20ed78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3d5c89ea-c30e-4717-9901-b73d51358ea3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c96b80a5-14f9-4f3d-b655-7d218b20ed78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d78d2601-1be3-4d7c-8e4b-b26c4c38d4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c96b80a5-14f9-4f3d-b655-7d218b20ed78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d78d2601-1be3-4d7c-8e4b-b26c4c38d4a5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="extended" id="i5511a272be4e4737bf9fb3e28ea6ff21_StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7b453e7d-bd63-48ba-9d8b-89c28270b72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7b453e7d-bd63-48ba-9d8b-89c28270b72d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_01a86923-974a-47c8-a31b-13ed26152313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_01a86923-974a-47c8-a31b-13ed26152313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7a25f7b3-3f64-476b-9898-0e6b6cf3b173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7a25f7b3-3f64-476b-9898-0e6b6cf3b173" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4e1989ea-2f99-4281-80b5-9a142a310546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4e1989ea-2f99-4281-80b5-9a142a310546" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86b0e1aa-a978-42c5-9a26-a135352ca921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86b0e1aa-a978-42c5-9a26-a135352ca921" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61e4a3b1-6845-498e-b803-a632b3b5d4c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86b0e1aa-a978-42c5-9a26-a135352ca921" xlink:to="loc_srt_RangeAxis_61e4a3b1-6845-498e-b803-a632b3b5d4c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61e4a3b1-6845-498e-b803-a632b3b5d4c0_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_61e4a3b1-6845-498e-b803-a632b3b5d4c0" xlink:to="loc_srt_RangeMember_61e4a3b1-6845-498e-b803-a632b3b5d4c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26f9f4b8-ab03-4135-8073-8bd1654994e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_61e4a3b1-6845-498e-b803-a632b3b5d4c0" xlink:to="loc_srt_RangeMember_26f9f4b8-ab03-4135-8073-8bd1654994e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b123453-90aa-4317-946d-0dfe7e7ca66a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_26f9f4b8-ab03-4135-8073-8bd1654994e4" xlink:to="loc_srt_MinimumMember_5b123453-90aa-4317-946d-0dfe7e7ca66a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79cd2951-1574-42fc-b976-a42b44e20113" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_26f9f4b8-ab03-4135-8073-8bd1654994e4" xlink:to="loc_srt_MaximumMember_79cd2951-1574-42fc-b976-a42b44e20113" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_40ba1711-01bf-4de0-b757-a231bf3ce79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86b0e1aa-a978-42c5-9a26-a135352ca921" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_40ba1711-01bf-4de0-b757-a231bf3ce79e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_40ba1711-01bf-4de0-b757-a231bf3ce79e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_40ba1711-01bf-4de0-b757-a231bf3ce79e" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_40ba1711-01bf-4de0-b757-a231bf3ce79e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c09a2d99-eeaf-4b68-bdf8-e9dc61b17660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_40ba1711-01bf-4de0-b757-a231bf3ce79e" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c09a2d99-eeaf-4b68-bdf8-e9dc61b17660" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a7c67ff6-c4a7-4a23-bb9f-88758259c765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c09a2d99-eeaf-4b68-bdf8-e9dc61b17660" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a7c67ff6-c4a7-4a23-bb9f-88758259c765" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="extended" id="ib8613ce151cb42e09435e065b316aee4_StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a9d6d7a4-7ab7-499e-8e1f-38702264193e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a9d6d7a4-7ab7-499e-8e1f-38702264193e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ca8e6e61-e0e1-4f90-80cc-0949dee31afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ca8e6e61-e0e1-4f90-80cc-0949dee31afa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5a12d56a-c8f7-4cb4-b5f1-c0a2be9e82e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5a12d56a-c8f7-4cb4-b5f1-c0a2be9e82e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fa42866-3f9d-4120-b01d-f1222cd74553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fa42866-3f9d-4120-b01d-f1222cd74553" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc27100a-5f90-44a7-ac3f-c317d0963e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc27100a-5f90-44a7-ac3f-c317d0963e2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fdcac7f7-0071-4c36-b0f6-2a13ea13f43d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc27100a-5f90-44a7-ac3f-c317d0963e2f" xlink:to="loc_us-gaap_PlanNameAxis_fdcac7f7-0071-4c36-b0f6-2a13ea13f43d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fdcac7f7-0071-4c36-b0f6-2a13ea13f43d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_fdcac7f7-0071-4c36-b0f6-2a13ea13f43d" xlink:to="loc_us-gaap_PlanNameDomain_fdcac7f7-0071-4c36-b0f6-2a13ea13f43d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f59513c8-5677-444a-85fb-0e71d1a2d90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_fdcac7f7-0071-4c36-b0f6-2a13ea13f43d" xlink:to="loc_us-gaap_PlanNameDomain_f59513c8-5677-444a-85fb-0e71d1a2d90c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember_af1d8b43-bc0c-4630-b6e6-f606493c9d1a" xlink:href="sgmo-20201231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f59513c8-5677-444a-85fb-0e71d1a2d90c" xlink:to="loc_sgmo_EmployeeStockPurchasePlanMember_af1d8b43-bc0c-4630-b6e6-f606493c9d1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7c69842-ce4b-4002-9005-b76461c637fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc27100a-5f90-44a7-ac3f-c317d0963e2f" xlink:to="loc_srt_RangeAxis_e7c69842-ce4b-4002-9005-b76461c637fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e7c69842-ce4b-4002-9005-b76461c637fa_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e7c69842-ce4b-4002-9005-b76461c637fa" xlink:to="loc_srt_RangeMember_e7c69842-ce4b-4002-9005-b76461c637fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f848e004-d554-4861-9f67-21cd7fdd13a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e7c69842-ce4b-4002-9005-b76461c637fa" xlink:to="loc_srt_RangeMember_f848e004-d554-4861-9f67-21cd7fdd13a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_81de429f-41c1-405e-96b7-da7eaf5133dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f848e004-d554-4861-9f67-21cd7fdd13a3" xlink:to="loc_srt_MinimumMember_81de429f-41c1-405e-96b7-da7eaf5133dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_30e08871-7e03-4db1-95a5-e4e3a495438b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_f848e004-d554-4861-9f67-21cd7fdd13a3" xlink:to="loc_srt_MaximumMember_30e08871-7e03-4db1-95a5-e4e3a495438b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sgmo-20201231.xsd#EmployeeBenefitPlan"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="extended" id="id6f67d7b977f4e088780768e0fe58f54_EmployeeBenefitPlan"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#EmployeeBenefitPlanAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="extended" id="i6c88dc7e2f864b41a47d300028d5ff49_EmployeeBenefitPlanAdditionalInformationDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxes" xlink:type="extended" id="i1fd7798668df4f0a89f8e64131ff34d7_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="extended" id="i0ba894124a06481f9a3cd1a044a998fa_IncomeTaxesTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="extended" id="i372af49438934133983602a5aad8350e_IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="extended" id="i5168364b2f764340884580a36f87e198_IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="extended" id="ib1915cf2c96c4e5783461f1894912dcc_IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="extended" id="i7885e319ff51453580c89d4017dd73c7_IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails" xlink:type="extended" id="i6670e9aa70b54915ae69bf015d933037_IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0213a8a6-fabf-4674-b4fe-ca82b2a5f059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_0213a8a6-fabf-4674-b4fe-ca82b2a5f059" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f212432e-a609-4f36-8d0f-82b017bc76ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f212432e-a609-4f36-8d0f-82b017bc76ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5848dbef-bd5d-4853-85b2-73f0d26cdf91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5848dbef-bd5d-4853-85b2-73f0d26cdf91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesTable_041841b6-a1cb-4945-bb76-b16fa96ee914" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:to="loc_sgmo_IncomeTaxesTable_041841b6-a1cb-4945-bb76-b16fa96ee914" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1cea14b6-3c7e-4788-aecb-1ad9ec14a912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_IncomeTaxesTable_041841b6-a1cb-4945-bb76-b16fa96ee914" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1cea14b6-3c7e-4788-aecb-1ad9ec14a912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_1cea14b6-3c7e-4788-aecb-1ad9ec14a912_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1cea14b6-3c7e-4788-aecb-1ad9ec14a912" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_1cea14b6-3c7e-4788-aecb-1ad9ec14a912_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_58107d03-2188-45fd-ad7f-b0d7ff8cce14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1cea14b6-3c7e-4788-aecb-1ad9ec14a912" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_58107d03-2188-45fd-ad7f-b0d7ff8cce14" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_0e69c2b8-d817-4097-896a-de488a75e89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_58107d03-2188-45fd-ad7f-b0d7ff8cce14" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_0e69c2b8-d817-4097-896a-de488a75e89a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended" id="i34020b5727d74c8997569f6cd0bb935f_IncomeTaxesAdditionalInformationDetail">
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f25bc1fe-b869-4724-bfdf-e00db091befc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f25bc1fe-b869-4724-bfdf-e00db091befc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_8b183c8b-66c5-4839-9b4e-ec7da1119811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_8b183c8b-66c5-4839-9b4e-ec7da1119811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3e36946c-ef5d-4fb6-bcf6-1091f131820a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3e36946c-ef5d-4fb6-bcf6-1091f131820a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_43ff113a-3666-48ef-872e-e8a4200a8772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_43ff113a-3666-48ef-872e-e8a4200a8772" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_e4cfe851-4bdd-4421-8aa3-b02e2565a8a7" xlink:href="sgmo-20201231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_e4cfe851-4bdd-4421-8aa3-b02e2565a8a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_c979c06a-6372-4def-b173-1327b1f8c47f" xlink:href="sgmo-20201231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_c979c06a-6372-4def-b173-1327b1f8c47f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_750d5792-e278-49ca-bdfd-215b7cd053b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_750d5792-e278-49ca-bdfd-215b7cd053b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesTable_f42680f2-1c36-49d2-898d-23f04ba9cf2b" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_sgmo_IncomeTaxesTable_f42680f2-1c36-49d2-898d-23f04ba9cf2b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8f7532d0-059b-474f-b746-3f0aef875583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sgmo_IncomeTaxesTable_f42680f2-1c36-49d2-898d-23f04ba9cf2b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8f7532d0-059b-474f-b746-3f0aef875583" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_8f7532d0-059b-474f-b746-3f0aef875583_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8f7532d0-059b-474f-b746-3f0aef875583" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_8f7532d0-059b-474f-b746-3f0aef875583_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e5324498-ad9c-4720-a24d-393bdca4105d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8f7532d0-059b-474f-b746-3f0aef875583" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e5324498-ad9c-4720-a24d-393bdca4105d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_d69ae4a8-759f-4d99-9eef-37fac719e9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5324498-ad9c-4720-a24d-393bdca4105d" xlink:to="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_d69ae4a8-759f-4d99-9eef-37fac719e9af" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="extended" id="i34619767654a4e48b9b35df2f6d0e2ba_IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="sgmo-20201231.xsd#RelatedPartyDisclosures"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="extended" id="i837fcdbfce26405dbea503ae1effdb13_RelatedPartyDisclosures"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosuresDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#RelatedPartyDisclosuresDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosuresDetail" xlink:type="extended" id="i923ba5466ea94ff19274be713be6856a_RelatedPartyDisclosuresDetail">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6dd8d5aa-19cc-4acf-bcbe-76187049837d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_b12773e4-e4d8-4a85-868c-758afeb2fce6" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6dd8d5aa-19cc-4acf-bcbe-76187049837d" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_b12773e4-e4d8-4a85-868c-758afeb2fce6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_94e22c03-2d9f-4027-97bf-8dffd0665593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6dd8d5aa-19cc-4acf-bcbe-76187049837d" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_94e22c03-2d9f-4027-97bf-8dffd0665593" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6dd8d5aa-19cc-4acf-bcbe-76187049837d" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bc87c625-f75e-46ae-bd79-78adc5fb6ba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:to="loc_srt_CounterpartyNameAxis_bc87c625-f75e-46ae-bd79-78adc5fb6ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc87c625-f75e-46ae-bd79-78adc5fb6ba2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_bc87c625-f75e-46ae-bd79-78adc5fb6ba2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bc87c625-f75e-46ae-bd79-78adc5fb6ba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5e24490-9b4f-4e88-9c0c-2676358cd434" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_bc87c625-f75e-46ae-bd79-78adc5fb6ba2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5e24490-9b4f-4e88-9c0c-2676358cd434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FormerExecutiveOfSangamoFranceMember_e1e54b34-186d-40f0-b2aa-b8c94df1805a" xlink:href="sgmo-20201231.xsd#sgmo_FormerExecutiveOfSangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5e24490-9b4f-4e88-9c0c-2676358cd434" xlink:to="loc_sgmo_FormerExecutiveOfSangamoFranceMember_e1e54b34-186d-40f0-b2aa-b8c94df1805a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_16cfb659-cad7-419b-83c9-5a2fec0baf41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_16cfb659-cad7-419b-83c9-5a2fec0baf41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16cfb659-cad7-419b-83c9-5a2fec0baf41_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_16cfb659-cad7-419b-83c9-5a2fec0baf41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_16cfb659-cad7-419b-83c9-5a2fec0baf41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0bd52aa-1f1c-4683-b541-8472a6d17d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_16cfb659-cad7-419b-83c9-5a2fec0baf41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0bd52aa-1f1c-4683-b541-8472a6d17d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_4d893347-debc-48fe-a082-08512187871a" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0bd52aa-1f1c-4683-b541-8472a6d17d82" xlink:to="loc_sgmo_SangamoFranceMember_4d893347-debc-48fe-a082-08512187871a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3daf9865-4594-47cb-a767-331294f9b5fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3daf9865-4594-47cb-a767-331294f9b5fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3daf9865-4594-47cb-a767-331294f9b5fe_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3daf9865-4594-47cb-a767-331294f9b5fe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3daf9865-4594-47cb-a767-331294f9b5fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5136600-b715-4630-a4d3-529780fd09dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3daf9865-4594-47cb-a767-331294f9b5fe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5136600-b715-4630-a4d3-529780fd09dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_33a4ab75-6129-487e-bbcb-c87630e301c6" xlink:href="sgmo-20201231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5136600-b715-4630-a4d3-529780fd09dc" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_33a4ab75-6129-487e-bbcb-c87630e301c6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="sgmo-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended" id="ia772a81b42fc4ca38bf5d92b66d6709b_QuarterlyFinancialDataUnaudited"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended" id="i6a8afcda213245fc9aa215f1b97fa5da_QuarterlyFinancialDataUnauditedTables"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="extended" id="icc245aafe49a41b292d19d07df0cecd5_QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgmo-20201231.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SubsequentEvents" xlink:type="extended" id="if0531faa2b2444f582a0c04eaf4a5c3e_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="extended" id="i41de2f3d963c4fb5ba009a1cdf8a971f_SubsequentEventsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e76027e8-bec9-4fe9-b072-a9d547400e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e76027e8-bec9-4fe9-b072-a9d547400e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross_74196c41-9536-47ea-96c9-8e8d2e4c96b7" xlink:href="sgmo-20201231.xsd#sgmo_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:to="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross_74196c41-9536-47ea-96c9-8e8d2e4c96b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d6369842-2c33-4e1b-b3b1-6114a71c7c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d6369842-2c33-4e1b-b3b1-6114a71c7c81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4064137c-a53a-42ea-8515-b52e4a76f6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:to="loc_us-gaap_SubsequentEventTable_4064137c-a53a-42ea-8515-b52e4a76f6ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_11720840-6c54-42a9-84c8-6c0d986d05b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4064137c-a53a-42ea-8515-b52e4a76f6ae" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_11720840-6c54-42a9-84c8-6c0d986d05b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_11720840-6c54-42a9-84c8-6c0d986d05b9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_11720840-6c54-42a9-84c8-6c0d986d05b9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_11720840-6c54-42a9-84c8-6c0d986d05b9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_344a2eb6-afa7-45f7-98f5-ff40b0ea260a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_11720840-6c54-42a9-84c8-6c0d986d05b9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_344a2eb6-afa7-45f7-98f5-ff40b0ea260a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_804f96a4-71db-40c1-be1e-bf04a504035d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_344a2eb6-afa7-45f7-98f5-ff40b0ea260a" xlink:to="loc_us-gaap_SubsequentEventMember_804f96a4-71db-40c1-be1e-bf04a504035d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b61f2bb9-0787-40ac-973f-34db0a003634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_4064137c-a53a-42ea-8515-b52e4a76f6ae" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b61f2bb9-0787-40ac-973f-34db0a003634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b61f2bb9-0787-40ac-973f-34db0a003634_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b61f2bb9-0787-40ac-973f-34db0a003634" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b61f2bb9-0787-40ac-973f-34db0a003634_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce3a092-be2e-4daa-a23b-667c859ea0a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b61f2bb9-0787-40ac-973f-34db0a003634" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce3a092-be2e-4daa-a23b-667c859ea0a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketStockOfferingMember_16c2aac8-3c84-4c6f-baae-fff5710dca85" xlink:href="sgmo-20201231.xsd#sgmo_AtTheMarketStockOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce3a092-be2e-4daa-a23b-667c859ea0a3" xlink:to="loc_sgmo_AtTheMarketStockOfferingMember_16c2aac8-3c84-4c6f-baae-fff5710dca85" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>sgmo-20201231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a450ce61-5a63-468d-aea1-980040e585ad,g:3eb33991-981d-4627-a625-d6dd25ee8674-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_d4ff914e-8b82-4353-bd24-912982da1f20_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_82c4b1ec-c4f2-4c3e-9d6d-b52243f1bbc7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9573d846-9364-49e4-975a-49a9d2686f23_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_06b54688-dd7b-467f-89a9-e996a64ac91b_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_e2a8c067-eda4-4cf0-b6f6-7c71bd915b2c_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_0a89072e-c5bc-462d-8eae-e33de5176b21_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6a050b12-98bf-4cc0-b8df-18a39b1ccd23_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_154544ae-a6f8-48e0-990f-4b1a56b2f5fb_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_61d0fb83-41ea-47d8-8113-9cc72977714b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional equity award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5650bc6c-d84c-482b-bc9a-094274b0e148_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_897b5aed-b018-40cf-8fee-aaa492c22fdf_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_7e9cccee-752a-4daa-9666-33db07842f07_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_b8a844cf-d5af-4803-a250-51a8662f7b03_terseLabel_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</link:label>
    <link:label id="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_label_en-US" xlink:label="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="lab_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_07f9188a-b8bd-4d3b-81ec-ea536c751c98_terseLabel_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average estimated fair value of shares purchased under ESPP plan (in dollars per share)</link:label>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_label_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan Rights Weighted Average Estimated Fair Value</link:label>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_documentation_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan rights weighted average estimated fair value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:href="sgmo-20201231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:to="lab_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6f6ca7e5-2d5f-4bb6-bbc8-144ead5a1e38_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestTable_b4febf25-d2b2-47c7-893d-314b62bea533_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestTable_label_en-US" xlink:label="lab_us-gaap_MinorityInterestTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestTable" xlink:to="lab_us-gaap_MinorityInterestTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_6c1e1e48-caf0-456e-b5c4-8e00aaa59999_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_2130d24d-1254-4701-bc94-043528507f18_terseLabel_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Stock Price Correlation</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_label_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Stock Price Correlation [Member]</link:label>
    <link:label id="lab_sgmo_MeasurementInputStockPriceCorrelationMember_documentation_en-US" xlink:label="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Stock Price Correlation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:href="sgmo-20201231.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:to="lab_sgmo_MeasurementInputStockPriceCorrelationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_11a76a0f-3de6-4660-8f0b-bf9ec85decdf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherProductsMember_76fd3a94-0f95-42ae-b461-d150299322d1_terseLabel_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_label_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_sgmo_OtherProductsMember_documentation_en-US" xlink:label="lab_sgmo_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember" xlink:href="sgmo-20201231.xsd#sgmo_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherProductsMember" xlink:to="lab_sgmo_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_86633cd3-10f6-4fe7-8c8b-08a31f908b9f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_53e827e9-a3a9-44c0-90b8-4029e019f8a4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualObligation_b9de7585-193e-4d69-aadb-d395764b892f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual obligation</link:label>
    <link:label id="lab_us-gaap_ContractualObligation_label_en-US" xlink:label="lab_us-gaap_ContractualObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualObligation" xlink:to="lab_us-gaap_ContractualObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_JefferiesLLCMember_c4e1bccf-35bf-4df3-8cae-311daafdbd62_terseLabel_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_label_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC [Member]</link:label>
    <link:label id="lab_sgmo_JefferiesLLCMember_documentation_en-US" xlink:label="lab_sgmo_JefferiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jefferies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember" xlink:href="sgmo-20201231.xsd#sgmo_JefferiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_JefferiesLLCMember" xlink:to="lab_sgmo_JefferiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTableTextBlock_699e5b01-16df-4ff5-bf09-7f0a38af2b38_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTableTextBlock" xlink:to="lab_us-gaap_OtherCommitmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7fac279d-d05e-4ae0-a199-fd2cb6307929_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f9746684-5a82-49a0-9f29-b71353ebd2a4_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d48947f8-7252-4d74-81e2-92fa338b6dbc_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_59f2eab8-36ca-4891-8164-60e5346ed64d_terseLabel_en-US" xlink:label="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum license annual fees specific reckoning period</link:label>
    <link:label id="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_label_en-US" xlink:label="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Sublicense Annual Fees Specific Reckoning Period</link:label>
    <link:label id="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_documentation_en-US" xlink:label="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum sublicense annual fees specific reckoning period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:href="sgmo-20201231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:to="lab_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1c2cf2e6-6d4a-41f1-858e-c1d8ea42f2d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_db42de89-ec3f-4a4f-965c-4c9d55ad93e8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_5fe1f636-666c-41c6-9568-80d91ff8ccfb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1143a891-49c3-4bdc-9c6c-02e9ba141bb3_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_04db9fe8-fbca-4472-8d47-58b038f5d4e9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_cbbd83d5-9a8d-430b-91f4-addfb8208a26_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_bca56887-36db-4b20-b339-4fe01d9e7871_periodStartLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of year</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_50449d83-3c6b-4e9c-a66c-d7fe6adcbf95_periodEndLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of year</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_1db18b53-66dd-42d8-9ef1-c02456d82417_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Lease Not Yet Commenced Amount</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Lease Not Yet Commenced Amount</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Lease Not Yet Commenced Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:href="sgmo-20201231.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:to="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SanofiMember_64f173d9-522a-467d-a498-7e43364b751e_terseLabel_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:label id="lab_sgmo_SanofiMember_label_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi [Member]</link:label>
    <link:label id="lab_sgmo_SanofiMember_documentation_en-US" xlink:label="lab_sgmo_SanofiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember" xlink:href="sgmo-20201231.xsd#sgmo_SanofiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SanofiMember" xlink:to="lab_sgmo_SanofiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_db79cbb9-7f30-4534-89e6-b68eba7a6868_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_6064e63b-41bd-494f-8b5f-2d9853c7daca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_09dcdcf1-f982-4618-be61-6dd088847adf_terseLabel_en-US" xlink:label="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions for tax positions of prior years</link:label>
    <link:label id="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</link:label>
    <link:label id="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_documentation_en-US" xlink:label="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits increase decrease resulting from prior period tax positions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:href="sgmo-20201231.xsd#sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="lab_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_344b7d39-1ee7-4ace-9ed1-38e73f296313_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_593e8421-4e2b-4ad7-b06c-6289a8f44c1c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_9040cad3-33da-43d8-93fa-ab2299d70c0a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses of available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7a301356-f7ef-486f-9dcf-02a2b570ab9e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_43637632-4b4b-4e61-8bd7-9668a09d76fd_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_757d7311-9708-4d3c-abcf-06d645ed8cd7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum percentage limit of employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_0c2bd788-3ec2-4c88-9f64-0ed813678d46_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options and RSUs outstanding (in shares)</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_c2d7c42e-5d1a-434a-a0c3-771adc111b03_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest upon acquisition of Sangamo France</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Business Combination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_12925ec1-c5b9-4a85-b9c3-dbbb9345ccfb_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_6e73d425-11a0-4933-b797-06e156fe2a3e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Awards, Tranche 2</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_bd1d56bd-1449-45da-ae6f-46937a967c33_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_de807fbf-d27e-498d-931c-bd38de5d3f74_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_22ebb335-d606-4f1b-bfd5-c0798587b385_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8c86fcc8-b9aa-4562-b04d-9d703e5978a7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_7c4a8937-66f4-4126-850a-e34f076c196c_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_625673dd-92cc-4a06-b778-b5ac3972e8f3_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_750bc7c9-1701-45b7-a1e5-dcd13379599d_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in fair value of free shares asset and liability</link:label>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_label_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Fair Value Of Free Shares Asset And Liability</link:label>
    <link:label id="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_documentation_en-US" xlink:label="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase In Fair Value Of Free Shares Asset And Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:href="sgmo-20201231.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:to="lab_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_ad58ed88-59d0-4f42-b605-62cb5b994295_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_c3aa7139-54f5-4de7-9b2f-89c2dc0955a1_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock percent under stock incentive plans for specified stockholder</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Percent For Specified Stockholder</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_978b68b0-4cd5-4021-8a6d-6b22ac8743ef_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_1e07fe48-d5e7-4ca2-b8ea-6fab8a484b4c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax at federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_f9e18862-32d8-4d47-848e-2d653252df28_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_99b28108-29ef-4360-8205-2563c55b805c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_c320c54b-a33b-40fd-9968-6eea7761e753_terseLabel_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_label_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California [Member]</link:label>
    <link:label id="lab_sgmo_RichmondCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_RichmondCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Richmond, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember" xlink:href="sgmo-20201231.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RichmondCaliforniaMember" xlink:to="lab_sgmo_RichmondCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_20cd1b8d-f4bf-4f77-87a6-42f25cf1a1b8_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_02ac437d-f778-4455-84af-459bf6e865ed_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum milestone payment receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:to="lab_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_0e1a2725-9419-4c45-8b64-ce34c26ff1c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5c97a36d-ecb6-4bec-8f9b-30ab8f2166e7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_4b168880-bb16-4baf-847f-01253a1b64ff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_71013883-7430-4f90-8d07-d216d838fb80_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Transaction Price</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementTransactionPrice" xlink:to="lab_sgmo_CollaborativeArrangementTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_7f2ae75c-e8a6-490a-8290-d529d4da495c_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0e94f480-5cb7-40b9-ba11-4f820f1f6ff4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_d1acd612-a102-4aeb-98ef-982c6370c1ee_terseLabel_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential amount to be funded for achievement of specified commercialized and sales milestones</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_label_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</link:label>
    <link:label id="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate additional revenue recognition milestone method revenue eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:href="sgmo-20201231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="lab_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_06163f1e-320d-4255-9a26-cc8a28cb3baf_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_73abbe5a-8849-41c6-9cd9-f7b14e1b0bcc_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_4a7fe33d-aa12-4c59-8b4f-945246446e52_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9cffb833-2e58-42b6-b892-38d5a12f8e26_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_649ad57a-c488-46f1-a814-5e6c7329a280_terseLabel_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of additional shares of Sangamo France</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_label_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest</link:label>
    <link:label id="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_documentation_en-US" xlink:label="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to additional paid in capital acquisition of non-controlling interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:href="sgmo-20201231.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:to="lab_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_539e1bed-c2cf-419e-894c-d3d4520e5e02_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost related to unvested stock options and RSU</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PurchasePlanPurchasePeriod_b683ab42-9f88-4ff4-a6a3-27c8ef742cf1_terseLabel_en-US" xlink:label="lab_sgmo_PurchasePlanPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase plan purchase period</link:label>
    <link:label id="lab_sgmo_PurchasePlanPurchasePeriod_label_en-US" xlink:label="lab_sgmo_PurchasePlanPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Plan Purchase Period</link:label>
    <link:label id="lab_sgmo_PurchasePlanPurchasePeriod_documentation_en-US" xlink:label="lab_sgmo_PurchasePlanPurchasePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase plan purchase period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanPurchasePeriod" xlink:href="sgmo-20201231.xsd#sgmo_PurchasePlanPurchasePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PurchasePlanPurchasePeriod" xlink:to="lab_sgmo_PurchasePlanPurchasePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_00d7987e-e6f5-4fd6-b36b-f3588ab00701_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_ce6faafc-bc1f-4764-9305-0b6e82c90283_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized loss before tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized loss before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20201231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BuildToSuitLeases_5afade60-2ca1-42b7-b579-5f3ecf15d18c_verboseLabel_en-US" xlink:label="lab_sgmo_BuildToSuitLeases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-suit leases</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeases_label_en-US" xlink:label="lab_sgmo_BuildToSuitLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build To Suit Leases</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeases_documentation_en-US" xlink:label="lab_sgmo_BuildToSuitLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build to suit leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeases" xlink:href="sgmo-20201231.xsd#sgmo_BuildToSuitLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BuildToSuitLeases" xlink:to="lab_sgmo_BuildToSuitLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_3d4eb5d5-e283-4217-b2be-6a2b455ec7c1_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified preclinical development clinical development and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_bd16588f-8b11-4c8d-bd6d-3b02b23d2086_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneThreeMember_3f16bbdc-a59e-402e-87b0-73f6c4b2f8cb_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_label_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneThreeMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneThreeMember" xlink:to="lab_sgmo_MilestoneThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_43be4c5c-8254-43bd-8e6f-0b8819dd4a90_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_8abd60fd-ed55-4951-bc23-c543b4522910_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_c52e6414-31d9-4816-8e90-72cde9a3109c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, maximum employer's contribution per employee</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShireAgMember_12180589-d872-475b-8fb8-19bfed873a34_terseLabel_en-US" xlink:label="lab_sgmo_ShireAgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire AG</link:label>
    <link:label id="lab_sgmo_ShireAgMember_label_en-US" xlink:label="lab_sgmo_ShireAgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire Ag [Member]</link:label>
    <link:label id="lab_sgmo_ShireAgMember_documentation_en-US" xlink:label="lab_sgmo_ShireAgMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shire ag.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShireAgMember" xlink:href="sgmo-20201231.xsd#sgmo_ShireAgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShireAgMember" xlink:to="lab_sgmo_ShireAgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a5a1e924-7347-4509-8e58-f48fa9354e34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_8dbaacf5-d298-42bb-8a80-2a3ca9d55822_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of milestones included in transaction price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_label_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Clinical Or Regulatory Milestones Included In Transaction Price</link:label>
    <link:label id="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_documentation_en-US" xlink:label="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of clinical or regulatory milestones included in transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:href="sgmo-20201231.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:to="lab_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_af58def3-ee73-41e7-bd2d-938681314472_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityMeasurementInput" xlink:to="lab_us-gaap_DerivativeLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_1de92d94-2ee8-4b8e-9a1c-e0021ad6250b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_fda0cdea-ebcd-4c15-b6f1-5c42bcc823fc_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_77b9f9d6-ae70-4d64-8dc3-b28a8ff67a34_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_9920175c-32dc-4d6a-aaba-020f0bf57d29_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_84ae131b-d128-4bb2-9c69-8847207eea73_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7a9f3af8-0b6a-4a0a-a34a-c8b370e99e40_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1ed50267-71f6-4b4a-ba33-1e656f2ac7b2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dfca7169-300c-44ff-a856-0b1d61db5719_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_f7be1f2b-b82a-4bbc-b67d-e2a682a8d6df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_Restated2018StockIncentivePlanMember_9fdbd3ff-4a2f-4631-9298-fd5d83c74bc3_terseLabel_en-US" xlink:label="lab_sgmo_Restated2018StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated 2018 Stock Incentive Plan</link:label>
    <link:label id="lab_sgmo_Restated2018StockIncentivePlanMember_label_en-US" xlink:label="lab_sgmo_Restated2018StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated 2018 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_sgmo_Restated2018StockIncentivePlanMember_documentation_en-US" xlink:label="lab_sgmo_Restated2018StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restated 2018 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_Restated2018StockIncentivePlanMember" xlink:href="sgmo-20201231.xsd#sgmo_Restated2018StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_Restated2018StockIncentivePlanMember" xlink:to="lab_sgmo_Restated2018StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_ca3f137d-ad5d-462b-a0a9-f3931470d1bd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Awards, Tranche 3</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_6980898d-d615-49b0-968b-8f1dc865c0ae_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Stock Price (USD) (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_7c3ce6fc-984f-4fa1-85b2-b8a810ed5394_negatedLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, gross unrealized (losses)</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_2acbe6f8-36c9-4593-9cf3-b8a7b7bb3238_totalLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, amortized cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Amortized Cost</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for Sale Securities Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare_89b9b3a0-2b27-4770-b34a-669779af9987_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, net Income (loss) per share</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Income (Loss) Per Share</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Net Income (Loss) Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementNetIncomeLossPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:to="lab_sgmo_CollaborativeArrangementNetIncomeLossPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_9aec7f07-5fad-49da-afac-fa82fcaa742a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate&#160;Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f9f00b56-e5f3-4aae-ac21-3091dc7e4296_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_c8cf9e7a-3875-4222-be1a-94e0a70b04cc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_6f51843b-69f0-443e-a4a1-a8a7c651d036_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_70a51c9f-c9fa-4901-b294-aeacfc7d6a8f_terseLabel_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease not yet commenced, area of real estate</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_label_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Lease Not Yet Commenced Area Of Real Estate</link:label>
    <link:label id="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_documentation_en-US" xlink:label="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Operating Lease Lease Not Yet Commenced Area Of Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:href="sgmo-20201231.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:to="lab_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_3d16f22f-87ba-444c-a20d-45f2be75c07f_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Option Pricing Method</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueOptionPricingModelMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Option Pricing Model [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:to="lab_us-gaap_ValuationTechniqueOptionPricingModelMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_80aaeb8c-54cd-42fc-9d91-96ef0612c27d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfResearchProgram_7ded26d7-c721-4622-bd9c-7902a41362fc_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research programs</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_label_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Research Program</link:label>
    <link:label id="lab_sgmo_NumberOfResearchProgram_documentation_en-US" xlink:label="lab_sgmo_NumberOfResearchProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of research program.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram" xlink:href="sgmo-20201231.xsd#sgmo_NumberOfResearchProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfResearchProgram" xlink:to="lab_sgmo_NumberOfResearchProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_376d1bdf-0d98-47e2-9915-c043b7a3a5c3_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on lease termination</link:label>
    <link:label id="lab_us-gaap_GainLossOnTerminationOfLease_label_en-US" xlink:label="lab_us-gaap_GainLossOnTerminationOfLease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnTerminationOfLease" xlink:to="lab_us-gaap_GainLossOnTerminationOfLease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_72eea542-b861-44f8-8ae8-47c73e3f9c7a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_97bc3a12-5405-42f8-a14e-da58aa19cbc2_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_b17653a0-e533-4820-8e78-ca42d8aedb58_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4b1e7b11-4806-46d9-a8ba-288d46ab27f0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b36e7652-29aa-4238-9370-aee3d965c10c_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_c82ef291-698b-4916-85d3-9d113978e5e5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_84baeb3e-4408-443d-8f6f-9b6b9ab1ec81_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LonzaNetherlandsBVMember_bc423cc7-1056-47ac-a261-b5a4ad6ec648_terseLabel_en-US" xlink:label="lab_sgmo_LonzaNetherlandsBVMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Netherlands, B.V.</link:label>
    <link:label id="lab_sgmo_LonzaNetherlandsBVMember_label_en-US" xlink:label="lab_sgmo_LonzaNetherlandsBVMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Netherlands, B.V. [Member]</link:label>
    <link:label id="lab_sgmo_LonzaNetherlandsBVMember_documentation_en-US" xlink:label="lab_sgmo_LonzaNetherlandsBVMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lonza Netherlands, B.V.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LonzaNetherlandsBVMember" xlink:href="sgmo-20201231.xsd#sgmo_LonzaNetherlandsBVMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LonzaNetherlandsBVMember" xlink:to="lab_sgmo_LonzaNetherlandsBVMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_bf67a7aa-23ab-47b9-ae2b-081158fdc2e5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_52a7a80d-4a88-4e80-84a2-797d551c968b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_89adde8f-7b2f-4daa-8e3d-e72c7a60b31f_negatedTerseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, increase (decrease) in net income (loss)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:to="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_3a2ee45e-917a-441f-b94e-a775348d6b1b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of additional Sangamo France shares</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_61312833-4fa5-46b3-a788-b4f19a9eea90_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional interest in subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_03b4b2d8-94cb-48d2-b5bf-7df90fa48e32_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_10720f82-6ea2-4a87-ba8d-89040ba6f1dd_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition estimated fair value liabilities of free shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Liabilities Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Liabilities Of Free Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_115fb356-a621-4348-afff-73c068e9efff_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_2e83aa79-a503-4465-835f-f8c5d63b4584_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_0d50a049-02ad-4f21-b32b-29c99df77515_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share - basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_58c88b2f-8eca-42fe-9cc2-68624c738a2f_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerSB525Member_4d86fad6-558f-4051-8a9c-67988e4886d6_terseLabel_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_label_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerSB525Member_documentation_en-US" xlink:label="lab_sgmo_PfizerSB525Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer SB-525</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member" xlink:href="sgmo-20201231.xsd#sgmo_PfizerSB525Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerSB525Member" xlink:to="lab_sgmo_PfizerSB525Member" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_b17fb678-5107-40bd-8221-1251fe5b187a_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of free shares held by the holders (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Free Shares Held By Holders</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of free shares held by the holders.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_8df80e94-5e18-49f3-b24f-c00a50f87f9d_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e305b8f8-65b2-4aa7-bc9c-7df2135d3dc0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_56bc495d-3d0d-4cd1-87ee-58ac4cd9cdff_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_28ebf678-7163-4956-ac3c-e47994b50ede_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_19bf4a3c-76ce-4ad4-bd67-66b7d764f8f7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_18a5f7dc-e0d1-4983-a77a-85dd28eb0034_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_d7bbbc51-e358-4e5f-9eaf-488425ee445e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_c50bfbec-bbd0-4f59-a04a-f51e04d8c294_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7945e6aa-e060-4fa5-8bd8-e98931d4f688_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest and/or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementReimbursableServiceCosts_317631da-2913-452c-b8fa-a89abaf73a55_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement reimbursable service costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementReimbursableServiceCosts_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Reimbursable Service Costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementReimbursableServiceCosts_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Reimbursable Service Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementReimbursableServiceCosts" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementReimbursableServiceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementReimbursableServiceCosts" xlink:to="lab_sgmo_CollaborativeArrangementReimbursableServiceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_ca548f51-314d-4c83-bced-ef87ac5ef0fb_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d86d2466-ef43-4934-95df-18be819314d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock reserved for issuance under plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="lab_us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_9d8b6c25-1673-48c9-8ba7-abd8c1092130_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_df9d749d-bab5-416c-a144-e615062a201a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_7212faa4-1448-4ebc-8219-e3dda46c1c2c_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EUR/ USD exchange rate</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_52025e72-ad7f-4393-9953-bcf03ecb142e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_db5984ed-2d66-460d-8dfd-dec6989c9a22_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Balance Sheet Details</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_4f4d5bcf-c7d4-4184-a7b5-8806f551e60c_terseLabel_en-US" xlink:label="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties to be received from sublicensing</link:label>
    <link:label id="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_label_en-US" xlink:label="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Royalties To Be Received From Sublicensing</link:label>
    <link:label id="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_documentation_en-US" xlink:label="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of royalties to be received from sublicensing.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:href="sgmo-20201231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:to="lab_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_89986e3d-3ca2-45dd-bf08-f1420bc8641b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SpecifiedStockholderOwnershipPercentage_4116eb73-da79-4d81-b5b2-390bd9f8677c_terseLabel_en-US" xlink:label="lab_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified stockholder ownership percentage</link:label>
    <link:label id="lab_sgmo_SpecifiedStockholderOwnershipPercentage_label_en-US" xlink:label="lab_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified Stockholder Ownership Percentage</link:label>
    <link:label id="lab_sgmo_SpecifiedStockholderOwnershipPercentage_documentation_en-US" xlink:label="lab_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specified stockholder ownership percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:href="sgmo-20201231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:to="lab_sgmo_SpecifiedStockholderOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_6c3e083e-acdf-45e5-8ca2-76a70929f040_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0e8a24aa-c023-4cf5-acec-d5030cdcbf8f_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_94309421-27a3-4f2c-b417-16295b26f902_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of equity interests agreed to acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Percentage Of Equity Interests Agreed To Acquire</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, percentage of equity interests agreed to acquire.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:to="lab_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_9a8e5a44-139a-48cc-a304-c3f2af5caf68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_9b3654cd-feae-4c52-aba4-081570a94eb8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_b7760643-184c-49e7-9281-d8be0ec6d6e8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DeferredTaxAssetsLeaseLiability_ba974c03-c4d9-4156-b710-5e0abacc37d9_terseLabel_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsLeaseLiability_label_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsLeaseLiability_documentation_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsLeaseLiability" xlink:href="sgmo-20201231.xsd#sgmo_DeferredTaxAssetsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DeferredTaxAssetsLeaseLiability" xlink:to="lab_sgmo_DeferredTaxAssetsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncomeTaxesTable_a561fadd-fc35-4cac-8934-24abbd40d487_terseLabel_en-US" xlink:label="lab_sgmo_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sgmo_IncomeTaxesTable_label_en-US" xlink:label="lab_sgmo_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sgmo_IncomeTaxesTable_documentation_en-US" xlink:label="lab_sgmo_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesTable" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncomeTaxesTable" xlink:to="lab_sgmo_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9ed610e6-c788-46e0-acfb-affadafb4895_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_bc68e8c5-7744-431c-8003-d8788ff2f8fe_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_18d512a2-9380-40e9-a9f2-b8337b25f818_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_fdc34dc0-7d3e-4c88-ac9b-77281963dd5c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures included in unpaid liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_eca06318-28f3-4e10-9579-022118d65187_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ac4d9929-e552-4454-8857-15e781665c08_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_bf57f62e-8cbf-4758-b490-95988833ebef_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_56ff4cf2-f510-4521-91eb-292cf5f15dfe_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_1eaaa20f-f125-4a63-9f62-2ec52acd1f90_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_a2385795-cd26-44d4-b398-e4a63d828487_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease agreement, extendable lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7b6832d6-0efd-4026-a2cd-9bf6f8e8aa87_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_35ef427f-86a4-48bc-8db1-8321e289c75d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5408082f-6189-4cc5-a62c-9fbebb162bf7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember_56cd470e-968c-4c0f-86b0-8c46706b7fea_terseLabel_en-US" xlink:label="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended collaboration and license agreement</link:label>
    <link:label id="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Collaboration And License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:href="sgmo-20201231.xsd#sgmo_AmendedCollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_AmendedCollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9eabc5fa-8026-475f-927c-a0ba9ebe09e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_2c552c1c-ee0d-4702-b775-2b9599e1b62a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_a756a094-960f-49a5-8497-96baa1439493_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_a229b5f4-9208-4a7f-97af-889d1056d104_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_2052679d-524d-4839-b2ca-4d178bfda80b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FeeDue_22956d61-7c05-4ca4-9a5a-db366309fcc4_terseLabel_en-US" xlink:label="lab_sgmo_FeeDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee due</link:label>
    <link:label id="lab_sgmo_FeeDue_label_en-US" xlink:label="lab_sgmo_FeeDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee Due</link:label>
    <link:label id="lab_sgmo_FeeDue_documentation_en-US" xlink:label="lab_sgmo_FeeDue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee due.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FeeDue" xlink:href="sgmo-20201231.xsd#sgmo_FeeDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FeeDue" xlink:to="lab_sgmo_FeeDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_b2d03d1a-3420-4910-aa9c-f0101748eb24_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_03c616c6-3d7e-4a66-b744-d9b427fbecb1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_7e199393-34d7-40b0-902f-8c20f94a015f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_8a11e3d4-abd8-4a02-8225-8bdeb3245866_terseLabel_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from public offering of common stock, net of issuance costs</link:label>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_cacf28b6-9592-4b34-b1e5-657c84a87e73_verboseLabel_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance of common stock, after deducting offering expenses</link:label>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_label_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Proceeds From Issuance Public Offering</link:label>
    <link:label id="lab_sgmo_NetProceedsFromIssuancePublicOffering_documentation_en-US" xlink:label="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds from issuance public offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering" xlink:href="sgmo-20201231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NetProceedsFromIssuancePublicOffering" xlink:to="lab_sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_fedd4f0f-4fa3-4173-82be-a1da7472762d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_79b97449-8e4d-44bb-8c3c-8606867b7d41_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Company's Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:to="lab_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_71ab9a08-8592-4f0e-b030-012f01b23823_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_702bd981-2c5f-413f-a486-37e04635f122_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_InterestAndOtherIncome_label_en-US" xlink:label="lab_us-gaap_InterestAndOtherIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Other Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndOtherIncome" xlink:to="lab_us-gaap_InterestAndOtherIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_3ad69f07-ec72-49ce-bdd0-4a0949c55ee0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_ca5212cf-a7c6-4172-bb45-683e3a13ed4a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_b556feb4-f602-4901-b1e5-48e9b4757af0_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under public offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_0bb73ffc-f864-4453-84b6-4424f292c177_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6d4e414f-8b8b-4d80-b536-19c307e6aad6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e57604d3-3ac7-430b-b557-60c2dabcd556_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, estimated fair value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_7da43681-ace0-4e4b-a0b2-776535ff2554_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_3edc49af-5050-4f55-9027-cec3624dda7e_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options expiration term</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options expiration term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a16aa0c1-2df7-4517-a7c0-6e28e30b76ee_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_eef8edcd-af39-422c-b227-38b0ac4265bf_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_4b16f029-659d-4aa6-a7b6-8bf3f463941d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f9943499-4e5e-4359-aa7d-d43dd644c094_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_30559b93-3412-4072-9eed-0d3273a33527_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_788fff2a-68ba-45e3-8ceb-33527d66c33e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FreeSharesLiabilityMember_ce6d55ba-de89-432e-b995-65d307e9848f_terseLabel_en-US" xlink:label="lab_sgmo_FreeSharesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares asset</link:label>
    <link:label id="lab_sgmo_FreeSharesLiabilityMember_label_en-US" xlink:label="lab_sgmo_FreeSharesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Liability [Member]</link:label>
    <link:label id="lab_sgmo_FreeSharesLiabilityMember_documentation_en-US" xlink:label="lab_sgmo_FreeSharesLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesLiabilityMember" xlink:href="sgmo-20201231.xsd#sgmo_FreeSharesLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FreeSharesLiabilityMember" xlink:to="lab_sgmo_FreeSharesLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0a393c4f-1fd3-4a28-9fca-fb06db3b955e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average estimated fair value per share of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_ba56072b-95e5-450f-bf0e-cc444bd3b7c6_terseLabel_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For Bio Medical Research Inc</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_label_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For Bio Medical Research Inc [Member]</link:label>
    <link:label id="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_documentation_en-US" xlink:label="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis Institutes For Bio Medical Research Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:href="sgmo-20201231.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:to="lab_sgmo_NovartisInstitutesForBioMedicalResearchIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_5971430b-9f57-4175-a931-ebf34eb34cde_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c3aa2993-beaf-44a9-a0ce-54ab7746f724_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrealized (loss) gain on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_63b2231e-d765-43be-8c5c-1a88d2fb456b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized loss on marketable securities, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_587611f5-447e-4353-92aa-3f6252f0bbee_negatedLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, liability, cumulative catch-up adjustment to revenue, change in measure of progress</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32cdfbfe-812b-47c6-a359-1e1ab61ff1cc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_081a1bab-16e3-49e9-b191-226085f5fe8b_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchServicesPeriod_00fbb45e-c4ad-4ad2-8b9f-da26b1e8927b_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed laboratory research reagents, research services period</link:label>
    <link:label id="lab_sgmo_ResearchServicesPeriod_label_en-US" xlink:label="lab_sgmo_ResearchServicesPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services Period</link:label>
    <link:label id="lab_sgmo_ResearchServicesPeriod_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesPeriod" xlink:href="sgmo-20201231.xsd#sgmo_ResearchServicesPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesPeriod" xlink:to="lab_sgmo_ResearchServicesPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_98c79fd5-7bd2-4f08-83bf-ae230bb0683d_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_337e7051-67de-492a-88a0-07e4e51dce69_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_94fc9029-28c6-4e61-bcd4-4e211a9c5052_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_e7984afa-a8c4-4765-8025-7f6e8ea981c9_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional neurological disease gene targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Number Of Additional Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:to="lab_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_79fc2045-728a-4e83-9095-4659e44a7fc4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_dc75be7a-9386-478d-8bcc-d882d8fb1b07_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_a597e414-60ba-43c0-a70d-c01119b8d50e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Benefit for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_ba2b2078-de9f-4346-ba9b-a977519d8b07_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:href="sgmo-20201231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ManufacturingEquipmentMember_a75b875c-9938-4e98-a9be-86a3d82e7fdb_terseLabel_en-US" xlink:label="lab_sgmo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing equipment</link:label>
    <link:label id="lab_sgmo_ManufacturingEquipmentMember_label_en-US" xlink:label="lab_sgmo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_sgmo_ManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_sgmo_ManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingEquipmentMember" xlink:href="sgmo-20201231.xsd#sgmo_ManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ManufacturingEquipmentMember" xlink:to="lab_sgmo_ManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_262f00fa-be91-418e-903b-2a5fe21d4c55_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_1d3b4e5f-da90-4a45-83e9-21e389e0ced9_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_2eeb9dbf-2f5e-478e-aa70-a51abc6533bf_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement provision, ownership percentage (less than)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_c7d46dc4-1294-45b1-b204-0630915b4a52_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketStockOfferingMember_8a2d91d8-5ce8-4155-8979-dec480e67917_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Stock Offering</link:label>
    <link:label id="lab_sgmo_AtTheMarketStockOfferingMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Stock Offering [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketStockOfferingMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketStockOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market Stock Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketStockOfferingMember" xlink:href="sgmo-20201231.xsd#sgmo_AtTheMarketStockOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketStockOfferingMember" xlink:to="lab_sgmo_AtTheMarketStockOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_02a7d141-b732-4949-b201-154185678115_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_5ae4d86c-734a-4c73-9953-c8f4c2d130fc_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average period of unvested stock options and RSU</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_8bfaf8e2-e5a6-4839-9bf1-d92a7a5ed101_terseLabel_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and other changes in right-of-use assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_label_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:label id="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_documentation_en-US" xlink:label="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization And Other Changes In Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:href="sgmo-20201231.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:to="lab_sgmo_AmortizationAndOtherChangesInRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f814e749-aa4f-46fb-bbc5-ad7f8b86081d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_28f4daf9-2498-43b3-a44d-63bdc433b3a1_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3f310cd2-fd0a-4812-92a1-8ed8b3edd24d_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_9c7c4a70-3fe0-4fda-9673-067f17984c22_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_b467bce1-b7a3-4542-9ce7-05b59f330b4d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_b85b3a86-5878-4b34-a259-f7bdfa1c58d3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of milestone</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e03ef0da-6b21-4362-b090-8f0441fae497_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_da4cc7ae-de6f-4776-8a88-932acfe546b9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_098269f4-242e-4837-91a8-c7ab6691339a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_ebc428a7-b9d1-4e2a-8453-c5df23c64320_terseLabel_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Laboratory</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_label_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Laboratory [Member]</link:label>
    <link:label id="lab_sgmo_OfficeAndLaboratoryMember_documentation_en-US" xlink:label="lab_sgmo_OfficeAndLaboratoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office And Laboratory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember" xlink:href="sgmo-20201231.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OfficeAndLaboratoryMember" xlink:to="lab_sgmo_OfficeAndLaboratoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_edc9eab2-0036-402c-9b4c-5c1932d24cf6_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone revenue receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_label_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Revenue Receivable</link:label>
    <link:label id="lab_sgmo_MilestoneRevenueReceivable_documentation_en-US" xlink:label="lab_sgmo_MilestoneRevenueReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone&#8203; revenue receivable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneRevenueReceivable" xlink:to="lab_sgmo_MilestoneRevenueReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_6b636089-cbfd-4e63-803f-c4b2b99aae8e_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration arrangement, commission fee, portion of gross proceeds, value</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:to="lab_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cd70453f-c359-43b1-b36c-c10112c3e90d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f8b5947b-9c5a-4447-abdb-ee8796b83184_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_068875cd-5a1b-42d9-b784-97ef630ad340_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_a56cc824-7fc7-4fc0-bea9-f98b7c413755_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_575aa865-480d-463d-8b91-c4081882b807_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax assets valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_fbcb13dc-58d2-488d-a3cc-e31c760f1bcf_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_f3b2f6a1-43e0-4bb0-b6ec-80d8e839d15e_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target selection period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementTargetSelectionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Target Selection Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:to="lab_sgmo_CollaborationAgreementTargetSelectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_d93557e6-b0ef-487e-bbfa-67e76d70f5b9_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement provision, expiration period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Voting Provisions Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:to="lab_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_cbb84eff-f52a-4e08-8c91-57062af805af_terseLabel_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_label_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone [Member]</link:label>
    <link:label id="lab_sgmo_PreApprovalMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_PreApprovalMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-approval Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember" xlink:href="sgmo-20201231.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PreApprovalMilestoneMember" xlink:to="lab_sgmo_PreApprovalMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_0e4cc5ef-9def-4a39-b8af-b619e044e974_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Axis]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneAxis_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_7b70abb7-f846-4f29-af6f-5eb630d55983_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Quarterly Financial Data</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchServicesMember_82a96a0c-b6a7-46b9-ac94-1490225340ec_terseLabel_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_label_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Services [Member]</link:label>
    <link:label id="lab_sgmo_ResearchServicesMember_documentation_en-US" xlink:label="lab_sgmo_ResearchServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research services.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember" xlink:href="sgmo-20201231.xsd#sgmo_ResearchServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchServicesMember" xlink:to="lab_sgmo_ResearchServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_d5824bd9-2087-47ca-b3e9-044d0c50040e_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of neurological disease gene targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargets_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_52d0d353-f53b-47ba-9d6a-01eb0bac647a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed ratio shares of common stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_01420c55-0107-4eb1-ac5d-d24acbf527f9_terseLabel_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_label_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Offering Agreement [Member]</link:label>
    <link:label id="lab_sgmo_AtTheMarketOfferingAgreementMember_documentation_en-US" xlink:label="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At the market offering agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:href="sgmo-20201231.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AtTheMarketOfferingAgreementMember" xlink:to="lab_sgmo_AtTheMarketOfferingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_da9cefdc-11c9-4d8c-854b-23974268ce65_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_076dde28-30cb-45ea-8655-3dbbc7d6e007_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of additional shares acquired</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_760d8cf8-5561-43ba-93f3-9c174c2e70c5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_307067ff-c027-422b-a321-de0e8f138636_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_8a188df3-d717-4edf-a292-6241a698f533_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_522fea99-4a40-4f5f-bd07-4ba00828c810_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease, cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_f94a351d-523b-4955-808a-5e2614c99d1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_14a35f02-f277-4bb5-ae74-f76d30bcf9aa_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement terms</link:label>
    <link:label id="lab_us-gaap_LicenseAgreementTermsMember_label_en-US" xlink:label="lab_us-gaap_LicenseAgreementTermsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement Terms [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAgreementTermsMember" xlink:to="lab_us-gaap_LicenseAgreementTermsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_9661ff16-53d9-490b-bf10-1d7e9b92127d_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of ordinary shares acquired (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Number Of Shares Acquired</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of shares acquired.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FreeSharesAssetMember_a55ae755-dead-47bf-bba0-0c51ba493c93_terseLabel_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free shares asset</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_label_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Asset [Member]</link:label>
    <link:label id="lab_sgmo_FreeSharesAssetMember_documentation_en-US" xlink:label="lab_sgmo_FreeSharesAssetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Free Shares Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember" xlink:href="sgmo-20201231.xsd#sgmo_FreeSharesAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FreeSharesAssetMember" xlink:to="lab_sgmo_FreeSharesAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_6b2dbb78-ce2a-419b-ad86-00d95cb8d0a2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_ca7972f3-dc84-4372-981b-e32578a8e1ed_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsMember_b0e96cfb-3e0a-4fd1-b170-4db188649b7d_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents:</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsMember" xlink:to="lab_us-gaap_CashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_376d89ba-d27d-4b2a-836b-8db0d8a29b81_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_9357dc08-dfa5-468f-98a2-ff2c644255fe_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e8b2ccae-86f9-479d-911f-82d59f758fb4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_458d5d4c-f21d-4339-bd31-46295621c4ce_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_f2d7db06-fb3f-4d5b-8d6b-db77b732f451_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_9f234296-7bcc-43ee-9443-347a3c08d47d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4eef5ec0-8e04-4952-9b29-382364883e8b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d8cf91eb-f101-4729-9d9d-c3ec96f2e8f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Stock Unit Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_09399af1-10af-497b-be03-70bcb6c1a465_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of share capital and voting rights acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_a9d8b182-319f-4b2e-8183-6411571ff30e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_96aec838-414e-4796-9d74-43c4e770a172_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_dcf21c6e-8b07-46bd-a1cc-1a0c37646834_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_3cabd08e-b872-49aa-ba7d-98402c491acc_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets held-for-use</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_2eb90999-e683-4aed-9102-aa5369ddd9bf_terseLabel_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock offering program, maximum value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_label_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program Maximum Value</link:label>
    <link:label id="lab_sgmo_StockOfferingProgramMaximumValue_documentation_en-US" xlink:label="lab_sgmo_StockOfferingProgramMaximumValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Offering Program, Maximum Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue" xlink:href="sgmo-20201231.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockOfferingProgramMaximumValue" xlink:to="lab_sgmo_StockOfferingProgramMaximumValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_3f7dc32d-3836-4e51-9605-de53f2f2bde9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_FormerExecutiveOfSangamoFranceMember_0d712aac-2840-4480-bb55-52ebba3ea1a2_terseLabel_en-US" xlink:label="lab_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Executive of TxCell</link:label>
    <link:label id="lab_sgmo_FormerExecutiveOfSangamoFranceMember_label_en-US" xlink:label="lab_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Executive Of Sangamo France [Member]</link:label>
    <link:label id="lab_sgmo_FormerExecutiveOfSangamoFranceMember_documentation_en-US" xlink:label="lab_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Executive Of Sangamo France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:href="sgmo-20201231.xsd#sgmo_FormerExecutiveOfSangamoFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:to="lab_sgmo_FormerExecutiveOfSangamoFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_20166526-e6d4-4c80-a51c-08db35cf9d5c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_c442549d-1b28-4f1d-8cbc-dbd9a380a39c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_e3396aa5-c72c-47f2-a6a8-252d8603e8a9_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_870b36f2-ea22-4465-8f9a-99bd1a440184_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2372c8b3-eff4-4362-ba74-08bc32c336f4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - long-term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_321123a4-47a8-48f5-90ae-b5b4cd70f59a_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of space leased (in sqft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_7e93ae92-565c-4432-a7f8-f1add2371c5b_terseLabel_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_label_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Contract Liability Milestone Payment Eligible To Receive</link:label>
    <link:label id="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_documentation_en-US" xlink:label="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer contract liability milestone payment eligible to receive.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:href="sgmo-20201231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:to="lab_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_92530f8e-92fe-41e7-81b3-d4c05422d001_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_a8c027b4-c06f-4acd-830a-1548e44c81fb_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expenses</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense" xlink:to="lab_us-gaap_LeaseAndRentalExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_de19b395-1615-48b2-9129-24d20ca59953_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net pension losses</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_b65102fa-0539-4212-853f-47de58b2fa88_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net operating loss carryforwards for state</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_1afcd14d-ddfd-4975-bfe0-1a10757b6a1c_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_8ac37750-5d2f-43d8-a8c7-a5e52bde9575_terseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement and Tender Offer Agreement</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_56f62cbc-8299-4e72-86e2-68af4fffd3b3_verboseLabel_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPA and TOA</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_label_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement And Tender Offer Agreement [Member]</link:label>
    <link:label id="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_documentation_en-US" xlink:label="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share purchase agreement and tender offer agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:href="sgmo-20201231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:to="lab_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_35440ebe-2da3-43c4-bce8-30107bd2d7c2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_c67769c0-ef70-4168-885e-fee77ffd5572_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_78036ed0-f04f-4580-9e60-264e0ac9fa33_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_00770f5c-c28f-47bf-8858-20dca4e39716_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested and expected to vest at end of period</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_424b0155-886e-42b9-a10c-af936e8348ff_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Clinical Development and Regulatory Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d7d71859-2629-4bb9-b65f-0b81fcffe09f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield of stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0c9c1113-4cd9-48f6-9d87-4d5362cc3032_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_69e8d348-9f0b-49c9-96c0-f5818a61c2e8_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government-sponsored entity debt securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_1ee5d378-f6a6-4243-abf4-002ccf0b5f5c_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_29253d2a-99f0-4029-9aa5-f1d8d6b25c5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_8372e025-921a-4b9c-b9d8-879718cc0b66_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License fee revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_63499044-5a1a-4ac9-9c5b-2c511d447f74_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, excess consideration received on transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:label id="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Excess Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:href="sgmo-20201231.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:to="lab_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_2ddb5009-7431-4c1c-a1c8-d2b651d23575_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement restriction, percentage of shares held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:to="lab_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_ff711097-c945-471a-8646-6f1edd99096d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a38d1b79-fc6c-476f-9448-7d028657b03e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6005f643-ae2c-4727-ab03-55d7020df31d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_81bc77f9-8786-4703-90cd-cf0fe079ddd3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9fc2bc97-a6bd-4490-9097-9d297b5977e3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BiogenMAIncMember_e2282fd4-73a0-45c5-bc57-5c58b43dc8b0_terseLabel_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA Inc</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_label_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA Inc [Member]</link:label>
    <link:label id="lab_sgmo_BiogenMAIncMember_documentation_en-US" xlink:label="lab_sgmo_BiogenMAIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen MA Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BiogenMAIncMember" xlink:to="lab_sgmo_BiogenMAIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a5bdda79-24bc-45f8-bdcb-dcc09407fca5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for issuance of future awards (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SeparateUpfrontFee_a6fa3a59-488c-46c8-aeed-57e893321d63_terseLabel_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate fee for additional term</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_label_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate Upfront Fee</link:label>
    <link:label id="lab_sgmo_SeparateUpfrontFee_documentation_en-US" xlink:label="lab_sgmo_SeparateUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Separate upfront fee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee" xlink:href="sgmo-20201231.xsd#sgmo_SeparateUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SeparateUpfrontFee" xlink:to="lab_sgmo_SeparateUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_66f102bf-0386-4264-b722-10f3e0216a35_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_2f28799a-3e1e-4e49-a902-beb23a4fe106_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f83252d7-25bc-4604-9bca-215ed9346757_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ffe5f0d0-a17f-4d5d-a2f0-61b8b9bf1aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GiroctocogeneFitelparvovecMember_6fa3560a-fc11-4ef6-afe1-cb821f942acc_terseLabel_en-US" xlink:label="lab_sgmo_GiroctocogeneFitelparvovecMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Giroctocogene Fitelparvovec</link:label>
    <link:label id="lab_sgmo_GiroctocogeneFitelparvovecMember_label_en-US" xlink:label="lab_sgmo_GiroctocogeneFitelparvovecMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Giroctocogene Fitelparvovec [Member]</link:label>
    <link:label id="lab_sgmo_GiroctocogeneFitelparvovecMember_documentation_en-US" xlink:label="lab_sgmo_GiroctocogeneFitelparvovecMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Giroctocogene Fitelparvovec</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GiroctocogeneFitelparvovecMember" xlink:href="sgmo-20201231.xsd#sgmo_GiroctocogeneFitelparvovecMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GiroctocogeneFitelparvovecMember" xlink:to="lab_sgmo_GiroctocogeneFitelparvovecMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_178633ce-94fa-4200-b91c-a31062f9fae1_terseLabel_en-US" xlink:label="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</link:label>
    <link:label id="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Issuance Costs</link:label>
    <link:label id="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Issuance Of Common Stock, Net Of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:href="sgmo-20201231.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:to="lab_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_9eb25d56-b437-40de-92b8-89b4363408fe_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Non-controlling Interest</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Noncontrolling Interest Table [Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of noncontrolling interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:href="sgmo-20201231.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:to="lab_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_a3a0ad0f-8b97-4e67-bbb2-b424a3795dc5_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, number of free shares outstanding subject to purchase (in shares)</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:to="lab_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_b1ca953b-fd8e-4e83-92d4-c12ccbaa1be7_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_d55a960e-4fe4-4afc-8b49-4f4df82a123c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net operating loss carryforwards for federal</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e16fdb63-3d36-4813-ab4c-1d0b438b792c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized stock-based employee compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AccruedResearchAndDevelopmentExpenses_62a765e0-0b1f-42f2-8601-7e48ec0cf75b_terseLabel_en-US" xlink:label="lab_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses</link:label>
    <link:label id="lab_sgmo_AccruedResearchAndDevelopmentExpenses_label_en-US" xlink:label="lab_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expenses</link:label>
    <link:label id="lab_sgmo_AccruedResearchAndDevelopmentExpenses_documentation_en-US" xlink:label="lab_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:href="sgmo-20201231.xsd#sgmo_AccruedResearchAndDevelopmentExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:to="lab_sgmo_AccruedResearchAndDevelopmentExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OneTimeLicenseFeeEarned_82ebad18-49f3-45f4-bee4-a097f3932301_terseLabel_en-US" xlink:label="lab_sgmo_OneTimeLicenseFeeEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time license fee earned on exercise of option</link:label>
    <link:label id="lab_sgmo_OneTimeLicenseFeeEarned_label_en-US" xlink:label="lab_sgmo_OneTimeLicenseFeeEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One Time License Fee Earned</link:label>
    <link:label id="lab_sgmo_OneTimeLicenseFeeEarned_documentation_en-US" xlink:label="lab_sgmo_OneTimeLicenseFeeEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One time license fee earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OneTimeLicenseFeeEarned" xlink:href="sgmo-20201231.xsd#sgmo_OneTimeLicenseFeeEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OneTimeLicenseFeeEarned" xlink:to="lab_sgmo_OneTimeLicenseFeeEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_77d52239-b2e0-45bf-aef2-e54ce46e36e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_8160580f-d16b-46b7-b849-bb1cd425e49b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_bcb82039-8ec9-4863-bbd3-6ad714ee92ab_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_dbfc32b7-35a7-4c9c-8560-14f8d1bee27c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total payments for the employees' tax obligations to taxing authorities</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_54461d17-3868-4764-aa1e-dda77f8fc1e4_terseLabel_en-US" xlink:label="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible stock-based compensation</link:label>
    <link:label id="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_label_en-US" xlink:label="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense Income Share Based Compensation</link:label>
    <link:label id="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_documentation_en-US" xlink:label="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax reconciliation nondeductible expense income share based compensation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:to="lab_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_775c39e6-3f84-4d25-a33a-d223e83fbb60_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_108a9854-05a9-4e1f-8326-8bfdb1bf64c5_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Data (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_a468d036-b7b7-4d25-b348-02650166f088_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, employer's matching contribution percent</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_52aeef33-ca89-4b00-b268-f946243f69d4_terseLabel_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to extend initial research term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_label_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:label id="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm_documentation_en-US" xlink:label="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Extend Initial Research Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:href="sgmo-20201231.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:to="lab_sgmo_NumberOfOptionsToExtendInitialResearchTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_9c0e02b8-a0cb-4e58-876a-f2553aa7279f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Domestic and Foreign Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_0460657b-8e93-43b1-a5ca-59cde4fb5edd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of related assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_ed1298dd-6bea-4fe3-87a8-34179d7ba4e2_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified sales milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Sales Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Specified Sales Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedSalesMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_34e81aef-5b85-4e02-bd79-85737375395f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BuildToSuitLeaseMember_5bb8d13c-549b-4e2b-aa35-b00764032ec1_terseLabel_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-Suit Leases</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeaseMember_label_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build To Suit Lease [Member]</link:label>
    <link:label id="lab_sgmo_BuildToSuitLeaseMember_documentation_en-US" xlink:label="lab_sgmo_BuildToSuitLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Build-to-suit lease.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseMember" xlink:href="sgmo-20201231.xsd#sgmo_BuildToSuitLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BuildToSuitLeaseMember" xlink:to="lab_sgmo_BuildToSuitLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_f5759aaa-42b4-44d0-9e45-abbf1cf14b5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_154380ea-57dd-4d86-ab43-ed46cf9c7c82_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of discount on marketable securities</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GainOnFreeShares_ef955905-d8e4-4692-945a-a69ed08d56a7_negatedLabel_en-US" xlink:label="lab_sgmo_GainOnFreeShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on free shares</link:label>
    <link:label id="lab_sgmo_GainOnFreeShares_label_en-US" xlink:label="lab_sgmo_GainOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Free Shares</link:label>
    <link:label id="lab_sgmo_GainOnFreeShares_documentation_en-US" xlink:label="lab_sgmo_GainOnFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain On Free Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainOnFreeShares" xlink:href="sgmo-20201231.xsd#sgmo_GainOnFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GainOnFreeShares" xlink:to="lab_sgmo_GainOnFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AnnualFeesRelatedToAgreement_99ec5aad-0910-452f-b618-09baeb59cea7_terseLabel_en-US" xlink:label="lab_sgmo_AnnualFeesRelatedToAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual fees</link:label>
    <link:label id="lab_sgmo_AnnualFeesRelatedToAgreement_label_en-US" xlink:label="lab_sgmo_AnnualFeesRelatedToAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Fees Related To Agreement</link:label>
    <link:label id="lab_sgmo_AnnualFeesRelatedToAgreement_documentation_en-US" xlink:label="lab_sgmo_AnnualFeesRelatedToAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual fees related to agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AnnualFeesRelatedToAgreement" xlink:href="sgmo-20201231.xsd#sgmo_AnnualFeesRelatedToAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AnnualFeesRelatedToAgreement" xlink:to="lab_sgmo_AnnualFeesRelatedToAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1337cbf1-3ed0-4315-ad24-563f8b6fcccd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_44c66512-3b22-43e6-85b1-961ea001f7e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_055fb849-bc02-40f0-9196-8b403d73cd5f_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_521b5922-ecff-4eac-a61f-72f91fb1fefb_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e678da52-6334-4c3f-a0bd-8e3a99331598_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c4699ba2-550e-45a6-b30d-17d8811d4513_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_165ad9c2-41eb-49a0-bf28-6ca9109c59b2_terseLabel_en-US" xlink:label="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under employee stock purchase plans, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_label_en-US" xlink:label="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued Under Employee Stock Purchase Plans Average Exercise Price</link:label>
    <link:label id="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_documentation_en-US" xlink:label="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued under employee stock purchase plans average exercise price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:href="sgmo-20201231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:to="lab_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_578d6f18-7116-4971-8526-4e8c86afe074_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_e56ff367-8f2a-4140-b1ee-4f24ecaa6bc8_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BrammerBioMAMember_ee94adad-10f8-4656-ad9a-b6ce316e8f02_terseLabel_en-US" xlink:label="lab_sgmo_BrammerBioMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brammer Bio MA</link:label>
    <link:label id="lab_sgmo_BrammerBioMAMember_label_en-US" xlink:label="lab_sgmo_BrammerBioMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brammer Bio MA [Member]</link:label>
    <link:label id="lab_sgmo_BrammerBioMAMember_documentation_en-US" xlink:label="lab_sgmo_BrammerBioMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brammer Bio MA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrammerBioMAMember" xlink:href="sgmo-20201231.xsd#sgmo_BrammerBioMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrammerBioMAMember" xlink:to="lab_sgmo_BrammerBioMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_f88dd44f-0dd6-417c-840c-34cbf61857ce_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_116313b5-f35f-4d64-8241-0d59db7c9243_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_48ad7f60-eb3c-441d-93d9-7d9f0a083bcb_terseLabel_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_sgmo_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember" xlink:href="sgmo-20201231.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_StockPurchaseAgreementMember" xlink:to="lab_sgmo_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d0c6c8ba-355e-4ba0-ae73-fbcf915c4946_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities &#8211; current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_dc33f632-46e5-4c44-a315-802b678e6f7d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities - current (included in Other accrued liabilities on the Consolidated Balance Sheet)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward_fdefd5f9-4823-4cbc-a8ff-ca487b79be88_terseLabel_en-US" xlink:label="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward_label_en-US" xlink:label="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets (Excluding Goodwill) [Roll Forward]</link:label>
    <link:label id="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward_documentation_en-US" xlink:label="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:href="sgmo-20201231.xsd#sgmo_IntangibleAssetsExcludingGoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:to="lab_sgmo_IntangibleAssetsExcludingGoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DowAgroSciencesMember_090cf2ce-de0a-41ef-a4ad-e4dad8093929_terseLabel_en-US" xlink:label="lab_sgmo_DowAgroSciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dow Agro Sciences</link:label>
    <link:label id="lab_sgmo_DowAgroSciencesMember_label_en-US" xlink:label="lab_sgmo_DowAgroSciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dow Agro Sciences [Member]</link:label>
    <link:label id="lab_sgmo_DowAgroSciencesMember_documentation_en-US" xlink:label="lab_sgmo_DowAgroSciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dow agro sciences.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DowAgroSciencesMember" xlink:href="sgmo-20201231.xsd#sgmo_DowAgroSciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DowAgroSciencesMember" xlink:to="lab_sgmo_DowAgroSciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_daf61dd0-6496-4d4e-b8b3-1a63cbb47cca_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone [Domain]</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementMilestoneDomain_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain" xlink:to="lab_sgmo_CollaborativeAgreementMilestoneDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_3a08b348-b02a-44d0-9631-e27abc38f3a0_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, increase (decrease) in revenue</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Revenue</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Increase (Decrease) In Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:to="lab_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_990c8f03-7e89-4835-a7da-133b21e87205_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement restriction expiration period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_aa21b04d-aabb-405c-807c-8831fac94fac_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues under agreement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c9b18efd-0455-434e-82ca-62082b929287_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2a13ece0-e5ac-4dae-99af-7c0b78b96cc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used for Estimating Fair Value of Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_0a771449-cee4-4042-b872-9de684f4ce0f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_fcb1efc4-8915-48d1-b246-542314145fd1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_678f6bb1-af9e-4f21-a40e-5016c84bfad2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_a7c6f4bc-81e6-4aa3-82de-7f42142fd696_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_5dec8a1a-f634-40bb-99d2-1e36f6d1c73c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_2680b81f-4928-4ede-83b7-576720b91cb1_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related to Sanofi agreement:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_b495b3bf-3f29-43e3-a43d-45cadc96eaed_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_014a658d-bfa9-449d-9699-090b2d92bdff_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33320491-e679-42ca-b2bc-0bbeee84b499_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7c0322ed-a438-42bd-b216-0db81ef406b8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PhaseThreeClinicalTrialMember_0bc96b9b-8fae-43fc-b7b6-9a1aac74757f_terseLabel_en-US" xlink:label="lab_sgmo_PhaseThreeClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Three Clinical Trial</link:label>
    <link:label id="lab_sgmo_PhaseThreeClinicalTrialMember_label_en-US" xlink:label="lab_sgmo_PhaseThreeClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Three Clinical Trial [Member]</link:label>
    <link:label id="lab_sgmo_PhaseThreeClinicalTrialMember_documentation_en-US" xlink:label="lab_sgmo_PhaseThreeClinicalTrialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Phase Three Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PhaseThreeClinicalTrialMember" xlink:href="sgmo-20201231.xsd#sgmo_PhaseThreeClinicalTrialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PhaseThreeClinicalTrialMember" xlink:to="lab_sgmo_PhaseThreeClinicalTrialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_85d91d70-5828-4130-b2f9-7460308e6279_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_d2df58c2-fbf4-4468-b10e-9652044e34be_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual&#160;Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_ac791b82-59f0-41a6-9ca4-c4829f50ef26_terseLabel_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_label_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]</link:label>
    <link:label id="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_documentation_en-US" xlink:label="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:href="sgmo-20201231.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:to="lab_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_6871fee7-65c3-47b6-88c3-7b80c850032d_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_5cfcdd9b-251a-4321-953f-e778e05d7983_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_f461742e-b35e-4e1d-995e-f32f0cc47041_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_10fdc97a-9d02-4cf7-9b1d-c794ed3468a9_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_c80539ef-1468-4a10-99ab-a9e65bb7949a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_b8f04320-6d0e-4b76-ac23-ab45879d047b_terseLabel_en-US" xlink:label="lab_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in capital shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_documentation_en-US" xlink:label="lab_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:href="sgmo-20201231.xsd#sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:to="lab_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_f0b28da7-7c8e-4c5a-9800-a8bb7ad47416_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_42af319e-bf37-4e03-919e-3bc6469d7c6b_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement restriction, ownership percentage (less than)</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:to="lab_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_3e69f9f2-3ee1-4d19-97aa-1bd22712232b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_185a7866-5e9b-4fe2-bf19-8e760a7280bb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_204bafbc-4704-4210-b220-e8af2272f829_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_448196f5-1cb3-457a-b414-c45a4dc3d8db_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_bdd9d1ba-3723-46c2-82b0-4274932d2a6d_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_606805d4-ea86-47bc-8f89-c9e6a9edb3af_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research grants</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_dd495b06-c773-43aa-bc89-4fb02e046a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise per Share Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_8626a8df-3a7b-4041-86b9-8a8461000bc2_verboseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer advance</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_88dc8227-3a43-4706-aa0a-9a161e75621f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4bf3bfe3-6b46-4f5c-8d3a-053871c3a88a_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_36b17618-ebc3-4c54-964f-3087d2485ee6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill impairments</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_5bcd5cc7-1ce8-4a33-9af7-9ae3920e7116_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_744233bd-09e1-4546-b107-d32a129646de_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_8bcf0a24-40a3-45c7-8138-ef7017877de5_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_ee92fdb8-5c99-4459-8263-d64e2d6b62e3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_KitePharmaIncMember_e3e46764-e8d7-4016-b003-3d2ac6be8980_terseLabel_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma, Inc. ("Kite")</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_label_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc [Member]</link:label>
    <link:label id="lab_sgmo_KitePharmaIncMember_documentation_en-US" xlink:label="lab_sgmo_KitePharmaIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Kite Pharma Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember" xlink:href="sgmo-20201231.xsd#sgmo_KitePharmaIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_KitePharmaIncMember" xlink:to="lab_sgmo_KitePharmaIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_f918c375-78e5-4872-888e-04624d43575a_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering price of common stock issued (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_8ca132c5-bd91-45e4-a022-b6d03dac7d02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_0699ad4e-5bb4-48ea-99f3-10abf8ed1e72_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_4c8cc521-1ce6-4659-803a-f1d1e223337b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collaborators</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2b5fd674-346b-43df-9e2b-65e55c0c3eae_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, gross unrealized (Losses)</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1f6bea8e-8f7a-4a3c-b588-bf6fe09f1e97_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_61543b4b-1d79-4688-a67d-8b7cb28a5186_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_8268038b-a1bf-4cee-8f1e-fcdba8a9cdee_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_63e73a78-fee0-4608-95b6-e2045d7d4605_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_d8bcef72-778e-4b26-a910-15f30f6280b9_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_9f7fd926-67d3-4799-bbe7-f17a75b0f7e9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_80df94ae-3a8f-48e7-bc63-8cab84203615_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of fair value per share of common stock on option grant date</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_82c36a91-becd-420e-bf72-ea026dbadcf2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_5a1229c4-9f3d-4425-8997-2cf2aca75662_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_fe07ffb8-4587-45cb-b59f-f6a605ae2d4b_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_528b30c0-676e-4c64-aeda-ae2a168ed1d1_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_2f66ac71-5c7c-43b2-af6a-f9084d60e7f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_1e71016f-ee36-428c-9469-49014a6e1e8b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_007e0fc1-c12b-4b66-a097-2dfa7d03845e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Value of Free Share Liability Assumptions</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7406bf26-290a-4e81-b78c-df87c1529766_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_a4eca88e-141a-41b6-b8f0-2bca2ccb8ad6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_d90ac146-61b1-4792-85da-327e4e7ec983_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0685adf8-0cb0-48a3-b1ef-0b5b21068eba_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangements and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_567e1fd7-ea4f-42fb-907b-300b7cf31bcf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_a5c2177c-c245-4db0-a2c3-3103eefbaf91_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount_7d62a900-6dfc-4eea-a540-d3488eb069b8_terseLabel_en-US" xlink:label="lab_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global Intangible Low-Taxed Income</link:label>
    <link:label id="lab_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount_label_en-US" xlink:label="lab_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Global Intangible Low-Taxed Income, Amount</link:label>
    <link:label id="lab_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount_documentation_en-US" xlink:label="lab_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Global Intangible Low-Taxed Income, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" xlink:href="sgmo-20201231.xsd#sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" xlink:to="lab_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_549612e8-0054-4c89-b398-78de3e7ab0e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_ee620850-5269-4fcf-a89a-01c3400c6735_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0c41dda3-820b-4677-90ee-aa0a46beb43c_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ce27e438-5abc-4010-a9d7-708bd5a302be_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_991b67ac-df07-4a07-a246-0231ce66e811_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_fae0ad7a-1534-42a5-95ac-50797240b6e3_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option maximum term for specified stockholder</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term For Specified Stock Holder</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award options maximum term for specified stock holder.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_ab0c80a4-e300-4160-bd7e-dfa1d820b908_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_72760c33-3348-4a49-b89a-cba9b2994fbb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and marketable securities</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_dd5b5d1c-a60a-4057-ba48-1cf90a96aa8b_negatedLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs related to Sangamo France acquisition</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_d5b04f78-3242-49cf-9565-09ab2abdf96c_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs related to sangamo france acquisition</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_c0619843-d949-4cf5-8718-c730a2933cfd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_ef674cde-126c-4b8e-85a0-561dede5d447_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_633559d3-7ed7-48df-8b3e-bdd64eaa0b3d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_00f8401b-c90c-4dbe-b4c1-c6af37ebdcb4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_47676a0d-89ce-49f2-bbb4-a4e3ec577627_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdateExtensibleList_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Extensible List]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:to="lab_us-gaap_AccountingStandardsUpdateExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_b2f8cbfa-1f60-45c2-8168-27b3fa9676ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_d17d9d9e-5ff8-48e3-ada4-d042680a7f2b_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_b7a018fe-b138-4b2f-bad6-1d63f5dd3ad7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_7bd642ae-00e0-4f24-adfe-90335ee7a63c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e04f13be-aecd-4497-bd3f-9cd5e1d56032_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_1f76dc17-87aa-4f3e-9545-4fac20975ea9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="lab_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_ad40711d-0c31-45d9-820f-b40c8e55b86e_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_116ecde5-4f9b-495b-86eb-0efddabff576_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, estimated fair value</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_9ad65ebd-8423-4fad-bf96-80f35d635fab_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_ebb4a391-785a-40e6-a2c3-3bed4cc2f5a1_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization cost</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSoldAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_2872e414-6f5d-4bec-a50f-bf15463ebf40_terseLabel_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition estimated fair value assets of free shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_label_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Assets Of Free Shares</link:label>
    <link:label id="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_documentation_en-US" xlink:label="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition Estimated Fair Value Assets Of Free Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:to="lab_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_1a2943a3-a921-48c8-90af-16b94d47a92a_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_584072f9-deb8-40e5-8b22-82abab7496fe_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_284594eb-dde5-4c6f-842c-327dbc91b08b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5263c5dd-3a6d-4e03-a7c2-84beec5e721f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_b343cd08-5cd7-4282-ac1c-3299d8f64007_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanMember_78b871ea-60f2-4848-89ac-cc438e9bff92_terseLabel_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2010 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sgmo_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sgmo_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember" xlink:href="sgmo-20201231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_EmployeeStockPurchasePlanMember" xlink:to="lab_sgmo_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_9475fc1d-2fe4-4f29-991f-8d744230214b_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Office Space</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_label_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research And Office Space [Member]</link:label>
    <link:label id="lab_sgmo_ResearchAndOfficeSpaceMember_documentation_en-US" xlink:label="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and office space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:href="sgmo-20201231.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndOfficeSpaceMember" xlink:to="lab_sgmo_ResearchAndOfficeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LicenseObligations_269bae10-8f27-47b4-a7fb-86ed6a97321a_terseLabel_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_label_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Obligations</link:label>
    <link:label id="lab_sgmo_LicenseObligations_documentation_en-US" xlink:label="lab_sgmo_LicenseObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations" xlink:href="sgmo-20201231.xsd#sgmo_LicenseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LicenseObligations" xlink:to="lab_sgmo_LicenseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_LaboratoryEquipmentMember_3ae02bf2-3ad6-45fb-8365-fef4ca8400a5_terseLabel_en-US" xlink:label="lab_sgmo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_sgmo_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_sgmo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_sgmo_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_sgmo_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LaboratoryEquipmentMember" xlink:href="sgmo-20201231.xsd#sgmo_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_LaboratoryEquipmentMember" xlink:to="lab_sgmo_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_7d080273-2a60-4906-9456-472898126ebb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accruals and reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_361cff2a-9dde-4af9-984f-fb9e63484b02_terseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_88e71382-5996-4bfe-a8d4-05ad3ab16693_verboseLabel_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research program to develop laboratory research reagents</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_InitialResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_InitialResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial research term of agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement" xlink:href="sgmo-20201231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_InitialResearchTermOfAgreement" xlink:to="lab_sgmo_InitialResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_eed24155-d5be-4d01-a8f9-d55c6156d46a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember_2fa23b4e-f4aa-4e49-892f-81d0e76b8369_terseLabel_en-US" xlink:label="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018 Stock Incentive Plan</link:label>
    <link:label id="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember_label_en-US" xlink:label="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand eighteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:href="sgmo-20201231.xsd#sgmo_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:to="lab_sgmo_TwoThousandEighteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_f081c10d-94d8-4b4b-b17e-3e1b505e2c66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_9c71f525-245b-4b34-8752-8a74cd56a30e_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_eb28aca1-2596-4d8d-80bb-aaaeb9bb5bb0_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fa57bc69-4c1a-486e-93df-d650cbaf411b_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_7d3e1ebd-9c82-4fe1-9516-8bfcd3d8ac3a_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_5878f40c-58f6-4f30-b96b-56619974be4e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b36d7bb4-d1dd-4bbf-9dc2-1ac0610024d2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_0ea5436e-d5d5-49b0-a424-28a3e35751cb_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value; 320,000,000 shares authorized, 142,063,203 and 115,972,708 shares issued and outstanding at December 31, 2020 and 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a64ffa0e-d7f8-4556-b787-25f328428a36_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_1c150e3e-c801-4d98-a179-766eed795c13_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_3ac339d1-6998-4a99-aef7-b671e1d13df7_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bbf39b3a-2a43-4e93-ba9f-65ae99e29059_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_38913daa-fcbd-481d-93e2-9ca62ccd5899_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_e7290b6d-61ec-40b4-b27b-ed8ec10dfeb0_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8e3572e3-21d5-4f2c-84b5-8920b2a21066_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_24f0fba7-167b-4edd-bffe-debe1cc0c0ba_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement estimated reimbursable service costs for new research plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:to="lab_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_53336c4c-1d16-426c-9acd-a6491d5cf7be_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exchange Rate Volatility Estimate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_c3b8cf25-bb47-46e3-a151-d867005fe7d8_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_8457d7be-62d7-42f0-b5b0-fa13bf3ac8eb_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product targets selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Number Of Product Targets Selected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:to="lab_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_3666fa48-8f29-4cfa-b799-e717be3732cc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_299c3d7e-5dec-482a-9d2d-0010b82137e1_terseLabel_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72</link:label>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_label_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72 [Member]</link:label>
    <link:label id="lab_sgmo_PfizerC9ORF72Member_documentation_en-US" xlink:label="lab_sgmo_PfizerC9ORF72Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer C9ORF72</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member" xlink:href="sgmo-20201231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerC9ORF72Member" xlink:to="lab_sgmo_PfizerC9ORF72Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_50aa9e5a-72f7-45d7-9f1b-feea8cf0786a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_5ffa7671-8421-48e0-8dea-4454f7fc8a1f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_081e55ba-e38a-4270-994b-be0f8ecccb83_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ValbonneFranceMember_b14d4dfe-5c83-4eb2-a2fa-2ca9f768caf1_terseLabel_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_label_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France [Member]</link:label>
    <link:label id="lab_sgmo_ValbonneFranceMember_documentation_en-US" xlink:label="lab_sgmo_ValbonneFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valbonne, France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember" xlink:href="sgmo-20201231.xsd#sgmo_ValbonneFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ValbonneFranceMember" xlink:to="lab_sgmo_ValbonneFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_57e54d68-a297-4531-822f-f67d3a6074e1_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_c578b9ad-b3ea-4b95-af68-cf9741276da3_periodStartLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity attributable to noncontrolling interest, beginning balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_ad010a92-fd9d-417a-8585-cf9faeb14c08_periodEndLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity attributable to noncontrolling interest, ending balance</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_10130425-aeb3-42f5-a8aa-56aaabac8d43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value per award of restricted stock units (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_4bba34c3-c0d1-42f6-8c34-14be5a136aa4_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of commercial milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Commercial Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfCommercialMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of Commercial Milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfCommercialMilestonesMember" xlink:to="lab_sgmo_AchievementOfCommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_90581352-3750-4fb1-8744-408103a6d3a3_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France Stock Price (EUR) (in Euro per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_ed60729b-c3d2-495e-97a1-651383cd88fd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_ae6e5dd4-8836-459f-bb9d-0e033651c151_terseLabel_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State research tax credit carryforwards</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_label_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Tax Credit Carryforwards Research State And Local</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_documentation_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets tax credit carryforwards research state and local.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:href="sgmo-20201231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:to="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_5d035a3f-3723-4efa-a0b3-c98602966df2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_62015578-abd4-4eed-bb25-b7e52f0369d3_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Major Customers, Partnerships and Strategic Alliances</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_011ff0d6-77bb-4c36-9965-3565943f7495_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_e315a998-eb2d-4c47-b657-8b141479e56b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_aac8dcec-3ab4-4d76-a606-05620beedd1b_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_8963700a-5393-4538-8b00-7feed00d0613_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_5fc04c07-db5a-4bb4-bbe6-bfc9b6b16de1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d3c04b48-abaa-47f6-bcde-cf351adad12b_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, at carrying value, total</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_b73d1ccc-b1ba-41c0-85b4-d70003f28347_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_5ff9a165-a33b-4a05-a6fc-1f48d33e7893_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_b594f1c1-bcf8-4b7b-9b3c-8ef3771cf7b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerMember_c04ede69-98fc-41cd-af35-236816e653a4_terseLabel_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer</link:label>
    <link:label id="lab_sgmo_PfizerMember_label_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer [Member]</link:label>
    <link:label id="lab_sgmo_PfizerMember_documentation_en-US" xlink:label="lab_sgmo_PfizerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember" xlink:href="sgmo-20201231.xsd#sgmo_PfizerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerMember" xlink:to="lab_sgmo_PfizerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_dba9be9b-55b2-4827-a4da-eefef3e41e3d_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified research, clinical development, regulatory and first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_42f6c8dc-42fd-4c89-9262-fcc9a003ec83_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_7d684564-3532-460a-b003-15df9303e848_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1440d291-6169-4303-b489-c956bd880d3f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Sangamo Therapeutics, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_02ce65d2-eb96-41b8-ae4b-1c9c29248575_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign rate differential</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_a23d06b8-6098-4e9a-9b3b-84b083f603b4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_e9b0c0f2-30ea-48aa-a6ce-5553db1a58ca_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SangamoFranceMember_80913c15-1539-4fd0-abab-551eff0e7fdb_terseLabel_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TxCell S.A.</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_label_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France [Member]</link:label>
    <link:label id="lab_sgmo_SangamoFranceMember_documentation_en-US" xlink:label="lab_sgmo_SangamoFranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo France</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SangamoFranceMember" xlink:to="lab_sgmo_SangamoFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_a567f8ab-d637-4402-85ba-2fba4b0b0f88_verboseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Previously agreed research, development and commercialization milestone payments, and royalties on sales of products</link:label>
    <link:label id="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_label_en-US" xlink:label="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment And Royalty Revenue Of Previous Agreement</link:label>
    <link:label id="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment and royalty revenue of previous agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:href="sgmo-20201231.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:to="lab_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_9776fafe-f0fc-43ea-9386-9648c31d79c0_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_90a8adbf-4dda-4c04-8521-bbe30cdfbe58_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bd550803-383a-4b6a-a91f-19e2427ff940_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_90a49ca7-2976-495f-b2e5-933601da5bf4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_cf21a919-0e50-4650-9a1a-030aef6d1484_terseLabel_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Institute for Regenerative Medicine ("CIRM")</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_label_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Institute For Regenerative Medicine Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California institute for regenerative medicine agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:href="sgmo-20201231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:to="lab_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_1073511e-2242-4305-a530-776791027d12_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_53962685-02ea-44ec-8a8c-b6d976a1188c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_5131ff66-5ae3-49dd-9909-cc63bb2063e4_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_59efb0bb-3d3f-40cb-b161-ef5066cc1116_terseLabel_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_label_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California [Member]</link:label>
    <link:label id="lab_sgmo_BrisbaneCaliforniaMember_documentation_en-US" xlink:label="lab_sgmo_BrisbaneCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Brisbane, California</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember" xlink:href="sgmo-20201231.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_BrisbaneCaliforniaMember" xlink:to="lab_sgmo_BrisbaneCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_23286801-aa28-486b-bbed-1939c1a151db_terseLabel_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C9ORF72</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_label_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C Nine O R F Seven Two [Member]</link:label>
    <link:label id="lab_sgmo_CNineORFSevenTwoMember_documentation_en-US" xlink:label="lab_sgmo_CNineORFSevenTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">C nine ORF seven two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember" xlink:href="sgmo-20201231.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CNineORFSevenTwoMember" xlink:to="lab_sgmo_CNineORFSevenTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_acd88636-bd9e-47e9-a4fe-a65be1a039dd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_02e8104d-f1b6-4cf1-a992-0756f439a693_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4adf90bf-c4b7-4f43-a64c-f9005e4360ac_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_9e745909-76db-407a-aab7-106daf3c7b4e_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_fd0d0240-5931-4e8e-81fe-e28eb32ec942_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs vested and expected to vest at end of period (in years)</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_a6e738a2-8db5-4ad6-a912-ea93b2eb8c7c_terseLabel_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in collaboration agreement scope</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_label_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope [Member]</link:label>
    <link:label id="lab_sgmo_ChangeInCollaborationAgreementScopeMember_documentation_en-US" xlink:label="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change In Collaboration Agreement Scope</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:href="sgmo-20201231.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:to="lab_sgmo_ChangeInCollaborationAgreementScopeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_0aa9850c-580e-4ad6-bcae-b11ec6378b16_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_f7ce8bb1-8d28-41df-a4fb-a374e1f5d26f_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss on disposal of property and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ebaacc75-1759-449f-a6e8-265ee60eaf6d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions based on tax positions related to the current year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2f31c8a2-d1cd-4c63-92cf-13238725c8de_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_0985ac5a-78e7-484a-96a1-1e71795ec882_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products approved</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements Number Of Products Approved Under Agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements number of products approved under agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1f3ea2a9-743b-42b8-9101-0e503b8166f6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_1e369474-bf8a-4785-9967-526be3e20594_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAbstract" xlink:to="lab_us-gaap_LiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_3f98796e-b0a6-496b-ad58-31256e57c4cb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneOneMember_adbac388-a201-49e6-8ab7-5a889bbd7e7f_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:label id="lab_sgmo_MilestoneOneMember_label_en-US" xlink:label="lab_sgmo_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneOneMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneOneMember" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneOneMember" xlink:to="lab_sgmo_MilestoneOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_898f9b28-763d-4f51-b6cb-9269e47db476_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PropertyAndEquipmentMember_87ca540c-b277-4701-b848-963cd39f10b2_terseLabel_en-US" xlink:label="lab_sgmo_PropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_sgmo_PropertyAndEquipmentMember_label_en-US" xlink:label="lab_sgmo_PropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property And Equipment [Member]</link:label>
    <link:label id="lab_sgmo_PropertyAndEquipmentMember_documentation_en-US" xlink:label="lab_sgmo_PropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertyAndEquipmentMember" xlink:href="sgmo-20201231.xsd#sgmo_PropertyAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PropertyAndEquipmentMember" xlink:to="lab_sgmo_PropertyAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_295e2ac5-ace0-42cb-8a65-2abd30fb61ae_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_MovementInMinorityInterestRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward" xlink:to="lab_us-gaap_MovementInMinorityInterestRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0216751c-9785-40f6-906b-fcc3966b1141_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_ec8045e3-71f4-49f3-9df5-01cc82b045a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0a5e50dc-52e2-4e01-aa3d-174b4561e43d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_41cc871e-90d3-4002-9f74-a58c3a4d3e2e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_e37ff75d-c2aa-44c7-a944-d0d264e5078c_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration arrangement, research period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_label_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:label id="lab_sgmo_CollaborationArrangementResearchPeriod_documentation_en-US" xlink:label="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Arrangement, Research Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationArrangementResearchPeriod" xlink:to="lab_sgmo_CollaborationArrangementResearchPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4f0be8f8-ac34-4863-b471-5a0026388a59_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_742abb43-4bf2-4c5d-af04-9fbfbb299287_terseLabel_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development and sales-based milestone payments to be received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_label_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Development And Sales Based Milestone Payments To Be Received</link:label>
    <link:label id="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_documentation_en-US" xlink:label="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent development and sales based milestone payments to be received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:href="sgmo-20201231.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:to="lab_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_4cf42781-9940-4e91-b9c6-5dbd6ba0575c_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of specified clinical development intellectual property and regulatory milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:to="lab_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_b1311c03-b9f9-421a-9184-fe3b8f543723_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_01351d02-2dff-49ad-bf75-155bc7476292_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income attributable to Sangamo Therapeutics, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_65dae252-3387-4b73-830a-3ccba26c1753_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_GrantFundingAmount_dd1eec7f-91e4-4891-a259-c7bd4d7abb5f_terseLabel_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funds due under the agreement</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_label_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Funding Amount</link:label>
    <link:label id="lab_sgmo_GrantFundingAmount_documentation_en-US" xlink:label="lab_sgmo_GrantFundingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant funding amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount" xlink:href="sgmo-20201231.xsd#sgmo_GrantFundingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_GrantFundingAmount" xlink:to="lab_sgmo_GrantFundingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_22e65776-814b-45be-874e-5db49f067b07_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_f19295ca-460f-4ca1-a5ed-0a4b5a0373d5_terseLabel_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_label_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement Of First Commercial Sale Milestones [Member]</link:label>
    <link:label id="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_documentation_en-US" xlink:label="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement of first commercial sale milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:to="lab_sgmo_AchievementOfFirstCommercialSaleMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_b9cb61e2-e767-4464-aebe-1a3f389782b6_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_14f20514-e5bd-44e7-91e9-d91eec4c41b1_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_7890876b-b25e-4ad9-a83d-3cf789a32bb3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_e261e708-99e9-4a5b-b3d1-0b1c1e96d595_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to non-controlling interest</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_e5dff58c-9a65-412a-96e7-72e4c314317a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_cccff8e9-a90b-4e06-b8e1-7cf4f3173db0_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_3aaf637a-0835-4bd4-9c61-d2028565b7e7_negatedLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs released (in shares)</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options released in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneTwoMember_06bb0335-69c2-4485-bcfb-7b9fa7474054_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_label_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneTwoMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneTwoMember" xlink:to="lab_sgmo_MilestoneTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e205469c-4902-46af-96f0-f377aa333291_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_11dd1226-06a5-48f6-ab25-dae63cf1d61d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_412fe4ab-3438-420c-bd75-f738f624bf21_terseLabel_en-US" xlink:label="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">French</link:label>
    <link:label id="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_label_en-US" xlink:label="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ministry of the Economy, Finance and Industry, France [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:to="lab_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_78949369-6c6d-4950-8fd6-b1380916b1f1_terseLabel_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_label_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Long Term Portion Of Lease Liabilities</link:label>
    <link:label id="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_documentation_en-US" xlink:label="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase Decrease In Long Term Portion Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:href="sgmo-20201231.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:to="lab_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_01ccc64c-59fc-4f47-82f3-0fc8743d2b17_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible asset impairment</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetImpairment_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Asset Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommonStockExchangeRatio_4ad2d8a0-db5d-40cf-bcb4-72d038e1a8bc_terseLabel_en-US" xlink:label="lab_sgmo_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of common stock subject to a stock option or stock appreciation right (in shares)</link:label>
    <link:label id="lab_sgmo_CommonStockExchangeRatio_label_en-US" xlink:label="lab_sgmo_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Exchange Ratio</link:label>
    <link:label id="lab_sgmo_CommonStockExchangeRatio_documentation_en-US" xlink:label="lab_sgmo_CommonStockExchangeRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock exchange ratio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonStockExchangeRatio" xlink:href="sgmo-20201231.xsd#sgmo_CommonStockExchangeRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommonStockExchangeRatio" xlink:to="lab_sgmo_CommonStockExchangeRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_b9fc17c0-d55b-416a-97b9-5cec19b83219_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_2f7bb411-6dca-47ad-a2c3-6c510801f888_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenues, non-current</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_0e7051fd-0c19-4496-99d0-2d87b589d904_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate fair value of RSUs vested in period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_e57ff586-d1ce-4cb5-ad04-5da6aed91a27_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable" xlink:href="sgmo-20201231.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable" xlink:to="lab_sgmo_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_d5d85347-becc-4450-a0e3-898e1f3ef320_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_7b851989-e6c6-432a-9fa3-f08fdb8f7213_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under employee stock purchase plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_f1723c95-375e-4518-87b1-5b8d20468dee_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_64c8a356-14e9-4ed3-bca3-d5810c9cb7c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_c33a96eb-96b7-4c06-8709-333ea55fdbce_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_c1fb847e-f0f9-463d-a697-9a81dbee6b90_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_163e5074-d26f-48a1-88df-52a941bf02d4_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_0f029058-1d4c-410d-9497-8cbbcf392611_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_a7f8513d-7e56-44b4-baf5-fb1031e49bc7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized under agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3304b2bf-5523-4fe5-be4a-ca060df53066_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_560276b7-351b-4b53-9c63-0c7414db0d98_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate employer's contributions to defined contribution plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_734cc429-e390-4e67-bcea-b7c52407fd2f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_c7b4ebfd-50d9-4b04-8deb-fac4dc38e2af_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_fa0ac57b-25be-4991-b25d-8fd8668080ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense:</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_AgreementTerminationTerm_a9ff17fa-e13c-4806-94f9-768427dc4196_terseLabel_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination, term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_label_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:label id="lab_sgmo_AgreementTerminationTerm_documentation_en-US" xlink:label="lab_sgmo_AgreementTerminationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement Termination, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm" xlink:href="sgmo-20201231.xsd#sgmo_AgreementTerminationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_AgreementTerminationTerm" xlink:to="lab_sgmo_AgreementTerminationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_63d2cc8c-9dfc-40f6-93ed-d1bc6243e1a6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_b557ec8b-80dc-4133-b894-fc00945c87ae_terseLabel_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of vesting installment</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_label_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installment</link:label>
    <link:label id="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_documentation_en-US" xlink:label="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award number of vesting installment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:to="lab_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_2eaad4a7-b23f-4272-89d2-18b800281ed1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c5c2bd21-7ed8-4dd8-8d7b-b4cf07c4dfba_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Public offering, common stock shares issued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_73dec003-310e-44f2-86ab-e43a7b74584e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PfizerGiroctocogeneFitelparvovecMember_fd8df748-7705-40a7-a856-e2dc7864eb44_terseLabel_en-US" xlink:label="lab_sgmo_PfizerGiroctocogeneFitelparvovecMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, Giroctocogene Fitelparvovec</link:label>
    <link:label id="lab_sgmo_PfizerGiroctocogeneFitelparvovecMember_label_en-US" xlink:label="lab_sgmo_PfizerGiroctocogeneFitelparvovecMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, Giroctocogene Fitelparvovec [Member]</link:label>
    <link:label id="lab_sgmo_PfizerGiroctocogeneFitelparvovecMember_documentation_en-US" xlink:label="lab_sgmo_PfizerGiroctocogeneFitelparvovecMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pfizer, Giroctocogene Fitelparvovec</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember" xlink:href="sgmo-20201231.xsd#sgmo_PfizerGiroctocogeneFitelparvovecMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember" xlink:to="lab_sgmo_PfizerGiroctocogeneFitelparvovecMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_be7c7d54-ac95-4ffe-8041-613cdeb48691_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_0ef713a3-7a50-42da-aef4-84bbbe1052dc_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, license fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementLicenseFee_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, License Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementLicenseFee" xlink:to="lab_sgmo_CollaborativeArrangementLicenseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_fe48738f-61bc-4df6-bff8-2fdbbf6c5063_terseLabel_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_sgmo_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:href="sgmo-20201231.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems" xlink:to="lab_sgmo_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_12b51621-33f7-465c-8a93-d5aee3c04710_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_597f6a00-2b8e-4f5e-8d95-f0f03980c738_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_838cfca0-39e9-4266-82e4-374aaa16b928_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 5,000,000 shares authorized, and no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_22659300-ba26-483c-a755-d7aa7d6a6906_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_bb2f93b2-68f4-4203-ad97-bf65935557a4_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_e330505b-46e9-4649-be7e-1dbd80ed8b52_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1c9ad9e7-0306-4a92-969e-84382ae398bb_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OtherThanTemporarilyImpairedInvestment_6bce5028-c8d4-4fd2-97de-4b73c1b77365_terseLabel_en-US" xlink:label="lab_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments other-than-temporarily impaired</link:label>
    <link:label id="lab_sgmo_OtherThanTemporarilyImpairedInvestment_label_en-US" xlink:label="lab_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Than Temporarily Impaired Investment</link:label>
    <link:label id="lab_sgmo_OtherThanTemporarilyImpairedInvestment_documentation_en-US" xlink:label="lab_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than temporarily impaired investment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:href="sgmo-20201231.xsd#sgmo_OtherThanTemporarilyImpairedInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:to="lab_sgmo_OtherThanTemporarilyImpairedInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_5e621e4c-b769-475a-9b79-9470f763c284_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivableCurrent" xlink:to="lab_us-gaap_InterestReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_68f86c0b-d5cd-4343-a0d4-19bc9e9f358a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_8797d8d3-34dc-459a-990e-1501e1fe92c1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of Sangamo France</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_b1cae4eb-39b0-4808-8e42-2414862078cb_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_label_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreement [Member]</link:label>
    <link:label id="lab_sgmo_CollaborationAndLicenseAgreementMember_documentation_en-US" xlink:label="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAndLicenseAgreementMember" xlink:to="lab_sgmo_CollaborationAndLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_749dd775-39df-4b24-b718-7d77e75f93df_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_6f310af5-395a-4b08-ad5d-4d142faa111a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a9f1c10d-10b6-4b6b-a22a-b6f2d8c8e7fb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_5e8d1dc2-03dc-4473-a072-b674e7fc7150_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_IncomeTaxesLineItems_2141b74f-1c72-4847-a6c8-49835aaf62c3_terseLabel_en-US" xlink:label="lab_sgmo_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sgmo_IncomeTaxesLineItems_label_en-US" xlink:label="lab_sgmo_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sgmo_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_sgmo_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesLineItems" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_IncomeTaxesLineItems" xlink:to="lab_sgmo_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_bab9f39f-6d09-4aad-a5ed-3ac5f8e8792d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_d94a9909-8a46-4e5a-990e-98adbae4c4f5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1440834f-6abe-4415-af21-bbfceb27fb2a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_41f68cc9-cce6-47e0-b5b5-352a786e49dd_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cdc96d05-5cfa-41aa-836c-7f86a50e38c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ca5996e2-0896-4ef8-812f-180589a85598_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_e6afa697-04a1-4fdf-a37b-e6d73e11d4b4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_282be438-8048-45a9-a3ad-1417cb9a2c8d_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_f16ee01e-eb5c-4b69-8a0e-a2e7f585c4d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0183aa2a-1920-400b-bc9a-59b51005eebc_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_bf42365e-08e0-4f8d-9d35-5eb67db87fee_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_c1089619-1308-423a-a024-401dfbcc0097_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum number of product targets to replace</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Maximum Number Of Product Targets To Replace</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:to="lab_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_49316606-8649-40fd-9a4f-c363ef8d5587_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net operating loss carryforwards for foreign</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ReducedRoyaltyRate_4af2b16d-7507-4b7c-945e-b0645e4f8373_terseLabel_en-US" xlink:label="lab_sgmo_ReducedRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced royalty rate</link:label>
    <link:label id="lab_sgmo_ReducedRoyaltyRate_label_en-US" xlink:label="lab_sgmo_ReducedRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced Royalty Rate</link:label>
    <link:label id="lab_sgmo_ReducedRoyaltyRate_documentation_en-US" xlink:label="lab_sgmo_ReducedRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduced royalty rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ReducedRoyaltyRate" xlink:href="sgmo-20201231.xsd#sgmo_ReducedRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ReducedRoyaltyRate" xlink:to="lab_sgmo_ReducedRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_f79e654b-8b36-49c3-806f-641f45f820c4_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research service fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_label_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:label id="lab_sgmo_CollaborativeArrangementResearchServiceFees_documentation_en-US" xlink:label="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Research Service Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeArrangementResearchServiceFees" xlink:to="lab_sgmo_CollaborativeArrangementResearchServiceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a189aff4-3667-4385-b575-5358e91925f5_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cd0cc55c-8884-49d3-a3a8-2dd6d1bee074_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0add8aed-b539-464f-8489-0fbe51803d3c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balances</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_02881e71-4cb9-4796-a972-95e7b41698e0_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_e4eac20c-fd3b-4d53-9dad-e7a08fe31a82_terseLabel_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_label_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone [Member]</link:label>
    <link:label id="lab_sgmo_SalesBasedMilestoneMember_documentation_en-US" xlink:label="lab_sgmo_SalesBasedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-based Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember" xlink:href="sgmo-20201231.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SalesBasedMilestoneMember" xlink:to="lab_sgmo_SalesBasedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3fc00a32-ac4f-4fe9-ad66-2cee75aff8fe_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_e6c03c08-0bef-4262-a0bb-8678ab5f23aa_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c81e7643-666c-4be5-9508-814518435256_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_c3eba9ec-073e-45e4-a96e-f85decb719cb_terseLabel_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_label_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments Received</link:label>
    <link:label id="lab_sgmo_MilestonePaymentsReceived_documentation_en-US" xlink:label="lab_sgmo_MilestonePaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived" xlink:href="sgmo-20201231.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestonePaymentsReceived" xlink:to="lab_sgmo_MilestonePaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ddebe720-bf90-456b-aea1-c8ee589b22df_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75760ae5-b57c-455b-b7cb-d91c3a9dd93e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d469d04e-985f-4bb6-b72e-1af654d1c0d6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4e7f7b01-bb80-42a0-b88a-5130a5894589_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_372264d0-88b1-4b06-a43c-a835c04203d9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_a3f5bacb-cb34-4a2e-9ed8-cc10fab3f473_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_01eb8a9a-b3ba-4d23-8a52-3270f67d13fb_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_2825d38c-6001-44e2-b239-fd12d48df730_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_7d8fd150-218b-49ea-af14-4df2be5f8483_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of upfront fee</link:label>
    <link:label id="lab_us-gaap_LicenseAndServiceMember_label_en-US" xlink:label="lab_us-gaap_LicenseAndServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServiceMember" xlink:to="lab_us-gaap_LicenseAndServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7f0780c6-eaf2-493c-9954-0480c06b7431_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_e93b58b8-617f-487c-b26d-455473c66483_terseLabel_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement, equity issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_label_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:label id="lab_sgmo_CollaborationAgreementEquityIssued_documentation_en-US" xlink:label="lab_sgmo_CollaborationAgreementEquityIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Equity Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborationAgreementEquityIssued" xlink:to="lab_sgmo_CollaborationAgreementEquityIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_f51e00e6-80e3-41cc-86f6-186f77420037_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_767f8bbe-eb85-46df-ba59-64ae57dff845_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_fc76c5e9-c253-49eb-836a-69f8c310d45e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Awards, Tranche 1</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_03575a80-4c71-425b-bd41-2eeaa55b0035_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for shares acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_f0ac6220-8fe2-4ece-878d-ecced87f3d02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_7ac005fa-4cf2-4e89-ab5c-5046752a3634_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:label id="lab_us-gaap_MinorityInterestLineItems_label_en-US" xlink:label="lab_us-gaap_MinorityInterestLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestLineItems" xlink:to="lab_us-gaap_MinorityInterestLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_c2f8c9e3-c686-42eb-9199-32ac736d5268_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated correlation Sangamo and Sangamo France stock prices</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_0620fd78-e14a-4393-8853-d2c9466fb3a6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_ffeb8d19-4af7-4b79-9943-50151cb4d57a_terseLabel_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative compensation earned</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_label_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned</link:label>
    <link:label id="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_documentation_en-US" xlink:label="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:href="sgmo-20201231.xsd#sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:to="lab_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0909f86c-87cd-4f3d-89f8-c812667bcafb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_abe403a5-ea2f-4ce1-b00c-1c479cd84db4_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reductions for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_320b5edd-bbe0-49b5-a419-bd0dfb1fefcc_terseLabel_en-US" xlink:label="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest for acquisition</link:label>
    <link:label id="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_label_en-US" xlink:label="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Or Part Noncash Non Controlling Interest Acquisition</link:label>
    <link:label id="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_documentation_en-US" xlink:label="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or part noncash non-controlling interest acquisition.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:href="sgmo-20201231.xsd#sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:to="lab_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_88d1929e-1635-4bae-ae04-2e8c71d02127_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_ad8cbc2e-39a4-4273-9a51-17c11ec9a2be_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_12222de2-2281-40e9-8934-ef894f48cafb_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_4e7de4e0-e9df-4015-91fe-a8aa5e83e2d8_terseLabel_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash equivalents and available-for-sale securities, gross unrealized gains</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents and available for sale securities, gross unrealized gain, before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_8c5f9d94-df8c-4963-bb49-2aa56eb2784b_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_a2fca0a3-e24f-4da6-ac55-ef2d409a5b02_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4f7a9ca0-132c-4618-82dc-3a4c2abece8c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SigmaAldrichCorporationMember_7214781e-b6c9-405a-b331-4db1eaeab17b_terseLabel_en-US" xlink:label="lab_sgmo_SigmaAldrichCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sigma-Aldrich Corporation</link:label>
    <link:label id="lab_sgmo_SigmaAldrichCorporationMember_label_en-US" xlink:label="lab_sgmo_SigmaAldrichCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sigma Aldrich Corporation [Member]</link:label>
    <link:label id="lab_sgmo_SigmaAldrichCorporationMember_documentation_en-US" xlink:label="lab_sgmo_SigmaAldrichCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sigma-Aldrich corporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SigmaAldrichCorporationMember" xlink:href="sgmo-20201231.xsd#sgmo_SigmaAldrichCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SigmaAldrichCorporationMember" xlink:to="lab_sgmo_SigmaAldrichCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_2386228c-b332-4f00-8b60-a6bbfab1828c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_8307d55d-68fa-4881-945c-a2b751324374_terseLabel_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:href="sgmo-20201231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_1884c3f6-3229-485a-a3ae-e2195ef341eb_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_9309e50f-2a41-427d-8091-bd3d856968f7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_c53e3369-42c6-43a0-952f-7edfd41fc211_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ed8139c3-54fe-4834-b82f-b9b29b67ee19_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_98bc784f-bdb4-4b8a-a412-26a95bd88f00_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_49ed0a2e-47aa-4692-a978-553f45702b65_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_e2f21033-c496-493e-b52b-57cff22a33f8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual&#160;Term</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b26fd262-d8c3-44bc-91b1-95d8f1555e52_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding at end of period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b0361ee5-86d0-40c1-91cc-fe1390faf4f5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_23eb4b80-5352-4115-8e0f-eebabed8f356_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_0501a1ec-c4ad-45cb-910f-e90e9a41d61f_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_a256094d-faf0-4e86-8a98-3dff99c802fd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_a52e8bd9-759d-4f62-b5df-49530993e09f_terseLabel_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_label_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]</link:label>
    <link:label id="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_documentation_en-US" xlink:label="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="sgmo-20201231.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="lab_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b8f7bcc9-2d39-42f7-8e53-4866825d52e4_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_8d9d0714-6f77-4f46-bf22-b36aaf124295_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross_6b304fa0-3975-48fa-b935-2e48d0ef09c0_terseLabel_en-US" xlink:label="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received on transaction, gross</link:label>
    <link:label id="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:label id="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="sgmo-20201231.xsd#sgmo_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_c4dcbe8e-d8ec-4d98-88d6-3c9cdcf5991d_terseLabel_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal research tax credit carryforwards</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_label_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Tax Credit Carryforwards Research Federal</link:label>
    <link:label id="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_documentation_en-US" xlink:label="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets tax credit carryforwards research federal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:href="sgmo-20201231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:to="lab_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b29e1fe8-a6f5-4bae-9046-9679cd29604f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_4730b868-280d-479c-8956-a32648d22c4f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs outstanding at end of period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_MilestoneAchievementMember_a11ef1a3-ce6c-4613-9a4a-749746b0017b_terseLabel_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achievement</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_label_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement [Member]</link:label>
    <link:label id="lab_sgmo_MilestoneAchievementMember_documentation_en-US" xlink:label="lab_sgmo_MilestoneAchievementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneAchievementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_MilestoneAchievementMember" xlink:to="lab_sgmo_MilestoneAchievementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_86344158-e9cf-4510-859e-22f70a4df4d7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of stock options and restricted stock units</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_52cab514-14e1-48ca-958b-00a8bbd90f0d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset, after allowance for credit Loss</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_fa942129-c467-46af-93ab-d28cbc966e33_terseLabel_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents, gross unrealized gains</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax</link:label>
    <link:label id="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents accumulated gross unrealized gain before tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="sgmo-20201231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_81e45b25-426d-4656-ac39-c82582abe99d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_e7506d4a-7264-4d73-8a2e-40c51ecbaee3_terseLabel_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended research term of agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_label_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:label id="lab_sgmo_ExtendedResearchTermOfAgreement_documentation_en-US" xlink:label="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended Research Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:href="sgmo-20201231.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_ExtendedResearchTermOfAgreement" xlink:to="lab_sgmo_ExtendedResearchTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_PurchasePlanOfferingPeriod_b50a81c0-6376-42ac-b850-5808032ddc5f_terseLabel_en-US" xlink:label="lab_sgmo_PurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase plan offering period</link:label>
    <link:label id="lab_sgmo_PurchasePlanOfferingPeriod_label_en-US" xlink:label="lab_sgmo_PurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Plan Offering Period</link:label>
    <link:label id="lab_sgmo_PurchasePlanOfferingPeriod_documentation_en-US" xlink:label="lab_sgmo_PurchasePlanOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase plan offering period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanOfferingPeriod" xlink:href="sgmo-20201231.xsd#sgmo_PurchasePlanOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_PurchasePlanOfferingPeriod" xlink:to="lab_sgmo_PurchasePlanOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_249546e4-337a-49c7-895e-4f35825a798a_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_53554522-e173-427a-b728-67be97856608_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_4506e453-bfb4-466b-a6af-163c9382f8c3_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_c0a9dc3b-f1d4-4687-87e3-661fd503faed_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares withheld from issuance in order to pay employee taxes (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bdb03ed6-9ef5-46c4-a11f-aa87096f0613_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f411a9e6-5e32-4733-88b6-48d3175949c8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_4c4d4f24-9917-4ff2-b2ca-450158c4a8e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested and expected to vest at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_bee1ea7b-a9cf-48c7-acc3-e778b918b3a2_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dc604179-de1d-4c3e-8cd1-6e6497d0c1c3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_e43e7087-f34f-497c-909a-931d91d4890e_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_0027f208-4cb9-4a89-ba3f-22bc27144b51_terseLabel_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreement, percent of initial recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_label_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:label id="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition_documentation_en-US" xlink:label="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement, Percent Of Initial Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:to="lab_sgmo_CollaborativeAgreementPercentOfInitialRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_ca2ac8bf-a6d0-4e43-8424-07b77cd1fd50_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>sgmo-20201231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:a450ce61-5a63-468d-aea1-980040e585ad,g:3eb33991-981d-4627-a625-d6dd25ee8674-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sangamo.com/role/Cover" xlink:type="simple" xlink:href="sgmo-20201231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_92c02b74-3b0f-4072-b82a-2bbba3d63ba5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_DocumentType_92c02b74-3b0f-4072-b82a-2bbba3d63ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_0b20171b-99d2-4b0b-9fc1-a02e957a3a1f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_DocumentAnnualReport_0b20171b-99d2-4b0b-9fc1-a02e957a3a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1e3c554d-a3a3-4ec2-839c-fc51a3805d00" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_DocumentPeriodEndDate_1e3c554d-a3a3-4ec2-839c-fc51a3805d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_d9176f86-52da-44be-818f-17adfcb47462" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_CurrentFiscalYearEndDate_d9176f86-52da-44be-818f-17adfcb47462" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_b525b321-f075-4d03-8628-8d26c850303b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_DocumentTransitionReport_b525b321-f075-4d03-8628-8d26c850303b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_65f96fa6-e0bb-4d35-a96b-6d2ffdbbacd7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityFileNumber_65f96fa6-e0bb-4d35-a96b-6d2ffdbbacd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_c14f82bd-3ca4-4c13-b042-3dd4df64d260" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityRegistrantName_c14f82bd-3ca4-4c13-b042-3dd4df64d260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0e141f0f-b23e-49c6-a6c0-5098bce378ed" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0e141f0f-b23e-49c6-a6c0-5098bce378ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_33432123-f44b-4f0d-8ca1-80a2aa794efb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityTaxIdentificationNumber_33432123-f44b-4f0d-8ca1-80a2aa794efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_f62f74f3-3fe7-4f75-a2f1-0a3a45917f49" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityAddressAddressLine1_f62f74f3-3fe7-4f75-a2f1-0a3a45917f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_6cd47d77-3c27-433c-ba34-45daa12cb346" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityAddressCityOrTown_6cd47d77-3c27-433c-ba34-45daa12cb346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_963c0258-b92c-4d2c-b678-0dbd1f28ec34" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityAddressStateOrProvince_963c0258-b92c-4d2c-b678-0dbd1f28ec34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_14f09395-40d3-4eb8-8e7a-b43bd9da834f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityAddressPostalZipCode_14f09395-40d3-4eb8-8e7a-b43bd9da834f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a48e4a5e-2dfb-444c-b660-4223b542c928" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_CityAreaCode_a48e4a5e-2dfb-444c-b660-4223b542c928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4121cc26-03d3-40ae-9d84-eca1ed9a0550" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_LocalPhoneNumber_4121cc26-03d3-40ae-9d84-eca1ed9a0550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_7c1da14b-3420-4fcc-89dd-381db238ba4b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_Security12bTitle_7c1da14b-3420-4fcc-89dd-381db238ba4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2b9cc021-0573-4636-8203-a04746a5c692" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_TradingSymbol_2b9cc021-0573-4636-8203-a04746a5c692" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_76c0dfb0-5d86-4f36-ad8f-bfa79f3385cf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_SecurityExchangeName_76c0dfb0-5d86-4f36-ad8f-bfa79f3385cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_b758addb-51ed-4123-b417-04c2cc45eff0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_b758addb-51ed-4123-b417-04c2cc45eff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_d0d20d16-2058-442b-ac0e-7063691985b2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityVoluntaryFilers_d0d20d16-2058-442b-ac0e-7063691985b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_4ae53070-eaaf-4cff-a4ef-97f7707e627d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityCurrentReportingStatus_4ae53070-eaaf-4cff-a4ef-97f7707e627d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_d2bc37ef-d072-4d31-8fae-7dfd01401704" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityInteractiveDataCurrent_d2bc37ef-d072-4d31-8fae-7dfd01401704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_3a1fcc31-90b2-4b1f-b864-f3085c3a0164" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityFilerCategory_3a1fcc31-90b2-4b1f-b864-f3085c3a0164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_b0fd9671-1c92-4b67-be7e-166d0a02df69" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntitySmallBusiness_b0fd9671-1c92-4b67-be7e-166d0a02df69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_509e1363-954c-434d-95ce-7096f31aebf2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityEmergingGrowthCompany_509e1363-954c-434d-95ce-7096f31aebf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9d850566-2b8a-4489-92f7-3b1c0a3834eb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9d850566-2b8a-4489-92f7-3b1c0a3834eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_dc9ec348-a6c0-4682-878c-7b3ed25f4d51" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityShellCompany_dc9ec348-a6c0-4682-878c-7b3ed25f4d51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_65c4cb55-97e1-447b-a193-26f488111169" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityPublicFloat_65c4cb55-97e1-447b-a193-26f488111169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_070d40ce-066f-4768-801b-f98a8bd6c785" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_070d40ce-066f-4768-801b-f98a8bd6c785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_21538356-2551-48b5-b487-7e22a0150da8" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_21538356-2551-48b5-b487-7e22a0150da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a90628d9-1d9c-41ee-8a2c-f97666014235" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_AmendmentFlag_a90628d9-1d9c-41ee-8a2c-f97666014235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_96aa64e8-c468-4908-b62d-3feb6731d79b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_DocumentFiscalYearFocus_96aa64e8-c468-4908-b62d-3feb6731d79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_42af35bd-a78a-45d1-9ced-892f45249754" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_DocumentFiscalPeriodFocus_42af35bd-a78a-45d1-9ced-892f45249754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_c490eade-2594-481f-9712-5d901d4661e5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5a0b378c-e079-48d3-b2e1-bcbbea4c7923" xlink:to="loc_dei_EntityCentralIndexKey_c490eade-2594-481f-9712-5d901d4661e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_76348ee6-6670-4163-853d-f9df1e4f691f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76348ee6-6670-4163-853d-f9df1e4f691f" xlink:to="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7c82188e-ad46-463c-817e-1add3a8decbc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7c82188e-ad46-463c-817e-1add3a8decbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fa174b6-03db-42d1-9258-2ef1937a11a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7c82188e-ad46-463c-817e-1add3a8decbc" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9fa174b6-03db-42d1-9258-2ef1937a11a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_928df905-e99c-4029-b7a1-d489bef437d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7c82188e-ad46-463c-817e-1add3a8decbc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_928df905-e99c-4029-b7a1-d489bef437d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivableCurrent_75d3e56b-fe94-4289-ba79-cfb820031a38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7c82188e-ad46-463c-817e-1add3a8decbc" xlink:to="loc_us-gaap_InterestReceivableCurrent_75d3e56b-fe94-4289-ba79-cfb820031a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4b72fc26-3eb7-4d45-b3bc-39052844d2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7c82188e-ad46-463c-817e-1add3a8decbc" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4b72fc26-3eb7-4d45-b3bc-39052844d2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a1f5b6f4-72cd-4b5a-a932-8c6be695dd1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7c82188e-ad46-463c-817e-1add3a8decbc" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a1f5b6f4-72cd-4b5a-a932-8c6be695dd1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_80826eea-b506-4e7b-b485-b3d65c288829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7c82188e-ad46-463c-817e-1add3a8decbc" xlink:to="loc_us-gaap_AssetsCurrent_80826eea-b506-4e7b-b485-b3d65c288829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_33047b1f-e037-4b5d-85a3-9e3b681640d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_33047b1f-e037-4b5d-85a3-9e3b681640d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3581b500-b321-41f0-b87b-1f5b6baa1707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3581b500-b321-41f0-b87b-1f5b6baa1707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_95d5c3b6-2f6f-422f-aba1-ac97d0231b0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_95d5c3b6-2f6f-422f-aba1-ac97d0231b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_003694cc-4aa6-4e67-8769-7d4dc1de7ae4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:to="loc_us-gaap_Goodwill_003694cc-4aa6-4e67-8769-7d4dc1de7ae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f4cc479-b581-4cfd-a4a4-8907f2e19057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6f4cc479-b581-4cfd-a4a4-8907f2e19057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3d9368fe-d6db-4345-8a0c-039c8ac314d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3d9368fe-d6db-4345-8a0c-039c8ac314d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_acd8fda2-7f0a-4659-9511-0221d7a342f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_acd8fda2-7f0a-4659-9511-0221d7a342f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_328967b0-66e2-40f0-bceb-1ea3f876ec58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_05183909-2452-41b2-b27d-74992e0f0f57" xlink:to="loc_us-gaap_Assets_328967b0-66e2-40f0-bceb-1ea3f876ec58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_76348ee6-6670-4163-853d-f9df1e4f691f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_10f81524-1ddf-443e-aa89-8a59271e699c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_10f81524-1ddf-443e-aa89-8a59271e699c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_0af396ce-c03b-4468-b069-a1f1ff23f01f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10f81524-1ddf-443e-aa89-8a59271e699c" xlink:to="loc_us-gaap_AccountsPayableCurrent_0af396ce-c03b-4468-b069-a1f1ff23f01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_da3cd65b-8ee8-4528-9888-81355ff25a97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10f81524-1ddf-443e-aa89-8a59271e699c" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_da3cd65b-8ee8-4528-9888-81355ff25a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f93ec975-fc61-4efc-b100-94e26452a349" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10f81524-1ddf-443e-aa89-8a59271e699c" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f93ec975-fc61-4efc-b100-94e26452a349" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ad1b8102-26a2-4763-b71c-f2f98c97cb9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10f81524-1ddf-443e-aa89-8a59271e699c" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_ad1b8102-26a2-4763-b71c-f2f98c97cb9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ff8c2450-8a82-41d3-bb96-f7bb969bf57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_10f81524-1ddf-443e-aa89-8a59271e699c" xlink:to="loc_us-gaap_LiabilitiesCurrent_ff8c2450-8a82-41d3-bb96-f7bb969bf57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ada836c9-1d4c-47f6-8740-b006f77db2a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_ada836c9-1d4c-47f6-8740-b006f77db2a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0cd541d5-1d73-491d-b554-a78f51065ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0cd541d5-1d73-491d-b554-a78f51065ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fadbb2ae-3472-4009-bd2b-8a97376ed552" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_fadbb2ae-3472-4009-bd2b-8a97376ed552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_604ae78b-f368-4ae2-b1a8-291b35e29523" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_604ae78b-f368-4ae2-b1a8-291b35e29523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e525faad-1b2d-4442-b99a-d21a773a0912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:to="loc_us-gaap_Liabilities_e525faad-1b2d-4442-b99a-d21a773a0912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8515b670-e18c-489a-90ac-353211fb17a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8515b670-e18c-489a-90ac-353211fb17a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_52719bfa-01a5-423b-a4a5-589392af7c9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_52719bfa-01a5-423b-a4a5-589392af7c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_59aee6ca-80a0-4068-a6de-7175564cd450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:to="loc_us-gaap_CommonStockValue_59aee6ca-80a0-4068-a6de-7175564cd450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c0e7954f-9cc8-4428-a838-74d443e45f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_c0e7954f-9cc8-4428-a838-74d443e45f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f39c86bf-149a-4f1f-9e44-557dfb16006f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_f39c86bf-149a-4f1f-9e44-557dfb16006f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7ce9da45-fc1a-4b75-902d-21c0c32d1ed8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7ce9da45-fc1a-4b75-902d-21c0c32d1ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ff756a01-4585-4a16-a4a1-df076c71c1fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:to="loc_us-gaap_StockholdersEquity_ff756a01-4585-4a16-a4a1-df076c71c1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_57e31dd5-3869-4737-adc2-3396595dff53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:to="loc_us-gaap_MinorityInterest_57e31dd5-3869-4737-adc2-3396595dff53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a3af7963-dbd2-49aa-a7cd-f772665d73b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_cdc0210a-7e32-4760-8b2d-2602a856cf1d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a3af7963-dbd2-49aa-a7cd-f772665d73b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8fcf793-0306-4712-812b-5417f35279cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_b905bc3b-0564-4c3a-80a3-83ced8069db3" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_b8fcf793-0306-4712-812b-5417f35279cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_866ee7a3-4d01-4cb6-a7da-374590eb9e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_21e365b4-d806-4379-92b0-1f0828c5883e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_866ee7a3-4d01-4cb6-a7da-374590eb9e96" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_21e365b4-d806-4379-92b0-1f0828c5883e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_95e56326-c817-4c9d-a217-68f3d23b9c4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_866ee7a3-4d01-4cb6-a7da-374590eb9e96" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_95e56326-c817-4c9d-a217-68f3d23b9c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6deea3aa-df96-460b-ba37-01407d8e8962" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_866ee7a3-4d01-4cb6-a7da-374590eb9e96" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6deea3aa-df96-460b-ba37-01407d8e8962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_13aef552-9d06-46a3-a2ab-8c1954acd8c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_866ee7a3-4d01-4cb6-a7da-374590eb9e96" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_13aef552-9d06-46a3-a2ab-8c1954acd8c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7a8df6c-18e5-4262-b1ef-30f9c6fcbda8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_866ee7a3-4d01-4cb6-a7da-374590eb9e96" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b7a8df6c-18e5-4262-b1ef-30f9c6fcbda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_4909d986-770e-4fe0-83a2-a24753d0b481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_866ee7a3-4d01-4cb6-a7da-374590eb9e96" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_4909d986-770e-4fe0-83a2-a24753d0b481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_edbaaa46-fe2f-4f0a-a1f5-568a037e5876" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_866ee7a3-4d01-4cb6-a7da-374590eb9e96" xlink:to="loc_us-gaap_CommonStockSharesIssued_edbaaa46-fe2f-4f0a-a1f5-568a037e5876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f9ba8851-eae1-4953-9990-d45e9a461b67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_866ee7a3-4d01-4cb6-a7da-374590eb9e96" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f9ba8851-eae1-4953-9990-d45e9a461b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b803cad3-5cbe-4473-9cc2-d6563dd1eacd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_RevenuesAbstract_b803cad3-5cbe-4473-9cc2-d6563dd1eacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb4cd2ad-5adf-41b2-afa4-546a0ec76df9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b803cad3-5cbe-4473-9cc2-d6563dd1eacd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cb4cd2ad-5adf-41b2-afa4-546a0ec76df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_83701522-4b7d-41c8-8968-9e8181ed4e66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_OperatingExpensesAbstract_83701522-4b7d-41c8-8968-9e8181ed4e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_8d499105-49c4-49ab-9a39-cfca0dc10d55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_83701522-4b7d-41c8-8968-9e8181ed4e66" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_8d499105-49c4-49ab-9a39-cfca0dc10d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_73f2a9f0-736b-47f3-b1fb-c01b6df32930" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_83701522-4b7d-41c8-8968-9e8181ed4e66" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_73f2a9f0-736b-47f3-b1fb-c01b6df32930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_68fd45b6-ede5-4387-9c91-3fd67329a29c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_83701522-4b7d-41c8-8968-9e8181ed4e66" xlink:to="loc_us-gaap_OperatingExpenses_68fd45b6-ede5-4387-9c91-3fd67329a29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3048dff5-8d8e-45d5-87da-2aae8c8e9b02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_OperatingIncomeLoss_3048dff5-8d8e-45d5-87da-2aae8c8e9b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndOtherIncome_cbb9ed94-0399-4240-aa62-d9850774dbb4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestAndOtherIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_InterestAndOtherIncome_cbb9ed94-0399-4240-aa62-d9850774dbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e443ff3-3ce3-47d2-b93d-29a7c0586ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7e443ff3-3ce3-47d2-b93d-29a7c0586ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7e75b4d7-0243-41d1-814f-698abea9323e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_7e75b4d7-0243-41d1-814f-698abea9323e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d1f96298-592e-4d79-8bd2-6eaae1097cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_ProfitLoss_d1f96298-592e-4d79-8bd2-6eaae1097cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_30c5cfb2-bcaa-4552-9bc5-8b864bbcffc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_30c5cfb2-bcaa-4552-9bc5-8b864bbcffc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3c58a1d-b7c6-49f0-9311-9bf6bc0c2f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_NetIncomeLoss_a3c58a1d-b7c6-49f0-9311-9bf6bc0c2f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_1a98eff6-fc10-4e34-b833-e29404654b81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_1a98eff6-fc10-4e34-b833-e29404654b81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_82973406-8d68-429a-b9b7-150324686bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_3ebb6fcc-b059-44ab-a507-d878bfb08139" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_82973406-8d68-429a-b9b7-150324686bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661bc1ce-fd76-442d-88d5-39ba7354f074" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_117ac976-2d4b-47ad-84c8-5baed261c425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661bc1ce-fd76-442d-88d5-39ba7354f074" xlink:to="loc_us-gaap_ProfitLoss_117ac976-2d4b-47ad-84c8-5baed261c425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3edf53e5-4c05-4b0e-a08d-d4f4c8038e75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661bc1ce-fd76-442d-88d5-39ba7354f074" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3edf53e5-4c05-4b0e-a08d-d4f4c8038e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865d5fa6-5e1f-47f4-a38b-54540f9ced24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661bc1ce-fd76-442d-88d5-39ba7354f074" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_865d5fa6-5e1f-47f4-a38b-54540f9ced24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c5335f15-bf9f-4847-8c04-57ee23434bc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661bc1ce-fd76-442d-88d5-39ba7354f074" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c5335f15-bf9f-4847-8c04-57ee23434bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6f165a64-36ba-4eb5-b310-6a93ad173ac7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661bc1ce-fd76-442d-88d5-39ba7354f074" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_6f165a64-36ba-4eb5-b310-6a93ad173ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2782da86-67bb-4c69-a4df-34e5644d1deb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661bc1ce-fd76-442d-88d5-39ba7354f074" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_2782da86-67bb-4c69-a4df-34e5644d1deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9af64ab4-0641-4cb9-8532-462097ef1fe8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_661bc1ce-fd76-442d-88d5-39ba7354f074" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9af64ab4-0641-4cb9-8532-462097ef1fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_eb91a3c8-9c4f-40f7-a500-ec0bfa067af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_13a1e29c-3b10-49c0-9712-a70fa21ebf83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_eb91a3c8-9c4f-40f7-a500-ec0bfa067af1" xlink:to="loc_us-gaap_StatementTable_13a1e29c-3b10-49c0-9712-a70fa21ebf83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_50369298-2cda-449c-93be-bbfbf93d0f08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_13a1e29c-3b10-49c0-9712-a70fa21ebf83" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_50369298-2cda-449c-93be-bbfbf93d0f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_50369298-2cda-449c-93be-bbfbf93d0f08" xlink:to="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_c77908c1-08d2-404d-8b25-c0421a1d577a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_CommonStockMember_c77908c1-08d2-404d-8b25-c0421a1d577a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_edaaec2f-3f35-41ed-b010-5d585d0cd782" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_edaaec2f-3f35-41ed-b010-5d585d0cd782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_bb3feebf-f2d9-42c6-93cb-faf08b178f7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_RetainedEarningsMember_bb3feebf-f2d9-42c6-93cb-faf08b178f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a396e630-d415-4e79-a9fd-75114f32bbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_a396e630-d415-4e79-a9fd-75114f32bbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_07827300-ef50-4b1f-9a88-7ef2e70c6813" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0a5f0663-4883-4bc7-bfc5-be4fd3b46c9a" xlink:to="loc_us-gaap_NoncontrollingInterestMember_07827300-ef50-4b1f-9a88-7ef2e70c6813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fa9874c4-bed0-4813-af54-511550d420d8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_13a1e29c-3b10-49c0-9712-a70fa21ebf83" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fa9874c4-bed0-4813-af54-511550d420d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e339aa0e-d6de-48ef-b583-f0c1027d11e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_fa9874c4-bed0-4813-af54-511550d420d8" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e339aa0e-d6de-48ef-b583-f0c1027d11e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_104a328c-87e5-4979-a882-f8c7d185a3bb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_e339aa0e-d6de-48ef-b583-f0c1027d11e0" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember_104a328c-87e5-4979-a882-f8c7d185a3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_13a1e29c-3b10-49c0-9712-a70fa21ebf83" xlink:to="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_426fbddc-fff2-4672-81d7-fe59a6956cd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_CommonStockSharesIssued_426fbddc-fff2-4672-81d7-fe59a6956cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48816d05-50ca-4bce-8359-e99799c83f9f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_48816d05-50ca-4bce-8359-e99799c83f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d9a2fa6-152b-4844-94a9-b2759d69f104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2d9a2fa6-152b-4844-94a9-b2759d69f104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_03750296-56b9-4e3c-9121-53c7955b4b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_03750296-56b9-4e3c-9121-53c7955b4b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e5ae7bbc-ab1e-4748-8624-3111c0aba9fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_e5ae7bbc-ab1e-4748-8624-3111c0aba9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6f023b44-bd3f-43f7-9319-231b30cd9910" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6f023b44-bd3f-43f7-9319-231b30cd9910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_123663b9-f61b-486e-8826-4420df193dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_123663b9-f61b-486e-8826-4420df193dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6dabf219-c9e3-4899-8341-229b13532d71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_6dabf219-c9e3-4899-8341-229b13532d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f3ed9d6-9325-476a-a7b7-c4517f2c24a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4f3ed9d6-9325-476a-a7b7-c4517f2c24a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_d80868e8-e5e4-4ca8-9acc-afea81dad9fb" xlink:href="sgmo-20201231.xsd#sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest_d80868e8-e5e4-4ca8-9acc-afea81dad9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_7d251b16-e10f-440b-a511-20eb8e154fe7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination_7d251b16-e10f-440b-a511-20eb8e154fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f9a87c74-473f-4e5e-81fa-3df2e2f0e8b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_f9a87c74-473f-4e5e-81fa-3df2e2f0e8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_66254cc2-ccc7-406c-8756-dc29a6fc69e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_66254cc2-ccc7-406c-8756-dc29a6fc69e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_95bf7957-827b-4902-8efe-f1f4e1c74e41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_95bf7957-827b-4902-8efe-f1f4e1c74e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5bb16597-f3e6-4fe3-a5d2-cf774ef2b174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5bb16597-f3e6-4fe3-a5d2-cf774ef2b174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_238b7354-d7aa-49e6-8687-f0bd81180aab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_ProfitLoss_238b7354-d7aa-49e6-8687-f0bd81180aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_4b4d224f-7cae-4de0-872c-6dd00d20703e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_CommonStockSharesIssued_4b4d224f-7cae-4de0-872c-6dd00d20703e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a0f76b3-e411-49df-96b0-a62c33da379c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2a0f76b3-e411-49df-96b0-a62c33da379c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdateExtensibleList_2197aac8-8d27-4c38-bb4b-31bb425ed126" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdateExtensibleList"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_8bfb2ac3-c2fc-4a00-8dfb-cc843fecc736" xlink:to="loc_us-gaap_AccountingStandardsUpdateExtensibleList_2197aac8-8d27-4c38-bb4b-31bb425ed126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="sgmo-20201231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_53e177a4-e0b5-445a-8adf-76d149b30f4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_1c859c34-97fb-424b-b797-15c9a1f882f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_53e177a4-e0b5-445a-8adf-76d149b30f4a" xlink:to="loc_us-gaap_StatementTable_1c859c34-97fb-424b-b797-15c9a1f882f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_c220cba1-6d5c-4942-a230-508c039c9d19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1c859c34-97fb-424b-b797-15c9a1f882f4" xlink:to="loc_us-gaap_LeaseContractualTermAxis_c220cba1-6d5c-4942-a230-508c039c9d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_a428a85d-a0b8-458c-a125-ac7a6a65fce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_c220cba1-6d5c-4942-a230-508c039c9d19" xlink:to="loc_us-gaap_LeaseContractualTermDomain_a428a85d-a0b8-458c-a125-ac7a6a65fce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeaseMember_e7ecdd78-43c2-48a2-bb60-43465d928987" xlink:href="sgmo-20201231.xsd#sgmo_BuildToSuitLeaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_a428a85d-a0b8-458c-a125-ac7a6a65fce0" xlink:to="loc_sgmo_BuildToSuitLeaseMember_e7ecdd78-43c2-48a2-bb60-43465d928987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33ece32d-eb03-45c1-ad36-7b2f4f7fb77a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1c859c34-97fb-424b-b797-15c9a1f882f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33ece32d-eb03-45c1-ad36-7b2f4f7fb77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19a1203c-757e-4ca3-9497-66e38d7c0661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_33ece32d-eb03-45c1-ad36-7b2f4f7fb77a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19a1203c-757e-4ca3-9497-66e38d7c0661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PropertyAndEquipmentMember_17d9f535-759c-4788-a096-73260277aefe" xlink:href="sgmo-20201231.xsd#sgmo_PropertyAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_19a1203c-757e-4ca3-9497-66e38d7c0661" xlink:to="loc_sgmo_PropertyAndEquipmentMember_17d9f535-759c-4788-a096-73260277aefe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1c859c34-97fb-424b-b797-15c9a1f882f4" xlink:to="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_40ac7c7f-d2ee-4da2-a1e2-eb4c9892030f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:to="loc_us-gaap_ProfitLoss_40ac7c7f-d2ee-4da2-a1e2-eb4c9892030f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_51e00365-5c8d-4bfc-a624-acfc53aac7d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_51e00365-5c8d-4bfc-a624-acfc53aac7d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9614069b-8f5a-4be5-b72e-c0246fc5167f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_9614069b-8f5a-4be5-b72e-c0246fc5167f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_82f89860-b270-45fc-8e19-66d30c8128a9" xlink:href="sgmo-20201231.xsd#sgmo_AmortizationAndOtherChangesInRightOfUseAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_sgmo_AmortizationAndOtherChangesInRightOfUseAssets_82f89860-b270-45fc-8e19-66d30c8128a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GainOnFreeShares_0545270e-7811-48be-91df-21ae4b9c9a2d" xlink:href="sgmo-20201231.xsd#sgmo_GainOnFreeShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_sgmo_GainOnFreeShares_0545270e-7811-48be-91df-21ae4b9c9a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3e09199d-038c-485c-ac96-350a120b0b1a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3e09199d-038c-485c-ac96-350a120b0b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_51cef562-311f-4646-98fa-d937781df361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_ShareBasedCompensation_51cef562-311f-4646-98fa-d937781df361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnTerminationOfLease_a6816eb3-3f64-471d-90ea-91469d8926d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GainLossOnTerminationOfLease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_us-gaap_GainLossOnTerminationOfLease_a6816eb3-3f64-471d-90ea-91469d8926d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BuildToSuitLeases_f3625960-4fe3-4bf6-a40e-dffb5ca58ee4" xlink:href="sgmo-20201231.xsd#sgmo_BuildToSuitLeases"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_2a8b100e-54f8-40c1-bf95-cb0d83beb820" xlink:to="loc_sgmo_BuildToSuitLeases_f3625960-4fe3-4bf6-a40e-dffb5ca58ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_710028c7-4d51-483c-89e2-6c0d4441ec82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_710028c7-4d51-483c-89e2-6c0d4441ec82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_33a3b35e-7b63-4bf9-81ce-6bd44988fd61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_33a3b35e-7b63-4bf9-81ce-6bd44988fd61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_93502b4a-165f-4ddc-88f8-8c1452a6e940" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_93502b4a-165f-4ddc-88f8-8c1452a6e940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f18c5bf8-5e07-4815-b56f-1db1824c6ed3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f18c5bf8-5e07-4815-b56f-1db1824c6ed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d0236c0a-7913-4aab-adb7-d0c970eea60d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_d0236c0a-7913-4aab-adb7-d0c970eea60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5dd4c9fb-54f2-4a52-bc59-3efa6481c3bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5dd4c9fb-54f2-4a52-bc59-3efa6481c3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_720ec6d1-c700-4520-a487-c73cc2980740" xlink:href="sgmo-20201231.xsd#sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities_720ec6d1-c700-4520-a487-c73cc2980740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_30e0c1be-e3fb-4210-a0a5-248447714652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc855b30-b6fa-4f15-8a17-8b9a01f63fca" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_30e0c1be-e3fb-4210-a0a5-248447714652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_081dca51-c457-41db-97bf-e724d0061c1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_6194709b-af9b-4c45-bb56-a3753e437808" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_081dca51-c457-41db-97bf-e724d0061c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_32552566-9b95-47d4-bcda-bdde3eb73b5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_32552566-9b95-47d4-bcda-bdde3eb73b5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fca92a94-d43d-4f7a-af3a-70dd7a580c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_fca92a94-d43d-4f7a-af3a-70dd7a580c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_51172077-4e30-495c-9d6f-36609e7321c8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_51172077-4e30-495c-9d6f-36609e7321c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aae0efa0-105d-4553-b7c0-46cc50810bdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aae0efa0-105d-4553-b7c0-46cc50810bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_92dd5e5e-35e4-48b0-8297-74a15500363d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_92dd5e5e-35e4-48b0-8297-74a15500363d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_611bd281-7f54-4e64-a20c-4787590846e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_88a94718-acc6-42f6-b68b-4b60f60ec487" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_611bd281-7f54-4e64-a20c-4787590846e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_05ad7e75-c295-4ace-af31-856da3dbe540" xlink:href="sgmo-20201231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_05ad7e75-c295-4ace-af31-856da3dbe540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_7169bbc6-0987-4840-a2ea-a31e06fde3f3" xlink:href="sgmo-20201231.xsd#sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts_7169bbc6-0987-4840-a2ea-a31e06fde3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_778d7435-cbbd-4a90-b064-5aed2164e03c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_778d7435-cbbd-4a90-b064-5aed2164e03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3a9a0881-94e8-4025-ba9b-02b26dba0ef4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_3a9a0881-94e8-4025-ba9b-02b26dba0ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ade1ae6e-a4fc-4db3-88ff-b3f4f53d8383" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_ade1ae6e-a4fc-4db3-88ff-b3f4f53d8383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80aef257-008e-43bb-9463-8ff7ec718a85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_029b2a41-d809-4e17-8037-8816fb551e8c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_80aef257-008e-43bb-9463-8ff7ec718a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_11881325-e594-4799-8b93-a76034ad5da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_11881325-e594-4799-8b93-a76034ad5da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cbb4742b-67ef-4aca-9bb7-79710c8c94d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cbb4742b-67ef-4aca-9bb7-79710c8c94d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab0627b5-beb2-40f0-8266-fdbec979f57c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ab0627b5-beb2-40f0-8266-fdbec979f57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69306518-88c3-473c-b6a1-5bdde90bdeec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_69306518-88c3-473c-b6a1-5bdde90bdeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7789471a-b84e-497e-8991-79da6cab0b2f" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_b4f1ac98-3660-4f05-806f-878825845a9b" xlink:href="sgmo-20201231.xsd#sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:to="loc_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition_b4f1ac98-3660-4f05-806f-878825845a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_79f98bf9-352d-45ca-9a02-ca4a6140b850" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_79f98bf9-352d-45ca-9a02-ca4a6140b850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9bb18621-6478-4a19-9bff-43889b1c5486" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_41ae03ee-fa1b-4979-935d-d36160021cd7" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_9bb18621-6478-4a19-9bff-43889b1c5486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5de29e28-7bc2-4622-8be6-76f57ed40e8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_2e10deba-cb88-4a33-8e65-271e12e99d0f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5de29e28-7bc2-4622-8be6-76f57ed40e8b" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_2e10deba-cb88-4a33-8e65-271e12e99d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_eff51c05-18b8-41c5-9d33-19e688531254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_eff51c05-18b8-41c5-9d33-19e688531254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_705ddb4b-c853-45de-b33c-ba5646a02b95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_UseOfEstimates_705ddb4b-c853-45de-b33c-ba5646a02b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_864a0b1c-c8f3-4041-b75d-dd4b8acfdd73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_864a0b1c-c8f3-4041-b75d-dd4b8acfdd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_96c91f4e-a36a-4d95-82e2-b9590e659201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_96c91f4e-a36a-4d95-82e2-b9590e659201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_ca6d6350-93f1-4caf-aabe-1f3623adb416" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_ca6d6350-93f1-4caf-aabe-1f3623adb416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9a481760-8f37-4969-b014-ef8b347607aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_9a481760-8f37-4969-b014-ef8b347607aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0391dc38-8254-44d2-a46b-d176cc5b3c97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_0391dc38-8254-44d2-a46b-d176cc5b3c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_507e287d-004f-46d1-be58-263440135481" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_507e287d-004f-46d1-be58-263440135481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_f001d7d9-a776-4ed8-a1a7-0c91663e1142" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_f001d7d9-a776-4ed8-a1a7-0c91663e1142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_e7dab1ea-c906-4cfe-b504-a132a39ca362" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_e7dab1ea-c906-4cfe-b504-a132a39ca362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b99a2031-46e9-40d9-8c5c-3fc02aedc80b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_b99a2031-46e9-40d9-8c5c-3fc02aedc80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3bf43c51-1bf6-4932-b530-41f3d06657cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3bf43c51-1bf6-4932-b530-41f3d06657cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_7b69d8c1-73e2-45ee-a83c-4bb160e8f25a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_7b69d8c1-73e2-45ee-a83c-4bb160e8f25a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ccc5d7d6-b3c8-40ea-91b7-4681d15e6a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_ccc5d7d6-b3c8-40ea-91b7-4681d15e6a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_e4207dfc-f3b3-4969-9854-920bc3c67be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_e4207dfc-f3b3-4969-9854-920bc3c67be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_032c46fe-fc4f-4ab5-984a-04f382361b14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_032c46fe-fc4f-4ab5-984a-04f382361b14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_833c44e1-50cf-41ce-a199-a96b2742f4fb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_833c44e1-50cf-41ce-a199-a96b2742f4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_de5a3efd-cea5-40a1-8de9-0e21ec95770e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_de5a3efd-cea5-40a1-8de9-0e21ec95770e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_690b406e-227d-4eba-bd19-17a2c5f5d76e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_690b406e-227d-4eba-bd19-17a2c5f5d76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4fb0ebc7-2023-405e-bb32-f24aceeb9420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1bf48b39-35a9-4944-a909-b0673ef5e465" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4fb0ebc7-2023-405e-bb32-f24aceeb9420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e83b2f70-a9de-408e-bdad-c137f4f09580" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_845ef356-1cac-4c96-a6d2-b7019208b9ca" xlink:href="sgmo-20201231.xsd#sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e83b2f70-a9de-408e-bdad-c137f4f09580" xlink:to="loc_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock_845ef356-1cac-4c96-a6d2-b7019208b9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_16fdc980-c781-4c1a-8110-e2278ea1e7c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e83b2f70-a9de-408e-bdad-c137f4f09580" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_16fdc980-c781-4c1a-8110-e2278ea1e7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_14047b93-3323-44e1-8817-f7ef71749076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e83b2f70-a9de-408e-bdad-c137f4f09580" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_14047b93-3323-44e1-8817-f7ef71749076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1dea0d07-f5eb-4f1f-ab40-c5b92cbf5e79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:href="sgmo-20201231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1dea0d07-f5eb-4f1f-ab40-c5b92cbf5e79" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5d9e3c23-409b-42fe-864f-e5269e0bf002" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:to="loc_srt_RangeAxis_5d9e3c23-409b-42fe-864f-e5269e0bf002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_39b8f8cb-4dd5-4428-8e5d-f2053c0a888a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5d9e3c23-409b-42fe-864f-e5269e0bf002" xlink:to="loc_srt_RangeMember_39b8f8cb-4dd5-4428-8e5d-f2053c0a888a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbecbca2-4c20-476d-a200-d1f3fa152d70" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39b8f8cb-4dd5-4428-8e5d-f2053c0a888a" xlink:to="loc_srt_MinimumMember_fbecbca2-4c20-476d-a200-d1f3fa152d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3211ad63-0da8-4a48-a389-22fdc513d4ad" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_39b8f8cb-4dd5-4428-8e5d-f2053c0a888a" xlink:to="loc_srt_MaximumMember_3211ad63-0da8-4a48-a389-22fdc513d4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5f2dc068-68f4-4630-a678-18c8604bf1b1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:to="loc_srt_CounterpartyNameAxis_5f2dc068-68f4-4630-a678-18c8604bf1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec689e2e-d187-4b95-8408-24500daa91de" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5f2dc068-68f4-4630-a678-18c8604bf1b1" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec689e2e-d187-4b95-8408-24500daa91de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_07aeb347-0d96-403b-b070-9b62539fbede" xlink:href="sgmo-20201231.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec689e2e-d187-4b95-8408-24500daa91de" xlink:to="loc_sgmo_PfizerSB525Member_07aeb347-0d96-403b-b070-9b62539fbede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_0460bceb-74ae-4677-869d-676095462577" xlink:href="sgmo-20201231.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ec689e2e-d187-4b95-8408-24500daa91de" xlink:to="loc_sgmo_PfizerMember_0460bceb-74ae-4677-869d-676095462577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f69f2cb7-3c03-4d16-9018-902490081f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f69f2cb7-3c03-4d16-9018-902490081f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_7a115781-49a0-470f-b8f2-a7c6819b2223" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_f69f2cb7-3c03-4d16-9018-902490081f07" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_7a115781-49a0-470f-b8f2-a7c6819b2223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ChangeInCollaborationAgreementScopeMember_a5f5e591-4ab2-4299-bfef-901ba9e72745" xlink:href="sgmo-20201231.xsd#sgmo_ChangeInCollaborationAgreementScopeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_7a115781-49a0-470f-b8f2-a7c6819b2223" xlink:to="loc_sgmo_ChangeInCollaborationAgreementScopeMember_a5f5e591-4ab2-4299-bfef-901ba9e72745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bca05c4c-b6b1-4c2a-9bbb-fce398fd46ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bca05c4c-b6b1-4c2a-9bbb-fce398fd46ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0aae6dd-4ab1-4196-aa09-5258db3390b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bca05c4c-b6b1-4c2a-9bbb-fce398fd46ea" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0aae6dd-4ab1-4196-aa09-5258db3390b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_04ac44f8-b8eb-4057-b495-ebfd10b25dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e0aae6dd-4ab1-4196-aa09-5258db3390b4" xlink:to="loc_us-gaap_CollaborativeArrangementMember_04ac44f8-b8eb-4057-b495-ebfd10b25dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:href="sgmo-20201231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_3cfcf948-894c-4d31-9b87-86095cd38571" xlink:to="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7513c922-71b7-4cf4-beb3-0fe4b0313b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7513c922-71b7-4cf4-beb3-0fe4b0313b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_331b3a3c-192d-4e2d-b2f7-d74bc3bb0f6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_ProfitLoss_331b3a3c-192d-4e2d-b2f7-d74bc3bb0f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_50812cb8-d449-4559-a284-202bce9a7ff7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_EarningsPerShareBasic_50812cb8-d449-4559-a284-202bce9a7ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_8d64faa7-f3d8-4034-9564-b29f645a3b46" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetImpairment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetImpairment_8d64faa7-f3d8-4034-9564-b29f645a3b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_df9e07ec-ff9f-4818-bd6a-d201f5e1e887" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_df9e07ec-ff9f-4818-bd6a-d201f5e1e887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_31063433-5562-4497-9275-b6bd3e6dcbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_31063433-5562-4497-9275-b6bd3e6dcbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_86332bbd-757d-46bb-bab8-dc8e1b534a94" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_86332bbd-757d-46bb-bab8-dc8e1b534a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_632b8526-e527-4481-871b-59941d83df74" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_632b8526-e527-4481-871b-59941d83df74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_c715b678-4608-4d83-84e1-b0507c93f44a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_528482a1-fe4f-4789-b6e1-95092de31283" xlink:to="loc_us-gaap_NumberOfOperatingSegments_c715b678-4608-4d83-84e1-b0507c93f44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1c40cdd3-a18d-4a2c-95ed-c19f0bc3abd2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1c40cdd3-a18d-4a2c-95ed-c19f0bc3abd2" xlink:to="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a0220cdb-3322-4ffd-a0d3-b8c8d1a6e661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a0220cdb-3322-4ffd-a0d3-b8c8d1a6e661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cfaeb4-0389-419d-9b72-a52c73d17170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a0220cdb-3322-4ffd-a0d3-b8c8d1a6e661" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cfaeb4-0389-419d-9b72-a52c73d17170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_a952530d-4ef8-42a9-bd3f-e53da05755c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d5cfaeb4-0389-419d-9b72-a52c73d17170" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_a952530d-4ef8-42a9-bd3f-e53da05755c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_76902c41-d03e-4ca8-81d5-e0006f621de7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_76902c41-d03e-4ca8-81d5-e0006f621de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3d0d55b0-5112-4eb9-89ed-d0feef28e054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_76902c41-d03e-4ca8-81d5-e0006f621de7" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3d0d55b0-5112-4eb9-89ed-d0feef28e054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_c90e5a4d-7516-4592-89b3-06cabb4137dd" xlink:href="sgmo-20201231.xsd#sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3d0d55b0-5112-4eb9-89ed-d0feef28e054" xlink:to="loc_sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember_c90e5a4d-7516-4592-89b3-06cabb4137dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bd885c84-8e70-4a65-818a-fca45c9eea4d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:to="loc_srt_CounterpartyNameAxis_bd885c84-8e70-4a65-818a-fca45c9eea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bd885c84-8e70-4a65-818a-fca45c9eea4d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_fb1f4804-961a-4561-b19c-7a7aa2f290a2" xlink:href="sgmo-20201231.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_PfizerMember_fb1f4804-961a-4561-b19c-7a7aa2f290a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_f0c68b64-827e-4b28-af44-db9d089e9ab3" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_BiogenMAIncMember_f0c68b64-827e-4b28-af44-db9d089e9ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_f63a12e0-2c46-4465-82a6-2a1ebe6f16c8" xlink:href="sgmo-20201231.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_KitePharmaIncMember_f63a12e0-2c46-4465-82a6-2a1ebe6f16c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_8f43954d-0bf1-4765-a972-dab040dd1b9d" xlink:href="sgmo-20201231.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_8f43954d-0bf1-4765-a972-dab040dd1b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_9863ff25-67e8-44cb-a350-a00679c53b01" xlink:href="sgmo-20201231.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f3d534e6-baa9-4ec0-98d4-17ee3fb1b8e0" xlink:to="loc_sgmo_SanofiMember_9863ff25-67e8-44cb-a350-a00679c53b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_79e0a490-6a05-44b0-9520-d1a579a8a23f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_20af7c2b-9bd8-4432-8d75-2f1c6357736e" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_79e0a490-6a05-44b0-9520-d1a579a8a23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_5bf4b272-221f-4896-ae10-59804ecb7527" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_79e0a490-6a05-44b0-9520-d1a579a8a23f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_5bf4b272-221f-4896-ae10-59804ecb7527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d53ee8ff-d7fe-45e3-969b-cf75d93feca9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_e94be1d3-e0f5-4057-b1dc-32a74c790da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d53ee8ff-d7fe-45e3-969b-cf75d93feca9" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_e94be1d3-e0f5-4057-b1dc-32a74c790da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6de82a88-98cd-47da-8d36-7bb19b7dc40c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d53ee8ff-d7fe-45e3-969b-cf75d93feca9" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_6de82a88-98cd-47da-8d36-7bb19b7dc40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5fd81ef-16f5-4406-96fa-a896d585550c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d53ee8ff-d7fe-45e3-969b-cf75d93feca9" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a5fd81ef-16f5-4406-96fa-a896d585550c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurement"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_c7e7d0ec-5275-48c0-af56-842cccadd170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_94486ee5-6958-4338-b833-b5a637b94677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_c7e7d0ec-5275-48c0-af56-842cccadd170" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_94486ee5-6958-4338-b833-b5a637b94677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_166585b8-5703-4a7e-9da0-5de0d11543a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8eb0f62f-3545-4216-aecb-1a1eb4d5ae87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_166585b8-5703-4a7e-9da0-5de0d11543a9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_8eb0f62f-3545-4216-aecb-1a1eb4d5ae87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_499aef7a-fe43-46c8-938b-cdfab537c1d4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_166585b8-5703-4a7e-9da0-5de0d11543a9" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_499aef7a-fe43-46c8-938b-cdfab537c1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_ce7264f6-e5e0-4a16-a29d-9d5322ac1549" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_ce7264f6-e5e0-4a16-a29d-9d5322ac1549" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4c2958ce-869d-4605-8c52-ea4d559823ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4c2958ce-869d-4605-8c52-ea4d559823ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf843462-da66-443a-a525-781dbb3c239a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_4c2958ce-869d-4605-8c52-ea4d559823ce" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf843462-da66-443a-a525-781dbb3c239a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_170d6e00-c53d-4c52-85b8-46e46d691852" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_bf843462-da66-443a-a525-781dbb3c239a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_170d6e00-c53d-4c52-85b8-46e46d691852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1d2a5def-b08d-498c-93e5-bc42318927c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1d2a5def-b08d-498c-93e5-bc42318927c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1d2a5def-b08d-498c-93e5-bc42318927c6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8f673753-854d-4258-a5e9-8dc06bf63340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8f673753-854d-4258-a5e9-8dc06bf63340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_926c42d9-0615-48da-b0a6-f861e7a10702" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_us-gaap_CertificatesOfDepositMember_926c42d9-0615-48da-b0a6-f861e7a10702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_070c2ec8-66c2-4f7f-ab2e-4e6f00530957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_070c2ec8-66c2-4f7f-ab2e-4e6f00530957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_fb961b0d-dcd5-415e-ac5a-4fbe701c43b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_fb961b0d-dcd5-415e-ac5a-4fbe701c43b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesAssetMember_bd2407a8-dfa9-468d-82fb-74d98376c39b" xlink:href="sgmo-20201231.xsd#sgmo_FreeSharesAssetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_sgmo_FreeSharesAssetMember_bd2407a8-dfa9-468d-82fb-74d98376c39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FreeSharesLiabilityMember_2895c85d-6287-47d5-9af3-4080c08633aa" xlink:href="sgmo-20201231.xsd#sgmo_FreeSharesLiabilityMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b9424469-9b6b-4d7a-8739-794f87aeff60" xlink:to="loc_sgmo_FreeSharesLiabilityMember_2895c85d-6287-47d5-9af3-4080c08633aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0d391d2-503a-4ef4-91f7-26b4b3efe018" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0d391d2-503a-4ef4-91f7-26b4b3efe018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e0d391d2-503a-4ef4-91f7-26b4b3efe018" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_899e6760-ccae-4475-9949-6f03f5818846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_899e6760-ccae-4475-9949-6f03f5818846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_194d39eb-0be1-443a-b794-d039939abc6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_194d39eb-0be1-443a-b794-d039939abc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_33c90453-6107-443c-9332-5ac7196f1743" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_322c4e58-0c43-42f0-a70c-0721c5c660e6" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_33c90453-6107-443c-9332-5ac7196f1743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_8343d660-158f-47d2-957f-b949e40af95a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:to="loc_us-gaap_InvestmentTypeAxis_8343d660-158f-47d2-957f-b949e40af95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d06cc675-1163-48f4-930b-a5b224c901aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_8343d660-158f-47d2-957f-b949e40af95a" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d06cc675-1163-48f4-930b-a5b224c901aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_8504993a-b02f-4a3d-8812-cff60a729d8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d06cc675-1163-48f4-930b-a5b224c901aa" xlink:to="loc_us-gaap_MoneyMarketFundsMember_8504993a-b02f-4a3d-8812-cff60a729d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_1e21c079-d467-4b76-a7a7-f037806d949a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_d06cc675-1163-48f4-930b-a5b224c901aa" xlink:to="loc_us-gaap_CommercialPaperMember_1e21c079-d467-4b76-a7a7-f037806d949a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9716cf42-5e97-4418-ab08-b6ed83a97ab1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_44f75733-fe05-4f6d-90b6-6fd8174218f0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_44f75733-fe05-4f6d-90b6-6fd8174218f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5351898-b8a9-4118-b26e-25bae39f7498" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f5351898-b8a9-4118-b26e-25bae39f7498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4e992e37-1f3c-48fd-9027-08726bcf9011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f6d6f4f1-64f9-420e-816f-71423b9429af" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_4e992e37-1f3c-48fd-9027-08726bcf9011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_440d74be-705c-4c61-b9f4-96797dcfe4cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_440d74be-705c-4c61-b9f4-96797dcfe4cd" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_6b994028-7d3d-4b1d-b334-93328c59c292" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_6b994028-7d3d-4b1d-b334-93328c59c292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4a8ca57-2532-4322-8b96-91e63093f41d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_6b994028-7d3d-4b1d-b334-93328c59c292" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4a8ca57-2532-4322-8b96-91e63093f41d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_2f76b6c5-0a67-4597-91a2-8953a26a4621" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4a8ca57-2532-4322-8b96-91e63093f41d" xlink:to="loc_sgmo_SangamoFranceMember_2f76b6c5-0a67-4597-91a2-8953a26a4621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1ccaa3b8-dbdc-4572-bf93-556c54960bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1ccaa3b8-dbdc-4572-bf93-556c54960bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f566a5a-8550-47b9-903b-12bc77e02466" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1ccaa3b8-dbdc-4572-bf93-556c54960bd0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f566a5a-8550-47b9-903b-12bc77e02466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_e8d9294b-3d3f-40ad-a059-42351a2fbbc3" xlink:href="sgmo-20201231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5f566a5a-8550-47b9-903b-12bc77e02466" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_e8d9294b-3d3f-40ad-a059-42351a2fbbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_10966208-fcb8-46c7-bd99-24b30cab002c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:to="loc_us-gaap_ValuationTechniqueAxis_10966208-fcb8-46c7-bd99-24b30cab002c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_344480cb-218b-43fa-9f24-652ddb3309a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_10966208-fcb8-46c7-bd99-24b30cab002c" xlink:to="loc_us-gaap_ValuationTechniqueDomain_344480cb-218b-43fa-9f24-652ddb3309a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_4bde7117-d6b8-40dc-9ed9-5f3b9fdb8c22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_344480cb-218b-43fa-9f24-652ddb3309a0" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_4bde7117-d6b8-40dc-9ed9-5f3b9fdb8c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f29786e3-602d-4683-b833-418098c94a33" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_6907ebb7-991b-40b2-9f38-dfd82067e0bd" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_6907ebb7-991b-40b2-9f38-dfd82067e0bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_bdec24ed-ccc4-41e9-bb7f-eee4f5173ac8" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_bdec24ed-ccc4-41e9-bb7f-eee4f5173ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_286326db-9142-4afb-a216-d9e433c30280" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_286326db-9142-4afb-a216-d9e433c30280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_c689bc2c-78ca-4b9a-aa74-5899ea2176b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_c689bc2c-78ca-4b9a-aa74-5899ea2176b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_ad7a717d-b099-43d6-ba7e-a2b99d9b5c27" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase_ad7a717d-b099-43d6-ba7e-a2b99d9b5c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_d0b4b4fe-ca2a-478b-8635-bac8767ae9d6" xlink:href="sgmo-20201231.xsd#sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability_d0b4b4fe-ca2a-478b-8635-bac8767ae9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_722bea04-f74b-4a6e-a947-03ae01ea118b" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7b9a5b22-30fb-4307-837e-62ef4264e80a" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_722bea04-f74b-4a6e-a947-03ae01ea118b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_172e32e2-c31c-43fa-a6bd-b11b8714e118" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_896d9961-8f8f-4979-8ada-3cca7abee88d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_172e32e2-c31c-43fa-a6bd-b11b8714e118" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_896d9961-8f8f-4979-8ada-3cca7abee88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_91804d4a-32fb-4aed-874b-4fe5fa702afb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_896d9961-8f8f-4979-8ada-3cca7abee88d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_91804d4a-32fb-4aed-874b-4fe5fa702afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0baa88-c960-4da9-892f-1ee8ea0392a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_91804d4a-32fb-4aed-874b-4fe5fa702afb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0baa88-c960-4da9-892f-1ee8ea0392a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_6619b39e-219d-4d0e-839e-5102d07b0a66" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8a0baa88-c960-4da9-892f-1ee8ea0392a3" xlink:to="loc_sgmo_SangamoFranceMember_6619b39e-219d-4d0e-839e-5102d07b0a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_326e794f-d2b4-441a-af01-78ee1bf6f97d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_896d9961-8f8f-4979-8ada-3cca7abee88d" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_326e794f-d2b4-441a-af01-78ee1bf6f97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_326e794f-d2b4-441a-af01-78ee1bf6f97d" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_548ac720-bb88-4b59-838f-c87f231470aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_548ac720-bb88-4b59-838f-c87f231470aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MeasurementInputStockPriceCorrelationMember_b2faec85-8c29-4baa-8bc5-0dbe45129652" xlink:href="sgmo-20201231.xsd#sgmo_MeasurementInputStockPriceCorrelationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:to="loc_sgmo_MeasurementInputStockPriceCorrelationMember_b2faec85-8c29-4baa-8bc5-0dbe45129652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_89e02e33-9cee-4ad2-998b-4873e2a73710" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_89e02e33-9cee-4ad2-998b-4873e2a73710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_0449ba7f-2748-4d40-a5a3-e3e458720a61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_0b0ba0f6-1a74-431c-9668-f8fdb983be6a" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_0449ba7f-2748-4d40-a5a3-e3e458720a61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_896d9961-8f8f-4979-8ada-3cca7abee88d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_27d623b3-47bb-4f81-9bec-fd4465ff32aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_SharePrice_27d623b3-47bb-4f81-9bec-fd4465ff32aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_4b263daf-2315-4e2d-a670-9f7fc88ada85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_4b263daf-2315-4e2d-a670-9f7fc88ada85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e70245d4-cad8-4c4b-998b-35b3751a63a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e70245d4-cad8-4c4b-998b-35b3751a63a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2f83918b-3508-4135-97f6-53c60974fd11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_2f83918b-3508-4135-97f6-53c60974fd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityMeasurementInput_f87d1955-123a-4fb2-a81d-fcd77e85c10d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeLiabilityMeasurementInput"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bb37ae1c-d8f4-4fe2-a598-cf5bca2eb827" xlink:to="loc_us-gaap_DerivativeLiabilityMeasurementInput_f87d1955-123a-4fb2-a81d-fcd77e85c10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1858c7c8-1d4d-4cf3-9e7b-e89ab354d794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f2fe4940-81ee-4749-b741-8fd2ebd988d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1858c7c8-1d4d-4cf3-9e7b-e89ab354d794" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_f2fe4940-81ee-4749-b741-8fd2ebd988d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e463710-aa2a-4d6b-90fa-72626496fcb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_4cd79ebf-32a9-48a7-953f-86896ed7cbcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e463710-aa2a-4d6b-90fa-72626496fcb2" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_4cd79ebf-32a9-48a7-953f-86896ed7cbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ad68caac-eb5a-4864-b032-5973f98cdccc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2e463710-aa2a-4d6b-90fa-72626496fcb2" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_ad68caac-eb5a-4864-b032-5973f98cdccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4b7b47e9-c002-4753-b99b-f4880e03f217" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_44ee1cbf-4e82-413a-b12e-bed648350da0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4b7b47e9-c002-4753-b99b-f4880e03f217" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_44ee1cbf-4e82-413a-b12e-bed648350da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_d1b01bdd-0c4d-43c1-90d5-617471f3bfb6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_44ee1cbf-4e82-413a-b12e-bed648350da0" xlink:to="loc_us-gaap_FinancialInstrumentAxis_d1b01bdd-0c4d-43c1-90d5-617471f3bfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_d1b01bdd-0c4d-43c1-90d5-617471f3bfb6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_d33faa5a-44fb-4178-a2d3-00a7aeaf5620" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_d33faa5a-44fb-4178-a2d3-00a7aeaf5620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ce4e09c4-2d6a-4dd9-9ed3-4de33d9fa14f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ce4e09c4-2d6a-4dd9-9ed3-4de33d9fa14f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d889dc7b-57d8-4cb7-8164-aef98a9dcb7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_d889dc7b-57d8-4cb7-8164-aef98a9dcb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_5c191d27-1dc6-41ef-b4b3-8cba33e23dc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_19877f5b-0702-4130-8a41-43acc9cb29f9" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_5c191d27-1dc6-41ef-b4b3-8cba33e23dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_377d7a6e-8fb5-49f1-9dfd-d3e5c58f3425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_44ee1cbf-4e82-413a-b12e-bed648350da0" xlink:to="loc_us-gaap_InvestmentTypeAxis_377d7a6e-8fb5-49f1-9dfd-d3e5c58f3425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_377d7a6e-8fb5-49f1-9dfd-d3e5c58f3425" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_4e4f0040-c76e-4323-8ad1-82d1c4de3d41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:to="loc_us-gaap_MoneyMarketFundsMember_4e4f0040-c76e-4323-8ad1-82d1c4de3d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_d879fed8-ae31-4131-b69d-7fd28c3a8cb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:to="loc_us-gaap_CommercialPaperMember_d879fed8-ae31-4131-b69d-7fd28c3a8cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsMember_51c9e41f-7bda-4dbe-8b20-202472a486be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashEquivalentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_c8cd0000-1f9e-4431-809d-920c04f7178c" xlink:to="loc_us-gaap_CashEquivalentsMember_51c9e41f-7bda-4dbe-8b20-202472a486be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_44ee1cbf-4e82-413a-b12e-bed648350da0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c37c3d16-2a14-4bdc-98c2-1c8a8e59b656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c37c3d16-2a14-4bdc-98c2-1c8a8e59b656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_fb35543b-a396-46fe-961e-00db75618df5" xlink:href="sgmo-20201231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_fb35543b-a396-46fe-961e-00db75618df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_429c0b56-472b-4e1e-b147-d6ca74a09ee8" xlink:href="sgmo-20201231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_429c0b56-472b-4e1e-b147-d6ca74a09ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8c415f68-a843-4d38-bfc4-8073c1f89cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8c415f68-a843-4d38-bfc4-8073c1f89cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_33cc9ef0-f610-4269-9b05-e9dbb5f02bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_33cc9ef0-f610-4269-9b05-e9dbb5f02bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d4fd514-971e-404f-9a9c-4642499b7363" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5d4fd514-971e-404f-9a9c-4642499b7363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f01ddc8c-6bab-499b-9a2d-5e706ea7bf4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f01ddc8c-6bab-499b-9a2d-5e706ea7bf4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b44f1987-f222-456c-8b85-779186a0d2d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b44f1987-f222-456c-8b85-779186a0d2d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_de6dc4c3-4c15-420a-8081-d7678b95f49e" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost_de6dc4c3-4c15-420a-8081-d7678b95f49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_cf548017-139a-4590-af63-56ed809d304b" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax_cf548017-139a-4590-af63-56ed809d304b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_36a1037f-8ef7-4b9b-8251-3dc82c373d5d" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax_36a1037f-8ef7-4b9b-8251-3dc82c373d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_b74d87da-58bd-4dd4-a9e0-fbf55a06c309" xlink:href="sgmo-20201231.xsd#sgmo_CashEquivalentsAndAvailableForSaleSecurities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9dca05f5-4e35-4b83-ba25-a4674caf989c" xlink:to="loc_sgmo_CashEquivalentsAndAvailableForSaleSecurities_b74d87da-58bd-4dd4-a9e0-fbf55a06c309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a9bcb2d-b0db-4d7f-aff0-d7e51964eb32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_16c4142e-31b6-4bbb-9638-6ce141f04acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a9bcb2d-b0db-4d7f-aff0-d7e51964eb32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_16c4142e-31b6-4bbb-9638-6ce141f04acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80a0dd2e-552c-4772-b60a-d433c373e721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a9bcb2d-b0db-4d7f-aff0-d7e51964eb32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80a0dd2e-552c-4772-b60a-d433c373e721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1bc53989-7319-436d-9358-c930cb433882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1a9bcb2d-b0db-4d7f-aff0-d7e51964eb32" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1bc53989-7319-436d-9358-c930cb433882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0b20cfd1-41bd-45fa-b2d3-35e028e6bb86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_15cccc5d-bbe4-44c5-99dd-efc275085997" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0b20cfd1-41bd-45fa-b2d3-35e028e6bb86" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_15cccc5d-bbe4-44c5-99dd-efc275085997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherThanTemporarilyImpairedInvestment_c7958009-ac42-4286-be43-41c8c057f03d" xlink:href="sgmo-20201231.xsd#sgmo_OtherThanTemporarilyImpairedInvestment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0b20cfd1-41bd-45fa-b2d3-35e028e6bb86" xlink:to="loc_sgmo_OtherThanTemporarilyImpairedInvestment_c7958009-ac42-4286-be43-41c8c057f03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliances"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efe88a5f-d7a1-44bf-b43c-189c62b57238" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b56a3a54-201d-41b1-b970-1d5a4aa91c7b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_efe88a5f-d7a1-44bf-b43c-189c62b57238" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_b56a3a54-201d-41b1-b970-1d5a4aa91c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42a19124-4041-4371-9fba-ba6c47380e18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2694129c-4448-4eb4-992a-6e98378064c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_42a19124-4041-4371-9fba-ba6c47380e18" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2694129c-4448-4eb4-992a-6e98378064c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_f30daf6f-20f3-443e-ba69-87dcf472903c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2694129c-4448-4eb4-992a-6e98378064c1" xlink:to="loc_srt_CounterpartyNameAxis_f30daf6f-20f3-443e-ba69-87dcf472903c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_f30daf6f-20f3-443e-ba69-87dcf472903c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_f6e46044-a5c3-4814-bfb7-aaee7cab8378" xlink:href="sgmo-20201231.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_f6e46044-a5c3-4814-bfb7-aaee7cab8378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_84189158-9d4d-468a-a1b5-1b62a8b04d97" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_BiogenMAIncMember_84189158-9d4d-468a-a1b5-1b62a8b04d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_22938b8e-50d3-404b-beb5-0499d7fdacce" xlink:href="sgmo-20201231.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_KitePharmaIncMember_22938b8e-50d3-404b-beb5-0499d7fdacce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_1a030fa3-b1a9-4d6f-a662-9db299b74708" xlink:href="sgmo-20201231.xsd#sgmo_PfizerGiroctocogeneFitelparvovecMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_1a030fa3-b1a9-4d6f-a662-9db299b74708" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_33d978ee-ea42-4d8d-bb13-f92b5d260b8a" xlink:href="sgmo-20201231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_PfizerC9ORF72Member_33d978ee-ea42-4d8d-bb13-f92b5d260b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_8a39d234-92a6-48b1-8f60-fbbc59b5df10" xlink:href="sgmo-20201231.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9dd314f7-f016-4e98-8325-fc7dcce43b21" xlink:to="loc_sgmo_SanofiMember_8a39d234-92a6-48b1-8f60-fbbc59b5df10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_702dfb88-4a47-4982-a950-cc522d2cb60a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2694129c-4448-4eb4-992a-6e98378064c1" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_702dfb88-4a47-4982-a950-cc522d2cb60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3521c64c-094f-4fa7-a618-8ef6b658b1b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_702dfb88-4a47-4982-a950-cc522d2cb60a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_3521c64c-094f-4fa7-a618-8ef6b658b1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c0b8080-551c-46e9-8a52-1e9463ec011e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5c0b8080-551c-46e9-8a52-1e9463ec011e" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c105cd73-27b3-4666-853e-9e07f4f294cc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_srt_CounterpartyNameAxis_c105cd73-27b3-4666-853e-9e07f4f294cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c105cd73-27b3-4666-853e-9e07f4f294cc" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d123c07e-52d3-472f-a63d-106a7469fa1b" xlink:href="sgmo-20201231.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_d123c07e-52d3-472f-a63d-106a7469fa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_e14557ba-21dd-409f-ad96-6afa4d282534" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_BiogenMAIncMember_e14557ba-21dd-409f-ad96-6afa4d282534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_e593538d-7144-4220-b142-a2a5e69480ae" xlink:href="sgmo-20201231.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_KitePharmaIncMember_e593538d-7144-4220-b142-a2a5e69480ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_6ad4adc5-7cd8-4098-a3c7-940e68022e7a" xlink:href="sgmo-20201231.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_PfizerSB525Member_6ad4adc5-7cd8-4098-a3c7-940e68022e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_87e2c6e9-7c44-4dc9-9927-595539ec4bdc" xlink:href="sgmo-20201231.xsd#sgmo_PfizerGiroctocogeneFitelparvovecMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_87e2c6e9-7c44-4dc9-9927-595539ec4bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_2e336c07-09ee-46f7-b213-6ddcc71b3884" xlink:href="sgmo-20201231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_PfizerC9ORF72Member_2e336c07-09ee-46f7-b213-6ddcc71b3884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_40c105a3-ee07-4f71-87ca-36486c94aef6" xlink:href="sgmo-20201231.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_SanofiMember_40c105a3-ee07-4f71-87ca-36486c94aef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShireAgMember_d4dbf232-d805-45a3-b35f-d40751e2a79f" xlink:href="sgmo-20201231.xsd#sgmo_ShireAgMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_ShireAgMember_d4dbf232-d805-45a3-b35f-d40751e2a79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerMember_cdbb1323-c2ec-47a8-b935-efd7acd3e2cd" xlink:href="sgmo-20201231.xsd#sgmo_PfizerMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3b0c1a1c-5dae-4cee-afdf-d6fbc1a21744" xlink:to="loc_sgmo_PfizerMember_cdbb1323-c2ec-47a8-b935-efd7acd3e2cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4e2d10ab-b94a-470b-9ce7-61374f958240" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4e2d10ab-b94a-470b-9ce7-61374f958240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4e2d10ab-b94a-470b-9ce7-61374f958240" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementMember_831cc329-d684-4792-ad01-986878a0baf1" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementMember_831cc329-d684-4792-ad01-986878a0baf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_df069b82-1820-4693-93d4-d0a38f8be1af" xlink:href="sgmo-20201231.xsd#sgmo_AmendedCollaborationAndLicenseAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:to="loc_sgmo_AmendedCollaborationAndLicenseAgreementMember_df069b82-1820-4693-93d4-d0a38f8be1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_941caa0e-2910-422f-b31f-2bae774864ca" xlink:href="sgmo-20201231.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4fc19f39-0d91-4c2f-b935-0728f8674c30" xlink:to="loc_sgmo_StockPurchaseAgreementMember_941caa0e-2910-422f-b31f-2bae774864ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_62841589-ec7c-466f-b64d-e58f9481142f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_srt_ProductOrServiceAxis_62841589-ec7c-466f-b64d-e58f9481142f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_62841589-ec7c-466f-b64d-e58f9481142f" xlink:to="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OtherProductsMember_5feb739e-3b1e-4762-af74-aa4620349737" xlink:href="sgmo-20201231.xsd#sgmo_OtherProductsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_sgmo_OtherProductsMember_5feb739e-3b1e-4762-af74-aa4620349737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_f1e9dde8-1e85-45ad-a39e-59a01ccb055c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_us-gaap_LicenseAndServiceMember_f1e9dde8-1e85-45ad-a39e-59a01ccb055c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CNineORFSevenTwoMember_4d8f4029-eabf-4565-b4fd-6f6ab27d2e90" xlink:href="sgmo-20201231.xsd#sgmo_CNineORFSevenTwoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_sgmo_CNineORFSevenTwoMember_4d8f4029-eabf-4565-b4fd-6f6ab27d2e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_7d0c2984-20ed-40d9-8472-03b3cb2e0ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_us-gaap_GrantMember_7d0c2984-20ed-40d9-8472-03b3cb2e0ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GiroctocogeneFitelparvovecMember_3afc5b40-4a19-4103-a506-84a3eed054b8" xlink:href="sgmo-20201231.xsd#sgmo_GiroctocogeneFitelparvovecMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d25b62d2-04eb-42c7-90ce-36aaef75cf61" xlink:to="loc_sgmo_GiroctocogeneFitelparvovecMember_3afc5b40-4a19-4103-a506-84a3eed054b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneAxis_0d925c42-d1fc-430d-8710-d7a63b311d34" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementMilestoneAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneAxis_0d925c42-d1fc-430d-8710-d7a63b311d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementMilestoneDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneAxis_0d925c42-d1fc-430d-8710-d7a63b311d34" xlink:to="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PreApprovalMilestoneMember_74ee4d11-74b6-493f-9ce5-60413dd1b48d" xlink:href="sgmo-20201231.xsd#sgmo_PreApprovalMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_PreApprovalMilestoneMember_74ee4d11-74b6-493f-9ce5-60413dd1b48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SalesBasedMilestoneMember_5cfb1598-458c-4246-87f3-ace5a4c49fc7" xlink:href="sgmo-20201231.xsd#sgmo_SalesBasedMilestoneMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_SalesBasedMilestoneMember_5cfb1598-458c-4246-87f3-ace5a4c49fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneOneMember_4e06ba67-0cac-43c2-b1a9-86ddc7174c2d" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_MilestoneOneMember_4e06ba67-0cac-43c2-b1a9-86ddc7174c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneTwoMember_33b03051-2733-4b0e-891e-c88e798527d4" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_MilestoneTwoMember_33b03051-2733-4b0e-891e-c88e798527d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneThreeMember_50ae3de5-68bc-4294-984f-79eb366e8dcf" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneThreeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_MilestoneThreeMember_50ae3de5-68bc-4294-984f-79eb366e8dcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PhaseThreeClinicalTrialMember_f8a64a6a-0bd6-4544-a38e-61154a68f1b1" xlink:href="sgmo-20201231.xsd#sgmo_PhaseThreeClinicalTrialMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CollaborativeAgreementMilestoneDomain_4a029b94-0d64-49b0-9ee5-cd10e0b63d97" xlink:to="loc_sgmo_PhaseThreeClinicalTrialMember_f8a64a6a-0bd6-4544-a38e-61154a68f1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_339035fe-6467-4411-8755-555f67f13675" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_srt_RangeAxis_339035fe-6467-4411-8755-555f67f13675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0075e9aa-8839-4924-bde9-04e7c4de1c51" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_339035fe-6467-4411-8755-555f67f13675" xlink:to="loc_srt_RangeMember_0075e9aa-8839-4924-bde9-04e7c4de1c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_28cccbce-dbab-4ef5-a6c5-8f2088a3f569" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0075e9aa-8839-4924-bde9-04e7c4de1c51" xlink:to="loc_srt_MaximumMember_28cccbce-dbab-4ef5-a6c5-8f2088a3f569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_500f5431-c1e6-490f-b749-869cbeb9465b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0075e9aa-8839-4924-bde9-04e7c4de1c51" xlink:to="loc_srt_MinimumMember_500f5431-c1e6-490f-b749-869cbeb9465b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_95b2e776-21bb-4f30-aa80-6a6772451b17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_95b2e776-21bb-4f30-aa80-6a6772451b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_95b2e776-21bb-4f30-aa80-6a6772451b17" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_ff450292-8a7d-4ece-bafe-30b1132d3a76" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_ff450292-8a7d-4ece-bafe-30b1132d3a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_014c7195-00f8-4286-81ce-59bba7ffb162" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_014c7195-00f8-4286-81ce-59bba7ffb162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_0203a82d-3d63-4c1e-8110-76282652f11f" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember_0203a82d-3d63-4c1e-8110-76282652f11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_988a96f1-b4bd-48b8-aa58-5ee93de4caaa" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfFirstCommercialSaleMilestonesMember_988a96f1-b4bd-48b8-aa58-5ee93de4caaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_2a161883-e739-4524-bc7e-de82af33e711" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember_2a161883-e739-4524-bc7e-de82af33e711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfCommercialMilestonesMember_4481e3d6-e2d7-492a-9a0f-af1178bfd623" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfCommercialMilestonesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfCommercialMilestonesMember_4481e3d6-e2d7-492a-9a0f-af1178bfd623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_70e86a80-cc53-43eb-9056-a8be441a6f65" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember_70e86a80-cc53-43eb-9056-a8be441a6f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_72a1c3f3-4754-4291-8a98-b6645772a4ac" xlink:href="sgmo-20201231.xsd#sgmo_AchievementOfSpecifiedSalesMilestonesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_AchievementOfSpecifiedSalesMilestonesMember_72a1c3f3-4754-4291-8a98-b6645772a4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_1f9dd6c4-d9ea-4892-99f3-204d1cf32440" xlink:href="sgmo-20201231.xsd#sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_1ef1fbce-1ff7-4d4e-ad4d-ce01bd666c02" xlink:to="loc_sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember_1f9dd6c4-d9ea-4892-99f3-204d1cf32440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_2bf76a00-5492-4567-b9da-ce4b6cb77603" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_517ffc5e-7f9c-45c7-b1a5-8989fa2e475d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ProceedsFromCollaborators_517ffc5e-7f9c-45c7-b1a5-8989fa2e475d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_97e723d1-e901-4883-9688-01454a9f423f" xlink:href="sgmo-20201231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_97e723d1-e901-4883-9688-01454a9f423f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementTransactionPrice_7f27d2ba-46a7-4f13-b8ce-52adebd087d0" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementTransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementTransactionPrice_7f27d2ba-46a7-4f13-b8ce-52adebd087d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementLicenseFee_7ae5adab-d732-4ef3-a753-01fdba3c1ef6" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementLicenseFee"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementLicenseFee_7ae5adab-d732-4ef3-a753-01fdba3c1ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7cadbba5-4cb4-4ba0-b210-e2a428bfa989" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts_7cadbba5-4cb4-4ba0-b210-e2a428bfa989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b332d9d0-e898-4d99-af7d-5c9cf417ad67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b332d9d0-e898-4d99-af7d-5c9cf417ad67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_29fad6b1-3657-4fbc-9210-dc5e4e86c1d3" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue_29fad6b1-3657-4fbc-9210-dc5e4e86c1d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_d0b3b036-bb67-4a86-8719-56f835e8137d" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeAgreementPercentOfInitialRecognition"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeAgreementPercentOfInitialRecognition_d0b3b036-bb67-4a86-8719-56f835e8137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_b4ee62ce-9e15-4ebc-ba0c-d5c0ab2d75e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSoldAmortization"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSoldAmortization_b4ee62ce-9e15-4ebc-ba0c-d5c0ab2d75e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b90c48e-b9cd-4242-9f96-ff21f016a1ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2b90c48e-b9cd-4242-9f96-ff21f016a1ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_cb8695cf-00fb-4835-9ca8-14407d7f7aa4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_cb8695cf-00fb-4835-9ca8-14407d7f7aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_90f119bc-5118-4e38-9377-05c5cfb33f72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_90f119bc-5118-4e38-9377-05c5cfb33f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_222b85ed-708c-49ec-9ea2-fcfa32484036" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable_222b85ed-708c-49ec-9ea2-fcfa32484036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_47d95211-adff-4f00-895a-e97c013f87ab" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargets"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargets_47d95211-adff-4f00-895a-e97c013f87ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_286f7998-7a07-49e5-97c6-ee755f8eed19" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementNumberOfProductTargetsSelected"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected_286f7998-7a07-49e5-97c6-ee755f8eed19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_2c0c55ad-8302-479a-a40f-4f80afbbb940" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAgreementNumberOfAdditionalProductTargets"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets_2c0c55ad-8302-479a-a40f-4f80afbbb940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_ade37d59-c9a8-43de-9fa4-29dd3a0f203c" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAgreementTargetSelectionPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationAgreementTargetSelectionPeriod_ade37d59-c9a8-43de-9fa4-29dd3a0f203c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationArrangementResearchPeriod_1321ea3c-3798-4553-919a-50491333d890" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationArrangementResearchPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationArrangementResearchPeriod_1321ea3c-3798-4553-919a-50491333d890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_9ec9e830-07f7-4429-adad-92a3dc79f4a8" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace_9ec9e830-07f7-4429-adad-92a3dc79f4a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_ab451127-a933-4188-b27b-08ccdaf296cd" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionPeriod_ab451127-a933-4188-b27b-08ccdaf296cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_0e9bc7a0-31eb-41b7-8d13-2aa6e9a3a035" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage_0e9bc7a0-31eb-41b7-8d13-2aa6e9a3a035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_1ee86e8d-eff6-4a26-a494-b53d879e2a60" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld_1ee86e8d-eff6-4a26-a494-b53d879e2a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_e709c018-e131-49ef-a2d7-d6f33fc8d410" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod_e709c018-e131-49ef-a2d7-d6f33fc8d410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_4870d54e-dd96-4a5f-8ed9-0e5d8254696f" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage_4870d54e-dd96-4a5f-8ed9-0e5d8254696f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_cb413fec-7448-4d86-9060-4a557fe73ae7" xlink:href="sgmo-20201231.xsd#sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction_cb413fec-7448-4d86-9060-4a557fe73ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAgreementEquityIssued_07a22fe3-96ef-48d9-abf4-b41a9bd991be" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAgreementEquityIssued"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationAgreementEquityIssued_07a22fe3-96ef-48d9-abf4-b41a9bd991be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_ad474c94-03aa-4392-81b6-ef1de8597694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_ad474c94-03aa-4392-81b6-ef1de8597694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_51be2b72-e54b-4db3-ba76-baaf14eb2493" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_51be2b72-e54b-4db3-ba76-baaf14eb2493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentsReceived_58897af3-48dc-474b-b0e6-d64a2856326a" xlink:href="sgmo-20201231.xsd#sgmo_MilestonePaymentsReceived"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_MilestonePaymentsReceived_58897af3-48dc-474b-b0e6-d64a2856326a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_bd3a3c8d-569e-43ca-9418-0e902660678b" xlink:href="sgmo-20201231.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_bd3a3c8d-569e-43ca-9418-0e902660678b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_623e34b8-2b0f-421e-94e6-1903edeff737" xlink:href="sgmo-20201231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_623e34b8-2b0f-421e-94e6-1903edeff737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_c2517806-d0fd-475f-ace0-938054b3d8c7" xlink:href="sgmo-20201231.xsd#sgmo_NumberOfOptionsToExtendInitialResearchTerm"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_NumberOfOptionsToExtendInitialResearchTerm_c2517806-d0fd-475f-ace0-938054b3d8c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ExtendedResearchTermOfAgreement_dbc8e523-52b6-4c2d-9a85-b764b53adf93" xlink:href="sgmo-20201231.xsd#sgmo_ExtendedResearchTermOfAgreement"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_ExtendedResearchTermOfAgreement_dbc8e523-52b6-4c2d-9a85-b764b53adf93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SeparateUpfrontFee_32f329b3-fe67-4afc-8064-be8c17c1e136" xlink:href="sgmo-20201231.xsd#sgmo_SeparateUpfrontFee"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_SeparateUpfrontFee_32f329b3-fe67-4afc-8064-be8c17c1e136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_f1f8bcbc-1fd6-4ed5-b4b7-586c45c98fe7" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan_f1f8bcbc-1fd6-4ed5-b4b7-586c45c98fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_748c9a55-c8ec-4ac4-a04e-8802946d5836" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_748c9a55-c8ec-4ac4-a04e-8802946d5836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_a94ffa6f-cd0c-4b58-9636-e0cd2dbf3d48" xlink:href="sgmo-20201231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_a94ffa6f-cd0c-4b58-9636-e0cd2dbf3d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneRevenueReceivable_de1f2d45-734c-4f1f-9a4d-4f37132fe5e3" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneRevenueReceivable"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_MilestoneRevenueReceivable_de1f2d45-734c-4f1f-9a4d-4f37132fe5e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_2d6c8011-48f3-4a31-ae5f-d6f003082913" xlink:href="sgmo-20201231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_2d6c8011-48f3-4a31-ae5f-d6f003082913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_8cbf2c31-0630-40b2-8ce1-cc4bc583cdb8" xlink:href="sgmo-20201231.xsd#sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice_8cbf2c31-0630-40b2-8ce1-cc4bc583cdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementResearchServiceFees_e21f00dd-b421-4f06-8447-d1a6ed2d2d2c" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementResearchServiceFees"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementResearchServiceFees_e21f00dd-b421-4f06-8447-d1a6ed2d2d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementReimbursableServiceCosts_0215de15-eb73-43d3-84c3-e9ff9179f6a4" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementReimbursableServiceCosts"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementReimbursableServiceCosts_0215de15-eb73-43d3-84c3-e9ff9179f6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AgreementTerminationTerm_8fe6ab83-4f86-4feb-b650-27b26b8d6c15" xlink:href="sgmo-20201231.xsd#sgmo_AgreementTerminationTerm"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_AgreementTerminationTerm_8fe6ab83-4f86-4feb-b650-27b26b8d6c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e4d4fd2e-a6f7-4258-8af0-1a7ef57ccec2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_e4d4fd2e-a6f7-4258-8af0-1a7ef57ccec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_163d122f-d5cf-43e3-aaef-c688be865a02" xlink:href="sgmo-20201231.xsd#sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned_163d122f-d5cf-43e3-aaef-c688be865a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac723909-e447-43bf-8700-2ca5eba29180" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ac723909-e447-43bf-8700-2ca5eba29180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_776af207-dd7e-4a24-bda9-c30f135ea2f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress"/>
    <link:presentationArc order="47" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress_776af207-dd7e-4a24-bda9-c30f135ea2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_c168621d-8e57-4bf6-9274-8fcf20504a82" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue"/>
    <link:presentationArc order="48" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue_c168621d-8e57-4bf6-9274-8fcf20504a82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_f1212418-60d2-42f6-936b-3ba2590ac0d1" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss"/>
    <link:presentationArc order="49" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss_f1212418-60d2-42f6-936b-3ba2590ac0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_066b2eee-2b5a-4a70-abb4-fb684c2e9c6d" xlink:href="sgmo-20201231.xsd#sgmo_CollaborativeArrangementNetIncomeLossPerShare"/>
    <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_CollaborativeArrangementNetIncomeLossPerShare_066b2eee-2b5a-4a70-abb4-fb684c2e9c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NumberOfResearchProgram_dff0afdb-30af-4f23-81c2-822e19ad440b" xlink:href="sgmo-20201231.xsd#sgmo_NumberOfResearchProgram"/>
    <link:presentationArc order="51" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_NumberOfResearchProgram_dff0afdb-30af-4f23-81c2-822e19ad440b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_GrantFundingAmount_3f3de6b0-6ef0-4af7-bce6-7976575d57fc" xlink:href="sgmo-20201231.xsd#sgmo_GrantFundingAmount"/>
    <link:presentationArc order="52" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_sgmo_GrantFundingAmount_3f3de6b0-6ef0-4af7-bce6-7976575d57fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d688be01-dbae-4e42-83da-6e32eb59f18f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="53" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_39b7955b-021f-4ebe-9328-af0f54e98b7a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d688be01-dbae-4e42-83da-6e32eb59f18f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d9e8de3-4ef4-447b-9f00-6f2f2ea3713a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a8228849-4915-4476-b5e5-0959107a7a1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d9e8de3-4ef4-447b-9f00-6f2f2ea3713a" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a8228849-4915-4476-b5e5-0959107a7a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ab97aee8-b6b2-4fc2-ba9b-610f161cba9a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a8228849-4915-4476-b5e5-0959107a7a1d" xlink:to="loc_srt_CounterpartyNameAxis_ab97aee8-b6b2-4fc2-ba9b-610f161cba9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ab97aee8-b6b2-4fc2-ba9b-610f161cba9a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_9ff0ee6f-1418-43c0-9198-f6e4a8397ae2" xlink:href="sgmo-20201231.xsd#sgmo_NovartisInstitutesForBioMedicalResearchIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_NovartisInstitutesForBioMedicalResearchIncMember_9ff0ee6f-1418-43c0-9198-f6e4a8397ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_14e7c264-1199-4ba3-9904-f6d6dabc113c" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_BiogenMAIncMember_14e7c264-1199-4ba3-9904-f6d6dabc113c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_KitePharmaIncMember_adb487ae-cb57-400b-9e24-db557a8f1b64" xlink:href="sgmo-20201231.xsd#sgmo_KitePharmaIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_KitePharmaIncMember_adb487ae-cb57-400b-9e24-db557a8f1b64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerSB525Member_f6e56773-aa06-4bba-8ec8-a1c8e469ef25" xlink:href="sgmo-20201231.xsd#sgmo_PfizerSB525Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_PfizerSB525Member_f6e56773-aa06-4bba-8ec8-a1c8e469ef25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_eabeb159-5ce4-4121-b455-09001385f42d" xlink:href="sgmo-20201231.xsd#sgmo_PfizerGiroctocogeneFitelparvovecMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_PfizerGiroctocogeneFitelparvovecMember_eabeb159-5ce4-4121-b455-09001385f42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PfizerC9ORF72Member_924f348b-a08f-48b4-876e-7d797d3d82a5" xlink:href="sgmo-20201231.xsd#sgmo_PfizerC9ORF72Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_PfizerC9ORF72Member_924f348b-a08f-48b4-876e-7d797d3d82a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SanofiMember_8e505504-b633-4d0a-a769-7936640ba0a2" xlink:href="sgmo-20201231.xsd#sgmo_SanofiMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_751c6528-ea15-4576-8907-4fa5607b082a" xlink:to="loc_sgmo_SanofiMember_8e505504-b633-4d0a-a769-7936640ba0a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b368712f-999a-4e39-8153-a4ad85a0cee1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a8228849-4915-4476-b5e5-0959107a7a1d" xlink:to="loc_srt_ProductOrServiceAxis_b368712f-999a-4e39-8153-a4ad85a0cee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b368712f-999a-4e39-8153-a4ad85a0cee1" xlink:to="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_19087b5b-ad1e-4b49-b75c-c3f5f01cea9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:to="loc_us-gaap_LicenseAndServiceMember_19087b5b-ad1e-4b49-b75c-c3f5f01cea9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesMember_ae01d857-49ac-4331-8b80-f3a1834660aa" xlink:href="sgmo-20201231.xsd#sgmo_ResearchServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:to="loc_sgmo_ResearchServicesMember_ae01d857-49ac-4331-8b80-f3a1834660aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAndServiceMember_10eddd22-9e19-41c2-adc3-145e17812902" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAndServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:to="loc_us-gaap_LicenseAndServiceMember_10eddd22-9e19-41c2-adc3-145e17812902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestoneAchievementMember_153da7b5-e9f6-4f01-a656-8eff6a12821a" xlink:href="sgmo-20201231.xsd#sgmo_MilestoneAchievementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_29855d5e-0931-4a48-8194-542a79eaa0b9" xlink:to="loc_sgmo_MilestoneAchievementMember_153da7b5-e9f6-4f01-a656-8eff6a12821a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ee30b696-6513-41e0-8103-800178b3bf43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_a8228849-4915-4476-b5e5-0959107a7a1d" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ee30b696-6513-41e0-8103-800178b3bf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_e0bfbb14-77f6-4646-a8d5-ab1001eccccd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_ee30b696-6513-41e0-8103-800178b3bf43" xlink:to="loc_us-gaap_RevenuesAbstract_e0bfbb14-77f6-4646-a8d5-ab1001eccccd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80c5c0ba-320d-445b-bf61-929e758309dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_e0bfbb14-77f6-4646-a8d5-ab1001eccccd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_80c5c0ba-320d-445b-bf61-929e758309dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68497934-207d-4aee-8764-72f67020d5eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_68497934-207d-4aee-8764-72f67020d5eb" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5207e0c4-4901-4fa9-9912-284da5ac6c39" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:to="loc_srt_CounterpartyNameAxis_5207e0c4-4901-4fa9-9912-284da5ac6c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5059c750-ab09-4721-852a-ef2bfd2ab850" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5207e0c4-4901-4fa9-9912-284da5ac6c39" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5059c750-ab09-4721-852a-ef2bfd2ab850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SigmaAldrichCorporationMember_39d0bf06-7307-4268-8a88-0eb456c86ed8" xlink:href="sgmo-20201231.xsd#sgmo_SigmaAldrichCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5059c750-ab09-4721-852a-ef2bfd2ab850" xlink:to="loc_sgmo_SigmaAldrichCorporationMember_39d0bf06-7307-4268-8a88-0eb456c86ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_95b6ac34-a407-4bc8-9b5e-2f7fd7e16d8c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:to="loc_srt_ProductOrServiceAxis_95b6ac34-a407-4bc8-9b5e-2f7fd7e16d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f66844e0-e1a4-4c87-8891-a3464c1ee847" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_95b6ac34-a407-4bc8-9b5e-2f7fd7e16d8c" xlink:to="loc_srt_ProductsAndServicesDomain_f66844e0-e1a4-4c87-8891-a3464c1ee847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_802e00c5-ded3-43c2-b112-d36607991228" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f66844e0-e1a4-4c87-8891-a3464c1ee847" xlink:to="loc_us-gaap_LicenseMember_802e00c5-ded3-43c2-b112-d36607991228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7ba0cc5f-9592-4843-a4b4-0c595d039684" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7ba0cc5f-9592-4843-a4b4-0c595d039684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc8b967-7ded-4d29-8b13-aa8f1d5bd79a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_7ba0cc5f-9592-4843-a4b4-0c595d039684" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc8b967-7ded-4d29-8b13-aa8f1d5bd79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_73866209-0100-4118-a49a-a58c7a884daf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_dbc8b967-7ded-4d29-8b13-aa8f1d5bd79a" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_73866209-0100-4118-a49a-a58c7a884daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_d558907c-14af-440c-a625-e5fafaff18f5" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchServicesPeriod_feb3b6cd-a077-45cc-b238-f7356d8d4346" xlink:href="sgmo-20201231.xsd#sgmo_ResearchServicesPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_sgmo_ResearchServicesPeriod_feb3b6cd-a077-45cc-b238-f7356d8d4346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_5cbb1df1-7c5f-489c-94a9-75278c04edd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_5cbb1df1-7c5f-489c-94a9-75278c04edd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cd8ad6a9-dad3-4057-b33d-bdcfa627a9ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cd8ad6a9-dad3-4057-b33d-bdcfa627a9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_346705c0-674e-4faa-a990-3a3fa09d552c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_346705c0-674e-4faa-a990-3a3fa09d552c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0ceaed1e-0799-423c-b46d-b1d4e6542665" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_0ceaed1e-0799-423c-b46d-b1d4e6542665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ReducedRoyaltyRate_1a28aa15-e552-47f7-bb8c-65fc61a9240a" xlink:href="sgmo-20201231.xsd#sgmo_ReducedRoyaltyRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_sgmo_ReducedRoyaltyRate_1a28aa15-e552-47f7-bb8c-65fc61a9240a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_59c0b7bc-ad5a-4497-91e6-b78d68c58f14" xlink:href="sgmo-20201231.xsd#sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive_59c0b7bc-ad5a-4497-91e6-b78d68c58f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2f006154-4f62-4d1c-b39c-ffbd702c6a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_4c48a711-a0c6-4395-818e-1d1f8909794b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2f006154-4f62-4d1c-b39c-ffbd702c6a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51a93648-804b-4524-86c3-94796c60c73d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_51a93648-804b-4524-86c3-94796c60c73d" xlink:to="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_9370514f-0688-4f63-85fd-7f8257cf7162" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:to="loc_srt_CounterpartyNameAxis_9370514f-0688-4f63-85fd-7f8257cf7162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_778e180b-9e42-49b3-9d30-34289b0bea5c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_9370514f-0688-4f63-85fd-7f8257cf7162" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_778e180b-9e42-49b3-9d30-34289b0bea5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DowAgroSciencesMember_84cfc43e-2c35-4f2c-8dee-3ee46a06d6de" xlink:href="sgmo-20201231.xsd#sgmo_DowAgroSciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_778e180b-9e42-49b3-9d30-34289b0bea5c" xlink:to="loc_sgmo_DowAgroSciencesMember_84cfc43e-2c35-4f2c-8dee-3ee46a06d6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_196c62f7-2942-435a-969d-896110dcecb9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_196c62f7-2942-435a-969d-896110dcecb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8a7d04ce-861a-42e4-805e-1e3b9170fbe3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_196c62f7-2942-435a-969d-896110dcecb9" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8a7d04ce-861a-42e4-805e-1e3b9170fbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseAgreementTermsMember_ff8b156b-59c2-42c3-a7e7-73d8ad03bb49" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseAgreementTermsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_8a7d04ce-861a-42e4-805e-1e3b9170fbe3" xlink:to="loc_us-gaap_LicenseAgreementTermsMember_ff8b156b-59c2-42c3-a7e7-73d8ad03bb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1e7f8524-15d0-4a79-981c-cc130c56991e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:to="loc_srt_ProductOrServiceAxis_1e7f8524-15d0-4a79-981c-cc130c56991e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_958c8c93-76da-4be3-9dd5-29990ce36da5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1e7f8524-15d0-4a79-981c-cc130c56991e" xlink:to="loc_srt_ProductsAndServicesDomain_958c8c93-76da-4be3-9dd5-29990ce36da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_556d8a96-e360-4f50-a396-8b7b44fae268" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_958c8c93-76da-4be3-9dd5-29990ce36da5" xlink:to="loc_us-gaap_RoyaltyMember_556d8a96-e360-4f50-a396-8b7b44fae268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_d1946e02-617c-4d8a-ae88-026f460d19bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_958c8c93-76da-4be3-9dd5-29990ce36da5" xlink:to="loc_us-gaap_LicenseMember_d1946e02-617c-4d8a-ae88-026f460d19bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_17ab1654-0b7d-4df8-9c6b-af93f7691346" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:to="loc_srt_RangeAxis_17ab1654-0b7d-4df8-9c6b-af93f7691346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f35fbfc3-714f-4723-b1e3-ade194ff159c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_17ab1654-0b7d-4df8-9c6b-af93f7691346" xlink:to="loc_srt_RangeMember_f35fbfc3-714f-4723-b1e3-ade194ff159c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_972baed0-2a47-4218-aedf-772802ac92c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f35fbfc3-714f-4723-b1e3-ade194ff159c" xlink:to="loc_srt_MinimumMember_972baed0-2a47-4218-aedf-772802ac92c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37a8f85d-7aa7-4471-a405-1e190b8dceef" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f35fbfc3-714f-4723-b1e3-ade194ff159c" xlink:to="loc_srt_MaximumMember_37a8f85d-7aa7-4471-a405-1e190b8dceef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_667f1497-2690-491e-a1b1-75dbfb7449e6" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_InitialResearchTermOfAgreement_41ce29f8-4cb6-4d2a-a075-db4476bb89df" xlink:href="sgmo-20201231.xsd#sgmo_InitialResearchTermOfAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_InitialResearchTermOfAgreement_41ce29f8-4cb6-4d2a-a075-db4476bb89df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OneTimeLicenseFeeEarned_093d7f1d-88c3-48d1-b96c-8ba26d1700f5" xlink:href="sgmo-20201231.xsd#sgmo_OneTimeLicenseFeeEarned"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_OneTimeLicenseFeeEarned_093d7f1d-88c3-48d1-b96c-8ba26d1700f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99782e05-312a-4480-ac86-d9f3c0a138a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_99782e05-312a-4480-ac86-d9f3c0a138a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_18807ceb-c0e8-488f-8d7b-bfb69f07d80b" xlink:href="sgmo-20201231.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_18807ceb-c0e8-488f-8d7b-bfb69f07d80b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_9f7832f2-ed2c-413a-ad44-78982073f866" xlink:href="sgmo-20201231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_9f7832f2-ed2c-413a-ad44-78982073f866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AnnualFeesRelatedToAgreement_1bf8d731-a394-4368-81d6-7755ed505297" xlink:href="sgmo-20201231.xsd#sgmo_AnnualFeesRelatedToAgreement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_AnnualFeesRelatedToAgreement_1bf8d731-a394-4368-81d6-7755ed505297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FeeDue_e04594ea-ab20-4e3b-8b1e-0f8e4c5643f1" xlink:href="sgmo-20201231.xsd#sgmo_FeeDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_FeeDue_e04594ea-ab20-4e3b-8b1e-0f8e4c5643f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_63a2ce97-8f1c-4df6-8aed-e9a869b20110" xlink:href="sgmo-20201231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_0b63b3ef-3e90-4bf0-b3fd-88673a8bc889" xlink:to="loc_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_63a2ce97-8f1c-4df6-8aed-e9a869b20110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofSangamoFrance"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFrance" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_527870f2-16fd-4d7d-9536-4b63e9548303" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3f76ab8e-c637-48f9-bcd0-8eea41244a27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_527870f2-16fd-4d7d-9536-4b63e9548303" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_3f76ab8e-c637-48f9-bcd0-8eea41244a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofAcquisitionofSangamoFranceTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_2cbafa1a-3fb4-4b68-a220-c733954eb10c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_492d4a28-d9a3-49f3-ad18-2d847af92729" xlink:href="sgmo-20201231.xsd#sgmo_ScheduleOfNoncontrollingInterestTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_2cbafa1a-3fb4-4b68-a220-c733954eb10c" xlink:to="loc_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock_492d4a28-d9a3-49f3-ad18-2d847af92729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofSangamoFranceAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_90035b6f-2372-46b1-a8a7-15b950a9c0c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_90035b6f-2372-46b1-a8a7-15b950a9c0c3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_55cd8479-7932-42e2-b057-ebd3066bbd73" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:to="loc_srt_OwnershipAxis_55cd8479-7932-42e2-b057-ebd3066bbd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_6d9bfc9f-b42e-4e1b-9a64-2d0b89b25869" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_55cd8479-7932-42e2-b057-ebd3066bbd73" xlink:to="loc_srt_OwnershipDomain_6d9bfc9f-b42e-4e1b-9a64-2d0b89b25869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_b287d96a-e4ef-4c6b-8e00-e6bcad83d6f7" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_6d9bfc9f-b42e-4e1b-9a64-2d0b89b25869" xlink:to="loc_sgmo_SangamoFranceMember_b287d96a-e4ef-4c6b-8e00-e6bcad83d6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b8f50815-47f8-448b-8d9c-655a9b60ad47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b8f50815-47f8-448b-8d9c-655a9b60ad47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3eb45fba-b0b2-4b24-9dad-cb68bc38503f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b8f50815-47f8-448b-8d9c-655a9b60ad47" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3eb45fba-b0b2-4b24-9dad-cb68bc38503f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_a27f0575-c03a-4eab-9dbc-39311af6cd8f" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3eb45fba-b0b2-4b24-9dad-cb68bc38503f" xlink:to="loc_sgmo_SangamoFranceMember_a27f0575-c03a-4eab-9dbc-39311af6cd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f88789d8-6c03-437b-82ca-690cc377e8bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f88789d8-6c03-437b-82ca-690cc377e8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99a45392-593f-44d3-8641-8abf5e36ca87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f88789d8-6c03-437b-82ca-690cc377e8bd" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99a45392-593f-44d3-8641-8abf5e36ca87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_7ead0e48-35de-4c75-824f-8f82d5bfcb7c" xlink:href="sgmo-20201231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99a45392-593f-44d3-8641-8abf5e36ca87" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_7ead0e48-35de-4c75-824f-8f82d5bfcb7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_140ab130-d60a-4a6f-930d-d42d7cca2ae2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:to="loc_us-gaap_ValuationTechniqueAxis_140ab130-d60a-4a6f-930d-d42d7cca2ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_ef2121f8-8bfa-4362-ac07-680a4edbaadf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_140ab130-d60a-4a6f-930d-d42d7cca2ae2" xlink:to="loc_us-gaap_ValuationTechniqueDomain_ef2121f8-8bfa-4362-ac07-680a4edbaadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_cda3342a-3824-4bb1-ba65-0625210fc294" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationTechniqueOptionPricingModelMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_ef2121f8-8bfa-4362-ac07-680a4edbaadf" xlink:to="loc_us-gaap_ValuationTechniqueOptionPricingModelMember_cda3342a-3824-4bb1-ba65-0625210fc294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_0d4c091a-bd9e-402e-a9ec-7b6f09c6657f" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_5579ff01-0beb-4da5-894c-2ef09c564264" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire_5579ff01-0beb-4da5-894c-2ef09c564264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_64f33a57-0a04-4471-9cef-2bbc6204be42" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_64f33a57-0a04-4471-9cef-2bbc6204be42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0903f26b-53c4-45ab-aa73-5765cbc85eea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_0903f26b-53c4-45ab-aa73-5765cbc85eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_77485551-8294-4c48-a04b-b2f5c6d1b19b" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders_77485551-8294-4c48-a04b-b2f5c6d1b19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ef5d3324-d0d9-4248-a838-73f4e6950e61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_ef5d3324-d0d9-4248-a838-73f4e6950e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d854967a-8c4d-4918-b4da-c43ad322c9b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_d854967a-8c4d-4918-b4da-c43ad322c9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_5ede7abf-cf05-4845-9de2-5abd61410c07" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares_5ede7abf-cf05-4845-9de2-5abd61410c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_c5e5fe4b-eadc-4969-a122-b4093c6d2645" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares_c5e5fe4b-eadc-4969-a122-b4093c6d2645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ca9b11d2-79f6-49bd-89a6-fe223f6809ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_ca9b11d2-79f6-49bd-89a6-fe223f6809ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_3c1251be-b482-4c78-b2b0-bf8e77d89478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_3c1251be-b482-4c78-b2b0-bf8e77d89478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_02cdd4f0-7a68-4829-8c57-78833ce45a43" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_690f527d-b615-429f-9412-2dc884dbb67b" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_02cdd4f0-7a68-4829-8c57-78833ce45a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_43dc23c0-14d2-4853-8a2d-0ffb9d18a907" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestTable_3bf54ce6-ae58-42e4-a032-1d769e5d7a89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_43dc23c0-14d2-4853-8a2d-0ffb9d18a907" xlink:to="loc_us-gaap_MinorityInterestTable_3bf54ce6-ae58-42e4-a032-1d769e5d7a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ddc8fbb5-f9e1-4350-a16e-16b332afdd4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_3bf54ce6-ae58-42e4-a032-1d769e5d7a89" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ddc8fbb5-f9e1-4350-a16e-16b332afdd4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_058dfcee-6792-4027-895d-69b7a5485b33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ddc8fbb5-f9e1-4350-a16e-16b332afdd4c" xlink:to="loc_us-gaap_EquityComponentDomain_058dfcee-6792-4027-895d-69b7a5485b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_1ba26e89-6b74-4b7e-86ad-42e51822bdb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_058dfcee-6792-4027-895d-69b7a5485b33" xlink:to="loc_us-gaap_NoncontrollingInterestMember_1ba26e89-6b74-4b7e-86ad-42e51822bdb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestLineItems_03cdf41b-53e4-4209-9751-48612d6acc48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestTable_3bf54ce6-ae58-42e4-a032-1d769e5d7a89" xlink:to="loc_us-gaap_MinorityInterestLineItems_03cdf41b-53e4-4209-9751-48612d6acc48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MovementInMinorityInterestRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestLineItems_03cdf41b-53e4-4209-9751-48612d6acc48" xlink:to="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2a1fac8d-fb5e-4979-87b8-4c3010af051e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:to="loc_us-gaap_MinorityInterest_2a1fac8d-fb5e-4979-87b8-4c3010af051e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_76a808dc-102e-4e1d-82ef-3386b0946ce3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_76a808dc-102e-4e1d-82ef-3386b0946ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a0c43d4-7346-4660-9f84-ebfa9144ae83" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a0c43d4-7346-4660-9f84-ebfa9144ae83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_dab5ac81-d859-4d0a-831f-69b8b83ed9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInMinorityInterestRollForward_14c0b9b2-0bd8-424c-813a-85cbd2f67dde" xlink:to="loc_us-gaap_MinorityInterest_dab5ac81-d859-4d0a-831f-69b8b83ed9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cb03a567-d515-4a40-a4ff-a9725125d162" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_80be7e48-6b87-422e-84a8-bfa2feb039c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_cb03a567-d515-4a40-a4ff-a9725125d162" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_80be7e48-6b87-422e-84a8-bfa2feb039c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6dfbaf6d-8b62-4416-b7a1-ceb10c278ed9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c0a75606-1b06-44eb-a1e3-3bafbbe8da17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6dfbaf6d-8b62-4416-b7a1-ceb10c278ed9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_c0a75606-1b06-44eb-a1e3-3bafbbe8da17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07133cc3-bfc7-4477-8b73-8ada7093f075" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6dfbaf6d-8b62-4416-b7a1-ceb10c278ed9" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_07133cc3-bfc7-4477-8b73-8ada7093f075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f8568063-0f3b-48dd-8387-32eae0973a13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_6dfbaf6d-8b62-4416-b7a1-ceb10c278ed9" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_f8568063-0f3b-48dd-8387-32eae0973a13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ebde0774-abe6-4451-b466-b226b16ca340" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5302336e-f212-420a-8033-6e00bed63ed4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_ebde0774-abe6-4451-b466-b226b16ca340" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5302336e-f212-420a-8033-6e00bed63ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_845d1ecc-74d8-46c9-a83f-b098d2e01201" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5302336e-f212-420a-8033-6e00bed63ed4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_845d1ecc-74d8-46c9-a83f-b098d2e01201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_845d1ecc-74d8-46c9-a83f-b098d2e01201" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LaboratoryEquipmentMember_cf1615f2-8d68-4cfe-b608-3b017e432df6" xlink:href="sgmo-20201231.xsd#sgmo_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_sgmo_LaboratoryEquipmentMember_cf1615f2-8d68-4cfe-b608-3b017e432df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_f11675ca-1d4e-485c-b1a8-aff82e928572" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_f11675ca-1d4e-485c-b1a8-aff82e928572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_2a81b8f5-38a8-486a-90d9-4f0505baf8d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_2a81b8f5-38a8-486a-90d9-4f0505baf8d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ManufacturingEquipmentMember_f6187033-7ebe-4915-96ad-189226a81a10" xlink:href="sgmo-20201231.xsd#sgmo_ManufacturingEquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_sgmo_ManufacturingEquipmentMember_f6187033-7ebe-4915-96ad-189226a81a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2ac26701-2547-474d-8834-864da1d33ebd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_543021e5-8682-48a9-a962-ed5343717604" xlink:to="loc_us-gaap_ConstructionInProgressMember_2ac26701-2547-474d-8834-864da1d33ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5302336e-f212-420a-8033-6e00bed63ed4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_65f0b33b-5385-4c07-802d-57771f2354ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_65f0b33b-5385-4c07-802d-57771f2354ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0463af9b-683a-448a-92bf-a44ae9433fd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0463af9b-683a-448a-92bf-a44ae9433fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba52733a-226a-4270-b63b-a61392082baf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_ba52733a-226a-4270-b63b-a61392082baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5dc345df-277d-4880-8e58-9f01c49003df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_33f33025-c375-4872-a5da-604c340cc273" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5dc345df-277d-4880-8e58-9f01c49003df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1e9f75c7-decc-48b3-ba36-fd9c8075ec4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_35a9387b-ad84-43db-99d7-3d685643a042" xlink:href="sgmo-20201231.xsd#sgmo_IntangibleAssetsExcludingGoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1e9f75c7-decc-48b3-ba36-fd9c8075ec4f" xlink:to="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_35a9387b-ad84-43db-99d7-3d685643a042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ea70a06-379c-4d63-987c-00c2b58a0715" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_35a9387b-ad84-43db-99d7-3d685643a042" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_5ea70a06-379c-4d63-987c-00c2b58a0715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_61b8abc3-89e6-485e-9f96-67c031a2dbce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_35a9387b-ad84-43db-99d7-3d685643a042" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss_61b8abc3-89e6-485e-9f96-67c031a2dbce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37f8bbd1-86c6-4f6e-a476-391680396023" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IntangibleAssetsExcludingGoodwillRollForward_35a9387b-ad84-43db-99d7-3d685643a042" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_37f8bbd1-86c6-4f6e-a476-391680396023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_875813a0-2a6e-41d9-ab4a-91731d50441a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_1e9f75c7-decc-48b3-ba36-fd9c8075ec4f" xlink:to="loc_us-gaap_GoodwillRollForward_875813a0-2a6e-41d9-ab4a-91731d50441a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_50964aae-53d6-448c-b28e-27dd11dfff29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_875813a0-2a6e-41d9-ab4a-91731d50441a" xlink:to="loc_us-gaap_Goodwill_50964aae-53d6-448c-b28e-27dd11dfff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_711204b6-2eec-43ab-87bd-72a5c31c7ca8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_875813a0-2a6e-41d9-ab4a-91731d50441a" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_711204b6-2eec-43ab-87bd-72a5c31c7ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bbed8b2f-b805-4eb3-b09b-29d32986047b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_875813a0-2a6e-41d9-ab4a-91731d50441a" xlink:to="loc_us-gaap_Goodwill_bbed8b2f-b805-4eb3-b09b-29d32986047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c50dd082-37a5-4581-8c1d-2cb242bb9adf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_2c345718-21c7-4e17-8c84-0ba070b58571" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c50dd082-37a5-4581-8c1d-2cb242bb9adf" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_2c345718-21c7-4e17-8c84-0ba070b58571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AccruedResearchAndDevelopmentExpenses_752717af-7802-4749-845e-35eca4806d69" xlink:href="sgmo-20201231.xsd#sgmo_AccruedResearchAndDevelopmentExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c50dd082-37a5-4581-8c1d-2cb242bb9adf" xlink:to="loc_sgmo_AccruedResearchAndDevelopmentExpenses_752717af-7802-4749-845e-35eca4806d69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_edd3d894-773d-4a86-9c4c-d890fa12cbc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c50dd082-37a5-4581-8c1d-2cb242bb9adf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_edd3d894-773d-4a86-9c4c-d890fa12cbc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_4d5d9283-112c-4e5e-a00f-26de562b90c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c50dd082-37a5-4581-8c1d-2cb242bb9adf" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_4d5d9283-112c-4e5e-a00f-26de562b90c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_50ad6326-5582-4cb8-a296-8c860f019db1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c50dd082-37a5-4581-8c1d-2cb242bb9adf" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_50ad6326-5582-4cb8-a296-8c860f019db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_9cf7a60d-b9f0-438a-9286-44ed1d15db18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c50dd082-37a5-4581-8c1d-2cb242bb9adf" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_9cf7a60d-b9f0-438a-9286-44ed1d15db18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2b575334-3e08-4cdb-8fdd-4b1523aac5b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetRelatedDisclosuresAbstract_c50dd082-37a5-4581-8c1d-2cb242bb9adf" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_2b575334-3e08-4cdb-8fdd-4b1523aac5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff3f91cb-1922-4c10-bc37-18003958235d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2e22ce30-6c29-4f65-a680-66cc2a91c9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff3f91cb-1922-4c10-bc37-18003958235d" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2e22ce30-6c29-4f65-a680-66cc2a91c9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_52befdb9-1b52-48e2-99e4-26880d7782ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b80a5f50-5670-4ee6-80f9-8e893b592c48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_52befdb9-1b52-48e2-99e4-26880d7782ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_b80a5f50-5670-4ee6-80f9-8e893b592c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTableTextBlock_672e304d-d16e-42e4-b3c2-93ee073d2acd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_52befdb9-1b52-48e2-99e4-26880d7782ca" xlink:to="loc_us-gaap_OtherCommitmentsTableTextBlock_672e304d-d16e-42e4-b3c2-93ee073d2acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51164ff0-72ee-4b75-86c3-c257722099e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:href="sgmo-20201231.xsd#sgmo_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_51164ff0-72ee-4b75-86c3-c257722099e8" xlink:to="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd78d22-bfe2-4227-93dd-0d2ad8c8cb2c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd78d22-bfe2-4227-93dd-0d2ad8c8cb2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e6e9d7c-c975-4991-8b41-dd29152a3a08" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0bd78d22-bfe2-4227-93dd-0d2ad8c8cb2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e6e9d7c-c975-4991-8b41-dd29152a3a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_OfficeAndLaboratoryMember_1d172c3f-e5b3-435e-86af-fb447a7b3e53" xlink:href="sgmo-20201231.xsd#sgmo_OfficeAndLaboratoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e6e9d7c-c975-4991-8b41-dd29152a3a08" xlink:to="loc_sgmo_OfficeAndLaboratoryMember_1d172c3f-e5b3-435e-86af-fb447a7b3e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ResearchAndOfficeSpaceMember_e859bfba-c0bc-41b6-b639-ee076538483d" xlink:href="sgmo-20201231.xsd#sgmo_ResearchAndOfficeSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3e6e9d7c-c975-4991-8b41-dd29152a3a08" xlink:to="loc_sgmo_ResearchAndOfficeSpaceMember_e859bfba-c0bc-41b6-b639-ee076538483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2ceaa7dd-9cf4-45ff-8131-7d3cf25c4fc0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:to="loc_srt_StatementGeographicalAxis_2ceaa7dd-9cf4-45ff-8131-7d3cf25c4fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2ceaa7dd-9cf4-45ff-8131-7d3cf25c4fc0" xlink:to="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrisbaneCaliforniaMember_cba83fe4-e80d-4563-9501-2d58d4633357" xlink:href="sgmo-20201231.xsd#sgmo_BrisbaneCaliforniaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:to="loc_sgmo_BrisbaneCaliforniaMember_cba83fe4-e80d-4563-9501-2d58d4633357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_RichmondCaliforniaMember_e686828f-8239-4bb9-a7ff-7ac6ea1a0c25" xlink:href="sgmo-20201231.xsd#sgmo_RichmondCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:to="loc_sgmo_RichmondCaliforniaMember_e686828f-8239-4bb9-a7ff-7ac6ea1a0c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ValbonneFranceMember_99a40cb4-d1fc-4287-a7e6-46ffe8a3fb0e" xlink:href="sgmo-20201231.xsd#sgmo_ValbonneFranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e395c3f4-8a97-4db7-becc-bee092cb2dff" xlink:to="loc_sgmo_ValbonneFranceMember_99a40cb4-d1fc-4287-a7e6-46ffe8a3fb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ebe8392e-13e1-474d-90d1-9017a7af74c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:to="loc_srt_RangeAxis_ebe8392e-13e1-474d-90d1-9017a7af74c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4618cd15-dc61-4c08-b400-ebdbc62d986a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ebe8392e-13e1-474d-90d1-9017a7af74c1" xlink:to="loc_srt_RangeMember_4618cd15-dc61-4c08-b400-ebdbc62d986a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_668f23d8-4c64-4e98-bc2e-502c5929d436" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4618cd15-dc61-4c08-b400-ebdbc62d986a" xlink:to="loc_srt_MinimumMember_668f23d8-4c64-4e98-bc2e-502c5929d436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_cb94499a-4080-40a2-869b-7ef7a1f75a58" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4618cd15-dc61-4c08-b400-ebdbc62d986a" xlink:to="loc_srt_MaximumMember_cb94499a-4080-40a2-869b-7ef7a1f75a58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:href="sgmo-20201231.xsd#sgmo_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesTable_d0d1bb85-263d-47c1-bf04-1771e881bc0d" xlink:to="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_e21a741d-1b5f-4642-b814-01bb89138d2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_e21a741d-1b5f-4642-b814-01bb89138d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_b4580feb-2da8-41bd-94d7-fdc5868a213a" xlink:href="sgmo-20201231.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate_b4580feb-2da8-41bd-94d7-fdc5868a213a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_a0327ff3-2e94-48ca-8d75-b1c964286a4b" xlink:href="sgmo-20201231.xsd#sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount_a0327ff3-2e94-48ca-8d75-b1c964286a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3d895a2d-aaf7-4dee-861a-77bf29293e9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_3d895a2d-aaf7-4dee-861a-77bf29293e9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_de1e06d2-c2d2-494a-90b9-5d77d58760b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeaseCost_de1e06d2-c2d2-494a-90b9-5d77d58760b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_c399543b-420f-4dcd-b50b-ad2fca93b0b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_VariableLeaseCost_c399543b-420f-4dcd-b50b-ad2fca93b0b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_cceb52ea-76b6-4b6a-a06f-267baca8e36a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeasePayments_cceb52ea-76b6-4b6a-a06f-267baca8e36a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_edf1db8b-33ae-455e-bcf9-bdecd3918f3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeaseExpense_edf1db8b-33ae-455e-bcf9-bdecd3918f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseAndRentalExpense_6a0bc6eb-206d-4b20-9dce-07eca0acabcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_LeaseAndRentalExpense_6a0bc6eb-206d-4b20-9dce-07eca0acabcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_11f89a41-1a88-4ec6-92ff-f80bf74641b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_11f89a41-1a88-4ec6-92ff-f80bf74641b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c608b0d4-938b-4acd-9236-99d57daa2f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c608b0d4-938b-4acd-9236-99d57daa2f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LicenseObligations_11134770-fd17-4bfa-9c4d-8e5f9f3e86df" xlink:href="sgmo-20201231.xsd#sgmo_LicenseObligations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_CommitmentsAndContingenciesLineItems_512e03b1-2ab0-4a6d-af18-05276e872467" xlink:to="loc_sgmo_LicenseObligations_11134770-fd17-4bfa-9c4d-8e5f9f3e86df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7175ef7c-1e73-44e5-b8de-7fe7f54055fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7175ef7c-1e73-44e5-b8de-7fe7f54055fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_13acedf7-d8bb-4fc8-91ce-036810b0b823" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_13acedf7-d8bb-4fc8-91ce-036810b0b823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d5c97305-1481-4c91-8037-577ca9360f12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d5c97305-1481-4c91-8037-577ca9360f12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_990dc98c-e346-43b9-b55f-2814cc8edb8d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_990dc98c-e346-43b9-b55f-2814cc8edb8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bcf2bcc6-cc53-45a9-a6cf-bcbf23f4e977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_bcf2bcc6-cc53-45a9-a6cf-bcbf23f4e977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_64962aeb-8360-4ae3-8f53-a505df5886f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_64962aeb-8360-4ae3-8f53-a505df5886f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c303bc1c-2693-441c-abcc-947f4a1ff4b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c303bc1c-2693-441c-abcc-947f4a1ff4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8688f2e7-522e-40dd-98bc-1baa9b661920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_8688f2e7-522e-40dd-98bc-1baa9b661920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_d30fd3bd-bd8d-44c0-af2d-b259ac3bec3a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_OperatingLeaseLiability_d30fd3bd-bd8d-44c0-af2d-b259ac3bec3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3316dece-cee1-47b0-a0e2-b703862a64ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3316dece-cee1-47b0-a0e2-b703862a64ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2426f1e9-4317-4995-84c9-e198c7a31a1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_2426f1e9-4317-4995-84c9-e198c7a31a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_52600483-f4d2-47d6-938d-658193971b0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ff782af6-285a-4ea9-90d1-485e4c9b6bc0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_52600483-f4d2-47d6-938d-658193971b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af1e1c0c-5e52-44cf-98ca-ad0296db8be3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_089fe74b-3866-4319-a6d2-36c3d2bdc071" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_af1e1c0c-5e52-44cf-98ca-ad0296db8be3" xlink:to="loc_us-gaap_OtherCommitmentsTable_089fe74b-3866-4319-a6d2-36c3d2bdc071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a9bd3198-c266-4a1a-b7d8-a254835b75fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_089fe74b-3866-4319-a6d2-36c3d2bdc071" xlink:to="loc_srt_CounterpartyNameAxis_a9bd3198-c266-4a1a-b7d8-a254835b75fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88bc5dec-29e7-4440-8e43-61b5196628db" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a9bd3198-c266-4a1a-b7d8-a254835b75fb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88bc5dec-29e7-4440-8e43-61b5196628db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BrammerBioMAMember_b5804942-e7aa-4395-972c-fc649fcfd965" xlink:href="sgmo-20201231.xsd#sgmo_BrammerBioMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88bc5dec-29e7-4440-8e43-61b5196628db" xlink:to="loc_sgmo_BrammerBioMAMember_b5804942-e7aa-4395-972c-fc649fcfd965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_LonzaNetherlandsBVMember_41a32d77-1690-4f60-bfab-5ecbaf3d90f7" xlink:href="sgmo-20201231.xsd#sgmo_LonzaNetherlandsBVMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88bc5dec-29e7-4440-8e43-61b5196628db" xlink:to="loc_sgmo_LonzaNetherlandsBVMember_41a32d77-1690-4f60-bfab-5ecbaf3d90f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_c98b3cc4-030e-47a1-bcbb-da90f408b107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_089fe74b-3866-4319-a6d2-36c3d2bdc071" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_c98b3cc4-030e-47a1-bcbb-da90f408b107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualObligation_b744f761-a430-4d51-8fa5-739162bb2a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractualObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_c98b3cc4-030e-47a1-bcbb-da90f408b107" xlink:to="loc_us-gaap_ContractualObligation_b744f761-a430-4d51-8fa5-739162bb2a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquity" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e422cc76-06db-4f5f-9595-b41a83c07af0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4a517030-4711-4b3f-b344-c59722ce9dcc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e422cc76-06db-4f5f-9595-b41a83c07af0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_4a517030-4711-4b3f-b344-c59722ce9dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_88560ddd-c949-489f-8984-db7eb9dcae40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8c9aef25-777a-4bda-8f1a-6cf02f451344" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_88560ddd-c949-489f-8984-db7eb9dcae40" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8c9aef25-777a-4bda-8f1a-6cf02f451344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d4b42c1f-72a1-4795-9852-e2c74c9c3cab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_88560ddd-c949-489f-8984-db7eb9dcae40" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d4b42c1f-72a1-4795-9852-e2c74c9c3cab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquityAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_336d3578-dc4f-45d8-a399-e1098be112e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_336d3578-dc4f-45d8-a399-e1098be112e8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b88efe6c-51d2-4a72-ac79-faa45e08c17a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b88efe6c-51d2-4a72-ac79-faa45e08c17a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d45aa1ac-e5f4-4d4f-a703-7ec30f8f8295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b88efe6c-51d2-4a72-ac79-faa45e08c17a" xlink:to="loc_us-gaap_EquityComponentDomain_d45aa1ac-e5f4-4d4f-a703-7ec30f8f8295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_6c0a7efa-f9a5-4ce8-a3e0-dd739026887a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_d45aa1ac-e5f4-4d4f-a703-7ec30f8f8295" xlink:to="loc_us-gaap_CommonStockMember_6c0a7efa-f9a5-4ce8-a3e0-dd739026887a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3d702d71-f16d-41bf-8a40-ec1a8d97b700" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3d702d71-f16d-41bf-8a40-ec1a8d97b700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ec401bd-3341-48c2-92d3-ed5ab05539ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d702d71-f16d-41bf-8a40-ec1a8d97b700" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ec401bd-3341-48c2-92d3-ed5ab05539ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockPurchaseAgreementMember_69010e07-8eda-4bc3-a1d4-8bf18d1f613e" xlink:href="sgmo-20201231.xsd#sgmo_StockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5ec401bd-3341-48c2-92d3-ed5ab05539ee" xlink:to="loc_sgmo_StockPurchaseAgreementMember_69010e07-8eda-4bc3-a1d4-8bf18d1f613e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_adeeee8c-9e58-4815-bd41-ee9bcef2d320" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_srt_CounterpartyNameAxis_adeeee8c-9e58-4815-bd41-ee9bcef2d320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd76b93c-1c6e-4776-8d89-ad6e71dfc477" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_adeeee8c-9e58-4815-bd41-ee9bcef2d320" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd76b93c-1c6e-4776-8d89-ad6e71dfc477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BiogenMAIncMember_caec44f7-6a9c-4641-b5d0-0b29832f7280" xlink:href="sgmo-20201231.xsd#sgmo_BiogenMAIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd76b93c-1c6e-4776-8d89-ad6e71dfc477" xlink:to="loc_sgmo_BiogenMAIncMember_caec44f7-6a9c-4641-b5d0-0b29832f7280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_JefferiesLLCMember_08c9d2f5-d702-4595-9ce4-3cfa35a13a26" xlink:href="sgmo-20201231.xsd#sgmo_JefferiesLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_bd76b93c-1c6e-4776-8d89-ad6e71dfc477" xlink:to="loc_sgmo_JefferiesLLCMember_08c9d2f5-d702-4595-9ce4-3cfa35a13a26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_98bb01b4-aba8-4957-af6a-3f1b68966365" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_98bb01b4-aba8-4957-af6a-3f1b68966365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_74a616ec-1849-4c60-9b1f-b2d3b54b9721" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_98bb01b4-aba8-4957-af6a-3f1b68966365" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_74a616ec-1849-4c60-9b1f-b2d3b54b9721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketOfferingAgreementMember_a6f2424e-4701-4cdc-bce2-95f8b80b8374" xlink:href="sgmo-20201231.xsd#sgmo_AtTheMarketOfferingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_74a616ec-1849-4c60-9b1f-b2d3b54b9721" xlink:to="loc_sgmo_AtTheMarketOfferingAgreementMember_a6f2424e-4701-4cdc-bce2-95f8b80b8374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_53f4455e-7c0c-49c8-8131-c3c987ab7e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_AwardTypeAxis_53f4455e-7c0c-49c8-8131-c3c987ab7e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5987df4d-1869-49cf-8f8a-f4e8c6471b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_53f4455e-7c0c-49c8-8131-c3c987ab7e03" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5987df4d-1869-49cf-8f8a-f4e8c6471b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eacda993-e871-491d-a5b0-97fab619755a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5987df4d-1869-49cf-8f8a-f4e8c6471b8b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eacda993-e871-491d-a5b0-97fab619755a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c61de8ad-cf8a-436c-a453-ab022975201a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5987df4d-1869-49cf-8f8a-f4e8c6471b8b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c61de8ad-cf8a-436c-a453-ab022975201a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_1a6070de-48e1-480b-a49b-56a7298dfd6f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_srt_RangeAxis_1a6070de-48e1-480b-a49b-56a7298dfd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b0837df3-cbb5-410c-859c-d10a2e57509c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1a6070de-48e1-480b-a49b-56a7298dfd6f" xlink:to="loc_srt_RangeMember_b0837df3-cbb5-410c-859c-d10a2e57509c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_642dc766-c4be-4cf4-974f-39b857133a45" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b0837df3-cbb5-410c-859c-d10a2e57509c" xlink:to="loc_srt_MaximumMember_642dc766-c4be-4cf4-974f-39b857133a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_2de5ef28-a80e-443f-b1b2-d2a78ae94a62" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_PlanNameAxis_2de5ef28-a80e-443f-b1b2-d2a78ae94a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_2de5ef28-a80e-443f-b1b2-d2a78ae94a62" xlink:to="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember_39651ebd-39b3-499c-8979-ad82fe4085b0" xlink:href="sgmo-20201231.xsd#sgmo_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:to="loc_sgmo_TwoThousandEighteenStockIncentivePlanMember_39651ebd-39b3-499c-8979-ad82fe4085b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember_35f38180-e18e-46b1-98de-3aa87aa65842" xlink:href="sgmo-20201231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:to="loc_sgmo_EmployeeStockPurchasePlanMember_35f38180-e18e-46b1-98de-3aa87aa65842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_Restated2018StockIncentivePlanMember_0b616e60-7dc3-49ee-91f4-fdaebe7892d0" xlink:href="sgmo-20201231.xsd#sgmo_Restated2018StockIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_80fcf434-5435-4d4e-8ab2-5040161499d0" xlink:to="loc_sgmo_Restated2018StockIncentivePlanMember_0b616e60-7dc3-49ee-91f4-fdaebe7892d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_e624518c-1180-40cf-b83e-a92e2186961d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_VestingAxis_e624518c-1180-40cf-b83e-a92e2186961d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_e624518c-1180-40cf-b83e-a92e2186961d" xlink:to="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8399aa7c-73f9-414b-93cb-912022943203" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8399aa7c-73f9-414b-93cb-912022943203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b489f875-8fea-448b-9ac9-d1f98b3f951f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b489f875-8fea-448b-9ac9-d1f98b3f951f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_af72d033-0e0f-4404-b530-6134e40c71a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3ffd895f-4efa-4486-9839-2364b2b5e67c" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_af72d033-0e0f-4404-b530-6134e40c71a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_936328e9-158a-494b-be52-890e622a42eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_8f351d2f-caac-4928-aec0-8e06809b2d15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_8f351d2f-caac-4928-aec0-8e06809b2d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_391d6991-e1d5-4df8-ae34-2474a698a6de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_391d6991-e1d5-4df8-ae34-2474a698a6de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_7fca691e-43d4-46a2-8ce8-c84996d80656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_7fca691e-43d4-46a2-8ce8-c84996d80656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b15d1105-08f9-4414-a3f2-ead6f5d7cb29" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b15d1105-08f9-4414-a3f2-ead6f5d7cb29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_338da8e0-a366-48bd-802b-4134c443d31e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_338da8e0-a366-48bd-802b-4134c443d31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_d567ce90-30ed-4340-82a6-2633d516c825" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_d567ce90-30ed-4340-82a6-2633d516c825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dbe6b7d9-b492-44cc-a24c-6f4d78e147f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_dbe6b7d9-b492-44cc-a24c-6f4d78e147f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_873e6e5b-4ffe-4b42-8c89-e42158268b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_873e6e5b-4ffe-4b42-8c89-e42158268b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_cff06ced-0ff9-4737-a20a-bdfbb8a78be6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_cff06ced-0ff9-4737-a20a-bdfbb8a78be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_NetProceedsFromIssuancePublicOffering_8b821b6d-d0bd-4f39-9b8d-f550a5c7cfee" xlink:href="sgmo-20201231.xsd#sgmo_NetProceedsFromIssuancePublicOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_NetProceedsFromIssuancePublicOffering_8b821b6d-d0bd-4f39-9b8d-f550a5c7cfee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockOfferingProgramMaximumValue_b2a1caec-6525-4cd0-b5f8-cff9afcf342e" xlink:href="sgmo-20201231.xsd#sgmo_StockOfferingProgramMaximumValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_StockOfferingProgramMaximumValue_b2a1caec-6525-4cd0-b5f8-cff9afcf342e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b1c8bed6-1a53-4be6-be23-70ad5061b3ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b1c8bed6-1a53-4be6-be23-70ad5061b3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_f964664f-995a-4684-b001-83b3177fc854" xlink:href="sgmo-20201231.xsd#sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance_f964664f-995a-4684-b001-83b3177fc854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cd956630-5eb2-4814-9526-5d023a837ed6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_cd956630-5eb2-4814-9526-5d023a837ed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74d218da-1cff-4b57-b184-7e39d6f89e4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_74d218da-1cff-4b57-b184-7e39d6f89e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SpecifiedStockholderOwnershipPercentage_6a17237a-59a3-4ee4-8684-41ff088eb598" xlink:href="sgmo-20201231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_SpecifiedStockholderOwnershipPercentage_6a17237a-59a3-4ee4-8684-41ff088eb598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_d15052d7-7659-48a3-8947-5e8bab425080" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_d15052d7-7659-48a3-8947-5e8bab425080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_1c550322-609a-48c7-b7e6-03087a3f9f18" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_1c550322-609a-48c7-b7e6-03087a3f9f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fcab35c2-3555-47cd-9fc1-dda0bf08a9c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_fcab35c2-3555-47cd-9fc1-dda0bf08a9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fc9e787b-da9b-4c6d-945e-6217ab0badb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_fc9e787b-da9b-4c6d-945e-6217ab0badb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_52142f7c-ba12-4bab-a62c-34614363eaf4" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_52142f7c-ba12-4bab-a62c-34614363eaf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_CommonStockExchangeRatio_9b679f5b-b03b-41f1-ba95-0011d1ed0c0a" xlink:href="sgmo-20201231.xsd#sgmo_CommonStockExchangeRatio"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_CommonStockExchangeRatio_9b679f5b-b03b-41f1-ba95-0011d1ed0c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_49f41102-28ed-4206-8696-a70035009485" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_49f41102-28ed-4206-8696-a70035009485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1563c19a-1a27-4caa-969a-9ec40c42e882" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_1563c19a-1a27-4caa-969a-9ec40c42e882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanOfferingPeriod_5dcb8a46-d61c-45b7-943a-e4b67c3658a1" xlink:href="sgmo-20201231.xsd#sgmo_PurchasePlanOfferingPeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_PurchasePlanOfferingPeriod_5dcb8a46-d61c-45b7-943a-e4b67c3658a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_PurchasePlanPurchasePeriod_d69336de-56da-4b04-ba39-7b263fdefe85" xlink:href="sgmo-20201231.xsd#sgmo_PurchasePlanPurchasePeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_PurchasePlanPurchasePeriod_d69336de-56da-4b04-ba39-7b263fdefe85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8c683a5a-7898-4860-bf16-58a86de66bca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_8c683a5a-7898-4860-bf16-58a86de66bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fd72dc51-d826-4c50-95a9-989bead8fda0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_fd72dc51-d826-4c50-95a9-989bead8fda0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f07389d1-5006-4f93-b110-a0cdf115705b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_f07389d1-5006-4f93-b110-a0cdf115705b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1a72c19e-7bbe-4b05-8c88-6f8e6b54a7c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1a72c19e-7bbe-4b05-8c88-6f8e6b54a7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5eedafd2-874c-404e-8896-d680889f45c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5eedafd2-874c-404e-8896-d680889f45c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_a8b72b52-6cd7-4cee-9ea5-772ee5053fdb" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_a8b72b52-6cd7-4cee-9ea5-772ee5053fdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_610608a6-a268-4a6c-a981-cedda2b75dc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_610608a6-a268-4a6c-a981-cedda2b75dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d8c09248-8391-4f8a-a066-a98fbb895ace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_d8c09248-8391-4f8a-a066-a98fbb895ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0bae2a82-2014-4260-bc59-536aaf41bf33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_0bae2a82-2014-4260-bc59-536aaf41bf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4d491d4b-516b-4fe3-aee4-5ced62ef293a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b1e1104e-d221-4bf8-bd56-1189f79bec5a" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4d491d4b-516b-4fe3-aee4-5ced62ef293a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquitySummaryofStockOptionActivityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bf7a9bd1-741b-4d36-be38-12154659e9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a70e50cf-8cbf-48f0-8b32-54a2ac9d311c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bf7a9bd1-741b-4d36-be38-12154659e9eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a70e50cf-8cbf-48f0-8b32-54a2ac9d311c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9169984d-d79e-4bc0-8e2f-40810ef66ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a70e50cf-8cbf-48f0-8b32-54a2ac9d311c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9169984d-d79e-4bc0-8e2f-40810ef66ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b2dcd9bd-f191-4360-8182-f9a1c067103c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a70e50cf-8cbf-48f0-8b32-54a2ac9d311c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_b2dcd9bd-f191-4360-8182-f9a1c067103c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_edffc823-84c0-480b-b5e3-369236a100be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a70e50cf-8cbf-48f0-8b32-54a2ac9d311c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_edffc823-84c0-480b-b5e3-369236a100be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d6a2d997-af56-4c99-9089-58afa9bc40ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a70e50cf-8cbf-48f0-8b32-54a2ac9d311c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_d6a2d997-af56-4c99-9089-58afa9bc40ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3398128a-c5a1-43bd-b6e4-eefce830036a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a70e50cf-8cbf-48f0-8b32-54a2ac9d311c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3398128a-c5a1-43bd-b6e4-eefce830036a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e3d02853-8898-45ff-bf64-1536cae3e87a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a70e50cf-8cbf-48f0-8b32-54a2ac9d311c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_e3d02853-8898-45ff-bf64-1536cae3e87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8723c850-d796-4528-8489-60b57ba67169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a70e50cf-8cbf-48f0-8b32-54a2ac9d311c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_8723c850-d796-4528-8489-60b57ba67169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_420abb48-d706-4697-8831-ad5e8e4d093b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bf7a9bd1-741b-4d36-be38-12154659e9eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_420abb48-d706-4697-8831-ad5e8e4d093b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2e68dad1-27c4-40bc-b8a8-abf07f2480a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_420abb48-d706-4697-8831-ad5e8e4d093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2e68dad1-27c4-40bc-b8a8-abf07f2480a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dad06564-cc2d-4d4d-bf87-1f04ebbcaf34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_420abb48-d706-4697-8831-ad5e8e4d093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dad06564-cc2d-4d4d-bf87-1f04ebbcaf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_efa4f287-5d12-43b1-982a-fb39fd3d5ce0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_420abb48-d706-4697-8831-ad5e8e4d093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_efa4f287-5d12-43b1-982a-fb39fd3d5ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dd996b2a-16cc-4eda-96bd-9f2b512003bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_420abb48-d706-4697-8831-ad5e8e4d093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_dd996b2a-16cc-4eda-96bd-9f2b512003bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46962e52-532a-4c30-b86d-7094e57aa8ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_420abb48-d706-4697-8831-ad5e8e4d093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_46962e52-532a-4c30-b86d-7094e57aa8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6dd0c159-4702-4f31-9441-b464807199df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_420abb48-d706-4697-8831-ad5e8e4d093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_6dd0c159-4702-4f31-9441-b464807199df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6d7712c3-da1d-4f7e-8fc4-146ea7f691a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_420abb48-d706-4697-8831-ad5e8e4d093b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_6d7712c3-da1d-4f7e-8fc4-146ea7f691a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b034f210-b25f-4b42-b25d-996c2a652ad2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bf7a9bd1-741b-4d36-be38-12154659e9eb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b034f210-b25f-4b42-b25d-996c2a652ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dbc9d952-0452-4ef2-a2ff-cb29245af438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b034f210-b25f-4b42-b25d-996c2a652ad2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dbc9d952-0452-4ef2-a2ff-cb29245af438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6ae7ea57-7fb1-4548-98f5-583919bd8add" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b034f210-b25f-4b42-b25d-996c2a652ad2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_6ae7ea57-7fb1-4548-98f5-583919bd8add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2bcc7825-5f3c-4717-a313-aaee9a91a9b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_b034f210-b25f-4b42-b25d-996c2a652ad2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_2bcc7825-5f3c-4717-a313-aaee9a91a9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_c55d8ac4-b187-47a6-b5a3-12d468998f47" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bf7a9bd1-741b-4d36-be38-12154659e9eb" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_c55d8ac4-b187-47a6-b5a3-12d468998f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f920d0d8-3c22-4e31-b5c7-f21a512af3f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_c55d8ac4-b187-47a6-b5a3-12d468998f47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f920d0d8-3c22-4e31-b5c7-f21a512af3f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ec522330-fe82-4645-a487-3ddf9f5cd98d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_c55d8ac4-b187-47a6-b5a3-12d468998f47" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_ec522330-fe82-4645-a487-3ddf9f5cd98d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_438e17ee-3cae-4cf3-b65b-2f2f6bab199c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_c55d8ac4-b187-47a6-b5a3-12d468998f47" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_438e17ee-3cae-4cf3-b65b-2f2f6bab199c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4551c3b1-0bd6-4c0e-9116-1a8bc9f9e9d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5667d62f-7ae6-46ef-bd6f-e129f195a1ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4551c3b1-0bd6-4c0e-9116-1a8bc9f9e9d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5667d62f-7ae6-46ef-bd6f-e129f195a1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c729b93c-535c-4b51-82ab-a98b9c07ea89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5667d62f-7ae6-46ef-bd6f-e129f195a1ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c729b93c-535c-4b51-82ab-a98b9c07ea89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12d54bd0-2b15-45b6-b6cd-792a63c9137d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5667d62f-7ae6-46ef-bd6f-e129f195a1ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_12d54bd0-2b15-45b6-b6cd-792a63c9137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_158c5586-6304-449a-beb4-02bb14d46ba3" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5667d62f-7ae6-46ef-bd6f-e129f195a1ee" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_158c5586-6304-449a-beb4-02bb14d46ba3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1162eecf-6334-473e-bee7-f2f31ce693a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5667d62f-7ae6-46ef-bd6f-e129f195a1ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1162eecf-6334-473e-bee7-f2f31ce693a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_36672dbc-a366-48ff-9594-0a187dfda3d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5667d62f-7ae6-46ef-bd6f-e129f195a1ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_36672dbc-a366-48ff-9594-0a187dfda3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_f3edb3bc-ca57-4da1-874a-925dab25ba72" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5667d62f-7ae6-46ef-bd6f-e129f195a1ee" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_f3edb3bc-ca57-4da1-874a-925dab25ba72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c49064ea-cd7f-4a68-9785-c95a03949b2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4551c3b1-0bd6-4c0e-9116-1a8bc9f9e9d1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c49064ea-cd7f-4a68-9785-c95a03949b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_11e042fb-1d36-43d4-9c3d-c6dddf820d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c49064ea-cd7f-4a68-9785-c95a03949b2d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_11e042fb-1d36-43d4-9c3d-c6dddf820d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_181fcc24-1baf-4013-ba29-1058ca31009e" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_c49064ea-cd7f-4a68-9785-c95a03949b2d" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_181fcc24-1baf-4013-ba29-1058ca31009e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_57797455-b006-4a86-949b-3bbcc628244d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4551c3b1-0bd6-4c0e-9116-1a8bc9f9e9d1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_57797455-b006-4a86-949b-3bbcc628244d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cac89153-d71e-46ac-a6f0-1978af43922f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_57797455-b006-4a86-949b-3bbcc628244d" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_cac89153-d71e-46ac-a6f0-1978af43922f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_3aef92c0-b4fd-4115-866a-4f4a93998d98" xlink:href="sgmo-20201231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_57797455-b006-4a86-949b-3bbcc628244d" xlink:to="loc_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_3aef92c0-b4fd-4115-866a-4f4a93998d98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f966cfdb-d145-4535-848d-536c6990efc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_189ea422-4692-4c39-9e97-d544288e57eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f966cfdb-d145-4535-848d-536c6990efc1" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_189ea422-4692-4c39-9e97-d544288e57eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c73acca-bb2d-4765-88ea-3366d812c107" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_07ccb8d1-48b8-47cb-ab36-f47f4b9852e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c73acca-bb2d-4765-88ea-3366d812c107" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_07ccb8d1-48b8-47cb-ab36-f47f4b9852e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0316e66a-90dc-4f2f-b1af-532fec8a847d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c73acca-bb2d-4765-88ea-3366d812c107" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_0316e66a-90dc-4f2f-b1af-532fec8a847d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_50156be7-65b5-42fa-a34b-6fffbf97b4d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3c73acca-bb2d-4765-88ea-3366d812c107" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_50156be7-65b5-42fa-a34b-6fffbf97b4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c631ad73-ba18-40ba-8eef-c2776a5f3da7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f498b5b4-f8ed-4296-b668-500602aaf977" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c631ad73-ba18-40ba-8eef-c2776a5f3da7" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f498b5b4-f8ed-4296-b668-500602aaf977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e9d5ecae-bc31-456c-ad34-778f248cc6e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f498b5b4-f8ed-4296-b668-500602aaf977" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e9d5ecae-bc31-456c-ad34-778f248cc6e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e21d7b38-682c-4ce9-9e8b-11feb5bac866" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e9d5ecae-bc31-456c-ad34-778f248cc6e0" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e21d7b38-682c-4ce9-9e8b-11feb5bac866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9750b1aa-cb7d-423d-bac1-a44c049f5b63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e21d7b38-682c-4ce9-9e8b-11feb5bac866" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9750b1aa-cb7d-423d-bac1-a44c049f5b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ea02ee29-51fd-488e-922f-e62cec3de3a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e21d7b38-682c-4ce9-9e8b-11feb5bac866" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_ea02ee29-51fd-488e-922f-e62cec3de3a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b5083a19-8ca6-4ba5-b938-dd6222b97718" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f498b5b4-f8ed-4296-b668-500602aaf977" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b5083a19-8ca6-4ba5-b938-dd6222b97718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_2523c2b0-74fb-4604-81c8-f40bfce5f84b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b5083a19-8ca6-4ba5-b938-dd6222b97718" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_2523c2b0-74fb-4604-81c8-f40bfce5f84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14d59d5a-1a2f-47ab-b02e-52eb974d4a5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53764305-ed49-4240-980d-f31094c72f06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_14d59d5a-1a2f-47ab-b02e-52eb974d4a5e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53764305-ed49-4240-980d-f31094c72f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3d5c89ea-c30e-4717-9901-b73d51358ea3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53764305-ed49-4240-980d-f31094c72f06" xlink:to="loc_us-gaap_AwardTypeAxis_3d5c89ea-c30e-4717-9901-b73d51358ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c96b80a5-14f9-4f3d-b655-7d218b20ed78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3d5c89ea-c30e-4717-9901-b73d51358ea3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c96b80a5-14f9-4f3d-b655-7d218b20ed78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d78d2601-1be3-4d7c-8e4b-b26c4c38d4a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c96b80a5-14f9-4f3d-b655-7d218b20ed78" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d78d2601-1be3-4d7c-8e4b-b26c4c38d4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_53764305-ed49-4240-980d-f31094c72f06" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_79731eaf-6dd9-400b-9ba7-d6e9f03b478d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_79731eaf-6dd9-400b-9ba7-d6e9f03b478d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53280104-203e-4075-96a4-43318dba4c36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_53280104-203e-4075-96a4-43318dba4c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c7493655-b6ce-4c0d-9aa5-50ab968e8559" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_c7493655-b6ce-4c0d-9aa5-50ab968e8559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a30d863c-964c-4894-9b18-4ab0fabe473a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_a30d863c-964c-4894-9b18-4ab0fabe473a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bfff8279-bf7e-42a5-995c-87ef7e36554d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_bfff8279-bf7e-42a5-995c-87ef7e36554d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_07528df0-dcd5-4859-a773-010885d06ba5" xlink:href="sgmo-20201231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_07528df0-dcd5-4859-a773-010885d06ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_79807b3f-e75c-4ac3-b78a-c98c4215e95c" xlink:href="sgmo-20201231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1954910f-cbe8-4b2e-9906-231a7d588a68" xlink:to="loc_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_79807b3f-e75c-4ac3-b78a-c98c4215e95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90646cab-dbb2-413c-98ff-39368d2f5b1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86b0e1aa-a978-42c5-9a26-a135352ca921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90646cab-dbb2-413c-98ff-39368d2f5b1f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86b0e1aa-a978-42c5-9a26-a135352ca921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61e4a3b1-6845-498e-b803-a632b3b5d4c0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86b0e1aa-a978-42c5-9a26-a135352ca921" xlink:to="loc_srt_RangeAxis_61e4a3b1-6845-498e-b803-a632b3b5d4c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_26f9f4b8-ab03-4135-8073-8bd1654994e4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_61e4a3b1-6845-498e-b803-a632b3b5d4c0" xlink:to="loc_srt_RangeMember_26f9f4b8-ab03-4135-8073-8bd1654994e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b123453-90aa-4317-946d-0dfe7e7ca66a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_26f9f4b8-ab03-4135-8073-8bd1654994e4" xlink:to="loc_srt_MinimumMember_5b123453-90aa-4317-946d-0dfe7e7ca66a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_79cd2951-1574-42fc-b976-a42b44e20113" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_26f9f4b8-ab03-4135-8073-8bd1654994e4" xlink:to="loc_srt_MaximumMember_79cd2951-1574-42fc-b976-a42b44e20113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_40ba1711-01bf-4de0-b757-a231bf3ce79e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86b0e1aa-a978-42c5-9a26-a135352ca921" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_40ba1711-01bf-4de0-b757-a231bf3ce79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c09a2d99-eeaf-4b68-bdf8-e9dc61b17660" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_40ba1711-01bf-4de0-b757-a231bf3ce79e" xlink:to="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c09a2d99-eeaf-4b68-bdf8-e9dc61b17660" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_a7c67ff6-c4a7-4a23-bb9f-88758259c765" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_c09a2d99-eeaf-4b68-bdf8-e9dc61b17660" xlink:to="loc_us-gaap_EmployeeStockOptionMember_a7c67ff6-c4a7-4a23-bb9f-88758259c765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_86b0e1aa-a978-42c5-9a26-a135352ca921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7b453e7d-bd63-48ba-9d8b-89c28270b72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7b453e7d-bd63-48ba-9d8b-89c28270b72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_01a86923-974a-47c8-a31b-13ed26152313" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_01a86923-974a-47c8-a31b-13ed26152313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7a25f7b3-3f64-476b-9898-0e6b6cf3b173" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_7a25f7b3-3f64-476b-9898-0e6b6cf3b173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4e1989ea-2f99-4281-80b5-9a142a310546" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13f63303-995a-4d42-a4d3-adab1a68c080" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_4e1989ea-2f99-4281-80b5-9a142a310546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81fb4ad4-2b03-4e96-9fb0-1db69c4a43f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc27100a-5f90-44a7-ac3f-c317d0963e2f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_81fb4ad4-2b03-4e96-9fb0-1db69c4a43f2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc27100a-5f90-44a7-ac3f-c317d0963e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_fdcac7f7-0071-4c36-b0f6-2a13ea13f43d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc27100a-5f90-44a7-ac3f-c317d0963e2f" xlink:to="loc_us-gaap_PlanNameAxis_fdcac7f7-0071-4c36-b0f6-2a13ea13f43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f59513c8-5677-444a-85fb-0e71d1a2d90c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_fdcac7f7-0071-4c36-b0f6-2a13ea13f43d" xlink:to="loc_us-gaap_PlanNameDomain_f59513c8-5677-444a-85fb-0e71d1a2d90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EmployeeStockPurchasePlanMember_af1d8b43-bc0c-4630-b6e6-f606493c9d1a" xlink:href="sgmo-20201231.xsd#sgmo_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f59513c8-5677-444a-85fb-0e71d1a2d90c" xlink:to="loc_sgmo_EmployeeStockPurchasePlanMember_af1d8b43-bc0c-4630-b6e6-f606493c9d1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e7c69842-ce4b-4002-9005-b76461c637fa" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc27100a-5f90-44a7-ac3f-c317d0963e2f" xlink:to="loc_srt_RangeAxis_e7c69842-ce4b-4002-9005-b76461c637fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f848e004-d554-4861-9f67-21cd7fdd13a3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e7c69842-ce4b-4002-9005-b76461c637fa" xlink:to="loc_srt_RangeMember_f848e004-d554-4861-9f67-21cd7fdd13a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_81de429f-41c1-405e-96b7-da7eaf5133dc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f848e004-d554-4861-9f67-21cd7fdd13a3" xlink:to="loc_srt_MinimumMember_81de429f-41c1-405e-96b7-da7eaf5133dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_30e08871-7e03-4db1-95a5-e4e3a495438b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_f848e004-d554-4861-9f67-21cd7fdd13a3" xlink:to="loc_srt_MaximumMember_30e08871-7e03-4db1-95a5-e4e3a495438b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_cc27100a-5f90-44a7-ac3f-c317d0963e2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a9d6d7a4-7ab7-499e-8e1f-38702264193e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_a9d6d7a4-7ab7-499e-8e1f-38702264193e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ca8e6e61-e0e1-4f90-80cc-0949dee31afa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ca8e6e61-e0e1-4f90-80cc-0949dee31afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5a12d56a-c8f7-4cb4-b5f1-c0a2be9e82e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5a12d56a-c8f7-4cb4-b5f1-c0a2be9e82e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fa42866-3f9d-4120-b01d-f1222cd74553" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9f4d3267-9218-46ca-b48b-20c0c1be43fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7fa42866-3f9d-4120-b01d-f1222cd74553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="sgmo-20201231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5357a27a-6b67-44e6-90fc-d95c269abc92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_20007ba4-25f2-4495-82a9-e7a4434125ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5357a27a-6b67-44e6-90fc-d95c269abc92" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_20007ba4-25f2-4495-82a9-e7a4434125ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#EmployeeBenefitPlanAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e9c799b5-0025-4122-9881-7c3bacafe57d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_50aa0797-1f9f-40be-86e1-e746191dcc13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e9c799b5-0025-4122-9881-7c3bacafe57d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_50aa0797-1f9f-40be-86e1-e746191dcc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_828876e5-0d58-4ea6-a06c-386bc095681b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e9c799b5-0025-4122-9881-7c3bacafe57d" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_828876e5-0d58-4ea6-a06c-386bc095681b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_a74d3355-b0c8-4d82-8174-f2f8b233198c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e9c799b5-0025-4122-9881-7c3bacafe57d" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_a74d3355-b0c8-4d82-8174-f2f8b233198c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_92d1c72b-da0b-4d7c-a3c2-3ef3bf9c1f74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e9c799b5-0025-4122-9881-7c3bacafe57d" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_92d1c72b-da0b-4d7c-a3c2-3ef3bf9c1f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxes" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3c41e628-ce61-4d64-b058-b097d06588ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2966c8ed-2e7d-4117-bba4-7f29b5588e2e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c41e628-ce61-4d64-b058-b097d06588ca" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2966c8ed-2e7d-4117-bba4-7f29b5588e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3f2c19ff-5fa6-4611-94a3-d24cc3da634d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_691f242b-07c6-45b7-b5bc-1cfdfcefb5ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f2c19ff-5fa6-4611-94a3-d24cc3da634d" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_691f242b-07c6-45b7-b5bc-1cfdfcefb5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b0626835-d853-47ec-acbd-7a785f0a7a87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f2c19ff-5fa6-4611-94a3-d24cc3da634d" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b0626835-d853-47ec-acbd-7a785f0a7a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c2329513-9d45-469e-b354-7eb6e72f219c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f2c19ff-5fa6-4611-94a3-d24cc3da634d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_c2329513-9d45-469e-b354-7eb6e72f219c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3c07b69c-be05-4844-8b59-7a959ed8ef9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f2c19ff-5fa6-4611-94a3-d24cc3da634d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3c07b69c-be05-4844-8b59-7a959ed8ef9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_0cd160c8-4743-48f4-901a-9d7b8fea65d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3f2c19ff-5fa6-4611-94a3-d24cc3da634d" xlink:to="loc_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_0cd160c8-4743-48f4-901a-9d7b8fea65d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6a983bf1-381b-4e29-a746-9b479ad1dac2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_eae55033-283f-40b9-a721-30e47a6dd917" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a983bf1-381b-4e29-a746-9b479ad1dac2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_eae55033-283f-40b9-a721-30e47a6dd917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_be9ed04a-e506-4476-97f1-7512ce8095a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a983bf1-381b-4e29-a746-9b479ad1dac2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_be9ed04a-e506-4476-97f1-7512ce8095a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9dce75ce-c700-40a7-a030-92436729475a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6a983bf1-381b-4e29-a746-9b479ad1dac2" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9dce75ce-c700-40a7-a030-92436729475a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b590fde8-8518-4e59-b45c-dc11712d2017" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_e9ccf961-bb1a-475c-8c63-80509575707b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b590fde8-8518-4e59-b45c-dc11712d2017" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_e9ccf961-bb1a-475c-8c63-80509575707b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_add5f97a-c64b-4111-bef3-416fd5c03bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_e9ccf961-bb1a-475c-8c63-80509575707b" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_add5f97a-c64b-4111-bef3-416fd5c03bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_60f1e33c-3e69-4067-a726-984bfdcd5196" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_add5f97a-c64b-4111-bef3-416fd5c03bc6" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_60f1e33c-3e69-4067-a726-984bfdcd5196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ac031b5d-cc8a-4d27-a09c-73c78e1b9a5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_add5f97a-c64b-4111-bef3-416fd5c03bc6" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ac031b5d-cc8a-4d27-a09c-73c78e1b9a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5f0623cb-daa1-420c-9094-b7b689f53fc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_add5f97a-c64b-4111-bef3-416fd5c03bc6" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_5f0623cb-daa1-420c-9094-b7b689f53fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_ab58a2d3-14eb-44aa-8403-c4248ca50c69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_add5f97a-c64b-4111-bef3-416fd5c03bc6" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_ab58a2d3-14eb-44aa-8403-c4248ca50c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0add7b39-41ea-4dfa-9773-be44c17d7682" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_e9ccf961-bb1a-475c-8c63-80509575707b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0add7b39-41ea-4dfa-9773-be44c17d7682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99227b4b-4d83-4a85-8574-611871ee9e5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0add7b39-41ea-4dfa-9773-be44c17d7682" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_99227b4b-4d83-4a85-8574-611871ee9e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4bf0a236-48df-4a99-884f-86ce550e3c19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0add7b39-41ea-4dfa-9773-be44c17d7682" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4bf0a236-48df-4a99-884f-86ce550e3c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7d61bb90-6c68-4115-863c-ccbb2d0f43c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0add7b39-41ea-4dfa-9773-be44c17d7682" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_7d61bb90-6c68-4115-863c-ccbb2d0f43c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_4467bbd3-8019-4a2e-a0b3-334292cbd37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_0add7b39-41ea-4dfa-9773-be44c17d7682" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_4467bbd3-8019-4a2e-a0b3-334292cbd37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_60bc4662-3bf4-4f03-9ad2-d2cd5df1c787" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_e9ccf961-bb1a-475c-8c63-80509575707b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_60bc4662-3bf4-4f03-9ad2-d2cd5df1c787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_90e3a889-0e83-4a53-8502-7e4443702f55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_90e3a889-0e83-4a53-8502-7e4443702f55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_07041c9f-3594-4d59-a9dd-c8ff49f62ec7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_07041c9f-3594-4d59-a9dd-c8ff49f62ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_fa647855-da72-43b5-8f9d-e704f99480cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_fa647855-da72-43b5-8f9d-e704f99480cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount_3c010785-5d05-4341-944c-23b99cb49c24" xlink:href="sgmo-20201231.xsd#sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:to="loc_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount_3c010785-5d05-4341-944c-23b99cb49c24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_7f126597-8884-4c4a-8e60-a73a7d3691a5" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:to="loc_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_7f126597-8884-4c4a-8e60-a73a7d3691a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7601bb8c-60b6-454b-8809-24b55a900926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_7601bb8c-60b6-454b-8809-24b55a900926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72ba04f5-b220-43cb-a00c-86c9eaac1ded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_72ba04f5-b220-43cb-a00c-86c9eaac1ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_606cbe4a-bc9f-476d-9ed7-6cbc45c06a17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_606cbe4a-bc9f-476d-9ed7-6cbc45c06a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_9fc96647-071a-42c5-977b-e862d35f412e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2a12ab89-d505-4c87-a20a-b18e15262ac5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_9fc96647-071a-42c5-977b-e862d35f412e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b5fde567-546e-482b-a812-c28ceab31ca4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_aab178c6-d1a4-4cd5-8aa0-4ca2f7697e35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5fde567-546e-482b-a812-c28ceab31ca4" xlink:to="loc_us-gaap_AssetsAbstract_aab178c6-d1a4-4cd5-8aa0-4ca2f7697e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_aab178c6-d1a4-4cd5-8aa0-4ca2f7697e35" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ecd159e2-047f-49dc-ab0a-8410504b9abb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ecd159e2-047f-49dc-ab0a-8410504b9abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4749a8f9-0603-4574-9577-b355f5fa2d00" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_4749a8f9-0603-4574-9577-b355f5fa2d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_84dc7a88-7cf4-4f77-ac32-2b206f5617db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_84dc7a88-7cf4-4f77-ac32-2b206f5617db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_433d793d-7b14-4314-8bd0-e98aba1c15c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_433d793d-7b14-4314-8bd0-e98aba1c15c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_bd008e3a-e0b1-4e71-8a98-4d73df08ca96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_bd008e3a-e0b1-4e71-8a98-4d73df08ca96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsLeaseLiability_7f6fe5c9-4fc0-47bc-9acd-723549a2bae0" xlink:href="sgmo-20201231.xsd#sgmo_DeferredTaxAssetsLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_sgmo_DeferredTaxAssetsLeaseLiability_7f6fe5c9-4fc0-47bc-9acd-723549a2bae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_48d142c3-177a-499a-a420-fc3f3aa2276c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_48d142c3-177a-499a-a420-fc3f3aa2276c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_19ef66f7-a498-406b-9383-f461bddae5e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_19ef66f7-a498-406b-9383-f461bddae5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_6e097dcf-0966-463e-a49e-62d1864e7135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_6e097dcf-0966-463e-a49e-62d1864e7135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_565700a1-e5f3-4727-bb93-0181d407698c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_565700a1-e5f3-4727-bb93-0181d407698c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_723be89b-da51-4835-9f96-5b5b1b40a299" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_dd606448-827d-4da9-83a8-49d0347e21e7" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_723be89b-da51-4835-9f96-5b5b1b40a299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAbstract_481b533e-aecc-412a-ad8f-915b2fcf876f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5fde567-546e-482b-a812-c28ceab31ca4" xlink:to="loc_us-gaap_LiabilitiesAbstract_481b533e-aecc-412a-ad8f-915b2fcf876f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e5f32906-18ea-4066-b130-0036101293ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_481b533e-aecc-412a-ad8f-915b2fcf876f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_e5f32906-18ea-4066-b130-0036101293ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_7d530511-0406-4eda-ab3c-c7e7aa86d287" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_481b533e-aecc-412a-ad8f-915b2fcf876f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_7d530511-0406-4eda-ab3c-c7e7aa86d287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_875951a0-f5ea-486e-afe7-3cee37b3287f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_481b533e-aecc-412a-ad8f-915b2fcf876f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_875951a0-f5ea-486e-afe7-3cee37b3287f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_79ecb1c9-009f-456a-8f0c-e69e2eb388e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAbstract_481b533e-aecc-412a-ad8f-915b2fcf876f" xlink:to="loc_us-gaap_DeferredTaxLiabilities_79ecb1c9-009f-456a-8f0c-e69e2eb388e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_43682b9b-aae2-4d94-b722-4fc7da096bef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesTable_041841b6-a1cb-4945-bb76-b16fa96ee914" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_43682b9b-aae2-4d94-b722-4fc7da096bef" xlink:to="loc_sgmo_IncomeTaxesTable_041841b6-a1cb-4945-bb76-b16fa96ee914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_1cea14b6-3c7e-4788-aecb-1ad9ec14a912" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesTable_041841b6-a1cb-4945-bb76-b16fa96ee914" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_1cea14b6-3c7e-4788-aecb-1ad9ec14a912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_58107d03-2188-45fd-ad7f-b0d7ff8cce14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_1cea14b6-3c7e-4788-aecb-1ad9ec14a912" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_58107d03-2188-45fd-ad7f-b0d7ff8cce14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_0e69c2b8-d817-4097-896a-de488a75e89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_58107d03-2188-45fd-ad7f-b0d7ff8cce14" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_0e69c2b8-d817-4097-896a-de488a75e89a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesTable_041841b6-a1cb-4945-bb76-b16fa96ee914" xlink:to="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_0213a8a6-fabf-4674-b4fe-ca82b2a5f059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_0213a8a6-fabf-4674-b4fe-ca82b2a5f059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f212432e-a609-4f36-8d0f-82b017bc76ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f212432e-a609-4f36-8d0f-82b017bc76ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_5848dbef-bd5d-4853-85b2-73f0d26cdf91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_b619de26-efc6-45b4-aa2c-dec8be3116c3" xlink:to="loc_us-gaap_DeferredTaxLiabilities_5848dbef-bd5d-4853-85b2-73f0d26cdf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesAdditionalInformationDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e33427cf-0aba-4cd5-b4af-12d18cdea061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesTable_f42680f2-1c36-49d2-898d-23f04ba9cf2b" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e33427cf-0aba-4cd5-b4af-12d18cdea061" xlink:to="loc_sgmo_IncomeTaxesTable_f42680f2-1c36-49d2-898d-23f04ba9cf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_8f7532d0-059b-474f-b746-3f0aef875583" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesTable_f42680f2-1c36-49d2-898d-23f04ba9cf2b" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_8f7532d0-059b-474f-b746-3f0aef875583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_e5324498-ad9c-4720-a24d-393bdca4105d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_8f7532d0-059b-474f-b746-3f0aef875583" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_e5324498-ad9c-4720-a24d-393bdca4105d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_d69ae4a8-759f-4d99-9eef-37fac719e9af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_e5324498-ad9c-4720-a24d-393bdca4105d" xlink:to="loc_us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember_d69ae4a8-759f-4d99-9eef-37fac719e9af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:href="sgmo-20201231.xsd#sgmo_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesTable_f42680f2-1c36-49d2-898d-23f04ba9cf2b" xlink:to="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f25bc1fe-b869-4724-bfdf-e00db091befc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_f25bc1fe-b869-4724-bfdf-e00db091befc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_8b183c8b-66c5-4839-9b4e-ec7da1119811" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_8b183c8b-66c5-4839-9b4e-ec7da1119811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3e36946c-ef5d-4fb6-bcf6-1091f131820a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_3e36946c-ef5d-4fb6-bcf6-1091f131820a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_43ff113a-3666-48ef-872e-e8a4200a8772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_43ff113a-3666-48ef-872e-e8a4200a8772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_e4cfe851-4bdd-4421-8aa3-b02e2565a8a7" xlink:href="sgmo-20201231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_e4cfe851-4bdd-4421-8aa3-b02e2565a8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_c979c06a-6372-4def-b173-1327b1f8c47f" xlink:href="sgmo-20201231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_c979c06a-6372-4def-b173-1327b1f8c47f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_750d5792-e278-49ca-bdfd-215b7cd053b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sgmo_IncomeTaxesLineItems_d7d35ad6-4a25-4cf4-97ee-ae1b5046b600" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_750d5792-e278-49ca-bdfd-215b7cd053b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_310afd13-8c6f-45f2-b04b-f10c6366a76d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3d75128b-8fbe-43f3-bf1d-af6ab3c30011" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_310afd13-8c6f-45f2-b04b-f10c6366a76d" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3d75128b-8fbe-43f3-bf1d-af6ab3c30011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_32db0196-53b5-41f6-9945-8c516fd6179f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3d75128b-8fbe-43f3-bf1d-af6ab3c30011" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_32db0196-53b5-41f6-9945-8c516fd6179f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3640ecee-6d6c-46a3-bba5-df8646c5b668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3d75128b-8fbe-43f3-bf1d-af6ab3c30011" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_3640ecee-6d6c-46a3-bba5-df8646c5b668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_3a555c31-5098-4224-9330-7c4afb7428af" xlink:href="sgmo-20201231.xsd#sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3d75128b-8fbe-43f3-bf1d-af6ab3c30011" xlink:to="loc_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_3a555c31-5098-4224-9330-7c4afb7428af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f66c568a-786f-41ba-a20a-672b44dacfe5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3d75128b-8fbe-43f3-bf1d-af6ab3c30011" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_f66c568a-786f-41ba-a20a-672b44dacfe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_238d75d5-f16e-4392-92ac-0dcf53b59646" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_3d75128b-8fbe-43f3-bf1d-af6ab3c30011" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_238d75d5-f16e-4392-92ac-0dcf53b59646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="simple" xlink:href="sgmo-20201231.xsd#RelatedPartyDisclosures"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_19dba058-0862-4626-8ddc-bc9f9cf65bd5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_10a4dc9e-50db-4570-b62f-aafe571a9264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_19dba058-0862-4626-8ddc-bc9f9cf65bd5" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_10a4dc9e-50db-4570-b62f-aafe571a9264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/RelatedPartyDisclosuresDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#RelatedPartyDisclosuresDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/RelatedPartyDisclosuresDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_68298233-f3f9-4808-8d6c-f6e9aa5f5faf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_68298233-f3f9-4808-8d6c-f6e9aa5f5faf" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_bc87c625-f75e-46ae-bd79-78adc5fb6ba2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:to="loc_srt_CounterpartyNameAxis_bc87c625-f75e-46ae-bd79-78adc5fb6ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5e24490-9b4f-4e88-9c0c-2676358cd434" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_bc87c625-f75e-46ae-bd79-78adc5fb6ba2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5e24490-9b4f-4e88-9c0c-2676358cd434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_FormerExecutiveOfSangamoFranceMember_e1e54b34-186d-40f0-b2aa-b8c94df1805a" xlink:href="sgmo-20201231.xsd#sgmo_FormerExecutiveOfSangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e5e24490-9b4f-4e88-9c0c-2676358cd434" xlink:to="loc_sgmo_FormerExecutiveOfSangamoFranceMember_e1e54b34-186d-40f0-b2aa-b8c94df1805a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_16cfb659-cad7-419b-83c9-5a2fec0baf41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_16cfb659-cad7-419b-83c9-5a2fec0baf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0bd52aa-1f1c-4683-b541-8472a6d17d82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_16cfb659-cad7-419b-83c9-5a2fec0baf41" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0bd52aa-1f1c-4683-b541-8472a6d17d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SangamoFranceMember_4d893347-debc-48fe-a082-08512187871a" xlink:href="sgmo-20201231.xsd#sgmo_SangamoFranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c0bd52aa-1f1c-4683-b541-8472a6d17d82" xlink:to="loc_sgmo_SangamoFranceMember_4d893347-debc-48fe-a082-08512187871a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3daf9865-4594-47cb-a767-331294f9b5fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3daf9865-4594-47cb-a767-331294f9b5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5136600-b715-4630-a4d3-529780fd09dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3daf9865-4594-47cb-a767-331294f9b5fe" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5136600-b715-4630-a4d3-529780fd09dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_33a4ab75-6129-487e-bbcb-c87630e301c6" xlink:href="sgmo-20201231.xsd#sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f5136600-b715-4630-a4d3-529780fd09dc" xlink:to="loc_sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember_33a4ab75-6129-487e-bbcb-c87630e301c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_6dd8d5aa-19cc-4acf-bcbe-76187049837d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_75cc7a13-831a-4a70-8a19-e29bfd4b9d48" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_6dd8d5aa-19cc-4acf-bcbe-76187049837d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_b12773e4-e4d8-4a85-868c-758afeb2fce6" xlink:href="sgmo-20201231.xsd#sgmo_BusinessAcquisitionNumberOfSharesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6dd8d5aa-19cc-4acf-bcbe-76187049837d" xlink:to="loc_sgmo_BusinessAcquisitionNumberOfSharesAcquired_b12773e4-e4d8-4a85-868c-758afeb2fce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_94e22c03-2d9f-4027-97bf-8dffd0665593" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_6dd8d5aa-19cc-4acf-bcbe-76187049837d" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_94e22c03-2d9f-4027-97bf-8dffd0665593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="simple" xlink:href="sgmo-20201231.xsd#QuarterlyFinancialDataUnaudited"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_c482ae33-1e00-44e8-a76f-fee925e926d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1f0bce19-8221-4d4e-bba4-c5242ebbc2a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_c482ae33-1e00-44e8-a76f-fee925e926d8" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_1f0bce19-8221-4d4e-bba4-c5242ebbc2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="simple" xlink:href="sgmo-20201231.xsd#QuarterlyFinancialDataUnauditedTables"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_d81a73b8-ee4b-4c61-b354-bdb0c3e07bbd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_21f13a95-0b41-4683-84bd-c98d7b048028" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_d81a73b8-ee4b-4c61-b354-bdb0c3e07bbd" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_21f13a95-0b41-4683-84bd-c98d7b048028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="simple" xlink:href="sgmo-20201231.xsd#QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bf800eb6-7e8c-4477-bbb6-564f34e2ed41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3c16d25-e231-477b-8a51-743f637c8b68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bf800eb6-7e8c-4477-bbb6-564f34e2ed41" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e3c16d25-e231-477b-8a51-743f637c8b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_41c7c001-caea-498a-82e6-5652937ee2cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bf800eb6-7e8c-4477-bbb6-564f34e2ed41" xlink:to="loc_us-gaap_OperatingExpenses_41c7c001-caea-498a-82e6-5652937ee2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_cdb30a21-a040-4860-87f4-f45c3f718301" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bf800eb6-7e8c-4477-bbb6-564f34e2ed41" xlink:to="loc_us-gaap_ProfitLoss_cdb30a21-a040-4860-87f4-f45c3f718301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1940a503-c913-4d81-80ea-33acf849234b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bf800eb6-7e8c-4477-bbb6-564f34e2ed41" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_1940a503-c913-4d81-80ea-33acf849234b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8cc473fe-6aef-448b-819a-da36111e5e3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bf800eb6-7e8c-4477-bbb6-564f34e2ed41" xlink:to="loc_us-gaap_NetIncomeLoss_8cc473fe-6aef-448b-819a-da36111e5e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_2bbb88bf-fadd-43d1-9696-f0101243cb90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_bf800eb6-7e8c-4477-bbb6-564f34e2ed41" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_2bbb88bf-fadd-43d1-9696-f0101243cb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEvents" xlink:type="simple" xlink:href="sgmo-20201231.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9f5349c8-bffe-4515-8b88-71e441f0ec4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_4e503488-6503-4cd7-bc71-5dd058dba3a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9f5349c8-bffe-4515-8b88-71e441f0ec4e" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_4e503488-6503-4cd7-bc71-5dd058dba3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="sgmo-20201231.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.sangamo.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_95173641-1b45-4b83-8292-230a916e2bb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_4064137c-a53a-42ea-8515-b52e4a76f6ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_95173641-1b45-4b83-8292-230a916e2bb5" xlink:to="loc_us-gaap_SubsequentEventTable_4064137c-a53a-42ea-8515-b52e4a76f6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_11720840-6c54-42a9-84c8-6c0d986d05b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4064137c-a53a-42ea-8515-b52e4a76f6ae" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_11720840-6c54-42a9-84c8-6c0d986d05b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_344a2eb6-afa7-45f7-98f5-ff40b0ea260a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_11720840-6c54-42a9-84c8-6c0d986d05b9" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_344a2eb6-afa7-45f7-98f5-ff40b0ea260a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_804f96a4-71db-40c1-be1e-bf04a504035d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_344a2eb6-afa7-45f7-98f5-ff40b0ea260a" xlink:to="loc_us-gaap_SubsequentEventMember_804f96a4-71db-40c1-be1e-bf04a504035d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_b61f2bb9-0787-40ac-973f-34db0a003634" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4064137c-a53a-42ea-8515-b52e4a76f6ae" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_b61f2bb9-0787-40ac-973f-34db0a003634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce3a092-be2e-4daa-a23b-667c859ea0a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_b61f2bb9-0787-40ac-973f-34db0a003634" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce3a092-be2e-4daa-a23b-667c859ea0a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_AtTheMarketStockOfferingMember_16c2aac8-3c84-4c6f-baae-fff5710dca85" xlink:href="sgmo-20201231.xsd#sgmo_AtTheMarketStockOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_0ce3a092-be2e-4daa-a23b-667c859ea0a3" xlink:to="loc_sgmo_AtTheMarketStockOfferingMember_16c2aac8-3c84-4c6f-baae-fff5710dca85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_4064137c-a53a-42ea-8515-b52e4a76f6ae" xlink:to="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e76027e8-bec9-4fe9-b072-a9d547400e03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_e76027e8-bec9-4fe9-b072-a9d547400e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross_74196c41-9536-47ea-96c9-8e8d2e4c96b7" xlink:href="sgmo-20201231.xsd#sgmo_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:to="loc_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross_74196c41-9536-47ea-96c9-8e8d2e4c96b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d6369842-2c33-4e1b-b3b1-6114a71c7c81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_b6429165-b305-47f8-a1c0-d7a56873c60e" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_d6369842-2c33-4e1b-b3b1-6114a71c7c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>sgmo-20201231_g1.jpg
<TEXT>
begin 644 sgmo-20201231_g1.jpg
M_]C_X  02D9)1@ ! @$ HP"C  #_X@Q824-#7U!23T9)3$4  0$   Q(3&EN
M;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@
M<U)'0@                  ]M8  0    #3+4A0("
M                                             !%C<')T   !4
M #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "
M&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D
M   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M
M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M" QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L
M971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV
M-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                    6%E:(
M     /-1  $    !%LQ865H@                     %A96B        !O
MH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*    ^$
M  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M    %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                  !D97-C         "Y)14,@-C$Y
M-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M     "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M
M('-21T(                             9&5S8P         L4F5F97)E
M;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M    +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR
M+C$                                  '9I97<      !.D_@ 47RX
M$,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P
M       !                         H\    "<VEG(     !#4E0@8W5R
M=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4
M %D 7@!C &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$
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M])5?E<F6-):?EPJ7=9?@F$R8N)DDF9"9_)IHFM6;0INOG!R<B9SWG62=TIY
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M]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4 9
M   !_]L 0P ," @/" \;$10;(QP<%QH@)"8F'" D("4T+R D*"<K*SDK)R@I
M,#(U,C I-SL[.SLW.SL[.SL[.SL[.SL[.SL[_]L 0P$-"PL0#A ;%!LD,B@A
M*#([-#(R,CL[.SL[.SL[.SL[.SL[.SL[0$! 0$ [0$! 0$! 0$! 0$! 0$!
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MQ\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#   !$0(1 #\
M]4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6<^9MSO(/W<XQA1ZTM U->BBBD,**** "BBC- !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#/\0?
M\@^X_P"N$O\ Z :\_P# 'B"TT-IA<,5$@0@[2P^7=D<9/\7IC@_CZ!X@_P"0
M?<?]<)?_ $ UYOX+\+P^)&E\UF41!>$P"2V>Y!Z;?3OUXYI;">YW/_">:1_S
MV_\ (<G_ ,31_P )YI'_ #V_\AR?_$UG_P#"L=/_ +\O_?2?_$4?\*QT_P#O
MR_\ ?2?_ !%'NA=G5Y2[CX.5=>"K$<$=0RG\B#]*\@\6Z*VAWK1ERX<;PS<M
MAB?O>IR#D]^O&<#UVRM5L84A7)$:*HSUPHP/3TKS?XG?\A!/^N"_^AO1'<)&
MS9^ [ZVB5%OG0 ?=0-M!/)Q^\'?V&?2N-M= :[U,V"N,B1TW$=DSDX^@X&>O
M&>]>SUYAHO\ R,[?]=[C^4E";U$T=@+"XT32[@/.\KB.5@[9##]WP 2S'@C/
M7O6)\+[B2?[3O8MEHVY)/+;\GGN<#)[XKJO$'_(.N/\ KA+_ .@&N1^%7_+S
M_P!LO_9Z.C'U-OQKXF?P] JQC]Y-N"D]%VXR<=SR,#IW/3!YZW\"ZAX@'VF\
MF*,PR P+L 23@C*A>N0!TSC /%4]?C6;Q*$8 AIK<$$9!!6/(Q7J!HV0;GF.
MH6NH_#^1&AE+Q/URN$+9Y4KN;!(4<\$C(!X-=R_B&*/3/[0.,>6&P#GYCQLR
M ?XCM)QP>M:$]M'=(4D4,IZA@"..>AIAM[>U@,>U$B"MD8 3!R6R.F.N:3=P
ML>>Z?I&I>.M\\\ICB+948)7(X^5-P& ,C/KZG=B>?X9SVB&6"?=(G*C;LY'/
M#;S@^GOW'6MF?QSI&D 0Q98*6&(4 48/OM!R2>1D'K51?']U>JQMK-W ) ;Y
MF&>V0J'U!(W?CWIZB#X?^)KC5&>UG8N40,K$#.!A2">_48.,GG)Z5T^MZHNB
MVCW+*6" <#C)) '/;D\^W8UY_P##'_D(/_UP;_T-*T/BK_R[?]M?_9*&M1WT
M*=GIFJ^/?WT\FR'<<<';QN^Z@QG&<;B<]LG!%.U'P=>>%(OMEM.S,A&[8FW"
M]23\QR 0,C!&.3P#7;>&XUBTZW"@ >3&>!CDJ"3^).3[UI4<P6.4T36)O%6D
M3H0#,(WCP"!DE/E;'&,YQZ9!QCH,KX;Z]+)*UG*Y8;,IN;IMP"HSSTYQG "G
M Y-=Q::?;V&?)C2/=C.Q0N<=,X ]:\YUZ%_"FN+=#.QY/,R!DX8_O%Y &>3C
MT!'.:%K<&>G5YW!>7'B?Q""CD1V[DC:P(VH0"1C&?,/!Z\'N!76^+-3_ +*T
MZ60'#%=JX;:<OQD'U'WN/3MUK#^&FE""U:Z8?-*Q"G@_*OIW&6SGUP.*2VN#
M.SHS13))%A4LQ "@DDG  '4YI#'T5R'_  L[3_[DO_?*?_%T?\+.T_\ N2_]
M\I_\73Y6*Z.OHKD/^%G:?_<E_P"^4_\ BZN:3X[L]9N5MHTD#/G!8*!P"W9C
MZ>E%F%SHZ***0SR_3D%]XF(DRV+B4C)/_+/<5_+:,#I@8Z5ZA7F.B?\ (SM_
MUWN/Y25Z=52$@J&ZLX;Y=DJ*X!SAU##/K@Y]:FILDBPJ78@!0223@ #J<U(Q
M(XEA4*H "@  #  '08KSS4O$=_XJO?LM@Q6,-D,NY#@  LQ!R%!SCIG(R"V!
M7<:Y(T5C.ZD@K#(00<$$*<'-<;\*XU+7#8&0(P#CG!WY&?? _(52VN)B_P#"
MJ_\ IY_\A?\ V=,T?Q#?>&;[[%?L65V'S.V<9X#AFZH>^>GL00?0:X#XJ1J&
MMVP,D2 G'.!LP,^V3^9H3OH#5CH/'@_XE$W_  #_ -&+7%^$)]3O4:QM2(T+
MEWDQRH9=N,Y[XXQAL]P 2.I\27#W7ASS7.6>*!B>G)9">E5_A? BV<LH'S-+
MM)]E4$?^A&A:(.I0U#X=7%JCW,=P9)4RX^0AB1SPP9CN]..3^=6OAYXDN=0=
MK28E]J%PS$EOO $$GK][CN.G(QCN*\M\*P_V=X@\A"=JR3)R>H4/C.,9Z _6
MA.Z#8[7Q=XE'ARW!7!ED.$!!*\$;B<$= ?7.2.V:Y33O">H>+(OM-U.RAB2@
M<%^&Y)"[E"@\8QU';&,Q_$^1C?1KDX$((&>,EFR<>^!^0KTE(UA4*H "@  #
M  '08HV0;L\ZU'PGJ'A.+[3:SLP4@N$!3A>02NY@P'.<]!VQG'7^%?$2^([;
MS,!70X=0>^.HYS@]L]P1SC-:SQK,I1@"&!!!&00>HQ7G'POG=;R6('Y6BW$>
MZL /_0C1N@V9#XMUJZT[6G9)&Q$4PNYMN"J,5P".&(Y'>K4WA+6M?D%[(Z1N
MV"H9G5E .5  4[<=>N?7YLU5\01K-XE"L 0TUN"",@@K'D8KU"ANUA)7.'\=
M^'F-BERTS,;:-$(;D,2RJ6Z\$YR>N< =LUD^ O#UQ>R"\27RTCD (7.YMI5B
MIQ@;2#ZGZ5U_CS_D$3?]L_\ T8M9_P ,?^0>_P#UW;_T!*+Z#MJ=?1114C*.
MM:M%HMLT\A'RC@$XW-CA1P>OTX'/05R'@K27UJY?5;D Y<[ 0WWLCYAD]%^Z
MO7!]"HJE=ZC_ ,)QJ/D/*(K:+<PYQD)U;YL?,1SS]U<\'!SVUOK.F6L:Q)/$
M%10H'FJ> ,#JU5LA'*^$?^1AO/\ MM_Z.6N^KS7PKJ]K#K=Q,\@5)?-VLWR@
M[I PY.,9 [X].M>E4I @HHJKJCRQ6LK19WB-RN!D[@IQQSGGM2&>>^' OBC7
MGN7)PA:501@X0A4'RGC;D'OG&#G.:],KSGX76F^XFGS]R-5QC^^<YS[;/UKT
M:JEN)$*V<*2F8(H=A@L%&XCC@GJ>@_*LZ_\ %NG:9,T$TNUUQD;'/4 CD*1T
M-:]8]_X3T[4YFGFBW.V,G>XZ  <!@.@I(9Q*QS>/M5\X)^XC9 0Q PF2<<<Y
M;#=,X)QG'->G5YGK6F7/@*X2>UD8Q.>C9(RH^ZV,*<@G'0]<8(S792ZL-2T>
M2[B)4M;R,,$Y#!3D9P#PPZ^V139*9S.K>)+_ ,1WILM/)5 2"RGKM(R^X9VJ
M.V#DCUR%#O\ A57_ $\_^0O_ +.N8\,>(/\ A'+AI]GF;HRN-VWJ5.<X/I73
M_P#"U?\ IV_\B_\ V%-IK8-"'0M<O/"=X+"]),9*@%FX4=%8,<?)QR.WL00?
M1*\>\4^)?^$ED1_*$>Q2.NYCDYY.!P.PQQD^M>LZ=-)<V\<D@VNT:EA@C!(!
M(P>1@TI(:,R'P?8PWQOL$N6+88Y4,>=P&,YSSR2 3P!@8YGQ7&J>(;4@ %C
M3@=3YI&3Z\ #Z"O0:\Z\372W'B.W49S$\"G/J7W\?@P_&A ST6H+FRAO5VRH
MK@'.'4,,^N#GUJ>BI&4]4U:VT:,2SML4MM!P3R03_"#Z&N+\7^*XM=C2QLR7
M,SKDXV@\_*OS 'EL'/ &!R<G'::II-MK,8BG7>H;<!DCD C^$CU-<MK_ (!@
MBB-Q9;HY(AN"@LV=N3QU8-Z8.,@# SFFK"=S<\(Z,VAV"1. ')+/@YY/Z<*
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MX'H1QG@]LZ/PVU:XU".:.9R^QD(+DLWS@@C))X^7CZFNGUBQ_M*TE@P"9(V
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M;:QSG: 21L'0_P#?([D=?KNL1Z%:M<.,XP N0"2>@Y_,]< $X.*NQ1+"H50
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBI&9_P#PC^G_ //O%_WZ3_"C_A']/_Y]XO\ OTG^%:%%%P,__A']/_Y]XO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11FB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "O+]2\7:IXA9K!(PAD<KM4$/CG*DD_]]' Z'.!D5ZA133L)HS/#>C_
M -A626Y(+#)8J,9).?QQTR>P'3I6G112&%%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 8'C70_[:L6VC,D7SK@<G'5>A/(Z =2!4W@_47U338I'R6 *DD-S
MM. <GKD8R1QG/?@;-%.^@"4M%%( HHHH **** "BBB@ HHHH **** "BBB@
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M\Y.,#KG;MQWS^%='12OK<=C&\*:"N@V:H0!(X!D/?/IG)^[G'''4]S6S112
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1BCZC2\_O#ZY5[G/?\(VW]ZC_A&V_O5T.*,4?4:7G]X?7*O<Y[_A&V_O4?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !111F@ HS11B@ HHHH **** "BBB@ HHHH ****
M "C-%(: %HI <TM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !10** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ,T48HH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=P/2L/Q%HPTG2+&Y@)7G>QW'=OE1&!&.F-F.V..IR: /5I)%A4NQ 50223@
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MW9&W&,YSTQCG-06FK6E^VR&:.1@,X1U8X]< GUKSWQ%/I]OJ,&ER9CL[7+,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH \G\2:;>6^K3:? 3MOW1\$!LY8MDD D!6W>^!SD5VGC6R$.A2PQ*=L:1@
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MTNCSA02<(>!GA74D_@!D^U=!10!P:>'YK[PLL#1D2Q;W56#!LK(Y^[C))4D
M8YR/K3?AY:3ZM<RZK= LS *C$* >-K$  = H7(P.6')SCOJ* .'TCP_<7)U5
M)(]HN9'$9D& 2#(0W0G +*0<?3D5F:7K]EX;LQI^HVC;T=FP8T8-DD!_F(SW
M4$9&!P>P]+HH Y#0KK5-7LKF0Q^4DD.+9$VICY7 P1@C^'!.!W7 KFO#NOZ9
MX;B$-W:,+B-]Q8QJ6YP5/SE2N!C ''&[J37JE% 'G_A$W$GB">6>'R&EMRX3
M&.&:/!]R?XC_ 'LY .0&CQ@=/4V>MVYD=2&4[(W!!SSC(7CD K[@X(.?0J*
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M]2TXHI(6=B3V&THYYZ?=5B!U.#BL[QK<RZ%K-MJ)0F)4"$XSU+[AU'.ULC.
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MW,_V:-I-I;8I.$&6.!G '<GM7#^!/#(ODDU"]C#O<,2HD0$8)W%\=/F)XX&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBL#7M=NK.ZCM+5%>1U+$/TQSC!W+_=.<^V* -^
MBLK3[J]2%YKT(@49PF20%SNSRPZ $8)JM9^-+&]G$(+ EL*2O!).!C!)Y]P/
M?% &]161JGBFSTB80R$ECC.T9VY[GG\<#)QVY&8M*\66^JW$D2@JL:E@[' (
M& 2<XQUX]NN.E &Y16-9^+;"^F\E'.20%+ @,2.@S^7.,GIFM(7T'F^3O7?_
M '=PW=,],YZ<_2@">BN>\3ZQ/H<T$JDF)F(<;01QCH< AB"<<XX^N3QAK$^F
M)$EN2))7XPH;( P1@@\DL,<4 =#17*#QPQM3<F#Y1*$'[SJ2I8_P]L#MSGVJ
M_%XF+WZ6+1%6*@L2P.#LWD<#G'3.1]/4 W**J:CJUMI*AIG"[C@<$D_@ 346
ME:_::SQ"V6"@E2"",_7KCOC(_,4 :%%9"^+-.9W3S1\BY)/0X)! /<_3KGC/
M.*^D^+;?4D<LZ1%9./,.,KG(/)'..#@G!YZ$"@#?HJ.&XCN%#HP93T*D$<<=
M17/ZMXP@TJ5E4F5@ -B\ $$YR_N". #@K@XS0!TE%8GAWQ-'KJ%2-LB %AQ@
M]LCG./7TR!D]:U8;J.=W16!:,@,.XR,C\Q_G@T 345E7>LNM\EI"@<X#2'<!
MM4G'KU&0<>G3KD8B:OJWB$O)9A8XD+ ;MI8D '!SNYYR. !G!)ZT =A17.-X
MFN-/M!-=0E6$_ED#CC!.X9SGTZX/7-;<.HVUPK,DB,$&6*L" /4X/'2@"Q16
M-)XPTR-BIE'!QPKD<>X4@_A5K3M=M-58K"X8J,D8(./7D#- %^BLB;Q;IL#%
M3,,C^Z&8?FH(_6K%AK=KJF?)D#$=N0>W.#@XYZ]* +]%9,'BFPN;C[.L@+$X
M!P=I// /3M]#D8)I=3\3V>DR"*1CN)&0HS@'N?\ #KTXH U:*HRZW:0VXN6D
M'EMC!Y.<]L#G/J,9&#GH:BLO$-K>VK70)5$)#;Q@@C''&<YR,8SG..O% &G1
M6-9^+;"^G\E'.20%+ @,2.@S^7.,GIFI&U2.Q#RS2KL5]O!W8/\ =P,G/MU%
M &K169HFOP:XK&+<"A&0XP>>AX)'8]^U6M0O5T^!YFQ\BDX)QDCH,^YXH LT
M5E>'-=77;??@*ZG# 'OZCO@]L^XYQFEA\3Z?<3"%906+8'#8)]FQ@Y[<\]J
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD*+ZY(!"]>^<L"!Q@#KS7=4R*!(,[5"[F+'  R3U)QW/K0!YI_S _P#M\_\
M:5=19P?\5#,S+_RQ#*2/9%R/U&1[BND\A,;=HQNW8P,9SNS]<\Y]>:4H"P;
MR 0#WP<9'XX'Y4 <=\1T8K V#@%P3VR=N!^.#^5<I%#*'E%NS,JJVXKE<ID
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW_5#_>_H: +]M(98U8]2 ?SJ2H+'_4I_NC^53T %%%% !1110 4444 %%%%
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M *>M.J/!IQ!H =3&^]0 :1L[J ),YHIN#2 &@!33J80:,-0 ^HSUI<-3<'-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ -9>C=6_#^M:AK+T;JWX?UH TBU.S32M.Q0 9IDO3\:?B
MF2]/QH ?FC-&*,4 -)YIV:0CFEQ0 F::QYI^*8P^:@!Q-+F@B@B@!I:G9I-M
M+B@ S49;FI,5&5YH DS1FC%(5H 0GFG9INWFG8H 0FFH>:>13%7F@!^:,T8H
MQ0 U3S3LTU1S3L4 &:C1JDQ3$6@!^:0FEQ2$4 "FES2**7% ",>*1#Q2L.*1
M!0 [-(QXI<4A%  #2YI *7% #9#Q0K42#BA5H =FD)I<4A%  #Q2YI .*7%
M#'-.4\4CBE4<4 +FFL:=BFLM "@TN:0"EQ0 QFYI],=>:?B@ S36/-.Q32.:
M '9HS1BC% #&/-/S3&7FG@4 &::#S3L4@7F@!<T9HQ1B@",-S4F:8J\T_% !
MFF@T[%-"T .S1FC%&* (U:I,TQ5I^* $)H!H(H"T +FD)H(HQQ0 B'BG9IJ
M8IQ% #2: 12X%(* ZAFN>UW6)()/*C.#W-=#C KG?$&EF20.GWFJ*M[.QT8/
MD]I[VPW1=9EDE$;G=GO72@@US.AZ88Y\R<%>:Z;%%.]M2L;[/VGN[",<4H(H
M8<48%6<HN::YXIV!37'% "@TN:0 4N!0 UB*=FFL*=@4 &:9(W2GX%1R#D4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M4 )2T&B@ II^]3J:?O4 .HHHH ::=333J "F_P 5.IO\5 #J*** $%+2"EH
M*8G4T^F)U- #Z**0T %+2"EH #34IQIJ4 .I#2TAH %I:1:6@!&Z4B=*5NE(
MG2@!U(>E+2'I0 "EI!2T -?I3J:].% !69KO^J'^\/Y&M.LS7O\ 5K_O?T-
M%RQ_U*?[H_E4]06/^I3_ '1_*IZ "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTT_>J2@!NVDV\T^F]Z #%&*6B@!@7YJ=MIJ_>-/H 0#%(%IU(M !MHVTZDH
M8B]:=MI(^].H :4H5:=2+0 ;:,4M% #$7BG;:1.E.H @NI/)C)]J@TR#RX]W
M=N34=\_VB181ZY/TK010HQ2+^&-@VT,O%.I&Z4S-(1%XHVTJ4M QCQA@0>]4
M=.;R6,)_AY'TK0-9U^#;R+,/7!^E)E1U5C0Q377BG*P89I'ID^0H7BEVT"EH
M :RTH6AJ&.!0!0O3YTBQ#UR:FOD'DD>@J*T'G2M+^ JS<C,;?[IJ31Z-(Q]0
MU9K&W4+]YJHZ?K\ZRA9#D&K5_IC:A K)U6L_2]*>ZF^;@(>:RDY<QWTHT'2D
MWN=>#GGUIV,TT+M 'I3ZW/,$Q3&'S5)33]Z@!<4F*=10 W%+MHI: $VTW'S?
MA3Z;_%0 N*,4M% #0M*10*6@! ,&F(,DU)3$ZF@!VVDQ3J* &XI<44M "$4U
M!3S34H 7%(1BG4AH 0"EVT+2T -*\4*.*4]*%Z4 &VD(IU(>E ""C%**6@!D
M@XI=M#]*=0 FVLW7/]4/]X?R-:=9FN_ZH?[P_D: +EC_ *E/]T?RJ>H+'_4I
M_NC^53T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MAI:2@#A_%%F)=9A\\%HG0J,= >U<LHAM6,7ED7$=P=G'5<UVWBG7;A+N*QMH
MPTC@MEN@QWJM#8:TUTLTL<1((RV.<4 =E"Q9 3UP*<:!G'-<A>WM\NJ(KG;$
M3P!UH Z\L!1D8ZUQ7B*]F_M'RR76(*.5IT]W)J4D=I!+\@7=N[F@#M!65HOW
MF^@JGX;U=Y;>02_,820<=\5<T;@M^% &HW2E%,9^*7S* 'U'+2^93)'R/QH
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M*2F^91YE "'[U25"7^:G^90 ^F]Z3S*;OYH DHIGF4OF"@ 7[QIU1!^:?YE
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MIK?>HS32^&H DHIOF4GF4 .I:9YOM2^90 ZF_P 5'F4W/S_A0!)13?,Q1YE
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MP*,"EHH 3BC;12T (PIJ8IYIJ4 +Q00*6D-   *,"A:6@!K 8H4 "E/2A>E
M!@4$"EI#TH !BCB@4M #7Q2C%(_2G"@!.*S==_U:_P"]_0UIUF:]_JA_O?T-
M %RQ_P!2G^Z/Y5/4-E_J4_W5_E4U !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ.IIP'-,4<F@"2BFX-!!H 6EIH%&#0 XTU*&%-04 24AHQ01Q0 +2TT"C!H
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M.AJ2J$0^PR[3]UNGUJ_2!K4;_%3ZB:55<+GDU+2YDQ!33UIU5;R[6T&3R3T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[<_E5#4KR.&..0GD8(K5G3S$(]0:XS4RY<;N@&!6-27+(Z<)352:3-X:H-2
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M9QWZ=#CN\4M '#Z1J#>&V=9HVS(JD#ITSCKV.>?3&,9Z;/A:*1C-<,NT3."
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M S6;KO\ JA_O#^1K3K,UW_5#_>_H: +EC_J4_P!T?RJ>H+'_ %*?[H_E4]
M:Y[4O$YADV0@,!U)R03[8(_/O_/?EC692C<A@0?H:XN^T6>VE*JC,N>" 6X[
M=!U]?\*RK2DEH=>"ITIR?,=+HVJ_VHA)&&7&0/<=?QYXYK0K$\/:0]GF:3AF
M& OH.#S[\?A_+;%73;<5?<RQ$8*HU'8SK/7$N[EK8HZ,N?O#L .N"<=>.QXY
MY K2K+T:Q>%I)YEQ)*Y/7<0O9<]./;MCTP-2J,0HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "H+Q)7B81G#$<$]*GI* .2UD7<9B17A67!R74<_C2V5AKHD
M#M)$5SSM6I_&"Z2X7[:,G^';G=^E<]HRZJUTOV$.EN#SY_I[4 >C+TI::N<#
M/XUG3^(+>WN5MLY=_2@#4HK&U3Q/;Z7,(F!)[X[9IVH^);;3XT?);S.@7F@#
M6K*T7JWT%7-/U"/4HA*AR#5/1R 7)]!_6@#4;I2U UW#C[Z_F*<+R'^^/S%
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M;\S_ (U!+\*;L2!/M3'/N?\ &O1X]6CDN3!GD#- &^Z^@K&$XSV-XJ]SS_\
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M38'DZ_"W4V_BB_[Z;_XFG?\ "J]3_O1?]]-_\17K5,?K5H#R?_A5>I_WHO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNVFNO% #UZ49IH6EVT #&ES366EVT +36HVFD:@!]%-P31M- "FEIN,4I&:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %)2TR7)4A>N.,T <?XHMIM-U*+4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *3'-+10!P_BF;[/K%NUQGR
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MXT#X(R*MTTIFDAJQQ7BOQ=JVF7"I9V_FQF,$DQR/\VY@1E6 Z 5C#Q]XE/\
MRY#_ +\3_P#Q=>D26@D''%4IK:2 _+TJDDQJ*97\+:Q>:I9B6\A\F3<PQ@C(
M'0[6R5],'TST(J?Q%J=Q86,DUHGFRKMVKM9\Y8 \*03@$FH_M_.UE/X5+;7B
MQ9P#SZT.G;4;IZ7.'_X3GQ3_ ,^/_DO/_P#%5L>%?%&NZI>"*[M/+B*L2_ER
M1XQT^^2#D\8'/.>@-=0=2]!2?VB3_":FQ/*7-V*X?Q-XMUW2[Z2&VM?,B7;M
M;R96SE03RK '!)%=6=0_V#^513WA<CY2*:B/E.$_X3OQ./\ EQ'_ (#S_P#Q
M5=]H-]/J%G'+<1^5(RY9?3^HR.<'D9P>15<Z@QXVU+%<RGHM4Z8W315\8:Q?
MZ1:K)91><YD"E=CO\I5B3A"#U YZ<UR'_"<^*/\ GQ_\EY__ (JN^WW#?PXI
M?](]14\GF+D\S!\&^(=7UB61;VV\E54$-L>/G/3#DDY'.1TQSU%=%+=%)-N.
M,4SRK@]Q5>5)-^TL.E-10U%'"KX[\3GI8C_P'G_^*J>U\;>)Y954V&06 /[F
M5.I_O,Q"_4\#J:Z_S9;%<D[A[5?M+M;A1CJ:'&PG"Q9W5S/C/7=4T;ROL,'G
M;]^_]V\F,;<?<(QG)Z^E=,,&A:@@\S_X3GQ3_P ^/_DO/_\ %5UG@W6=3UF*
M1KZW\DJP"G:R9R.?E<D\>O0YP.AKHJ#0!2U"XEMK266)=TB1N57!.6"D@8')
MR>PYKS[_ (3GQ3_SX_\ DO/_ /%5Z7&.*?0!P&A^+_$5]>1Q3V6V-VPQ\J6/
M [G<[$<=<=^@Y(KOLTM- H X?Q)XKU[3;Z2&UM/,B7;M;R97SE03RK '!)%9
M?_"<^*/^?#_R7G_^*KTZ@]* *&A7EQ?64<MQ'Y4KKED]/ZC(YP>1G!Y%1>)+
M^ZTZPDFM8_,E7;M7:SYRR@\*03@$FM->12@8H \Q_P"$Y\4_\^/_ )+S_P#Q
M5;'A7Q1KNJ7@BN[3RXBK$OY<D>,=/OD@Y/&!SSGH#7:FCK0 BMDUY[JOC+Q'
M;74L45ENC21U5O(F.5#$ Y#8.1W'%>AX H;@4 >9?\)SXI_Y\?\ R7G_ /BJ
M](MIGEB1I%V,R@LN0V"1R,C@X/&>]2CI28H P_&&K7^D6JR647G2&0*5V._R
ME6).$(/4#GIS7'_\)SXI_P"?'_R7G_\ BJ],/%.H Y+P=XAUC699%O;;R550
M0VQX^<],.23D<Y'3'/45U3&GTQQS0!YI_P )SXH_Y\?_ "7G_P#BJEM?&WB>
M65%:PR"P!_<S)U/]YF(7ZG@=37I(HH :37(>,/$FLZ/=+'96WG1F,,6\J1_F
M+,",H0.@''7FNO84X4 >8_\ "<^*?^?'_P EY_\ XJNS\+:I>ZK9B6\A\F3<
MPQ@KD#H=K9*^F#UQGH16W3"* *^IW$MK:RR1+ND2-V5<$Y8*2!@<G)[#FO/?
M^$Y\4_\ /C_Y+S__ !5>F 4M ' :'XO\17UY'%/9;8W;#'RI8\#N=SL1QUQW
MZ#DBN^S11@4 <+XE\5Z]IM])#:VGF1+MVMY,KYRH)Y5@#@DBLS_A./%'_/A_
MY+S_ /Q5>G4PDYH IZ'>7%]9QRW$?E2NN63T_J,CG!Y&<'D50\7ZM?Z1:++9
M1>=(90I78[_*58DX0@]0.>G-;V*3I0!YE_PG/BG_ )\?_)>?_P"*KH?!WB'6
M-8ED6]MO)55!#;'CYSTPY).1SD=,<]1769I#S0 F0:\]U3QEXCMKJ6**RW1I
M(ZJWD3'*AB <AL'([CBO0\"A3S0!YBWC3Q,W6P'_ (#S_P#Q5>@V]ND\2O(F
MQV4%ER&P2.1D<'!XSWJ[WH(H'<X[QO+JFDPQG3D=BSG<442$ #@;2K<'U[8Q
MWKD/^$A\8C^&?_P%'_QJO8%XI<T"O<Y/P?K>L7\+F^AV;-BJ2C1LQP=Q()^G
M( &2<=,#>CU$%MK*<U>I !2'<\Q/COQ./^7'_P EY_\ XJI+;QYXDDE56L@0
M6 (\J5.I_O,Q"_4\#J:])>/=5:6QWT78TD6@P->?ZGXOOEN9!%( @<A=JJ1@
M' .2#G/7K]*W/%%E<"P?8<@$%AU^4'Z'H<$^P-<&CM&P9200<@C@Y'>HG)G3
MAZ46F]S>@U_6KQ=T9=P#C*Q*1GTX2NVT>6XEM8VG&)".1C'?CCL2,$CU[#I2
MV%R[P1^9]\HI;(P<D#/';FK8YZU:5C&K)2TLD9/B>YO+>W5K4,7\P [5WG&&
M[8/?%<Q_:NO_ -V3_OR/_B*[X=:4FDU<5.JHJUDSF?"]_J=Q,R72MMV9!:/9
MR"!C. .0?T^M=+F@<T8%-*Q,Y<SO:QYE_P )SXH_Y\?_ "7G_P#BJEM?&WB>
M25%-AD%@"/)E3J?[S,0OU/ ZFO2&.* :9(9K,UTYC'^]_0UI@5F:Z,1K_O?T
M- %VQ_U*?[H_E4]06/\ J4_W1_*IZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI_NC^53U!8_ZE/\ ='\JGH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_A4E-_BH 6D-.HH C%/H I: $[TQ.IJ2F(>30 Z@TM% #:6BEH 8U"4\TU*
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M7\(EZ9H,:.*IUFU%EL49HSBF2/MYIHZ!MQ*(QSZU*&S65J.H"% 6'>K<5WN
M('453AI<S55<UBV#2$4!LC-!(J#04"BC-)N% "/3J8Q!IV10 M-/6ER*0]:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %96B_>;Z"M6LK1NK?04 :;=*<*8S<4X$T +3)>E.R:9*>*
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MRD.!Z]:DM=>MKV9H4/S)UZ=OQI+37K:\F:%&RR=>1_C5*;]3-TETT!-95.)
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MHAUZVGMC<@_(._'^-278T*#S6=%X@M9K8W0;Y!WR/\:/[>MOLWVG/R>O'^-
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "LK5/$MKI,@C?+-C)" ''IG)'7_/
M:M6N*U"86-_=><2/-@<+P3G<%V]%'ICVQ@DGD@'86]S'>()(SN5AD$5SI\/6
M?B#Y;E=PCY')'6IO"EO,FGD-D;F)7/\ =(';L"<G]>]7-'ZM^']: &:KX6L-
M9CC29,K%C;R1C%+JOA:QUI8UG3<(L;>2,8K4*&C:: ,O5?"MAK3QO.FXPXV\
MD=*36/"]AK+1O.FXQ$;<$CI6KM(I'&.: .5\6>&HM5F6=D+-&.#DC_\ 76/)
MX;35I5=XV+)C!Y'2O0R*390SHIXGD@X6NF<C+\.[6\997SN'H:N6W@2Q2=;F
M0;G3H22.GM71$-2[#0<:HP3N9ESX7L;R\6]=,RIT.3V]J;=>%K"[O!>NF95Q
M@Y/\JU<$4UEYXH-#/E\-64U\+YD_?   Y/;VIK^%K&2^%^4_?#^+)_ETK4"F
MC8: ,Q?#%DE\;\)^^;^+)_E2)X5L(KW[<$Q+ZY/\JTRC&EVF@#,@\,6-O>F^
M5,3-G)R3U]J;:>%K&QO&O(TQ*^<G)[^U:NTTPJ2: ,ZR\+6%A=M>1IB5LY.3
MWZT:?X6L=*N7NHDVR2=3DGK6IM-&PT 9>G>%['2;B2XB3:\PPQR3G//X4:5X
M5L-&F>:!-K29W')/6M/8:78: ,O3/"MCI$LDL*;6F^]R3FC2/"]AHID,";?-
MSNY)ZUJ;2*0 DT 9FE^%['1_,$*;?-)W<DYS2Z7X7L=%6184VB7.[DG.:T]I
MHVM0!E:5X7L-'21(4VB7.[DG.:73/"UCI%N]M"F$D^\,DYS6IM:C:30!E:;X
M3L-)AD@A3"2YW#).<\4:?X6L-.M7M(DQ')G<,DY_&M4J335!H S+/PG865H]
MFD>(I?O#).?QI;;PI86EHUFB?NGZC)K4VFC8: ,FW\)V%M9M9*G[I^JY-*OA
M.P2Q-B$_<DY*Y/?WK5V&C:: ,L>%[%;(V(3]SZ9/\Z:WA.P>P%@4_<CMD_7K
M6MM.*1%(% &9+X6L9;$6!3]R/X<G^=%QX5L+JS6R=,Q)P!D]O>M3::"K4 9=
MUX6L;RT6R=,Q+T&2/UI+WPI8:A:)9R)F./&T9(QCWK4"L*4@T 9>H^%K#5+=
M+:5,I&!M&2,8I+_PK8:I;);2IE(_NC)&*U&4D4!6- &9JGA6PUB%(9DRL6-H
MR1C%1:MX1LM76-9 <1 !<''3I6SM-(4- &1J_A2SUA8Q*"?*^[@TFJ>$;/5_
M*\P']Q]W!(_E6RJL* A% &-JWA2TUIXVD!S%C;@XZ4NI^%+35I$ED!)B "\D
M=/I6NR&EV$T 8VI>$;/5IHY9 <QXQSCI2ZGX4L]4N4N9,[X\8P?2M@(12>7B
M@#'O_"-IJ%VMXX)D3&#N(Z>PXI;_ ,*VE_=I=."7B((YXXK8,9-&P]* ,:X\
M)6ES>K>L#Y@]^/RZ4LWA.TGOA?$'S%&.IQ6NR$4NQO6@#'?PC9R7@O"")![\
M4'PK:-?F^P?,/OQ^72M?RS04)H R(?"UI'?&_ (D^O%)%X1LX;PWH!\S/J:V
M-A-+L- &/:^%K2VOGOESYDG7GBBS\*6=A>->H#YC @\YZUK%"33]I% &+IOA
M*TTRX>X0'=(3G))ZTFG^$K/2;I[F-3ODSGG-;(0BD )- &3IWA2STN:2>,'=
M+G.3GK3=+\)6>CR/)$IS)G.3ZUM!"*01FBX&'I?A.ST>:26,',PPV?0U+I/A
M.TT4N8@?WN<\YZ_6M94.:7RC0V*R,;3/"-GI"R+&#^^^]S2Z1X2L]&218@0)
M00V3GK]:V=AIH0T#,?2_"5EI,4D48.V7.<GUI=,\)6>E6[V\8(60DGGUK9*$
MT '- &-IWA.TTZWDMXP=DF0><]:73_"=IIUJUH@.Q^N36J$/..].V&@#%M/"
M%G8V;V: A'.3DY_^O3K;PG9V]D;( ^6W7DYK8*M1Y;'K0!BV_@^SM;)K$!O+
M;KSS^=.7PE:"Q^PX(C^O/YUL[#2&,T 8G_"'V4EC]BP?+],_UZU)+X2LY[,6
M14B-??FM94-.V&@#'G\)6<]B+$J?+'OS3;KPA9WMHMFP.R/IS_7K6UL- 0XQ
M0!C7OA.TO[1;1P=B=!G^O6FZCX1LM1M4M)%.V/[N#Z5M[#05P,4 8^H^$[/4
M[=+=P=L>,8/I46J>$;75A''("5B QSCI]*W%4XXI=AIW%**9B:QX2M-9@2!P
M<1XQ@^E.U/PI::ND:R@_NL8P<=/I6P4;&*-A-(:2,?5?"=IK)B\U2?)^[@X_
ME2:KX3LM5,9E4DQ8VX/I6SY9)S2,I6@#(U;PG::W)')*#F+&,''2C4?"5GJL
M\<\@.Z(87G'3Z5L!"12F,F@#&U3PE9ZK,D\@.Z+I@^E+J'A6TU*Z2ZD!\R/&
M,=.*UBC"G;&]: ,>^\)6E_=K=N#O3I3;WPK9WEZMVX.]>F,X_P *VMC>M(P(
MH QIO"=I=7POF4^8OH>/RITGA.TDOA?$'S%]_P"G2MC832>6: ,<>$K,7QOM
MI\P^_%.7PG:+J']H8/F8QUXK6*M2[#0!C6_A2TM[TWJJ1(?<T6_A.SM+QKM0
MV]\YYXK9VD4TJ<X% &39^%+2PNWO%!WR=>?Z=*++PI:6-TUT@.]NO-:XC(I=
MA H QM/\)V>F7,EQ&&#2YW<^M+IOA6TTJY>YC!WOUR<_SK7V$TNPT 8^D^%;
M329I)8@=TF<Y)[TS2O"-GH\DDL0.9<[N<]>O6MO:U-VD-0!DZ1X3M-%$@B!_
M>YSDGO2:5X2L]'\SRP?WN<\^M;.PT;2* ,;2_"5II*2QQ@[9OO<D_P Z-+\)
M6>CQ20Q [9,[LG/6MC8<_6EV&@#%TWPC9Z7#) @.V7ELFETSPK::7;R6T8.R
M3KDG_&MD(P%(JL* ,:R\)6=A9O:*#Y<G49YY]Z6T\)6EA9M9J#L;KSS6SM:D
M$96@#&B\(6<-BUB ?+8Y.2>_OUIR>$[2*R-D ?+/7G^O6M8+VIVPT 8P\)6:
MV/V$ ^6/<YH/A2TDL19<F,>_/Y]:V=AIH0T 8\GA"TELOL)!\L>_]>M.N?"E
MI=V8LV!*)TYK7\LT,A- &+=^#K.^LUM'!V(>.:??^$[/4+5;5P=B=,$YXK7"
M&EV&@#&O_"5GJ5JEJX.R(Y'.#^E&H^$K/58$AD!VQ=!G'\JV&4XH"EN: ,?4
M_"5IJL<<4@.V+&.<=*35?"%EK$<22AL0XVX/I6R8R:"A H R-6\)6>LJBR G
MRL8P?2C5O"EIK31O*#F$8'..GTK7"&CRR: ,C5_"EIJ_EM*#^Y((P?2C4_"M
MIJTJ32 [H\8YQ_*M=T-+M8T 9=YX;M;VYCN'!WQCY<&I->XC7_>_H:T-K>M9
MVN_ZI?\ >_H: +UE_J4_W1_*IJ@L?]2G^Z/Y5/0 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU(1DT +111F@!AZT^FGK3J "DI<XI,T +1103B@"->M24P#!-/H *0"EI :
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MI[X'?'L.,YJ'1_$45ZHCF94FR05P5YW8 ^;OTXSF@"7^Q9#_ ,M6I/[#<_\
M+5JU0:6@#)_L-O\ GJU+_8C?\]6K5HH Q+K19A&=DK9I+/1IS'\\K9J37->.
MFLL,2&25P2% /3GG@9/(Z#L#R.*?H7B"+6U./E=>JDYX]0>,C^1_#( ?V(__
M #U:D.B/_P ]6K6HH R?[#D_YZM2_P!B-_SU:M6@\4 8-_H\XCS'*V:E@T20
MK\TS4FOZ\VB20_*"KEMWKQCISCOWZ^W6M&SOH+Y<Q.&X!X/(STR.H_&@"D-$
M?_GJU(=!8]9"?KS6N** &01^2BK_ '0!^5/HHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ KF]8TNZL;C[;9@9(^=0!SSDG!ZYQSC!STR2:Z2B@#FO"-I/%+/*T9B21AA
M2N#U)P.G !QTY[8P172T44 %%%% !7'^)=!GN[[=$A83*,L?NJ5P">.GR@=<
MYR<9.,=A10!FZ!ITVF6_EROO;/J2 ,  #/;CT'6M*BB@ HHHH 1T612K $$8
M(/(YKA]9\-'39B8HFE216P &)4]CD>A/&>HR#ZUW-% &5X;TV72[41RG+$DX
MZA<X^7^O'&2?J=6BB@ HHHH XZ?Q"%NI+:]3?&)B5)'*@'Y>,<C&/<@G[P.*
M/$J7,VH0R6P8DQ*59.1]X]^F/F&<\8//!KI]0T^+4XC%(,@_F#ZCW_STI-+L
MFTZW6$L7V C)&.YQW/0<4 /L(YHH569M[XY(  _3'3I[]:L444 %1W4I@B9P
MNXJI( ZG SCOUJ2@T <+#KL6N0?9;PX8ME9   #SC<.!WQZ8/.,9J!=#NT(M
MA"1(LNX3 D+C [XZ<9!SD= ,UV.L:/%K,6Q^"/NL.H/^'J._UP1=AC\E%3).
MT 98Y)P.I/K0 \4444 %97B/49=-MP8AEW<(O?!(/..YXX'KZ]*U:* .+DAO
M+^86ET^)MHDB8;>",Y7*KGG')SP5!&>,D45[?WT#/"T<D;8>3! 8+]!CH".N
M#G'3%3>(?#%QJ5[YD0&UU&69@ "!C&!ST ['D_EU5M MK$L2YPBA1GKP,4 2
M"BBB@ K&\1ZA<V@BB@P&F<+O(R!R,#H1SG\@>/39HH Y VEYJ]M-9S'=+;.C
M*<C!RIP,X],G)YR1G&#5GP]X5ETV1+AY,'!W(!QR.A;/..#TQD?C46H^%IM5
MU%Y6.V(E.<\G"@' Y[C'/UYKJZ "BBB@ KGM>NKV:[CM+9MA*;RW;@\9^4D#
M*_0YP:Z&B@#@FL)/$-D;M5W3HY#8/W@ .B@8R!@ #K@]216EX5TR:.ZDN#$8
M4*E0K;L\E3_%R>G)]>GH*^E>%+J"Z4R'$<4FX<CG'0@#=C.T9S@XKLP<T  H
MHHH *YK7[_5$E?[.I6.%<EL+SD9)^;KCI@?CU KI:9-OV-LQNP<;LXSCC..<
M9H XJ]O+;6;1;>U39(90WEX/)(.2"!C SW(P!V  KI-!@OH(]MTP;A=N.6''
M()Q@_7GOR:JZ'I-TEP][<$!Y 1M ' RN.0<=%Z<\=3G-;U !1110 5RE[KM_
M'+)<(!Y$$OEE>,G!P3G&>X^F1P<&NKJMJ+SQP,8%#2#& W3J,]QVSWH X:VA
MC\YYH(#/"P*E#RZ[OIDCIPW/'&=V<=3X3LI[&S"RY!+%@">0"!QCMSDX]^><
MT>&])FT]9))CF29@QP>/7L!SDG...F*V: "BBB@ KD]7U[RM0:UG -O@*PVY
M/*AMV>N03V[=!GFNLKG=9\*?VK=K,&VJP&_KGCH1U'(X[8QGF@##D^U/9FWC
MB,L#.QB<+EAM?KP.,\]0#R>W%=AHMO-:VD<<OWU7!QCMT''H,#_'K2Z7I<6D
M1>5'G&226.22?R'05=H **** "N/C\4F"]FAN3NBWLH^4'&&QSTR,=>IKL*Y
MN_\ "7]IWKSR/A&VX"_>X4#J1@<CWS[4 9&C>%9]1C69G\K&-F%^8\D[N"IZ
M]#U_#%=V*KV%E'IT*PIG:H[\GGDG\35B@ HHHH CN5D:)A&0'*G:3T!QP>A[
MUPJZ[%K,7D7O!&2LJCD'ME0.G8XZ\<9^8=\:Y*#P&GFMOD/E_P .W ;\<@CC
MVZ]>.E &1:Z#=S2)$(6C9'.Z3D<9&#R0"5YQM/(^F:]#Q3885MT5%&%4  >P
M&!3Z "BBB@#'\4W\^G6OF0\'> 3C. <\^G7 Y]?6L;1?$=C:D>8&WE &E?YB
M3R2#C)QT /4C /W1767-M'=H8Y!N5A@@UAZAX>FOBEN"B6T9! 7._I[@C.2>
M<]\G)H R/"2:@641Y6 ON8E5P?4 GDYVXXZ5W H%% !1110!S_C'4Y]/A019
M7>2"P[<=.G!.<@Y!XXKE-6OH]5>,1H2X55+'[SG  ) SSG/<DUZ+=VD=]&8I
M!E6QD9(Z'/;!ZBLB30[B\NXY)618H#F-8P0>"",Y&!P!G''& !G- &;X<TRX
M>^-R8S F#E>0"2 ",$@XR=PX(&,=JZ[%+10 4444 8/BO5KC2X@81C<0"YP<
M=3@ ]SCJ1C'OTYB37B)$ND)$^,2<#8P' [^@&1@#/(P1SW>HV*ZC \+='&,^
MAZ@]1T/-<_9^%;N.6(22J8[=]R #G[P;!X&,X]3CM0 SPW;7,FH27+1&)60[
MMP;DM@G&X@\D$]\#CT-=;24HH **** .:U+7I8K\P[Q'' NYLX)?@-M&>YS@
M $=SGH*R;@KXIO2MN-H=%+EU4D;3C(Y)'&!@$9[\<UT&OZ ^I2)/"P26/&-P
M)!P01ZXQSV.>]&BZ+/:SO=7#AY'&WY>F..>@YX';\\\ %K0]*;1X/*+[QN)'
M&,9QQC)[\_C6C110 4&BB@#BKGQ*[W,@D/\ HX8H8\ .0589Y"MU&3R",@5E
M""*>60V\+RH4.T?-E">A.T'.,' R<C&3G-=+J_A22>Y^U6[A7W!L,.,COD ]
MP.".3DY[5>T'1Y-,$DDK;I)FRV.G4].!ZG/Y8XY )_#]E)I]G'%)]Y0<X.>K
M$X_6M"BB@ JO?W+6<+2*C.5'"J,DYX__ %^U6** .+LHI[W4$^WHQ\U6:-3]
MT$8/3/' P0>>FX=ZGUR*Z_M9/LORNT0R0!C&6!+<$8P!UST&.<5M:_I\^HQ(
M(2%>.57!;I\H/L>YJ_!OV#?C=@9VYQGOC/.,T $._8N_&[ SMZ9QSC/.,U)1
M10 5GZ]=SV=L6@5F<D ;5W8SWQ[#]<5H44 <1:6MSJS3V5RQ\T!9%W'*J1UZ
M' R' X&!Z< 52CT.\W) L!217SYF6QZCD$J,>HYZ <YSU>M:-->3Q7,#*LD1
M_B+ $=<<?B".X)YK9H 3%+110 5E>)-1FTRV,D2Y/0L<87) S@\DY/'&.Y]#
MJU'/"MPA1AE6!!'L1@T >>3ZX;I5F9F%S$<*R@;2O7!YZC)Z#!'!SU&GI(N]
M4U*.[,6SY<LVUMIX(!&3W! &"?[V,9J7_A#;O;]G\Y?)W[ON_-G;C./T^][U
MUPH 6BBB@ K \7:U-I,:+%PTA/S=<;<=CQSG_/;?JMJ-BNI0/"W1QC/H>H/4
M=#S0!PVH:P?$$$4++F</@$8 (;CU&"3CMCCJ,XKI/#WAM]%<N9-VY,%0,#.0
M<YSSCD#@=:JV/A:YBEB$L@,5NQ9 HYY;//'<C)Y/H/6NHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** #%%%% !1110 4444 %%%% !1110 4444 %<_JOCBPTF4Q$L[
M*2&$8!P1C@DD#\LXP0<5T%<&)[SP3<7,SPF:.=]P<, ."3SA3@G?CH!GID4
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M4]7YQD?=^;/0MV&<98 ]'HQ110 4444 %%%% "4M)2B@ HI": ,47 6BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "@T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !10** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *CN=_EML^]@X^O:I** ,+&I_YV48U/_.RMVB@#
M!QJ?^=E+C4_\[*W:* ,+&I_YV48U/_.RMVB@#"QJ?^=E&-3_ ,[*W:* ,+&I
M_P"=E&-3_P [*T;'5X-1DEBC)+0-M;((Y]OQ!'X>F";F: ,+&I_YV48U/_.R
MMW-16UW'=ABC!MK,IQV*G!!_S[]#0!CXU/\ SLHQJ?\ G96[FC- &%C4_P#.
MRC&I_P"=E:\]Y':E0[!?,8*N>Y() _''].M34 8.-3_SLI<:G_G96[1F@#"Q
MJ?\ G91C4_\ .RMVB@#"QJ?^=E&-3_SLJU9^(;6]MEN=WEHS$#S<)R,]R<'I
MV)_,'&D#0!AXU/\ SLHQJ?\ G96EJ.J0Z4BO*<!W5!]6]3T  R23V'K5N@#"
MQJ?^=E&-3_SLK:@N$N4#QL&4]"I!'''44^@#"QJ?^=E)_P 3/_.RKFM>(+;0
M4#3$Y;.T*,DXQGT'&>Y'M65%\0]/DSD2+A21E1SCL,,>3[X'J: +6-3_ ,[*
M,:G_ )V5L6EW'?1++&P96&01_G\QVJB?$MFOG98@6Q4.=K8!9BN.F3R.PQSU
MZX *N-3_ ,[*,:G_ )V5>EUVUA\G<^/M&/+^5N<XQVX^\.N*=%K$$]V]H"?,
MC4,1@XP<=_;(_/ZX ,_;J?\ G91MU/\ SLK=(S29Q0!AXU/_ #LHQJ?^=E;H
M.:JSZG%;S)"Q^:0$C\* ,S&I_P"=E&-3_P [*W-U*3B@#"QJ?^=E&-3_ ,[*
MW<T9H PL:G_G91C4_P#.RM34M1CTJ!IY,[4'.!D\G 'XDX_G1IU^NIP+.JLH
M<9 <8.,\'&3UZCVH RL:G_G92XU/_.RMVC- &%C4_P#.RC&I_P"=E;N:,T 8
M6-3_ ,[*,:G_ )V5J:CJ$>EP-/)G:@YP,GDX _$G'\Z;I>I)J]NMQ&"%?. V
M >"1V)]* ,S&I_YV4N-3_P [*W:,T 86-3_SLHVZG_G96[FDH P\:G_G91C4
M_P#.RMW-175W'9)YDC!5! )/3YB /U/7MWH Q\:G_G91C4_\[*W.:YZX\>:=
M;2^5EFYP6094<XZY!..N0#D=,T 2XU/_ #LI,:G_ )V5/K'BJST94+DN9!D"
M/#'!_BZ@8].>>W0X6Q\46=_;-<AMJQ_>#\,/3(&>O;&<]!SQ0!!C4_\ .RC&
MI_YV4W3_ !M8ZC<?9U+ DD*6 "D]@.<\]L@>G7BDU3QQ8Z7,83N=EZ[ " ?3
M)8<CO^77(H ?C4_\[*,:G_G96Q:7<=]&LL;!E89!'^?S':I: ,+&I_YV48U/
M_.RM2VU*"\DDBC8,T) 8#/!.>,].QSCIT-6: ,+&I_YV48U/_.RM:&^BGE>%
M3EXMNX8/&X9'.,'(]*GH PL:G_G91MU/_.RMW--Q0!B8U/\ SLHQJ?\ G96Z
M*BNKN.R3S)&"J" 2>GS$ ?J>O;O0!CXU/_.RC&I_YV5N'-*,T 86-3_SLHQJ
M?^=E;M% &%C4_P#.RC&I_P"=E;M% &%C4_\ .RC&I_YV5NT4 86-3_SLHQJ?
M^=E;M% &%C4_\[*,:G_G96[10!A8U/\ SLHQJ?\ G96[10!A8U/_ #LHQJ?^
M=E;M% &%C4_\[*,:G_G96[10!A8U/_.RC&I_YV5NT4 86-3_ ,[*,:G_ )V5
MNT4 86-3_P [*,:G_G96[10!A8U/_.RC&I_YV5NT4 86-3_SLHQJ?^=E;M%
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M4_\ .RC&I_YV5NT4 86-3_SLHQJ?^=E;M% &#C4_\[*7&I_YV5NT4 9FF_;
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MG#$L!"M;\('^9,?*,'(;^Z.N<]".<@MO#]U+?1W]S*I=%*[(T.T## 88G/\
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M?@Q=6OTN<@(<>8#NR=OI@]Q@'IC&>36OK^F-K%G);J0I<#!/3*D,/SQCV]Z
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M?K0!SOCK4HO/M[24?N]ZR2'G[N2O&#GINSQGIBG>"KV".[N+6!BT1/F1_*0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 8.@:?;R)+NB7Y9W #@,0!C SST^M:>HV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/_ &Y/_P ^[?K_
M /$T?VY/_P ^[?K_ /$UK>6*/+% &3_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK
M[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-
M']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L%
M&1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\
M^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D_
M_/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ_
M_$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^
MO_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!
M1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']
MN3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1
M_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/
MNWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\
MS[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$
MUK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\
MQ-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L
M% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3
M_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;
MD_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K
M_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NW
MZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK
M[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-
M']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L%
M&1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\
M^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D_
M_/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ_
M_$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^
MO_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!
M1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']
MN3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1
M_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/
MNWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\
MS[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$
MUK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\
MQ-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L
M% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3
M_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;
MD_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K
M_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NW
MZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK
M[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-
M']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L%
M&1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\
M^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D_
M_/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ_
M_$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^
MO_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!
M1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']
MN3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1
M_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/
MNWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\
MS[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$
MUK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\
MQ-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L
M% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3
M_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;
MD_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K
M_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NW
MZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK
M[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-
M']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L%
M&1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\
M^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ__$UK[!1L% &1_;D_
M_/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^O_Q-']N3_P#/NWZ_
M_$UK[!1L% &1_;D__/NWZ_\ Q-']N3_\^[?K_P#$UK[!1L% &1_;D_\ S[M^
MO_Q-']N3_P#/NWZ__$UK[!2;!0!D_P!N3_\ /NWZ_P#Q-%:WEBB@!U%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%)NH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "B@T@H 6BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "B@T@H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]L<TK#-VBN!_X3/79_GCM/D;E?W4K<'D<@@'CN ,UI^'_'::E/\ 9;A/)EX
MR3@L."N" 5.>@.?3.<9?*Q7.KHJOJ%U]@MY)\9\N-FQG&=H)QGGTKD++XFPO
M#(TT>UU^XJDG=DG SC P,9)Z\D#M0DV.YV]%<5X4\<76MW8MY(EPP)W1[AM
M!.2"6SDX'48)[YK:\3>*H/#:#(WR-T0'''<DX.!Z<<GIW(+,5S;HK@?^$SUV
M?YX[3Y&Y7]U*W!Y'((!X[@#-3:?\17@E,-_"8SD<JK#&<8RC9/0DY!SC&%HY
M6%SN*Y2W\927FL_8$0",,ZDMG<2BL21@X R/0\<\9P-_5[F>SM9)($\R15RJ
M^O\ CCK@<GH.37CEIJ-SI-X+CGS4<D[P2<G(8'//.2#W_&G%7!L]OHJGI-[)
MJ-LLTD9B9LY1LY&"1W ZXSTKGM<\?1V,QMK:,S2993U # [0,8RW/ICM@\\*
MP[G6T5P/_"9Z[!\\EI\B\M^ZE7@<GDD@<=R#BNC\,^*H/$B' V2+U0G/'8@X
M&1Z\<'KV)&F*YMT5C>*]?;P[:B94#EGV#)P 2K$'WZ=./J*P+WXF1BT5H4'G
M,3E6R54 ]SA=V1TQT[GC!$FPN=Q17%6?CBZNM,GNO*4/ 4 /S;&+O@C&<C (
M_B/4'CI6]X9\1Q^)(#(%V,C89=P;'<'MP?H.01VS19A<UZ*3-<OIWC-M4U8V
MD2!H@&&\')RN?FR,C:3P/7(.><4K#.IHHHH *;)(L*EF( 4$DDX  ZG-.KC/
MB;J3VUK';KTF8EC[1X..G<D'.1T]Z:5P91U+Q??^(+AK735.W!^8##$ $$Y;
M 4<\=&SCD$XI(?AC<7.7GN '+$G:IDSGG)+%3DG/;\:Z'P-HZZ7IZ/P7G =B
M/1A\HS@'@=N<$G%=#3;ML*QY?>Q:OX#=2LA:(DA>K1_>SM*G[I.,\<\G#=:[
MSP_X@@\0P>;'PPX92>5/]0>Q[^Q! O7EG%?Q-#*H9'&"#_G\CU!Y%8'A?P6O
MAN9IO-,A9-H^7: "03W;/0>G?KV&TT%K&)\1M:NK.ZCABD:,"/=\C,I)9B.<
M'G&WCZFN_P UYE\3O^0@G_7!?_0WK?O_ !TUQN33H7G*XRVQBHSC' &XYY'.
MWD<9%#6B"YU]%<#%\1;RPDV7MOMS@\!HV R03A\[O;D=.OIW%G>17\2S1,&1
MQD$?Y_,=0>#2:L.Y-17):OX\&D:E]D:,;%*AGW'/S!3NP%/W03QR3QR.^9J/
MQ.>.YQ;QJT2D#+[@S8/)'/RY[9!/<^@.5BNCT"BJ+ZM':V8NK@&(;$+ @DJ6
MQQ@#/!..E<A)\0;[4&/V*V+!2<DJTAP?N\)C;T/<^QXH2;"YWM%<''\0;[3V
M'VVV*AB,$*T9P/O</G=U'<>YYKMK.\BOXEFB8,CC((_S^8Z@\&AJP[DU%<9K
MGCF72M4^R[4$2-&'9@S-A@"Q&".@/3!Z>^*AN_'&H7<K&PMS)$IV[C'(V2.I
M^4C'48!YQR<9P#E8KG<T5Q&@?$"2YNC;WJI%U&[E I7.0V]CZ8]CQCGAMWXY
MU"[E8V%N9(E.W<8Y&R1U/RD8ZC /..3C. <K"YW-%</HWCN[EOUM;R-8]YV\
M*ZL&;[N02W7@=!USG KN*&K#N%%<EKGC]+&;[-;1F:3+*>H ;.T#&,MSZ8[8
M//&=_P )GKL'SR6GR+RW[J5>!R>22!QW(.*.5BN=]16)X9\50>)$.!LD7JA.
M>.Q!P,CUXX/7L3MTAA17&:K\02)S;6,7G-T##+ D<G"J,L !UR/7D=8X/'EY
M8@&^M712V-RJR=N!A^IX_O#CMQR^5BN=O17,:)X[@UN]^S*A4,I*LQY) R1M
M ('&3G=V]3BNAO+R*PB::5@J(,DG_/Y#J3P*5ADU%<+/\0+S4'(L+8NJ]2RL
MYYZ<(?EZ'N<^U1I\0-0T^1?MMMM1O17C;@C)&\D' /3CMR*?*Q7.^HJ&SO(K
M^)9HF#(XR"/\_F.H/!K U'QS!I>H?8Y%(50-TA)X)7<,* 2>H';D],#E6&=+
M17"W?CV]O)V6P@\V-,#)C=B>O.%(P#C@'GC/L'6?Q"GM)5BOX#'N.=P#+A3P
M#L;)/(.2#TZ D<OE8KG<5S<=GJ@UMIMQ%J5Z%P5/R 8"Y.#NYS@=#SS@])7.
MCQ0W]M'3BHV[.".3NVA^>0 ,9'0G/?G@0V=%139)%A4LQ "@DDG  '4YKB=0
M^(KSRB&PA,AR>65CG&<X1<'H <DYQG*T)7"YW%%<''X\U*P8->6I6,D#(1XS
MD^[D@\ \<9]178:5JL&M0">$Y4]<]0>X([$?_7&00:&K"N7****0SF/'VNR:
M/:*D3;9)F(R <[0/F(/8\@>O/'/(YCPAXEO+;4$AN)'9)L#$I9CEAE",Y(R2
M/8@Y/8BQ>'_A*/$:Q[?D@;:<KNXB)+;ADC#-E<^A'&>*M?$S3VA:&_1B"I"<
M'!!&74C ^N3GTQWJUV)\SO**JZ7?KJ=M'<+C$B X!W8)'(S['@^XJ:YN$M(V
ME<X5%+$\G@#)Z5!1)17 R_$2\OY-EE;[L9/(:1B,@ X3&WWY/7KZQO\ $#5-
M.=3<VP56SP5DC)QZ%B>F1G@T^5BN>A453TK5H-9@$\)RI]>H/<$=B/\ ZXR"
M#6!XG\=IH<QMXTWR!>220JDC*]OFZY."/KG."P[G5T5Y_)XRU^%2S6H 4$DF
M&4  =3G=6WX5\:1>(#Y+@1R@=,\-@<D?X<G'.3S@Y6*YTM%-DD6%2S$ *"22
M<  =3FN)O/B%/=RM%80&3:<[B&;*C@G8N".2,$GIU )X$KCN=Q17G[^-]:M!
MYDUJ%12-Q,4J<9Q]XD@9Z#@\]JZCPYXF@\21LT8*LFW<K=MP['N.#Z'CD#BA
MIH5S8HKEO$?C-O#M\D+('C:-6.#A@2Q!/H>!TXY[BNGCD690ZD$, 00<@@]#
MFE88ZBL_7=8CT*U:X<9Q@!<@$D]!S^9ZX )P<56\)ZU-KUGY\J!#O8<9"D#'
M(SGUQU/(/T!8#9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY!Z?]=U_] >ICN-[&_X?_P"0?;_]<(O_ $ 5R!_Y&[_/_/O77^'_ /D'V_\
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MD Y/->A4/L""BBBI&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*$PL>9ZKXKO/&$8L[> C<06 .\D C'.T!0#C)^G(&<]/;^$!!HSV&X;Y 6+
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M]D.X9Y.WC;]YSC.,YV@9[X. :]*HS3N%C/T+1X]"M5MTYQDEL $D]3Q^0ZX
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M'!P3)D9[<;!G\Q]:]!HIW"QPOA+PS=7=U_:5]G=N)57'S$]-Q!' '\(XZ C
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ML!!ERN?OL5P<_*%X)'7DX&<>HZ7P7X<;P_;'S,>;*06QS@ <+UP<9.2.YQR
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 ,*B@*/2GXHQ2Y4 W:/2C:/2G8HHY4%V-VCTHVCTIU%'*@
MNQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'
M*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU
M%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCT
MIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHV
MCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCT
MHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-V
MCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V
M-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4
M%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HH
MY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.
MHHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>
ME.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&
MT>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>
ME&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQN
MT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@N
MQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*
M@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%
M'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTI
MU%'*@NQNT>E&T>E.HHY4%V-VCTHVCTIU%'*@NQNT>E&T>E.HHL@NQA4>E* !
M3L48H2!ZB"EHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%-616) (.TX..QP#C\B* '44F:*
M %HHHH **** "B@T"@ HHHH **** "BBB@ HHHH ***,T %%,,BA@N1D@G'?
M QG\LC\Z?0 44U'609!!Y(XYY!P1^!%.H **** "BBDS0 M%)FEH **** "B
MB@T %%(*6@ HHHH ***3- "T49HH ***3- "T4"B@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M. >1SG\ZIZGH,UO:"))RD,,+%PJY+$9+'[PX;)X)P./PO>*M+;5+)E7.Y#O
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*EM[A+I=Z'(-5K^UC6!SCHC?RJ#0/]0/Q_F: -2BBB@ HHHH **** "BBB@
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M!&Z4+TH;I0O2@!::M.IJT .IC=:?3&ZT /I#2TAH !2FD%*: &+UI],7K3Z
M&]Z=3>].H :].%->G"@ - H- H #35^]3C35^]0 ZD:EI&H 6D;I2TC]#0 D
M?2G4V/H*=0 E+24M #6ZTZFOU%.H 0T#I0:!TH 4]*:E*:2.@!U)2TE "TV2
MG&FR4 .'2B@=** &K3J:M.H 8HYI]-7K3J $-**1J6@!K]*$Z4/TH3I0 XT@
MI32"@!:8W6GTQNM #Z#10: "DI:2@!$IU(E+0 4444 ->G"FO2K0 &@4&@4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M- #%ZT^F+UI] #>].IO>G4 ->G"FO3A0 &@4&@4 !IJ_>IU-'WJ '4C4M(U
M"TC]#2TC]#0 D?04ZFQ]!3J $I:2EH :_44ZFOU%.H 0T#I0:!TH #2)3CTI
MJ4 .I*6DH 4TV2G&FR4 .'2BBB@!JTZFK3J &KUIU-7K3J $:EI&I: &OTH3
MI0_2A.E #C2"E-(* %IC=:?3&ZT /IK4ZFM0 X4E**2@ 2EI$I: "BBB@!KT
MJTCTJT !H%!H% "TU>IIU-7J: '4E+24 +39.E.ILG2@!5Z4M(O2EH ****
M&]Z=33]ZG4 !H%!H%  ::E.--% #J;WIU-[T .IDM/IDG:@!]%%!H 1>E!SV
MH7I2T 0I$BMN  /J!4U,7K3Z &M3J:U.H 1NE"]*&Z4+TH #0M!H6@!:2EI*
M (-1_P"/>3_<;^55/#_^H'X_S-6]1_X]Y/\ <;^55/#_ /J!^/\ ,T :=%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &?J
M!S+&/>K]9FH?\?2?\!_]"-:9'% !2TS!I^* &GK3J80<T[!H 1Z<*8XI0#0
MXTBTA%(H- #Z:.M+@TW!W4 /H-(!2$&@!QIK=*,4,.* !.E.ID8XI<&@ [TZ
MF@4I% #).HJ2HY!T^M/(H &Z4+TI"#2XH 6FK1@TB T /IIHP:,4 .I'I,&D
M<&@!PZ4&D .*4B@ 6E[TT"E H :/O4_O3 /FIQ'- "FBFD&EP: !NE"]*1@<
M4(#B@!U-6C!H44 .IC]:?BF..: 'TC=*3%##B@!PI#1BDQ0 +UIU, YIP% "
M=Z=3<<TN#0 CTX5&X-.4&@!QH%(P-( : '4T?>I2*: =U #Z1J3%!% #J1^A
MHQ2,.#0 1]!3J;&.!3B* $I:;BC!H 'ZBG5&XY%/Q0 &@=*"* .* %/2FI2L
M*:H- #Z2@"DP: '&FR48I)!0 Y>E+28XI,&@ 6G4U11@T (O6GU&HYJ3% "-
M2TUQ2XH 1^E"=*1AQ0HXH ?31UI0*3'- #C3&^\*7%-8?-0!)36HP:&% #A1
MVIN#2D4 )'TIU, IQ% "T4W!I2* $>E6FN*4#B@!30*0BE H 6F+UI<&FJ/F
MH DI*3!HQ0 ZFOT-&*1QP: ')T%+35' I<4 "TM- HP:  _>IU,8'=3@#0 I
MH%-(-*H- "FFBA@:0"@!]-[T8-&.: '4R3M3B*8XZ4 24&C%(10 +TI:;BE
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MTZ@#)\0_ZL?45HVW^K7Z5G>(?]6/J*T;;_5K]* )30*#0*  TU?O4XTU?O4
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M_P!QOY54\/\ ^H'X_P S0!IT444 %%%% !1110 4444 %%%% !1110 4444
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M% "TE+24 0:C_P >\G^XW\JJ>'_]0/Q_F:MZA_Q[R?[C?RJIX?\ ]0/Q_F:
M-.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTJ=*=0!&'&:=Y@I<<TM $,KCBGEQ1)CCZT^@",O2[Z<<4#% #=]-1ZEIJXH
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MJ]33J:O4T .I*6DH 6LOQ-_QY/\ 5?\ T(5J5E>)_P#CR?ZK_P"A"@";0_\
MCTC_ -T5?JCH?_'I'_NC^57J "BBB@!O>G4WO3J  T"@T"@ --2G&D3I0 M-
M[TX4WO0 ZF2]*?3)>E #Z*** $7I2TB]*6@!B]:?3%ZT^@!K4ZFM3J $;I0O
M2ANE"]*  T+0:%H 6DI:2@"#4?\ CWD_W&_E53P__J!^/\S5O4?^/>3_ '&_
ME53P_P#Z@?C_ #- &G1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61
MK.F76JR+&L@2''S[20YSG(Z8QC^9)!P*UZQ=9U6]TZ=1%"98RO.T,6SSQD9Q
MVZCGG\ #.N/!^F6F/,F9,]-SHN<?5:NV.C7&FO&;6;= <%ED.X8)SE2!CD'/
M&.>I(Z<_?W4=_=B9HFF,BE?)W,KHR8R.!DCJ1ZY.0"#71^$K*>PLPLN02Q8
MGD @<8[<Y./?GG- &W10** "BBB@#+U#_CZ3_@/_ *$:T^U9FH?\?2?\!_\
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M]?#_ +U7]*_X]D_W15#7/]?#_O4 ;(Z4+0.E"T *::OWJ<::OWJ '4C4M(U
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MZ=3>].H #10:!0 UV$8R> /6FPR)(N4((/<<U'J/_'O)_N-_*J7A[_CW_/\
MF: -44WO3J;WH =3)>E/IDO2@!]%%% "+TI:1>E+0 Q>M/IB]:?0 UJ=36IU
M "-TH7I0W2A>E  :%I3TI%H 6DI:2@"#4?\ CWD_W&_E53P__J!^/\S5O4?^
M/>3_ '&_E53P_P#Z@?C_ #- &G1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7(>(;V;[>89)VMXQ&"I0,<YQG(4YZYZ],=.<GKZY_Q3!>D+)"%D12-
MT;1J_.3SR"3G.#C!'7UP 96@Z3)K<!F8M%(K?),O!(Y# @;<]\MG))Z\$5T^
MCP75O $N&5V4X!7)R.,9) Y_SUS7.?\ ">?9OW?V?;LXQOQC'&,;.,5HZ7>Z
MGJ5V)'0PP $%6 R3CW ;J?88&.O4 Z#I1110 4444 9>H?\ 'TG_  '_ -"-
M:?:LR_\ ^/I/^ _^A&M,]*  4M(*6@!IZTZD/6C- "/3A37-.%  :1:4T@-
M"TW^+\*=FF \T /H- -(30 M(W2C-#'B@!$Z4ZFQGBES0 HHI :4F@".3J*D
MJ.0]/K4A- "-2BD)I<T %-6ES2(: '4T=:7-'% "TCT9I&- "CI0:4=*#0 B
MTII :4<T ,'6G]Z:/O4I- "FBD)I<T (W2A>E(QXH4T .IJTN:%H CGN8K?
M=@N[ID@9^GK6%K-W#]KA.X=?6F>+5WRVX]68?JM6U\,6S@$C)'KS0!K1SI)T
M(/TIV<U@6%K]AU HI^4J#BN@S0 "E-)F@GB@!J]:?34YIU #35+7?^/.3_=J
MZ:HZX<V<G^[0!+I7_'LG^Z*H:Y_KX?\ >J_I7_'LG^Z*H:Y_KX?]Z@#9'2A:
M,\4*: %IH^]3LTT'YJ '4C49H)H 6HKJ<6\9<]JEJKJO_'N_TH =8W(NXPXX
MS5BL_0N;9?:M ]* $I::#2YH 1^HIU,<\BG9H #0.10:.U &#/K%U-.\4,>0
MHZU3M)-1TI&8QC')ZUH:1_Q]S5I:CQ Q_P!DT -TN\_M"!9<8W#I5D5G^'<?
M8T_'^=:% #C39*=G--<T .'2BCM29H 1:=2+1F@#&T__ (_Y_P /Y5M5BZ=_
MR$)_P_E6U0 C4M(:,T (_2A.E#'BA3Q0 XT@I<YI,T *:8WWJ=FF_>(- #Z"
M**0F@!:2C-&: !*6FH:<30 4&DS2F@#%\3_ZI?\ >%;*=*QO%!_=+_OBMA3Q
M0 IH%!- H 6FKU-+FFJ>: 'TE&:,T +65XG_ ./)_JO_ *$*U,UE>)CFR?ZK
M_P"A"@"QH?\ QZ1_[H_E5ZJ&A?\ 'HG^Z/Y5?H 1:6D!HS0 A^]3J:3\U.S0
M &@4A-&: (-1_P"/>3_<;^54O#W_ ![_ )_S-7-1/^CR?[C?RJGX?_X]_P _
MYF@#5IO>ES1GF@!:9)VI]->@!U%(3S1F@ 7I2TF:4&@!J]:=3 >:=F@!&IU(
MU+0 C=*%Z4.:13Q0 XTBTM(#0 M)2@TW- $.H_\ 'O)_N-_*JGA__4#\?YFK
M>H?\>\G^XW\JJ>'_ /4#\?YF@#3HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ ILDBQ*68@  DDG  '4YIU,G\ORV\S&S:=V[&,8YSGC&.M #;:[BO%
MW1.K@'&48,,^F14M>97;PW=T?[*699'8YV'8FW(' '(4G!Y( ]/3>L=:UC2Y
M8XKV,,LT@0-E006('5,CU." 3Z\4 =?1110 4444 9>H?\?2?\!_]"-:9'%9
MFH?\?2?\!_\ 0C6GVH 113L4BTM #2.:7%(>M.H 8XIP%(].% "$4@%.-(M
M!MIH7FGTWHU "[:"M+0: $VTC#BG=:1AD4 -C'%.VTB=*=0 W'-+BC'-+0!'
M(.E/(S3).HJ2@!I%+BAJ!R* #;346GTU: %VT@&33J:.M "[:1EIU(]  !Q0
M10.E'6@! *4#!H4TIXH 8!\U.(R:;WS3Z $*T;:4T4 -9>*$7BE;I0O2@ VT
MBBG4U: .>\5_ZZW_ -X_S6N@C^Z/I7/^*_\ 76_^\?YK70Q_='TH Q<9U,_[
M@K::L;_F)G_<%;3=* #%!'%**#0 Q!@T_%,7K3Z &XJCK@_T23_=J]5+7/\
MCTD_W: )-*_X]D_W15#7/]?#_O5?TK_CV3_=%4-<_P!?#_O4 ;&,BA12@?+0
MO2@ VTT+\U/IH^]0 NVD(IU(U  !5751_H[_ $JW535?^/=_I0!#H(_T85H$
M5GZ#_P >PK1H :%I=M%+0!&XY%/VTUQR*?0 A%)VI32=J ,?1Q_I4M:.H_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC\^* -70<_9A6@#FN8LM=DT^$+)"PP<9XQ_.NFC?S #Z@'\Z %')I:0<&EH
M:_44ZFOU%.H 0TG:E-)VH Q]'_X^I:T=2_X]W_W36=H__'U+6CJ7_'N_^Z:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[M;#4 .%)2BDH $I:1*6@ H-(:4T 8OB?_5+_O"ME.E8OB@XB7_>'\ZV4Z4
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M^X*V';% #Q0::&R*0F@ 7K3ZC5N:=NH #5'7/^/23_=J[GFJ6MG_ $.3_=H
METK_ (]D_P!T50US_7P_[U7]*_X]D_W15#7/]?#_ +U &R.E"TF>*0&@!]-'
MWJ,T@/S4 /I&I-V*0MF@"#4_^/:3_<;^1K.\*_\ 'NW^_P#T%:&I'-M)_N-_
M(UG^%?\ CW;_ 'S_ "% $OB3_CV/^\*T+/\ U2_[H_E6?XE_X]O^!"KUH?W2
M_P"Z/Y4 3TM,WTN^@ /6G5$Q^:G[Z %-)VH)I,\4 9&C_P#'U+6CJ7_'N_\
MNFL[1C_I,M:.I?\ 'N_^Z: *WAW_ (\T_'^=:-9GAWBR3\?YUH@\T /--DH)
MILAH D'2BFD\49H 5:6F*]+F@#'T_P#X_P"?\/Y5M5AZ>?\ 3Y_P_E6UNH 5
MJ6F%J4&@ ?I0G2D<\4(>* 'T@I":3- &/XA_UD7^]6ROW1]!6-X@/[R+_>K9
M7[H^@H QT_Y"9_W:V&K'3_D)'_=K78T /I*3- -  E.J-33LT *:IZO=M9P%
MUZU:)K-\0G-J?J* *,]I>ZO$N2%!YYJ3^T+JPE2.3!! Y%:^G_ZE/I63KIQ<
MQ?6@#=)R*!3<\4H- #J:O4T9I%/S4 /HIN^DWT /K*\3?\>3_5?_ $(5IAJR
MO$I_T-_JO\Q0!9T/_CTC_P!T?RJ]6?HA_P!$C_W1_*KV: %%+3 V*7=F@ /W
MJ=3"?FI<T .- IA-&: (M1_X]Y/]QOY52\/?\>_Y_P S5S4#_H\G^XW\JI>'
MS_H_Y_S- &M3>]*33<\T /IDG:ES39#0!)0:;GF@MB@!5Z4M,#T[=F@!J]:?
M42GFGYH #UIU,8TN: %;I0O2F.:53Q0 XT+2$TBM0 ^DI-V::#0!'J/_ ![R
M?[C?RJIX?_U _'^9JW?G-O)_N-_*JGA__4#\?YF@#3HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^]0!LCI2BCM0* "FC[U.IH^]0 ZD:EI&H K:G_Q[2?[C?R-9_A7_CW;_?\
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MO6GT -:G4UJ=0 C=*%Z4-TH7I0 &A:#0M "TT4ZDH @U'_CWD_W&_E53P_\
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M1O;%5-;D5IX1GG=6!/JQTJWC95)#=C4\]T))()F5BQ/;H* .U[4"FJ<K2K0
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MRO$__'D_U7_T(4 3:%_QZ1_[HJ_5#0_^/2/_ '15^@ HHHH ;WIU-[TZ@ -
MH- H KZC_P >\G^XW\JH^'_]1_GU-7M1_P"/>3_<;^54O#W_ ![_ )_S- &K
M3>].IO>@!U,EI],EZ4 /HHHH 1>E+2+TI: &+UI],7K3Z &M3J:U.H 1NE"]
M*&Z4+TH #0M*>E(M "TE+24 0:C_ ,>\G^XW\JJ>'_\ 4#\?YFK>H_\ 'O)_
MN-_*JGA__4#\?YF@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 +2TBTM #3UIU-/6G4 ->G"FO3A0 &D6E-(M "TW^+\*=3?XOPH =0:*#0
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MI63KG_'S%]:UM/\ ]2GTK)US_CZB^M &[VH%':@4 +35ZFG4U>IH =24M)0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<53EUXVE^+7!9RO#XI\2R&"+RP"WG-R:U?[&7[1L(R2N2WO3Z 95M(MO+>*
M6)0YS]*KS:C-I=LCQH3D]#6GI]K*]U=0MW3"GUR*J2:=J&GQ@8#X/2E<!KW#
MR20S,I+L?R!KM >*Y:VT>]FN$F?Y5') /K748XH^8"]JQ[K_ )"*?[M:PZ5A
M:M*\-\C+V7D4+4#?8]O:L;2.+F7ZU!%K,7G$JV6*]/>E\.AS++O/S%J;3 Z
MGFES3#S2^U( 8\4*>*0CBA3Q]:-0';J0,!2<4;11>X]#G/&!R\';EOYK5.ZU
MY+*6*)LDYX/^>E7/%V?,@QZMC\UHFT=99(VD W-^E-:B(],FQJ+%B267T]ZZ
M@\USEC;O%J#(PX"\&NB-#T <#0:9]VG"DP$7K3LTU12FA.X!5'7#_HDG^[5P
M\&J>M_\ 'I)_NT[@2:7_ ,>R?[HJCKH_?0G_ &JO:8<6R?[HJAK9S+#_ +U
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MS3G4YW<+'!:S!J"R#SF!W$B,#L<\_P!*Z?0(;N*+%R0S>HJGXJXFM_\ >/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?AQP[RD'/S&L.UU>XENY(&7(7&3Z\>M:WA1@#*NW;AJ>P)-G0'I3@<T@I0:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M $#&C)S3Z0T -=R 3[5ST5K<ZNK@R;5)QQ712_</TK*\/C"/_OT 47TFYTN
M!)3P:KWQ,E_"RJ"[Q5O:QS#^-9L'_']#_P!<: *<'AR.SFEFC&9/XO?/:JEL
MJ_8@RKM)GZ?B*[1HPH8CJ17(C_CT'_7Q_6@#KWB5R"1G;R*P=3^>[=3_ ,\6
MKH:Y_4A_IC?]<3_2@#$BTN'5+#R@@"@G<Q'-+>:7!I=O' 5X)&Q@/?O72:%
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MH UMQQ0&-/'2A: &DFFJQW5+31]Z@!-QI"Q-24AH JZEG[-)_N-_(UG^%?\
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MKM.X5T,/"#Z4 *":7)I0:6@"+<<TX$TI^]3J (V8TH)IYHH P]&_X^Y_]_\
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MWO3J  T=J#0* ,/1?^/F?_?_ *5H:M_QZR?[IJAHHQ<S_P"_5_5C_HLG^Z:
M(=!_X]5K1[UG:%_Q[+6CWH 6F2=J?3)>U #Z*** $%8__,2'^X:V!6/_ ,Q(
M?[AH V&Z5C>&C\LG^^?YUM'I6+X;&%D_WS_.@#8:G4UJ=0 C=*%Z4-TH7I0
M&A:#0M #J;2TE $&H_\ 'O)_N-_*JGA__4#\?YFK>H_\>\G^XW\JJ>'_ /4#
M\?YF@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_5C_ 'A6C!]P?2@!]%%% #>].IO>G4 !H%!H% '"RZO?:?>SK!"9!OZBDO\
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MG K-T2S>S#AA]YR?SK2S34/J<T /I!R:-PI >: '4CT;J1FH 4=*6D#<49H
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M6V+2C#%CD4 ;[4ZFL:7=0 -TH7I2,>*%;B@!30M!-(#0 ZDI0:;N% $.H_\
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M &3XA_U8^HK1MO\ 5K]*SO$)Q&/J*T;;_5K]* )"* *4T"@!,4@'S4ZFC[U
M"XI"*=2-0!6U3_CVD_W&_D:SO"O_ ![M_O\ ]!6CJ?\ Q[2?[C?R-9WA9@+=
MLG^,_P A0!+XD_X]C_O"K]H/W2_[H_E6?XCD46^,C[P[UHVG^J7_ '1_*@"7
M%&**6@!CCD4[%(_44Z@!"* *#0.E "/PI^E9'AS[K?[QK7?[I^E9'AS[C?[Q
MH V *,4HI* #&*:XIYIDM #L<48I1THH 116//\ \A!?I6NM9%Q_Q_K]* -9
MONG_ #VK'\._?E_WJV6Y!_SVK&\._?E/^U0!M8HQ0U+0 UAQ0HXH?I0G2@!<
M8HQ2FD% !BL.^YU.'_=-;IK+NM-,]['.#P@(_.@#4I&%+36H 7% %**2@!$%
M.(I$I: $Q6;XBC+VIP,X(K3I'7<* ,"V\36]K"H<$8&.AJ"[OTU&YC"*>#DD
M]*M>)HD6%?E'WQ6PD*+_  B@"3'% %!/% H ,4U1S3Z:O4T +BC%+2&@"*Y_
MU3?[I_E6?X:_X]OQ/\ZT+G_5-_NG^59_AK_CV_$_SH 77_\ 5K_O5HP#Y!]!
M6?KW^K'^]6C!]P?04 .Q1B@4M #2/FI0*0_>IU "$4 4IH% &'H7-S.?]NM#
M5?\ CUD_W369+I=U;3R2Q, &.>M5XTU#58F!9<'C@^] &KH6#;+6@1S5?3K0
MV<*QGJ.M6.] "XIKBGTR3M0 ['-!%+2&@!,5DCY-1 '=#6O61C_B9#_<- &L
MV<5C^'.CGK\YK9/(-8OAKA9/]\_SH VFHQ2-3J &L.*%'%*W2A>E !B@"@T+
M0 H%-Q3J2@"#4!BWD_W&_E53P_\ Z@?C_,U;U'_CWD_W&_E53P__ *@?C_,T
M :=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &7J'_ !])_P !_P#0C6GVK,U#_CZ3_@/_ *$:T^U  M+2+2T -/6G4T]:
M=0 UZ<*:].%  :1:4TBT <OXD\1SV%T(H6&$ + KG)/.#GMC'3'7KZ8]EXEN
MH#(6D)WJ<9&\ ]L D!?PR/\ 9/;8%HMWKD@95950$AAG^!1P.A.3WXQGOBLK
M2=%N;F4121;4R6)>,CMCKE6//8-[XZT 7?M-WK&GB4CS6CN0<;0> O3:,9&3
MS[>U7U\:P(,21NK D$  XP?<J?TIW@I2EJX/:9AP01]U>XX-= : .7M)WUG4
MX[I(V$:(1N88!X8?3JV, GU]<=0:#36Z4 "=*=34Z4Z@ %% HH CDZBI*CDZ
MBI* ,_7?^/5OI4VF?\>Z?05#KO\ QZM]*FTS_CW3Z"@"U35IU-6@!U-'6G4T
M=: '4CTM(]  .E!H'2E% "+2FD7I2F@!@ZT_O3!UI_>@ -%!HH 1NE"]*&Z4
M+TH 6FK3J:M #J8W6GTQNM #Z1NE+2-TH 44&@4&@!B]:?3%ZT^@!O>G&F]Z
M=0!7N[5;H 'M4J)L 'I2O3A0 AH6E- H #35^]3C35^]0 ZD:EI&H 9/"+B,
MH>C CCW&*PKW05M86*.W'/7_  Q70U4U7_CW?Z4 8=AH"7\"O(QZCOZ5TJ($
M  Z"J&@_\>PK1H :O6G4E+0 U^HIU-?J*=0 AH'2@T#I0 C@D'Z5D^'4*(V?
M[QK8/2FI0 X4E+310 XTV2G&FR4 .'2B@=** &K6-J=O<I<+-$,ULK3J .=B
MUN[GD:()RN/Y5:T"RFM@[2=7;.*OQ6<<4C2#J_6K(H 1J6D:EH :_2A.E#]*
M$Z4 .-(*4T@H 4TQOO4^F-UH ?36IU-:@!PI*44E  E+2)2T %!HH- &+XG_
M -4O^\*V4Z5C>)_]4O\ O"ME.E  :!0:!0 M-7J:=35ZF@!U-;K3J2@".Z_U
M3?[I_E6=X:_X]OQ/\ZTW42 J>XKGKS2I=-A9HI",9/'O0!H:]_JQ_O5H0_<'
MT%8%AI4U_#'(\A/?!KH(UV#'I0 Y:6D6EH ;WIU-[TZ@ - H- H :Z;P1ZU#
M;6RVZ[5]:L&FI0 ZF]Z=3>] #J9+TI],EZ4 /I#2T&@!I.*PKRY^P7_F,I*E
M>HK>7I05!H Q/^$H@DR%5B0.E'AC)B9MI4,Q/-)IBK]MDXK= Q0 UJ=36IU
M"-TH7I0W2A>E  :%I3TI%H 6DI:2@"#4?^/>3_<;^55/#_\ J!^/\S5O4?\
MCWD_W&_E53P__J!^/\S0!IT444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 9>H?\?2?\!_\ 0C6GVK,U#_CZ3_@/_H1K3[4
M"TM(M+0 T]:=33UIU #7IPIKTX4 !I%JC=:O%83K%-A ZDJ[$!21U4^F!@@G
M@YQUZP6&I[A%;QD3.J+YCJ^5&!@DM@Y)(X'4]3@4 1ZQX8CU:99=VS@!L <X
M]^QQQDY[>E9L&C3:A/<6\L\A6/;@;BV=WS*3GKC'(QUZ$5UE9VGV$MK<SRNP
M82E<8X.%!X(]LX]^M $NDZ7'I$(B4YYR2>Y/4^W3_/6KAHI#0 M(W2EI&Z4
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M^E"=* '&D%*:04 +3&ZT^F-UH ?0:*1J %I*6DH $I:1*6@ H-%+0!A^*/\
M5+_OBME.E4M7L/M\87T(-74& /I0 IH%!H% "TU>IIU-7J: '4UNM.I#0 M1
M3Q+,I5NAJ6FOTH ;;Q+"@5>@J2D7I2T (M+2+2T -[TZF]Z=0 &@4&@4 !IJ
M4XTU* '4WO3J;WH =3)>E/IDO2@!]!HH- "+TI:1>E+0!BZ<K?;9&-;511QJ
M&) &:EH :U.IK4Z@!&Z4+TH;I0O2@ -"T&A: %I*6DH @U'_ (]Y/]QOY54\
M/_Z@?C_,U;U'_CWD_P!QOY54\/\ ^H'X_P S0!IT444 %%%% !1110 4444
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M+&@PJ@ #KP!@=: '0Q>0BIDMM &6.2<#&2?7UI5/-'S&F@'- $E!IN&I"&H
M?2,>*3:U-96H <G2G5'&3BG8:@!<\TM1\YIV&- #9>HJ2HI >/K3\,: %-**
M8RM0%:@!](E)AJ:FZ@"2DR*3:U-*M0!)37-&&I&5C0 X=*4\4T!L4A5J '+2
MTQ5:E ;- "=Z>*B ;=3P&H 5J4&F$-2@-0 K=*1#2,K8H0,* 'TU:,-35)H
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M=6@'5OT/^%+_ &Q;_P![]#_A44&BQ)G=\WYC^M3?V/;_ -W]3_C0 G]KV_\
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M[^I_QH 3^V+?^]^A_P *0ZM;G^+]#_A3O[(M_P"[^I_QJ*?18F V_+CZG^M
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MKV_][]#_ (4G]KP8^]^A_P *=_9%O_=_4_XTTZ1;X^[^I_QH !JUN/XOT/\
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M$<#'XG_&F0:-"!\PS^8_K0!)_;%O_>_0_P"%']KV_P#>_0_X4?V1;_W?U/\
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MJ?\ &@"*\U2":%U!Y*D#@]Q]*-!4K ,^_P#,U+_8]O\ W?U/^-6H85MUVJ,
M4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\575Q:VA, .2<$J"2%P23QTZ=>WUK$T7Q*]B6$[/)#OVK)M/7)/.>>0<XR2
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M110 4444 %%%% !1110 4444 %%%% !3&A1V#D LN<$CD9ZX/;-/HH ****
M"BBB@!D<*0YVJ!N))P ,D]2?>G"EHH *#110 UHP_! /(///0Y'Y&G444 %%
M%% !3$A1&+A0"V,D 9..F3WQ3Z* "BBB@ (S37174JP!!&"#R.:=10 U$6-0
MJ@  8 ' P*=110 4444 9EAX=M=.G:= =S$XSC"YZA0 ,>GTX]:TZ** "BBB
M@"MJ-@FIP-"Y(5L9VXSP0>X/I2V5C#IT?EQ*%7)/<]?<\FK%% !1110 5E3>
M&K2YNC<R L6QP3\O  ' '/3H21[5JUD^*=3DTBP>:/[_   =I8 L0,^@P.F>
M,X'.<$ UJ*XJ+1M8D@2]ANV9Y$#[&X7YUS@ EE[X ( [\8K;U#Q&FB10&Z&'
MFP&"\[<+\QXSD!B!C.<'(SB@#:J*Y@6ZB:)LX=2IQUY&*5+B.1V16!9,;@""
M1GD9';/:F"\A968.N(R0QW# *]03VQWSTH KZ5HL&C*1$#EL9+').,X]N,]@
M*OUQ7B/QW$T&+*4B02#.4ZKM))&Y<=<#L>/3D]C#<1SYV,&VL5.T@X(Z@XZ$
M>E $E%16MW%?1B2-@RDD CI\I(/ZCKW[5AG7+F#6_L3J/*D0%#WX4DMWZD$8
MXZ COD T=5T.#6&0R[OW9/ . <XR#QGMVQ5V&%;=%11A5  'L!@5QNM>-9;+
M5%@4J(8W4.<;LYQN/'(VYZ#N#G/0;&NZI<07MK:P$9E<EQP6V+C/7H"-WN<<
M&@#=HJM<ZG:V;;9940D9P[JIQZX)J>218E+,0 H)))P !U.: '52L-%M=+8M
M"@4L,$Y)/ZDU-:W]O?9\J1'VXSL8-C/3H3Z5F>'-?_MJWEN'PB)*X!/'R@ @
MMDD9P>>U &U138Y%E4,I!# $$'((/0YIU  :K7^GP:F@25=R@YQDCG!'8CUJ
MS10!';6T=I&(XP%51@ 5)110 4444 4GT6UDN/M)0&3(.22>@P.,XX^GOUJ[
M110 4444 -=!(I4]QC@D'GW'(JO9Z=#I^[RUP7.6))8D^Y))_P ^]6J* "BB
MB@ JK>:7!?L#*I;:00"S;>/]G.T]>X]NE6J* "BBB@ IKQB0%6&01@@\CFG4
M4 16UM'9QB.,;548 %2T44 %%%% $$MA!/*LK(I=1@$C)'.?T/3TYQU-3T44
M %%%% !56TTR"PW>4@7><G'^>GH.@[5:HH 0#%+110 5#=6<5ZNR10P!!P1G
MD?Y_$<=*FHH **** "@T44 0K9Q)*9@H#L "V.<#_/Z#T%3444 %%%% !5.W
MTBUMI6F5!O<DECDG)SG&<XSD],5<HH **** "JU_IT&IH$F7<H.<9(YP1V(]
M:LT4 16]O':1B.,!548 %2BBB@ I,4M% %%M&M7N/M)0&3(.22>0,#C../I[
M]:O444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M: ):*** "BBB@ HIIE1022,+UYZ<9Y]..:5'$@# Y!&01R.: %HI'<1@L3@
M9)/ XI: "BBB@ HHI&<(,DXY Y]S@?K0 M%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4&D-9/B#2[O5$18)S#M;)VY&<X'4$'@9XZ$XSCJ*A%2:3=O,3T-:EKCA
MX2U/:/\ 3I-W&1E\=LX._G'..!GV[=9 KQQJKMN8* 6P!D@<G Z9]*NI3C':
M2?WB4B2EKF-<T'5-0N_,AN3'$0HP&92/7A>&]<DCTZ 50C\+ZW',"+P[0PY,
MDA. >NT@@_0G';-7&A!J_.E]X<S[';4E+7+:EX9U*[GDE2\90W*J-R@=<+\K
M8  QS@D\DC/7*G",GJ[#;L;^I7PTVW:8C.T=![G _4U%HNK#68?-"[<,5(SG
MI@]>.Q]*YMM*O],T^X^U2^;N\K;\[OC#\_> QG(Z5+X2>2QG-NY^62-9%SGG
M(!XSCL3G_=]J52*C)I._F"=S9O?$$=G=QVN-Q<@$@CC<<#C^?3 YYK5-<(0]
MS=V]XY_X^)^!Z!'50,\?3IVSWJ]J^H0WMZ]O<2E(47 \ONWRDYP&S@Y^F/7.
M9&=9FC-<SX?N7DDFMHI&>,*"CL"=O& ,$?IP/E.!S6=?FVB4RFZ=[E1P4)*Y
M/. 0!@<]CZ\?PT =N*6N5U/5YY-*BF5BK.P4E3@\;L\C&,E<\?2F:I;W'AYH
M[E9GD&55P['G&3COQUZY(/(SV .MKFX_%LUSDQ6SNH)&02?Y*<'VS725R'A:
M[NH+9A%!Y@\P\^8J<X7C!H UDUZ5;:2XE@:,1XP">22<=P,#D<_ETK6AE6=
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M6SLCKEQ<QRRR;4DP%#\?>;L01Q@8K1\/-+!)-:N<K RA,\G:V2.1[ ?3I[
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M (+/74N+5[AU,?E%@RD\Y7MSCDY YQSQ573/$YOKA87A,?F*2I)SG@G/('!
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M=V,>^,5=HH XZXDEU*RMH$PS$OZ _N^ .H ^4]_:H9[AHM.-NS89)RI7(S@
MD].HW?K6KI?AN2PO/-)&Q,[>Y.<@ \#D#D_I[)+X8>2^\W(,9?><\GJ"1C Z
MG/X=?< 9J>JRZ>T=E"X4HJ*SL..@'<$ 8Y/7]#F?2M=?RYFG8,("/F0=<DCM
M@=AC@>].U?1Y&NENHD63LR-CGC&>3CI^1 .#S3++19;B.=9E6+SMF F,#9SG
M )&,^_KTH J#Q;*I\P["I.-@W!AUYW$8],]?H.:275X['4);@?,&B3:.1G<(
MSZ'''-);:->VH,8@B.3C>^&[GG!8^O\ =^H-:%UX>-]>2R28V.@VG)R&P!G
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M5TEP3NP,$$\#YEXY].G':IGTN_OK25)G7?,5(7^%<$$C(!],8Y'&<G)-;U%
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M#\Q&0JC)ZX^@_$COBN36*6W4Z2?O/,A+*-PVE03P0#Q@'\^@ZWHWNVUB<Q!
M^S&)"2-HV 'Y>YX/MTH Z+3M5@U5-\39QC(/!&1W'^1Z&JE[XHL[&7RF))!P
M=HR!]?\ ZV3QZU3TNWFMKR>1FC,AC!\J(D GL3NZ'CW^]DXSS0\,K>O:NL(B
M*%R")=Q/*KGIQC% &CXGU,BQ26!\"1P-RG!QACUZCD<]^Q[UK7.IV]I(D3MA
MI" HP2>3@=!QSZUQ]]"+?253S!)BX/W22!\K<#/Y]!U_$W="B_LV^*WG,TB*
M49CNZY!&<]>WX$ \C(!TU_.;:"21>J(S#/3@$US:V.H);?;1<G=L,FTY*X(S
MW..G;;@'@>M=)?K&T$@D.%*-N(Z@8.3W[5S!L;F#3W"W"FWV$J0,,>I*]L;B
M<'DGMCDB@#HM(OO[2MDFQ@L.?J#@]SQD<>U46\1?\3(6@7Y<8)VG.[&<^ZX]
MAZYQ4OA9&CL(\C&0QY]V)'YBJ$&V/77WCEXQLR.^U>1^ 89^HH U=4URVT@#
MS#\Q&0JC)ZX^@_$COBGZ;JD&JINB.<8R#P1GU'^1Z&LBS0-KLQ(SB($>W"#^
M1IPB$6MCR0 #$3)C'?/Y$G:>.>_<T ;;7<22B$L-[ D#/.!_G^?H:2.^AEF:
M$-\Z $COSS^/7MTK'\22?V=-;WF!A'*MQ\Q##\.@W8YZGZUA6KO9S+JKK^[D
MF?Y0<M\V[)Z8XY],X[#F@#MDNXI Y##$9(8YX! !//MGGTK,B\6V,LOE[B!Q
MAB,*<X_$=>X ]ZQY4FCT5Y&&XSR[VS\N,L.<=\E1TQU]!4ES;7ESIJB0P+$(
MT()W[@ !CL>3TXZYP.M '1:CJL&E)OE;&<X Y)QZ#_(]346EZY;:L/W9^8#)
M5A@]<?0_@3VS7/7)N!J< C*LRP@*[DE6&ULL<9///?W[U?MK2<:FLLSQ*YC/
MRQ[LL!QSG_/R\#@D $NAWTDMS=F1_EC< 9.  "X^@X'/YFM6QU"'4D+Q-N .
M,X(YP#W ]:X6ZL[FZFNS&?D1V9QNP#AB1QWQ@G\/7&>UT>>VGME-OP@&,=QZ
M@^_KZ]><YH S/%E]-;B*&-_+\UB"V=N,%>_8<\__ *\FEV<T+F6.[^T;5.4S
MD'(.!DNVWD=<?UJUJ*6-S>10RIND()''  R>>1D<' Y[^O.7JD46E:E"T'R%
M_P#6!1A=F1DXQ@# .?3&>#S0 Y]$NYH6NKB=DE16(P<!<9S]S/4#^''N#6OH
M%])J-HDL@^8Y&>!G!QG@_P"'.>,8K)NS<>+<K"P2!' ).<L1R3CT'8''J>>G
M1V]O':1B-!M51@ 4 5M8U$:7;-*>H&%![D].X^I]LUB:G?7-KI$;E_GE8$L"
M0<-N<8(QCC ],<"I_''_ !YK_P!=1_Z"U3^*VCM].9.F2BJ .."#CCIP#0!)
M:^*+.[G\E2<GH2,*3Z<\Y^H'\LRZEK]KI?#MEO[J\MV_ =<\D9[51\5Q6[Z?
MN 7Y=OED8[D<#';;VZ8&>U1+J4EQ>&.WCC,X0"21LA?EX8 =<9P,]3QQ@ T
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MWY=<\D9[5S%[_P @.#_KJ?YR5KR:D;B_>.TC0R@8>23(&%X(P.>N!GOZ8 -
M&MIVJP:JF^)LXQD'@C([C_(]#527Q581$CS,D''RJQ[XSG&"!UX/3IFLOP^9
M4U6=7922A+>7]S.5^G(R1SSG.><T_P 'VD5U8R*Z@AY"#D=0%4CGVSQZ'D4
M:NHL=0M/-MY""HWJ4YSM!^4COGICUZCM3=.UV*XM$N)65,G:>>-V<8]L]?8<
MGCFJ?@ARUFP)SB1@/;A3_,U!X0M(KVQ99%# 39P1GD*O^?IQTH Z>N9\27LS
M7<=JLODJR[BV=O=NIR.PX'&3U[8Z:LB2+3[[4#&T>Z5$R21\O88(S@G##L?K
MQ0 FAV;P%G^U>>I&,=0",'KN;MV]_I6*)(_$K223SB- 2(T+!>G1B">>O/<G
M(R *M01K8:SY5OD(R9D4#Y0<$CMP.1CTS@>E5/"6F077G"9,LN%PPZ9SGOP>
M/0$8X/)H W/#2W:V^+@YYRI+!R01GJ,\>AR?P %-U][B62&UA?R_.+989SA
M#QC_ ">F0,U6\'(T*31@AD64A6'<XP>YXP 1]>IJ?Q%:QW4D(\WRY0S&/(R"
M1@X]N0,?E@T 5HY+K0+J**24S1SDCYA\P/ [D\<COZ\9K/U>]GGFN&,YA\D@
M*FXC=UY&,'GKT/49..:DU"WNA?6OG2"1RZ_*@X 5A\WXX))P.A[#C;U;2+";
M-S.,;1\QR1D 8 ..O7COT'M0!EW&J7&I?9[2-]CRH&=N,],_PGC(!...".F2
M*ZFN."3)#]J3]W)=R+&O;:AX4# &/NCG!XP1@UK>'=1FE,EK-\SP$#<#D$>Y
MZ9'OR>XR#0!-XCU8Z3;[E/SN<+T/U./8?7G&:J:W?3Z7;0Q%L%P%>49;& ,D
M=\GD^O!QSR&>*%62ZM%(R#*00>1RR5H:Y-; 1Q7"Y21\;CD*I R.1T)Z=N,Y
M.!0!CSZ3?10^?;W33;3G )(..N/F8'Z=_P!#/X@N+IOLL6\Q-,</L/0_*.QZ
M#<>,\U#J'AN+1H'GBFDC*CKGKGHORA3R<<]/:HKJ];4/[/E;JTAS]5= 3T'7
M&: +,V@ZA;KOCNG=EY .0#CMRQ'YC'K5ZS\1Q2V/VJ3C:=K!03R/Y9XQDX&<
M9J_?WT6FQ&60X _,GT'O_GI6!X>6ZM--+P*KL\A(#'''"GTY^7U'U[4 65\:
MV38R'&3CE1QTY.">.>V3QTZ9O:AJ<D4*/;QF4RXVX!  (R&)QP.1P2/KP:H)
M>:XQ ,,8R>I/ ]^')K=AW[!OQNP,[>F<<XSVH QO"-W+>VSO(Q8F5N2?]E3C
MV'/0<4SQ-K+VZ&" DR8RVT9VKCDY'0]/H.>.#4'A!I%T^4QC+!WV@]"=BX';
MO52.._TRUG\V$N95(9S(&.-NT<?,3C)/TZ\"@#J=.E:>VC=CDM&I)]RH)JKK
M2WDP2.W^7>V'<%<A>G0X/?/'/'O4?ABZEN;11(A38 H)X#  8(SST_ ]CV$N
MHZ[;Z?!YVX/NSM"D')'N,\#N>WUP* ,::WE\-7$)CE:3SGPR-_$21N8=!GD=
M3G..2,X-=NIIKQHO.-NL<6X') 8\>F"?3C/0X&<U;T[1+B6Z^UW95FP-JC)V
MG^7R]NO/.<\G0U32+340'F'W!][.W@')!/I_+G&.M & -<N)+&"%6Q-.Q7<2
M,[=VW/!R/3)&>&/7!KITMB(!$SDG9M+ X;IC=GGGO7*\1Q2ZA$-JP@1P<'&,
M[2V"!G.XD9SR3G.*T="O+FUN6L;AMY"[@P)8]N"<9[]\>G(*T 3Z!?RN\EK,
M<O <!CPS+S@X_+GOD?4[-<]9?\AR?_KD/Y1UT- !1110 4444 %%%% !1110
M 5DZ@3_:%L,=I>>,?=_.M:B@ KB=-U6?[(]LL32###*YX#@]@I[Y/6NUS573
MM-CTQ"B9PS%N3G&<#'TXH YR;3KNVA@C=6>(??2,DG)8MSCKV]L@X(R#5W0M
M,DMKQYA$8XVCPH9@3U7J,D@G&<'ITKH0** ,#2-,FM].EB88=_,P/^ [1[<D
M?3&#FJ>DZ1+,T+.C!561'##;P=Q!'()!WXX'&*ZO-&: .9T^XO-'B-L+<LP;
MAE!VG=W)QSCCTXX.,57U.V=)YVGX#VX(*]"RF,8'7C<,<\X_.NNJ.>!+I#&X
MRK#!!H Y&UN7U"Q2QB0EF8Y8CY<!MQYSVR,\=_4BIYM/DCN62:)YD Q$%8[
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M= ZG(8 CZ'FGU#9P?98DCSG8H&>G08J:@ HHHH **** "BBB@ HHHH ****
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MX/\ O]'_ /%52\9^#(/&,"HS&-XB2C@;L;L;@5R,@X'<$$#G&0>._P"%'?\
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M9VCZ/_9GF,S;WE?<S8V_IDCJ3^=:-% !C%%%% !1110 4444 %%%% !1110
M48HHH .E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMR*)(%"H H'8# _(4V&TBML^6BKGKM4#I]* ,*RT"[2*/$[1E1]T#*YW$]B
M>O.<_7&*U=:V_8Y=PR/+;MGG'!_ ]^W6KE#H) 5(R",$'D<T 9@&[3%'E^;^
MY3Y<XSP/U'4=_3FL"&VANKN$VF]E5E+;ONJ-V[;GMCGN<]B379(@C 4#  P
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MI:* $V"C8*6B@!-@HV"EHH 38*-@I:* $V"C8*6B@!-@HV"EHH 38*-@I:*
M$V"C8*6B@!-@HV"EHH 38*-@I:* $V"C8*6B@!-@HV"EHH 38*-@I:* $V"C
M8*6B@!-@HV"EHH 38*-@I:* $V"C8*6B@!-@HV"EHH 38*-@I:* $V"C8*6B
M@!-@HV"EHH 38*-@I:* $V"C8*6B@!-@HV"EHH 38*-@I:* $V"C8*6B@!-@
MHV"EHH 38*-@I:* $V"C8*6B@!-@HV"EHH 38*-@I:* $V"C8*6B@!-@HV"E
MHH 38*-@I:* $V"C8*6B@!-@HV"EHH 38*-@I:* $V"C8*6B@!-@HV"EHH 3
M8*-@I:* $V"C8*6B@!-@HV"EHH 38*-@I:* $V"C8*6B@!-@HV"EHH 38*-@
MI:* $V"C8*6B@!-@HV"EHH 38*-@I:* $V"C8*6B@!-@HV"EHH 38*-@I:*
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M9Q[DX.0:ZN[TZ*\DCD?.8B2 #@9..OTQ3[RT2_B:)^C#MP?4?K0!D7-P7U:
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M#OU_#BKFGVKV<01Y#(03RW7G\S^9/Y<  LT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M7+^(;*2SLE620R$2\$Y'!4\=3GD=3SV'%3C3Y[NXD@2=XU@6-0!GH5]BO/%
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M_9I)DA=G8(!B&%?J<GVQQCJ!R,9K+L;B2WLKI5+)L9"!G# EL'D '.  ?Y4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
#/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>sgmo-20201231_g2.jpg
<TEXT>
begin 644 sgmo-20201231_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1"<17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0>.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A<6EB(%-H
M96AZ860   'J'  '   (#   "&H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BK_P  1" 'W!!T# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM]1D,<,<Q1=[R2C>0.I&T8SQ3=*\/RR>-]&NO!WAS6/#]I;R!K][\NBRKD9
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MV'B/X:ZEXGUFXN)]8Q/*MVT[ Q% 2 !G&.._KQBO4/#WA'1_#%G+!IEMS/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@#R+0/B-K^H?&:7PU<R0'3EO;N$*L(#;8Q(5^;_@(KUVOGCPG_R<K/\
M]A.__P#09J^AZRI-M._<]C-J5.E4IJ"M>*?SU"BBBM3QPHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y^?PFK^)+G6[;5]0M+NXB
M6%O*$+*J+CY5WQL0"1D\\FN@HIIV Q9?#,=U/IT^H:C>W<VG7!N(9)/*4DE<
M;2$101^ /O4MCX>M+"357ADF8ZI,9IM[ [25V_+QP,>N:U:*+L5D<ZG@K3XM
M)TNRMKB[@DTDDVEXCKYT>?O#)4J00<$%<$5KZ?8-8QR"6]NKV21][2W+*3T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX#'\*ZRD]D-!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M /GCPG_R<K/_ -A._P#_ $&:OH>OGCPG_P G*S_]A.__ /09J^AZQH[/U/<S
MK^+3_P "_4****V/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"O
M!?V=U(4M;N"9P,E8Y Q ]>*L5X)\"_\ D>+S_L'/_P"C(Z][JYQY78F+NKA1
M114%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\\>$_^
M3E9_^PG?_P#H,U?0]?/'A/\ Y.5G_P"PG?\ _H,U?0]8T=GZGN9U_%I_X%^H
M4445L>&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '@GP+_Y'B\_[
M!S_^C(Z][KP3X%_\CQ>?]@Y__1D=>]UK5^(SI_"%%%%9&@4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 ?/'A/_DY6?_L)W_\ Z#-7T/7S
MQX3_ .3E9_\ L)W_ /Z#-7T/6-'9^I[F=?Q:?^!?J%%%%;'AA1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!X)\"_^1XO/^P<__HR.O>Z\$^!?_(\7
MG_8.?_T9'7O=:U?B,Z?PA11161H%%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS/\ OD@<=RP[5ZI6E65W9$0C;5A1116)H%%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH%U2YMHY'9 ,A 7XP.0!GKN]:SOA0[7$'C](;C[:KX:.9(1$)MPF^<(/N[L
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MF3C 'T _*O4ZTA)RC=GGXRC&A6=..VGXI/\ 4****HY HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHK@OBMX^C\&^'6@LY =7O5*6R \
MQCH9#].WO]#4RDHJ[-J%">(J*E36K/*_C'XL'B3QD-*M)-VGZ22I(/$DW\1_
M#I^!]:]%^#/A3^RM ;6KN/%UJ _=9'*1#I^9Y^F*\>^'7A*7Q9XHALWW&W0^
M=>2^BYY&?4GC\:^JXHDAA2*)0D:*%50. !T%<]%.3<V?29O5AA:$,#2^?]>;
MU'4445U'RI\L_%SQ_P#V]\1[K3K>7-EI+&V0 \-(/]8W_?7'_ 16=I.HX92#
M7">/]%U+PC\2M7L]51E>2ZDGCD/26-V+*X/?(/YY':KVC:GD+DU[6!Q'*N4\
M_$TKNY]$>$-:AN;<VEUAHY!@YK-U+P]>6?BBV72RRRO,I@D7L<\&N'T+6&AD
M0AOUKWWP;"U[ID&I7<?S8(A+#G'0G^GYUZ6(K+#Q=5;/2WF>;2H2G544=0H(
M4!CDXY..M<=XO^)>D>$[D6.U[_4VQBT@Y*YZ;CV)[  GVK7\6>)[/PIH,E_>
MOAV/EV\>,F64@[5 _#)] #7F7PRM1H]U<ZQJ\"ZCJ=XY>2]8_/'GDA0>F3G/
M3L.U?).M1I.]5GO3E;0UU^)_B6 "YU+P;?6]D>3)]GE^4>I."1^*BNN\/>.=
M%\10H]I<HK,=N"X(W>FX=_8X/M6_!/'<P)-"VY'&5-<KXJ^'VG:\)+W30NEZ
MT!F.^@7&\_W95'$BGOGGT-=*J4IZ2C;S7_!)Y9K6+OZG745PWP]\676HM=:!
MK\9@UC36,<L;-G./0]Q@@@]P1Z&NYK.I3=.5F:1DI*Y5U34;?2-)N]1O6V6]
MI"\TK>BJ"3_*OCNY\97'BCQ!=ZM>-^\NI2^W/"+V4>P&!^%?5?Q"T6[\1?#K
M7=)TT_Z7=V;QQ G&YL9"Y]\8_&OA2SEN--OY+6Z1X9HG*/&XPR,#@@CL16V&
MJ^RG<SK0YXV/9]$U3RY48-7K6G3VWB+0S:3$>:%^0^]?.^D:ED+S7HWA?6Y(
MKF-8R2S$  =Z^FC)5H*SLUL>%6IM,[/P'I6H67CPB$M'#'&WVCCAE[#\\5ZX
M3@9/ JAI%C]EM1))&%N)@#*>_L/\^]<5\6?$H@T=O#.FW?E:KJ2#<5',4&[#
M$GMN *C\?2OF\=B8UJOM'HCV<-3=*BE+<;K/Q>LX]4;3/"NG3Z[=J<$VZEDS
M[;02P]^![U!%\5=1TZ1?^$L\.W&EPL>)I8GC3_OH@K^9%6_AT-/\-:)!IR62
M0-)CS;M3EIG]6]O3L!7H#HDL;)(JNC##*PR"/I7/3Q%":]R*:^=RUS35U(H:
M3K^G:U$'L+A7)7=L)YQZCL1[C(K1KS?Q7X&ET,/XA\!QFUN+<F:XTV#B.X Z
MM&O19 /3ANA'-=7X/\3VWBSP[#J-LPW$ 2*.S8_D?_K=JN=.+CSPVZ^14923
MY9[F[575-1M](TF[U&];9;VD+S2MZ*H)/\JM5SGQ"T6[\1?#K7=)TT_Z7=V;
MQQ G&YL9"Y]\8_&L#4^5+GQE<>*/$%WJUXW[RZE+[<\(O91[ 8'X5T^B:IY<
MJ,&KQBSEN--OY+6Z1X9HG*/&XPR,#@@CL17<Z1J60O-?0X'$Z)'EXBCK<^B-
M.GMO$6AFTF(\T+\A]ZH> ]*U"R\>$0EHX8XV^T<<,O8?GBN,\+ZW)%<QK&26
M8@ #O7T!I%C]EM1))&%N)@#*>_L/\^]:8VJJ%*45JI_AW.7"49.M?HB^3@9/
M KSG6?B]9QZHVF>%=.GUV[4X)MU+)GVV@EA[\#WIWQ9\2B#1V\,Z;=^5JNI(
M-Q4<Q0;L,2>VX J/Q]*=\.AI_AK1(-.2R2!I,>;=J<M,_JWMZ=@*^95>A3=I
MO7L>S.6O+>Q4B^*NHZ=(O_"6>';C2X6/$TL3QI_WT05_,BN\TG7].UJ(/87"
MN2N[83SCU'8CW&15]T26-DD571AAE89!'TKSGQ7X&ET,/XA\!QFUN+<F:XTV
M#B.X ZM&O19 /3ANA'-=2E2J:-<OFMOF)JI'5.YZ116%X/\ $]MXL\.PZC;,
M-Q $BCLV/Y'_ .MVK=K"<7"3C+=&L9*2NCB/BWXR_P"$)^'UW?1/MN[AA:VO
M/1WSS^"AC^%?,FE:KYN&9LD\DDU[5^TYX>U'6?AW:WVFQM,FEW7GW,:<D1E2
MN_'L>OL2:^8]%U)D8*3R*[,'6]G*W<Y\13YU<]R\-:R;>X0[N]>AZU90>(=$
M%U;@?:(U^8#N*\'TC4ONG=7K7@'4KB_U&*R@&\OU'8#N3[5]%*2E%58NSC^1
MXE2D^:R.N^%-I>VVFWQG9A:-*!$A[,!\Q'_CM=MJ.I6>D:?-?:E<);6T*[I)
M'. !_C[=ZDM;:.TMD@@4*B#@ ?F:\;^)&JQ>-/%%IH5A=%]-TR8F^5"0)I00
M-H/^R-PSV)/I7RN)Q$*E656>B9[L(NE22?0V'^+M]JUPZ>#_  S>ZE#&<&?R
MF8?DO _%L^U7=+^*T7VU+'Q+ILVDW;G"QSJT;-] X&?P)KIO#5_9?8XM.M;.
M.P$*8C@C^Y@>G^?SK4U'3+'5[)[35+."\MW&&BGC#J?P-*%>C.-XQ37J[_U\
MAJ,I*ZE_D/L[VVOX/-M)5E3.#CJ#Z$=0?8U/7E&JV5[\*]8@U/2Y);CPU<2+
M%+!*Y9K,D\+N/)C)X!/*G Z&O4;.[AOK.*ZMFWQ3('0^H-.I322G%W3_ *LR
MH2;?++<FKB?BUXR_X0CX?7=_$^V[N&%K:\]'?//X*&/X5VU>,?M-^'=1UGX=
MVM[IL;3)I=UY]S&G)$94@OCV[^Q)K):,T/%-*U7SL,S9)Y))ZUWWAO6#;W"'
M=WKP[1=1*,%)Y%=[I.I?=.ZOIL'B5-69X^(HV/>]5M(/$>ABXAQ]HC7G'<59
M^%%G?6T.HM*S"S+J$0CC?W(_#'Z5R7@/5+B\U&&S@!=I#@CV[U[7:6L=G;+#
M"H55YX&,D]37/CZOLJ3H;IZKR1.!HR]IS]$)>WMMIUC->7\Z6]O"I>260X50
M.YKS:;XOSZG>20>#?#MYJJQG#3"-B/R4<?B0?:LOXIZPOBS6;?POI=X1;64Q
M?4=O1W&-L8/MR3Z''<5Z!X4O;""Q@TNTL8].2-<111\J?QZY[\]?6O CB*$)
M<KUEV/5E*\N6]CG-/^*_DWB6GBK29](F<X3SU:+?]-X /X-7?6.HVNI0^;9S
M"11]X="OU!Y%.O+*UU&U>UO[:*YMY!AXID#JWU!KS#Q#HMW\,[M/$'AIY&T-
M6"W=BS%A:@G[RYY\O/5?X>HXZ=2]G5=K<K_#\=B7SPUO=?B>K454TK4K?5]+
M@OK1MT4R[A['N/P-6ZYFG%V9LFFKH^8?CQX[:]^(B^'X9/\ 1M*0!P#P96 )
M/X @?G7,Z5J6=I!I/VA/!VH^'/B5<Z\R,^GZO)YL4PZ*^T!D/OQD>U<CHFIY
M5>:]3 XCD]TX\12YO>/H'P;XA$$JHYRIX(-:'BKP[]JNH[C34WBX8 *OJ:\K
MT;5"C*0U?0'P[BGO-)6^NU_=Y_<[AU([UZ]>LJ,?K$=]K=SRH8>4ZBBCK-+M
M9++2;6VFD,LD,2HSL<DD"N2\:_$FT\,7L>DZ?;/J>LS ;+6+)V9Z;L<Y/H.?
MI6_XJ\2V7A+P[/JVHY,<6%1%ZR.3A5'U->4^ 5N(=>O_ !(0EU?W[M)(\R;C
M&I.=JGL,8'T KY&>(I4GS53W9RY58VTUGXKNOVQM"A$/7[.'B#X_W2V?PSFM
M?1?B;;S78T_Q!:RZ;?=XI8RC?7:>H]U+5V.FZA'J5F)HQM(.UUS]TU7U[P[I
MGB736LM8M5GC/*MT>-NS*W52/45TQKPFM8JWEI_7S%R/>,C0BECGB66%U>-Q
ME64Y!%/KS'PGJ>H>#_&$G@[7YVN(9AYEA=L,>:A. 3_M9^4CUP>]>G5-2GR/
M1W3V+A+F6NX4445D6%%1W%Q#:6[SW4J0PQC<\DC!54>I)J'3]2LM6LQ=:9=1
M74!8J)(F##(."* +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4CHLB,DBAE8896&01Z4M% %>QTZRTNV^SZ;9V]G "6\JW
MB6-<GJ<  4P:5IXU,ZD+"U%\5VFZ\E?-(QC&_&<8]ZIS^+?#EM<26]QX@TN*
M:-BCQR7L:LC X(()R"#VK4AGBN84FMY4EB<95XV#*P]01UI:&LE4C[TKJ_XE
M*/P_HT6H&_BTBQ2\)W&X6V029]=V,TZ\T32M1N8[C4-,L[J>+_5RSVZ.R=^"
M1D5>HHLB?:3O>[*L.F6%OJ$U]!8VT5Y.,2W"0J))!QPS 9/0=?2HQHFE#5/[
M3&F68O\ _G[^SIYO3'W\9Z<=>E7J*+(.>7<I7^C:7JK(=4TVTO3']PW$"R;?
MIN!Q3[33+#3Y)9+"QMK5YL>:T,*H9,<#<0.<>]6J*+(7/*W+?0SX?#^C6\T\
MUOI%C%+<*4F=+9%:53U#$#D'T-36^EZ?:6'V&TL;:"TY_P!'BA58^>OR@8YJ
MU5>_OK;3-/GOKZ40VUNADED()VJ!DG YHT17-.3M=L@L-!T?2YFETS2K&SD8
M89[>V2,GZD 5+'IEA%J4NHQ65NE[,NR2Y6)1(Z\<%L9(X''L*CT;6M/\0:7'
MJ.CW N;20D+(%9<D'!X8 CD>E7J%;H$W44FIWOL[E6UTRPL;BXGLK*WMIKIM
M\\D,2HTS<G+$#YCR>3ZFK5%%,AMMW84444""BBB@ HHHH **** "BBB@ HHH
MH **** "BBN3\>>/M/\ !&E[Y=MQJ$R_Z/:!L%O]IO11Z]^@]DVDKLUI4IUI
MJG35VSHM1U*RTFR>[U.ZAM+=/O23.%'TYZGVKRCQ%\?;.VD>#PUIQO",@7-R
M2B9]0HY(^I%>0^)O%6K>+=3:]UFY,AY$<2\)$OHH_KU/<FL:N2==OX3[#!Y#
M2@N;$>\^W3_@G;ZA\7_&FH;E_M;[*C'.RVA1,?1L;OUK)/CGQ:\F\^)-4SG/
M%VX'Y9Q7/BIHR,UCS2?4]N.$P\%:,$ODCJK'XF^-;&16CUR>8+U6X"R@C_@0
M-<WK.HWVNZO)J6L3O<74IRSMV] !T ]A5JV6-C@UI)IBS+E<&DVVK,N&'HTY
M<T(I/R1[?\(H_#-MX7$'AZ_BO+QP)+TD;9-W3E3R%'0=OSKT"OD8V-WI5U'>
M:=-);W$3;DDC;:RGZU[5\./BPOB&9-&\1^7;ZJ>(I@-J7/MCL_MT/;'2NNE5
M3]UGR.:955A*6(@^9;ONO^ >GT445T'S1Y]\7_AC:_$?PLT<2I%K-F"]C<'C
MGO&Q_NM^AP:^.[476E:E-IVHQ/;W5M(8Y8I!AD8'!!K]!:\*_:!^$QUNS?QC
MX;@_XFEHF;V",<W,0'WP.[*/S'T%7";A*Y,H\RL>4>'C=7;.UK'O$"[W)'"C
MMGZFO1+/]HG4- ,=MKGA^">TB 3=9,8V11QPK9!^F14_PNTJTM? "6EPJFYU
M-!<RR=P2/D7Z!?U)KBO&?AX132KMZ$]J]JO1E5I)O='AT<8E7<5L==\8O%MG
MXR\%>'?%WA>=[K2[&\>.]3;A[=W4!?,7MT(ST^88ZTGA?Q];QZ28Q*FR11G.
M.U<7\(YKGPUJ&K3R0+=:7<[(+BSF :.<<E@0>. 1^=>K:G\(]!O+*T\4?#.V
MAM[N$^<ME(Q:&<@YV[6)"."..W8^H\+$Y<YQC.>B?4]5SA5;2W1Z7X-\\^%[
M:6Y5D:;=*JL,$*Q)'Z<_C6Y7'^!_'<7B>%K._A:RU>V)CN+:1=I##KP>A]OQ
M&1784W2=&T'T-H-..AYOXZMET/X@Z!XE@(B^T;K2Y;H'*@NF?<KYB_B!7I (
M905.0>01WK"\9>&8/%OA>YTN8[)& D@E'6.5>5;^A]B:Q_AKXH_MC0QI6I'R
MM8TO-M<PN?F.WC=_C_\ 7K=^_27>/Y/_ ()*]V;\SM:^??VB/A)_:%O+XU\-
MV_\ ID"[M1@C',J ?ZT#^\!U]1SVY^@JS_$%T;'PUJ=VO)M[2649_P!E"?Z5
MSFI\(Z-?94<\CK7H_AK5-2T9(==L;:*7R7/E?:$+(S#J< CI_.N9U'X;ZG8V
M.C:YIHWZ;JLZVKOC_CWE) ^;V.<@^Q'I7N\VD:?<>#;?3K&-4%A$(XQW9?4^
MY.2?<U[F&4VI0?31GBXVO&DXM==3,T;]IBVAODM?&.CM:1L=OVRS8NJ^[(><
M?0GZ5S'Q0U8Z=\7TUOSA/I.LV<$MA=(<QNJKM(!^O./]JN*\6Z" TGR_I7?_
M  ODT]?!=EX<\=646H:/<.TD8N%R;4LQVLIZJ".N/7/KGSZF!G4<H16RN=L,
M3"4$Y/<Z'3?&7]J6=KIUKB6:0^7"B#YF9J]RB5DA17.650"?4UXU>^ YOA9K
MG_"4^![07NEE?])M&!EEMT/4H3DE/7'(]QT]1\-^);#Q1I,=]ILFY64%D)Y7
M/\Q[UY]'!^Q@YQ=T]_(WA:,G$UZ\V\,0)X8^*^M:/"1':7Q6[@BS@#S 6.!Z
M!UD'_ A7I-<!\4-#G^SV?BW2%;^T]#;S"$_Y:PYRRGUQU^FZNNBUS.+V>G^7
MXE5$[770[^BLSP_KUEXDT6#4M.D#QRJ"RYR8V[J?>M.L6G%V9:::NCYZ_:,^
M%4=S9R^.-!B6.Y@ .I1+QYJ=!*/]H< ^HY[<^#:-?94<\CK7UW\;+EHOA\MN
MIPMY?00O[KDOC_QRO!OB/\'KKPIJNCZEH(9M)U<PQ2$\_99W SG_ &2<D?B/
M3/11O"TUU=C*I9W3Z$OAK5-2T9(==L;:*7R7/E?:$+(S#J< CI_.N^T;]IBV
MAODM?&.CM:1L=OVRS8NJ^[(><?0GZ5IS:1I]QX-M].L8U06$0CC'=E]3[DY)
M]S7B'BW00&D^7]*]'%T)3CS/='DX/&*4W'H=K\4-6.G?%]-;\X3Z3K-G!+87
M2',;JJ[2 ?KSC_:KJ]-\9?VI9VNG6N)9I#Y<*(/F9FKGOA?)IZ^"[+PYXZLH
MM0T>X=I(Q<+DVI9CM93U4$=<>N?7/77O@.;X6:Y_PE/@>T%[I97_ $FT8&66
MW0]2A.24]<<CW'3Q,3ECE./M-+JZ/2YH5;N/0]EB5DA17.650"?4T^LCPWXE
ML/%&DQWVFR;E9060GE<_S'O6O5RBX/EEN=*:DKH\V\,0)X8^*^M:/"1':7Q6
M[@BS@#S 6.!Z!UD'_ A7I-<!\4-#G^SV?BW2%;^T]#;S"$_Y:PYRRGUQU^FZ
MNL\/Z]9>)-%@U+3I \<J@LN<F-NZGWK:I[\(S^3^6WX&</=DX_,T71)8VCE5
M71@596&00>H(KX[^-WPL?X>^(QJ^BPM_8%_(?+"\BVD/)C/MU*^W':OL:O-_
MCL$F^&WV&49BOKZ&!_IDOQ_WQ64(N4DENRY-)-L^5])O_D5MW%>G:%XQUSX?
MK]IM=/M96N(P76Y1MP7K@$$8SQ7.:'\-[[PS\4;?2]=02Z?'$-0AE(^6YCXV
MC_OH@,/8]B*]4\<Z7!JEJ+^!1EQ\X'8U[-%2K46GLSQ<3B%0KJ*-/P1^T)H?
MB75HM&URU?1-1F8)"SOO@E8] &X*D^A'XUY!H&KW/A7Q;J6CZV&BOK6[D$GF
M=7^8D-[@@YS[UR'B'0)&O%2V4^<SA8\=<D\5]":'IWACX@10:/XYTZ*YU6WB
M\NVU ,8YI% Z;U()(ZC.<_S\JM@9U*<G;1'I*M":47U-3PCXBD\2>*[46WS>
M4#+,R# 50I'/U) KU2O&=%COO@KJO]G7T N_#=[*/*U!(P'5CP%D/9OJ<'M@
MY%>P6MU#?6L=S:R"2*095AWKFIX7ZO37+JGU-:=E[O4AU?2[;6]%N],ODWV]
MW"T4@]B,9'N.M<?\);V9O#,FF7D@>YT^5HI!GE2&96X_WD)_X%7>5YAKJ+\/
M?B5#XCC5QH^N'R+\+]V*;L_XXS^#>M=5+WHRI]]O5?TPJ:-2['I]-=%DC9)%
M5T8$,K#((/8BDBFCGA26!UDC<!E=3D,#W!I]<YJ?''QQ^& ^'GB:/5-&4+HF
MI.QBC!_X]Y.K1_[O<?EVYY72;_Y%;=Q7TE\4-,MO%?Q0\.^'-44R6+VK/(@.
M,[Y,$@]CB/K7CT'PNO/"/Q?30M7!GTI ;R"=AQ<PJ1A3[[B P^O8BN[#\T)1
M2^U_G8Y:\H\DI/H;F@^+=;\!*+ZTL+:5[B($K=(VX*>>"",9XKT'P9^T5HFN
MZM#I'B.S;1+R9@D4QDWP.QZ#=P5S[\>]5/&VF0:M9"_@4;F7#@=C7@7B;06,
MQ$*$N6P@'<]A71C*#?[PX,#BU-<K.RM]2NO"?Q$UO2M<#1W27\LFY_\ EJKN
M65QZ@@@UZ]X8\2OXC\2:?!:X=U97D*# 5%ZD_P OQK,\-6?AWQG9V/A_Q_IT
M-]?6L*Q6E\S%)3@<IO4ANN<<\_7K+I^GWWP1U=PL'V_PQ>R &\"?O83T"R-_
M(_=/L:\BME;6(M/1[KS.Y2A-*HMCVFHKFVAO+2:VNHUE@F1HY$89#*1@@_@:
MCL-0MM3L8[NRE$D,@R".WL?0U9JFFG9G4FFKH\Z^%+/I:ZIX;GF,C:=<R1(&
M/S;5; )^J&,_G7HM>9^-[9O!OC:R\=6:,UK,1:ZK&G]TC:K_ ,A^"UZ-9WEO
M?V<5U9RK-!*H9'0Y!%;UO>M4[_G_ %J9T_=O#M^1F>+/"VF^,_#-WHFLQ"2W
MN%X;'S1L/NNOH0:^(O$WA;4_A[XPN-$U=2"C9AF ^6:,_==?K^AR*^]J\/\
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M:6=OINOP-N:Z@B4/')V8_P!]3[_GFO&Q&7.5)5)_#<];VL*LN1;G4> ([LZ
MUY>QM$;M_,C1Q@A,8!([9ZUU->;^$O%VK:/JP\+>.8C'>(/]'NP<I.G3<#W'
MZCOZUZ14.C[%**VZ,VIR35ET.!^+%@AT?3];'R2:7>(S2C^")SL8_0$J?PKL
M])ODU/2+6]B<.L\2OE3QDCG]:??V-OJ>GW%C>QB6WN(S'(A_B4C!KSKP'K'_
M  B.M77@779?+-O(7T^=SQ+$QRHS_GG(K:-YTN5;K7Y=1/W9\W<]-HHHKG-3
MQ?Q?;WGQ7^(C^$H+N6VT#2VS>O"<&5QC/Y$A1Z')[5ZOH.@:=X:TB+3-'MQ!
M;1Y(&22Q/5B3R2?6O//@>@N+'6]3DYGNKPLS'KRS-_,UZI6];W7R+I8SIZKF
M84445@:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6#XV
M\12>%/"%[K$%M]ID@"A(SG;EF"@MCL,UO4R6*.>%XIXUDC<%71UR&!Z@@]:3
MO;0NG*,9IS5U?5=SBOAAXZO/'&D7<VHV<5O/:RA"T (C<$9X!)(([\GJ*[BJ
M]E86>FVPM].M(+2 '(B@C"*#]!Q5BE%-*S-,1.G.JY4X\L7LCP'1]6\':9XT
M\=?\)K;V\_FZC)]E26T,S'$DN\(<':>5[CMZ5O?#W4;GP+\)]2US6(919O/Y
MMC:N?F8-@#Z!B?T)[UM>$O!-Y%KGCE?$=@HT_6KLM 2Z/YB%YCNP"2IPZGG!
M_*L?2? 'B6?X=ZWX/U5!#''<"73+II59) &SM(4DJ#C/(_C/IBL$I+6W<^AJ
MUL/4YH.6EX7UTM97Y>S77<2/XN:O8G3KW5SX=N+"]D57M].O"]U:AN<NNX]!
MUP.O!P36WJ?CCQ$/B5=^%-"TZQN&6!'AEN&9!'E0S-(0>5&<8 SR*S-#\/:Y
M##86%W\./#L4D!C2;4YFA<.JX!?8HW;B!G.>M4-1GU>U_:&OY] LH;ZY2R0M
M;2R^7YJ;$R%8\!NAR>.*=Y):LCV6&G4DH1CI&3W5MU;9Z?-^IO:/\1=7EMO%
M-CK=A:P:UH-I+<J(=QAEVJ2."<XSM[\@]JA\)_$/Q1K42:OJFAV]MX=BMI9+
MF]CSN+1JQ)0%L[<J1T/UJ#2/!7B*>+QEK>MVL5OJFMV4UM;6,<RMMW(0 6!V
M]E&<]B3BN@\'^%KVV^$,?AO6$^R74MM<P2@,K^7YCR8.5)!X8'K3CSMF%;ZG
M"$N51;;BM]KKWFM>C]4<@_Q@UMM,;7((_#JZ>)<#39+T_;BF[&=N<?IG'.".
M:W/$7Q+O(M4T+3_#R:; VKV:7BW>K2,L**V<(=I'S?+^9 Q6%H?A'Q#H.E_V
M1<?#[0=8EC=A%JMQ)#@@L3EP1O;&?;C [5TOC+2-5O+6TT^+P9IFN6*6:HHC
MN%MFM9>0=A;HF N ,'BDN>QK4C@U62C%6U^TMNG7\[7#Q+X[UKPMX(L]0U+3
M;,:I=7/V<;)2UL!R1)D'." #C.:LV^N:]+X+U^]U^VT.\CM[%YK:6PD,UM<X
MC<LC*3G PH/KNXK(T7POXE\._#2VTFXTBQ\02-<L]QIUQ. $B(X5';Y001GV
MW<>M4_#/@37;#2?&#-IR:7'JUE+#9Z2ET)0KE& R^=O?&?<] *=Y7,O9X90E
M9QNI;]U=;*]UIZJW4M6OQ&&B_"31]6CTFT6]U"62"VL+-/*A#"1QD#G X!([
MD_E/=>-_%?A;6M*A\:Z?I1LM3D$2S:<\FZ!N.&W$YQD=/?!K*E^'&NW?PET#
M3UCCM]:TBXDG%O+(I5LRNV-RDC."IZ^U7=3T'Q=X]UK1O^$BT:WT/3]-F$\V
M+M9GG;C.W;TZ8YZ9ZFE>=ON-.7!N3?NM7G?76WV>777Y7\RS)XX\5W_C[6?#
M/A_3M,E>RVM%/=,ZK&F!N+X.6)+  *!6M\._&EWXNM-0BU6TBM=0TV?R9UA)
MV'KR,DXY4CJ>E4_#GAG5K#XO^(M;N[79IUY"%@F\Q3O/R?P@Y'W3U H^&OAG
M5O#^J^)IM7M?L\=]>^;;GS%;>NYSGY2<?>'7%5'FOKYG/76&]C)12NE!JSUN
M]^OWG?4445L>*%%%% !1110 4444 %%%% !1110 4444 8OBSQ/9^$?#EQJU
M\-XC^6*(-@RR'[J@_P!>P!/:OE#6]9O/$&M7.IZE(9+BX<LW/"CLH] !P!7>
M_&WQ4^K^+?['@?\ T/2_E(!X>4CYCT[?=[]#ZUYG7#6GS2L?>9-@E0HJK)>]
M+\N@4445@>Z%.#8IM% %J"XVL,FMRPO]I'-<T#4T4QC;(- '>QR17<6'QN[&
MN=U?3S%)YL64=3D%>"#3;+4",<UH7$ZW-OD]0*8SV;X3>/#XKT5M/U*0MJU@
MH$C,>9X^@?Z]C[X/>O0J^2/#^O3^$_%UGK%L"P@D_>1@X\R,\,OX@G'H<'M7
MUG;W$5W:Q7-LXDAF021N.C*1D'\J[J,^:-F? 9S@EAJW-!>[+\'U1)1UHHK8
M\0\UU[P/=Z9J!NO#T/F6;G/V>/K"?0#NOH!TZ5Q_BG1;^]B4BQG\UB%YC(Y/
M%>]5Y)\3?B L>JC0=+FX@8&[=3U;LGX=_?Z5[6#Q=6I:BTGY^1X^)P-*,G63
ML^QSUSX4'A_3XK2/#[%R[@<.QY8_G5[P1XJ?PSJWV>Z8_P!G7+ 2@_\ +-NS
MC^OM]*+;7DU/3Q%.06 X)K OH@)#CI7O^Q56A[*HC@IU)4Y\RW/6/&_AX.J^
M*M%>.#4[*/=(X.%NH1SM)'\0ZJ?7CH:W;7Q# QV70\MNFX#@_P"%<1X:U:ZO
M/A?JEO=MN6U @B<]=K8&W\,_J*TXHS</(!U1RK CH1V(_P ]:^96'2<J51_#
ML=N*Q<Z3C4I]=SNHY4FC#Q.KJ>A4YKR/XK:%=:!K,'C;0G>#YECOC'QL/1)?
MI_"?P]Z]-T=XQ:B%4".O)Q_%[_6K5_8V^IZ?<6-[$LMO<1M%*C=&4C!%<<)N
MC4NCTHN->DFNIR_@/QO'XJLFANPL.I0#]XB])!_?7^H[5OZ_:F^\-ZG:+]Z>
MTEC'_ D(_K7SY!'J'@;QA/9"0_:M)F'ER'_EM"PRC'ZKP?<&OH71M5@UO1[?
M4+7_ %<RY*D\J>A!^AKIQF'C!*K3^&7X>1-"JY7A/=' ?"*&T\0?"5;"^C$L
M1<K(A['"L"/0@\@]B*JS^%]:T*]=$A>[M<_)-$N<K[@=#3O@_G2=>\5>'#PM
MG?.8AZ)O./\ QUDKU*66."%Y9G6..-2SNQP% ZDTUBIT*KE'52UMZF57"4\1
M349]#Y^U#P;<:UX@AM98)(()"7E=T*@*.2.>YZ?C3]6TO['(8PFU5X  Z 59
MUWXCOK7BAIK-V6Q@.R!>F1_>/N?\*M7FH1:K:B3C?CFOH\+SWYVM]_(\>I#V
M;Y$[I'2_#3Q<7VZ!J4GSJ/\ 1)&/4?W/P[?EZ5=N-$;PAXQAU'12D6G:D[BX
ML^@CEV%BR#^ZVWD=F (ZFO*9#);7*RP.4DC8,C*<%2.AKUB_U*?4M$\.W5TN
M)I4DE<*O7$9!( ^N?QKRL=A51K*<=I:,[Z=>4J$EUCL=1:Z[:7&%=O)?T<\?
MG_C6B0LB$, RL,$'D$5Q-K#YACFPKJ<,.X8>OTKL;66.6W4Q*%4#&T?P^U>5
MB*4:;]TUP.+E73C/='ANIIJ7PG\>,-*)_LN^)FMHV^XZYR\)]USD'K@U[)X>
MU^T\2:/%?V1P&XDC)YC;NIK-^('A4>+?"4]G#M6^A/GV4A_@E7I^!Y4^QKR3
MX=>+&T/58II@T=G=?N[J$_\ +-@<'CU4Y_#-=<*:Q=%V^./XHVE)T*FOPO\
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MW1ZDX^TA>+UZ&EX>U^T\2:/%?V1P&XDC)YC;NIKC_C="7^'\<X&1:ZA;R-[
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M)T&H#S?VD;$PGF.Q42?]\RG^1%>J5Y#\+9G\8>/M?\9LK"U9S#:[O[N %_\
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M&\%V]SI'CM+JR=H9%A=@ZG!!&"#^=?6_@KQ9%XIT<.VU+Z#"W$0]?[P]C_\
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M1[88F.#%$>>1ZM@'V&.AS7J==U&'*KL^$SK&K$5E3A\,?SZA1116YX(4444
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M++YQA.[W.3%1<HVZ'HZ3B1>:]F^$-R\GA>YMV.5@N3L]@0#C\\G\:^?[.]W
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M\(,EQ:0-=7ZC_C\N/F<=0=HZ+P2..<=S77UTTZ-M9'RN89VZJ=/#Z+OU^78
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M4O /A?6/%LIET^SEEM(3^\EQA2W]T$\9]?:O=?'OP7\,?$#5[74]26:TNX6
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M_P"?O_R&G^%'_"2ZM_S]_P#D-/\ "G[*0<Z.^HK@?^$EU;_G[_\ (:?X4?\
M"2ZM_P _?_D-/\*/92#G1WU%<#_PDNK?\_?_ )#3_"C_ (275O\ G[_\AI_A
M1[*0<Z.^HK@?^$EU;_G[_P#(:?X4?\)+JW_/W_Y#3_"CV4@YT=]17 _\)+JW
M_/W_ .0T_P */^$EU;_G[_\ (:?X4>RD'.COJ*YC2=7OKFU9YY]S!R =BCC
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M]17 _P#"2ZM_S]_^0T_PH_X275O^?O\ \AI_A1[*0<Z.^HK@?^$EU;_G[_\
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MVBL+[1-_SVD_[Z-<U=:G?+>3*M[< "1@ )6XY^M'LV'.>A45YO\ VIJ'_/\
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M[-OF.6Q][UJ94VE<%*[L=)1116984444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7,>/=>U;P_H4=SHAT:&2281O=ZW>?9[6W!!PS'JV3@!1SS73UROCZ'5I]
M'A32_"VF>*H?-S<Z9J$B1[P!E60N"F0?4?2@#@]/^(7CGQ9\-=3?1K""/7QJ
MJ:;8ZAID+36<HWC?./,# 1A5<;CD9([\5[!('6Q82-N<1$,P&,G')KS?X->"
MM:\*'Q#>ZU90:/#J]VL]MHMM/YJ60&[/(^7)W <?W![ >E7'_'K+_N'^5-;@
M85<'\0O'&J>&+N"#0;.WO'M[634=168,3':HRJ2N&&&.6QG(^4UWE<?<?#NR
MU/Q)K&KZU?7ER=1CCMXX;>YFM5A@5<&,^7(/,!)+'=QSTKI=^ABCK+>XBN[6
M*YMG$D,R"2-UZ,I&0?RJ2L7PAH,WACPI8Z+/?G4/L2&*.<Q>62@)V@C)Z+@9
M]JVJ8@K@8==\6M\37\*R7^BF*/35U%KA=+E#,#+L\L#[1P>^[GZ5WU<^GA;9
M\1Y?%?VS/F:6-/\ LOE=,2;]^_/X8Q^-)C.@HHHIB,7Q?XEA\(>$;_7;F%[A
M;2,%84.#([,%1<X.,LP&<''7!K*TG7=4'B"UTS6]=\,O?2*?M&DVQ:.Z@/EE
MQMS*QDP,9^1,J2V>,';\2>'['Q5X<O-%U4.;6\38YC.&4@@A@3D9! (R".*Y
M^'P5J\_BKP]K.N^((+\Z"DZPK%IYA><RQA"TC>:P)P ?E51G/%)WN/0[2N4O
M/^/Z?_KHW\ZZNN4O/^/Z?_KHW\ZH1S/B/7KK3M0TK2=*ABDU'5976)Y\^7$D
M:[G=@.6P",+D9SU%2^'=7;4VNE.L:/JRQ;")=,;!7.>'3>^.G!W<\\#&2NO^
M'1K%QI]];71LM2TV5I+6X\L2*-PVNC+D;E8<'!!Z8-0Z!X<N=*U[6=7O[^*[
MN=6,&]8;8PI'Y2%1@%V/(/K2UN&ECH****H1R>H^*+EO$5]IEA<:?IUMI<,4
ME]J&HJ616DSL0*'0=.=Q;VQ6[HMZVH:3'<-=65X6+#S[!]T4@#$ CDXZ<C)P
M<C)QFLZZ\-W,?B2;6]"U".RN;J)8KN.XMC/%-L^XV Z,& .,[L8[=ZF\)>'A
MX6\,VVD_:?M1A9V,WE[-Q9RWW<G'7'4U*O<>AM44450CC9]7\21^/(?#Z7FE
M>7-9O>"8Z?(2H#[=F//Y/OQ]*[*L67P_YGC:#Q#]IQY-BUI]G\OKE]V[=G\,
M8_&MJI0V;^A?\>+_ /70_P A5VZ6X>UD6REBAN"I\N2:(R(I]2H921[9'UJE
MH7_'B_\ UT/\A6E3 XCP;KWB77/$&M6VIW>E?9='OFLW6WL)$>?Y,A@QG8)R
M1QAN!UYR.WK \-^%_P#A']3UV[^U_:/[7OC>;/*V>3E0-N<G=TZ\?2M^I6PV
M%<UXO\2W6B-I>GZ3;17&J:Q<FVM?/)$46%+-(^.2% SM&"?45TM8/BCPNGB)
M+&:&[>QU'39_M-E=H@?RWP00RG[RD'!&0?<4W>P$7AK6Y-2O;NVEU_0=9,"J
M2=*RCQ-D@J\?F2<<<'<.<C'&:Z.N7T#PI>Z;XMU7Q#JVJ6][=:C!# 8[:S:W
M2,1YYPTCDDY]1TKJ*$ 5RGB#Q+J$7C'3/"V@);)>W=O)=SW5W&TD<$*' PBL
MI=F8X^\,>]=77-Z]X5FU#Q%IWB#1M173M5L8W@+RV_GQ3POR4= RGA@""&&.
M>O8=P1MZ>+X62#53;M=*2&>V#!'&3A@K9*Y&"5R<'C)ZTS5O^07-_P !_P#0
MA3]/ANH+)$U"Z6[N<DO*D0C4DG.%7)P!T&23@<DGFF:M_P @N;_@/_H0H$<U
M7$CQA>7WVZ\AU'1M%TVWNGL[=]44LUU(A.YL^8@1>@ PQX)/I7;5QM[X%NFT
M_5],TC5X[33=69Y)8)[0S-$[_?,;"1< \<$-@CCK0[] 5CKH)?.MHI<H=Z!L
MQON4Y'9N,CWJ2H+*V%EI]O:JQ<01+&&(Z[1C/Z5/3$1SS);V\DTIPD:EV.,X
M &37.>%]7USQ#86NLLMC!I]VS,EH8W\Y(^0&,F[:2<9V[!P>M=+)&DT3Q2J&
M1U*LI[@]17/^'_#FH>'X(=/@UA)=*MV;R87M?WP3DA#)NP0,_P!P'WI.]QG1
M44450BIJ0OC9DZ9<6]O,IR6N+=IE*X/& Z'/3G/X5A^ ]9U;Q'X:MM9U62R"
M72L4@MK=T,9#E>6:1MW3T%=*Z[XV7.-P(S63X3T#_A%_"]GH_P!I^U?90P\[
MR]F[+ENF3CKCK4]1]#8KL:XZNQI@<9\3?$6N^$/"-YXAT:73FBLUC#VMW:.[
M2,\JID.LJ[0-V<;3TZ\UU.G1ZA%:;=6N;:ZN-Q_>6ULT"8[#:SN<^^:R?'7A
M;_A-?!=_H'VS[%]L\O\ ?^5YFS9(K_=R,YVXZ]ZZ"IZCZ!1113$>?^+/B!?Z
M#XNCMK.WM9=&L/LW]LW$@;?;BXD*)M(( (P&.0>"*] K@KCX56&HVWB'^U]2
MO;B[UR:21IH;B:".)2H6)3$LFR38 ,%@<]^.*[#1[.XT[1+*RO;O[;/;P)%)
M<^7L\XJ -Q7)P3C/6DK]1NQ=HHJMJ,%Q=:7=6]E<_9+B6%DBN-F_RF(P&VY&
M<'G&13$<1X>^(%_JGCMM/O+>UCT6_>ZCT>YC#>9.ULP63<22"#\Y& .%KT"O
M/HOA+86&EZ!%I.IWMM>Z+/%-'<2SS31N5_U@$+2;$#Y.=N,9KT&DK]1NQS6K
M?\A2;_@/_H(KG/%/B"+POX:N]7FA:<6ZC;$IP79F"J,X..2.<5T>K?\ (4F_
MX#_Z"*P?$&AVOB30;G2KXNL-PH!:,X9"""&'N" :K6V@NHW2%UU0#KLNGR[X
ME)%I"\9B?NOS.V\>_P O3H<\:E9FDV>KVP UC58;[9&$7R;3R-Q[N^7;)X[;
M1R>#QC3H0@KF]>\175KK]KHFE_9HKB6W>[GN[P$Q6T"$ L5!7<2>/O#'4UTE
M8>K^'7O=9M-9TV\%EJ5K&T(D>+S8Y8F.2CIE2>1D$,,'UH=^@T3>']3;4[69
MVU+3-3$<FT7&FM\A& <,NYMI&>FXY&#QG%:U87ACP[+H/]IR75ZEW<:C>M=R
M-' 8E4D ;0I9CV]>];M"V$%<Q-KNIZCXQN]"T,VENNG0)+=7-W"\V7DY5%17
M3^$9+;O;'>NGKGKGPW=Q>)YM<T+48K.>[A6*[BN;4SQR[?N. '0JP&1U(((X
MXI.XT;MN9C;1&Z6-)R@\Q8V+*&QR 2 2,]\#Z5UO@O\ Y??^V?\ [-7)0(\5
MO''+*TSJ@5I6 !<@<L0  ,]>!BNM\%_\OO\ VS_]FJ9_"..Y1^*WC'4O!/A6
MUO\ 1?[.%S<:A#:;]2W>1&KYR[%2" ,9)[#-8C^)?'=[\-=1NK&[\/ZIK=Q<
M16VF3^%]]S#&68!FE,FY0%&XDG@#K75^/K2^N_#\2Z=X7TSQ24N5>73=1=%6
M1-K<HS@J'#%>2,8W5RWPB\#ZMX;UCQ)KFK:7::!'K,L1@T6TF$B6JH&Y)7Y<
MG=V]^G2N8V/2[59DLX4NI!+.L:B1P,!FQR<=LFI:** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *9,I>"15Y)4@?E3Z* ,;[!<_\ //\ \>%'V"Y_YY_^
M/"MFBM/:,CE1C?8+G_GG_P"/"C[!<_\ //\ \>%;-%'M&'*C&^P7/_//_P >
M%'V"Y_YY_P#CPK9HH]HPY48WV"Y_YY_^/"C[!<_\\_\ QX5LT4>T8<J,;[!<
M_P#//_QX4?8+G_GG_P"/"MFBCVC#E1C?8+G_ )Y_^/"N?N?#NJ274KI:Y5G)
M!\Q>1GZUW-%'M&'(C@?^$:U;_GT_\B)_C1_PC6K?\^G_ )$3_&N^HI^UD'(C
M@?\ A&M6_P"?3_R(G^-'_"-:M_SZ?^1$_P :[ZBCVL@Y$<#_ ,(UJW_/I_Y$
M3_&C_A&M6_Y]/_(B?XUWU%'M9!R(X'_A&M6_Y]/_ "(G^-'_  C6K?\ /I_Y
M$3_&N^HH]K(.1' _\(UJW_/I_P"1$_QH_P"$:U;_ )]/_(B?XUWU%'M9!R(Y
MC2=(OK:U9)X-K%R0-ZGC ]#5[[!<_P#//_QX5LT4O:,.5&-]@N?^>?\ X\*/
ML%S_ ,\__'A6S11[1ARHQOL%S_SS_P#'A1]@N?\ GG_X\*V:*/:,.5&-]@N?
M^>?_ (\*/L%S_P \_P#QX5LT4>T8<J,;[!<_\\__ !X4?8+G_GG_ ./"MFBC
MVC#E1C?8+G_GG_X\*K:CI=Y/821Q0[G;&!N [CWKHJ*/:,.5' _\(UJW_/I_
MY$3_ !H_X1K5O^?3_P B)_C7?44_:R#D1P/_  C6K?\ /I_Y$3_&C_A&M6_Y
M]/\ R(G^-=]11[60<B.!_P"$:U;_ )]/_(B?XT?\(UJW_/I_Y$3_ !KOJ*/:
MR#D1P/\ PC6K?\^G_D1/\:/^$:U;_GT_\B)_C7?44>UD'(C@?^$:U;_GT_\
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>sgmo-20201231_g3.jpg
<TEXT>
begin 644 sgmo-20201231_g3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A<6EB(%-H
M96AZ860   60 P "    %   $*:0!  "    %   $+J2D0 "     S8Q  "2
MD@ "     S8Q  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M *!MG_X&O_\ &JJT4 6O[?U+_H&V?_@:_P#\:H_M_4O^@;9_^!K_ /QJJM%
M%K^W]2_Z!MG_ .!K_P#QJE7Q!?@_O=-@*]_*NRS?@&11^M5** .CLKZ&_@\R
M G@X=&&&0^A%6*YG3)&A\00A?NW$3JX]=N"I_#+?G734 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_01744 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R^H?\
M(R7O_7&'_P!GIE/U#_D9+W_KC#_[/3* "BBB@ HHHH **** "BBB@ ILA=8G
M,:AW"DJI.,GL,]J=5?4);F#3;F73X!<W21,T,+,%$C@?*I)Z9- '$6GCOQ'_
M ,)M:^'=5\+VD$LD#W,SV^I"<V\2@X9@$&,G '/.:?X-\<>(O%L=A>CPY8VV
MF7C',PU4-*B@D$^7M!/(Z5D^ [/Q9I5Q=MK_ (2E?4=8F9]0U=M1A(48.Q1&
M"3M48  />M/X8_#VP\->'M+NM4T6WM_$,*N)K@$,X)9A]X$@_*0* ,R/XLZR
MGAX>)+WPI$F@"[-M)<Q:@&E7$FS/EE1GGMFO45(90R]",BO,? OPGTNUTF*Z
M\5:1OU5+N6;9)<L\>/,)0[ Q3ICM7I] !1110 4444 %%%% !1110 4444 /
ML?\ D8+'_=E_]!%=17+V/_(P6/\ NR_^@BNHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@#F-24IXDN=W_ "T@B9?< N#_ )]ZCK=U/31?
MHCQN(KB+/ER$9'/52.X.!^0-8C6>J1L5;36D(_BAF0J?^^BI_2@!M%+]FU+_
M *!5Q_W]B_\ BZ/LVI?] JX_[^Q?_%T )12_9M2_Z!5Q_P!_8O\ XNC[-J7_
M $"KC_O[%_\ %T )12_9M2_Z!5Q_W]B_^+H^S:E_T"KC_O[%_P#%T )12_9M
M2_Z!5Q_W]B_^+H^S:E_T"KC_ +^Q?_%T )12_9M2_P"@5<?]_8O_ (NC[-J7
M_0*N/^_L7_Q= "44OV;4O^@5<?\ ?V+_ .+JHMU<MK4FEC2[K[5';K<L-\6-
MC,RCG?URIH M44OV;4O^@5<?]_8O_BZ/LVI?] JX_P"_L7_Q= "44OV;4O\
MH%7'_?V+_P"+H^S:E_T"KC_O[%_\70 E%+]FU+_H%7'_ ']B_P#BZ/LVI?\
M0*N/^_L7_P 70 E%+]FU+_H%7'_?V+_XNC[-J7_0*N/^_L7_ ,70 E%+]FU+
M_H%7'_?V+_XNC[-J7_0*N/\ O[%_\70 E%+]FU+_ *!5Q_W]B_\ BZ5;/5'8
M*NFNA/\ %+-&%'_?)8_I0 NG@MXALPHSMCE=O8?*/YFNHJAI>F"Q5Y)6$MS*
M '<#  '15'H,GZYJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)-JW_0F:S_W^M/\ X]1_PDVK?]"9K/\ W^M/_CU '245S?\ PDVK?]"9K/\
MW^M/_CU'_"3:M_T)FL_]_K3_ ./4 =)17-_\)-JW_0F:S_W^M/\ X]1_PDVK
M?]"9K/\ W^M/_CU '25S4/\ R52[_P"P+!_Z/EI?^$FU;_H3-9_[_6G_ ,>K
M)34-<7QG/K!\'ZMY$FGQVH3SK7=N61V)_P!=C&'% '=45S?_  DVK?\ 0F:S
M_P!_K3_X]1_PDVK?]"9K/_?ZT_\ CU '245S?_"3:M_T)FL_]_K3_P"/4?\
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M"R_X\+?_ *Y+_*IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!"Y_[[_^M1]3EW0?65V/1Z*\X_M?4O\ H(7/_??_ -:C^U]2_P"@A<_]]_\
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M]T!]5EW/3:*\R_MK4_\ H(W/_?=']M:G_P!!&Y_[[H#ZK+N>FT5YE_;6I_\
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MQ_WRO^%=A16\<15BK)F,J%.3NT<?_P *[M?^@C<?]\K_ (4?\*[M?^@C<?\
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M (5W:_\ 01N/^^5_PKL**/K5;^8/JU+M^9Q__"N[7_H(W'_?*_X4?\*[M?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.2<UV5%"JS5K,'3BQD,2P6\<,>=L:A5R<G &.M/HHK,L**** "BBB@ HHHH
M**** "BBB@ K,U"WEEN 8U)&/2M.B@J,N5W,'[#/_P \S^1H^PS_ //,_D:W
MJ*9I[9F#]AG_ .>9_(UR_C3Q3'X4M!& LFH3+F*$_P (_O-[?SKO=0:[33;A
MM-2.2[$9,*RG"EL<9-?+VN3:E/K=T^N&7[=YA$PE&"#Z8]*#T<#3]O)N6R*U
MW=SWUW)<W<K2S2MN=V/)-0X.,XXK8\,^&;[Q3JZ6.GI@=99F'RQ+ZG_#O7O
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M@ HHJM?:C9Z9"DNH745M&\BQJTKA06)P!SWHW LT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5B>,_^1'UK_KRE_\
M036W574["+5=*N;"X+K%<Q-$Y0X8 C!QGO073:C--GRA17NW_"E?#?\ S]:E
M_P!_4_\ B*/^%*^&_P#GZU+_ +^I_P#$55SZ/^TL/Y_<>$T5[M_PI7PW_P _
M6I?]_4_^(H_X4KX;_P"?K4O^_J?_ !%%P_M+#^?W'!?"#_DH$/\ UPD_]!KZ
M KA_"/@CPUH^N37NB7]S<7-FS02QR2*0C$8(("@UW%)GCXZM&K5YH]@HHHI'
M"%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>sgmo-20201231_g4.jpg
<TEXT>
begin 644 sgmo-20201231_g4.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 'V L4# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MINEZ7!-?RW-]!I:(BFZ;!D9U7@.>,]Z .FHHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!/A_XH^&5K\/=0\*Z>_@^T2-+72XH_*2V\LY1HF4AD<'G<I!Y.2<G/%_#/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM:%K>K_;([A9)0=RLXW\E<,@R"#GC%?27[0/P)'QFT_P]?:7K3^%O&GAB_\
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MO]*2.=1EG!(1E//]ZDUCP;::%>7]_%/>7E_>)Y=Q>7DYDDG4'(WC '! Q@#
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M HHHH **** "BBB@ HHHH **** "BBB@#RW]IC18]8^#VLLSM')9M%=1,O\
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M8;>-44L4(Z =<U]"_#768/$'P_\ #U_;AA%+91 !Q@@JH4@_B#7SX+H*P)/
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M*V;U*J6+I1C#UU^Y:'RN/H913I/ZI6E*?I9?>]3TZBBBOI3YH**** "BBB@
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MWE-;Z-9S-S!:M@F5A_STEQD]P,#N:\]^%OPW_P"$ZU@V-Q!YGAO3W!U:;?\
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M?.6M;K<<YB4<J5Y/'0$X([]%X3TK5O%&LW/B3Q#<M?:Q?-O9V&!&O95'90.
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M]U-<[?MP:Z&_[US6I-UKZ7#'P^-GN<_J#=:YV^DQFMO4&Y-<YJ$G6OJ,/$^
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG\*^H_A"0?A-X*(Y']B67_HA* .NHHHH **** "BBB@ HHHH **** "BBB@
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MATYK.W;3S%Y!M#$IB,>,;-F,;<<8QBI[>WBM8(X((TAAC4(D<:A550,  #H
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M>+H/A9\5)H_^$H8,= \2(GEVWB2W09R.R72+_K(N_P!Y<@\>[5\T?0!1110
M4444 %%%% !7DWQV^.4GP0U+P%/>:0MSX8UW6DT?5-7DG\I-*\U<0S.2,;3)
MA3DCKQD\5ZS7GWQ]^%-E\;/A#XG\'7HVG4;1A;SA%9X+A?FBE3=P&5PI![8H
M T?C!\2M-^#OPO\ $_C75G1;'1+"6[99'V"5P/W<0/8NY5![L*J^&?B1]F^$
M^B^+OB -/\$7%Q817>H6]S>IY%F[*&*>:V <9ZU\;^'_ (L7'[8UC\&OA)J$
MQ&NZ3=R:E\2K%;D-) =+D$2V\ZE-DBW%SY;E02,*?2O3?%G@S1_C%^W*_AKQ
M_I-OJ/AGPSX2AOO#^C:@5DL[V::9DGG,#95VC "#C@=>U 'TWH/C30/%%K8W
M&CZU8:I!?0M<6LEG<I*L\:D!G0@_, 67)'3(JOKOQ%\+>%ULSJ_B/2],%Y=?
M8K?[5>1Q^=/NV^4N3RV01@<YKY@L?A/X,^%?[?7@R/P?%#HZ:CX4U.>Z\/6+
M+':6K"2!5GC@7B,RX()  ;RAZ&C]D7X!>"O%&E>,/%OB71;3Q3JTGC+6!9G6
MK=+E--2*^DPEL'!\L%P9"1R68GTH ^B? 7C#Q%XB\1^-K;6M&T_3='TC41::
M7?6FI)<M>1A SM*@YA=21\K<X(-6]*^+?@C7+W5K/3O%VB7MUI+^7J$,%_$S
M6K9QB0!OEYXYKXQ^)%TR_#GX]:;+K<WAS2=;^*MGHVK:M!((WM;&X^Q13L&/
M3*,5S_M5H?M\?LO_  C\ _L=>+;[0O"&C>&=3T:UM_L%]80I;W,K"5$\N208
M:;<I)(8G)&>HH ^@_%7QCU'P[^TUX6\&27-A!X3U#PO?:Q=W$X"LDL,T:HPD
M+8";7.1CWS7I7@[QYX;^(6EG4O#&O:=X@T]7,9N=-N4GC##JI*DC-?&OC;X=
M^%_BA^U%^SEHOBY8[S2QX&N+M-)N%9H=1FB$+K'(H.&5<>9M;*G9@@UTWCOP
M/X?^ _[7WP-_X5OIMGX0_P"$O_M+2]?TG1K80VU_:00>=%(\2C8K1RGB0 ,?
M,QG'% 'NGP1^(VI^/(?'KZP;=!H?BS4M&MVA38/L\#J(]V2<M@\GO74>%_B9
MX1\;:AJ-AX?\3:3K=[ITGDW=O87D<TD#\_*ZJ20>#U]*^'/BI>:B_P &_'^@
MV9"6'B/XSW.CZFSWXL4:UDG3=$\Y5O*60@(6VG ;IS77ZY^S5XCD\0>!M7\*
M_!_P3\)]4\/ZW:7;:[H/B(+)):!U2XMY46R3SA)$67#-]XCGDT ?;$DB0QL\
MC*B*,LS'  ]2:^=O!/Q(^(_Q-^._B)=+\0^$]-^'7AW6&T:326C:?4M1*6ZR
MR3I(& 0;ID &",(W-?06I:;:ZQI]Q8WUO%=V=Q&T4UO,H9)$(P58'J"*^:_V
M9?@KX!\-^+OBKK.E>#M%T[5M)\8WMI87EK91QRVL)L;7,<; 95?WC\#CYSZT
M >_:EX^\-:/?:197VOZ;:7FL2F#3H)KI%>[D )*Q GYR,'@>E0ZY\3/"7AKQ
M!IV@ZMXFTG3=:U%MMGI]U>1QSW!]$0G)_"OC3_@FS\'_  AJ?[*>@>,;SPII
M_B'Q7'?:G/:7>IQ+<2P21W4JQI TF?)&5!PF!N9F/))KIOV1?V?/AQ\5O@FW
MC3QIX;TOQ;XS\57MY>:WJ&KQQW=U:7/G.AMTD(+1")54  @C /I0!]@V>IV>
MH12RVMU#<1Q.T4CQ2!@CJ<,I(Z$$$$=JYK2/BYX'\07>KVNF>+]$O[G2,_VA
M%;W\3M:XZ^8 WR_C7YK^'-0NO G[)_CGP[X<U>\O?#VJ_&5_#>H:TMTTDSZ3
M),JRRFX0\;U55,F<$2'GYJ^A_P!M+]F3X2^#OV5?&FJZ%X<TGP3J.DZ6S6>I
M:-%'9SSL %%O)(H!E67.QE8DMN]: /L.ZUBQL?\ CYO;>W_=--^]E5?W:XW/
MR?NC<,GIR*SM+\>>&]:T&36[#7]-O='C+![^"[C>!"IPP+@X&,>M?*/B3X::
M)\5OCU\ M)\1QR7FCP> [J\FTW?_ */>E#9A8[A.DD88A]IX+(OI4B_LK_#P
M?MC7.E0:+%:>#YO"<6LW7@^W18]&NKQ;EK>.:2U $;,J D9'4YH ^M/#OB;2
M/%VEQ:GH>IVFKZ=-_J[JRF66-L'!PRDBLL_$[P@OC#_A%#XGT@>)O+\[^Q_M
ML?VK9_>\O.['X5\F:II]G^SMX]_:9LOAW9Q^&;9? %OXGM[6Q4);VEZD=Y'Y
ML46-J9$:,0!@E<XKD/#_ .S'<>+OV>]/L=-^#'@F^O=2TI+NW^(!\6YU.2XD
M42K??:!8[]V\A\!L#ITH _0"ZU*TL6"W-U#;L5+@2R!3M'4\GH/6L7PC\1_"
MOC[3KN_\->(]+UZQM)&AN+C3[N.:.%U&65F4D @>M?%/Q1^';>.OVG?V2O#/
MQ+BM=?N5\.ZJVJ)!</);7D\-M$VYF.#(C,@8AN&R000<5V4?PU\+_#?]O_PW
MH7A;0M/\/>'_ !!X OO[4T;3+9+>SO&CN557DA0!7;;(RY(/% 'O_P +_CQX
M:^*VN^+-)TJ98[OP_JTFDNLD\3&Z9$5S+$%8DIANOL:](KY._8\^$_@O0?B-
M\9]3TWPEHNGZAI7C6[L["[MK"..6U@,$0,43!<HGS-\HP/F-?6- !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!'<2^1!)(>B*6_(
M5\7?LXL^O:?XM\:SV4=I/XFUNXO(]IW,L6XCRR?17W_G7TM\?M7?0O@GXWO8
MKG['/'I%SY4V<%9#&0N/?)%>#_ _28M ^$/A:WA)*RV2W39/\4O[QOU8U]+E
M,/<G+NTCP<PG^\BNR;_3_,]"\_;WIWVK'>LJ2YV]ZKO?>]>^J-SY2OBN4WOM
MWO0=2QWKFVU#WJ)M2_VJU6&/%J8ZW4ZC^TO>F_VE[URK:G_M4W^U/>K^J^1P
M2S#S)/B#XN;2=$,,,FVXNCY:D=0O\1_SZUY5I>ORZ/>QW,."5X*'HR]Q4/CK
MQ#_:7B"8!OW=N/)7(].OZYKG&O/>O7HX11A9K<Y9XUM\USW73=>M]:LQ<6[Y
M'1T_B0^AI\EQ[UX78Z_<Z3<>=:S&-^X[-[$=ZZRR^*D+1XOK9E?^]!R#^!Z5
MRSR^<7>"NCICF49*T]&=[)-[U4EE]ZYY_'^B,/\ C_4?\ ;_  K.O_B-I%N!
MY<LET3_SR0C'USBE#"U/Y6<]3%4_YD=/))FO.?B!XN3RY-+LWW,>)Y5/ _V1
M[^M97B#X@7VK(T,(^QVYZA#\Y^IKE8;>?4+N*UM8S-<3-M11_,^PKV:.'CAX
MNM7=DCQ:E:6)FJ-%7;*LS!>2<#WJYX?T8^(=8BLO-\F-E:1W49.U<<#ZYKJU
M\%V_AS5-*DO&2]-QNAD\W&Q9,$C _#'/K7%>+O%6F>!?B!916'F"564W4(!"
M1;AT'KD$';TZ5Y-;.WB.?#T8.+:T?7[NA]!A.'Y0G"K.2E;=6T^_K;T/8=+T
MVQ\-V8@LH5B]7/+M]35RTTRZUBSO;Q9[.QL+, W%]J%RMO!'DX +MQD^G6N<
M?68[NW2:)]T<@RIKG_BMI'A7XP? W4OAQXNU6^\/V[:I%K-AJNGP+<-'<(C1
ME9(BR[T*,> 0<D'/%?"UJ\K<L%=GZ!A<+3;YJKM$Z3Q7I]YX=OFLM02/>R"1
M6C<212QL,AE8<,I'<5YY<>*GT"&?3[,QWENX(6*0G]QD<@'N/8UT=EX7O[3P
M9X-^%MSJ4$E_I-@T'@W7K8>59>*;(?,UO\Q/D7T?>(M\V.*\RN('M)I()8F@
MEC8H\4BE61@<$$'H0:]S)<L68N4Z\[*+LX]?GV/#X@S+^S%&G1A?F5U)[6\K
M;LKL-J@56F-3R-529NM?JL8J*45LC\A;<FY/=D$C57D:GR/5:22K&B.1J@9O
M>B1ZA=Z"T=#X%\?:O\-_$<&LZ-.(YT&R6&0;HKB(_>BD7HRD<$&O=;&Z\*ZY
MX%:[@AF;X8K*9;JQA'FWW@2[<\S0CK)ISDY9/^6><CC./F&23WK<\!_$/6?A
MKXE@UK19Q'.@*2PR#=%<1'AHY%Z,I'&#7SV:97]<M7H/EK1^&7Z/R/J,HS;Z
MES8?$+GH3TE']5YG?^-O!FI> M:_L_4?+E22,3VE[;-OM[R!N4FB<<,I'Y=#
M6-')[U[-IM_X4\1?#N:ZMH9O^%7&4R7EA"IEO? =XWWKB =9-.<\O&/]7U'R
MCY/+O&?@W4O .N'3M1\N59$$]K>VS;[>\@;E)HG'#*1CZ=ZYLOS+ZW?#XA<M
M:.Z[^:_K\##-,E_LZ4<3AI<^'G\,NWD_/\_4JPR5H6[]*QH9.G-:-O)TKJK(
MVP4M4:5]:C4M)O+1FVB>%HRWID5]R?L=^)KKQ5^SQX3N;V=9[F"*2T)4 ;4C
MD9(U/N$"5\06C;L ]#Q7T_\ \$^KB-/A]XOT]9MS6OB";;"3]R,QQA<#L"5;
M]:^'SRG?#\W9H_3\FJ6JI=TSWGXI?"W0/C!X2GT#Q!!(T+.L]M=VSF*YLKA3
MF.X@D',<B'D,/H<@D5YW\+_BAK_@OQ9;?"WXI7"/XC9#_P (_P"*-HCM_$L"
M#GCI'=H,>9%WSO3*GCW.N9^(7PW\-_%3PZ=#\4:8FJ:>)H[F-?,>*2&:-MR2
MQ2H5>-U/1D8'!(S@D5\$?:G345X]_P ,H> /[WBK_P ++5__ )*H_P"&4/ '
M][Q5_P"%EJ__ ,E4 >PT5X]_PRAX _O>*O\ PLM7_P#DJC_AE#P!_>\5?^%E
MJ_\ \E4 >PT5X]_PRAX _O>*O_"RU?\ ^2J/^&4/ ']_Q5_X66K_ /R50![#
M15/2-+@T/2K/3K7S3;6D*01>?,\TFU5"C<[DLQP.68DGJ2:N4 >>>!?@-X/^
M''Q&\;^-]"L&M=>\8R6\FJ.7S&6A5E4QKCY,[B6Q]X\FJ'QC_9S\*?&K4M#U
MG4Y-2T;Q-H3,^E^(-#NVM+VUW#E0XZH3R58$'%>I5Y1\5?VB-)^&/C;0/!D&
M@ZWXN\7ZU;37UMHVA11&46\7WY7:62- N> -Q)/:@#-^&_[)?@CX:_$!/'EM
M/K6L^-FAF@N=>UK4GN;B[241@K)G@A?*&T  +N;'6O0?AW\.-&^%^BW>EZ$D
M\=I=:A=:G(+B4R-YUQ*TLI!/0;F.!V%;VEWK:EI=G=O:S63W$*2M:W( EA+*
M#L< D;AG!P2,CK5J@#S]?@5X-?2?'&E7FEC4],\:7DM]K-I?.98YI)(TC;:#
M]P;47&.A&1S7DFL?\$_?AYXL\/KX?\5:[XR\6^'[6#[/INF:QKLDL.FCY &A
M  .\!-H9MQ"DCO7TW10!XO\ $3]DKP%\3M7\+ZMJO]KVVJ^&-/\ [.T>^TW4
M9+>:S4%")$9?^6@V ;CGC(QS5OX8_LS^&_AMXTN_&4^JZ]XP\87%J+$:WXFO
MS=SP6X;<8X> L8)V[L#)VBO7:* //9O@+X*O?"/BWPQ?Z0NJ:)XIU"YU/5+6
M^8RK)/.0SLN?NX(!7'W<#%</H'['?AG2]6T&XU3Q9XT\6:=X?N(KG2=&U[7)
M+BSM9(EVQL4 !D*'!7>3@@5V_P "OC?H7[07@4^*_#MM?6NG"^N+#R]0C5)?
M,AD*.<*S#!(XY_*O0Z "N=\+> ]*\'S>(I-.296U[4I-6O?,E+YG>..-BN?N
MC;$G ]_6NBHH X;X+_!OPW\ _A]8^"_"<5S#H=G)-+$EW.9I-TLC2/ESR?F8
MUYUXB_8M\%:QKWB*_P!,UGQ3X2LO$KF37-'\.:N]G9:@Y4JS/&!\K,"=Q0J6
MSS7OU% '@TG[,?P^^%GP&\>^#?#O@FXU_P -:PUSJ4_A:*ZR9Y&"MY4#.<)@
MHNP9X*CFODGQM\%9/BA\/-'\&>'_  +\8-7U*\5;2RL_B---'I'A=60+)<%S
MA9I(UW>7RWS$>G/Z7UF^'?$FF>+M&MM6T:^AU+3;D$PW5NVY'PQ4X/L01^%
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M]FC$?W3<Q@_H:PM(TN/P]X?TS2X"3#9VT=NA/4A5 %;/[<I_XQQUW_KZLO\
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MX5&0PS+U:"579'"D'!!&2,'R+QQ\#OCU\:K[P=+XS\1^#M$TWP[K>GZJVDZ
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M5:?X?\6^ _&_POO-6NOL>DS>+=&>WM[^7!.Q95RJMP,!R,E@!S7T70 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R
M/Q ^$/@CXKPV<7C/PGH_BA+-F>V&JV4=QY+$8)7<#C(]*UO"7@_0O 6@VVB>
M&]'LM"T>U!$-CI\"PPQY))PJ@ <DFMBB@ HHHH **** "BBB@ HHHH ****
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M_C=>_P!%?)GTQX!_PVMX*_Z%OQ]_X2-]_P#&Z/\ AM;P5_T+?C[_ ,)&^_\
MC=>_T4 > ?\ #:W@K_H6_'W_ (2-]_\ &Z/^&UO!7_0M^/O_  D;[_XW7O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%Q_[+7=C<;*I@Y8O U5:%^E[[=[6//R_+XT\=#!9A2=YM6]ZUEWTO<Y3XE?
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M5#!;Y(!],J?7)_\ ':^>QU3DINV[T7S/NLJH\]17V6IGR:5_PMS]H?PQX?\
M)-Y8W&I?:;F*1]F;6'_6+^ W,/I7Z/@;0 .E?%?["GA!O$'C?Q;X[N5\R"V4
M:78O+%]XY)>16/0CYU/U%?:M?F6<55*NJ4=HJQ^K973M2=1[R84445X1[(44
M44 %%%% !1110 445!?7UMIEG/=WD\=K:P(9)9YG")&H&2S,>  .YH GK/TW
MP_I>CW>H75AIMG8W6H2B>\FMH$C>YD "AY& !=L #)R<"OGZ7_@H5\#X_$D>
MF+XHN)K%D+'Q!#IT[Z4F 20UR%VCIC/3/&:^B-.U&UU?3[:^LKB.ZL[F-9H9
MX6#)(C#*L".H((- %FBBB@ HHJE<ZU86>I6>G3WD,-]>+(UM;NX#S!-N\J.^
MW<N<=,B@"[17/6OQ"\.7WCF^\&P:Q;2^*+&T2_N=+5CYT5N[;5D(_ND\5T-
M!1110 445Q?PG^+6@?&;P[>:UX=:X:RM-1NM+E^U0F)A/!(8Y !W&X<'O0!V
ME%%5)M7L;;4+:PFO;>*^N0S06KRJ)90HRQ5<Y( ZXZ4 6Z*** "BBB@ HHHH
M **X>V^,7AV[^,MY\,(Y+D^*K31EUZ6,P$0BU:41 ^9T+;C]WTKN* "BBB@
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ME>T>5>\Y=4^T;+3S?=G=F6986OAOJ^&C:\N9^ZH]&MKRNW?NEV1&TE=9\/\
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MO(OAWJ_[0WQ2_97TSXVO\9(] O-.T>XU.+P_!H4$MO?I:M(Q^U2$[BTHB/W
MH4,!UYKW_3?@?XJB_:H\;_$:Y^P?V-KG@FWT.%8YCY@NTD+."I'">C9_"F?"
M'X#^)O O[$*?"K4&LG\5+X:O]+/DS$V_GS),$&_'W<R+DX]>* /&?$'COXUZ
MY^SVG[2MG\2H="LK?2$U^+X?VVDQRV$ENHW&"6X8^:S,,Y==N. !WKV*\^..
MN:Q\;/V?K?3939>'/''AS4-4O=.D57.X06TT/S8R"GF,..#D\54D_9Y\4Q_L
M!GX.(UC)XN_X1+^QMWG$6WVC9C[^,[<]\52\=?L\^/=/T#X(>*O!5SIEU\0/
MAII*Z8VB:G*T>GZG'+:Q07"F51N1E,8=&P0=N".> #H_$WQ2\2:?^W%X,\ 0
M7^SPKJ/@Z\U2YLO+4[[B.XVJ^[&1@<8SBOG#X4_&S6O@]^S)):>%H[4^,/&'
MQ6U/PSHUQJ"%[2VN)[Y_WTP!R55%<X&<G%>_?"CX3_$7Q7\?)/B[\5=.T/P]
MJ6F:.^@Z)HV@W<ET!#))YDDTTK  L20H4 8QFN+TO]BWQ%=_ %O#UUJMCH_C
MO2O'%WXU\.ZC'FXM[2Y-V\L'FK@;P8V*L",#?WQ0!B?&G0_C_P#LW^!K#7[;
MXRW7CVRO-5TVPU?^T]&MX)K&.2Z16GMFCX .[RV5PW# @@BN7_:,^%_Q!UG_
M (*#_"J/3/BQ=Z+-JUAJUQI$J:/!*=%AC@7S85#-^]$H!!9L%<\5WGQ6^&W[
M2?[0WA+3=%\2:;X/\'6FEZAI^I3P:7J,UPVL2Q7"LZ;BH$,04%]I#%F"C/%=
MS^TC\'OB+J_QL^&/Q4^&T&B:MJ_A:&^T^?2=<N'MXGANH]IE#H"<KC[O?(]*
M *'B_6_B?\=OCEXH^'W@WQA-\-?"W@F*S&JZ]:V$5S>ZE>3Q>:(8?,)6.)8W
M4L2,[L8XJ?X7^-?B3\.?B7XH^%/CW7XO& @\.OX@\/\ BUK9+:YN8U<I+#-$
MA*EHV*_,,9&.*L^./A3\4/AS\;=:^)?PG31O$$'BJ&UA\1>%]>NY+93+ A2.
MZMI@&"-L"(5*X.,U-\*O@Y\1=6\;>*OB9\4+O2[?Q9JNBMH&F^'=%E>6QTRU
MW%\^:XW-([X+$ #MCT .'_8GN/C#\=OAKX#^*7C7XFR06<AD*>']*T^%(K^!
M'EC+7;LN[S&<9'E[0%5>I8X[;]BWXI^)_B9^SWJGB7Q-JC:MK$6LZO EQ)&B
M[8X;AUB3"@#"@ >O'-=7^Q[\)]<^!W[-_@KP/XD-L=;TBWECN?L<ADBW-/(X
MVL0,\..U?/>AV_CW]F+PSXY\&^&M4^'MY\/8M0OKZ/Q+K&MF.\TU;AGEFBGM
ME/[R1"2JA64G R.U 'T!^QKX\UWXF_LV^#_$WB6_;4];O_MC7%TR*A;;>3HH
MPH  "JJ].U<#\1?%?Q%^-?[1FM_"KP)XQ?X<:%X1TZTO]=UNWL8[F]NI[@%H
M88/,RBILY8D9R!C-;_\ P3VL+K3?V-_AG%>13PS-9SS 7*E9&22ZF='(/]Y6
M5OHU4_B5\(?B1X)^/5U\6/A+%HVLS:]96^F^)?#FN7+VZW0AR(;B&8!O+=5P
MNW&#G)H \M^#'A_QI\-_V\O%_P#PL'Q''XL:S^&JM:>(%LA:R75K'?(V9D4E
M?-4E@2O!&WBMSX>^'?CY^TEX)M?B='\6YOABNLH;O1/">GZ5;W5I#;;V,!N)
M7R\AD3:6V[<9X':NB^#_ ,$_BO<?M(:Y\4?BA+X?^S:YX2;0_P"QM&D=TTXB
MZ1UARX_>Y0,S2<<G&, 5E^#? ?[1_P  ?"\GP\\$VGA/QMX7L=T6@>(M?OY;
M>\LX&D)6.XA52)?*4A5V%<[1QVH SKW]I;XF:_\  OP?>6EI8Z-\25\?6O@[
M6+>52EG-<)<!)0I^9EAD!7G&X G'K2>.HOV@O@?\4O!"6?Q0LOB!9^.M4FTB
M73]:T>.TM])D*-,LT B8LRJB2?(S<[5&[G(ZK2?V3=:\)_"WX?:#;:S%KVOZ
M;XYL_%^OZG=%HQ>R_:1)<O&#G;\OW5_V<<9KU/XP?#C5O&_C3X4ZMIIM_L_A
MGQ$VI7RS.5;R3:3Q93@Y;=(G''!/I0!Y)X7M?BW\$?VB/!6B^+?BE_PL;PAX
MUCO8#%?:5%:36%Y#"TR^3Y7_ "S8 CYB<8 ]ZR]!7XO_ +57B+QGK^@_$^]^
M$_@S1M9N]!T6QTW2K>YN+U[=A'+<W#2DC:95<*JXX'.._N'Q,^'.K>+OBQ\*
M/$%D8%T[PS?7UU?&1R'VRVCQ($7')W,,\C KQ^Q^&?QO_9]\7>-+?X6:;X:\
M9>!_$FH7&N6MCK^H2VEQI-[-@S*& ;S(6<,^T8(W8&.<@'ED?QH^+3?L\_M8
M/XXURQO/%7@R]>PL9;.PC6TB18(R&CBD5LJ^=^'W<L>U>@Q^.OBIX^\?_#7P
M/X6\4V7AFSUCX:IK.J:DUBDLMO*QMU\Z"/A3("VU5)"*'9L-@+6'H_[)'Q4A
M^!_[2/ASQ!JFBZYXM^(MZU]97UHS06\CR0H&#*03$%8%0.> #7L?P[^!VO\
MA+XM>!?$MU+:26&D?#Q?"UVL;G>+M9;9@5&/F0B*3GC&!QSP 87P3U3Q_P##
M7]H;7OA9XU\=R_$33;S0H_$>CZG>V4=O=VX\YH)8)/+ 5ERH8'&>3]*^F*\D
MG^%NL3_M50?$/?;KH$/A'^Q=N\F9K@W;RGY<<*%(YSU.,5ZW0 4444 %%%%
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MQ7,WD!4GBOJJ-2Z/S/%89Q9CR'%1[ZFFCQVJNPKN4CPI4A+B*.ZA:*095O\
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MT/XR?%;6-5D;YY+33-':"!!UDD<VPVJ/7'TSD9]I7X#^+EZ?'/QR/I;:5_\
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M:K%X=F6#6=5TG1[B[T_3G+;2)KB-2B[3D-S\I!ST->=?L4_'B";]F_QIX_\
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MS-?1M;/:M$2)!,CX,97!SNQQS7S]^S/'&?V\?VL9-B^:K^'5#8Y -DV1GT)
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M3S:=9I$[A=VT%@,X&YOSKI&\,VNEPZY<Z'86%CJVJ RS3M#A9YPFU'FV\MT
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MBK5?"5Y/K'PE\2RZ5)G?_8=^VZW8_,2$;MU50IP !U-?387-(-ZODE_Y*_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
&4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>sgmo-20201231_g5.jpg
<TEXT>
begin 644 sgmo-20201231_g5.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" /5 M0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKK_X'77_ ,=H_P"&:?AI_P!"NO\ X'77_P =KTVBCF\P/,O^&:?AI_T*Z_\
M@==?_':/^&:?AI_T*Z_^!UU_\=KTVBCF\P/,O^&:?AI_T*Z_^!UU_P#':/\
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M $*Z_P#@==?_ !VC_AFGX:?]"NO_ ('77_QVO3:*.9]P/,O^&:?AI_T*Z_\
M@==?_':/^&:?AI_T*Z_^!UU_\=KTVBCF\P/,O^&:?AI_T*Z_^!UU_P#':/\
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M^T'IBY_TCQ.W^[H;?_$4>UCW#^Q<9_(_N/=J*\(_X:%T[H#XL?Z:,!_-:/\
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MS#K"8[/'HMZP/T.W%9]Q^T!I\<BK#-XCU:0G!_L[1=B#_O\ !:W[7P))P I
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M,HD4G4\^]>(:+\:_'FB*L;WVGZ_#NW,NHV_ES$?]=(\?^@UU%G^T8D@?^WO
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MGFD;/9"1_G\JT+3P=:P_=@4GU;D_K7:QV 7'%3I9CGBM%8YI8J?0Y:/P\H4
M)@4\Z"O&%YKJA:>M>>_%KQI>Z"VF>&/#</VOQEK[&"PCSA85Z-,Y[!1G'T/8
M&NFC3=::A$\W$Y@L/3=2;.<\8^,!I>M0>&O#>EOXF\6W'*:=;'Y8%_ORM_"*
MZKPE^R%-KS)K'Q.U>3Q!=L PT>T=HK&'C[IP<L1DCC'3J:]<^ /P!TSX3:)(
M W]I:_>_O-2U:4?O+B3J0">0@/0?B>:]BOM-B_L]@HP^./<UZ_M*>&:C36O<
M^#Q6*Q&/3G5E:/8\'GT'2?!=F;;1]-M-+B 52MK"L>X 8&X@98^YYKD+OQ R
MRME^_-=-\6]63PW;R32 W '!6#YMI_VO2OG74OB5,;A_*LU\O/&]^?TK]!RS
M#*O2YD?BN<9C5H5N2)ZQ-KZW,+P3A9H9!AXI%#(P]"#QBO.O%7PE\->(KAM0
MTG=X7UQ3NCO-.^2,MD??CZ$<=!CKT-<_'\2FW'[1:[5[&-LX_.M>T\5V^H1[
M[>;?ZJ>&7ZBN^MEZ:LT<&&SRK1ES7LS#T7Q)J6DZW'X6\8K#%=3?N[74'&ZT
MON>!G^%B.Q[^E=U8Z5>>%I&ETB\U'PXW.?L$I,!)]8R"O7_9%<GXB6R\7://
MI6HJ)(9!\DG4Q..CKZ$&MWX&^++K5X[WPGKDIEU_1U&V<G/VJW/"N,]2. ?J
M/0U^<YQDZP]ZM-:=3^@^%.+WF$5A<2[OI_D=YI?Q<\::<I,\6C>)$50H<!K*
M<X'(RNY2??BNGC^/FEW3)!K7A36[(;0=\2)=KN[X*'<*PKKPG;W#;A'Y<G]]
M.*A_X1_R6_>Q2,A_CMWP1[E3G]#7QUFNI^D2AA:C^&S\G8ZRQ^+WP[OY)$_X
M2.32)%;E-2MI8L>V&7^M7T^)'@9FV1>.]'=O]J8+_.N*M?#$%\F(+_>PX*/$
M-P]B,YJ*;X=--Q)'9S#_ *:19_I2M+L8>SPU_>G)?=_D=[+X]\(Q(6?QMHJ+
MZ_:5/]:K_P#"R/ .-TGCS39%')6%BQ/MP*X5?AC"C I9::I_V8?_ *U//AN/
M3CMEO+:%NT=O'N;Z8I<LET0U2PWV:C_#_(ZVU^.G@RQ61M+75M5=>#-9Z;*V
M[VW, *R]0^.FL7RQC2_"4D ;):?6;Y$ ]/DCW&L8:'<7$G[LS!>FZ4"/\<#)
MJQ;^"$?FYDDN#W5CA?RJO>V*5+"QU>K\_P#@&!JWC+Q;K64O?$BZ=%\P:UT&
MW$1&>QD;<YX^E8MGX96WN&N+;2WENCR;N]D+RMQC.]B6_#->J6?A>.W 6.)8
MP!V6KRZ"J]JT5-;LT^O0IJU.-CRS_A'-2G7]Y*D>1R$S^7O^=6$\,31XV.D9
MSG<(06^N237IIT51T7]*8VC@?P\U?*D9/'<QY]_8MS_%=3D_\!']*:='N/\
MGZGS]5_PKOFT?_9J%M(XZ4%+$IG 2:'<3?ZR99EZ!98@V*JGP[=Q,3%,H7LK
M X'X'/\ .O1&TKVIC:5[5)M'$GF5YX=-XR/?:8D\D9&RX@;;*I]5889?P-:N
ME^)O%'A_9%9:V-0@3"BSU^+S3QV688<<<<[J[5M)_P!FHY-&5QAT##T89K+E
MUN:O$QFK35T+I?QLFL_+76?#>H6OSE3<:7(MY"1V.TXD _"NRT3X[>$+Z-1_
MPDMG:RLWEFWU -;2[O0AP*\]D\*IUA9[=\8^0\=?0UGWGAN[DC\N>&&^MSP0
MZ G'N#U_"B\H['+*CAJW5K\?S/9DMM.U!U.FZE:R;N51+A)%_ @YJV?#FJ1M
M@6XD7'#*<#\C7STWPUTC49EV:78>8O3R?]'D!_2K<GPWN+=<1IJ48':'4YL_
MEOJ7>^QB\/'955\U_P $]\70]3. +(D_6F3:'JL:DM:!%'5F<8KP#_A KS.-
MVO?0ZC<8_P#1E2?\*Q:ZC(GM[Z93PPGU*4Y^N7HUZHGZK%:NJON_X)[/>W&G
M6"N^H^(=+LD49.^Y0$?@36-_PO#P-H8$6GZQ)K$\W)32[>2Y<X]2!CO7F$/P
MPTW2HSOTO2[1,[LW"B1B?R)-:,.BW,T:I;_)'_>\O8@'H._Z52NMC18>A)>]
M-O\ !&UJGQQUG5.-&\+FV0[A]JUVY" \\'RH\L#]37"ZQJFO>*RT>M>(;O48
MVQFPTQ/LMOD#H0IW'\6KKK7P2LG-U))<L>H8X7\A6[:^&TB7"QK&OHH%-1<O
MB-E5P^'_ (<?U/+K'PS<6MOY%A8V^FP<$<#)^H'?W-7(O!\SLKSSM(P/H,?X
M?I7J":&J]J<=''9<?A6RBB)9@WK<\X7POC[S2MGMYA _(8I/^$4MU8MY 8^K
MDM_.O1)-+"]A5:2SB4X+KFGL0L4V<-_PC=O_ ,^\?_? J-O#=NW!MT_!0*[=
MK2+^\M,^Q1MT8$U+-5B&<+)X3M9.&AW8& 2QX_6F?\(R8U/E3S1GW.X?D:[T
MZ9[4G]E]\9J318IH\RO_  3%>2&6:SM[B7(82H#%-D=PZ\C\ZL6L_B#P\LBV
M/B+7M-BSD(T_VF+..PD#<>V:]#;2O;%,;2>V*CE1K]:YM)ZG+V_Q2\>PVBQI
MKVDWQ7O=:7M;\2CC^5:]M\</&T<"I+I7AVZ/=A+,H;\,''YU/+X<BD.?+VL>
MZ?+_ "J-=#E@^XL$ZY^Y<1+G_OH"E9]S&7U9K^&A&^-WB<@@^%_#>[U-Q+_\
M15*\^,'CBX519Z;X8TPCK)LDF/Y97^=:,GV.RMS-?V$=G H^:<JAB'/<]OQK
M-U#QGX%TD WFO:+!N_O2(<_D#6L:%2I\%V<4\3@L/_$@EZLI7_Q*^(&KJBR>
M*+>Q5>6_L[3D1C]&8M_*L2_T?5O$9>35M5US6$E7:1<W;QQ;?0JI5?S%=)I_
MC[PYK*NNB:MIMPJ]96G6-!] <$UL?V&]VJRW4K72L,KVC/T ZBE.E*.DT_F=
M%'%T)>]145Z6//;#PZEHICTVQMH,G#&% !QZD  UK6WA!YN;N5IO^F:_*O\
M]>NZATE4  4!1QTJW'8!>U$8I&L\9*VC.4M?#<<* )&JC_9&*N+HJK_#72?9
M:1K:MKHX95Y2ZG/?V0.FVH9--2/[V!]:W;S,?RKP2.M9K6Y;J<GWI.:+C)[M
MF5);Q8Z$U T,?:,@UKM:]:B-K[5',="D98@C.,AA74?LEJ([?XA@=/\ A*9?
M_2>"LDVQ]*V?V4%VQ?$4?]33+_Z3P5I3E>1X&=RYJ,?4^EK'[HK5C[5E6/W1
M6K'VK5GR"'T445)04444 %%%% !1110!\/:QI]UI/[77Q/>=2@NM+M;F(^L9
M95!_-34>NZV\#, YKH/VI]-_X07X^>#/&1\Q--U^TDT*]F:4",2KEH<CT +G
MZ@5YKXPNF@FD!XQP:_5<BE&M1AZ'XUQ73G"4N4\_\2>(I+C7KUGD)(? Y[#I
M6:VJ%NK5D>+)WCU+SQ]V08X[$5E0ZF?7]:^^5**2LC\MIU935VSIWN@W6J%U
M<?*368-2]ZJ7.IK@C=46.N,>K(M2N.M<W>3=:OWET),\UBW$FYL=2>E5T.F,
M3N_!LS-I\.3R"0/I7L/P)T6Y_P"%[7,Q&8DT)96(.1B3;LS[\&O,/A[H<^L7
MVF:5 "9IW6/CJ,GD_@,U](_LY>$SXS\2>/O%*W<\6EM=QZ-8JL6P20P#J#[$
ME?J*_/N)*RC1DNY^K\&T;XB$WHKGK,D44.?,=(^_S$"H5\N=@(8IIR>?W<9/
MZG%=/;^";>USY<LRD]3OS_.K#:#(JX%_=XZ8$M?C_-(_H/V\>AR+>%;C5$9Y
MX_LP53Y2,?FW= S8_E3%C$;"*Y3[+.."K\*?HW0BNN72;J$DIJ4Q'_315?\
MF*22SO6)62:VNHC_  30X_E1<E5I-ZO0YT6/M2_9-HZ5>DTN>W!,$/DG/W89
M-T9_X W(_ U$U]';R,MY#)" <>9L./R[?F:.8V4G(K?9]O&,&E\NM.&.WNDW
MP2I(N,_*:ADMP,\TN8/4HN4@C>1R%1%+%LXP ,UYU^R_I(\;>*/$?Q4U6-O,
MU&=K#1UE7'E6<9V[E'8L1@X[AO6M'X[:U'X;^$7BJ[;>VZR>W4(<$-+^[!_
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M/7\JGG-K%2.V9F'&/K5S]EE#&WQ'4\_\53+_ .DT%21QAB.:/V85VS?$D?\
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M:%Q8VTS[U7R)>OF0G:<^M5)IM0M?N.M]'_=8;7_/O4#:@/6FM?#UJ>0VC='
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M_P"B6KO+6^A:RMU 4*(4  XQ\HI5(J5KGIY;5J46Y4VT_(^<?$'[.ES8KO\
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MDG7RV4*WZ5T>S4MC=J4-'$-TO?.*E21^,YIC26<*EG14'7ER/ZU7;4K'_EG
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MVNF!=+M]PV8V9WYQU^??^!%?3?BK4H/AOX#UG7Y=GF6ELS1!@=ID/RHO'JQ
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MK=CTVXT71UZ&7_O[5*32](1L@2MCL9#BO)_^%R:-=7#0V^I?;9>ZV<4EP?\
MQQ323_$R(C$5GJ]TYX6.'2[C)^F4 _6L76/4AELEI*?XGK*MI5NZNEM$'!X)
MYK@OV?Y5GU[XIR( JMXLEQM&!_Q[05F1:WXBO(?-B\&^)&7MFUC7/YR4O[+;
MW<DGQ(>^LIM.NF\4RE[6XQYD?^C0<'!(KJP\^:6J/!SBA3I45RSN[]SZ0L?N
MBM6/M658_=%:L?:NQGR<1]%%%26%%%% !1110 4444 %%%% #6JC>=#5YJHW
MGW302SQ[]HO_ )(IX^_[ =[_ .B6KU>U_P"/.W_ZY)_Z"*\H_:*_Y(KX^_[
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M_5'E+?%S0FY_X2'3/_ R/_XJJUQ\7= ACWMK^G$?[-TC'\@:]HF\'33?] N
M?],M/7^I-$7@7;@M=PD_[-C"/_9:?LY=R?[8P\=Z:^__ (!X2GQHT.XD*0WT
MEPW_ $PM9I/_ $%#5Q?B-%(NY+;574]UTBZ/_M.O>(_"[0XV:C+&?]B"$?\
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M_/RO_?L4?\)MXA_Y^5_[]BM+^QAZ4?V,/2B\0][N9O\ PFWB'_GY7_OV*/\
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M^5_[]BC_ (3;Q#_S\K_W[%:7]C#TH_L8>E%XA[W<S?\ A-O$/_/RO_?L4?\
M";>(?^?E?^_8K3_L4>E']BCTHO$/>[F9_P )MX@_Y^5_[]BI(_&>OD\W*X_Z
MYBKW]CC^[3UT<#'RT7B'O=Q+3Q3K$C#=.I_X *X_]GMI+K7?BK++\TC>+9<G
M'_3K;UWMKIFUA\M<C^SK;?\ $W^*_'W?%\H_\E;>E=7T-Z:;W/:K-.!6BHJO
M!'M JPM0="'4444%!1110 4444 %%%% !1110 4UEIU% 'FW[1,?_%A/B,?^
MI>OO_1#UN6]J#:V__7)/_0161^T4/^+!_$;_ +%Z_P#_ $G>NEM5_P!#M_\
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M_P"DMM7J2KR*\R_9W7&M_%P?]3C/_P"DMM31I%6/8U6GT4M4:!1110 4444
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MHJMI>I6>N6YN--O+;48 =IELYEF4'TRI-63E>H(^O% !124M @HHHH ****
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M&"BXX>"?80=Z6DI:X3M"BBB@ HHHH **** "BBB@#SS]HK_D@?Q&_P"Q>O\
M_P!)WKI+3_CSM_\ KDG_ *"*YO\ :*_Y('\1O^Q>O_\ TG>NEL_^/.W_ .N2
M?^@BDS.1+^='YT45)F.B8+(A/ !!-?FS^S+'^T!^R:WQ!T>']GS4/&4&N^(9
MM4CO(M=M[550Y4#&'W9&#G(Z]*_22EW'UIE)V1\1?''X=_%CQEXL^#O[1?A;
MX>"#X@^%XIK;5O >H:G$S-:MYG$<RX4OB67G.?F3Y3@J<^R\)?$[]M3X\?#+
MQCXZ^&=S\*_A_P" 99KZ"WU&\$E_?WA9" %PI5 T41Y09"MR=PV_=GOWI=Q/
M4YH#F/SU^%%O\:/V#]0\7?#_ $#X,7?Q.\%:MKTVH^'=6TO45C9!(JJ$N#M;
M: J1@LP0 J_+ C'2_$[PW\;O"_Q8\"?M':+\.1JNO_V!)HGBOP#:ZG')+;Q*
MTC1M#*%._P"\&.W<0=HP1DU]R[B.AQ2 D=^:8<Q\5?"_2_C7\6/VQO GQ:\:
M^ &\#^"[/0;ZRM--EO8I[BRWIPTV%5MTK$87!*[3D#OT?[ /P3\9_!F/XOCQ
MAHS:.VN>+);_ $\--')Y\'S8<;&. =PZXKZRY^M'UYI!S:'RE^UE\-?B-I7Q
M@^'?QP^&6C#Q?JOA6WGTW4_#!G2![NSD+.6C9A][+'..>%P#S7 :+:_'/]H#
M]JSX*_$SQ%\+YO '@/PZ]\@L+R^BFNXC);2*UQ*,*ZAV:- F,C83C!R?NS)]
M?UI68MG/- <Q\O\ [)OP?\6_#GXD?M$:KXBTHZ=9>*/%5S?:0[2H_P!I@8R%
M9 %)P"''7!Z\<5Y1^S)^S'\1O!O[ _Q?^&^O>'SI?C#7Y=4&G:?)<Q-YWFVL
M4<9WJQ50SHPY(Z9Z$5][<],T?E0%S\_/''@/XS_&#]@>^^&5]\);CPWXBT$:
M-8Z?"VKV]PVJ1V\B^=, "!&%" X).=W&<5T_Q(\,_%#]G+XR:%\7/"/A:/X@
MV>H>$+3P]K_A6VND@OH7MD4K+$3N,H#=0BD_+Z'(^W,D]37CG[0G[)WP[_:9
MCL7\:6%XVIZ="\%AJFGWLEO/:*[!F*@'83D#[ZM0/F/CCPCX@\=?'C]O^6S\
M=Z$G@.?4OA_J%E::(MTE[-IUK-#M629DP-[%B^TX(X!Q7F&C_LAZQ\+X'\#>
M(OV6;SXH>)Q).FG^,-,\5W%KI]Y'D^4\L:MMB &/E8H3TXZU^CG[/_[*OP[_
M &:[&[3P9I4JZC?(L=]K&H3FXO+L*<C>YX SSA H[XKUW<>1GKUH#F/D#Q)^
MSQKVG^+OV4%\-^#[31=%\%SWDFM6>GW?FP:89;>,8$CD/+EPPW8))Y/7-:/Q
M&^"_C+7/^"BGPP^)-CHS3>"M(\-S6=[J@FC AF/VH!"A;>?]='T!ZGT./J[U
MHY]:!7,+QAX#\-?$+3(M.\4^'].\1Z?#,+B.VU.V6>-) I7> PX.&(SZ$UQ_
M_#,'P=_Z);X3_P#!3%_A7IM% KL\/U+P_=?LUWL^O>%+":\^%\S>9K7A>S0O
M)HIP ;VQC R8L#,L ]W09W ^RZ/K%CXATFSU32[R'4=,O(5GMKRV</'-&PRK
M*PZC%6U8JVX'D5XEK&BWO[.NJ7WB;PU93:A\-+R5KG7O#=HI>31I&.7O[)!U
MB/+2P+TY=!]X4ROB]3VVC\ZJ:1K%CX@TFSU32[R#4=-O(EGMKNW</'-&PR&5
MAP1BK>:1 ?G24N:3=2 ,TFZF,WJ:A:;Y@HY)X %,"5I*C\[<P R3Z"IH]/9L
M-</Y:]E7J:MQ^7 N(D5??O\ G0VD5RE1+&>;E@(D]7-3+80)@N[2GN!P*DW;
MN2<_6C-9\SZ%60*L*8V0KD=VYJ0W#=L#Z"H\T5-V42?:)/[V*!<2#^*H\T9H
MU[A<D^T/Z@_A36\N1LO"C'&,XYIN:,T)M=0&-8V[8QOB^AS43:;*O,3K*/3.
M#5C-&><]ZOF?4GE1GEVC;:ZE&]#3UE![U?:0.NV15D7T-5I-/5R3;ML/]QNG
MX&K33)<>PU6IP.>]52SPMLD4H_H:D63-.Q!-S2_G35;UI=U2,7\Z-W.<9]01
MU]J** /ESX(P_P##/?[27BWX/$>5X2\6)+XN\)+CY8)"?].M1U. V'!8@8.%
M%?4=?,W[>&E7>B_#WPU\5=)@,NM?#;7+?6P1M(^QLWEW08'!8;&SM!'([U]'
MZ3JMOKNEV6IV99K2^@CNH"PP?+=0RY';@BJ+EM<M?G1^=%%20'YT?G110 ?G
M7/>//'NB?#/PK>^(O$5ZMAIEHN6D;EG8]$1?XF)X %;TLR6\+RRR+%$BEFD<
MX"J!DD^P%?*7A2WE_:J^*]QXQU-3-\.O#MRUMH&FRD&.[N$.'NF4<,/0G/;W
MKMPU#VS;EI%;G/6J.-HQW?\ 5Q+7POXZ_:JN%U+QE+=>$OARS>;8>&;1S'<W
M:_P-<L.<$<X]^ .I]JTWP!HGP_T--.T+2[;2K1!Q%;1!<GN2>I)]37H^FZ>M
MNBD ;A65XXO+*"Q0W4A0\X5?O-[5Z,,1>HJ<%:/D<M:BJ=)SD_>[L\+\6:AY
M+/BN'DUME/#<57^,VN:EI[":R98K.1MI; ,BMV![8/\ 2O%+CQ-J3.6-Y+G/
M8X%?J&!PRJ4E(_$LRQM:&(<;GMZ^('C;._GUS7,>,?"^B>./+GN5;3]8A(:W
MUBQ_=W,1&<?,.HYZ'^=><0^/-0M3^]9;E.X<8/YBMJS\80ZG&?+8K(!EHVZB
MM:N!3Z&='-JM+XGH>_\ P!_:+U0>([7X=_$26-M;=-NDZ\O$>J*.@;TEQ^9Z
M\\GZ:YYK\XM6TF7XA62Z-;133:FSA[%K9"TT4XY5DQSGCM7U+X-^-'BJ+P;I
MGAP^&_\ A-/BI:P)%J&GZ?=@65H<X$E[>$&.%BN&,8WR'LK<U^8YS@882JG#
MKT/V#(\PECZ-WTZGN.H7UMI6GW-_?7,-C8VT;2SW5S((XHD4$LS,>   22>F
M*_-S]M+]M[X@:5J3^(/@#XSU?4/!E@PL=7OX_#MM-HT-UD*J6UY)$6E=CR5&
MY>05;!P/K-OV;;SXJ7EIJOQPUY?&DD#K/!X/TH/;>';.08P3&3ONF!!^>8X(
M8C8.E>QR>%="FT>QTF71-.?2K"2*6TT_[,GV>!XCF)DCQM!0@%>." 1TKYS0
M^HT1XA^QUX3^*\'@6/QC\9O%VI:SXQUV%7CT20+!:Z5;G#*IAC55,[<%F(^4
M848^8MR'[6WAN3P#X\T+XG6D3G2[R,:+KRQIPBDYBF.%]3@DGJ$ KZRW$L3G
MD]365XI\+Z9XU\.ZAH6LVJWFEW\+03P,<;E/H1T(Z@CN*[,'B'AJRJ+H<.+H
MK$TG39^?OC [&+HXDC8;D=#D,IY!![CWKR/Q%"3,;J/D]' _G7L'C#P7?_!W
MQ4_@7Q+*[:7*2?#VNW Q'/&3Q!(_0,,XR>AQG@C'#:]X=N-,U"6WN(6AE4X:
M.1<$?A7[=EN84ZU-69_/V<Y16P^(]I%:'GPOCZTK:D<'FK^I^%9-QDM3CGF,
M_P!*Y^ZLKFV;;)$Z'_:4U[/M$SRX49]$237Q;/-49[K=G)H:WE8X"L2>@ -6
M[7PU<7!WS PQ^G\1_"HE-)'7&A+JBOH]N9KL2N/E0Y%>W:;I-[H_@5(;.-F\
M3^+I5TG285&9%C<@22@ Y''?\#UJAX#^'-C::?)XG\4O_9OABQ7?B0$-<D=%
M4=2">..2>!WQ]5?LK_"N_P#%OB@_%GQ-8_8K7R3;>%])F^]:V_0SE1PK,.@Y
MX.>P-?%YWF<*5-QB_P"NQ]QP_E=2I5]I45D?1WPU\%VOPY\!:%X9LU46^EVD
M=N"I.&8#YF&?5BQ_&NFID?>GU^2R;DVV?L,4HI)!1112*"BBB@ HHHH ****
M "BBB@#SS]HK_D@?Q&_[%Z__ /2=ZZ.S_P"/.W_ZYI_Z"*YS]HK_ )('\1O^
MQ>O_ /TG>NCL_P#CSM_^N:_^@BDS.>Q+1114F(4444 %%%% !1110 4444 %
M%%% !1110 4444!J%%%% !1110 4444"N%*K&-@RG#"DHH&>+:SH]Y^SOJE[
MXD\-V<U_\-+R5KG7?#EJA>719&.7OK)!UA)RTL"].70?>%>OZ5JUEK^EV>IZ
M9>0ZAIUY$L]M=V[AXIHV&0RL.V*NQ"16#(&XZ8%>):UH=]^SIJ=YXD\.V4][
M\,KR1KC7/#EM&7DT61N7OK)!R82>98!TY=!U%/<U^+U/:":C:0+ZU5T_6+/6
MM+M-2TV[AO\ 3KR)9[:[MW#QRQD9#*PZ@BDDFBB@>ZNI1!9Q]7)Y/L*F<HTX
MN<G9(S492?+%:D\,4MY(5C&%'WG/05H0QQ6N1&-\G>1NOX5XI\0O'OB6WOK'
M5O##;K'3F8SZ*P'^FQGJ<]=X&<#W]:],\#>-]*^(7AVWU?29O,AD^62)N'A<
M=4<=B*\K"9IAL<VJ$KV/4K9?7PL%.HMS?)+').324II*]$X0HHHH **** "B
MBB@ HHHH **** "BBB@>Q!JVJ6FEZ3=WNI.L=C:1-/-,W_+-%!+-GZ"L'PQX
MFTKQEX=L_$'AZ_35-$O%WPW48.,=P0>017@?[2OB2Z^+/CBQ^#6BRNFGJ$O_
M !3>1=8H <I #G&6(Y'^%>K^$A_PBMO;6VFQK!90(L26J@"/8!@+@<=*]JG@
M92H\[>KV]#S_ *PI5'%;+J=['*&[U,K>]55$=Y#]IM!_OP]U]Q2PS;J\V46G
M9FZ+?XT4Q6I]2,YCXI>$+;X@?#/Q9X:N[)=1@U32KFV-K(2!*S1G:.O][%>3
M_L'>,I?&?[*?@5KJ6ZFU/28)-$OFNVW2"XMI#&RDYY   !]!7T';G_2(_P#>
M%?*?_!.G5K>\^#_C/38WS<Z;XXUF.=,?=WSEE_2FC3[)]44445)F%%%% 'AO
M[8WC"[\._")M&TQI%U;Q3>1:);M&A8A7YE(P1@A V#ZBNF^'MAIWP^\*Z5H%
MCM6UTZW6W3:, D?>;&>,MD_C7D_[6&H73_&KX+:8LVRR%Y/J#1'H9(RB@_7#
M$?C5_5/%4EJQ&[ ^M?9Y=@?K&'274^2S+,E@JCDSVW4_B-9:'9/=7,JK$A Z
M]23@"O//$GB5]6G:>:0,6&5QT [ >U>#?$KX@RS):6?F-M.9&YX/;!KDK?XE
M:M90^3!>-Y6,*K@-M^E>_0X?<;36Y\?6XH]M%Q>QW_Q>U:&/P^\#E6EG<+&I
M/(P<DCZ=/QKPF=JU-6URYUBX,UW.T\I&-S'M6-</QUK[3"8?ZO34'N?!XNO]
M9JN9G7DVVNR^$?P7\3_%+4(;NP!TO1$E\N76)T)CW9 V1J.9&.<8''/.*\_U
M*7Y3S6NO[0/C?2/ *^"K#77LM&0N0MN D_EMG,?F#D)DDX&#D]>U1CEB94N7
M"M*3ZOHNYT8!895>;%)N*6RZ_P# /I76M<\'?".UGT:TFEGO67R[FTTRZ OI
MI >1<7D9/D1,,?NX3OPP)8$$5G_ OXW:G'\>M%\/2M:Z7X2UBRFMK/1=.MA%
M;07 8NK*!R78[RSMDD\U\I^"[QMD\>[@29'X]3^=>G^ =4;2_B]\,;T)O9-:
M"_\ ?2%<?^/5\7C<GIT*,Y3?--K=GZ+E>;U*]14X14*<7HEV\S]+?UHI6&UF
M'O25^8GZ8%%%% '/>//A_H'Q,\.3Z'XDTZ/4].F'W)!\T;8QO1NJL/45\@>/
MO@KXU^$<,D-WILWQ,\"0C]S=VV!JVF1#H"/^6@ ^HXSQTK[@I0=O3BN_"XVK
MA7>&QPXC"4\2K21^<6E:!X8\:N?^$9\3VKSX9GT[4P;>YCQC@J?3U.,U;;X*
M^)Y%#)8Q.IZ%;A"#[]:^S/B!^SU\//B<S2Z_X6L9[Q@W^FP+Y,P9NK;DQN;W
M8&O.+[]B'PO]D6#2?%_C#22OW?\ B;-*BCT"?*!7U=+B#2TFT?-5,AI7ORH^
M>(O@7XA9_P#2DM=/A'6:>==H_*DCM? W@?4HK.2:;QOXH9PD.CZ5&9B)<@;2
M!P#D_P 1Y]*^C+7]A_P7-:10:SX@\6:Z P:1;G5F$,F.QCP>/QKH?V6?!&@>
M%=0^)=OI.C6=@FG>)YK&U:.(&2* 6UNWEB0Y;;N).">IK/$9\Y*T6W^!T8;(
MJ<97M;\3A_A9^S/K_P 1=9LO%/Q:@CL].M2)M+\'P-F.-CR'N3_$P&!M^N<=
M#]:0QQQQK&B*D: *J*,  = !Z4[9NXSQ3L"ODZ^(J8B7--GUE##PH1Y8 O&:
M=2+2USG2%%%% !1110 4444 %%%% !1110!YY^T5_P D#^(W_8O7_P#Z3O71
MV?\ QYV__7-?_017.?M%?\D#^(W_ &+U_P#^D[UT=G_QYV__ %S7_P!!%)F<
M]B6BBBI, HHHH **** "BBB@ HHHIV8!14=Q/%:0233RI#%&-SR2,%51ZDG@
M?C7CFO?'#4?%&H2Z/\.;!=3EC;9/K=TI%I <G@ _?/'ZURU\13P\>:H['9A\
M+5Q+M!:=SV*YNH+*'SKF>.VASCS)G"+GTR3BN0OOC5X#TVYEM[GQ9ID4\9PR
M>:20?P&*\W@^"KZ],MYXTUR_\3W>5)CDE,=N,$G 0=1SWKK=*^'OA[0XF2QT
M2QMT;JHA!_GFOGJN=\K_ '<#W(9722_>3;?D:4?QZ^'<G3Q?IJ^S2$?TKJ]%
M\3:3XBACDTO4[34%D7<@MYE9B/7;G/Z5Q5QX4TFXA>*72[-T88*_9TY_2N.U
M3X&^&+J036%M+H5ZH(2YTN5HF!/<@=?H:PCGTK_O(%RRN@U[LFO74]XHKP2W
M\8>//A2P;5BWC?PTIS)=*NV]MD[DX^\ *]B\(^,-(\=:+%JNB7BWEFYVDCAD
M8=59>QKZ+"XZCBHWIO7L>+B<#5PNKU7<V:***]#T/.\PK+\1>*-)\(Z<]_K.
MH0:=9KUDG?&?8#J3]*YKXG?%&W\ V]O9VEN=5\37_P EAI<9^9S_ 'W]$!ZG
MVK@= ^%%WX@U1-?\>7G]O:SG=%;9/V:V'953H<9/->/C,PAAO<BKR/9PF7NK
M'VE5VC^++T_QWUOQ5*8O WA.:]@Y']IZL3;P=,@@=?SZU5;2/BIKTD$FH^-+
M?1T"?/#I%J%(/H=V0?K7J%OIZQQHJH%51@*HP!]!VJU]BVC[M?/2Q.+K:\UO
M0]F,</1TA!?F>,:G\'-9UJ83:CX_UZX<# *N(_T0@4:-\+M;\*WR7>E^/=:C
ME5@Q2?$R/@_=8.3P>]>PS084\5033WU"Z6!/E'5F/15[FN?EQ+E=2=S5XF*C
MRM*WH>7QV]Y\##=>)=%LIK[X;W,IF\0>';%&9]#F.6DOK% ,F!B=TL ^[RZ#
M[RUO>*_$S>(KBVN+>>&XT2:(3Z=+:2!X)X6&5D5APV?7MTI_B3QU*NJ00:),
M;>QL7^3;TF?NS>H/(Y]:X"Z@A^'5O=ZSHMG-<_#R>5KG6_#UHA>;P_,QR]_8
MH.6MR23+ /N\LHZ@X8S%PSRC++Z56U2/W2MN*CAIY;..,JT[P?WHZ>"8]>E<
MS)=7OPK\6?\ "7:-&\VE3D+K.FP_QI_SU5?[PZUT3*BQ6]Q!<PWUC=1+<6E[
M:N'AN(6&5D1AP00:D5DDC*2*&1AM92,@@]17YGA\3B<HQ5VK23U1]A*-+%TM
M-8R/;-!URP\3:1::IIEREW8W2"2*5.X/;'8^HJ]7SA\-_$[_  C\9)X>O)&'
MA#6I2UB[_-]DN3U3/96/]*^CLGO7[YEV.IYA0C6IO<_,,=@YX.JXO;H+129-
M)N->G8\X=13<FC)HL!X=^T5^UMX<_9]U+1M &D:GXT\;ZT1]@\,:$@>Y=,X\
MQS_ N?7KSZ&LKX)_M.>-?B%\0H/!_C3X+>(_AY>W%I/?0ZA>.LEF8XRHVEAT
M<D],UX]X#N(/#7_!5+X@#QM/;C5-7\/PCPA-/@8A^3=%&Q_C*K(,=3TK[;UG
M7+7P[I=[?:A.+>TLK:2\GR?F6&-2SOMZD  U=K%'A'Q4_;1\)?"C]H_P3\(]
M2@\R\\1(IGU(7"JFGR2$BW1UZDN0/^^U]ZWOVM?VEK/]E'X6P^,KW0KCQ )]
M2BTR.SMYEC(=TD?<S'L!&1QSDBOS \1>.K'XU>$OC!XNUGPAXVN?B'XLU>WU
M+PMJNEZ/<36EC;VS?Z,J2@9 *EQE?]C^[7M'[:WQH3X^_P#!-GX=^,  NHS^
M(K&VU&$@KY=Y%!<QRK@DD#<I(SR0<T^4=CW+7/\ @H)XG^&UK8ZQ\2_@#XN\
M&>$[BYBM9-;9TF2W,AX9E')&W<<<$D8')K[(M;J&]M8;FWE6>WF19(Y8SE74
MC((/H0:_-_\ ;2\7_'>^^ ^G:7\4_"?AOPO\,-1U?3+;7M4\)WSZA?I:>8K
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M[?>+_0^K#Z]S25S_ (%^('AKXG:&-9\*:W::[IVXH\EJWS1,.J21G#1L/[K
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M:4]%^)E:7X3O-#>T^'7A7;=?$'Q$NR\O4^YIEL?OLS=N,\5]X_#+X?:;\*O
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M[QEJFK1ZK<VUY=R%XW.50X7Z@>E?1NLZD"C$L HY)/ ^M?-?C[5HM9\27=S
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M[+J?+Z1>IXC\9_VEKSP-\0=,^'7@CPC<>/?B#?0+=MIZSBVMK.W)/[R>8@[
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M%&12 6BDR*,B@!:*3(HR* %HI,BC(H 6BDR*,B@#FOB-\-_#_P 5O"USX?\
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M'V6(L1]E(P=[$#)8\X$>3Z0^$_VB-+^'^GQK\.O#6RRN%3[=/XHNI9+B249
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M+#*H='4Y#*1D$5FWT76O,?!?C_0_!&MR:%!K*ZEX5N)6;3[QPR26I)R8Y48
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ME/'.,=#7UM7Y?FV+=>IRGZYE>%5&FF)1117SY[@4444P"BBB@ HHHH ****
M"EI*X/XV?%JQ^#/@&[U^ZB^V7986]AIZL ]U<-PB#V[G . #50BYR45N3*2B
MN:6QG?&?X]:-\(;6WL_)DUSQ7J'R:9H-GS-<.>%W8^XN>I_*O*['X%>+OC7=
MIKGQAU:1[8,7M_".ES-%96PQ@;V!R[8SGG_@1%='\ ?@A>:?J5SX]\:2#5/'
MVL_OIYI =M@C=((@?NX& 3^'3K]%V]C##;D,JX[YKU'*GA-(:RZO_(Y8TIXC
MWJCM'HCQ)O"FC>!]+6QT73+32[6,';%:Q*@YZGCN>]<%K&N%)F7<3^->H_$H
MQV,,I23S9N2+=<;C^N!^-?)GB;XC7IOI%CMHX-I*LLA+'(/Z5]QD]/ZQ#F9^
M99_C*F'J<L-#T[_A(W1LJ[#'H:Q/%&E^'_&UJ+;7=+@OU&=LC+MEC)QRKCD'
M@=#7ES?$2_#Y:. KGD $$_K5^P\?6U\PCDS;3'HK'(/T->_4P"['S-+-ZL;7
M9W/@+XL>+OV<+J!'O;KQE\,(R!/;SG??Z8AX+QG^)%.#MZ8)Z?>K[<\+^*-+
M\9Z#8ZUHM]%J.EWL8E@N86RK*?Y$="#R""#7Y]_\)"T+'YL@C!!Z$>AK7_9Z
M^*A^!_Q2@T6:X,?@+Q3/Y:0LX$6FWIZ.-W"JW0X/X<"OA\WR?EBZU-6:_$_2
M,CSU8B2HU&?H&!BEIJ]Z=7PY^A!1110 4444 %%%% !2&EHH 8:\:^-WPUU"
M[OK3QKX6B4^(=.4BYM5&#?V_=">[ =,]?P%>SXHP,=*Y\10AB*;IS6C.BA6E
MAYJI#H?//AOQ'8>,](34-/<]=DT#\20R#JC#L1^M3SVO7BG_ !P^&_\ PB=K
MK'Q&\,WB:-=:?:R7FJVIC+0WD4:EV.P?QX!^N>QZ\UH7Q,L-2NETW7+:;PUK
MF!FSOP4#D@$;&/!Z].M?D>:9)5PLVTKQZ'WF#QD*\>:#_P" :-Q:^U9T]KGM
M7526@D4,IW*>0P.0:J36'/3BOF)8=IVL>[3Q)R4EF=W2F+9,6Z5TTFG'LM+'
MI).21M Y)["G'#M[([OKB2W,:VTXENE:LTEGH.GR7VH3I:VD0R\DAP!]/4^U
M8&O?$/2?#]R+"Q5]=UESMCL;$;_FZ#<PX SCWYJ]X9^$.J>+-0@UGQW,MP\?
M,&C0'_1XAV+8/)ZG'TY[5[.%P#D[R1Y>*QEE>3LCA=9O_$OQ@U**#P]I+/X9
MMIE8_;,QPW14@YD.02O(.T'..>O3TE/"?Q$U*Q>&\\<+I</"I:Z39*L<: 8
M0D*P ]*]3M=+CM;=(HHUBBC 5(T4!5 Z  =!4C6V.U?3TO;48<M-V1\U6Q4*
MK^%:'C^F_#/QAH\YFM_B3JQDQ_RVA$H_)W(KBO$WP]^(NF^(!XEM+RUU;5$)
M$EQ;H(I9D'3S$X5N.,#FOI"2WJO);\8K&I4K\O+)W7F53KJ$N:R^X\E\(_$>
MQ\62'3KV%]'UZ+Y9;"Y&TEN^S/7Z=:Z2>SZC%3>./AQI/CBW O86BO(N8+Z#
MY9HF[$'O@XX/X8KRO4O&7BWX37<5AXAMUU_2G($.HI\KD9Y!/3<!V./J:\"M
M@HU7>GH^QZU&JI_!OV.]GL^O%49;$GC%9UK\8O"]PL(O9+K299?X;RW9%'_
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M_P#UR7_T$4G",U:2N0ZDJ;3B['C5Y^SM=:/'*?"'C'4M(RJA+2](N(1@^IY
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M_8YGQ#JS+YJ@\D%?TKQ3^U&21D9OF5BIY]*]'\63M%.X/'->/^(-UK?-*O\
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M.3RU><_$K_@G'X>^+7AJ4^+/&FM>)_&]Y>6\U[XJU:4L8X%<&6*UME(CA#(
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MZ:$ XK2AM@O:I<@C$@MK0+CBK\<>VG+&%J55K-LW2!5IU%%24%%%% !1110
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M[^U$WQ%\%M_S,FG?]_J]Q_X1G1?^@/IW_@'%_P#$T?\ ",Z-VT?3C_VYQ_\
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M15U8<5(L>.U3<M11%'"!VJ55IP6G5)8@&*6BB@84444 %%%% !1110 4444
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ME8$5Z=H=UYDB=PV#7G8VDG!GM93S4\0FMF?HI^S+\1O^%I?!/PQK<LT<U_\
M9Q:WH1BQ2>/Y6#$\[L $_P"]7J5?)_\ P3QUM[GX>^+-'955--UR5TV_]-1N
M_I7U?_%7X5BJ?LJ\X=F?T5A:GM:,9^0M%%%<IU!1110 4444 %%%% !1124
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MJ*;NHW4 .HINZC=0 ZBF[J-U #J*;NHW4 .HINZC=0 ZBF[J-U #J*;NHW4
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M:W4;JJ_:/]HT?:/]HT6"Z+6ZC=57[1_M&C[1_M&BP71:W4;JJ_:/]HT?:/\
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M%_W\%'_".:EZ1?\ ?P460:DWVX?WJ/MP_O5#_P (YJ7I%_W\%'_".:EZ1?\
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M&LIP0PEM7,3 CH?E(KQGF\HO6GH?6?ZIIQTJZ^A]N45\Z_#WXZ:GX?N8M/\
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M+7_8WR_^DMO29M3ZGM]O]T5;6J=M]T5<6L6=BV'4444AA1110 4444 %%%%
M!1110 C57GZ&K#57N/NF@3/*_P!HGCX%_$0GI_PC]]_Z):HM'^.7@6^-M:Q^
M([=)3&HS,CQ)P!_&RA?UJ3]HK_DA/Q%_[%Z^_P#1#U\Z1V:&WA!0%=B]O:O,
MQV,GA>7D5[GO93E=+,E/VC:L?7]C?VNJ6L=S9W,-W;2?<FMW#HWT(X-9WC#Q
M1:^"_#=_K-YEHK6/<(U(W2N>%1<GJ37ROX?U+4O!6I+?:%=-92;MTMODF"XZ
M_+(G0]3R.1US7=_$_P"(<'Q \#^&_LK"W=M29=0L3@F*2.,NJGVS\P/<5E'-
M8U*,G:TD;5.':F'Q-.+?-"3W.#O+C4/%&L2ZQK,YN=0F)(R?E@7M'&/X0!QQ
MUJ1K557IBK%N@51WJ21E[UX<8J2YI;L_1HJ-)*$%9(RI+<52N;5)HVCD4.C#
M!7L:UI&5LXJK+@FO/JI+8[(OFW+VI_$;4/%GA71_"EU+([:7(QO9B?\ CY5<
M?9\^N 3G/= <TRWA4*/7UK"L%VZW?8&,QQ$^_P!ZMF:79 QSSTKHIUG4?--G
M)##T\/%PI*R;;^\6:XC7HNZJC7",V"-IJO).%[U4DN!WHJSBT=%.$B[/;K(I
M5@&1A@@C((KV_P"!OCRVL_A]J5MK%]';P>'7V&XFDR1;D!HR?IG8.I)%>%V]
MP)(0?PJ""-KS7)[??_H?EQ2S08R))%+>63]-S?G4X3%O#U>:.MSAS3+HYA1]
MG/1IK7\SV/6OVAM6U"X(\.:3;VMCC"W&J!C+)GH1&I&WOU)S[5G:;\=O&6FL
MGVZVTO5H]V74(T$C#T# E1^*FN8AA"KR*62$$=*]9XC$M\W/J>7#*,OC'V?L
M_P#/[SVSPG\=/#?B6XALKEYM#U*7 6WU!=JNV,D)(/E/MD@GTKT7::^/KRPB
MN(WBD19(V&"I&177^!/B]JO@3;9ZKY^M: JJD?\ %<VBCCC/^L7'8\C'&>E=
MF'S37DKZ>9\WF7#?)'VF$=_+_(^D>E%5-)U:SUW38+_3[F.\LYUW1S1G*L/Z
M?2K=?2)J2NCX*47!\LM&%%%%!(4444#"BLCQ9XHL?!N@W&JZB[+;Q$*$C&7D
M<G"HH[DFO"M:^,WC+6IBUC+;^'[0.2D442S3;>P=GRN?]U1]37#B,92P^DGK
MV/7P.58G'J]):=SZ,KP;]HK6I-0U[1O#H_X\X8O[1G&X8D?<4C4C_9PQ]]P]
M*YR/XJ>.K*9)EUY;H(<F"[M(C&_'1MBJP'T(KG/$WC(^-/&T^H36C6-VUG%'
M+ 6W+E2PRC=U/!Z=\5XN+S*E6HN,-#Z[*\AK8/%QJ5K-+MW+-NJ(HI[LOX5G
M_:0J]:K7.HB)"<\UY<<5",;'W?LI-W+TVWVJE-$&]#Z^E9,FJ.W.\CZ&ECU5
M@V&;</>N&I6C([(TI):D%FQ\.W3VH&+2=B\#Y^ZQ^\G^%:HNLKUYJ"\@BU2U
M,+XVMR&'53V(]Q63;W4KVX\P8E5BC\?Q X)K&GB726@I4E)[&PEY\Y3=QBJ-
MTOF:QI4H^ZKNI_%3_A6:U\8Y@*M1S>9/8GTG/_H#5C+$*I-'4Z/) ZF>ZV6I
MPV.E9S70#9!Q]*K7UT5A8 UD-?8'6NGZ]S*QA'#7-\7"72M'( <C!!Z$5[-\
M!OB##IVAZKH>LW:6]IHL(NK:XF. MJ205)SSM;@<="*^>X+[$X /-69C]JU+
M2%)81R3&.0#(WKC.T^HR ?PJ\)C71K*<=3S\TRN.,P[IU-.S['NVL?M&:C>-
MN\.Z#%]DS\D^J2,K2KZA%Y7/N3]*N:;^TDB.%UKPW<VR*F6GL)EG&>_RD*0.
M_4UY[% FRJEQ;IR17NRQ6)@N?F/G?[#P$H^SY/G<^IM!U_3_ !/I<.HZ7=I>
M6<HRLD?8]P1U!'<'D5H5\Q?#'QL?A]XH47,K+H.I.L5TK, D$O1)N>@_A;IQ
M@]J^G?H<U[V#Q2Q5.^S6Y^>YIELLOKN'1[,****[SQ HHHH **** "BBBF 4
M44H!/05-[%)7V.4^)/CB+P#X7FO]B3WTC""RMG.!+,W0'V')/L/>OFNSTV1I
M)[N[D:YOKJ0S7%PYRTDAZDG]!["O1?C[-+<>.-"M'?\ T>WT][A(\<>8\A0G
M\E%<5),((?4GM7S6*J>UK.$OLGZAD.$CA\*JWVIE&:U'/%9UW9I,CQNH>-AA
ME/>K<VHX;# 8]J@DN%8XS7A8AQ6Q]I2O+=%6#6-3UC4+:UU.X:YBT>U%K9M(
M=S^4[;OF)ZD;0OT K>1U"BN7#+;^(HF^;-Q 5]LJ<_GC-:TU\(5'=C2H8CK)
MW,W1C!<L%9%^20>M5I,=ZSFU5MW(&/:E%XLBY!K2I74E8TA2=[A?6<-Y"8I5
MWHWY@CH1Z$5ZS\(OC!?QZM:^'?$5Q]K@N2(K'49"/,5\<12G^+/9NN>#UKR-
MKCWJ&Z475K(H8J^-RN.JL.01]"*PH8N>'JJ46<N89;3QU"4*BUZ/JC[:HK!\
M/^)([KP/IFNZE/#;1R:?'=7,K,%C0E 6.>P%<!K'[15DK$:#HEWK";L"YG86
MT3KC[RY!8_BHK[V6)ITXJ4WN?BU++L37FX4H7L>NT5Y+H?[1.D3LB:]IMUH!
M8D&X)$]NOIEU^89]2H ]:]7AFCN84EAD66)U#)(A!5@>A![BKI5Z=97@[F6)
MP5?".U:+0^BBBMSA"BBBF 448YQWK"\1>.O#WA/(U?6+.QDV[Q#)*/-(]0@Y
M/X"LY2C!7;-84IU':"NS=HKD-#^+O@[Q%,(;/7K83LP18KG,#LQZ!0X!/X5U
M]*%2%17B[E5*%6B[5(M"K]X5Y+\!?^1C^+7_ &.$O_I+;UZ/JWBC1O#K1?VK
MJUEIOF?<^U7"Q[L>F37F7[/-Y!J&L_%6YM9H[FWD\72M'+$P96!M;?D$=11S
MQ;LGJ7"G.*YFM#W2U^[5Q:IVOW:N+4'0AU%%%(84444 %%%% !1110 4444
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MX'7WKIP&*J2K^T6MCGS7!0GA_8M[GN]O\=O"$T\:-=7ELCM@7%Q9.D0]RQ'
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MD;;XW 96]0:L:5J!D4*V,,>_>H=*M96L432V:ZNFD9GMY%S#&I)P2_\ "?\
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MY>]6QX6^(NL8EO;_ $_0XB@(AAB\X@GUST/T)KWWPK\/=.\-Z;'::?9Q6D"
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M+.WT%.69XBM:,4:4<'0I^]49YQ\3(I?"?B[_ (3VPA:33+M%MM>MX^3MX"S
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MGF0GD;L'(_$=Z\!Y3@Y3YI13?H8TXU(+V?MY/R1W5Q^T=\*M#L52+QCI!@B
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M^Z3O_LBN)_:(_P"2%_$/_L7[[_T2U=I:_P#'K;_]<E_]!%;Q1S5';8L>8_\
M>;\Z/,?^\?S-,YI44LZ@'DG%5RQ[&/-+N?.'[3FN7OQ"\7>'/@WI%RT"ZP/M
MVOW$;?-%8H<^7Z@O_*O>O!^A:?X;T>RTZQA6VLK2)88(5Z(BC %?,7PDUZ'Q
M7\8OBMXV:::<'4%T>S:;HEO$/NKZ8<,/QKV7_A.D@ &_&*^A^I5'24(+_ASP
MI9C1HS=2H]3UR\U6WT^SDGDD"(@Y_P ![UXYXT\53ZNTBAC%;G.(U/WOKZUQ
M'BCXUQKX@-A*Y_L^,!793]V3U^@Z5DZMX[TD6OV@ZC#Y1Z$-D_EUKKPF4U*4
ME*4;L\C'9Y1KTW&+T/'OBMIL.FZ]FW4)%.GF%5' ;/->?S-CO74^./$@\2:P
MUPB%($7RXP>I /4^_-<C<MC-?J.'C*-*,9;GX[B9J5:3CL5)+R2W?S(W9'7D
M,IP:V]+\9->_N+@@7 Z,.-__ ->N1OKC;GGBL"XOFCD5D;#*<CZUT.FI&'-)
M['KMXT&O:;<Z?=+OM[A"K9&<9Z,/<5]3_L:_$:?QI\,9O#NK2B36?"\W]G3;
MGW/+!C]TY_#Y23U*DU\9Z%JWVNWADS]X9/M7MO[(FK3:3^T%J>GK.D=GK6B&
M:2+ R\D+@( ?7#.?QKX//\+&5)RZK4_3^%\7./+<9J'AN3P?XD\2^#K@N387
M+7%D7.2]LYR"./<$^[8KS3Q)I[1R.2".>]?8'[27PWN]<L;/QCH4!GU[14(D
MMHUR;NV/+(<<DKDD?4]\5\[WEK;>*-)BU&QPT4RY*YY1NZGW%?SYCL*Z<W![
M=#^\>$,\ABL-!MZK1GAVL:0TSF6(9<=5'<5C1Q'.#7K%UX?:.3F/%9UQX5AN
MFRT15_[R\&O ]FXZ,_5)8B$U=,X:WB[5K6</([FNDM_ L089EE!^@KH]%\*V
M]G(KK&7D!X=^WX4E&QYE>NK;FAX-TDV%HN\?O9#N?V]!7:ZYJ7_"/^$]0OE)
M698]D6,9\QOE7]2*K:+IIW+\M;?AOPZ/B5\4M&\.1KYND:.PU'5' W*67[D1
MXQDG@C/0GNM>KA:+E9=6?!9MC(4*<ZDGI'4]@^&?P9.@_#_0;9M0OM.U$6ZR
MW,;;759'^9EV'C@DCKVK9O/AOK+-MMM=MWB_Z>;09_\ '37H?/&.E'-?9?V;
MAG%)Q/YQJ9OBY595.;=GG,'PDGEC)N]:"R'_ )]K1,?^/<U'XE^'&D>'_"FI
MWB)+>WD< "RWCF0)E@"P7H, D_A7I7-,FA2XA>*5!)%(I5T89# C!!I?V9AH
MQ?)!7(_M7%2DG.;MV/*[6\M=#TN.WLXU1(U &T 9&.OU-8E[XP53C/%=9J/P
MSO;/?_9-W%/;#_5VEYD,@S]U9!V ]0:XG7O#UQ9@KJ.G7%CU_>,N^/@]=ZYX
M^H%?%8J.8X5<JC[J['W&#KX'$M-RU?<2WU^WU:&>SG >&12"/3M_GZ5I>!=*
MCOA>+?[+J[CE\IFD4-\H4;2,] >OU)KD(K6UT_Y_/CEYPL<3AV<]@ *[/P^W
M]@PW$\Q'VF=O,D"GA<  */H!_.O/P^)DI7KZ(]/%4J:25%ZFK?>$=&FN"[:=
M%O'&]1M_EBL:?P381QLMO=W=MDY \TD#Z U=;Q2K9)8<\XJG-XDC;()KU:TL
M)46AY]*&)3,+Q%X=O=,T_P Z&_5XE*B5S$JN%) W CTS7HGA^&QT>QCAMU58
ME&<C^(_WB>Y-<W'J\&J6<MK-@HRF-OH15"SN[AM'\HN3+!F!_7<O'ZC%>?3Q
M4,))U(HZ:E*I57+49S?Q.T'5]-\:3>,_!IMKZ]FMUM=4T6^Y@OXE'&/1@!C^
M7>N(\*> OAW\5-0N+70M7UKX=:\Q+7/AX3;/F[F-3@$'*].>*[>\OKA>E>:_
M%C^R+K0WN-1W1:TI TR2US]J:<\*JXY()QFOK\IXD>)J0PLX-WT373U.Z.!?
MLKJ5FNO^9[E\*_AOKOP=TBYL+6+2]?BGE,DEQ&SVUY.Q;AI7?*M@$^]>V6$A
M9%++M; R,YP?2O./AC/XB_X0;1O^$H11K0MT\YE;);@8+^CX/S>X-=]I\V[%
M?<UXOJ?!8MSE4;GJ^YT<!R,=*G$T;,R!U+K]Y0>1]:I0R_*.:QM.\.KI_B?4
M-8-TTGVH8$)SA/7ZUY+BNIY/+>YLZE(([>1QV%<%J6!FNPUBX'V249[5PVI3
M#:>:]'"';AXLYO4FZURVI-UKH=2F'S8-<OJ$@Y&:^JP\M$>]1BSG-2%LM['+
M*0)L83FF?:"IQG%5=3M6FU2*<L/+0?=]ZK7EZEK"\TK;8XQN8^E>U%Z'KPIF
MK'=%6Z\5:DVWEG+ YXD4KST]JYVSU&.\MXYXGW1N,@U9NKR1;-S""9#QQ_.L
M9ERI:'0_##1YM!FNFN" [<)M.<C/7^5>R:/><KWKQKPQ</;1VZR,6?N2?7M7
MIFBW7S*,YKY_&1;E<\;%4WN=+I-C;^%='O4FEC@TN&26Y1G<_NXV)D8,3P &
M+8 X"[1VKQ7PSX./[3^M7'BC5X6TGP!#*8K#3[8"*XU1EX,T\@&2G& N3Z>M
M7_VF/%L\/AC2_!NGI,=4\62+9QM$V/W8D02*?9E<C\:]Y\/Z':^&-#T_2+%/
M+L[&!+>)<<[5&,GW/4^Y->/4DZ,5/JSQZ]:6$H^TC\<MGV7<=HN@Z;X;TZ.P
MTFPM]-LHP D%M&$48^G4^YJ]1S1S7FMM[GRLI2FW*3NPVT8]J.:.:1(8]J,4
M<T<T (5# @C(88(/((KA=>^%=K=%Y]&D739FY:W=2UNYSDG;U4GU%=WS1S7)
MB,-2Q4>2K&Z.O#XJKA9<])V/G_7O">H:4Q%_I\T '2XA!EB/&?O+R/Q%<[]D
MD;YK><3*.T;!J^H\GD=CP:\O^.'B3PE\-_",NN:OH]K?WS?Z-IUBJ8ENIV^[
M&@7D\X)Q_45\I5X752?^S3:9]G@^):G,H5:=SQ_7/B'9^ =/^TZS=BW@^ZJ-
MRTA_NJO<UE^'-'^*'Q.4'P[HT'@GPY(Q:._UP%YRI!^Y%UQN''0C/>NX^!O[
M/4\=VGC7X@QKJ/B>X&^UTR8!H-+0\A0IXWXP/;IZU]%1VI//\Z]W"9+A,#&U
M;]Y/N]ODCIQV<N4OW"L?-^E_L=VEY+%<^*_&FO\ B"?RPKQQ3_94#=RI3G'U
MK5M?V-?A=9W!FDT>[OG/7[9>O*#]<U] - /QJK/'MS7O4ZUM(:+R/FZF85Y/
M63/$M2_9/^%E];^3_P (O';#^]:RLC?GFN=U+]C/X?2V3PV$^M:7,?NRI?M*
M%_X W!KWZ8XJC(^,^M>M2Q-=?#-KYGG5,3S:3U]3Y"\9_L0ZVOF3^'/%$6J[
M%41V^J)Y,C'OEU^4#\*^?O&GP_\ %7PXNO(\1:-=:;DX29US$_) VN..<' Z
M^U?INUP(\EFP!4-Y#IOB33YK"^@M]1LIE*26]P@=&!&#P?8GFO?PV=XS#OWG
MS+S/G\5DN69BG&I12?=:,_*AM0//S55FO"V>:^J_CY^QZ-+L[WQ%X&66:VC_
M 'L^B\N\:X^9H3U8#&=AYQTZ8KY6BT2[O%/DQ,ZYVELC@^]?<8/,Z.,A>+UZ
MH_+<VX9KY8_:4WS4^_\ F4)K@M5K1;5FF%PXX!^3C]:UM/\ !KF1#/F5R<+%
M&"<GT]Z]<T'P'IGP]TU/%/C0!(XRIL='0;IKF4_=7;W.<<>_/I5XC&4Z$6VS
MQL/@*N(DH16G5A#X=U/1_"%EX=TVW>;QIXU9;6TMX_\ 606N<N_;!(![],BO
MHG0]!M_#WAG3M)LD>.UL8%MA'(#N4J,$'/.<YK6_9K^#>KZ?JM]\1_'$"Q^*
MM5CV6.GN-QTJT/(3_9=AC('0<5Z=XP\ S:E>2ZEI;(+J50)[68X28C@,&_A;
M'?H:_GSB^%7-TO8OX7>W<_HCA&I2RG2HMU:_]=SPNXL'\S[QQ77_ +'R[=+^
M(@_ZFN;_ -)H*T'\&ZJY&[0;\-W"A",_7=S3?V6;.;3V^)EO<0_9YD\62[HM
MP;;_ *+;\9%?%9#@\1AZ\I58M*W4^]S['8?$X:,:<DW?H?0EK]VKBU3M?NU<
M6ON3X5;#J***0PHHHH **** "BBB@ HHHH 1JKW'W35AJKW'W30)GE?[1'_)
M"_B'_P!B_??^B6KM+7_CUM_^N2_^@BN+_:(_Y(7\0_\ L7[[_P!$M7:6O_'K
M;_\ 7)?_ $$5T1.6J2T^'_71_P"\/YTR@,5((.#5'.?$_P #]0B7PSXLBBXF
MB\2ZAYI[\S,5_2M35?$#PR$>8>#ZU2N[(^ OCY\2?##1P00:L\>O6"Q _,K+
MAU'&,CEC]:YGQ-?F.1Z_6<JY:L$^]C\9XE52FKKH<-J'B*6ZOKB61R7>1B?S
MJJVI>9W%<YK5TUKJLXZ*S;E_&H(]4]Z^P]FDE8^$A6E);G227(;O6?=SC::H
M?VE[U3NM2'/-39G1%%?49^O-<Y>2]:T+ZZ#=#6)=29)%/8Z(Q.V\&R%K"/\
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MKY5PL?F[I,_ZF/,CY_W5R?TKMM*\#ZW+;3ZA%!&%N6S]AN3Y<F%& ^[G!/\
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M $&P]/)0CE@/XB._ !KB_@/<R>$==O\ P!J$ZBX\*ZY&+9F<;GM)&W(2 !G
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M?<?G.9555Q,K;+3[A/PH_"ES[T9]ZYCRQ/PH_"ES[T9]Z $_"C\*7/O1GWH
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MZ3CTKY"K-U)N3ZGQ=:;J3<WU%HI./2CCTK,Q'+U'UKR7X"?\C'\6O^QPE_\
M26WKUE?O#ZUY-\!/^1C^+7_8X2_^DMO42-J?4]OM?NU<6J=K]VKBU@SL6PZB
MBBD,**** "BBB@ HHHH **** $:J\_0U8:J\W>@3/*_VB/\ DAGQ#_[ %]_Z
M):NTM<?9;?\ ZY+_ .@BN,_:*_Y(9\1/^P!??^B6KL[7_CUM_P#KDO\ Z"*Z
M(G+5)<BC(HP*,"K.<,BC(HP*,"D ;J\,_:\?R? >@3E<)#KD#LWH-KU[GQ7F
M/[2FAOKGP8\0I#"LL]JB7:[CC:(W#.?KL#5Q8Z#EAYQ6]CV\EJ*EF%&4MKH\
M[TG41#&O..*Z.VU[8H^:O+]%U;[=I=G=@;?.B5]JG(&1TJ\=7*]S7S>72T2/
MWRM@%6=SL_%_B1O[!F4/C) //O67X(\21S64]KOQ)&V_!/4'N*Y#6-2:\L)X
M0WS,IQFN C\0W&GS">"5H95[K_6OK;JUSKP^3*KAY4UO<^@[S4L]ZY/Q5K\>
MEZ1=7,CA=J$)GNQ' KSJ;XO7Z18:"!VQC=R!^(S7"^)O&-[X@D#W,@V)]R).
M%7Z>I]S7-5K**-L-D=6$USZ)%'4-0W$G/6L.:\^;K4-Y>EB:RY+C)ZU\[6Q1
M]Q'W4;"W7(YKKO"]UBRZY^<UYRMQMQS7;>&V:.QCS_$=WYUY%3$71ABJEX'H
M>FS;MM=1X2B6Z^+/P[B)P3J$C=?2(G^E<5I#%BM>A?!G2HM=^/FB%A*1I%A+
M>%E^ZLAX3/U#'\JY<+>IBH)=SXC.:JI8&M-_RL^OR1FDR*./>C K]1Z'\O!D
M49%&!1@4"#(HR*,"C H ,BC(HP*,"@ R*,BC HP* #(HX((/(/!!'!]J,"CB
M@#X[^,GP#O\ X4ZKJ?BCPKITNL^!+R0W.K^'[;_7V+'[UQ;#N!R2H[=01T\?
MD\+0>(-._MGPU<KKNDL<&2W7$L)_NRQ_>4_F/>OTDKP_XC?LJ:)XEUF3Q'X1
MU&X\">*W.Z2\TY<V]QTR)8<@'..<8SWS7T^7YS4P_N39\UF&34<7K8^'M0\-
MP7N?-C^;& W1A6%<>!RK'9<?+_M+S7TQXH\%_$SPJDG_  E?PYL?&ULBHIUC
MPW)MF;G&3'C<6QV50!ZUR>J^(?!&CNBZIX!\8Z7(1PMU8R1Y_-Z^NIYU&2O^
MI\E+A_DTB[>IX7_P@[;OGG&WOM7FNP\&_"'4/$,@&GVABM_X[R880#Z]_H/T
MKU32[JSO&MSX7^$'BC6;FX<)&VHV;16XSW\URRKVY./K6]XR^#_Q7\1?#_7]
M<\57MIX5TJRLI+A?#NCGS+B<KGY)9!P 1C(4L#Z"L*^=):)V9VX7AWVM2,=[
M_)'EGB+Q%:^$[>3P1\/EDU+7;PK;WVL6PW'<>L41'5OIT^N:]_\ @K^R1<1^
M&=,C\?W,CZ?;DS0>&;=MD0D8Y,EPR_?<]Q^!)IO[''@/2M4GU'QI#I(L+&T*
MZ?H]OD,D9V W$F3\S.7_ (FYP0.U?5=?(8_'3G-P@]>K/T^AA89)'V%'X^K[
M>2_S*FEZ58Z'I\5CIMI!864(VQV]O&$10/0"N*_:&_Y-[^*?_8IZM_Z225W^
M!7 _M"8_X9[^*?\ V*>K?^DDE?/SVU,E)U)\TM;G.6?PTT_XJ_LU>#-%NPL5
MQ_PC]C+97FW+VLX@39(I'(YZX/(.*P?@S\2KS6-)B\/^(E:/Q7I=X^E7JNV6
M=DC9UE)QSN5&^I!/<5Z?\&_^2.^ L_\ 0 L?_1"UY)XY\(Q:%^UIX.UJ B.+
M6[*Z,\2D_--%"5+GG'*LH'T->A@I^[[.7R/HLNK*IS8>>VZ\@UR^\5_%;XK:
MEX.\-ZU<>%=#T**-]5U2WC_?R3-AA%&^>/E(^OS9!Q56XM-8_9K\;:0EWKUW
MXB\$>);LP3W&I8,]E=MT?*C!#\9&!^?-;/[.LMS!\4/B_::G-&=2;5+>78C9
MS%Y;;#^"E ?>N^^.W@<_$+X5Z]I,/%\L7VJS<L1LGB^=#QSVZ=SBMYUG&K[-
M_"=53%.CBHX=VY-/^'/._%%FOAW]JKP)JMS!)<6^L6,^EH6PR13CYEV@].%)
M)]37T&S;B23DGO7R/XN\=7FO_"SX7?$:V=8I/#NJ1_VFC*SM"Q AER,9^4 D
M_7O7U=INI6>M6%O?Z?<1W5E<H)89HF#*Z'D$&L,5%KE?R.+-:<HQIS[:?<>%
M?%J&'X=_';PCXU=(TTG6X6T+4Y/+R%8X,3LV<<X5>>@1JX;PK;7?[,/CZ[O'
M6=O FI7[6>HR.A=;4M\]O,I')7;(%8X/(<=EKZ.^)WP^L/B?X*U'P_J "K<+
MNAN&7<;>8?<D'N#[C()'>O'/!FM6VI)J'PQ^)]M%#XG%JMG]HN&_=ZO; GRI
M8Y#U8$DXSG.3UR!M1J*I3Y'Z/T._ XB.(PWLY:V5FO+H_D?1,4T=Q&DD3K)&
MX#*ZG(8$9!!]*?D5XO\ LQZY?IH_B'P7J\\UU>^$[XV<=Q,""]JV3">I[*?H
M-HKVC KSJD/9R<>Q\OBJ+P]9TWT#(HR*,"C K,Y R*,BC HP* #(HR*,"C H
M ,BC(HP*,"@8<5Y7\</@]+X^MK/7O#MP-'\=Z*3+INI1\%P.3!)_>1NG/J?4
MUZI@4<5=.;IR3B:4ZCHR4HG@GPR^)T'Q(M[O1=;L_P"P_&FF_N]2T:;Y6R/^
M6D6?O(>O&<?D2>)O!!5G>-=R?2NP^,'P)T?XL"TOUNI]!\46'-CKEB=LT9ZA
M7_O+G!QU'.",UYA_PM#QA\)Y4T[XK:$]QIX(1/%NC1F6V<$J 94 RAR3DX&<
M<*>M?1X7&6?-2>O;_(^FP^+C4LXNS[&+=^%V5C\G3VK*NK&'3V EZGL!TKVW
M0]0\*_$"T^UZ%JUGJ4156)MI063/3<G53[$ UC:U\*Y;W5$=?F@:12_8A<\_
MI7TE/-DE:>A[<<4E\6AYM8:7'=('CY7OD<BM>U\/GIL_2L[P)XD^+.J?M?>/
M_ &KZ'I</P<T?3UFLFCAA$EHLL>;65)%/F,\C)(&#9P >!P3[?'X9M-/A,MP
MZHB*79Y&"J .2?I7GTL\^L1DW&UC&GF'M4W:QP.E>%7F<!4)]\<5V^E^'[?2
MX#/<,B+&I=Y'8!$ &223Q@5Q7B3]H+P5X;F&G:1+)XLUN08@TS08S<-(V"1\
MZ_+VYP21Z56M?A=\0/CE*D_CZ?\ X0WP?N##PQILI-Q=INSBXD'0<+T_)37'
MB,7*6LW9'-B,4DKS=D9OB'Q)K7[0&L7'@SP!.]IX6A;RM=\5*"%8?Q6\![DC
MJ1Z]AR?H;P9X/TKP#X9L- T6U6TTZSC"1QJ.6/=F/=F/)/>I_#/A?2?!NAVN
MCZ)80Z;IMNN(K>!,*.Y)]2<Y)/)K3XKYVO7]K[L59?UN?+XG%.L[+1(,BC(H
MP*,"N(X R*,BC HP*8"J>1]:\E^ O_(Q?%K_ +'"7_TEMZ]:7&X?6O)O@'_R
M,7Q:_P"QPE_]);>HD;4^I[=:_=JXM4[;[M7%K!G8MAU%%%(84444 %%%% !1
M110 4444 (U5YN]6&J&84 >5_M%?\D+^(?\ V +[_P!$M796N/LMO_US7_T$
M5R/[1*_\6)^(G_8OWW_HEJZZU_X]+?\ ZY+_ .@BMH'+4).*.*./6CCUK4Y@
MXHXHX]:./6@ XJ#4+&#5+"YLKF-9K>XB:&2-^C*PP0?;!J?CUHX^M)JZLRXR
M<9*2Z'Q%H.G3^$M4UGPC>DB[T:Y9$++M,D+'*.!D]0<_\"%:4Q//->E?M->
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M4<>M''K7WA^(AQ1Q1QZT<>M !Q1Q1QZT<>M !Q1Q1QZT<>M !Q1Q1QZT<>M
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MX8?3=6UX'_Y.<^+N?^@+H'_H-Q7K7XUA2KU(IJ+L:2Q%6"Y8NQSO@_X>>&/
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M^!=M_P#&*/\ A0.L?]%?\??^!=M_\9HYP]D^YZ)N7UHW+ZUYW_PH'6/^BO\
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M_P 8HYP]D^YZ)N7UHW+ZUYW_ ,*!UC_HK_C[_P "[;_XS1_PH'6/^BO^/O\
MP+MO_C-'.'L7W/1-R^M&Y?6O._\ A0.L?]%?\??^!5M_\9H_X4#K'_17_'W_
M (%VW_QFCG#V+[GHFY?6C<OK7G?_  H'6/\ HK_C[_P+MO\ XQ1_PH'6/^BO
M^/O_  +MO_C%'.'LGW/1-R^M(<>M>>?\*!UC_HK_ (^_\"[;_P",4'X :P0?
M^+P>/A[_ &NV_P#C%+G'[)]S(\#G_C)WXN>G]BZ!G_OFXKUK(]:\(\.^"[G6
M_CU\5] A\3ZUI=S%HWAT'6K.6,7LFQ;C)9BA7YOXOE^F*[7_ (9_UC_HKWC[
M_P "[;_XS2C*Q<Z?,]ST+</6EW+ZUYY_PH#6/^BO>/O_  +MO_C-)_PH'6/^
MBO\ C[_P+MO_ (Q5>T,_9/N>B;E]:-R^M>=_\*!UC_HK_C[_ ,"[;_XQ1_PH
M'6/^BO\ C[_P+MO_ (Q1SA[)]ST3<OK1N7UKSO\ X4#K'_17_'W_ (%VW_QF
MC_A0.L?]%?\ 'W_@7;?_ !FCG#V+[GHFX>M)D>M>>?\ "@=8_P"BO^/O_ JV
M_P#C-'_"@=8_Z*_X^_\  JV_^,4N</8ON>B#&X<UYG^SW'NUOXMG_J<9O_26
MWJS_ ,*!UC_HK_C[_P "[;_XS76?"WX5V?PMT[5;>WU74];N=5OVU*\OM6E6
M2:69D1"<JJ@#;&O %3*5S6%/E.TC7:*E6D I:S-A:*** "BBB@ HHHH ****
M "BBB@ HHHH 3;1MI:* &[:-M.HH ;MHVTZB@8W;1MIU% ANVC9[TZB@!GEB
MN;\9?#?PSX^LS;^(-%L]33C#31C>,=,,.1CZUT](W2IE%25F7"<J<N:#LSYS
MU3]C/1H[@2^&_$VL: HC*^27$ZDDYS\W0>PKD/%7P(\3_#7X3_%;4]5\2VFL
MZ>?!FL0)$ENR3;FM7(8L>,8!X]Z^N<"O/OVA[6>^^ 'Q,MK:"2YN9O#&IQQ0
M0(7DD8VL@"JH&222  .37%' X>$U4C&S1[$\ZQ]2C*A4J.47IKK^)Y9XR_9W
M\6>/M:BU?3_%=CI6F7-K:@0FV9IDVPHK?-G!R03^57=$_8ST#[49O$FOZMXC
MX4B)I!!&"#DY"_>!]#7NWA]670M-5E*E;6(%2,$'8.#6DM+ZCAW-S<+M@LZQ
M\:,:$*K44K::&)X7\$:%X)T];'0M*M=,ME&-EO&%SSGD]3U/4UM[!3J*[TE%
M61XTI2F^:3NQNRC;3J*9(W;1MIU% QNVC;3J* &[:-M.HH ;MHVTZB@!NVC;
M3J* &[:-M.HH ;MHVTZB@!NVC;3J* &[:-M<YXF^)/A/P7=QVOB#Q3HNA7,J
M>9'#J>H0VSNN<;@'8$C/>K'ACQSX=\;0W$GA[Q!I>O);D+,VF7L5R(R<X#%&
M.,X.,^AH V]M&VE%+0 W;7G7[1MK-??L]_%"VMH9+FXF\+ZI'%#"A=Y&-K(
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MB@8W;1MIU% #=M&VG44 -VT;:=10(;MI=M+10 E+110 4444 %%%% !1110
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MM!7O@3PSX2\.0V?B_7[#79;5)+262RB #7,>P_/=,<9+8!J[XW^)GQ'\#_\
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M>?BK\)?BYX(^-?PNT:T\:^(+7PY:^'/$'A*[O5MO,C2)$\R"5BJY&W^(]0"
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M(ZGG!Z4 ?7JMFG4U>_.:=0 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% "8%&!2T4 )@44M% "8'I1M'I2T4 )M
M'I1@4M% "=*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sgmo-20201231_g6.jpg
<TEXT>
begin 644 sgmo-20201231_g6.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +F _\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBDH 6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1124 +17GW[0'B'4/"?P/\ '>LZ3<M9:G8Z-=36URF-T4@C;:PSW!Y'
MN*^9/V<_!/Q2^('PS\#_ !A\>_&_Q!I]O;V<>IS:+8PP"SGLXESF<[=Q:2--
MSGU8XQ0!]N4E?E)I?[2EQ\;Y-?\ %GB[]I\?!Z_^US?\(_X5TQ T5M&H98WN
M/D).[CH<D9/&0*]$TK]NKQ]X@_8E_M_34BOOB1-XGC\%P:I:HACEF=?-6X5.
MF3'\F/[Q#>U ['Z,45^>GQ]^#_QW_9_^ ^O^.=.^/7B'Q)JT-JC:UI]S;Q^4
M5<JCR6Q W(4SG)_A![UL?$?XV^/-'U?]B^"R\4WUO#XN6R_M\*5/]I;ELMWF
MY7OYDG3'WC0!]Y5Y%X)_:0T3QM^T!XY^$L&G7MKKGA6VANY;N3:8+F-UC)V8
M.05,J#!Z\^E>3_M8_%3Q;X&_:8_9QT+0=?NM+T;Q!K$MMJMC#M\N\C$MNH5\
M@G@.V,$=37F_PZ\56/@;_@HE^TMXBU*58+#2O"T=Y/(V<*B1V;$\?2@1]_5%
M=7,5G:S7$[K%#$ADD=NBJ!DD_A7P%\&? _Q__:C\#W7Q>F^,M]X'N-7>:X\,
M^'M*C1["&-24"3@KNVEHP#C+8#-U; R/@'J7QJ^/OP3^,.F:C\3[SP]XNT3Q
M'*)[V*))D54603VJ<?+%E2!M[**!GWYX*\;:#\1?#-CXA\,ZM;:WHEZI>WOK
M1]T<H!()!^H-;M?GC_P3OM_$'PP_9OU/XGZ[XWDF\ V^EW,EKX7>(>39/&Q9
MI-^,Y.,<?WJM?"#X>?'[]JSX=O\ %74/C/JG@*[UAI;GPYH>BQQ_8K>+E5\W
M(+8.,=S@$GDT ?H)17YU)^V)X_\ $O[$WQ3O;J].D_$/P+?#0[O7M/"@7#"3
M;YR @A6(4@\8SR.M>Z_ /X2_$Z^;PI\2_&_Q?US4KVZTU;JZ\*V\,*:7B2(%
M5&!NZ;6)_O9H$?4%(:^6_P!C/XJ^*_'?[.WBWQ#XAUB76-9L=:UF*WNKE02J
M12/Y:8  (7  'I6E_P $_?B+XE^*7[.=GK_BS5[C6]8EU?48FNKG&[8EPRHH
MP!P ,"@#I?CU^V!\//V;]<TS2?&DNK0W6HVYNH&L--EN8R@8J0648!R.GIS7
MF,/_  5)^!5Q(L<5[XCF=F"*L>@SL23P  !U]J^K-2T+3=:\O^T-/M;_ ,O[
MGVF!9-N?3<#BOAC_ ()6Z'IM_P""_B?/<Z=:7$]OXSG\F26!&:+$<9&TD9&#
MR,=*!GWA:W"7EO#/'N$<J!UW+@X(R,CMUJ>F\U\ ^ ]0^*7[>'Q \<:YI/Q-
MU+X:_"W0;]M(TVTT!4^U7<T9#"24.#CY6!)SU8 #Y2:!'W_17PE\=OBQ\3/V
M2/@3X?\ "7B7XD6FN>-_%6LS65IXSO+,JNEZ?E3+/(!]^2,2#!QT/?:,^/:C
M^U=;?L]Z_P"'/$GA;]I"X^.%E<Z@MOK_ (6U.)%=H7 W3V[!0$9=F!G^\O')
MH'8^_IOCUI4/[1,'PB;3;O\ M2;0CKBZB"OD;1(4\K&=V[ +9Z=J@^"?[1&B
M_&WQ)\0=#T[3[S3K_P %ZS)I%XMUM*S;6=5E0J>A,;\'D8&>M>*WD@F_X*=:
M/(!@-X!+?G,]>7_L\^)/$/@^X_;6UOPG;"\\2:?KEU<6$)C\S=*LEV0=G\1'
M7;WQCO0!^B5%?FO^SGXUUOXA:UX4O/#O[4E_=^/Y+F+^W/ _C2S2.-]B$3P)
M&JAMP;*J<Y.,XSQ7Z3#[U AU%%% !1110 4E+24 )CBLKQ5XFL/!OAO4M<U6
M9;?3M/@:XGD;LJC/YGH/<UJGZ5\S_M@:K+XNU#P7\*;1V7_A(KO[9J;*&^2Q
MA.6SCJK-\I^H-;X>E[:I&!A7J>QIN9@_ G0+_P"(WB74OB[XH@;^U=;)32+6
M5F/]GZ>#A%4'H6QN/&:^D],LQ&HXQWKE-%^SZ?;PPPJ(X8D5$0?PJ!@#\@*Z
M&#6$C')KV,2I2]V*LD>=1G3I1]YZG30J%Z<&JFKZI'8V<DDKB.-1RW]*S/\
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M;PC<ZA;ZW\1M90OJNN7,@@D8=(MV79>>A;@>@3'2OH]:[L3+V:6'ALM_-_\
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MI*M]I:/]&4_>5SV.BBBO/("BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ!>_L_?%)+O2]5M-;LXL++/9MOANK9OO C.0P&>.Q ]:]X_X1^Q_Z-I/_?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUW9]OF%??O%><?'SPEX5\4_#V_/BJYCTVUM%,T.I$#?;2= 5_O9Z;?XLXK?
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0-+N-3NOXA"ORI[LQ^51]37U-\-?V'[:W\J\\;:C]K?J=-T]BL??AI.&;L>
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M;JK#U'\J]/ XZI@YWB]#R\?@*>.I\LEJ?FIXL\,W6BZA-:W4#031G#(PY_\
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MWT87:!*@926P%4G."HP0<#'Z>?EY])ZI=/8Z;=W*J&>&%Y%#="0I./TK\AO
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ I#2T4 ?&?[6GPE\2^&?BE9?&3PIH
MEKK=K8VH?6+.?YSF(;1*4/4"/;ROW3'N[5Z'\'?B%)\5/AWI?B>6Q337OC*#
M:QR&14V2,G#$#.=N>G>N]_:4UI-"^ OCFZ;&#I<L'XR#RQ_Z'7BG[(_R?L^>
M%PQP=UR!GC/[]\5[<).KA+R6L79>AXDHJEBFH[25V>PT4IXZ\4E<AUA7!?%3
MXH:/\/(8(M5O;>VCN+6YG=)CAWC2,@",?Q.9&C&WN"?2NSU;5++0M,NM1U*Z
MBLM/M8S+/<3,%2-!U)-?%&EC_AJ[]JS2+74(F'APY=+5MP_T&(%\/CE&E'/;
M[Z^U=V%HJ;=2?PQU.+$57!*$/BD['T%_P3D\#RZ#\)=6\03)-&^N7W[M9%PC
M0PJ561/4$LX^JU]9BL_0=!T_POH]GI6DV<5AIMG$L,%M"N%C4= !_7O6C7D5
MZOMJDJCZGK4*7L:<8=A:2EHK W&UP?QE^)T'PK\%W&J;%N-3F/V?3[,YS/.W
M"J .H[FNZEE2&-Y'8(BJ69F.  .2:\,\'Z2WQP^(TGCG4D6X\(Z0[6WA^U=B
M5GE4X>Z*'CKPN?3(XK:E%-\T]E_5BXI;O8O?L\?!VY\%V=WXF\3*ESXRUIS/
M<3.=[VZMSY0)/7UQ[#/%>T4W!IV.:FI4=27-(4I.3NQ:***S)"BBB@ HHHH
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M:6@ HI*KZAJ-KI-C/>7MQ%:6D*EY9YG"HB^I)Z4 >+?ML9_X9E\:XX_=V_\
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M*L>:#'4445F:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOM888'WKU&2-9(V5U#HPPRL,@CN#7Q1\*9G_ &:OVOM=\"RLT7A7Q>WVJPW
M[%F;+( <8)^\A[ !17HTV\10=.7Q1U7IU7ZGFU$L/651;2T?KT9]M44E+7G'
MI!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4UN:=2-0!\^_M*?LUP?$RUEU_P]%';>*H$^=/NI?*!]UC
MV<=F_ U\'W=K/I]W/:W4,EO=0.8Y895VNC@X((]:_7 YKP+]I+]FNW^)UI)K
MV@1QVOBJ%/F'W5O5'\+>C^C?@:=S[+)<Z>%:P^(?N='V_P"!^1\G?LX_\EV\
M%_\ 7\?_ $6]?IA7YK?L^V-QIO[07A*SO()+6[M]0:.6&52K(PC<$$5^E(IL
MCB:2EBHM.ZY5^HM%%%2?(!124;A0 M%)FC<* %HI,T4 +1110 4444 %%%%
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MM2NJKM;HM/\ @G@Y_9Q\'A%?6[C6/$ESO,DLNIZC(Z2N3G)BSMS]!5E_@_\
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M.<91C8XNM65)\MV[K:QP'CK3?^&:OVA-)\4:;_H_A/Q*_DW\7/EQ%F'F< <
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M"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0SVI598)%D#NH905.1P>#S^%3^*K>QMK6VN?"4L,-C<L6NX;@YFL9#R5P?\
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MAV?/@%*M6Z.6R\TMOS/?/A[\8O"'PO\ B=X7^%GA>U@FT"^\Z&Z\0228>>^
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/XP?"BY9-T'F+'[;OM,9KTLNCS8F-_/\CS<P;6'E;R_,^DI$$<CHHPBG  [
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M.Z7>S;?-N;6*9]HXW,@8X_$UI4CRFFG9BT444""BBB@ HHHH **** "BBB@
MHHHH **** "BBB@!.:^/?^"ATD=G;?"V\<*/)U_<S?[("L1^E?85?*O_  4;
MT>*\^ \&HL!Y]CJD/E-W'F J<5W8%VQ,/4X<<KX>?H>JK.+E5G3[LJB1?H1D
M?SI:S?#+"3PQHK!MP-A;_,/^N2UI5I)6DT9Q=TF>/?$^*T\2_'OX,^&YH&O/
M+U"XU2YM\$H(TC(C<_21 ?KBNY^/*AOCU\ 0P!_XF^H'!_Z]#7.> ([GQ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M O\ Z$U>G4&6*LL142[O\PHHHH.4**** "BBB@ HHHH **** "BBB@ HHHH
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M;$3?D_P5C11Y</!=VOQ=SZ*HHHKS#U HHHH **** "BBB@ HHI#0 'I7Q_\
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MEC5T=71AD,IR"/8T[-8&XM%)FB@!:*** "BBB@ HHHH **** "BBB@ HHHH
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M&7QY:Q\ _#OP_<6?A.Q58H=+M!M1B,9FNI?N[F/S$$X&>]?>_P"R_P#L_0?
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M:7::+IUO86%O':6=N@BB@A4*J*.@ JZO2DQ2BO"-=6[L6BBB@ HHHH ****
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M?J!4EO\ L$^/+B/<;"PA_P!F74L']%-?HY[TM=/]K8Y[U7]YR>QP-M,)3_\
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MW%W&ZOK5X#;Z? V<F0CE^.RCG\J#:C1G7J1I4U=O0^=_VO/B5=^/O&EC\.M
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MTW-+4[84I2=D2W%P>_6NS^&/P.\7?&"X_P")%I^+!6VR:C<MY<"$=1NZL?8
M^^*]@_9I_9)D^(4=OXD\712V^AL0]KI_*/=K_>?NJ'TZGZ5]_:'X0M]-TZ.V
MLK:&TMHE"QPQ*$10!@  >U?"YIGZHMTZ&_<_2<HX9]I%5<3]Q\?>&/V*/"WA
MNS5O$5_>>(+K;\T<;FV@4YSE0IW?F2*ZN/P+X.\+7 ETWPQI=G,%V^8ELN\C
MW/>O9/&7^B^8K#:5XP>U>)>)]26%G9W5$7J6. *Y<#SXSWINYGFV+IY=[E&-
MC*U_PVFMZVM[I]_I>C2?89(9%N0T8=@<QL-B-G!^G'K6'=?"'P7J%E;K)9O:
MZG%#M;5--N'AED<C+.Q&-_.2-P_"H[[7+:1E9;RW/RD',P'7O4L>K QJ8Y Z
MXP&4Y!K'#\/T,-CZ^,C'WJEK_+^M2*W&&(Q. P^#G+W:;?X]_P!#I/#?Q1^*
M/P<DWPZBWQ0\+*Q+V.H-LU.!.?N2]'QQP>,<!<U]._"/XU^%?C3H/]H^'+]9
M9(P/M6GS?)<VK'^&1.HY!&1P<'FOCY=>>%LA\=Q6)<W&H:'XDM_&?@RX32?%
M]D/FP,0:C%U:"91P<]CZX]B.;'9+&HG*DK2_,]?+.(KM0J.Z/T8S0IKQ[P3^
MT=HWC;X)ZCX\A@^QW&FQ/'>:;,<M#=J %A)'.&<J <<A@>*YS]F'QCXO\6:W
MXE.NZI-JEE''#(QFC 6&Y<LS1QX^ZH39\O3D>IK\WK8B.'Q,<+->_*_X=S]2
MHX>6(PTL7!^Y&WX]CZ%S2TU32UU',+1110 4444 %%%)0 M(U%(W- %/5]6M
M-#TRZU&^G2VL[6-I999"%"J!DDDU^=OCWQ7K?[3?Q?MX-.CE6&XD^RZ=;'++
M;P@_-*P[9^\3]!7HG[87QV7Q)J$G@C1;B*32+1PVH7,;9\V93_J\],*>OJ>.
MQ%>@_L:_!=O#&@OXQU>V,>JZDFVSCF3:\%O_ 'N>A?KT'&*H^SP=)93A'CJJ
M_>2TBOU/?/ O@^R\ ^$=+T'3T"VUC"(@><N?XF.>Y.3^-;PI,&E J3XZ4G.3
ME+=BT444$A1110 4444 %%%% !1110 4444 %%%% !1110 5#<V\5W$T,\23
MPM]Z.10RGZ@U*3BOG3]M?]K$?LI^ ](U2RTV#6]>U2^6"UT^X8JC1+\TS$J<
MJ=O"GD9(S0!]!V=A;Z?'Y=K;Q6T1.XK"@09]< 5+'"D,:HB*B*,!5& /PK!^
M'WC?3OB1X'T+Q3I$JS:;J]G'>0,N?NNH..0.AR.G:JNH?%KP/I.F6NHW_C/P
M_9:?=220P7=QJD$<4SQG$BHY?#,IX(!R.] '2_98?+2/RH]D9!1=@PI'3 [4
M[RT$AD"KO( +8Y(&<#/XG\ZX?XN_&;PW\&_AIJ/C;6KN*32[: 2P+#,FZ\9A
M\D<1)PQ;MC/&3VK%\._';3?BA\$;OQQX!NM,OK_^R#?QV&H7D:BTF,/F+#=E
M6_=$?Q9(Q[4 >IK"@D:0(HD8 %\<D#.!G\3^= A179PBAVQN8#DXZ9-<5\,/
M&FI:O\)-#\3^-'T72K^?3TO;^73;U9-/BRNXLDQ8J4QSNW$>YZU8M_C)X NM
M-DU&'QSX;FT^.9+=[J/5[=HEE<$HA</@,0#@9R<&@#IKK2;.\F2:XL[>>9
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MJVF? _\ :V^)'@G55.DPZ].KZ0)7'EL-S21CCH75^,X^[CKBOMKBOE;_ (*
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M^92PP<G R:Y7]H;5KB3_ (*/?LZ6\-[*;"33KJ80QRGRF)6X^; .#D <^PH
M^NOB)\,_"WQ:\,R^'_&&AV?B#2)'$OV6]C#JL@!"R+W5@&.&'(S7G'PH_8M^
M#?P6\0+KGA7P7:VVKH=T-Y>2R7<D!P1F(RLWEG#$97%>:_!G7H]-_;2_:6U#
M5;YHM/T_3-(FEEGD)2")(YRQQV 4$\>E1V7_  4H\&W3-K!\">.8_A\)!"?&
MG]D%[!6\WRV9BI($8/\ $"3VVYXH ^O0,4&F03)<PQS1G='(H=6QC((R*DH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP7\7?B'8?L[7.O\ Q,L;6W^'.@Z2UUI7B0W+3WMU!$TGFB2,,S'8$VCA3A5
M#9R,_2?VIOVF/B=X3U+XB_#_ .%WAQ_A^K^;IMGJ<[MJ=];HQ61TVRJ,@HQP
M5'7"[\<@C[HW4;J^1O&G[=4=Y^QV?C1X(TR![Z*_M]/NM*U57<6LQF19XSL*
MER%;*L",[E)'5:[KX,^/?CEX^\8V.L^(_"/AOP[\,M5L7O;2,74DFKVRD#R$
MFP2A=P=Y  "@X)W#! /H"BD'2EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH 0U\1?L0Z?JOB[Q5\8=>2_DTYM2O5
MMC=Q(&E1Q)*S%=V1NPPP2"!Z&OM;4+V/3;&YNYCMAMXVE<^BJ"3^@KY/_P""
M=,B7'@KQ[/'@B7Q'(P;U4QH1_.O0H7CAZLO3\SSZ]I8BE'U_(^C? _PS\._#
MN&Y&C6"QW=XYEO-0G8RW5W(226EE;+.<D]3@9P !74[:7%%<#;D[L[HQ459!
M7R;\/2C?\%#/B(4((_L",';Z[;7/ZU]95\6? /S?^&]/BB9V8R?9+K&[^[Y\
M&W],5W86/N57_=_5'#BG:=)?WC[4HHHK@/0"D/2EHH ^0_%4UOIO_!1GPM)(
MZQ"?P^4R?XG9)U4?4X%?7=?&/[16BS:3^VQ\'=;#Y34Y(+4+GIY4IW?F)17V
M=NKT,5K"E+^[^1P86ZG5C_>%HHHKSSO/B/\ 8KN9-2_:.^,-YJ$KSZHTCAGD
M.24%RP')]@H^@K[;KXX_9:TY=)_:\^-UHGW8POZS;OZU]CUZ.86=:Z[+\D>=
M@+^QU[O\Q*^3/VHOA#>>+OC!X3?38&4Z\OV2>X#9VM'R6QV"Q]^F<5]:5#)9
MPS7$4[Q1M-"&$<C*"R9ZX/;.!GZ5RT*TL//GB>I&3B[H^8_CI^R?9W>@Q:KX
M(M!!J=A L<^G1\+>(H^\OI+W_P!KZ]?CZ:-X7>.1&CD0[61UPRD=00>AK]8M
MIKPSX_\ [-.G_$FQN-8T.*+3_%2 ON7"QWG^S)Z,>S>O7U'J83,'#W*SNNYW
M8?$\KY9GRM\$?C=JGP;U[S(PU[H5TP^W:=NX8=/,3/1Q^O0]B/T&\*^*M+\:
M:#::QHUVE[I]TNZ.1.WJK#J&!X(/((K\O]=T+4?#.K3:9JUE-I]_ <203KAA
M[^X]QQ7<_!'XW:I\&]>\R+?>:%=./MNG9X;MYB9X#@?GT/8CIQF%59>TI[_F
M=F(PRK+GI[_F?H]D4M<]X)\<Z+\0-#BU;0[U+RT?AL</&W]UU_A/L:Z#-?.-
M.+LSPVG%V8M%)12$+1110 4444 %%%% !1110 444E "T4F:,T +16#XT\<:
M-\/]#;5M;NOLMF'6)=J-(\CMT1$4$LQP> .@/I4?@?X@:'\1-)DU#0KPW4$4
MIAE5XVBDB<?PNC ,IP0>1R"#6?M(<_L[Z]C3V<^3GMIWZ'144FZC<*T,Q:*3
M-% "T4F?:DS0!E^*_#MIXN\-:IHE]$L]GJ%M);2QO]UE=2"#^=?GSX4:]TSP
MW?\ A751(-:\+7<FFW'F!@SH&)BDPW.&7D?[.WUK]&3\W%?(W[7GPSN?"7B"
M'XJ:)927%FT(LO$MM;QJ2;<?<N<=25. 3SP%SPM?19)BUA\1RRVE^9\UGV">
M+PS<=T?.>L7ACD;GO7F^K,;.^D&3Y;G<OX]J]$\36RLL=U;N)K69!)%*O1E/
M0UPNIVXOHRC\,OW6]#7[;0J1G!-'\UUZ,L+B&I+0S5U YZT_^T<=ZP[CS;24
MI(I5A^M1-=5LSMC'JC9GU#.>:R[F\W9JI)='DU5DFSWJ-CHC$6XFSFK?A^$O
M<-,>B\"L^&WDOIMB# ');L*[OP+X1NO$VMVFD6"DEF^:7;D1KGYG/M6%2:A%
MREL='*Y-4H*[9V_AN&70O 6O:Z(//N[I/['TR$QEC/<3_(54 ==I.#Z\5^DW
MP=\$CX<_"_PQX;&POIUA#!*Z1[-\@4;F(]2<D^]?)OP#^']K\3_BSIWV1%G\
M"^ ,%9MN8[[4F'7.W#;/O'GKM(ZU]Q+7XSGF+^L5^5=/Z1^Z9#@_JN'3?]=Q
MU%%)7S1]0+2&C=36=54LQVJO)8G % "M7C?Q_P#VBM,^$&EFSL_+U+Q1<+^X
MLMV5A'_/27'0#L.I/XD<+\?_ -KJV\-->>'O!<D=]JNTQS:LI#0VS'J$[.X'
MX ^N"*^++R\GO[J:[NYY+FXE8O+/,Y9G8]22>235'V64Y#+$6KXI6AT75_\
M -'Q9XNU;QMK4^L:Y?27U]-]Z64\*O95'0*/05]+_LN_LPG4VM/&/C&TQ:#;
M-IVES+CS>ZS2@_P]"J]^IXZM_9?_ &7SJC6GC#QC9XLQB73M*G7_ %O<32@_
MP]U7OU/&,_97 'H*6QU9SG$8Q^IX/1+1M?D@^[[U0U;Q%I>@QJ^I:A;V*,<
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MX/\ .U;PAYVM:.HW/9-\UU#SS@ ?.OTY'/'&:\'\.>)-6\&ZQ'J.CWL^F:C
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M.]?/XG)G%<]!_+_@GT^$SJ-3W:OW_P# *_QD^"US\!+BX M+O6OA;>.SV]U
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MR@D*.Y]*^+?^"9>D6ESX=^*?BF>Y6[\1:KXNO$O6FP]Q L;D)&SGYB".0":
M-KXS?MD>+)_BMJ7PF^!_@I?&WC?3E!U#4+V4)86!P#M?#+D]CN9!DC!-=7^S
MO\0?VB=6\93Z'\8?AQH^C:<UJ]U'KNC7JM$C A5A,8DDW,WS'.X8 ''->*_\
M$W[^P\*_$WXY>$/$31VGQ$/B*2Z>.Z7_ $B6TR=H60_> 8D[0>-V<<U]V:IK
M%EHMC>7=]=1VUM:0/=3N[8\N)02SGV !Y]J!GRA^UU^W2G[-WQ:\">%;2TM;
MZVNG%UXCDG!8VMDS! 4V-E9!S)@J05  Z\>\_'#XF3_#7X)>*?&^DP17]QIV
MF->6L<^1&[$#86QSCY@2."<8R.M?E'??M#^"_B)JWQTU_P <>%?$NNZQXXC-
MAH5QIMI%+%IUI%S;[96PPRRINVKRBCO7T=\+_C-/\5O^"9_CG3M4=WU[PKIK
MZ->&7(=U3887.XEB3&5!)Q\RM0%C1\#_ !X_;7^(7@O2?%6A_#WP/?Z)J=LM
MW;3>:(VEC(R#L:[W GT(S7IO@;]KCQO\:_V;+[Q]\.O!5I?>,-!U3[)K'ANZ
MG8B:.+#SK;. -TC(RE01P21AB #XI\!?$'[8%I^S]X03P+X;\%WGAA-)C72Y
M;EP+MH<85FW3A=^.>1^%>R_\$P]/\.6G[-[7&BW%U/JMWK%U+KRW0 \N_!56
M5 "1LV+'@YY!R<$X ![S\"?CAX;_ &@OAS8>+_#,S&VF)AN;2; FL[A<;X9!
MV9<CZ@@C@BO0:^*OV(;>/0?VF/VG= TV;&AVVNPW,%E"=L%M)(\^]4C'RJ?E
M5>!T0#L*^U10(6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** .5^*F?^%7^,/^P/>?\ HAZ\=_8!
M_P"39?#_ /U]7G_H]Z]E^)\;3?#/Q;&BEG;2+Q54=R87XKP?_@GCX@MM2_9^
MATN)9!<Z3J$\%QN&!N=O-&/7Y7'XYKN@F\+.W\R_)G#-_P"U0]'^A]/T445P
MG<)7QYXRTE-+_P""BW@RXCX.HZ6\[X[D6\\?\D%?8?K7R=\2E_XV#?# ^NA3
M?^@W==V#>L_\+_(X,6M(?XD?65%%%<)WA24M% 'Q9_P46O?]*^&MG_>U%IOR
M9!_[-7VB.U?&O[;V@GQ;\;/@IH);:E_=RQ'_ +^PU]E+7?7_ -WHKU_,\^A_
M'JOT_(=24M)7 >@?&^CZ0GA__@H]?) =J:CHTE[(/[S-$!_[)7V17QI\9=-N
M/#/[>OPQUB&XR-<A2V:,#&U(PZL,]\[A^5?97I7?B]53EWBOPT.#"Z.I'M)C
MJ***X#O"BBB@ I&Z4M(: $VUX[\8OV9O#7Q2$U] HT37\$K>VR +*Q.<RI_%
MW^;KSWZ5[%1S5PG*F^:+U-*=25.7-!V9^97Q*^#OBGX5WACURP;[(S$1:C;Y
M>WE&3@AOX3QG!P1Q7J_P5_:ZU3PDUOI'C!I=8T?*HNH?>N;9<8Y'_+1>G^UU
MZU]K:AIUKJEI):7MM#>6LHQ)!.@=&'H5/!KYJ^*'[%.DZMYM]X+NAHMR?F.G
MW!+VS'C[K<LG0^N2>U=ZQ$*RY:J^9[L,;1Q,?9XI?,^A_"_BS2/&>CP:IHM]
M#J%E,H99(6SCV(Z@^QK6W?-7YMV[_$/]F_Q,)3%=:%.Q&\.OF6EVJGH2/E<<
MXR#D9."*^H_A'^U]X<\:"#3_ !'M\.:RV$WR-_HLS8/*O_">G#8Y.!FN:I0<
M=8ZHY<1ETZ:]I2]Z/D?0=%,CE66-71@Z,,AE.01ZTNZN8\@=129HS0 M%%%
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M'1-$;C^SK%RN\<C$C\%L@GC@>QKR3&,"I;6VFOKJ&VMH9+BXF;9'%$I9G)[
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M(,K/93+(N,D9X/J#^5?*4DD;?\%&Q_PD$UU$L>F*-"#C$;,;8;E!_N\S_P#
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M/FF]W^B/SK.L]KYO))KE@ME^K[L%&*6BBOISYD6BBB@ HHHH **** "BBB@
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M8]SU- 'B7P;_ &._!/PG^&?B/PC=&X\6R>*/,_X2'5M6;-QJ>\$8;!^50"<
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M.!DEN,]*\]PFV>@IPMH=9XR\8:5X!\+ZEX@URZ%GI6GQ>=/,03@9   '4DD
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MYD3K+$XW)(G(93T(^M?H3XC\.V'BK0-0T;4X!=:=?0-;SPM_$C#!^A]#V-?
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M+B9CM5L<[<_S]J^@/@_\)T_:4\0:KXLU1)+?P5IMO)IGAY-C1_:)2,-=J<Y
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MD5D<!D8$%6&00>U?+WQ*_81T#7-<F\0>!-;NO >N,WF!;3)MC)N#;MH(9?\
M=4@9[5]245M2K5*#YJ;L85:,*RY:BN?!?C#]EK]H75M5MWN/%6E>*)+&0R6.
MK:A.!<09&"(]T;%01U&3FM;1?V4_COXHTR33/%/Q-&BZ.[*);&PE:02KD$GY
M!& W'4]Z^WMM&VNS^T*NR2T\D<G]GTKW;;^;/)_@;^S5X0^ ]C(=&@>^U>?/
MVC6+T!KB0?W00,(OLO<DUZOBE_&C%<$YRJ2YIN[.^%.-./+!60M%%%06%%%%
M !1110 4AI:2@#EOB1\-]"^*WA*\\.^(K-;NPN%X/22%Q]V1&_A8'D$5\>ZS
M^R#\:O ]N-"\!>/5O_"F]I8[2^G\CRB3W0HZDGKE<#VK[KP:3;[UU4<54HKE
MCMV>IR5L+3KOFEOW6A\)> _V1/CMI^FWVG'X@VO@ZPN&:26'396F6Y=OO,^T
M)R>YS7H/@_\ X)[>#K*\AO\ Q?KFK>,;Q47,=S,8XE<')Q@[BIZ;6)&*^K=M
M&*VGCZ\MG;T5C*.!H1W5_74R_#OAG2_".CVNDZ-86^EZ9:KLAM;5 D<8] !6
MI^%&**\_5N[.^UE9!6!J7C[PYHWBO2?#%]K5E:>(=6CDFL=-EF"S7"1XWE%[
MXS^.#C.#6_7PQ^T6B_\ #S+]G<E1D:7<X/X75 S[GW4FX5\*:;^T-^T'\8/C
MQ\8OAS\/AX7TVT\,ZF+>'6M3A+-I\2LRJ G(F:0HWWON\X[5N?L[_M"_&;XI
M>'/C'\/KZ/P_)\8/!$QM+?6&!33IY'=U&Y%7JGEO@XP?ER.N0#V'QS^VE\(/
MAY\2+3P)J_BR'_A)9KI;.2UM8GF%M*V-JR%00"2P&!D@G! KV[<"H(Z'I7Y:
M?L;^%_CA/^TG\0KV-/!]_):^*%7QRU]"I>2;S)-[6C"/<N"9&7&T$[<U]E_L
MI_&3Q)\6K[XMQ^(9K>=/#WB^[TO3O(@$?EVJ!=D;8^\1S\QY.:!GT#NHW5\5
M>!_VR_&4?[+_ ,8OBAK&F6VNZGX9\2W6GZ;IUM$8HHX T"QJY7YF5#*69NI5
M3R.M/^ ?Q&_:$\47W@/7W\8^"?B=X6UR.W;7=,TV&*TO/#\<P5][;&)=E7<I
M4XY&,=P"/J;PC\5_"7CWQ!XDT/P_KMMJFK>')UMM6M8-VZTD;=M5L@#)VMTS
MTKK,U\?_  ?_ &@(M+^(G[4_B#Q!IFFV.B>#;N"0MI-BD=S/'%#,&,C\&9V\
ML8W'@M@5PF@_$S]L#XN>"KGXI^$E\+:'X7N0;S2O"EY;![JXMD)!!D9<AF"$
MC)^;=Q@8H ^^]U&ZO@KXD?\ !0+7]6_9)\*?$OP+IUOIWB'4M?BT/4+6ZC\Y
M89E&^5(MW#!QM )Z"3U&:K_%K]H+]I?X!Z]X/\:^-H/#)\$>(-5BLIO"=A&&
MN+'S!\L;7!&68 %BP. WR\C!H ^_<TM(!CO2T %%%% !24M% #3SQ7"_&3X0
MZ+\:/!=QH&L*8SN$UI>Q#$MK./NR(?4>G<5W>*"H-5&4H24HO5$RC&:Y9+1G
MYX:_X;UC2?$$7@CXA;-/\4;672O$3\6FM1+P S]%E QUY/?MGS/Q-X7O-!U!
M[:]MY+><?P.,9'J/45^EWQ*^%WASXM>&I-"\3:>M_9,PD1@2LL,@Z/&XY5O<
M5\B_$'X6>,/@S:R6NNZ;<?$?X=0[O(U*U3=J>FQY&!*!RZ@$C*^G\(K[S*\]
M<?<J?UZ?Y'YYG'#L*UYP7]>?^9\V-;D&JEYI,5XN)(\^A'4?C7K<?P[TWQA8
MG4?!>MVVN6N-QMV8).GU7USQR.W6N0U7PQ?Z-(R7UE-:E3M/F(0,^F>AK[FC
MF%.KLS\YK9)6HN]OF>;W?A65<F"0,/1^#^=9LN@WT;$>0S^ZD$5Z2]D?2HFL
M2>U=?UE&$<+6CI8\X7P_?2-M,&S/=B,5;M_"IX,\GU1/\:[AK''48K6T3P+J
MWB*0#3[":=2,^9MPF,XSN/'Y5G/%1BKMF\<'6J.R1PL.FQP1A(U"IV _K7=_
M#SX1W_C2XBN)0UII"MF2Z88+@=0GK]>@KOH/AKX:^'-B-8\<:I;HJX9+7=\K
M'.,!>LG..G'/-=_X*^$_C#]HJ.'SH;SX?_#3RQL^4)?:HA. %7_EDA [^O?K
M7SV-SF%.'N/3O_D?2Y?P_*<U*JKOM_F8_A'P/<_'W4&\$>$ =)^'.EN(M:UZ
M$?\ 'RP.3;6Y_B)_B?W^@/W+X>T"P\+Z'8Z/I=NMII]C"L$$*=$11@"J_@_P
M;H_@'PW8Z#H%C%INE648CAMX1@ >I]2>I)Y)K9VXK\PQ>+GBI7>Q^L87"0PL
M++<A^QP?:OM/DQ_:-FSSM@W[?3/7'M4ZBCO17 =PM%%%, HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>sgmo-20201231_g7.jpg
<TEXT>
begin 644 sgmo-20201231_g7.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +'!6H# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** (Y+B*-L/(B'T9@*;]L@_Y[1_]]BN!\??L^^ ?B?K2ZOX
MFT!=3U!8E@$QNIH_D!) PC@=SVKY[^"_P8^%T/PSU[QCXHT(R_V+JUZ/M*W%
MQNCAA<; %5QG ]LFF>M1PN'JTG/GE=65E%/5WM;WEV/LBBO,]%_:!\-:]8ZE
MJMM;:L/#=C9?;7UV33Y%M)!N ,<9QN=QGD!?7FH?"O[0FB>(O$D&B7VC:]X6
MN[QRFG/K]@UM'?X_YY,2<G&" <$Y'&:#E>#Q"O>#TW_K\^W4]2HKROQ-^T9X
M<T*_O].L=/UKQ+J^GS-%>:?HM@T\MNJXW2/T 3D<YY[5HS_'CPD/ ]AXHL[N
M;5+349/(L;2Q@:2ZNI^?W*1==^1T.,4!]3Q%D^1Z['H=%>?^#_C9X?\ %>@:
MSJEQ'?>'/[%Q_:=KKEN;:6TR"PW@\<@9X)ZBN9A_:J\)F.>_NM,\1:=X< S;
M>(;K2I5L;L]A&^,C)R!N"]*+#6"Q,FXJ#NOZ_KR/9J*X#Q9\;_#'A'1]'O)I
M+J_N]:A$VEZ786[37EX"H8!(QR.".6P 3UI_@OXR:)XQM-1)M]0T/4]-@^TW
MND:O:M!=PQX)#E#]Y2!U4D<B@CZK7Y/:<CM_2_/3U.\HKQE?VJO"-Q'9WUGI
M^OWOAZ4[;C7XM+D%C9MD#;*Y YR1G:#C-==X\^,7ASX?VNG&ZEGU*_U12VFZ
M9I4)N;F]XS^[5>H(Q\Q('/6BS*E@\1&2BX.[_3?[NIW%%<5\//BQI/Q$:YMH
M+;4-&UFT57NM'UBV-O=PJWW6*'JI]02.17:TCGJ4YTI<DU9A11109A1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5'<7$5I;R3SR+##&I=Y'.%50,DD]A4E>/_M">(KC[%I?A73Y%%YK$RK(-
MP!V;@J@\=&8]?]@^M=>%P[Q5:-):7_!=6>7F>.CEN$GBI*]MEW;T2^;,K6OB
M5XE^)VM7&A^!8S;6,7RS:FWRG:<C.2/D'7&!N..W(J_I/[-.ELYNM>U6]U6^
MDD\R1HV$:L3R02<L><\Y&:](\%^$+'P3X?MM,L8E4(H,LF/FEDQ\SL?4_H,"
MMZO0J9BZ/[K!>Y#O]I^;9X6'R&.*2Q&</VM5ZV?P1\HQVT[N[9Y??_LY^#KR
M,+'%>6A!SNAN"2?^^@P_2N3O/AKXS^$^Z_\ "&JR:KIR$M)ITBDG!.3^[SAN
M .5PWM7OE%94\TQ,=*DN>/52U1TU^&\OJ>_0A[*:VE#W6ONT?S1QGPU^)MC\
M1=.D>*,VFH6^!<VC')3/<'NIKLZ\%^*VEM\+_'NE>-M+1H[2YE\N^AC&%)_B
M&,C[ZY.#_$F:]XCD$D:N.C#(J,;0IP4*]#X)[+LUNOD;91C*]5U<'C/XM)I-
MK:2>L9>5^J[H=1117F'T04444 %%%% !37D6-=SL%7U8X%>:?'OX[Z-\!_"/
M]J7X%YJ5P3'8::KA7N' Y)]$7C+8XR!U(K\SOBA\>O&WQ=OII=?UN=[-VRFF
MV[&.UC )*@1@X)&X_,V6Z<UTTJ$JFNR.:K7C3TW9^M$OBW0X;];&36+".\;[
MMNUR@D/_  '.:THYXYO]7(K_ .ZP-?B)N.<YYK9\.>-O$/@^=YM"UO4-'EDP
M':QNGAW@'.&VD9'UKH>#[2.=8SO$_::BOSS^$W_!0+Q3H-Y#:>-[>/Q%IC$A
M[RWC6&[CR1S@81P!GY<*>?O5]^:!KUAXHT2QU?2[E;O3[V%9X)TZ.C#(/_UJ
MY*E*5/XCKIU8U/A-"BBBL38**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&S@2&WBC@A086.-0JJ/0 =*EI'G8BM[>::V2LMOT27X!1110<H4444 %%%%
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MDCY^4G)W844451(5]S_\$[?BM<746M> ;Z5I8[=/[1T_<2=B[@LT8)/3+(P
M'4R'O7PQ7K'[*OB)_#'[0/@NZ2,2^=?"S*D]IE,1/X;\_A6-://!HVHRY)IG
MZT4445X1[H4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\
MBZ/^%M77_0B>*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T
M(GBO_P  5_\ BZ/^%M77_0B>*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]
M#HKSS_A;5U_T(GBO_P  5_\ BZ/^%M77_0B>*_\ P!7_ .+H^HU_Y?Q7^8?V
MQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\ BZ/^%M77_0B>*_\ P!7_ .+H
M^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\ BZ/^%M77_0B>
M*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\
MBZ/^%M77_0B>*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T
M(GBO_P  5_\ BZ/^%M77_0B>*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]
M#HKSS_A;5U_T(GBO_P  5_\ BZ/^%M77_0B>*_\ P!7_ .+H^HU_Y?Q7^8?V
MQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\ BZ/^%M77_0B>*_\ P!7_ .+H
M^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\ BZ/^%M77_0B>
M*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\
MBZ/^%M77_0B>*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T
M(GBO_P  5_\ BZ/^%M77_0B>*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]
M#HKSS_A;5U_T(GBO_P  5_\ BZ/^%M77_0B>*_\ P!7_ .+H^HU_Y?Q7^8?V
MQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\ BZ/^%M77_0B>*_\ P!7_ .+H
M^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\ BZ/^%M77_0B>
M*_\ P!7_ .+H^HU_Y?Q7^8?VQ@OYW_X#+_(]#HKSS_A;5U_T(GBO_P  5_\
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MU.!R:NT5RU<35K:3EIVZ?);'I8;+\+A-:,$F]WO)^LG=OYL****YCT HHHH
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M%6X?^0?K'_76;_T&O-Q6*K5Z[JS=G^6I]!EN787!X18:DE*+6K_FO%7;]?\
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MB,2(>_/8^XJ[7R^(J5*M1RJ;_EY'Z1@Z%'#T(QH?#;?OY_,****YSM"BBB@
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MC+AFE?D@\=LXQ]:]'#_N*;Q+WVCZ]7\E^+78\#'?[;B(Y>OAMS3_ ,-[*/\
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M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !5>_OHM-L;B[G)$,"-(Y
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M/+?#N-QTX+-<3[2G%WY5&W,]/B?RV.'\=?#]-4TVVDTJ-+>YLD"1QH,;D X
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M]<8))QG[*KRZD'3ERL]2G452/,@HHHK,T"BBB@ HHHH **** "BBB@ HHHH
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M 69=2NYE*R74TBGJK2$C^=5J**L84444P"BBB@ HHHH **** "BBB@ HHHH
MVM+\7:CI>%$OVB+_ )YS<_D>HKL=)\<6%^ LY^QR]Q(?E_!O\:\THK&5&,A'
MMJL'4%2&'J*6O']/UJ]THC[-</&O]SJOY&NGT_XC,,+>VN?]N$_T/^-<<L/)
M;:BL=S169I_B33M3(6"Y7>?X'^5OR-:5<[36C$+1112 **** "BBB@ HHHH
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M?\ETU?\ [ L7_HVO0J\]T[_DNFK_ /8%B_\ 1M>A5WXSXH?X8_D>)E7P5O\
MKY/_ -*84445P'MA1110 4444 %%%% !2,P522< =2:Q=8\6V&D90OY\_P#S
MRCY(^I[5PFM>*;W6LJ[^3!_SQC/'XGO6\*,I^2&=;K7CNUL=T5H/M4PXW=$'
MX]_PKB=4UR]UAR;F8LG:->$'X?XU0HKNA3C#884445L,**** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E'[/?_()\3?\ 89F_
M]!6O5Z\H_9[_ .03XF_[#,W_ *"M>KUZ>9?[W/\ KHCY[A__ )%E'T?YL***
M*\P^A"OEW_@HA_R0_3/^PY#_ .B)Z^HJ^7O^"AX!^!VG9."-<@P/7]S/6]'^
M)$QK?PY'YP4445[AX04444 %%%% !1110 4444 %%%% "K]X?6OV,^"__)'?
M O\ V K'_P!)TK\<U^\/K7[&?!?_ )([X%_[ 5C_ .DZ5Y^,^%'H83XF=G11
M17F'IA1110 4444 %%%% !1110 4444 %%%% !1110 4444 >>Z=_P ETU?_
M + L7_HVO0J\]T[_ )+IJ_\ V!8O_1M>A5WXSXH?X8_D>)E7P5O^OD__ $IA
M1117 >V%%%% !117+>*/&*Z8S6MGMDNOXGZB/_$U<8N;L@-?6-?L]%CW7$GS
MD?+$O+-^%<'K7C.]U3='$3:V_3:A^8_4_P"%8<T\ES*TLKM)(QR68Y)J.O0A
M1C'5ZLH****Z!A1110 44M><_%3X^>#_ (0P.FKW_P!IU7;F/2;+#W#<9&1T
M0'U8@5482F^6*NQ'HP!8X R:Y;QE\4?"7P^A:3Q!X@L=.<(76W>4--(!U"H.
M6/L*^(?B=^V%XU\>"6STEU\*Z2XVF*Q<FX<?[4O4=C\H!'J:\.FDFO+B6>>1
MYYY6W22RL6=V]23R37L4LMD]:KL9N?8^WO%O[=WA73?/B\/:+?ZY,I7RY[C%
MM X[]<N,?[M>7:U^W=XWN[QGTO2-&TVU*X$,T;W# ^N_<O\ *OG)8:D$->G#
M T(_9OZD\TF>IW7[6'Q5NIFD7Q9-;!CGRX;:$*/IE"?UJ'_AJ?XK_P#0YW?_
M (#P?_&Z\S$-+Y-='L*7\B^Y"U[GIL?[57Q7C<,?&%S(!_"UO!@_DE=CH_[<
MWC^REMA?V>CZC;QC$B_9VBDE_P"!AB ?^ UX 8:0PU,L-1EO!!KW/LSPO^WM
MHEXP3Q#X9O--9G"B6PF$\:KW9MVUOP ->X>"?C=X&^(A1-#\1V<]RP8BTG;R
M)\#J?+?!Q[U^7[0TQHR"#W!R#WKBJ9=1E\.@^9GZ]E2O48I*_.'X;_M2^/?A
MRT4/]I-KVE*>;'5&,G!/.V3[RG\2!Z5]?_"7]J#P=\5/(LC<?V%K\GR_V;?,
M!YC<\12='Z$XZXZBO(K8*K1UM=>1HI)GK]%+TI*X"PILDB1 %W5 3@%B!D]A
M]:?@]<<5YK\>/^1<\.?]C)I__H;5+=E<Z,/2]M5C3O:YZ45*]1BDKSW1O&ND
M:3XFU&PB@U9VU#Q%<6$MU=RB2"&X5-P"\_)&P!"KZ@U=U;XJZ?I5]K-JNGWE
M])IUQ!9#[*4;[3=2KN\A.>&502Q; 'K1S(T>$J\W+&-]+_I^9VM%<'<_%ZRT
MP:Q%JFDWFFZCIUE_:(L9)H9&N8 <,T3HQ4[3P03Q72^%_$$GB;31?-I5YI4+
MD&%;[:'E0J"'V@DJ.<8;!HYDS.>'JTX\\EI\OP[_ "->BN*NOB8[7FKQZ7X7
MU?7+;2YOL]Q=6?EA3(" RQJS!I"I/.T'I46I?%B"UFUD66AZAJMMH_%]<P21
M1B)P-SH%=@SLHZA0:.9%K"5GM'\5Y;ZZ;K<[AI40D,ZJ0NX@L!@>OT]Z=UZ<
MBO'?%VK6GB#5-;U.QE$]E>>!99H9!_$C/*0:[_Q%(\/PSU.2-FCD31)&5U."
MI%N2"#V-+FW+GA7#DN]9:>ATFTGH,_2C!/2O(O /PQTOQ)\+_#E[]LU33]9N
M]/AG;4[;49_,$I .[:SE2,]5(P>E<7XFO_%7C:V^&=BVKOI7B%M4U*SENK9R
M(YI;8?(SA2 0Q09'0;C2YK*]CIA@(5*CA&I\+:=UM9-WW=UH_P#(^D*=&SQR
M!HV97'1E."*\EU;QY)XN^'%O=[)-*UFUU>SL]2L5<K);S"X0.IZ':PY&>H-7
M_BU%J'C36['P+HU[-IUQ<0S:C>7=N[1M#$@*PKN _BE(R.N$-/FT,(X.7,HU
M';5W\DK-OSWT[GL=CXOU2PP!<><@&-LPW?KU_6NJTGQ]:7;".[3[(Y_BSE/S
M[5XI\,_%,GC#P7I]_<)Y6H1@VU["5*E+B,[)!@\@9&1GL:Z>LY4H35['%4IN
ME-TY;K0]M5@ZAE(93R"*6O-?"/B9]+N%MKB3-E(<?-_RS/K]*])ZUY]2FZ;L
MS$6BBBLP"BBB@ HHHH \Y^"__'MXK_[#MS_[+7HU><_!?_CV\5_]AVY_]EKT
M:N_'?[S+^NAXF2_\B^E\_P V%%%%<![84444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MY;\!X396_BRT<_O8M:F#+WZ*/Z&O4J\D\$J/#/QL\7:4YD8:FBW\+O\ *.NY
M@/7F1A_P UZW7IYCK7Y^DDG]Z1\[D+M@O8O1TY3B_E)_I9A1117F'T05\H_\
M%%M6MK?X2Z%ISOBZN=76:-?58X9 Q_.1?SKZNKX*_P""DGB7S_%'@_P_Y)'V
M6SEOC+GAO-?8%Q[>0?\ OJNC#J]1'/B':FSXTHHHKVSQ HHI* %HJ_IN@ZEK
M186%A<7>W&3%&2!GOFNDC^#_ (ID"DV4*!AGYKA,CZC-;PH5:BO"+?R."OF&
M$PSY:U6,7YM(XRBNTD^#_BE,XLX7 &?EN$_EFN=U'PSJ^D &]TVZM@QP&>(X
M)]J)X>K35YP:^0J.88/$/EHUHR?DT9M%.:-X_OQNG^\I%,# ]#FL#T-]A:**
M*  <$5^N7[,OB ^)?@'X(O2,%=.2U/\ VQ)B_P#:=?D;7Z8?L#^*)->^ \=C
M*8@VCZA/:1JA^;RVVR@L/]Z5Q_P&N+%J\$SMPKM-H^D****\D]8**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#SW3O\ DNFK_P#8%B_]&UZ%7GNG
M?\ETU?\ [ L7_HVO0J[\9\4/\,?R/$RKX*W_ %\G_P"E,****X#VPHHI&8*I
M). .30!A>+M?_L6QV1'_ $J;*IS]T=VKS DL2222>23U-:/B'53K&JS3YS&#
MMC'^R/\ 'K6;7JTH<D?,H****V&%%%% !3)YXK6WEGGE2"")2\DLK!410,DD
MGH!5;6M:L/#>D7>JZK=Q6&G6D9EGN9CA44=_KZ#O7Y]_M!?M*ZI\7]0FTW3&
MFTSPC$VV*USMDNL?QS8]>R=!WYKKP^&GB)66W<F4N4]'^.G[:$UX9]$^'LA@
MMOFCGUQT^>0=/W /W1U^<\^@[U\I7$T]]<27%Q-)<7$K;I)IG+NY]68\D^YI
MJ1YJQ'%7U-&C"A'E@C'66Y$D-3+#[5.D53)%704HD"PUTVB_#7Q+XATB75--
MT2[O+"/.9HX\AL==O]['M53P_H4WB'7+#3+=6::[F6%0@R>3R1]!D_A7WYH>
MCVWAW2++3+)!%:VD2Q1@<# '7^OXU^3<><;RX1A0IX>FIU:EW9WLHK=Z:W;T
M7H^Q]+D^4K,7.4W:,?S/SN\D@D="#@T>377?$:ZM-3\?>(+NP18[.6]D,:JH
M4#!P>.W(-<[Y8SCO7ZAA:TL1AZ=>4>5RBFT]U=)V?IL>%4IJ$W%.]F4S#3&A
MKJO"'A&?Q=K LHG$$:J9)KAAE8T'<UCR69^TRQ0YGV.5#1@G.#C/XUUV=KG&
MJ]*565!2]Z*3:[)WM]]F930U$T/M7=Z7\*_$NK+O336MHAC,ET1$,'N,]:V'
M^&6@>'V)\1>*;=7C(9K6Q&]V4^G?/T!JE3EV/'K9UE]*7LU4YY_RPO-_=&]O
MG8\EDC Y/%6M+\/:IK,P33M/NKR4#>!!&21CN#7IO_"4>!?#+?\ $H\.2:O<
M1M\MSJ+_ "N#UX_Q6LS5/C1XEN8A!8R6^CVRD[([*$+@>G.1^0%'+%;LYWC<
MPQ'^[87E7>HU'_R6/-+[['T)\"?BEX]\#Z>;'QV8;O08;<&VGO+E?M<( ^[G
M^(8_O<CU/2O:M%\9>(O'VFV^H^'X+"'2K@$+?>:)0?\ :'_ZC7YJ:GJ%[JD@
M>]NY[QU^ZT\A?'TR>*[OX)_'/6_@KX@6XM&>^T6=@+[27?"2K_>3^[(.Q[]#
M[>;6PU.SG2@N;S_RV&L#CZ_^]XII=J:4?_)GS2^YH_0*S\$:E->07>K^(+JY
MEC()AMR40D'(]/Y4_P")OA.\\9:5I-M9/%'):ZO:W[^:2 8XV)8#WYXK3\%^
M--'^(7AJTU[0;M;S3KD<-T>-A]Y'7^%@>"#6W7S%>I.L[5.GE:Q[N786EE;Y
ML,G=N[;;DV_-MMGFNH_"V[U30_&EI)-!'=ZEK3:SID^"P@D5E:)F''.00?9C
M6;J'P;O=4^'-E97LEGJ'B==0_MB]DN=RPWEPQ/F1LR;6"D'"MU7 [5ZY17+R
MH]V./KQM9[._X6^X\0TGX.7-WHOB*0^%-(\*:C>:;)86B0ZA-=R NWS,[DE0
MA 7@#/%>TV$+6MC:0L07AACC)'3*J ?Y5-1345'8RQ&*J8GX_P!7^;;Z=SS;
M3])\9^!;^ZTW0=,TO6="O+Z6\AN+N[:W>Q\P[F1U"DR#=G!7G!Y%<EXB^"^H
M+XBUFY@\,Z1XF&L7<ETM]>:A/;&P9U&5>-3^]0-DC;R1UQ7NU%+E1O3S"K3E
MSQ23>^ZOYNS_ "M?K<\YO/AG<HEQ;V M;>U_X19M#AB0L%27<Y!&<G9\PZG-
M=?K&D3:AX-OM)C91<3::]FK-]W>82@)]LUKT4^5(Y98FI-IR>VIYAX;TGXC:
M'X+TWP[:V_A^PELK..TCU1[F68KM !?RMF"<9P,XS26?P?ET._\ APNGW2SV
MOAVZN[J]FN"1)</-&0SJ.>2Y)QGBO4**7*C=XZI=N*2O>]EO=-?DW;U/,?B%
M\*[[7/$UEK6@W,-F]Q<6PUB";.RYBAE5T=?21=I&>X-6K3X3QZQXA\0:]XAF
MG.H:C=?N!87DL'E6J +%&VQAN( ))]2:]$HHY5>XOKU=04$[65K];::7^2^2
ML<-X'\ S^ _%.O?89M_AS4Q'<I#+(SRQ70&V1BS9+;P <D]J[FBBJ2ML<U6K
M*M+GGOI^&@5Z=X+U8ZEI*QR-NFM_D;)Y(['\OY5YC72> [\VNM"$D[+A2I'N
M.0?Y_G6-:/-#T,#TJBBBO+)"BBB@ HHHH \Y^"__ ![>*_\ L.W/_LM>C5YS
M\%_^/;Q7_P!AVY_]EKT:N_'?[S+^NAXF2_\ (OI?/\V%%%%<![84444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;KS@_P 1_P#K8_.MJ,>::&<O1117JE!1110 4V::.WADFFD2&&-2[R2-M5%
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MWAF<Q7B/+%_=D'ZC].>E=GH_B*SUI,P28?\ YYMP?_K]1^= &I1110 4444
M%%%% !1110 4444 %%%% !15/4=6M=+A,EQ*$_V>YYQ_6N)U+Q=>Z[(+;38W
MB1N,C[Q[=OJ.E 'H D1F*AE+#J,\TZO,_P#A%=;L\WJ!A*02Q5AOY]0/QZ5I
MZ-X\DAD$.IIC/24#W'Y]_P J .YHJ"TO(+Z$202K*GJIJ>@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#A_$7P8\*>(W:233_ +%.S!FELF\LG QC;ROZ=JQ!^SGX6 P+C4@/
M^NZ?_$5ZG17H0S#%TX\L:KMZGA5<BRNM-U*F'BV_)'R7^U1X9T#X)_"Y]6TY
M[N?5KRZCL[5+F9&C!.6=F7:"PVHPX/5EKY!T'XX7=O</_:MC#- PX^Q((W!_
M$X->U?\ !13QRNK_ !"T/PQ#+')'H]F9IE4'<DTQ!*G_ ( D1_X%7R/7M8;'
M8J,5)U&WYG@XO(,KJ.5-4$EY:/[S3\2Z[)XEURZU*6-87G;/EIT4 8 ]^!7W
MO_P3I\&+I?PXUWQ))'*EQJU\($9F^1X85^4@>N^24$^P]*_/45^O/[.W@63X
M;_!?PKH5PLD=W#:":YCFQNCFE)ED3CL&=@/I7FXRHY1NWJV?08"C&E:$%:,5
M9?DCXO\ CQ=_9OVS/$4>,_:(H(_I_H<3?^RU?KD/VK=0.E_M=:O=>9Y*QSV6
M]_13;0AOT)KKZ^UR*=\-R]O\C\7XXH\N81J])+\4W_F@HK/U3Q!IFAM&NH7]
MO9-)DH)G"EL=<5P?C#XS65C"]OH9%Y=9VFX8?ND]Q_>/Z5[-;$T:";G+_,^.
MP>5XS'R4:%-M/K;3[]BW\5O'H\/6)TRR?_B97*X9E/,*'O\ 4]OSKPRXN9KR
M7S;B:2XEQCS)7+-^9I;N[GO[J6YN96GGE;<\CG)8U%7Q.+Q4L54YGMT1^Z9/
ME-+*<.J<=9/=]W_EV"BBBN(]T^W_ /@FK:Q,WCVX,:F=191K)CD*3,2/Q*C\
MJXG_ (*&>"%T'XK:;X@@@2*'7+(>8ZL29)X3L9B.WR-"./2N[_X)I_\ 'O\
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M;"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:"7RX+ZVNH+A?[Z"%I /^^HU/X5[,W[2BWY'C07LZR7F?IY1117BGM!1110
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M=F_]":O"/M3T6BBB@ HHHH **** "BBB@ HHHH *9,SI#(T:>9(%)5,XW''
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MQDT#Q3XITVUTO0&2.SG+"\<R!"1QA>?X>I./05L_#OX=Z?\ #W1Q;6JB6[D
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M0S)K7B_6)+4,D5O#:PW)'*N69G4?5=N:^7=<LXM.U:[M(;I+V&&5HUN(ONR
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M %R_QKT*W_X]XO\ ='\J )*S[.^N+B^EADM6AB0-AC[$ <].1D_A6A7'^/\
M5KJQCAB@9HT?YBX/H?\ ]7YT ;UYJ3Q:A#:?96FCEP&;' !_S^A]LZ$<:Q($
M10BC@*HP!7(>!=9O;V.XCG#3(B;U8^N>GX\_D:UX-<N9;*>8V;*\<BH%_O9
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MM!9ZKIE[JMW<^(KNZD\FX6X.R.; ^0;%].3UZ_E7J]G!':VL44,*V\2* L2
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M!_,5Z'6;X?TW^R=)M[<C$@7<_P#O'DUI5YE27/*YY84445D(**** /.?@O\
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M5/;4K^R=G=KG:W3Y4K7Y;?:U=[=CTZBO--'\;>)/B+:F?PU;V>EV,>%>]O\
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M+C68OM%N MX@X]''H?>NJC5Y?=>PT>:44Z2-HI&1U*.IPRL,$&FUZ)04444
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MCC;@=1GTZ#GKS6MHO@-5VSZ@Y>7KMSZ=/IQCC]:ZZ"WCM8EBB18XU& JC %
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M@VJH["GUY52;F[D!11168!1110 4444 ><_!?_CV\5_]AVY_]EKT:O.?@O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME\_S84445P'MA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)?J/YM7@GVYUU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7R7_P4
M9\06]G\+_#VC,["ZOM4^T(HZ&.*)@V?QE2OK2OSW_P""C7BB:^^)'A[0A.CV
MFGZ;]H\M1\R2RR,&R?=8XO\ )KIPZO41S8B7+39\CT445[1XI]S?\$V-#9;/
MQOJ[PH5=[6UBF*_,"HD9U!]#N3\A7VU7R?\ \$Y7C/PD\0*/]:-98MSV,$6/
MY&OK"O$Q#O49[>'_ (2"BBBN<Z#\QOV\/#TFB_M":C=NVY=4L[:\0>@">3C\
MX3^=?/%?4W_!13_DM>D_]@*'_P!'SU\LU[M'^'$\*LK5) ."*_7+]F7Q$/%/
MP#\$7PC,6S3DM"I]8"82?Q\O/XU^1M?HO_P3P\4#5?A)JVC27+S3Z7J3,L3'
M(BAE12H'L764_4FL,5&\+]C?"RM.W<^J:***\D]8**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \]T[_DNFK_\ 8%B_]&UZ%7GNG?\ )=-7
M_P"P+%_Z-KT*N_&?%#_#'\CQ,J^"M_U\G_Z4PHHHK@/;"BBB@ HHHH ****
M"BBB@ HHHH 1E#J58!E/!!'%<YJW@6QO]SP9M)3S\GW2?I724549..J8'ENI
M>#=3T_)$7VF,?QP\\>I%8C*58JP*L.H(P17MM9FK>';'6%/GP@2=I4X8?C77
M'$?S(=SR2BNCUGP1>Z;NDM_]+@'=1\X^H_PKG/4=#77&2DKH844458PHHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M53GT<5^&GZ'AY7[KQ%)[QJ2_\FM)?@PHHHK@/<"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ K'U?PM8:QEI(_*F_YZQ\'\?6MBBFI.+N@/.-2\ WUIN:
MV9;N,<@#A_R[U@W&F7EJ[)+:S(R]?D/\Z]EI.O!Y%=,<1);CN>);AZT5['<:
M39W4>R6UB=?0H*S[CP;I%PH'V018[Q$J:V6(CU0[GEE%>C7'P]TZ0?NGFA/^
M]N_G5;_A6]MVO9O^^5J_;P"YP5%=Q)\-Q_!?-_P)*D3X;P8^>]ES_LJ*?MH=
MP.#I55I&"HI=CT51DUZ5:^ ]+M]A='G9>OF-P?PK:M--M;%0MO;QQ =-JBLY
M8B/1!<\PLO"NJ7V#':LBD9#2G:*W+/X<2M@W-VJ#'*Q+D@_4UWE%82Q$WMH*
MYR]O\/=.C7$KS3-Z[MO\JNV_@W2+=-OV19?]J0EC6W163J3?4"C;Z'I]I_JK
M.%/^ @U\^_%_7?&%I\2;S2]$NM2BTQ;2.X:UTX*&\H "1UXY.37TA7)ZOX#7
M5/'^C^*!?RP2:? \!MU4;958D\G\?T%>CE^)AAZKG52>CWUUZ?Y'SF>X&OF&
M&C1H3<7S1NXNSML_N3O;K8X_X"+X?DM[^[TOQ%J&KWMP%$]OJ<G[V':3_!GU
M/4>U>N5YMXX^"MCX@O/[8T.Y?P[XA3!2\M?E5CG/SJ.OU]JQM%^,&J>#-0CT
M7XB61L96)$.L0KFWE&>"<=#U_+I6]>C]?DZ^'ES/K%_$O3NO37R.#!XK^Q81
MP>.@H06TU?D=WUO=P;\W;LSV*BHK6ZAOK>.>WE2>&0;DDC8,K#U!%2UXFVC/
ML$TU=!1112&%%%% !1110 4444 %%%% !1110 4E+5#7M4&B:'J&H,N\6MO)
M/MSC=M4G'XXJHQ<FHKJ1.:IQ<Y;+4X3X%R&\T'7+\+B&]U>XGB/JN0/Y@UZ5
M7#_!73I--^&6B)(03-&UT,=EE=I /R85W%=F.DI8FI;:[_#0\K)X2AEU!2W<
M4WZO5_F%%%%<)[ 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!@^-O^1=N/PJ+P'_R _P#@?_LB
MU+XV_P"1=N/PJ+P'_P @/_@?_LBT ='6=K$-G]G-Q=KN6+GKC\/U(^A/K5F3
M4+>&X6!Y5$S8PO?DX'TR:Y34?%EC<7?]C:L38/=$I;R.K"-VR1L+>I].,\XJ
MHQE-VBKLSJ5(4H\U1V7GYEBW\766N72VC1LJL_RNK?@"<CW_ %KH[?R+18K.
M-E4H@"QYYP*Y'1? KZ?J/GW$B^5&X*<YSALC^0_,UUG]FPF[%S@^;G=U[[=O
M\JDT)%NX661A*I6/ASGI]:&O(%C1S*@1SA6SP:KKHMJD<B!#M<*#S_=)(_G2
M2:+:R0+$RMM7<!SS\QR: +?VB/SO*WKYN,[,\XIJW<++(PE0K&<,<]*C_LV
MW8N-I\P'=U[[=O\ *LV\DT315:*\OK:S,@4;9YU0D _+@$^M4HN3LD1*<::Y
MINR-.?4+6VMUFFN(HH6Z.[@ _C7D^@>.+#0/%'B::8^;'--$EK,QX>)5. I
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ML<,2!$51@  8 %3445Y^^K/<225D%%%%(84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!B^+[>2
MZT&X2-=S=<5S?A?4X;C2FTXS_9)]X.YNAX (^O&>>/UKO64,I!&0>"*Y'6O
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M9\+?"FB2VRVEQ9Z;!'/"O19M@,GX[RQ_&EBY6@D/"1O-LZ^BBBO*/5"BBB@
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M]"*GKS7=:,^A34E=;!1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M *$#5/\ P(CH_P"%C>(_^A U3_P(CKT&BCZQ1_Y\K[Y?_)!]1Q?_ $&3_P#
M:?\ \@>??\+&\1_]"!JG_@1'1_PL;Q'_ -"!JG_@1'7H-%'UBC_SY7WR_P#D
M@^HXO_H,G_X#3_\ D#S[_A8WB/\ Z$#5/_ B.C_A8WB/_H0-4_\  B.O0:*/
MK%'_ )\K[Y?_ "0?4<7_ -!D_P#P&G_\@>??\+&\1_\ 0@:I_P"!$='_  L;
MQ'_T(&J?^!$=>@T4?6*/_/E??+_Y(/J.+_Z#)_\ @-/_ .0//O\ A8WB/_H0
M-4_\"(Z/^%C>(_\ H0-4_P# B.O0:*/K%'_GROOE_P#)!]1Q?_09/_P&G_\
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M !2$!@01D&EHH YO7/!5IJ2EX +>?.<J.#R/_K_G7-Q7&M>$;C8ZM-$QSTW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS:>VRVADCMM24$ "WG^210&ZE7RN?QKK_P!I'Q!//X/TOPMH]PHU3Q9>Q:=
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$D.] VQA_>&<'W%:=%%>2>L%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!17A_P"T1^UIX0_9]L3!=R#6/$;KF+2+60!D']Z5OX%_4]AWKYDL]+_:1_;"
M47=S>GP%X*N3@(V^VC>,X.5B'[R89 Y<@<\'%>C1P4ZD/:U&H0[O]%U."KBX
MPE[."<I=E^KZ'V]XB^+G@GPG]I&L>+=&T^2VR)H9KZ,2H1V*9W9]L5P]O^V)
M\&KJX2"/Q[I_F.VT;XYE7/\ O% /UKQWPC_P3.\%6,T%UXH\1ZSXCN"N;F%)
M%MX9'/<%1O _X%79?\.\?@G_ - +41_W%[G_ .+K7V> CHYR?HE^IGSXV6JA
M%>K?Z'NOA_X@^%_%<RPZ+XCTK5IV3S!#9WL<K[?7:K$XKH*^)O%/_!,O1HUF
MN?!GC;5=%OR_[I;Y5FA1#U7*[7_'=7'K\4OVA?V/[N*/QS9-XU\%JRI]N,AG
M1%X "SXWQD*O1QMR>]/ZE2K?[M5N^ST8GBZE'_>*=EW6J_S/T)HKS;X)_M >
M$?CSH)O_  Y>_P"EPJIN]-G^6>V8]B.XST8<']*])KRYPE3DX35FCT83C4BI
M0=TPHHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHK@/C)\</"?P+\-_VQXGOO*\QMEO90 /<7+>B)GH.I8X ]>0#<(2J248*
M[9,I1A%RD[)'?UA:_P"//#7A681:UXATO29BGF".^O(X7*^H#,"17PD_QG_:
M"_:ZU":#X=Z>_@[PDKX%^LA@4@%Q\USC<Y(X*QC;E1G%==X8_P""9>ES;+GQ
MGXZU36;U7Y6Q188VC'\)+[WSUY!%>I]2I4?]YJ6?9:OY]CS?K=2M_N].Z[O1
M'O%U^V)\&K.XD@D\>Z?YD;;6\N.9US[,J$'\#79^'OC%X%\6+;'2/%^BWSW1
M"PQ1WT?F.3T 0G=GVQ7C?_#O'X)_] +43_W%[G_XNN1\7?\ !,_P+J$TUSX9
MU_6O#<X3_1X3*+F%)!T8EQO(SZ,*7)@):*<EZI?H/GQT=7"+]&_U/L.BOSUN
M_"?[2'[()%WI&HMX^\&6QR\,:O.BH65FW0$EX\LQ&8R>Y.!7TC^SC^U]X2_:
M ACT]#_8OBM8O,ETJX8$28/S-"_\8Q@X^\,]" 365;!3A#VM-J<.ZZ>JZ&E+
M&1G+V=1.,NS_ $?4]YHHHKSCO"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HK \<^.M#^&_AF\U_Q%J$6FZ7:KEY9#RQ[*HZ
MLQ[ 5\1>*OVMOBI^T9XDN?#/P2T*ZL-+5C')J[(!*%.!N>4_)#U! 4E_K7;A
M\)4Q%Y1TBMV]CDK8JG0LGJWLEN?=.N>*-&\+PQRZSJUCI,4AVI)?7*0JQ'4
ML1DUYOK7[6?PA\/WSV=YX\TP3I]X0;YU'_ HU8?K7SAX?_X)SZWXRDDU7XG_
M !$OKW4[G]])#II\PI*Q^;=++G?]0JUZA9_\$Z_@Q#:Q1SZ5JEW,J@//)JLZ
MLY[DA6 'X"NGV.!IZ3J.7HO\SG]KC)ZPIJ/J_P#(]8\-_M"?#7Q9:_:-,\<:
M)+'G;B:\2!L_[LA4_I7H$<BS1JZ,'1AN5E.00>A!KY.\4_\ !-7X7:PL0T>[
MUOPX5!W_ &>[^T"3TSYP;'X8KR[5/V<?V@/V:_,U7X<>+IO%.E1DS3:?'D2<
M @9MY"R287G((.<8%-8;"UM*-6S[25OQ0OK&)I:U:=U_=?Z'Z"45\J?L\_MU
M:-\1]2A\+>-K/_A$O&/F&#;*K1V\L@_@._YHG/\ =;OWZ"OJNN"M0J8>7)45
MF=M&M3KQYJ;N%%%%<YN%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRMBO<IR_M"DZ<_XD5=/NNS_0\><?J-15(?!)ZKL^_P#F?HE1117AGL!1110
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MF?\ #='Q%_Z(9KW_ 'YN?_C-=='"U<0FZ:V\TOS.:KB*=%I3?X,^T:*^+O\
MANCXB_\ 1#->_P"_-S_\9H_X;H^(O_1#->_[\W/_ ,9KH_LW$]E]Z_S,/K]#
MN_N?^1]HT5\7?\-T?$7_ *(9KW_?FY_^,T?\-T?$7_HAFO?]^;G_ .,T?V;B
M>R^]?YA]?H=W]S_R/M&BOB[_ (;H^(O_ $0S7O\ OS<__&:/^&Z/B+_T0S7O
M^_-S_P#&:/[-Q/9?>O\ ,/K]#N_N?^1]HT5\7?\ #='Q%_Z(9KW_ 'YN?_C-
M'_#='Q%_Z(9KW_?FY_\ C-']FXGLOO7^8?7Z'=_<_P#(^T:*^+O^&Z/B+_T0
MS7O^_-S_ /&:/^&Z/B+_ -$,U[_OS<__ !FC^S<3V7WK_,/K]#N_N?\ D?:-
M%?%W_#='Q%_Z(9KW_?FY_P#C-'_#='Q%_P"B&:]_WYN?_C-']FXGLOO7^8?7
MZ'=_<_\ (^T:*^+O^&Z/B+_T0S7O^_-S_P#&:/\ ANCXB_\ 1#->_P"_-S_\
M9H_LW$]E]Z_S#Z_0[O[G_D?:-%?%W_#='Q%_Z(9KW_?FY_\ C-'_  W1\1?^
MB&:]_P!^;G_XS1_9N)[+[U_F'U^AW?W/_(^T:*^+O^&Z/B+_ -$,U[_OS<__
M !FC_ANCXB_]$,U[_OS<_P#QFC^S<3V7WK_,/K]#N_N?^1]HT5\7?\-T?$7_
M *(9KW_?FY_^,T?\-T?$7_HAFO?]^;G_ .,T?V;B>R^]?YA]?H=W]S_R.T_X
M*'?$!O!?[/EW8PRS17.N7*62M$.#&,O(&]BJD?C7>_LD_#R/X9_L_P#A'3 D
M0NKBU74+J2+.))9AOW<]]I4?A7PM^UI^T%XG^-GA_P -:1X@^'^H>#+2'41(
ML]ZDJB8L-A4;T7H"3Q7Z9^$K./3?"NC6D)!AM[*&)".FU8U _05T8JG+#8.G
M2ENVV_R,,/..(Q4ZL=DDE^9K4445XAZYF>)M8D\/^'M2U.*PN=4DL[=YULK,
M S3E5)V(">IQBOSX\)_M6?%WXA?M*?#B+68;OP;X:U74O(AT18'BCN(>58N7
M&Z0@[1GH#G&*_1JOC3]J+C]M3]GD#@>=)_Z,%>ME\H7G"4$VT]>UDSS<:II1
MG&3236G?5'V71117DGI!7R3_ ,%)O!<>M?!&R\11K(;W0=2BD0Q)G]W(?+?<
M>H49#>F17UM7C_[7_/[,?Q(R,_\ $GF_I79@YNGB:<EW1RXJ*G0G%]F;7[.O
MBJ;QM\#O!6LW$:Q3W&FQJZJQ893]WG)]=N?QKT:OS6_9B_:G\:?#'X4VN@:5
M\-=7\7V4-U,\>H6Z3/&-Q!\L;8V P<]^]>L?\-T?$7_HAFO?]^;G_P",UW5\
MMK^UER)6N[:K_,XJ./H^RCS-WLNC_P C[1HKXN_X;H^(O_1#->_[\W/_ ,9H
M_P"&Z/B+_P!$,U[_ +\W/_QFL/[-Q/9?>O\ ,W^OT.[^Y_Y'VC17Q=_PW1\1
M?^B&:]_WYN?_ (S1_P -T?$7_HAFO?\ ?FY_^,T?V;B>R^]?YA]?H=W]S_R/
MM&BOB[_ANCXB_P#1#->_[\W/_P 9H_X;H^(O_1#->_[\W/\ \9H_LW$]E]Z_
MS#Z_0[O[G_D?:-%?%W_#='Q%_P"B&:]_WYN?_C-'_#='Q%_Z(9KW_?FY_P#C
M-']FXGLOO7^8?7Z'=_<_\C[1HKXN_P"&Z/B+_P!$,U[_ +\W/_QFC_ANCXB_
M]$,U[_OS<_\ QFC^S<3V7WK_ ##Z_0[O[G_D?:-%?%W_  W1\1?^B&:]_P!^
M;G_XS1_PW1\1?^B&:]_WYN?_ (S1_9N)[+[U_F'U^AW?W/\ R/M&BOB[_ANC
MXB_]$,U[_OS<_P#QFC_ANCXB_P#1#->_[\W/_P 9H_LW$]E]Z_S#Z_0[O[G_
M )'VC17Q=_PW1\1?^B&:]_WYN?\ XS1_PW1\1?\ HAFO?]^;G_XS1_9N)[+[
MU_F'U^AW?W/_ "/M&BOB[_ANCXB_]$,U[_OS<_\ QFC_ (;H^(O_ $0S7O\
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M%%%> >V%?G5\9O W[3'@.U\1^,=<^+%OHV@QW$LR)#K<L0VLQ\N**(18W$8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK)&X#*ZG(8'H0?2GUY!ZAF^)+^ZTOP[JE[96WVR]MK66:"WP3YLBH2J<<\D
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBBO'/H0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9?<CT,#D>79=+GPU%*7?=_>[L****\\]T**** "BBB@ HHHH **** "BBB@
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M3>H9+>Y5&4.H)&<, 1R#U%><?M):A;6/AK0Q/\0[CX=O)JL*QW5O$\AO#GF
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M5*C""C?F:3?;7Y'5AZE6K*;E;E3:\]"2BBBO/.X**** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ ILF[8VP
MOC@'IFG44 >&WGQ&^+UOXTA\-#PKX1^USV,VHQRMK-P(_)CDCC.X^1D-F5>,
M8X/->B:;\4/#4FE-/>^)_#\=S:VT<VH"WU.)XK8GY22Q(PF_*AF SCUJAJ.@
MW\WQLTO6$MF;3(O#MY9O<<;1,]Q;LJ?4JC'\*\>A\(^)? ?P#\-VEIX;$-V-
M=DNM;>WL(KN]MK?[9+(+B&)E99)0/+(RK$#D D5Z*C3JJ.R>GZ^O;\3@YJE-
MO=K7]/\ ,]^C^(7A:;28]5C\2:2^F2>84O5OHC"WEJ6DP^[!VJ"3SP 2:&^(
M7A9?#O\ ;Y\2:2-"W^7_ &G]NB^S;LXV^9NVYSQC-?-?@SX5>(=>\8Z7>ZSI
M.J7NA?\ "9-KD<NKQ0P2F+^SRB320Q!53,JK\@4'IN&<UK:]X%NM'U?QCJFJ
M:9X@M+2+Q8NIZ+>:#90WIMMUBD3SFW<,'0MN4X1F#<X'6F\/24N7F_KM_7W"
M6(J6YN7^N_\ 7WGO^I>/O#&BZ/::MJ'B+2;'2[P@6U[<7L4<,V1D;'+8;@$\
M'M4LWC;P[;Z//JTNO:9'I=NP2:]>\C$,;$*P#/G )#*>3T8>M?/?A?0/%>@Z
MOX-\:Z_X$FUF.'1+G3SHVD6MM'+I]P]R7%R('D"HTT?+A6.TL1TS7)Z?X3U'
M5K"?5[70[_0=.T/QWJ%[>Z7I%O;7UU9[K2)8Y4B=7C<JS!F50Q7<=N2HIK"P
M?VOR^[^N_P!X\1-?9/JT^//#2Z1;ZJ?$.EC2[A7>&]^VQ^3(J ERK[L$*%8G
M!XP<U)%XRT"?P\VO1ZYITFAJI9M36[C-L #@DR9VXSQUKY_\'?"A]6\2^%-=
M>S\1:CIDWB2YU:Z7Q)!;VYB9;)XX[A;>)5$:N^SY64-E02!47CKX<^*+:'4+
M^SLM2ATJS\;3:S-:Z2D,EQ+:FUB1)HH95:.79*"^QAGY25YQ4_5Z7-R\W]=B
MO;U.7FY?Z[GT=H?B#2_$^GI?Z/J5IJMBY*K<V4ZS1L1U 921Q6#_ ,+"TW1+
M?4;GQ/K.@Z+;PZ@]G#*VIH%.%5@LA?:%EP22G.!BN5^ V@PV?_"2ZS%_PDA.
MKW,<CR^(;*VLO/**5\V."%4*9& 2Z*QVCBO-?'/@N;3-6UC5[[3/$EMJ']O:
ME<:7?Z/IL.HP&.:UACV3P.&)60H5#!1C!RZYJ(T8.HX-_P!?UY?(J5::@II?
MU_7_  Y]*S:UI]OI8U.6^MH]-\M9?MCS*(=AQAM^<8.1SGO5'1_''ASQ%J=W
MINE:_IFI:A:9^T6EG>1RRPX.T[T4DK@\<]Z\A^(4&LR_L>ZK;>(=(L]%UC^P
MQ!<:99@)!"<A510"0HV[> 3MSQTK U;P_<^)->\"V7A'P)>>'-2\(F0WT]U#
MY-NL'D.ILEFR/M*3,$R1D8PS8;@$</&2;;ZM=+:?YA*O)-)+HO74][T/QYX:
M\3W]S8Z/XATO5;VU!,]M97D<TD6#@[E5B1SQSWKDOB%\:-(T/P7XGO\ PWK.
MBZUKFBP>;)81W:3&,B14/F(C;@ 3CMS7A.A^$?&7C#6M!FMM/UJPOK71=3T^
M[N+[2;33[;3+F2V94MX!&BR2QB3&&+.F IR3TW[C2EU[X+R>"M)^'.K:;XIT
MW0UL9+F738H8X)OD\Q4F+8D\PJ6!3>I_BP>*W^K4X35W?;Y:]?Z_X./UB<HN
MRMO_ $CZ*O?%VA:;<7EO>:SI]I<65N+NZBFND1H(2<"1P3E4S_$>*BT_QSX<
MU;0[C6;+7]+O-'M]WG:A!>1O!'@9.Z0-M& >YKYZO/!_C3X?>"_&NBP^'AXA
MUF^O8[N?Q6;:.]EU2S:0>8S0R-@SPI]V(_NS@;1U6LQ?AWXE\12>)=6BTO5?
M$>ER:IHVII::[:VUC-J\%N)!,@B5$12,K@2*A;;ANU0L-3:OSZ?\-_GWZ:EO
M$3O;E_K4^F=#\<>'/$R[M'U_3-5&QI<V5Y'-\BD!F^4G@$@$]B13_#_C+0/%
MGVD:'K>G:R;9@L_V"[CG\HG. VTG!X/7TKYF\7:;J_Q.\>^,K/2/!EYX1U+4
M/!+10+J300SWS"\3(81LX7 &P%SSNZ8I\'@'5_'6EZVVAS>-;'7K70)M*MUU
MFPL]*M%WXS:[H(XV<C;\KKN1<Y#4?586NY6_07UB=[*-SUKQC\<=,LM8\*Z?
MX9U;1==FU#7H-*U"."Z6=[:-P^6PC?*V5Q\W'M79ZQXDDTGQ-IUE++I5OITU
MO//-)=7PBN1Y8SF.(KAD Y9MPVCM7SY>Z OC#7OA&/#OPVU+0&\*:K"-1FNK
M58%L(E0JT*L3^_7(#;UW+T.<DBN^^,G@W6O$'C_0K_3=/DNK:WT+6+:29",)
M++ %B7D]6/%*5*FG&.VC_6PXU)M2EOJOT/0H_B5X1F^W>7XHT:3[!$)[O;J$
M1^SQG&'D^;Y5.1R>.167X1^-7@SQIX/?Q-9:_80:3$Q2XENKN)/LYW%0)#N(
M0G&1D\@@UQ>A?"\Z3J'P=:#P]!;1:5I=Q:ZF8XD BWVJ#8_J#(#QSSS7 ^&=
M!N])T/P/=77@W4+JW\&:KJ"ZQI@T_P#>%I"_DW<"D8N%0'.4)(#<#(Q0J-*2
MT?Y>?YV7WH;K5$]5_6GY7_ ^F]%U[3?$FGQW^D:A:ZI8R9V7-G,LL;8.#AE)
M!KSSXQ?&^/X4ZCH]JFF-J@F#7FI,DFS[!8HRH]PV1@_,Z@ D=_2H?@SH]R_B
MSQQXGBT6?P[H6O36TEE8W<(@FD:.,K)<-&#E-Y(X;#';D@&N5M/AQX[\;>*/
M'7B2>72M$AUQ'T2"PUO39;F5-/C!564QW*JOF%F<C'I]*B%.G&H^=Z+]>FG;
M]"IU*DH+D6K_ $Z_/]3U_P <>-;3P7X'U+Q(^+JWMK?S8EB.X3,V!&H(_O,R
MC/O7G-G\?[QO WA_Q%?Z(-//]M+HGB.TD+L^E2EMA;*@[E#E.>F'!S7#6/@'
MXF^)-%\!^![^*UM8O"5VUS>ZUJ<'VJTU'[,P6R C#(QW [S\PV[!G-:__"H/
M%<WC+QOH^NK8ZAX>\<Z47N+W1[,V<%CJ$0VI(RM*\A9AM;<#C*"MHTJ,%:<D
MWO\ +;\M?N,I5:LG>*:7Z_UI]YZSKWCR6Q^)'ASPC8VJW5Q?P3WU[*P;%K;1
MX56X&,NYVC)[&NRKQ?\ 9X\*^*E;5_%7CNT6U\3W20Z5'%DMLM;9=JN"6/\
MK7+2'IR:]HKBK1C"7)'6WYG72E*<>9]0HHHK V"BBB@ HHHH **** "BBB@
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MP02UT&/2]:T6=FOYXHD$EIYME.LK-_>W2F,L.<G%=,J=-J\G:5MO/7_)??\
M(YXU*B=DKK]-/\W]WS/;;'QQX<U37KC0[/7],N]:M@QFTZ"\C>XBVD!MT8.X
M8)&<CC(K&^)GQ>\-?".UTF?Q'?):)J=['90*9$4Y8@&0AF'[M,@LPSM!%?/?
MPO\ AC?PR^"O#%^_C33=8\/W!NYWM],L(+&UF$;[Y?M0BW3I*7(VAW8[LN!B
MN_\ CCX!U=? >DW%U>:CXX?2_$=AJDWG64#7$=JDB^:L<<$2[QCDC!)YZXQ3
M]A2C5C%RNF+VU25-R4;,]+T_X@:?-=:E/<ZOH*:(AB^Q7L.IH[2AH/.;S%(
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M110 4444 %%%% !1110 4444 %%%% $-Y>0Z?9SW5S(L-O C2R2-T55&23[
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M)HX9GC/E88A5&%(7%8_B+0[.^?XL6OP_\,:II6GS:3HDLNG1V,ULUW MW/\
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M%3&3B[IZC:4E9G,^"_AUH?@$ZC)I4$YN]1D66\O;ZZENKFX*KM0/+*S.0HX
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MK[?H7[=\KE;9V_IG??%3QGJ7A+1=+&BQ6<VJZMJ=OIEM)?%O(A:4G,CA2"P
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M5K?Y7"BBBL#8**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\;^+A-H-[H5Y;V>IW$DZ6DSQW9:--TRJSR"$@!F&7 X+4Y8)QC=2N_\ A_\
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>sgmo-20201231_g8.jpg
<TEXT>
begin 644 sgmo-20201231_g8.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#T17AI9@  34T *@    @ ! $[  (
M   .   (2H=I  0    !   (6)R=  $    <   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %-A<6EB(%-H
M96AZ860   60 P "    %   $*:0!  "    %   $+J2D0 "     S0Q  "2
MD@ "     S0Q  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MUM?8V=KAXN/DY>;GZ.GJ\?+S]/7V]_CY^O_$ !\!  ,! 0$! 0$! 0$
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M_0+U/_OF/_XJOGZBO3^ITNQP?6:A] _\+_\ #W_0+U/_ +YC_P#BJ/\ A?\
MX>_Z!>I_]\Q__%5\_44?4Z78/K-0^@?^%_\ A[_H%ZG_ -\Q_P#Q5'_"_P#P
M]_T"]3_[YC_^*KY^HH^ITNP?6:A] _\ "_\ P]_T"]3_ .^8_P#XJC_A?_A[
M_H%ZG_WS'_\ %5\_44?4Z78/K-0^@?\ A?\ X>_Z!>I_]\Q__%4?\+_\/?\
M0+U/_OF/_P"*KY^HH^ITNP?6:A] _P#"_P#P]_T"]3_[YC_^*H_X7_X>_P"@
M7J?_ 'S'_P#%5\_44?4Z78/K-0^@?^%_^'O^@7J?_?,?_P 51_PO_P /?] O
M4_\ OF/_ .*KY^HH^ITNP?6:A] _\+_\/?\ 0+U/_OF/_P"*H_X7_P"'O^@7
MJ?\ WS'_ /%5\_44?4Z78/K-0^@?^%_^'O\ H%ZG_P!\Q_\ Q5'_  O_ ,/?
M] O4_P#OF/\ ^*KY^HH^ITNP?6:A] _\+_\ #W_0+U/_ +YC_P#BJ/\ A?\
MX>_Z!>I_]\Q__%5\_44?4Z78/K-0^@?^%_\ A[_H%ZG_ -\Q_P#Q5'_"_P#P
M]_T"]3_[YC_^*KY^HH^ITNP?6:A] _\ "_\ P]_T"]3_ .^8_P#XJC_A?_A[
M_H%ZG_WS'_\ %5\_44?4Z78/K-0^@?\ A?\ X>_Z!>I_]\Q__%4?\+_\/?\
M0+U/_OF/_P"*KY^HH^ITNP?6:A] _P#"_P#P]_T"]3_[YC_^*H_X7_X>_P"@
M7J?_ 'S'_P#%5\_44?4Z78/K-0^@?^%_^'O^@7J?_?,?_P 51_PO_P /?] O
M4_\ OF/_ .*KY^HH^ITNP?6:A] _\+_\/?\ 0+U/_OF/_P"*H_X7_P"'O^@7
MJ?\ WS'_ /%5\_44?4Z78/K-0^@?^%_^'O\ H%ZG_P!\Q_\ Q5'_  O_ ,/?
M] O4_P#OF/\ ^*KY^HH^ITNP?6:A] _\+_\ #W_0+U/_ +YC_P#BJ/\ A?\
MX>_Z!>I_]\Q__%5\_44?4Z78/K-0^@?^%_\ A[_H%ZG_ -\Q_P#Q5'_"_P#P
M]_T"]3_[YC_^*KY^HH^ITNP?6:A] _\ "_\ P]_T"]3_ .^8_P#XJC_A?_A[
M_H%ZG_WS'_\ %5\_44?4Z78/K-0^@?\ A?\ X>_Z!>I_]\Q__%4?\+_\/?\
M0+U/_OF/_P"*KY^HH^ITNP?6:A] _P#"_P#P]_T"]3_[YC_^*H_X7_X>_P"@
M7J?_ 'S'_P#%5\_44?4Z78/K-0^@?^%_^'O^@7J?_?,?_P 51_PO_P /?] O
M4_\ OF/_ .*KY^HH^ITNP?6:A] _\+_\/?\ 0+U/_OF/_P"*H_X7_P"'O^@7
MJ?\ WS'_ /%5\_44?4Z78/K-0^@?^%_^'O\ H%ZG_P!\Q_\ Q5'_  O_ ,/?
M] O4_P#OF/\ ^*KY^HH^ITNP?6:A] _\+_\ #W_0+U/_ +YC_P#BJ/\ A?\
MX>_Z!>I_]\Q__%5\_44?4Z78/K-0^@?^%_\ A[_H%ZG_ -\Q_P#Q5'_"_P#P
M]_T"]3_[YC_^*KY^HH^ITNP?6:A] _\ "_\ P]_T"]3_ .^8_P#XJC_A?_A[
M_H%ZG_WS'_\ %5\_44?4Z78/K-0^@?\ A?\ X>_Z!>I_]\Q__%4?\+_\/?\
M0+U/_OF/_P"*KY^HH^ITNP?6:A] _P#"_P#P]_T"]3_[YC_^*H_X7_X>_P"@
M7J?_ 'S'_P#%5\_44?4Z78/K-0^@?^%_^'O^@7J?_?,?_P 51_PO_P /?] O
M4_\ OF/_ .*KY^HH^ITNP?6:A] _\+_\/?\ 0+U/_OF/_P"*H_X7_P"'O^@7
MJ?\ WS'_ /%5\_44?4Z78/K-0^@?^%_^'O\ H%ZG_P!\Q_\ Q5'_  O_ ,/?
M] O4_P#OF/\ ^*KY^HH^ITNP?6:A] _\+_\ #W_0+U/_ +YC_P#BJ/\ A?\
MX>_Z!>I_]\Q__%5\_44?4Z78/K-0^@?^%_\ A[_H%ZG_ -\Q_P#Q5'_"_P#P
M]_T"]3_[YC_^*KY^HH^ITNP?6:A] _\ "_\ P]_T"]3_ .^8_P#XJC_A?_A[
M_H%ZG_WS'_\ %5\_44?4Z78/K-0^@?\ A?\ X>_Z!>I_]\Q__%4?\+_\/?\
M0+U/_OF/_P"*KY^HH^ITNP?6:A] _P#"_P#P]_T"]3_[YC_^*H_X7_X>_P"@
M7J?_ 'S'_P#%5\_44?4Z78/K-0^@?^%_^'O^@7J?_?,?_P 51_PO_P /?] O
M4_\ OF/_ .*KY^HH^ITNP?6:A] _\+_\/?\ 0+U/_OF/_P"*H_X7_P"'O^@7
MJ?\ WS'_ /%5\_44?4Z78/K-0^@?^%_^'O\ H%ZG_P!\Q_\ Q5'_  O_ ,/?
M] O4_P#OF/\ ^*KY^HH^ITNP?6:A] _\+_\ #W_0+U/_ +YC_P#BJ/\ A?\
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M%_\ A[_H%ZG_ -\Q_P#Q5'_"_P#P]_T"]3_[YC_^*KY^HH^ITNP?6:A] _\
M"_\ P]_T"]3_ .^8_P#XJC_A?_A[_H%ZG_WS'_\ %5\_44?4Z78/K-0^@?\
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M%_\ A[_H%ZG_ -\Q_P#Q5'_"_P#P]_T"]3_[YC_^*KY^HH^ITNP?6:A] _\
M"_\ P]_T"]3_ .^8_P#XJC_A?_A[_H%ZG_WS'_\ %5\_44?4Z78/K-0^@?\
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M%_\ A[_H%ZG_ -\Q_P#Q5'_"_P#P]_T"]3_[YC_^*KY^HH^ITNP?6:A] _\
M"_\ P]_T"]3_ .^8_P#XJC_A?_A[_H%ZG_WS'_\ %5\_44?4Z78/K-0^@?\
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M@7J?_?,?_P 57S]11]3I=@^LU#Z!_P"%_P#A[_H%ZG_WS'_\51_PO_P]_P!
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MMF4-$&VX//Z9_2O&Z*3H1:0U5DF>C:+XZTBU\&^*-/G@>VN-5,IMX88\HFY
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M]1S7D.LC3!JTXT,SM8[OW1GQOQ[XJA113I*GLPG4<]PHHHK8R"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OJ+X1?
M\DMTGZ2_^C6KY=KZB^$7_)+=)^DO_HUJX<;_  UZG7A?C?H=I1117D'I!111
M0!Y#^T'_ ,@+1_\ KY?_ -!KP>O>/V@_^0%H_P#U\O\ ^@UX/7M83^"CRL3_
M !&%=]X8\8Z7I/PSUW0KLS?;+X.(=L>5Y4 9.>.E<#171."FK,QC)Q=T%>A0
M^--*C^#TGAMC-_:#/N'[OY,;L]<UY[11*"E:_0<9.-['HT/CG2H?A3#H(\YK
M^.X67;L^0@?[5='?_$OP;J5_IFN7EMJ+ZE9*H%JI A!/#-G') )(Z9Q7BU%9
M/#P>O]:EJM)'INI>-/"FH_$.;4[[39+_ $ZZC12[@I);L,Y90#SU%6[KQ[X6
MT3PCJ&E^&#J>H27Y"M_:3 K$,'D<<_3_  KR>BG[".@>VEJ>K:=\0/#>L^&-
M/T_QC_:%O/IQVQO8-@2J.F?PXQ7%^--<T[6]:WZ+9FUL8EVQAW9F?U8Y/'TK
MG:*<:48NZ)E4E)69VGP]\7:=X=GN[37K);K3KU"LC! SID8R*V-=\;^&].\$
MS^'?!-O<^5>.S3RW8P5!QD #K_3%>9T4.C%RYF-5)*-@HHHK8R"BBB@ HHHH
M *ZKX9?\E,T3_KX_]E-<K75?#+_DIFB?]?'_ +*:SJ? _0NG\:/JRBBBOGCV
M@HHHH *X+XD_#JX\=SZ?);ZA%9_9%D4AXRV[<5]#[5WM,DFBBQYLB)GIN8#-
M7"4H2O'<B<8RC:6QX;_PSW?_ /0>MO\ P';_ !H_X9[O_P#H/6W_ (#M_C7M
M_P!LMO\ GXB_[[%'VRV_Y^(O^^Q71]9K_P!(P]C0_IGB'_#/=_\ ]!ZV_P#
M=O\ &C_AGN__ .@];?\ @.W^->W_ &RV_P"?B+_OL4?;+;_GXB_[[%'UFO\
MT@]C0_IGB'_#/=__ -!ZV_\  =O\:/\ AGN__P"@];?^ [?XU[?]LMO^?B+_
M +[%'VRV_P"?B+_OL4?6:_\ 2#V-#^F>(?\ #/=__P!!ZV_\!V_QH_X9[O\
M_H/6W_@.W^->W_;+;_GXB_[[%'VRV_Y^(O\ OL4?6:_](/8T/Z9XA_PSW?\
M_0>MO_ =O\:/^&>[_P#Z#UM_X#M_C7M_VRV_Y^(O^^Q1]LMO^?B+_OL4?6:_
M](/8T/Z9XA_PSW?_ /0>MO\ P';_ !H_X9[O_P#H/6W_ (#M_C7M_P!LMO\
MGXB_[[%'VRV_Y^(O^^Q1]9K_ -(/8T/Z9XA_PSW?_P#0>MO_  ';_&C_ (9[
MO_\ H/6W_@.W^->W_;+;_GXB_P"^Q1]LMO\ GXB_[[%'UFO_ $@]C0_IGB'_
M  SW?_\ 0>MO_ =O\:/^&>[_ /Z#UM_X#M_C7M_VRV_Y^(O^^Q1]LMO^?B+_
M +[%'UFO_2#V-#^F>(?\,]W_ /T'K;_P';_&C_AGN_\ ^@];?^ [?XU[?]LM
MO^?B+_OL4?;+;_GXB_[[%'UFO_2#V-#^F>(?\,]W_P#T'K;_ ,!V_P :/^&>
M[_\ Z#UM_P" [?XU[?\ ;+;_ )^(O^^Q1]LMO^?B+_OL4?6:_P#2#V-#^F>(
M?\,]W_\ T'K;_P !V_QH_P"&>[__ *#UM_X#M_C7N*7,$C;8YHW;T5@34G3K
M2^M5EU&L/2>QX5_PSW?_ /0>MO\ P';_ !H_X9[O_P#H/6W_ (#M_C7MWVVU
M_P"?F'_OX*/MMK_S\P_]_!4_7:G\WY%_5(_RGB/_  SW?_\ 0>MO_ =O\:/^
M&>[_ /Z#UM_X#M_C7MWVVU_Y^8?^_@H^VVO_ #\P_P#?P4?7:G\WY!]4C_*>
M(_\ #/=__P!!ZV_\!V_QH_X9[O\ _H/6W_@.W^->W?;;7_GYA_[^"C[;:_\
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MM_C7N,D\,./.E2//3<P&:9]MM?\ GYA_[^"CZ[47VOR!86#V1XC_ ,,]W_\
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M_P !V_QKV[[;:_\ /S#_ -_!1]MM?^?F'_OX*/KM3^;\@^J1_E/$?^&>[_\
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M_P# =O\ &O;OMMK_ ,_,/_?P4?;;7_GYA_[^"CZ[4_F_(/JD?Y3Q'_AGN_\
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MS7_I![&A_3/$/^&>[_\ Z#UM_P" [?XT?\,]W_\ T'K;_P !V_QKV_[9;?\
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M (9[O_\ H/6W_@.W^-'_  SW?_\ 0>MO_ =O\:]O^V6W_/Q%_P!]BC[9;?\
M/Q%_WV*/K-?^D'L:'],\0_X9[O\ _H/6W_@.W^-'_#/=_P#]!ZV_\!V_QKV_
M[9;?\_$7_?8H^V6W_/Q%_P!]BCZS7_I![&A_3/$/^&>[_P#Z#UM_X#M_C1_P
MSW?_ /0>MO\ P';_ !KW%+F"1@J31LQZ .":DH^M5EU&J%)['A7_  SW?_\
M0>MO_ =O\:/^&>[_ /Z#UM_X#M_C7M[7=LC%7N(E8<$%P"*3[;:_\_,/_?P5
M'UVI_-^1?U2'\IXC_P ,]W__ $'K;_P';_&C_AGN_P#^@];?^ [?XU[=]MM?
M^?F'_OX*/MMK_P _,/\ W\%'UVI_-^0?5(_RGB/_  SW?_\ 0>MO_ =O\:/^
M&>[_ /Z#UM_X#M_C7MWVVU_Y^8?^_@H^VVO_ #\P_P#?P4?7:G\WY!]4C_*>
M(_\ #/=__P!!ZV_\!V_QH_X9[O\ _H/6W_@.W^->W?;;7_GYA_[^"C[;:_\
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MV_Y^(O\ OL4?;+;_ )^(O^^Q5_6:_P#2(]C0_IGB'_#/=_\ ]!ZV_P# =O\
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M[[%'VRV_Y^(O^^Q1]9K_ -(/8T/Z9XA_PSW?_P#0>MO_  ';_&C_ (9[O_\
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M9JS_ "&J5%.Z_,EHHHKE.D**** "N#^(_P#K]/\ ]U_YK7>5P?Q'_P!?I_\
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M* "BBB@ KIO '_(W0_\ 7-__ $&N9KIO '_(W0_]<W_]!KKP?^\T_5''CO\
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MU^@X;^!#T7Y'YMBOX\_5_F%%%%;G.%<1\1_]5I_^])_[+7;UQ'Q'_P!5I_\
MO2?^RUV8+_>(_P!=#RLX_P!QG\OS1PE%%%?2'YZ%%%% !1110 444H!9@%&2
M> * $J:ULY[V;R[:)I&]AT^M:D&B);*LVK.R C*P)R[?X4Z>\N9%%O9QI96^
M?N _,WU-8NK?2!V1P_+K5T\NO_ ^?W&=>Z7=V&#<184]'4[E/XCBJE;\LM[I
MM]+"LD5Q$?O1,VX,*;+IEKJ/S6&;6X[V\IX)_P!DU,:ME[WWE3PR;:I[KH_T
M?4PJ*DGMY;:9HIT*.IP0:CKHO?8XFFG9A1110(**** "BBB@#<\'?\C99_5O
M_037JU>4^#O^1LL_JW_H)KU:O!S+^*O0^VX?_P!VE_B_1'BOB?\ Y&G4?^OA
MOYUE5J^)_P#D:=1_Z^&_G657Y77_ (TO5_F?M>'_ (,/1?D%%%%8FX4444 %
M%%% !4L5M+-N,:$A5+$^PZU+:VZLIGG.V-3\N5R'/]VKENLNI-Y,$<CD%@D"
M<!,]\^GM6L*=]S&=3EVZ%"2U:.X2$O&2V,$."!GWI9K*:$%BNY=Q4,IR"1UZ
M5NMHLBL5>;38GY_=M(<C/:JMY:7&E_-*C6Q*G:Z'<C@C&!Z?6MI8=Q3;1C'$
MJ323U_K^NIB45>GB2YA,\";&4?-$J]!_>S5&N:4>5G5&7,@HHHJ2@HHHH **
M** "O8/!'_(GV7_ _P#T,UX_7L'@C_D3[+_@?_H9KV\E_P!XEZ?JCP,^_P!V
MCZ_HS?HHHKZT^-"BBB@#C?B-_P >%E_UU;^5>?UZ!\1O^/"R_P"NK?RKS^OH
M\#_ 7S/@,Z_WV7R_(****[3QPHHHH **** "B@#)XK8M]$$*+/JKF%#RL2C+
MO_A42G&.YK3I3J/W3-MK6>\F$5M$TCGLHJ:]TF\L%#7$7R'HZG<OYBM"XO9S
M$;>PB2RMR.F?F?ZFGRR7^F7K)%-'*K*"8V;<K5E[2=^GH=2H4E%WN_/I]V[_
M  ,"BMZ33K34N;0?8[D]89#E6^A[5C7-M+:3M#<(4=>H-:1J*6G4YZE"5/7=
M=R*BBBM# **** "BBB@ K6\+?\C18?\ 73^AK)K6\+?\C18?]=/Z&LJW\.7H
MSIPO^\4_5?F>N4445\H?IP4444 %<'\1_P#7Z?\ [K_S6N\K@_B/_K]/_P!U
M_P":UVX'_>(_/\CR,Y_W&?R_-'$T445]&?GX4444 %%%% !5S2/^0Q:_]=5_
MG5.KFD?\ABU_ZZK_ #J)_"S6C_$CZHGUB:1[V9E=@OF,I&> <U3A_=QM,>HX
M7GO5V2&2[UBZM(EW/)*VP8[YJ&ZLKA'\D1,1%P<+W[UG%I)1-ZD92DYVZ_B0
M,?.M@QY:/@\]J?92R++G>P1>2,]:=!:W$<GS0MM/#?+VJ2]LY=-9+>=-KN0Y
MX[=OZU3:^$A1FO?MM_2)O$AW:MD]3$A_\=K)K5\1_P#(5'_7&/\ ]!K*HI?P
MT+%?QY^H4445J<X4444 %%%% '0>!_\ D:K?_<?_ -!->G7'_'K+_N'^5>8^
M!_\ D:K?_<?_ -!->G7'_'K+_N'^5?/YE_%^7^9]SP]_NS_Q?HCP2BBBOR<_
M;PHHHH **** "E')I*4=: -5OW&T+@"",, LA(+GH>.AY%7-6NGTFT32[5MD
MDB![J0=7)[9]!_6LX1+ DJQOY@*+(I((SCD\59\41EM46Z7F*YC5T;L>U=UY
M1IR:WT^[7_@'G\L958Q>VOWZ?\$Q:W=!OO/<:3?,7M;@[5#<^6W9AZ5A5I:!
M;/=:Y;(G #AF/H!U-84)251<O4Z<1&+I/FZ%AT>*Y\N<[F#&"52[ -Z9/3M6
M1*GES.G!VL1P<BM?4'2^O)V5L+<7)<$<D#GG%8\BA9&5&W*"0&QC(IUM]":%
M[:C:***YSI"BBB@ HHHH *]D\'?\BCI__7,_^A&O&Z]D\'?\BCI__7,_^A&O
M<R3^/+T_5'S^??[O'U_1G+?$_P#X_-/_ .N;_P Q7"5W?Q/_ ./S3_\ KF_\
MQ7"5R9G_ +W/Y?DCMRK_ '*'S_-A1117G'IA1110 4444 7+ !%FG(4F-?E^
M?:03P"/6M?38HT,UQ<CS(;%/-*$G$DC=.#]*P[>%98Y6WD/&-RJ%SNYY^E;M
MFOVG3]4MH^9)(TF0 YW!<YKMP^ZT[_K_ , X<3L]>WZ?HV8E_?W&HW33W4A=
MSTST ]!4=O<S6DZS6TC1R*<AE."*BHKD<I.7,WJ=BC%1Y4M#IKQDOK*#4T 3
M[03#<J"0"PZ'CUK'O%+6L<CD%T8QLQ<EFQTX/08K51#;^%;:&3A[FX\U0>RJ
M.OZUC742;#/O.Z21L+CMZY[UV5[M7>[2O_7];G%A[)V6R;M_7];%6BBBN$[P
MHHHH **** "NF\ ?\C=#_P!<W_\ 0:YFNF\ ?\C=#_US?_T&NO!_[S3]4<>.
M_P!UJ>C/6:\.UK_D/7__ %\R?^A&O<:\.UK_ )#U_P#]?,G_ *$:]W//X</4
M^>R#^)/T11HHHKY<^M"BBB@ HHHH *U(XU2W@1MNU@99-KD[@.Q Z=*RZT((
M$14*2%O.B8'(( ;GCWK6EN8U=C4GNWTC2(WB)^VWX+O+GYD3L ??^E<X268D
MG)/4UMZXAGTW3;Q.8_)\EL?PLO;]:PZTQ+?-R]%:QGA4N3FZMN_W_H:FC:J]
MC/Y,W[RTF.V6(\@CUQZU:U"V.G7TD*N66V?Y#N8;HSV]JQ[6![F[BAB!9W8
M 5O:^R/J=VB-N"A+<$'J1C/UZ5I3;=%WZ/3\?^ 9U4E75NJU^]?\$PKR,17<
MBKM SD!6R #SUJ"I;F-8;AHXWWJO\1&.WI45<DOB9V1^%!1114E!1110 444
M4 >S>$?^12T__KE_4ULUC>$?^12T_P#ZY?U-;-?H.&_@0]%^1^;8K^//U?YA
M1116YSA7$?$?_5:?_O2?^RUV]<1\1_\ 5:?_ +TG_LM=F"_WB/\ 70\K./\
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M=PHHHJB HHHH **** .@\#_\C5;_ .X__H)KTZX_X]9?]P_RKS'P/_R-5O\
M[C_^@FO3KC_CUE_W#_*OG\R_B_+_ #/N>'O]V?\ B_1'@E%%%?DY^WA1110
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M=/\ ^N9_]"->YDG\>7I^J/G\^_W>/K^C.6^)_P#Q^:?_ -<W_F*X2N[^)_\
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M3ZK?7FDW-E:Z0S+;>0&6-!E92>N1_%4EW=76F1Z2FE;H$G(>58_E#R%N5/\
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MK^//U?YA1116YSA7$?$?_5:?_O2?^RUV]<1\1_\ 5:?_ +TG_LM=F"_WB/\
M70\K./\ <9_+\T<)1117TA^>A5ZSTF6\LY+D300PQL%9I7V\_E5&N@TR2&+P
ME>M<0>>GVA?D+E?3N*RJR<8Z=SIPU.-2;4]DF_N1DW-C]G"[;FWG+'&(7+$?
MI426TKS1Q["K2,%7<,#)K5TK_2]74Z9%%9-&A8LY,@ '?GO6XDJ76CY^T7%X
M(KV,)-<#KSU4]<5E*LX:-?U^1TT\)&JG).V_SMZZ_@<A=V4]E</#.O,9P2.G
MYU'Y,N,^6^/7::Z][NXO?$&HV5\6-FL;$QM]V/ R"/0TFH:O/9^(+.W\UA:^
M4H:,'AMPQR.]2J\]%;6URY8.DKRYFE>VWGZ[''X.W.#CUJ[9:5+>VTLZRPQ1
M1$!FE?;R>G;VK1URW_LFQ%DO!GF:4@?W02%_D#45C_R*>H?]=8__ &:M'4;A
MS1[F$<.H57"?1-O[KE.XTB>WA28/%-"[;?-B;<JGT-5I+9XYFB7$A7J8\D5N
M:"#'HU\\V1"[1JF?XFWKT_#-:-S?16VIWT,K7-H)98\WD"_=&Q>"?3VJ/;24
MG&U[?\#_ #-EA:<H1G>U_P#@_P"74X\(Y;:%8MZ8YH,;AMI1@WICFNS6%[5-
M3NKN4O<[8V$]H@#A6SR,XYX&:KQ7+ZCY$MCYJ2P([/?7D8.5 /<9)(H^L-ZI
M:?\  !X%*R<M7TMYV[_\#S.4:-T^^C+]1BAHW09=&4>XQ7:2W$;Z!'.6N-2$
M=XN&F7)?CD+[5%(W]KHTHO'>V6X4S6UVF7BRX "GH!SZTEB'U0W@([1E=VOT
M_P _RN<@8W"[BC!?7%-KL;S4H(M2NK29=0N(]I7[+L4HHQP0,\>N:XX_>..*
MWI5'-:JQR8BA&B[1E??\ HHHK4Y3<\'?\C99_5O_ $$UZM7E/@[_ )&RS^K?
M^@FO5J\',OXJ]#[;A_\ W:7^+]$>*^)_^1IU'_KX;^=95:OB?_D:=1_Z^&_G
M657Y77_C2]7^9^UX?^##T7Y&E;:)-<Z<+UKBV@A9S&#-)M)(Q[>]17^ESZ<T
M0E*2+,NZ-XFW*P]C6S#-;P^!X#=6@N0;N3 ,A3'"^E;-A%97T.GW9B, A@D\
MJU^\20#\P!ZGC-=L<+"HE&+ULG]_X'#/%U*;<I+2[7W;>?X'#1VLTLZ1"-@T
MAPNX$4^[L+BROI;25"98F*MM!(_"NHAUI)T"!M2N)EG4I/.H_<G/(R#Q]*FN
M)+QM9UFY?43:VT$WEO)@F11R0J'MT]A4_5:;CH[_ /#/S\BOK=12M*-M//NO
M+S['%,C(<.I4^A&*T[#0)M25?LUW9[RI<QM*0RCW&*U?%KB?3-*G)E=WB/[R
M< .PR>M4_"/_ "&)?^O=_P"E9JA&.(5*6J=OQ-'B)RPSJQT:OY[%0:'/)YIM
MKBVN!#'YCF*0G R!Z=>:SC&ZL%9&#'H".370>%)WMH=6EB.'6T^4^AW#FM6-
M+S4;+1;F.6,WO[S,\Z[R%7GGJ>,U<<-"I!2CH^WSL3+%3I3<9:I==NESC5MI
M6D1-C*78*"PP,FI+NPN+.]DM9%W21G#;.17:1RI=:%<YN[F_$-S%MFN%X!S_
M  9YJ*]$UI>ZE=M?FQMFFVEH5_>N0H( /8?4U;P<5&]_R\_.W3N9K'2<VK?G
MY>5^O8XKRI-^W8V[TQS2>6^_9L;=_=QS7>ZI?QV=Z)I(KH&:S0&[C3][%R>2
M>U5);A[#4$OII)-1BFMF6&Z@BQ*@'&XYQS[U,L'&+MS;>7_!*CCIR5^3?;7K
M]W_!.-,;JP5D8,>@(YI6C=,;T9<],C&:[NTMS/?6M[->?VA"(9/LSM'^^R #
M@D]2">.:SAJEO>6ZPN-0O)$N(RD]RH/E'=TR">OI2E@U%:R]/ZN..-E)Z1]?
MQ[HY8PRCK&XYQ]TT^&TDFE,9*Q$*6_>9%=N^HW,NI>(%>4LEO%OA0G*QL.C
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MELS-M]/FN;*XNH]OEV^-^3SSZ?E5<QN%W%&"^I%=1I<UK/H&I>1:"W4-'O\
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M#?P(>B_(_-L5_'GZO\PHHHK<YPKB/B/_ *K3_P#>D_\ 9:[>N(^(_P#JM/\
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M#S_*2W20@H/4D#//TK2%.K4]^_S]#*=2E37L[?+U_ Q;>\GM4E6WD*+,NR0
M#YAG.*FBU>^A2W6*Y95MB6B  ^4GK]?QJ[=+I%OY4Z02-O&)+-Y"K1-Z[L<B
MI]7ATG3X[7R]/D9KBW$N3<GY221CISTJE3G%-J>WK_D2ZD)-)P;OY+_,H2>(
M-4EB,371\MB"55% R#GL*1-?U)'E87.3*VY]R*P)]<$5GJI=@JC))P!71WOA
MN.VTG32&S>7,_ER<Y5<]!]>:4/;U$Y1D]/,=18>DU&45KY?UV,T>(-4$BO\
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M&WS",CO[UF4I)9B2<D]:2M(QY8J)SU)^TFY]V%%%%49A1110!T'@?_D:K?\
MW'_]!->G7'_'K+_N'^5>8^!_^1JM_P#<?_T$UZ=<?\>LO^X?Y5\_F7\7Y?YG
MW/#W^[/_ !?HCP2BBBOR<_;PHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KV3P=_R*.G_]<S_Z$:\;KV3P=_R*.G_]<S_Z$:]S)/X\O3]4
M?/Y]_N\?7]&<M\3_ /C\T_\ ZYO_ #%<)7=_$_\ X_-/_P"N;_S%<)7)F?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH Z#P/\ \C5;_P"X_P#Z":].N/\
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M "-EG]6_]!->K5Y3X._Y&RS^K?\ H)KU:O!S+^*O0^VX?_W:7^+]$>*^)_\
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MM1<L0%4L &STP>AS2KH=\^FK?K$#;M-Y ;<,[_I_6CVGF+ZO_=&_VO=>J_\
M?-']KW7JO_?-3W/AS4;34H+&>)!/<?ZM1("#SCKVYI]KX8U&ZA$BB&,,Q5!-
M,J&0CKM!//X4>U5KW']6=[<GX%7^U[KU7_OFC^U[KU7_ +YIEQIEU:6J7%Q$
M8T=V0!N&##@@CJ*D?1[N*^M[21466Y"F/+@#!Z9/:G[3S)]@OY1/[7NO5?\
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M.<<#OSZ4MYX;U*P>U2YB56NBHB <'.1D9].M'L':_*'UA7MS?B5_[5N?5?\
MOFC^U;GU7_OFKD/A;4IFF!$$(AD\MGGG6-6;T4DX)^E5+S2+VPCD>[A\L1S>
M2V3SNQG\L=Z'0LKN(+$7=E(3^U;GU7_OFC^U;GU7_OFF/IT\;VJR!%^U()(B
MS@ J21DGMR#5E_#^HQR7B2PB/[&,S,[ *.<<'H<^U+V-_LC]O;[1#_:MSZK_
M -\T?VK<^J_]\U2HJ.2/8OVD^Y=_M6Y]5_[YH_M6Y]5_[YJE11R1[![2?<N_
MVK<^J_\ ?-==\,K^>X\<6\<A7:8I.@_V:X2NR^%?_(^V_P#URD_]!KIPL(JO
M#3JCEQ<Y/#SUZ,]VKYU\0ZG<)XFU-5*X6[E ^7_;-?15?-/B/_D:=4_Z_)?_
M $,UZ^;13A&YXN3R:G.W8B_M6Y]5_P"^:/[5N?5?^^:I45\_R1['TGM)]R[_
M &K<^J_]\T?VK<^J_P#?-4J*.2/8/:3[EW^U;GU7_OFC^U;GU7_OFJ5%')'L
M'M)]R[_:MSZK_P!\T?VK<^J_]\U2HHY(]@]I/N7?[5N?5?\ OFC^U;GU7_OF
MJ5%')'L'M)]R[_:MSZK_ -\T?VK<^J_]\U2HHY(]@]I/N7?[5N?5?^^:/[5N
M?5?^^:I4H!8@*,D]A3]G'L'M)]RY_:MSZK_WS1_:MSZK_P!\U+:>'=7OF M=
M/N'ST/EG%/U'PYJ.E0>;?0^6 <'GH?2K]AI?ET,_K&O+S:^I7_M6Y]5_[YH_
MM6Y]5_[YJE16?)'L:>TGW+O]JW/JO_?-']JW/JO_ 'S5*BCDCV#VD^Y]$^!I
M&F\$:7(_WFAYQ_O&M^N>\!?\B'I7_7'_ -F-=#7V=#^%'T7Y'PN(_C3]7^84
M445L8A7G/Q;NY;6'2_*(^9I<Y&?[M>C5YG\8_P#4:3_O2_R6NG"Z5D>?F23P
MDT_+\T>=?VO=>J_]\T?VO=>J_P#?-4:U-.\/WNIP"6W\E49]B>=,J%V]%R>>
MO:O<=1K5L^,C14G:,;D/]KW7JO\ WS1_:]UZK_WS3H-$O[F"[EB@)6S_ -=G
M@K^%(NBWSP6,RQ?N[Y_+@;(PS;MN/;FCVGF5]7_NB?VO=>J_]\T?VO=>J_\
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MHSJ:***^C/EPHHHH \_^+-U):Z7IYBQEIF!R,_PUY=_:]UZK_P!\UZ7\8?\
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MSS17,DEO$T,BDY4@D_,.>O/Z5P>SP[ZV_I'H^TQ*Z7_IG"7=E<V$YAO(6AD
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M2HIZ6Z]/+3\28PK->]?IU\]?P-&Y\,V%WX.BU?2EFAN&9V,$DF_**2#@X'(
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ML9U.;E]W<%T*=M$EU(.NR.39LQR1_>^E6I_"MS"BN959'MA."![@;?KS3O\
MA*Y_)^S>2@M3$R-$ .<DDG/XTJ^+)UM[F#R5*3PK&,_P%2/F%;+V)@W7(6\.
M@*T0O(S>K'YAM\=L9QGUQ2R^'1']E0W),UP =OE\*#GOGVH/B"/YKA;)1?-%
MY9FW'&,8SCUQ4<GB.ZENK5V9S%;J (MQVDC/./QI?N1_OB@+=8=0\NYW>3'+
MLD=1VSS72:QHV@S:9)<^&WNY3;J&F:11L ^OK570_$5M9S7T>I627-M>9)#+
MDQL>A%:=WXGTFP\&2:)HL;R27+$S3.N!S5TU3Y'=K]?D14E5YU9/]/.YQ->_
M_#;_ ))_IWTD_P#1C5X!7O\ \-O^2?Z=])/_ $8U=.5_QGZ?Y'+FW\!>OZ,Z
MFBBBOH3YD**** /.?C#_ ,@G3?\ KNW_ *#7DU>L_&'_ )!.F_\ 7=O_ $&O
M)J]K"?P4?(9I_O4OE^1TECING)X734KNRNKR5[@Q;(9M@48)S]T^E7)?#&GV
M_B%EF:8:<EJ+F101OCS_  9]>*RX/$D]EX:CT^PFN+:=;@R-+$^T,N#QP<]Z
M?8^)6L=/NSM-QJ%W(/-EN4$JL@Z##9YZU3C4U:,XSHV2?Y?U>YH6_ANRM[C6
M_ML-Q<I8*&A2*3:9 6 !S@]CFH;[3]&L]+LM3:PNUCN&9&MGN0&!'\0;;T_"
MK,GCA&T^<Q136^I3VRPM/!A%!#*01CIP"/QK)U?Q!_;NEVXU'SGU"W&Q9=V5
M=/?WYZTHJHW[Q<Y4%%J&]NWG_ETV.A;PYX?;Q1#I"V]W&&B$K3&Y!P,=,;?U
MK/@\+6O^GF9G=(Y8?L[HW#1R2* >G7:WYTQO%=L?%2:K]GE\I;?RMG&[.,9I
M--\71VWAPZ==P22R++&T<H(X19 Y4Y^G%*U5+[BN;#MN]NOY:%O6_#MGILEP
MD6BWABC^[<M>+MZ==NW-37'AS1H_$,>D)87N9(]WVHS_ "J=I.<;?;UK'U;4
M-!U+49[\?VBDTK!@FV/:#@>^>U:$WCR636Y) UR=-FA\F2V9^@QR0,X!S2M4
MLK#YJ',[VM==GIKY?\$Y&>+R;F6(,&".5W#O@XS4=2W!A-P_V4.(=WR!_O >
M]15UK8\Q[A2@9.!25)#)Y,Z28W;6!P>] CU#P?H\VE:7'*VOI9-< .T!3I]>
M:N7/C PZO+IFIZ>=0L^%%PD?WLCT_P#KU2">%/',*2R2+8:C@;AG;D_R-='=
MOK>C:+FP^PR6UM#PQ8] /IBO*DTY>\M?N_$^GIIJG:F_=75:W]4]CSO7/#=E
M>>,4LM$<1PS1^:V1Q%ZTRR\#FXG@F6Y$]BP=F=%P?D!R,>^*@TKQ,MK?ZIJE
MY\]_/&5BPN5R3S_*M.QUN['A&[O[N;RQ(ZVT(C&T*N06( []:ZG[2*LO0\R*
MP\Y.37=_)&)J^FV\BP#2;*Y28 ^<C#('/!%8YL;I4#-!(%)V@[>]=T_B_3O-
MNKJ&\N$N7B6&'()"J!R?J232?\)GI[26S&0K;A5$D!BR05&0<_4"JC.HE\)$
MZ-"3OSG"36EQ; &>%XP>!N&,UM>!O^1XTO\ Z[?T-4M9UR[UBZD-Q.[P^:SQ
MHQX7/I^%7? W_(\:7_UV_H:UG?V;OV.>DHK$1Y=KK\SW^BBBOGS[@**** "O
M*_C'_P ?6D_[DO\ -:]4KS'XNVEQ<W.EFW@EEVI+GRT+8Y7TKIPO\9'G9DF\
M+*WE^9Y=6[;:SISV=M'JMA+/):#;$\,H3*]0&R#G!],=:S?[+U#_ )\;G_OR
MW^%']EZA_P ^-S_WY;_"O9ERRW/E(<\-E^!K_P#"6S/I^J13Q9GOG#K(AP(O
M4 >F,BI;OQ<MS:QQ"T*;;1X7(;[SLNW=T] /RK#_ ++U#_GQN?\ ORW^%']E
MZA_SXW/_ 'Y;_"HY*9K[:O:W]=SH+?QF-UBUY;.[VT4D4CQ2!6DW;?FSC@_+
M4=OXATJVFE(MM1F2:%H7\Z[5F /H=O%8?]EZA_SXW/\ WY;_  H_LO4/^?&Y
M_P"_+?X4>SIA[:M_2+&J:E;W-M;V>GV[V]I;EF D?>[,V,DD #L.U9E6_P"R
M]0_Y\;G_ +\M_A1_9>H?\^-S_P!^6_PJURI61C+GD[M%2BK?]EZA_P ^-S_W
MY;_"C^R]0_Y\;G_ORW^%/F1/)+L5**M_V7J'_/C<_P#?EO\ "C^R]0_Y\;G_
M +\M_A1S(.278J45;_LO4/\ GQN?^_+?X4?V7J'_ #XW/_?EO\*.9!R2[%2B
MK?\ 9>H?\^-S_P!^6_PH_LO4/^?&Y_[\M_A1S(.278J45;_LO4/^?&Y_[\M_
MA1_9>H?\^-S_ -^6_P *.9!R2[%2BK?]EZA_SXW/_?EO\*/[+U#_ )\;G_OR
MW^%',@Y)=CHOAE_R/=I_USD_] ->VW?_ !Y3_P#7-OY5XU\-[&[@\;VLD]K-
M&@23+/&0!\A[FO9;H9LY@.3Y;?RKR,=K4^1]3DZ:H:]_\CY<J[I.I2:3J,=U
M$BOMX9&Z,#U%-_LK4/\ GPNO^_+?X4?V5J'_ #X77_?EO\*^ 2DG='Z>W"2L
MV:C:[96=JT&C6DT*S2*\S7$H=CM.0%P!@?GT%:$?CE8_$1OUL?\ 1O+VB#?R
M&^]NSC^_DUS?]E:A_P ^%U_WY;_"C^RM0_Y\+K_ORW^%:JK56WY&3I47O^9O
M6?C1[/4+2=;<O'%"8IHV;_6<DY'H>:'\3:?=6,4-U!J*-'OQ]FNPBMN.>1M-
M8/\ 96H?\^%U_P!^6_PH_LK4/^?"Z_[\M_A3]K5M;]!>QHWO^IMP^(M+BCL)
MFL+E[RPC*0L9U\L_.S L-N3][UKG)9&EE:1SEF.2:L?V5J'_ #X77_?EO\*/
M[*U#_GPNO^_+?X5G)SDK-&D8TX.Z?XE2BK?]E:A_SX77_?EO\*/[*U#_ )\+
MK_ORW^%1RR[&G-'N5**M_P!E:A_SX77_ 'Y;_"C^RM0_Y\+K_ORW^%'++L'-
M'N5**M_V5J'_ #X77_?EO\*/[*U#_GPNO^_+?X4<LNP<T>Y4HJW_ &5J'_/A
M=?\ ?EO\*/[*U#_GPNO^_+?X4<LNP<T>Y4HJW_96H?\ /A=?]^6_PH_LK4/^
M?"Z_[\M_A1RR[!S1[E2BK?\ 96H?\^%U_P!^6_PH_LK4/^?"Z_[\M_A1RR[!
MS1[E2OH7X??\B#I7_7(_^A&O!?[*U#_GPNO^_+?X5[YX#C>'P+ID<J,CK&<J
MPP1\Q[5ZF6)JJ[]CQ\VDG1C;O^C.&^-'_'_I/_7*3^:UYC7J?QAM+FYOM+-M
M;RS!8Y,^6A;'(]*\W_LK4/\ GPNO^_+?X5SXZ+>(EI_5CJP$DL-'7^KE^RU>
MQ.EI8ZQ9RW"0.7A>"4(PSU!R#D<"KT'C$Q2Z@6M!Y=Q!Y,"*V!" NT'W^7BL
M+^RM0_Y\+K_ORW^%']E:A_SX77_?EO\ "L%4JK;\CH=.E+?\SH[;QP8+#3K=
MK9V-HCK(WF#][GIV[4RS\:>59:?!=VSRM9RES(LF&9=C*!TZC=UKG_[*U#_G
MPNO^_+?X4?V5J'_/A=?]^6_PJO;5OZ_KR)]C0_K^O,W8_$6F0:@EQ';ZE*I2
M1)$GO%?AEQ\OR\'FL_4]6M)M-CT_2[>:"V60ROY\@=F8^X &!].]4O[*U#_G
MPNO^_+?X4?V5J'_/A=?]^6_PJ7.HU:WX%*G23O?\2I15O^RM0_Y\+K_ORW^%
M']E:A_SX77_?EO\ "LN678VYH]RI15O^RM0_Y\+K_ORW^%']E:A_SX77_?EO
M\*.678.:/<J45;_LK4/^?"Z_[\M_A1_96H?\^%U_WY;_  HY9=@YH]RI15O^
MRM0_Y\+K_ORW^%']E:A_SX77_?EO\*.678.:/<J45;_LK4/^?"Z_[\M_A1_9
M6H?\^%U_WY;_  HY9=@YH]RI15O^RM0_Y\+K_ORW^%']E:A_SX77_?EO\*.6
M78.:/<J5V7PK_P"1]M_^N4G_ *#7,?V5J'_/A=?]^6_PKKOAC87D'CFWDGM9
MXD$4F6>,@?=]371AHOVT-.J.;%2C[">O1GM]?-/B/_D:=4_Z_)?_ $,U]+5\
MY^(=,OW\3:FR65PRM=RD$1,01O/M7JYHFX1L>/E+2G*_8PZ*M_V5J'_/A=?]
M^6_PH_LK4/\ GPNO^_+?X5X7++L?0\T>Y4HJW_96H?\ /A=?]^6_PH_LK4/^
M?"Z_[\M_A1RR[!S1[E2BK?\ 96H?\^%U_P!^6_PH_LK4/^?"Z_[\M_A1RR[!
MS1[E2BK?]E:A_P ^%U_WY;_"C^RM0_Y\+K_ORW^%'++L'-'N5**M_P!E:A_S
MX77_ 'Y;_"C^RM0_Y\+K_ORW^%'++L'-'N5**M_V5J'_ #X77_?EO\*/[*U#
M_GPNO^_+?X4<LNP<T>Y4HJW_ &5J'_/A=?\ ?EO\*/[*U#_GPNO^_+?X4<LN
MP<T>Y7$T@A,(=O+)R4SQFEAE,+[@JMQC#"I_[*U#_GPNO^_+?X4?V5J'_/A=
M?]^6_P *=I=A<T>Y.NL,%0&WB.SH=OMBFS:JTP ,$2_[JU%_96H?\^%U_P!^
M6_PH_LK4/^?"Z_[\M_A57F3:F.&HJ%Q]EASV.#_C5::02R;@BIP.%J?^RM0_
MY\+K_ORW^%']E:A_SX77_?EO\*E\SZ#3@NI[YX"_Y$/2O^N/_LQKH:P/ T;Q
M>!]+25&1UAY5A@CYCVK?KZZC_"CZ(^,K_P 67J_S"BBBM3$*\S^,?^HTG_>E
M_DM>F5YQ\7;6XN8=*^S022[6ESY:%L<+Z5TX7^,C@S%-X6=O+\T>3UL6>JVC
M::MCK%O-/#$Q>%H) C+GJ"2#D52_LO4/^?&Y_P"_+?X4?V7J'_/C<_\ ?EO\
M*]E\KW/D8\\7=(W(O&&Q[TM:#$R*L"JV!%M! /OPQ_.GVWC+R=/L;>6V9VM@
MX=P^-^5*CMV!'Y5@?V7J'_/C<_\ ?EO\*/[+U#_GQN?^_+?X5'LZ9LJU=?\
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M;_LK4/\ GPNO^_+?X4?V5J'_ #X77_?EO\*.678.:/<J45;_ +*U#_GPNO\
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M_"C^R]0_Y\;G_ORW^%)\KW&E-7LMRI15O^R]0_Y\;G_ORW^%']EZA_SXW/\
MWY;_  I\R)Y)=BI70>!O^1XTO_KM_0UE?V7J'_/C<_\ ?EO\*W?!.GWL7C33
M'EM)T19N6:)@!P>^*BHUR/T-L/&7MH:=5^9[O1117SY]R%%%% !117)^-?$E
M]H$UFMAY6)E<MYBYZ8]_>L:]:%"FZD]D;X>A/$5%3ANSK**\K_X6+K?I;?\
M?H_XT?\ "Q=;]+;_ +]'_&O-_MC#>?W'J?V)B_+[SU2BO*_^%BZWZ6W_ 'Z/
M^-'_  L76_2V_P"_1_QH_MC#>?W!_8F+\OO/5**\K_X6+K?I;?\ ?H_XT?\
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M2?S6O0Z\\^)__'QIW^Y)_-:\S-?]TE\OS1ZN3_[[#Y_DS@Z***^*/O HHHH
M**** "BBK-E$LEQF39L0;F#MC<!VIQ5W84GRJY);V:A5>Z#_ #-M$*CYV]"/
M:IR<0E#Y$ =%4C;N8]3GV/%2VMD^J7D0$I1N7+[LB*,>ON*FGUV&P8P:+;QJ
MB\&>5=SN?7T%=D8QC'F;LOS.*4Y2ERQ5W^"*D $:+$IAE <-LD7:2?3)[5$]
MHDJGR@T<JKDQL.7))^[[5>B\2O,?+U:VANH6X;Y-K#Z$47NGI;7,=S;3,\,Z
M[K:4MC:1U4_2AQC*-XZK\5_7J)2G&5IJS?W/^O0PR"K$,,$=0:2K=Z$<1SQA
M5\Q<,H;)R.I/UJI7))6=CMC+F5PHHHJ2@HHHH **** .D\!?\C?;?[C_ /H)
MKU>X_P"/67_</\J\H\!?\C?;?[C_ /H)KU>X_P"/67_</\J^MR?_ '5^K_)'
MQF=_[W'T7YL\$HHHKY(^S"BBB@ HHHH **** )8(&N) J\#(W/CA1ZFKJ111
MJPBB$A"L'DD.%SD<KZ_2EC1(K>.+<H\P%Y723JG]WV-7H8;32-/CN[]#/--E
MK>V8_*H_O-773I_\%]CCJ5?^ NY0DVO="=IHMZ'C;$=IQP.,8IT@C>,F:%77
M+'S(.I/N.PJ8^*M0W?(($3_GF(ABK*&V\0V\BP0K:ZBJYVQG"3#TQV-6E"=U
M!W?IO^?Z&;<X6<U9=T]OP7ZF'<VK6[<,)$[2*#M/MFH*U$6-H_L_&R13L\R3
M_5L.I/%9A&"17+.*6J.RG)M68E%%%9F@4444 %%%% !7LG@[_D4=/_ZYG_T(
MUXW7LG@[_D4=/_ZYG_T(U[F2?QY>GZH^?S[_ '>/K^C///C9_P A#2?^N4G\
MUKR^O4/C9_R$-)_ZY2?S6O+Z_2\+_!B?)QV"BBBNDH**** "BBB@ JSI]A<:
MG?1VEFF^:4X5<XS5:M+P_?C2_$%G>-]V*4,WTJ972=@(HM'U&>1D@LIY649.
MR,GCUXJW::#>Q7<<FIZ9>BT1@9ML+ [>_P"E;VHP0:1XDGCFN+Y89 71K9N&
M0D;<<=,5(R0W\B6%G<ZQ]IN?EC$S_*<]SQTK!U&UY$W*7C)],:.V%MI;:==;
M00JD;7C/0G'?@UR5;_C.\BN_$DBVYW16Z+"I'?;_ /KK K6DK00UL%%%%:#"
MBBB@ HHHH *[3X4?\C_;?]<9/_0:XNNT^%'_ "/]M_UQD_\ 0:QK_P *7H)[
M'O5?,GB3_D:M5_Z_)?\ T,U]-U\R>)/^1JU7_K\E_P#0S7GX#XI$0,RBBBO6
M- HHHH **** "BBB@"[!I%Y<Z;)?00EX8Y%C8KR=Q!(XZ]C3XM"U6:,21:==
M.C=&6%B#^E;OA&07NCZIHX8K-*JSP[3R2F00/?#&GZ;<VAA\I[G6 X9MJ0MP
M%!/M6#J23:)N+X5TW[!?,=5T*>YN)!BWCF3;&?[Q.?PKG-8>QDU69]*CDBM6
M;*))U7VKM=/N((/M>KQ7%\\%E RC[6V<RMT X]J\]HIW<FV"$HHHK<H****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[8-/BB0Y!2+C@CI7/$Y)QQ245HHI.Z ****H84444 %%%% !1110!]&> /\
MD0=)_P"N/_LQKHJYWP!_R(.D_P#7'_V8UT5?-U?XDO5F+W"BBBLQ!7!?$_\
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MK5TU=:#L=!XIUR_TJ;38K"2.&-[%)&40H=S%FR>1[5F>+8('ATO5885ADU&
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M/0@@"F:<D>G^'IM5\M9+CSEBA+#(CR#DX[]*HWCZ4+;98)<O*SY\R;"[1Z
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MY'^V_P"N,G_H-8U_X4O03V/>J^9/$G_(U:K_ -?DO_H9KZ;KYD\2?\C5JO\
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MS[_>8^GZL****]L\ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_L&O::^KR9-8=W[_ *(^/SQIXF-NWZL****]H\$**** "BBB@ HHHH ****
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MT5J?\(YJG]MC21;9NSR%##!'KNZ8]Z+#P[J&I75U;VZ1A[//GF698PF#CJQ
MZU7LYWM8GVD+7N9=%;<GA+5(KB&)_LH\]6,<GVN/RVQC(W[L9Y'&:G?P-K<=
MY':&.V-S*?EB6[C+'@GH&ST%/V-3^5D^WI?S(YVBM*TT'4;V6YCMX 7M6"R@
ML!M).!U]Q5RX\':I:EUG>Q5T.&C^W1;@?3;NSFDJ<VKI#=6FG9M&#1702>"=
M9CW!DMC(L?F&%;N,R8QGA V3QVQ6 05)!&"."#VI2A*'Q*Q4:D)_"[B4445!
M8445*]M/$5$D,B%_NAE(W?2F(BHI_DR[F'EOE!EAM/R_6E6WF=U1(I&9AE5"
MDDBBS"Z(Z*F%I<-,8E@E,@ZH$.1^%,>&6//F1NF#@[E(P?2BS"Z&45KZ-X8U
M77H99=,M_-2(X8[@.?QK-N;::TN'@N8VCE0X96'2J<))*36A*G%R<4]4=)\-
M_P#DH&F_5_\ T6U>_P!> ?#?_DH&F_5__1;5[_7OY7_!?K^B/G,V_CKT_5A1
M117J'D!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5Y/\:?\ CZTC_<E_FM>L5Y/\:?\ CZTC_<E_FM<.
M8?[O+Y?F>AEO^]1^?Y'E]=Q<76E0>"=!.IVMQ<LKRE!!<"/;]WKE3G]*X>BO
MG*=1PO;J?45*:J-7>QZ''KD,MK<ZY?7'V![^X5(A%%YK>6ASM/([J.:GU"WT
MVPT'5Y;F.2XL;NXBGB6&41LP8#GD''S9XKS6BM_K3MJCG^J*^C_K^D=IK_ER
MRZ!+I@)TB+8D+NV7#$C<']^!6G;7)M_&WB6>&4(ZVTS(X/0A3C%><45*Q%I<
MUOZM8IX:\>6_E^-SUC1YK2YTJQOK5D4W.I1-+$6'R. <_AT/XUA:C:ZB-=$T
MOA^UMK=;U";M$8-CS!@Y+$<_2N$HJI8GFBDU_7W$1PO+)M/^OO/3)9M,?7-=
M_LFWF_MDQLL8DG#)("O.T;1S[9->:-G<=W7/-)1656K[3I8WHT?9=;[!1116
M!N:^A^)-1T*^CGM+APBL-T9.0P]*]O3Q7%=6< TY%N+N:,,4W86//]XU\\U(
MMQ,B;4D95] :[</C)T4UNC@Q."A7:ELSZ.L-+W2"[U&9;NZ]1]Q/8"O-?BSX
M@%SJ,6D6[YC@PTN#U;TKE_#WC'5/#]SNAG>2$@AHF;@^]8U[=27U]-=3'+RN
M78GW-=%?&QJ4>2"LWN<V'P,J=?GF[I;'JVN-#=:?+;:(T<>I"WB:?(&9(\'A
M3^=-$-@^GZC;&S2YG%C$P+/R>%SCZ=?PKS>WBM6+-)?,C #!P:D^SV83=_:+
M>9M&0 ?3FI^LW=[?B7]5LK<S^XZWQ%X<T&Q\(_:;4?OMBLDH;.YCU!KSNKZP
MPR+L-[M0'@,#4,]O#$A,5PLAR. #7)6DINZ5CLHQ=-<LI-G3_"[_ )'^T_ZY
MR_\ H!KW.[_X\I_^N;?RKPSX7?\ (_VG_7.7_P! ->YW?_'E/_US;^5>UEO\
M!^K_ $/"S3_>%Z+\V?+E6+&6ZAOHGL&=;@,/+*=<U7K9\*7<%GX@AEN)!",%
M5E(_U;'HWX5X$%>25['T=1V@W:Y=O3XN\Q$O$N5:=#$JA%&X'DCC_=_2L^W;
M6[72I/LXG2S:0QN0OR[B-I'XCBMW2S+X;L+@7\L227%Q&88UE63."<O\I(&
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MZV_CS1C#_836EWI2J!&T41W*ON,_K5.]TKP-9:@^K7^KWD>H$^;)Y<H&7ZG
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M<JJ[0"YP!Z57LY]QV+6O2Z-)/&-"MIX$4$2>=(&W'/!& ,5T_P &O^2E6O\
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M?\*F\-?W;O\ [_\ _P!:C^S:_D']JX?S/#:*]R_X5-X:_NW?_?\ _P#K4?\
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M /\ K4?\*F\-?W;O_O\ _P#UJ/[-K^0?VKA_,\-HKW+_ (5-X:_NW?\ W_\
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M^B?^%)^$O[E[_P"!'_UJ/^%)^$O[E[_X$?\ UJ/K5,.9&U\-?^2;Z+_UP_\
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M?\*F\-?W;O\ [_\ _P!:C_A4WAK^[=_]_P#_ .M1_9M?R#^U</YGAM%>Y?\
M"IO#7]V[_P"__P#]:C_A4WAK^[=_]_\ _P"M1_9M?R#^U</YGAM%>Y?\*F\-
M?W;O_O\ _P#UJ/\ A4WAK^[=_P#?_P#^M1_9M?R#^U</YGAM%>Y?\*F\-?W;
MO_O_ /\ UJ/^%3>&O[MW_P!__P#ZU']FU_(/[5P_F>&T5[E_PJ;PU_=N_P#O
M_P#_ %J/^%3>&O[MW_W_ /\ ZU']FU_(/[5P_F>&T5[E_P *F\-?W;O_ +__
M /UJ/^%3>&O[MW_W_P#_ *U']FU_(/[5P_F>&T5[E_PJ;PU_=N_^_P#_ /6H
M_P"%3>&O[MW_ -__ /ZU']FU_(/[5P_F>;?#?_DH&F_5_P#T6U>_URVD?#S0
M]$U6'4+%;@3PYV[Y<CD$=,>]=37K8*A.A3<9]SQL?B(8BHI0[!1117:< 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %8VO>+-(\-/ NKW#0F<$Q[8V;.,9Z#W%;->1_&S_C[T?\ W)?Y
MK6]"FJE118TKLZS_ (6GX3_Y_P"3_P !W_PH_P"%I^$_^?\ D_\  =_\*\!H
MKT_J-+NR^5'OW_"T_"?_ #_R?^ [_P"%'_"T_"?_ #_R?^ [_P"%> T4?4:7
M=ARH]^_X6GX3_P"?^3_P'?\ PH_X6GX3_P"?^3_P'?\ PKP&BCZC2[L.5'OW
M_"T_"?\ S_R?^ [_ .%'_"T_"?\ S_R?^ [_ .%> T4?4:7=ARH]^_X6GX3_
M .?^3_P'?_"C_A:?A/\ Y_Y/_ =_\*\"I*/J-+NPY4>_?\+3\)_\_P#)_P"
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M * :]VN_^/&?_KFW\J\_$4HTJG+$EJS.5_X6GX3_ .?^3_P'?_"C_A:?A/\
MY_Y/_ =_\*\!HKT/J-+NRN5'OW_"T_"?_/\ R?\ @._^%'_"T_"?_/\ R?\
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M7SG7:?"C_D?[;_KC)_Z#6=3!TX0<E?0'%6/>JY2Z^)7ABSO)K6XO9%EA=HW
M@<X8'![5U=?,GB3_ )&K5?\ K\E_]#-<F%HQK-J1,5<]K_X6GX3_ .?^3_P'
M?_"C_A:?A/\ Y_Y/_ =_\*\!HKO^HTN[*Y4>_?\ "T_"?_/_ "?^ [_X4?\
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M?^ [_P"%'_"T_"?_ #_R?^ [_P"%> T4?4:7=ARH]^_X6GX3_P"?^3_P'?\
MPH_X6GX3_P"?^3_P'?\ PKP&BCZC2[L.5'U+INHVVK:=#?6+E[>==R,5(R/H
M:LUSO@#_ )$'2?\ KC_[,:Z*O(FE&32,PHHHJ "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y'\;/\
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M1110 4444 =E\*_^2@VG_7.7_P! ->[7?_'C/_US;^5>$_"O_DH-I_USE_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MFF:;&;N]2*2 O&LBQ!P&*A6R,YXZ4_4FL;;Q%I:WUI;K/=VXCU&!$ 5-Q(R
M/NMMP>,4L?B;09]6O=3F,]M=[5AL6\@2B) ,;L9'S8_*L6UL+74_$UHMA?W%
M\TTH:>2:#R]HSR?O&B,?YM- ,O6M..DZU=6))/D2%03W%4*U_%.H+JGB:]NH
MCF-Y3L/MVK(KJA=Q5QA1115#"BBB@#LOA7_R4&T_ZYR_^@&O=KO_ (\9_P#K
MFW\J\)^%?_)0;3_KG+_Z :]VN_\ CQG_ .N;?RKQL;_&7H9RW/E>BBBO9- H
MHHH **** .@\+6D1%_JEQ&DJZ=#YJQR#*LYSMR.XR.E;NDQM=:%;_P#"-_V8
M=2GE/VJ.Z$6\GL$5^,=>@K&\*NLVGZSIH#&>[MLPJ/XF3)Q^.:9#+H-SIMO'
M=F?2[ZV^5I8(O,\X>I&1@US33<F26]<U2XTG5U>'24TZZ:$)<K<6R.DC@XWH
MK @ X[5:\<ZK-;7JV-O!9Q036J,X2TC#9.<D,%R.G:L?Q)K4&I1V5I9F66&R
MBV"XG^_*2222.PYQCFE\1Z['?ZY;WVF,Z&&!$#,H!##/;\:(PUBVN_\ P %\
M&Q6SZ^);V>VABABD?-S@J3M('!Z\X.*Z2WTF;Q#>6#O=6-]IANMDQMK1;=EZ
M<' !KF[+Q"MY>X\3@WENT;(&VC=$2.& &,D&M*U\3Z=X>L[6UT4SW86Z%S-)
M*GE[L8PH&3Z=:513;NEJ#N2Q7<'B:UUJT>TMHA;1&XM'BA5#&%8+M) !;AN^
M:A6#1C\/]3?3X9)+F-H-]Q,!D$LN0OH.U1W&L:)I]KJC:(]Q+<ZB/+7S(@@@
MC)W$9R=W('I678ZI;V_A34].DW^?=/&T>!QA6!.3^%"B[:;70%K[-%JO@HW,
M4:I=:9($D*J!OC;."?4C:?SKG*ZBR?\ LKP#?/*</JDJQQ(>"53.YO\ QX5R
M];4^O:XT%%%%:#"BBB@ KZ)^'G_)/]*_ZY-_Z&U?.U?1/P\_Y)_I7_7)O_0V
MKS\?_#7J1+8X;XV?\A#2?^N4G\UKR^O4/C9_R$-)_P"N4G\UKR^M\+_!B..P
M4445TE!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=I\*/^1_MO
M^N,G_H-<77:?"C_D?[;_ *XR?^@UC7_A2]!/8]ZKYD\2?\C5JO\ U^2_^AFO
MINOF3Q)_R-6J_P#7Y+_Z&:\_ ?%(B!F4445ZQH%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 ?1G@#_ )$'2?\ KC_[,:Z*N=\ ?\B#I/\
MUQ_]F-=%7S=7^)+U9B]PHHHK,04444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^^J/:!<VZ*Q/-D_YZ-_WU1YLG_/1O^^J/:!<VZ*Q/-D_YZ-_WU1YLG_/1O\
MOJCV@7-NBL3S9/\ GHW_ 'U1YLG_ #T;_OJCV@7-NBL3S9/^>C?]]4>;)_ST
M;_OJCV@7-NBL3S9/^>C?]]4>;)_ST;_OJCV@7/J?P!_R(.D_]<?_ &8UT5<O
M\-B3\-]&).3Y'4_[QKJ*\"I\;]3)[A11168@HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M%/C_ /\ '[H?_7.;^:5[77BGQ_\ ^/W0_P#KG-_-*Z,-_%0UN>/T45Z=8V$\
M?@;0[C2K#1VDFDD%S)>I!N8#;C!DY/4]*].4N4L\QHKU:UTC1?\ A)M:O[#3
MEU"Q61+:.&*$R(LCL-S+QP -V#TZ57T[0)M,TGQ!%:66GRWUM>HL37R1$*C
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M3/%9M37<_P!IOIY^?WLC/SUY.:AK17MJ 4444QA1110!]1_#7_DF^B_]</\
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M_H;5AB_@7J*1YY\?O^0EHO\ UQE_FM>15Z[\?O\ D):+_P!<9?YK7D5:X?\
MA(:V-,Z[<GPRNAE(_LRSF<-@[MV,=<XQ^%$&OWEIHO\ 9MFWV=&F\UY8F97<
MXQ@G/2LRBM>5 =(_CC4I='DL)HH)#+;BV>X<,9&0%B,G.,Y8]JIR>)+J?2;2
MQN(89OL<@:&=P?,4?W<YQC\*QZ*.6('0)XROT\5/KXBM_M3Q^64VG9C8$Z9S
MT'K4VD>/-6T?2IM/@6"6"642XE4DH?;!Z5S-%+DB^@'2WGC".]NI;J3P]I2W
M4LAD:91+NWDYW??QUJN/%VH+XEEUH+#YL^!-!M)BD4*!M(STP/6L*BCDB!)<
M2B>YDE6)(0[$B./.U?89R<5'115C"BBB@ R<8R<>E=]HGBG1X/#NEVEY>W]K
M-8RL[+;#Y9,G.#Q7 T5$HJ6XCTT?$72C(R_99(X9Y91*$ZJCKMW#W[U>\,ZU
MI=S'_9FF--)#:6\A#.0))&<KPH(QQM_6O)* 2.AQ]*AT8VT"QZ[J>MV6APO;
MW=_=*+Z( *T:&2VVD8&W&,''IWKFM5\96MYI-]9I+<RM))#Y4D@ )5"2>@&.
MO2N'))ZDGZT41I)!8W?&6LV^O>))K^S#")U4 ..>!6_\&O\ DI5K_P!<)?\
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M,6=V.2Q/>F5NMAA1113&%%%% !1110 4444 %%%% !1110!]1_#7_DF^B_\
M7#_V8UU%<O\ #7_DF^B_]</_ &8UU%>)4^-F04445 !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\JI@DC'7Z5Y[_P *;\9?\^,'_@2G^-?2%%5#$3A'E07/F_\ X4WXR_Y\8/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7E_Q?U74--NM*&GWMQ:B1)2
MXAE*;L%<9Q7J%>1_&S_C[T?_ ')?YK75A$G65RH[G!?\)1KW_0:O_P#P)?\
MQH_X2C7O^@U?_P#@2_\ C6517N<D>QH:O_"4:]_T&K__ ,"7_P :/^$HU[_H
M-7__ ($O_C6511R1[ :O_"4:]_T&K_\ \"7_ ,:/^$HU[_H-7_\ X$O_ (UE
M44<D>P&K_P )1KW_ $&K_P#\"7_QH_X2C7O^@U?_ /@2_P#C6511R1[ :O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5 $M%1?:$]_RH^T)[_E0!+147VA/?\J/M">_Y4 2T5%]H3W_ "H^T)[_ )4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M444 %%%% !1110 4444 =E\*_P#DH-I_USE_] ->^5X'\*_^2@VG_7.7_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MYM^#G_)3+'_KE-_Z+-?25>7C&W4U[$2W"BBBN,D**** "BBB@ HHHH ****
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M$.DXKV:W_I!11176<84444 %%%% !1110 4444 %%%% !1110 4444 %<?\
M$^5HO!<FPXWS*I]Q@UV%<O\ $2S:\\%W01=QB(EP/;_]=;4;*K&_<:W/"***
M*^B-CK/#TJZU9QZ7*72YM\M;2@X7'=6/8>]7M9=O#=@=X)OKF(QKLD\R.-3P
M3NP.2,\5'I\?]F:/;00MY<ET@FN',#OO4CY4RH.!_A2VT:W?F:-._F03HS0#
MR'3RY.2,;@,<X%<;^*_0DXDG)R:2G2(8Y&0]5)%-KL*/3O@],QDU.$GY%5&
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MO7'S28X7V%8U\1&DO,3=C9\/Z3'HFAVUC'UC7YCZL>M:5%%>"VY.[,@HHHI
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4^+_6K]:93XO]:OUH N4444 %%%% !7BGQ_\ ^/W0_P#K
MG-_-*]KKQ3X__P#'[H?_ %SF_FE=&&_BH:W/'Z***]8T"BBB@ HHHH ****
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M6-K9KMM8(XA_LKS^=3T45JHJ*LC&4G)W;"BBBF(**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M:\:2*5D574]0PR*=10!BW?@_0+YBUSI<+$_W<K_(BHX/!'ARV</#I40(Z99F
M_F:WJ*T]I.UKL=V1P6T%LFRVACB7T10/Y5)1168@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *?%_K5^M,I\7^M7ZT 7**** "BBB@ JK>Z5I^HE#J%A;793.PSPJ^W/
M7&1Q5JBC8#+_ .$8T#_H!Z;_ . D?^%'_",:!_T ]-_\!(_\*U**KF?<#+_X
M1C0/^@'IO_@)'_A1_P (QH'_ $ ]-_\  2/_  K4HHYGW R_^$8T#_H!Z;_X
M"1_X4?\ ",:!_P! /3?_  $C_P *U**.9]P,O_A&- _Z >F_^ D?^%'_  C&
M@?\ 0#TW_P !(_\ "M2BCF?<#+_X1C0/^@'IO_@)'_A1_P (QH'_ $ ]-_\
M 2/_  K4HHYGW R_^$8T#_H!Z;_X"1_X4?\ ",:!_P! /3?_  $C_P *U**.
M9]P,O_A&- _Z >F_^ D?^%'_  C&@?\ 0#TW_P !(_\ "M2BCF?<#+_X1C0/
M^@'IO_@)'_A1_P (QH'_ $ ]-_\  2/_  K4HHYGW R_^$8T#_H!Z;_X"1_X
M4?\ ",:!_P! /3?_  $C_P *U**.9]P,O_A&- _Z >F_^ D?^%'_  C&@?\
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M5+10 FQ?[H_*C8O]T?E2T4 )L7^Z/RHV+_='Y4M% ";%_NC\J-B_W1^5+10
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JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>sgmo-20201231_g9.jpg
<TEXT>
begin 644 sgmo-20201231_g9.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ?C"7\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTJQS6\<P1B)!DKYA7/<*#WK]YJ_ O_@JI_R?'X^_ZXZ;_P"D%O0!]@?\$Q?
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M;7^JZG+J=U=W+]9)FU*Z+G_OK/%>E_';XZ^$OV=/AQJ'C3QE>FUTRUQ'%#"
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MXL:3!8W7B+Q5X:: N8KOPKKMSI<P+ #+&%@),8X#A@#VK^<CX,_&#Q/^S_\
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M2?\ T&\H ]F\=?\ !/7XERZ+,?!G[57Q4MM75<Q)KNOW,UO(W]UFBD1D!_O
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MU%>>-M8\??&/XF7NFZ ;2"WTRU\8:A;K-)+YC,\CK*&P!$  I&=QST%>1?\
M!77P?IGP_P#CM\.O#&C0?9M)T?X?Z?86D7=8H[N]1<^IP!D]S7T+_P $.?\
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MWXM?LZV?Q.T:."S\;>._!VIVNGBPM-0\/^*]0M]NT-Y<DL?G;)G!;+2.#(^
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MNRTI[F/Q-?,T*SSI$7 \WG:&)_"OVFUO]C^POO!%UHNF_%#XJZ7J[H?*U_\
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MPO[5WP3_ &@?V5_%'A/Q%IGQW^(/B_X?7^L6ME-)=>(+U9[.1Y!A)U$I5D<
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M_A_6;O3(KJ7Q->J\J0S,BLP$N 2%!.*_H?K^;;]L3_DZ_P",/_8VZI_Z524
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M>.]6\?\ Q?\ B9?V&A?9+>UT^U\9:A;J\DPE9G=DE#?*(U  ('S-G/%>7_\
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M:Q;V]YXMOI7M]\LT31[_ #<L-T!()YPV,G&:_;.OQ6_X+5_\G3>%O^Q,M?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUZ#_ ,$6O@C/+;^*?BKJJR/;PLVB:''(Q*(S;'NY54]"=L";AUPX[4 ?2_\
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M[+,ETT'@9=1;7=9U)9R+A='B9'DL$'99)V0Y!R#(>"H(KZ&_X+@_\B#\+/\
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MQ_$54[U']Y%]*_9:X_89\17EO+!/^TI\79H)5*21R:M$592,$$>5R"*_&/\
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ML\4?C[052VUJV&%,_&([M%'\,F#D#[KAATVY /J>BBB@#^7CXB?;3\0/$_\
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M;6/EA96Q8W$I']U?,0D^@/I7V+0!\J_M+?\ )YW[)G_7[XD_]-R5XY_P60^
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M4\77:M['[)9G^1%?6G@7X3Q>"?BI\2/%T$L7E^,)+"X>WC3:8Y;>W,+,>QW
M(?J#F@#T.BO /&_Q_D;]K;X<?"#PWJ4+3-;7VM>*8XU21XK5+9EM8&)!V%Y9
M$D.,-B-/X7Y]_H **** /Q+_ ."SW_)U^B?]BE9_^E5W7T!_P0^_Y$'XI_\
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MAFC:*:/Q%?H\<BE65@(@00>A!KNO^"8\BS?L-?#!D.X>5?K^(U"Y!_45Z_\
M!KX3Q?".V\86MO+$]KKGB6^U^*.%-HA%R5=H\>S!NG&"* /0Z*\ \*?'^3XA
M_MA^(OAYX?U*&Z\,>#_#9DUGR%1P^K37,8CC+X)'E1)("JD?-*P8908]_H ^
M2O\ @JI_R8YX^_Z[:;_Z7V]?D#^PK_R>!\)/^Q@M_P"=?K]_P54_Y,<\??\
M7;3?_2^WK\@?V%?^3P/A)_V,%O\ SH _HSHHHH _$O\ X+/?\G7Z)_V*5G_Z
M57=>Z_\ !#G_ )%7XM_]?NF_^B[BO*_^"V7A6YLOCQX&\1&!ELM1\.?84FQ\
MKRP7,KN/J%N(_P Q7H__  0WU2%M.^,&FEE%PLNEW 7/+*1=*2![$#_OH4 ?
MJ97R!^VQ_P G!?LH_P#8YR_^BXZ^OZ^.OVDM03QQ^W9^S7X)L/\ 2;G03J?B
M?5%CY^S0B$+ [^@:2-EY[LOK0!]BU^*W_!:O_DZ;PM_V)EK_ .EU]7[4U^*W
M_!:O_DZ;PM_V)EK_ .EU]0 O_!._Q9\?? ?P-^*/B+X/:/X*U_2],NH[K4=-
MUZ.\DU*=UA)Q:I"Z(WR9.UF#$C"Y. ?G;]H?]M#XG?M436%KX\UR.+0+6?SH
M])TBU$5M$QR#)L+;I'"D@;W.,D C))_0;_@B$P_X5=\3%R-PUFV)'?\ U!_P
MKY\_X*H?L8_\*9\=M\3?"=CL\$^)+D_;;>!,)IM^V2PP/NQR\LO8-N7@;!0!
M]U?L"_L8_"?X*^%]-^(OA#6IO'FKZ]8!K?Q+=((E2!\%DA@!(B.1AMQ9P0RY
M R*^Q*_&#_@E-^V?_P *H\9)\)_%U]L\(>(+G.E75P_R:=?O@!,GI',<#T#X
M/&YS7[/T ?+\G_*3BW_[(_+_ .GJ.MS]M7]D?1?VMOA5+H\WDV/BO30]QH6K
MNO\ J)B!F-R.3%)@*P[85@"5 K"F=5_X*=6H+ $_""4 9Z_\3I/\#^5?4- '
M\P&K:3XK^"/Q(FL;M+SPSXP\-WXSM;9-:W$3 JRL/<!@PX(((R#7Z;^&_P!L
MC3OVM+G]F"2]>&S\>Z+X]MX=<T],*')MY MU$/\ GG)@\?PL"O3:6]>_X*8?
ML+K^T%X3?Q_X,L1_PL;1+?\ >VT*_-K%JHSY6.\R#)0]6&4YRNW\M_V&8VB_
M;$^$R.I1U\0VX96&"#N/!H _HRKX@_;_ /V!?%7[7_CKP9K6A^,=/T73]*M6
ML;JQU*.1A&K2%WGAV [G(VJ5;:#Y:_,*^WZ* /D#]L+]@U/CU^SOX(\ >#]3
ML]'U7P2L$.D7&J!A#) D A:.1HU9EW!8VW!3RG3G(]@_9*^"^J?L]?L]^$?
M.M:RNNZII,,HGNXBQB#23/+Y<98!BB;]JY .%Z#H/7Z* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X3XT?!'P=^T#X%NO
M"7C?2$U;2)F$B?,4EMY0"%EB<<HXR>1U!((()!_,O7O^"6?QM_9W^(EKXW^
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M(E<%3C/RD$8(/Z/:7<7-UIMI->6OV&[DA1YK7S!)Y+E063<.&P<C(X.*M44
M>>_&S7OB-H?A1O\ A6/A73?$WB*</&AU?4A9VUH=ORR.-I,HS_ "N<?>%?&/
M[&?P4_:7_9H\9>/M9\3^#-#\<2>-;F*]U&^7Q%';W:W"-*Q?)C8.&\Y_E.W!
MQ@CD']$** (;226:UADGA^SS,BL\.X-L8CE<CK@\9KX\_;Z^$_Q7_::^&=S\
M/?#'P^THVJ:I%>0Z]J>N1*0(MP#10A,JS!V4ECPI88.>/LFB@#\2O /_  2_
M_:?^&?C31?%?AZ'0;#6]'NH[RTN%UA/E=#D C'*GH0>""0>#7ZR:+XU^*/\
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M3'[2]KI"6M]^RG=3>(E0(TEKXOL19-(<?,#\VU><XW''3=WKZZHH _+'6O\
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M(8PS!BL1((!$BR*<C.T E3]':I^TQ^TQ<:4]II/[*ES!X@92BRWWBZQ:RCD
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M[<'[*/A\^"H?A/;^,O"UN[-9VE]J5JWV4LQ8B&:.XX0DEBC X).-N3GWO4_
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MW$, =S8^[:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **\X\2?'SPGX5^-WA'X5W]TR>*?$U
MA=7]E&,;%2'!VN2<@N!,5P#GR'SCC/H] !1110 4444 %%%% !1110 4444
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MXI%_A=3D$?B"003N>*]>N?#6C27]KH6I>(I8V ^PZ3Y/GD'JP$TD:D#TW9]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *CGGCM89)II%BAC4N\DC!550,DDGH *DKY@_P""A/Q8'@/X
M'IX6M+^73M:\>7J>'H;FVMY;F6UM).;VY$42M(XCMQ)P@+9=< ]* /ST_:KF
M\=:EKGA_]LO2;B9=,E\7M9Z%:NI @TVU(6QE8=0L[0W1<'C]XO)WU^POPU\?
M:7\4_A_X=\7Z+)YFEZY80W]ODY*K(@;:WHRDE2.Q!%?(WQ:^,7[/7Q _9FU?
MX/V6I:W9:0=%73-+#>"]:(M9(47[+(?]#YV/'&Q]<'UKA/\ @C;\<)=<^&_B
M;X2:Q(\6K>$[EKRQMY@5<6DSGS4VGD>7/N)SC_7J.U 'W%\4OC;X#^">C_VG
MXY\6:7X9M"I:,7TX66;'41Q#+R'V12:X#Q!^V[\&O"7PK\/_ !!UOQA%I>@>
M((WETI)K>4W=XJN4+);JIDQD<DJ ,C)&:Y;_ (*2>%=(UO\ 8[^)5[>Z;:W-
M]9V$4EO=20JTL++<Q,-CD97G/3U/K6?_ ,$X_ASX;L?V3_A]K_\ 9-O<ZWJ>
MELEUJ%TOG3M%YTJB$,V2L0&<1KA<LQQEF) /5OA;^U9\*OC%X!U;QGX9\8V,
MWA[1\_VG<WNZT-C@$YF64*4! )#$8.#@G!KE/AS^WY\!_BQX]@\'>&O'MO>:
M[<R>3:13V5S;1W3X)V1R2QJK-Q@#.6/W<U\=_LE_!_PG<?\ !1CX_>%)](AE
M\*Z:SZE;Z"<BP\];F,Q%X/N.(C-(45@50D$ %5(V_P#@L#H>F>#X?@QXOT?3
M[;3?$5CKC10W]I$L4HC01R1J649(5D!7/W<G&,F@#](M6U:RT'2[O4M2NX-/
MT^TB:>XNKJ01Q0QJ,L[,3A0 "237@FK?MZ?!W1+*+5+O5M<C\-2S""/Q-_PC
M6H_V2[D@#;=^1Y;#) W*2.1SCFOGS_@I_P#$>?5OB/\  [X)M<R6WASQ=KMK
M/X@5'V?:+;[7#%'&3_=R96(Z91#VK[NUWP7H?B3P?>>%=1TRVN/#UW9MI\NG
M>6!"8"FSRPHX "\#'3 Q0 FG^.O#FJ^$8/%-IKNFW'AJ: 74>L)=(;5HC_'Y
MN=NWWS7FGA']L7X/>.M:\4Z?H7CC3=1A\,60O]6U1'*V%M$6VY^T-B-^>Z$C
MGKGBOBS_ ()AZU>>!_CE\;OV<=5E_MSPUH-W=WEA'?H'53;7BVTC!3QB3?"^
M.@*Y'4U2_8X^#_A'Q1^W[^T;IVJ:+;W>C:-JDUU::.X_T(2_;'V,\'W'V9)1
M6!5200,JI !]D?"G]O#X'?&KQT/!_A/QO#>^()&=;:UN+.XMA=;02WE/(BJY
MP"< Y(&0*]SUC6+#P_I=UJ6J7MOING6L;37%W=RK%%"@&2SNQ 4 =R:_-K_@
MJ!X;TKX?_'K]FCQ?X>TZUTC6SK;0R7%G"L1E6"XLWB#;1SM,DF/9R*[_ /X+
M*:EXBL?V6=,ATAIX]'NO$%O%K#0$X,(BE:-),?\ +,RB,\_Q*GK0![WJ'[;'
MPJTO0;;Q%=ZAKEOX0N91#%XID\-:BNE,Q8HI%R8-A0L,"3.P]FQS7=>#_C]\
M,?B%K$6D^%OB-X3\2:M*C2)I^DZW;7-PRJ,L1&CEL =>.*Y;Q59>%/%O['^I
MP1I:/X,N_!+F';M,*6GV+*,N, !5"D$8QM!&,5\T?\$=?!<'_#-;^(]4\.:?
M'J8UZ]ATK66L8UNWL_+A# 3;=Q3SO/7[QZ$=J /OVO+/VJ(]>F_9K^*">&#*
M-=;PY?BU\C=YN[R'R(]O._;G;CG=BO4Z;)(D*%W941>2S' % 'Y__P#!)_\
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M7!X(F8'(XH _1^BN7^%GC0?$CX8^$/%JQ+ NO:/9ZJ(ESA//@27:,^F^NHH
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M[Q/IM\]OXAN?#>GZ+;7C'+IO=+9F!Z[Q"'(;J" >U 'TCX]_;,^%/P[DU/\
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MO#&D>(=%NEO='U:TBOK.Y4$"6&5 Z-@\C*L#@\\T ?F5_P $E>/VD?VA /\
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M6_X55HWQH\-&32/''@;4+=O[7LF\N?[))($ W#DE)FB9>?E#2?WC7WO7S/\
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M_M,:Q+X+2Q?X;_$NUD338=3E9;73;I6PC2D L5MGFS_M0RD9W D 'Z,_#_\
M:B^&GQ2\97GA3POK]QJOB&R=X[RQ72;V)K-EW;EG9X56$Y1AARN6&T<\5ZM7
MFG[/OP9T;X*?#^'3=-N_[:U+496U36/$,F#-K%],=\UU(PZ[F)P,D!< =,UZ
M70 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\0/B'X"\)S>!?A_KUE8:?IFG26TEF-2>$S/+J MG :*-A+''&"%+!';: P)
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M: /S4M_B3H?PQ_X+.>/;WQ%J,.D:9J&EVNFF^N6"0122:;8F/S'/"!G14#'
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M.X+DD'.?U#KC_$WP;\ ^-=8CU;Q#X'\-Z]JL>"E]J>D6]S.N!@8=T+# XZT
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M^=?45/\ MI?!VX_:B_8/\#ZI\/YHO$FJ>&[6QU6&VTTB>2ZB^RB.:*,+D^8
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MX/V2Y-+?5+1=2OM9LFMK3SE\V95+.S*N<D!1G/3IZBOK[_A4_@?_ *$WP_\
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M!?AI^T!\(VOK^Y\"WLET7CTZ:.8P%XI$NECD16:.-X>?E(*R%ONJQKH_AO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKAC@UUFC?M&_&C4O#L>M2?LT:N+2:)9X8[7Q;IDLSQLF\/L+J1P1\OWL\;:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %>'^,?VKM#TGXHW?PV\(^&]=^)/
MCJQ@6YU#3/#JVZQ:=&<8^T7%Q+%%&Q##"[BW(R!FO<*^1[.Q^%W[-G[17CZ^
M\'V_B/Q_\8O'K)?7GA/2Y([@V<>XL7=V"1VD3.X8M/)G!78,<$ [_P"#O[8G
MA7XK?%#7/AG?:-K?@;XCZ,ADN?#OB&&)9)(P V^&2*1XY!M=&X;D-E=R@FL7
MXZ?M\?#;X%^,M+\(7T>L:SXGU"\CLH[.QL'2%&:01EFGE"QD*3SY9<CN!FOE
M?3KCQ+>?\%B/!=YXJT73?#VKW>@32-8:7?/>*D?]GW2IYDK1Q[I,*,[5VC
M+8R=W_@KWIMMJ7B+]GB&YA65)O$-Q _8E&>T#+D<@&@#VOXQ_P#!2;X<_"+6
M+F!/#WBWQ?HUC/\ 9M1\1>'],$NF6LH;:8_M#NB.X;@[21GC.>*^COAM\1=!
M^+7@31?&'AB]&HZ#K%N+FUN I4E22"K \JRL"I4\@J1VKA?VE/"^D6O[)WQ/
MT.VTVUM=(MO!^I1V]E;Q+'#"L=I(8PB@84*54C XP*^/?V,_BQJ7PF_X)4>)
M_%ME,!J&@C5O[-:1=RQ3-)^Z.#U EEW8[\T ?5VN?M7:7-\0M7\$> ?"6O\
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MU0_VE9/>6;WB&-+1Y(4EB,FQR^ )%YDSS@"O:OBS\#_BQ\9OAMXB\$:]\1/
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MU_PQH7@_Q=;3^'[V;3=7U#4+.WCLK*ZBW!H6E6=@[[EVXC#_ 'E)PIW5[=7
M_ CP1X1^'_PE\-Z3X'D2[\-FT2YM]063S'O_ #1YC74DG\;REBY;N6[#BN^H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT3X??$^S\0_#OQIHJ&+6!J^E3RFZNG8O-<L45I=\CL7;>@.6/WNI -+X"_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.\/>'=*\(Z)9:-HFFVND:391B&VL;&%8884'1410 H^E:- !1110!YA\=/\
MFGW_ &-^G_\ M2O3Z\P^.G_-/O\ L;]/_P#:E>GT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% 'F'QT_YI]_V-^G_P#M2O3Z\P^.G_-/O^QOT_\ ]J5Z?0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 >8?'3_FGW_8WZ?\ ^U*]/KS#XZ?\T^_[&_3_ /VI7I]
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!YA\=/^:??]C?I__M2O3Z\P^.G_ #3[_L;]
M/_\ :E>GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'F'QT_P":??\ 8WZ?_P"U*]/K
MS#XZ?\T^_P"QOT__ -J5Z?0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM;C/!  /TCHJ"QOK?5+&WO+.>.YM+B-9H9HF#)(C %64CJ"""#[U/0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% 'F'QT_YI]_V-^G_ /M2O3Z\P^.G
M_-/O^QOT_P#]J5Z?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** /,/CI_S3[_L;]/_ /:E>GUY
MA\=/^:??]C?I_P#[4KT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F'QT_YI]_V-^G_^U*]/
MKS#XZ?\ -/O^QOT__P!J5Z?0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*_%#XG>'/@WX#U?QCXM
MU%=+T#2XO-N+AE+'DA555'+,S%5 '4D5X+^U]_P4$\ ?LHVKZ6^/%?CN10T7
MARQG"&$$9#W,N&$*XY P7;(PN,L-+X?:UX3_ ."C'[)\%UXM\*7ND:'X@+QS
M6#7!#Q302X$T$P"[@'3(;: <%64C((!^;7[0W[:OQ;_;Z\;+\,OA7HNI:=X5
MO'*1Z)8'_2M00'F6]E!VI$,@E,B-?XBV 1^I?[&OP6\1_L_?L\^&/!/BK7?[
M>UNQ61YI$<O%;AW+BWB9@"40' )[YQ@8 U_V?OV8_AY^S)X9DT;P)HBV)G(:
M\U*X;S;R\8=#+*1D@9.%&%&3@#)KU6@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>L:M
M:Z#I-[J=]*(+*R@>YGE(R$C12S-^ !-7*H:_H=IXFT+4M'U"/SK#4+:2TN(\
MXW1R*489]P30!^:VO?M9?$?]J;]GOXZ?$?PMXPF^&GA/PBOV;3-'T2-!JMUT
M837%V<M"&## @VGAEW_*2WT,GC#XY? W]HCP%X0\3Z[8?$KX:>,[J:PM_$%U
MIT=EJ>G7*6\LPAD\@+$^Y8B0VP;L-]W;S^6'[2W[,?Q;_8>UKQ)IUM>:A-\/
M?$4;:?\ VY8@FSU&W8Y2&Y7E4E']UNX)0D<U^H/[&_[?7@7]L'['H6LZ7;>'
M_B-I^;R/2;H"6*9D5@T]G(PSN"LV5.'56;!906H YS]J?QE^TI\:/%VM^#OV
M>K5-"\,^'I?L>K>*I+N&WEO;X(KO;6[O\P6/<JLR ?.&4L-I!^2OV5?V[OC5
M\%?VCK3X:_&'4-4\0V%[JL>BZA8ZW();O3;B218UFCEY+*"RDKN*LI)7D@U^
MR_3I7Y/^&?A+_P ->?\ !5+QAXXTR#S/ 7@O5[2:^U)1^[GN;*"*&*)6'#EY
M[<MZ>6A]L@'Z9?%[XC6/PA^%WBKQIJ6&M-#TZ:^:,G'FLB$I&/=VVJ/=A7Y-
M-H__  45U)C=HWBZ)+C]ZL:WUE&%#<X"E\KUZ'I7VY_P4N\!?%?XK_ FS\'?
M"SPY<:Y-?ZE'<:M);WUO;F*W@_>(H$LB%BTOEL-F<>4<]17YJWO[17[8G[(V
MN6)\7:OXNLX-VU(/%R-J%E= 'E!+)N#=/^6;A@.A% 'Z;_L46?Q:^'/P/\4>
M*/VAO$&IR:RL\UXUOJDT<W]GV$$62W[O(RQ\QC@G@)7B_P"RE\6_''_!0KQI
M\4-=U#QOXB^'GA303;VV@:/X5NEM6B:;SB);B3:6F=5B0E6.PES@ "MCQM^V
M)9?M-?\ !-?XI>,=+MFTC7[;36TC6=-C)86\LK1QOL8_>C>.4D'L"P/*FN%_
MX(?*/^$!^*AQS_:=D,_]LI* /3O^";O[:?B+X]7'B;X;?$*6&]\<^%T::/58
M45/[1MEE\IV=% 4.CE 6& PD'&02WW/7X:_\$X]9N=+_ ."C5I;0-(L6HSZU
M:W 3HR"&>4!O;?$A^H%?N50 445QWC+XG6?@O5(K&XT;7-1>2$3"73;$SQ@%
MF&TL#PWR]/0CUH P?CI_S3[_ +&_3_\ VI7I]?/_ ,0OB=9^--4\!6-OHVN:
M<\?BFPF,NI6)@C(#,-H8GEOFZ>@/I7T!0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9>0?U3T71=/\-Z3::7I-C;:9IEG$L-M9V<2Q0PQJ,!410 H [ 5=HH ****
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MX7W >;2?&?@;7+5ED=9%FMIHB.?F!^5E/.>&1AV(XSOCE^SUX"_:.\*IX?\
M'V@QZS90R&:VD$C13VLA&-\<B$,IQU'0X&0:\I^&O_!.?X-?"Z2X73++7KS3
MK@[KC2+_ %RY>PN&QC,UNK+',,<;9 RX[4 ?,7[%'[*.JWW[)W[16FV3M+I/
MCA[NP\+27!XNX;99TM[KL-DDCKANXCSTQD_X(D3/I^A?&+1;N-K74++4+!I[
M:92DD9*W"$,IZ$&,@CL0<U^FMK:PV-K#;6T,=O;0HL<4,2A410,!5 X  & !
M7BGC/]CGX=>,/&VJ^+((]:\*Z[K4)M]9N/"NL7&F#58SU6Y6)@KD\Y; 8Y.2
M>* /SF_X)0_"NY\;?M:>-_B,D>_0/#JWB0W8SMDNKJ1DC5?7]SYS'TRG]X5^
MQ-<G\+_A3X2^"_@^S\+>"M"M?#^A6N3':VP)+,>KN[$M(YP,LQ+' R:ZR@ H
MHHH \P^.G_-/O^QOT_\ ]J5Z?7F'QT_YI]_V-^G_ /M2O3Z "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO0*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH \P^.G_-/O\ L;]/_P#:E>GUYA\=/^:??]C?I_\ [4KT
M^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'^ 7A)/#?@/P_;:!I8;S)%B+/+/)_?ED8EY&]V)P.!@ "NZH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /,/CI_S3[_ +&_3_\ VI7I]>8?'3_FGW_8WZ?_ .U*]/H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKSWX\?'/PO^SG\,]4\<
M>+IY8M+LMJ+#;J'GN9F.$BB4D99CZD  $D@ F@#NM0U"UTFSFO+ZYAL[2%=T
MEQ<2".-!ZLQ. /K7B7[95O\ %'7_ -G778?@K-O\778B\J:UN$BG-J3F4VTC
M$*)"O0Y!P3M.[;7Y2_$?XU?'7_@J#\3E\(>%-+ELO"L$HECT.VE*V-E'GBXO
MI\8=AV)'48C3).?UZ_9=^"4G[.OP)\*_#^;6)=>N-)@<37TF0K222-(RQ@GY
M8U+E5'H!WH ^#/V-_P#@DO+#?0^-/CU&MU>>;Y\'A%9UF5FSG?>2J2'R>?+4
MD'C<QR4K]0;&QMM,LX+.SMXK2TMXUBAMX$"1QHHPJJHX     Z5/10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% 'F'QT_YI]_V-^G_ /M2O3Z\P^.G_-/O^QOT_P#]
MJ5Z?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@#S#XZ?\T^_[&_3_P#VI7I]>8?'3_FG
MW_8WZ?\ ^U*]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** /,/CI_S3[_ +&_3_\ VI7I]>8?
M'3_FGW_8WZ?_ .U*]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#S#XZ?\T^_[&_3_ /VI7I]>8?'3
M_FGW_8WZ?_[4KT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ JAKVO:;X7T>\U;6-0M=*TNSC,US
M>WDRQ0PH.K.[$!0/4UYQ\:OVIOA7^SQ)80_$#QC9Z#=7Q'V>SV27%PRYQO,4
M2LZIG/SD!>",YKRC]NO]FOQ#^VA\&?#6F^ O&%AIEN+N+5 MY)(+'4H'C^1F
M>-6/RAMZ_*0<]N" #Y<_:B_X*\:C<>)(_"GP"L%O2MPL3>(KZS,S7C[L".UM
MR,[6.!N<;FR0%'#'[_TWP7;?'SX'^%[7XP^"M,NM2OM/M;W5-#O+<216EZ8P
M7"!B2A5F8##;@"1D\Y\I_9!_X)\^ /V5;.#5?+7Q5X]9,3>(;V(#R,C!2UCY
M$2]1NR7.3EL?*/J>@#/T'P_IGA71;/2-%TZUTG2K.,0VUC90K##"@Z*B* %'
ML!6A110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >8?'3_FGW_8WZ?_ .U*]/KS#XZ?\T^_[&_3_P#VI7I] !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ\-W(U3^P=2?9>:=/Y;P^<FTXECVS.N\9&' 8*2!0!YS^US^U=\8M-\7ZEX
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MI" LI/S*.[+^=>]4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %175U#8VLUS<S1V]M"C22S2L%1% R68G@  9)-9-UXV
M\.V7B:U\.7&OZ7!XAND,MOI,MY&MW,@!)9(BV]AA6Y ['TKX"_X*4?";]I7X
M[?$/0?!?@*PFN/A?>6T?F_8KM((7N=Q,AO26#;5&PJI!4XX!?@ '8_$K_@KA
M\*_!WQ6TOPAX=TV_\<Z?)=K:ZCKVE2*(("QV_P"CJ03<D'K@JI'W6:O3/VM/
MV"?!?[7GB3PUK?B+6M9T:]T>(VK'3'CVW%N7+E"'5@K;B<./4Y!XQPW['O\
MP3%\#_LYS6'B?Q1)%XW^($!66.[ECQ9:?(.0;>(]7!Z2O\W *A#FOM2@#B/A
M#\%?!?P'\'P>&? V@6N@Z5'\SK"N99WQ@R2R'+2.?[S$GMT %=O110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+F)E^L[N@]XS78_\$/+I&\&_%BU_Y:QZAI\C#/.&CF X_P" &OTB\(>$=&\
M^&-,\.^'=-@TC1--@6WM+*V7;'%&.@'\R3R223DFO!;[]BNQ\/\ Q&\4^,/A
MCXXUGX577BR(1Z_8Z+:VLUM=,"Q$T:31MY$OSR'<G=B0 2<@'YY_\$M?AS=^
M,/VX/%/BV*-FTGPNFH3R72\Q^=<.\$4>?5D>9A[1FOV>KR[]GG]F[P1^S%X'
M'ACP58R10R/YUYJ%XXDN[Z7&/,F<  G'0* H[ 9->HT %0365O<,&E@BE8#&
MYT!./QJ>B@#RKXW65O;M\/FB@BB8^+M/&Y$ ./WGI7JM>8?'3_FGW_8WZ?\
M^U*]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[H4W*N0WSD KM4$-7ZUT44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%?%?BK]HS]HGQI^TW\
M3?AI\(M!^'<FF^"DL&FN/%GVP3R_:+=9,AH90I^8L,;1@ <FM3^V?VZO^@#\
M#_\ OYJ?_P =H ^P**^/_P"V?VZO^@#\#_\ OYJ?_P =KD/'7[2'[57P+\1?
M#V7XD^'OA7)X;\3>*+'P])_PC_V]KI3.QR5,DVU<(KX)#<XX- 'W?1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \P^.G_-/O^QOT_P#]J5Z?7F'QT_YI]_V-^G_^
MU*]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&8*I). .230!
M\;?LV_\ *0S]JO\ ZXZ!_P"D8K[)SCD\"OR4\7?MW^&_V8?VQOVC_$6EZ>OC
MFY\0'2;32_L%X@L_,@M LS23+NX5SMVJ"25897&:\DN/'?[7'_!1J^N;72$U
M"/P?)(8Y;?3,Z9HD*YY225CF?'4JS2-Z#I0!^I?Q<_;L^!OP5\^'Q!\0--N=
M2BR#I>C,;^YW?W66'<(S_P!="M?FQ^VA_P %-M#^/A\%67@WP=?6=MX5\36O
MB2"_UN=%:Y> .%B:"/=M4E\EO,SQC'.1['\(?^")FCVD=O=_$WQ[=:C/@-+I
M?AF$01*?3[1*&9Q](T/O6Q^V!^R5\)_V>]!^!B>!_!MGIEQ>?$O2+2[OIV>Y
MN;B(B4LCR2EFV$@$H,+P..!0!\[_ /#>/[9'[14YC\!:7>VMI(=K+X.\-F6)
M?]Z>592GUWBIC^SW^WY\4^=3U'QI;6DGWEO_ !9'9Q<^L*W /<_P5^U$<:0Q
MK'&JHB@*JJ,  = !3J /Q63_ ()1_M.:JPFO/$NAQRS',GVKQ!<NPSU+%8FS
M^!-'_#E7XX#D>*OA^#_V$;[_ .0Z_:FB@#\6#_P2V_:GT!6DT[Q-ICNYVLMC
MXDN(V(YY.Y%R/QSSTIK? W_@H!\*/FL-1\;7EI']P67BB/48O^ PF=B/O?W!
MZ]LC]J:* /Q0?]O#]L_X"R*_CG2M0FM(SN"^+O"I@A89_P">L20LPSWW^V:]
M5^'_ /P6^G62*'QQ\,(WC./,O/#^HE2OKB"53G_OZ*_5EE#J58!E(P0>AKR+
MXB?LB_!?XK)-_P )/\-/#M]/,,/>0V2VMT?^V\.R3_QZ@#S?X6?\%,OV??BF
M884\:+X5OY,?Z'XHA-CM^LQ)A_\ (E?3>DZO8Z]I\%_IE[;ZC8SKNBNK2598
MI%]59201]*_//XI_\$6/ASX@6:X\">+M:\(739*6NH(NHVH/91]R0#W+MCT/
M2OE_5OV+?VN?V.=0N-6^'E_J6J:;&WF/<>"KUYEE Y'FV3 -(>.1Y;CCJ>,@
M'[;T5^07PC_X+(?$#P+J0T3XP>#8=?%NPBN+RPB_L_48B.IDA8>6[?[($7UK
M] _@7^W)\&?VA!;V_ACQA:VVM38 T/6,6=]N/\*HYQ*?^N3./>@#WJBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BO-OC;^T9\
M//V=_#_]K>//$UIHJ.I-O9EO,N[HCM%"N7?GC(&!W(KX>\$?\%=-4^+'[1WA
M3P7X.^&C7/A/6-2BT]I+F5FU,H[8:X"IF-%1<NRG=\J-EQU !]C?M)?M9?#O
M]E?P]!J/C?5)$O+Q7-AH]C'YMY>E<;MBY 4#(RSE5YQG/%?F1XM_X*.?M&?M
M3_$JR\/_  5T:Y\-P1S"6WTS1X%N[J55(P]U.Z[5C]1A$&<,6ZU^A/[47[!?
MP[_:R\7>'?$7BV[UFPU#2(/LA.DW"1BZM][.(GWHV,,S?,N#AC[8]=^$_P %
M_!'P-\,IH'@7PW8^'-,7!=+5/WDS 8#RR'+R-_M.2: (/$/PKT;XO_#C2M!^
M*7A[1_$LOD6\U]:R0^9;K>*@WO"3\RC<7 (P=IP>I%1>*/@#X!\6?"*\^&%U
MX;M+3P-=0I"^D:8#9QJJR+(NWRBI4AT5LCJ1SG)KT&B@#X__ .'3_P"S;_T*
M&H?^#N[_ /CE'_#I_P#9M_Z%#4/_  =W?_QROL"B@#X__P"'3_[-O_0H:A_X
M.[O_ ..5](_"7X3^&?@?X TOP7X/L7TWP]IOF?9K:2>2=E,DC2.2[L6.7=CU
MXSQ@5U]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F'QT_YI]_V-^G_
M /M2O3Z\P^.G_-/O^QOT_P#]J5Z?0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \P^.G_-/O\ L;]/_P#:E>GUYA\=/^:??]C?I_\
M[4KT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKX6_P""AW_!0ZS_ &=M,NO
MG@2ZAO\ XF7<6)KA<21:)&PX=QT:8@Y2,],AFXVJX!<_;Z_X*+Z5^S3:W/@S
MP8UOK7Q,GB^?=B2WT=6&0\P_BE(.5B^C-Q@/\A?L8?\ !/\ \5_M8^*#\7/C
M1=ZC_P (MJ$_VT+>2,+[7V)^]NZQP< ;A@L  F!AATW_  3U_P"">=[\6=4@
M^,OQGMI[[2+J8W^FZ/JA+RZO(QW?:KK=R8B3N"MS(3D_)]_]<HXTAC6.-51%
M 5548  Z "@"EH.@Z;X6T6RTC1["WTO2K&)8+:SM(Q'%#&HPJJHX  J_110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /,
M/CI_S3[_ +&_3_\ VI7I]>8?'3_FGW_8WZ?_ .U*]/H **** "BBB@ HHHH
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M2TJ[BOK5I=8NG59HW#H2IDPP#*#@\''-?5=%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >8?'3_FGW_8WZ?_ .U*]/KS#XZ?\T^_[&_3_P#VI7I]
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML40' !K]FO@O\'?#/P%^&^C^"O"5D+/2-.CV[FP9;B0\O-*W\3N>2?P&
M=-X>\/Z;X3T'3]%T:Q@TS2=/@2VM;.V0)'#$@"JB@=  !6C110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBW7?AJ]E!=L#+/;OP)H^O0!E_B4#!/TS0 4444 %%%% !1110 4444 %%%%
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M/A/]EWX3>!_'E_XTT/P!H>G^*+V8SRZDEJ&D20DEFCW9$1))R8PN<\UZC10
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MFHSXDO+Z0#[\TN 6/)PHPJY.T#->HT44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2,P522< <
MDFEK$\;>'Y/%G@O7]$AN393:EI]Q9)<KUB:2-D#CZ%L_A0!\E?$[_@H%?ZAX
M%^)GB'X+^$;;Q=HO@9#'?^+=:NS!IGV@'E+>)/WMU@8Y#1K\P.[!4MWGA?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ)17B?[/7[8WPO\ VH-0UVQ\!:S<7UYHX5[B"[LY+9FB8E5E0.!N4D8]1D9
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M_P##[QMKD?C2_M;:6"[EF#2P&.1F/V9?,&7B16V#<!E1]U1A1[(JA5  P!P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV@\;FD!^Y0!^C=%>5_LP?'.P_:-^!_A?QW9>7'/?VX2_M4/_ ![7B?)/%CJ
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M'(*G!!!! (Q6]7POI?AN/]AO]L;PWHWAW=9?!SXO2RVRZ,I_<:1K: ;#"O\
M DN44*#_ !$8Q$@'W10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F
M'QT_YI]_V-^G_P#M2O3Z\P^.G_-/O^QOT_\ ]J5Z?0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %#7]>T_PMH>
MH:SJ]Y%I^E:?;R75U=SMMCAB12SNQ[  $_A7X?>+-7\5?\%3/VTH-.TMKFQ\
M(6[&*V++E=+TB-QYEPR]/-D)!P>KR(F=J@CZ"_X*[_M;2220_ ?PC=/+<3&*
MX\226I)8Y(:"R&.23\LC#WC'=A7U'_P3N_9)C_9=^"\+ZO:JOCSQ$$O=:D(!
M:W&/W5H#Z1ACGU=GY(VX /HWP+X'T7X:^#=&\+>';&/3M$TFU2TM+:/HB*,#
M)[L>I8\DDD\FMZN*^(OQL\ ?".U-QXT\9:)X97;N6/4KZ.*60?[$9.YS[*":
M^>])_P""I7P$\0?$[1?!>DZUJNHRZM=)90ZPFFO%8),[!45VD*R %B!N"%><
MD@<T ?7--=UC5F9@JJ,EF. !ZU\G_P#!1#XP?&SX1_#OP_+\%_#USJ=[J5Y)
M;ZAJ=CIIU&XL%" Q;(-K#YSO^=D91L ZL*_/N/\ 9+_;4_:J99?&EYKEEI=P
M<X\8:NUI;)GK_H:DLGX0B@#]K+O4[2QTV;4+BXCBL886N)+AF^18PNXMGTP,
MYK\\/BA_P6J^'?A^6XMO W@W6O%TT;,BW=_*FG6S^C+Q)(1WPR(?I7U)^Q[^
MSMJ/[.?[/FF?#SQ)KD7BJXB>XDF948VT:2L28(P_)C&3U R68X&<5C>#/^"=
MO[._@759=1L/ACI=Y<R2&0#5Y)M0B3)R%6*=W0 =OES[T ?.W[%/_!2CXC_M
M1?M!0>#M2\ Z5;>%I[6>:6^TB.X:732D;.CSRLY0H[*(P-J'<Z\\8/2_\%%_
MV9OC_P#M >+O#$?PT\1^5X+%D;>^TC^TS8QQW.]B9Y<']\K(R*!ABNPX'S$G
M[CT30-,\,Z>EAH^FVFE6,?W+6Q@6&)?HJ@ 5?H _(WX??\$1/$UYY<OC?XDZ
M7I2]7MM!LI+QF]O,E,04^^UOZU^FG@7X(^%O GP9TWX716C:OX2L]-.E/;ZJ
M1.;F%@0XEX .[<V0 !SP ,"N^HH \4\&_L5_ GP%,LVC_"KPRDZDE9KRQ6\D
M0GNKS;R/P/M7L6GZ;::39QVEC:PV=K&,)!;QB-%'H% P*LT4 ?GU_P %1/C;
MX>AU_P"''P5\2Z[)X8\)>(;N+6?%FK+!-+MTR*4[(46)&9FDDC?HIVM'&3P3
M7J.E_P#!33]E?1=-M-/L/B)':6-I"D$%O#X?U-4BC50JJH^S<    >U?5%]H
M]AJC(;RRM[LIPIGB5]N>N,CBJO\ PB>A_P#0&T__ ,!8_P#"@#YK_P"'HW[,
M7_13/_*!JG_R-7S9X5_:T^%&@?\ !0C2/$7PN\5_V]X6^*<46C^)=/BTZ[MO
MLVIA@EK=!9HD#;V95.W.-TS'[PK])_\ A$]#_P"@-I__ ("Q_P"%2V_AO2;.
M9)H-+LH)D.5DCMT5A]"!0!HT444 %%%% !1110 4444 %%%% !1110 4444
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MOVNOA/%X,O\ 7KKPW);:A'J=K?V\(G59D22,!XBR[U*ROQN4YP<]C\J^%_\
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M')WQQ-UZAWSGY1@M^N>AZ'IWAG1[+2=(L+?3-+LHE@MK.TB6**&-1A415
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M5F!R V'?(7Y53[!H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#S#XZ
M?\T^_P"QOT__ -J5Z?7F'QT_YI]_V-^G_P#M2O3Z "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***1F"J23@#DDT +17'^'?C%X#\7
M>*KWPQH?C/0-8\164?FW.E6&I0S7,29P6:-6+  D9XXW+G&1GX^_X*"?\%%/
M$7[*?C+3O!?A/PE:WVKWFGKJ#:QK0D-JJL[(JQ1H5,C H226 ' P>: /O&O#
M/VROVFM-_96^"6J^*YC%<:[/_H6B:?(?^/F\8':2.NQ "[>RXSEA7Y<6^I?M
MP_M:2C5O[2\4:#X>C_?G4&G_ .$=TN"(#)DW#RO-51D[AYC#%<CXX\3>/O\
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M/V/_ !,?'7P?UO4O$FEV9,B7^@;HM4MH^I6:W4GS4Q@'9N! .Y5%>O?LQ_\
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M[OP7^T;8Z4_B75)-5U*XG\'6MS/=3L2=[R3%V[GY0=H+,0.3GLO^% _M<_\
M1U&G_P#A":?_ /$5XU^R+^P3^S-\=?@'X/\ $4UB->\1R:; =;^PZ_/N@O"G
M[Q)(TD_=-N!^4@>W%>R_\.G_ -FW_H4-0_\ !W=__'* #_A0/[7/_1U&G_\
MA":?_P#$5U/[%_[*?BC]F!?'?_"0>/8/&$?BC45U7[+::4MA#;7)W^?*J*Q4
M>9F,;55541+@=ARW_#I_]FW_ *%#4/\ P=W?_P <KC/V%_AKH7P5_;%_:5\"
M>$X9['PQI<.AFULY;AYMI>W:1B6<DD[I&Y/8XH ^\Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_@MWKEUYL/@/X;6&G#D)>>(;U[DGW,,0C"G_ +:-0!^M=<_XP^(7A?X>:?\
M;O%/B32?#=E@G[1JU]%:H<>A=@#7XTK\8OVZOVJ#C0(O%UII5Q_JWT.Q71;/
M!["[(CS^,IKHO!__  1Y^-'Q%U#^U?B)XUTGP_+.09I)KB75K_WW %4/_?TT
M ?J1\*OVEOA?\<-8U32? OC73/$NHZ8@ENK>S=MRH3MWKN WID@%ER 2,GD5
MZ97RM^Q]_P $]O!?[(>N:AXBT[6]3\2^)[ZR_L^2^O52**.$NKLL<2]-S(F2
MS,?E&,<Y^J: /C#_ (*.:'^TCKVD^$K3X$W.HQ:;,\T6L+H-VEK?>8=ODL96
M966, /RC#!/S=J^+_"__  2-^/GQ2U%=6^(?BK2]"FEQYTNJ:A)JE^/^^,HW
M?_EK7[/T4 ?GM\-_^"+GPI\.F*;Q?XH\0>,;A<;H82FGVK^N47?)^4HKZF^&
M_P"QW\%/A,(F\,?#3P_9W$6-EY=6HO+I<>DT^^0?]]5['10 BJ%4 # '  I:
M** "BBB@#D/'WP?\"_%2&.+QEX.T+Q2L8Q&=7TZ*Y:/_ '6=25_ BL_P'^S]
M\,OA=>&\\(_#_P -^'+X\&\TW2X89\>GF!=V/;.*[^B@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@#S#XZ?\ -/O^QOT__P!J5Z?7F'QT_P":
M??\ 8WZ?_P"U*]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **^
M?/VA/V\/@]^S3J$ND>*_$$MWXDCC64Z#H]N;F["L,KNY$<9(P0)'4D$'H<U\
M:7G_  6FU7Q%\1-%TKP;\)WO=(N+R.W>WN;MIM2O%9@-L,<:[4D.< $R G%
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MWHLVXPMD\ !]Q_NBN7_9IE2;_@H1^U1)&ZR1O;^'V5U.0P-F,$'TKR?XX?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110!YA\=/\ FGW_ &-^G_\ M2O3Z\P^.G_-/O\
ML;]/_P#:E>GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB&VL;&%8H84'95 P*U*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** /,/CI_S3[_ +&_3_\ VI7I]>8?'3_FGW_8WZ?_ .U*]/H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR76KZ 6MQK&JW/GW3P[@WEC 5%4LJL0JC) SG Q[S10 4444 %%%% !1110
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M) /O\P^M?2?@'_@CE\#?"_E2^(+GQ'XRF7F2.\OA:V[?18%1P/\ MH:^[**
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M/02&OVDH \[_ &BO&>J?#GX!_$;Q3HDJ0:QHWA^^O[.62,2*DT<#NC%3P<,
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M);?4=0N[66Z2RVJAB3RXV7F0E_F)P/+QC+#'P<G_  4(_;,UQ'@T_P .W9F
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M9P,LW=F..68EB>22:Z.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MW\HNT<EQ<M''N=9)'D"HN,E?FPN" >F?MU?\F?\ Q;_[%^X_E7Q5_P $-?\
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M?^":_A>X\0?\%$7OX8]\6AG6=0G;^XC)); _]]7"C\:_<"OEC]A7]BE/V4=
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M &00.%*]:S/V8_C5X\\#_%R__9Z^--['J_B^SLO[1\->+$78OB#3UR#O&?\
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M_:Q_;+\$_L?Z/H%YXLL]5U.ZUR:6*QL=)A1Y&6((978NZ*%7S$'7)+# QD@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\(O#5[L\1^)H/,U>6%OFM=.)(\OCHTQ!7_<5\CYP:[#_ ()8_LD_\**^$?\
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MO_\ EIR?X4J_MT?MO>*.=(T'6AYO[I/[-\$>=\_JNZ%\MSTY'M0!^U-?&O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3$^/HI-?2?@'_@H1^SW\1C&FG?$[2+"X?CR-<WZ:P/\ =S<*BD_0FLKX@?\
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M/B&GV_P[IE\NJ:IYBGR;FX)_T:R0'_EFH5<KSB.,*?O@U^VG3@<"OR6^#_\
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M%<M'@HQW(<D=!\Z'2OV_?VC@IF/CNRL[CJ)9$\.P%#W*9@W+CGH<]LU^V=%
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M=,<EHI(E\S8TB@-E0,XXY,;X^T;']A/]G[3V9HOA)X8<L,'S[,3#\ Y./PH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\P^.G_-/O^QOT_\ ]J5Z?7F'QT_YI]_V-^G_ /M2O3Z "BBB@ HHHH ****
M*>KZ18^(-+N],U.SM]1TZ[B:"XM+J-9(IHV&&1U8$,"."#7Y*?MJ?\$RM=^$
M.JS?%'X#F^.F64OVZ;0K&5_MVE,IW>=:.#O>-3SM!WIU&X9V_KO10!^;W["G
M_!4RQ^(1T[P%\8KNWTGQ0=L%CXFDVQ6NH-T"3]%BE/9N$8_W3@-^D-?GW^W9
M_P $P-)^,W]H^.OA=!;:%X[;=/>:3D16>KMU)':*<_WONL?O8)+U\Z_L<_\
M!1OQ7^S3KZ_"GXXVNI2^'M-E^PK=WL3G4=#(XV2*1NEA7CY?O*/N[@ M '['
M45G>'?$6E^+M#L=:T34+;5=)OHEGM;VSD$D4T;#(96'!%:- !1110 4444 %
M%%% !1110 4444 %%%% !7A?[2/[%_PO_:HDT^Y\;Z7='5M/A:WM=5TVZ:WN
M(XB=Q3NK+N)(#*<$G&,G/NE% 'YD^-/^"(/ABZWMX2^)^KZ7R2L6M:=%>Y]
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \F_:#_9?\ ?M,:!;Z?XRTMVO;,[]/UJPD\B_L'Z[HI0.F<':P*D@$C(
M!'AT/[)/[1?A.)M-\)?M6ZJ-#V^7''XA\.V^H7<2=A]HD9F8_P"T-IK[*HH
M^5?AS^P%H6G^.+/QS\5_&.M?&SQI9$-9W7B/"6%FP.=T%H&95YP<%F4$ @ C
M-?55%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110!YA\=/\ FGW_ &-^G_\
MM2O3Z\P^.G_-/O\ L;]/_P#:E>GT %%%% !1110 4444 %%%% !7S-^V5^PI
MX,_:V\/M<RK'X?\ '=I%ML/$4,0+$#I#<*/]9%_X\N<J>H;Z9HH _#;X+_M"
M?&'_ ()D?%>Y\!^.M(NKWPC)-YMUH<DFZ*6-CC[982GY<G';Y6P5<*PRO[*?
M!_XR>$?CQX%L?%O@K6(=8T:Z^4LGRR02  M%*AY1UR,J?4$9!!.#^T3^S7X(
M_:>\"2^&?&FG><J[GLM2M\+=V$I&/,A?!QT&5.5; !!XK\@-<\,_'#_@E)\:
M$U+3K@ZGX4U"38EV$8Z7K<*Y(CF3/[J903QG<O)4LI.0#]TJ*\2_99_:X\#_
M +6'@L:QX8N?LFKVRJ-3T"Z<?:K%SZC^.,G[L@&#T.&!4>VT %%%% !1110
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MM-. W<"21P#Z 5ZS<6\5Y;RP3Q)/!*I22.10RNI&""#P01VJ2B@#PRU_8;^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F'QT_YI]_V-^G
M_P#M2O3Z\P^.G_-/O^QOT_\ ]J5Z?0 4444 %%%% !1110 4444 %%%% !7.
M?$+X=^&_BMX0U'POXMT>VUS0=0C\NXL[I<JW<,#U5@>0RD$$ @@UT=% 'XE?
MM+_L=_$S_@GW\0H/BE\*=8U&Y\(6TVZ#5X!NN-.#'_47B ;7B;A=Y&QNC!20
M#]]_L0_\%"/"_P"U5I<&A:O]G\-?$JWBS/I!?$-\%&6EM2QR1@$F,DLO/W@-
MU?65_86VJV-Q97MM#>6=Q&T,UO<('CE1AAE93P002"#P<U^2_P"V]_P3-U?X
M6ZI/\5/@0EXEA9R_;[GP_I\CB[TQU.[S[-@=S(",[!\R8RN5X4 _7"BOSF_8
M+_X*@6/Q-_LWX??%R\@TOQ@=MO8>(9,16^J-T"3=%BG/8\*YX&UL!OT9H **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9^)7Q%T'X2^ ];\8>)[
MU=/T+1[9KFYF;K@<!5'\3LQ"JO4LP'>NFK\:/^"D?[46K_M1?&+3/@A\-/-U
M;0]/U%;1DLFR-7U0G9P>ABB)*@GC.]CD!2 #A?AKX4\5_P#!4;]LJ^UW7UGM
M/"=NZW&H^6YVZ;I:,1#:1MT\Q^5R.K-+)C@BOW$T71['P[H]CI6F6D5AIMC
MEM:VL"A8X8D4*B*!T    ]J\8_8X_9?TG]E'X-:?X6M?*N]=N<7FMZD@_P"/
MJ[*@,%)Y\M!\B#C@9QEFKW2@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /,/CI_P T^_[&_3__ &I7I]>8?'3_ )I]_P!C?I__ +4K
MT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _._]O7_ ()@Z?\ %K^T
M?'_PHM+?2?&IW3WVA+MBMM6;JSIT6*<\^BN>NTDL?%_V)_\ @I9KGP9U:+X4
M_'<7XTNQE^PV^M7\;_;=(93M\FZ4C<\:XQNY=.AW+C;^O%?*'[:__!/_ ,)?
MM8:1+J]EY'AOXC6T6VUUQ(\)= #Y8;H 9=.@#CYDXQD J0#ZETO5+/6]-M=0
MTZ[@O["ZB6:WNK:0212QL,JZL#AE((((X-6J_$3]GK]J[XJ_\$Y_B5/\,_B=
MH]_>>$(YLW&BS-NDM48G_2;"0G:R-R=H.QB#]ULFOV1^&/Q1\+?&3P7I_BOP
M=K%OKFA7R[HKFW/W6_B1U/*.O0JP!!ZB@#JJ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)7O7=B?]IER?4XH _13X+_'3P3^T%X/3Q-X&UN/6--\PPS+L:.:VE R8I8V
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MKE/GTVU=>9G4CY9I%.,=50X/+L!^B]%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !5:QTVTTN%XK*UAM(GD:5D@C"*78Y9B .I)))[F
MK-% !1110 4444 %%%% !1110!YA\=/^:??]C?I__M2O3Z\P^.G_ #3[_L;]
M/_\ :E>GT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 ?-O[5W[!OPW_:LL9+O5+7_ (1[QDD>VW\3:;&HGX&%6=.!
M.@XX;# #"LN37Y@7^A_M'_\ !+/QV;RTF:X\(7EP ;B,-<Z)JH'195X,,N!_
ML2#!VLR\G]T:S]?\/Z7XJT6\TC6M.M=6TJ\C,5S8WT*S0S(>JNC AA]10!\O
M_LI?\%'/AG^TQ'9Z//<KX,\=2 *V@ZI* MP^.?LLW"R_[IVOU^7 S7UA7Y?_
M +5G_!'NSU!KOQ+\#KM=-O 3*_A/49SY+GKBVG8Y0^B2$CG[Z@8KQOX'?\%(
M/C+^R3XB/@#XR:%J?B73-/81/::SNAU>R3L8YG'[Y,<@/G<,;75<4 ?M)17D
M?P!_:K^&?[2^C_;/ WB.&]O(XQ)<Z/<XAO[7M^\A)SC/&Y=RD]&->N4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5\Q_MH?MU>$?V2O#4EL7A
MU[Q_>0[M.\/1R?=SP)K@CF.('_@3XPO=E\B_;I_X*=:'\$+>_P#!7PSN;3Q%
M\0"&AN=07$MGH[=#D])9QV3E5(^?IL/S3^QK_P $[_%?[3WB,?%KXXW.I+X<
MU";[:MM?2N-0UUCR'=C\T<!X^;AF7&S:N&H Y?\ 9?\ V5/B'_P40^*U[\4O
MBGJ5\O@TW6;O4I,H^H%2?]$LQT2)?NEE^5!P,MG'[/\ @_P?HO@#PQIOAWP[
MIEOH^AZ;"MO:6-JFV.)!V'J>I)/))))))-6- T#3?"NBV.CZ-86^EZ58PK!:
MV5I$(XH8U&%55'  '85H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 >8?'3_ )I]_P!C?I__ +4KT^O,
M/CI_S3[_ +&_3_\ VI7I] !1110 4444 %%%% !1110 4444 %%%% !1110
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MGPA^T]_P4N^('[36M'X;_!#2-6T?1M2<VJR6<;/K&J@]54)GR8R,Y526('+
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >8?'3_FGW_8WZ?\ ^U*]/KS#XZ?\
MT^_[&_3_ /VI7I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !65XF\)Z)XUT>;2?$.CV&NZ7
M-_K+'4K9+B%_JC@@]?2M6B@#XD^,G_!(_P""/Q(::[\.0ZA\/-4?YMVCR^;:
M,WJUO+D >T;(*^0O&7_!(?XX_"O4O[8^&GC#3_$4\&?(EL;N32-0_#<VQ?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 >8?'3_FGW_8WZ?_ .U*]/KS#XZ?\T^_[&_3
M_P#VI7I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 07EE
M;ZA"8;J"*YA)R8YD#J<>QJA_PB>A_P#0&T__ ,!8_P#"M:B@#)_X1/0_^@-I
M_P#X"Q_X4?\ ")Z'_P! ;3__  %C_P *UJ* (K>VALX4A@B2"%!A8XU"J/H!
M4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 >8?'3_FGW_8WZ?\ ^U*]/KS#XZ?\T^_[
M&_3_ /VI7I] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!YA\=/^:??]C?I__M2O3Z\P
M^.G_ #3[_L;]/_\ :E>GT %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F'QT_P":??\
M8WZ?_P"U*]/KS#XZ?\T^_P"QOT__ -J5Z?0 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 C,$4LQ"J!DD]!7DLW[7'
MP6MO'#>$)OBAX7BU];?[2T#ZG$(@-^S9YQ/E^;GGRMWF8^;;MYKY&_X+-_%3
MQ3X)^%_@7PWHUQ<6>@^)+VZ&L2VTAC,R0K$8[9F!SL?S78COY0JW\ =7^"?[
M47[0L5KX5\-Z->> V^%$-E<^&YK% MA.NIMNA>/'$BAEPZ]<AE8Y!H _06WN
M(KJ".>"1)H9%#I)&P964C(((Z@CO7EOC[]JCX4?##Q!<:'XD\:Z?8ZO:Q">Z
MM(EDN'M(SC#S^4K>2.1S)MX(/2O"?#OA?4/^"??[)OQQEMYFDT[1]6O]1\)R
M7<PG @G@MDM$89R-D[,C @;BC-C# GR#_@CCI</CCX6_&35-?+:MJ/B#6%MM
M3NKQO,END:!F;>S9+9,TA.>NXT ?HSX<\2:3XPT.RUK0M3M-9TB]C$MM?6$Z
MS03(?XD=201]#VK2K\D/^"*_QLU&W\9^+OA7?7CRZ1=6)UO3H)6)6">-T294
M]-ZR*Q'_ $RSW.?UOH **** /,/CI_S3[_L;]/\ _:E>GUYA\=/^:??]C?I_
M_M2O3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBO,+C_DY2T_[%9__ $JKT^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HKS#]FW_ ))!I'_7:Z_]*)*]/H **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKS#X\?\ 'CX*_P"QIL/YO0!Z?111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117F'@G_DN?
MQ+_ZXZ9_Z):@#T^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBO,/V:/^2)>'/^WG_P!*9: /3Z*** "BBB@ HHHH **** "BBB@
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M,_$7P%T37/B!XZT]]'\3^(;9+.RTJ88GL[(,)&,R_P +R.L9V'E1&,X)(7]
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M_P (#\2?^BJ_^6[;?_%4?\(#\2?^BJ_^6[;?_%5Z?10!YA_P@/Q)_P"BJ_\
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M ,57I]% 'F'_  @/Q)_Z*K_Y;MM_\51_P@/Q)_Z*K_Y;MM_\57I]% 'F'_"
M_$G_ **K_P"6[;?_ !5'_" _$G_HJO\ Y;MM_P#%5Z?10!YA_P (#\2?^BJ_
M^6[;?_%4?\(#\2?^BJ_^6[;?_%5Z?10!YA_P@/Q)_P"BJ_\ ENVW_P 51_P@
M/Q)_Z*K_ .6[;?\ Q5>GT4 >8?\ " _$G_HJO_ENVW_Q5'_" _$G_HJO_ENV
MW_Q5>GT4 >8?\(#\2?\ HJO_ );MM_\ %4?\(#\2?^BJ_P#ENVW_ ,57I]%
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MBJ_^6[;?_%5Z?10!YA_P@/Q)_P"BJ_\ ENVW_P 51_P@/Q)_Z*K_ .6[;?\
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M_P (#\2?^BJ_^6[;?_%5Z?10!YA_P@/Q)_Z*K_Y;MM_\51_P@/Q)_P"BJ_\
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MO_BJ]/HH \P_X0'XD_\ 15?_ "W;;_XJC_A ?B3_ -%5_P#+=MO_ (JO3Z*
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MMO\ XJO3Z* /,/\ A ?B3_T57_RW;;_XJC_A ?B3_P!%5_\ +=MO_BJ]/HH
M\P_X0'XD_P#15?\ RW;;_P"*H_X0'XD_]%5_\MVV_P#BJ]/HH \P_P"$!^)/
M_15?_+=MO_BJ/^$!^)/_ $57_P MVV_^*KT^B@#S#_A ?B3_ -%5_P#+=MO_
M (JC_A ?B3_T57_RW;;_ .*KT^B@#S#_ (0'XD_]%5_\MVV_^*H_X0'XD_\
M15?_ "W;;_XJO3Z* /,/^$!^)/\ T57_ ,MVV_\ BJ/^$!^)/_15?_+=MO\
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M[^*OPWL_ ]WX9EOKG5]0M=2MKF;4[B..7[,[E@R((X_))"*<[2[;LG:/N/\
M81_;2L_VQ/ .I75UIL.A^+]"DCAU73[=V>%A(I,<\1;D(Y20;225*$$G() /
MIRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKW]D/X'S?LY_L\>$/ =XUM+JFGPR27\UJ2T<EQ+*\LA#$ L 7V@D=%%?$?\
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MS#DYD8%C@  'VK7YB_LO_M#?&;QA_P %+_'?@K7_ !#>WOA:TO-8AN=%D/\
MHMG;0.RV[PICY?F$(W#E@Y)R37Z=5X'\.?V98? W[6WQ1^+ZM;^5XJTNPM+:
M*,GS(I%&+K<,8 8P6S#!.27SC R ,_:V^.'Q)^"OPZ\0^(/ OP[@\1Q:/8M?
M76K:IJ,4-M#&H)=E@5O-F* $LI\OC[K-R*^<O^"6'[3GQ&_:6\8_%S4O'WB"
M351:1:8;*RCC6&ULP[76X11J !D*H).6.T9)KZL_;$_Y-0^,/_8I:I_Z2R5\
M ?\ !#7_ )"OQD_ZXZ3_ .A7E 'VM^W1^U4O[)?P3E\26=I#J/B74KE=-T>T
MN,^5Y[*S&60 @E$522!U)5<C=D?*GB37/C'IW[".E_M'VGQA\42>/QY6K7>G
MLT!TF2UENQ"(5LQ$(UVJR/N.2<..A&WK?^"S7PQUGQ?\!_#/BC2[::[M?#&J
M.^H)%D^5!.@3SB/171%)[>9GIDCSSX>_M$?#_P 4?\$F]>\)ZEXFTBS\4Z5H
M5WI#:+=7L<-S),LK-;&.-B&DW*8SE0>0PZ@T ?7?["7[64?[6WP;_MV]MH=/
M\5:3<?8-9L[?/E>9M#)-&"20DBG(!/#*XYQD_1]?E3_P0VL;M6^,=Y\RV##2
M8>1P\@^UGC_=!Y_WQ7ZK4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !2,-RD9Q]*6B@#\H?^"DW[0/QB_9;
M^,FB:-X)^*FO)H^K:0NH&UOH;28P2>=)&51_)!*D(IPV2#GGT^@OAKX ^/WQ
M&_9O\*?$#PI^T#K47C/6-$@U-=-UK2--GTZ25T#F'_CW#("> ^6(S7R/_P %
MM/\ DOO@7_L61_Z53U^E/[%/_)H_PA_[%FQ_]%+0!\N?L:_\%--4^('Q,_X5
M-\9](M/#OC0W;Z=:ZG:J88IKM&*&UGB).R4L"H93M9L+M!QG]#J_GW_X*(6Y
M\!_MW_$:?1)/L-S;ZE9ZG#-;G!CN)+6WN"X_VO,<M]:_1#]O7]M[Q+\+O!?P
M[\(> 9$T_P >^/+*"[?4'B#G3[:4*@,8/'F/(S $@[0C<9*D 'WQ17YP?MD>
M*O&'[ >L?"GQOX5\<^*?$UA?3R:?XET?Q-K-QJ$&JE%1C,JS.PMY&7>,Q!0N
M$P, @^S?MX?MI?\ #//[/>B>)/"#Q3>)O& 1=!DN8PZPQ-&LCW+(>&V(Z *<
MC=(N00"* /KFBORY^.WP_P#CGX%_9K^$/Q;^'GCOXD>)OB#?):WOB*.UU.ZO
MHI5N8?/3_006B$43GR]JQ[3O!([U^B7P7U[Q-XH^$G@_5_&>E?V)XKOM+MY]
M4T_84,%PT8+J4/*'/\)Y7H>E 'G_ .W%XT\4_#O]E'XB^(O!=T]CXBL;!'@N
MHQEX$,T:S2+Z,L32,#V(!KQC_@FK\=O%OBC]D7Q%XW^*>OW.K6NBZG?-%JU^
MV^X:RA@BE<LW5]KF4 GGC'0"OK[QYX1L_B!X'\0^%]1&;#6M.N--N.,_NYHV
MC;]&->=_LE?!&7]GW]G7P=X OS;3:AIUJYOWMR7BDN)9'EEP2 67<Y )'0"@
M#\_/VE_$W[<7BCP_JGQ3M;;4_AYX"M8S>V_A_1[^&.^L[$#>)KA$/F,P0@N"
M<KALHH!KV7_@ES^W#XH_:*BUSP%X]E_M3Q/HEH-1MM;5%1KNU\Q8V695 7>C
M/& P'S!N1E2S?7G[0WCG2_AK\"_'GB767C73[#1KEW63&)6:,HD>#U+NRH!W
M+"OB/_@CI^S5JG@'P7KOQ5\06LEE<^*(8[/1[>4%7^PJV]IB/21PFWVCW<A@
M: .Y_P""A/[9'B+X4^,/!7P@^'5_%I7C/Q7+"+O6GB$K:;;33>3'Y:D$>8[;
MSD@[53@98%>0_:<^/'C#_@GQ\:OAS,/%_B'Q]\._$T$JZOI?B>Z2[N(VA>-9
M)K>;8K(VV96V?<)!& "-OR[^UMJ=QXB_X*S6%M.[I';>*/#EE KC/EIMLR<>
MQ9W;_@5>Q?\ !<Y1N^"C8&XC6P3W_P"7#_&@#]3--U*VUC3;2_LIEN;.ZB2>
M"9/NR1LH96'L00:LUXA^Q#K5SX@_9&^$MY=NTD__  CUK 6;J1$GEJ3^""O;
MZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&!FNDKB?A#\%_!?P'\'P^&/ N@V^@:/&QD:.$L\DTAZR22,2TC'@98DX  X
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M)]22226.222223F@#>HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "OQV_P""W'_):/AY_P!B_)_Z4O7[
M$,NY2,D9&,CK7S5\2/\ @GG\'/B_XA_MSQI9>(/$NK"(0+=:AXAO)&2,$D(O
M[S"KDDX&!DD]Z .@_8]U>QT/]C3X5ZEJ-Y;V&GVGA6SFN+NYE6.*%%A!9G8G
M"@ ')/3%?DE:_#G5O^"BW[='BG4?#]I=Q>$-0UCSK_6/+)2TTV(".-V8C DD
MBB 1#SN;'121^IUC_P $[_@G:Z)!H=QI&OZGX?@ \K1;[Q1J3V*8;=Q )PGW
MN<$8YZ5[AX ^&OA7X5^'X]#\'^'M-\-:2C;_ +)IELL*,Q !=MH^9B ,L<DX
MY- 'Y*_\%HO =YX=^,'PY\26]KY?A^7PZND6J[0T4<EM<2N8\=/N7$?!Z@'K
M@X^V/AK#^R9\0?@C8?$K_A OA;8:.UDL]^L^@:<)+*;9F2"1!&3Y@(("@$MQ
MMSD9^A?BU\'O!_QS\%W7A3QQH<&O:)<,KF"8LC1NOW9(W4AD<<_,I!P2.A(K
MP[X3?\$U_@3\'/'-MXMT?PY=7^KV<OG67]KWKW,5I(.CHAP"PZ@ON(/(P0"
M#Y;_ ."R'@&YU#X-_!OQ1HFB3:1X9T0SV$FFK;K"NG+<0VY@C:)/EC"BW:/
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MUK'V/R)]4L[6.W7RKR"=M[)<NPRL3 84\D=!R/:_^'U?P0_Z%;X@?^"ZQ_\
MDR@#[_HKX _X?5_!#_H5OB!_X+K'_P"3*/\ A]7\$/\ H5OB!_X+K'_Y,H ^
M_P"BO@#_ (?5_!#_ *%;X@?^"ZQ_^3*/^'U?P0_Z%;X@?^"ZQ_\ DR@#[_HK
MX1\._P#!97X%:YK5G87&E^,]$AN)%C:_U'3K;R(<D#<_E7+OM&<G"G@5]W4
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MP7^V9XE_:F_;8UCX10>*-:^&_@JS-_:Z>/#MO;_;]0N+4G<;B>:*3R59(YF
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M6H6H ?\ L.T\131WQZ93SG'D[NO/2L/]E.\\/?L\_LCZA\=?B#=;]<\7Q_\
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MO?2YX@DC/^KE/\)!VL?EPIP&_1"OYQ/VL=,?X7_M??$B/0W.FR:;XHN+RQ:
MX-N3-YT>WTVEACZ4 ?T=UY?^TU\:[/\ 9Y^!OBWQY=^6\NEV;?8X)#Q/=N0D
M$?K@R,N<=!D]JZ[X<^)G\:?#WPOXAD"J^K:7:W[!1@ RPJYP/^!5\G_M;_#>
MZ_;/^(VK?![3[U[70_!>A2:UJ$T;[4?7+F)TTNWD/7:B>;,P]'0=Z +O_!+W
M]I>]_:#^ ,ECXBU*34O&7A:[-EJ%Q</NFN(9"TEO.WU&^/W,)/>OL6OP,_X)
MQ_&ZZ_9P_:PTW3M<:33M)UZ5O#>L03_+Y$C2 1.P/0I,J@D]%:2OWSH ^:/V
MX/VUM$_8_P# ]K,+6/7/&>KAUTG1V<JGRCYIYB.1$I(&!RQ. 1\S+X+^Q[X#
M^*O[9WA.;XJ_%_XH^+-/\.:E<RQ:/X7\)ZB^CVLL4;E'DD\@AF3>K(HSN^0L
M6.17PC_P4\\;WWC3]L_QTEW(S6VC&WTJSC8G$44<*,0,]C(\K?\  Z_:C]D_
M0HO#7[,'PGTZ*-8A%X6TUG50 #(UM&\AX]79C^- 'R7^UUX#^+'[&?A*/XJ_
M"'XG^*]6\.:7/$FL^%?%VH/K%M'"[!%>(S$NJ;BJLH.X;]P88->]_L2_MG:%
M^V!X!N+R.V31?%^DE(]8T82;E0L/EGB)Y,3D-C/*D$'/#-VG[76BP>(?V6?B
MW97"AD;PKJ4J[AD!X[9Y$/X,JG\*_&;_ ():^.+WP;^VAX,MK:5DM-=CNM*O
M(U)Q)&T#R(#])8HF_P" T ?OK7D_[2'@&;Q;\-?$&H6'BKQ+X4U?2])NY[*[
M\/ZM+:!95C+JTB*=L@R@'S \%L8SFO6*Y3XL_P#)*_&7_8%O?_1#T ?B[^Q7
M\9?B[^T=^T=X8\ >)?C3\0;'1M4CNWFGTK6VCN%,5K+*NUI%=1EHP#E3P3TZ
MU[Y^W!K'[0O[#>H>&?%'A;XW:_XJ\):I,]DL/B*&VN9K>95WB.7,>V4.@8AP
MJL-K="03\:_\$]OB#9?"W]K'P?XDU&PU74[2TBOE>UT6QDO;I]]G,@V1("S8
M+ G'0 GM7O/[?O[5I_;"\<^&OA=HFF'P#H6DW;74VH>/'72W:X*% TBL3Y4:
MJS8SEFW9(&,4 ?HK^PG^UA_PUM\&?^$AOK*'3?$VEW1T_5[6VW>290JLLL>2
M2$=6!P22"&&3@$_*OA+P[^UPG_!12:\U&?Q,? ']N3/+-)/(=!.C[FV(B9\K
M?Y6T!0-XD.3SDU]+?L/_ +*6F_L\_L]3Z%IOB]-;U/Q(S:A>>)=!D1HM[1A$
M^R.P961 /E9@=Q)) !VCX?\ @[^UI\<(_P!OJR^%.M_$K4=?\-67C"\T*>*Y
MM+53=0P32Q@L4B4@G8"<8H _8&BOB?\ X*2_MSZA^RQX>TGPSX,^ROX^U^&2
M=+JX42KIEL#M$_ED8=V;<$#97,;$@XP>"^.%A\9OV?/V3]'^-^G_ !J\5:SX
MSMHM.OM:TW5Q;3:3+'<M'&T4=MY0V;7F0;@V2 QX.W: ?HK7S_\ '+]K+2?A
M9\9_AA\+=.%OJ7BSQ=JL,-U Y)%A8L2&E8 CYW(VH#QPS'@ -1_9/_:8G_;&
M_9WN/$.C3P>$O&41ETN^*P?:HK&]" B:.-F&]"KJZACC.5);:2?R%T/P?XIN
M?^"B7_"+?\)[J+>+(O&LNFKXRG@6:Z\V.9HQ<&)R5)PHPA. , <"@#^@BBO#
M;'4-5_91^!WC#Q1\4OB3>_$6+2O,U'^TKS3X;*54V(D=JB194EI!A2?XI<=!
M7S1^ROXN^+?[>G@OXA?$'4OB+J_P]MH;Y]*\,:/X7>.&VLYTA63S+@M&7N%S
M+$"&8 _O,!?E"@'Z$T5\2?\ !-']M/6_VEO"^O>%O'3PR^.?#(C=[Z*,1_;[
M5B5\QE7Y1(CC#%0 =Z$#K7#>$_VK/%G[;/[86J_#'P/XJOO!7PK\.V=W=7>I
MZ T::CJRPND(D2=T?RT:65-H0 E,DG) 4 _12OR/_P""I_Q6^(_P"^/.CV_@
MCXE^+]%TW7-(&ISZ?'K$WD13&>5#Y2Y^1"%7Y1P,<8Z5UW[/?[37QF^%/[>6
MH? /QAK.J>//#-QJEQ8VDVM1AKZ"W$;2V]V)0H+ Q*A<'*D%B,'KY;_P6T_Y
M+[X%_P"Q9'_I5/0!^JO[/NL7OB#X"?#75-3NI;[4;[PSIMS<W4[%I)I7M8V=
MV)ZL6))/J:[^ORB^,EW^TAX1_8C\#_%2R^)*>!O#NCZ/HUO9^$M!AVS-:-'%
M#%<SW><O(Y,;F';L57QG*G/U+_P31_:<\1?M,? >[N_&$RWGB?0-1;3;F_6-
M8_MD9C22.5E4!0^&*G  .P'O0!]<45^-O[;G[5_QR_9Y_:@\0^"/#'Q3UNZT
M*V^R7%O#>6UF\H$T,<C1[A ,@,Q .,XQG)&3WO[>GC+]J7X*^$?"GQ-U3XII
MX>CUC4?LW_"'^'+=8H='=HGECB:<Y-V=J.'9QC</E!4C !^JM%>!_L-_'S4_
MVD/V:_#/C+74B37F,UEJ+0J$22:&0H9 HX7>H5B!P"Q XQ7R78_M@^-_VROV
MS$^$_@#Q?=^ OAEI[7GVG5]!2)K_ %..!3F5)I$;RU=@H3:.%;<VXX  /TPK
MY/\ ^"EMQK_A']F'Q#X\\+>+?$'A37_#KVAA?1M2DMXYDFNX8'65%.U^),@G
MD$<'!(/SW\5/VM/'/[ O[6&G^!O%'BO5/B+\*M6L;74 _B#RYM3L()7>)W2=
M$4R%'A<[6!W+QPQW5]#?\%/KB*\_8+^)$\$BS02KI;QR1G*LIU.T((/<$4 >
M4_\ !(7XP^./B]X*^(USXV\5ZMXIN++4+2.VDU6Z>=H5:.0L%+'@$@?E7Z"5
M^97_  0_./A_\4R>!_:=E_Z*DJ6Q_;!\;_ME?MF)\)_ 'B^[\!?#+3VO/M.K
MZ"D37^IQP*<RI-(C>6KL%";1PK;FW'  !^F%%?F7\5/VM/'/[ O[6&G^!O%'
MBO5/B+\*M6L;74 _B#RYM3L()7>)W2=$4R%'A<[6!W+QPQW5]/\ [=7[6X_9
M5^!\/B?1K6WUCQ!K5RECHR3'=;AF1I#.^T@LBHO0'DL@X!) !]*T5^<O[/*_
M&+XV?L@^*/C7J?QE\4VGCB:+4KS1;>S:"/3(5M=P$;VODE&WO$ZDXX4C'.<\
MI_P3M_:0^._[5'Q#N4U_XTHEMX>EAO=0\-R^%[ ?VE9,=K;+B.-6C(; .!D;
ME()R< 'ZBT5^0_[?WQL_:/\ V2_C)'IFD_%C6+SPAK=N;_2+BZLK,R( VV6W
M9A" S1MMY ^ZZ9YS7WS\/_%$7CK]C72/%2_$;785N/#W]KW/BY?LOVZ!T0RS
M[AY/D_NV5XRNSHA&<_-0![_17@'[$^D_$7_A1VA^)?BAXPU/Q/XH\1VD.HO:
MWL4$46GQ-N:*.-8XU.XQNA?>3\PP,8.??Z "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJNJ:7::WIEWIVH6T5Y87D+V]Q;3*&CEC=2K(P/4$$@CWJU10!\K2?\$N_P!F
M.21G/PR +')VZ[J8'X 7.!2?\.N/V8O^B9_^5_5/_DFOJJB@#Y5_X=<?LQ?]
M$S_\K^J?_)-'_#KC]F+_ *)G_P"5_5/_ ))KZJHH ^5?^'7'[,7_ $3/_P K
M^J?_ "37G_[0G_!.']G;P/\  +XE^)-$^'GV+6M'\,ZGJ%C<_P!MZC)Y,\5K
M))&^U[@JV&4'# @XY!%?=5<O\5/ Z?$_X8^+_!TEXVGQ^(M'O-(:\6/S# )X
M'B,@7(W%=^<9&<=: /CW]GO_ ()P_L[>./@%\-/$FM_#S[;K6L>&=,U"^N?[
M;U&/SIY;6.21]J7 5<LQ.%  SP *] _X=<?LQ?\ 1,__ "OZI_\ )-9/A/\
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MX'>-?@'^S]%\-M:\0:1>R:7#<1:3K&FQ2*R"5Y9,RH_!*/)Q@\@8(XR?R/\
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M/VVOV1_B/^V!X2\)^'O^$A\,^&[/2I?M]VPBN)FFNRC(0AXQ&%9L9R23VQR
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MRXKPO4_^4LZ?]E3A_P#2]:^]?V'OV$/B%^QSXM\1:@/%?AOQ%IFN6:P7%O\
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MT_;MT34?#G_!/SXA:=J^NW'B;5(=.M_M6K74,<+W,AO(69_+C 5%R2%4#"J
M,G&2 ?,O_!#7_D%?&3_KMI/_ *#>5\T_\%5(FUG]N;Q)86,)FO&M=,MA''RS
MRM;1E1]2&45Z%_P2B\%_$K6+#XFZ]\+O%UAH7B#3'TZ)](\06[SZ1JD<@N#M
MG$9$D;H8P5D0Y 9QC#<?3OP3_P"";GBBZ_:,N?C7\=O%.C>)?$GV\:G;Z3X?
MCD-I]I4CR7=Y40[(@J[8PO55RQP0P!Y;_P %N+'4[?P[\%/,D,ME"=3BG=0=
MIGV6FTGZA9,?\"KTO]CK]G#P1^TI^R)X1N=3\=_$*]L9[$Z5JFA0^,+P6$4D
M+;#!]FW;%3"HP3& K+CC%?5W[4'[-_AW]J;X3WW@GQ#+)9;I5N['4H$#265T
M@(255) 889E*Y&59AD'!'PW\#O\ @G3^U!^S]KVHV7@CXWZ!X7\+ZA)_I,MM
M%+=2.,;?-^QS0&)9-O&1(#P/F] #ZU^'_P"SC\/_ -G/X-_$WPE\/)Y_*N;2
MYN+ZTN[_ .TO!.]H0NX=4W($.#U&#7YJ?\$8?^3K];_[%*\_]*K2OUZ^%'PE
MT[X6>!_^$?6]O-?N;IY+G5=8U63S;K4[J0 2S3-ZD *%'"JJJ.%%? O@O_@E
M_P#%OX"_'Z\\6_!OXG:%X;T"59H+>?5+9[F]AMI2"8'A:)HY=N%PQ=22@.!0
M!\O_ /!1'_E)%K'_ %^Z'_Z2VM?J9_P4*B:;]B_XK*@R1I0;\!-&3^@-?)7Q
M@_X)%>,/'7Q8O?&.E_%.WN)[EX+J6\UZWDENY[I8T\V5]F$4-(K%4481=JC@
M5^@'C#X</\7O@UJ_@KQU]F677--DL-1DT9F$:,X(\R'S!D$'# -G!&#D=0#\
MY_\ @ABPW?&M<C<1HA [_P#+_P#XUK?\%QO^15^$G_7[J7_HNWKKOV:_^":O
MQ._9Z\7^)+;3?C%:V/@?Q!'':ZG_ &3IQ34KRW1F(5&?(MI,.Z^8C,5WDCD*
M1Z#^W9^Q1XX_:_NO#-AIWB3P_P"&_#OAWS6M!<Q3S74[2I$&,A'R@#R\ #).
M<D]@ >(+8W^H?\$/4CTX,95LFED51DF%-=+2_@$#$^P-5/\ @B+\3+#^R?B-
M\/YYTBU,7$.N6L+'YIHRGDS$#_8*P9_ZZ"OL;]E']G;7O@M^S^OPD\<W>A^*
M] MHKFVADM(I5^T6]Q)+)-%.C\$9E8 @\J<8&,GXU\0?\$C?B+\-?BM'XK^!
M?Q-L= AM[@RV+:O-/!>6:,,,GF11.LPP2N&"AE.&SSD _4>&UMK6:5HH8H9;
MAM\C(H5I&  R?4X &?85^,7[9G_!.V[TRUNOC+\#W_X2CX=:HAUAM-L0?M.F
MQO\ O"\*XS)",DX #QC@@A2P_2[]GC]GWQ1\/;I_$_Q-^(-]\3?'\ML;1+Z>
M,0V>G0,59XK6%<!2[*N^3 9]B<#&#Y1\&_V?OVE/V</!]UH'A+QAX"\8:5=7
M%Q=0:5XI6^@31WD=FV03Q*[2QDD$JR)R6QC)W 'G?_!)?]KSQ9\:M+\0_#SQ
MM?3:YJ/AVUBO-.UBX.Z>2U+>6T4S=7*,4VL<L0QR?E%?97A#]H[X7^/O&]YX
M/\.>.]#UGQ-:&02Z9:7BO+E/OA1_'MP<[<XP<UXU^Q;^PKIW[+G@_P 2'5-4
M36/&GBA#'JFHZ>AA@MXOFVPVP(RJ@N26(&2%X 4"OA:U_P""?/B[]E/]J;X'
MW%AXPL_$%SJ_C&$65O8021W(L+=EENII5/ 40[@Z@D8;KS0!^RM5-6_Y!5[_
M -<7_P#035NN+^*=GXYU/P]-8^!I]#L[ZY@FB>\UOSF6!F4!'1(Q\^,L2"1T
M'7)H _!7_@GC_P GI?"K_L)M_P"B):_:G]NK_DS_ .+?_8OW'\J^)?@__P $
MD?B5\%_BAX9\<:1\1/"]UJ.A7L=[%!=6-P8I=IY1L$'!!(R#D9K[?_: ^&/Q
M$^-?P!U?P-;7WAG1=:UV%[+4KR1;B>WCMVZF$85MY&/O<#)ZT ? O_!#G_D:
MOBW_ ->6F_\ HRXKQ7_G+A_W4S_V[K[I_8?_ &#OB'^QUXQU_4E\6>&_$.EZ
MW9K;W-M]GN(I%>/>T+*W(QN;#9'W2<<UYS)_P3!^*DO[1P^,C?$#PI_;_P#P
MD8\2?8UL+D6_FB?SO*Z[MG&WKG'?/- &/_P7(L;]])^#]X@8Z7'/JD4N!PLS
M+:E,GU*I)CZ&OJC_ ()L_$K3_B9^QUX%6WFCEN]#MFT*_M\Y,,D!*JK#_:B,
M3_1Z],^/G[/V@_M-_!^X\$>-XA$;A8[A;O3SE[*\0<2PEQV)9>1\RLP.,U\&
M_"+_ ()F_M&_ /QA>-\/OC=HOAK0K_:EY=6\<[32JI.UFM'B:)F )P3(",D
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M_A\6=U'"EM$VZ+RY<EA(&+DL<@^8_P OW=OU=#YGDQ^:%$NT;PA)7=CG&>U
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M2Q!"^8"$^8FOT\^#'P5\(? 'P#8^#_!6E)I>CVI+GG?+<2G&Z:5SR[M@9)[
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MEDCZY"G>R]<@&@#YN_X+&:;J-I^UO!<WFYK.Z\/6;V3%2%$:O*K*#W^<.?\
M@0K[Z_X*)3P'_@G#XK,1"Q26&B>4 ,9'V^S( _ 5W?[7G[&NA?MA?#O3+#7[
MD:%XPTJ-I-.UBR4RQV\KJOFQLK8,D+%5X^5OE!!'(/C?Q,_9)_:*^-7P7\,_
M!OQ1XQ\":?X.TUK:.]\0Z<MY-J=_#;J%A#V[HL8;A68B7YF53P,@@'G7_!#[
M2;Z'P'\5-3D5QIMSJ5C;P,5.TRQQ2M)@]SB6+/X5\O\ AM@O_!6^8L0!_P +
M-NQS[W<E?LG\ _@=X;_9T^%NC>!?"T<@TW3U8O<7!!FNIF.Z2:0@#+,3VX
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M2=OQ7\*OVS_VO_ WPWT#1?#WAO5-5\-Z;91V^G74WA*2<"U1 L:B5(P'554
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(F/\0(*CKGC[WHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRWQ1^T5X8\)
M?'[P;\(;R#49/$_BJQN;^SFA@5K:-(5=B)&W9!8128PI'R\XR*J?M;6O@2]_
M9S\<P?$S4;[2O [V:C4KO3'9;E%\U/+$>%;+&38H!!!W888)K\SM%UOQS]L\
M!:KX.U+QAJ/AFTT'6T\+:QK.EVTGBT:4/LRW;6<2W 28(I/DM(48*TVP-M0
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MST\PD4 ?>5>/?'G]J+PI^SQX@^'^C^)++6+NY\::G_9=@VEVHF6*3=&NZ7+
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M*\&U[]LOP);_  "N?BSX=AUKQ?H#/<06,.EZ3<M-=S0EPP*F/,,>8VS)*%4
M>I /D/\ P3Y_:X7XN>![:U\2PZ_<>,/$&N:G>&XCT:[?385:1Y$B%WL,2JB+
ML4%^,!>IH ^UZ*\T\??M!^%? .L7.B>3K7B?Q#:PK<W.C>%=(N-4NK:)AE6F
M6%&$6X?=#E2W\(:D^"/[1WP__:&TN^N_!.NK?S:?+Y%_IUQ$]O>63Y(VRP2
M.N2" <8)4@'(. #TRO [C]M3X?+^T/H'P9LX]9O?%NK-,/,_LYX+6W6.&64L
M9)=AD!$3 -$KJ3_%Q7;^/?CWX3^'_BBR\+7$FH:UXMO+=KR'P_H.GS7]YY"D
M*9G2-2(H\G >0J"00"2#7POXJ^+OAGXQ?\%3O@/J/A]KR*YT[2;[3M2L-4L9
M;.\LKA(;]_)FBE4,K 2 ]P0W!- 'Z6T45#=W<&GVLUU=31VUM"C22S3,%2-
M,EF)X  !))H FHKP34_VV/AKIFBW/B';XFO/!5L2)O%]CX:OI])7#;2PG2([
MT!X\Q R9X#5Z5_PN+P/_ ,*ZB\>GQ9I">#)81<)KCW:+:E"<#YR<;L_+M^]N
M^7&>* .QHKYZTS]OGX(:OX(U[Q=;>,%;0-(U :6;AK297O;DH'$=M$5\R8D'
M^%>Q/W1FND_9\_:Q^&W[3EOJI\#:Q+<WNE,%O=-OK9[:Z@!)"L48<J2",J2
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M/^'_ (S_ +,>I:5HFGZ9?7?C,_:;BSMDA><M=6;L9"H&\EBS9.3EF/<U^C5
M!1110!YG\=/VD/AW^S?X?M]7\?\ B*'18;IS':VX1IKFY88W>7$@+,%R,MC
MR,D9%<=\!_VY_@W^T;K1T/P?XJ!\0;6=-)U*W>TN)5 ))C#C;)@ DA"2 ,D
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MOBO4Z "N&^-_Q?T?X"?"OQ!X^U^WOKO2-%A26>#3HA).^Z18U"J2!]YUR20
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M9T5XM\/?VO/AU\0OB)/X!%SJGACQQ&GF)X?\4Z9-IEW.F"=T2RJ!)P"V%))
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M\4U;]KOP%93:L=,B\1>+-.T=WBU35_#.@7>HV%DZ??5IXD*.5'+",N5Q\V*
M/:ZY#XF?%+0_A3H]I>ZRUQ-<7]W'8:=IMA%YUYJ%R_W88(Q]YL D\@*JEF(
M)IOPV^,'@[XP>"(O%W@O7;?Q%H$BL1<V8;<K*,LC1D!T<?W&4-R..:_/3XO?
MM3Z!XD_X*-? _6?L/BH^%O#^B7\K6-QX<O8[PW$T%ZA>*T:(2R#Y(/G52!L;
MGY6P ?6?@?\ ;>\'^)OC4GPGU_PWXI^'GCF=/,LM/\4V<,:7JE68>5+!-*A)
M56ZD E2H)(Q7T37GOA/_ (0GXT#P]\1(_#'FZGIQGBTO4->T5[34++)*2[%G
M19(PV#V&0?0UZ%0!2UC5[70=+NM1O7>.TMHS+*T<32-M'HB LQ]@"3V%>._
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNHFD_P"$MO3#H[*F6&B66Z*TV#K^^;S[CW^T+Z"OG_\ X)UZM\3OBI\%M?\
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M%R&9<9^N/@+>?%GXQ>*H/'_Q/\*P_#;1]-@EAT'P<MV;FZ,TN%DO+M]J@,J
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M ?0U5]0M!J%C<VIEF@$T;1F6W<I(FX$;E8=&&<@]C5BO /C]^T%\1?@[X_\
M#]EH'P3USXC^#KVV\R^UGP]<"2YM9=[ QBWV\X4(V690V_ (*F@#XP_;>_9C
M\4?LCZC%^T?\,/B+XGN]5L[V"'6$\07S7LS1R.$3,IP9(=WEQF%PW##!XQ7Z
M8> /$S>-/ GASQ"]L;-]6TVVOVMR23$98E<I^&['X5\\?%S0_%7[9WA&#P"?
M!FN?#WP!?7=K=>(=4\4+#!>W=O#,DPM+2WBE=E=WC7=++L" '"N3Q]/6-E!I
MME;V=K$L%M;QK%%$@P$10 JCV  H ^!_^"H/_)4_V6?^QS'_ */LZ^_Z^ /^
M"A&@^./BE\3/@W/X+^&WBKQ%;>!_$#ZGJ5U#9".*15FMR$A9V&\D0N<\+RO/
M)Q]T^&/$"^*-'AU!=/U#3!)D&UU2V:WG0C^\A_GT- &M17Q]KG[5GQ>\'_MA
MVG@?7_AA]C^$.IZG!H>G^)E@E,DMS+$SQ2K-N\ME+(P:,+E0,ELC#?8- $-W
M=P:?:S75U-';6T*-)+-,P5(T R68G@  $DFOFOP-X0D_:0^.FF_&?68)H_ _
MA:&6S\"6%RA4WLDG$^KLAY"N $A!Y**),#*UY9^UY\4/C9XH^(4/A3PQ\"?$
M'BWX9:;,3J:-<+:1^()5/RQLP#$V@(R4P/-P WR95ZNH?M>?M87&FO::-^RM
M+I=ZR^7;SW5^9H83T!*!4R!Z;A0!!_P6DT6XO_V8/#=]#O:.P\56[3*H^4(]
MM<H&/T8J/^!5]M_#>XAN_AYX7GMU"6\FE6KQJ#D!3"I _*N'^*/P)_X77^S?
M?_#/QCJS:AJ.HZ3%;76M>4H)OD"NMR$   $R!]H &.!BO'?@[\3/BI\'O@78
M_#G7?A3XEUWXE>&K,:-I=QIT2RZ/JJQJ4M;@WI8)%'L5-XE*N,'Y<G: #QC_
M ()KVT^L?MA?M6>(8B9-/;7;B/S4_P!6[RZA=.N/7A&_ ^]?1_\ P4A_Y,E^
M*7_7E;_^E<%:G[$_[,K_ +,?PB.EZK=1:EXRUN[?5O$&H0Y*273_ ,"9_@1<
M+G R=S8&[ QO^"@D&O>,OV<?%_@+PKX1U[Q1XAUVVMTMUTRTWP1@7*.QDE)"
MKA8VXY/*\8.0 =?^Q3_R:/\ "'_L6;'_ -%+7M=>"_L576L:9^SYX)\)>(O"
MNN>%M>\.Z1!87<&K6GEH[1C9NCD!*N#MSUR,\@53_:5^.'Q;^#?C#PK)X,^$
M=Q\3/!EW&XU:3296-_;2AOE"( 0%V_-DJ0Q!7*<$@'AW_!2;]DGPW)\-=1^-
M/@BSA\(?$7P?)'JS:AI2"W^V(DBEF<*/]:G#K)U^7!R"-OV-\&?%UU\0/@_X
M&\47T?E7VMZ%8ZE/'M"[9)K=)&&!TY8\5XEXE?QK^V%X57PG=^ -;^&/P\OY
M83KUUXJ>&'5+^W1U=[.VMH7<QB0KM::1E(0G:K$_+]+V5E!IMG!:6L*6]K;Q
MK%%#&H5411A5 '0  "@#YL_X*56L5Y^Q%\4%FC60+:VLB[AT9;V @_@17C_Q
M M8KO_@CE:I,@=5\$Z9( 1T97@93^! ->R_\%!M/\0>,/V9_%G@GPKX4UGQ3
MX@\010PVT.F6V^.()<1.[2N2 H"J<#DDXXZD>)>*K;QOJ?\ P3=M/A/;?"[Q
MBWCPZ#:Z(^GMIP$:/%)&&E,N[;L*(6&"3R!@<X /;OV"_ 7AVQ_8W\!0PZ-9
MA->T2.75=T88WS.A1O.)R7&SY #P% 48  KQ3_@C&QC_ &>/'%L&;R(?&5RL
M:$DA1]DM>GY5[5^R9XBUCX<_LJ^$]&\1^!?%>GZ_X9TV&PNM*_LTO-/(-X!A
MP=K@A0<Y&W<N[%>1?\$L?!OCCX,>#/%O@[QUX$\0>&KO4M<DU>TNKNU!MF1H
M(T*M(K':P,70@9W#!- 'WE7P#^U!<_&7]EC]J+5?CQX.\+/\0_A_KFCVVG:Y
MI5NS&:R6#'.%!9!P7$H5E&^0,!D$_?U?,S_%GX@?#/\ :2^(=GK/@'Q9XA^&
M&H"RN-+UO1;)[X6=PMG$L\?DJ3(8V(7F-3APW!RQ4 9^RA^T-\(OVHO%VO>/
M?!4]UI_C:32;33M9T/4$2*>."&65XI,+D2#=,Z^8K'C8"%.!7CG[$_\ RD _
M:N_Z_8O_ $?)77_ ?X 2:A^VIXM^.6C^$K[X>^#KK1O[.BT_4;7[#<ZM>NRF
M>Y-KG=%'A%SO56=_GQR37$>%? _QD_9[_;B^+>NZ!\+[CQMH/Q#VS:?J\=_'
M;V=H^X/NN9""452SAEQN(4; ^: +'@GQK)\3/^"O/BW3M;+-:>"/"LMMH%O*
M#B&5UM#-(HZ!G6XG^;NNT=A7<?\ !5[X>6'B[]D+7=?D@SK/A2\M-3TZYC.V
M2(M<1P2@$<X*2L2/5%/85SW[1?[-_P 0_ '[47A?]I3X8:7'XMU:*&*S\5^&
M+5Q!+?1^5Y#RP;VP<Q;0$)RK11M\_P V.D_:'O\ Q;^V9\+Q\+?"/@/Q5X1L
M/$%U;G7_ !!XRTPZ;'IEI#.LK+&CMNGF9HE51&&3!)+@$&@#P?XF?&[5/C!H
M/[#OASQ7-)/I?C+4+6_\11W"#9J<UO+;Q1"3LRO(SLR]#O4XX%?>_P ?/@+X
M4_:1^&]YX)\8PW,FDW$L<ZRV<HBG@E0Y62-B" >2.000Q&*^=?VVOV&Y_BM\
M!? VC_#(KIWBGX;H@\.Q23^5YL*QQJT7F<!93Y,3*YP-R<D;BPY[X7_M+?M:
M_$+3;;P7=? @>&/%.Q;:[\>:Y*]OIUOP UR+4QCS7P=P2.0J6[8R  5O^"J/
MA.P\ _L&Z+X9TH2C3-%U'2M.M1/(9)/)AB>--S'J=JC)[U6^#7Q;TK]I']HS
M_A6/Q3LKGP]%X,LK2Y\->"+_ &_9M:D2(,;^=@2)W5-DD4/W%5B_SLI*Z7_!
M0KX6^*/$?[,.@_"+P'X3\2^-=8M+NSN)M2BM08Y!&DGFS2RD@-+([;F SRY)
MQ6/^UA\#M;^,/P*^'_Q'\&>%/$_A[XZ>#/L%M8Q1:>8KMRJHTD;G.TQQG<ZR
M9*Y#+_RT- 'Z#].!P*6O%_V9_B]XT^)'@S3[?XB_#[6_ _C.WM\7_P!JM<65
MPZ[09(9 Q #9SL;!'S#D#<?:* /@#]@_QK)\7/VTOVH/%>N%I-9TZ[M]$TQ9
M0=UKI\=Q<QF)0?NC_1X"P'5LGJ353_@L)X?;PSX!^&_Q:T)WT[QEX8\216UK
MJ4'#QQO'),,^NV6",@'@;W_O&M;7/@3X]_91_;&UKXS^ /#5[XZ^'GC82KXE
MT#1]K:A8RR,LLD\<3,!-F53(-IS^\D3 R&/4?'GP3KO[>%[X%\(+X.\0>$OA
MCI6K1:]X@U;Q19G3KF[,<;+'96UNQ\TEA+)O=E55P,$D;2 >3_\ !3:2#X@:
M;^RW?WMLT#:QKL)D$;&.6))Q:LZ*ZD,IY'((.5!ZBOT T[X:^$='U>PU:Q\+
MZ-::KI]F-/M+^&PB2XM[8  01R!=RQX &T'''2OB/_@H]X5\=?$CQ5\*;/X?
M_#7Q%XB7P7K7]J75Q;6BQVC*ODLD<3%AN^X1P,#&,U]T^%?$0\5:%;:F--U'
M2#,#FSU6W,%Q&0<$,F3C\"0>QH UZ_/KP-:Q6W_!97X@M%&J&;P?'))M&-S>
M18C/Y 5^@<C^7&SD,VT$X49)^@K\^O"^G^-['_@I1XE^+4_PP\81^ ]2T5=&
MAU$Z?F0,L-N/-:(-O"%X64<9P02!R  9<O@G0O%'_!8S6H=7TNWU&!/#$.H"
M&X3?&;B." 1R,IX8KA2,@X*JPY4$:G_!2:PM[/\ :8_9&UB"%(=4?Q:MNUV@
MQ(T:WE@RH3W +N0.V]O4TS1['QS#_P %)=5^+DWPN\8Q> KG1?['COSIP,NX
M01CS#$&+;2Z%1QG!!('.+_\ P4$\->.?B1\9O@=J'@SX>>)O$5KX#UYM4U.Z
MMK(+$Z^?:.%B+L/,.('Y''(YZX '?\%.O&4NK^./V?\ X/SSF+PUXT\4VYUY
M,E1-;I=6T:1LPZKF:1B/5$/:OJC]ICP[IVL?LT_$S2;JSBDT_P#X1C4 +<*
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M;31A;B[\+V&7\I,9#B*PC&  ,!F ^7VH _0^UM8;&!8+>&.WA7[L<2A5'.>
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M,_VDOB'9ZSX!\6>(?AAJ LKC2];T6R>^%G<+9Q+/'Y*DR&-B%YC4X<-P<L5
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MJ -;_@I5HMD/V@_V3=7%NJZBWC&*T:X ^9HA=V3!3Z@,6(]-Q]:ZS]N#PO\
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MF;DX#-$I(Y8<U],44 <M\,/A]8_"SP'I'A?3I9;F"QC;?<SX\RXF=VDFF?&
M&DD=W(  RQP *ZFBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=K=/JGFJ=QR@R JX7:%^6@#[EJA_;VF"PN+[^T;3[%;LRS7/GKY<3*<,&;.
M0>#GI7PK^S]\%OBY'^QCX]\!?'BTUG2Y]%MKJ;0+J#Q'F8P?97V1O):7!\Q(
MI 2(Y<K@J-I"C'-_\$XOV<_"?QN_9!\/O\0$NO$^B0ZA?+9^'I;F2"P@;SFW
M3-'&R^=*2>&D)" #8%)9F /T3TS5;+6K&*]TZ\M[^SER8[BUE62-\'!PRD@\
M@U7T?Q)I'B!K@:7JEEJ1MVV3"SN$E\IN>&VDX/!X/I7YH?L?_"""3]HK]H3X
M MKFKP?"/2=0^W?\(_:W;Q&Y5F*"!YU(E$11E#A&4R>4FYL;@VCXL^%7A_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% 'GO[0'B[1O!?P9\;7^MZG:Z9;+HEZ0UU,L>\^2P"
MKDC<Q)4 #DE@.]?&7_!%WQEHK?L[^(_#K:I9QZY#XHGN#I[3J)S#);6P20)G
M)4LCKGU0U]\Z[X3T/Q1Y']LZ-I^K^1N\K[=:QS^7NQNV[@<9P,XZX%4M/^&_
MA+2;R&\L?"VBV=W"VZ.XM]/ACD0^JL%R#]* .B9@JDDX Y)-?G'X,\>>&V_X
M+&>-)QKNGF"?PPNGQ3?:4\N2Y6WM&:)6S@N CY .058=017Z-NJR*RLH96&"
MK#((]*Y=/A3X)C967P=H"LIR&72X 0?7[M 'SI#XR^#?[85[\1?AA\4K+0+O
MQ!X0U^_T]+2\D%O<BU64B&ZMI"P=3LVJY1OO)R & /@_[''P U*ZT?\ :I^$
MGA_Q%+KGP@O%ET;P]K-RXE@^VR0R*[1LORNT>Z)9&089HT( Z5]_:]\'? 7B
MHN=:\$>'-7+R-,WV_2;>?<[,69SO0Y8L22>I))KI-*TFQT'3;?3]-LK?3K"W
M01PVMK$L442CHJJH  ]@* /S#_8?_;@T']E3P?J'P/\ CRNH>"]6\*WLZ6-Y
M+I\T\9AD<R&)EB1GSO9V5PI5DD7!  )^K8_V@/%WQ:^#_P 4?B)\/-(O[7P]
M8^'[E?![7UH([C6;Q(I7:\6)E+"(,(EB4X+D29'*X]U\3?#/P?XTO[:^\0^%
M-#UZ]M<>1<ZGIT-Q)%C.-K.I*]3T]371QQK%&J(H1%&%51@ >@H _./_ ()Z
M_M*_"_2OV?6L[B_N]9^-.N7MVVLV,5O)>:UK5TTDAA8-C+H(B@W,P2/#EF7Y
MFIO_  1M^)NAV/P1\0>"Y)+C^W[?Q%=7]U$(&$=I:M:VX6::4@(@9XG0 G<6
M!^7 )'Z":/X&\-^'=4O-3TKP_I6F:E>$FYO+.RBBFG).27=5!;) /)[5+:^$
M-"L;*^L[?1-.M[2_=I+NWBM(UCN&;[S2*!AR>Y.<T ?GY^P+XW\/W_[<7[4O
MV?6K";^U=6\VP*7"D7:)=W"LT1S\X!=.5R/F'K7Z-5S5G\,_!^G7<-U:>%-#
MM;J%Q)%-#IT*.C Y#*P7((/<5TM !7YT?M]>%_&?[/?[17@;]H'X76?VK6?$
M"GPCJEB%RES<RQE+1G'\6["CG@-;Q>M?9O[1'QXT7]FWX4ZKX]\0:?J>IZ9I
M[Q1O;Z3"LDQ:201J?F955=S#+,1^)(!\)^%_Q:A_;N^(W@OQ1H/AW7-(^%7@
MF>35VNM?MDA.J:R8VBMXXE5V#);J\LC,&(\PH.V2 >K:+^SC::/^R7/\&DND
M+77ANYTBYU"0%O,N[B)_/N3GDEII'D]<FOB']C']NO2_V4_#-Q\#?CY9ZEX1
MU/PK<RP6.I&RDGC\AI"_ER+&I<@,S%)%5E9&7I@%OU(KF_%'PU\(^-[JWN?$
M7A71=?N+?'DS:IIT-R\>"2-I=21R3T]: / ;?]H[Q3\9OA3\4/'_ ,,=*OXO
M#&E>';I/"]Q?V7E3ZUJ2QN[7,43C<88]L:)G'F.TH(^45X'_ ,$]?VE?A?I7
M[/K6=Q?W>L_&G7+V[;6;&*WDO-:UJZ:20PL&QET$10;F8)'ARS+\S5^C5O;Q
M6=O%!!$D$$2A(XXU"JB@8  '  ':L?1_ WAOP[JEYJ>E>']*TS4KPDW-Y9V4
M44TY)R2[JH+9(!Y/:@#\]/\ @CW\7/#/AWX#^(_"FHWK6FKVOB*ZO[SSHS'!
M96K6UNJ333-A$5GB= "VXL#A< D7/^"0/CC0;JS^,.CQZK:'4KCQ.VH06QF4
M// ZL%D1<Y890Y('&1ZU]_CP+X;6PO+$>'M*%E>3?:+FV^Q1>7/+G/F.NW#-
MGG)YJ'3?ASX4T:^BO=/\,:-8WD)S'<6VGQ1R(2,9#*H(X)_.@#HJ\2_;2^#=
M]\?/V8_'?@O251]9O+1+BP1^-]Q!*DZ1@]BYCV9Z#?S7MM% 'YO_ +*/_!3[
MP1X(^%^F^ _C6=4\&^,_"EN-*EDFTV>5;I(5V1[DC0O'*%4*RNH!(W9Y(7Z(
MU+XV3>./V;?BE\0?$$;^$/!FHZ1>1>&[/6U6VN9K9;1P+B16Y#SR,VR/)RB1
M$#+FO<-9^%O@OQ%K<>LZMX1T'5-8C(*:A>:9#-<+@ #$C*6' '?M6OK?AW2?
M$ULEOK&EV>JVZ/YBPWUNDR*V"-P# @'!(S[F@#XS_P""2/B?2&_8[TZR&J6?
MVNPU.^-W 9U#P R[@7&<J"'4Y/J*X'_@GGXVT&X_;._:MABU>QE;6-?-QIY6
MX0B[C2\O S1<_./WJ<KG[P]:^^+3X;^$K!;A;7PMHMLMQ$8)A#I\*B6,D$HV
M%Y7*@X/' ]*2Q^&GA#3;R&[L_"NB6EU"P>*>#3H4=&'0JP7(/N* /S:^%7C>
M#_@G_P#MX?%/1_B-'+I'@/XC7;ZAI7B)HW-LN9WEAW-_=07$D4AY*L%)PIW5
M+_P4<_:,\!^*/B#^SSK?ACQ!#XATGPYXH^WWVK:2IN;./;+:R%%F4%)) J%C
M&I+*"NX#<N?TK\4>#/#_ (XT_P"P>(]"TWQ!8YW?9=4LX[F+/KM<$55B^''A
M*W_L;RO"^BQ_V*7;2]NGPC[ 7QO,'R_NBV!G;C.!0!\+_P#!73X@^'O$G[(?
MA]M/U2*1]4\0VL]G;RJT4\T2Q7 :01. ^SI\Q&#N7!^89J?\%1OB%X9UO]AO
MPM#IVOZ=?S:E?Z;+:1VUTDCS1B"1BZJ#DJ!U/8D#O7WUK/@7PUXCO!=ZMX>T
MK5+H*$$]Y913/M&<#<RDXY/'O5$_"?P0< ^#O#YQP/\ B5P?_$4 >1?%+QUX
M<N?V&?%.J1:[ITFG7/@.ZBANEND,<CMI[!44YY8EE 7KE@.]>?\ _!)WQ'IN
MI?L8^$],MKZWFU#3KK4([JU253)$6O)9%W*#D9613SZBOJ0_#?PDVGK8GPMH
MIL5E,ZVW]GP^6)" I<+MQN( &>N *YGXBZ++\-OAGXOUOX:>"]+G\96^E3MI
MUG9VD<+7,P4E$.T L-P!VY^;&."<T ?GI\)_VFO@1X9^+GQ8\7W_ ,0/$WP
M\0ZOK4MI-X=T72&G@N88BP6YGCEL[I!<-(TCMM6/83MPV79_JC]D/XG_ +-3
M:GJNB_"CQO;:[XM\17#ZGJEUJTDZZKJ\_P S-(YG1"Y4%SL10%!8[1DD^$_
M/]K7]FR#P#I^@?&O2XM&^*-JS/XA;QQX9>YNKK4'):>8R>2^T$_=5]A5=J!<
M**]+T'P7\'/VB/'7@77?@O\ #O3]-L- U^#7+[X@:;X>_L: B!BQM8F,<3W3
MRMM5L*T:H68MNVJ0#[7KX4_X+!>+-&L_V4Y=$FU2T36+S6K,06'G+Y[[=SL0
MF<X"\DXQR/45]UUS^J?#WPKKE_+?:EX9T?4+V7'F7-U812R/@ #+,I)P !]
M* /GO]F?]J'X/>'?V7?A?#J?Q1\'V%UI?A32;2^M;C6[9)[>9+2-&C>(OO#A
MD8;<9^4U\\_M4_$[Q5_P4*N]/^#_ ,"]+U"Z\!"^2?Q#XYO+9X-+D"$%$1V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
6%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>sgmo-20201231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sgmo="http://www.sangamo.com/20201231"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="sgmo-20201231.xsd" xlink:type="simple"/>
    <context id="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iee1b756f6c0a4abe92e4664a43ad8035_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i22a6be9ae52e4042a972a3c232e7c320_I20210219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2021-02-19</instant>
        </period>
    </context>
    <context id="id3b91f3cd3c1451a8c20a0625df26f83_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if6f46cdcf64446fbb0ec043c3e9bfa14_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i15b7ca23b9754fce9a17de50c7c8a39a_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i202e314c35d9413996c927fa899da1c2_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ia4b56ade4b50487fb2fbba4e2c124931_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="iedb5b79c99094b17a8f2ce637a6f9a2d_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i1099157ecec044679915cbcb253acd13_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ief4531bd4090429ab0a53e48c051817f_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i22d2afa166f04addaba3df267d7905bc_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3d05b39e6b184c809c28b20cda11f744_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6d6997ffafa040db837de130bd2c9cc5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i5eb85ed8fe2a4cc9a528a3f2afd5ee04_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i79a71c8223434e32990a220f63b9c4bd_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i651b9b252cc242febd5e34ac22fad42d_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i6d4c9fcbe5f94694af0132cce7457120_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1f51a95393aa40d082b4cca44112fce1_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i921be278c72e486185352cb920f4347b_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ib5022310b80e40a9adf07bedacb21665_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iabf107dbdd5b48f8903b89e3c7cea36e_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ia6f7ea91dc8646daa2cc71ca00f38850_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i80940087d3b44c008290532496a8063a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iddc7094e93e045b7b4aade122a21ba69_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i4d0c82cbf5e5409490970fcf70c60bb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3d79e000a7564936afd32ea6d9c1290e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i1f5e0542d6f24c119eae1888c0d6a5a8_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i21e69f23c33c473daf20855d84a342a2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iae1f574b2f8c4344aa08242f7ae98ac4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibf0ea9431c824de99c89f4536634ee4b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia724ba89921d4bbfb3ab7f41022dfa7c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if95cd0d324cb450abdb22b5197a92e30_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1627062e2d1a4e6db06f7f2ed164591a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0eae3c26ed10449298243b22f0dc770f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2728c5446992435fa94d6ae800954885_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3d1e7cbe14db45d6a003fba4484e6074_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idcd9bdcf4f1749ed855ea52ac19c1e57_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i66dc03e15abd412984fd7c2b45d9d856_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3eca6f8c437940cbabb9d377e58e590a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ie858b057f0224ebf8778dd6b34548eab_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7c141aaf58334fba855db4ee4e38db81_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic0ad2d8d5ce840e99dbd93fd64e0439e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i8133ce2775074245969bc9f50d4ffa89_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i196e1cc25f284d418cc58737e82a5139_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if1555d5279c444f89f02b32de1c4f4c5_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerSB525Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:ChangeInCollaborationAgreementScopeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibe21513e3cbc4ef9b8379cf9af56af7d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic2340761cd284f108a1e5d64cc980af8_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i30e0b646a8df46a79e760eb6aaef235e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i88b6be668e8d446b9d5199171f704f9f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaf6e9495caa24ce480ffea19c28f507b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i04e7b9f9d96a4feca307fbdfe9824533_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ifafcd10a99b94ea9a3cd858f75019057_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae79ca8469af4ddda9eb0ae2461bfda7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib362499858ff441b81abb16c4b161e94_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="id5af392ecf9040dd85a30262c5b91b6a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i21037a15db8240bba2e6a6eacf66d265_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i05a8036803764bc19d8b0408d9a6778e_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iffb1c905529f4b78895e5ec6a2fb1454_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i75abcc855e7c486a8f9453c309984ec6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifef75ce3e3d4408195a24cf8317ce59b_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">sgmo:RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ie917e6f491354d9cacd7d16bca15c4ad_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b662a6bf84f48d6baa29804b606526c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if3a7053c82b34112baeacb539acdacee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ife4a9b65e8c8453ab64e7777ee2d3100_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i538799473b654234a0fff4940007026d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if3382b9ba2d54e45aab7d37fe53c048f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4bf0705352c54572bf4f38ac982a31be_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26c02145fa9242f38709a5edc46b448e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa885c5039e145c09f646a2a7f4b8107_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9b3adc9c15cd451ba7eaf4b09cd384e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i561ac4ef919945fa872f15ce1139a321_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i031949a99f364927ac232102e610e2ca_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i98278431e88f4c0db17846d0b3dbbad8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id6465df1f81a4ab5a788482e7565d968_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id92a9f54439349c1a5e6a1bba22a0d23_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1a201eb484d4bd5a0b59012ba2f791d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i16d9dab193d54c309786833b5661b693_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if5c17352407648038a079be92904f2a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i307cf2a5e93040adbb97545d97da4f9a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id8632ee484ed4ce287dd150a59f7e976_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifed10ba46af8409e8b84b8e8186dc592_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib8205c80a5c0477aaa06acb0a8e8e7da_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4478684879bc414381bb41ce8b5add16_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3e83dea29142486786bea569ac583153_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i638b4338e64c4c0c9035f64c4bda767b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie6648a09a42b483cb342868211de9128_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaea9ff66312d4cb985f8cc0115634d45_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0bb9617224f949bbaa727b52246f5819_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i290f705cf9df4b7c8d071b425026aec8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaaaf320a38a84e55affa256f7f30ad18_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c791708c2b54c489b0564343ced9b29_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1bd782cef16a4070ae70af4879663f30_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5de38cf429814456bca0ed781cb6c510_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i452c62674a9a4271ba5e89c6c050a050_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1cc2751230724e7381a103381d9dfb53_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia9ba3950185d4776adff785cc0c2a7d2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9b12148036dc4575b8e1a20cf11d14ac_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e9967af55594a0298a27d240144e1ee_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i67764fa5748c4450ae52695bab506bb9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4407422f7c044d0fbec953a99a3872a1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3bfe2c49f1a646b8b8fc3e3df333620f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iaa947c04f600459f8abe14c30287d39d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id6756c61effe4e938932ae8029a287b7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8674e557d87406d95862eb814aebd8d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7a51c69784164925a1155915e905a9e6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i233261fb4cbb44eda76666923ba0fa00_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iecff100e21624aa380f317bd2cc77424_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibad5f02563ca4f3a935b0a28075cfc38_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ief8529b02bab4938b24e07cedff4a61f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="icb3348e7e8ad4e5e8f79068e98c38849_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i409228d676604420a5080c8402d96e8f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib6e07e12ba97461c86c7911b067139c0_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic469cb9c12c84ba284e53503bcfe990f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i89d852320136494288e8326d40cbfdf4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0b619f4f00de4396b3df3e86c1308164_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ica609585796849f4b3f75e74fd3cd261_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ifc061743215f46799ca3ad39e4073044_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e0cda171ca943959c35929427e42666_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sgmo:FreeSharesLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic88a281a19cc4a8daaf8b3f721602378_I20180720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-20</instant>
        </period>
    </context>
    <context id="i7377f8b263024b66ad603bd494ee0f22_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i333a5711c7bb4f51917b34946c0b9f23_I20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueOptionPricingModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="i16391b7df5174ed5b8c2310d931447ad_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibda42ad49ccb40e6a99670b2432a3b0a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40c0c8a181b34eaaa65d8a1d56afba94_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i40f0fb62debc4ccf8d53156b1bc24685_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i00900b9889da4cdaa8eb8e2b586dcb12_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i297eba0e37914b6d8ec0577f4ee289d4_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1da1bc0ccada4c6289947f9de2c4b135_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">sgmo:MeasurementInputStockPriceCorrelationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9bff90492d5f446284b8b7c02033b51f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie2a3f456b9804ec4b6dd169a8bd7f4ba_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibaa6bc7784424a67be7faba1d682b136_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i010cb6bb38804fb49deced19c47e723d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd6eb7b715da4cb69e1a51dd18e5bc9d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id11b23041c6d4a04a5f707b52b28660f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33732cfa0f614ab6a16f0a26f36db075_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i25b9c44848094c8188cda00e8392c015_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7aae7219ce14478f887d9df6f6050a1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3f6d62eac76941a9907a1769725bc84f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2fd506f04f5e450699099f18e1a52d5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie054ce2f1c4741c38e021cbc84c88cae_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i166d41c1d13840e79f6069d74eed0581_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i195f8095900e47b59c48f9b46ca9e135_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib59efa220c014139a6c6518f23eb3381_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6edba78934f34526818d49f23b52582d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ie90d9c1847f64dc498789d1a25747db7_D20200801-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="ie25f2c3034b549c1a2403b3c2b59e8be_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i08c85ff8ca5b455fa7266f68c7634773_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="i679870fa4aa947f2b092c683d49e48be_D20200727-20200727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-27</startDate>
            <endDate>2020-07-27</endDate>
        </period>
    </context>
    <context id="ic9662bfa60bd435086718d9bfee03841_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i41532f5f82c84a95a08ae7d3f428f14a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i65e104e30eb7451ebcb1b6d67543ae50_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib3b3cfc543ee4dfbb9fa9f54e698bbe0_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i09bf3f7bc1bf4ca2aee88d98cbb49c11_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:NovartisInstitutesForBioMedicalResearchIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-08</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="if650f84ed8e44993a9c4382072ecf061_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="iecf6454954a34af8a88c9bb4071baf99_D20200501-20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i1c641a230af14951931f575b265aa8bf_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="ia7101296ba8e4016aee3ac0bd6885981_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PreApprovalMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i36d7c81806f3497d988a10597afd1494_I20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:SalesBasedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i9997a66b33774bf8874b84e01397ca61_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i2433e456bdfb43a4aa95fe4c28d4d208_D20200201-20200229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-29</endDate>
        </period>
    </context>
    <context id="i336e9bea9e624f2d85ca346d8219bd49_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="iae50536cbc814ac6a99bb260423fdb2e_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icccc34360eed452f9ad238a715656769_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="icb0c68923ff146d280fb7f97045dad9b_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6dbd4261e96a4a87808a78d8e6b23ba1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie4b362953ca94b868a22eeeacdc5d1c8_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i791f1d7d58614b2e92e9f6fca8affadb_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i86be779bb370428988a0873a257efbeb_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i622b78d941574e52bc533f27c36c5fe7_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ic0e221499b664eee8f775e18eb6f11f8_D20180404-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-04</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="i6b05e76cf87f4a609ff6d9a1d6be38e3_D20180404-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-04</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="i15ca38def7cc4d739746ecdfadfe6b6c_D20180404-20180405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-04</startDate>
            <endDate>2018-04-05</endDate>
        </period>
    </context>
    <context id="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifd8eb466e5ab46dcbfe11a464c069eff_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i279331e783974f13b570a80bdae2914d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic99454b17cf8426abe411aa4bfe33b84_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie7c5dfd1e85a4c9aa4e84a23484dc176_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1bfa78bdc3244b5693d30aa711524848_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibd7a58620bca4d85b6783c708b906014_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if07241a21483414fa49f01f2b3ff040d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i160f22e556494a06802b40e3edf5f834_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3d31979f09c648999fccb66122fd46ee_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9fc50ac5b1034ddcab9f5dc7d229bd83_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i42157f7e86b3408ab390ad6b9ce433d2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i16e9fd5645c342c6a53a2d4075df3f32_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i16d56044bc30409491f4cd99b8ed0162_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="i828ebcc51b3447ab9fb4c223a4ed2af9_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:GiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ie7ce5c1ee6e64ac5b1260a8a278341bf_D20170501-20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="ic844e08373f649f89686b25d4f48e080_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:GiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="ic3ea3fbe1ff04cd78a9c151aab7fe03c_I20170531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-05-31</instant>
        </period>
    </context>
    <context id="i108f738726ee4d188ea13f5c58559305_D20170501-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:GiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i56711bf4d33b463384f2cf6fa4b99cdc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:GiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iadfc90055252476ea94b6b78e49c2e2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i55dfc2b24f4d4413a989e868a6ffeb5d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i13a9ae1225e7485bb10275ccee50ca2d_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2e6d1ed2be0044ea9cbcaf840d0780e9_D20191201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ieae2c1f6faba4e33888460da2e302ddf_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:AmendedCollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i24940a7706ea4d2d978b4613538afbda_D20201001-20201030">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-30</endDate>
        </period>
    </context>
    <context id="i9ccabe9bc30f4799a7625faed92a6917_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6100f8c9e8534579a67d80618dd87117_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia5c0d2ceb04c46e0a6ca01fc7f9e2ee7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i22cdf77958324fea8f5137db56d2e321_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i435e100ac21c4e6f970572239a77eda2_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7fb94b0bae17481a87c59979d81ce0ca_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae47e409b4ea42aabf27810d9f1f5f22_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i9745d562dd854f4fb6b39832e3c4a5b4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i9782c197ba3149bb984663397b6a69d2_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i10f82f0783e54af6831a3e260dd85a3a_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7e8f31eadadf4aefb75c29f6979d4b3e_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib0ee411f36884cd796eb1615539214bc_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i233ad9c6f5b64570a51d2349ba0f80be_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerGiroctocogeneFitelparvovecMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7f3fd66a77ca4c298f3fc4272b6044f2_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if4d9b4cf1fe14e8c82e398543c33609d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3baf5d6da95a464d83ca547a1f07fb10_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ie4c4b9a1b3734f819b23f8fd6c8bebc0_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i5f62390b2d3a48338361f2876c31e6ab_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfCommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="iee59d8fb45e041e791c0ab5b1d0fec94_D20171201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8179c5be57324f34a1d01a5075b4a59a_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="ifaa9934a0caf4048ad529227a6b3e342_D20171201-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i3c9f2942ee064c10a7180d004ca68961_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4e2d17dcf5e64a158d897e7941665566_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i51fd8b7623f54652888d1fbd20802015_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaeb550dc7fee4f0daa6ea8fc7073f7db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2886651fadc8409c8daddb378e4b5b45_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iacbb3e15255f4990bd049724d75ef0f1_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i26f68e79e666471ea1075c8953d1f9ed_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1d058778fed0482c9abdb1e80bf3e5f0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ibf79dd2baa0749b1942c7d86d20c6f21_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1df52988f363438398a2de08f94aa387_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i85bea8547944486692a85e6b523ddecd_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:PfizerC9ORF72Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ibe586645e7eb480fa88f004968e69f26_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i9122d80b46af45729722b3a5a580fddc_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i42a8f2c72a0c4b7da4f6fe01645f2fbc_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:AchievementOfSpecifiedSalesMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i91c96f778c484ff7b36d40e42b5cef1a_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="i3117020fd58a4382be68a9dd0e475832_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idd4d071a5a1240e899107dc0bc2d0d7f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id81a1acd8821404c8ec43c3bcbc17cf3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i034bd4a542ff4479990ca46381d0f393_D20140101-20140131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-01-31</endDate>
        </period>
    </context>
    <context id="ic6f1610375924f09a443d3568cdc1d68_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1a4ecba9c6614c06b7f7c8459b127a96_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4dc2cac8272f43ee8e45b5b6bd542b3e_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="i9b1c3dc836d24210b520f3db7f97f9c0_D20190801-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i94120f03c5fd4072a8bb3031d5eaff43_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="sgmo:CollaborativeAgreementMilestoneAxis">sgmo:MilestoneTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ib3a5217c51de4459902f1b79d64f6c95_D20140101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i78bd26e8f611439f93e83caa744593ce_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7cd52bb2ae3a4d5e9b83e8bb8f82e121_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i0aacd04dbe964a6fa6e32e1188460504_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="iaedf24cb2ecc475bb59fce790b63d4dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0224ad04487349818fda88d3a4f7b06f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i739d766508794dde903e7ea835312bb5_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:ResearchServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic9bbe06eb17f4e4389ae875bb992beae_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i61957911f74047ab839b3929a36f2784_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ief2fc4f96355416b89ed85d1b3204e27_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sgmo:MilestoneAchievementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib6851909816f43d9927a3b74f4eb9ae0_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i41b192f0b536424dbbf09712a8ca6db3_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SanofiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i6a973ce71ad84032872771f13a2ca702_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i764803be26a0446cb2b582d6f52c4848_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i7808e1ec9ea64ec3bca436fa6a85404a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i194b83713fb341fbbd2acdc7368d1a8a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CaliforniaInstituteForRegenerativeMedicineAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i64443d1a16cd488f905e7295d699439b_D20120101-20120131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2012-01-01</startDate>
            <endDate>2012-01-31</endDate>
        </period>
    </context>
    <context id="i56dfa7a7f694412ca8f155eddda57f6b_D20140101-20141231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="i7d2161524129470cafb1f5a6567f6cba_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8e5077542aaf42a4bb4062f041a4038c_I20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="i7b3feba275324427aa270226c8ff4256_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6b3e32e94c384b1e966f84999353cd18_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="if86082d75aed4dbdb15c659083e9bf9b_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i01464b993796404cb11757f956a8a3c7_D20070101-20071231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-01-01</startDate>
            <endDate>2007-12-31</endDate>
        </period>
    </context>
    <context id="iccfbbecbaede42b5845fac46fdce4a09_I20091031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-10-31</instant>
        </period>
    </context>
    <context id="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-10-01</startDate>
            <endDate>2009-10-31</endDate>
        </period>
    </context>
    <context id="ief34bca385d04e8aa286ffe64c5ec431_I20091031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2009-10-31</instant>
        </period>
    </context>
    <context id="i706a8d68f1cf40cb9c3132b4ff11e8f2_D20091001-20091031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2009-10-01</startDate>
            <endDate>2009-10-31</endDate>
        </period>
    </context>
    <context id="i546676fe6a9d40ddaa72ca93f19fcba8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if616c1c1a07f410682a95cb374ebf65f_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iad0d9ea6bdab481590237f5b575dc744_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-01-01</startDate>
            <endDate>2005-12-31</endDate>
        </period>
    </context>
    <context id="ib2df94fee7564a61bb14696381264213_I20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2005-12-31</instant>
        </period>
    </context>
    <context id="ia280905d8bb74bf892bb6bdb624a87ea_D20050101-20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-01-01</startDate>
            <endDate>2005-12-31</endDate>
        </period>
    </context>
    <context id="id5fceb7cf1e54c71be44f291df33cab6_D20050101-20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-01-01</startDate>
            <endDate>2005-12-31</endDate>
        </period>
    </context>
    <context id="i8b580b7103874a51aa8d767ed03b3928_D20050101-20051231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2005-01-01</startDate>
            <endDate>2005-12-31</endDate>
        </period>
    </context>
    <context id="i1e7888a0f40541728fa78e28fb8d32b9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i13e149c04b9c44ae968ce27839b0ff98_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i6d636ae7fc074737a7f48065c83c1704_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7a7eb33edfe747c3aefde90c4e3c2a60_D20181001-20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-01</endDate>
        </period>
    </context>
    <context id="i02eebe0086a243caa7e9e1bb622faf7a_D20181001-20181123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-11-23</endDate>
        </period>
    </context>
    <context id="i4a6b2a742e264c81a0162eee4479ebde_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i592fbd2441fa41bd9d36900308836ecc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i0581803351f54eeebd9c251d33078aec_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if6f3f191be824087ad8c554b2a988bfa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i5224f1a418c04fb395423371d5cd63de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i796f26491be441f2a96fe82d3903003f_I20181001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-01</instant>
        </period>
    </context>
    <context id="i727255e08dff491997abe1595a807416_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib03bf486440e4058b398c99085b2e3bb_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i17ed21c4f31a48f9884d2e5a34a07660_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i78b6fc4c001f43229955467cb883d455_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idd01b55790404653a8dbf54a898c83e9_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b618149cf52411482e490b4cfbaa70b_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i0f9736e534b649e19378d63d2cb29bd7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7127032c342b4a9ba46f6b46c2355df9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="idc0d4241c9514c2bbe8a711b6b6d76c7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie7bb97c3073446b9aa8c3f008be817ce_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia6609b14089f4212a584aa69b64acfc5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:BrisbaneCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibbb078359b94445aa19de4957f01c8a3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:OfficeAndLaboratoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia9ddad8fdf914a9eb455c759a9202939_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:ValbonneFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ad9465ba0dc4a299f459f90c677d791_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i06474dbe630c4f41836daafffa78c161_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">sgmo:RichmondCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="ie376e3e497f44b6090164ea2f06721ba_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5adb6c8a5fbe4ae8998f2aaff0f11681_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i99562ae603894a8189b5ff099684f86d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BrammerBioMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i68aebf0104924b419a789b0d776a9b5e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:LonzaNetherlandsBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i04133be982284def86006aea3fb52327_I20200629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <instant>2020-06-29</instant>
        </period>
    </context>
    <context id="i34bcdc0ce9f64813a8d36f116a1f90eb_D20200401-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:BiogenMAIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i77930a25b46346a2979712dac12ee7a0_D20190401-20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="i30d8dda504854d9ca7d63f9a88cc3816_I20190430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="ic46aca1e871a400a88bda284834701ce_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="ie0bb49a1111a409c8731842f7bda4df1_I20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="i075446115f764740898840df11c14db0_D20200805-20200805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-05</startDate>
            <endDate>2020-08-05</endDate>
        </period>
    </context>
    <context id="ic740901c064241959e061ee1525d0c94_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:JefferiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1a2222cfa49440338b7416d398920ffc_D20180401-20180430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-01</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="i66466b43ef874206b64889bb27cb2d08_I20200531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:Restated2018StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i91713b083997409ea11ba55173dcc112_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib8715c1886674912998f731a86a14a57_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ief4c9ff8ff294f60aa457e9361e9bea3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i18bf0cf17b5642529f184871db5ac039_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i6aabd68f41804669ac596bb7586ed7bc_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="icc4c94703dab45468283cb739266adc8_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i042ac2c793264cb2bd18dd2abe87d7dc_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i53b6b787aad747bb9826358cf0f80be9_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icd4d7fedb43e46f1ab4828dbcde9c9f3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ic393a32a90e74583a781dcf3a5e9a6ee_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9d397545580d4460a2a0fec1fc8ba1a5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6df1c8f3c9a84c598d0ae819a426267c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5cec61b66c8248d2abcb75627ce796b4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i855baf86bae64ff0bd95f564c7fd3fd0_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idf94cc35763140c7b88de393e914a63c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f5dfc4d40fd4effae8227da27de4cfc_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7597d30081de44f3921ada32f9dbc896_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i223299de6a284218a780245b2f4e9fb8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9a566e45d4414942be208342c5c516a6_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ia188228a2f714148b418bbafdff8df68_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i3f59d4e0ade74a58893ddc753841891e_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i279740780022456087bde23ef4f549fa_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ib90a62c3edc44c90a63b7c1744a27bb7_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i3d3f08aef11f4a318908f591e111b593_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i29b01dbcc0f74a77aa727c03cc8da109_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifd84dea3dd62427db0d47cb010b83133_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i1cc661d039934a93b782c591c4f4b854_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iae60b3bb0a244843baf181d3d3f789f8_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icc4caf6b9fb443ea9a67e1cd79ff3121_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i51512ee82f7c4322a3633294ba2c9a7c_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i43e320fb9b704556adf1b2e8fe7699a4_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i311774a19c3b43b292a88509437d6a57_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="ia4f372a7d1ad4108a38bfe05388f5e5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i218e12e36203494ba48b0ba0613475c4_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i83b08e5e95284441967eed76e78797ba_D20180101-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i7b08863acefe4d8ca8e10ed1322fc31b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i0470d6b5a9684856b669c0c4cd5d041f_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia9b4e0c3f43d4338ab8fc2ce3ffce740_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:MinistryOfTheEconomyFinanceAndIndustryFranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i84d0b5985441420eb3dbc496787e07aa_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:FormerExecutiveOfSangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id6374baea04443699a67c6e73111ae5d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sgmo:FormerExecutiveOfSangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:SangamoFranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sgmo:SharePurchaseAgreementAndTenderOfferAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i48f4d381b117429fa8a27a467285b605_D20210101-20210219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-02-19</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="segment">
        <measure>sgmo:segment</measure>
    </unit>
    <unit id="eurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product_target">
        <measure>sgmo:product_target</measure>
    </unit>
    <unit id="option">
        <measure>sgmo:option</measure>
    </unit>
    <unit id="product">
        <measure>sgmo:product</measure>
    </unit>
    <unit id="milestone">
        <measure>sgmo:milestone</measure>
    </unit>
    <unit id="program">
        <measure>sgmo:program</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="installment">
        <measure>sgmo:installment</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml80L2ZyYWc6OWU5Yjk0NTEzNjZkNGYzMjkzNDIzN2YwZWQxMjM3ODkvdGFibGU6OTczM2JjMWM0MzA3NGRmMjg2MjM2Yzk4NDAxNmQ4MDgvdGFibGVyYW5nZTo5NzMzYmMxYzQzMDc0ZGYyODYyMzZjOTg0MDE2ZDgwOF83LTEtMS0xLTA_8af205dc-dc55-442b-80cf-c582528bc901">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml80L2ZyYWc6OWU5Yjk0NTEzNjZkNGYzMjkzNDIzN2YwZWQxMjM3ODkvdGFibGU6OTczM2JjMWM0MzA3NGRmMjg2MjM2Yzk4NDAxNmQ4MDgvdGFibGVyYW5nZTo5NzMzYmMxYzQzMDc0ZGYyODYyMzZjOTg0MDE2ZDgwOF85LTEtMS0xLTA_05e2f740-62d8-4c38-b215-b435b80e3d8c">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml80L2ZyYWc6OWU5Yjk0NTEzNjZkNGYzMjkzNDIzN2YwZWQxMjM3ODkvdGFibGU6OTczM2JjMWM0MzA3NGRmMjg2MjM2Yzk4NDAxNmQ4MDgvdGFibGVyYW5nZTo5NzMzYmMxYzQzMDc0ZGYyODYyMzZjOTg0MDE2ZDgwOF8xMC0xLTEtMS0w_ab750bd7-69cd-4998-b34c-74b83c8313c2">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml80L2ZyYWc6OWU5Yjk0NTEzNjZkNGYzMjkzNDIzN2YwZWQxMjM3ODkvdGFibGU6OTczM2JjMWM0MzA3NGRmMjg2MjM2Yzk4NDAxNmQ4MDgvdGFibGVyYW5nZTo5NzMzYmMxYzQzMDc0ZGYyODYyMzZjOTg0MDE2ZDgwOF8xMy0xLTEtMS0w_98dbd816-ba57-4d24-b9c8-0a1afe6a8f49">0001001233</dei:EntityCentralIndexKey>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMy0wLTEtMS0xNjEyL3RleHRyZWdpb246NzFmN2MwOTg1MThiNDk5OTlkYTc2YjZjNWE1N2ExODRfMzg0ODI5MDY5NzMxNA_3e224bd6-7770-4f80-a1e8-1ea28d8e7eec">us-gaap:AccountingStandardsUpdate201409Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:AccountingStandardsUpdateExtensibleList
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTUtMC0xLTEtMTYwOC90ZXh0cmVnaW9uOjNhOGYyMjhiMzNkMTQzZWM5ZjU0ZmEzZWZjMTM0MGFiXzM4NDgyOTA2OTcyOTg_5213575c-8402-4879-a9de-4af8a6520892">us-gaap:AccountingStandardsUpdate201801Member</us-gaap:AccountingStandardsUpdateExtensibleList>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ie917e6f491354d9cacd7d16bca15c4ad_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTY1MDM_37296027-8590-4fe0-b3ed-3ef8d7731671">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xNjgwL2ZyYWc6YmQzNjY4Mzk4ZjFjNGJmZWExNTJhODRhYTA1YzMyMGMvdGFibGU6YjRhNDllMjEyYTQwNDAxMjk0YjNmM2FkNTVkOTExYjIvdGFibGVyYW5nZTpiNGE0OWUyMTJhNDA0MDEyOTRiM2YzYWQ1NWQ5MTFiMl8xLTEtMS0xLTIzMDA_625b2d8a-b01c-4c68-8a56-750c0175397a">us-gaap:AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="ie376e3e497f44b6090164ea2f06721ba_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzY5Mw_274e8caf-5cf0-4157-9146-6781d7736ff8">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xNjg5L2ZyYWc6M2MxYTRlYWVkNTRjNDZmNjg0YWJmYWFjN2YwYjlkN2MvdGFibGU6OTY1NTI3ZDYzMzM4NDg3OWE5MmJkNTQ4ZWYzM2I2MWQvdGFibGVyYW5nZTo5NjU1MjdkNjMzMzg0ODc5YTkyYmQ1NDhlZjMzYjYxZF8xLTEtMS0xLTIzMjk_5af04a9a-3dee-4a86-8af7-818b6fac7a75">us-gaap:AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i042ac2c793264cb2bd18dd2abe87d7dc_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTIvZnJhZzo3YzVhOGI5OGNmOTE0NmQzYjBjYTJlN2E0OWJhMGVmZi90YWJsZTo2ZWY0ZTQ3ZTAzN2U0YmRhOTBlMmQwODg2ZTA1MGY5NC90YWJsZXJhbmdlOjZlZjRlNDdlMDM3ZTRiZGE5MGUyZDA4ODZlMDUwZjk0XzItMS0xLTEtMA_678f73b7-5810-49c3-bc11-d65d0984b088"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i53b6b787aad747bb9826358cf0f80be9_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTIvZnJhZzo3YzVhOGI5OGNmOTE0NmQzYjBjYTJlN2E0OWJhMGVmZi90YWJsZTo2ZWY0ZTQ3ZTAzN2U0YmRhOTBlMmQwODg2ZTA1MGY5NC90YWJsZXJhbmdlOjZlZjRlNDdlMDM3ZTRiZGE5MGUyZDA4ODZlMDUwZjk0XzQtMS0xLTEtMA_33a40771-d126-4def-8ef0-42432e54baad"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="icd4d7fedb43e46f1ab4828dbcde9c9f3_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTIvZnJhZzo3YzVhOGI5OGNmOTE0NmQzYjBjYTJlN2E0OWJhMGVmZi90YWJsZTo2ZWY0ZTQ3ZTAzN2U0YmRhOTBlMmQwODg2ZTA1MGY5NC90YWJsZXJhbmdlOjZlZjRlNDdlMDM3ZTRiZGE5MGUyZDA4ODZlMDUwZjk0XzYtMS0xLTEtMA_2965c0b7-852b-40ea-9089-32489e68ef7a"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic393a32a90e74583a781dcf3a5e9a6ee_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTIvZnJhZzo3YzVhOGI5OGNmOTE0NmQzYjBjYTJlN2E0OWJhMGVmZi90YWJsZTo2ZWY0ZTQ3ZTAzN2U0YmRhOTBlMmQwODg2ZTA1MGY5NC90YWJsZXJhbmdlOjZlZjRlNDdlMDM3ZTRiZGE5MGUyZDA4ODZlMDUwZjk0XzktMS0xLTEtMA_6f761cd8-dd7c-4809-aa21-ddad54b8333e"
      unitRef="number">0.0208</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8xODE_e43ff816-8248-485b-b791-a861b2669082">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MTg1MzAwZjVhOTFiNDMyOWFiY2Y1OWU3MmU5OGY2ODUvdGFibGVyYW5nZToxODUzMDBmNWE5MWI0MzI5YWJjZjU5ZTcyZTk4ZjY4NV8wLTAtMS0xLTA_f7e5fd6e-d03b-41e5-8cb8-f03127b3e0bd">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zMDg_0d322f2c-f264-471c-b845-009ce531a935">2020-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zMDg_3d992c01-d9ee-493e-84d3-4efae693811b">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6YTM4OGEzMzJkNjQ1NDM4YTk0ZTczMjJhZjBhYjI5MzYvdGFibGVyYW5nZTphMzg4YTMzMmQ2NDU0MzhhOTRlNzMyMmFmMGFiMjkzNl8wLTAtMS0xLTA_4b79ade3-e803-4690-8db9-334d71f0b4d8">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zOTk_a9c426fc-fa2c-4f81-8616-b94eee56b597">000-30171</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF80OTg_4b896b11-8861-4775-99e7-601c91d3ebea">SANGAMO THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY18wLTAtMS0xLTA_5cbd6c91-ea0e-4d27-805c-f8433f1779a2">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY18wLTQtMS0xLTA_75e849ae-0bb6-4ce6-8462-1a929d385a9f">68-0359556</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY18zLTAtMS0xLTA_87ca8d34-0a06-4758-8ebe-a62f5099d8e0">7000 Marina Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY180LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZTg4YTgwMTI3YzU0YTFhOWI1OTk0M2EyYTMzNWRkMl80_b29b9efc-b122-4897-859c-23085633097a">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY180LTAtMS0xLTAvdGV4dHJlZ2lvbjo2ZTg4YTgwMTI3YzU0YTFhOWI1OTk0M2EyYTMzNWRkMl84_1f656e99-551c-475b-894e-acb155577dec">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6MDRjYjg1ODA4YWNkNGRhYzk5YmM1M2UxZDk2MmU1ZGMvdGFibGVyYW5nZTowNGNiODU4MDhhY2Q0ZGFjOTliYzUzZTFkOTYyZTVkY180LTQtMS0xLTA_471a7ea5-c96f-4457-b72a-de59fe3ec7e6">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF82NTU_2af9534e-d08d-4dfd-806a-cdd0a0d98908">510</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF82NTk_181e0517-b531-4e3a-80ca-6b98679d26ec">970-6000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6ZGU1MThlYTNjNjlmNDkyMDg0ZjM1NzlkN2JiNDk5YTcvdGFibGVyYW5nZTpkZTUxOGVhM2M2OWY0OTIwODRmMzU3OWQ3YmI0OTlhN18xLTAtMS0xLTA_228a1fc3-343c-4224-9424-bce1e365bc31">Common Stock, par value $0.01&#160;per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6ZGU1MThlYTNjNjlmNDkyMDg0ZjM1NzlkN2JiNDk5YTcvdGFibGVyYW5nZTpkZTUxOGVhM2M2OWY0OTIwODRmMzU3OWQ3YmI0OTlhN18xLTEtMS0xLTA_a8240a3e-4de6-489a-9573-59a48f3e72ed">SGMO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6ZGU1MThlYTNjNjlmNDkyMDg0ZjM1NzlkN2JiNDk5YTcvdGFibGVyYW5nZTpkZTUxOGVhM2M2OWY0OTIwODRmMzU3OWQ3YmI0OTlhN18xLTItMS0xLTA_db9bddfa-dc52-4d46-900e-ed5de7272d03">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODY2_b59025c4-6d22-4a47-9f99-d4fb8271ae48">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODY5_a6658fe2-2d04-4b70-8f53-ccd26ab1ada6">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODY3_a6ae2481-c2de-4f31-a55e-a550415686b7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODcw_4f9bbdf8-b188-4880-93d2-b3ad3ecba118">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6OWJmNWZkZWEzNDI1NGJkZDg1ZWVmYzEzZWZhNDliMmYvdGFibGVyYW5nZTo5YmY1ZmRlYTM0MjU0YmRkODVlZWZjMTNlZmE0OWIyZl8wLTAtMS0xLTA_490bfb17-f222-4c06-8d5d-ffefd1bc0fe7">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6OWJmNWZkZWEzNDI1NGJkZDg1ZWVmYzEzZWZhNDliMmYvdGFibGVyYW5nZTo5YmY1ZmRlYTM0MjU0YmRkODVlZWZjMTNlZmE0OWIyZl8xLTQtMS0xLTA_973c3a0e-b87c-445c-a00c-2a2b0efb6797">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGFibGU6OWJmNWZkZWEzNDI1NGJkZDg1ZWVmYzEzZWZhNDliMmYvdGFibGVyYW5nZTo5YmY1ZmRlYTM0MjU0YmRkODVlZWZjMTNlZmE0OWIyZl8yLTQtMS0xLTA_19c31e88-92ca-4adc-a7c5-9cb6eaca9121">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zMjk4NTM0ODg3NTU2_abce3f40-8971-4270-a63c-68f1f8a42df3">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODcx_fde17f04-d386-4149-99ec-e2a7a85dc706">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="iee1b756f6c0a4abe92e4664a43ad8035_I20200630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8xMDk5NTExNjMyMDI0_8b152bf6-69ef-4e68-ad0c-4f272ffb79fc"
      unitRef="usd">1262431735</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i22a6be9ae52e4042a972a3c232e7c320_I20210219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zMjE5_47645386-8355-485c-be53-7ec4cd9be023"
      unitRef="shares">143251243</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xL2ZyYWc6ZTIwMzc1YjhjZDdiNDlhOGE3ODQ2MTk0NmZkOTdlZGQvdGV4dHJlZ2lvbjplMjAzNzViOGNkN2I0OWE4YTc4NDYxOTQ2ZmQ5N2VkZF8zODY1_5c0dc9d7-9178-4536-91ea-cc8a92cc7527">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"&gt;Certain information required by Part III, Items 10-14 of this Form 10-K is incorporated by reference to the registrant&#x2019;s definitive Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;.&lt;/span&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMy0xLTEtMS0w_91a5b4c1-eb5e-4113-8f66-3f1b855c380a"
      unitRef="usd">131329000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMy0zLTEtMS0w_264fe9d2-ee02-4fbe-9b15-f9552cf039a5"
      unitRef="usd">80428000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNS0xLTEtMS0w_1a443dfa-5d77-4d1d-b327-85a14bca9b89"
      unitRef="usd">510094000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNS0zLTEtMS0w_cc09bc0b-74c9-42af-ac36-9cef9c09f068"
      unitRef="usd">282046000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNi0xLTEtMS0w_476177eb-6246-477c-9d26-809af0bb083c"
      unitRef="usd">1035000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNi0zLTEtMS0w_072a0d9e-1085-437c-a53e-2a471b4f33bc"
      unitRef="usd">682000</us-gaap:InterestReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNy0xLTEtMS0w_e3ae44c0-9eea-436d-ad55-a7c15875a6f9"
      unitRef="usd">5224000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfNy0zLTEtMS0w_63da99ca-92ed-4df6-b535-b7cf4026a6ff"
      unitRef="usd">36909000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfOC0xLTEtMS0w_5ffdcbcc-5595-4f62-8ccb-bc955f078fcf"
      unitRef="usd">11986000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfOC0zLTEtMS0w_a372bf15-bf83-46f7-aa39-8e1bdc3f0003"
      unitRef="usd">5408000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfOS0xLTEtMS0w_6168cacf-076d-47e7-a146-b01cdeeac456"
      unitRef="usd">659668000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfOS0zLTEtMS0w_8297dc80-ad69-4539-9b56-3a14b9affa10"
      unitRef="usd">405473000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTAtMS0xLTEtMA_c5c63c5c-1edb-4c49-9db3-ef1972e83c2e"
      unitRef="usd">50530000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTAtMy0xLTEtMA_ee93bb1d-610a-424c-9306-e3128bc944d6"
      unitRef="usd">21832000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTEtMS0xLTEtMA_1a464f95-3d54-4064-b04a-649329d2605f"
      unitRef="usd">41324000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTEtMy0xLTEtMA_e959d7d9-c217-4103-b876-cf9acf262571"
      unitRef="usd">29926000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTItMS0xLTEtMA_d7df4965-14cd-447d-9bc8-b7e73a16175a"
      unitRef="usd">58128000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTItMy0xLTEtMA_ad5f3a30-1501-497a-8666-21ec40d80e15"
      unitRef="usd">53156000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTMtMS0xLTEtMA_26db89a0-e682-4903-9d7a-2f1cd5240bfc"
      unitRef="usd">42798000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTMtMy0xLTEtMA_5f78b0b9-deb1-4f5a-9115-5a79741f5814"
      unitRef="usd">39273000</us-gaap:Goodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTQtMS0xLTEtMA_15a07be4-de5b-4803-aac8-b9e74349012a"
      unitRef="usd">71045000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTQtMy0xLTEtMA_7657c3d8-2703-40b8-8bc2-a0fd33489eb3"
      unitRef="usd">77289000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTUtMS0xLTEtMA_169eba40-1342-4b79-ac1e-29c278c5d6a5"
      unitRef="usd">13557000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTUtMy0xLTEtMA_c4c41b28-4fb2-425d-b51e-8993b42d0619"
      unitRef="usd">9067000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTYtMS0xLTEtMA_765a1bcf-58a4-456c-9d85-ef4991c11214"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTYtMy0xLTEtMA_521dedbe-1457-41d5-9d1f-ecdb9dacc18b"
      unitRef="usd">1500000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:Assets
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTctMS0xLTEtMA_b1462a66-4949-4a84-a4fd-a87203e0fef2"
      unitRef="usd">938550000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMTctMy0xLTEtMA_a4390181-4d7e-4ff5-854c-2b5181f1cd85"
      unitRef="usd">637516000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjAtMS0xLTEtMA_05ab8b29-7720-44f2-a454-0e43d9734874"
      unitRef="usd">12553000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjAtMy0xLTEtMA_b7565d19-95de-4b25-9fbc-74036c61fd41"
      unitRef="usd">6671000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjEtMS0xLTEtNTM3OA_0285c5d8-475d-497f-823c-c1ffa97ffd8e"
      unitRef="usd">18612000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjEtMy0xLTEtNTM3OA_267bfd59-c987-4e42-a125-b910d00a9a3c"
      unitRef="usd">10885000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjEtMS0xLTEtMA_a511be9b-fde9-465f-b83d-436a700e30c5"
      unitRef="usd">20738000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjEtMy0xLTEtMA_3bf4f646-04f7-4e15-a969-e53e67ee411b"
      unitRef="usd">13605000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjItMS0xLTEtMA_c44d6ba3-23d7-4552-b131-b7eca356309b"
      unitRef="usd">91644000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjItMy0xLTEtMA_de35a0b0-7b3c-41c4-be9c-34e2b7a99487"
      unitRef="usd">38711000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjMtMS0xLTEtMA_ba1fc418-3ebd-4860-8a93-fd2e3d500684"
      unitRef="usd">143547000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjMtMy0xLTEtMA_e7defcaf-7ad9-41ef-acfa-d5fc0e246eb0"
      unitRef="usd">69872000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjQtMS0xLTEtMA_e3692664-00fc-4f5f-a4d0-a3fcd3adcb3a"
      unitRef="usd">245045000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjQtMy0xLTEtMA_0b655e2f-1cd6-4b98-8bb7-7c28a1f841d9"
      unitRef="usd">81432000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjUtMS0xLTEtMA_056a18d0-ca52-4e22-9942-3013841477cc"
      unitRef="usd">38396000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjUtMy0xLTEtMA_639a7630-cb02-49f0-a907-78da77058817"
      unitRef="usd">41192000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjYtMS0xLTEtMA_9e754358-6be2-4e97-bb2a-a25b48b01793"
      unitRef="usd">7185000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjYtMy0xLTEtMA_3b55164b-8af0-4b02-8833-bdf2d3138104"
      unitRef="usd">6570000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjctMS0xLTEtMA_81f2438d-c785-42ba-8b43-c7fcc00b1fac"
      unitRef="usd">7011000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjctMy0xLTEtMA_5fff0711-e4e8-4ebe-a5d8-d92948749f32"
      unitRef="usd">5711000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjgtMS0xLTEtMA_7bcdc5a5-c3ff-4bbe-8e85-c60242af631c"
      unitRef="usd">441184000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjgtMy0xLTEtMA_ad11383c-909b-4534-afc3-116fc1235d62"
      unitRef="usd">204777000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjktMS0xLTEtMA_06b90adb-6f47-4e0a-b6e2-2b33498f71a7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMjktMy0xLTEtMA_9e9a3cd1-5336-48a5-a061-ad04248a9170"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzIx_15af6f8a-75b8-48ef-a46d-f3051b23963b"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzIx_c74887c3-5672-4eb7-8100-471b83d45a79"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzM1_e585f574-2a12-411a-9290-b72485249bca"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzM1_fc009e23-f1cc-41d1-a736-4bed1ae7b42a"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzYw_25576737-2d9b-42f4-9136-534210c4be18"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzYw_4cbb366c-d72f-42ae-819b-86fa5763e405"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzYw_7932965d-63bd-419c-a4ea-56dac52ddf90"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMC0xLTEtMC90ZXh0cmVnaW9uOjQzYjI1MTc1MzczZDQwMGI5YTU5ZjYyNjRjZTFjOGY4XzYw_83fe3a4b-e05f-4609-9383-e7251ca9cbdb"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMS0xLTEtMA_e015b47f-76fa-4eea-a270-4d82b68cde64"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzEtMy0xLTEtMA_70ae7de6-b62b-4742-8142-00dc5bdc481a"
      unitRef="usd">0</us-gaap:PreferredStockValueOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzE4_503b5833-bbdd-4195-953b-ffcd3b303eec"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzE4_87460c8f-be0e-4df3-87af-aef0f73d500b"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzMy_60eb80f9-81c2-4321-b84f-45d4ff214839"
      unitRef="shares">320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzMy_be5e3c3c-2d7a-46a7-b33b-bc942054ec74"
      unitRef="shares">320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzU0_095446f2-47a4-4440-925e-46f4e557655e"
      unitRef="shares">142063203</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzU0_7a80ebd3-80d8-476c-94d7-e69989724253"
      unitRef="shares">142063203</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzYx_732cc5c6-f709-4043-9566-330d10d80301"
      unitRef="shares">115972708</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMC0xLTEtMC90ZXh0cmVnaW9uOjZkOTQ4NzE5ZmE4NDQyYjNhMjE0M2Q0ZTVjYWQ2NDc1XzYx_943bf96e-782b-4a98-98d0-9c1f3802177f"
      unitRef="shares">115972708</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMS0xLTEtMA_b5170ba8-56cb-473c-8817-d0ffaa927368"
      unitRef="usd">1421000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzItMy0xLTEtMA_889d4b25-f50d-4d51-aa9d-11872cd6ccbb"
      unitRef="usd">1160000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzMtMS0xLTEtMA_c1a4ad9d-d990-40cf-9308-2fd2b84341d5"
      unitRef="usd">1269375000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzMtMy0xLTEtMA_0ee55b8a-3403-4893-8977-edcdc1c5853a"
      unitRef="usd">1090828000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzQtMS0xLTEtMA_6fdeebc0-fd3a-4032-8ad5-b2832aadb7fe"
      unitRef="usd">-777981000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzQtMy0xLTEtMA_f1342f0e-7bbc-4f38-b519-feb2b7855f5e"
      unitRef="usd">-656985000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzUtMS0xLTEtMA_8d2553cd-a63a-4dac-9d09-2f70a2b7a85c"
      unitRef="usd">5419000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzUtMy0xLTEtMA_f6d2485e-7c5b-4fe0-9b5a-0ad5fe4e54ae"
      unitRef="usd">-2449000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzYtMS0xLTEtMA_e4206fbe-bc76-4471-bcdd-5dc8e7ffc938"
      unitRef="usd">498234000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzYtMy0xLTEtMA_bc9eea20-0557-4539-aff5-9cb561bdde28"
      unitRef="usd">432554000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzctMS0xLTEtMA_862a92b9-a131-48f1-ba4c-eac3a913eebf"
      unitRef="usd">-868000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzctMy0xLTEtMA_db136bf7-842a-4eb0-b2ce-4469e99e1808"
      unitRef="usd">185000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzgtMS0xLTEtMA_2aa27cd3-b2ee-44a9-8463-d37a9d64ca8b"
      unitRef="usd">497366000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzgtMy0xLTEtMA_302a43ff-7ed4-4a53-b948-96f4f323842a"
      unitRef="usd">432739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzktMS0xLTEtMA_ff98f1c2-7efc-4f58-a73d-493addbee421"
      unitRef="usd">938550000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83MC9mcmFnOmYzOTRjOWY3YTE1OTQ0NTM5ODZkMGI3NjEzOGM4YmI0L3RhYmxlOjYxYmE5NTcwZmUzMDRlNDc4NGQ0ZmEwNGU2NDA4OWU0L3RhYmxlcmFuZ2U6NjFiYTk1NzBmZTMwNGU0Nzg0ZDRmYTA0ZTY0MDg5ZTRfMzktMy0xLTEtMA_2718e9e0-4916-4a24-bd53-112e7b6e9d21"
      unitRef="usd">637516000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNS0xLTEtMS0w_3a893e17-d559-4fc4-bf62-e0d79b4a771d"
      unitRef="usd">118192000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNS0zLTEtMS0w_75240a92-4d4c-45bc-a067-bdfd2625593f"
      unitRef="usd">102428000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNS01LTEtMS0w_83770339-8877-4a29-884a-1f354364e078"
      unitRef="usd">84452000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNy0xLTEtMS0w_9874b099-d565-4ecc-9c3b-6b2d5400720d"
      unitRef="usd">180647000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNy0zLTEtMS0w_6c6956e4-9dd2-4d7d-bb26-9d03b15f13ef"
      unitRef="usd">145922000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfNy01LTEtMS0w_cd851e60-7c6f-4e3f-ac50-4ebace1d234f"
      unitRef="usd">114866000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOC0xLTEtMS0w_34de09c5-3fb7-455a-9841-3a4145bcce83"
      unitRef="usd">67097000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOC0zLTEtMS0w_2b9d9810-94fb-4dc1-b583-afd1f38f5db1"
      unitRef="usd">61686000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOC01LTEtMS0w_3b881846-d787-49ec-9a11-6a96b56df684"
      unitRef="usd">46736000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOS0xLTEtMS0w_6fb7bb87-16b4-4604-9ce5-f62973eb0696"
      unitRef="usd">247744000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOS0zLTEtMS0w_b406ac29-3b36-471f-ae33-235f977681b7"
      unitRef="usd">207608000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfOS01LTEtMS0w_4d99ba5b-ecdd-41dd-a75a-dacb97e30a02"
      unitRef="usd">161602000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTAtMS0xLTEtMA_8c90aaac-c01b-4139-becc-567f5577f9ef"
      unitRef="usd">-129552000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTAtMy0xLTEtMA_e6c04df6-9b55-471a-a7a9-ec626314c775"
      unitRef="usd">-105180000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTAtNS0xLTEtMA_c978a024-b522-477b-91cd-522b4ba686a4"
      unitRef="usd">-77150000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTEtMS0xLTEtMA_53d8615e-c22f-43b1-968a-1d96f1d879f3"
      unitRef="usd">8775000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTEtMy0xLTEtMA_a268edaf-e787-4728-b591-b11dc2161539"
      unitRef="usd">9761000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTEtNS0xLTEtMA_ec56b452-9d1e-40a0-a99a-5a189854bfa8"
      unitRef="usd">8261000</us-gaap:InterestAndOtherIncome>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTItMS0xLTEtMA_c46fed7a-df9f-4de3-8313-ba2cc415882d"
      unitRef="usd">-120777000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTItMy0xLTEtMA_fc573cab-6ad8-448b-8821-c0f44cb69507"
      unitRef="usd">-95419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTItNS0xLTEtMA_627a043e-6407-45f0-bf78-9694bb9fd9d4"
      unitRef="usd">-68889000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTMtMS0xLTEtMA_8f859092-7241-413b-91b4-69b1e8858513"
      unitRef="usd">345000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTMtMy0xLTEtMA_d3cb24c9-6819-4241-b2af-4a1ce092eefe"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTMtNS0xLTEtMA_3d48c79e-e7e2-4f2d-9d7e-703b32d37d8f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTQtMS0xLTEtMA_f7b1df83-45a7-4786-9495-dfca38964e46"
      unitRef="usd">-121122000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTQtMy0xLTEtMA_8d210a0a-ef9f-40fa-83b3-2cccc9b7286f"
      unitRef="usd">-95419000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTQtNS0xLTEtMA_9d7c7749-89ae-4a44-b9bb-58a3dad07212"
      unitRef="usd">-68889000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTUtMS0xLTEtMA_e4f1e61c-a46d-4ac1-8b42-18a345b242ff"
      unitRef="usd">-126000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTUtMy0xLTEtMA_cdc0cb7b-5161-47ca-abb0-715a6b962a77"
      unitRef="usd">-233000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTUtNS0xLTEtMA_6aa1f7b0-f22e-4248-bce1-527b5bddf590"
      unitRef="usd">-555000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTYtMS0xLTEtMA_4890a941-955a-46ca-b727-8e11356d1e06"
      unitRef="usd">-120996000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTYtMy0xLTEtMA_c9b1a9b0-6aa7-4429-a667-438bfe694db5"
      unitRef="usd">-95186000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTYtNS0xLTEtMA_17f222bc-8634-4ba2-8a04-0808e3bfca61"
      unitRef="usd">-68334000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTctMS0xLTEtMA_ab60242c-c946-4f0e-ab11-dbdd66ed3c22"
      unitRef="usdPerShare">-0.90</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTctMy0xLTEtMA_a8e0613c-f15c-4711-ba25-e53fd74abb47"
      unitRef="usdPerShare">-0.85</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTctNS0xLTEtMA_67e647ab-8186-47fb-9020-2230168d7f69"
      unitRef="usdPerShare">-0.70</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTgtMS0xLTEtMA_265841b8-93e1-4c66-b714-7e5777b376c4"
      unitRef="shares">134449000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTgtMy0xLTEtMA_c14912fc-d033-4eb2-b250-f3041c191cfd"
      unitRef="shares">112114000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83My9mcmFnOjdiOWZiMjIwNDQxNzQ0MzlhNDM0ODE4OTYxZTI3YzNkL3RhYmxlOjEyNmZlMTQyNDFkNDQ2NjhiNWZhYTVlNzM2NWRkOTQwL3RhYmxlcmFuZ2U6MTI2ZmUxNDI0MWQ0NDY2OGI1ZmFhNWU3MzY1ZGQ5NDBfMTgtNS0xLTEtMA_6115e244-c6b4-4c4b-ae0f-a60a742b299a"
      unitRef="shares">96941000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:ProfitLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMi0xLTEtMS0w_e4f41ce4-8cad-4206-b448-aa80ad9576ee"
      unitRef="usd">-121122000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMi0zLTEtMS0w_fed71a00-25cb-4ef9-9f2f-4c4bacd4fce6"
      unitRef="usd">-95419000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMi01LTEtMS0w_c6e7f049-4fdd-4e7a-b8dc-928754ba41c6"
      unitRef="usd">-68889000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMy0xLTEtMS0w_3da83126-e61f-43de-815e-4ecc5f67ea06"
      unitRef="usd">8345000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMy0zLTEtMS0w_4696d378-3505-42aa-961d-9b4f9eb688a7"
      unitRef="usd">-1573000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfMy01LTEtMS0w_03d79088-9152-41d8-80cc-1db5529e1f29"
      unitRef="usd">-1148000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNC0xLTEtMS0w_8ddd492c-b9df-4175-99c3-a505e89d0c87"
      unitRef="usd">193000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNC0zLTEtMS0w_5b81ae24-1473-455a-b271-45912820bb17"
      unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNC01LTEtMS0w_ba6a99da-f7e8-4337-b20e-5f8605bc685b"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNS0xLTEtMS0w_bcd70945-d648-460f-a0f5-95cfd5bd30fb"
      unitRef="usd">-284000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNS0zLTEtMS0w_6b29bd4d-ab9d-42c3-9a1f-64c5a5ab057a"
      unitRef="usd">592000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNS01LTEtMS0w_a3176012-5ef4-4358-8c80-ff1bd492c0b8"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNi0xLTEtMS0w_b0900fa7-dd98-4fa7-8c6f-d6aac25d79a7"
      unitRef="usd">-113254000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNi0zLTEtMS0w_51417b7b-604e-488b-9c63-17c7c3a37d51"
      unitRef="usd">-96428000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNi01LTEtMS0w_6e88c82f-ab89-43c3-9c36-cb07ea1d0969"
      unitRef="usd">-70062000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNy0xLTEtMS0w_7550c2ab-d309-44c6-a814-bf9f5769b067"
      unitRef="usd">-126000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNy0zLTEtMS0w_0bcbb0f9-1285-43e7-b270-91a68bca287f"
      unitRef="usd">-233000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfNy01LTEtMS0w_5a79375c-f2b5-4515-a5e0-369e872991ed"
      unitRef="usd">-574000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfOC0xLTEtMS0w_c5616375-cee3-4460-bf2b-1b5a5959a4fd"
      unitRef="usd">-113128000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfOC0zLTEtMS0w_72fd2a05-491c-48aa-845d-3f57ddf1190a"
      unitRef="usd">-96195000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83Ni9mcmFnOjI3YzZkNGY1ODNhZDRkNjViZDRiYzA4OTdkNDRkMjBhL3RhYmxlOjk2OGQ0YTczOGMzZjQwYjNiZTc1NTI5MTE0YzA4MDdhL3RhYmxlcmFuZ2U6OTY4ZDRhNzM4YzNmNDBiM2JlNzU1MjkxMTRjMDgwN2FfOC01LTEtMS0w_74042fdb-0635-4f24-ae5a-7201bcf21361"
      unitRef="usd">-69488000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="if6f46cdcf64446fbb0ec043c3e9bfa14_I20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS0xLTEtMS0w_bb888fb4-cf5f-4932-8b83-da72a4c057ff"
      unitRef="shares">85598534</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if6f46cdcf64446fbb0ec043c3e9bfa14_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS0zLTEtMS0w_fac5e6b7-5f82-4fdd-a9e2-9a73eba5524e"
      unitRef="usd">856000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i15b7ca23b9754fce9a17de50c7c8a39a_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS01LTEtMS0w_d1ec945a-cb1c-49b5-9f0c-ec233abd31c8"
      unitRef="usd">682809000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i202e314c35d9413996c927fa899da1c2_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS03LTEtMS0w_64ae72ce-e4e8-4294-bb68-7076411e7647"
      unitRef="usd">-495479000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia4b56ade4b50487fb2fbba4e2c124931_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS05LTEtMS0w_eb1daa3f-f57d-4734-adf1-75f77db0c521"
      unitRef="usd">-286000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iedb5b79c99094b17a8f2ce637a6f9a2d_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS0xMS0xLTEtMA_0e11f546-f765-4ddf-8782-ccd84e70843e"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1099157ecec044679915cbcb253acd13_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfOS0xMy0xLTEtMA_22ec992b-1deb-47f3-ae82-2f7ff485e88f"
      unitRef="usd">187900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ief4531bd4090429ab0a53e48c051817f_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTAtNy0xLTEtMA_5503780c-9672-4422-95a3-36365315e3f0"
      unitRef="usd">1117000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22d2afa166f04addaba3df267d7905bc_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTAtMTMtMS0xLTA_477459bc-25ac-49ed-a422-8898dceefa21"
      unitRef="usd">1117000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTEtMS0xLTEtMA_3551f207-0305-42d2-8e92-da441b23b5cd"
      unitRef="shares">2103727</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTEtMy0xLTEtMA_7788d54e-694e-4183-936e-3ad8e23c6c02"
      unitRef="usd">20000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTEtNS0xLTEtMA_1616916a-f9fb-4766-afb4-4c85a71163d8"
      unitRef="usd">14447000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTEtMTMtMS0xLTA_7421066e-9de9-4a6e-8707-85422496e454"
      unitRef="usd">14467000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTItMS0xLTEtMA_86b89ef2-76f4-4c98-bcfb-764ae88cdf24"
      unitRef="shares">328710</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTItMy0xLTEtMA_438c22ce-f232-4cda-9f64-7c734981bba5"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTItNS0xLTEtMA_9547f3ca-f5d6-401a-86c6-894a3d68dfd1"
      unitRef="usd">1480000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTItMTMtMS0xLTA_887393cc-5b58-4d34-a61d-f1d2795509ef"
      unitRef="usd">1484000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTMtMS0xLTEtMA_ceee4359-099c-4b14-bb36-3627e3165e5d"
      unitRef="shares">14156500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ic82be4da0a814be2bd33db99d51e7b0c_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTMtMy0xLTEtMA_0aeedfc5-c81c-4acb-9d69-85d8ef6462f3"
      unitRef="usd">142000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTMtNS0xLTEtMA_e9c4128c-2fde-4d62-b74e-06484bc210f9"
      unitRef="usd">215616000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTMtMTMtMS0xLTA_8b7e9b39-b129-49b1-8515-5d282b686555"
      unitRef="usd">215758000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTQtNS0xLTEtMA_21dec7f6-c8e8-4112-9511-bb1ba47ea7c1"
      unitRef="usd">14677000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTQtMTMtMS0xLTA_dc6ebd9c-5fa0-4448-8768-72c010b8bb2d"
      unitRef="usd">14677000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i7ee567e73d7e4bae962af8b07ef04ff8_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTUtNS0xLTEtMA_0dfc982c-e025-466a-9272-94cf718c0397"
      unitRef="usd">603000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTUtMTMtMS0xLTA_3598f89f-eb3e-42eb-aebd-3c35b8b4d324"
      unitRef="usd">603000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i3d05b39e6b184c809c28b20cda11f744_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTYtMTEtMS0xLTA_a212ffa9-ce26-48f4-9f51-b4d45a4bd17c"
      unitRef="usd">1313000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTYtMTMtMS0xLTA_e67a26ab-d63e-4f3f-8ca2-5dcbe066383f"
      unitRef="usd">1313000</us-gaap:NoncontrollingInterestIncreaseFromBusinessCombination>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i6d6997ffafa040db837de130bd2c9cc5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTctOS0xLTEtMA_8f5e49ed-68e6-48b1-a188-622b8477c3f5"
      unitRef="usd">1129000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i3d05b39e6b184c809c28b20cda11f744_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTctMTEtMS0xLTA_53010239-2b51-4760-8e75-731945a24c74"
      unitRef="usd">19000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTctMTMtMS0xLTA_5800f087-a5f7-482c-b8ca-f1522b60d754"
      unitRef="usd">1148000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i6d6997ffafa040db837de130bd2c9cc5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTgtOS0xLTEtMA_f596cc03-bb20-493d-a127-ebe8404f9a45"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTgtMTMtMS0xLTA_c969dcf1-297e-458b-b6c0-8c2a48b29607"
      unitRef="usd">21000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6d6997ffafa040db837de130bd2c9cc5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTktOS0xLTEtMA_2df7e42d-19b8-47b1-8cc8-793d313dbffe"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMTktMTMtMS0xLTA_72b1ad54-566d-45ae-a57f-369b669966b8"
      unitRef="usd">-4000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i5eb85ed8fe2a4cc9a528a3f2afd5ee04_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjAtNy0xLTEtMA_02dd4d76-8df1-4384-9234-a49f06c36bb5"
      unitRef="usd">-68334000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i3d05b39e6b184c809c28b20cda11f744_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjAtMTEtMS0xLTA_2fd447c6-b68d-494f-b702-1f1a59bdd5c9"
      unitRef="usd">-555000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjAtMTMtMS0xLTA_16c6c1b5-199a-4935-90e6-2f7b978de442"
      unitRef="usd">-68889000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i79a71c8223434e32990a220f63b9c4bd_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtMS0xLTEtMA_af66246a-f534-42b0-8cca-27e1bf6a9a74"
      unitRef="shares">102187471</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79a71c8223434e32990a220f63b9c4bd_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtMy0xLTEtMA_12c05272-34a6-47c7-b87c-82957ae88680"
      unitRef="usd">1022000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i651b9b252cc242febd5e34ac22fad42d_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtNS0xLTEtMA_b707baf1-598c-4e7e-b4fd-ba441c44c2a1"
      unitRef="usd">929632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6d4c9fcbe5f94694af0132cce7457120_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtNy0xLTEtMA_e366d1a4-2442-4079-86fb-9d42e9dddb9c"
      unitRef="usd">-562696000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f51a95393aa40d082b4cca44112fce1_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtOS0xLTEtMA_2b6761f9-ff8a-44d7-abdd-67d04f32feae"
      unitRef="usd">-1440000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i921be278c72e486185352cb920f4347b_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtMTEtMS0xLTA_c7ba27f4-3630-4fcb-8993-0a6ee43e3f67"
      unitRef="usd">739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjEtMTMtMS0xLTA_92282760-398e-4dfc-8be1-a655debfc02b"
      unitRef="usd">367257000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5022310b80e40a9adf07bedacb21665_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjItNy0xLTEtMA_7ec59ddc-fa08-4632-8ec1-60fac6a20edf"
      unitRef="usd">897000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabf107dbdd5b48f8903b89e3c7cea36e_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjItMTMtMS0xLTA_f29204e4-3fe6-4dae-9159-1a0418348285"
      unitRef="usd">897000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjMtMS0xLTEtMA_850d9d92-8372-41cd-a1df-502f6a9b3316"
      unitRef="shares">885873</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjMtMy0xLTEtMA_596ff1c3-99e1-40f3-869f-bda587aad057"
      unitRef="usd">9000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjMtNS0xLTEtMA_f30aa6ce-c525-45d2-8dfd-5c9b9bfdab4c"
      unitRef="usd">3668000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjMtMTMtMS0xLTA_847901d1-94ce-4064-b718-ef822459e4c8"
      unitRef="usd">3677000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjQtMS0xLTEtMA_56cbdbff-625d-491d-82fd-2115c863ff79"
      unitRef="shares">249364</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjQtMy0xLTEtMA_5c297cea-2470-4faa-bc34-ed6f7804681a"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjQtNS0xLTEtMA_eaf960d1-a5a8-4959-9ad5-fb0da1bac788"
      unitRef="usd">2042000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjQtMTMtMS0xLTA_a6f7f712-ef87-465e-bf77-80172b249a9c"
      unitRef="usd">2044000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjUtMS0xLTEtMA_3be46960-4a37-42f4-8115-43803962211b"
      unitRef="shares">12650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i18fa89c7d919405e8e4b094fe2ea0a77_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjUtMy0xLTEtMA_a9edb9a7-9a8f-4966-9a4f-73c7b7d069ad"
      unitRef="usd">127000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjUtNS0xLTEtMA_26b4bc4a-8971-46bb-b7bd-092929a948b6"
      unitRef="usd">136181000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjUtMTMtMS0xLTA_864c3971-7a0c-4464-8788-819f0ad3b33c"
      unitRef="usd">136308000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjYtNS0xLTEtMA_7694aafc-ff8c-4d32-87af-80791b83770b"
      unitRef="usd">19330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjYtMTMtMS0xLTA_d1572393-07c0-4fa8-b3f7-6a97f582310e"
      unitRef="usd">19330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="ia6f7ea91dc8646daa2cc71ca00f38850_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMTEtMS0xLTA_1be1165a-641f-4d24-8ad2-74f66b235b82"
      unitRef="usd">-321000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMTMtMS0xLTA_7625b419-8dce-4fec-8e1b-03ea03f30511"
      unitRef="usd">-321000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i7f9a3717cdb4418e85176b7e7741dcf0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtNS0xLTEtMA_006185b4-99aa-4400-8280-9057d21e3a68"
      unitRef="usd">25000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtMTMtMS0xLTA_2a5465b7-7dc2-440e-aafe-609da7f3fdf3"
      unitRef="usd">25000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i80940087d3b44c008290532496a8063a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktOS0xLTEtMA_e39f3371-b339-49ea-82d8-2d52babd63f0"
      unitRef="usd">1573000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ia6f7ea91dc8646daa2cc71ca00f38850_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMTEtMS0xLTA_402b2701-f9b6-42a3-8f04-8f4b89338165"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMTMtMS0xLTA_c1a144ae-f8d8-4ead-898c-8f2d9e8a049e"
      unitRef="usd">1573000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i80940087d3b44c008290532496a8063a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzAtOS0xLTEtMA_a26e341b-c170-4677-82fc-a965fed6e054"
      unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzAtMTMtMS0xLTA_b85afea3-49b5-48dd-a191-6d0037367194"
      unitRef="usd">28000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i80940087d3b44c008290532496a8063a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzEtOS0xLTEtMA_ebcc4f3f-44fb-4616-b9e6-2ec92cb810dc"
      unitRef="usd">592000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzEtMTMtMS0xLTA_c7cd98d9-61c8-44ed-bcda-4418c48619ea"
      unitRef="usd">592000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="iddc7094e93e045b7b4aade122a21ba69_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItNy0xLTEtMA_16d5f482-13e2-4c57-9c4b-9551c90178ee"
      unitRef="usd">-95186000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia6f7ea91dc8646daa2cc71ca00f38850_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItMTEtMS0xLTA_0e3543a2-f33c-45ae-ac96-df7755bea8ab"
      unitRef="usd">-233000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItMTMtMS0xLTA_4dec8ed4-e5a9-4b91-aaf6-d79e8761a3d5"
      unitRef="usd">-95419000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i4d0c82cbf5e5409490970fcf70c60bb2_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMS0xLTEtMA_3ce3a770-dc82-43d9-aff8-c51a15708a55"
      unitRef="shares">115972708</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d0c82cbf5e5409490970fcf70c60bb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMy0xLTEtMA_12b526c1-5bd4-4b5a-b62f-64d9c9655608"
      unitRef="usd">1160000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d79e000a7564936afd32ea6d9c1290e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtNS0xLTEtMA_efff0718-f46b-47be-92b6-8963c19f289d"
      unitRef="usd">1090828000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1f5e0542d6f24c119eae1888c0d6a5a8_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtNy0xLTEtMA_cd098e08-b316-49d5-8015-384074eef343"
      unitRef="usd">-656985000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i21e69f23c33c473daf20855d84a342a2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtOS0xLTEtMA_7288612f-2c55-418a-9601-2ba92c037c7b"
      unitRef="usd">-2449000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iae1f574b2f8c4344aa08242f7ae98ac4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMTEtMS0xLTA_70e330a5-5226-42b8-af59-649b404a6f08"
      unitRef="usd">185000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMTMtMS0xLTA_4f3e08a9-eaa0-4f6a-a940-cba0b5fa64a3"
      unitRef="usd">432739000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMS0xLTEtMTU2NQ_7fa11a3d-2a18-4393-89c1-cecbaa572b9b"
      unitRef="shares">1395956</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMy0xLTEtMTU2NQ_b198344f-9382-4b09-a4d9-8c9d0e552a6f"
      unitRef="usd">14000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctNS0xLTEtMTU2NQ_d66d4cd1-a1e7-4c2e-b984-be1dac548e25"
      unitRef="usd">8545000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjctMTMtMS0xLTE1NjU_ecc48d56-8db1-49fa-a3ff-79d6bb84d0c2"
      unitRef="usd">8559000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtMS0xLTEtMTU2NQ_97cb2469-437c-42d3-9b40-ede82300fc5b"
      unitRef="shares">274382</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtMy0xLTEtMTU2NQ_26e29698-fd8d-4f17-a35f-8e535b73dc34"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtNS0xLTEtMTU2NQ_686630e5-8bf9-47ff-9895-504e1fb8c8df"
      unitRef="usd">2012000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjgtMTMtMS0xLTE1NjU_12b8bff5-835e-40eb-bf76-bc7084877181"
      unitRef="usd">2015000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMS0xLTEtMTU2NQ_2789ff6d-250c-49ee-9188-e03f2891c4aa"
      unitRef="shares">24420157</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i42b015fcbf5440fdabe4f1f13324f8da_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMy0xLTEtMTU2NQ_5e05bd9a-567f-4a87-b80e-cd0b76b7ad3a"
      unitRef="usd">244000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktNS0xLTEtMTU2NQ_127a501c-bed8-4d07-a0dd-272aa7a7b50c"
      unitRef="usd">142282000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMjktMTMtMS0xLTE1NjU_8558fbb5-2912-4b18-ba43-04f0289312c2"
      unitRef="usd">142526000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6991d96d75654869bbdbe9d5704dc527_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzAtNS0xLTEtMTU2NQ_cd56a1aa-6d80-4af4-923e-15d13671fe9b"
      unitRef="usd">25708000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzAtMTMtMS0xLTE1NjU_585a4ed5-637e-42c5-9ba8-1f8cfd4bc05d"
      unitRef="usd">25708000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="ibf0ea9431c824de99c89f4536634ee4b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzEtMTEtMS0xLTE1NjU_09a8793a-96d5-4eea-a1dd-900221102e8f"
      unitRef="usd">-927000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzEtMTMtMS0xLTE1NjU_d3f0c202-db5b-4af4-b295-0891aaf35e1c"
      unitRef="usd">-927000</sgmo:AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ia724ba89921d4bbfb3ab7f41022dfa7c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItOS0xLTEtMTU2NQ_e6959866-bb08-4cba-a10c-404ee8c12846"
      unitRef="usd">8345000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzItMTMtMS0xLTE1NjU_3e70ebc0-9194-4f30-b2bb-ba5693bce4ac"
      unitRef="usd">-8345000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ia724ba89921d4bbfb3ab7f41022dfa7c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtOS0xLTEtNTU2MA_d1004658-a4b2-4ea2-8332-8a09e92aaed9"
      unitRef="usd">193000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMTMtMS0xLTU1NjA_360aa1c6-b58a-4cd1-9152-d8827b4a060c"
      unitRef="usd">193000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia724ba89921d4bbfb3ab7f41022dfa7c_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtOS0xLTEtMTU2NQ_85e593d2-250b-4ea9-9418-e4b55266ca51"
      unitRef="usd">-284000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzMtMTMtMS0xLTE1NjU_215a5905-2ffd-4d56-9c5a-0ab2fe4bd551"
      unitRef="usd">-284000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="if95cd0d324cb450abdb22b5197a92e30_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzQtNy0xLTEtMTU2NQ_661e25c2-95ee-4f5e-8810-8ac022f8b4c9"
      unitRef="usd">-120996000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibf0ea9431c824de99c89f4536634ee4b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzQtMTEtMS0xLTE1NjU_2f3526c9-a5b2-4d90-b630-aaacfc1e51d5"
      unitRef="usd">-126000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzQtMTMtMS0xLTE1NjU_e89898da-d040-459c-beaf-e6e75904372b"
      unitRef="usd">-121122000</us-gaap:ProfitLoss>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1627062e2d1a4e6db06f7f2ed164591a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtMS0xLTEtMTU2NQ_66aa6039-16a0-4db0-8fa4-6829591bb5bb"
      unitRef="shares">142063203</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1627062e2d1a4e6db06f7f2ed164591a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtMy0xLTEtMTU2NQ_1ad68d70-a419-4c06-9c4f-4365f2afdf1a"
      unitRef="usd">1421000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0eae3c26ed10449298243b22f0dc770f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtNS0xLTEtMTU2NQ_6fe791c9-e370-4508-9906-b9ce53460216"
      unitRef="usd">1269375000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2728c5446992435fa94d6ae800954885_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtNy0xLTEtMTU2NQ_9bd15b02-ba2f-4113-a015-a5633798f9ed"
      unitRef="usd">-777981000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3d1e7cbe14db45d6a003fba4484e6074_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtOS0xLTEtMTU2NQ_502dd295-0b47-403b-9fad-5f5f67f1c322"
      unitRef="usd">5419000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idcd9bdcf4f1749ed855ea52ac19c1e57_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtMTEtMS0xLTE1NjU_c4ed8f03-0575-4865-8a5e-1ecd3c259a53"
      unitRef="usd">-868000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml83OS9mcmFnOmFlMWE0Njg3YjhhNTQzZGM5YmNhOTYzODFlNmMzYmU3L3RhYmxlOmYxNDVhNWExMjM2ZTRhZGI4OTNjM2IzYTkyNmEyZTY0L3RhYmxlcmFuZ2U6ZjE0NWE1YTEyMzZlNGFkYjg5M2MzYjNhOTI2YTJlNjRfMzUtMTMtMS0xLTE1NjU_c8cfc398-ce27-4c71-976e-d56c8c05f432"
      unitRef="usd">497366000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMy0xLTEtMS0w_5cb4f1ac-5e3f-468c-8d6e-7fb76c32204c"
      unitRef="usd">-121122000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMy0zLTEtMS0w_91853b78-cc1d-4aa2-bcc3-697ec84e1c50"
      unitRef="usd">-95419000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMy01LTEtMS0w_fb88be44-6c40-49e2-95f0-def1d53bc70d"
      unitRef="usd">-68889000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNS0xLTEtMS0w_12b5a665-df89-4b9e-85d4-45722ac04c8d"
      unitRef="usd">5682000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNS0zLTEtMS0w_73261503-9106-4a7c-a530-2fc76460e13d"
      unitRef="usd">3930000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNS01LTEtMS0w_bf23cb73-9d7a-4238-9829-ab416e1af18e"
      unitRef="usd">2359000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNi0xLTEtMS0w_ed10fba4-bfba-4f8b-892c-091a48644afd"
      unitRef="usd">825000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNi0zLTEtMS0w_1a80f700-b449-43bd-be87-06831424e2f6"
      unitRef="usd">4708000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNi01LTEtMS0w_86d637a9-d0fe-4aa7-ad17-12788198f6d9"
      unitRef="usd">5829000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNy0xLTEtMS0w_18479a4f-9eb6-4c17-a6f0-d3bd809e8af0"
      unitRef="usd">-7687000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNy0zLTEtMS0w_da504d8a-0197-4a37-bf78-e9cbbc4fee79"
      unitRef="usd">-5677000</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:AmortizationAndOtherChangesInRightOfUseAssets
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNy01LTEtMS0w_f56893d9-b60a-47a2-9225-945bc60739a9"
      unitRef="usd">0</sgmo:AmortizationAndOtherChangesInRightOfUseAssets>
    <sgmo:GainOnFreeShares
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfOC0xLTEtMS0w_974c6988-f55f-45dc-822e-a9d1db527a23"
      unitRef="usd">63000</sgmo:GainOnFreeShares>
    <sgmo:GainOnFreeShares
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfOC0zLTEtMS0w_d7ef6aa1-c63e-4ea2-afeb-7732692c2eeb"
      unitRef="usd">488000</sgmo:GainOnFreeShares>
    <sgmo:GainOnFreeShares
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfOC01LTEtMS0w_1c5102cb-feaf-41b9-b9a3-b166992f4893"
      unitRef="usd">0</sgmo:GainOnFreeShares>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTAtMS0xLTEtMA_60b20577-6d93-42e4-b6ef-af5bc5e3db15"
      unitRef="usd">-222000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTAtMy0xLTEtMA_e86d1894-d32f-4b1c-a8ac-b7d5447b9ea4"
      unitRef="usd">-68000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTAtNS0xLTEtMA_b33c5782-47e2-40b8-ab75-adb59ed85b3f"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTEtMS0xLTEtMA_fb180db5-470e-4d7c-97bd-c33b099c3942"
      unitRef="usd">25708000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTEtMy0xLTEtMA_2f7f2991-7fd8-4954-a61e-82bd57607f8c"
      unitRef="usd">19330000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTEtNS0xLTEtMA_2a154522-f8b5-4673-baf3-f9ff6911093e"
      unitRef="usd">14677000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTMtMS0xLTEtMA_7240a97c-e4ed-4407-adac-2cd2b1d1d16b"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTMtMy0xLTEtMA_a6b59460-b16c-456f-a1c1-d3b9a2ad4731"
      unitRef="usd">-218000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTMtNS0xLTEtMA_21a28e70-a409-4ff4-b52e-1255c58327df"
      unitRef="usd">0</us-gaap:GainLossOnTerminationOfLease>
    <sgmo:BuildToSuitLeases
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTQtMy0xLTEtMA_40e012a0-ad44-42ca-a371-85658d1338f2"
      unitRef="usd">0</sgmo:BuildToSuitLeases>
    <sgmo:BuildToSuitLeases
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTQtNS0xLTEtMA_24ab2296-140e-48c9-b391-a4c023d11a05"
      unitRef="usd">966000</sgmo:BuildToSuitLeases>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTctMS0xLTEtMA_a163d9e9-05ef-4811-9783-ff1a6d34b81c"
      unitRef="usd">353000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTctMy0xLTEtMA_75865483-2ba3-4461-82c1-f51ce8b8e822"
      unitRef="usd">307000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTctNS0xLTEtMA_2ebcc4e2-7d34-4542-b972-e9e5ebb68e67"
      unitRef="usd">135000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTgtMS0xLTEtMA_8c298376-3bef-4d52-8f30-072208d32c9d"
      unitRef="usd">-31685000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTgtMy0xLTEtMA_e043bfcf-55f3-41ba-8707-2463a35f85fd"
      unitRef="usd">32236000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTgtNS0xLTEtMA_e41dab0e-b75e-4a62-b685-3f23d13da82a"
      unitRef="usd">1330000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTktMS0xLTEtMA_1dff1ad4-b1c7-4d0a-b47c-9ba1a41757a7"
      unitRef="usd">10411000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTktMy0xLTEtMA_8cb7cbe8-a160-4e11-bac8-2eb39d977ac3"
      unitRef="usd">6660000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMTktNS0xLTEtMA_926313f9-71be-464a-b2e3-e29713eca93d"
      unitRef="usd">2828000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjEtMS0xLTEtMA_5b3f9046-c4e5-4dbc-98f4-3600c0c16ad9"
      unitRef="usd">10703000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjEtMy0xLTEtMA_86ffb13f-8011-4f18-b137-6b90cefc3f87"
      unitRef="usd">-4192000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjEtNS0xLTEtMA_2144b048-3e38-446d-b023-e664b0f27187"
      unitRef="usd">-6372000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjItMS0xLTEtMA_c0bca357-76ef-4f4d-8a77-4981eb6d6d52"
      unitRef="usd">6877000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjItMy0xLTEtMA_c8fbdd16-a044-455c-ac92-1e3881df2518"
      unitRef="usd">4129000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjItNS0xLTEtMA_e14e1185-3114-4805-9149-cff9ede0c5db"
      unitRef="usd">2604000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjMtMS0xLTEtMA_05ff662f-69d2-44df-bfdd-1265cece0960"
      unitRef="usd">216546000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjMtMy0xLTEtMA_9602ad1f-2695-44d5-95a2-fcc3e462fe0f"
      unitRef="usd">-35693000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjMtNS0xLTEtMA_ee901139-1d01-41b9-8edf-0d679ea933e1"
      unitRef="usd">99364000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjQtMS0xLTEtMA_f258d9ab-d63f-4496-b44b-0da784d034b6"
      unitRef="usd">-3761000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjQtMy0xLTEtMA_aa0fb39c-06c4-4c5d-a58e-2993a4fea705"
      unitRef="usd">-1800000</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjQtNS0xLTEtMA_7209b6a0-71cd-4f6a-a6e2-cd912ed5b994"
      unitRef="usd">0</sgmo:IncreaseDecreaseInLongTermPortionOfLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjUtMS0xLTEtMA_83462334-9948-4ac6-bf93-e48d9ac111a0"
      unitRef="usd">1300000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjUtMy0xLTEtMA_be50ec1b-1674-440d-b977-29fe0d7ddd98"
      unitRef="usd">3749000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjUtNS0xLTEtMA_24cb331e-d04b-43c3-8281-e024719f3fbe"
      unitRef="usd">1963000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjYtMS0xLTEtMA_59b9b011-4e79-4389-bc74-7dadefdbb88b"
      unitRef="usd">169875000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjYtMy0xLTEtMA_b76a2052-cfda-4bc2-9e3b-e142be1f70b3"
      unitRef="usd">-144402000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjYtNS0xLTEtMA_396e738d-6055-478b-b4ab-ff9bd57cb5e1"
      unitRef="usd">36550000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjgtMS0xLTEtMA_702d8161-8b64-41e5-8ec0-6d53f772d74d"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjgtMy0xLTEtMA_77fd5b27-9648-4fcf-97e2-7bb610aea086"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjgtNS0xLTEtMA_7923797a-199c-48f0-9886-b7bd46f1a816"
      unitRef="usd">75647000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjktMS0xLTEtMA_beb0d48f-00bc-4a2e-a034-637890cb1a28"
      unitRef="usd">570779000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjktMy0xLTEtMA_914e45fe-a512-4d61-8b0e-d644719cc8fe"
      unitRef="usd">443711000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMjktNS0xLTEtMA_7ef4f4a6-d5c2-4f77-b2f6-e7970f43ad97"
      unitRef="usd">451239000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzAtMS0xLTEtMA_11cf818d-539b-43b9-873a-9f590eff43a8"
      unitRef="usd">314570000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzAtMy0xLTEtMA_065c20d5-1bba-44fb-a543-e25c635e5412"
      unitRef="usd">404847000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzAtNS0xLTEtMA_bc3c59d7-9062-4f65-9c89-21cee2270feb"
      unitRef="usd">391845000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzEtMS0xLTEtMA_297defee-ec8b-4879-9126-c30e96e9df37"
      unitRef="usd">14714000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzEtMy0xLTEtMA_2338b794-50b5-4211-968b-e838e48348a6"
      unitRef="usd">20675000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzEtNS0xLTEtMA_29e0a9cf-a1bc-4014-b971-9eacbb589f34"
      unitRef="usd">43065000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzItMS0xLTEtMA_b7cd90b1-6d99-4efb-9819-f269b788cf45"
      unitRef="usd">704000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzItMy0xLTEtMA_786ca13a-98d6-48da-abd5-b3f8c5e5b746"
      unitRef="usd">262000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzItNS0xLTEtMA_482af546-270b-40df-bdfd-b062c5e40f70"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzUtMS0xLTEtMA_0108d647-dc03-4d9b-b8cc-193920030df3"
      unitRef="usd">-271627000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzUtMy0xLTEtMA_eb2860f4-3c52-4456-89c5-82f5e65ca065"
      unitRef="usd">-59801000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzUtNS0xLTEtMA_c9cfb309-c7d3-40dd-b2cd-89934d7634ec"
      unitRef="usd">-178106000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzctMS0xLTEtMA_5bcdc003-9f61-4a06-b068-4746ef65038c"
      unitRef="usd">0</sgmo:NetProceedsFromIssuancePublicOffering>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzctMy0xLTEtMA_e8a1afe3-81c6-4707-81ec-85117ce58e0d"
      unitRef="usd">136308000</sgmo:NetProceedsFromIssuancePublicOffering>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzctNS0xLTEtMA_2b04692e-de2c-4509-bed7-230055e10f68"
      unitRef="usd">215758000</sgmo:NetProceedsFromIssuancePublicOffering>
    <sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtMS0xLTEtMzU2NQ_bd3ef52b-cc70-41da-942b-93e06deafb39"
      unitRef="usd">142526000</sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtMy0xLTEtMzU2NQ_d86be87a-88a4-4272-9957-369e68d7787d"
      unitRef="usd">0</sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtNS0xLTEtMzU2NQ_481a3d2f-32ae-40d9-af2d-0c853a6e3905"
      unitRef="usd">0</sgmo:ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtMS0xLTEtMA_c5d95e3b-7d7a-45c6-905c-c2aac57b8e43"
      unitRef="usd">765000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtMy0xLTEtMA_d390188a-f266-499e-adcf-1dc068ad221e"
      unitRef="usd">422000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzgtNS0xLTEtMA_f58f0b8a-ab15-442a-bf1b-a4d2e0d323fc"
      unitRef="usd">254000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzktMS0xLTEtMA_df672156-ab78-431a-9c28-3f89e97d2795"
      unitRef="usd">2015000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzktMy0xLTEtMA_5dc366bf-9482-485d-87ed-ad598aea6960"
      unitRef="usd">2044000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfMzktNS0xLTEtMA_3674a3f9-df37-41af-8400-cc3b5893e6ba"
      unitRef="usd">1484000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDAtMS0xLTEtMA_d14ece2c-389d-4ad1-bcdf-330c8bb084fe"
      unitRef="usd">9324000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDAtMy0xLTEtMA_d5896c87-f2bc-4be3-acc6-a83b9eb1d3d6"
      unitRef="usd">4099000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDAtNS0xLTEtMA_3002750a-d0c4-468e-9c7a-bcdbcfeb4562"
      unitRef="usd">14721000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDEtMS0xLTEtMA_e074d325-5a61-4dae-9a02-e19d1a70e825"
      unitRef="usd">153100000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDEtMy0xLTEtMA_a4ca2ddb-9326-4940-abaf-a9131f0c0f18"
      unitRef="usd">142029000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDEtNS0xLTEtMA_143cfc13-7205-427e-9338-2e31ae4fdcbe"
      unitRef="usd">231709000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDItMS0xLTEtMA_7e06340e-2989-4b78-9823-79c3b1717723"
      unitRef="usd">-447000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDItMy0xLTEtMA_b0629036-edd0-462b-a226-80a7b555b065"
      unitRef="usd">184000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDItNS0xLTEtMA_80700e5c-4127-4aa4-a2e8-ad3705ef8a18"
      unitRef="usd">439000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDMtMS0xLTEtMA_9bb360d9-c3e5-40a7-ba4d-9a4239f08056"
      unitRef="usd">50901000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDMtMy0xLTEtMA_c196557e-42b0-4aef-959d-6ff408346b14"
      unitRef="usd">-61990000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDMtNS0xLTEtMA_00b0c802-7c2b-4c06-85bd-0251b26f1142"
      unitRef="usd">90592000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDQtMS0xLTEtMA_3b210d98-79b8-4817-be0f-af39ddbc8e58"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDQtMy0xLTEtMA_b75bc04f-645a-4273-a5f7-a2926ce8e52b"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i1099157ecec044679915cbcb253acd13_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDQtNS0xLTEtMA_79213399-fdb1-4f02-8364-f07de87eba27"
      unitRef="usd">53326000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDUtMS0xLTEtMA_6fd03223-eacc-4cba-901d-3b01e5d5a3ae"
      unitRef="usd">132829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDUtMy0xLTEtMA_d7d52aee-f98e-40a5-9797-bffbdb0d275a"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDUtNS0xLTEtMA_e42da688-0be4-4429-b8c0-4d3e742c082d"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDctMS0xLTEtMA_634f2547-7ca1-4ac4-b599-35107a39d072"
      unitRef="usd">0</sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition>
    <sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDctMy0xLTEtMA_66a755ee-2c78-4693-a0af-b986ae32a712"
      unitRef="usd">0</sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition>
    <sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDctNS0xLTEtMA_3be0ae62-415f-4f95-bcdc-9aa07f94ca63"
      unitRef="usd">1313000</sgmo:NoncashOrPartNoncashNonControllingInterestAcquisition>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i66dc03e15abd412984fd7c2b45d9d856_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDgtMS0xLTEtMA_ad458279-5b21-4db0-be38-c0abc897598f"
      unitRef="usd">4569000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i3eca6f8c437940cbabb9d377e58e590a_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDgtMy0xLTEtMA_db924a19-a6ea-4490-b8ac-94217c0c8b9c"
      unitRef="usd">2114000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ie858b057f0224ebf8778dd6b34548eab_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDgtNS0xLTEtMA_95f6e154-23be-40c5-88be-0af9ca95ea9c"
      unitRef="usd">4953000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i7c141aaf58334fba855db4ee4e38db81_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDktMS0xLTEtMA_0693b4fa-f08d-4ec5-9658-d3e807b2722d"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ic0ad2d8d5ce840e99dbd93fd64e0439e_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDktMy0xLTEtMA_dd7667f3-0edb-4faa-b85c-a3ac99bdb2db"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i8133ce2775074245969bc9f50d4ffa89_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNDktNS0xLTEtMA_503be08b-9fb7-4323-bd6c-d9ae039991d8"
      unitRef="usd">2950000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNTAtMS0xLTEtMA_23317cd5-8c55-4a41-ba9c-36797959e901"
      unitRef="usd">1333000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNTAtMy0xLTEtMA_ff8d9a9b-86d0-4aae-8e71-7195b8260dd0"
      unitRef="usd">31291000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84Mi9mcmFnOjk5MzdmMTQ4NmFkZjRmZTRiMmM1OTcwNzI0ZTgzMjdiL3RhYmxlOmNkMTUxZTgwODE2ZDRlZmM5NmU4NGM5NjIwYzA0MTFlL3RhYmxlcmFuZ2U6Y2QxNTFlODA4MTZkNGVmYzk2ZTg0Yzk2MjBjMDQxMWVfNTAtNS0xLTEtMA_0b515a63-8389-4ff0-a44e-10d282873919"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTE_933a90b7-3b0c-43a4-b127-f4a2f682ce55">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo Therapeutics, Inc. (&#x201c;Sangamo&#x201d; or &#x201c;the Company&#x201d;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases using its platform technologies in gene therapy, cell therapy and genome engineering. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Management&#x2019;s Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of December&#160;31, 2020, when combined with additional capital raises and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next 12&#160;months from the date these Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#x2019;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#x2019;s stockholders, and any debt financing may include covenants that restrict the Company&#x2019;s business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, including the estimated fair value of common shares issued as part of the transaction price, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#x201c;Sanofi&#x201d;) and Pfizer Inc. (&#x201c;Pfizer&#x201d;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $8.9&#160;million, decreased net loss by $8.9&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.06 for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, the Company recorded adjustments to revenue related to a change in estimate in connection with the giroctocogene fitelparvovec collaboration agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;). This change in estimate was driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $5.7&#160;million, decreased net loss by $5.7&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.05 for the year ended December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received from the Company&#x2019;s collaboration partners are generally not refundable and are recorded as revenue as it fulfills its performance obligations. The Company&#x2019;s performance obligations are satisfied over time (i.e., stand ready obligations) or using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of December&#160;31, 2020, no impairment of goodwill or indefinite-lived intangible assets was identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Valuation of Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of December&#160;31, 2020, no impairment of any long-lived assets was identified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cash, deposits in demand money market accounts, and commercial paper.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Restricted cash consists of a letter of credit for $1.5&#160;million as a deposit for the Brisbane lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#x201c;AOCI&#x201d;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments with high credit ratings which are expected to bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities and issuers of investments to the extent recorded on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug (&#x201c;IND&#x201d;) application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers was interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTY1MDM_37296027-8590-4fe0-b3ed-3ef8d7731671"&gt;three&lt;/span&gt; to five years. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, materials and supplies and overhead allocations consisting of various support and facility-related costs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#x201c;RSUs&#x201d;) and employee stock purchases related to the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#x2019;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#x2019;s Consolidated Financial Statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within other accrued liabilities on its Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted the Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on January 1, 2019, using the modified retrospective approach with a cumulative-effect adjustment. The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of December&#160;31, 2020, 2019 and 2018 were 14,237,871, 10,750,550, and 9,048,793, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting. As of December&#160;31, 2020 and 2019, substantially all of the Company&#x2019;s assets were maintained in the United States. For the years ended December&#160;31, 2020, 2019 and 2018, substantially all of the Company&#x2019;s revenues and operating expenses were generated and incurred in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2018-18&#x201d;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2017-04&#x201d;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#x2019;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December 15, 2019. ASU 2017-04 required the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 326) (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &#x2013; Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). The guidance removes exceptions to the general principles in Income Taxes (Topic 740) for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cloud Computing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles-Goodwill and Other-Internal Use Software: Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2018-15&#x201d;). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance becomes effective for annual reporting periods beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard on January 1, 2020 using the prospective method. The adoption of ASU 2018-15 did not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDY_3da82dd7-82b3-4216-8d25-79243c931374">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S.&#160;GAAP&#x201d;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTI_ca12f965-d6e5-4537-8c55-a54b2278da32">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, including the estimated fair value of common shares issued as part of the transaction price, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#x201c;Sanofi&#x201d;) and Pfizer Inc. (&#x201c;Pfizer&#x201d;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $8.9&#160;million, decreased net loss by $8.9&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.06 for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;During the year ended December 31, 2019, the Company recorded adjustments to revenue related to a change in estimate in connection with the giroctocogene fitelparvovec collaboration agreement with Pfizer Inc. (&#x201c;Pfizer&#x201d;). This change in estimate was driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance.</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i196e1cc25f284d418cc58737e82a5139_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTA5OTUxMTY2ODQ4NQ_dabf28c4-1fbf-4cf6-a9d4-674afcbfd3aa"
      unitRef="usd">8900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="i196e1cc25f284d418cc58737e82a5139_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTA5OTUxMTY2ODQ3MA_c6c465b6-4d3d-4345-b5a9-6d9f7ac35f18"
      unitRef="usd">8900000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i196e1cc25f284d418cc58737e82a5139_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTA5OTUxMTY2ODQ1NQ_56b0b357-c59c-4b05-b6c7-537bb1545923"
      unitRef="usdPerShare">0.06</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1555d5279c444f89f02b32de1c4f4c5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfNDYwMw_515304c3-1708-47eb-9a0a-fc36af0df90c"
      unitRef="usd">5700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ProfitLoss
      contextRef="if1555d5279c444f89f02b32de1c4f4c5_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfNDYzNw_e25d9381-a024-4843-908b-7fd0b8ee86ee"
      unitRef="usd">5700000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="if1555d5279c444f89f02b32de1c4f4c5_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfNDcwNA_2b2115cf-a3ca-40e4-8553-f129183eac4b"
      unitRef="usdPerShare">0.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDc_5d88bee9-bd22-4f66-8b0b-d30092a14c18">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC Topic 606&#x201d;). The Company&#x2019;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#x2019;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#x2019;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#x2019;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Funds received from the Company&#x2019;s collaboration partners are generally not refundable and are recorded as revenue as it fulfills its performance obligations. The Company&#x2019;s performance obligations are satisfied over time (i.e., stand ready obligations) or using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDA_b992c75b-354f-456b-ad2c-42d02e1b00dc">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Novartis Institutes for BioMedical Research, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibe21513e3cbc4ef9b8379cf9af56af7d_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMi0xLTEtMS0w_c057ec93-713d-4515-a2d3-26093381de4b"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic2340761cd284f108a1e5d64cc980af8_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMi0zLTEtMS0w_3838f410-524e-48a2-95a7-e79fbacb1241"
      unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i30e0b646a8df46a79e760eb6aaef235e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMi01LTEtMS0w_33488b64-5b27-4721-9451-ba21fcbfdc47"
      unitRef="number">0.47</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i88b6be668e8d446b9d5199171f704f9f_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNC0xLTEtMS0yNjc1_140bef75-1dd3-454c-8af5-626ebe67b727"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iaf6e9495caa24ce480ffea19c28f507b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNC0zLTEtMS0yNjc1_06a57c77-1a3a-4698-b9c6-b340d45bb5a3"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i04e7b9f9d96a4feca307fbdfe9824533_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNC01LTEtMS0yNjc1_c573c306-1443-4041-9866-501e39ab2238"
      unitRef="number">0.30</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifafcd10a99b94ea9a3cd858f75019057_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMy0xLTEtMS0w_f72f67aa-3055-4cff-920c-9f9c015e5c4b"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iae79ca8469af4ddda9eb0ae2461bfda7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMy0zLTEtMS0w_c458bbd3-84b7-448f-b488-a225c9a25113"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib362499858ff441b81abb16c4b161e94_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfMy01LTEtMS0w_adbcb9d4-8129-4759-b4cc-89cac2dcff16"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id5af392ecf9040dd85a30262c5b91b6a_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS0xLTEtMS0yNDYy_ff7b7105-da4e-47b2-9a07-fdc734a8511d"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i21037a15db8240bba2e6a6eacf66d265_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS0zLTEtMS0yNDYy_3edf9bbc-8549-46bd-a827-633a3dc321ea"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i05a8036803764bc19d8b0408d9a6778e_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS01LTEtMS0yNDYy_7be49b4d-9538-4ccd-ad6e-41bee8aa8530"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="iffb1c905529f4b78895e5ec6a2fb1454_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS0xLTEtMS0zMTc_43938f2d-194d-4c3c-aee0-e0ba7877448c"
      unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i75abcc855e7c486a8f9453c309984ec6_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS0zLTEtMS0zMTM_a0fb8d14-f4ef-475a-8fe9-faeed6d8d98c"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifef75ce3e3d4408195a24cf8317ce59b_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjc4YzFkMjc5MTlmOTQ0MTBhN2QyMGNjNGZjMWZjZDIyL3RhYmxlcmFuZ2U6NzhjMWQyNzkxOWY5NDQxMGE3ZDIwY2M0ZmMxZmNkMjJfNS01LTEtMS0zMTM_d69ae6d9-aa53-4ccd-bef5-c58a99c95cce"
      unitRef="number">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDE_54317c18-add4-4227-b105-752f6b393aaf">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#x2019;s Consolidated Balance Sheets. Any excess of purchase consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTA_bf5c5a55-d5f7-46ef-9234-086fabe88fa7">Goodwill and Intangible AssetsGoodwill represents the excess of the purchase consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetImpairment
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMzI5ODUzNDk1NTYxNg_69c11715-9813-4604-8a46-f998989f0ffd"
      unitRef="usd">0</us-gaap:GoodwillAndIntangibleAssetImpairment>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDI_8d6385b6-2de9-4359-bf00-3933eacbe010">Valuation of Long-Lived AssetsLong-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMzI5ODUzNDk1NTYyNw_7b9c29c9-fc33-49f2-ba54-48b2493dce4c"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5MzM_fe726a22-cb90-4d86-9eb7-54071d3f8bc2">&lt;div style="margin-top:12pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5Mzc_60bb82c1-87f0-401a-ae6f-121cb150bbcd">Cash, Cash Equivalents and Restricted Cash&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; cash, deposits in demand money market accounts, and commercial paper.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTQ2MTk_10c09fc4-fcdc-45b2-9ef2-196ebc826d6f"
      unitRef="usd">1500000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5MzQ_fe424033-999b-4832-8740-237921fff118">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5Mzg_60a7d7c8-bffa-4ea7-9b8e-cddb808cd6c0">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of cash, cash equivalents and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.350%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.600%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfMi0xLTEtMS0w_215b51e2-22c3-4698-8da3-df2eb63a1f92"
      unitRef="usd">131329000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfMi0zLTEtMS0w_e4a42600-24d9-4836-8933-e0bb63143932"
      unitRef="usd">80428000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfMi01LTEtMS0w_4cdff864-e98f-41aa-91fc-cc63246a9bda"
      unitRef="usd">140418000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNC0xLTEtMS0w_448b456d-6fd9-4a02-b46a-a2301bb2eb17"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNC0zLTEtMS0w_3db423bf-6e56-4c96-a443-8060f735be60"
      unitRef="usd">1500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNC01LTEtMS0w_ed71f1bb-5476-48bc-bbc2-df249dc7148e"
      unitRef="usd">3500000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNS0xLTEtMS0w_3e821767-0878-4c83-9eaf-dbbda6f6c3d1"
      unitRef="usd">132829000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNS0zLTEtMS0w_72161764-a224-4bad-8a9c-54686d30c102"
      unitRef="usd">81928000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RhYmxlOjBlNDlmNWE4Y2Q1ZDRhOTg4ZGQ0YTliMGNlYWQwNWVlL3RhYmxlcmFuZ2U6MGU0OWY1YThjZDVkNGE5ODhkZDRhOWIwY2VhZDA1ZWVfNS01LTEtMS0w_d4e407c3-255b-4c5c-874f-c8f874b0dfda"
      unitRef="usd">143918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTM_c04506f8-edf5-4b55-b624-875ae6cb492c">&lt;div style="margin-bottom:3pt;margin-top:18pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#x201c;AOCI&#x201d;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#x2019;s cost basis, the financial condition and near-term prospects of the investee and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMzI5ODUzNDk2MTIwMQ_54337b1c-e0a6-4f47-a801-3132013d373d">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk and Other Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments with high credit ratings which are expected to bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities and issuers of investments to the extent recorded on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug (&#x201c;IND&#x201d;) application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#x2019;s suppliers was interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5MzU_bc55c045-95f4-40cc-a093-61a2405e6ab6">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTY1MDM_37296027-8590-4fe0-b3ed-3ef8d7731671"&gt;three&lt;/span&gt; to five years. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6b662a6bf84f48d6baa29804b606526c_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTY1MDk_84b802dc-db20-4a10-8005-0d91bfd926b4">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDU_be26215e-77c6-4386-8ac6-ac7c10b38aa1">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, materials and supplies and overhead allocations consisting of various support and facility-related costs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTg_400296f4-93d2-494b-a88f-eb98e07c10d9">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTk_f7da9f06-64f6-43a5-9034-83d1768b3bb0">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#x201c;RSUs&#x201d;) and employee stock purchases related to the Employee Stock Purchase Plan (&#x201c;ESPP&#x201d;) based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#x2019;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NDk_938d7fcb-a047-4c72-872b-381f1aec9f3f">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#x2019;s Consolidated Financial Statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within other accrued liabilities on its Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMzI5ODUzNDk2NTkzNA_5fb50575-6528-4ff8-8539-603a983e4cb4">&lt;div style="margin-top:6pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company adopted the Accounting Standard Update (&#x201c;ASU&#x201d;) No. 2016-02, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on January 1, 2019, using the modified retrospective approach with a cumulative-effect adjustment. The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#x201c;ROU&#x201d;) assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the implicit rate in the Company&#x2019;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#x2019;s operating leases is recognized on a straight-line basis over the lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NjA_f8312a85-7da5-4ba5-b177-aeecaa8889c9">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company&#x2019;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#x2019; equity. Revenues and expenses from the Company&#x2019;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#x2019;s Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTQ_9532408e-0bb8-428b-a8a5-bbcd6e3f7eab">&lt;div style="margin-top:12pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period.&lt;/span&gt;&lt;/div&gt;The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders.</us-gaap:EarningsPerSharePolicyTextBlock>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjE1Njc_961eeabb-6560-448c-8da9-2b3c9dac452c"
      unitRef="shares">14237871</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjE1NzE_d74ebbf5-3b90-434c-987b-466486013541"
      unitRef="shares">10750550</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjE1Nzk_7f7434d9-9506-47e0-88f5-21eb27c436e4"
      unitRef="shares">9048793</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5Mzk_d899d7bf-4bdb-4b63-96e1-4d910390047d">SegmentsThe Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjE2MzA_ed30218e-6ff5-485d-b723-88dc65635b07"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMjg5NTc_407117d3-eebb-410f-b1f6-989b5239fea1">&lt;div style="margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2018-18&#x201d;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Goodwill Impairment Testing&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, the FASB issued ASU No. 2017-04, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2017-04&#x201d;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#x2019;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December 15, 2019. ASU 2017-04 required the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Credit Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments &#x2013; Credit Losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 326) (&#x201c;ASU 2016-13&#x201d;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &#x2013; Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). The guidance removes exceptions to the general principles in Income Taxes (Topic 740) for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on the Company's Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cloud Computing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the FASB issued ASU 2018-15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles-Goodwill and Other-Internal Use Software: Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2018-15&#x201d;). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance becomes effective for annual reporting periods beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard on January 1, 2020 using the prospective method. The adoption of ASU 2018-15 did not have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzk3NQ_11b4a6e2-1e78-4a68-9d50-5bfeabda5d33">FAIR VALUE MEASUREMENT&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities and the free shares asset.&#160;The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;i.e.,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; supported by little or no market activity).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash Equivalents and Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally classifies its marketable securities and some cash equivalents as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Free Shares Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the July&#160;20, 2018 Share Purchase Agreement (&#x201c;Sangamo France SPA&#x201d;) to acquire Sangamo France (see Note 5 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Acquisition of Sangamo France&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;), the Company entered into arrangements with the holders of approximately 477,000 &#x201c;free shares&#x201d; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $0.2&#160;million on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#x201c;Monte Carlo simulation model&#x201d;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Consolidated Statements of Operations. The Company purchased approximately 111,000 and 322,000 shares during 2019 and 2020 respectively, of the 477,000 total free shares for a cash payment of approximately $0.3&#160;million and $0.7&#160;million respectively, upon exercise of the put options. As of December&#160;31, 2020, approximately 44,000 free shares remain outstanding and subject to purchase by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the free shares&#x2019; asset was approximately $0.2&#160;million at December 31, 2019. The Company recognized a gain due to an increase in the fair value of the free shares of approximately $0.1&#160;million for the year ended December&#160;31, 2020, offset by approximately $0.2&#160;million for the shares purchased during the year, resulting in an asset balance of approximately $0.1&#160;million at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Free Shares valuation assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR/ USD exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated correlation Sangamo and Sangamo France stock prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR/ USD exchange rate volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate and cost of debt by expected exercise date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzk3Ng_50900710-6c33-43de-b0d0-6683c33753b1">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value measurements of the Company&#x2019;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Free shares asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if3a7053c82b34112baeacb539acdacee_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNS0xLTEtMS0w_fd3904c9-bf32-4508-9650-6fd18a8757a1"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ife4a9b65e8c8453ab64e7777ee2d3100_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNS0zLTEtMS0w_4b12becd-3c5f-42ec-b00b-d044b10ce9d5"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i538799473b654234a0fff4940007026d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNS01LTEtMS0w_f8b6879c-855e-492d-9ce9-0a17cd82a9ae"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if3382b9ba2d54e45aab7d37fe53c048f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNS03LTEtMS0w_dda45472-e79e-4951-8bcd-d57231bb6e3e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4bf0705352c54572bf4f38ac982a31be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNy0xLTEtMS0w_17a8de45-92e0-44f1-b354-aa40562604ba"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i26c02145fa9242f38709a5edc46b448e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNy0zLTEtMS0w_13416993-ebd6-47d9-9553-07a45a50efea"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaa885c5039e145c09f646a2a7f4b8107_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNy01LTEtMS0w_6dc93880-3d8a-4619-914c-4af0bfc9cec4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9b3adc9c15cd451ba7eaf4b09cd384e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfNy03LTEtMS0w_81d74dc0-e910-4705-8cfe-49617fea8567"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i561ac4ef919945fa872f15ce1139a321_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfOS0xLTEtMS0w_c0933f27-73f8-4e68-b0cf-5b17395f7484"
      unitRef="usd">213533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i031949a99f364927ac232102e610e2ca_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfOS0zLTEtMS0w_d1227494-5a26-4376-984c-43cd1de0bd99"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98278431e88f4c0db17846d0b3dbbad8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfOS01LTEtMS0w_6fb39f9c-ea43-4ec2-8352-4536070b64e8"
      unitRef="usd">213533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6465df1f81a4ab5a788482e7565d968_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfOS03LTEtMS0w_d4e5a4a2-a534-4e7f-9dd7-108875c6fbef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id92a9f54439349c1a5e6a1bba22a0d23_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTAtMS0xLTEtMA_c73070fc-a047-45be-a08a-50df92492e28"
      unitRef="usd">59574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie1a201eb484d4bd5a0b59012ba2f791d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTAtMy0xLTEtMA_38cd0a8b-ce7f-4c6f-a1df-7b79f79f95dc"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i16d9dab193d54c309786833b5661b693_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTAtNS0xLTEtMA_674e930f-7284-4fc3-8288-2b4f8d0fff74"
      unitRef="usd">59574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if5c17352407648038a079be92904f2a3_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTAtNy0xLTEtMA_383a8b92-ef3c-492c-b749-7917a2fedd4e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i307cf2a5e93040adbb97545d97da4f9a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMS0xLTEtNzU0MQ_e7672b94-30f8-4182-b232-ef1a8f4f833e"
      unitRef="usd">12311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8632ee484ed4ce287dd150a59f7e976_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMy0xLTEtNzU0MQ_28b9f7bb-1d7e-4a03-aa00-6eb8302f7765"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifed10ba46af8409e8b84b8e8186dc592_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNS0xLTEtNzU0MQ_2e6e0b5d-ecea-4978-b289-39d750dd097d"
      unitRef="usd">12311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib8205c80a5c0477aaa06acb0a8e8e7da_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNy0xLTEtNzU0MQ_bfae44ef-7289-405e-b841-d0bca7c4f4ee"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4478684879bc414381bb41ce8b5add16_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMS0xLTEtNDcw_3a4ed37c-e492-4efb-a848-37a001cf5b64"
      unitRef="usd">17908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e83dea29142486786bea569ac583153_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMy0xLTEtNDcw_736e6ac6-4e81-4bd6-b46b-5d63b10bc0b1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i638b4338e64c4c0c9035f64c4bda767b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNS0xLTEtNDcw_7dc5db33-7120-4fdd-8c2f-5a4298a930be"
      unitRef="usd">17908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie6648a09a42b483cb342868211de9128_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNy0xLTEtNDcw_b7344abc-22ce-4a3d-8009-845d537f3853"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaea9ff66312d4cb985f8cc0115634d45_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMS0xLTEtMA_9e38a1ae-af95-4a9e-8bec-72f06024587e"
      unitRef="usd">257298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0bb9617224f949bbaa727b52246f5819_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtMy0xLTEtMA_1459cd70-0964-426e-8ae4-4c4898534f66"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i290f705cf9df4b7c8d071b425026aec8_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNS0xLTEtMA_eab17e3f-1211-4d96-87c6-35c862989164"
      unitRef="usd">257298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaaaf320a38a84e55affa256f7f30ad18_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTEtNy0xLTEtMA_0209078c-c521-4229-83d9-1ddf8d924dc0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4bf0705352c54572bf4f38ac982a31be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTItMS0xLTEtMA_c3b22f3c-2f24-4d32-be4a-9ec0c68c3abb"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i26c02145fa9242f38709a5edc46b448e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTItMy0xLTEtMA_358adf1b-3a76-4198-911d-8f8a2a3d02ba"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa885c5039e145c09f646a2a7f4b8107_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTItNS0xLTEtMA_411969a7-9373-40a0-ab2f-77a78c8da059"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9b3adc9c15cd451ba7eaf4b09cd384e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTItNy0xLTEtMA_7b502cff-f3f6-4a32-9bfd-a31969c83ece"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4bf0705352c54572bf4f38ac982a31be_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTMtMS0xLTEtMA_f5c371fb-e5b3-4e94-8842-96de207c148d"
      unitRef="usd">613789000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i26c02145fa9242f38709a5edc46b448e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTMtMy0xLTEtMA_96ad94f7-deda-4da6-aa20-766f60d01ab5"
      unitRef="usd">53165000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="iaa885c5039e145c09f646a2a7f4b8107_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTMtNS0xLTEtMA_137035eb-5c28-4e7a-a8b6-4d5937b8aefd"
      unitRef="usd">560624000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9b3adc9c15cd451ba7eaf4b09cd384e5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTMtNy0xLTEtMA_cb368ec3-287a-47f1-acd9-781fb33ac17d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3c791708c2b54c489b0564343ced9b29_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTUtMS0xLTEtMA_d5809cf7-f90b-4a68-9a55-5e71886c1c1a"
      unitRef="usd">70000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1bd782cef16a4070ae70af4879663f30_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTUtMy0xLTEtMA_e62f60d5-ee07-4d7a-b237-2f4999fcfbaa"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i5de38cf429814456bca0ed781cb6c510_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTUtNS0xLTEtMA_1360b414-0867-454a-93bb-96885d1323eb"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i452c62674a9a4271ba5e89c6c050a050_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmU3ZGYwMjM3NjgxMzQ4OGY4ZGRiOTVkMjM1YTM4NjU0L3RhYmxlcmFuZ2U6ZTdkZjAyMzc2ODEzNDg4ZjhkZGI5NWQyMzVhMzg2NTRfMTUtNy0xLTEtMA_85d4a657-0167-4c56-9ff1-bcb4e18deb71"
      unitRef="usd">70000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i1cc2751230724e7381a103381d9dfb53_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNS0xLTEtMS0w_5c43032a-c367-4f79-9b17-a864843cb60c"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia9ba3950185d4776adff785cc0c2a7d2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNS0zLTEtMS0w_bd6af0c9-87a2-4137-8f88-30d125212497"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i9b12148036dc4575b8e1a20cf11d14ac_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNS01LTEtMS0w_e1d8dad9-f525-49cc-b5b6-54b7ee04eac9"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4e9967af55594a0298a27d240144e1ee_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNS03LTEtMS0w_9c0eb5a8-9336-458a-9ef0-54c41521de11"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i67764fa5748c4450ae52695bab506bb9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi0xLTEtMS00NjM_3a6fabde-2d03-48b1-9161-711f031ab9c9"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4407422f7c044d0fbec953a99a3872a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi0zLTEtMS00NjM_61826e3a-6f92-4575-ae5e-7bf67bf5a2f6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3bfe2c49f1a646b8b8fc3e3df333620f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi01LTEtMS00NjM_9c01836a-90ff-4097-9fc0-724e37ef931d"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaa947c04f600459f8abe14c30287d39d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi03LTEtMS00NjM_70de8c0a-ffbe-4805-abb9-195b9d7f3626"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id6756c61effe4e938932ae8029a287b7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi0xLTEtMS0w_b5eb4eff-7fb1-4930-86bf-9b9ff8e13e0b"
      unitRef="usd">33495000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia8674e557d87406d95862eb814aebd8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi0zLTEtMS0w_dcde8b49-c846-4f3c-89e4-e4df0347b995"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7a51c69784164925a1155915e905a9e6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi01LTEtMS0w_17bb5a8a-ba8e-4910-8d51-52cbb052b082"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i233261fb4cbb44eda76666923ba0fa00_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfNi03LTEtMS0w_ed8a11ae-6009-4b49-9b8b-5797f14c888b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i67764fa5748c4450ae52695bab506bb9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOC0xLTEtMS0w_9539e4f9-45be-4a99-87e3-85255c5122ff"
      unitRef="usd">155368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4407422f7c044d0fbec953a99a3872a1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOC0zLTEtMS0w_64980128-e485-48f5-b840-6e9b2c9fd506"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3bfe2c49f1a646b8b8fc3e3df333620f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOC01LTEtMS0w_79bf8ed0-73d0-4471-bc8b-9090223b58c1"
      unitRef="usd">155368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa947c04f600459f8abe14c30287d39d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOC03LTEtMS0w_210d409b-17f5-4834-bb51-92439febc671"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iecff100e21624aa380f317bd2cc77424_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOS0xLTEtMS0w_5809c7ac-ce3b-4a12-aa24-4f173b60abe1"
      unitRef="usd">95017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibad5f02563ca4f3a935b0a28075cfc38_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOS0zLTEtMS0w_77f65813-c1f1-46d1-b819-62a45de73fb4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ief8529b02bab4938b24e07cedff4a61f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOS01LTEtMS0w_5f715f32-a9b3-405c-970d-66adf937fdab"
      unitRef="usd">95017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb3348e7e8ad4e5e8f79068e98c38849_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfOS03LTEtMS0w_df92dd12-846a-430e-9526-9d6c3bab8786"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i409228d676604420a5080c8402d96e8f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTAtMS0xLTEtMA_f1100602-72c8-4868-82ba-256c9c9ce600"
      unitRef="usd">53493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib6e07e12ba97461c86c7911b067139c0_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTAtMy0xLTEtMA_24dec97b-bc2b-45a0-a27c-7876cda318d8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic469cb9c12c84ba284e53503bcfe990f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTAtNS0xLTEtMA_6e9aac05-c188-4084-b2ed-aaf761e66636"
      unitRef="usd">53493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i89d852320136494288e8326d40cbfdf4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTAtNy0xLTEtMA_112d6f2c-f29e-4d6b-ad88-983f38465ce2"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id6756c61effe4e938932ae8029a287b7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTEtMS0xLTEtMA_7fd8bd90-3322-40d1-9777-64670dc7cdc2"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia8674e557d87406d95862eb814aebd8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTEtMy0xLTEtMA_e900d15d-11be-405e-bd6d-2a7f759619da"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7a51c69784164925a1155915e905a9e6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTEtNS0xLTEtMA_be2c4fce-803d-4516-885c-a19b87ebf63e"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i233261fb4cbb44eda76666923ba0fa00_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTEtNy0xLTEtMA_857ba7f1-7975-4410-8f94-9c0341850a89"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id6756c61effe4e938932ae8029a287b7_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTItMS0xLTEtMA_ea8cbfea-0a91-4074-b6d2-909068eb736b"
      unitRef="usd">337373000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia8674e557d87406d95862eb814aebd8d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTItMy0xLTEtMA_0e5556a8-6735-4bd5-9d8d-a68f99bbf3a7"
      unitRef="usd">30496000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7a51c69784164925a1155915e905a9e6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTItNS0xLTEtMA_b2e2a4d4-0274-4001-a3f6-f42fbe6beddb"
      unitRef="usd">306877000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i233261fb4cbb44eda76666923ba0fa00_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTItNy0xLTEtMA_83f7dd24-23d1-4e1d-b988-a5b6e0dc1b96"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i0b619f4f00de4396b3df3e86c1308164_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTQtMS0xLTEtMA_16ed1519-63fc-497f-ae7c-1b930330db8f"
      unitRef="usd">236000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ica609585796849f4b3f75e74fd3cd261_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTQtMy0xLTEtMA_4ccf4974-b521-400b-a178-411d5f84f831"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ifc061743215f46799ca3ad39e4073044_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTQtNS0xLTEtMA_096b6dd7-606c-4237-a405-498b8c10d151"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4e0cda171ca943959c35929427e42666_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmEwYTk2OGNiNDZmNzRjM2I5N2I3NmIwMDBiNGU0YTY5L3RhYmxlcmFuZ2U6YTBhOTY4Y2I0NmY3NGMzYjk3Yjc2YjAwMGI0ZTRhNjlfMTQtNy0xLTEtMA_74d711e7-afdb-4015-b297-f58665580fbc"
      unitRef="usd">236000</us-gaap:AssetsFairValueDisclosure>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMjU0Mg_bbffd6fe-c9ba-46d3-a247-5fd5b1b79779"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMjg0Mg_ecbc5cdf-989c-4df1-917b-8c5633f6b66d"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i7377f8b263024b66ad603bd494ee0f22_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzQzNA_76e2abc3-40cb-406c-9f96-281f04e62773"
      unitRef="shares">111000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMjE5OTAyMzI1OTg0Ng_277edf15-9fae-4000-8209-12f610ad1660"
      unitRef="shares">322000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzQ1MQ_bbffd6fe-c9ba-46d3-a247-5fd5b1b79779"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i7377f8b263024b66ad603bd494ee0f22_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzUwOA_ef8e351e-d2ef-4da3-9454-b2cd9011bd7f"
      unitRef="usd">300000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMjE5OTAyMzI1OTg5Mg_2f1ee5e7-e8e9-40fe-a317-e9f5fe8012cf"
      unitRef="usd">700000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzU2OQ_2a47d0f6-c69e-483e-bcbe-c718bbb874c5"
      unitRef="shares">44000</sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="i333a5711c7bb4f51917b34946c0b9f23_I20181001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzY4Nw_43c85e38-cf07-4b0d-a8d1-9cac7f4d2b02"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability
      contextRef="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzgxOA_b38aaab6-242f-4851-b838-ff7cee5572aa"
      unitRef="usd">100000</sgmo:IncreaseInFairValueOfFreeSharesAssetAndLiability>
    <sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares
      contextRef="i16391b7df5174ed5b8c2310d931447ad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzk2Mw_fed56b50-c757-441e-aec9-24a817ed020b"
      unitRef="usd">100000</sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RleHRyZWdpb246NGRmOWNkZjE1OTY0NGMzOGIxMzMwZWM3YThlNGM2ODhfMzk3Nw_ecbf34cd-9739-406f-8e1a-1ad1ccd204c5">&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.684%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.389%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Free Shares valuation assumptions:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR/ USD exchange rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated correlation Sangamo and Sangamo France stock prices&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo stock price (USD) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sangamo France stock price (EUR) volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR/ USD exchange rate volatility estimate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk free rate and cost of debt by expected exercise date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Varies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:SharePrice
      contextRef="ibda42ad49ccb40e6a99670b2432a3b0a_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfMi0xLTEtMS0w_2ca2094e-8a46-4168-b2b7-7a4093d066d3"
      unitRef="usdPerShare">15.61</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="i40c0c8a181b34eaaa65d8a1d56afba94_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfMi0zLTEtMS0w_19b61492-7970-47bb-9de4-0efd61f9a9c7"
      unitRef="usdPerShare">8.68</us-gaap:SharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i40f0fb62debc4ccf8d53156b1bc24685_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfMy0xLTEtMS0w_b2ad96fd-93d8-4141-9790-0b7440f15522"
      unitRef="eurPerShare">3.85</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i00900b9889da4cdaa8eb8e2b586dcb12_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfMy0zLTEtMS0w_5700d7bd-612c-453a-9ac9-74d1c653587a"
      unitRef="eurPerShare">2.14</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNC0xLTEtMS0w_e437c797-bfd5-4f41-b54b-ab42489bab01"
      unitRef="number">0.82</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNC0zLTEtMS0w_e936f58c-78be-4373-80fe-f22b53727e50"
      unitRef="number">0.91</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i297eba0e37914b6d8ec0577f4ee289d4_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNS0xLTEtMS0w_21b5bcc1-1e88-4845-a18a-6b1e03d00a4f"
      unitRef="number">1.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i1da1bc0ccada4c6289947f9de2c4b135_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNS0zLTEtMS0w_828ab2f5-a724-4dca-8bab-aa1e98efbccf"
      unitRef="number">1.000</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i9bff90492d5f446284b8b7c02033b51f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNi0xLTEtMS0w_b23556c7-518d-4366-806d-96f6659484ca"
      unitRef="number">0.889</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ie2a3f456b9804ec4b6dd169a8bd7f4ba_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNi0zLTEtMS0w_fd7b494a-220c-4873-9101-d58b0bfd7352"
      unitRef="number">0.725</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="ibaa6bc7784424a67be7faba1d682b136_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNy0xLTEtMS0w_96fd5768-7ff4-4bd9-9104-dacc013c4c10"
      unitRef="number">0.889</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="i010cb6bb38804fb49deced19c47e723d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfNy0zLTEtMS0w_8e14ba71-c4f8-4650-8525-2be5cce2005b"
      unitRef="number">0.725</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="idd6eb7b715da4cb69e1a51dd18e5bc9d_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfOC0xLTEtMS0w_5cfb4307-f072-45ee-8b22-434c21c498c5"
      unitRef="number">0.063</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:DerivativeLiabilityMeasurementInput
      contextRef="id11b23041c6d4a04a5f707b52b28660f_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85MS9mcmFnOjRkZjljZGYxNTk2NDRjMzhiMTMzMGVjN2E4ZTRjNjg4L3RhYmxlOmE0NDg0YjZkMmI2ZjQ0NTE4MmViYzEwMjk3NDQwNDRlL3RhYmxlcmFuZ2U6YTQ0ODRiNmQyYjZmNDQ1MTgyZWJjMTAyOTc0NDA0NGVfOC0zLTEtMS0w_41f5190d-5428-45b5-8bb1-93108e48c829"
      unitRef="number">0.066</us-gaap:DerivativeLiabilityMeasurementInput>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfNTk4_367d3de7-6eb6-4eda-8724-3f26b303d85d">CASH EQUIVALENTS AND MARKETABLE SECURITIES&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no realized losses from the sale of marketable securities for the years ended December&#160;31, 2020, 2019 or 2018. No investments were other-than-temporarily impaired at either December&#160;31, 2020 or 2019. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#x2019;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#x2019;s ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these marketable securities at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfNTk5_39fcba61-2470-4611-9658-5c2340541e33">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below summarizes the Company&#x2019;s cash equivalents and marketable securities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;213,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,311&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,908&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;613,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,999&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government-sponsored entity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash equivalents and marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i33732cfa0f614ab6a16f0a26f36db075_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMy0xLTEtMS0w_6a9407ff-adf1-4d8c-a92b-651119e71991"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i33732cfa0f614ab6a16f0a26f36db075_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMy0zLTEtMS0w_896cf895-926b-4f4d-95fe-7dd9585df765"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i33732cfa0f614ab6a16f0a26f36db075_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMy01LTEtMS0w_92c895f2-94cb-4994-9829-e1f94fc16803"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i33732cfa0f614ab6a16f0a26f36db075_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMy03LTEtMS0w_b40fc630-17be-4dd7-8ab5-501e4106bc1c"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i25b9c44848094c8188cda00e8392c015_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNS0xLTEtMS0w_459c1fa4-2ea0-4681-bb24-a67acd1f4d08"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i25b9c44848094c8188cda00e8392c015_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNS0zLTEtMS0w_a67fad99-341c-45d1-a9bd-b4bb79a783ef"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i25b9c44848094c8188cda00e8392c015_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNS01LTEtMS0w_9a06c5b9-9e67-41a7-9986-79ed88a56520"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i25b9c44848094c8188cda00e8392c015_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNS03LTEtMS0w_5667a7ad-1922-45ae-9216-f9334d91c863"
      unitRef="usd">53165000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7aae7219ce14478f887d9df6f6050a1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNy0xLTEtMS0w_e6182fb2-8fe0-4ea3-881d-c88b6b10d97b"
      unitRef="usd">213500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7aae7219ce14478f887d9df6f6050a1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNy0zLTEtMS0w_b21eeb10-2cd9-4c99-a6b2-10955d1b7d20"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7aae7219ce14478f887d9df6f6050a1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNy01LTEtMS0w_91403874-ab7e-4830-8412-0b68fa31b472"
      unitRef="usd">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7aae7219ce14478f887d9df6f6050a1b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfNy03LTEtMS0w_9efb97d4-34ca-4868-822e-685292752854"
      unitRef="usd">213533000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3f6d62eac76941a9907a1769725bc84f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOC0xLTEtMS0w_bd62dfa1-f0c5-46d6-9788-f61c363939bf"
      unitRef="usd">59575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3f6d62eac76941a9907a1769725bc84f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOC0zLTEtMS0w_924de231-cdc0-4a72-9567-2fe5c1ec1afa"
      unitRef="usd">16000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3f6d62eac76941a9907a1769725bc84f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOC01LTEtMS0w_e53d8824-b6c0-4e51-baa9-c0b047a4fb0f"
      unitRef="usd">17000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f6d62eac76941a9907a1769725bc84f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOC03LTEtMS0w_e093724c-e535-4184-ab15-2cf2de6b4bf0"
      unitRef="usd">59574000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2fd506f04f5e450699099f18e1a52d5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0xLTEtMS03NTQ2_fe8388b6-6c97-48c7-bc99-d1852f6d6894"
      unitRef="usd">12311000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2fd506f04f5e450699099f18e1a52d5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0zLTEtMS03NTQ2_2fcb5826-b2ec-4e6e-8bc7-fee4964715ae"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2fd506f04f5e450699099f18e1a52d5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS01LTEtMS03NTQ2_44ecb1b6-8e1c-4c24-b6cc-ce645e438d77"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2fd506f04f5e450699099f18e1a52d5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS03LTEtMS03NTQ2_b70c9f69-2f59-4e25-8ac9-58420c6ffa79"
      unitRef="usd">12311000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ie054ce2f1c4741c38e021cbc84c88cae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0xLTEtMS01NjQ_8f267830-a981-494a-ac6b-03edf8d9e07c"
      unitRef="usd">17905000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie054ce2f1c4741c38e021cbc84c88cae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0zLTEtMS01NjQ_4f5e491c-181e-47d2-be34-4a271a8a757a"
      unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie054ce2f1c4741c38e021cbc84c88cae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS01LTEtMS01NjQ_721980c7-b8cd-485a-b318-9049a37359c3"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie054ce2f1c4741c38e021cbc84c88cae_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS03LTEtMS01NjQ_39771141-00a7-4a0c-a86e-b1358ef8299e"
      unitRef="usd">17908000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0xLTEtMS0w_59b46117-a751-4e34-8909-72c5a262b659"
      unitRef="usd">257284000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS0zLTEtMS0w_5986dd97-e43e-4468-ae4f-94e2818dec32"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS01LTEtMS0w_87ca486a-dffe-453e-bead-38f27d3928a5"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2136910e1e244e2199fdaaeffaa4ca6f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfOS03LTEtMS0w_6d7260db-5e87-4d83-81cd-1bbc9f2a61c4"
      unitRef="usd">257298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTAtMS0xLTEtMA_8813fa6c-cd9a-4cb8-82bf-7f55824060f7"
      unitRef="usd">560575000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTAtMy0xLTEtMA_c5d90aaa-f5d7-42b5-a8d1-bbfda9772184"
      unitRef="usd">86000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTAtNS0xLTEtMA_f4d3972a-9414-462b-81d5-a525450fd97a"
      unitRef="usd">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTAtNy0xLTEtMA_e7abaa92-f575-4828-9dba-641f5c4ee60d"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTEtMS0xLTEtMA_e9b6f3c4-5ede-483f-b76a-63adbfc5b7b4"
      unitRef="usd">613740000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTEtMy0xLTEtMA_d3179ff6-e773-471c-8aaa-0fcf8f407ec5"
      unitRef="usd">86000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTEtNS0xLTEtMA_cca69f88-9f0a-440b-868e-68abf2ed11f1"
      unitRef="usd">37000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTEtNy0xLTEtMA_032896c3-98d3-4496-bb98-ca9088f16bc4"
      unitRef="usd">613789000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i166d41c1d13840e79f6069d74eed0581_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTQtMS0xLTEtMA_af35f377-35e5-4bc4-973b-944c4567af8e"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i166d41c1d13840e79f6069d74eed0581_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTQtMy0xLTEtMA_b52631c4-a13e-46d1-afc8-0efc21975118"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i166d41c1d13840e79f6069d74eed0581_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTQtNS0xLTEtMA_30adad0c-45ee-42c6-a75d-d7f147c30992"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i166d41c1d13840e79f6069d74eed0581_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTQtNy0xLTEtMA_dc83b739-fa5d-4282-8d1a-0fa7b85788c6"
      unitRef="usd">30496000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctMS0xLTEtNTYw_7e9a0671-cb2e-47e3-947d-d15db5722e6b"
      unitRef="usd">2998000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctMy0xLTEtNTYw_930c65c3-f351-4329-8546-7e56eaca1445"
      unitRef="usd">1000</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctNS0xLTEtNTYw_4ce090ca-d6e9-44d8-b37f-ac05cd895315"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctNy0xLTEtNTYw_5d868edb-8ac8-4e69-8f90-faeffbfa6a5f"
      unitRef="usd">2999000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i195f8095900e47b59c48f9b46ca9e135_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTUtMS0xLTEtMA_d860e03d-89fe-423c-9fd3-799c98443d2f"
      unitRef="usd">33494000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i195f8095900e47b59c48f9b46ca9e135_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTUtMy0xLTEtMA_e210f2ea-3aa8-4f8e-adeb-bcf5813007a8"
      unitRef="usd">1000</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax>
    <sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i195f8095900e47b59c48f9b46ca9e135_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTUtNS0xLTEtMA_48541a24-44b8-457d-bd61-1c868bd8ff9e"
      unitRef="usd">0</sgmo:CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i195f8095900e47b59c48f9b46ca9e135_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTUtNy0xLTEtMA_12fd54a2-16e9-4326-9ae5-b3018eebddc6"
      unitRef="usd">33495000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctMS0xLTEtMA_307a4805-1e4b-4558-a287-b24beb0e2364"
      unitRef="usd">155230000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctMy0xLTEtMA_7b335830-938b-42c0-a7d1-51b71fa6ee98"
      unitRef="usd">145000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctNS0xLTEtMA_adcb74a0-6b37-42a5-829d-37253d3525e7"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c5d08f53b63435a9ebaa62fc5e33576_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTctNy0xLTEtMA_d19eee0a-e560-4fee-9d1c-8dcbf78983da"
      unitRef="usd">155368000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib59efa220c014139a6c6518f23eb3381_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTgtMS0xLTEtMA_3b60b78d-1f0d-464a-9c9f-750d610155aa"
      unitRef="usd">94905000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib59efa220c014139a6c6518f23eb3381_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTgtMy0xLTEtMA_f8330c50-676e-4503-8acc-503561014d85"
      unitRef="usd">115000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib59efa220c014139a6c6518f23eb3381_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTgtNS0xLTEtMA_e0b1f8f6-65b5-4269-93e5-a485a2b9d2ac"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib59efa220c014139a6c6518f23eb3381_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTgtNy0xLTEtMA_ba1ead97-14be-4a91-a3fc-c88da0809c47"
      unitRef="usd">95017000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6edba78934f34526818d49f23b52582d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTktMS0xLTEtMA_e4a3e185-abc9-40d7-a059-d6f2660c7a48"
      unitRef="usd">53411000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6edba78934f34526818d49f23b52582d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTktMy0xLTEtMA_7a6a905a-3d51-46b4-89a3-6d7a723b4d4d"
      unitRef="usd">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6edba78934f34526818d49f23b52582d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTktNS0xLTEtMA_bc907e9e-4aad-4ffd-a675-31638a6502f3"
      unitRef="usd">9000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6edba78934f34526818d49f23b52582d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMTktNy0xLTEtMA_caa391f5-954a-4e13-a127-3d053b72cab4"
      unitRef="usd">53493000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjAtMS0xLTEtMA_9bf341df-9027-43cd-b13f-5aeae672991b"
      unitRef="usd">303546000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjAtMy0xLTEtMA_6f1d1081-3bda-4891-9988-2d4728522c31"
      unitRef="usd">351000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjAtNS0xLTEtMA_ee52e31c-3162-46ff-9ee2-fba336ad867d"
      unitRef="usd">19000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjAtNy0xLTEtMA_80ec471d-526c-4b93-b147-1e3b8d03b27a"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjEtMS0xLTEtMA_953d87d4-1ee7-4511-a319-abec5f829783"
      unitRef="usd">337040000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjEtMy0xLTEtMA_2b4d73aa-c9c5-4b5d-9c83-d773eab45f52"
      unitRef="usd">352000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjEtNS0xLTEtMA_ef6dfbda-00f5-4053-b305-f41b6c173cbe"
      unitRef="usd">19000</sgmo:CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax>
    <sgmo:CashEquivalentsAndAvailableForSaleSecurities
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOmRjNmJkM2JlNzU5ZDRiMTRiMGQ4NGZmMmQ5ZjEzOTQ0L3RhYmxlcmFuZ2U6ZGM2YmQzYmU3NTlkNGIxNGIwZDg0ZmYyZDlmMTM5NDRfMjEtNy0xLTEtMA_57cea4f7-d964-44a4-bac4-1921640499e6"
      unitRef="usd">337373000</sgmo:CashEquivalentsAndAvailableForSaleSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfMzI5ODUzNDg4NTI1Ng_5bf07fa7-8303-4e5f-9976-8b35980dd40b">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of marketable securities by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;282,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;560,624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfMi0xLTEtMS0w_c92458bd-8f1a-49af-8aef-dffdf9f16103"
      unitRef="usd">510094000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfMi0zLTEtMS0w_566ed2af-6363-4e27-96e4-ac05795c2267"
      unitRef="usd">282046000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfMy0xLTEtMS0w_3aa5b3d3-6942-463f-b065-ca0a416914be"
      unitRef="usd">50530000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfMy0zLTEtMS0w_837088f8-a24f-4726-9f24-757d50f2a4c0"
      unitRef="usd">21832000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfNC0xLTEtMS0w_494d0d67-ff09-4429-9ae6-27cda758b640"
      unitRef="usd">560624000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RhYmxlOjNhNmEyOTQwYTA2YzRiMjk5NGI5MjMzM2JjYzU4NjBlL3RhYmxlcmFuZ2U6M2E2YTI5NDBhMDZjNGIyOTk0YjkyMzMzYmNjNTg2MGVfNC0zLTEtMS0w_009c1871-80dd-4cfb-95ca-5da787078932"
      unitRef="usd">303878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfMjcx_c22bc051-78e1-435e-82f8-054de4b70d19"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfMjcx_d17fb8f4-2053-4c2a-bd65-d64031cf141b"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfMjcx_f93eeb92-576a-45ee-9598-03e6e74399fd"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <sgmo:OtherThanTemporarilyImpairedInvestment
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfNTI2_5cec25d6-8dbc-4e0f-b7bb-186068869934"
      unitRef="usd">0</sgmo:OtherThanTemporarilyImpairedInvestment>
    <sgmo:OtherThanTemporarilyImpairedInvestment
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85NC9mcmFnOmQ0ZjIxOThkMDA3NTQ5ZDJiZmQ2Mzk3MGI4ZTg0YWRkL3RleHRyZWdpb246ZDRmMjE5OGQwMDc1NDlkMmJmZDYzOTcwYjhlODRhZGRfNTI2_d2710929-9f33-4a4a-a91e-a96ee60b8b33"
      unitRef="usd">0</sgmo:OtherThanTemporarilyImpairedInvestment>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI4NQ_effbfc5f-06fe-4473-8a0f-3db10eeb4e93">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Collaboration Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Novartis Institutes for BioMedical Research, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#x201c;Novartis&#x201d;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#x201c;ZFP&#x201d;) transcription factors (&#x201c;ZFP-TFs&#x201d;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company performs early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, investigational new drug-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#x2019;s proprietary adeno-associated viruses (&#x201c;AAVs&#x201d;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All payments received under the agreement, when earned, are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and estimated research costs of $20.1&#160;million for identified research projects over the estimated research period. None of the development and commercial milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Novartis in accordance with ASC Topic 606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its performance obligation. As of December&#160;31, 2020, the Company had deferred revenue of $70.9&#160;million related to the upfront license fee received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $4.1&#160;million of upfront license fee and $1.1&#160;million research reimbursement costs as revenue related to the Novartis agreement during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $1.5&#160;million for financial advisory fees related to the Novartis collaboration and license agreement during the year ended December&#160;31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized this $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic 340, Other Assets and Deferred Costs. The Company amortized $0.1&#160;million during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Biogen MA, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#x201c;BIMA&#x201d;) and Biogen International GmbH (together with BIMA, &#x201c;Biogen&#x201d;) for the research, development and commercialization of gene &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;regulation therapies for the treatment of neurological diseases. The Company and Biogen plan to leverage the Company&#x2019;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#x2019;s common stock (the &#x201c;Biogen Shares&#x201d;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.45&#160;billion in first commercial sale and other sales-based milestone payments. In addition, the Company is also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#x2019;s disease, ST-502 for synucleinopathies including Parkinson&#x2019;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company performs early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#x2019;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e., through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to 10 targets. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#x2019;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#x2019;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The stock purchase agreement also provides that until the first anniversary of the effectiveness of the collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#x2019;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the two-year anniversary of the effectiveness of the collaboration agreement, (ii) the date that Biogen beneficially owns less than 5% of the Company&#x2019;s common stock and (iii) the date the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic 606 and concluded that Biogen is a customer. As of December&#160;31, 2020, the transaction price includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#x2019;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of December&#160;31, 2020, the Company had deferred revenue of $183.2&#160;million related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized $21.4&#160;million of upfront license fee and the excess consideration from the stock purchase, and $6.5&#160;million research reimbursement costs as revenue related to the Biogen agreement during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the upfront license fee of $125.0&#160;million and 2% of the excess consideration from the stock purchase of $79.6&#160;million, as a contract asset. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic 340, Other Assets and Deferred Costs. The Company amortized $0.4&#160;million during the year ended December&#160;31, 2020. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as reduction in proceeds during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Kite Pharma, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#x201c;Kite&#x201d;), which became effective on April 5, 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#x201c;ZFNs&#x201d;) and viral vectors to disrupt and insert certain genes in T cells and natural killer cells (&#x201c;NK-cells&#x201d;) including the insertion of genes that encode chimeric antigen receptors (&#x201c;CARs&#x201d;), T cell receptors (&#x201c;TCRs&#x201d;), and NK-cell receptors (&#x201c;NKRs&#x201d;) directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the research program term and subject to certain exceptions, except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;treating cancer, any cell therapy product that, as a result of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ex vivo&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the effective date, in April 2018, the Company received a $150.0&#160;million upfront payment from Kite. In addition, Kite will reimburse the Company&#x2019;s direct costs to conduct service under the joint research program provisions of the agreement, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones in this agreement are achieved.&#160;Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first 10 times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event. In addition, the Company will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The initial research term of the agreement is six years. Kite has an option to extend the research term for up to two additional one-year periods for a separate fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service costs of approximately $3.4&#160;million. The Company concluded the transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. The Company concluded that the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. Kite has the right to terminate this agreement, in its entirety or on a per licensed product or per candidate target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#x2019;s bankruptcy or material, uncured breach.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the primary performance obligations within the Kite agreement as: (1) a license to the technology along with the stand-ready obligation to perform research services, and (2) the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#x2019;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2020, and 2019 the Company had deferred revenue of $81.4&#160;million and $106.5&#160;million, respectively, related to this agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Giroctocogene Fitelparvovec Global Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company originally received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in the giroctocogene fitelparvovec Pfizer agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement based on an escalating tiered, double-digit percentage of the annual net sales of such product. These royalties are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the giroctocogene fitelparvovec Pfizer agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. As of December&#160;31, 2020, the total transaction price under this agreement is $134.0&#160;million, which represents the upfront and research services fees of $79.0&#160;million and two unconstrained milestones achieved of an aggregate amount of $55.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price, as all such milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#x2019;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified one performance obligation within the giroctocogene fitelparvovec Pfizer agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete, as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;services through 2020, the estimated period the Company will perform research services. The estimate of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. The Company satisfied the deliverables and research services responsibilities within the arrangement which were completed in December 2020. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020. As of December&#160;31, 2019, the Company had deferred revenue of $4.0&#160;million related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company entered into an amendment to the collaboration agreement, pursuant to which the Company transferred the IND for giroctocogene fitelparvovec to Pfizer. Upon this transfer the Company achieved a $25.0&#160;million milestone as the conditions for achieving the milestone were met. The cumulative revenue recognized in connection with this milestone was $25.0&#160;million as of December&#160;31, 2020 and included $1.3&#160;million recognized during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company determined that there was a high probability of achievement of a $30.0&#160;million milestone with Pfizer for giroctocogene fitelparvovec. The milestone was subsequently achieved upon dosing of the first subject in a Phase 3 clinical trial in early October 2020. The cumulative revenue recognized in connection with this milestone was $30.0&#160;million during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Pfizer giroctocogene fitelparvovec agreement:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee and research services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, the Company updated its estimated project cost and related revenues under this program. This adjustment was a direct result of the increase in project scope during the first quarter of 2019 and the corresponding costs, which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon transfer of the IND for giroctocogene fitelparvovec to Pfizer. This adjustment was a direct result of the decrease in project scope during the fourth quarter of 2019 and the corresponding costs, which resulted in an increase in the measure of proportional performance. During the year ended December 31, 2019, the Company recognized $15.7&#160;million in revenues related to the Pfizer giroctocogene fitelparvovec agreement, which included approximately $8.7&#160;million acceleration in revenues recorded in the three months ended December 31, 2019 related to the updated estimated project cost, offset by approximately $3.0&#160;million reduction in revenues recorded in the three months ended March&#160;31, 2019 related to the updated estimated project cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the giroctocogene fitelparvovec collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs, after the successful IND transfer of the giroctocogene fitelparvovec product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $2.4&#160;million, decreased net loss by $2.4&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.02 for year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;C9ORF72 Research Collaboration and License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis (&#x201c;ALS&#x201d;) and frontotemporal lobar degeneration (&#x201c;FTLD&#x201d;) linked to mutations of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#x2019;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2 gene.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;15 years after the first commercial sale of a licensed product in a major &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following termination by the Company for Pfizer&#x2019;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gene for a period of time. Following termination by Pfizer for the Company&#x2019;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene for a period of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Pfizer agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $17.0&#160;million, which represents the upfront fee of $12.0&#160;million and one unconstrained milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has identified the performance obligation within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. The Company satisfied the deliverables and research services responsibilities within the arrangement which were completed in September 2020. As a result, the Company recognized the remaining deferred revenue from the upfront payment in September 2020. As of December&#160;31, 2019, the Company had deferred revenue of $8.0&#160;million related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, the Company earned a $5.0&#160;million milestone associated with the completion of the Company&#x2019;s research activities in its collaboration with Pfizer to develop genome regulation therapies using ZFP-TFs for the treatment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;-related ALS and frontotemporal lobar degeneration. This milestone was achieved upon Pfizer&#x2019;s notification to the Company of its election to pay the first development milestone payment under the collaboration agreement. This milestone payment is non-refundable, and the Company recognized on a cumulative basis $5.0&#160;million for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Pfizer &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; agreement:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimate in connection with the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; collaboration agreement with Pfizer. These adjustments were a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. These adjustments increased revenue by $8.8&#160;million, decreased net loss by $8.8&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.06 for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sanofi Genzyme&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#x201c;Sanofi&#x201d;)), to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#x201c;SCD&#x201d;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#x2019;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#x2019;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#x2019; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price as of December&#160;31, 2020 of $93.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones of $13.5&#160;million and estimated research costs of $59.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the constrained clinical or regulatory milestones have been included in the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Sanofi in accordance with ASC Topic 606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the estimated period the Company will perform research services. The estimate of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#x2019;s current assumptions regarding the timing of its deliverables. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of December&#160;31, 2020 and 2019, the Company had deferred revenue of $1.2&#160;million and $1.7&#160;million, respectively, related to this agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company achieved a $6.0 million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $5.8&#160;million as of December&#160;31, 2020 and included $0.1&#160;million recognized during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the Company achieved a $7.5 million milestone with Sanofi upon dosing of the first subject in the SCD Phase 1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $7.2&#160;million as of December&#160;31, 2020 and included $0.1&#160;million recognized during the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi. This adjustment was a direct result of the decision in March 2020 to increase the project scope and the corresponding costs, both of which resulted in a decrease in the measure of proportional cumulative performance. This adjustment decreased revenue by $2.2&#160;million, increased net loss by $2.2&#160;million and increased the Company&#x2019;s basic net loss per share by $0.02 for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;California Institute for Regenerative Medicine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, the California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#x2019;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta&#160;thalassemia. As of December&#160;31, 2020, the Company had received $5.2&#160;million under the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these Consolidated Financial Statements. In the event that the Company terminates a CIRM-funded clinical trial, it will be obligated to repay the remaining CIRM funds on hand. As of December&#160;31, 2020 and 2019, $6.4&#160;million and $5.7&#160;million, respectively, including accrued interest, related to this award is recorded as a loan in other non-current liabilities on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amended Collaboration and License Agreement with Takeda&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2012, the Company entered into a collaboration and license agreement with Shire International GmbH, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;), to research, develop and commercialize a ZFP therapeutic for treating Huntington&#x2019;s disease. The Company received an upfront license fee of $13.0&#160;million in 2012 and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;recognized a $1.0&#160;million milestone payment in 2014. Takeda does not have any milestone payment obligations, but is required to pay single digit percentage royalties to the Company, up to a specified maximum cap, on the commercial sales of therapeutic products for Huntington&#x2019;s disease. The Company is required to pay single digit percentage royalties to Takeda, up to a specified maximum cap, on commercial sales of therapeutic products from programs returned under the original agreement (which include blood clotting Factors VIII and IX) that use two zinc fingers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the agreement, the Company granted Takeda an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use the Company&#x2019;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the huntingtin gene (&#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HTT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene&#x201d;). During the term of the agreement, the Company is not permitted to research, develop or commercialize, outside of the agreement, certain products that target the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;HTT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; gene. The agreement may be terminated by (i)&#160;the Company or Takeda, in whole or in part, for the uncured material breach of the other party, (ii)&#160;the Company or Takeda for the bankruptcy or other insolvency proceeding of the other party and (iii)&#160;Takeda, in its entirety, effective upon at least 90 days&#x2019; advance written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the agreement with Takeda in accordance with ASC Topic 606 and concluded that Takeda is a customer. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Takeda apart from the research services to be performed pursuant to the Takeda agreement. The Company satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. As a result, the Company recognized the remaining $2.3&#160;million of deferred revenue from the upfront payment during the year ended December 31, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not recognize any revenues under the Takeda agreement for the years ended December&#160;31, 2020, 2019 and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Agreement with Sigma-Aldrich Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2007, Sangamo entered into a license agreement with Sigma-Aldrich Corporation (&#x201c;Sigma&#x201d;) to provide Sigma with access to Sangamo&#x2019;s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC (&#x201c;DAS&#x201d;), a wholly-owned subsidiary of Dow Chemical Company. Sangamo developed laboratory research reagents using its ZFP technology over a three-year research services period. Sangamo has since transferred the ZFP manufacturing technology to Sigma.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0&#160;million consisting of a $4.9&#160;million purchase of 636,133 shares of Sangamo common stock, valued at $4.9&#160;million, and a $15.1&#160;million upfront license fee. Sangamo is also eligible to receive commercial license fees of $5.0&#160;million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones, Sigma will make milestone payments to Sangamo up to an aggregate of $25.0&#160;million. Sangamo does not have additional ongoing performance obligations under the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement with Sigma for the years ended December&#160;31, 2020, 2019 and 2018, were $0.5&#160;million, $0.6&#160;million and $0.5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Agreement with DAS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2005, Sangamo entered into an exclusive commercial license with DAS, with an initial three-year research term. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP-TFs or ZFNs into humans or animals for diagnostic, therapeutic or prophylactic purposes. In 2008, DAS exercised its option and obtained a commercial license to sell products incorporating or derived from plant cells generated using the Company&#x2019;s ZFP technology. The exercise of the option triggered a one-time commercial license fee of $6.0&#160;million, payment of the remaining $2.3&#160;million of the previously agreed upon $4.0&#160;million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#x2019;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December&#160;31, 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $0.3&#160;million to $3.0&#160;million and total $25.3&#160;million &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;over 11 years. The Company has identified the performance obligation within this arrangement as a license to the technology. In the event of any termination of the agreement, all rights to use the Company&#x2019;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo&#x2019;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#x2019;s ZFP technology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the agreement with DAS were $3.0&#160;million, $3.0&#160;million, and $3.0&#160;million during 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ie90d9c1847f64dc498789d1a25747db7_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQ1OA_c2940d46-ccbb-453d-8bb7-ed646c94242c"
      unitRef="usd">75000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ie25f2c3034b549c1a2403b3c2b59e8be_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTI5NA_90436c7b-539f-4820-9336-b44d23feac76"
      unitRef="usd">420000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i08c85ff8ca5b455fa7266f68c7634773_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTM0OA_39e4c1af-aced-4947-b750-ccf27c816034"
      unitRef="usd">300000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i679870fa4aa947f2b092c683d49e48be_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQwNg_b76680ff-14d9-4f75-9340-7d842a254756"
      unitRef="usd">95100000</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementLicenseFee
      contextRef="i679870fa4aa947f2b092c683d49e48be_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTM2Nw_e9ed832f-0f76-4830-8156-a142db04f983"
      unitRef="usd">75000000.0</sgmo:CollaborativeArrangementLicenseFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i679870fa4aa947f2b092c683d49e48be_D20200727-20200727"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTM4Nw_adeda9f5-3c12-4ec7-afef-df28cfacd4b6"
      unitRef="usd">20100000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic9662bfa60bd435086718d9bfee03841_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQyNQ_655ef93a-e488-4961-bd02-0e3b70e335a1"
      unitRef="usd">70900000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41532f5f82c84a95a08ae7d3f428f14a_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcxMjQxNw_4bf6f572-0ceb-40c2-8871-b8d4f9048cf4"
      unitRef="usd">4100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65e104e30eb7451ebcb1b6d67543ae50_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcxMjQ1MQ_087b09ee-9854-4069-aacc-04cd020bdf4f"
      unitRef="usd">1100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="ic9662bfa60bd435086718d9bfee03841_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQ3Nw_98e12fbb-1127-4f16-ae0e-37dab6f80035"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="ib3b3cfc543ee4dfbb9fa9f54e698bbe0_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjIzNA_133c2fe7-dc0f-410e-a450-03f13bae3a76"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="ie90d9c1847f64dc498789d1a25747db7_D20200801-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTQ5Ng_64264f1e-233c-414a-94a2-25c7ebf93768"
      unitRef="usd">75000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="ic9662bfa60bd435086718d9bfee03841_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTUxNA_1a856f3c-0609-4f62-a917-9a3f4a4f142c"
      unitRef="usd">1500000</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i09bf3f7bc1bf4ca2aee88d98cbb49c11_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTYwOQ_4aaaef57-3db2-45c6-86be-5aaef87b3d68"
      unitRef="usd">100000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDYxMw_1f488b73-ae50-4a9b-a483-49b27f21aa2a"
      unitRef="shares">24420157</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if650f84ed8e44993a9c4382072ecf061_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDYyMw_4327490a-c60c-46f8-8d28-2f4c0de6b24c"
      unitRef="usdPerShare">9.2137</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDY0MA_062585dd-a880-4bf3-ac8b-a2a234da661f"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDY2MA_6532a2bb-f3b7-4082-b6d9-e62e345046b5"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ProceedsFromCollaborators
      contextRef="iecf6454954a34af8a88c9bb4071baf99_D20200501-20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTEyNQ_c6183ecf-6d09-4b5d-94da-fd86157c5250"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i1c641a230af14951931f575b265aa8bf_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDY3OQ_f7bad75b-74f1-4c2c-8175-bbac18fbc042"
      unitRef="usd">2370000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="ia7101296ba8e4016aee3ac0bd6885981_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDcyMQ_37639100-e4b3-407c-bb19-a741611b8c2c"
      unitRef="usd">925000000.0</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable
      contextRef="i36d7c81806f3497d988a10597afd1494_I20200229"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDcwMQ_8c57d2a2-b1d5-45f8-a168-58f751cfbc92"
      unitRef="usd">1450000000</sgmo:CollaborativeArrangementMaximumMilestonePaymentReceivable>
    <sgmo:CollaborativeArrangementNumberOfProductTargets
      contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjIzOA_0653acf6-c919-45a2-8595-86e2b4b1eede"
      unitRef="product_target">12</sgmo:CollaborativeArrangementNumberOfProductTargets>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="i1c641a230af14951931f575b265aa8bf_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0MQ_552d0d3b-8c70-4ac1-b6e3-f11265557a0a"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborationAgreementNumberOfAdditionalProductTargets
      contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0Mg_368600b2-39c1-452b-82de-6282215cc1e9"
      unitRef="product_target">9</sgmo:CollaborationAgreementNumberOfAdditionalProductTargets>
    <sgmo:CollaborationAgreementTargetSelectionPeriod
      contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0Mw_00d3f2b5-76e1-47fa-8822-aeacf5613758">P5Y</sgmo:CollaborationAgreementTargetSelectionPeriod>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="i1c641a230af14951931f575b265aa8bf_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0NA_0085e78f-73a0-4eac-a386-6c4023304d41"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborativeArrangementNumberOfProductTargetsSelected
      contextRef="i1c641a230af14951931f575b265aa8bf_I20200229"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0NQ_80a56a9b-5db8-4949-9261-715a4cb961bc"
      unitRef="product_target">3</sgmo:CollaborativeArrangementNumberOfProductTargetsSelected>
    <sgmo:CollaborationArrangementResearchPeriod
      contextRef="i9997a66b33774bf8874b84e01397ca61_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI0Ng_d4376931-b3f0-49a8-8eb7-3da901d1fce5">P7Y</sgmo:CollaborationArrangementResearchPeriod>
    <sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2NjI5Ng_70921711-44a1-4801-afa2-048d8e9cc0c6"
      unitRef="product_target">10</sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace>
    <sgmo:CollaborativeArrangementStandstillRestrictionPeriod
      contextRef="i2433e456bdfb43a4aa95fe4c28d4d208_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2MDY3OA_afba260c-0b2f-4ada-9635-e3e074a7e508">P3Y</sgmo:CollaborativeArrangementStandstillRestrictionPeriod>
    <sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage
      contextRef="i336e9bea9e624f2d85ca346d8219bd49_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI1MA_81889e8b-ccc2-4779-b032-7e32fc9656b8"
      unitRef="number">0.05</sgmo:CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage>
    <sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld
      contextRef="i336e9bea9e624f2d85ca346d8219bd49_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI1NA_cf1df317-c8c5-4eb4-9d44-e98f7639aa4e"
      unitRef="number">0.50</sgmo:CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld>
    <sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod
      contextRef="i2433e456bdfb43a4aa95fe4c28d4d208_D20200201-20200229"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI1OA_ee911873-706c-47e3-b60a-edbe07d6151f">P2Y</sgmo:CollaborativeArrangementVotingProvisionsExpirationPeriod>
    <sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage
      contextRef="i336e9bea9e624f2d85ca346d8219bd49_I20200228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI2MA_b38d9153-8a98-4f88-8db3-a56048a33d30"
      unitRef="number">0.05</sgmo:CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDkzMQ_0faf2db6-d896-43cf-aa3b-14f872f0dc6b"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction
      contextRef="iae50536cbc814ac6a99bb260423fdb2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDk1MA_c8770666-3cd8-4a14-a2de-a116c8d3af85"
      unitRef="usd">79600000</sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDk5MA_26cf7cb1-a5e9-4fa6-ad6e-bf922403016e"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="icccc34360eed452f9ad238a715656769_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMDk3MA_d8598018-4412-404c-9276-6c18c3baaba6"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <us-gaap:ContractWithCustomerLiability
      contextRef="icccc34360eed452f9ad238a715656769_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTAxMA_2e2d7b9a-23af-4191-96f6-83874ac16960"
      unitRef="usd">183200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb0c68923ff146d280fb7f97045dad9b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcxMjgzMg_5849a27e-ef57-42ba-96a0-82f21d897437"
      unitRef="usd">21400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6dbd4261e96a4a87808a78d8e6b23ba1_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcxMjg1MA_8bd1dd8d-41e3-445b-968f-29c17044b18c"
      unitRef="usd">6500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue
      contextRef="ie4b362953ca94b868a22eeeacdc5d1c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTAyOA_94b9426c-2c7c-40bd-85e0-e59b1d18bfa0"
      unitRef="usd">7000000.0</sgmo:CollaborationArrangementCommissionFeePortionOfGrossProceedsValue>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="i791f1d7d58614b2e92e9f6fca8affadb_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI2NA_49d1d690-e3e1-4a08-a015-73cebbc5a3c4"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i529d81f2073e4a95b47a2cc403353ebb_D20200408-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTA0OA_2400410e-1c14-43e9-bd18-5510a782f41f"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI2OA_5eb3283d-ad14-41d8-83b8-bdaceb31e51d"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTEwNA_27e102af-f4cd-44bb-a84b-62af755cb7aa"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="ie4b362953ca94b868a22eeeacdc5d1c8_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTE0Mw_c9658029-ab94-4155-8acd-95d3c647a226"
      unitRef="usd">4100000</us-gaap:ContractWithCustomerAssetNet>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI3Mg_eb04db6d-7165-4bec-8bd0-e494b0bfa2e7"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <us-gaap:ProceedsFromCollaborators
      contextRef="i4cfbfe221f12464495880e53f4100ad4_D20200201-20200229"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTI1NQ_e6048dfa-8232-4104-9afd-478cadada163"
      unitRef="usd">125000000.0</us-gaap:ProceedsFromCollaborators>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI3Ng_9429c472-31c8-4a40-be14-213af42335a0"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction
      contextRef="iae50536cbc814ac6a99bb260423fdb2e_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTE2Mg_402c836a-479b-4a79-981a-67669f1c8740"
      unitRef="usd">79600000</sgmo:SaleOfStockExcessConsiderationReceivedOnTransaction>
    <us-gaap:CostOfGoodsAndServicesSoldAmortization
      contextRef="i791f1d7d58614b2e92e9f6fca8affadb_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTE5Nw_0d33bec9-db39-4013-b5db-4e7d25bfd2fc"
      unitRef="usd">400000</us-gaap:CostOfGoodsAndServicesSoldAmortization>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i86be779bb370428988a0873a257efbeb_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTIxNQ_2a36b4aa-6aab-4fc0-93f8-21822ab49aef"
      unitRef="usd">2900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <sgmo:CollaborativeAgreementPercentOfInitialRecognition
      contextRef="ibd72e169b82344a7aa67c2b9525ed478_D20201001-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDk0NzgwMjQwMjI4MA_7bc6cb8c-6361-45cb-a008-4efc4e4e9308"
      unitRef="number">0.02</sgmo:CollaborativeAgreementPercentOfInitialRecognition>
    <sgmo:CollaborationAgreementEquityIssued
      contextRef="icccc34360eed452f9ad238a715656769_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTIzNQ_699350fe-9496-475a-896c-a40d07af316f"
      unitRef="usd">145400000</sgmo:CollaborationAgreementEquityIssued>
    <sgmo:MilestonePaymentsReceived
      contextRef="i622b78d941574e52bc533f27c36c5fe7_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQwNQ_fc534fb2-fb51-48ed-8908-98694384147a"
      unitRef="usd">150000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ic0e221499b664eee8f775e18eb6f11f8_D20180404-20180405"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjgxNw_1f943d02-f1dc-4071-8cbd-acdb13bea104"
      unitRef="usd">3010000000.00</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="i6b05e76cf87f4a609ff6d9a1d6be38e3_D20180404-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjkxNw_ba1337f8-610e-4551-bd40-474afff3b1a7"
      unitRef="usd">1260000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived
      contextRef="i15ca38def7cc4d739746ecdfadfe6b6c_D20180404-20180405"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzA1OQ_1c3b5ffb-8386-4383-abee-00f55cacac68"
      unitRef="usd">1750000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDAzNA_92b2318e-e8a2-49f1-90d9-e01e20f390f7">P6Y</sgmo:InitialResearchTermOfAgreement>
    <sgmo:NumberOfOptionsToExtendInitialResearchTerm
      contextRef="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDA5NQ_27623c9f-c788-42e4-9674-f1be9d1d184a"
      unitRef="option">2</sgmo:NumberOfOptionsToExtendInitialResearchTerm>
    <sgmo:ExtendedResearchTermOfAgreement
      contextRef="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI3NA_1d671f64-7063-45ff-a31f-be15ac1cab8f">P1Y</sgmo:ExtendedResearchTermOfAgreement>
    <sgmo:SeparateUpfrontFee
      contextRef="i147f502ab8d94b1f89a9c2ad5143e2d2_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDE0Nw_66f60c2a-9042-4efb-abdd-9dafbbd36545"
      unitRef="usd">10000000.0</sgmo:SeparateUpfrontFee>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan
      contextRef="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDQ2MQ_08a5cb03-8e5d-4a6c-ad31-9742755146ae"
      unitRef="usd">3400000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDUzMw_73523854-dcfc-434d-b2da-8226e780f4f9"
      unitRef="usd">189300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDU3Ng_6f4d4f19-ab63-434b-b569-764924553b0a"
      unitRef="usd">150000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i5d5eca39f0894f78aeb8f4163902885d_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNDU4Mw_49246a7b-429c-4a16-a8e2-3d2c153717ce"
      unitRef="usd">39300000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ifd8eb466e5ab46dcbfe11a464c069eff_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNzEyMg_fdab5189-0adc-41bb-8033-b13ad0478676"
      unitRef="usd">81400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i279331e783974f13b570a80bdae2914d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfNzEyOQ_e54870c5-2d7a-42d3-9ad7-9fd96eb0bab9"
      unitRef="usd">106500000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ic99454b17cf8426abe411aa4bfe33b84_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3Mzg_172d0686-1621-4a48-bccf-f6719debeaa9">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.086%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.553%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.004%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Kite agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of license and stand-ready fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7c5dfd1e85a4c9aa4e84a23484dc176_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfMy0xLTEtMS0w_2ad3c177-bef9-4940-953b-d5b75c14fb18"
      unitRef="usd">25046000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bfa78bdc3244b5693d30aa711524848_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfMy0zLTEtMS0w_4e611650-d812-44db-affd-49d8aa910bf6"
      unitRef="usd">24977000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd7a58620bca4d85b6783c708b906014_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfMy01LTEtMS0xNDE_59732352-11e3-473f-ab80-dac2492c061e"
      unitRef="usd">18545000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if07241a21483414fa49f01f2b3ff040d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNC0xLTEtMS0w_7e128333-7943-43b9-acf4-88113fb1bf2b"
      unitRef="usd">3562000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i160f22e556494a06802b40e3edf5f834_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNC0zLTEtMS0w_7c8c0c1d-67ac-489f-a831-3a272f83e271"
      unitRef="usd">9373000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d31979f09c648999fccb66122fd46ee_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNC01LTEtMS0xNDE_69046952-b1cd-433a-a19c-4668f514490c"
      unitRef="usd">6972000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic99454b17cf8426abe411aa4bfe33b84_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNS0xLTEtMS0w_493e89bc-c181-41a9-a758-1d77a3fb97db"
      unitRef="usd">28608000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fc50ac5b1034ddcab9f5dc7d229bd83_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNS0zLTEtMS0w_496cb753-4bc5-4eee-bfb3-d5ef7f931954"
      unitRef="usd">34350000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42157f7e86b3408ab390ad6b9ce433d2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjIwNThkYWMwMjkwMTQxMjBhYzBkNDZkOWE1YTlmNTRjL3RhYmxlcmFuZ2U6MjA1OGRhYzAyOTAxNDEyMGFjMGQ0NmQ5YTVhOWY1NGNfNS01LTEtMS0xNDE_5e5c32cc-d9f8-4e8a-a03b-c3915077dd5e"
      unitRef="usd">25517000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i16e9fd5645c342c6a53a2d4075df3f32_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODA3OQ_32ebba4d-5242-485c-aaf0-fdfbeba3c0c1"
      unitRef="usd">70000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i16d56044bc30409491f4cd99b8ed0162_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODM2OQ_2bb4a79b-5b1e-4f38-a1b5-ac16d5d0cb60"
      unitRef="usd">208500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive
      contextRef="i828ebcc51b3447ab9fb4c223a4ed2af9_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODQ5OA_9dca6ef0-ee42-4801-985f-ee286580c352"
      unitRef="usd">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ie7ce5c1ee6e64ac5b1260a8a278341bf_D20170501-20170531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODgyNw_d0d74b94-d0e9-4a6c-a619-2e6cae416ba0"
      unitRef="usd">475000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ic844e08373f649f89686b25d4f48e080_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODg1Mg_9fb26f26-4874-4358-afde-1ea44a99e8db"
      unitRef="usd">300000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestoneRevenueReceivable
      contextRef="ic3ea3fbe1ff04cd78a9c151aab7fe03c_I20170531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfODg3Ng_65f0c4bd-e57d-4c15-b14a-58dc474c3791"
      unitRef="usd">175000000.0</sgmo:MilestoneRevenueReceivable>
    <sgmo:MilestonePaymentsReceived
      contextRef="i108f738726ee4d188ea13f5c58559305_D20170501-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTg0Nw_b4c5d2cc-f657-422d-b37e-3b0733494f51"
      unitRef="usd">55000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfOTUxMA_3c380c1c-9e87-4ee1-b9e7-4156e510dd91"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i56711bf4d33b463384f2cf6fa4b99cdc_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfOTU1NQ_350e5d00-c7f9-4be3-9af0-8b3d038c31eb"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfOTgyNw_c665db12-f729-4a36-9792-d61323484b4e"
      unitRef="usd">134000000.0</sgmo:CollaborativeArrangementTransactionPrice>
    <sgmo:CollaborativeArrangementResearchServiceFees
      contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfOTg5MA_9ba564d3-f8b9-4f54-a22e-47e530f818e1"
      unitRef="usd">79000000.0</sgmo:CollaborativeArrangementResearchServiceFees>
    <sgmo:CollaborativeArrangementReimbursableServiceCosts
      contextRef="iadfc90055252476ea94b6b78e49c2e2c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMTgxNA_823a220d-34c4-47d8-86f3-dba9fe11a0a1"
      unitRef="usd">55000000.0</sgmo:CollaborativeArrangementReimbursableServiceCosts>
    <sgmo:AgreementTerminationTerm
      contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTE4OTc_58295caa-3947-492e-aad4-3d94fda36ba4">P15Y</sgmo:AgreementTerminationTerm>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i55dfc2b24f4d4413a989e868a6ffeb5d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTM1NTU_24a61da4-5f10-4903-acbc-4827fa4ad278"
      unitRef="usd">4000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i13a9ae1225e7485bb10275ccee50ca2d_D20191201-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMjcwNA_c418aff5-0430-4cc7-9fd0-c6ecf9b7a987"
      unitRef="usd">25000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i2e6d1ed2be0044ea9cbcaf840d0780e9_D20191201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcwNTg1NQ_0479bf30-33f3-429c-b4df-97134f63826a"
      unitRef="usd">25000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ieae2c1f6faba4e33888460da2e302ddf_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcwNTgzOQ_f1daaab0-c4ed-4ad7-84dd-9215a24f5798"
      unitRef="usd">1300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i24940a7706ea4d2d978b4613538afbda_D20201001-20201030"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMjkxNQ_8273122b-01a1-410e-b1ba-75b7e6502469"
      unitRef="usd">30000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned
      contextRef="i9ccabe9bc30f4799a7625faed92a6917_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMjg3Ng_ecd2ddb9-6de7-4046-a5af-2e1b9f12c070"
      unitRef="usd">30000000.0</sgmo:ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i6100f8c9e8534579a67d80618dd87117_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3Mzk_44101e2a-7eee-4f9a-a0ae-55bf2b048704">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.909%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.851%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Pfizer giroctocogene fitelparvovec agreement:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee and research services&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5c0d2ceb04c46e0a6ca01fc7f9e2ee7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfMy0xLTEtMS0w_75e1d809-d2c9-457f-9d16-4365dfcd4158"
      unitRef="usd">3111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22cdf77958324fea8f5137db56d2e321_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfMy0zLTEtMS0w_6ab3cccc-9919-4673-bcc4-4176f2178159"
      unitRef="usd">15697000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i435e100ac21c4e6f970572239a77eda2_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfMy01LTEtMS0w_9ba8ef80-3924-40fe-804a-c104fc1971ae"
      unitRef="usd">37810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7fb94b0bae17481a87c59979d81ce0ca_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNC0xLTEtMS0w_e87b1152-59ac-4473-96a7-d2c10e11c073"
      unitRef="usd">31338000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae47e409b4ea42aabf27810d9f1f5f22_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNC0zLTEtMS0w_d30aca47-201d-4f22-83ef-69f2a83951a6"
      unitRef="usd">23662000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9745d562dd854f4fb6b39832e3c4a5b4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNC01LTEtMS0w_57450216-537c-42cf-929c-5623e53ed92a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6100f8c9e8534579a67d80618dd87117_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNS0xLTEtMS0w_957f0dae-2c8b-4252-a575-e1a668c6b705"
      unitRef="usd">34449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9782c197ba3149bb984663397b6a69d2_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNS0zLTEtMS0w_10a42aa9-512b-4675-93d4-e2d597af36bc"
      unitRef="usd">39359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i10f82f0783e54af6831a3e260dd85a3a_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjdlMzUxOWE2NDViZDQxMWY5ZTEzMDdjMmY0YTNjZDJhL3RhYmxlcmFuZ2U6N2UzNTE5YTY0NWJkNDExZjllMTMwN2MyZjRhM2NkMmFfNS01LTEtMS0w_72489285-582c-4a61-9dbe-169592de1b35"
      unitRef="usd">37810000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22cdf77958324fea8f5137db56d2e321_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTUzMTc_b432aecb-57f4-4c2b-b531-b535c618e227"
      unitRef="usd">15700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e8f31eadadf4aefb75c29f6979d4b3e_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTU0MDE_763f556c-3465-4551-9863-156d627c59ce"
      unitRef="usd">8700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress
      contextRef="ib0ee411f36884cd796eb1615539214bc_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTU1NjE_3adffbbd-2c55-4d93-b8c5-1247f48d741d"
      unitRef="usd">-3000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue
      contextRef="i233ad9c6f5b64570a51d2349ba0f80be_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMzY3MA_4ca54d7e-8cf9-466d-9187-8771345651f6"
      unitRef="usd">2400000</sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
      contextRef="i233ad9c6f5b64570a51d2349ba0f80be_D20200301-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMzY5OQ_7892c31e-9a87-4a18-90f9-b0827452b4b3"
      unitRef="usd">-2400000</sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss>
    <sgmo:CollaborativeArrangementNetIncomeLossPerShare
      contextRef="i7f3fd66a77ca4c298f3fc4272b6044f2_D20200301-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyMzcxMA_5f481ba3-bbe0-4ea6-b809-296236f2f9ff"
      unitRef="usdPerShare">-0.02</sgmo:CollaborativeArrangementNetIncomeLossPerShare>
    <sgmo:AgreementTerminationTerm
      contextRef="if4d9b4cf1fe14e8c82e398543c33609d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTkwNjM_5fd15a49-53fc-43bd-ac29-5763a065918e">P15Y</sgmo:AgreementTerminationTerm>
    <sgmo:MilestonePaymentsReceived
      contextRef="i3baf5d6da95a464d83ca547a1f07fb10_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNTY0MQ_228920e3-ab99-4326-8f99-7c1f17bef630"
      unitRef="usd">12000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="ie4c4b9a1b3734f819b23f8fd6c8bebc0_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNTcwNg_9968af45-3c9c-4fb5-a2d9-e10b89b1d8a1"
      unitRef="usd">60000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i5f62390b2d3a48338361f2876c31e6ab_D20171201-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNTg5Mw_4b6559ff-ca8d-4b49-ba69-fbf62182d0db"
      unitRef="usd">90000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestonePaymentsReceived
      contextRef="iee59d8fb45e041e791c0ab5b1d0fec94_D20171201-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzODI2OQ_c0122644-845b-44cb-842f-18a6233b6f9b"
      unitRef="usd">5000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="iee59d8fb45e041e791c0ab5b1d0fec94_D20171201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2NjMwMw_502df2bf-2d8f-421d-a014-9add263b0085"
      unitRef="milestone">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="iee59d8fb45e041e791c0ab5b1d0fec94_D20171201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2NjMxMQ_78b452fb-bed9-4d39-93bc-ad24e881f596"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i8179c5be57324f34a1d01a5075b4a59a_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNzc5Ng_45972014-1787-4859-a15d-4855737da3f5"
      unitRef="usd">17000000.0</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ifaa9934a0caf4048ad529227a6b3e342_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNzgwNg_0e391027-0ae0-42dd-a413-8b2b47da2f34"
      unitRef="usd">12000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i8179c5be57324f34a1d01a5075b4a59a_D20171201-20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyNzk0Nw_a9db7fb9-6a19-40e1-8123-d7936d7d5d51"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i3c9f2942ee064c10a7180d004ca68961_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE1NDk_dab25db8-7c94-48d3-bcc4-f1c8dd073cdb"
      unitRef="usd">8000000.0</us-gaap:ContractWithCustomerLiability>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i4e2d17dcf5e64a158d897e7941665566_D20200901-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyODc1Mg_64f46222-a2ba-40f3-8537-e7a41fa7da62"
      unitRef="usd">5000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i51fd8b7623f54652888d1fbd20802015_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMyODc3MA_a0b0511c-27f7-41be-957d-9cbc27b64069"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="if4d9b4cf1fe14e8c82e398543c33609d_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3NDE_493084be-df8f-40ee-bcde-54ed2312e11a">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.386%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Pfizer &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; agreement:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:15pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimate in connection with the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C9ORF72&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; collaboration agreement with Pfizer. These adjustments were a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. These adjustments increased revenue by $8.8&#160;million, decreased net loss by $8.8&#160;million and decreased the Company&#x2019;s basic net loss per share by $0.06 for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaeb550dc7fee4f0daa6ea8fc7073f7db_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfMy0xLTEtMS0w_6b64fdb3-2ce0-4993-aba0-8dcd90c750d8"
      unitRef="usd">7985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2886651fadc8409c8daddb378e4b5b45_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfMy0zLTEtMS0w_ce2e60eb-c1a1-4811-8b49-b27f20497a28"
      unitRef="usd">1827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacbb3e15255f4990bd049724d75ef0f1_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfMy01LTEtMS0w_64e6dfb2-50a7-453f-b1f6-fa95bb4fed0b"
      unitRef="usd">2188000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26f68e79e666471ea1075c8953d1f9ed_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNC0xLTEtMS0w_dd73838c-c2ef-4633-801b-97aa4ec4a469"
      unitRef="usd">5000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d058778fed0482c9abdb1e80bf3e5f0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNC0zLTEtMS0w_ba4fece1-c2cf-4ed7-a1ed-1a3fce6cf3d9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf79dd2baa0749b1942c7d86d20c6f21_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNC01LTEtMS0xMzM1_3a123543-9a1f-4430-ba90-b015d23bed77"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if4d9b4cf1fe14e8c82e398543c33609d_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNS0xLTEtMS0w_f5be605c-429f-4ab4-8359-a01251fdaa72"
      unitRef="usd">12985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1df52988f363438398a2de08f94aa387_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNS0zLTEtMS0w_e00d6930-182f-4399-a7b4-6af64fc3d967"
      unitRef="usd">1827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85bea8547944486692a85e6b523ddecd_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOmFiYWQyYWQ2ZjBkODQ1MGJiNDM3NGYxNDE2ZmM1NDA4L3RhYmxlcmFuZ2U6YWJhZDJhZDZmMGQ4NDUwYmI0Mzc0ZjE0MTZmYzU0MDhfNS01LTEtMS0xMzM1_5a33cce1-e2d3-46e1-829f-9fa1f7d867eb"
      unitRef="usd">2188000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue
      contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMDc4Mg_8b079ba8-7e9d-4be0-bbcd-5ce47f2e72db"
      unitRef="usd">8800000</sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
      contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMDgwMQ_11e9ae11-09d4-4569-9313-44eadc10bb95"
      unitRef="usd">-8800000</sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss>
    <sgmo:CollaborativeArrangementNetIncomeLossPerShare
      contextRef="ia254d28909db4fce8ca3387c1f15c8fa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMDc2Nw_2bbc5eee-ed86-4199-bcd0-ff74f6de077a"
      unitRef="usdPerShare">0.06</sgmo:CollaborativeArrangementNetIncomeLossPerShare>
    <sgmo:NumberOfResearchProgram
      contextRef="ibe586645e7eb480fa88f004968e69f26_D20140101-20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjIxNzY_830bf22c-6f0b-4b2e-b6e1-6cebf9ad55f8"
      unitRef="program">2</sgmo:NumberOfResearchProgram>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="ibe586645e7eb480fa88f004968e69f26_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQwMzk_cfbe4299-a081-475e-ae1e-fc3b112c28c8"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i9122d80b46af45729722b3a5a580fddc_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQyNjM_420b2cbd-f3d9-47df-848e-2c9aa7459f11"
      unitRef="usd">115800000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i42a8f2c72a0c4b7da4f6fe01645f2fbc_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQzNzc_5a4cdeb5-3622-4376-be34-edb0c3a70c02"
      unitRef="usd">160500000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i91c96f778c484ff7b36d40e42b5cef1a_D20140101-20140131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQ2MTg_d910fb1e-cb30-48ef-8a5f-34b77bb64a15"
      unitRef="usd">276300000</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <sgmo:MilestonePaymentsReceived
      contextRef="i3117020fd58a4382be68a9dd0e475832_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjQ5Mjc_6a6f0387-5d0b-41c7-adcb-8ab113b1e98e"
      unitRef="usd">6000000.0</sgmo:MilestonePaymentsReceived>
    <sgmo:MilestoneRevenueReceivable
      contextRef="idd4d071a5a1240e899107dc0bc2d0d7f_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjUwMDk_298668c6-dc1a-4d0f-849a-e10be64749de"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement
      contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjUwNjQ_6c857be3-1df4-40c0-bd5d-654b2a828192"
      unitRef="product">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
    <sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice
      contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjUxMDk_a98a62a0-e2d2-4591-b4f1-0e3dd6cb4ff9"
      unitRef="milestone">0</sgmo:NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice>
    <sgmo:AgreementTerminationTerm
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjUzOTk_537e664b-063d-4989-9877-6f9263601c6e">P180D</sgmo:AgreementTerminationTerm>
    <sgmo:CollaborativeArrangementTransactionPrice
      contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjU3OTg_ff45bc62-602a-4027-a35c-f3b9b0bc3433"
      unitRef="usd">93300000</sgmo:CollaborativeArrangementTransactionPrice>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjU4Mzc_2e1c8afd-2bab-4600-a719-7cfc22f86c61"
      unitRef="usd">20000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:MilestoneRevenueReceivable
      contextRef="id81a1acd8821404c8ec43c3bcbc17cf3_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjU4NTU_2b6d0ba5-b7ca-4851-80c9-13cbecc025bb"
      unitRef="usd">13500000</sgmo:MilestoneRevenueReceivable>
    <sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts
      contextRef="i034bd4a542ff4479990ca46381d0f393_D20140101-20140131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMjYxMg_55bd49d9-0103-4ef8-a1c1-194ec33231f2"
      unitRef="usd">59800000</sgmo:CollaborativeArrangementEstimatedReimbursableServiceCosts>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ic6f1610375924f09a443d3568cdc1d68_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjc4NjA_75cd69e2-f2af-471c-a6c0-49c356e48745"
      unitRef="usd">1200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i1a4ecba9c6614c06b7f7c8459b127a96_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjc4Njc_107e6d4b-824c-4874-b896-6b03ce129a7f"
      unitRef="usd">1700000</us-gaap:ContractWithCustomerLiability>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i4dc2cac8272f43ee8e45b5b6bd542b3e_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjc5NTE_15c1f8fc-578d-44a2-a731-0cb6f644792c"
      unitRef="usd">6000000.0</sgmo:MilestoneRevenueReceivable>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i9b1c3dc836d24210b520f3db7f97f9c0_D20190801-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjgxMDE_cc4ef05b-34a4-444d-8eff-7302ba0fcf17"
      unitRef="usd">5800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcwNTcyOQ_759a90fc-15d2-4e22-aea4-df4ff9ac59c2"
      unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <sgmo:MilestoneRevenueReceivable
      contextRef="i94120f03c5fd4072a8bb3031d5eaff43_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjgyMjY_0bdc46ae-4e11-4a08-b8d8-c55a180cc59c"
      unitRef="usd">7500000</sgmo:MilestoneRevenueReceivable>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ib3a5217c51de4459902f1b79d64f6c95_D20140101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjgzNTY_5fb19d70-aabc-437f-9952-b69a510e65ab"
      unitRef="usd">7200000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i812f33c7e8c14fd08fb2a7dedbc894db_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMTA5OTUxMTcwNTc0OA_fef2d7a6-35ab-474c-a5d6-f51bf3db400d"
      unitRef="usd">100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3NDI_96879cc7-864f-4ab4-b555-3b7925328485">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues recognized under the agreement were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related to Sanofi agreement:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognition of upfront fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestone achievement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78bd26e8f611439f93e83caa744593ce_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfMy0xLTEtMS0w_8d4d4b42-0a32-430c-9c75-92173dcf7782"
      unitRef="usd">298000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cd52bb2ae3a4d5e9b83e8bb8f82e121_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfMy0zLTEtMS0w_0e964408-5a18-4593-963f-c1fd66ede4a7"
      unitRef="usd">3494000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0aacd04dbe964a6fa6e32e1188460504_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfMy01LTEtMS0w_65b590ab-78f5-4c53-b235-1b7f8bc4f628"
      unitRef="usd">4013000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaedf24cb2ecc475bb59fce790b63d4dc_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNC0xLTEtMS0w_767fefba-a66b-4b37-8451-e07c4db83379"
      unitRef="usd">4823000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0224ad04487349818fda88d3a4f7b06f_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNC0zLTEtMS0w_532a4c61-f8de-4b04-a429-4bed941e997e"
      unitRef="usd">6367000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i739d766508794dde903e7ea835312bb5_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNC01LTEtMS0w_340c8c95-b2c9-4fff-b323-27eaf1288ac5"
      unitRef="usd">9503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9bbe06eb17f4e4389ae875bb992beae_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNS0xLTEtMS0w_d71a93cc-18ec-4db4-9e51-e899629e07a0"
      unitRef="usd">201000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61957911f74047ab839b3929a36f2784_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNS0zLTEtMS0w_faec9e20-1a4d-4ad0-b7da-53e6ac6e9fff"
      unitRef="usd">12819000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief2fc4f96355416b89ed85d1b3204e27_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNS01LTEtMS0w_7ee1d78f-9de5-4195-8ba6-66992a8aa1c0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNi0xLTEtMS0w_13ee8ad5-098c-44a9-8391-282ed5a24c4b"
      unitRef="usd">5322000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6851909816f43d9927a3b74f4eb9ae0_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNi0zLTEtMS0w_7ec2e8b7-7d47-4d91-a5e0-0e7d817894b9"
      unitRef="usd">22680000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41b192f0b536424dbbf09712a8ca6db3_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RhYmxlOjhlNDhiYjkzODRlNTRiZmU5N2U1MzNlY2QyNWYwZWQ5L3RhYmxlcmFuZ2U6OGU0OGJiOTM4NGU1NGJmZTk3ZTUzM2VjZDI1ZjBlZDlfNi01LTEtMS0w_20fbf896-0ae5-469a-9a87-8c463d5530c8"
      unitRef="usd">13516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue
      contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMjU1Nw_667c41c3-ff69-4389-949e-f6e694feedad"
      unitRef="usd">-2200000</sgmo:CollaborativeArrangementIncreaseDecreaseInRevenue>
    <sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss
      contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMjU3NQ_34716a35-a055-4f54-b5a6-ddada6cb1ec0"
      unitRef="usd">-2200000</sgmo:CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss>
    <sgmo:CollaborativeArrangementNetIncomeLossPerShare
      contextRef="ide3e9e954238434a909d5baaf7251fd7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjE5OTAyMzMzMjU0Mg_f959e2eb-43a5-469b-add2-d527efaac87c"
      unitRef="usdPerShare">-0.02</sgmo:CollaborativeArrangementNetIncomeLossPerShare>
    <sgmo:GrantFundingAmount
      contextRef="i6a973ce71ad84032872771f13a2ca702_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjkwMzA_27529387-7e69-49da-ba6e-a7ad95b573c3"
      unitRef="usd">8000000.0</sgmo:GrantFundingAmount>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i764803be26a0446cb2b582d6f52c4848_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMjk0NDI_824ad513-c72e-41dc-91cf-f68b5febba2a"
      unitRef="usd">5200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7808e1ec9ea64ec3bca436fa6a85404a_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzAxMDA_4a1f5dc9-d027-4b85-a643-8b583e4348c2"
      unitRef="usd">6400000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i194b83713fb341fbbd2acdc7368d1a8a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzAxMDc_ee0af2e0-ebe6-4cea-a60e-47b009fd7ede"
      unitRef="usd">5700000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i64443d1a16cd488f905e7295d699439b_D20120101-20120131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzA2NDk_bfca44a1-6332-408c-9e60-346fa2ee0c2b"
      unitRef="usd">13000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i56dfa7a7f694412ca8f155eddda57f6b_D20140101-20141231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzA2ODM_ad4b5d20-ac89-4927-b440-9d015065b852"
      unitRef="usd">1000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <sgmo:AgreementTerminationTerm
      contextRef="i7d2161524129470cafb1f5a6567f6cba_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzIwMjM_a9009911-106f-4461-a13b-b96a1a1e0c9a">P90D</sgmo:AgreementTerminationTerm>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i8e5077542aaf42a4bb4062f041a4038c_I20171231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI1Nzc_fd4c703e-f59c-4c8b-94a5-a79be9f00d13"
      unitRef="usd">2300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b3feba275324427aa270226c8ff4256_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI2OA_34ef71a8-6731-43c0-96ae-9c8f87f391e5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b3e32e94c384b1e966f84999353cd18_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI2OA_3ef8e925-37fd-42e8-93a4-31af41266c09"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if86082d75aed4dbdb15c659083e9bf9b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI2OA_4918525d-9f33-4166-950c-e60bbf4035e3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:ResearchServicesPeriod
      contextRef="i01464b993796404cb11757f956a8a3c7_D20070101-20071231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI3NQ_a011e356-d90e-44c1-bd90-02f29c46a887">P3Y</sgmo:ResearchServicesPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="iccfbbecbaede42b5845fac46fdce4a09_I20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM4Nzg_bdf4f85c-d0de-4029-a941-61489b4a557a"
      unitRef="usd">20000000.0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM4OTc_f448667f-ae10-4d0e-8c6d-e9e35895cfb8"
      unitRef="usd">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM5MTI_870cfbdb-e9f5-44a2-a933-f43dfbd6f99c"
      unitRef="shares">636133</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM5NTc_08651543-9fdc-48d9-ae00-aab1838510b6"
      unitRef="usd">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ief34bca385d04e8aa286ffe64c5ec431_I20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzM5Njc_70ed7f6d-0b66-41e6-a88b-98558392f089"
      unitRef="usd">15100000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
      contextRef="i706a8d68f1cf40cb9c3132b4ff11e8f2_D20091001-20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQwNTQ_19991ce4-d41e-4842-82fa-4a6c79a8cdcd"
      unitRef="usd">5000000.0</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
    <sgmo:ReducedRoyaltyRate
      contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQxNjA_4bf0e626-41cf-4fa5-b9cb-a751b89d8c31"
      unitRef="number">0.105</sgmo:ReducedRoyaltyRate>
    <sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive
      contextRef="i052b7ef1d0924980a50539e74e89e966_D20091001-20091031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQzNDk_92fcbd14-1a2d-4500-8f7c-e48859ddd62d"
      unitRef="usd">25000000.0</sgmo:CustomerContractLiabilityMilestonePaymentEligibleToReceive>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i546676fe6a9d40ddaa72ca93f19fcba8_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQ1MzA_fe3496a0-43ae-4884-a488-dc5ab3fb6dda"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if616c1c1a07f410682a95cb374ebf65f_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQ1MzQ_f2bd62a6-3c7b-4a54-84f2-8d50beb04726"
      unitRef="usd">600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad0d9ea6bdab481590237f5b575dc744_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzQ1NDE_9a41d44c-c698-4a08-996b-eb0464c7e1a8"
      unitRef="usd">500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:InitialResearchTermOfAgreement
      contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzI5ODUzNDk2OTI3Ng_1b1187f1-5464-44f0-8f65-7ab9ca569cd6">P3Y</sgmo:InitialResearchTermOfAgreement>
    <sgmo:OneTimeLicenseFeeEarned
      contextRef="ib2df94fee7564a61bb14696381264213_I20051231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzUzNjU_7c8752fe-6524-42fb-a2d9-ad895cff9e82"
      unitRef="usd">6000000.0</sgmo:OneTimeLicenseFeeEarned>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia280905d8bb74bf892bb6bdb624a87ea_D20050101-20051231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzUzOTQ_f78daf37-b26b-44cf-9252-7c8f3aa1b18c"
      unitRef="usd">2300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement
      contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzU0Mjc_12d38765-3018-4d0a-9433-62049f403e63"
      unitRef="usd">4000000.0</sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement>
    <sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing
      contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzU3MzY_7e63a2c5-0109-4302-87cd-7cd1c07e72f3"
      unitRef="number">0.25</sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing>
    <sgmo:AnnualFeesRelatedToAgreement
      contextRef="id5fceb7cf1e54c71be44f291df33cab6_D20050101-20051231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzYxNDc_82b2a32e-5838-473f-9b31-0edc47f0ded1"
      unitRef="usd">300000</sgmo:AnnualFeesRelatedToAgreement>
    <sgmo:AnnualFeesRelatedToAgreement
      contextRef="i8b580b7103874a51aa8d767ed03b3928_D20050101-20051231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzYxNTM_43780b76-ad01-46ed-b82c-8f4368583fec"
      unitRef="usd">3000000.0</sgmo:AnnualFeesRelatedToAgreement>
    <sgmo:FeeDue
      contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzYxNjY_83244560-f71f-4f00-98d6-c8ead0f78ca5"
      unitRef="usd">25300000</sgmo:FeeDue>
    <sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod
      contextRef="ic852a176146340e1b539fc32aa55cad2_D20050101-20051231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzYxNzQ_6225d80f-0af0-4adb-a4e1-8f78d499e79a">P11Y</sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e7888a0f40541728fa78e28fb8d32b9_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY2ODk_3e4dd82a-256b-45c7-8221-0953d035e468"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13e149c04b9c44ae968ce27839b0ff98_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY2OTM_444be296-3362-4f1b-9481-a0b07a5c65d2"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d636ae7fc074737a7f48065c83c1704_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml85Ny9mcmFnOmI4YTA1ZjQwNTk2ZDQ4ZTlhOWMwZmZjZWE0YzAxODdkL3RleHRyZWdpb246YjhhMDVmNDA1OTZkNDhlOWE5YzBmZmNlYTRjMDE4N2RfMzY3MDE_e9abe9d1-a1f7-45c0-a26d-485dec977a18"
      unitRef="usd">3000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzM2Nzk_f9bbbce1-8dd0-4b36-beb8-73da7cf5eed0">ACQUISITION OF SANGAMO FRANCE&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July&#160;20, 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#x2019;s share capital. The Company entered into the Sangamo France SPA with certain shareholders of Sangamo France, pursuant to which it acquired 13,519,036 ordinary shares of Sangamo France (&#x201c;Ordinary Shares&#x201d;) as part of a block transaction that closed on October&#160;1, 2018 (the &#x201c;Acquisition Date&#x201d;). Additionally, the Company and Sangamo France entered into a Tender Offer Agreement pursuant to which Sangamo agreed to acquire 11,528,635 Ordinary Shares for the same price per share as the Sangamo France SPA via a cash tender offer that closed on November&#160;23, 2018. Following the block transaction, cash tender offer, and other open market purchases of shares, the Company owned 98.2% of the Ordinary Shares as of December&#160;31, 2018 (or 25,047,671 Ordinary Shares). In addition to the Sangamo France SPA and the tender offer agreement, the Company also entered into arrangements with the holders of approximately 477,000 &#x201c;free shares&#x201d; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#x201c;Free Shares Options&#x201d;). During 2019, the Company acquired approximately 111,000 vested free shares, increasing its ownership of the Ordinary Shares from 98.2% to 98.7%. During 2020, the Company acquired approximately 322,000 vested free shares, pursuant to the exercise of the put options for approximately $0.7&#160;million of cash, increasing its ownership of the Ordinary Shares to 99.8% as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of $0.2&#160;million. See Note 2 &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2013; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Free Shares Asset&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for information regarding the valuation method. The fair value of the Free Shares Options will vary based on future changes in the Company&#x2019;s stock price during the option period. The fair value of the Free Shares Options was estimated to be an asset of $0.1&#160;million as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic 805, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Combinations, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in exchange for total consideration of approximately $45.9&#160;million at the Acquisition Date. The operating results of Sangamo France after the Acquisition Date have been included in the Company&#x2019;s Consolidated Statements of Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no goodwill impairment during the years ended December&#160;31, 2020, 2019 or 2018 and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of December&#160;31, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-controlling Interest&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the remaining non-controlling interest was determined based on the number of outstanding shares comprising the non-controlling interest and the $2.99 acquisition price per share as of the Acquisition Date. The non-controlling interest is presented as a component of stockholders&#x2019; equity on the Company&#x2019;s Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-controlling interest as of December&#160;31, 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire
      contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzE0MA_19270489-694c-47e0-841f-b5b88d0894d6"
      unitRef="number">1</sgmo:BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i7a7eb33edfe747c3aefde90c4e3c2a60_D20181001-20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzMwMQ_0a0a1d9e-4261-4e65-a94a-ed16a92a6881"
      unitRef="shares">13519036</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i02eebe0086a243caa7e9e1bb622faf7a_D20181001-20181123"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzU3Mw_a0609b13-4224-403a-b154-7413eb6fb47c"
      unitRef="shares">11528635</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i4a6b2a742e264c81a0162eee4479ebde_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzgxOA_404203f5-c6d0-4f1c-a48d-87280cfa44de"
      unitRef="number">0.982</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i592fbd2441fa41bd9d36900308836ecc_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzg3Mg_2bb5eaf8-a24a-41e0-a235-0603eb9b0e12"
      unitRef="shares">25047671</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders
      contextRef="ic88a281a19cc4a8daaf8b3f721602378_I20180720"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwNDA_bbffd6fe-c9ba-46d3-a247-5fd5b1b79779"
      unitRef="shares">477000</sgmo:BusinessAcquisitionNumberOfFreeSharesHeldByHolders>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i7377f8b263024b66ad603bd494ee0f22_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzE1Mjc_76e2abc3-40cb-406c-9f96-281f04e62773"
      unitRef="shares">111000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i4a6b2a742e264c81a0162eee4479ebde_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzIzODA_00adb8f6-0d00-4485-b35e-c7ae49a1c357"
      unitRef="number">0.982</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i0581803351f54eeebd9c251d33078aec_I20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzE2MDE_51f33f15-6a2c-407f-820b-aeea6bf31823"
      unitRef="number">0.987</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="ifd607b4fc2514ac087f6a2aa05fa467b_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzIzMzY_277edf15-9fae-4000-8209-12f610ad1660"
      unitRef="shares">322000</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="if6f3f191be824087ad8c554b2a988bfa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzIzNjk_402f0c91-5043-4a9e-ba42-da3b43fcf32e"
      unitRef="usd">700000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i5224f1a418c04fb395423371d5cd63de_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzIzNTQ_ddda84e9-44b8-4f68-8cb9-940592c25457"
      unitRef="number">0.998</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares
      contextRef="i333a5711c7bb4f51917b34946c0b9f23_I20181001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzE3MTY_43c85e38-cf07-4b0d-a8d1-9cac7f4d2b02"
      unitRef="usd">200000</sgmo:BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares>
    <sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares
      contextRef="i16391b7df5174ed5b8c2310d931447ad_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzIwMzk_fed56b50-c757-441e-aec9-24a817ed020b"
      unitRef="usd">100000</sgmo:BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i7a7eb33edfe747c3aefde90c4e3c2a60_D20181001-20181001"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzEwOTk1MTE2MzE4OTI_2ea6aff2-d058-461b-8f69-1841bb771ed2"
      unitRef="usd">45900000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzI0MTI_3ac73438-1152-42f9-9258-2505c3c0ae59"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzI0MTI_afaf2702-4087-4b33-93fd-36406b7feb96"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzI0MTI_e231650e-0af6-4345-9ded-644391a16c75"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i796f26491be441f2a96fe82d3903003f_I20181001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzI5NzY_74108d9b-f95f-4e4c-adb6-4d959f37a4d7"
      unitRef="usdPerShare">2.99</us-gaap:BusinessAcquisitionSharePrice>
    <sgmo:ScheduleOfNoncontrollingInterestTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90ZXh0cmVnaW9uOjI1OThlNDQ2M2NjNjQxNjI5ZTA2ZjY3ODM5ZmI3YzZmXzM2ODE_ea48a9db-01cf-4e12-a57d-3259960851b0">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-controlling interest as of December&#160;31, 2020 was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of additional shares acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</sgmo:ScheduleOfNoncontrollingInterestTableTextBlock>
    <us-gaap:MinorityInterest
      contextRef="iae1f574b2f8c4344aa08242f7ae98ac4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90YWJsZTo2YWJkOTY5MTQyZjI0MmU4ODcxNzk5MTVkYzVkMzhkNi90YWJsZXJhbmdlOjZhYmQ5NjkxNDJmMjQyZTg4NzE3OTkxNWRjNWQzOGQ2XzctMS0xLTEtMA_a7d64920-fa6e-46b6-9006-3232114eb358"
      unitRef="usd">185000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90YWJsZTo2YWJkOTY5MTQyZjI0MmU4ODcxNzk5MTVkYzVkMzhkNi90YWJsZXJhbmdlOjZhYmQ5NjkxNDJmMjQyZTg4NzE3OTkxNWRjNWQzOGQ2XzgtMS0xLTEtMA_a9bfce5b-834d-4ee7-9da7-e46596b6b4ab"
      unitRef="usd">927000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90YWJsZTo2YWJkOTY5MTQyZjI0MmU4ODcxNzk5MTVkYzVkMzhkNi90YWJsZXJhbmdlOjZhYmQ5NjkxNDJmMjQyZTg4NzE3OTkxNWRjNWQzOGQ2XzktMS0xLTEtMA_8eda3e1e-ac0a-4626-8120-a7b7906f5cde"
      unitRef="usd">-126000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterest
      contextRef="idcd9bdcf4f1749ed855ea52ac19c1e57_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDAvZnJhZzoyNTk4ZTQ0NjNjYzY0MTYyOWUwNmY2NzgzOWZiN2M2Zi90YWJsZTo2YWJkOTY5MTQyZjI0MmU4ODcxNzk5MTVkYzVkMzhkNi90YWJsZXJhbmdlOjZhYmQ5NjkxNDJmMjQyZTg4NzE3OTkxNWRjNWQzOGQ2XzEwLTEtMS0xLTA_1fe93ccd-590e-4dbf-8286-69ea7d0f9085"
      unitRef="usd">-868000</us-gaap:MinorityInterest>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzQ5NA_43f434c5-3ff2-4786-8cf0-26b38350bc65">OTHER BALANCE SHEET DETAILS&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense was $5.7&#160;million in 2020, $3.9&#160;million in 2019 and $2.4&#160;million in 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in intangible assets were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in goodwill were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer advance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease liabilities &#x2013; current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzQ5NQ_bd630e41-d73c-4b84-9d93-c2ebdca2c783">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Manufacturing equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,416)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,681)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i727255e08dff491997abe1595a807416_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzItMS0xLTEtMA_e24080e0-f8d5-4190-b264-6b07125519db"
      unitRef="usd">24737000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib03bf486440e4058b398c99085b2e3bb_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzItMy0xLTEtMA_f1833e7b-ccea-4cff-a7e5-6ef7008472b9"
      unitRef="usd">17179000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i17ed21c4f31a48f9884d2e5a34a07660_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzMtMS0xLTEtMA_3197b3eb-9ec1-4475-9ecd-f922f72ac879"
      unitRef="usd">4870000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i78b6fc4c001f43229955467cb883d455_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzMtMy0xLTEtMA_617ca324-4bcc-45d5-b8c5-6d70872fbba6"
      unitRef="usd">4639000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idd01b55790404653a8dbf54a898c83e9_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzQtMS0xLTEtMA_d03d21d9-af05-4996-8402-129527032922"
      unitRef="usd">15953000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4b618149cf52411482e490b4cfbaa70b_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzQtMy0xLTEtMA_63101a92-48fd-48dc-934e-73bf8bc5aaac"
      unitRef="usd">13888000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i0f9736e534b649e19378d63d2cb29bd7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzUtMS0xLTEtMzUyMA_e81c86a0-9903-4219-b5e6-537264e041fb"
      unitRef="usd">1089000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7127032c342b4a9ba46f6b46c2355df9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzUtMy0xLTEtMzUyMA_0f49e69c-ab3b-4223-98a5-d03cb6eb92c2"
      unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="idc0d4241c9514c2bbe8a711b6b6d76c7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzYtMS0xLTEtMA_8dbad4ce-766a-4cb6-8f62-2db6b6bad4d7"
      unitRef="usd">12091000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie7bb97c3073446b9aa8c3f008be817ce_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzYtMy0xLTEtMA_1a166fba-ba05-495f-9f06-3e614aa24617"
      unitRef="usd">5901000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzctMS0xLTEtMA_f6e7567e-e6d4-4784-a734-882798c5a680"
      unitRef="usd">58740000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzctMy0xLTEtMA_2c57f9db-f700-431e-8a95-01796b1801c4"
      unitRef="usd">41607000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzgtMS0xLTEtMA_3a97f3bb-19cd-499b-96cf-3f7d4b61f1c4"
      unitRef="usd">17416000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzgtMy0xLTEtMA_7fb1163b-0a4c-4f81-b111-bbce82b3fdd8"
      unitRef="usd">11681000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzktMS0xLTEtMA_5250c44d-2c10-4afb-8454-57578bcbc193"
      unitRef="usd">41324000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo0OGQwOGQzZTEyOTI0NTg4OGJjYjY0OTE5NjkwMGNjMS90YWJsZXJhbmdlOjQ4ZDA4ZDNlMTI5MjQ1ODg4YmNiNjQ5MTk2OTAwY2MxXzktMy0xLTEtMA_c053dfe6-1683-4453-a213-ea3025ea377e"
      unitRef="usd">29926000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzE4Mw_d59990bc-5e84-42d7-996b-7b0a77608d00"
      unitRef="usd">5700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzE5Mw_625fb359-c61f-4c8a-b8e8-2d06ffdc5a65"
      unitRef="usd">3900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzIwNg_f4a04b96-17c8-49e2-bd65-b63cf4d36b03"
      unitRef="usd">2400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzQ5Ng_fbdcf3e7-b554-4133-a69d-079a3cdcb54b">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in intangible assets were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.352%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,087)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in goodwill were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.823%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(771)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at end of year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzItMS0xLTEtMA_894a5164-9e45-46fa-a928-b463e119df61"
      unitRef="usd">53156000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzItMy0xLTEtMA_9663dfa0-8f1e-4f04-86c5-bd06bfe3dfb0"
      unitRef="usd">54243000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzQtMS0xLTEtMA_06b1f433-ed0c-4c97-a3b5-6fd71f51aa58"
      unitRef="usd">4972000</us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzQtMy0xLTEtMA_1b268b76-2c74-4821-859c-26123a1380d2"
      unitRef="usd">-1087000</us-gaap:IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzUtMS0xLTEtMA_bcab23dd-3f04-4ad3-a0fb-55efb37830f2"
      unitRef="usd">58128000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo4Nzc0ZDk3MWE4YTE0YmExOGM3MmNkNzQ3MGExMWEzYi90YWJsZXJhbmdlOjg3NzRkOTcxYThhMTRiYTE4YzcyY2Q3NDcwYTExYTNiXzUtMy0xLTEtMA_6b26a9db-4b27-48ff-88b1-239ee2680186"
      unitRef="usd">53156000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzItMS0xLTEtMA_bf43e516-495c-457c-91d9-a08b56dac9de"
      unitRef="usd">39273000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzItMy0xLTEtMA_34fd1107-abf0-471f-b61d-e45d5cbcbf94"
      unitRef="usd">40044000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzQtMS0xLTEtMA_4e63ec2c-950a-44a6-8233-8cb7bb9e854d"
      unitRef="usd">3525000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzQtMy0xLTEtMA_3a041c98-aec7-4b89-8ee2-2997b5797a16"
      unitRef="usd">-771000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzUtMS0xLTEtMA_605a501b-3c06-46c6-b2af-5b62392e62c5"
      unitRef="usd">42798000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTo5MzkxZjAzOTkwMTQ0MGY0YTVkNGMwN2M4MDBiMDRkZC90YWJsZXJhbmdlOjkzOTFmMDM5OTAxNDQwZjRhNWQ0YzA3YzgwMGIwNGRkXzUtMy0xLTEtMA_43ec4d62-0ba3-44bb-a266-2782175cf998"
      unitRef="usd">39273000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90ZXh0cmVnaW9uOjNhNzk2NzliNWFlMzQ3MzZiNjM2ZDY2MTcyOWNkOGY2XzQ5Mw_0147f986-59fd-4258-a8f5-801abc52af86">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consist of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer advance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Operating lease liabilities &#x2013; current&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzMtMS0xLTEtNDEyNg_04705276-b38f-4b68-864a-c763b2bef7af"
      unitRef="usd">5000000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzMtMy0xLTEtNDEyNg_5d6c3feb-b925-4e24-bc81-ba0d7a01bf56"
      unitRef="usd">0</us-gaap:CustomerRefundLiabilityCurrent>
    <sgmo:AccruedResearchAndDevelopmentExpenses
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzMtMS0xLTEtMA_c088d770-bc17-4bd8-8d84-8fa391f16ebc"
      unitRef="usd">4257000</sgmo:AccruedResearchAndDevelopmentExpenses>
    <sgmo:AccruedResearchAndDevelopmentExpenses
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzMtMy0xLTEtMA_b9bb5614-bcfa-4b42-8d8f-b9ae279d5a44"
      unitRef="usd">4102000</sgmo:AccruedResearchAndDevelopmentExpenses>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzQtMS0xLTEtMA_c671bf7e-cb3f-401d-b40c-62c26208c161"
      unitRef="usd">3690000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzQtMy0xLTEtMA_96798900-b4c6-4417-ac35-8a40b661811f"
      unitRef="usd">3214000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzUtMS0xLTEtMA_66ec16a2-90bb-4ebe-9262-8aba8ed7cab2"
      unitRef="usd">1532000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzUtMy0xLTEtMA_7bfa5176-1a7f-4800-95e8-bb32d19d73f0"
      unitRef="usd">1118000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzctMS0xLTEtMA_d8f98311-dc45-4880-9896-fe32f06bc748"
      unitRef="usd">4133000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzctMy0xLTEtMA_aff02bb4-5736-4585-a47a-a236e6c514b6"
      unitRef="usd">2451000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzgtMS0xLTEtMA_ad8c02f4-81fe-417a-8a88-1932ae4b9170"
      unitRef="usd">18612000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDMvZnJhZzozYTc5Njc5YjVhZTM0NzM2YjYzNmQ2NjE3MjljZDhmNi90YWJsZTozMjdkNjQ4MmExOTE0M2QzYTcxMGJjYjEyNmRhYTEwOS90YWJsZXJhbmdlOjMyN2Q2NDgyYTE5MTQzZDNhNzEwYmNiMTI2ZGFhMTA5XzgtMy0xLTEtMA_d4aa5d8d-2f54-4568-acc3-574561a6b701"
      unitRef="usd">10885000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzQxODA_53a7809c-0f47-4a9d-b648-f05de0ef5dac">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 54,200 square feet of research and office space in Richmond, California, pursuant to leases that expire in August 2026. In addition, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;leases approximately 20,800 square feet of office, and research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through March 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company entered into an amendment to an existing lease to acquire approximately 8,500 square feet of research and office space in Richmond, California that expires in August 2026. Total lease payments over the life of this amended lease are approximately $1.6&#160;million. Variable lease payments include the Company&#x2019;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The amended lease was effective October 1, 2020, and the Company recorded a lease liability and corresponding ROU asset of $1.3&#160;million upon inception of this amended lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzY5Mw_274e8caf-5cf0-4157-9146-6781d7736ff8"&gt;five&lt;/span&gt; to 10 years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2020, the Company incurred $10.4&#160;million of lease costs included in operating expenses in the Consolidated Statement of Operations in relation to these operating leases. Variable lease expense was $2.3&#160;million for the year ended December&#160;31, 2020 and was not included in the measurement of the Company&#x2019;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#x2019;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense due to the Company&#x2019;s election to not separate lease and non-lease components.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December&#160;31, 2020 was $6.4&#160;million and was included in net cash provided by operating activities in the Company&#x2019;s Consolidated Statement of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense related to lease agreements was $10.4&#160;million, $7.9&#160;million, and $2.3&#160;million for 2020, 2019 and 2018, respectively. Future minimum payments under lease obligations at December&#160;31, 2020 consist of the following (in thousands):&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as of December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current (included in Other accrued liabilities on the Consolidated Balance Sheet)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, the weighted-average remaining lease term is 7.6 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.1% for the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have any financing leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contractual Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total commitments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lonza Netherlands, B.V.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contractual commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also had $1.0&#160;million of license obligations related to its intellectual property as of December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sangamo is not party to any material pending legal proceeding. From time to time, Sangamo may be involved in legal proceedings arising in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="ia6609b14089f4212a584aa69b64acfc5_I20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzgy_2ec0e7fd-c998-49f1-b414-14d18847c129"
      unitRef="sqft">87700</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="ibbb078359b94445aa19de4957f01c8a3_I20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI2NA_14588999-09ff-439c-b645-37ff48c6444c"
      unitRef="sqft">54200</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="ia9ddad8fdf914a9eb455c759a9202939_I20201231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzQyNQ_336067f5-9612-4900-9a1f-20c8963daf01"
      unitRef="sqft">20800</us-gaap:LandSubjectToGroundLeases>
    <sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate
      contextRef="i8ad9465ba0dc4a299f459f90c677d791_I20200531"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzQ5NDc4MDIzMzE4NTQ_1d5908ac-b92b-45e8-8e21-a894ed2e4ab3"
      unitRef="sqft">8500</sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate>
    <sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i8ad9465ba0dc4a299f459f90c677d791_I20200531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzEwOTk1MTE2MzU3NzI_0df728bb-a583-44a7-8e2d-6877781d7064"
      unitRef="usd">1600000</sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount
      contextRef="i06474dbe630c4f41836daafffa78c161_I20201001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzEwOTk1MTE2MzU3NTM_2aed6bb8-34e7-4ada-ab76-0d16a981f070"
      unitRef="usd">1300000</sgmo:LesseeOperatingLeaseLeaseNotYetCommencedAmount>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i5adb6c8a5fbe4ae8998f2aaff0f11681_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzM4NDgyOTA3MDUzNTA_fbe34e5e-4385-4abb-8353-62f6f894bc11">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseCost
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzE2NjI_4f7431f1-549a-4f44-820b-9daf51a7b217"
      unitRef="usd">10400000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzE4MjE_9ba7ac33-ed3c-460e-bdd6-29a9833cd802"
      unitRef="usd">2300000</us-gaap:VariableLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzIyOTY_0a45b75c-b3c0-4852-b4f7-fa5e7d43e32b"
      unitRef="usd">6400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI0NTY_1b976bfd-b481-4ece-a480-62933c956c8e"
      unitRef="usd">10400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI0NjA_2ea88c87-4cc3-4d04-adaa-7e27075de15b"
      unitRef="usd">7900000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI0Njg_79962c4b-244d-4fe7-b006-7e9f73782132"
      unitRef="usd">2300000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzQxNzk_4d69103f-2dab-42f8-8c3c-c9fb3bc00d0f">Future minimum payments under lease obligations at December&#160;31, 2020 consist of the following (in thousands):&#160;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,756&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,422&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported as of December 31, 2020:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - current (included in Other accrued liabilities on the Consolidated Balance Sheet)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities - long-term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzEtMS0xLTEtMA_2655289f-2bbc-40a2-8a60-bf6181128a05"
      unitRef="usd">6191000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzItMS0xLTEtMA_ae7fb50c-1286-4c60-8b9c-5aec859a403b"
      unitRef="usd">6756000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzMtMS0xLTEtMA_291b260c-f30f-41f7-9bfe-1aa46f214db3"
      unitRef="usd">6851000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzQtMS0xLTEtMA_dcc28a91-66cb-4c3a-9218-9f00bb09d17b"
      unitRef="usd">6995000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzUtMS0xLTEtMA_7ef64c0c-4e04-4682-91a7-a8f77ef50498"
      unitRef="usd">7058000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzYtMS0xLTEtMA_cdde31b5-159f-4616-9370-9440810d162a"
      unitRef="usd">19571000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzctMS0xLTEtMA_16c93c12-d197-4177-8633-6a776bf8bc70"
      unitRef="usd">53422000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzktMS0xLTEtMA_625c3e26-0954-4ca5-a02c-048e925071f4"
      unitRef="usd">11336000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzEwLTEtMS0xLTA_3a5d2b6e-bdac-46c9-8c25-89c730ab251b"
      unitRef="usd">42086000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzEzLTEtMS0xLTA_59253b85-0768-480b-996f-c85c77be2d63"
      unitRef="usd">3690000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzE0LTEtMS0xLTA_6bef4d19-ac2a-45f6-91a2-9c700244892d"
      unitRef="usd">38396000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTpmMmUwYTkwNGY0MDQ0ZTQyYjJmNDIzMDQ1YjdkNjRlMC90YWJsZXJhbmdlOmYyZTBhOTA0ZjQwNDRlNDJiMmY0MjMwNDViN2Q2NGUwXzE1LTEtMS0xLTA_e944b093-840f-4d56-bfce-1420d1081305"
      unitRef="usd">42086000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI2NTc_d29fad78-a295-4eb5-b53c-cebe70b6e02c">P7Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzI3NzA_3c3b77fe-6499-4b49-8e62-5cad971be752"
      unitRef="number">0.061</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OtherCommitmentsTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzMyOTg1MzQ4OTAxOTY_850fb769-2553-483b-9ba1-f4e9bf405d12">&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of December&#160;31, 2020 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.221%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.147%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Total commitments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Expiry date&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lonza Netherlands, B.V.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contractual commitments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherCommitmentsTableTextBlock>
    <us-gaap:ContractualObligation
      contextRef="i99562ae603894a8189b5ff099684f86d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTowOTdiZDMyY2Y4NGM0MmE0YTAyMTk3NTgyMGZhYzY2MC90YWJsZXJhbmdlOjA5N2JkMzJjZjg0YzQyYTRhMDIxOTc1ODIwZmFjNjYwXzEtMi0xLTEtMjMy_1e40f10d-fcea-44a3-9971-d59a84db36aa"
      unitRef="usd">7736000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="i68aebf0104924b419a789b0d776a9b5e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTowOTdiZDMyY2Y4NGM0MmE0YTAyMTk3NTgyMGZhYzY2MC90YWJsZXJhbmdlOjA5N2JkMzJjZjg0YzQyYTRhMDIxOTc1ODIwZmFjNjYwXzItMi0xLTEtMjMy_9779d0a4-6e51-4235-a2ee-104e29c2faab"
      unitRef="usd">13771000</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90YWJsZTowOTdiZDMyY2Y4NGM0MmE0YTAyMTk3NTgyMGZhYzY2MC90YWJsZXJhbmdlOjA5N2JkMzJjZjg0YzQyYTRhMDIxOTc1ODIwZmFjNjYwXzMtMi0xLTEtMjMy_93da9c0e-55dc-4ddf-9883-d3a3aa7b8b09"
      unitRef="usd">21507000</us-gaap:ContractualObligation>
    <sgmo:LicenseObligations
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzM5MzE_f9fefba6-df86-4ede-a136-1c57ca10edc9"
      unitRef="usd">1000000.0</sgmo:LicenseObligations>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzY0OTY_91930e8a-17de-4494-9f21-24f4a08bd336">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s Certificate of Incorporation authorizes the Company to issue up to 5,000,000 shares of preferred stock, which may be issued at the discretion of the Company&#x2019;s Board of Directors. As of December 31, 2020, no shares of the Company&#x2019;s preferred stock have been issued or are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, the Company&#x2019;s stockholders approved an amendment to the Company&#x2019;s Certificate of Incorporation to increase the total number of shares of the Company&#x2019;s common stock authorized for issuance from 160,000,000 shares to 320,000,000 shares. As of December 31, 2020, 142,063,203 shares of the Company&#x2019;s common stock are outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the collaboration agreement with BIMA described in Note 4 of these Consolidated Financial Statements, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase the Biogen Shares at a price per share of $9.2137, for an aggregate purchase price of $225.0&#160;million. The Company closed the sale of the Biogen Shares in April 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2019, the Company completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 12.7&#160;million shares of its common stock at a public offering price of $11.50 per share. The net proceeds to the Company from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $136.3&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2018, the Company completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 14.2&#160;million shares of its common stock at a public offering price of $16.25 per share. The net proceeds to the Company from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $215.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;At-the-Market Offering Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the Company entered into an Open Market Sale Agreement&#x2120; with Jefferies LLC (&#x201c;Jefferies&#x201d;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#x2019;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#x2019;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. As of December&#160;31, 2020, no shares had been sold under the sales agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company&#x2019;s stockholders approved the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan (the &#x201c;2018 Plan&#x201d;). In connection with the approval of the 2018 Plan, no additional equity awards will be granted under the previous 2013 Plan, however all outstanding equity awards under the 2013 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such awards and the terms of the 2013 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, the Company&#x2019;s stockholders approved an amendment and restatement of the 2018 Plan, to, among other things, increase the aggregate number of shares of the Company&#x2019;s common stock reserved for issuance under the 2018 Plan by 9,900,000 shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The exercise price of a stock option granted under the 2018 Plan may not be less than 100% of the fair market value of the Company's common stock subject to the stock option on the date of grant, and the option term will not exceed 10 years. If the person to whom the stock option is granted is a 10% stockholder of the Company, and the stock option granted qualifies as an incentive stock option, then the exercise price per share will not be less than 110% of the fair market value of the Company&#x2019;s common stock on the date of grant, and the option term will not exceed five years. Generally, stock options granted under the 2018 Plan vest over four years at a rate of 25% on the one-year anniversary of the date of grant and 1/48 per month thereafter and expire 10 years after the date of grant, or earlier upon termination of employment or services to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The number of shares of common stock reserved for issuance under the 2018 Plan will be reduced: (i)&#160;on a 1-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&#160;by a fixed &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ratio of 1.33 shares of common stock for each share of common stock issued pursuant to a full-value award granted under the plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares subject to any outstanding stock options or other awards under the 2018 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those stock options or awards will be available for subsequent issuance under the 2018 Plan. Any unvested shares issued under the 2018 Plan that the Company subsequently purchases, pursuant to repurchase rights under the 2018 Plan, will be added back to the number of shares reserved for issuance under the 2018 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the ratio at which the share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the 2018 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, there were 10,942,576 shares of the Company&#x2019;s common stock reserved for future awards under the Company&#x2019;s 2018 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2010 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2018, the Company&#x2019;s stockholders approved an amendment and restatement of the Company&#x2019;s 2010 Employee Stock Purchase Plan (&#x201c;the ESPP&#x201d;). As amended, the ESPP provides for a total of 4.6&#160;million&#160;shares of common stock reserved for issuance thereunder. Eligible employees may purchase common stock at 85% of the lesser of the fair market value of the Company&#x2019;s common stock on the first day of the applicable two-year offering period or the last day of the applicable six-month purchase period. As of December&#160;31, 2020, there were 2,483,218 shares of the Company&#x2019;s common stock reserved for future issuance under the ESPP. The ESPP expired on April 30, 2020. The ongoing offering will continue through the end of its 24 months offering period ending on October 29, 2021 at which point the ESPP will be fully terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Activity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise per&lt;br/&gt;Share Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,829,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,563,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,162,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,751,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,478,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,478,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,127,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value of options exercised was $5.4&#160;million, $4.7&#160;million and $27.0&#160;million during 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2020, the aggregate intrinsic values of outstanding and exercisable options were $69.6 million and $29.0 million, respectively. The aggregate intrinsic value of options vested and expected to vest as of December&#160;31, 2020, 2019 and 2018 was $69.6&#160;million, $7.5&#160;million and $24.5&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2020, 2019 and 2018, the Company awarded 2,517,101, 834,745, and 346,055 RSUs, respectively. The RSUs awarded in 2020, 2019 and 2018 had an average grant date fair value per award of $8.06, $9.49 and $17.87, respectively. These awards generally vest in a series of three successive equal annual installments. The aggregate fair value of RSUs vested during 2020, 2019 and 2018 was $3.7&#160;million, $2.0&#160;million and $0.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s RSU activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&#160;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested and expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RSUs that vested in 2020, 2019 and 2018 were net-share settled such that the Company withheld shares with value equivalent to the employees&#x2019; minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately 90,617, 39,160, and 20,193 for 2020, 2019 and 2018, respectively, and were based on the value of the RSUs on their respective issuance dates as determined by the Company&#x2019;s closing stock price. Total payments for the employees&#x2019; tax obligations to taxing authorities &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.8&#160;million, $0.4&#160;million and $0.3&#160;million in 2020, 2019 and 2018, respectively and are reflected as a financing activity within the accompanying Consolidated Statements of Cash Flows.&#160;These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzY3_c5d95157-2e91-49a7-9f98-e46ea76db273"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM4NDgyOTA3MTE1Mzk_cfed0e93-853b-4bba-a05b-f077c1060a21"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM4NDgyOTA3MTE1Mzk_eb5fe95b-00ce-477f-8cb7-54a1e25554ca"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i04133be982284def86006aea3fb52327_I20200629"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2NDIwNzk_c3db9a82-6a27-48bc-92b8-3c6e379acc5d"
      unitRef="shares">160000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iee1b756f6c0a4abe92e4664a43ad8035_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2NDIwOTM_4bd979e3-08c1-4a63-904e-29c400ac4f8d"
      unitRef="shares">320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2MzkxOTU_53a9a6bb-8e97-47c2-8a56-3780f17441cd"
      unitRef="shares">142063203</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="if650f84ed8e44993a9c4382072ecf061_I20200430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIxOTkwMjMyNjI5MDE_5e11d075-9e8e-4257-8d06-04e0f10d896a"
      unitRef="usdPerShare">9.2137</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i34bcdc0ce9f64813a8d36f116a1f90eb_D20200401-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIxOTkwMjMyNjI4ODc_3e4c3368-3e3e-4b92-9aa1-5cd785f7113e"
      unitRef="usd">225000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i77930a25b46346a2979712dac12ee7a0_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzMyNw_7892b148-6579-4596-ab00-3691de5b04d7"
      unitRef="shares">12700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i30d8dda504854d9ca7d63f9a88cc3816_I20190430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM4Nw_ecfe6f0e-7bbd-419e-94c8-97853b431b5d"
      unitRef="usdPerShare">11.50</us-gaap:SharesIssuedPricePerShare>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="i77930a25b46346a2979712dac12ee7a0_D20190401-20190430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU3NA_f05a7e70-c46c-4735-8eda-2b2b9f372aa6"
      unitRef="usd">136300000</sgmo:NetProceedsFromIssuancePublicOffering>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic46aca1e871a400a88bda284834701ce_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzcwNg_d665bfa5-14c3-402f-a157-17ea96d64f8c"
      unitRef="shares">14200000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="ie0bb49a1111a409c8731842f7bda4df1_I20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4Xzc2Ng_2592c6e9-fb8c-4c72-99a3-59ff8e4408b0"
      unitRef="usdPerShare">16.25</us-gaap:SharesIssuedPricePerShare>
    <sgmo:NetProceedsFromIssuancePublicOffering
      contextRef="ic46aca1e871a400a88bda284834701ce_D20180401-20180430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4Xzk1Mw_1e316f1d-68be-4dfc-9a26-cac9d70411df"
      unitRef="usd">215800000</sgmo:NetProceedsFromIssuancePublicOffering>
    <sgmo:StockOfferingProgramMaximumValue
      contextRef="i075446115f764740898840df11c14db0_D20200805-20200805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIxOTkwMjMyNjQ4NDE_087f994f-67e6-4e7b-8d68-6a67815fcfe7"
      unitRef="usd">150000000.0</sgmo:StockOfferingProgramMaximumValue>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="ic740901c064241959e061ee1525d0c94_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5NDc4MDIzMzQzNDE_5d474e7c-29c3-48a6-a660-9e7b050c6159"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i1a2222cfa49440338b7416d398920ffc_D20180401-20180430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzE3MzI_278481c2-925a-4453-818e-094992adf1f7"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <sgmo:CommonStockAdditionalCapitalSharesReservedForFutureIssuance
      contextRef="i66466b43ef874206b64889bb27cb2d08_I20200531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2Mzc1OTc_af044e3d-7fcf-41e7-9b27-5290d8d3e67e"
      unitRef="shares">9900000</sgmo:CommonStockAdditionalCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIwODM_714819b6-a940-4b13-8a76-5b5cdcab8cb6"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i91713b083997409ea11ba55173dcc112_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIyMjc_bca04d73-0e77-40d5-be2b-95d468c6bbde">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <sgmo:SpecifiedStockholderOwnershipPercentage
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzIyODY_8abcb32a-d151-426d-8a7a-ec01bb61c71c"
      unitRef="number">0.10</sgmo:SpecifiedStockholderOwnershipPercentage>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI0NDM_8ef4488d-d215-4c0a-ba02-104d892786d2"
      unitRef="number">1.10</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI1NTk_61cd1364-fb25-4193-9c41-3ea814e5e281">P5Y</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI2MjY_5aea839d-a8c9-4388-a533-4a80c0b8bbc8">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib8715c1886674912998f731a86a14a57_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI2NDI_acda93b1-91f3-4df2-8315-3d649ad091ce"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm
      contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI3Mjk_dfb70174-619c-46cb-80b5-e8db052580cb">P10Y</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm>
    <sgmo:CommonStockExchangeRatio
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzI5MzI_3c8902ce-fb1f-4cc8-a8ff-7dd7b63dc25a"
      unitRef="number">1</sgmo:CommonStockExchangeRatio>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzMwODI_6369e4ee-3a77-48ab-b9d2-f48267b6b4d6"
      unitRef="number">1.33</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <sgmo:CommonStockExchangeRatio
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM2ODk_42dbb62a-c6cc-4520-9a77-235810b8c1ad"
      unitRef="number">1</sgmo:CommonStockExchangeRatio>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="i1e97e6982b074e869d54dcec87643ad7_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzM3MTA_6369e4ee-3a77-48ab-b9d2-f48267b6b4d6"
      unitRef="number">1.33</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ief4c9ff8ff294f60aa457e9361e9bea3_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2NDA4MjI_63e9c407-c57e-4135-98fe-b442d4b1b6a4"
      unitRef="shares">10942576</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i18bf0cf17b5642529f184871db5ac039_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQwODk_1a645163-a321-4fa4-ad74-73b95c6d6069"
      unitRef="shares">4600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i6aabd68f41804669ac596bb7586ed7bc_D20180601-20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQxOTI_76e66e75-4763-44f8-b183-356765de78b1"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <sgmo:PurchasePlanOfferingPeriod
      contextRef="i6aabd68f41804669ac596bb7586ed7bc_D20180601-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzMyOTg1MzQ4OTc5MDc_429b7bba-4d95-46be-a1bb-8b7f5c1d0a2c">P2Y</sgmo:PurchasePlanOfferingPeriod>
    <sgmo:PurchasePlanPurchasePeriod
      contextRef="i6aabd68f41804669ac596bb7586ed7bc_D20180601-20180630"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzMyOTg1MzQ4OTc5MDg_eee1c8af-8474-474a-8150-c620a549aca6">P6M</sgmo:PurchasePlanPurchasePeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzEwOTk1MTE2NDEwNjA_c8156773-b558-4b67-a9e3-2b31e52684e8"
      unitRef="shares">2483218</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzY0OTU_00e625a2-f053-4ef3-b203-a6c55d23787f">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise per&lt;br/&gt;Share Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In&#160;thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,829,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,563,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,162,268)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,751,746)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,478,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options vested and expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,478,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,127,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.48&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzItMS0xLTEtMA_13404154-b069-41a8-ae98-d689951dce90"
      unitRef="shares">9829287</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzItMy0xLTEtMA_44165c34-a3b3-4560-861b-58631b122497"
      unitRef="usdPerShare">10.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzMtMS0xLTEtMA_1f1bdb01-382d-4826-a78d-d8c28927234c"
      unitRef="shares">4563425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzMtMy0xLTEtMA_bb80aaf1-165a-453e-9110-40979b1f63e8"
      unitRef="usdPerShare">8.09</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzQtMS0xLTEtMA_d5d99526-d4c8-4a7b-97c0-37188555e994"
      unitRef="shares">1162268</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzQtMy0xLTEtMA_a3a887b5-448b-458a-a946-c3456422d859"
      unitRef="usdPerShare">8.02</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzUtMS0xLTEtMA_0fddafb4-115c-4932-a6d3-c452ac003ec4"
      unitRef="shares">1751746</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzUtMy0xLTEtMA_61f7eef7-1101-4a9d-a5d2-734bb0f834bf"
      unitRef="usdPerShare">10.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzYtMS0xLTEtMA_fc155af6-3dfe-4b49-8fb0-a29f0e91c168"
      unitRef="shares">11478698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzYtMy0xLTEtMA_84de63b8-2117-4514-8d32-dc8a69cf91db"
      unitRef="usdPerShare">10.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzYtNS0xLTEtMA_47ae5424-2f58-418d-bee9-a3fc7209d473">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzYtNy0xLTEtMA_43912fbd-9a32-444d-8c0e-0829fab49594"
      unitRef="usd">69616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzctMS0xLTEtMA_fae265bc-8257-434c-b4e6-b25c7320b080"
      unitRef="shares">11478698</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzctMy0xLTEtMA_a8ae7442-cfd0-40bd-ac19-492a01d97db0"
      unitRef="usdPerShare">10.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzctNS0xLTEtMA_2d508bf6-c7fa-479e-a55a-c272881e2284">P7Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzctNy0xLTEtMA_49c7f9db-6916-424a-bdac-33ba25df4e94"
      unitRef="usd">69616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzgtMS0xLTEtMA_f81875e2-29f5-48c5-85dd-9772edc72831"
      unitRef="shares">5127517</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzgtMy0xLTEtMA_83e11517-c1e5-4731-9ab7-b1a6dca81f89"
      unitRef="usdPerShare">10.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzgtNS0xLTEtMA_2d8ff22f-75e6-47f8-9dc9-785eee37a586">P6Y5M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTo0MWQ2NGI3ODk0M2M0MjBkOTA4YzcxOTZhYmY1Y2MxMS90YWJsZXJhbmdlOjQxZDY0Yjc4OTQzYzQyMGQ5MDhjNzE5NmFiZjVjYzExXzgtNy0xLTEtMA_24794c84-fd6a-4b42-a094-a5fa975206fb"
      unitRef="usd">29025000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ2NDM_edefd8a8-d3da-455c-bfa2-53ee12f8abe0"
      unitRef="usd">5400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ2NDc_6192d4b6-36d3-492a-940b-a4463bd8c927"
      unitRef="usd">4700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ2NTQ_683fa230-8c7b-46e9-aac8-1c396af1fbd7"
      unitRef="usd">27000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ3NzU_ec91116e-36c5-4510-85b7-c19de20ed984"
      unitRef="usd">69600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ3ODI_c0c03c35-7c7c-4cc0-8061-c1761f173005"
      unitRef="usd">29000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ4OTM_989261a3-0e47-4fff-ab07-a8cf445593dc"
      unitRef="usd">69600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ4OTc_f44ae4bd-febc-4d39-b42a-394a264b77e7"
      unitRef="usd">7500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5MDQ_d752fc96-335b-4998-860f-88f4aae255b8"
      unitRef="usd">24500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5ODc_7eca0e76-b4ad-4cd7-8206-58445ddc0c5a"
      unitRef="shares">2517101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5OTE_73908d6f-55ec-4d37-a4f9-3023685154f4"
      unitRef="shares">834745</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="icc4c94703dab45468283cb739266adc8_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzQ5OTk_01f017d0-420d-4e6b-8126-1cc29734cc4c"
      unitRef="shares">346055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUxMDY_ecc79caa-3980-4636-83e2-e5758079583c"
      unitRef="usdPerShare">8.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUxMTA_a41a9b2f-6add-427a-9191-a69a9ba86bd0"
      unitRef="usdPerShare">9.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="icc4c94703dab45468283cb739266adc8_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUxMTc_2ac7962e-4a9e-4394-833e-1f2b13df2919"
      unitRef="usdPerShare">17.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment
      contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUxNzg_1cf6988b-6006-4b4e-97ff-bc85e95a1f15"
      unitRef="installment">3</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUyODQ_d5e4e488-7ecf-464c-8e6e-c1543645d987"
      unitRef="usd">3700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUyODg_ba0272a7-f6d1-4d75-9c31-1eff3a7ac4aa"
      unitRef="usd">2000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="icc4c94703dab45468283cb739266adc8_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzUyOTU_c788ed28-a7be-4987-a2d6-e3ee22daed9f"
      unitRef="usd">600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzY0OTc_74a5a6d5-a648-46ab-9420-5ed200c7f56c">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s RSU activity is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.351%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.562%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&#160;Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&#160;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;862,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs awarded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,517,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(324,305)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(384,118)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs outstanding at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs vested and expected to vest at December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,671,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzItMS0xLTEtMA_fa0d8db3-6226-4c53-b593-d9a5ae55bd51"
      unitRef="shares">862850</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzMtMS0xLTEtMA_800aaff5-125f-4979-993b-efa83639c0d3"
      unitRef="shares">2517101</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzQtMS0xLTEtMA_ef5aa686-3631-487a-a531-821c20f022c9"
      unitRef="shares">324305</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzUtMS0xLTEtMA_d4b40c49-2ec9-42e4-bd85-a7027d04c40d"
      unitRef="shares">384118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzYtMS0xLTEtMA_e8287dd7-55c1-45dc-9f54-0676f952dbd8"
      unitRef="shares">2671528</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzYtMy0xLTEtMA_ae305884-ec40-4e62-abc6-34ef14e4f933">P1Y2M8D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzYtNS0xLTEtMA_b1f87485-b9f8-4340-a6e4-cbc7b15046cd"
      unitRef="usd">41689000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzctMS0xLTEtMA_35e54161-e8c3-4332-a3a0-67e12dc13115"
      unitRef="shares">2671528</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzctMy0xLTEtMA_9e85788e-25d2-46dc-8260-ee1862e6b022">P1Y2M8D</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm>
    <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90YWJsZTpjMDU1OTVhNDIwYmU0MjVmYWEyMWM3ZDAzZTQ3NzI1MS90YWJsZXJhbmdlOmMwNTU5NWE0MjBiZTQyNWZhYTIxYzdkMDNlNDc3MjUxXzctNS0xLTEtMA_6e91dbb9-7667-4de3-93fe-9e9ba542129a"
      unitRef="usd">41689000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU2OTA_33b30ce7-0fc7-4afe-ade4-40fe7c8f9121"
      unitRef="shares">90617</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="i2a738f79b71a4fbcb3ee3bae594343d4_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU2OTQ_9db650f5-2d3a-4568-bc71-2dbf9dbd613c"
      unitRef="shares">39160</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="icc4c94703dab45468283cb739266adc8_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU3MDI_56c6d5e7-51b3-415c-a73b-cbebd23ffa60"
      unitRef="shares">20193</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU5NDI_c80ba334-aa16-4c75-8a90-f329fa40b6ed"
      unitRef="usd">800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU5NDY_05103c87-9c62-4131-b9ca-662a0e301bdc"
      unitRef="usd">400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDkvZnJhZzo2MTNmZWJjYzczMGE0YmViYTkzZDFhMTRjNTRkM2MyOC90ZXh0cmVnaW9uOjYxM2ZlYmNjNzMwYTRiZWJhOTNkMWExNGM1NGQzYzI4XzU5NTM_7e9d16b1-90ec-4836-8c81-8eab26e39b9f"
      unitRef="usd">300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzIxNjI_076aeaa8-8947-441f-affc-d0ac26c8b299">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, total stock-based compensation expense to be recognized in future periods related to unvested stock options was $35.5&#160;million, which is expected to be expensed over a weighted-average period of 2.72 years. As of December&#160;31, 2020, total stock-based compensation expense to be recognized in future periods related to unvested RSUs was $17.1&#160;million, which is expected to be expensed over a weighted-average period of 2.07 years. There was no capitalized stock-based employee compensation expense as of December&#160;31, 2020, 2019 or 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee stock-based compensation expense was determined using the Black-Scholes option valuation model for stock options and employee share purchases under the ESPP. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company bases its determination of expected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average estimated fair value per share of options granted during 2020, 2019 and 2018 was $5.25, $6.37, and $11.39, respectively, based upon the assumptions used in the Black-Scholes valuation model. The assumptions used for estimating the fair value of the employee stock options were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34-0.61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68-2.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53-2.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51-5.57&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50-5.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59-5.61&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.61-80.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.46-78.39%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.33-75.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employees purchased 274,382, 249,364 and 328,710 shares of common stock through the ESPP at an average exercise price of $7.34, $8.53, and $4.51 per share during 2020, 2019 and 2018, respectively. The weighted-average estimated fair values of shares purchased under the Company&#x2019;s ESPP during 2020, 2019 and 2018 were $8.02, $4.70 and $7.07, respectively, based upon the assumptions used in the Black-Scholes valuation model.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for estimating the fair value of the ESPP purchase rights are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53-2.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53-2.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16-2.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.02-91.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.02-91.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.21-83.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzIxNjM_8c419ccb-06de-49cc-8292-0960810c00b9">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9d397545580d4460a2a0fec1fc8ba1a5_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzItMS0xLTEtMA_4993534e-a7c3-4f8b-b066-d64afd8b63b9"
      unitRef="usd">13523000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6df1c8f3c9a84c598d0ae819a426267c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzItMy0xLTEtMA_f9a09772-178e-419e-bd30-3cc2636da25a"
      unitRef="usd">10135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5cec61b66c8248d2abcb75627ce796b4_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzItNS0xLTEtMA_a5c993b6-6913-49af-a1b9-cdbf6c1527c0"
      unitRef="usd">8249000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i855baf86bae64ff0bd95f564c7fd3fd0_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzMtMS0xLTEtMA_54602c28-be5e-4eb2-8652-11fe97f7d6ac"
      unitRef="usd">12185000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idf94cc35763140c7b88de393e914a63c_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzMtMy0xLTEtMA_98a9b7a9-1036-43aa-84bd-3eb9fecc65dc"
      unitRef="usd">9195000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f5dfc4d40fd4effae8227da27de4cfc_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzMtNS0xLTEtMA_03480567-6127-4f40-9ae5-e2685c47da6e"
      unitRef="usd">6428000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzQtMS0xLTEtMA_9a20e96a-1e3b-48a0-b2eb-b74a0bd7052a"
      unitRef="usd">25708000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzQtMy0xLTEtMA_3d1d7059-71a8-42f7-ac3a-a2238c7811f7"
      unitRef="usd">19330000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo2NWVmOGRlZjY0MDg0MTcxOTczYTA3NzVmMmZhMzkzNi90YWJsZXJhbmdlOjY1ZWY4ZGVmNjQwODQxNzE5NzNhMDc3NWYyZmEzOTM2XzQtNS0xLTEtMA_3d15f0af-ffbf-476c-b746-b3506d96ae60"
      unitRef="usd">14677000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzMxMw_6a031e3e-92e1-4362-a9df-ad145b7b280d"
      unitRef="usd">35500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzM4NA_611a729e-5707-4d3d-922e-fdbc2a220839">P2Y8M19D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i7597d30081de44f3921ada32f9dbc896_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzUwMQ_7e35c84a-199e-48a6-928b-5930370ee860"
      unitRef="usd">17100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i7a3fcb405fcf4036ad180a558281fb24_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzU3Mg_228ed19f-25fc-4dfb-a254-013a505c489d">P2Y25D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzU4Ng_1729cb67-4771-49ad-8b2b-c778748ce694"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzU4Ng_32080797-af88-497a-93f1-ed263bd43eb8"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzU4Ng_b9dffc62-b8dc-4514-9c73-0e19546a2fca"
      unitRef="usd">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE0Njk_e6e76ddd-67ea-4741-8473-dca778b2bfe6"
      unitRef="usdPerShare">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE0NzM_69922504-372d-414c-a01b-0538ea5c9814"
      unitRef="usdPerShare">6.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE0ODE_6dd63d7a-dce6-4434-96d2-d6a15280b7f9"
      unitRef="usdPerShare">11.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzIxNjQ_b37d9a31-421a-4d86-aedd-8f61b6a1eea0">The assumptions used for estimating the fair value of the employee stock options were as follows:&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.058%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.418%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.34-0.61%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68-2.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.53-2.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51-5.57&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50-5.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59-5.61&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77.61-80.32%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76.46-78.39%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.33-75.49%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i223299de6a284218a780245b2f4e9fb8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItMS0xLTEtMC90ZXh0cmVnaW9uOjE2NDMxMDU4MjBjOTQ4YjE4NzE1NWY1ZjM4Y2Y4YjY2XzEwOTk1MTE2Mjc3ODA_5f707715-7ca7-4e98-ba67-ccce964b0544"
      unitRef="number">0.0034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9a566e45d4414942be208342c5c516a6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItMS0xLTEtMC90ZXh0cmVnaW9uOjE2NDMxMDU4MjBjOTQ4YjE4NzE1NWY1ZjM4Y2Y4YjY2XzEwOTk1MTE2Mjc3ODQ_5e5b1ed1-281c-47f5-b001-b9ffe07b289f"
      unitRef="number">0.0061</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia188228a2f714148b418bbafdff8df68_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItMy0xLTEtMC90ZXh0cmVnaW9uOjdhZmEzNDhiZTNhMTRlZTg5OWE5OGYzZmZhZDBmYjJiXzEwOTk1MTE2Mjc3ODg_9961bd02-dea3-419d-b566-ec3df83febf5"
      unitRef="number">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i3f59d4e0ade74a58893ddc753841891e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItMy0xLTEtMC90ZXh0cmVnaW9uOjdhZmEzNDhiZTNhMTRlZTg5OWE5OGYzZmZhZDBmYjJiXzEwOTk1MTE2Mjc3OTI_08e3ab66-130c-4e3e-b2b2-9ce1b9b182fb"
      unitRef="number">0.0225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i279740780022456087bde23ef4f549fa_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItNS0xLTEtMC90ZXh0cmVnaW9uOmFhYTljNzU0MmFhNDRhZDE4YmIyN2Q5MmY0NzkwZWY5XzEwOTk1MTE2Mjc3ODA_9794cf60-7d9a-499a-8ce5-3c65af2723f7"
      unitRef="number">0.0253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib90a62c3edc44c90a63b7c1744a27bb7_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzItNS0xLTEtMC90ZXh0cmVnaW9uOmFhYTljNzU0MmFhNDRhZDE4YmIyN2Q5MmY0NzkwZWY5XzEwOTk1MTE2Mjc3ODQ_75edf83f-6468-4593-8b09-92803d75e8a2"
      unitRef="number">0.0296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i223299de6a284218a780245b2f4e9fb8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtMS0xLTEtMC90ZXh0cmVnaW9uOmJhOTc1NGU3ODVkNjQ3MmU5OTQwYWYwYTg2MjM1OWI2XzEwOTk1MTE2Mjc3ODA_f781fd8c-98f7-4a06-bf96-34a313ce180a">P5Y6M3D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9a566e45d4414942be208342c5c516a6_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtMS0xLTEtMC90ZXh0cmVnaW9uOmJhOTc1NGU3ODVkNjQ3MmU5OTQwYWYwYTg2MjM1OWI2XzEwOTk1MTE2Mjc3ODQ_ac547e43-7178-4ccb-a929-423b69d632c8">P5Y6M25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ia188228a2f714148b418bbafdff8df68_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtMy0xLTEtMC90ZXh0cmVnaW9uOmE3ZGI1OGY1YzllNzQ4OWViOGNlMWY3MzNkNmFlY2VlXzEwOTk1MTE2Mjc3OTA_e5de1157-dab1-49f4-b2fc-30748d7ade11">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i3f59d4e0ade74a58893ddc753841891e_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtMy0xLTEtMC90ZXh0cmVnaW9uOmE3ZGI1OGY1YzllNzQ4OWViOGNlMWY3MzNkNmFlY2VlXzEwOTk1MTE2Mjc3OTQ_e9be15a4-cbdf-4760-840a-79fe4bcb2cec">P5Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i279740780022456087bde23ef4f549fa_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtNS0xLTEtMC90ZXh0cmVnaW9uOjg4NmVhZDMwYWRlMjRmMjhiNDZkMWFhZDQzZTI3YzAzXzEwOTk1MTE2Mjc3ODA_594a35e2-2574-4587-98d7-1183fa527fca">P5Y7M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ib90a62c3edc44c90a63b7c1744a27bb7_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzMtNS0xLTEtMC90ZXh0cmVnaW9uOjg4NmVhZDMwYWRlMjRmMjhiNDZkMWFhZDQzZTI3YzAzXzEwOTk1MTE2Mjc3ODQ_c994f597-567a-4b39-b334-07ed463e7dd5">P5Y7M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i3d3f08aef11f4a318908f591e111b593_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzQtMS0xLTEtMA_17832e59-ef50-4590-8249-f2fc6c590fa4"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i29b01dbcc0f74a77aa727c03cc8da109_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzQtMy0xLTEtMA_61656d62-8aac-410d-8bbb-0f2b3449141e"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ifd84dea3dd62427db0d47cb010b83133_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzQtNS0xLTEtMA_1c220b9a-9af6-4fef-ad0a-52c2d70bd4db"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i223299de6a284218a780245b2f4e9fb8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtMS0xLTEtMC90ZXh0cmVnaW9uOmVlNzJhOGUwYTk1MzRkNjRhMDJmOTZhNmFjY2M3NmE4XzEwOTk1MTE2Mjc3ODA_6f0ca2c4-479f-4db4-8ae6-87f28c9dfc7f"
      unitRef="number">0.7761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9a566e45d4414942be208342c5c516a6_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtMS0xLTEtMC90ZXh0cmVnaW9uOmVlNzJhOGUwYTk1MzRkNjRhMDJmOTZhNmFjY2M3NmE4XzEwOTk1MTE2Mjc3ODQ_37041d8b-9e43-4b56-8424-9a20cd39e155"
      unitRef="number">0.8032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia188228a2f714148b418bbafdff8df68_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjllMjFkMjM4YzMwZjQzMDQ4ZjBhMGJhOTUwMGY0ZGY1XzEwOTk1MTE2Mjc3ODA_4eb9aae5-000e-4d87-82c4-4a1868209750"
      unitRef="number">0.7646</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i3f59d4e0ade74a58893ddc753841891e_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtMy0xLTEtMC90ZXh0cmVnaW9uOjllMjFkMjM4YzMwZjQzMDQ4ZjBhMGJhOTUwMGY0ZGY1XzEwOTk1MTE2Mjc3ODQ_7911d5f5-6f99-4f9f-b410-ea4cd6d09cf2"
      unitRef="number">0.7839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i279740780022456087bde23ef4f549fa_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtNS0xLTEtMC90ZXh0cmVnaW9uOmU2YWI5ZmI3N2Q3YjQ1NDhhMGU0YjliMDVjNmI3NDdhXzEwOTk1MTE2Mjc3ODA_4b2b7b94-63e6-422f-979f-0d3a90605d6d"
      unitRef="number">0.7233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib90a62c3edc44c90a63b7c1744a27bb7_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTo3MDU3OTQ0YTI0YWQ0NzQ3OGE2NjJjMjQ0MDg2Mjk3NS90YWJsZXJhbmdlOjcwNTc5NDRhMjRhZDQ3NDc4YTY2MmMyNDQwODYyOTc1XzUtNS0xLTEtMC90ZXh0cmVnaW9uOmU2YWI5ZmI3N2Q3YjQ1NDhhMGU0YjliMDVjNmI3NDdhXzEwOTk1MTE2Mjc3ODQ_078ecb3d-1b69-4a74-9999-85228f7899dc"
      unitRef="number">0.7549</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE2ODk_4067c420-a8c8-45b9-a5d3-5b0ede88fb3a"
      unitRef="shares">274382</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE2OTM_9f439866-4909-4e65-aab9-93183a2a9f3c"
      unitRef="shares">249364</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE3MDA_dbf059bf-2110-4a7d-9fae-458576cc70d2"
      unitRef="shares">328710</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE3NzU_7fdb4493-97fb-4a7c-8746-100b85bf3bc3"
      unitRef="usdPerShare">7.34</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
    <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE3Nzk_c6991f39-64d3-4309-8154-7fd2f1e9abd5"
      unitRef="usdPerShare">8.53</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
    <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE3ODc_90630efb-869f-4cc6-8e73-2aebeb978a8d"
      unitRef="usdPerShare">4.51</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
    <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE5NTA_dabc593e-8f66-4d30-a52a-52d65c1e0f7c"
      unitRef="usdPerShare">8.02</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
    <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE5NTQ_c1756098-1dc0-4f80-a785-8969e5576116"
      unitRef="usdPerShare">4.70</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
    <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzE5NjE_ae2ed5c5-fc6a-400a-a46c-99807b3145c2"
      unitRef="usdPerShare">7.07</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90ZXh0cmVnaW9uOmNlYTIwNGE3MmI1NjQ1ZWRiNzY5MDUzMTcxZTA3YmQ4XzIxNjU_0794b4fa-4591-4668-aa06-2292cb6f1a94">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used for estimating the fair value of the ESPP purchase rights are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.601%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53-2.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.53-2.42%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.16-2.80%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5-2.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield of stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.02-91.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.02-91.96%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.21-83.25%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i1cc661d039934a93b782c591c4f4b854_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItMS0xLTEtMC90ZXh0cmVnaW9uOmIxMTU1MTljYjk2YzQ3NjRiMWY0MzBmMTYwZGQ1MmQ4XzEwOTk1MTE2Mjc3OTY_da63a44d-5cf0-490c-be5c-3bc13fa0171f"
      unitRef="number">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="iae60b3bb0a244843baf181d3d3f789f8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItMS0xLTEtMC90ZXh0cmVnaW9uOmIxMTU1MTljYjk2YzQ3NjRiMWY0MzBmMTYwZGQ1MmQ4XzEwOTk1MTE2Mjc3ODQ_1826fa9b-01ad-4bd6-aff6-b78bf8fa9ca8"
      unitRef="number">0.0280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="icc4caf6b9fb443ea9a67e1cd79ff3121_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItMy0xLTEtMC90ZXh0cmVnaW9uOmNiMzY0YTk3YTg3NTQ2NzM4MTNlZTk3NTE5MmI0NjY3XzEwOTk1MTE2Mjc3ODA_18c5c7ab-85e4-4da4-915e-a85b36c9158d"
      unitRef="number">0.0153</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i51512ee82f7c4322a3633294ba2c9a7c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItMy0xLTEtMC90ZXh0cmVnaW9uOmNiMzY0YTk3YTg3NTQ2NzM4MTNlZTk3NTE5MmI0NjY3XzEwOTk1MTE2Mjc3ODQ_0edce150-bf24-42b8-82ac-1fd24e462066"
      unitRef="number">0.0242</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i43e320fb9b704556adf1b2e8fe7699a4_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItNS0xLTEtMC90ZXh0cmVnaW9uOmVlYzA3YWY5ZjFkODQ5M2M4NjFiODk4MmQ5NDNjMzk3XzEwOTk1MTE2Mjc3ODA_a565330c-e9af-4319-912a-f9a505b72954"
      unitRef="number">0.0216</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i311774a19c3b43b292a88509437d6a57_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzItNS0xLTEtMC90ZXh0cmVnaW9uOmVlYzA3YWY5ZjFkODQ5M2M4NjFiODk4MmQ5NDNjMzk3XzEwOTk1MTE2Mjc3ODQ_9681bce7-8ec9-4444-9160-d0fa0dc2e175"
      unitRef="number">0.0280</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i1cc661d039934a93b782c591c4f4b854_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjBmNTkyYmY1MmNjNzRiYmE4MmQ4ODI5MjRlM2ZiNGZlXzEwOTk1MTE2Mjc3ODA_fc1fe112-5535-4cde-a074-c46ba7fdcb9e">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="iae60b3bb0a244843baf181d3d3f789f8_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtMS0xLTEtMC90ZXh0cmVnaW9uOjBmNTkyYmY1MmNjNzRiYmE4MmQ4ODI5MjRlM2ZiNGZlXzEwOTk1MTE2Mjc3ODQ_97cd78d5-dc28-47c3-8a3e-f5f8f82d000e">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="icc4caf6b9fb443ea9a67e1cd79ff3121_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjdjNzkyM2JjNzk5OTRlMjNhZDE4ZDAzM2NkODc0NGYwXzEwOTk1MTE2Mjc3ODA_1ee42d9a-54ba-4c5b-9ce7-2a587fc5071f">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i51512ee82f7c4322a3633294ba2c9a7c_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtMy0xLTEtMC90ZXh0cmVnaW9uOjdjNzkyM2JjNzk5OTRlMjNhZDE4ZDAzM2NkODc0NGYwXzEwOTk1MTE2Mjc3ODQ_ac51641f-2cdf-4f54-b877-e33216079cf9">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i43e320fb9b704556adf1b2e8fe7699a4_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtNS0xLTEtMC90ZXh0cmVnaW9uOjUwYWYxZjMzMTYyNjRjOTViMzNhYTQxNjRmMGVhNWQxXzEwOTk1MTE2Mjc3ODA_95d45470-0384-42c6-862f-f4faaceca99d">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i311774a19c3b43b292a88509437d6a57_D20180101-20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzMtNS0xLTEtMC90ZXh0cmVnaW9uOjUwYWYxZjMzMTYyNjRjOTViMzNhYTQxNjRmMGVhNWQxXzEwOTk1MTE2Mjc3ODQ_f4147d51-a125-4879-9968-bb0776fc7f4c">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ia4f372a7d1ad4108a38bfe05388f5e5d_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzQtMS0xLTEtMA_4459dd14-f16b-4bfc-9494-e58f457d85c1"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i218e12e36203494ba48b0ba0613475c4_D20190101-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzQtMy0xLTEtMA_641228c8-ae7a-4c7a-9347-bce193f6a675"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i83b08e5e95284441967eed76e78797ba_D20180101-20181231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzQtNS0xLTEtMA_e05ac946-d62a-4425-b791-5e2e38df526b"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i1cc661d039934a93b782c591c4f4b854_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjhlYmM3NDEzMjE4YTRkYmViOGVmMmRmNzdiMmRmODQ1XzEwOTk1MTE2Mjc4MDM_2d453a5d-9f9c-4607-90a2-2a3c31c27200"
      unitRef="number">0.5102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="iae60b3bb0a244843baf181d3d3f789f8_D20200101-20201231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtMS0xLTEtMC90ZXh0cmVnaW9uOjhlYmM3NDEzMjE4YTRkYmViOGVmMmRmNzdiMmRmODQ1XzEwOTk1MTE2Mjc3OTU_1561b9f2-8660-42a4-a3b3-31ba1c53ff35"
      unitRef="number">0.9196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="icc4caf6b9fb443ea9a67e1cd79ff3121_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtMy0xLTEtMC90ZXh0cmVnaW9uOjgzZTNmM2I5Y2MzMTRjNjZiMjc0Y2ZiZTlmOGMwZmMzXzEwOTk1MTE2Mjc3ODA_962c770f-570d-4248-8f06-fdde1309bbc2"
      unitRef="number">0.5102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i51512ee82f7c4322a3633294ba2c9a7c_D20190101-20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtMy0xLTEtMC90ZXh0cmVnaW9uOjgzZTNmM2I5Y2MzMTRjNjZiMjc0Y2ZiZTlmOGMwZmMzXzEwOTk1MTE2Mjc3ODQ_a9144f35-ec3f-4a0f-9cef-e9e3f28e4869"
      unitRef="number">0.9196</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i43e320fb9b704556adf1b2e8fe7699a4_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtNS0xLTEtMC90ZXh0cmVnaW9uOmRjNzY4NzJiOWUyMTQ4MTdiYTRjOTUxMjI3MWE2ZDViXzEwOTk1MTE2Mjc3ODA_02a5c2f8-5ef7-4ce7-8cb3-aa3cef003238"
      unitRef="number">0.7321</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i311774a19c3b43b292a88509437d6a57_D20180101-20181231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMTUvZnJhZzpjZWEyMDRhNzJiNTY0NWVkYjc2OTA1MzE3MWUwN2JkOC90YWJsZTpkNzliODZjMDUyY2Y0MzJlYjIyZTRkYmFhOTI2M2FjMC90YWJsZXJhbmdlOmQ3OWI4NmMwNTJjZjQzMmViMjJlNGRiYWE5MjYzYWMwXzUtNS0xLTEtMC90ZXh0cmVnaW9uOmRjNzY4NzJiOWUyMTQ4MTdiYTRjOTUxMjI3MWE2ZDViXzEwOTk1MTE2Mjc3ODQ_70d90dc9-f733-4c24-b7ad-718c279fb13d"
      unitRef="number">0.8325</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzU3OQ_e3441527-7398-45e6-9c32-56801aabfa68">EMPLOYEE BENEFIT PLAN&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code covering all full-time employees (&#x201c;Sangamo 401(k) Plan&#x201d;). The Sangamo 401(k) Plan is intended to qualify under Section&#160;401 of the Internal Revenue Code.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company matched employee contributions equal to 50% for the first 8% in 2020, 2019 and 2018, up to a limit of $4,000 in 2020, 2019 and 2018. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan by the Company were $1.2&#160;million, $0.9&#160;million, and $0.8&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzMzMA_918b9c4c-299a-4370-951b-2d5c88a753e0"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzMzMA_d9b2aab0-558b-4999-a195-fa0d2bfd549a"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzMzMA_dfdbc9af-c5be-4482-8ff4-b345b39ae4fd"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM0Nw_4fc6551c-f582-444f-86c7-76a18391044f"
      unitRef="number">0.08</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM0Nw_9fccc3ed-b1f3-4876-b40a-c679ce62de52"
      unitRef="number">0.08</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM0Nw_de5470aa-e38b-45c1-80c6-3c97d5f47faf"
      unitRef="number">0.08</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM4NQ_4b8224ed-f1f6-4532-b13f-ed6665a81aa3"
      unitRef="usd">4000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM4NQ_eca14762-3a6b-4bd6-a794-65917efc7cb0"
      unitRef="usd">4000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzM4NQ_f6d3b77e-2657-40d7-add9-953331ce7cf9"
      unitRef="usd">4000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzUxNw_77433917-4320-437c-97c6-c30db38eec17"
      unitRef="usd">1200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzUyMQ_befed431-0af5-4c46-98b5-6229f491bc0e"
      unitRef="usd">900000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjEvZnJhZzpkYmI3ZGIyMTgxMmU0N2I2YmU0NjY5NmYyMjhhMjI3MC90ZXh0cmVnaW9uOmRiYjdkYjIxODEyZTQ3YjZiZTQ2Njk2ZjIyOGEyMjcwXzUyOQ_47453a15-6c29-4c81-b6b5-f9b6591bfe57"
      unitRef="usd">800000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjU_333583a5-1651-4774-b4b5-f55b4299351b">INCOME TAXES &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of loss before income taxes were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between the income tax expense and the amount computed by applying the federal statutory income tax rate to loss before income taxes is explained as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global Intangible Low-Taxed Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and December 2020, in response to the COVID-19 pandemic, the CARES Act and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic. The Company does not expect any significant benefit to its income tax provision as a result of this legislation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred tax assets and liabilities based on tax jurisdictions are presented on the Consolidated Balance Sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (included in Other non-current assets on the Consolidated Balance Sheet)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the Company acquired Sangamo France. The Company recorded goodwill and intangible assets as part of accounting for the acquisition of Sangamo France. There is no corresponding tax basis for the goodwill or intangible assets. A portion of the intangible assets acquired were for the use in a particular research and development project and are considered indefinite-lived assets with no tax basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the fair value of the unrealized gain (loss) on marketable securities are recorded as a component of accumulated other comprehensive income (loss), net of a provision for income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. The Company regularly assesses the need for a valuation allowance against its deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that the Company&#x2019;s deferred income tax assets will be realized. In evaluating the Company&#x2019;s ability to recover its deferred income tax assets within the jurisdiction from which they arise, the Company considers all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. Accordingly, based upon the Company&#x2019;s analysis of these factors the net deferred tax assets have been substantially offset by a valuation allowance. The valuation allowance increased by $26.6&#160;million, $29.6&#160;million and $45.3&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2020, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $622.6&#160;million and $261.7&#160;million, respectively. The federal net operating loss generated before 2018 will begin to expire in 2024 and will keep expiring through 2037, if not utilized. Federal net operating loss generated in 2018 will carry forward indefinitely. If not utilized, the state net operating loss carryforwards will begin to expire in 2029, respectively. The Company&#x2019;s French net operating loss carryforward balance is $145.9&#160;million, which carries over indefinitely. The Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;also has federal and state research tax credit carryforwards of $21.9&#160;million and $18.3&#160;million, respectively. The federal research credits will begin to expire in 2021, while the state research credits have no expiration date. Utilization of the Company&#x2019;s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before utilization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to reinvest the earnings of its non-U.S. subsidiaries in those operations. The Company does not provide for U.S. taxes on the earnings of foreign subsidiaries because the Company intends to reinvest such earnings offshore indefinitely. However, if these funds were repatriated, the Company would be required to accrue and pay applicable U.S. taxes and withholding taxes. Due to the cumulative losses generated in foreign countries there are no earnings to repatriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files federal and state income tax returns with varying statutes of limitations. The tax years from 2002 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files United Kingdom and French income tax returns, and the tax years from 2008 and thereafter remain open in the United Kingdom and 2016 and thereafter in France are still subject to examination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2020, the Company had no accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate will not be affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MTk_73907f9f-a92a-4e59-86e0-8d29ee1aa88f">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The domestic and foreign components of loss before income taxes were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(126,624)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(77,354)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65,695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,194)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzItMS0xLTEtMA_50e70cbf-5e64-4806-b2e3-08267fdf145e"
      unitRef="usd">-126624000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzItMy0xLTEtMA_70664c95-9fbf-456e-83b4-13bcc1313438"
      unitRef="usd">-77354000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzItNS0xLTEtMA_2149da36-b549-46fa-a99c-9df8e140e047"
      unitRef="usd">-65695000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzMtMS0xLTEtMA_f1783f40-214e-449c-99f0-538d2ef1f207"
      unitRef="usd">5847000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzMtMy0xLTEtMA_64b8865a-0268-40c4-8cec-ff19327bae03"
      unitRef="usd">-18065000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzMtNS0xLTEtMA_9c857f56-f1e3-46df-9a81-e06b04b0319f"
      unitRef="usd">-3194000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzQtMS0xLTEtMA_e61828bb-6fef-4c95-83b5-c9fd506beb50"
      unitRef="usd">-120777000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzQtMy0xLTEtMA_d7746092-80da-4d08-9cde-e9a332a0f6d9"
      unitRef="usd">-95419000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNTY4ZjVjMTQwMGU0NGJmYjk5M2JlMzg3OGQxYmJmMC90YWJsZXJhbmdlOmU1NjhmNWMxNDAwZTQ0YmZiOTkzYmUzODc4ZDFiYmYwXzQtNS0xLTEtMA_d1993b89-d937-4b90-bc76-a6a08a2cd885"
      unitRef="usd">-68889000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjA_01a6d1a5-77ad-4310-8685-ebae7fa4d66f">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax expense consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(474)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzQtMS0xLTEtMA_ce34d462-c8e3-4f71-b26f-46b23fc6970d"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzQtMy0xLTEtMA_e84651a1-6790-4483-97ec-c13cee5091ad"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzQtNS0xLTEtMA_18828cc7-c42a-497d-8adf-8a80214a9dea"
      unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzUtMS0xLTEtMA_332cfd9d-a390-424c-a1fc-2620fd8f1dd2"
      unitRef="usd">133000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzUtMy0xLTEtMA_97e0ddd2-c3f7-4622-a6c9-21edfc4ae2e8"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzUtNS0xLTEtMA_3367940f-17e9-4b62-b2ad-326fc747e52b"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzYtMS0xLTEtMA_0983db3a-c627-4c36-9d5d-2104703aa758"
      unitRef="usd">686000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzYtMy0xLTEtMA_53bb5854-d9c5-49a4-b1b4-448ef73ca708"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzYtNS0xLTEtMA_067fb365-c59a-4da2-b65c-0e2176c01468"
      unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzctMS0xLTEtMA_0fa5750e-a986-4fc4-8f43-213c25da4357"
      unitRef="usd">819000</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzctMy0xLTEtMA_7a28025c-1d92-41e3-a1b5-1987fb64052e"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzctNS0xLTEtMA_5aab27af-d4e0-47bc-b31c-f1e91c863346"
      unitRef="usd">0</us-gaap:CurrentFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzktMS0xLTEtMA_e2533f85-8d35-4c7f-9890-90fbd1c16468"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzktMy0xLTEtMA_343a9d42-6def-4cae-b021-cfdea917836c"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzktNS0xLTEtMA_a19dfc0c-dcc2-4473-a7c1-88f3f22616e5"
      unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEwLTEtMS0xLTA_8a062978-429d-426e-bf1d-697136800361"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEwLTMtMS0xLTA_205c7872-af6c-40fa-aca9-e3d917cccbbb"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEwLTUtMS0xLTA_a230c2e5-da61-4a64-8eb8-e05cdc72780f"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzExLTEtMS0xLTA_bf4927c5-b30a-4eff-9316-10f36c94f989"
      unitRef="usd">-474000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzExLTMtMS0xLTA_ce7de7ba-9469-469e-9b26-ca63655abb82"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzExLTUtMS0xLTA_b62b3e2b-5145-4835-bea1-524f1d0a131a"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEyLTEtMS0xLTA_93463860-0d3a-446f-acfe-584644dcfe3b"
      unitRef="usd">-474000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEyLTMtMS0xLTA_d78c02c7-2532-473c-a1d7-1a58612e8c10"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEyLTUtMS0xLTA_3fc7cfd8-2e8c-4b3e-ba84-66bd35d8292a"
      unitRef="usd">0</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEzLTEtMS0xLTA_fa691dbe-687a-4c10-8ddb-9f9f23926b8d"
      unitRef="usd">345000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEzLTMtMS0xLTA_a35ac73e-129c-45d8-90c6-1d59712095c1"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTozOGFkNDkxMTQwZWY0ZDI1YmFiNzNkMTg0MjJlMGJiZS90YWJsZXJhbmdlOjM4YWQ0OTExNDBlZjRkMjViYWI3M2QxODQyMmUwYmJlXzEzLTUtMS0xLTA_21926571-6549-43c4-a87e-e173a094507c"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjE_38b5edb9-7bff-4c21-8188-e31b783d2838">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The difference between the income tax expense and the amount computed by applying the federal statutory income tax rate to loss before income taxes is explained as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.748%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax at federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25,363)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,038)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,597)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign rate differential&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global Intangible Low-Taxed Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,729)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,657)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,429)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,005)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,537&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March and December 2020, in response to the COVID-19 pandemic, the CARES Act and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic. The Company does not expect any significant benefit to its income tax provision as a result of this legislation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzItMS0xLTEtMA_421b9277-d787-43fc-9d79-c8d1c3a3928f"
      unitRef="usd">-25363000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzItMy0xLTEtMA_a47ebc70-2322-4cf8-85ea-ab7cc3998889"
      unitRef="usd">-20038000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzItNS0xLTEtMA_a2be099f-9b0e-4425-bef8-3ec06243f90c"
      unitRef="usd">-14467000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzMtMS0xLTEtMA_15518454-4a4c-4b2a-a78b-b842bfb9d645"
      unitRef="usd">-3168000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzMtMy0xLTEtMA_c03ddca5-5af9-4094-a807-ced7b8dd3e82"
      unitRef="usd">-9597000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzMtNS0xLTEtMA_aec1c04e-3c1d-453a-bacd-9845bb1beb0e"
      unitRef="usd">-2849000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtMS0xLTEtMA_dc0b9e49-4701-486f-9dce-d72548fab398"
      unitRef="usd">376000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtMy0xLTEtMA_c22f039e-b508-491d-a372-e25f9c01582b"
      unitRef="usd">-665000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtNS0xLTEtMA_f8384f3e-c3b1-428d-aec8-5f2304664de6"
      unitRef="usd">-177000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <sgmo:EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtMS0xLTEtNzA4OA_4c2f07a1-bc70-44cd-9737-3f47c142169c"
      unitRef="usd">1335000</sgmo:EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount>
    <sgmo:EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtMy0xLTEtNzA4OA_d792dd09-774e-4012-9286-86cb51e1e8da"
      unitRef="usd">0</sgmo:EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount>
    <sgmo:EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzUtNS0xLTEtNzA4OA_9b0ea891-cab5-4693-808d-101c98ae3a58"
      unitRef="usd">0</sgmo:EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount>
    <sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzYtMS0xLTEtMA_5484c413-66e7-4955-8eb6-c1d282766bce"
      unitRef="usd">4232000</sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation>
    <sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzYtMy0xLTEtMA_8a03d310-ef7a-4e3a-bfa5-bb13a2402270"
      unitRef="usd">2817000</sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation>
    <sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzYtNS0xLTEtMA_4b9840d6-af7d-4dfe-b374-06fe39e53d9d"
      unitRef="usd">-2729000</sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzctMS0xLTEtMA_0968255c-ed0a-4f25-b801-c13f2f51df32"
      unitRef="usd">3657000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzctMy0xLTEtMA_5fd50c54-142b-419e-a5f9-a0372d177803"
      unitRef="usd">3429000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzctNS0xLTEtMA_fd17dc73-1ea3-4b9d-804c-47df6863897a"
      unitRef="usd">1005000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzgtMS0xLTEtMA_e9986ed0-a240-424e-b910-4fb40ec3833d"
      unitRef="usd">26537000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzgtMy0xLTEtMA_ada7ada9-b525-4853-a69e-62ec811718e6"
      unitRef="usd">29655000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzgtNS0xLTEtMA_df1e4a80-a296-4074-a802-06eea823ada4"
      unitRef="usd">20271000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzktMS0xLTEtMA_a5b87491-66fe-4fdf-a72e-714cf0ecd6ed"
      unitRef="usd">53000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzktMy0xLTEtMA_7889e240-b689-498a-9a2c-8f8b73ba292e"
      unitRef="usd">1257000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzktNS0xLTEtMA_c6ad0e73-00be-4919-83ef-149b09f1617a"
      unitRef="usd">956000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzEwLTEtMS0xLTA_63a1377f-9b54-45f6-a9a0-564bc896792a"
      unitRef="usd">345000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzEwLTMtMS0xLTA_7ec7aaed-6ec1-411f-a978-b47f9c87389d"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpjNTdkMzgyMGYyM2U0YjdkODE4YjMxYTY0MzkzZmMxMC90YWJsZXJhbmdlOmM1N2QzODIwZjIzZTRiN2Q4MThiMzFhNjQzOTNmYzEwXzEwLTUtMS0xLTA_1c4da127-fbdc-4268-a7b7-94087c2b1596"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjM_bcd07041-82a2-4985-a98e-d3679773aa08">Significant components of the Company&#x2019;s deferred tax assets and liabilities are as follows (in thousands):&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:74.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accruals and reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;215,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;214,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,321)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,609)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,510)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,656)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31,831)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34,265)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The deferred tax assets and liabilities based on tax jurisdictions are presented on the Consolidated Balance Sheet as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.607%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.183%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (included in Other non-current assets on the Consolidated Balance Sheet)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,185)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,711)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzQtMS0xLTEtMA_34bcca24-e536-4709-b015-31b2d8cd06c6"
      unitRef="usd">164276000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzQtMy0xLTEtMA_093f87c2-0cf4-4d5e-a985-bc45937f6ffb"
      unitRef="usd">133765000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzUtMS0xLTEtMA_ff68c2ec-68bd-4b5c-8dd5-b35d633bce65"
      unitRef="usd">27679000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzUtMy0xLTEtMA_9a516a33-9f71-41cd-aa3a-efc557ac1d82"
      unitRef="usd">21459000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzYtMS0xLTEtMA_9a210c0b-e597-4aef-a529-3693aff07ccd"
      unitRef="usd">5321000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzYtMy0xLTEtMA_326e6e1e-3760-4cd1-8e6e-928e5102b05b"
      unitRef="usd">4194000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzctMS0xLTEtMA_f6d63be1-536e-4825-82de-a8d7573d6518"
      unitRef="usd">20681000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzctMy0xLTEtMA_9d06e67a-5925-4493-97a0-bda494259bf8"
      unitRef="usd">32171000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzgtMS0xLTEtMA_08a241f4-5d17-4340-8d53-ac27fdfce301"
      unitRef="usd">10525000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzgtMy0xLTEtMA_a657b90c-a221-497c-aa91-728c150fc78d"
      unitRef="usd">11282000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <sgmo:DeferredTaxAssetsLeaseLiability
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzktMS0xLTEtMA_e21b2e65-1897-4edf-8fe6-a9b8aa46309b"
      unitRef="usd">10251000</sgmo:DeferredTaxAssetsLeaseLiability>
    <sgmo:DeferredTaxAssetsLeaseLiability
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzktMy0xLTEtMA_c1a2296f-1b3a-409d-950e-f658e7010184"
      unitRef="usd">11722000</sgmo:DeferredTaxAssetsLeaseLiability>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzExLTEtMS0xLTA_97cf7893-36be-438d-938a-100d4dd86375"
      unitRef="usd">430000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzExLTMtMS0xLTA_7491b7bb-59a1-4a5b-8fef-0ab79f95dbc2"
      unitRef="usd">675000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzEyLTEtMS0xLTA_630274fd-2f4d-41ae-b3c0-577298d69162"
      unitRef="usd">308000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzEyLTMtMS0xLTA_8f12f6ab-253f-42c0-b945-abb0c8a59344"
      unitRef="usd">151000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzEzLTEtMS0xLTA_2b312d3f-ce05-443c-9bb3-f1690d7b5624"
      unitRef="usd">239471000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzEzLTMtMS0xLTA_594cfe32-3168-4b24-9eea-879adbeed08c"
      unitRef="usd">215419000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE0LTEtMS0xLTA_0dc19ba9-e340-4034-a617-3ff2b6bc901e"
      unitRef="usd">214351000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE0LTMtMS0xLTA_9b8b4d6b-b839-43b2-bab7-64796743a246"
      unitRef="usd">187724000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE1LTEtMS0xLTA_e50d7d33-fdd0-41f8-bb5c-bfef485a362e"
      unitRef="usd">25120000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE1LTMtMS0xLTA_13fce361-cab5-4dfc-955b-a17a98d6afee"
      unitRef="usd">27695000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE3LTEtMS0xLTA_549cde03-8140-4800-abf8-c274bf48d6b6"
      unitRef="usd">14321000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE3LTMtMS0xLTA_d3cda8f8-704e-4eb3-8c21-d05040587627"
      unitRef="usd">13609000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE4LTEtMS0xLTA_5564280d-bcec-4ad6-9440-6e5a30875aa4"
      unitRef="usd">17510000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzE4LTMtMS0xLTA_76cdd903-4560-497c-849f-3f8a73e1e6ee"
      unitRef="usd">20656000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzIwLTEtMS0xLTA_eb42a51a-1d1a-4190-ba3f-583fe2b03301"
      unitRef="usd">31831000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzIwLTMtMS0xLTA_446ba377-5803-4c7e-94f7-3935103ea0c4"
      unitRef="usd">34265000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzIxLTEtMS0xLTA_41befb91-c5c5-43ed-8171-0ff752141332"
      unitRef="usd">6711000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTo1ZWM3NjNhMGJiMjc0ZmRjYWY4MDU5ZDlkZjhkNWIxNS90YWJsZXJhbmdlOjVlYzc2M2EwYmIyNzRmZGNhZjgwNTlkOWRmOGQ1YjE1XzIxLTMtMS0xLTA_f29e9121-9790-47da-b693-8459bfe3838b"
      unitRef="usd">6570000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i7b08863acefe4d8ca8e10ed1322fc31b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzItMS0xLTEtNjc3Ng_49ea02ad-d0c5-4231-853c-9acb90455e58"
      unitRef="usd">474000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i0470d6b5a9684856b669c0c4cd5d041f_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzItMy0xLTEtNjc3Ng_43744302-6bad-4da8-b27f-e177a73421b1"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzMtMS0xLTEtNjc3Ng_24078e8e-72a6-4167-88cd-0d8ae73cfa2f"
      unitRef="usd">7185000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzMtMy0xLTEtNjc3Ng_d422effc-2cc3-43c2-9214-042d7decad89"
      unitRef="usd">6570000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzQtMS0xLTEtNjc3Ng_38795168-a011-4ebf-82ec-881d15df84e5"
      unitRef="usd">6711000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTpmZWZmMGQxODU4NjQ0NDM0OGFmY2EzYWYwY2IyNmYxNi90YWJsZXJhbmdlOmZlZmYwZDE4NTg2NDQ0MzQ4YWZjYTNhZjBjYjI2ZjE2XzQtMy0xLTEtNjc3Ng_894b930e-ddfc-4306-bc0d-c3c6718dad32"
      unitRef="usd">6570000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI0NDQ_9aca500f-b64f-4f35-86e4-48d4ae3cb5ba"
      unitRef="usd">26600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI0NDg_013dd1cc-8f96-412d-9428-add07ce5de8c"
      unitRef="usd">29600000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI0NTU_2a6fd790-ac3e-4dfc-b230-d411ed8bc54e"
      unitRef="usd">45300000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI2MjI_bb571e16-221a-4131-b583-8d6dbac4d522"
      unitRef="usd">622600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzI2Mjk_3db99109-9041-42af-9d7e-7200f9244457"
      unitRef="usd">261700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="ia9b4e0c3f43d4338ab8fc2ce3ffce740_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzMwMjk_02da88a5-4911-444a-9137-31e62b12d77e"
      unitRef="usd">145900000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzMxNDI_7039ea4a-dbe9-4bc5-96e2-7bd98a0cd6ce"
      unitRef="usd">21900000</sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal>
    <sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzMxNDk_55cd5827-4ae5-435d-9436-d20ebde9dbae"
      unitRef="usd">18300000</sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzYxNDE_0418de03-3ebf-4860-a9c9-edde8626ccd5"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90ZXh0cmVnaW9uOmYzNzhmMjEzODlkZTRiMGE5MWYyZmQwNTU1ZWRlNjY5XzY1MjQ_5d9656b3-2389-4025-b37a-e1ba7ed669d0">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.243%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.631%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions based on tax positions related to the current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reductions for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzItMS0xLTEtMA_7148699a-7d0e-4815-b332-1b5b3ef5cb16"
      unitRef="usd">11630000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzItMy0xLTEtMA_5a54184b-ecef-4808-a5c6-39577938edc0"
      unitRef="usd">6288000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i1099157ecec044679915cbcb253acd13_I20171231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzItNS0xLTEtMA_9fc5b329-5a5e-401b-bd75-5c56d140f360"
      unitRef="usd">5659000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzMtMS0xLTEtMA_ffb43e01-a8db-4b3b-9408-73205c1704dd"
      unitRef="usd">2834000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzMtMy0xLTEtMA_2d93bb8f-6a1a-4e38-981a-ab82debb69e1"
      unitRef="usd">5393000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzMtNS0xLTEtMA_e6a9a3d9-8a5b-4467-bbd0-cfc3d5609841"
      unitRef="usd">636000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzQtMS0xLTEtMA_80e8a4d6-8fac-4a68-85a8-cd4b5a032218"
      unitRef="usd">1982000</sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzQtMy0xLTEtMA_e779faf8-0277-46c0-a711-5d34ae9ecf64"
      unitRef="usd">0</sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzQtNS0xLTEtMA_fcbd491a-a465-4c0f-a090-d6968d2c95ef"
      unitRef="usd">0</sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzUtMS0xLTEtMA_1e785925-88ab-40da-bddf-ca34e7a1d8be"
      unitRef="usd">3554000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i4e809eab377149b09fdf7f3e0331209b_D20190101-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzUtMy0xLTEtMA_fcd8233d-ca67-4f68-87ab-462e7897bb85"
      unitRef="usd">51000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i28ce6efd8d9f4cd4b8843db9eca524b9_D20180101-20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzUtNS0xLTEtMA_31932c24-39a8-48cf-8e59-661def204a6a"
      unitRef="usd">7000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="id3b91f3cd3c1451a8c20a0625df26f83_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzYtMS0xLTEtMA_022bf952-5339-4e80-b5bd-8717fa0bc1a2"
      unitRef="usd">12892000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i9d614d3fc8d0454b92de5bfcfd33999d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzYtMy0xLTEtMA_218c468d-63f6-4d0c-9335-b5a17c0bb007"
      unitRef="usd">11630000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjQvZnJhZzpmMzc4ZjIxMzg5ZGU0YjBhOTFmMmZkMDU1NWVkZTY2OS90YWJsZTplNDYzMDMzMDRkMjQ0MDdiOGE0YTkwNzFjY2NhNjBkOS90YWJsZXJhbmdlOmU0NjMwMzMwNGQyNDQwN2I4YTRhOTA3MWNjY2E2MGQ5XzYtNS0xLTEtMA_4c445f35-3731-426f-be14-6844910e2f4a"
      unitRef="usd">6288000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzI1OQ_e1129744-6c26-4649-a65f-4c10d6861e66">RELATED PARTY TRANSACTIONThe Company acquired 185,400 and 52,700 vested free shares from a former executive of Sangamo, pursuant to the exercise of the Free Shares Options for approximately $0.4&#160;million and $0.1&#160;million of cash, during the years ended December&#160;31, 2020 and 2019, respectively.</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="i84d0b5985441420eb3dbc496787e07aa_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzEwOTk1MTE2MjgwNjM_c9149f70-8898-4e37-901b-64e915f3c868"
      unitRef="shares">185400</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <sgmo:BusinessAcquisitionNumberOfSharesAcquired
      contextRef="id6374baea04443699a67c6e73111ae5d_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzEwOTk1MTE2MjgyMTU_a1b30433-3af8-4c79-b8e5-5e31790005c1"
      unitRef="shares">52700</sgmo:BusinessAcquisitionNumberOfSharesAcquired>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i84d0b5985441420eb3dbc496787e07aa_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzEwOTk1MTE2MjgxMjA_db99e0ab-3ad3-4096-906d-151eff45298b"
      unitRef="usd">400000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="id6374baea04443699a67c6e73111ae5d_D20190101-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMjcvZnJhZzphNTQwNjgyNDUyZGE0YmNhYWIzNmRlZmZhOWVjODFmNi90ZXh0cmVnaW9uOmE1NDA2ODI0NTJkYTRiY2FhYjM2ZGVmZmE5ZWM4MWY2XzEwOTk1MTE2MjgyMzA_eadc2842-0bf8-4b39-8be0-3671718fa2e7"
      unitRef="usd">100000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:QuarterlyFinancialInformationTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90ZXh0cmVnaW9uOmE1ODY5NjRiZmFlODQ0NmJhODEyNzVkYWVkMThhMTJlXzUxMg_217bcef7-271b-463e-8c95-374e754848c3">QUARTERLY FINANCIAL DATA (UNAUDITED)&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2020. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90ZXh0cmVnaW9uOmE1ODY5NjRiZmFlODQ0NmJhODEyNzVkYWVkMThhMTJlXzUxMw_e47c3e97-6f47-430e-bea5-888767f4d491">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2020. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.164%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Q4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;69,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,974)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,965)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,508)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,675)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,203)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,356)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,361)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to non-controlling interest&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(61)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net (loss) income attributable to Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,913)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35,929)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,550)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40,604)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.37)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.01)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.41)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMS0xLTEtMA_063cfe4b-3bd1-493e-994a-32713db95f0c"
      unitRef="usd">13076000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMy0xLTEtMA_f2f9af31-5232-498b-abf4-34582c3734c1"
      unitRef="usd">21553000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItNS0xLTEtMA_f845c80e-4551-49ae-86b5-cdf450574f12"
      unitRef="usd">57763000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItNy0xLTEtMA_68e3d6b9-3cfc-4192-ba09-7c14ee1386aa"
      unitRef="usd">25800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItOS0xLTEtMA_ad191302-0df0-48da-878b-e366a4bb3fc1"
      unitRef="usd">8071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMTEtMS0xLTA_a3b32d88-a435-4247-bf85-2071b2e228f4"
      unitRef="usd">17548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMTMtMS0xLTA_25574157-54c7-4a48-a165-ade8b89d21dd"
      unitRef="usd">21958000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzItMTUtMS0xLTA_f220b52a-6b6a-480e-b80e-d68f69cfa774"
      unitRef="usd">54851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingExpenses
      contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMS0xLTEtMA_e8e4dd82-420a-4113-b447-a0d9143dfdea"
      unitRef="usd">57598000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMy0xLTEtMA_f5736fe7-d62b-4513-917e-ca970159a3a8"
      unitRef="usd">59450000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtNS0xLTEtMA_a84d4ca3-e10b-40d1-8efe-b5f670c202d3"
      unitRef="usd">61464000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtNy0xLTEtMA_8eb57bfb-6929-4b37-9a7a-c238c35ebc35"
      unitRef="usd">69232000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtOS0xLTEtMA_0bd9d9af-709e-4f2f-b5c2-a149e98dda02"
      unitRef="usd">51968000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMTEtMS0xLTA_c5ab3fdb-cb72-475e-8b4e-6450c09d9438"
      unitRef="usd">51052000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMTMtMS0xLTA_1014b03e-bae6-442b-9d60-d16c688b467b"
      unitRef="usd">51206000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzMtMTUtMS0xLTA_992f4c81-61bc-47e1-a302-1b73203ccec7"
      unitRef="usd">53382000</us-gaap:OperatingExpenses>
    <us-gaap:ProfitLoss
      contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMS0xLTEtMA_a887488a-060a-42be-a5ce-bd57a66d2d29"
      unitRef="usd">-42974000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMy0xLTEtMA_009a219a-b195-488a-909b-5cfff01220e1"
      unitRef="usd">-35965000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtNS0xLTEtMA_d9a6aa38-94aa-4ed0-86f1-d758de577866"
      unitRef="usd">-1508000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtNy0xLTEtMA_ce4a9f03-7fb8-470c-afdf-4403e7443e75"
      unitRef="usd">-40675000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtOS0xLTEtMA_a6818b25-2472-4cea-b673-80cd914b677b"
      unitRef="usd">-42203000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMTEtMS0xLTA_2e600102-cf50-42a5-808e-26aaf916a33c"
      unitRef="usd">-30356000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMTMtMS0xLTA_88aa08ea-6cb1-4642-91ae-8bb5fb8a3954"
      unitRef="usd">-27361000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzQtMTUtMS0xLTA_59d52605-0270-4a26-b7f1-bb2043a60b2c"
      unitRef="usd">4501000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMS0xLTEtMA_02e82e90-642c-4272-b65e-87b08aabaf7e"
      unitRef="usd">-61000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMy0xLTEtMA_215c8add-94aa-441b-82c6-65e501275803"
      unitRef="usd">-36000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtNS0xLTEtMA_9b26a3a6-e264-48ff-9f76-980944c3679e"
      unitRef="usd">42000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtNy0xLTEtMA_92716a50-6086-430d-9269-6dd8ca95923d"
      unitRef="usd">-71000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtOS0xLTEtMA_928c23e8-4333-4261-8905-f1dd3faab100"
      unitRef="usd">-53000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMTEtMS0xLTA_43071d34-5133-4093-83bf-3d74e2bb6972"
      unitRef="usd">-72000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMTMtMS0xLTA_d9e2f4cc-70fe-4d1a-903a-96c8323884a5"
      unitRef="usd">-54000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzUtMTUtMS0xLTA_bf5df110-f286-4931-bd1b-8cece07208a4"
      unitRef="usd">-54000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMS0xLTEtMA_6a7d6cbd-3e2e-43f5-b8ed-1fac6c768fdf"
      unitRef="usd">-42913000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMy0xLTEtMA_12c5081d-9484-4304-b997-f172131bb7c1"
      unitRef="usd">-35929000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtNS0xLTEtMA_13a65313-307e-4427-a5a8-530c76c15e42"
      unitRef="usd">-1550000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtNy0xLTEtMA_c718968c-6ab9-43ec-bbbf-5d0cc2271d88"
      unitRef="usd">-40604000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtOS0xLTEtMA_c3dd59f4-8286-479d-867b-b3090d1eb2f0"
      unitRef="usd">-42150000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMTEtMS0xLTA_dc028808-88d0-458c-bf09-d3bb9e0ef017"
      unitRef="usd">-30284000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMTMtMS0xLTA_e16f8809-578a-499a-841d-8eb8826cb9a4"
      unitRef="usd">-27307000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzYtMTUtMS0xLTA_993f22f2-46ed-4838-8b57-698b28debd6c"
      unitRef="usd">4555000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="iaa91e56d3f3c44d7a579dccc8b03a417_D20200101-20200331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMS0xLTEtMA_fd509cf3-2642-4558-ae85-e6eb3d63e7cf"
      unitRef="usdPerShare">-0.37</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i951c6e4b27144bdfa7e68c6b8a2b85d7_D20200401-20200630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMy0xLTEtMA_3b1e1fa2-6c19-44aa-9ef7-32da169eb115"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i19c0587e2f324a668f2e6ea8dccc72f4_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctNS0xLTEtMA_5cf08e64-62db-4ad3-943a-eebdc2aee4a8"
      unitRef="usdPerShare">-0.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i915d7a150498418da35f6b4f9e547a02_D20201001-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctNy0xLTEtMA_3d58f38d-9a4f-4247-a317-aa7675c70d2e"
      unitRef="usdPerShare">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="if83f07dd5cfc4bd6a5b16c42e9e2d73a_D20190101-20190331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctOS0xLTEtMA_e38a4e11-a36f-4d35-b34a-c0af5effa2e0"
      unitRef="usdPerShare">-0.41</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="i92bddd8b771a4fa9854e9398137505a1_D20190401-20190630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMTEtMS0xLTA_20a36e3b-9399-4d15-a759-8d1a5d01e4f4"
      unitRef="usdPerShare">-0.26</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="icc35b287b11a4550a840d31a17f848d1_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMTMtMS0xLTA_665a54fd-a721-4f55-bb23-f528f4c40012"
      unitRef="usdPerShare">-0.24</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="ie02c1e2f0f114ac6994b9809d10679c2_D20191001-20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzAvZnJhZzphNTg2OTY0YmZhZTg0NDZiYTgxMjc1ZGFlZDE4YTEyZS90YWJsZTpmODMxODljM2E4YmM0NTMyOTAyZDg1NzczZmJiZjM3NS90YWJsZXJhbmdlOmY4MzE4OWMzYThiYzQ1MzI5MDJkODU3NzNmYmJmMzc1XzctMTUtMS0xLTA_3a67972a-ae85-44ee-9647-de912c300f65"
      unitRef="usdPerShare">0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzMvZnJhZzozOWQzNzA2ZWU3Y2I0YjY1YWY5ZTMzNTQyMzliMmI1MS90ZXh0cmVnaW9uOjM5ZDM3MDZlZTdjYjRiNjVhZjllMzM1NDIzOWIyYjUxXzY0NjA_322984f2-69a9-49bf-a648-58e3e261fd32">SUBSEQUENT EVENTSIn the first quarter of 2021 through February 19, 2021, the Company sold 1,034,762 shares of its common stock for gross proceeds of approximately $16.1&#160;million from an at-the-market offering program under an Open Market Sale Agreement&#x2120; with Jefferies dated August 5, 2020. After deducting sales commissions and expenses, net cash proceeds through February 19, 2021 under the at-the-market offering are approximately $15.7&#160;million.</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i48f4d381b117429fa8a27a467285b605_D20210101-20210219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzMvZnJhZzozOWQzNzA2ZWU3Y2I0YjY1YWY5ZTMzNTQyMzliMmI1MS90ZXh0cmVnaW9uOjM5ZDM3MDZlZTdjYjRiNjVhZjllMzM1NDIzOWIyYjUxXzEwOTk1MTE2NDIzNjU_f6bdcf82-5a4c-41f6-b5ad-62b719adc213"
      unitRef="shares">1034762</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sgmo:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i48f4d381b117429fa8a27a467285b605_D20210101-20210219"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzMvZnJhZzozOWQzNzA2ZWU3Y2I0YjY1YWY5ZTMzNTQyMzliMmI1MS90ZXh0cmVnaW9uOjM5ZDM3MDZlZTdjYjRiNjVhZjllMzM1NDIzOWIyYjUxXzEwOTk1MTE2NDIzNzM_9fc63c2d-8c70-4cef-b5fa-8d0b60423178"
      unitRef="usd">16100000</sgmo:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i48f4d381b117429fa8a27a467285b605_D20210101-20210219"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMzMvZnJhZzozOWQzNzA2ZWU3Y2I0YjY1YWY5ZTMzNTQyMzliMmI1MS90ZXh0cmVnaW9uOjM5ZDM3MDZlZTdjYjRiNjVhZjllMzM1NDIzOWIyYjUxXzEwOTk1MTE2NDIzODk_742009bc-a9ac-45aa-8ddc-1110017286b5"
      unitRef="usd">15700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061182155160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 19, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">68-0359556<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7000 Marina Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">970-6000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.01&#160;per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,262,431,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,251,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Certain information required by Part III, Items 10-14 of this Form 10-K is incorporated by reference to the registrant&#8217;s definitive Proxy Statement for the 2021 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">.</span><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061182459256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 131,329<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">510,094<span></span>
</td>
<td class="nump">282,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">1,035<span></span>
</td>
<td class="nump">682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">5,224<span></span>
</td>
<td class="nump">36,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,986<span></span>
</td>
<td class="nump">5,408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">659,668<span></span>
</td>
<td class="nump">405,473<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">50,530<span></span>
</td>
<td class="nump">21,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">41,324<span></span>
</td>
<td class="nump">29,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">58,128<span></span>
</td>
<td class="nump">53,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">42,798<span></span>
</td>
<td class="nump">39,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">71,045<span></span>
</td>
<td class="nump">77,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">13,557<span></span>
</td>
<td class="nump">9,067<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">938,550<span></span>
</td>
<td class="nump">637,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">12,553<span></span>
</td>
<td class="nump">6,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">18,612<span></span>
</td>
<td class="nump">10,885<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">20,738<span></span>
</td>
<td class="nump">13,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenues</a></td>
<td class="nump">91,644<span></span>
</td>
<td class="nump">38,711<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">143,547<span></span>
</td>
<td class="nump">69,872<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">245,045<span></span>
</td>
<td class="nump">81,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">38,396<span></span>
</td>
<td class="nump">41,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income tax</a></td>
<td class="nump">7,185<span></span>
</td>
<td class="nump">6,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">7,011<span></span>
</td>
<td class="nump">5,711<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">441,184<span></span>
</td>
<td class="nump">204,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, $0.01 par value, 5,000,000 shares authorized, and no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 320,000,000 shares authorized, 142,063,203 and 115,972,708 shares issued and outstanding at December 31, 2020 and 2019, respectively</a></td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">1,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,269,375<span></span>
</td>
<td class="nump">1,090,828<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(777,981)<span></span>
</td>
<td class="num">(656,985)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">5,419<span></span>
</td>
<td class="num">(2,449)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Sangamo Therapeutics, Inc. stockholders&#8217; equity</a></td>
<td class="nump">498,234<span></span>
</td>
<td class="nump">432,554<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="num">(868)<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">497,366<span></span>
</td>
<td class="nump">432,739<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 938,550<span></span>
</td>
<td class="nump">$ 637,516<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061260430472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">320,000,000<span></span>
</td>
<td class="nump">320,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">142,063,203<span></span>
</td>
<td class="nump">115,972,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">142,063,203<span></span>
</td>
<td class="nump">115,972,708<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061267117192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 118,192<span></span>
</td>
<td class="nump">$ 102,428<span></span>
</td>
<td class="nump">$ 84,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">180,647<span></span>
</td>
<td class="nump">145,922<span></span>
</td>
<td class="nump">114,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">67,097<span></span>
</td>
<td class="nump">61,686<span></span>
</td>
<td class="nump">46,736<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">247,744<span></span>
</td>
<td class="nump">207,608<span></span>
</td>
<td class="nump">161,602<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(129,552)<span></span>
</td>
<td class="num">(105,180)<span></span>
</td>
<td class="num">(77,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">8,775<span></span>
</td>
<td class="nump">9,761<span></span>
</td>
<td class="nump">8,261<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(120,777)<span></span>
</td>
<td class="num">(95,419)<span></span>
</td>
<td class="num">(68,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(345)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(121,122)<span></span>
</td>
<td class="num">(95,419)<span></span>
</td>
<td class="num">(68,889)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Sangamo Therapeutics, Inc. stockholders</a></td>
<td class="num">$ (120,996)<span></span>
</td>
<td class="num">$ (95,186)<span></span>
</td>
<td class="num">$ (68,334)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)</a></td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)</a></td>
<td class="nump">134,449<span></span>
</td>
<td class="nump">112,114<span></span>
</td>
<td class="nump">96,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061182291816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (121,122)<span></span>
</td>
<td class="num">$ (95,419)<span></span>
</td>
<td class="num">$ (68,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">8,345<span></span>
</td>
<td class="num">(1,573)<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension losses</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized (loss) gain on marketable securities, net of tax</a></td>
<td class="num">(284)<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">(113,254)<span></span>
</td>
<td class="num">(96,428)<span></span>
</td>
<td class="num">(70,062)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive loss attributable to non-controlling interest</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(574)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss attributable to Sangamo Therapeutics, Inc.</a></td>
<td class="num">$ (113,128)<span></span>
</td>
<td class="num">$ (96,195)<span></span>
</td>
<td class="num">$ (69,488)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061188839848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Cumulative Effect, Period of Adoption, Adjustment</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th">
<div>Accumulated Deficit </div>
<div>Cumulative Effect, Period of Adoption, Adjustment</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Non- Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,598,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balances at Dec. 31, 2017</a></td>
<td class="nump">$ 187,900<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 682,809<span></span>
</td>
<td class="num">$ (495,479)<span></span>
</td>
<td class="nump">$ 1,117<span></span>
</td>
<td class="num">$ (286)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,103,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">$ 14,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">14,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">328,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 1,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,156,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">215,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">215,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">14,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination', window );">Non-controlling interest upon acquisition of Sangamo France</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,129)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension losses</a></td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(68,889)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,187,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Dec. 31, 2018</a></td>
<td class="nump">$ 367,257<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="nump">$ 1,022<span></span>
</td>
<td class="nump">929,632<span></span>
</td>
<td class="num">(562,696)<span></span>
</td>
<td class="nump">$ 897<span></span>
</td>
<td class="num">(1,440)<span></span>
</td>
<td class="nump">739<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201409Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">885,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">$ 3,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">3,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">249,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">249,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 2,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">136,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">136,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs related to Sangamo France acquisition</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="num">(1,573)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,573)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension losses</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (95,419)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95,186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Dec. 31, 2019</a></td>
<td class="nump">115,972,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,972,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Dec. 31, 2019</a></td>
<td class="nump">$ 432,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,160<span></span>
</td>
<td class="nump">1,090,828<span></span>
</td>
<td class="num">(656,985)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,449)<span></span>
</td>
<td class="nump">185<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingStandardsUpdateExtensibleList', window );">Accounting Standards Update [Extensible List]</a></td>
<td class="text">us-gaap:AccountingStandardsUpdate201801Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,395,956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">$ 8,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">8,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">274,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 2,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">2,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">142,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 244<span></span>
</td>
<td class="nump">142,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">25,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest', window );">Acquisition of additional shares of Sangamo France</a></td>
<td class="num">(927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(927)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustment</a></td>
<td class="nump">8,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net pension losses</a></td>
<td class="num">(193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized loss on marketable securities, net of tax</a></td>
<td class="num">(284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(284)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (121,122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances (in shares) at Dec. 31, 2020</a></td>
<td class="nump">142,063,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,063,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balances at Dec. 31, 2020</a></td>
<td class="nump">$ 497,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,421<span></span>
</td>
<td class="nump">$ 1,269,375<span></span>
</td>
<td class="num">$ (777,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,419<span></span>
</td>
<td class="num">$ (868)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital acquisition of non-controlling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingStandardsUpdateExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates amendment to accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 24: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingStandardsUpdateExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183520776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (121,122)<span></span>
</td>
<td class="num">$ (95,419)<span></span>
</td>
<td class="num">$ (68,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,682<span></span>
</td>
<td class="nump">3,930<span></span>
</td>
<td class="nump">2,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of discount on marketable securities</a></td>
<td class="num">(825)<span></span>
</td>
<td class="num">(4,708)<span></span>
</td>
<td class="num">(5,829)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets', window );">Amortization and other changes in right-of-use assets</a></td>
<td class="num">(7,687)<span></span>
</td>
<td class="num">(5,677)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GainOnFreeShares', window );">Gain on free shares</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net loss on disposal of property and equipment</a></td>
<td class="nump">222<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">25,708<span></span>
</td>
<td class="nump">19,330<span></span>
</td>
<td class="nump">14,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Net loss on lease termination</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeases', window );">Build-to-suit leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="num">(353)<span></span>
</td>
<td class="num">(307)<span></span>
</td>
<td class="num">(135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">31,685<span></span>
</td>
<td class="num">(32,236)<span></span>
</td>
<td class="num">(1,330)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(10,411)<span></span>
</td>
<td class="num">(6,660)<span></span>
</td>
<td class="num">(2,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and other accrued liabilities</a></td>
<td class="nump">10,703<span></span>
</td>
<td class="num">(4,192)<span></span>
</td>
<td class="num">(6,372)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">6,877<span></span>
</td>
<td class="nump">4,129<span></span>
</td>
<td class="nump">2,604<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenues</a></td>
<td class="nump">216,546<span></span>
</td>
<td class="num">(35,693)<span></span>
</td>
<td class="nump">99,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities', window );">Long-term portion of lease liabilities</a></td>
<td class="num">(3,761)<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">3,749<span></span>
</td>
<td class="nump">1,963<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">169,875<span></span>
</td>
<td class="num">(144,402)<span></span>
</td>
<td class="nump">36,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(75,647)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(570,779)<span></span>
</td>
<td class="num">(443,711)<span></span>
</td>
<td class="num">(451,239)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">314,570<span></span>
</td>
<td class="nump">404,847<span></span>
</td>
<td class="nump">391,845<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(14,714)<span></span>
</td>
<td class="num">(20,675)<span></span>
</td>
<td class="num">(43,065)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Purchase of additional Sangamo France shares</a></td>
<td class="num">(704)<span></span>
</td>
<td class="num">(262)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(271,627)<span></span>
</td>
<td class="num">(59,801)<span></span>
</td>
<td class="num">(178,106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136,308<span></span>
</td>
<td class="nump">215,758<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts', window );">Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs</a></td>
<td class="nump">142,526<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(765)<span></span>
</td>
<td class="num">(422)<span></span>
</td>
<td class="num">(254)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">2,015<span></span>
</td>
<td class="nump">2,044<span></span>
</td>
<td class="nump">1,484<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from exercise of stock options and restricted stock units</a></td>
<td class="nump">9,324<span></span>
</td>
<td class="nump">4,099<span></span>
</td>
<td class="nump">14,721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">153,100<span></span>
</td>
<td class="nump">142,029<span></span>
</td>
<td class="nump">231,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(447)<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">50,901<span></span>
</td>
<td class="num">(61,990)<span></span>
</td>
<td class="nump">90,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">81,928<span></span>
</td>
<td class="nump">143,918<span></span>
</td>
<td class="nump">53,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">132,829<span></span>
</td>
<td class="nump">81,928<span></span>
</td>
<td class="nump">143,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition', window );">Non-controlling interest for acquisition</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">1,333<span></span>
</td>
<td class="nump">31,291<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_PropertyAndEquipmentMember', window );">Property and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in unpaid liabilities</a></td>
<td class="nump">4,569<span></span>
</td>
<td class="nump">2,114<span></span>
</td>
<td class="nump">4,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=sgmo_BuildToSuitLeaseMember', window );">Build-to-Suit Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental cash flow disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in unpaid liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,950<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AmortizationAndOtherChangesInRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization And Other Changes In Right-of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AmortizationAndOtherChangesInRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BuildToSuitLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build to suit leases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BuildToSuitLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GainOnFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain On Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GainOnFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Long Term Portion Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or part noncash non-controlling interest acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock, Net Of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121604053&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_PropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_PropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=sgmo_BuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=sgmo_BuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061177642392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo Therapeutics, Inc. (&#8220;Sangamo&#8221; or &#8220;the Company&#8221;) was incorporated in the State of Delaware in June 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017. Sangamo is a clinical-stage genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients with serious diseases using its platform technologies in gene therapy, cell therapy and genome engineering. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S.&#160;GAAP&#8221;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Management&#8217;s Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is currently working on a number of long-term development projects that involve experimental technologies. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and marketable securities as of December&#160;31, 2020, when combined with additional capital raises and expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next 12&#160;months from the date these Consolidated Financial Statements are issued. Sangamo will require substantial additional financial resources to complete the development and commercialization of its product candidates. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, including the estimated fair value of common shares issued as part of the transaction price, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#8220;Sanofi&#8221;) and Pfizer Inc. (&#8220;Pfizer&#8221;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $8.9&#160;million, decreased net loss by $8.9&#160;million and decreased the Company&#8217;s basic net loss per share by $0.06 for the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, the Company recorded adjustments to revenue related to a change in estimate in connection with the giroctocogene fitelparvovec collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;). This change in estimate was driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $5.7&#160;million, decreased net loss by $5.7&#160;million and decreased the Company&#8217;s basic net loss per share by $0.05 for the year ended December&#160;31, 2019.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi Genzyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as it fulfills its performance obligations. The Company&#8217;s performance obligations are satisfied over time (i.e., stand ready obligations) or using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts. As of December&#160;31, 2020, no impairment of goodwill or indefinite-lived intangible assets was identified.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Valuation of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset. As of December&#160;31, 2020, no impairment of any long-lived assets was identified.</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.</span></div><div style="margin-top:15pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cash, deposits in demand money market accounts, and commercial paper.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Restricted cash consists of a letter of credit for $1.5&#160;million as a deposit for the Brisbane lease.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:3pt;margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Marketable Securities</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments with high credit ratings which are expected to bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities and issuers of investments to the extent recorded on the Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug (&#8220;IND&#8221;) application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers was interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTY1MDM_37296027-8590-4fe0-b3ed-3ef8d7731671">three</span> to five years. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, materials and supplies and overhead allocations consisting of various support and facility-related costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#8220;RSUs&#8221;) and employee stock purchases related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#8217;s Consolidated Financial Statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within other accrued liabilities on its Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on January 1, 2019, using the modified retrospective approach with a cumulative-effect adjustment. The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Foreign Currency Translation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Consolidated Statements of Operations.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders. Stock options and RSUs outstanding and ESPP shares reserved for issuance as of December&#160;31, 2020, 2019 and 2018 were 14,237,871, 10,750,550, and 9,048,793, respectively.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting. As of December&#160;31, 2020 and 2019, substantially all of the Company&#8217;s assets were maintained in the United States. For the years ended December&#160;31, 2020, 2019 and 2018, substantially all of the Company&#8217;s revenues and operating expenses were generated and incurred in the United States.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2018-18&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill Impairment Testing</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2017-04&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December 15, 2019. ASU 2017-04 required the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Credit Losses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326) (&#8220;ASU 2016-13&#8221;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes &#8211; Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). The guidance removes exceptions to the general principles in Income Taxes (Topic 740) for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on the Company's Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cloud Computing Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other-Internal Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2018-15&#8221;). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance becomes effective for annual reporting periods beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard on January 1, 2020 using the prospective method. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179383704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text">FAIR VALUE MEASUREMENT<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents, marketable securities and the free shares asset.&#160;The accounting guidance establishes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value as follows:</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">i.e.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> supported by little or no market activity).</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Equivalents and Marketable Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally classifies its marketable securities and some cash equivalents as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Free Shares Asset</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the July&#160;20, 2018 Share Purchase Agreement (&#8220;Sangamo France SPA&#8221;) to acquire Sangamo France (see Note 5 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisition of Sangamo France</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), the Company entered into arrangements with the holders of approximately 477,000 &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option). The Company initially recorded a liability of $0.2&#160;million on the acquisition date. The put options were classified within Level&#160;3 of the fair value hierarchy as the Company utilized a binomial-lattice pricing model (the &#8220;Monte Carlo simulation model&#8221;) that involved certain market conditions to estimate the fair value of the options. The assumptions used in this simulation model are reviewed on a quarterly basis and adjusted, as needed. Subsequent changes in the fair value of the free shares are recorded in general and administrative expenses in the Consolidated Statements of Operations. The Company purchased approximately 111,000 and 322,000 shares during 2019 and 2020 respectively, of the 477,000 total free shares for a cash payment of approximately $0.3&#160;million and $0.7&#160;million respectively, upon exercise of the put options. As of December&#160;31, 2020, approximately 44,000 free shares remain outstanding and subject to purchase by the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the free shares&#8217; asset was approximately $0.2&#160;million at December 31, 2019. The Company recognized a gain due to an increase in the fair value of the free shares of approximately $0.1&#160;million for the year ended December&#160;31, 2020, offset by approximately $0.2&#160;million for the shares purchased during the year, resulting in an asset balance of approximately $0.1&#160;million at December&#160;31, 2020.</span></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.684%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free Shares valuation assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR/ USD exchange rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated correlation Sangamo and Sangamo France stock prices</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD) volatility estimate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR) volatility estimate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR/ USD exchange rate volatility estimate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate and cost of debt by expected exercise date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179197208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Cash Equivalents and Marketable Securities</a></td>
<td class="text">CASH EQUIVALENTS AND MARKETABLE SECURITIES<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,740&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,494&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,495&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,368&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,493&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,373&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,530&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,832&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no realized losses from the sale of marketable securities for the years ended December&#160;31, 2020, 2019 or 2018. No investments were other-than-temporarily impaired at either December&#160;31, 2020 or 2019. The Company considers factors such as the duration, the magnitude and the reason for the decline in value, the potential recovery period, creditworthiness of the issuers of the securities and its intent to sell. For marketable securities, it also considers whether (i) it is more likely than not that the Company will be required to sell the debt securities before recovery of their amortized cost basis, and (ii) the amortized cost basis cannot be recovered as a result of credit losses. No significant facts or circumstances have arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. Based on the Company&#8217;s review of these securities, including the assessment of the duration and severity of the unrealized losses and the Company&#8217;s ability and intent to hold the investments until maturity, there were no other-than-temporary impairments for these marketable securities at December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061177920424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Major Customers, Partnerships and Strategic Alliances</a></td>
<td class="text">MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Agreements</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Institutes for BioMedical Research, Inc. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 27, 2020, the Company entered into a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc. (&#8220;Novartis&#8221;) for the research, development and commercialization of gene regulation therapies to treat three neurodevelopmental disorders. Under the agreement, which was effective upon execution, the Company granted Novartis an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain of its zinc finger protein (&#8220;ZFP&#8221;) transcription factors (&#8220;ZFP-TFs&#8221;) targeted to three undisclosed genes that are associated with certain neurodevelopmental disorders, including autism spectrum disorder and intellectual disability. The Company performs early research activities over the collaboration period for each gene target and manufacture the ZPF-TFs required for such research, costs of which will be funded by Novartis. Novartis is responsible for additional research activities, investigational new drug-enabling studies, clinical development, regulatory approvals, manufacturing of preclinical, clinical and approved products, and global commercialization. Subject to certain exceptions set forth in the agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product targeting any of the three genes that are the subject of the collaboration. Novartis also has the option to license certain of the Company&#8217;s proprietary adeno-associated viruses (&#8220;AAVs&#8221;) for the sole purpose of developing, manufacturing and commercializing licensed products arising from the collaboration.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, Novartis paid the Company a $75.0&#160;million upfront license fee in August 2020. In addition to this fee and the cost reimbursements for early research activities, the Company is eligible to earn from Novartis up to $420.0&#160;million in development milestones and up to $300.0&#160;million in commercial milestones. The Company is also eligible to earn from Novartis tiered high single-digit to sub-teen double-digit royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments will be subject to reduction due to patent expiration, loss of market exclusivity and payments made under certain licenses for third-party intellectual property. The agreement will continue, on a product-by-product and country-by-country basis, until the expiration of the applicable royalty term. Novartis has the right to terminate the agreement, in its entirety or on a target-by-target basis, for any reason after a specified notice period. Each party also has the right to terminate the agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All payments received under the agreement, when earned, are non-refundable and non-creditable. The transaction price of $95.1&#160;million includes the upfront license fee of $75.0&#160;million and estimated research costs of $20.1&#160;million for identified research projects over the estimated research period. None of the development and commercial milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Novartis in accordance with ASC Topic 606 and concluded that Novartis is a customer. The Company has identified a single performance obligation within this arrangement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Novartis apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing research services through the estimated research period. The estimation of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its performance obligation. As of December&#160;31, 2020, the Company had deferred revenue of $70.9&#160;million related to the upfront license fee received.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $4.1&#160;million of upfront license fee and $1.1&#160;million research reimbursement costs as revenue related to the Novartis agreement during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $1.5&#160;million for financial advisory fees related to the Novartis collaboration and license agreement during the year ended December&#160;31, 2020, equal to 2% of $75.0&#160;million received for the upfront license fee related to the collaboration and license agreement with Novartis. The Company recognized this $1.5&#160;million as a contract asset as such amount represents a cost of obtaining the agreement. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Novartis in accordance with ASC Topic 340, Other Assets and Deferred Costs. The Company amortized $0.1&#160;million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biogen MA, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020, the Company entered into a collaboration and license agreement with Biogen MA, Inc. (&#8220;BIMA&#8221;) and Biogen International GmbH (together with BIMA, &#8220;Biogen&#8221;) for the research, development and commercialization of gene </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulation therapies for the treatment of neurological diseases. The Company and Biogen plan to leverage the Company&#8217;s proprietary ZFP technology delivered via AAV to modulate expression of key genes involved in neurological diseases. Concurrently with the execution of the collaboration agreement, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase 24,420,157 shares of the Company&#8217;s common stock (the &#8220;Biogen Shares&#8221;), at a price per share of $9.2137, for an aggregate purchase price of approximately $225.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement became effective in April 2020 following the termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and satisfaction of other customary closing conditions, including the payment of $225.0&#160;million for the purchase of the Biogen Shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, Biogen paid the Company an upfront license fee of $125.0&#160;million in May 2020. The Company is also eligible to receive research, development, regulatory and commercial milestone payments that could total up to approximately $2.37&#160;billion if Biogen selects all of the targets allowed under the agreement and all the specified milestones set forth in the agreement are achieved, which includes up to $925.0&#160;million in pre-approval milestone payments and up to $1.45&#160;billion in first commercial sale and other sales-based milestone payments. In addition, the Company is also eligible to receive tiered high single-digit to sub-teen royalties on potential net commercial sales of licensed products arising from the collaboration. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the collaboration agreement, the Company granted to Biogen an exclusive, royalty bearing and worldwide license, under its relevant patents and know-how, to develop, manufacture and commercialize certain ZFP and/or AAV-based products directed to up to 12 neurological disease gene targets selected by Biogen. Biogen has already selected three of these: ST-501 for tauopathies including Alzheimer&#8217;s disease, ST-502 for synucleinopathies including Parkinson&#8217;s disease, and a third undisclosed neuromuscular disease target. Biogen has exclusive rights to nominate up to nine additional targets over a target selection period of five years. For each gene target selected by Biogen, the Company performs early research activities, costs for which are shared by the companies, aimed at the development of the combination of proprietary central nervous system delivery vectors and ZFP-TFs (or potential other ZFP products) targeting therapeutically relevant genes. Biogen has assumed responsibility and costs for the IND enabling studies, clinical development, related regulatory interactions, and global commercialization. The Company is responsible for manufacturing activities for the initial clinical trials for the first three products of the collaboration and plans to leverage its in-house manufacturing capacity, where appropriate, which is currently in development. Biogen is responsible for manufacturing activities beyond the first clinical trial for each of the first three products. The Company&#8217;s research activities for any targets will be performed over the period not to exceed seven years from the effective date of the agreement (i.e., through April 2027). Subject to certain exceptions set forth in the collaboration agreement, the Company is prohibited from developing, manufacturing or commercializing any therapeutic product directed to the targets selected by Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collaboration agreement continues on a product-by-product and country-by-country basis until the expiration of all applicable royalty terms. Biogen has the right to terminate the collaboration agreement, in its entirety or on target-by-target basis, for any reason after a specified notice period, and also has the right to replace up to 10 targets. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach. In addition, the Company may terminate the collaboration agreement if Biogen challenges any patents licensed by the Company to Biogen.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the stock purchase agreement, Biogen has agreed not to, without the Company&#8217;s prior written consent and subject to specified conditions and exceptions, directly or indirectly acquire shares of the Company&#8217;s outstanding common stock, seek or propose a tender or exchange offer or merger between the parties, solicit proxies or consents with respect to any matter, or undertake other specified actions related to the potential acquisition of additional equity interests in the Company. Such standstill restrictions expire on the earlier of the three-year anniversary of the effectiveness of the collaboration agreement and the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The stock purchase agreement also provides that until the first anniversary of the effectiveness of the collaboration agreement, Biogen will hold and not sell any of the Biogen Shares and from the first anniversary through the second anniversary, Biogen will hold and not sell at least 50% of the Biogen Shares, in addition to being subject to certain volume limitations. The stock purchase agreement further provides that, subject to certain limitations, until such time as all remaining Biogen Shares may be sold pursuant to Rule 144 promulgated under the Securities Exchange Act of 1933, as amended, within a 90-day period, Biogen may request the Company to register for resale any of the Biogen Shares on a registration statement to be filed with the Securities and Exchange Commission.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Biogen has agreed that, excluding specified extraordinary matters, it will vote the Biogen Shares in accordance with the Company&#8217;s recommendation and has granted the Company an irrevocable proxy with respect to the foregoing. Such voting provisions expire on the earlier of (i) the two-year anniversary of the effectiveness of the collaboration agreement, (ii) the date that Biogen beneficially owns less than 5% of the Company&#8217;s common stock and (iii) the date the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration agreement is terminated; provided, however, that in no event shall such expiration date be prior to the one-year anniversary of the effectiveness of the collaboration agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the collaboration agreement with Biogen in accordance with ASC Topic 606 and concluded that Biogen is a customer. As of December&#160;31, 2020, the transaction price includes the upfront license fee of $125.0&#160;million and the excess consideration from the stock purchase of $79.6&#160;million, which represents the difference between the $225.0&#160;million received for the purchase of the Biogen Shares and the $145.4&#160;million estimated fair value of the equity issued. The equity issued to Biogen was valued using an option pricing model to reflect certain holding period restrictions. None of the target selection fees and clinical or regulatory milestones have been included in the transaction price, as all such amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that nomination of additional targets and achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified a single performance obligation within the Biogen collaboration agreement, which is a stand-ready obligation consisting of a series of distinct days of research services, during which Biogen obtains access to the Company&#8217;s license and research resources. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services corresponding to the targets selected by Biogen. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the upfront license fee and the excess consideration from the stock purchase will be recognized over time on a straight-line basis consistent with the resources expected to be dedicated to providing the research services through April 2027, the estimated period of the obligation. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverable. Revenue from the reimbursement by Biogen of shared costs of early research activities performed by Sangamo is recognized as the research services are performed. As of December&#160;31, 2020, the Company had deferred revenue of $183.2&#160;million related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $21.4&#160;million of upfront license fee and the excess consideration from the stock purchase, and $6.5&#160;million research reimbursement costs as revenue related to the Biogen agreement during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company paid $7.0&#160;million for financial advisory fees during the year ended December&#160;31, 2020, equal to 2% of $225.0&#160;million received for the sale of shares and 2% of $125.0&#160;million received for the upfront fee. The fees incurred related to both the collaboration agreement with Biogen and to the stock purchase agreement for the sale of shares. The Company believes that the allocation of fees on a relative fair value basis between the two agreements is reasonable. The Company recognized $4.1&#160;million, which represents 2% of the upfront license fee of $125.0&#160;million and 2% of the excess consideration from the stock purchase of $79.6&#160;million, as a contract asset. This balance will be amortized and included in general and administrative costs on a systematic basis consistent with the transfer of the services to Biogen in accordance with ASC Topic 340, Other Assets and Deferred Costs. The Company amortized $0.4&#160;million during the year ended December&#160;31, 2020. The Company recognized $2.9&#160;million, which represents 2% of the $145.4&#160;million estimated fair value of the equity issued, as a share issuance cost and recorded this amount in equity as reduction in proceeds during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Kite Pharma, Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, the Company entered into a global collaboration and license agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), which became effective on April 5, 2018, and was amended and restated in September 2019, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, Sangamo is working together with Kite on a research program under which the companies are designing zinc finger nucleases (&#8220;ZFNs&#8221;) and viral vectors to disrupt and insert certain genes in T cells and natural killer cells (&#8220;NK-cells&#8221;) including the insertion of genes that encode chimeric antigen receptors (&#8220;CARs&#8221;), T cell receptors (&#8220;TCRs&#8221;), and NK-cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets. Kite is responsible for all clinical development and commercialization of any resulting products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Kite an exclusive, royalty-bearing, worldwide sublicensable license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> using selected ZFNs and viral vectors developed under the research program to express CARs, TCRs or NKRs directed to candidate targets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the research program term and subject to certain exceptions, except pursuant to this agreement, the Company is prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, the Company will be prohibited from developing, manufacturing and commercializing, for the purpose of </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treating cancer, any cell therapy product that, as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ex vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> genome editing, expresses a CAR, TCR or NKR that is directed to a candidate target.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the effective date, in April 2018, the Company received a $150.0&#160;million upfront payment from Kite. In addition, Kite will reimburse the Company&#8217;s direct costs to conduct service under the joint research program provisions of the agreement, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. Sangamo is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01&#160;billion if all of the specified milestones in this agreement are achieved.&#160;Of this amount, approximately $1.26&#160;billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75&#160;billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i)&#160;only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first 10 times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event. In addition, the Company will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of licensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initial research term of the agreement is six years. Kite has an option to extend the research term for up to two additional one-year periods for a separate fee of $10.0&#160;million per year. All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. In connection with the amendment and restatement of the agreement in September 2019, the Company entered into a new research plan with Kite, with estimated reimbursable service costs of approximately $3.4&#160;million. The Company concluded the transaction price under this agreement is $189.3&#160;million and includes the upfront license fee of $150.0&#160;million and $39.3&#160;million estimated reimbursable service costs for identified research projects over the estimated performance period. The Company concluded that the estimated fees for the presumed exercise of the research term extension options and all milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the development and sales-based milestone payments have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Kite in accordance with ASC Topic 606 and concluded that Kite is a customer. Kite has the right to terminate this agreement, in its entirety or on a per licensed product or per candidate target basis, for any reason after a specified notice period. Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the primary performance obligations within the Kite agreement as: (1) a license to the technology along with the stand-ready obligation to perform research services, and (2) the ongoing research services. Revenue from the upfront license fee relates to access to the license and Company&#8217;s obligation to stand-ready to perform such research services as additional targets are selected by Kite. As a result of this obligation to perform research services when and if requested throughout the duration of the contract, the fee for the license and the stand-ready obligation will be recognized over time on a straight-line basis through June 2024, the estimated period of the stand-ready obligation. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December&#160;31, 2020, and 2019 the Company had deferred revenue of $81.4&#160;million and $106.5&#160;million, respectively, related to this agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"/><td style="width:58.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.004%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,608&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:15pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Inc.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Giroctocogene Fitelparvovec Global Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2017, the Company entered into an exclusive, global collaboration and license agreement with Pfizer, pursuant to which it established a collaboration for the research, development and commercialization of giroctocogene fitelparvovec, its gene therapy product candidate for hemophilia A, and closely related products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this agreement, the Company is responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for giroctocogene fitelparvovec, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of giroctocogene fitelparvovec. Sangamo may also collaborate in the research and development of additional AAV based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company originally received an upfront fee of $70.0&#160;million and is eligible to receive up to $208.5&#160;million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and up to $266.5&#160;million in payments upon first commercial sale milestones for giroctocogene fitelparvovec and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in the giroctocogene fitelparvovec Pfizer agreement, is up to $475.0&#160;million, which includes up to $300.0&#160;million for giroctocogene fitelparvovec and up to $175.0&#160;million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer agreed to pay the Company royalties for each potential licensed product developed under the agreement based on an escalating tiered, double-digit percentage of the annual net sales of such product. These royalties are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third-party intellectual property. To date, two milestones of $55.0&#160;million in aggregate have been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the giroctocogene fitelparvovec Pfizer agreement.</span></div><div style="margin-bottom:10pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. As of December&#160;31, 2020, the total transaction price under this agreement is $134.0&#160;million, which represents the upfront and research services fees of $79.0&#160;million and two unconstrained milestones achieved of an aggregate amount of $55.0&#160;million. Sangamo is responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met. None of the constrained clinical or regulatory milestones have been included in the transaction price, as all such milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of the agreement, the Company granted Pfizer an exclusive worldwide royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by the Company for the purpose of developing, manufacturing and commercializing giroctocogene fitelparvovec and related products. Pfizer granted the Company a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture the Company&#8217;s products that utilize the AAV delivery system. During a specified period, neither the Company nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the product in a country, (ii)&#160;the expiration of regulatory exclusivity for a product in a country, and (iii)&#160;15 years after the first commercial sale of a product in a country. Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec and related products will automatically terminate. Upon termination by the Company for cause or by Pfizer in any country or countries, Pfizer will automatically grant the Company an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize giroctocogene fitelparvovec in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified one performance obligation within the giroctocogene fitelparvovec Pfizer agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete, as it does not have stand-alone value to Pfizer apart from the research services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services through 2020, the estimated period the Company will perform research services. The estimate of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. The Company satisfied the deliverables and research services responsibilities within the arrangement which were completed in December 2020. As a result, the Company recognized the remaining deferred revenue from the upfront payment in December 2020. As of December&#160;31, 2019, the Company had deferred revenue of $4.0&#160;million related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company entered into an amendment to the collaboration agreement, pursuant to which the Company transferred the IND for giroctocogene fitelparvovec to Pfizer. Upon this transfer the Company achieved a $25.0&#160;million milestone as the conditions for achieving the milestone were met. The cumulative revenue recognized in connection with this milestone was $25.0&#160;million as of December&#160;31, 2020 and included $1.3&#160;million recognized during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company determined that there was a high probability of achievement of a $30.0&#160;million milestone with Pfizer for giroctocogene fitelparvovec. The milestone was subsequently achieved upon dosing of the first subject in a Phase 3 clinical trial in early October 2020. The cumulative revenue recognized in connection with this milestone was $30.0&#160;million during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:57.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.964%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Pfizer giroctocogene fitelparvovec agreement:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee and research services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,810&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company updated its estimated project cost and related revenues under this program. This adjustment was a direct result of the increase in project scope during the first quarter of 2019 and the corresponding costs, which resulted in a decrease in the measure of proportional performance. In December 2019, the Company updated its estimated project cost and related revenues upon transfer of the IND for giroctocogene fitelparvovec to Pfizer. This adjustment was a direct result of the decrease in project scope during the fourth quarter of 2019 and the corresponding costs, which resulted in an increase in the measure of proportional performance. During the year ended December 31, 2019, the Company recognized $15.7&#160;million in revenues related to the Pfizer giroctocogene fitelparvovec agreement, which included approximately $8.7&#160;million acceleration in revenues recorded in the three months ended December 31, 2019 related to the updated estimated project cost, offset by approximately $3.0&#160;million reduction in revenues recorded in the three months ended March&#160;31, 2019 related to the updated estimated project cost.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the giroctocogene fitelparvovec collaboration agreement with Pfizer. This adjustment was a direct result of the decision to decrease the project scope and the corresponding costs, after the successful IND transfer of the giroctocogene fitelparvovec product candidate to Pfizer, both of which resulted in an increase in the measure of proportional cumulative performance. This adjustment increased revenue by $2.4&#160;million, decreased net loss by $2.4&#160;million and decreased the Company&#8217;s basic net loss per share by $0.02 for year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">C9ORF72 Research Collaboration and License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a separate exclusive, global collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat amyotrophic lateral sclerosis (&#8220;ALS&#8221;) and frontotemporal lobar degeneration (&#8220;FTLD&#8221;) linked to mutations of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. Pursuant to this agreement, the Company agreed to work with Pfizer on a research program to identify, characterize and preclinically develop ZFP-TFs that bind to and specifically reduce expression of the mutant form of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the terms of this agreement, the Company granted Pfizer an exclusive, royalty-bearing, worldwide license under the Company&#8217;s relevant patents and know-how to develop, manufacture and commercialize gene therapy products that use resulting ZFP-TFs that satisfy pre-agreed criteria. During a specified period, neither the Company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2 gene.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the agreement has a term that continues on a per licensed product and per country basis until the later of (i)&#160;the expiration of patent claims that cover the licensed product in a country, (ii)&#160;the expiration of regulatory exclusivity for a licensed product in a country, and (iii)&#160;15 years after the first commercial sale of a licensed product in a major </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market country. Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party. The agreement will also terminate if the Company is unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time. Upon termination for any reason, the license granted by the Company to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate. Upon termination by the Company for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, the Company will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following termination by the Company for Pfizer&#8217;s material breach, Pfizer will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gene for a period of time. Following termination by Pfizer for the Company&#8217;s material breach, the Company will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene for a period of time.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received a $12.0&#160;million upfront payment from Pfizer and is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay the Company royalties based on an escalating tiered, mid- to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products. To date, a milestone of $5.0&#160;million has been achieved and paid, however no products have been approved and therefore no royalty fees have been earned under the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pfizer agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Pfizer in accordance with ASC Topic 606 and concluded that Pfizer is a customer. The Company concluded the total transaction price under this agreement is $17.0&#160;million, which represents the upfront fee of $12.0&#160;million and one unconstrained milestone in the amount of $5.0&#160;million. None of the constrained clinical or regulatory milestones have been included in the transaction price. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-evaluate the transaction price, including its estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has identified the performance obligation within this agreement as a license to the technology and ongoing research services. The Company concluded that the license is not discrete as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services over the estimated period the Company will perform research services. The estimation of progress towards the satisfaction of its performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. The Company satisfied the deliverables and research services responsibilities within the arrangement which were completed in September 2020. As a result, the Company recognized the remaining deferred revenue from the upfront payment in September 2020. As of December&#160;31, 2019, the Company had deferred revenue of $8.0&#160;million related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company earned a $5.0&#160;million milestone associated with the completion of the Company&#8217;s research activities in its collaboration with Pfizer to develop genome regulation therapies using ZFP-TFs for the treatment of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-related ALS and frontotemporal lobar degeneration. This milestone was achieved upon Pfizer&#8217;s notification to the Company of its election to pay the first development milestone payment under the collaboration agreement. This milestone payment is non-refundable, and the Company recognized on a cumulative basis $5.0&#160;million for the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Pfizer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> agreement:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,985&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimate in connection with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collaboration agreement with Pfizer. These adjustments were a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. These adjustments increased revenue by $8.8&#160;million, decreased net loss by $8.8&#160;million and decreased the Company&#8217;s basic net loss per share by $0.06 for the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sanofi Genzyme</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2014, the Company entered into an exclusive worldwide collaboration and license agreement with Bioverativ Inc., (now Sanofi Genzyme, a global business unit of Sanofi S.A. (&#8220;Sanofi&#8221;)), to develop therapeutics for hemoglobinopathies, focused on beta thalassemia and sickle cell disease (&#8220;SCD&#8221;). The agreement was originally signed with BIMA, who subsequently assigned it to Bioverativ Inc., which was later acquired by Sanofi. Under the agreement, the Company is jointly conducting two research programs: the beta thalassemia program and the SCD program. In the beta thalassemia program, the Company is responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both programs, Sanofi is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Sanofi has the right to step in and take over any of the Company&#8217;s remaining activities. Furthermore, the Company has an option to co-promote in the U.S. any licensed products to treat beta thalassemia and SCD developed under the agreement, and Sanofi will compensate the Company for such co-promotion activities. Subject to the terms of the agreement, the Company has granted Sanofi an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by the Company for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. The Company also granted Sanofi a non-exclusive worldwide, royalty-free fully paid license with the right to grant sublicenses, under the Company&#8217;s interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, the Company is not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the agreement, the Company received an upfront license fee of $20.0&#160;million and is eligible to receive up to $115.8&#160;million in payments upon the achievement of specified clinical development and regulatory milestones, as well as up to $160.5&#160;million in payments upon the achievement of specified sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is up to $276.3&#160;million. In addition, the Company will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. Sanofi reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. To date, a $6.0&#160;million milestone has been achieved related to ST-400 for beta thalassemia and another $7.5&#160;million milestone has been achieved related to SCD, however no products have been approved and therefore no royalty fees have been earned under the Sanofi agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement may be terminated by (i)&#160;the Company or Sanofi for the uncured material breach of the other party, (ii)&#160;the Company or Sanofi for the bankruptcy or other insolvency proceeding of the other party; (iii)&#160;Sanofi, upon 180 days&#8217; advance written notice to the Company and (iv)&#160;Sanofi, for certain safety reasons upon written notice to, and after consultation with, the Company. As a result, actual future milestone payments could be lower than the amounts stated above.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All contingent payments under the agreement, when earned, will be non-refundable and non-creditable. The transaction price as of December&#160;31, 2020 of $93.3&#160;million includes the upfront license fee of $20.0&#160;million, two unconstrained milestones of $13.5&#160;million and estimated research costs of $59.8&#160;million for identified research projects over the estimated performance period, as all unachieved milestone amounts are fully constrained. As part of its evaluation of the constraint, the Company considered numerous factors, including the fact that achievement of the milestones at this time is uncertain and contingent upon future periods when the uncertainty related to the variable consideration is resolved. The Company will re-</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. None of the constrained clinical or regulatory milestones have been included in the transaction price.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Sanofi in accordance with ASC Topic 606 and concluded that Sanofi is a customer. The Company has identified the performance obligations within this arrangement as a license to the technology and ongoing research services activities. The Company concluded that the license is not discrete as it does not have stand-alone value to Sanofi apart from the research services to be performed pursuant to the agreement. As a result, the Company recognizes revenue from the upfront payment based on proportional performance of the ongoing services through 2022, the estimated period the Company will perform research services. The estimate of progress towards the satisfaction of performance obligation and project cost is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. Revenue from the reimbursable costs related to the integrated service deliverable is recognized as the research services are performed. Related costs and expenses under these arrangements have historically approximated the revenues recognized. As of December&#160;31, 2020 and 2019, the Company had deferred revenue of $1.2&#160;million and $1.7&#160;million, respectively, related to this agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company achieved a $6.0 million milestone with Sanofi upon dosing of the third subject in the ST-400 beta thalassemia Phase 1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $5.8&#160;million as of December&#160;31, 2020 and included $0.1&#160;million recognized during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the Company achieved a $7.5 million milestone with Sanofi upon dosing of the first subject in the SCD Phase 1 clinical trial. The cumulative revenue recognized in connection with this milestone was approximately $7.2&#160;million as of December&#160;31, 2020 and included $0.1&#160;million recognized during the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company recorded an adjustment to revenue related to a change in estimate in connection with the collaboration agreement with Sanofi. This adjustment was a direct result of the decision in March 2020 to increase the project scope and the corresponding costs, both of which resulted in a decrease in the measure of proportional cumulative performance. This adjustment decreased revenue by $2.2&#160;million, increased net loss by $2.2&#160;million and increased the Company&#8217;s basic net loss per share by $0.02 for the year ended December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">California Institute for Regenerative Medicine</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, the California Institute for Regenerative Medicine (&#8220;CIRM&#8221;) granted a Strategic Partnership Award for $8.0&#160;million to fund the clinical studies of a potentially curative ZFP therapeutic for the treatment of beta thalassemia based on the application of Sangamo&#8217;s ZFN genome editing technology. The grant exists through December&#160;31, 2022 and provides matching funds to support the evaluate ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta&#160;thalassemia. As of December&#160;31, 2020, the Company had received $5.2&#160;million under the award.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the CIRM grants, the Company is obligated to pay royalties and licensing fees based on a low single digit royalty percentage on net sales of CIRM-funded product candidates or CIRM-funded technology. The Company has the option to decline any and all amounts awarded by CIRM and as an alternative to revenue sharing, the Company has the option to convert the award to a loan. No such election has been made as of the date of the issuance of these Consolidated Financial Statements. In the event that the Company terminates a CIRM-funded clinical trial, it will be obligated to repay the remaining CIRM funds on hand. As of December&#160;31, 2020 and 2019, $6.4&#160;million and $5.7&#160;million, respectively, including accrued interest, related to this award is recorded as a loan in other non-current liabilities on the Consolidated Balance Sheets.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amended Collaboration and License Agreement with Takeda</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2012, the Company entered into a collaboration and license agreement with Shire International GmbH, a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;), to research, develop and commercialize a ZFP therapeutic for treating Huntington&#8217;s disease. The Company received an upfront license fee of $13.0&#160;million in 2012 and </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized a $1.0&#160;million milestone payment in 2014. Takeda does not have any milestone payment obligations, but is required to pay single digit percentage royalties to the Company, up to a specified maximum cap, on the commercial sales of therapeutic products for Huntington&#8217;s disease. The Company is required to pay single digit percentage royalties to Takeda, up to a specified maximum cap, on commercial sales of therapeutic products from programs returned under the original agreement (which include blood clotting Factors VIII and IX) that use two zinc fingers.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the agreement, the Company granted Takeda an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use the Company&#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the huntingtin gene (&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene&#8221;). During the term of the agreement, the Company is not permitted to research, develop or commercialize, outside of the agreement, certain products that target the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HTT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> gene. The agreement may be terminated by (i)&#160;the Company or Takeda, in whole or in part, for the uncured material breach of the other party, (ii)&#160;the Company or Takeda for the bankruptcy or other insolvency proceeding of the other party and (iii)&#160;Takeda, in its entirety, effective upon at least 90 days&#8217; advance written notice.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the agreement with Takeda in accordance with ASC Topic 606 and concluded that Takeda is a customer. The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Takeda apart from the research services to be performed pursuant to the Takeda agreement. The Company satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. As a result, the Company recognized the remaining $2.3&#160;million of deferred revenue from the upfront payment during the year ended December 31, 2017.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not recognize any revenues under the Takeda agreement for the years ended December&#160;31, 2020, 2019 and 2018.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement with Sigma-Aldrich Corporation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2007, Sangamo entered into a license agreement with Sigma-Aldrich Corporation (&#8220;Sigma&#8221;) to provide Sigma with access to Sangamo&#8217;s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to Dow AgroSciences LLC (&#8220;DAS&#8221;), a wholly-owned subsidiary of Dow Chemical Company. Sangamo developed laboratory research reagents using its ZFP technology over a three-year research services period. Sangamo has since transferred the ZFP manufacturing technology to Sigma.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0&#160;million consisting of a $4.9&#160;million purchase of 636,133 shares of Sangamo common stock, valued at $4.9&#160;million, and a $15.1&#160;million upfront license fee. Sangamo is also eligible to receive commercial license fees of $5.0&#160;million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones, Sigma will make milestone payments to Sangamo up to an aggregate of $25.0&#160;million. Sangamo does not have additional ongoing performance obligations under the agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement with Sigma for the years ended December&#160;31, 2020, 2019 and 2018, were $0.5&#160;million, $0.6&#160;million and $0.5&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Agreement with DAS</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2005, Sangamo entered into an exclusive commercial license with DAS, with an initial three-year research term. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP-TFs or ZFNs into humans or animals for diagnostic, therapeutic or prophylactic purposes. In 2008, DAS exercised its option and obtained a commercial license to sell products incorporating or derived from plant cells generated using the Company&#8217;s ZFP technology. The exercise of the option triggered a one-time commercial license fee of $6.0&#160;million, payment of the remaining $2.3&#160;million of the previously agreed upon $4.0&#160;million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#8217;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010, the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December&#160;31, 2012.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $0.3&#160;million to $3.0&#160;million and total $25.3&#160;million </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">over 11 years. The Company has identified the performance obligation within this arrangement as a license to the technology. In the event of any termination of the agreement, all rights to use the Company&#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo&#8217;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#8217;s ZFP technology.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the agreement with DAS were $3.0&#160;million, $3.0&#160;million, and $3.0&#160;million during 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179939288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Sangamo France<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition of Sangamo France</a></td>
<td class="text">ACQUISITION OF SANGAMO FRANCE<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July&#160;20, 2018, Sangamo entered into various agreements with the goal of eventually acquiring 100% of Sangamo France&#8217;s share capital. The Company entered into the Sangamo France SPA with certain shareholders of Sangamo France, pursuant to which it acquired 13,519,036 ordinary shares of Sangamo France (&#8220;Ordinary Shares&#8221;) as part of a block transaction that closed on October&#160;1, 2018 (the &#8220;Acquisition Date&#8221;). Additionally, the Company and Sangamo France entered into a Tender Offer Agreement pursuant to which Sangamo agreed to acquire 11,528,635 Ordinary Shares for the same price per share as the Sangamo France SPA via a cash tender offer that closed on November&#160;23, 2018. Following the block transaction, cash tender offer, and other open market purchases of shares, the Company owned 98.2% of the Ordinary Shares as of December&#160;31, 2018 (or 25,047,671 Ordinary Shares). In addition to the Sangamo France SPA and the tender offer agreement, the Company also entered into arrangements with the holders of approximately 477,000 &#8220;free shares&#8221; of Sangamo France pursuant to which the Company has the right to purchase such shares from the holders (a call option) and such holders have the right to sell to the Company such shares from time to time through mid-2021 (a put option) (collectively the &#8220;Free Shares Options&#8221;). During 2019, the Company acquired approximately 111,000 vested free shares, increasing its ownership of the Ordinary Shares from 98.2% to 98.7%. During 2020, the Company acquired approximately 322,000 vested free shares, pursuant to the exercise of the put options for approximately $0.7&#160;million of cash, increasing its ownership of the Ordinary Shares to 99.8% as of December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Acquisition Date, the fair value of the Free Shares Options was estimated to be a liability of $0.2&#160;million. See Note 2 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Free Shares Asset</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for information regarding the valuation method. The fair value of the Free Shares Options will vary based on future changes in the Company&#8217;s stock price during the option period. The fair value of the Free Shares Options was estimated to be an asset of $0.1&#160;million as of December&#160;31, 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisition of Sangamo France was accounted for as a business combination in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in exchange for total consideration of approximately $45.9&#160;million at the Acquisition Date. The operating results of Sangamo France after the Acquisition Date have been included in the Company&#8217;s Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no goodwill impairment during the years ended December&#160;31, 2020, 2019 or 2018 and, as noted below, substantially all of the non-controlling interest on the Acquisition Date was subsequently acquired by the Company and, accordingly, substantially all of the goodwill is allocated to the Company as of December&#160;31, 2020 and 2019.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-controlling Interest</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the remaining non-controlling interest was determined based on the number of outstanding shares comprising the non-controlling interest and the $2.99 acquisition price per share as of the Acquisition Date. The non-controlling interest is presented as a component of stockholders&#8217; equity on the Company&#8217;s Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest as of December&#160;31, 2020 was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of additional shares acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(927)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179937976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Other Balance Sheet Details</a></td>
<td class="text">OTHER BALANCE SHEET DETAILS<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,681)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense was $5.7&#160;million in 2020, $3.9&#160;million in 2019 and $2.4&#160;million in 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in intangible assets were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in goodwill were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Accrued Liabilities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer advance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liabilities &#8211; current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,612&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,885&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061177892760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo occupies approximately 87,700 square feet of office and research and development laboratory facilities in Brisbane, California pursuant to a lease that expires in May 2029. Sangamo also occupies approximately 54,200 square feet of research and office space in Richmond, California, pursuant to leases that expire in August 2026. In addition, the Company </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">leases approximately 20,800 square feet of office, and research and development space in Valbonne, France, subject to leases that expire beginning in June 2025 through March 2028.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company entered into an amendment to an existing lease to acquire approximately 8,500 square feet of research and office space in Richmond, California that expires in August 2026. Total lease payments over the life of this amended lease are approximately $1.6&#160;million. Variable lease payments include the Company&#8217;s allocated share of costs incurred and expenditures made by the landlord in the operation and management of the building. The amended lease was effective October 1, 2020, and the Company recorded a lease liability and corresponding ROU asset of $1.3&#160;million upon inception of this amended lease. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of these leases also include renewal options at the election of the Company to renew or extend the lease for an additional <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml8xMDYvZnJhZzpmMDUxNzhlYWY2YjQ0NmJkOTk4MDFiMjdiMjlkOTRiYy90ZXh0cmVnaW9uOmYwNTE3OGVhZjZiNDQ2YmQ5OTgwMWIyN2IyOWQ5NGJjXzY5Mw_274e8caf-5cf0-4157-9146-6781d7736ff8">five</span> to 10 years. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company performed evaluations of its contracts and determined each of its identified leases are operating leases. For the year ended December&#160;31, 2020, the Company incurred $10.4&#160;million of lease costs included in operating expenses in the Consolidated Statement of Operations in relation to these operating leases. Variable lease expense was $2.3&#160;million for the year ended December&#160;31, 2020 and was not included in the measurement of the Company&#8217;s operating ROU assets and lease liabilities. The variable expense consists primarily of the Company&#8217;s proportionate share of operating expenses, property taxes and insurance and is classified as lease expense due to the Company&#8217;s election to not separate lease and non-lease components.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of operating lease liabilities for the year ended December&#160;31, 2020 was $6.4&#160;million and was included in net cash provided by operating activities in the Company&#8217;s Consolidated Statement of Cash Flows.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense related to lease agreements was $10.4&#160;million, $7.9&#160;million, and $2.3&#160;million for 2020, 2019 and 2018, respectively. Future minimum payments under lease obligations at December&#160;31, 2020 consist of the following (in thousands):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,086&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as of December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current (included in Other accrued liabilities on the Consolidated Balance Sheet)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, the weighted-average remaining lease term is 7.6 years and the weighted-average incremental borrowing rate used to determine the operating lease liability was 6.1% for the Company&#8217;s operating leases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any financing leases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Commitments</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total commitments </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,736&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,771&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual commitments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,507&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also had $1.0&#160;million of license obligations related to its intellectual property as of December&#160;31, 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo is not party to any material pending legal proceeding. From time to time, Sangamo may be involved in legal proceedings arising in the ordinary course of business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179937976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Certificate of Incorporation authorizes the Company to issue up to 5,000,000 shares of preferred stock, which may be issued at the discretion of the Company&#8217;s Board of Directors. As of December 31, 2020, no shares of the Company&#8217;s preferred stock have been issued or are outstanding.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, the Company&#8217;s stockholders approved an amendment to the Company&#8217;s Certificate of Incorporation to increase the total number of shares of the Company&#8217;s common stock authorized for issuance from 160,000,000 shares to 320,000,000 shares. As of December 31, 2020, 142,063,203 shares of the Company&#8217;s common stock are outstanding.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the collaboration agreement with BIMA described in Note 4 of these Consolidated Financial Statements, the Company entered into a stock purchase agreement with BIMA, pursuant to which BIMA agreed to purchase the Biogen Shares at a price per share of $9.2137, for an aggregate purchase price of $225.0&#160;million. The Company closed the sale of the Biogen Shares in April 2020.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, the Company completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 12.7&#160;million shares of its common stock at a public offering price of $11.50 per share. The net proceeds to the Company from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $136.3&#160;million.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2018, the Company completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 14.2&#160;million shares of its common stock at a public offering price of $16.25 per share. The net proceeds to the Company from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $215.8&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">At-the-Market Offering Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the Company entered into an Open Market Sale Agreement&#8480; with Jefferies LLC (&#8220;Jefferies&#8221;) with respect to an at-the-market offering program under which the Company may offer and sell, from time to time at its sole discretion, shares of the Company&#8217;s common stock having an aggregate offering price of up to $150.0&#160;million through Jefferies as the Company&#8217;s sales agent or principal. The Company is not obligated to sell any shares under the sales agreement. As of December&#160;31, 2020, no shares had been sold under the sales agreement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company&#8217;s stockholders approved the Sangamo Therapeutics, Inc. 2018 Equity Incentive Plan (the &#8220;2018 Plan&#8221;). In connection with the approval of the 2018 Plan, no additional equity awards will be granted under the previous 2013 Plan, however all outstanding equity awards under the 2013 Plan will continue to be subject to the terms and conditions as set forth in the agreements evidencing such awards and the terms of the 2013 Plan.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, the Company&#8217;s stockholders approved an amendment and restatement of the 2018 Plan, to, among other things, increase the aggregate number of shares of the Company&#8217;s common stock reserved for issuance under the 2018 Plan by 9,900,000 shares.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exercise price of a stock option granted under the 2018 Plan may not be less than 100% of the fair market value of the Company's common stock subject to the stock option on the date of grant, and the option term will not exceed 10 years. If the person to whom the stock option is granted is a 10% stockholder of the Company, and the stock option granted qualifies as an incentive stock option, then the exercise price per share will not be less than 110% of the fair market value of the Company&#8217;s common stock on the date of grant, and the option term will not exceed five years. Generally, stock options granted under the 2018 Plan vest over four years at a rate of 25% on the one-year anniversary of the date of grant and 1/48 per month thereafter and expire 10 years after the date of grant, or earlier upon termination of employment or services to the Company.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of common stock reserved for issuance under the 2018 Plan will be reduced: (i)&#160;on a 1-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&#160;by a fixed </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ratio of 1.33 shares of common stock for each share of common stock issued pursuant to a full-value award granted under the plan.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares subject to any outstanding stock options or other awards under the 2018 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those stock options or awards will be available for subsequent issuance under the 2018 Plan. Any unvested shares issued under the 2018 Plan that the Company subsequently purchases, pursuant to repurchase rights under the 2018 Plan, will be added back to the number of shares reserved for issuance under the 2018 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the ratio at which the share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the 2018 Plan.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, there were 10,942,576 shares of the Company&#8217;s common stock reserved for future awards under the Company&#8217;s 2018 Plan.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2010 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2018, the Company&#8217;s stockholders approved an amendment and restatement of the Company&#8217;s 2010 Employee Stock Purchase Plan (&#8220;the ESPP&#8221;). As amended, the ESPP provides for a total of 4.6&#160;million&#160;shares of common stock reserved for issuance thereunder. Eligible employees may purchase common stock at 85% of the lesser of the fair market value of the Company&#8217;s common stock on the first day of the applicable two-year offering period or the last day of the applicable six-month purchase period. As of December&#160;31, 2020, there were 2,483,218 shares of the Company&#8217;s common stock reserved for future issuance under the ESPP. The ESPP expired on April 30, 2020. The ongoing offering will continue through the end of its 24 months offering period ending on October 29, 2021 at which point the ESPP will be fully terminated.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Activity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:47.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise per<br/>Share Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,829,287&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.71&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,563,425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,162,268)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.02&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,751,746)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,478,698&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.02&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.80</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,616&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at December 31, 2020</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,478,698&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.80</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,127,517&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.71&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.48</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,025&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value of options exercised was $5.4&#160;million, $4.7&#160;million and $27.0&#160;million during 2020, 2019 and 2018, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2020, the aggregate intrinsic values of outstanding and exercisable options were $69.6 million and $29.0 million, respectively. The aggregate intrinsic value of options vested and expected to vest as of December&#160;31, 2020, 2019 and 2018 was $69.6&#160;million, $7.5&#160;million and $24.5&#160;million, respectively.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, 2019 and 2018, the Company awarded 2,517,101, 834,745, and 346,055 RSUs, respectively. The RSUs awarded in 2020, 2019 and 2018 had an average grant date fair value per award of $8.06, $9.49 and $17.87, respectively. These awards generally vest in a series of three successive equal annual installments. The aggregate fair value of RSUs vested during 2020, 2019 and 2018 was $3.7&#160;million, $2.0&#160;million and $0.6&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.351%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate&#160;Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,850&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs awarded</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517,101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs released</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324,305)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671,528&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,689&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested and expected to vest at December 31, 2020</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671,528&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RSUs that vested in 2020, 2019 and 2018 were net-share settled such that the Company withheld shares with value equivalent to the employees&#8217; minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately 90,617, 39,160, and 20,193 for 2020, 2019 and 2018, respectively, and were based on the value of the RSUs on their respective issuance dates as determined by the Company&#8217;s closing stock price. Total payments for the employees&#8217; tax obligations to taxing authorities </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.8&#160;million, $0.4&#160;million and $0.3&#160;million in 2020, 2019 and 2018, respectively and are reflected as a financing activity within the accompanying Consolidated Statements of Cash Flows.&#160;These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179939288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,523&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,135&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,249&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,708&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,330&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,677&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, total stock-based compensation expense to be recognized in future periods related to unvested stock options was $35.5&#160;million, which is expected to be expensed over a weighted-average period of 2.72 years. As of December&#160;31, 2020, total stock-based compensation expense to be recognized in future periods related to unvested RSUs was $17.1&#160;million, which is expected to be expensed over a weighted-average period of 2.07 years. There was no capitalized stock-based employee compensation expense as of December&#160;31, 2020, 2019 or 2018.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Assumptions</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee stock-based compensation expense was determined using the Black-Scholes option valuation model for stock options and employee share purchases under the ESPP. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company bases its determination of expected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average estimated fair value per share of options granted during 2020, 2019 and 2018 was $5.25, $6.37, and $11.39, respectively, based upon the assumptions used in the Black-Scholes valuation model. The assumptions used for estimating the fair value of the employee stock options were as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.418%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34-0.61%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68-2.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53-2.96%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51-5.57</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50-5.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59-5.61</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.61-80.32%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.46-78.39%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.33-75.49%</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employees purchased 274,382, 249,364 and 328,710 shares of common stock through the ESPP at an average exercise price of $7.34, $8.53, and $4.51 per share during 2020, 2019 and 2018, respectively. The weighted-average estimated fair values of shares purchased under the Company&#8217;s ESPP during 2020, 2019 and 2018 were $8.02, $4.70 and $7.07, respectively, based upon the assumptions used in the Black-Scholes valuation model.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for estimating the fair value of the ESPP purchase rights are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53-2.80%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53-2.42%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16-2.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.02-91.96%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.02-91.96%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.21-83.25%</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061178012424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">EMPLOYEE BENEFIT PLAN<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code covering all full-time employees (&#8220;Sangamo 401(k) Plan&#8221;). The Sangamo 401(k) Plan is intended to qualify under Section&#160;401 of the Internal Revenue Code.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company matched employee contributions equal to 50% for the first 8% in 2020, 2019 and 2018, up to a limit of $4,000 in 2020, 2019 and 2018. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan by the Company were $1.2&#160;million, $0.9&#160;million, and $0.8&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179428952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of loss before income taxes were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,624)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,354)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,695)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,065)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,194)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,777)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,419)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,889)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the income tax expense and the amount computed by applying the federal statutory income tax rate to loss before income taxes is explained as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:61.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,363)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,467)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,597)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,849)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Intangible Low-Taxed Income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,657)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,429)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,005)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and December 2020, in response to the COVID-19 pandemic, the CARES Act and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic. The Company does not expect any significant benefit to its income tax provision as a result of this legislation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit carryforwards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,681&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,251&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,722&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,510)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,656)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,265)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,711)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,570)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax assets and liabilities based on tax jurisdictions are presented on the Consolidated Balance Sheet as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other non-current assets on the Consolidated Balance Sheet)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,570)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,711)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,570)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the Company acquired Sangamo France. The Company recorded goodwill and intangible assets as part of accounting for the acquisition of Sangamo France. There is no corresponding tax basis for the goodwill or intangible assets. A portion of the intangible assets acquired were for the use in a particular research and development project and are considered indefinite-lived assets with no tax basis.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the fair value of the unrealized gain (loss) on marketable securities are recorded as a component of accumulated other comprehensive income (loss), net of a provision for income taxes.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. The Company regularly assesses the need for a valuation allowance against its deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that the Company&#8217;s deferred income tax assets will be realized. In evaluating the Company&#8217;s ability to recover its deferred income tax assets within the jurisdiction from which they arise, the Company considers all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. Accordingly, based upon the Company&#8217;s analysis of these factors the net deferred tax assets have been substantially offset by a valuation allowance. The valuation allowance increased by $26.6&#160;million, $29.6&#160;million and $45.3&#160;million for the years ended December&#160;31, 2020, 2019 and 2018, respectively. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2020, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $622.6&#160;million and $261.7&#160;million, respectively. The federal net operating loss generated before 2018 will begin to expire in 2024 and will keep expiring through 2037, if not utilized. Federal net operating loss generated in 2018 will carry forward indefinitely. If not utilized, the state net operating loss carryforwards will begin to expire in 2029, respectively. The Company&#8217;s French net operating loss carryforward balance is $145.9&#160;million, which carries over indefinitely. The Company </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also has federal and state research tax credit carryforwards of $21.9&#160;million and $18.3&#160;million, respectively. The federal research credits will begin to expire in 2021, while the state research credits have no expiration date. Utilization of the Company&#8217;s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before utilization.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to reinvest the earnings of its non-U.S. subsidiaries in those operations. The Company does not provide for U.S. taxes on the earnings of foreign subsidiaries because the Company intends to reinvest such earnings offshore indefinitely. However, if these funds were repatriated, the Company would be required to accrue and pay applicable U.S. taxes and withholding taxes. Due to the cumulative losses generated in foreign countries there are no earnings to repatriate.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files federal and state income tax returns with varying statutes of limitations. The tax years from 2002 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files United Kingdom and French income tax returns, and the tax years from 2008 and thereafter remain open in the United Kingdom and 2016 and thereafter in France are still subject to examination.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2020, the Company had no accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate will not be affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,630&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,659&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,892&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,630&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179868792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transaction</a></td>
<td class="text">RELATED PARTY TRANSACTIONThe Company acquired 185,400 and 52,700 vested free shares from a former executive of Sangamo, pursuant to the exercise of the Free Shares Options for approximately $0.4&#160;million and $0.1&#160;million of cash, during the years ended December&#160;31, 2020 and 2019, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061177657944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text">QUARTERLY FINANCIAL DATA (UNAUDITED)<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2020. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:23.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q4</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,076&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,553&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,763&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,071&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,548&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,958&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,851&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,968&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,974)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,965)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,675)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,203)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,356)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,361)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to non-controlling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to Sangamo Therapeutics, Inc.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,913)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,929)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,604)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,150)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,284)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,307)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,555&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179237720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTSIn the first quarter of 2021 through February 19, 2021, the Company sold 1,034,762 shares of its common stock for gross proceeds of approximately $16.1&#160;million from an at-the-market offering program under an Open Market Sale Agreement&#8480; with Jefferies dated August 5, 2020. After deducting sales commissions and expenses, net cash proceeds through February 19, 2021 under the at-the-market offering are approximately $15.7&#160;million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183224680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Consolidated Financial Statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S.&#160;GAAP&#8221;) and include the accounts of the Company and its subsidiaries. All intercompany balances and transactions have been eliminated in the Consolidated Financial Statements. For consolidated entities where the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to non-controlling interests on its Consolidated Statements of Operations equal to the percentage of the economic or ownership interest retained in such entities by the respective non-controlling parties.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. On an ongoing basis, management evaluates its estimates including critical accounting policies or estimates related to revenue recognition, including the estimated fair value of common shares issued as part of the transaction price, clinical trial accruals, fair value of assets and liabilities, including from acquisitions, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimates in connection with the collaboration agreements with Sanofi Genzyme (&#8220;Sanofi&#8221;) and Pfizer Inc. (&#8220;Pfizer&#8221;). These changes in estimates were driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance. These adjustments increased revenue by $8.9&#160;million, decreased net loss by $8.9&#160;million and decreased the Company&#8217;s basic net loss per share by $0.06 for the year ended December&#160;31, 2020.</span></div>During the year ended December 31, 2019, the Company recorded adjustments to revenue related to a change in estimate in connection with the giroctocogene fitelparvovec collaboration agreement with Pfizer Inc. (&#8220;Pfizer&#8221;). This change in estimate was driven by changes in project scope and related project costs which resulted in changes to the measure of proportional cumulative performance.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for its revenues pursuant to the provisions of Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC Topic 606&#8221;). The Company&#8217;s contract revenues are derived from collaboration agreements including licensing arrangements and research activity grants. Research and licensing agreements typically include upfront signing or license fees, cost reimbursements for research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. The Company has agreements with both fixed and variable consideration. Non-refundable upfront fees and funding of research and development activities are considered fixed, while milestone payments are generally identified as variable consideration. Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenues under research grant agreements are generally recognized when the related qualified research expenses are incurred. Deferred revenue primarily represents the portion of research or license payments received but not earned.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the appropriate amount of revenue to be recognized as the Company fulfills its obligations under its agreements, the Company performs the following steps: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations based on estimated selling prices; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. The Company&#8217;s performance obligations include license rights, development services and services associated with regulatory submission and approval processes. Revenues from research services earned under collaboration agreements are generally recognized as revenue as the related services are provided. Revenues from non-refundable upfront fees are recognized over time either by measuring progress towards satisfaction of the relevant performance obligation, using the input method (i.e., cumulative actual costs incurred relative to total estimated costs) or on a straight-line basis when a performance obligation is expected to be satisfied evenly over a period of time (or when the entity has a stand-ready obligation). Significant management judgment is required to determine the level of effort required under an arrangement, and the period over which the Company expects to complete its performance obligations under the arrangement, which may include total internal personnel costs and external costs to be incurred as well as, in certain cases, the estimated stand-ready obligation period. Changes in these estimates can have a material effect on revenue recognized. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. The Company includes the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, the Company re-evaluates the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjusts its estimate of the overall transaction price. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. The estimated period of performance and project costs, such as personnel and manufacturing cost, are reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accounting for these arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. The Company uses key assumptions to determine the stand-alone selling price, which may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success. Related costs and expenses under these arrangements have historically approximated the revenues recognized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, the Company may be exposed to credit risk generally associated with biopharmaceutical companies or specific to its collaboration agreements. To date, the Company has not experienced any losses related to these receivables.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Funds received from the Company&#8217;s collaboration partners are generally not refundable and are recorded as revenue as it fulfills its performance obligations. The Company&#8217;s performance obligations are satisfied over time (i.e., stand ready obligations) or using the input method (i.e., cumulative actual costs incurred relative to total estimated costs). Revenue is also recognized when the Company has incurred qualified research and development costs that are reimbursable from its collaboration partners and when there is reasonable assurance that such costs will be reimbursed. Any payments received from a collaboration partner in advance of the completion of the relevant performance obligation are recorded as deferred revenue.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for acquisitions using the acquisition method of accounting, which requires that assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, liabilities assumed and any non-controlling interests in the acquired target in an acquisition be recorded at their fair values as of the acquisition date on the Company&#8217;s Consolidated Balance Sheets. Any excess of purchase consideration over the fair value of net assets acquired is recorded as goodwill. The determination of estimated fair value requires the Company to make significant estimates and assumptions. As a result, the Company may record adjustments to the fair values of assets acquired and liabilities assumed within the measurement period (up to one year from the acquisition date) with the corresponding offset to goodwill. Transaction costs associated with business combinations are expensed as they are incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets</a></td>
<td class="text">Goodwill and Intangible AssetsGoodwill represents the excess of the purchase consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination. Intangible assets with indefinite useful lives are related to purchased IPR&amp;D projects and are measured at their respective fair values as of the acquisition date. Goodwill and intangible assets with indefinite useful lives are not amortized. Intangible assets related to IPR&amp;D projects are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed&#160;finite-lived&#160;and would then be amortized based on their respective estimated useful lives at that point in time. The Company tests goodwill and indefinite-lived intangible assets for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate the fair values of the assets are below their respective carrying amounts.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Valuation of Long-Lived Assets</a></td>
<td class="text">Valuation of Long-Lived AssetsLong-lived assets, including property and equipment and finite-lived intangible assets, are reviewed for impairment whenever facts or circumstances either internally or externally may suggest that the carrying value of an asset may not be recoverable. Recoverability of these assets is measured by comparison of the carrying amount of each asset to the future undiscounted cash flows expected to result from the use of the asset and its eventual disposition. If the asset is considered to be impaired, the amount of any impairment is measured as the difference between the carrying value and the fair value of the impaired asset.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities are stated at their estimated fair values. The free shares asset or liability is measured using a binomial-lattice pricing model and is reviewed each reporting period and adjusted, as needed, and is expected to approximate fair value.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted Cash<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> cash, deposits in demand money market accounts, and commercial paper.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:18pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Marketable Securities</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive loss (&#8220;AOCI&#8221;). The Company classifies those investments that are not required for use in current operations and that mature in more than 12 months as non-current marketable securities in the accompanying Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge, if material, when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on marketable securities are included in interest and other income, net, which are determined using the specific identification method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Other Risks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, and marketable securities consist of financial instruments that potentially subject the Company to a concentration of credit risk to the extent of the fair value recorded in the Consolidated Balance Sheets. The Company invests cash that is not required for immediate operating needs primarily in highly liquid instruments with high credit ratings which are expected to bear minimal risk. The Company has established policies relating to the quality, diversification, and maturities of securities to enable the Company to manage its credit risk. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, and marketable securities and issuers of investments to the extent recorded on the Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain materials and key components that the Company utilizes in its operations are obtained through single suppliers. Since the suppliers of key components and materials must be named in an investigational new drug (&#8220;IND&#8221;) application filed with the U.S. Food and Drug Administration for a product, significant delays can occur if the qualification of a new supplier is required. If delivery of material from the Company&#8217;s suppliers was interrupted for any reason, the Company may be unable to supply any of its product candidates for clinical trials.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets which is generally <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjI0NjcyZTUwMzA0NzRjMWJhOTY3M2VjMTZjMTc3NjYyL3NlYzoyNDY3MmU1MDMwNDc0YzFiYTk2NzNlYzE2YzE3NzY2Ml84OC9mcmFnOmJkYmYyNzk1MDYzMjRjM2E4MDE2NGU0MTNmYWFkNzdiL3RleHRyZWdpb246YmRiZjI3OTUwNjMyNGMzYTgwMTY0ZTQxM2ZhYWQ3N2JfMTY1MDM_37296027-8590-4fe0-b3ed-3ef8d7731671">three</span> to five years. For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, clinical studies performed by contract research organizations, materials and supplies and overhead allocations consisting of various support and facility-related costs.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">General and Administrative Expenses</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist of finance, human resources, legal and other administrative activities. These expenses consist primarily of personnel costs, including salaries, benefits and stock-based compensation, facilities and overhead costs, legal expenses, and other general and administrative costs.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (&#8220;RSUs&#8221;) and employee stock purchases related to the Employee Stock Purchase Plan (&#8220;ESPP&#8221;) based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. The Company accounts for forfeitures in the period they occur.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes a tax benefit from an&#160;uncertain&#160;tax&#160;position&#160;only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the Company&#8217;s Consolidated Financial Statements from such positions are measured based on the largest benefit that has a greater than 50% likelihood of being realized. The Company recognizes interest and penalties associated with tax matters as part of the income tax provision and includes accrued interest and penalties with the related income tax liability within other accrued liabilities on its Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company adopted the Accounting Standard Update (&#8220;ASU&#8221;) No. 2016-02, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases (Topic 842)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on January 1, 2019, using the modified retrospective approach with a cumulative-effect adjustment. The Company determines if an arrangement is or contains a lease at inception by assessing whether the arrangement contains an identified asset and whether it has the right to control the identified asset. Right-of-use (&#8220;ROU&#8221;) assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. Lease liabilities are recognized at the lease commencement date based on the present value of future lease payments over the lease term. ROU assets are based on the measurement of the lease liability and also include any lease payments made prior to or on lease commencement and exclude lease incentives and initial direct costs incurred, as applicable.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the implicit rate in the Company&#8217;s leases is generally unknown, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of remaining lease payments. The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of a lease in a similar economic environment. The Company considers its credit risk, term of the lease, and total lease payments and adjusts for the impacts of collateral, as necessary, when calculating its incremental borrowing rates. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company&#8217;s operating leases is recognized on a straight-line basis over the lease term.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has elected to not separate lease and non-lease components for its real estate and copier leases and, as a result, accounts for any lease and non-lease components as a single lease component. The Company has also elected to not apply the recognition requirement to any leases with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:174%">Foreign Currency Translation</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company&#8217;s foreign subsidiaries is primarily the Euro. Assets and liabilities denominated in foreign currencies are translated to U.S. dollars using the exchange rates at the balance sheet date. Foreign currency translation adjustments are recorded as a component of AOCI within stockholders&#8217; equity. Revenues and expenses from the Company&#8217;s foreign subsidiaries are translated using the monthly average exchange rates in effect during the period in which the transactions occur. Foreign currency transaction gains and losses are recorded in interest and other income, net, on the Company&#8217;s Consolidated Statements of Operations.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share attributable to Sangamo Therapeutics, Inc. stockholders has been computed by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders is calculated by dividing net loss attributable to Sangamo Therapeutics, Inc. stockholders by the weighted-average number of shares of common stock plus potentially dilutive securities outstanding during the period.</span></div>The total number of shares subject to stock options and RSUs outstanding and the ESPP shares reserved for issuance, which are all anti-dilutive, were excluded from consideration in the calculation of diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text">SegmentsThe Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (ASC Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2018-18&#8221;), which clarifies that certain transactions between participants in a collaborative arrangement should be accounted for under ASC Topic 606 when the counterparty is a customer. In addition, ASU 2018-18 precludes an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. ASU 2018-18 is effective for all interim and annual reporting periods beginning after December 15, 2019. On January 1, 2020, the Company adopted ASU 2018-18. The adoption of ASU 2018-18 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Goodwill Impairment Testing</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test of Goodwill Impairment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2017-04&#8221;). The new guidance simplifies the subsequent measurement of goodwill by eliminating Step 2 from the goodwill impairment test. ASU 2017-04 requires goodwill impairment to be measured as the amount by which a reporting unit&#8217;s carrying amount exceeds its fair value, not to exceed the carrying amount of its goodwill. ASU 2017-04 requires prospective application and is effective for annual periods beginning after December 15, 2019. ASU 2017-04 required the Company to amend its methodology for determining any goodwill impairment beginning in 2020. On January 1, 2020, the Company adopted ASU 2017-04. The adoption of ASU 2017-04 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Credit Losses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments &#8211; Credit Losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 326) (&#8220;ASU 2016-13&#8221;). ASU 2016-13 implements an impairment model, known as the current expected credit loss model, that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. ASU 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019 and must be adopted using a modified retrospective approach, with certain exceptions. Early adoption is permitted. On January 1, 2020, the Company adopted ASU 2016-13 by using a modified retrospective approach. The adoption of ASU 2016-13 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes &#8211; Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). The guidance removes exceptions to the general principles in Income Taxes (Topic 740) for allocating tax expense between financial statement components, accounting basis differences stemming from an ownership change in foreign investments and interim period income tax accounting for year-to-date losses that exceed projected losses. The guidance becomes effective for annual reporting periods beginning after December 15, 2020 and interim periods within those fiscal years with early adoption permitted. On January 1, 2020, the Company early adopted ASU 2019-12. The adoption of ASU 2019-12 did not have a material impact on the Company's Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cloud Computing Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the FASB issued ASU 2018-15, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles-Goodwill and Other-Internal Use Software: Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2018-15&#8221;). ASU 2018-15 aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The guidance becomes effective for annual reporting periods beginning after December 15, 2019 and interim periods within those fiscal years with early adoption permitted. The Company adopted this standard on January 1, 2020 using the prospective method. The adoption of ASU 2018-15 did not have a material impact on the Company&#8217;s Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061182879784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from major collaboration agreements and research activity grants as a percentage of total revenues were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pfizer Inc.</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kite Pharma, Inc.</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biogen MA, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sanofi Genzyme</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Novartis Institutes for BioMedical Research, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Restrictions on Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of cash, cash equivalents and restricted cash reported within the accompanying Consolidated Balance Sheets to the amounts reported within the accompanying Consolidated Statements of Cash Flows is as follows (in thousands):</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.350%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,329&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,428&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,418&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,829&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,918&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179357272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value measurements of the Company&#8217;s cash equivalents, marketable securities and the free shares asset are identified at the following levels within the fair value hierarchy (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurement </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,999&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,999&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,877&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Free shares asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Summary of Estimated Fair Value of Free Share Liability Assumptions</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"/><td style="width:72.684%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Free Shares valuation assumptions:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR/ USD exchange rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated correlation Sangamo and Sangamo France stock prices</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo stock price (USD) volatility estimate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sangamo France stock price (EUR) volatility estimate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR/ USD exchange rate volatility estimate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk free rate and cost of debt by expected exercise date</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Varies</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179189272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the Company&#8217;s cash equivalents and marketable securities (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,165&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213,533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,575&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,574&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,311&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,908&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,284&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,298&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,740&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">613,789&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,496&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,494&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,495&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,230&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,368&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government-sponsored entity debt securities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,493&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,040&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337,373&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Investments Classified by Contractual Maturity Date</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of marketable securities by contractual maturity were as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,094&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">282,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,530&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,832&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">560,624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183284872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite")</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues recognized under agreement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.076%"><tr><td style="width:1.0%"/><td style="width:58.086%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.553%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.004%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Kite agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of license and stand-ready fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,545&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,562&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,608&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,350&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,517&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember', window );">Pfizer, Giroctocogene Fitelparvovec</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues recognized under agreement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:97.368%"><tr><td style="width:1.0%"/><td style="width:57.909%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.851%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.964%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Pfizer giroctocogene fitelparvovec agreement:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee and research services</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,111&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,810&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,662&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,449&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,359&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,810&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues recognized under agreement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:59.457%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.659%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Pfizer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> agreement:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,985&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,985&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,827&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:15pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2020, the Company recorded adjustments to revenue related to changes in estimate in connection with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C9ORF72</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> collaboration agreement with Pfizer. These adjustments were a direct result of the decision to decrease the project scope and the corresponding costs due to advancement of the program, which resulted in an increase in the measure of proportional cumulative performance. These adjustments increased revenue by $8.8&#160;million, decreased net loss by $8.8&#160;million and decreased the Company&#8217;s basic net loss per share by $0.06 for the year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues recognized under agreement</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues recognized under the agreement were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related to Sanofi agreement:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognition of upfront fee</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,823&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,503&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestone achievement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,680&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,516&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179471112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Acquisition of Sangamo France (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock', window );">Summary of Non-controlling Interest</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-controlling interest as of December&#160;31, 2020 was as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of additional shares acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(927)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss attributable to non-controlling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(868)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ScheduleOfNoncontrollingInterestTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ScheduleOfNoncontrollingInterestTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179859928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consist of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,737&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,888&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Manufacturing equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,091&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,740&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,607&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,416)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,681)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,324&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,926&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in intangible assets were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,243&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,087)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,156&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in goodwill were as follows (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.823%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at beginning of year</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,044&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(771)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at end of year</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,798&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,273&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.372%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer advance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Operating lease liabilities &#8211; current</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,612&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,885&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179138232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text">Future minimum payments under lease obligations at December&#160;31, 2020 consist of the following (in thousands):&#160;<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,191&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,756&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,422&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Imputed interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,336)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,086&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported as of December 31, 2020:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - current (included in Other accrued liabilities on the Consolidated Balance Sheet)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities - long-term</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,086&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsTableTextBlock', window );">Other Commitments</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the non-cancelable material contractual commitments under manufacturing-related supplier arrangements as of December&#160;31, 2020 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.221%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.147%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.805%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.322%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Party</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total commitments </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Expiry date</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brammer Bio MA - a Thermo Fisher Scientific Inc. subsidiary</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,736&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonza Netherlands, B.V.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,771&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contractual commitments</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,507&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about obligations resulting from other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179141976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity is as follows:</span></div><div style="margin-bottom:6pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:47.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise per<br/>Share Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,829,287&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.71&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,563,425&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,162,268)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.02&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,751,746)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,478,698&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.02&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.80</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,616&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at December 31, 2020</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,478,698&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.80</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,616&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,127,517&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.71&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.48</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,025&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s RSU activity is as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.351%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.562%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual&#160;Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate&#160;Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2019</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">862,850&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs awarded</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,517,101&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs released</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(324,305)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(384,118)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs outstanding at December 31, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671,528&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,689&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs vested and expected to vest at December 31, 2020</span></td><td colspan="2" style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,671,528&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.19</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,689&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179430568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows total stock-based compensation expense recognized in the accompanying Consolidated Statements of Operations (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,523&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,135&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,249&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,195&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,428&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,708&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,330&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,677&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used for Estimating Fair Value of Employee Stock Options</a></td>
<td class="text">The assumptions used for estimating the fair value of the employee stock options were as follows:<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:55.058%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.418%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.34-0.61%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68-2.25%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.53-2.96%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51-5.57</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50-5.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59-5.61</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.61-80.32%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.46-78.39%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.33-75.49%</span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used for estimating the fair value of the ESPP purchase rights are as follows:</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.523%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53-2.80%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.53-2.42%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.16-2.80%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5-2.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield of stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.02-91.96%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.02-91.96%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.21-83.25%</span></div></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061272802456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Summary of Domestic and Foreign Components of Loss Before Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The domestic and foreign components of loss before income taxes were as follows (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(126,624)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(77,354)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65,695)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,847&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,065)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,194)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,777)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,419)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68,889)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Benefit for Income Taxes</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">819&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(474)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the income tax expense and the amount computed by applying the federal statutory income tax rate to loss before income taxes is explained as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.561%"><tr><td style="width:1.0%"/><td style="width:61.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax at federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,363)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,038)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,467)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes, net</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,168)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,597)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,849)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign rate differential</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global Intangible Low-Taxed Income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,335&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,817&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research credits</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,657)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,429)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,005)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,537&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">956&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March and December 2020, in response to the COVID-19 pandemic, the CARES Act and the Consolidated Appropriations Act, 2021 were passed into law and provide additional economic stimulus to address the impact of the COVID-19 pandemic. The Company does not expect any significant benefit to its income tax provision as a result of this legislation.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Company's Deferred Tax Assets</a></td>
<td class="text">Significant components of the Company&#8217;s deferred tax assets and liabilities are as follows (in thousands):<div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:74.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit carryforwards</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,679&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,459&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,681&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,171&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,251&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,722&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accruals and reserves</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax asset</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,471&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">215,419&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">214,351&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,724&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,695&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Liabilities:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,321)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,609)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,510)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,656)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,831)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,265)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net deferred tax liabilities</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,711)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,570)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The deferred tax assets and liabilities based on tax jurisdictions are presented on the Consolidated Balance Sheet as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.607%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.183%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (included in Other non-current assets on the Consolidated Balance Sheet)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,185)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,570)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,711)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,570)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock', window );">Summary of Activity Related to Company's Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands):</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.631%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning balance</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,630&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,659&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions based on tax positions related to the current year</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,393&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions for tax positions of prior years</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,982&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reductions for tax positions of prior years</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,554)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending balance</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,892&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,630&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,288&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061177872936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Financial Data</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2020. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.</span></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:23.164%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.730%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Q4</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,076&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,553&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,763&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,071&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,548&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,958&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,851&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,598&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,450&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,464&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,968&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,052&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,206&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,974)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,965)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,508)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,675)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,203)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,356)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,361)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,501&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to non-controlling interest</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net (loss) income attributable to Sangamo Therapeutics, Inc.</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,913)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,929)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,550)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,604)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,150)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,284)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27,307)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"/><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,555&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.37)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.01)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.41)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121640914&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061181197832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 25,800,000<span></span>
</td>
<td class="nump">$ 57,763,000<span></span>
</td>
<td class="nump">$ 21,553,000<span></span>
</td>
<td class="nump">$ 13,076,000<span></span>
</td>
<td class="nump">$ 54,851,000<span></span>
</td>
<td class="nump">$ 21,958,000<span></span>
</td>
<td class="nump">$ 17,548,000<span></span>
</td>
<td class="nump">$ 8,071,000<span></span>
</td>
<td class="nump">$ 118,192,000<span></span>
</td>
<td class="nump">$ 102,428,000<span></span>
</td>
<td class="nump">$ 84,452,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(40,675,000)<span></span>
</td>
<td class="num">$ (1,508,000)<span></span>
</td>
<td class="num">$ (35,965,000)<span></span>
</td>
<td class="num">$ (42,974,000)<span></span>
</td>
<td class="nump">$ 4,501,000<span></span>
</td>
<td class="num">$ (27,361,000)<span></span>
</td>
<td class="num">$ (30,356,000)<span></span>
</td>
<td class="num">$ (42,203,000)<span></span>
</td>
<td class="num">(121,122,000)<span></span>
</td>
<td class="num">$ (95,419,000)<span></span>
</td>
<td class="num">$ (68,889,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetImpairment', window );">Goodwill and intangible asset impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets held-for-use</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber', window );">Stock options and RSUs outstanding (in shares) | shares</a></td>
<td class="nump">14,237,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,750,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,237,871<span></span>
</td>
<td class="nump">10,750,550<span></span>
</td>
<td class="nump">9,048,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member', window );">Pfizer SB-525 | Change in collaboration agreement scope | Collaborative arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,900,000<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share, basic (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerSB525Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerSB525Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_ChangeInCollaborationAgreementScopeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061180591128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail) - Revenue from Contract with Customer - Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Biogen MA Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Kite Pharma, Inc. ("Kite")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Novartis Institutes For Bio Medical Research Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179390040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 131,329<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
<td class="nump">$ 140,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Non-current restricted cash</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 132,829<span></span>
</td>
<td class="nump">$ 81,928<span></span>
</td>
<td class="nump">$ 143,918<span></span>
</td>
<td class="nump">$ 53,326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061181776120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 560,624<span></span>
</td>
<td class="nump">$ 303,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">213,533<span></span>
</td>
<td class="nump">155,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">59,574<span></span>
</td>
<td class="nump">95,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">12,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">17,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">257,298<span></span>
</td>
<td class="nump">53,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">33,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">560,624<span></span>
</td>
<td class="nump">303,878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">613,789<span></span>
</td>
<td class="nump">337,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">213,533<span></span>
</td>
<td class="nump">155,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 1 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">560,624<span></span>
</td>
<td class="nump">303,878<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">560,624<span></span>
</td>
<td class="nump">306,877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 2 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">213,533<span></span>
</td>
<td class="nump">155,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Level 3 | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">59,574<span></span>
</td>
<td class="nump">95,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">59,574<span></span>
</td>
<td class="nump">95,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Corporate debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">12,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">12,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Certificates of deposit | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">17,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">17,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Asset-backed securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">257,298<span></span>
</td>
<td class="nump">53,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">257,298<span></span>
</td>
<td class="nump">53,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | U.S. government-sponsored entity debt securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis | Free shares asset | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=sgmo_FreeSharesLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179838536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Nov. 23, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase', window );">Business acquisition, number of free shares outstanding subject to purchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="nump">11,528,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Business acquisition estimated fair value liabilities of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="nump">25,047,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability', window );">Increase in fair value of free shares asset and liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares', window );">Business acquisition estimated fair value assets of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement | Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Business acquisition estimated fair value liabilities of free shares</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Estimated Fair Value Assets Of Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Estimated Fair Value Liabilities Of Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase In Fair Value Of Free Shares Asset And Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061180792728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">EUR/ USD exchange rate</a></td>
<td class="nump">0.82<span></span>
</td>
<td class="nump">0.82<span></span>
</td>
<td class="nump">0.91<span></span>
</td>
<td class="nump">0.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Measurement Input, Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Sangamo Stock Price (USD) (in dollars per share)</a></td>
<td class="nump">$ 15.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember', window );">Stock Price Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility Estimate</a></td>
<td class="nump">0.889<span></span>
</td>
<td class="nump">0.889<span></span>
</td>
<td class="nump">0.725<span></span>
</td>
<td class="nump">0.725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Exchange Rate Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility Estimate</a></td>
<td class="nump">0.063<span></span>
</td>
<td class="nump">0.063<span></span>
</td>
<td class="nump">0.066<span></span>
</td>
<td class="nump">0.066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France Stock Price (EUR) (in Euro per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Measurement Input, Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Sangamo France Stock Price (EUR) (in Euro per share) | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 3.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 2.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Measurement Input Stock Price Correlation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Estimated correlation Sangamo and Sangamo France stock prices</a></td>
<td class="nump">1.000<span></span>
</td>
<td class="nump">1.000<span></span>
</td>
<td class="nump">1.000<span></span>
</td>
<td class="nump">1.000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Stock Price Volatility Estimate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityMeasurementInput', window );">Volatility Estimate</a></td>
<td class="nump">0.889<span></span>
</td>
<td class="nump">0.889<span></span>
</td>
<td class="nump">0.725<span></span>
</td>
<td class="nump">0.725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=sgmo_MeasurementInputStockPriceCorrelationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179623864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">$ 131,329<span></span>
</td>
<td class="nump">$ 80,428<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">560,575<span></span>
</td>
<td class="nump">303,546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">560,624<span></span>
</td>
<td class="nump">303,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost', window );">Total cash equivalents and available-for-sale securities, amortized cost</a></td>
<td class="nump">613,740<span></span>
</td>
<td class="nump">337,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax', window );">Total cash equivalents and available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax', window );">Total cash equivalents and available-for-sale securities, gross unrealized (losses)</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities', window );">Total cash equivalents and available-for-sale securities, estimated fair value</a></td>
<td class="nump">613,789<span></span>
</td>
<td class="nump">337,373<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents accumulated gross unrealized loss before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">30,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents accumulated gross unrealized loss before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,999<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">213,500<span></span>
</td>
<td class="nump">155,230<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">213,533<span></span>
</td>
<td class="nump">155,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, at carrying value, total</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">33,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax', window );">Cash equivalents, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax', window );">Cash and cash equivalents accumulated gross unrealized loss before tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents, estimated fair value</a></td>
<td class="nump">53,165<span></span>
</td>
<td class="nump">33,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">59,575<span></span>
</td>
<td class="nump">94,905<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">59,574<span></span>
</td>
<td class="nump">95,017<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">12,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">12,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government-sponsored entity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">257,284<span></span>
</td>
<td class="nump">53,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">257,298<span></span>
</td>
<td class="nump">$ 53,493<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale securities, amortized cost</a></td>
<td class="nump">17,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale securities, gross unrealized gains</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale securities, gross unrealized (Losses)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, estimated fair value</a></td>
<td class="nump">$ 17,908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and cash equivalents accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for Sale Securities Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized gain, before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and available for sale securities, gross unrealized loss, before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179429480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 510,094<span></span>
</td>
<td class="nump">$ 282,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">50,530<span></span>
</td>
<td class="nump">21,832<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total</a></td>
<td class="nump">$ 560,624<span></span>
</td>
<td class="nump">$ 303,878<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061259955032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash Equivalents and Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OtherThanTemporarilyImpairedInvestment', window );">Investments other-than-temporarily impaired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OtherThanTemporarilyImpairedInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other than temporarily impaired investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OtherThanTemporarilyImpairedInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061079544200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="16">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1">13 Months Ended</th>
<th class="th" colspan="1">17 Months Ended</th>
<th class="th" colspan="1">37 Months Ended</th>
<th class="th" colspan="1">41 Months Ended</th>
<th class="th" colspan="1">84 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 29, 2020 </div>
<div>USD ($) </div>
<div>product_target</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Jan. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>product </div>
<div>milestone </div>
<div>option </div>
<div>product_target </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>milestone</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2020</div></th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace', window );">Collaborative arrangement, maximum number of product targets to replace | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs related to sangamo france acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,800,000<span></span>
</td>
<td class="nump">$ 57,763,000<span></span>
</td>
<td class="nump">$ 21,553,000<span></span>
</td>
<td class="nump">$ 13,076,000<span></span>
</td>
<td class="nump">$ 54,851,000<span></span>
</td>
<td class="nump">$ 21,958,000<span></span>
</td>
<td class="nump">$ 17,548,000<span></span>
</td>
<td class="nump">$ 8,071,000<span></span>
</td>
<td class="nump">$ 118,192,000<span></span>
</td>
<td class="nump">102,428,000<span></span>
</td>
<td class="nump">$ 84,452,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,011,000<span></span>
</td>
<td class="nump">5,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,011,000<span></span>
</td>
<td class="nump">$ 7,011,000<span></span>
</td>
<td class="nump">$ 7,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,011,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember', window );">California Institute for Regenerative Medicine ("CIRM")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_GrantFundingAmount', window );">Funds due under the agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Research grants | California Institute for Regenerative Medicine ("CIRM")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For Bio Medical Research Inc | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For Bio Medical Research Inc | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="nump">$ 95,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementLicenseFee', window );">Collaborative arrangement, license fee</a></td>
<td class="nump">75,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="nump">20,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,900,000<span></span>
</td>
<td class="nump">70,900,000<span></span>
</td>
<td class="nump">70,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Collaboration arrangement, commission fee, portion of gross proceeds, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Collaborative agreement, percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For Bio Medical Research Inc | Collaboration and license agreement | Maximum | Achievement of specified preclinical development clinical development and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">420,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For Bio Medical Research Inc | Collaboration and license agreement | Maximum | Achievement of commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA Inc | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA Inc | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaborators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue', window );">Collaboration arrangement, commission fee, portion of gross proceeds, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition', window );">Collaborative agreement, percent of initial recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSoldAmortization', window );">Amortization cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,370,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargets', window );">Number of neurological disease gene targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected', window );">Number of product targets selected | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets', window );">Number of additional neurological disease gene targets | product_target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementTargetSelectionPeriod', window );">Target selection period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract with customer, asset, after allowance for credit Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA Inc | Collaboration and license agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationArrangementResearchPeriod', window );">Collaboration arrangement, research period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA Inc | Collaboration and license agreement | Pre-approval Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 925,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA Inc | Collaboration and license agreement | Sales-based Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable', window );">Maximum milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA Inc | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,200,000<span></span>
</td>
<td class="nump">183,200,000<span></span>
</td>
<td class="nump">183,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod', window );">Agreement restriction expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage', window );">Agreement restriction, ownership percentage (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld', window );">Agreement restriction, percentage of shares held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod', window );">Agreement provision, expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage', window );">Agreement provision, ownership percentage (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction', window );">Sale of stock, excess consideration received on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreementEquityIssued', window );">Collaboration agreement, equity issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs related to sangamo france acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,608,000<span></span>
</td>
<td class="nump">34,350,000<span></span>
</td>
<td class="nump">25,517,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,046,000<span></span>
</td>
<td class="nump">24,977,000<span></span>
</td>
<td class="nump">18,545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 189,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,400,000<span></span>
</td>
<td class="nump">106,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,400,000<span></span>
</td>
<td class="nump">81,400,000<span></span>
</td>
<td class="nump">81,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Initial research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm', window );">Number of options to extend initial research term | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ExtendedResearchTermOfAgreement', window );">Extended research term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SeparateUpfrontFee', window );">Separate fee for additional term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan', window );">Collaborative arrangement estimated reimbursable service costs for new research plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration and license agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,260,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration and license agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Collaboration and license agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,010,000,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember', window );">Pfizer, Giroctocogene Fitelparvovec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,449,000<span></span>
</td>
<td class="nump">39,359,000<span></span>
</td>
<td class="nump">37,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue', window );">Collaborative arrangement, increase (decrease) in revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss', window );">Collaborative arrangement, increase (decrease) in net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember', window );">Pfizer, Giroctocogene Fitelparvovec | Phase Three Clinical Trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned', window );">Cumulative compensation earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember', window );">Pfizer, Giroctocogene Fitelparvovec | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,111,000<span></span>
</td>
<td class="nump">15,697,000<span></span>
</td>
<td class="nump">37,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress', window );">Contract with customer, liability, cumulative catch-up adjustment to revenue, change in measure of progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember', window );">Pfizer, Giroctocogene Fitelparvovec | Amended collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,985,000<span></span>
</td>
<td class="nump">1,827,000<span></span>
</td>
<td class="nump">2,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,985,000<span></span>
</td>
<td class="nump">1,827,000<span></span>
</td>
<td class="nump">2,188,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72 | Maximum | Achievement of specified preclinical development clinical development and first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | C9ORF72 | Maximum | Achievement of commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,322,000<span></span>
</td>
<td class="nump">22,680,000<span></span>
</td>
<td class="nump">13,516,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue', window );">Collaborative arrangement, increase (decrease) in revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss', window );">Collaborative arrangement, increase (decrease) in net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNetIncomeLossPerShare', window );">Collaborative arrangement, net Income (loss) per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs | program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298,000<span></span>
</td>
<td class="nump">3,494,000<span></span>
</td>
<td class="nump">4,013,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts', window );">Collaborative arrangement estimated reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Maximum | Achievement of specified clinical development and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Maximum | Achievement of specified sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Collaboration and license agreement | Milestone Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG | Collaboration and license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 134,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementResearchServiceFees', window );">Research service fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementReimbursableServiceCosts', window );">Collaborative arrangement reimbursable service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AgreementTerminationTerm', window );">Agreement termination, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue', window );">Collaborative arrangement, increase (decrease) in revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss', window );">Collaborative arrangement, increase (decrease) in net income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementNetIncomeLossPerShare', window );">Collaborative arrangement, net Income (loss) per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.02)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Maximum | Achievement of specified clinical development intellectual property and regulatory milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Maximum | Achievement of first commercial sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Other products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborativeArrangementTransactionPrice', window );">Collaborative arrangement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Giroctocogene Fitelparvovec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice', window );">Number of milestones included in transaction price | milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer | Giroctocogene Fitelparvovec | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AgreementTerminationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement Termination, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AgreementTerminationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementEquityIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Equity Issued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementEquityIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementNumberOfAdditionalProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Additional Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementNumberOfAdditionalProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreementTargetSelectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Target Selection Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreementTargetSelectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationArrangementResearchPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Research Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationArrangementResearchPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementPercentOfInitialRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Percent Of Initial Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementPercentOfInitialRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement estimated reimbursable service costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Increase (Decrease) In Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, License Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Maximum Number Of Product Targets To Replace</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNetIncomeLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Net Income (Loss) Per Share</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNetIncomeLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementNumberOfProductTargetsSelected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number Of Product Targets Selected</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementNumberOfProductTargetsSelected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementReimbursableServiceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement Reimbursable Service Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementReimbursableServiceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementResearchServiceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Research Service Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementResearchServiceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementStandstillRestrictionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Standstill Restriction Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementStandstillRestrictionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative arrangement transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions Expiration Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent development and sales based milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ExtendedResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Extended Research Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ExtendedResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_GrantFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant funding amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_GrantFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of clinical or regulatory milestones included in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfOptionsToExtendInitialResearchTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Options To Extend Initial Research Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfOptionsToExtendInitialResearchTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Excess Consideration Received on Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SeparateUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Separate upfront fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SeparateUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSoldAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSoldAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PreApprovalMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_SalesBasedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PhaseThreeClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_PhaseThreeClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_AmendedCollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_AmendedCollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedSalesMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborativeAgreementMilestoneAxis=sgmo_MilestoneThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_ShireAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_ShireAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_AchievementOfFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_GiroctocogeneFitelparvovecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_GiroctocogeneFitelparvovecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061181253592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="nump">$ 57,763<span></span>
</td>
<td class="nump">$ 21,553<span></span>
</td>
<td class="nump">$ 13,076<span></span>
</td>
<td class="nump">$ 54,851<span></span>
</td>
<td class="nump">$ 21,958<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 118,192<span></span>
</td>
<td class="nump">$ 102,428<span></span>
</td>
<td class="nump">$ 84,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For Bio Medical Research Inc | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember', window );">Novartis Institutes For Bio Medical Research Inc | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA Inc | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember', window );">Biogen MA Inc | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,608<span></span>
</td>
<td class="nump">34,350<span></span>
</td>
<td class="nump">25,517<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,562<span></span>
</td>
<td class="nump">9,373<span></span>
</td>
<td class="nump">6,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember', window );">Kite Pharma, Inc. ("Kite") | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,046<span></span>
</td>
<td class="nump">24,977<span></span>
</td>
<td class="nump">18,545<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember', window );">Pfizer, Giroctocogene Fitelparvovec</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,449<span></span>
</td>
<td class="nump">39,359<span></span>
</td>
<td class="nump">37,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember', window );">Pfizer, Giroctocogene Fitelparvovec | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="nump">$ 8,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,111<span></span>
</td>
<td class="nump">15,697<span></span>
</td>
<td class="nump">37,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember', window );">Pfizer, Giroctocogene Fitelparvovec | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,338<span></span>
</td>
<td class="nump">23,662<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,985<span></span>
</td>
<td class="nump">1,827<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,985<span></span>
</td>
<td class="nump">1,827<span></span>
</td>
<td class="nump">2,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member', window );">Pfizer C9ORF72 | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,322<span></span>
</td>
<td class="nump">22,680<span></span>
</td>
<td class="nump">13,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Research services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,823<span></span>
</td>
<td class="nump">6,367<span></span>
</td>
<td class="nump">9,503<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">3,494<span></span>
</td>
<td class="nump">4,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SanofiMember', window );">Sanofi | Milestone achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue related to Sanofi agreement:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
<td class="nump">$ 12,819<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_ResearchServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_ResearchServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerGiroctocogeneFitelparvovecMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sgmo_MilestoneAchievementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_PfizerC9ORF72Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SanofiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SanofiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061180518424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2009</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142,526<span></span>
</td>
<td class="nump">$ 136,308<span></span>
</td>
<td class="nump">$ 215,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="nump">$ 57,763<span></span>
</td>
<td class="nump">$ 21,553<span></span>
</td>
<td class="nump">$ 13,076<span></span>
</td>
<td class="nump">$ 54,851<span></span>
</td>
<td class="nump">$ 21,958<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">118,192<span></span>
</td>
<td class="nump">102,428<span></span>
</td>
<td class="nump">84,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchServicesPeriod', window );">Developed laboratory research reagents, research services period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering, common stock shares issued</a></td>
<td class="nump">636,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ReducedRoyaltyRate', window );">Reduced royalty rate</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive', window );">Development and sales-based milestone payments to be received</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation | License agreement terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation | License fee revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">$ 15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customer contract liability milestone payment eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ReducedRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduced royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ReducedRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchServicesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research services period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchServicesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061180303848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with DAS (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2005</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 25,800,000<span></span>
</td>
<td class="nump">$ 57,763,000<span></span>
</td>
<td class="nump">$ 21,553,000<span></span>
</td>
<td class="nump">$ 13,076,000<span></span>
</td>
<td class="nump">$ 54,851,000<span></span>
</td>
<td class="nump">$ 21,958,000<span></span>
</td>
<td class="nump">$ 17,548,000<span></span>
</td>
<td class="nump">$ 8,071,000<span></span>
</td>
<td class="nump">$ 118,192,000<span></span>
</td>
<td class="nump">$ 102,428,000<span></span>
</td>
<td class="nump">$ 84,452,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OneTimeLicenseFeeEarned', window );">One-time license fee earned on exercise of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement', window );">Previously agreed research, development and commercialization milestone payments, and royalties on sales of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing', window );">Percentage of royalties to be received from sublicensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FeeDue', window );">Fee due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod', window );">Minimum license annual fees specific reckoning period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms | Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences | License agreement terms | License fee revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AnnualFeesRelatedToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual fees related to agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AnnualFeesRelatedToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FeeDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fee due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_FeeDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment and royalty revenue of previous agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum sublicense annual fees specific reckoning period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OneTimeLicenseFeeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One time license fee earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OneTimeLicenseFeeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties to be received from sublicensing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_DowAgroSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061182823144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Sangamo France - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Nov. 23, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 20, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="nump">11,528,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of share capital and voting rights acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Business Combination, Consideration Transferred</a></td>
<td class="nump">$ 45,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Purchase price per share (in dollars per share)</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | SPA and TOA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire', window );">Percentage of equity interests agreed to acquire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="nump">25,047,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders', window );">Number of free shares held by the holders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Business acquisition estimated fair value liabilities of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares', window );">Business acquisition estimated fair value assets of free shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | SPA and TOA | Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares', window );">Business acquisition estimated fair value liabilities of free shares</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | SPA and TOA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.80%<span></span>
</td>
<td class="nump">98.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Cash paid for shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Estimated Fair Value Assets Of Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition Estimated Fair Value Liabilities Of Free Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of free shares held by the holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, percentage of equity interests agreed to acquire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueOptionPricingModelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061180328376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Stockholders' equity attributable to noncontrolling interest, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Fair value of additional shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">$ (71)<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="num">$ (36)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
<td class="num">$ (54)<span></span>
</td>
<td class="num">$ (72)<span></span>
</td>
<td class="num">$ (53)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="num">$ (233)<span></span>
</td>
<td class="num">$ (555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Stockholders' equity attributable to noncontrolling interest, ending balance</a></td>
<td class="num">(868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(868)<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember', window );">Non- Controlling Interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInMinorityInterestRollForward', window );"><strong>Stockholders' Equity Attributable to Noncontrolling Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Stockholders' equity attributable to noncontrolling interest, beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Stockholders' equity attributable to noncontrolling interest, ending balance</a></td>
<td class="num">$ (868)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (868)<span></span>
</td>
<td class="nump">$ 185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInMinorityInterestRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInMinorityInterestRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_NoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183576824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 58,740<span></span>
</td>
<td class="nump">$ 41,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(17,416)<span></span>
</td>
<td class="num">(11,681)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">41,324<span></span>
</td>
<td class="nump">29,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">5,682<span></span>
</td>
<td class="nump">3,930<span></span>
</td>
<td class="nump">$ 2,359<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">24,737<span></span>
</td>
<td class="nump">17,179<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,870<span></span>
</td>
<td class="nump">4,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">15,953<span></span>
</td>
<td class="nump">13,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ManufacturingEquipmentMember', window );">Manufacturing equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,089<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 12,091<span></span>
</td>
<td class="nump">$ 5,901<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183706552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IntangibleAssetsExcludingGoodwillRollForward', window );"><strong>Intangible Assets (Excluding Goodwill)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Balance at beginning of year</a></td>
<td class="nump">$ 53,156<span></span>
</td>
<td class="nump">$ 54,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustment</a></td>
<td class="nump">4,972<span></span>
</td>
<td class="num">(1,087)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Balance at end of year</a></td>
<td class="nump">58,128<span></span>
</td>
<td class="nump">53,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning balance</a></td>
<td class="nump">39,273<span></span>
</td>
<td class="nump">40,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustment</a></td>
<td class="nump">3,525<span></span>
</td>
<td class="num">(771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, ending balance</a></td>
<td class="nump">$ 42,798<span></span>
</td>
<td class="nump">$ 39,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IntangibleAssetsExcludingGoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets (Excluding Goodwill)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IntangibleAssetsExcludingGoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183344216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Customer advance</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">4,257<span></span>
</td>
<td class="nump">4,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities &#8211; current</a></td>
<td class="nump">3,690<span></span>
</td>
<td class="nump">3,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,532<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">4,133<span></span>
</td>
<td class="nump">2,451<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total other accrued liabilities</a></td>
<td class="nump">$ 18,612<span></span>
</td>
<td class="nump">$ 10,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:AccruedLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:AccruedLiabilitiesCurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061180281512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease, cost</a></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, cost</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease, expense</a></td>
<td class="nump">$ 10.4<span></span>
</td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LicenseObligations', window );">License obligations</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember', window );">Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate', window );">Lease not yet commenced, area of real estate | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount', window );">Lessee Operating Lease Lease Not Yet Commenced Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember', window );">Office And Laboratory | Brisbane, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember', window );">Office And Laboratory | Richmond, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="nump">54,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember', window );">Research and Office Space | Valbonne, France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased (in sqft) | ft&#178;</a></td>
<td class="nump">20,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Lease Not Yet Commenced Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Lease Not Yet Commenced Area Of Real Estate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LicenseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LicenseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_RichmondCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_OfficeAndLaboratoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_BrisbaneCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=sgmo_ValbonneFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183462424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">$ 6,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">6,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">6,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">6,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2025</a></td>
<td class="nump">7,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">19,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">53,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Imputed interest</a></td>
<td class="num">(11,336)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">42,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities - current (included in Other accrued liabilities on the Consolidated Balance Sheet)</a></td>
<td class="nump">3,690<span></span>
</td>
<td class="nump">$ 3,214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities - long-term</a></td>
<td class="nump">$ 38,396<span></span>
</td>
<td class="nump">$ 41,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">us-gaap:AccruedLiabilitiesCurrent<span></span>
</td>
<td class="text">us-gaap:AccruedLiabilitiesCurrent<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179844840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Non-cancelable Material Contractual Commitments (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">$ 21,507<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember', window );">Brammer Bio MA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">7,736<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_LonzaNetherlandsBVMember', window );">Lonza Netherlands, B.V.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Contractual obligation</a></td>
<td class="nump">$ 13,771<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BrammerBioMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_LonzaNetherlandsBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_LonzaNetherlandsBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061176049144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 30, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 29, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000,000<span></span>
</td>
<td class="nump">320,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">320,000,000<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,063,203<span></span>
</td>
<td class="nump">115,972,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Net proceeds from issuance of common stock, after deducting offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 136,308<span></span>
</td>
<td class="nump">$ 215,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Additional equity award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,563,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 5 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SpecifiedStockholderOwnershipPercentage', window );">Specified stockholder ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder', window );">Purchase price of common stock percent under stock incentive plans for specified stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder', window );">Stock option maximum term for specified stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommonStockExchangeRatio', window );">Share of common stock subject to a stock option or stock appreciation right (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400<span></span>
</td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and expected to vest, aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,600<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="nump">24,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,517,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Total payments for the employees' tax obligations to taxing authorities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 765<span></span>
</td>
<td class="nump">$ 422<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance of future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Compensation Awards, Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Share-Based Compensation Awards, Tranche 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Additional equity award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value per share of common stock on option grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm', window );">Stock options expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Fixed ratio shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance of future awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,942,576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember', window );">2010 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value per share of common stock on option grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock reserved for issuance under plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PurchasePlanOfferingPeriod', window );">Purchase plan offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PurchasePlanPurchasePeriod', window );">Purchase plan purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_Restated2018StockIncentivePlanMember', window );">Restated 2018 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance', window );">Increase in capital shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | 2018 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options | 2018 Stock Incentive Plan | Share-Based Compensation Awards, Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options | 2018 Stock Incentive Plan | Share-Based Compensation Awards, Tranche 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,517,101<span></span>
</td>
<td class="nump">834,745<span></span>
</td>
<td class="nump">346,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value per award of restricted stock units (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.06<span></span>
</td>
<td class="nump">$ 9.49<span></span>
</td>
<td class="nump">$ 17.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment', window );">Share-based compensation arrangement by share-based payment award, number of vesting installment | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate fair value of RSUs vested in period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld from issuance in order to pay employee taxes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,617<span></span>
</td>
<td class="nump">39,160<span></span>
</td>
<td class="nump">20,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Share-Based Compensation Awards, Tranche 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember', window );">Jefferies LLC | ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_StockOfferingProgramMaximumValue', window );">Stock offering program, maximum value | $</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember', window );">Stock Purchase Agreement | Biogen MA Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="nump">$ 9.2137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="nump">$ 225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,200,000<span></span>
</td>
<td class="nump">24,420,157<span></span>
</td>
<td class="nump">12,650,000<span></span>
</td>
<td class="nump">14,156,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock issued (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Net proceeds from issuance of common stock, after deducting offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 215,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase plan offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PurchasePlanPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase plan purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PurchasePlanPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of vesting installment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options expiration term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options maximum term for specified stock holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SpecifiedStockholderOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specified stockholder ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SpecifiedStockholderOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockOfferingProgramMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Offering Program, Maximum Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockOfferingProgramMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_Restated2018StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_Restated2018StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_JefferiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061259958088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">9,829,287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares) | shares</a></td>
<td class="nump">4,563,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares) | shares</a></td>
<td class="num">(1,162,268)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled (in shares) | shares</a></td>
<td class="num">(1,751,746)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of period (in shares) | shares</a></td>
<td class="nump">11,478,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at end of period (in shares) | shares</a></td>
<td class="nump">11,478,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at end of period (in shares) | shares</a></td>
<td class="nump">5,127,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise per Share Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share) | $ / shares</a></td>
<td class="nump">8.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">8.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled (in dollars per share) | $ / shares</a></td>
<td class="nump">10.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">10.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">10.02<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual&#160;Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at end of period (in years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest at end of period (in years)</a></td>
<td class="text">7 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at end of period (in years)</a></td>
<td class="text">6 years 5 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of period | $</a></td>
<td class="nump">$ 69,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest at end of period | $</a></td>
<td class="nump">69,616<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable at end of period | $</a></td>
<td class="nump">$ 29,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061259907640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at beginning of period (in shares)</a></td>
<td class="nump">862,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded (in shares)</a></td>
<td class="nump">2,517,101<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">RSUs released (in shares)</a></td>
<td class="num">(324,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited (in shares)</a></td>
<td class="num">(384,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at end of period (in shares)</a></td>
<td class="nump">2,671,528<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">RSUs vested and expected to vest at end of period (in shares)</a></td>
<td class="nump">2,671,528<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual&#160;Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">RSUs outstanding at end of period (in years)</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm', window );">RSUs vested and expected to vest at end of period (in years)</a></td>
<td class="text">1 year 2 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate&#160;Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">RSUs outstanding at end of period | $</a></td>
<td class="nump">$ 41,689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue', window );">RSUs vested and expected to vest at end of period | $</a></td>
<td class="nump">$ 41,689<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options released in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061180634568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 25,708<span></span>
</td>
<td class="nump">$ 19,330<span></span>
</td>
<td class="nump">$ 14,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">13,523<span></span>
</td>
<td class="nump">10,135<span></span>
</td>
<td class="nump">8,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 12,185<span></span>
</td>
<td class="nump">$ 9,195<span></span>
</td>
<td class="nump">$ 6,428<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183215512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost related to unvested stock options and RSU</a></td>
<td class="nump">$ 35,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of unvested stock options and RSU</a></td>
<td class="text">2 years 8 months 19 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized stock-based employee compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated fair value per share of options granted (in dollars per share)</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 6.37<span></span>
</td>
<td class="nump">$ 11.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan (in shares)</a></td>
<td class="nump">274,382<span></span>
</td>
<td class="nump">249,364<span></span>
</td>
<td class="nump">328,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice', window );">Stock issued under employee stock purchase plans, average exercise price (in dollars per share)</a></td>
<td class="nump">$ 7.34<span></span>
</td>
<td class="nump">$ 8.53<span></span>
</td>
<td class="nump">$ 4.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue', window );">Weighted-average estimated fair value of shares purchased under ESPP plan (in dollars per share)</a></td>
<td class="nump">$ 8.02<span></span>
</td>
<td class="nump">$ 4.70<span></span>
</td>
<td class="nump">$ 7.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost related to unvested stock options and RSU</a></td>
<td class="nump">$ 17,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of unvested stock options and RSU</a></td>
<td class="text">2 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan rights weighted average estimated fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued under employee stock purchase plans average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183215512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail) - Employee Stock Options<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield of stock</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.34%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">2.53%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months 3 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 7 months 2 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">77.61%<span></span>
</td>
<td class="nump">76.46%<span></span>
</td>
<td class="nump">72.33%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.61%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 6 months 25 days<span></span>
</td>
<td class="text">5 years 7 months 13 days<span></span>
</td>
<td class="text">5 years 7 months 9 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">80.32%<span></span>
</td>
<td class="nump">78.39%<span></span>
</td>
<td class="nump">75.49%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061182219624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail) - 2010 Employee Stock Purchase Plan<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield of stock</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.53%<span></span>
</td>
<td class="nump">1.53%<span></span>
</td>
<td class="nump">2.16%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">51.02%<span></span>
</td>
<td class="nump">51.02%<span></span>
</td>
<td class="nump">73.21%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.42%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.96%<span></span>
</td>
<td class="nump">91.96%<span></span>
</td>
<td class="nump">83.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061177815352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer's matching contribution percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum percentage limit of employee contributions</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined contribution plan, maximum employer's contribution per employee</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Aggregate employer's contributions to defined contribution plan</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061182217064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (126,624)<span></span>
</td>
<td class="num">$ (77,354)<span></span>
</td>
<td class="num">$ (65,695)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="nump">5,847<span></span>
</td>
<td class="num">(18,065)<span></span>
</td>
<td class="num">(3,194)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (120,777)<span></span>
</td>
<td class="num">$ (95,419)<span></span>
</td>
<td class="num">$ (68,889)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183649976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Benefit for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">686<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit', window );">Subtotal</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(474)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Subtotal</a></td>
<td class="num">(474)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061272519192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="num">$ (25,363)<span></span>
</td>
<td class="num">$ (20,038)<span></span>
</td>
<td class="num">$ (14,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net</a></td>
<td class="num">(3,168)<span></span>
</td>
<td class="num">(9,597)<span></span>
</td>
<td class="num">(2,849)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Foreign rate differential</a></td>
<td class="nump">376<span></span>
</td>
<td class="num">(665)<span></span>
</td>
<td class="num">(177)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount', window );">Global Intangible Low-Taxed Income</a></td>
<td class="nump">1,335<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation', window );">Non-deductible stock-based compensation</a></td>
<td class="nump">4,232<span></span>
</td>
<td class="nump">2,817<span></span>
</td>
<td class="num">(2,729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(3,657)<span></span>
</td>
<td class="num">(3,429)<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">26,537<span></span>
</td>
<td class="nump">29,655<span></span>
</td>
<td class="nump">20,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 345<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Global Intangible Low-Taxed Income, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense income share based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061267010552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Company's Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 164,276<span></span>
</td>
<td class="nump">$ 133,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">27,679<span></span>
</td>
<td class="nump">21,459<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">5,321<span></span>
</td>
<td class="nump">4,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">20,681<span></span>
</td>
<td class="nump">32,171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">10,525<span></span>
</td>
<td class="nump">11,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">10,251<span></span>
</td>
<td class="nump">11,722<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accruals and reserves</a></td>
<td class="nump">430<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">151<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">239,471<span></span>
</td>
<td class="nump">215,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">214,351<span></span>
</td>
<td class="nump">187,724<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">25,120<span></span>
</td>
<td class="nump">27,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="num">(14,321)<span></span>
</td>
<td class="num">(13,609)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(17,510)<span></span>
</td>
<td class="num">(20,656)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="num">(31,831)<span></span>
</td>
<td class="num">(34,265)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total net deferred tax liabilities</a></td>
<td class="num">$ (6,711)<span></span>
</td>
<td class="num">$ (6,570)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061283061096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets &amp; Liabilities, Balance Sheet Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">$ 25,120<span></span>
</td>
<td class="nump">$ 27,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liabilities</a></td>
<td class="num">(7,185)<span></span>
</td>
<td class="num">(6,570)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="num">(6,711)<span></span>
</td>
<td class="num">(6,570)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">$ 474<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061266950584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in deferred tax assets valuation allowance</a></td>
<td class="num">$ (26,600,000)<span></span>
</td>
<td class="num">$ (29,600,000)<span></span>
</td>
<td class="num">$ (45,300,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred tax assets, net operating loss carryforwards for federal</a></td>
<td class="nump">622,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets, net operating loss carryforwards for state</a></td>
<td class="nump">261,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal', window );">Federal research tax credit carryforwards</a></td>
<td class="nump">21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal', window );">State research tax credit carryforwards</a></td>
<td class="nump">18,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and/or penalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember', window );">French</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Deferred tax assets, net operating loss carryforwards for foreign</a></td>
<td class="nump">$ 145,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research federal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research state and local.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179905640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 11,630<span></span>
</td>
<td class="nump">$ 6,288<span></span>
</td>
<td class="nump">$ 5,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">5,393<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="nump">1,982<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="num">(3,554)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 12,892<span></span>
</td>
<td class="nump">$ 11,630<span></span>
</td>
<td class="nump">$ 6,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increase decrease resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061179515384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Disclosures (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2018</div></th>
<th class="th"><div>Nov. 23, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="nump">$ 262<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="nump">13,519,036<span></span>
</td>
<td class="nump">11,528,635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember', window );">TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">322,000<span></span>
</td>
<td class="nump">111,000<span></span>
</td>
<td class="nump">25,047,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sgmo_FormerExecutiveOfSangamoFranceMember', window );">Former Executive of TxCell | TxCell S.A. | Share Purchase Agreement and Tender Offer Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired', window );">Number of ordinary shares acquired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,400<span></span>
</td>
<td class="nump">52,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Payments to acquire additional interest in subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionNumberOfSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition, number of shares acquired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionNumberOfSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_SangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sgmo_FormerExecutiveOfSangamoFranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sgmo_FormerExecutiveOfSangamoFranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061180731304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 25,800<span></span>
</td>
<td class="nump">$ 57,763<span></span>
</td>
<td class="nump">$ 21,553<span></span>
</td>
<td class="nump">$ 13,076<span></span>
</td>
<td class="nump">$ 54,851<span></span>
</td>
<td class="nump">$ 21,958<span></span>
</td>
<td class="nump">$ 17,548<span></span>
</td>
<td class="nump">$ 8,071<span></span>
</td>
<td class="nump">$ 118,192<span></span>
</td>
<td class="nump">$ 102,428<span></span>
</td>
<td class="nump">$ 84,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">69,232<span></span>
</td>
<td class="nump">61,464<span></span>
</td>
<td class="nump">59,450<span></span>
</td>
<td class="nump">57,598<span></span>
</td>
<td class="nump">53,382<span></span>
</td>
<td class="nump">51,206<span></span>
</td>
<td class="nump">51,052<span></span>
</td>
<td class="nump">51,968<span></span>
</td>
<td class="nump">247,744<span></span>
</td>
<td class="nump">207,608<span></span>
</td>
<td class="nump">161,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(40,675)<span></span>
</td>
<td class="num">(1,508)<span></span>
</td>
<td class="num">(35,965)<span></span>
</td>
<td class="num">(42,974)<span></span>
</td>
<td class="nump">4,501<span></span>
</td>
<td class="num">(27,361)<span></span>
</td>
<td class="num">(30,356)<span></span>
</td>
<td class="num">(42,203)<span></span>
</td>
<td class="num">(121,122)<span></span>
</td>
<td class="num">(95,419)<span></span>
</td>
<td class="num">(68,889)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to non-controlling interest</a></td>
<td class="num">(71)<span></span>
</td>
<td class="nump">42<span></span>
</td>
<td class="num">(36)<span></span>
</td>
<td class="num">(61)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(126)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
<td class="num">(555)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Sangamo Therapeutics, Inc.</a></td>
<td class="num">$ (40,604)<span></span>
</td>
<td class="num">$ (1,550)<span></span>
</td>
<td class="num">$ (35,929)<span></span>
</td>
<td class="num">$ (42,913)<span></span>
</td>
<td class="nump">$ 4,555<span></span>
</td>
<td class="num">$ (27,307)<span></span>
</td>
<td class="num">$ (30,284)<span></span>
</td>
<td class="num">$ (42,150)<span></span>
</td>
<td class="num">$ (120,996)<span></span>
</td>
<td class="num">$ (95,186)<span></span>
</td>
<td class="num">$ (68,334)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.01)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.37)<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (0.26)<span></span>
</td>
<td class="num">$ (0.41)<span></span>
</td>
<td class="num">$ (0.90)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm140061183210424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event - At-the-market Stock Offering<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 19, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">1,034,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Sale of stock, consideration received on transaction, gross</a></td>
<td class="nump">$ 16.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received from sale of stock</a></td>
<td class="nump">$ 15.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Consideration Received on Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>95
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&ULK9EM;]LX$L>_"N$K#KN
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MTM!I&_O3MK^,Z0G=SKHXC5%D;?S.%S* N9LZ4#!*44S,$;>!XSB.T\2\*78
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M)76'@#)DX=JF[(L.D Y\C\"B9CZD!3)\W72$,,\0L I*JA,+H^HMTH4S9#;
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MLVJ%< 0^[F)P,$\D\"?0 7AB@Y7;)X*N-*)#482'++Y23T@HKG_]"%,N38K
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M(+FN-4YO60ZL":O,O,* -7$[/8]/V<L0Q@X"@U2+]!B2?4'G/0;NSF",V10
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MB1_*'G%CF"&PF)KM^7'"F.LD(4A4HN&!P<C'+ 0$(62._@A13@ASL4O8#)R
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M'/I+U^SHN[J730<"2?_$+FG3X@/P^:II.OT%-_!?WO[3_P)02P,$%     @
M,()84GW1KFY%"@  JQL  !@   !X;"]W;W)K<VAE971S+W-H965T.2YX;6R]
M65MSV[@5_BL8-]NQ9VA)I*R+92<SCN-,T]EL73O./G3Z )&0A#5), !H1_OK
M^QT I*B+G79WIB\B01R<ZX>#<Z#+9Z4?S4H(R[X7>6G>'JVLK6;]ODE7HN"F
MIRI18F:A=,$MAGK9-Y46/'.+BKR?# ;C?L%E>?3NTGV[U>\N56US68I;S4Q=
M%%ROWXM</;\]BH^:#W=RN;+TH?_NLN)+<2_L0W6K,>JW7#)9B-)(53(M%F^/
MKN+9^S.B=P1?I7@VG7=&ELR5>J3!I^SMT8 4$KE(+7'@>#R):Y'GQ AJ? L\
MCUJ1M+#[WG#_Z&R'+7-NQ+7*?Y697;T]FAZQ3"QXG=L[]?PW$>P9$;]4Y<;]
MLF=/.SP[8FEMK"K"8FA0R-(_^??@A\Z"Z>"%!4E8D#B]O2"GY0=N^;M+K9Z9
M)FIPHQ=GJEL-Y61)0;FW&K,2Z^R[CUQJ]I7GM6"?!3>U%O"XO>Q;\":*?AKX
MO/=\DA?XQ G[K$J[,NRFS$2VS: /I5K-DD:S]\FK'#^(M,>&<<2203)XA=^P
MM73H^ U_;.D':=)<D;&&_>MJ;JP&./[]BHRS5L:9DW'VI[WY SY7G^[8UZN?
M'V[8YYNK^X>[F\\WOWQA7U:"7:NBXN6:%9Z_8:G0%IN/<6.$-8R7&<LEG\M<
M6HEI;MF"M'IR6M$^P%Y*:ZUEN20\2Q,Q6:9YG=&'E)L5$]]J"7)HCCELU4=A
M^3P7S-"ZP!52++19:('O*TZ*. 5Z3DF>IJHN+7%<UC+C92J8,,1% JH@Q6*L
M/ 4OS5;XX3I=K2/VO)+IBE5:*I+S.RA)B"RK&I;51F1X=Y_(&NZV=2'L2F4J
M5TO22Y;!,22Z8S<W;*%R9" S8S^+)Y&S>,8>2I[]ABT&MM]J10](3CT7GRV"
M]:0&_ @KR3)AC"1WX NI4FP"S3)NX1.EF<PPE"G/(U:7<(X%8Q(0@@2*3HPN
M@DK)C/US5X\]!4IE@W(1L0F^\8ZC>34W0C]1O"(F)!34+).(N,W7GKX914Y1
M4P/^'+KR' 0NI'6>,RMTP=3"?7 Z=U5>7[CX>Z6',W;KM56Z$Q8KTE4IO]4B
MJ*X)5+J-96O.7-D5,W)9R@7<!1=:Y;78Q*[K8));EQL;V3&3/=&+8$=5*4V^
MFZ^AJ+68@T*E"A[T/H/N)QZAA_F;QN:PR_[ZEVD23R[,G]\7SEB/BH4D('CP
M>% 26'/R)@*)D 6,=U1LMP@[=I.J-I!D3F8,65(4<P2YR93L< YB7Y3E>8/]
M!G!-#-F5P^6,7>_8.:.L+M:-$Q<UI+(W;#2,XO&H^^(\E5QTWKS 0! >S5SS
M_'S(B3/R?B%T"DRRBE<P+HF'T6@X;-?MCJ^51O1I\V5B;KL!&9U'H\E92[@S
MO$;N=,"SPH4^$Y4RTK(XB89QW)+M#)VS3N<\?40@.[+B270^F&Y6;0\?>O<]
MME1/0I<4D%-3J=(H#18$"KO>4ST93:+D?,-@=QP</!Y$XZ1CX<[84^WBUP'U
M,(3?L#&\.YF>;\4Y<-V$]^,>PM^PR> @$MS$#E#C\_\+4(>#Z.Q\W'W95V\?
M;='Y^?G&[5LCK]UP"&ZCANDVQ7^+Z7@TBH;C#EQVQB]C^GP4#>))2[@S_)]Q
M-B)C-GMI9Q@,'@RCZ62CW.[X#Z!L.)Q$P\EP.TAC<)W\ &7)\' <_8P#QLV.
M#IV8W&]TZ)932U$BQ=(9F.801$D:YR^6OYSGC2K$ 9--@]D>^U3BX*_]P4+Y
MOV6==<AP=HNR<VPW$ XUP%8UT56A/4)1O6:^,LI1FNQ6+D1!E5./_?K'Y+1%
MQQ.7N:\K3(UB0^X8Y_C@=#:NL!1ENB(!Z&'TD\!YV7ZA::3:7#YV/1K1NX4.
M2ZWJ"C3NB$79]-TQID7D\T[=IS*<E^XP-V+O>]!(82V"I]=-6='PPM03K-6N
M:IEK]4BO) "E<+OO."MKE[*@KJ];NJ4R%8D5^'R7!1$KG7G*4+VN9QTGK*7(
M,ZS6(A0I+F;D%2>ZGPF@1_LJE(084V,8VNR(V6=U:B0%.42UX\XM'\XED:O%
MHC$'+:[0@LIOE*:\HWT(/O:5H,*"535J\]2Y$$Y%P]OV%8$_7+BN2 ;/,DED
M0$DHY@J^ACX.9:XF=1LC%%)47&9<9UU:0A/HX3T2"43UV(T/H-*>8M,!-.LR
MN7"6N#(6GJ<M"YB7L&OML$M?6E6I3\^(+IB9JM(K3?K#+0[/>6L NA)7G%-]
MWZ#<,85)3<<A-A!#T*D)<!2"PWFMW [1KI(]G\ON?2YSQQA^73=FZMPV_OI[
M#0.3@3LBIYZ:W=:($"QB5TNP<(?D,26]9'!QS\LE+Q1XNQ[K_O;*3<07)X1X
MGOJB>X?JV$"17P U%BJR&#4-D1KI55_LKCB)NE4Q'21"NY1#0C1HEJ%\IO+5
MD:Y4[K?7HKM+8-O99!(-!@,6#.@4RD'S ^*K6ILZ- >^T^EJ ]>XL:8+&"*I
M&G^Y/!5.CX56Q99FQQS)&QA0%1E]XE,Z+6@(5AQI=(NQ$=0:J2WI^S(DT$]$
M[KE".ENN6"&S4U3G,4D%Y!JAO:TS2)8R]&'HT"B? )*;IHO\\F;02\ KSP/"
M7'O6B1SUGY[G1@B"(K;/GM!C-"550-[!=B.XMM&PME#E=Z?77):J@+:G.;<X
M,S:IU25@=DS+0HSI8@@\N,[A0EG4>2=3;^!*QYDLGU3^!/Y-\MG;O^19M-,^
MY^ZH'0P)9H>;"*32(OAA<X$@S9XB;O=K\23%LT\='.F8(UGK?.WO21Q"FAN#
MB%Q3"I'1R7J/)AHU &U,  ^;P;#]'JYQ<[>B<2)#J+$B%"%!4 $\T-64.\[%
M]TJ49L/XFHJZ7%+ ,W9O\6C[UW^@NN0=%S3!:[9%MK,CXSAV.Y*D#I/$O0<%
M,W^1XLIUFG8-)B8JX8H,ND0(9C7;VKI"L&ND2\Z^3JKXVF6OO:0 7 ];7),@
M?)BT'[8%UJAGX0ZJI4WKU0[<>Y16\7FO,XYV,]&9T[BK*UH00IW"H4#G5E-U
MF'K^&Q38RBWS=7=G[%TJ[$<[W"6$,O89\-GSP69O8R_L-4S;T23<+,NP&9>D
M=5:[O,-+.N91.6S.KM=1>"@:<:L)A8]6K%$G(/$34@]X%B4'606GO&)4PRK(
MW> QP*P1$X4SL:FRPMTF=F'NCH/7%=YW73+H;7_JGL2;$[N3*F8>Z0[WS5ED
MK$H??97+CA_N/YR@X8A'O7&,Y[2'QFWGT-JBOWFX.Z%T.!R?H7GJ34?M(.G%
M9PS3?0:>P+5/(,P5H(/>-,'/><QN0LI#9E1:BY"X&HF$T9>E&Q8/!KT!^ZE]
MOFP2TB^W_KAIL^QTVCO'HDG2&W76OFCECUF\8.VAA6/DA9_P.\;OG32/'KB^
M.B_)&<;Z>YNY Q]E27?/VN8'=R/[E6OJ9/SCT#5_O_,'"KKTI?N;R#!WB>W_
M2VF_MO]$7?D_8#;D_F\LM)I+M$;HQ198BC0V.O(%1#.PJG)_Q\R5M:IPKRN4
M^4(3 >87"I59&)" ]O^Y=_\!4$L#!!0    ( #""6%(#*.AB'08  ,D.   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;+57:V_C-A;]*Q=N4"2 QM;#
M\B-- C@9=QML,YB=9+H?BGZ@)=HB(HDN227U_OH]EY(53QZS,P7VBRT^[NO<
M<R_)LT=M[FTAI:._JK*VYX/"N>WI:&2S0E;"#O56UEA9:U,)AZ'9C.S62)%[
MH:H<Q6$X&55"U8.+,S_WT5R<Z<:5JI8?#=FFJH397<I2/YX/HL%^XI/:%(XG
M1A=G6[&1M])]WGXT&(UZ+;FJ9&V5KLG(]?E@$9U>CGF_W_";DH_VX)LXDI76
M]SRXSL\'(3LD2YDYUB#P]R"O9%FR(KCQ9Z=ST)MDP</OO?:??>R(926LO-+E
MOU7NBO/!;$"Y7(NF=)_TXR^RBR=E?9DNK?^EQW9O"HM98YVN.F&,*U6W_^*O
M#H<#@5GXAD#<"<3>[]:0]_*]<.+BS.A',KP;VOC#A^JEX9RJ.2FWSF!50<Y=
M7 E;T/+/1CV(4M;.DJASNA'F7CJQ*B7=RJPQRBEIST8.]EAJE'6Z+UO=\1NZ
MHYAN=.T*2\LZE_F7"D9PM/<VWGM[&7]5XWN9#2F) HK#./R*OJ2//O'ZDC?T
M7=</TKJ* P_HO5PY'S[#X78'H=/OBY5U!@SZXRM&Q[W1L3<Z_K] _C]T+VY_
MH>6_/E__MOAU^>'NEA8?WM/-XM,_EW>+RU^7=+N\^OSI^NYZ>4MWA:36X(I+
MLRM+]1^$Z[!TI:NMJ'<__C"+H^E/EC+V6C[SNGKRVCZA=:QJJ-"-Q19[<DJ+
M2AL'Q3G]PVAKN]^E=0I5A5ED558K:?K,TM4S8Z=,)+GK[-&Z@6(ZHC0)HDF*
M#^]E_-,77]WBG7:BW _VJ_O_;OKFM3!.&8)*FDQ!?BNV\"^.DB -0QI'=#P[
M:8=)@GUFJPU"03L A0Z02.=!.DTIFM!Q-#UIAV.ZDH!CK3)(6-)K2&VU58ZB
M.$BBZ(63W?3"6NG>K41V#\@.;$338!["1DC',.%',_H\O!W21C](4S.[W]FM
MKJTVD,2(R?W<TSB=!O%L3-&<CM.3=CB?[=&;A#Z.&>)(. Z,)_&X6_T.9AS1
M!)A-QR&^H.RH5=?-SN;/F0!GOI$)21B,YY,WF- MODQG,$>(3X#S>-X%E220
M&1\L^HEOITJ4ID&<A!2-TS8O&">3V5>X,A^W>8P@D)S0/ W":/K]B02EQV#+
M'!2=G_C1/-G'%(*OXPDE*18CK/+$;#K[.WE,DFD0^CPF:<R)9'WM=#)-?'-9
M"V4(NAK))']=T6I'&8X(;JT-7$ _X)4=/4HC25A:ZQ*]Z65+>=DR/%MNO'R]
M(6P'36@GA2%MJ)36]XLH#$)D]8CB60SW)T\"8NV@K9=QA='-IJ UK@Q^!L"B
M!I#0. IF2=Q!=M27PM$3F$_-DPJ14ZUQ>1&E[W\E&A^B7AM=^29K@?3;X.#*
MY7>U]B6?H2\#[^H$6_$_&]('C>#[4ZT%4D.+>><*4;]SLF+^&57N2,%)Q502
MCJ3B/:_@VBJ>#[^("SFS*I?P:HW,:?S;)BLX8>QOWH#@N'(%?E2)3:U<DTO/
M)YX!'!87LGUXN<SX&..<>;:T8EOMF.$ V<B,^;\CU)72>4 9?%8.MSU70,[Z
M'LHBRMJ&?>J&!TBR904T5,U*R6DLEN60<+%['?L VTF45A^$^EA(C]&Q.N%5
M90GGFJ12W4N R>@BUXX_W.$)B@M=6>*,11RH+8:[,]\%_V7YKN2:E?8QM[&@
MD$1_B&;:.KZ)*GC)@1TK.,2Z7MN"JJ[9JU6OD_,-1#"TN+FR@1;/CIR>058A
M9WQ" 2S.L&4:9,ID366=J#,X6@A4!GAD9<T!J3KW!UH?/H(H!,>#=4;A4&4N
M':>R90GYTI9_(ZN%+'/N( =@#^D25_0<A?SJ)<;(!WXHM*KLLX376=GDW L\
MEHR%Y1K:&]ZSVF-N)9#D1M4M-O7S&M^3_;D+8J5*%O24[.E8Z++=?EB[#?C_
MU!.##E5?T6@JKQ3UOJ1;\:Z^K'RCO2!/+\I]^-K]=G3PO, IM_&/*#!+P\'V
MI='/]N^T1?L\>=K>/O)P?&Y4;=&0UQ -A]-T0*9].+4#I[?^L;+2#D\?_UG@
MK2D-;\#Z6J,O= ,VT+]>+_X+4$L#!!0    ( #""6%+@WM>;U"    &&   9
M    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;.U=ZW/;1I+_5U Z[552!5$B
MJ8?EV*Z293OQ[MI66<I>7:[N P@,R8E!@,$ DKE__?5CGGA0E&*OLZG[L%F9
M!&9Z>OKYZY[AL[NR^J260M31YU5>J.=[R[I>/ST\5.E2K!(U*M>B@&_F9;5*
M:OAGM3A4ZTHD&;VTR@\G1T>GAZM$%GLOGM%G5]6+9V53Y[(05U6DFM4JJ38O
M15[>/=\;[YD//LK%LL8/#E\\6R<+<2WJG]=7%?SKT(Z2R94HE"R+J!+SYWL7
MXZ<OC_%Y>N ?4MPI[^\(5S(KRT_XC[?9\[TC)$CD(JUQA 3^[U9<BCS'@8",
MW_28>W9*?-'_VXS^AM8.:YDE2ER6^7_)K%X^WWNR%V5BGC1Y_;&\^TGH]9S@
M>&F9*_IO=*>?/=J+TD;5Y4J_#!2L9,'_GWS6?-CEA8E^84)T\T1$Y:ND3EX\
MJ\J[J,*G833\@Y9*;P-QLL!-N:XK^%;">_6+=\FO915=TD2B4G%TE51U 7\M
MY5I%29%%\'12BX5,HXL\ETF1"O7LL(:I<8##5$_SDJ>9#$PSGD3ORJ)>JNAU
MD8DL'. 0:+:$3PSA+R=;1WPETE$T'<?1Y&ARM&6\J67$E,:;#HSWH5HDA?QG
M@K(21Y=EH<I<9@F+#K#AJA)*%#5_4,ZC-[( 7L@D!P8!?T!.:Q7]S\5, ;O2
M^G^W4'1L*3HFBHZ_]M9LG0:U_JE:)ZEXOK?&-5:W8N_%NXN_?O@87?Y\??/A
MW>N/US#WQ<>;]_#73V^OKJ.+]Z^BZYN/%S>O?WQ[&5W\_>]O+]Y?OKX&KN5Y
M,BLK9M+%HA*:+^_+6Z!=JNAMH6I9-[50$1B4Z*4LWXE,IL#%CS!U4J7+&)Z!
MG?U01']M\DTT.>,=CJ-Z*6""U3HI-A$,*BJ11;*HRRB)TF!>Y$PN4S <(DH,
M#:!6]?(1='SWG__Q9#(Y^L&\2?\<__ ]O88D5?;Y3-R"C5O3;$A#6JY@WU!$
MM%BAV"Q$@>\LFIP_@B&J9"V!#EA)#6:UAH^ YJ@0355Z0P)IF51EE8$ C**?
M08MX?KO".+I;RG09W24J$O.Y(',7-6N81'P6:<."[7-Q427 Q\QQ)<%'T[Q1
M\&8<5>4FR>M--(/UR6)!:P(3FV=@H83A<!PU1(J$7:[ UM["D-$:I!*W'=_X
M5)1W!\OR+L8%ZO7$8,&*9@YZTE2BPRL1I:*JP9\@OW#<?\HBC>9  LRSKLI:
MP%=F7WYY<V6W!+2A4&DEU\19'+ZLE/_DP<T;MX%U4BT$+A\93RR'E4B5YJ6"
M#W&?8$^6L!\)TJA4"=3AXR1(AL)MNQ2#> (S,^(=L%^M(K6&;:F:E7V(%@]2
M#%X)OFGX]60F<UEO1M&-MUEK4:$+AKU-*M +(W;LUF2-$E3>:ID(]0'>E&5&
M BL2>(-$D%=/T_M[@6__<O4&&053_-9(U#)\4S7PII/UM%2P,; _6N9DGH.<
M1',4ABR:;:Q,C9QT21Q2@3PJ.<L%C9IDF40:8=T]"T(&W@I0U$6B'RK RV=5
MLS@013++D;&J!@;CHRG\DQ38VXW8:%I9;:)D#;)SF^3*ESX< E8!AL^\[XV$
MS.&W8$WP?UF3UO V?KS(RQD\T5'Q473=S'Z%K42I,D(".B5()E6D@.>P<) @
M6;35UU=-X!5,N)0SB2(WK\J561=0W%E %1#"NKK1ID6 Y*6&>KWMY@E8.4[*
MTM^2>/Q"Z;7HYP*Q\C86>%I&RT310R5K'RS?V&!/F[TEHAZ.SWZ@=:XK*8 R
MV*-,%.6!IVRWLFJ4<$I\<?&/K@D&3RVB=5.M07-QEF%.M4T-?J;)=#L,RY<*
MOR&V]RR\U_A:;JP3F05[F43[9R>C(XC>P$D#:YHU# Q6TO!G#LP']EPT"W#U
MY.Q&X'NL;K!]@H'Q.5P 4P2/5D*N9DVEM)-E!1\P#AWQ$KE<D!["\/!PP:NU
MJVC6^,7^,1#C* <J?2<''X-VEB@V2)=^97K4>L4QW'LC-&Y&B.XA"A:"]F@)
MD7:$.Y2+@PQ>(&4#63VHA0 *RV9FOV ?1L81#&&);DF2':E]LE22"[)F#Y<%
M6 5LH7&5ZV3#>V$,HG+6 "AO.!/)&EH@>TFP#FM9Z; 3? _1 ?G1)U%;9PS.
M@#ALAU^!HFC':[1+DZZT5L@J.U@#US:A=T%E@Q>T;_&CHQRM&7"G:,"G8Q1E
M>' PVQP8\\'ZTQ1UM<&/]9^8%DF%D4 M<V*26Y/1>K"C0&&">VN8!2'<RK,B
MQH!4F$>1T,/W$&37HJUJL%H,"W O*P$#P8*)8#9N2)CV;IHN\C0%JD6B\,%Y
MC8Z7G+&<2]CMH@0;*;2C'$6OT4LR\P+3=A]E1$5*3#'++M$(\UC6X,V2XE/5
MK.N4*(?$$J9%O],4:8/B/:O038\PIG<[#@Y*2/1#37_D!X*/"B.RF*QW418'
MD-["P\1RW#?\*(7Q98T?L0!0Q)2P5((13LE\[I^?C,:> F,,(Y@#?:8+WPCL
M&TZ&7GM%%MS:(ALR[(--<>/CYD \"7M)6V$?!Y%#S?&BFIXQS8Z]!Y-B6#X<
MAOL&:YE <#Q#>Z$7F!F/W.$)<!3-4\XQ4++"_57$Y7F3@[4%M<&D#](JH.1"
MT6Z;T!7BX;P)%,$^W?+X^#GP 06@:(#@LE$FA/4#27P%/]:..EU*6"X+'X_O
M&^6:'0>P3:")!0'3QH+Y@MJ^P%<I29@W% $R2Q6+%.VY>:M&#<H3&S*+"#17
MDGP9XGFE'.B5^2TRQ#?S9&4J<:"Y(H;X'2[7[?O0?/?M($=R;.',5IF-)'-"
M<7$EUA"9X:PZ8J:W?+8!J\W6FP62\2$E3Y<)<%.1QY-5VJQ431EY5*:@UR$C
M(,(1"OU,O1S.425;DRK#8?B[B^O+Z 8BFS0Z/3HUNZ@73P+A!]N)QH]$:W(T
M9Y[&)=J5F@R#9BLANN:HFR8FQN*0586+9-W"&8PAT )1BW19E'FY8']5%HL2
M^6GU%=$%>*/E_5MKP(',N# G&&=,BL!TU9B'@5J!BQ?\.6DQ\CD[2'*T 2A8
M1(T+3DD=K?OND((/S^SBT?5#1-5@%JO79+>'E#O!$9J\I;Q@G<M% :DK2CX(
M"=!@9S0V4YMRPA S"D? %Z/ 4683,%_[CB'N8<!>-A #W6,5;]S7V@#!E+ :
MA8N^2ZJ,C;J"K]5<ZPL^U"\'%("P4>;PD]3\5HH[F/NW!K@L,/8DI<E^!<DC
M7P3[)$2&?U((-,\I&NI) T!'*A8KU:QTM@39&U!I[  L1*=K:%G[J:0]@B=>
M@;M<S4 K#4(8[M<RR1"Z%55%?.,=(T=V-#JWKJEE[?J<GW'+H4!;<<@@@O9\
M'<S0-PBR;'_L/6=W,HCPM0=-G(RU"'0R;RU*QGD/?KN!(2%F0C7K<*<%-6 &
M P2=!$YZ;@'/)+M%^&*#Q*M!(G8!Y78D+X[$;QB]PA23OW0##AL;F82P?Z<"
M,A\,&0[N,!G&@%MD&=&](A),MIZLI1<^H*]A/)D?5>2^RQEZ&<,0S^[<X!2S
M)->.@%,+& GH0@H80W(^$#/YRN 7&2B-1*='<* .PC!:5AM0430-*<?)[%15
M;5=N72GHB;%)OM7<S5%-CV'[/I"'O$!.<*[XRBC?)1+4<HYV8?M^H+BS*+^4
M)7 @>G>A(5S(I=^(6=4@P/#EH.3V+ :A>/GVW85%*/!]_>!;G*<P0-:/J]E/
MT7<U?$.<X1'?XF!F&'KKZZ'-9D""G$W\2&@F>&_&T21,I=J^VEO1&N21<!Z@
MI$H6XEYTYY<W5WZ$D$&V?TN\OY5)=''Q#QQL!8DF*BJFD.BI]$(^B8T&J&1Q
MRX&705^[]%Z6A?8F^<:)L@7!>^&L(2"N)1X03Z6?,$2 :*]')F@'_0""X5'\
MG)\E^V-?GQS'QR"/XY.S2"TAJE1#&!EN+M#(LW^'3P1B$EW3VT9:8HS\$QWZ
M@I_DP3FU&TW&TS.3$@--"_2QM7 TV320D,_/%%L &_<G$\_DLDP,,!",4YI
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MIYTMM\*0 [2'W)V!RL'N:4R'B@MY#JFBL:U$K4ZL<VX;]&)5-G=^G P9H*-
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MZ/3!@H H^=FTP9-AIR:-PKN"2GS&;K4PRJ#1D!PVDH1>N<*>+<V;$APY!O!
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MT:59B%HCU'%X)[J'2QM@D/'F &6FQ$)/'@+,IDOF7X(J?Q%0N=1%3L1Z/35
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M#\#W\[*LS3]P CPQ3^2]^#]02P,$%     @ ,()84OL*:%(7!P  B!(  !D
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MP*2/O38W.3TL2515N!RF5#34G)MY+GF>Y\AUVJI3?Y)8<CJ_A'M5B@3&X2B
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MV5).DIMVOWZ4[;STL 8';/LBRQ+YD \I4AIMM/EJ5T(X>*E*9<>]E7/KL\'
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M%\#]A=9N^^,-[!Y]D[\!4$L#!!0    ( #""6%*7])U-]P<  .03   9
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M/1ZVF G?E,*-T[G_CC/3SNG47RX%#A"&%N#]7&M7W= &]8>]ZU\!4$L#!!0
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M#&NMD5^%XR"=N"O'H^,AO2CERAEM#R:HM/-BMA?ZYCSPKD$3SCZCOW ^ 0(
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M_2?%H[I399)UFY^Z1=-KQMA];+14*6]1%,.=B"E*![@9A>%WM?1SF97"9T/
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M9L$DFC24?.'U'2<*OCOIX+;WVRA[;3G0]E(:!U%\'HRCUI*3P8BHPKXAK$?
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MN84OU4<3.2[=I=Q:3:><XNQH6I1";1%A@A(S;F$FF!Q$EJ"=0[3<P4QJF.0
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M17S";'GKF&FY.1YGA0 !QVWL #40P_DM]C?HU!I7RI!1&5]4W.H.6)K&EI7
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MO-5%DT02*0]X,1U<XG;CU$V$H*,Z:$$V[T,F3;XH_D%SL[$I!XM>*<@\V9L
MFPQ81\TTZ3$F-UX (QBY9"(<%L^(9,_<$W*,?VE)' _%P=FJQ)3?+:6T9"Y$
M&(W2(P RLQJEE6ML#,3!#_6S!\<)#4>+Z?8V^._:NJYO8S90N(\:;W@DX922
MBRTWYZ=[9*XI?5+\8CY-F+(O?[V0/SKS*:BID /3&;7$3XR%'I67,*V+2TS<
MVS%([F2$FR@KQMC4ZP4UG"F#79:DEJ:O"3%YT9;H61L.]N'U5D8ZL = ^CXC
MCVCSJ$\A\S*#,FB$$/Q@ ]IM*+!3IHT''BAGUE'S7#F");>>"2KZO2 CY/\A
M:L=\%TVZAAP)):<K]]&2.PVJ"#\,0>_8%K&OE=-XTYEB1BS[ -+D6N,(D<3=
M^*U6F8%RF']9"V2GH<I>5' \1,@<>9-U-*%14*@%+Y&*[H'%6KE8)V.:V-:/
MUXG%I&HLA/\B>P>W)NE0=E_0/3EZ01+AA92T;N3S#JP,R I3TI0*8*P23GC.
M< ,$Z<A4 ;Z>GOV%\>>V#=NJI<7C?Y9H66859%?N:AAV!R(:0$]W5"/,1U=<
ME/YP?4>17,#F0_5Y8J^@,-5)2%:,ND*Z)L69':EGC]U0-D@!G=*<L:WF_'0?
MS(]XK\NXSOR2%W/E7S9[G?88N>VD^+"G.FF\H>1#<(A^;A;%Q=GYL_G9Q:R0
MI1_R&/6+KRX>(3K^R]0]7L1(]\6<?YU.XN[H%A5*W7=252##CD5O+)T334S2
MYS]7^Q?:8'.6"JI9.MG281?J4Z.+[CJN ("+C]Z>H1% NU>Q187C_6#^/ULH
M+E'G-VIH5XN^Z%A*V.B#?\8CKM1KS4P[>!GB37+CFO4<:WW!P7T;$1YZ$*5K
M=%3^PV:X"FF_$H?,2!,1D'HC!V. RCID>NC/E)U/[Y,T^VNO,R^17#_B?+A"
M+.RX8%8YLJSI\'F7 ,B>S8JQ3[R8J2<%,?BV>L%+#DMPJ>.I >%O/V2=<>FZ
M(_<WY!B2L3T<&]'Y,)KRR?>E2 B<Q8;J?CPE/G(NKNG)30+TM:.Z!C<SDB9S
M6 J1V&DPZT*-)))NI7:P2Z^]2ICB[\37'+<7%0MNEN7JZX]U<U>/A =.[ZA"
ML+'GL6E;ON&C/2*-J_G"7=+&P27X#''=\5TF1R2.<Y\YMED?G  OZ;<V]=$T
M:A9^9$?7)DO,-@/\([!C^87V(L7#_6C9'91#?JQU_*9#G&N7JTLXE223TMC*
M$311O ,\MO$"2UO?NI8;AJ?JTH/"RRRL'."2:7V:DAH*<6A8\D%S8,5::L#Q
M"-+-%.9^R075+*T68J9I(\2+XNFST<LF#G!2X87FU'4XPR88EJ'W;&;J$*;W
M,Z*B&V<_83..9]DEGZC1D8SW25HT'/U("X;*7I2C=%1YZDZ(47UT5*VK0FT/
MO5'/UW;J.U29;^IYX$:MX\0[SGCHC>X HM:C/=9!!% :U3;IV$D^YA1TV>0^
M?-<$%YL&7XY<H(6*<G @0[40]KOB90(2S*M8!4"\N@3*OK&W);1X87:IL1QG
M1*VL*8QD'$$Z@ :F\:CT-L%%3>";4P[=16P O?A,VR8$'VY3%U?4G+,Z\+!,
M-9GS^P/+<3H*0J)P-:$\D]]+'!A\+6NE]Q/S50>: *%L6M\V"^G#/@IDP=%I
MDHN)=4796>U_)S R>U BI$3ETJ93=F CJ1M>AZ696G(Y<L%7P'/6[8=\ET-8
MGZQ1,DDUG%0TD8OI!L"W5]?J^5/>#NO*H%4%053EZ@[)_3?9[/5D<F@4K0,T
MI+XRL#F6#;''>W.$AACWE_':3\G:P'>Q12B[.%INEQA'E QJ'?7+9-CZ@K:8
M+QGQF[K$^:1LQ4[7B]/-J#\#2_R(K7GO +8;3"Z/2M1]%RE>3=V@.;S16I/@
M('BMV=/$N9_Q+:8I0\6$%?)?WW'6IW2WKN3&D8D+L[]T>4E*W-$5_[:<*R_5
M/5WIB6EI;H=.+AVFU'C3=S2FC5 <\=>B>.TJ O9?B(F\O/O_ PO[JO=92U*)
MY\:(->D:.8VJ4^P<.WTO3G?HWMC-Y'# %[Z:FF;V7UB'\!T8&W8E?XK70_7<
M*#>\WG;MNC02"G87EL!+2.0BIS!32%Z)7L<4^N)/(B5VOEV<;EC#&RD&O^\
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MN&8-$X#D7JU2?&UTG1)H2U?2$8=WG7$H^45NPOCO5X2)W^O81OV+E$VOXRD
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M(<42BL6#2Q0/-#C5S*FR(3J E(38-;DT)%$"&3;UBHA1*W5OB;PX&P'>Q[N
M<!9Q[3RV(R#<XKC:7-SN(6O)FU'BD'<FQ0B_O)\8_<>7F:&JZ;G[L2>$#6.S
MRWZ#:FHZ,F,O]FGF'\Z/_<+YM<:W^+M;-\VZP[L]O@D_]!&$?BAL:HC8-[FB
MXMZUV@<*/$X< ; )''6-L="-W'ZN/S0R$MX]/;*%^"'(&C"Z7O0=\N\RBF#V
M$.I7[C?R0G)8!Y?N<9!$L*X"K&F8I";2A)O:0\-WTH3Q^P&(_7T\($SF0],.
M5%CW0I8_5=;$^OW+9&V\8\-YOD 1^S2&S18@[3%_G'K!Z66WX]':TS_-E(TE
M>QXGO_L),K*A7S?U'!_S3X"&3PO]!=5+_MW0^#C__.I/IMU@OKJR:WCU;/'\
MZ0-NA] _NF9/OR*Z;#H02/HGMGW;%A^ []=-T^D?N$'X7=GO_Q=02P,$%
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M(J/A@,11'/7@C;J\C#S>Z!&\2_?]>WTP5J.._ND),.X"C'V \2,!]OB\DDJ
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MGN&\H;LC=G=C5>N/M4ME<7;URPK#.M=. .]72MF[&V>@_Z/C]!]02P,$%
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MJ2&>TK L^%E$ZQWX?&T,[0U/T#ZT\[]02P,$%     @ ,()84J+U<41O!
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M.E16@?ZOI#2GB770/1-G_P%02P,$%     @ ,()84A_!]W1Z!P  &A0  !D
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M[6'8 R/1-E%)]$@Z3HO]^)&2(MD6S6@=AN8AUL<]AX>7E_=><;BC["M?8RS
M2YX5_'*P%F)S85D\6>,<\7.ZP85\LZ0L1T+>LI7%-PRCM 3EF>78=F#EB!2#
MT;!\]L!&0[H5&2GP P-\F^>(?1OCC.XN!W#P^N"1K-9"/;!&PPU:X0467S8/
M3-Y9#4M*<EQP0@O \/)R< 4OYDX)*"U^(WC']ZZ!FLH3I5_5S32]'-A*$<YP
M(A0%DC_/^!IGF6*2.OZJ20?-F JX?_W*_JF<O)S,$^+XFF:_DU2L+P?1 *1X
MB;:9>*2[6UQ/R%=\"<UX^1_L:EM[ )(M%S2OP5)!3HKJ%[W4CM@#..$)@%,#
MG&, / %P:X#;%^#5 *\OP*\!?M\Y!#4@Z#M"6 /"OH"H!D1] 7$-B(\ GG=J
MX>S7E;./(.ZI:<-FL7NO-GQ=;EBNMU4%5AF5$R30:,CH#C!E+_G411G:)5X&
M(RG4+EP()M\2B1.C7]D*%>0[JK9$D8)%M1T!78(%615D21)4"'"5)'1;"%*L
MP /-2$(P!V?@*DV)0J(,3(LJ)2B>]Q,L$,D^#"TA):J!K*26,Z[D."?DN.">
M%F+-P4V1XE2#GYGQT#$06-(WC8.<5P>-'2/C!"?GP(4?@6,[]I?%!+Q_]X&O
M$<-<H^[:S+7 &\EE'W!I6"9FEMFVZ,-R8V:Y1ZPS+PW+I][>@?%;WOG<VSL-
MEX;EMK=W3"S3WMXQL<Q^(';P2A8Q\0Y8H'+427?=_7O7]V"=]V>-# MZL)?<
M)MFX);G[/R2;/^:2#$P%SOF?!BE>(\4KI7@GI#SB9UQLM1X:5TB_1*HNYGGD
M^)&M_H;6\_YN[QKZ81BX'<.)AA'Z?M?PIFL(73L,.H:?-$-[D0\[AI]U0\?E
M= X-;S5#AY*S8SCM&D9VV!UYIB&$$8R=CN6=QM)V/*<[]EPSMN?Y!Y0'X> W
MX> ;P^$7V>]FE&O#H4(&>V.>>780^MUX\#OJSJ!O=Z<QT1BZ?AQT*6\TEIX3
MAUXW(KJ6GF]K D+#Z(1NT+6\U:FT7;\;C5.M2L?N!OA,XTSH0.AHHD)#&OL>
MC+M1H;$,HBB*3X9%T(1%8 R+SY2F.Y)E9;(BA4#%BCQE&"#.9<"0?(,(4]E<
M5QJ"SDQ/B D;,:%1S+093N7+C!:KLTQ^P:25&@[6.$O/9!-VMN58)RCL*RAJ
M!$5&07,L!&9*3,*P; 1UFR?J;FU?DTIG;]L=2(P;B;%1XD+0Y"N@&U5Q>+F*
MCXLO',C/42X7,U45YCTIZIKY ?P-3M;-<=QQ'_0<-XQ">+01-8:VS!:^?SSG
MOHQW?1GG7</8]J(P=O5>A';[E6";\^,V?ZJ66G[_,U26YKJ3X<IKU:6V7[>[
MXD^HV?MF@48U#TOR7:I9C,]\QY?#7Z_EQL1R@P+Y.92A)\KJ%F/%,"XW#$^D
M;F79OG^6VY@Q!>Q*/]3EM+J<G]W?P+;7@NZ/=CBS&GI01V/-MKS3&/JA85_"
MMO^"Y@;,4'%G4%/F]?)T'9A)7ML/0'-#<(-8(=>' QGN55+XJ$Y[2%+FBU2%
M$=M[J5)'VWQKYU2-%^ZGWW,[.)Z0ULH_,9NVC$%S';LG!<FWN2FNVBH$PY\>
MY&T%@N82=,,%R9&015 6O>4V ZHB<B6%X:Q\7A5'[8J8J5WP#<LU-LELJQ T
MEZ%[]/*&_YTV%3OVS_:_TV9BQYR)_XO_WZ#V3_O?VCOORC%;E:>X')3SK;Y&
MFZ?-2?%5>5YV]'P,+Z90\WP&+^;5.7!+7QU+WR.V(K*5R/!2#F6?AW+#LNJD
MM[H1=%.>MCU1(6A>7JXQ2C%3!O+]DE+Q>J,&:,[;1_\ 4$L#!!0    ( #""
M6%+=DH36C@,   T.   9    >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;+57
MVV[;.!#]%4+  BV0M2YV[*2P#?C2[@;;[!HVVCX4^\!((XF(1+HD';?]^AU2
MLN2T%ITNDA>;I.:<X<SA93C>"WFO<@!-OI8%5Q,OUWK[QO=5G$-)54]L@>.7
M5,B2:NS*S%=;"32QH++PHR 8^B5EW)N.[=A*3L=BIPO&826)VI4EE=_F4(C]
MQ N]P\":9;DV _YTO*49;$!_V*XD]OR&)6$E<,4$)Q+2B3<+WRS#D0%8BX\,
M]NJH34PH=T+<F\Y-,O$",R,H(-:&@N+? RR@* P3SN-+3>HU/@WPN'U@?V>#
MQV#NJ(*%*#ZQ1.<3[\HC":1T5^BUV/\)=4"7AB\6A;*_9%_;!AZ)=TJ+L@;C
M#$K&JW_ZM4[$$2 <=@"B&A#]"!AT /HUH/]4P* &#&QFJE!L'I94T^E8BCV1
MQAK93,,FTZ(Q?,:-[ALM\2M#G)[^(S/*V7=:B< 3LJD6 !$IV;",LY3%E&LR
MBV.QXYKQC*Q$P6(&BOQ.UO  ?(?-5(J2("_5D+&8K*C4'*2Q1D$*>B=DY6&6
M20!<-EI99VM00&6<(SW*S_0W\H>DYN.K)6C*BM>MC\K%0G!T$FO,DL[)PN8'
MY)'5N\KJM,^+ _T,?;]GL5F^=HH<F[HV7S-U/_8UYM9DR(_K/,ZK/$8=>0PC
M<HMSRQ5YRQ-('A/X*$JC3'109AXY&9<0]T@_O"!1$ 4G)K1X,CR\/@%?/AU^
MY8BFWZRSON4;=/"M4O8=I(-HT! -+%&_@^AGL<CG]VA#;C24ZE^'A\O&PZ5[
MJB"-!SSUS":0]1(_M23</(.@%P2_G5+N?^*69W"CGW&/$C!L$C!T$LV9R("3
MVQFYX;&#;]3PC5Y(LJO&P]4S2>;FB09=DKEQG8K],NQ1^-=-^-=.GK^8!K+*
M*=Z#%T:S'GGEF3'OM8,\#-HK(G@A_<*C:RA\)@7/$'5+> ;8[P(NSP'/R1A&
M;18B)]7?X@%O3J901*69WFF\6K&\(;@CR2TD>!47[9WIWIQA>S*'_9>2MSVT
MP\%SR>LFZE;7C>O<H;^.>YR"]E8)W<?SAG*1,A=5>SZ'PY=2K#VSP]%S*>8F
MNNQ4S(V+HD[)W,!PV*69?U0G8]F8V?>&(K:RK0JS9K1YT\QL)?_#^-R\=6S]
MW=)4#Z5;*C/&%2D@1<J@-\)%(:NW1]718FNK\3NAL7:US1S?:R"- 7Y/A="'
MCG'0O "G_P%02P,$%     @ ,()84NXVG03@ @  # @  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S8N>&ULC59=;]HP%/TK5M2'5FJ;[Y96@-0"U?:P#95U
M>YCV8(PA5AV;V@YT^_6[=D(:(.WR K9SSN$>'^>:_E:J9YU1:M!KSH4>>)DQ
MZUO?UR2C.=:7<DT%/%E*E6,#4[7R]5I1O'"DG/M1$%SY.6;"&_;=VE0-^[(P
MG DZ54@7>8[5GWO*Y7;@A=YNX9&M,F,7_&%_C5=T1LW3>JI@YM<J"Y93H9D4
M2-'EP+L+;R>IQ3O #T:WNC%&ULE<RF<[^;P8>($MB')*C%7 \+6A(\JY%8(R
M7BI-K_Y)2VR.=^H/SCMXF6--1Y+_9 N3#;R>AQ9TB0MN'N7V$ZW\N *)Y-I]
MHFV%#3Q$"FUD7I&A@IR)\AN_5OO0((3).X2H(D1="7%%B+L2DHJ0="6D%<%9
M]TOO;N/&V.!A7\DM4A8-:G;@=M^Q8;^8L.=D9A0\9< SPV]JA07[B\O4Q +-
MR@.#Y!+-V$JP)2-8&'1'B"R$86*%II(SPJA&%^B1$BD(XZSD V>$=>9TW&#R
M4K -YE08C4['U&#&]1GPGF9C='IRADX0$^A[)@L-%-WW#3BR=?FDJOZ^K#YZ
MI_HQ)9<H#L]1%$1!"WW4F1[>M-#'W>F]%OJD._UZG^Y#BG6441UEY/3B#E&>
MHY$4&H):O"4[551#$G54#TQ@" ]S-(-%FKN4?MW-M5'P^O[^H**XKBAV%27O
M5%0?!F('].TPM"5=2J5.RG:WS3",PSB"7#;-1(]AO2")>ONH<8M8$B3A&VS/
M3U+[23[T\U6*"U(H!1:@1\(^,6)HZ:[-42EVU2PB#8(#/UU XV-0W 3MF4EK
M,^E_PSD_2L;%=> -80U+:ZGLPI:9#%Y:D]'&$8/UQAG:M8$'N(1:HTY;HHYZ
M1U$?PWKAS5'4+6))?!,>P";'L#2.HZN#/?0;G=3>DU^P6C&A$:=+X 67UR"@
MRKNGG!BY=LUU+@VT:C?,X+JFR@+@^5)*LYO8?EW_ 1C^ U!+ P04    "  P
M@EA2@)> 1GL)  !.5@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6S-
M7&UOVS@2_BN$L1]V@4W,$46]+)( 6_>*6Z ]%,UV[\/A/B@VDPBU+:\D)UM@
M?_Q1\LM0%D51MG(@"C1^&5)#CO@\G#$?W;QF^;?B68B2_+5:KHO;R7-9;GZ9
M3HOYLU@EQ76V$6OYS6.6KY)2OLV?IL4F%\FB;K1:3CU*@^DJ2=>3NYOZL\_Y
MW4VV+9?I6GS.2;%=K9+\^SNQS%YO)S Y?/ E?7HNJP^F=S>;Y$G<B_+KYG,N
MWTV/O2S2E5@7:;8FN7B\G?P*O\S ]ZH6M<D?J7@ME->D&LM#EGVKWORVN)W0
MRB6Q%/.RZB.1?U[$3"R755?2D3_WO4Z.%ZT:JJ\/O7^H1R]'\Y 48I8M_YTN
MRN?;230A"_&8;)?EE^SUGV(_(E[U-\^61?T_>=W;T@F9;XLR6^T;2P]6Z7KW
M-_EK/Q-* _ [&GC[!IYM [9OP.J![CRKA_4^*9.[FSQ[)7EE+7NK7M1S4[>6
MHTG751SORUQ^F\IVY=V'),W)'\ER*\@GD13;7,@@E>2*W.\"2[)'HK<IJJ]F
M2?%,_O'G-GU)EM5G/Y-?7Y)TF3PLQ96\R:[NY<?D7LRW>5JFHB#)>D$^Y$)^
M]ISD@GQ,DX=TF9;?R8_O12D;_B2O_/7^/?GQAY_(#R1=D]^?LVTA6Q4WTU(.
MMW)Z.M\/[=UN:%['T-Z+^35A\#/QJ$<US6?6S2%N-I_*23[.M'><::_NC_7.
MM)RDHA#E;C8.4U#-SGYV%T3>WU^J2<O3]5-M]:]LG1\_>)<4:4'^\U%>@/Q6
MBE7Q7X-[[.@>J]WS.]S[/2N3I;RS\F\R$#)\I#A&33?UN\YXW5F%%2]W/*"!
MY]],7]0I;ILQRJ(P.IHU?/6/OOI&7S]E:_%][RMYW+;NCD:G_-@I=S$^P=&]
MP"(^\VJ]"5QONM#L^@G4T# (^$EDVE:,^G&@#TQX=#(T.CG+5BN1SU/IZ2;9
MB-PP[NC89>1B6.*C>_$X89G%K0GWXCC6SS=0A&\ZYK+=]];P AAG[.3NT-@!
MYRSH6+B@T WTW"'Y)LN34DBN?2@[O6WVCA +3F(L(,C"J"B[[ZVQEF,>GJ*L
MQBSF%,*.8"',@AEG9R(OT\=T+L-5L_U";+(B+4TS@6@+3L(M(-Z"#>#:AZH-
MJ. Q@(X8(**"&5+KN;EZ2.;?Y$38+1>$5G 26P'!%6S0U3X&;8R%,*8=H.4A
MR'IFD/UZ?7]-GK(7D:^KG>]5L<G615;-BGQ7[5[ML<Q#I/3 Q>!XRG[6&S,X
M^]X:U,-#+XY.P$QCQYD?LXX@(O1Z9NBMY_.ESF+J%/0P.P_5[)@F!.'2\YV,
M&&*NQT?:0^X[ZMM$:LR8C!7OB!5BKS<J]GJ:+:\N&]'8F=(1#T':,X.T?F+K
MN-H/(FPY%P +H_AT$&T[QD+YKV,0R 9>=/X"(7^305F7AQCOQ2ZN&H;HSVRV
MV#:KAK5WS;I5HS$SY%X,&8.9]]9] 1R0G3%D >;DEILI=0V;+;=-AL;:V^CN
M%(TA+3#S+GIH9<6W2]$T=J84C2%+,#-+]-U&'\6+6!(P!0>!G@5.WCV([.P<
M9-?&K8W+VL6O@6_#XD?T9F;T'GJ712TWZ*FG)I.FEPCV[)QRR3"B9.U=OG:B
MVV:&B?:1#GPS'5@NCZ&$Z2/,^TXF!CY2@F^3&-BL&5^WUV^'4F-F"B52@W]!
M2M (Y0#J])4JMI/Y@H],X(^4+\S\=B+0@14^<H,_:A+@MS?WIXAF-&EZB03A
MFPG"[A[R3/% C/>=K-?X"._^2-7P=WX;G5O1&E(QYXC??-2*.=?LZ76YI<;.
ME%MRA'MNWM6/09G[2_0/HFW':!"%'95DCI3 S91@N4J&DB9'J.?,Q:7#D0RX
M399@LW1X>^-_NG2,)DT'E9]'QT@+O&%DR9$-N).9 D<BX"-E"C/>3@$,P(;L
MP$?- 'A[>Z_-,S5VICR3(UEP,UG8W5#,]-LY@GY 7;Q[ D3YX!R4U_Z\W\;H
MT^5O-&DZB @>C%KM#]I;]I:7)I.FEPCSP3G%GF%D&;3+0"W7329-UY$  C,!
M6"Z'H109(, '3OXB&R@G8$8[ M.?"QA-F@XB!01CY )L&$4&2 "!D^E!@(@?
MC'58)C"E!\VC2<@!X:@;_["]H3^]AXPF32^1",)+B_C##]"$B/*AD]7\$ $^
M'/4 36AW@$9C9CA $R*FAY=A>F<PK<KL(4)[Z"2TAPCMX:BUGK ?WXTF32^5
MTXV7X7M_.$UUH!"!/G02Z$,$^G#4<SNAIJ*O6Z5M,\,JC9 8HLLJ^OUA-24I
M$4)_Y&1A/T)VB$;- :+^',!HTO02*2*ZK*H__%1CA( ?.5G2CY )(IN2OGT(
MVW5]PZG&"/$^,N/]F3&RHL4(\3P*G8R6<O9]U)).9/V+;810'EU6I>F+E(GQ
M8H3HV,GZ38S8'=O4;ZPC%;<K-(9U%2-"QY?5V?NB92*R&!$X=K+8'B-,QZ,>
MR8FMR^DQ G%\63E]^+GO&-$W=K*6'B,PQS:U=/OXM OJAG/?,<)O?-F)R(X8
M6;%4K"B,G#P@"505(8VL0K(NG !5I$7TLM))7[A,5 54$2%1)XLH0!49$AU7
MAT3;!1+#"@.J2(SH9262OJ"9& NH(D>B3I9(@"J")#JN(HE:ET" *GHD>ED1
M9$2Q#%!%RD2=K(D 5<1,=%PU$]4<@-$I9G2&!LD,J.K2'GGIV,&VHD9HR$F=
MK)F JDF%4:LFA^Y,91.SS8FG"BOTJ%/?+-I&9E7UJ.!D>05462N,6F Y=->_
MR#6&QD6N\$J/TO7-PF[D9E4""T[6:4!5TL*HE9I#=^9%;EW. 552VZ.I[8MV
M_7B6HGH\BYSE:K*-RGR%2CPG2SB@*&[!>_NCEH=KJ%$+N\*FB&VA1VT[.&QV
M5*OH9\%SLJH#B@ 7O',.40X-H'6U!Q3I+?1H;\^/GY$\%4TM>$Y6?4"1T<+_
M04<+&H%L9_P4@+]0'=L=/R,+*CI9<%,H"XI2%LZ2R@Z,W_X:W 9 %7$L7*B.
M'<1[BCX6W!3( E,?2O/FIR9GH%//L@Z)%BCJ6>B1S[X1\2EZ6&!NEH84&2VP
M<XY&#HV@?;U($=!"CX+VC8A/4<8"<[,TI,ABX>UUL3/0*%Z[XJ?(7>%"O>N9
MQ*?H7<%-P2LHBE<X2_(Z,'[[:W C@DZ59WU63UK]E.1/Z;H@2_$H6]'KZB1@
MOGMVZ>Y-F6WJQW\^9&69K>J7SR)9B+PRD-\_9EEY>%,]4?3X"-F[_P%02P,$
M%     @ ,()84@\"-7PK!   X0\  !D   !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&ULO5=1;Z,X$/XK5K0/K=0&# '251JI:2Z]KJ[;:-/=>SC=@P-.\"W@
MK&V25KH??V.'$+H!EGMH7Q(,\WF^F?D\(X]V7'R7,:4*/:=))J][L5*;CY8E
MPYBF1/;YAF;P9<5%2A0LQ=J2&T%)9$!I8CFV[5LI85EO/#+OYF(\XKE*6$;G
M LD\38EXF="$[ZY[N'=X\86M8Z5?6./1AJSI@JJOF[F E57N$K&49I+Q# FZ
MNN[=X(]W>*@!QN(;HSM9>48ZE"7GW_7B/KKNV9H136BH]!8$_K;TEB:)W@EX
M_"@V[94^-;#Z?-A]9H*'8)9$TEN>_,DB%5_WACT4T17)$_6%[WZG14">WB_D
MB32_:%?8VCT4YE+QM  #@Y1E^W_R7"2B L"#!H!3 )RN +< N%T!@P(PZ KP
M"H#7%> 7 +\K("@ @2G6/KNF-%.BR'@D^ X);0V[Z0=37X.&BK!,2W&A!'QE
M@%/C&6$"?2-)3M$#)3(7%'2FT"6ZB2*FQ4(2=)_M):^E<S:EBK#D'"R^+J;H
M[,,Y^H!8AIYBGDN217)D*:"E-[?"@L)D3\%IH/ 8JCZR\05R;#RL@=^VPS_S
M;1\Y;B-\V@Z?TK"/7./=L6O@OW6&XZL:^*P[O([\73O\4YY ['8=W (AE&IP
M2C4X9C^WD<Y2H04-<P&UI_("W6RAV&29T$N0P*4D"45__0$@=*]H*O]N<>F6
M+EWC<M#@<DY>M.(D4ASZTH^<"8K(47LL4U10J;3&9+Z4+&)$ +6Z0N\=><:1
M;L';<6 /1M:V6LU3&\=W7MO,3FWLTN)5C(,RQD%KC)-<PALI]P%*$]L%RO)T
M207B*[02E"(9$P@4P;B0"@X2R]8ZX'^@9>O4;'(1QM!RT9E.A#$]K\O!GHA?
MX3X8V'8#?Z_D[[7R?WK6LP(M^C?]EHK[Y6[^>XDL*%T&K0%\+E/-!6069NXA
MW87DHE_D=1*<Y!6['KZR7?^U>&YK#+'G#'W7JZ_!L QAV+4&Z%^TT$S1_""*
MFS4HR#1N4 YZHED$T3ZN5O!;?FI)XU7)X>J]*H?MXX"R.]:N>DQBFD1H^8)4
M3%',$XA7_J*$=X6?5V<C"!H/!ZZ,4/R_CS>"GL5@9H*R5GK$;LV(31A9LL0D
M[Z> :@GCTV;5R/;8XK'SMF=A6CBH)M)UG&HBB\EY:H<Q/K&;U=@YGCT(_  W
M!'L<+OC=I@NN&R\G(9\:N8TE.XX/W#X_[K,0KAEPSH%F14T_'0DB)=TW@(/,
M7FKC.!T1N)'B<4+@]A'1_0P8FAWD/RT\>IV('H</]M^VCP+J<6/"FPL6ZC']
M0%7,H[9F=YQ3.'BW#GN<++A]M+Q1_YH4;MO[EU6YN^C+[P,1:Y9)E- 5H.Q^
M '"QOT_N%XIOS'5FR15<CLQC#'=P*K0!?%]QK@X+?4,J;_7C_P!02P,$%
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M*X<=I!1A7Y<::J"6]F'(Y@.!316V#234(\%0!+6W%T..C=:@J<)AT_>(,.1
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M86G><Y2VP.P70NBWB7TRNG^(]!]02P,$%     @ ,()84LI."K"8 @  F 8
M !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&ULC5513]LP$/XK5K0'D"A)
MTY8QU$9J&Z;Q@(2HV!ZF/;C)M;%P[&!?6]BOW]E)LX!HX26QG?N^N\^??1GO
MM'FT!0"RYU(J.PD*Q.HJ#&U60,GMN:Y T9>5-B5'FIIU:"L#//>@4H9Q%%V$
M)1<J2,9^[<XD8[U!*13<&68W9<G-RPRDWDV"?K!?N!?K MU"F(PKOH8%X$-U
M9V@6MBRY*$%9H14SL)H$T_Y5.G+Q/N"G@)WMC)E3LM3ZT4UN\DD0N8) 0H:.
M@=-K"W.0TA%1&4\-9]"F=,#N>,_^W6LG+4MN8:[E+Y%C,0DN Y;#BF\DWNO=
M#VCT^ (S+:U_LET3&P4LVUC490.F"DJAZC=_;O:A ^A?' #$#2!^"Q@>  P:
MP."S@&$#&/J=J:7X?4@Y\F1L](X9%TUL;N WTZ-)OE#.]@4:^BH(A\F<VX)=
M/VW$EDM0:!E7.;OEYA&0+R6P!60;(U" 93TVS7/AW.*2W:CZR#GO3E(*%O*4
M(AX6*3OY<CH.D6IS&<*LJ6-6UQ$?J*,?LUNML+#L6N60OR8(252K+-XKF\5'
M&5/(SMF@?\;B*([>*6C^:7C_VSOP]//PRR-J!JU/ \\W.,!WH[9@L706G;$4
MENB-<L;A2]>DW].E14.WZ<^1I,,VZ= G'1Y(>@]<BK^0,ZFM)7*]8GQ+3KN3
MT2/_>Y8.#;-M]O=LKS.,? ;7@[8)F;'M^O!A1'HLXI6P42ML=%189S>9Q@),
M#PNN>@AEI0TW0KXP459<F+<GL=8T^E#3L8BZXK!S9TLP:]_[+,OT1F%]R-O5
MMKU.?5=YLSZCMEMWR?\T=<^F:[P6RC()*Z*,SK]2/:;N@_4$=>4[PU(C]1D_
M+.C7 <8%T/>5UKB?N 3MSRCY!U!+ P04    "  P@EA2G7-K>=@6  "@J
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M0%A6XP)J-"AL./<F&A@V5:,!8I6:C4-5^C1 ;!@3)AKD-7T[(\ -UVI4SVO
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M$#00&!J,9[T8"%0,7E$(&G3W.7'HVXJK$"<*4<=U/,4H.U5I]3P4]+M0H&<
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MG]CZBA8)><I?R!*1_Z)U86MW4+@2DJ4%&!BD<;;Y)S^+#[$# #]Z@%, G+8
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M,H#W<\;D]D8%*(]4A_\!4$L#!!0    ( #""6%+!MGK/2@4  "H7   9
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MK?#SUKY;X1>M?;?"+W\L[I]_;.JNVL-'%OBB-=SS'8N@5U6)7JZOMT??#63
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M7N/536MMDTI;<$*;'Z 'SE0NT1W+(-LG<'6@3;3!-MI)T,DX@_0:A?XE"KS
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ML!9<Z?9GA[G^0P%A#/3W)>=J.S$.FG^>\5]02P,$%     @ ,()84KK%905
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MM5HDRB)8V(?5/KCIM+'PI6M/6]BO7]M)0]FE?8*7QF//G#/GU)ED&Z6?3 F
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M%]?;,TBXILZ!1*9Q D!?@']?ZY;V=/H[K=OJ,( J.+,=U^ET2V][Y&RH!^E
MBYI*NJ!ZB']?5\W=>KOL%4"]G?0OA5B"11R&X@UF79^_$3UAW5&RZ\H>M^GQ
MQ&+==5&EYA-GWET550J[DYD[L"B2JJB>JIIYYC?ST6OG8]J0J[KIY;(=HRC?
M/(KWK<OZ:6X<$(-%:ESUKI)ZJ&!@[TLEN5']QN2L?BW2B#08*)[CW;LCB&E9
M; _U]JGZFM]6WG3=]$@1Y>S';8\4&ZK]J"1,:B#,LC!]#K+UFH>+SL&)0+RT
M%)NP+!8AJ]]YB-<;W+CCIVIK;&XQ[';=5\7L.6:*_ZJ8..\W$&@FR9CIR5@+
MV#^JJ&*2=]F!\"Z3O,M^'N\:5!L;UDP2+],3[RTO-N>0EA\^G$/<SC[=H3-X
MAKF*&NT9)/&R R%>)HF7&5[6#QYQBGC1%JH?93].,^,3R\8?MVN<MQNUQ:H[
M)TD,&;0YKG=;NG?-[RK=K>-4='C/RR1I,0-IM9N$=:* (>^">,4C='<F:G!=
ME"27L /9*#&)^\R ^UY8)$V5+>5Q(MDX_+9RY;R:%.-6)4*PS>;R3QO7+_8;
MTS[=*$'>U8/\.2!7 $16';GA/@^*-HQ@N[2Y% .)>%[I;W$TH0I+7YCEVAY(
M7G#U_;3JA.:#^@J@K5"BNGL@G3-70KAKZ)S]4#2[=-6.&2Z.$'6C]KY/TB$]
MDM<]DL0!44R[94WO[(RJ.F][9\>4#9[X<25EN89#Y/EC&/A-].T[-M@X6K[_
M0W]9F=#:5^ )[2YQCQ2;#)T:<B4#NGH&_'\<^[UTU7-MQ:E>)8]4.8+I3(GC
MM/&#+?'[R#LO6<$>!X5\"0.MB="3E#\Y+"^R>%O\ANLQSK)X4WQ<<P\ 30C
M]\LXSG87XF=A]0\_3_\'4$L#!!0    ( #""6%*?J_X84P0  )42   9
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;+68;6^C.!#'OXJ56]VUTK9@)SSM
M)9'Z=+I]L;M5L]U][< D006<M9VDE>[#GVT(I H0@N[>)!CLF=\,9OZVQSO&
M7\0*0*+7-,G$9+"2<OW)LD2X@I2*:[:&3#U9,)Y2J9I\:8DU!QJ906EB$=MV
MK93&V6 Z-O<>^73,-C*),WCD2&S2E/*W6TC8;C+ @_V-IWBYDOJ&-1VOZ1)F
M()_7CURUK-)*%*>0B9AEB,-B,KC!GVZ)JP>8'C]BV(F#:Z1#F3/VHAN?H\G
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MTRJY86&:4Y1V@_F^%$*_3JR!MMV=_@M02P,$%     @ ,()84AS99RS^ @
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M2@"^;QB3IQ?EH+H!3OX&4$L#!!0    ( #""6%*A.ZQ/F@,  (<.   9
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M)KM</?#]'U [E!J^%<^E_47[^FSHH=5.*LYJL+: T:+Z)R^U$&< G%X X!J
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MZ:2("T@'_7":0=:9OH T.8"FRF1':=\J],T"3-JAN=+4R$^+-?I,J$3?"=L
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M3;,'TBXP[U="Z+>!_4#=/D[^ U!+ P04    "  P@EA2-3JNB^("   ="0
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MO9N!%B6:SMY,%%_;7K?@2G=..RSU8XC"!.CO2\[5;F(VZ)[7R1]02P,$%
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M(?LJ?9C*7AF8$LCK":5B/U 3U-WWY#]02P,$%     @ ,()84E6RM'3C P
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MFQCYR*:+;09:'.J^;BLT=HGU:X:=/T@#P.\[(?3+P"S0_9=8_ ]02P,$%
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M[YJ>3_S@*LEPV#@;K>]H(,B;QW[/VA#42W5R#7'F:M:YFEUUM86L3O^_K=E
MSZ<@#/LI&T&%7L_9"&8V;BWNK,57K>%1^1_E%0_+RX_G_:R,H(9%F Q19T78
M.'!/[JD2Y-[>]XJDYAAJSNYNM'M2K.U-VAO?X%.C>1G\"M.\4[Y2B0>+(@7L
M,.3D9H:29'/W-QTM*GL;/@F-=ZMMYOA< FD .+\30K]VS += VSU+U!+ P04
M    "  P@EA2257]AFL#  "Q#   &0   'AL+W=O<FMS:&5E=',O<VAE970W
M,"YX;6R]5VUOVC 0_BNG:!]::2-QWH )D+HRM$E[0:7;/DS[8)*#6$MB9CNE
ME?;C9X<TA29$2!O[DL3V/7>^>\[GRVC+Q4^9("JXS])<CJU$J<UKVY91@AF5
M/;[!7*^LN,BHTD.QMN5&((U+4);:KN.$=D99;DU&Y=Q<3$:\4"G+<2Y %EE&
MQ<,;3/EV;!'K<>*&K1-E)NS):$/7N$#U93,7>F376F*682X9ST'@:FQ=D=<S
MXAM *?&5X5;N?8-Q9<GY3S-X'X\MQ^P(4XR444'UZPZO,4V-)KV/7Y52J[9I
M@/O?C]IGI?/:F265>,W3;RQ6R=@:6!#CBA:INN';=U@Y%!A]$4]E^81M)>M8
M$!52\:P"ZQUD+-^]Z7T5B#V =K0=X%8 ]U2 5P&\4P%^!?!/!005(#@5$%:
ML(S]+EAEI*=4T<E(\"T((ZVUF8^2KA*M \QRDUD+)?0JTS@UN<&4*HQA3H5Z
M@"F34<IE(5#"Q1059>DEO((OBRE<O+B$%\!RN$UX(6D>RY&M] :,&CNJC+W9
M&7./&/L<J1XXY"6X#AFTP*^[X9_X70]<[RA\V@V?8M0#K[3N.BWPMR?#R; %
M/CL=_FSSMN:L)LZMB7-+?=Y)Q-T*FDNZ.ZS?/VA1>*\PDS\Z#'FU(:\TY!\Q
M-*</NI(H"8KK.O"K8 *!QC$SMFBJ,T*A3A=E4D,62\EB1@7#MNR8[@P%I2%3
M\NXF?<<?V7?[)#1EW- ]E)DU99Q:XL!'O_;1[_3Q]M[4-ECTKGH=$0MJ;<%Y
MJ0EK0V'GMC\5V1(%\!5P$;-<WPP@$VH.;T54#!>&EG+NLNV\[O2'>Y$D7D"&
MCA<>AORZ19 $[B#T@O;(]VL7^J=&'G[#PNP4YH6($GU;P-5:()KD UUOX!;S
M6'O[>;72SWJI(XR#>@^#\_(UK T-S\O7=-B@P7-U$^$\.T1-,4)(0VS6%',#
MQ^^'?=).*G&>;A7G?Q6-RM)AU7CN<(N0YQPI"F3O;B2=7IC>1?/U]AZCPC1
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MYGD%T+^_2*G>7RH'W;7I^%]02P,$%     @ ,()84ELG 'V, @  _ 4  !D
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( #""6%)T:93T7 4  /LO   /
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M\'@7VFNNZG/+XH]545Q1QA*6>:?486@[TU\,;YYKUY_K[O?^ U!+ P04
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M4N\R?AURN?9\K_'Z/TGU>#XW7R]_67[OG-R7"\[U;45Y^@M02P,$%     @
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MSC;]6SX;_[YY_@)02P$"% ,4    "  P@EA2!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #""6%)-
M<^P,[@   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( #""6%*97)PC$ 8  )PG   3              "  <P!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ ,()84K;((.CP!@
MW!H  !@              ("!#0@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( #""6%(9&#I!!0<  '<<   8              " @3,/
M  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    "  P@EA2<(4.
ML-8"  "C"0  &               @(%N%@  >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&UL4$L! A0#%     @ ,()84GQ=JEV6!   MA   !@
M ("!>AD  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( #""
M6%*P"S:SC0,  /T*   8              " @48>  !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"% ,4    "  P@EA2)UV[KA@)  !*,   &
M        @($)(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%
M  @ ,()84HJ^C"FB"0  &BH  !@              ("!5RL  'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( #""6%(A?!@I4R8  ,A]   8
M              " @2\U  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"
M% ,4    "  P@EA2?=&N;D4*  "K&P  &               @(&X6P  >&PO
M=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ ,()84@,HZ&(=!@
MR0X  !D              ("!,V8  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX
M;6Q02P$"% ,4    "  P@EA2X-[7F]0@   !A@  &0              @(&'
M;   >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    ( #""6%+[
M"FA2%P<  (@2   9              " @9*-  !X;"]W;W)K<VAE971S+W-H
M965T,3(N>&UL4$L! A0#%     @ ,()84HMGMR5M!     H  !D
M     ("!X)0  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #""6%*(3?:HO0P  ,8B   9              "
M@96X  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ ,()8
M4C[?)B:C @  C04  !D              ("!B<4  'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6Q02P$"% ,4    "  P@EA2F=KWF40$  !G"0  &0
M        @(%CR   >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0
M   ( #""6%+A\O6;V@(   \&   9              " @=[,  !X;"]W;W)K
M<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ ,()84E7D/RYG(@  8W8
M !D              ("![\\  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q0
M2P$"% ,4    "  P@EA2D(F< N,#  # "P  &0              @(&-\@
M>&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( #""6%*YSV'
MUP0  &0-   9              " @:?V  !X;"]W;W)K<VAE971S+W-H965T
M,C0N>&UL4$L! A0#%     @ ,()84B_6^.I2!   I@H  !D
M ("!M?L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4    "  P
M@EA2O<BPPD$%  #T$   &0              @($^  $ >&PO=V]R:W-H965T
M<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( #""6%)QD"?>B@(  '0%   9
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M970S,2YX;6Q02P$"% ,4    "  P@EA2'\'W='H'   :%   &0
M    @($D&0$ >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    (
M #""6%)N:4N7+P0  $H)   9              " @=4@ 0!X;"]W;W)K<VAE
M971S+W-H965T,S,N>&UL4$L! A0#%     @ ,()84D<>HI2#!0  >Q<  !D
M             ("!.R4! 'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"
M% ,4    "  P@EA2W9*$UHX#   -#@  &0              @('U*@$ >&PO
M=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( #""6%+N-IT$X (
M  P(   9              " @;HN 0!X;"]W;W)K<VAE971S+W-H965T,S8N
M>&UL4$L! A0#%     @ ,()84H"7@$9["0  3E8  !D              ("!
MT3$! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    "  P@EA2
M#P(U?"L$  #A#P  &0              @(&#.P$ >&PO=V]R:W-H965T<R]S
M:&5E=#,X+GAM;%!+ 0(4 Q0    ( #""6%*C/B3:* 0  #L3   9
M      " @>4_ 0!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%
M  @ ,()84B+]_:IT!@  NR<  !D              ("!1$0! 'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    "  P@EA2I[EO5Y "   M!@
M&0              @('O2@$ >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+
M 0(4 Q0    ( #""6%+*3@JPF (  )@&   9              " @;9- 0!X
M;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#%     @ ,()84IUS:WG8
M%@  H*@  !D              ("!A5 ! 'AL+W=O<FMS:&5E=',O<VAE970T
M,RYX;6Q02P$"% ,4    "  P@EA2_DO^R8T&  "B)   &0
M@(&49P$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( #""
M6%(%]Y3W&@4  %X5   9              " @5AN 0!X;"]W;W)K<VAE971S
M+W-H965T-#4N>&UL4$L! A0#%     @ ,()84L&V>L]*!0  *A<  !D
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M=#4P+GAM;%!+ 0(4 Q0    ( #""6%*ZQ64%0 ,  % )   9
M  " @5.) 0!X;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @
M,()84FE B=3#!   YQ,  !D              ("!RHP! 'AL+W=O<FMS:&5E
M=',O<VAE970U,BYX;6Q02P$"% ,4    "  P@EA2&055#IH#   ="P  &0
M            @('$D0$ >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4
M Q0    ( #""6%*_DE0K90(  '4&   9              " @965 0!X;"]W
M;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%     @ ,()84O>Q='**"@
M!#H  !D              ("!,9@! 'AL+W=O<FMS:&5E=',O<VAE970U-2YX
M;6Q02P$"% ,4    "  P@EA2GZO^&%,$  "5$@  &0              @('R
MH@$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+ 0(4 Q0    ( #""6%*G
MQ2)870,  /H*   9              " @7RG 0!X;"]W;W)K<VAE971S+W-H
M965T-3<N>&UL4$L! A0#%     @ ,()84AS99RS^ @  UPD  !D
M     ("!$*L! 'AL+W=O<FMS:&5E=',O<VAE970U."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #""6%(JF2G_O0(  &H'   9              "
M@4.] 0!X;"]W;W)K<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ ,()8
M4D"OF4T1 P  B0L  !D              ("!-\ ! 'AL+W=O<FMS:&5E=',O
M<VAE970V-"YX;6Q02P$"% ,4    "  P@EA25;*T=.,#  !7#   &0
M        @(%_PP$ >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0
M   ( #""6%+L$/#Y!@0   T.   9              " @9G' 0!X;"]W;W)K
M<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @ ,()84@BVQMZ) @  /@<
M !D              ("!ULL! 'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q0
M2P$"% ,4    "  P@EA2'HB51"T#   X"@  &0              @(&6S@$
M>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4 Q0    ( #""6%+,V7VC
M30,  (P)   9              " @?K1 0!X;"]W;W)K<VAE971S+W-H965T
M-CDN>&UL4$L! A0#%     @ ,()84DE5_89K P  L0P  !D
M ("!?M4! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX;6Q02P$"% ,4    "  P
M@EA2$7RZHC0%  !"%0  &0              @($@V0$ >&PO=V]R:W-H965T
M<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( #""6%);)P!]C (  /P%   9
M          " @8O> 0!X;"]W;W)K<VAE971S+W-H965T-S(N>&UL4$L! A0#
M%     @ ,()84H0$AMA[ @  1 X   T              ( !3N$! 'AL+W-T
M>6QE<RYX;6Q02P$"% ,4    "  P@EA2EXJ[',     3 @  "P
M    @ 'TXP$ 7W)E;',O+G)E;'-02P$"% ,4    "  P@EA2=&F4]%P%  #[
M+P  #P              @ '=Y $ >&PO=V]R:V)O;VLN>&UL4$L! A0#%
M  @ ,()84JQM4%<\ @  KRH  !H              ( !9NH! 'AL+U]R96QS
M+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ,()84D!K%[H  @  QBD
M !,              ( !VNP! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
/ %  4 #G%0  "^\!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>392</ContextCount>
  <ElementCount>506</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>104</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedStatementsofOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2107102 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Cash Equivalents and Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities</Role>
      <ShortName>Cash Equivalents and Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2117104 - Disclosure - Major Customers, Partnerships and Strategic Alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2123105 - Disclosure - Acquisition of Sangamo France</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionofSangamoFrance</Role>
      <ShortName>Acquisition of Sangamo France</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2127106 - Disclosure - Other Balance Sheet Details</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetails</Role>
      <ShortName>Other Balance Sheet Details</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132107 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2137108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2142109 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2148110 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2150111 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2159112 - Disclosure - Related Party Disclosures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RelatedPartyDisclosures</Role>
      <ShortName>Related Party Disclosures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2161113 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2164114 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2308302 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/FairValueMeasurement</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2313303 - Disclosure - Cash Equivalents and Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables</Role>
      <ShortName>Cash Equivalents and Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Acquisition of Acquisition of Sangamo France (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables</Role>
      <ShortName>Acquisition of Acquisition of Sangamo France (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2328306 - Disclosure - Other Balance Sheet Details (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetailsTables</Role>
      <ShortName>Other Balance Sheet Details (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OtherBalanceSheetDetails</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2333307 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/CommitmentsandContingencies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2338308 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2343309 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/StockBasedCompensation</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2351310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/IncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2362311 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2409404 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Fair Value Measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2414407 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415408 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416409 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Cash Equivalents and Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2419410 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2420411 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2421412 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2422413 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with DAS (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with DAS (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425414 - Disclosure - Acquisition of Sangamo France - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail</Role>
      <ShortName>Acquisition of Sangamo France - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2426415 - Disclosure - Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail</Role>
      <ShortName>Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2429416 - Disclosure - Other Balance Sheet Details (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail</Role>
      <ShortName>Other Balance Sheet Details (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/OtherBalanceSheetDetailsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2430417 - Disclosure - Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail</Role>
      <ShortName>Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail</Role>
      <ShortName>Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2435420 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2436421 - Disclosure - Commitments and Contingencies - Non-cancelable Material Contractual Commitments (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail</Role>
      <ShortName>Commitments and Contingencies - Non-cancelable Material Contractual Commitments (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2440423 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441424 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail</Role>
      <ShortName>Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2449429 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2453431 - Disclosure - Income Taxes - Summary of Benefit for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Summary of Benefit for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454432 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2455433 - Disclosure - Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2456434 - Disclosure - Income Taxes - Deferred Tax Assets &amp; Liabilities, Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets &amp; Liabilities, Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457435 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2458436 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2460437 - Disclosure - Related Party Disclosures (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/RelatedPartyDisclosuresDetail</Role>
      <ShortName>Related Party Disclosures (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/RelatedPartyDisclosures</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2463438 - Disclosure - Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail</Role>
      <ShortName>Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="sgmo-20201231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2465439 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/role/SubsequentEvents</ParentRole>
      <Position>72</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="sgmo-20201231.htm">sgmo-20201231.htm</File>
    <File>sgmo-20201231.xsd</File>
    <File>sgmo-20201231_cal.xml</File>
    <File>sgmo-20201231_def.xml</File>
    <File>sgmo-20201231_lab.xml</File>
    <File>sgmo-20201231_pre.xml</File>
    <File>sgmo-20201231xex311.htm</File>
    <File>sgmo-20201231xex312.htm</File>
    <File>sgmo-20201231xex321.htm</File>
    <File>sgmo-20201231xexx211.htm</File>
    <File>sgmo-20201231xexx231.htm</File>
    <File>sgmo-20201231xexx41.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>sgmo-20201231_g1.jpg</File>
    <File>sgmo-20201231_g2.jpg</File>
    <File>sgmo-20201231_g3.jpg</File>
    <File>sgmo-20201231_g4.jpg</File>
    <File>sgmo-20201231_g5.jpg</File>
    <File>sgmo-20201231_g6.jpg</File>
    <File>sgmo-20201231_g7.jpg</File>
    <File>sgmo-20201231_g8.jpg</File>
    <File>sgmo-20201231_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>101
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sgmo-20201231.htm": {
   "axisCustom": 1,
   "axisStandard": 30,
   "contextCount": 392,
   "dts": {
    "calculationLink": {
     "local": [
      "sgmo-20201231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sgmo-20201231_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "sgmo-20201231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sgmo-20201231_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sgmo-20201231_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "sgmo-20201231.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 691,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 10,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 14
   },
   "keyCustom": 100,
   "keyStandard": 406,
   "memberCustom": 59,
   "memberStandard": 43,
   "nsprefix": "sgmo",
   "nsuri": "http://www.sangamo.com/20201231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sangamo.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Cash Equivalents and Marketable Securities",
     "role": "http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities",
     "shortName": "Cash Equivalents and Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117104 - Disclosure - Major Customers, Partnerships and Strategic Alliances",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances",
     "shortName": "Major Customers, Partnerships and Strategic Alliances",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123105 - Disclosure - Acquisition of Sangamo France",
     "role": "http://www.sangamo.com/role/AcquisitionofSangamoFrance",
     "shortName": "Acquisition of Sangamo France",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127106 - Disclosure - Other Balance Sheet Details",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetails",
     "shortName": "Other Balance Sheet Details",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132107 - Disclosure - Commitments and Contingencies",
     "role": "http://www.sangamo.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2137108 - Disclosure - Stockholders' Equity",
     "role": "http://www.sangamo.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142109 - Disclosure - Stock-Based Compensation",
     "role": "http://www.sangamo.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148110 - Disclosure - Employee Benefit Plan",
     "role": "http://www.sangamo.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2150111 - Disclosure - Income Taxes",
     "role": "http://www.sangamo.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159112 - Disclosure - Related Party Disclosures",
     "role": "http://www.sangamo.com/role/RelatedPartyDisclosures",
     "shortName": "Related Party Disclosures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets",
     "role": "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2161113 - Disclosure - Quarterly Financial Data (Unaudited)",
     "role": "http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited",
     "shortName": "Quarterly Financial Data (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:QuarterlyFinancialInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164114 - Disclosure - Subsequent Events",
     "role": "http://www.sangamo.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308302 - Disclosure - Fair Value Measurement (Tables)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementTables",
     "shortName": "Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313303 - Disclosure - Cash Equivalents and Marketable Securities (Tables)",
     "role": "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables",
     "shortName": "Cash Equivalents and Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ic99454b17cf8426abe411aa4bfe33b84_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
     "shortName": "Major Customers, Partnerships and Strategic Alliances (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ic99454b17cf8426abe411aa4bfe33b84_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Acquisition of Acquisition of Sangamo France (Tables)",
     "role": "http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables",
     "shortName": "Acquisition of Acquisition of Sangamo France (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sgmo:ScheduleOfNoncontrollingInterestTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328306 - Disclosure - Other Balance Sheet Details (Tables)",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetailsTables",
     "shortName": "Other Balance Sheet Details (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333307 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.sangamo.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2338308 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.sangamo.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343309 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2351310 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.sangamo.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2362311 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)",
     "role": "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables",
     "shortName": "Quarterly Financial Data (Unaudited) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i915d7a150498418da35f6b4f9e547a02_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetImpairment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibe21513e3cbc4ef9b8379cf9af56af7d_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
     "shortName": "Organization and Summary of Significant Accounting Policies - Revenues from Strategic Partnering Collaboration Agreements and Research Activity Grants (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibe21513e3cbc4ef9b8379cf9af56af7d_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies - Reconciliation of Cash and Cash Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409404 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail",
     "shortName": "Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i4bf0705352c54572bf4f38ac982a31be_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Fair Value Measurement - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
     "shortName": "Fair Value Measurement - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "sgmo:BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyExchangeRateTranslation1",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)",
     "role": "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail",
     "shortName": "Fair Value Measurement - Summary of Estimated Fair Value of Free Share Liability Assumptions (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibda42ad49ccb40e6a99670b2432a3b0a_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Operations",
     "role": "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414407 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "role": "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
     "shortName": "Cash Equivalents and Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415408 - Disclosure - Cash Equivalents and Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)",
     "role": "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail",
     "shortName": "Cash Equivalents and Marketable Securities - Summary of Available-for-Sale Securities by Contractual Maturity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416409 - Disclosure - Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail",
     "shortName": "Cash Equivalents and Marketable Securities - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product_target",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419410 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sgmo:CollaborativeArrangementMaximumNumberOfProductTargetsToReplace",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product_target",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i915d7a150498418da35f6b4f9e547a02_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420411 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i65e104e30eb7451ebcb1b6d67543ae50_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421412 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i01464b993796404cb11757f956a8a3c7_D20070101-20071231",
      "decimals": null,
      "lang": "en-US",
      "name": "sgmo:ResearchServicesPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i915d7a150498418da35f6b4f9e547a02_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422413 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with DAS (Detail)",
     "role": "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
     "shortName": "Major Customers, Partnerships and Strategic Alliances - Agreement with DAS (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ic852a176146340e1b539fc32aa55cad2_D20050101-20051231",
      "decimals": null,
      "lang": "en-US",
      "name": "sgmo:InitialResearchTermOfAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425414 - Disclosure - Acquisition of Sangamo France - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
     "shortName": "Acquisition of Sangamo France - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i9d614d3fc8d0454b92de5bfcfd33999d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MinorityInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426415 - Disclosure - Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)",
     "role": "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
     "shortName": "Acquisition of Sangamo France - Summary of Non-controlling Interest (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "sgmo:ScheduleOfNoncontrollingInterestTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:MinorityInterestDecreaseFromRedemptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429416 - Disclosure - Other Balance Sheet Details (Detail)",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail",
     "shortName": "Other Balance Sheet Details (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i9d614d3fc8d0454b92de5bfcfd33999d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430417 - Disclosure - Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail",
     "shortName": "Other Balance Sheet Details - Schedule of Intangible Assets and Goodwill (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i2d806df2b49e4a9fa01d2e42d94d14e0_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsNetExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CustomerRefundLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)",
     "role": "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail",
     "shortName": "Other Balance Sheet Details - Summary of Accounts Payable and Accrued Liabilities (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CustomerRefundLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Commitments and Contingencies - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
     "shortName": "Commitments and Contingencies - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435420 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)",
     "role": "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail",
     "shortName": "Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436421 - Disclosure - Commitments and Contingencies - Non-cancelable Material Contractual Commitments (Detail)",
     "role": "http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail",
     "shortName": "Commitments and Contingencies - Non-cancelable Material Contractual Commitments (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherCommitmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractualObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Stockholders' Equity - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
     "shortName": "Stockholders' Equity - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "iee1b756f6c0a4abe92e4664a43ad8035_I20200630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i9d614d3fc8d0454b92de5bfcfd33999d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440423 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)",
     "role": "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail",
     "shortName": "Stockholders' Equity - Summary of Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i9d614d3fc8d0454b92de5bfcfd33999d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i9d614d3fc8d0454b92de5bfcfd33999d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441424 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)",
     "role": "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail",
     "shortName": "Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i9d614d3fc8d0454b92de5bfcfd33999d_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Stock-Based Compensation - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
     "shortName": "Stock-Based Compensation - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "if6f46cdcf64446fbb0ec043c3e9bfa14_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Stockholders' Equity",
     "role": "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "if6f46cdcf64446fbb0ec043c3e9bfa14_I20171231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i3d3f08aef11f4a318908f591e111b593_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
     "shortName": "Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i3d3f08aef11f4a318908f591e111b593_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ia4f372a7d1ad4108a38bfe05388f5e5d_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)",
     "role": "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
     "shortName": "Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ia4f372a7d1ad4108a38bfe05388f5e5d_D20200101-20201231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449429 - Disclosure - Employee Benefit Plan - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail",
     "shortName": "Employee Benefit Plan - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail",
     "shortName": "Income Taxes - Summary of Domestic and Foreign Components of Loss Before Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2453431 - Disclosure - Income Taxes - Summary of Benefit for Income Taxes (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail",
     "shortName": "Income Taxes - Summary of Benefit for Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454432 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail",
     "shortName": "Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455433 - Disclosure - Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail",
     "shortName": "Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "id3b91f3cd3c1451a8c20a0625df26f83_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456434 - Disclosure - Income Taxes - Deferred Tax Assets & Liabilities, Balance Sheet Location (Details)",
     "role": "http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails",
     "shortName": "Income Taxes - Deferred Tax Assets & Liabilities, Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i7b08863acefe4d8ca8e10ed1322fc31b_I20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457435 - Disclosure - Income Taxes - Additional Information (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail",
     "shortName": "Income Taxes - Additional Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i9d614d3fc8d0454b92de5bfcfd33999d_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458436 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)",
     "role": "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i1099157ecec044679915cbcb253acd13_I20171231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460437 - Disclosure - Related Party Disclosures (Detail)",
     "role": "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail",
     "shortName": "Related Party Disclosures (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i84d0b5985441420eb3dbc496787e07aa_D20200101-20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sgmo:BusinessAcquisitionNumberOfSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i915d7a150498418da35f6b4f9e547a02_D20201001-20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463438 - Disclosure - Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)",
     "role": "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail",
     "shortName": "Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i915d7a150498418da35f6b4f9e547a02_D20201001-20201231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i48f4d381b117429fa8a27a467285b605_D20210101-20210219",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465439 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.sangamo.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "i48f4d381b117429fa8a27a467285b605_D20210101-20210219",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107102 - Disclosure - Fair Value Measurement",
     "role": "http://www.sangamo.com/role/FairValueMeasurement",
     "shortName": "Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sgmo-20201231.htm",
      "contextRef": "ibc6193286afa47c8b3d36abd5bf93672_D20200101-20201231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 104,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sgmo_AccruedResearchAndDevelopmentExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses.",
        "label": "Accrued Research And Development Expenses",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenses",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AchievementOfCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Commercial Milestones.",
        "label": "Achievement Of Commercial Milestones [Member]",
        "terseLabel": "Achievement of commercial milestones"
       }
      }
     },
     "localname": "AchievementOfCommercialMilestonesMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of first commercial sale milestones.",
        "label": "Achievement Of First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Specified Clinical Development and Regulatory Milestones.",
        "label": "Achievement Of Specified Clinical Development And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development and regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified clinical development intellectual property and regulatory milestones.",
        "label": "Achievement Of Specified Clinical Development Intellectual Property And Regulatory Milestones [Member]",
        "terseLabel": "Achievement of specified clinical development intellectual property and regulatory milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedClinicalDevelopmentIntellectualPropertyAndRegulatoryMilestonesMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified preclinical development clinical development and first commercial sale milestones.",
        "label": "Achievement Of Specified Preclinical Development Clinical Development And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of specified preclinical development clinical development and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedPreclinicalDevelopmentClinicalDevelopmentAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones.",
        "label": "Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]",
        "terseLabel": "Achievement of specified research, clinical development, regulatory and first commercial sale milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.",
        "label": "Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]",
        "terseLabel": "Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AchievementOfSpecifiedSalesMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Achievement of Specified Sales Milestones.",
        "label": "Achievement Of Specified Sales Milestones [Member]",
        "terseLabel": "Achievement of specified sales milestones"
       }
      }
     },
     "localname": "AchievementOfSpecifiedSalesMilestonesMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to additional paid in capital acquisition of non-controlling interest.",
        "label": "Adjustments To Additional Paid In Capital Acquisition Of Noncontrolling Interest",
        "terseLabel": "Acquisition of additional shares of Sangamo France"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalAcquisitionOfNoncontrollingInterest",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate additional revenue recognition milestone method revenue eligible to receive.",
        "label": "Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive",
        "terseLabel": "Potential amount to be funded for achievement of specified commercialized and sales milestones"
       }
      }
     },
     "localname": "AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AgreementTerminationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement Termination, Term",
        "label": "Agreement Termination, Term",
        "terseLabel": "Agreement termination, term"
       }
      }
     },
     "localname": "AgreementTerminationTerm",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_AmendedCollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Collaboration And License Agreement",
        "label": "Amended Collaboration And License Agreement [Member]",
        "terseLabel": "Amended collaboration and license agreement"
       }
      }
     },
     "localname": "AmendedCollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AmortizationAndOtherChangesInRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization And Other Changes In Right-of-Use Assets",
        "label": "Amortization And Other Changes In Right-of-Use Assets",
        "terseLabel": "Amortization and other changes in right-of-use assets"
       }
      }
     },
     "localname": "AmortizationAndOtherChangesInRightOfUseAssets",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AnnualFeesRelatedToAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual fees related to agreement.",
        "label": "Annual Fees Related To Agreement",
        "terseLabel": "Annual fees"
       }
      }
     },
     "localname": "AnnualFeesRelatedToAgreement",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_AtTheMarketOfferingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering agreement.",
        "label": "At The Market Offering Agreement [Member]",
        "terseLabel": "ATM Agreement"
       }
      }
     },
     "localname": "AtTheMarketOfferingAgreementMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_AtTheMarketStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At-the-market Stock Offering",
        "label": "At-the-market Stock Offering [Member]",
        "terseLabel": "At-the-market Stock Offering"
       }
      }
     },
     "localname": "AtTheMarketStockOfferingMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BiogenMAIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biogen MA Inc",
        "label": "Biogen MA Inc [Member]",
        "terseLabel": "Biogen MA Inc"
       }
      }
     },
     "localname": "BiogenMAIncMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrammerBioMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brammer Bio MA",
        "label": "Brammer Bio MA [Member]",
        "terseLabel": "Brammer Bio MA"
       }
      }
     },
     "localname": "BrammerBioMAMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BrisbaneCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brisbane, California",
        "label": "Brisbane, California [Member]",
        "terseLabel": "Brisbane, California"
       }
      }
     },
     "localname": "BrisbaneCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BuildToSuitLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Build-to-suit lease.",
        "label": "Build To Suit Lease [Member]",
        "terseLabel": "Build-to-Suit Leases"
       }
      }
     },
     "localname": "BuildToSuitLeaseMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_BuildToSuitLeases": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Build to suit leases",
        "label": "Build To Suit Leases",
        "verboseLabel": "Build-to-suit leases"
       }
      }
     },
     "localname": "BuildToSuitLeases",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Estimated Fair Value Assets Of Free Shares",
        "label": "Business Acquisition Estimated Fair Value Assets Of Free Shares",
        "terseLabel": "Business acquisition estimated fair value assets of free shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueAssetsOfFreeShares",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition Estimated Fair Value Liabilities Of Free Shares",
        "label": "Business Acquisition Estimated Fair Value Liabilities Of Free Shares",
        "terseLabel": "Business acquisition estimated fair value liabilities of free shares"
       }
      }
     },
     "localname": "BusinessAcquisitionEstimatedFairValueLiabilitiesOfFreeShares",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesHeldByHolders": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, number of free shares held by the holders.",
        "label": "Business Acquisition Number Of Free Shares Held By Holders",
        "terseLabel": "Number of free shares held by the holders (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesHeldByHolders",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "label": "Business Acquisition, Number Of Free Shares Outstanding Subject To Purchase",
        "terseLabel": "Business acquisition, number of free shares outstanding subject to purchase (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfFreeSharesOutstandingSubjectToPurchase",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionNumberOfSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, number of shares acquired.",
        "label": "Business Acquisition Number Of Shares Acquired",
        "terseLabel": "Number of ordinary shares acquired (in shares)"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSharesAcquired",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition, percentage of equity interests agreed to acquire.",
        "label": "Business Acquisition Percentage Of Equity Interests Agreed To Acquire",
        "terseLabel": "Percentage of equity interests agreed to acquire"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfEquityInterestsAgreedToAcquire",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CNineORFSevenTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "C nine ORF seven two.",
        "label": "C Nine O R F Seven Two [Member]",
        "terseLabel": "C9ORF72"
       }
      }
     },
     "localname": "CNineORFSevenTwoMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CaliforniaInstituteForRegenerativeMedicineAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California institute for regenerative medicine agreement.",
        "label": "California Institute For Regenerative Medicine Agreement [Member]",
        "terseLabel": "California Institute for Regenerative Medicine (\"CIRM\")"
       }
      }
     },
     "localname": "CaliforniaInstituteForRegenerativeMedicineAgreementMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents accumulated gross unrealized gain before tax.",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax",
        "terseLabel": "Cash equivalents, gross unrealized gains"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and cash equivalents accumulated gross unrealized loss before tax.",
        "label": "Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax",
        "negatedTerseLabel": "Cash and cash equivalents accumulated gross unrealized loss before tax"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities.",
        "label": "Cash Equivalents And Available For Sale Securities",
        "terseLabel": "Total cash equivalents and available-for-sale securities, estimated fair value"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecurities",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for Sale Securities Amortized Cost",
        "label": "Cash Equivalents And Available For Sale Securities Amortized Cost",
        "totalLabel": "Total cash equivalents and available-for-sale securities, amortized cost"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized gain, before tax.",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Gain Before Tax",
        "terseLabel": "Total cash equivalents and available-for-sale securities, gross unrealized gains"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "sgmo_CashEquivalentsAndAvailableForSaleSecuritiesAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash equivalents and available for sale securities, gross unrealized loss, before Tax",
        "label": "Cash Equivalents And Available For Sale Securities Gross Unrealized Loss Before Tax",
        "negatedLabel": "Total cash equivalents and available-for-sale securities, gross unrealized (losses)"
       }
      }
     },
     "localname": "CashEquivalentsAndAvailableForSaleSecuritiesGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ChangeInCollaborationAgreementScopeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change In Collaboration Agreement Scope",
        "label": "Change In Collaboration Agreement Scope [Member]",
        "terseLabel": "Change in collaboration agreement scope"
       }
      }
     },
     "localname": "ChangeInCollaborationAgreementScopeMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAgreementEquityIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Equity Issued",
        "label": "Collaboration Agreement, Equity Issued",
        "terseLabel": "Collaboration agreement, equity issued"
       }
      }
     },
     "localname": "CollaborationAgreementEquityIssued",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationAgreementNumberOfAdditionalProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Additional Product Targets",
        "label": "Collaboration Agreement, Number Of Additional Product Targets",
        "terseLabel": "Number of additional neurological disease gene targets"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfAdditionalProductTargets",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationAgreementTargetSelectionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Target Selection Period",
        "label": "Collaboration Agreement, Target Selection Period",
        "terseLabel": "Target selection period"
       }
      }
     },
     "localname": "CollaborationAgreementTargetSelectionPeriod",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement.",
        "label": "Collaboration And License Agreement [Member]",
        "terseLabel": "Collaboration and license agreement"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreements number of products approved under agreement.",
        "label": "Collaboration And License Agreements Number Of Products Approved Under Agreement",
        "terseLabel": "Number of products approved"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborationArrangementCommissionFeePortionOfGrossProceedsValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "label": "Collaboration Arrangement, Commission Fee, Portion Of Gross Proceeds, Value",
        "terseLabel": "Collaboration arrangement, commission fee, portion of gross proceeds, value"
       }
      }
     },
     "localname": "CollaborationArrangementCommissionFeePortionOfGrossProceedsValue",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborationArrangementResearchPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Arrangement, Research Period",
        "label": "Collaboration Arrangement, Research Period",
        "terseLabel": "Collaboration arrangement, research period"
       }
      }
     },
     "localname": "CollaborationArrangementResearchPeriod",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Axis]",
        "terseLabel": "Collaborative Agreement Milestone [Axis]"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneAxis",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CollaborativeAgreementMilestoneDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement Milestone",
        "label": "Collaborative Agreement Milestone [Domain]",
        "terseLabel": "Collaborative Agreement Milestone"
       }
      }
     },
     "localname": "CollaborativeAgreementMilestoneDomain",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_CollaborativeAgreementPercentOfInitialRecognition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement, Percent Of Initial Recognition",
        "label": "Collaborative Agreement, Percent Of Initial Recognition",
        "terseLabel": "Collaborative agreement, percent of initial recognition"
       }
      }
     },
     "localname": "CollaborativeAgreementPercentOfInitialRecognition",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "label": "Collaborative Arrangement, Agreement Restriction, Percentage Of Shares Held",
        "terseLabel": "Agreement restriction, percentage of shares held"
       }
      }
     },
     "localname": "CollaborativeArrangementAgreementRestrictionPercentageOfSharesHeld",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement estimated reimbursable service costs.",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCosts",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "label": "Collaborative Arrangement Estimated Reimbursable Service Costs For New Research Plan",
        "terseLabel": "Collaborative arrangement estimated reimbursable service costs for new research plan"
       }
      }
     },
     "localname": "CollaborativeArrangementEstimatedReimbursableServiceCostsForNewResearchPlan",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)",
        "label": "Collaborative Arrangement, Increase (Decrease) In Net Income (Loss)",
        "negatedTerseLabel": "Collaborative arrangement, increase (decrease) in net income (loss)"
       }
      }
     },
     "localname": "CollaborativeArrangementIncreaseDecreaseInNetIncomeLoss",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementIncreaseDecreaseInRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Increase (Decrease) In Revenue",
        "label": "Collaborative Arrangement, Increase (Decrease) In Revenue",
        "terseLabel": "Collaborative arrangement, increase (decrease) in revenue"
       }
      }
     },
     "localname": "CollaborativeArrangementIncreaseDecreaseInRevenue",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, License Fee",
        "label": "Collaborative Arrangement, License Fee",
        "terseLabel": "Collaborative arrangement, license fee"
       }
      }
     },
     "localname": "CollaborativeArrangementLicenseFee",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "label": "Collaborative Arrangement, Maximum Milestone Payment Receivable",
        "terseLabel": "Maximum milestone payment receivable"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumMilestonePaymentReceivable",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementMaximumNumberOfProductTargetsToReplace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "label": "Collaborative Arrangement, Maximum Number Of Product Targets To Replace",
        "terseLabel": "Collaborative arrangement, maximum number of product targets to replace"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumNumberOfProductTargetsToReplace",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNetIncomeLossPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Net Income (Loss) Per Share",
        "label": "Collaborative Arrangement, Net Income (Loss) Per Share",
        "terseLabel": "Collaborative arrangement, net Income (loss) per share"
       }
      }
     },
     "localname": "CollaborativeArrangementNetIncomeLossPerShare",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets",
        "label": "Collaborative Arrangement, Number Of Product Targets",
        "terseLabel": "Number of neurological disease gene targets"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargets",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementNumberOfProductTargetsSelected": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Number Of Product Targets Selected",
        "label": "Collaborative Arrangement, Number Of Product Targets Selected",
        "terseLabel": "Number of product targets selected"
       }
      }
     },
     "localname": "CollaborativeArrangementNumberOfProductTargetsSelected",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_CollaborativeArrangementReimbursableServiceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement Reimbursable Service Costs",
        "label": "Collaborative Arrangement Reimbursable Service Costs",
        "terseLabel": "Collaborative arrangement reimbursable service costs"
       }
      }
     },
     "localname": "CollaborativeArrangementReimbursableServiceCosts",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementResearchServiceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Research Service Fees",
        "label": "Collaborative Arrangement, Research Service Fees",
        "terseLabel": "Research service fees"
       }
      }
     },
     "localname": "CollaborativeArrangementResearchServiceFees",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "label": "Collaborative Arrangement, Standstill Restriction, Ownership Threshold Percentage Ownership Percentage",
        "terseLabel": "Agreement restriction, ownership percentage (less than)"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionOwnershipThresholdPercentageOwnershipPercentage",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CollaborativeArrangementStandstillRestrictionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Standstill Restriction Period",
        "label": "Collaborative Arrangement, Standstill Restriction Period",
        "terseLabel": "Agreement restriction expiration period"
       }
      }
     },
     "localname": "CollaborativeArrangementStandstillRestrictionPeriod",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction price.",
        "label": "Collaborative Arrangement Transaction Price",
        "terseLabel": "Collaborative arrangement transaction price"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionPrice",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "label": "Collaborative Arrangement, Voting Provisions Expiration Period",
        "terseLabel": "Agreement provision, expiration period"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsExpirationPeriod",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "label": "Collaborative Arrangement, Voting Provisions, Ownership Threshold Percentage",
        "terseLabel": "Agreement provision, ownership percentage (less than)"
       }
      }
     },
     "localname": "CollaborativeArrangementVotingProvisionsOwnershipThresholdPercentage",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Increase in capital shares reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_CommonStockExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock exchange ratio.",
        "label": "Common Stock Exchange Ratio",
        "terseLabel": "Share of common stock subject to a stock option or stock appreciation right (in shares)"
       }
      }
     },
     "localname": "CommonStockExchangeRatio",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent development and sales based milestone payments to be received.",
        "label": "Contingent Development And Sales Based Milestone Payments To Be Received",
        "terseLabel": "Contingent development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_CustomerContractLiabilityMilestonePaymentEligibleToReceive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer contract liability milestone payment eligible to receive.",
        "label": "Customer Contract Liability Milestone Payment Eligible To Receive",
        "terseLabel": "Development and sales-based milestone payments to be received"
       }
      }
     },
     "localname": "CustomerContractLiabilityMilestonePaymentEligibleToReceive",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Lease Liability",
        "label": "Deferred Tax Assets, Lease Liability",
        "terseLabel": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards research federal.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research Federal",
        "terseLabel": "Federal research tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets tax credit carryforwards research state and local.",
        "label": "Deferred Tax Assets Tax Credit Carryforwards Research State And Local",
        "terseLabel": "State research tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_DowAgroSciencesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dow agro sciences.",
        "label": "Dow Agro Sciences [Member]",
        "terseLabel": "Dow Agro Sciences"
       }
      }
     },
     "localname": "DowAgroSciencesMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Global Intangible Low-Taxed Income, Amount",
        "label": "Effective Income Tax Reconciliation, Global Intangible Low-Taxed Income, Amount",
        "terseLabel": "Global Intangible Low-Taxed Income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationGlobalIntangibleLowTaxedIncomeAmount",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "2010 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan rights weighted average estimated fair value.",
        "label": "Employee Stock Purchase Plan Rights Weighted Average Estimated Fair Value",
        "terseLabel": "Weighted-average estimated fair value of shares purchased under ESPP plan (in dollars per share)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgmo_ExtendedResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extended Research Term Of Agreement",
        "label": "Extended Research Term Of Agreement",
        "terseLabel": "Extended research term of agreement"
       }
      }
     },
     "localname": "ExtendedResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_FeeDue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fee due.",
        "label": "Fee Due",
        "terseLabel": "Fee due"
       }
      }
     },
     "localname": "FeeDue",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_FormerExecutiveOfSangamoFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Executive Of Sangamo France",
        "label": "Former Executive Of Sangamo France [Member]",
        "terseLabel": "Former Executive of TxCell"
       }
      }
     },
     "localname": "FormerExecutiveOfSangamoFranceMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_FreeSharesAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free Shares Asset",
        "label": "Free Shares Asset [Member]",
        "terseLabel": "Free shares asset"
       }
      }
     },
     "localname": "FreeSharesAssetMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_FreeSharesLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Free Shares Liability",
        "label": "Free Shares Liability [Member]",
        "terseLabel": "Free shares asset"
       }
      }
     },
     "localname": "FreeSharesLiabilityMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_GainOnFreeShares": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain On Free Shares",
        "label": "Gain On Free Shares",
        "negatedLabel": "Gain on free shares"
       }
      }
     },
     "localname": "GainOnFreeShares",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_GiroctocogeneFitelparvovecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Giroctocogene Fitelparvovec",
        "label": "Giroctocogene Fitelparvovec [Member]",
        "terseLabel": "Giroctocogene Fitelparvovec"
       }
      }
     },
     "localname": "GiroctocogeneFitelparvovecMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_GrantFundingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant funding amount.",
        "label": "Grant Funding Amount",
        "terseLabel": "Funds due under the agreement"
       }
      }
     },
     "localname": "GrantFundingAmount",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income tax reconciliation nondeductible expense income share based compensation.",
        "label": "Income Tax Reconciliation Nondeductible Expense Income Share Based Compensation",
        "terseLabel": "Non-deductible stock-based compensation"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail",
      "http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_IncreaseDecreaseInLongTermPortionOfLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease In Long Term Portion Of Lease Liabilities",
        "label": "Increase Decrease In Long Term Portion Of Lease Liabilities",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLongTermPortionOfLeaseLiabilities",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_IncreaseInFairValueOfFreeSharesAssetAndLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase In Fair Value Of Free Shares Asset And Liability",
        "label": "Increase In Fair Value Of Free Shares Asset And Liability",
        "terseLabel": "Increase in fair value of free shares asset and liability"
       }
      }
     },
     "localname": "IncreaseInFairValueOfFreeSharesAssetAndLiability",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_InitialResearchTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial research term of agreement.",
        "label": "Initial Research Term Of Agreement",
        "terseLabel": "Initial research term of agreement",
        "verboseLabel": "Research program to develop laboratory research reagents"
       }
      }
     },
     "localname": "InitialResearchTermOfAgreement",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_IntangibleAssetsExcludingGoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible Assets (Excluding Goodwill)",
        "label": "Intangible Assets (Excluding Goodwill) [Roll Forward]",
        "terseLabel": "Intangible Assets (Excluding Goodwill)"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillRollForward",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_JefferiesLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jefferies LLC",
        "label": "Jefferies LLC [Member]",
        "terseLabel": "Jefferies LLC"
       }
      }
     },
     "localname": "JefferiesLLCMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_KitePharmaIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Kite Pharma Inc.",
        "label": "Kite Pharma Inc [Member]",
        "terseLabel": "Kite Pharma, Inc. (\"Kite\")"
       }
      }
     },
     "localname": "KitePharmaIncMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Lease Not Yet Commenced Amount",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Amount",
        "terseLabel": "Lessee Operating Lease Lease Not Yet Commenced Amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAmount",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Lease Not Yet Commenced Area Of Real Estate",
        "label": "Lessee Operating Lease Lease Not Yet Commenced Area Of Real Estate",
        "terseLabel": "Lease not yet commenced, area of real estate"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedAreaOfRealEstate",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "sgmo_LicenseObligations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License obligations.",
        "label": "License Obligations",
        "terseLabel": "License obligations"
       }
      }
     },
     "localname": "LicenseObligations",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_LonzaNetherlandsBVMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lonza Netherlands, B.V.",
        "label": "Lonza Netherlands, B.V. [Member]",
        "terseLabel": "Lonza Netherlands, B.V."
       }
      }
     },
     "localname": "LonzaNetherlandsBVMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Manufacturing Equipment",
        "label": "Manufacturing Equipment [Member]",
        "terseLabel": "Manufacturing equipment"
       }
      }
     },
     "localname": "ManufacturingEquipmentMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MeasurementInputStockPriceCorrelationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input Stock Price Correlation",
        "label": "Measurement Input Stock Price Correlation [Member]",
        "terseLabel": "Measurement Input Stock Price Correlation"
       }
      }
     },
     "localname": "MeasurementInputStockPriceCorrelationMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneAchievementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Achievement",
        "label": "Milestone Achievement [Member]",
        "terseLabel": "Milestone achievement"
       }
      }
     },
     "localname": "MilestoneAchievementMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone One",
        "label": "Milestone One [Member]",
        "terseLabel": "Milestone One"
       }
      }
     },
     "localname": "MilestoneOneMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment and royalty revenue of previous agreement.",
        "label": "Milestone Payment And Royalty Revenue Of Previous Agreement",
        "verboseLabel": "Previously agreed research, development and commercialization milestone payments, and royalties on sales of products"
       }
      }
     },
     "localname": "MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestonePaymentsReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments received.",
        "label": "Milestone Payments Received",
        "terseLabel": "Milestone payments received"
       }
      }
     },
     "localname": "MilestonePaymentsReceived",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneRevenueReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone\u200b revenue receivable.",
        "label": "Milestone Revenue Receivable",
        "terseLabel": "Milestone revenue receivable"
       }
      }
     },
     "localname": "MilestoneRevenueReceivable",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_MilestoneThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Three",
        "label": "Milestone Three [Member]",
        "terseLabel": "Milestone Three"
       }
      }
     },
     "localname": "MilestoneThreeMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MilestoneTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Two",
        "label": "Milestone Two [Member]",
        "terseLabel": "Milestone Two"
       }
      }
     },
     "localname": "MilestoneTwoMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum sublicense annual fees specific reckoning period.",
        "label": "Minimum Sublicense Annual Fees Specific Reckoning Period",
        "terseLabel": "Minimum license annual fees specific reckoning period"
       }
      }
     },
     "localname": "MinimumSublicenseAnnualFeesSpecificReckoningPeriod",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_NetProceedsFromIssuancePublicOffering": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from issuance public offering.",
        "label": "Net Proceeds From Issuance Public Offering",
        "terseLabel": "Proceeds from public offering of common stock, net of issuance costs",
        "verboseLabel": "Net proceeds from issuance of common stock, after deducting offering expenses"
       }
      }
     },
     "localname": "NetProceedsFromIssuancePublicOffering",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_NoncashOrPartNoncashNonControllingInterestAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash or part noncash non-controlling interest acquisition.",
        "label": "Noncash Or Part Noncash Non Controlling Interest Acquisition",
        "terseLabel": "Non-controlling interest for acquisition"
       }
      }
     },
     "localname": "NoncashOrPartNoncashNonControllingInterestAcquisition",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_NovartisInstitutesForBioMedicalResearchIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis Institutes For Bio Medical Research Inc",
        "label": "Novartis Institutes For Bio Medical Research Inc [Member]",
        "terseLabel": "Novartis Institutes For Bio Medical Research Inc"
       }
      }
     },
     "localname": "NovartisInstitutesForBioMedicalResearchIncMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of clinical or regulatory milestones included in transaction price.",
        "label": "Number Of Clinical Or Regulatory Milestones Included In Transaction Price",
        "terseLabel": "Number of milestones included in transaction price"
       }
      }
     },
     "localname": "NumberOfClinicalOrRegulatoryMilestonesIncludedInTransactionPrice",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfOptionsToExtendInitialResearchTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Options To Extend Initial Research Term",
        "label": "Number Of Options To Extend Initial Research Term",
        "terseLabel": "Number of options to extend initial research term"
       }
      }
     },
     "localname": "NumberOfOptionsToExtendInitialResearchTerm",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_NumberOfResearchProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of research program.",
        "label": "Number Of Research Program",
        "terseLabel": "Number of research programs"
       }
      }
     },
     "localname": "NumberOfResearchProgram",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_OfficeAndLaboratoryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office And Laboratory",
        "label": "Office And Laboratory [Member]",
        "terseLabel": "Office And Laboratory"
       }
      }
     },
     "localname": "OfficeAndLaboratoryMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OneTimeLicenseFeeEarned": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One time license fee earned.",
        "label": "One Time License Fee Earned",
        "terseLabel": "One-time license fee earned on exercise of option"
       }
      }
     },
     "localname": "OneTimeLicenseFeeEarned",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and summary of significant accounting policies.",
        "label": "Organization And Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_OtherProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other products.",
        "label": "Other Products [Member]",
        "terseLabel": "Other products"
       }
      }
     },
     "localname": "OtherProductsMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_OtherThanTemporarilyImpairedInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other than temporarily impaired investment.",
        "label": "Other Than Temporarily Impaired Investment",
        "terseLabel": "Investments other-than-temporarily impaired"
       }
      }
     },
     "localname": "OtherThanTemporarilyImpairedInvestment",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties to be received from sublicensing.",
        "label": "Percentage Of Royalties To Be Received From Sublicensing",
        "terseLabel": "Percentage of royalties to be received from sublicensing"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesToBeReceivedFromSublicensing",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_PfizerC9ORF72Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer C9ORF72",
        "label": "Pfizer C9ORF72 [Member]",
        "terseLabel": "Pfizer C9ORF72"
       }
      }
     },
     "localname": "PfizerC9ORF72Member",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerGiroctocogeneFitelparvovecMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer, Giroctocogene Fitelparvovec",
        "label": "Pfizer, Giroctocogene Fitelparvovec [Member]",
        "terseLabel": "Pfizer, Giroctocogene Fitelparvovec"
       }
      }
     },
     "localname": "PfizerGiroctocogeneFitelparvovecMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer.",
        "label": "Pfizer [Member]",
        "terseLabel": "Pfizer"
       }
      }
     },
     "localname": "PfizerMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PfizerSB525Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pfizer SB-525",
        "label": "Pfizer SB-525 [Member]",
        "terseLabel": "Pfizer SB-525"
       }
      }
     },
     "localname": "PfizerSB525Member",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PhaseThreeClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase Three Clinical Trial",
        "label": "Phase Three Clinical Trial [Member]",
        "terseLabel": "Phase Three Clinical Trial"
       }
      }
     },
     "localname": "PhaseThreeClinicalTrialMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PreApprovalMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-approval Milestone",
        "label": "Pre-approval Milestone [Member]",
        "terseLabel": "Pre-approval Milestone"
       }
      }
     },
     "localname": "PreApprovalMilestoneMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Issuance Of Common Stock, Net Of Issuance Costs",
        "label": "Proceeds From Issuance Of Common Stock, Net Of Issuance Costs",
        "terseLabel": "Proceeds from issuance of common stock in connection with the Biogen collaboration agreement, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_PropertyAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property and equipment.",
        "label": "Property And Equipment [Member]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyAndEquipmentMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_PurchasePlanOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase plan offering period.",
        "label": "Purchase Plan Offering Period",
        "terseLabel": "Purchase plan offering period"
       }
      }
     },
     "localname": "PurchasePlanOfferingPeriod",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_PurchasePlanPurchasePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase plan purchase period.",
        "label": "Purchase Plan Purchase Period",
        "terseLabel": "Purchase plan purchase period"
       }
      }
     },
     "localname": "PurchasePlanPurchasePeriod",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_ReducedRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduced royalty rate.",
        "label": "Reduced Royalty Rate",
        "terseLabel": "Reduced royalty rate"
       }
      }
     },
     "localname": "ReducedRoyaltyRate",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Cumulative Compensation Earned",
        "terseLabel": "Cumulative compensation earned"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCumulativeCompensationEarned",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ResearchAndOfficeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and office space",
        "label": "Research And Office Space [Member]",
        "terseLabel": "Research and Office Space"
       }
      }
     },
     "localname": "ResearchAndOfficeSpaceMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services.",
        "label": "Research Services [Member]",
        "terseLabel": "Research services"
       }
      }
     },
     "localname": "ResearchServicesMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ResearchServicesPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research services period.",
        "label": "Research Services Period",
        "terseLabel": "Developed laboratory research reagents, research services period"
       }
      }
     },
     "localname": "ResearchServicesPeriod",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_Restated2018StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restated 2018 Stock Incentive Plan",
        "label": "Restated 2018 Stock Incentive Plan [Member]",
        "terseLabel": "Restated 2018 Stock Incentive Plan"
       }
      }
     },
     "localname": "Restated2018StockIncentivePlanMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk",
        "label": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk [Member]",
        "terseLabel": "Revenue From Collaboration Agreements, Grants And Licensing Concentration Risk"
       }
      }
     },
     "localname": "RevenueFromCollaborationAgreementsGrantsAndLicensingConcentrationRiskMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_RichmondCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Richmond, California",
        "label": "Richmond, California [Member]",
        "terseLabel": "Richmond, California"
       }
      }
     },
     "localname": "RichmondCaliforniaMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Consideration Received on Transaction, Gross",
        "label": "Sale of Stock, Consideration Received on Transaction, Gross",
        "terseLabel": "Sale of stock, consideration received on transaction, gross"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SaleOfStockExcessConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Excess Consideration Received on Transaction",
        "label": "Sale of Stock, Excess Consideration Received on Transaction",
        "terseLabel": "Sale of stock, excess consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockExcessConsiderationReceivedOnTransaction",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_SalesBasedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales-based Milestone",
        "label": "Sales-based Milestone [Member]",
        "terseLabel": "Sales-based Milestone"
       }
      }
     },
     "localname": "SalesBasedMilestoneMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SangamoFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo France",
        "label": "Sangamo France [Member]",
        "terseLabel": "TxCell S.A."
       }
      }
     },
     "localname": "SangamoFranceMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SanofiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi",
        "label": "Sanofi [Member]",
        "terseLabel": "Sanofi"
       }
      }
     },
     "localname": "SanofiMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ScheduleOfNoncontrollingInterestTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest.",
        "label": "Schedule Of Noncontrolling Interest Table [Text Block]",
        "terseLabel": "Summary of Non-controlling Interest"
       }
      }
     },
     "localname": "ScheduleOfNoncontrollingInterestTableTextBlock",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofAcquisitionofSangamoFranceTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues",
        "label": "Schedule Of Revenue From Strategic Partnering Collaboration Agreements And Research Activity Grants As A Percentage Of Total Revenues [Table Text Block]",
        "terseLabel": "Schedule of Revenue from Strategic Partnering Collaboration Agreements and Research Activity Grants as a Percentage of Total Revenues"
       }
      }
     },
     "localname": "ScheduleOfRevenueFromStrategicPartneringCollaborationAgreementsAndResearchActivityGrantsAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sgmo_SeparateUpfrontFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Separate upfront fee.",
        "label": "Separate Upfront Fee",
        "terseLabel": "Separate fee for additional term"
       }
      }
     },
     "localname": "SeparateUpfrontFee",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options released in period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period",
        "negatedLabel": "RSUs released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value",
        "terseLabel": "RSUs vested and expected to vest at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "RSUs vested and expected to vest at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term",
        "terseLabel": "RSUs vested and expected to vest at end of period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of vesting installment.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installment",
        "terseLabel": "Share-based compensation arrangement by share-based payment award, number of vesting installment"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number",
        "terseLabel": "Stock options and RSUs outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options expiration term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term",
        "terseLabel": "Stock options expiration term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options maximum term for specified stock holder.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term For Specified Stock Holder",
        "terseLabel": "Stock option maximum term for specified stockholder"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Percent For Specified Stockholder",
        "terseLabel": "Purchase price of common stock percent under stock incentive plans for specified stockholder"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_SharePurchaseAgreementAndTenderOfferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share purchase agreement and tender offer agreement.",
        "label": "Share Purchase Agreement And Tender Offer Agreement [Member]",
        "terseLabel": "Share Purchase Agreement and Tender Offer Agreement",
        "verboseLabel": "SPA and TOA"
       }
      }
     },
     "localname": "SharePurchaseAgreementAndTenderOfferAgreementMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_ShireAgMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shire ag.",
        "label": "Shire Ag [Member]",
        "terseLabel": "Shire AG"
       }
      }
     },
     "localname": "ShireAgMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SigmaAldrichCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sigma-Aldrich corporation.",
        "label": "Sigma Aldrich Corporation [Member]",
        "terseLabel": "Sigma-Aldrich Corporation"
       }
      }
     },
     "localname": "SigmaAldrichCorporationMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_SpecifiedStockholderOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified stockholder ownership percentage.",
        "label": "Specified Stockholder Ownership Percentage",
        "terseLabel": "Specified stockholder ownership percentage"
       }
      }
     },
     "localname": "SpecifiedStockholderOwnershipPercentage",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued under employee stock purchase plans average exercise price.",
        "label": "Stock Issued Under Employee Stock Purchase Plans Average Exercise Price",
        "terseLabel": "Stock issued under employee stock purchase plans, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "sgmo_StockOfferingProgramMaximumValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Offering Program, Maximum Value",
        "label": "Stock Offering Program Maximum Value",
        "terseLabel": "Stock offering program, maximum value"
       }
      }
     },
     "localname": "StockOfferingProgramMaximumValue",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_StockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "terseLabel": "Stock Purchase Agreement"
       }
      }
     },
     "localname": "StockPurchaseAgreementMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_TwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized tax benefits increase decrease resulting from prior period tax positions.",
        "label": "Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions",
        "terseLabel": "Additions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sgmo_ValbonneFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valbonne, France",
        "label": "Valbonne, France [Member]",
        "terseLabel": "Valbonne, France"
       }
      }
     },
     "localname": "ValbonneFranceMember",
     "nsuri": "http://www.sangamo.com/20201231",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r43",
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": {
     "auth_ref": [
      "r100",
      "r107",
      "r193",
      "r317",
      "r318",
      "r319",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjustment"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r100",
      "r107",
      "r193",
      "r317",
      "r318",
      "r319",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r100",
      "r107",
      "r193",
      "r317",
      "r318",
      "r319",
      "r359",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r274",
      "r276",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r489",
      "r534",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r274",
      "r276",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r489",
      "r534",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r162",
      "r248",
      "r251",
      "r490",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r162",
      "r248",
      "r251",
      "r490",
      "r533",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r254",
      "r274",
      "r276",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r489",
      "r534",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r254",
      "r274",
      "r276",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r489",
      "r534",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r248",
      "r252",
      "r536",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r248",
      "r252",
      "r536",
      "r568",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdateExtensibleList": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r104",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r195",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r359",
      "r360",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates amendment to accounting standards.",
        "label": "Accounting Standards Update [Extensible List]",
        "terseLabel": "Accounting Standards Update [Extensible List]"
       }
      }
     },
     "localname": "AccountingStandardsUpdateExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r18",
      "r166",
      "r167"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of discount on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "Total other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r219"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r49",
      "r51",
      "r52",
      "r520",
      "r545",
      "r549"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r48",
      "r52",
      "r53",
      "r97",
      "r98",
      "r99",
      "r396",
      "r540",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r317",
      "r318",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r278",
      "r280",
      "r323",
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r230",
      "r231"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Issuance costs related to Sangamo France acquisition",
        "verboseLabel": "Issuance costs related to sangamo france acquisition"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r280",
      "r308",
      "r322"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Arrangements and Non-arrangement Transactions"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r181",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r145",
      "r154",
      "r160",
      "r189",
      "r390",
      "r398",
      "r419",
      "r495",
      "r518"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r42",
      "r90",
      "r189",
      "r390",
      "r398",
      "r419"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r406"
     ],
     "calculation": {
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total cash equivalents and marketable securities"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale securities, gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r175"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Available-for-sale securities, gross unrealized (Losses)"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r172",
      "r201"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r176",
      "r179",
      "r512"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r176",
      "r178",
      "r511"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r169",
      "r173",
      "r201",
      "r499"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Total marketable securities",
        "totalLabel": "Total",
        "verboseLabel": "Available-for-sale securities, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofAvailableforSaleSecuritiesbyContractualMaturityDetail",
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r171",
      "r201"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r171",
      "r201"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities, non-current"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r282",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r273",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r273",
      "r275",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of share capital and voting rights acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Purchase price per share (in dollars per share)",
        "verboseLabel": "Sangamo France Stock Price (EUR) (in Euro per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r375",
      "r376",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Business Combination, Consideration Transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Cash paid for shares acquired"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisition of Sangamo France"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFrance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r87",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Capital expenditures included in unpaid liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r27",
      "r81"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and cash equivalents, at carrying value, total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total cash equivalents",
        "verboseLabel": "Cash equivalents, estimated fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r82",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r75",
      "r81",
      "r86"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash as reported within the Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r75",
      "r421"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsMember": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Equivalents [Member]",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "auth_ref": [
      "r108",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of change in accounting estimate.",
        "label": "Change in Accounting Estimate by Type [Axis]",
        "terseLabel": "Change in Accounting Estimate by Type"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "auth_ref": [
      "r108",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities.",
        "label": "Change in Accounting Estimate, Type [Domain]",
        "terseLabel": "Change in Accounting Estimate, Type"
       }
      }
     },
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r379",
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Major Customers, Partnerships and Strategic Alliances"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliances"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r227",
      "r500",
      "r525"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r224",
      "r225",
      "r226",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Shares reserved for issuance of future awards (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Ending Balances (in shares)",
        "periodStartLabel": "Beginning Balances (in shares)",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r17",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r17"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value; 320,000,000 shares authorized, 142,063,203 and 115,972,708 shares issued and outstanding at December 31, 2020 and 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r55",
      "r57",
      "r58",
      "r64",
      "r505",
      "r529"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss attributable to Sangamo Therapeutics, Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r57",
      "r63",
      "r386",
      "r387",
      "r402",
      "r504",
      "r528"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r55",
      "r57",
      "r62",
      "r385",
      "r402",
      "r503",
      "r527"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r133",
      "r134",
      "r165",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r133",
      "r134",
      "r165",
      "r416",
      "r417",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r133",
      "r134",
      "r165",
      "r416",
      "r417",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r129",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r133",
      "r134",
      "r165",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r135",
      "r416",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r133",
      "r134",
      "r165",
      "r416",
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r235",
      "r237",
      "r249"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "terseLabel": "Contract with customer, asset, after allowance for credit Loss"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r235",
      "r236",
      "r249"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": {
     "auth_ref": [
      "r238"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress",
        "negatedLabel": "Contract with customer, liability, cumulative catch-up adjustment to revenue, change in measure of progress"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r235",
      "r236",
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r235",
      "r236",
      "r249"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenues, non-current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r250"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Recognition of milestone"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.",
        "label": "Contractual Obligation",
        "terseLabel": "Contractual obligation"
       }
      }
     },
     "localname": "ContractualObligation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r255",
      "r269",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSoldAmortization": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for allocation of cost of intangible asset over its useful life directly used in production of good and rendering of service.",
        "label": "Cost, Amortization",
        "terseLabel": "Amortization cost"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSoldAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r356",
      "r363"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r356"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r356",
      "r363"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "verboseLabel": "Customer advance"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r186"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "terseLabel": "Realized losses of available-for-sale securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Axis]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r357",
      "r363"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "totalLabel": "Subtotal"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r357",
      "r363"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r14",
      "r15",
      "r347",
      "r496",
      "r517"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "negatedLabel": "Deferred tax liabilities",
        "terseLabel": "Deferred income tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r357",
      "r363"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r348"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r350"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax assets",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails",
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Deferred tax assets, net operating loss carryforwards for federal"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Deferred tax assets, net operating loss carryforwards for foreign"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "Deferred tax assets, net operating loss carryforwards for state"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r353",
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "verboseLabel": "Research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "terseLabel": "Accruals and reserves"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r349"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r335",
      "r350"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTerseLabel": "Net deferred tax liabilities",
        "negatedTotalLabel": "Total net deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails",
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r272"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Aggregate employer's contributions to defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Defined contribution plan, employer's matching contribution percent"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Amount",
        "terseLabel": "Defined contribution plan, maximum employer's contribution per employee"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Maximum percentage limit of employee contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlanAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r79",
      "r143"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure derivative liability.",
        "label": "Derivative Liability, Measurement Input",
        "terseLabel": "Volatility Estimate"
       }
      }
     },
     "localname": "DerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r65",
      "r105",
      "r106",
      "r107",
      "r108",
      "r109",
      "r113",
      "r114",
      "r116",
      "r117",
      "r118",
      "r121",
      "r122",
      "r506",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Earnings per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)",
        "verboseLabel": "Net loss per share - basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r119",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r421"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r309"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "terseLabel": "Capitalized stock-based employee compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost related to unvested stock options and RSU"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average period of unvested stock options and RSU"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred compensation related to equity-based payment arrangements. Includes, but is not limited to, employment contracts with one or more selected officers or key employees. Excludes broad group equity-based compensation plans, defined benefit pension plans, defined benefit other postretirement benefit plans and other deferred compensation that is not equivalent to a defined benefit pension plan or a defined benefit other postretirement benefit plan.",
        "label": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation [Domain]",
        "terseLabel": "Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation"
       }
      }
     },
     "localname": "EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r102",
      "r110",
      "r112",
      "r126",
      "r193",
      "r230",
      "r231",
      "r317",
      "r318",
      "r319",
      "r359",
      "r360",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r406",
      "r407",
      "r408",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Free Share Liability"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Value of Free Share Liability Assumptions"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r269",
      "r407",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r406",
      "r407",
      "r410",
      "r411",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r255",
      "r257",
      "r262",
      "r269",
      "r407",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r255",
      "r257",
      "r262",
      "r269",
      "r407",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r269",
      "r407",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r269",
      "r462",
      "r463",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r412",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair value on recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r181",
      "r182",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r429",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "verboseLabel": "EUR/ USD exchange rate"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Net loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r432"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain (Loss) on Termination of Lease",
        "negatedLabel": "Net loss on lease termination"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r206",
      "r208",
      "r494"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, ending balance",
        "periodStartLabel": "Goodwill, beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetImpairment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.",
        "label": "Goodwill and Intangible Asset Impairment",
        "terseLabel": "Goodwill and intangible asset impairment"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetImpairment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r211",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill and Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r79",
      "r207",
      "r209",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairments"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Research grants"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r79",
      "r217",
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment of long-lived assets held-for-use"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r216",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Valuation of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r94",
      "r364"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Domestic"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r60",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161",
      "r491",
      "r501",
      "r507",
      "r531"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r94",
      "r364"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofDomesticandForeignComponentsofLossBeforeIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r338",
      "r345",
      "r352",
      "r361",
      "r365",
      "r367",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r111",
      "r112",
      "r144",
      "r336",
      "r362",
      "r366",
      "r532"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      },
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "totalLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail",
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Income tax expense:"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofBenefitforIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r59",
      "r87",
      "r332",
      "r333",
      "r345",
      "r346",
      "r351",
      "r358",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax at federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State taxes, net"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r337"
     ],
     "calculation": {
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "negatedLabel": "Research credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofDifferenceBetweenBenefitforIncomeTaxesandFederalStatutoryIncomeTaxRateDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and other accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Net changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Indefinite-lived Intangible Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r213",
      "r215"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsScheduleofIntangibleAssetsandGoodwillDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Investments Classified by Contractual Maturity Date"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r492",
      "r514",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Cash Equivalents and Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Area of space leased (in sqft)"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expenses"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r447"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease agreement, extendable lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letter of credit"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r90",
      "r155",
      "r189",
      "r391",
      "r398",
      "r399",
      "r419"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesScheduleofCompanysDeferredTaxAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r90",
      "r189",
      "r419",
      "r498",
      "r523"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35",
      "r90",
      "r189",
      "r391",
      "r398",
      "r399",
      "r419"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseAgreementTermsMember": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Terms of the license agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "License Agreement Terms [Member]",
        "terseLabel": "License agreement terms"
       }
      }
     },
     "localname": "LicenseAgreementTermsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseAndServiceMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset and performance of related service. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License and Service [Member]",
        "terseLabel": "Collaboration agreements",
        "verboseLabel": "Recognition of upfront fee"
       }
      }
     },
     "localname": "LicenseAndServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License fee revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Stock Price Volatility Estimate"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Exchange Rate Volatility Estimate"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Measurement Input, Share Price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinistryOfTheEconomyFinanceAndIndustryFranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of France.",
        "label": "Ministry of the Economy, Finance and Industry, France [Member]",
        "terseLabel": "French"
       }
      }
     },
     "localname": "MinistryOfTheEconomyFinanceAndIndustryFranceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r40",
      "r90",
      "r189",
      "r419",
      "r497",
      "r522"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "periodEndLabel": "Stockholders' equity attributable to noncontrolling interest, ending balance",
        "periodStartLabel": "Stockholders' equity attributable to noncontrolling interest, beginning balance",
        "terseLabel": "Non-controlling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r231",
      "r388",
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedLabel": "Fair value of additional shares acquired"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Noncontrolling Interest [Line Items]",
        "terseLabel": "Noncontrolling Interest [Line Items]"
       }
      }
     },
     "localname": "MinorityInterestLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestTable": {
     "auth_ref": [
      "r40",
      "r68",
      "r384",
      "r397"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.",
        "label": "Noncontrolling Interest [Table]",
        "terseLabel": "Noncontrolling Interest [Table]"
       }
      }
     },
     "localname": "MinorityInterestTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInMinorityInterestRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]",
        "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest"
       }
      }
     },
     "localname": "MovementInMinorityInterestRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r54",
      "r56",
      "r61",
      "r80",
      "r90",
      "r101",
      "r105",
      "r106",
      "r107",
      "r108",
      "r111",
      "r112",
      "r115",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161",
      "r189",
      "r419",
      "r502",
      "r526"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net (loss) income attributable to Sangamo Therapeutics, Inc.",
        "totalLabel": "Net loss attributable to Sangamo Therapeutics, Inc. stockholders"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r54",
      "r56",
      "r111",
      "r112",
      "r393",
      "r401"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss attributable to non-controlling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination": {
     "auth_ref": [
      "r232",
      "r374",
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in noncontrolling interest from a business combination.",
        "label": "Noncontrolling Interest, Increase from Business Combination",
        "terseLabel": "Non-controlling interest upon acquisition of Sangamo France"
       }
      }
     },
     "localname": "NoncontrollingInterestIncreaseFromBusinessCombination",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r231",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non- Controlling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "verboseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r153",
      "r156",
      "r159",
      "r161"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r441",
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease, cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease, expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities - current (included in Other accrued liabilities on the Consolidated Balance Sheet)",
        "verboseLabel": "Operating lease liabilities \u2013 current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r434"
     ],
     "calculation": {
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities",
        "verboseLabel": "Operating lease liabilities - long-term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesSummaryofFutureMinimumPaymentsunderContractualObligationsDetail",
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r437",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating lease, payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r446",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease, weighted average discount rate, percent"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r445",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating lease, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r1",
      "r96",
      "r139",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r34"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsSummaryofAccountsPayableandAccruedLiabilitiesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesNoncancelableMaterialContractualCommitmentsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table Text Block]",
        "terseLabel": "Other Commitments"
       }
      }
     },
     "localname": "OtherCommitmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r45",
      "r50",
      "r420",
      "r427"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "negatedLabel": "Foreign currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r47",
      "r49"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Net pension losses"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r46",
      "r49"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Change in unrealized (loss) gain on marketable securities, net of tax",
        "verboseLabel": "Net unrealized loss on marketable securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesDeferredTaxAssetsLiabilitiesBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Taxes paid related to net share settlement of equity awards",
        "terseLabel": "Total payments for the employees' tax obligations to taxing authorities"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedLabel": "Purchase of additional Sangamo France shares",
        "terseLabel": "Payments to acquire additional interest in subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r170"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r254",
      "r256",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r282",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by shareholders, which is net of related treasury stock. May be all or a portion of the number of preferred shares authorized. These shares represent the ownership interest of the preferred shareholders.",
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, $0.01 par value, 5,000,000 shares authorized, and no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds from collaborators"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r72",
      "r312"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from exercise of stock options and restricted stock units"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r54",
      "r56",
      "r74",
      "r90",
      "r101",
      "r111",
      "r112",
      "r145",
      "r153",
      "r156",
      "r159",
      "r161",
      "r189",
      "r385",
      "r392",
      "r394",
      "r401",
      "r402",
      "r419",
      "r507"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r220",
      "r524"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r28",
      "r87",
      "r220",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of related assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QuarterlyFinancialInformationDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Quarterly Financial Information Disclosure [Abstract]",
        "terseLabel": "Quarterly Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_QuarterlyFinancialInformationTextBlock": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.",
        "label": "Quarterly Financial Information [Text Block]",
        "terseLabel": "Quarterly Financial Data (Unaudited)"
       }
      }
     },
     "localname": "QuarterlyFinancialInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnaudited"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r449",
      "r450",
      "r451",
      "r454",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/RelatedPartyDisclosures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned": {
     "auth_ref": [
      "r328",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Compensation Earned",
        "terseLabel": "Revenues under agreement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r327",
      "r582"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r87",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r13",
      "r81",
      "r86",
      "r569"
     ],
     "calculation": {
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Non-current restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesReconciliationofCashandCashEquivalentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r6",
      "r13",
      "r86",
      "r569"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r20",
      "r231",
      "r320",
      "r521",
      "r544",
      "r549"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r102",
      "r110",
      "r112",
      "r193",
      "r317",
      "r318",
      "r319",
      "r359",
      "r360",
      "r540",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r152",
      "r157",
      "r158",
      "r162",
      "r163",
      "r165",
      "r247",
      "r248",
      "r490"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedSummaryofQuarterlyFinancialDataDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r133",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue from Contract with Customer"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesRevenuesfromStrategicPartneringCollaborationAgreementsandResearchActivityGrantsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r253"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:",
        "verboseLabel": "Revenue related to Sanofi agreement:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r444",
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty revenues"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Consideration received from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock, price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accounts Payable and Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r177",
      "r180",
      "r183",
      "r184",
      "r185",
      "r187",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Revenues recognized under agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of Benefit for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Company's Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r280",
      "r307",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationStockBasedCompensationExpenseDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r280",
      "r307",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Summary of Domestic and Foreign Components of Loss Before Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetailsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.",
        "label": "Quarterly Financial Information [Table Text Block]",
        "terseLabel": "Summary of Quarterly Financial Data"
       }
      }
     },
     "localname": "ScheduleOfQuarterlyFinancialInformationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/QuarterlyFinancialDataUnauditedTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r92",
      "r452",
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r329",
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithDASDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesRevenuesRecognizedunderAgreementDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r86",
      "r493",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Restrictions on Cash and Cash Equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r282",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r287",
      "r295",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Assumptions Used for Estimating Fair Value of Employee Stock Options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Stock options vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual\u00a0Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "RSUs forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units awarded (in shares)",
        "verboseLabel": "RSUs awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value per award of restricted stock units (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "RSUs outstanding at end of period (in shares)",
        "periodStartLabel": "RSUs outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "RSUs outstanding at end of period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield of stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Stock reserved for issuance under plan (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual\u00a0Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r297"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Options canceled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)",
        "verboseLabel": "Additional equity award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average estimated fair value per share of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r289",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at end of period (in shares)",
        "periodStartLabel": "Options outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Options outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted- Average Exercise per Share Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r300"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options vested and expected to vest at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Options vested and expected to vest at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options vested and expected to vest at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r279",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Equity Award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-Based Compensation Awards, Tranche 1"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Share-Based Compensation Awards, Tranche 3"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-Based Compensation Awards, Tranche 2"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r87",
      "r282",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Sangamo Stock Price (USD) (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Stock options granted vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate\u00a0Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "periodEndLabel": "RSUs outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Aggregate fair value of RSUs vested in period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r302",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockBasedCompensationAssumptionsUsedforEstimatingFairValueofEmployeeStockOptionsDetail",
      "http://www.sangamo.com/role/StockBasedCompensationWeightedAverageAssumptionsUsedforEstimatingFairValueofESPPPurchasedRightsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable at end of period",
        "verboseLabel": "Options exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options exercisable at end of period (in years)",
        "verboseLabel": "Stock option maximum term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding at end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vested and expected to vest at end of period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of fair value per share of common stock on option grant date"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Public offering price of common stock issued (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "terseLabel": "Shares withheld from issuance in order to pay employee taxes (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r39",
      "r97",
      "r98",
      "r99",
      "r102",
      "r110",
      "r112",
      "r126",
      "r193",
      "r230",
      "r231",
      "r317",
      "r318",
      "r319",
      "r359",
      "r360",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r428",
      "r540",
      "r541",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceSummaryofNoncontrollingInterestDetail",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r126",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r16",
      "r17",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock under employee stock purchase plan (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/StockBasedCompensationAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "verboseLabel": "Public offering, common stock shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r230",
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r16",
      "r17",
      "r230",
      "r231",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquitySummaryofStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r16",
      "r17",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock under employee stock purchase plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r16",
      "r17",
      "r230",
      "r231"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under public offering, net of issuance costs",
        "verboseLabel": "Common stock issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAgreementwithSigmaAldrichCorporationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r16",
      "r17",
      "r231",
      "r281",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r17",
      "r22",
      "r23",
      "r90",
      "r168",
      "r189",
      "r419"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Sangamo Therapeutics, Inc. stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r90",
      "r97",
      "r98",
      "r99",
      "r102",
      "r110",
      "r189",
      "r193",
      "r231",
      "r317",
      "r318",
      "r319",
      "r359",
      "r360",
      "r383",
      "r384",
      "r400",
      "r419",
      "r422",
      "r423",
      "r428",
      "r541",
      "r542"
     ],
     "calculation": {
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balances",
        "periodStartLabel": "Beginning Balances",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets",
      "http://www.sangamo.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r89",
      "r231",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Fixed ratio shares of common stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r429",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r429",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r429",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r429",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r456",
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail",
      "http://www.sangamo.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.",
        "label": "Summary of Positions for which Significant Change in Unrecognized Tax Benefits is Reasonably Possible [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Company's Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Other Balance Sheet Details"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OtherBalanceSheetDetails"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r181",
      "r182",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Type of Arrangement and Non-arrangement Transactions"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail",
      "http://www.sangamo.com/role/MajorCustomersPartnershipsandStrategicAlliancesAdditionalInformationDetail",
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetail",
      "http://www.sangamo.com/role/RelatedPartyDisclosuresDetail",
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember": {
     "auth_ref": [
      "r255",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, bonds and other debt securities issued by US government sponsored entities (GSEs), for example, but not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB). Excludes debt issued by the Government National Mortgage Association (GNMA or Ginnie Mae).",
        "label": "US Government-sponsored Enterprises Debt Securities [Member]",
        "terseLabel": "U.S. government-sponsored entity debt securities"
       }
      }
     },
     "localname": "USGovernmentSponsoredEnterprisesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CashEquivalentsandMarketableSecuritiesSummaryofCashEquivalentsandAvailableforSaleSecuritiesDetail",
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofFairValueMeasurementsofCashEquivalentsAvailableforSaleSecuritiesandFreeShareLiabilityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r331",
      "r342"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Reductions for tax positions of prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r339"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "terseLabel": "Accrued interest and/or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Additions based on tax positions related to the current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesSummaryofActivityRelatedtoCompanysUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r127",
      "r128",
      "r130",
      "r131",
      "r136",
      "r137",
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedLabel": "Increase (decrease) in deferred tax assets valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/IncomeTaxesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueOptionPricingModelMember": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating price of option.",
        "label": "Valuation Technique, Option Pricing Model [Member]",
        "terseLabel": "Option Pricing Method"
       }
      }
     },
     "localname": "ValuationTechniqueOptionPricingModelMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/AcquisitionofSangamoFranceAdditionalInformationDetail",
      "http://www.sangamo.com/role/FairValueMeasurementAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r442",
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease, cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/CommitmentsandContingenciesAdditionalInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/StockholdersEquityAdditionalInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Estimated correlation Sangamo and Sangamo France stock prices"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/FairValueMeasurementSummaryofEstimatedFairValueofFreeShareLiabilityAssumptionsDetail"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.sangamo.com/role/ConsolidatedStatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21728-107793"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e777-108305"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=121640914&loc=d3e1280-108306"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "270",
   "URI": "http://asc.fasb.org/topic&trid=2126967"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26626-111562"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27198-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27232-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=SL120269820-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27290-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27337-111563"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27340-111563"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27357-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919244-210447"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919253-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919258-210447"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922888-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922895-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=SL37586934-109318"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32559-109319"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=109240200&loc=d3e30755-110894"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121604053&loc=SL77918607-209975"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918666-209980"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122739-111746"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e640-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62586-112803"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=SL120269850-112803"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121641442&loc=d3e19393-158473"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611197-123010"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=SL120429264-123010"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401592&loc=d3e611379-123010"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r583": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r584": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r585": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r586": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r587": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r588": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r589": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r590": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r591": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(2))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.19)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>102
<FILENAME>0001628280-21-003069-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-003069-xbrl.zip
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MS6R$$E"YE+O+FUL.7(XF,112%#4D-JG8%F1B<9I#4GD)46:?PZ;EA[^!V?G
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MQQ^//'_0*NI"RYG\? HT(*B<*"4L-@1VD1VJ/BVM=QG<Y2R\<G0Q*1>J!.G
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M8@->IUJH3P60U@.@WP-@.2(H66\ L1G]"J!3U)22]AGD?UHBA+4(6@^ FQH
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M$YAK= :3,HD22*B5#+ *F4NM0.).>T#@3LFN[HRF6T+@G*R%R($C%0E .=:
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ML&CNMZ2%Z5W1=^6JU%\B(3\6/#L\F0+\4USS'L\^$NZLNMC\FUT\YNR,7RI
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MNL:/-()3&BFWIM&UTNA*UUK&^M0I0>'*!%5N$78N*<?!YQI#!?(*:_4%6U^
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M7#3%5V?:[KO8ZQ#AC#>/A"#?[;AO!0F7M P3563-&9D\<,L))[!M>KV5)5%
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M,N=%R"DC4LZK&%)A8[E"=8"5>A1-K1KI;L32+26^2ZC(FVRY9(#<?K$I9!T
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MW2ZX+#M.*7_NH8,V'V'N?^+4S]7,#VGB3Y)'_HTLM+U/M;\&S6ZUUO0;;BO
MP#?LJ=L==KMNT!@..K6V)V2C\^SU)YDM,K1RVB.5=UF7#WF<+#W<N%62Y-.D
MC3C)X9/_SD+DE\ F*:DRI03Q[!K^64< 9?DCRO)5!*.%^3*YP.&LV-^UR:D/
M35P?DF@6YR*E],XT^_6(JOF7:+6:G:&LN: F--S&H%UU.\-FW?7]H ;[Z8E
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M_0KCYE1UV<PY?^,V:TVVF"(I5KBD*HQ]Y9QK H[,#0(AQR0-S2S&<I),QT#
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M-78BKYCFIH ].7*^I=GQ)5(F93EIJ-3-BT[G-LEX/P53@INC858%"IJAR^1
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M)%T0--XP5V@;W;.32A>FJ/&QJD)1&S^4S+X54AF'T0!G_!VU?=32(%OP_N?
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MQDE:]/NAI5 M[@,Y2&=XUS%ROG*7U/O,3X%%4YXR#FC*J16Q)VM_U-Y@WGF
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M/\O=9#ATN'8L%F\;6L%,DYDSAK?S3:M+K^Y<CGZ[&*ED&U# Z2@CB6"E!*@
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M#"J]0MU'A-]FZE]>.R>-9Z2%<T94+(>8#:Z+M@LR5*@$+:;2H8=*<PA-O/:
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MWX?. !ZJ?:?LX2D8H.49U>Z1\ATR927 ^A3P"RXIRM"S<J<+UCD_GQ[0=I@
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M(;_2H#>DBC &0:4$;6J\/^'1"Z:L$\UI]U.';1>R;*8';.)O4J7#UY=^H(#
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M'FFAX\QX:)\78!<V*&>I>MK<VZ+E_[*8-W-\E[+P23+@Y>NSK?W%PH"%R6(
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M3G")IQIQ=Y2YAZ,74AJTJ)L"R@0^%>UV[ X_J;F=R:*.Q6SO*Y BG:^4YG2
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ME-8,9'BD="[F?'G"/>*,QKRT\B"^(YS0Z,Y"#K$?#$D#\(^2<L'Z%!6^3;,
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M*(?G+,0Q,\WKAGI6G+4-SE*\CG1_QOF<-WXJOX3E5Z?'*4.KOM:(,0&VXE/
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MK2>@I)1'NXMDTH;1H!XJL^>'VF@BK#QGJG)+3SDM\%B8L<(Y@Z,9"H(]A/4
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MY7#TO+-0$G1WHEELP7+"%?M<Q[VN!*<4RAH8W"A%+@MO"B'8&@_M8" 5!9V
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M:CGC4 ]S2W-#PY(;WV_ 16H&)9DJ2(TN!<W.R'+5JJI)K6"Q A3:42T7\[8
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M79/L6=Y[6I  Y4=X!T5:QQ5L]6U3[5GO<DD'SL/IZW/I@3L5UAYF2UCXXYV
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M<Z$1PSSQ:)?YO[A4EJ+8J>_\."%(N.:PU"'>18([%2S3&MX;ZJ&L%U3(I:E
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MF,8.A? 37WQVY"<B4,$1Y@P+?_27K[XZ\CM"U"\\H E@-@Z&LP^4>>!O"@N
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MWCOO*-)]A^>7]*,:;C8@OK+*:9C@\.,%HT*9/0,:4=*NU4I;O0V ^QCI?F
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MMK(S %%Q]E%/$=14R[I?38>BMK=/GL\^$:LUQ+;C]]DQ#FWR/5 D;@;#C=1
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M-U>Y-&1+'8H?+KX=*]/ \\2@@V>ZKW?LZQ)610N74@NV2N=U'F_/;G>VK\^
M*XPP97%RV%[']L!K*R8K!H6FHT07HY1JM?<\6RZ11^*@;)_A(P+:E2-A3"QA
M*BPI3!7/:L7T*MR+O*M;8W'!;6!9.1%1$)Z(]=2#7*5D08W:X?\.3QR?63:D
M/-F$JHQV7BHM/R^I<E^[KB:IL7,S$&&"LZ8Y)(35Q+'C@H5EF15;*@,R;XPY
M;;*[!V_Y7_5U#H<TUHNBF(XM8PWMF^2AN+3V7,RB%E$&0[=[*8028Y"*$$6U
MB_1WM"])U?G\C!A4@]Z$X>+(0<>+5;KDY]PBS[-*1;5RO..=JZ7J(4QM"IB-
MZ5W!3C'[DI3TSMJ];YR:8,R)W:*#4?5O6&G"M?Y<:=ZU"U\G2/^ISY[VVVTR
MC6>D =- Q4I=7$HU,G:F$8(7UP"CDHF3TJ=F.H9]0I==;EX6S+'^1]+(1TI[
ME?D[7CG,E\[!1EURAB)O6$D@HF*H];0KU^10TX^@T.BO=U](+ZIEES(C,=N\
M7(9U3WW75.GH-!744!?61Z!LC=#NN6$^^'[6N$6F8+.NP"%QR2TWA=V@#2.9
M) E$B\TMC7[Q%3/G0U?. \$A]X(_+NS)$TBD&H">KY]>P\QWH 1E2Q'-/@)9
M2.OVHSA.>F@?#CF?0/V@YN/?4J<\38X=.6= 2Q$*(E@$NG$&K_MC+MBN/F!H
MW JL![QO[/2-/YT[DD>?S N^KGW-=W3+3'&U<3*N-XXC,*\1'(7D($SB$V52
M@WPF)YVV^+Y0SBS1=>.&"=7 .))6M2:W]-6X[/K/K@<15.6*<P?ASUDEX\C[
MU>NPB@YLTL^NQH25'VSR*:WY:F(K&C\NT8[@@>(OQ0K$E%HO?FD(((HE3XN;
MPR_@<W 2#%PV]R'#@,@$USADXX2)QZ^FH& XTS2D!SK&\=>C\#%RE!1_0NMS
MG;/K$M= ].7Y<"=3K6DO)/RLJ3[U>0I*RY1&_ )0#1=P5WVHCPUMH$2H=S:.
MXK@1B-[W3WF]([VQ?U&7 &%Q&( #7STF.2RR8G,[H/QQ[A[_,O_*$&PZD@R=
MIZ)[L@-[,(DH]'R$.VXNPM[@U=D),2X3J=*S,:;Y$%>YQ3U&%_D@"[1/3,)(
M%HEL(]!0AHP=3+3&90_7L[R1\4PZ*W!)HYZ8H%7[AS)ASC*V7VG9)4JCY$I5
M]EN->C\21./@M?NJJL-H9C@1%O?Q@,,\2&B&?SDA*SRRXJL3LN+C&,LGQKHP
MPM?GSRC[G%*V4@ZL,8X_(E5.6DI,8I!CQ$B<N8>3 'ARW0CB2BY_W+D[PNL;
MYX,82_4K\Y\++F+''URG42=!H9?OLDMA-Q!?R[GL(VV0*G6(K-+ S5%HQCBE
MUX!$40=V0W(GL80IW@PI'?:[B9C-<Z^EU-#>P_7_XG#$ZBIH)3+21@LU,C./
MC?-4][^L.!>M\@HQ;J3Y1B)@I0#9IMX6! 9<<7PU.;&NE9JIU_&_HK>G;'UK
M5SJE#&+,:D@_D5X^-R@W@&)[4O0[D7!PW18CN5IZ>>1T:>>'!1""R(S%XVDY
MV:DTCWB=T$\RS52F/N<(D:2OSW>+,)LMN[RQ>R,))UW_V%32@:[PL*4$HR'2
M@HW@BF[DHOTD7+:$+$OI_"06-(=F51N#!W&^:A: "CV-#P00^_KT2X0'K#5A
MZ,"G??]8=C7MPUF_K&UE5RX )OZ6E#TP?.6>)4_<F$X5=B8#WPJ:"2]SPYB3
M("6M!.N+ISG%WNGS&8KQL)A[\3(7\@;[1C0NJ'$E34+!E$3\;XJCQS43(ZTT
M \'9%K>M[TC&_8GN?;K-(TG1(,5H2:*X(]($CJM&D%%*LT0^<&GU<I6%V,>8
MVUHF..X@$MJ4Z)3+B!@@>0ET&3 KD1RIN%6XM3UMKL#O1JD)T35*25//,9_;
M?K)I5+=;T$J]Q#EOW<-D:F(TL\*_I,VV&&I$\BD#TN 7R2LJR_ 6'6>_:,H/
M?"EJQRMDI(<5B='3=SY[V8.^Z%*3FY?<+'S9RBE5)-2=WAA2*\*_'K;_FOZW
M.7-^^XV_I$Q)O^;5X\7UF1H@)V&CV')YU0!^VW3=N><R:Z8R'7Q#1L6L1:Z:
MVMS7W3U@2_$+*$B0*/#I\;J*DO9(H,LD#9''E.ZH"$9--:^BI4)H(]=5M@__
M%=8\_%#<=BH2T^U;NK0, B19#+T.C1I'I4E$35L?@2P&H N[,JLBM:4KF D?
MM9%19\;(;3]2RW@>=D7KA\'TB]X*%?1I)L(_T$'J%84=YU'L?XIY\+I'/DKS
M7 U2_[^P4#0!"7:_)ALCLIR0%9<7(8O 1A=\NP>EU>Z!T?K7P]QQKIDOI2VE
M/9;ME)*)6<0'^YR"TK#Z6][?^:[ _^[74'(%L3]]^8\7S\X>?6W?(G4Q>EW
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MZS\^]:O L>7;B[]]ZP:Z#?YTU2W!Y"E;X/OPI_ I*M?E^8P0PH\_>_*-^*X
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M9]ID<<*_;SEZC-5#=T[J8>M7 BGH0WR2H-IU@W61"JTW1(Z'?"<C!&.S=J
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MNH[7XQ1 %AQ=:.'P"X"E'H-<4@?'VU;\M5X-O8#8I+QB'+)>"$:92Q-9J2)
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MDUCK>:N01KNVO/[2GB>XH!(#=@/H9<N89(VXG(5X1TDL)M@/3'@;6G+43.N
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M]=WGJXMWN[9-E$XV (&IBL;_JLA3*Z@:<TX<(U[=S>D@'""4!;\'E[]2W!R
M[F!MZ;83\AOF)2H$UYT]X.+["6Z\892"J_@&>[]E>1I'H>^)8GNI0LQ)]74>
M<Q5G\ M<N_V#_AE!ARF+PM_SAWQ\%/:;0_;&*>.'+1C17?P9;MU9EH[](3DI
ME(1Y'9P!47UA=5V!G0)#.ED]I/Y!>+IL%</E2VC&]_<H&2(.))1.Y7>-;:A
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M @,Q+]!K* -8J& 4H4."%@=\4L&9$6,Q1,L<QC0C,S/#CZ>XQ3-F^H4_@+X
M$QVL?O,+-L_QE3F<OF0!AWDR47">RF"29S,8QB*85&65J[7>HA<)#*",EC9!
MQV6X(!=EQ7KMX_EPIA*0L,E@W.'1H'ACP!_#)X(' 8?WCN?3R9.'P]:&P1#.
M$SHM=*9@B&46TOZ+\'R&W0G>\\)K&1JK8I3'0[:Y?XU 9B["X )>$/1$0X N
M.T]3G,9GQ4*5!N]AI8+>P=[?]H-_9E7 L@HCB=C.GV1)DMWB8,>^=M3:+(B2
M##XE3\D9X*6V]ZWF1$9U5][QVW>:I/1-6 B4N+*$K:2UT"O<4$;C0"6%N@6Q
M5.QYP #9MUMNVF[=Q=7#7EH7L,QCOFE"\:!&VK.@:7V[>^Q:I? G/GST9)@E
M]J:A7Y)S#B(ZXZW"B $LY1[^-S4RCD"1H&LX5.4M.H;>#_>=L=++R<?<Z&D8
M&N"GG1I/WW<^5TH]!P-@>X<HZQ6QBG_#I34G51_5 7G4H#KO\!<?RZ0&V=L:
M\W[U6,2\GY;EO'CU\N7M[>T^')']Z^SF9?SU_QMGHS^_/,]!]8,)\5*-KZ/\
M)<887H+KU.L?'KZ$<?=.^J?]4Y#'@X/^\6G_97$]R_90HN +O?UI.7OQEQ6"
M,Y$;>0(B 5\A$273R6MOA8))KL1WMG!GKO_T%/HSA(U)8#/,Q73Y[@UMH!KF
M%%CLGX:DC-:Z&)[0O_MTH_*;6-WNSOU%P\:@,3:G#T;P&64BX+8&/P,NDVP6
MC\"3&8/EGRI6ZV#%P7^#J5/*_9[#JQ,.5TL:A*(E9#6-8H6F'=BDF7F,F)_T
M.S3^:,L3E&%4J.!@Q,:5"G!&657@;<:16HQPHSF/;QXK_%6.HD)7QRQF=5].
M81C7T^"'^$?XSHU*LCG>#%I=ZUF2R@<3T_Q[GF?C"HQLN&/&9.> @?I## _!
M7Z49/,A,"'\*'\EG&/O)T)"&K:C0Q@;7CFE[35R_*;HK^X9Z\;6GEY!/N&Q5
M3K9\34B:BX;"].I^T_4ZGAR?4EV\U_2D=_ID:T!VP,GC\ >L%S_S5J=WM$^M
MC'^.\PQ\BU&&IA\HTE(E8'K=@+2.0C#X"^,P%L'E3WO'_>.01#9!KZ&Q=V&
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M(J6Y["<+P(+[O/BE5-SG-)R\QM;TDP!UQ;1P #+"2HLF QT9:[PF)R!G5PO
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MD?M/ 6Y.OA7=P]]D67R3MML-_JR$/Z=5Y0&P)^'"]PCE*B:<!S$1D0I)%.C
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M\[,4X@VH#XT0/X403Y2(6+N>="*'!)&K"*>*$S )%'&Y9E$@A>!AL'?@AG9
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M-!#8!M^F]<DT;_P2.Z8]-.*[9O&MYG5Z'O5Y1$():@-'!2(,79=$ +ZQ"Q8
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M,2XB)7^ 80OYZ1'PU?#3CO-3HAQ':.:2A"ILF (&A@S0P(AT3*4.(LXDAMA
MC\/_+0%K.8M9<GRXMG');(,E0:U4R)8W8"@/='<9GCP?#0=#6"\HN U3;H4I
M/][\PSPO\ ,W("Q&#RQ+.!$4F-)S.:.. MZDX:H@MYY+\P$<=3H8C!J$VQXS
M<15%KN\K$@<L 6:2&G0V8*O03R2PF:NYX^T,,S7P5 .."H3+A._%!.S%&.Y,
MH<".U!*,@E@JC\5Q(ISMZ& -/.T<,X5NHEW)(Z(=#^#)=P01;N@2'3"/*BE4
M%$=[!]WL?LUK>=TL-6=N97TKF^#)V$\:IU\WF4(89<-AUJE_ '\]>3K?=3^+
MY>#ZQZ)IW#V+L+X)YR\IGI7&)@[U(AXD)( +GW"ML7(H< B/0Q;YH8JUS_<.
M3-" O=IJ&N%8$G8K!WA7!'@]&3B- &]&@">1S\"1V$G-)Y'/P!H,. ,%'OYP
MG%AY4:QX2&4=!7BC0==ZQN<P R#KUB(XER^EB:NL3TA/?Z $?_H":^6M[R<>
MO).WCO^\_?BY=7WV^<0Y8[".R[\^?_S[3UB'HO_W_83_XSENY)FBP"@V%I5'
MA.=&),'>8Y'KN%JK[4;F&O:I,?N$ =A-*DQ(I!T-BEWBDC"0"9$Z<9+ --:-
M5@_+O=J*S_J^_FEC-FQB*+5@O[/;?WQ'1Z&3"%!+%"/<991$(0=CWHMYDC#*
M0U=LQ\/8,-/.,5.D/>TJ5Q$6!V"N^C(@D0M78:0$9X['M<+)\"YS'A>2VP%H
M:WS=VV;'#\X_CO X]Q. M4!RPCEWB& >7+)^PC6&Z3Q/US'?8(Z;&C_W=ADI
MD"%<DS%H9HZ9^>PK(G@<$.T+$8J <>:Y./J V8[OVLQQE\"UU?,*MG*M-JRW
M1=;[^.V?P&5*><HG2> (PAWN@G7I^\1UG9@"-SJN0W="/VMNQ!IPD^!NE A?
MDR!$=Z04(1'8W%0HN--"A]$@2 #(J&<#JMF!,S]K]KZX',):)3!GR:%UK)7N
M1+ION=2V\'8T'T(6LRWX9D_#@[[J]NTC@GB/ZB.V*S& C<PJ&$NM<0\UKO]5
M);4R+\FC@1/)D'B^0M<_F$78:I3$3I)(*5C@^B'(FLW9=J>Y/2QRM_7N?[LB
MM1L93-!([>.D=A*P"T,1\XAY)/&<F/#8HP2$-2:4A@%3L:]4A).<;9#/&DGM
MLR^2/X1U(HUEV^K)-"9IUU*REPYEN^GXMRUE87(F[^!(3KM'^8%4T*@!HI6
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M$T9.X]+8 3VE08B:(\1$\7$=)CG.? UTS F7'F"%X"$1?L(3E[FA:9*/;I#
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MGNJ+4N<]C<'9[I6EO_5T%P3@MV4\G ^N?6B>L>9L\;K7T;W7 RW[ZMKDB<>
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M'&:=VH_^77G_][+I5C=>^_#.%*0W<+T27'^LFDP\%(X4G!*!LTNX#PI7%+"
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MVE]#A]<&V1IDJ\^N:U\!VR#;0Y&-CI%-^3I('"X(3V)0VG0@213&B@@6!AZ
M&VAT_AH:V6X$V3:4/KO5=(;761_^V;74J-_7775K#?OPM+:)&EDR_CP:##$&
M^IB<UUUKF;=9VW)I=#H?7NO^4=;I]?6U[@[2K[HR.S0_Q:/B$"_Q#//5'W;C
MR\F)'HX/M*6'Y\FE_-8@W2I(=ULQ3]U8AJ!F^T3[%#0W-]8DI)X&S%/*2_Q
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M7]G+6.,/[</9XO!N"<,7.Q4[%3L5.Q4[==%.?UM"6\L@C5')RXH6<QR<9BH
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M5326*:)\<#S)7M""*.D4*,5)\!'? <+W7:<+NE>'[H5M!)%A:Z4'Y 45B(M
M<Q^9@(0WSK@8K.-^9Y?UI+PYO;$@O.,(+VU4BYV*G8J='IN=EE V'#0V8!U3
MBG"3_)(8HHH,</)/*3:N*)NM4C:+H5O-53)<(,CPI&\XEAPY132"J"GEP@#W
MNI4V:E6%BJ4<<=W!VW1NHPI.S_K#<X#9BV>3D3])2*K.^G;P.&O8MC4,^V)F
MR?9#KV9V;,?;E5#L4DSX^V(H5DCO\A@,)*G(/>U(0)HF'X\2(KR6+$9E=G8I
M-STF;[8(+8GI;07[AD.QWP1S437+8GDA&NNIR54$B'*5]V=9BYQG'$&046G,
MI28V8;F@^ &CN"O1V +P50%\(2 +-AJ)D]=BA=5IL18&&1L$B@X'2](CKW3R
M6F@/\P+RK0-YJ?4K=BIV*G9Z;';:PH!L$3<K\UX68K(V>2E1$9J#L IQ*0"Y
MJ!32F"CJ*#<V-Z+*ZJ9+@8A24+MT3/9LXOJU3V]&R,"ZK(RM+W[-#YMQ4XID
MMRDZFZZ_?:L$8Y>CP+>+P5CF@,ODX2&>?'C$:>1($R+RX";,C*24$+>S2VA/
M"MQ+#V*'4E,E^[S5\=B;\"T*YH[PG<=?K8'@C%7(6!T1-U*FGWA$BGGE5,#2
MV)#AVZ64<L'M0XW %DC_**07(JY4.NX\MT@;19)/XAQRR@6$#4W_6<.UDPG2
M3/:(7M4TC@+KCL>(BIV*G8J=BIVVUTY;&',M<N:'/93%NE?)/<M21EGL$>>2
M(ZVT1IJ8B&U@CC$_U3,,=VE3S[HK7S>"RO;Q1RX7>N>PZ66E]P]-0=SBC%#)
MW!4[%3L]^.#%WF7;X.9XN)=N:SXYVW]EZ[ _>&;/ZK'MM\D%=WWKRVOX[Z1N
MZC&\@=&GVL-4)KP&/_PP:(_2*H8B%)82"N\6XQXJCWVRT>=A'TDGA-S[3]F(
M-%:&.)W$(,Z9"--C[-Y9B$((A;B+G8J=BIV*G3HCA-89]BA"J&-":#%B$HA0
ME.4I1\JWFVHT<BPJ)*U14>C<ZAHZJ(3679:V$3SO^>GCG[$\C)6]A$XUK9;*
M+[ZQ@P_V=%C]CQO]8[?*_TO6&7CXH:#*%H=\2VB^V*G8J=BIV*G8J=BIV&D=
M Z+SC@ZPA@2O)9?!6NJ](MYB')G6XB[1Y,M)T5.7J?EP.KR3O[0@#8]BZ7V_
M K?(7YD%2QP0(H5%DI.(>* <:1LH4CQ*Z2@33M.=749O%L4M/0NZ@+N3X%Y!
MA*2 NTO@GL<\E*3"<6*0#KD[6@2/-!"', .+6618$-(A<)>V:'^Q!:_=2U>-
MH&_S0(KQ\#(@,@V#5':.I<?9#ZT$[XN=BITVHR%64&[R ZF4>97I!4L^RR19
M),-2DN'#8KT(QI+HI!F0,=8BGIX,I*G&R&"A B7 K,R=B<0]!$-!<F'<8J=B
MIV*G8J?N*)@51$&*@MF8@ED,>E KN!1.(14\S1(&D+41D,0FV&329%C6'0GS
M*.H[7@Y'Z9^#RD]&(QCX\VH\2H?KMZ5/E;T$2BGE*-'T8J=BIV*G8J=BI\W;
M:1G]G-1S.HA6@3G.??J)&BP8Y49:C26SJZRS/AJ?P"B73X_@! 9-_0GV!WYX
M"K\-FV8F-9[-E,;Q7&C,!?FQ_5(4]E(*^^/X:*%[.3.1,4608\P@GKPFI&G0
MB 9!G75!LHAW=DE/W#+S^4$4#?S ,7YRK<UE OY+4S\9U/W_;V<\ROL%"FXV
MC9O%6AN.J:,J&2X:)Q&GEB$=,4]_<*<-8YI(D9^W:Y@I:U9W8SYES>HT]N91
M(4\LX=P"BCHM51QL0-IHG[!'@P%M<5K'.K5H/8I.*8<PKO(FN S4?D("-*5'
M2LDE%#L5.Q4[%3L5.VW>3FN. =U=-+^:RH:]06@_]6K8C$<PKD>0U?)3&$"L
MQ^U4V;F&3FKC*!8AO:20_KJW&/RQ5 +CQ"%/\FQ*F>>ZT.B1-5)$"!*PX#N[
M]&;/P5(@UEV0%S+>#CMMM*"ED'$WR'@QJN&TL!$L0\G" G$= K+)ED@&C)EB
M4A'3(38N([9NCX!,!B-(I_X50O7!UH,J ?O4CC["V+H^5 WXR:@>U]!<#M@:
MVR^/<ZI6R1P7.Q4[%3L5.Q4[==%.70R6O+U4%_\:]O,=_35IC"S:CP9O+J7%
MWJANTEN+TQJ*0/\A@?[B2JF,\YY'%A'GT2$NB43.@$04O*'>:8*#W]D5AG9H
M1$.!>J'D!V2G+H9,"B6OF9*O5((H'XP.!DGB=2)F",CYD#<[$^VYEB0] EWC
MY$=3#)*+0$H)2(F^%SL5.Q4[/6P[+9/-"L&KY#"#26J,"Z<<MS8 H=12XJPT
MRS2INW/-[JO1,-;CK,N*X%I*<.V/#^?3U(D,(G)-$6% $?="(>.Y0T8(XI/)
ME ;8V36B1[3L1IZJX+?P[ .RTV8[_18RO3>9+NXAPL $9Y:BR)A'7%A UAN)
M0E1*" =66[>S2]E]=C$4B'89HJOLUUNDT#K0.X\]\71[-02.0%B#N#,D]Z9)
MZ%4&M)+$LB!:+<2)Z0: 'T5_FJ>VGWLO-94=5\_!PZF#4<5(K\H ND]7&C<<
M!1BA\?#L239 ,^S7H<H7M)4L]4V2FDYINLY3 7M-O8L"!$^^F\%&X>BCPEYB
MY^C[_=OH:?_PY1*T]&QX>CH<M&VTVL%JS;29UB5'X<)1=^"H"WYJW37F@5FE
M,$H2,+EK+!AD8]3("V*)4%A;D2B*$-$SBO;4RJ;+WPTJ6Y0L>R38OT6@_!#P
ME]I-W2+^9-A/-[AY\=])/3[?'_C^)-_55\-1NW-Z/![5;M*64!X/RVR!U=#$
M0E2'.D&E)TBX)&>X$Q8Y22.2/)CDCP@AL<[[J1,5%((H!'&%(%B6N^ETK!*2
M&R9M#(R"E>G)(=1@* 2QK02QT$D\/>$1*Z)1Y-(AKAP@0YU$VDCFB8E4FY )
M AO<T[?L4"@D\0!)8IDX!TGZ 0M.@XR4>Y++,H!HK3T.T@JKO\T2RX<W"EUL
MAB[F>L(';#3@/)292,1-$$AC(A#3'"N>H, XV]F50O:,OD_KWL(3#XTG* &9
MEA/F&?-<L6 CQ5J(H+EEG-J_<#<*3VP)3RQ45"NJM23)T:!>",2)MLC('.IV
MUE"/F?(JYS]ZG-\G@%I88AM88IF\)B0YH;BC47O..+<6:\II5!:,MIY_FR0*
M 72  !8SH H#8]@*)"C-712=1C8*@Y(KZ3CF5L8V\G"+2B@NQ>,F 1,DX8%%
MKP/F@CM# P@7?0R,&6-"B3ML+S\LY%AS+EQ;@R"1/.)16F0-Q\@[BYV(5B9=
MN+/+&>TI=E,C=)$CRES4OYB+.HSIGN0L8#J%A+UJ<I9^A"\P\G73OCM]>7B6
MS=M4=A"J>I!Y80!3POA<CT^JC+I1[?-HU=EA$HVLJN'"%A>F+)GRI2[Y[#&G
M?CC',5@'/))(&*,\ZM#N::5X5IJ2N/9>N=^%X4F+>Z2F>>#VSZ>V@9"W7\&@
M:=OIEKSPLL.D+QROX[?T\/?W*EJ2:U00M40CS@Q#VGB"/"1RM4)19UR.Z3(C
M>D;<K.8MI:+;"O=;LKSWP_HW7*N;>/ZW[4_@.W N,NF.<#Z_ F='C$Z^<$2&
MY5(/APVR/!BDO0D8A*#)ETIPY@7'#QC'TA@2C Q*2,&U-,X%!R8(A7GP@JH[
MX/B^2W:!^.H@?GAUQ0Y2!NX#09: 0MQ30,YHCAR08'TR.%"QLZM[@M\[7%)0
M7C;@%#L5.Q4[%3MU1MTX+XEA5$L;+5=>.Q:8M"X(%PV3BA9ULU7J9A[G?4$.
M_WS['KSG.@B)=' $<1,MLBQ&I$R0SNE<B4Q;>2/N'>G=XCTUVQW/3><VJN#T
MK#\\!YB]>#89^9.$INJL;P>/LQ7NMD9F7\PLV7[HU<R.;6_P$IU==NK]55_/
M*.\HEP9QICSB-#"4,^(( FC*,(Y>Y-(8Q7M,=ZFY56EDM]6QV6\"NJB;9?%\
M-3Q+)5 CC48QZ("2 542-R(B#8()IUCPC._LWMSH7Y#\<)#<E>AL ?FJ0'XM
M0"NUE R#0#IYI(BKY+P8;002F .)3GL=8JYG3:8M0-\VH)<>P<5.Q4[%3H_-
M3EL8H"T"9V5>S+48+:$N:9N8% X3@#@&AUQ4$CFOL.9:*:+)5.&LJF*_U-RN
M.49[2T'M^ 2JI_7P ^2W^GWKAJ,VY5'9#R-HQP)>%M?6%X?UPV;<E#K;;8KF
MINMOWRK!V^5H\N/UX"U5VL0H Z(">\0- #)$:P28Y58)Q'-K$TOR'J>X1X3J
M4#JK9*VW.GY[$\)%Z=P1PE?CM;E=A0O&(B%51-QJA9S&@'S 3DFG;& MA$L]
M[4/&;E<BM@76/PKK:Q%:0I45F'CD(&C$ U;(XI 6:D6M55:YM&#G*GG:H_=/
MJQ9H;T=,J=BIV*G8J=AI>^VTA3':(FE^V%.Y%I/50NCHG$#4D+SSCVCD+&<(
M\XBI-HS07#>;-8V@7=K&^RBZT;<02/9H(%_DO%K\/HWHMY&A2K:OV*G8Z<$'
M,?;"GY-FG#-"S?%P+]W6?'*V_\K687_PS)[58]MODPWN^O:9U_#?2=W48W@#
MHT^UAZE4> U^^&'0'J55#44L+-5,:>]Z_,,'(2VQ%LF@,>(V<F0H T1$($G]
MD0BYZ0<5*YP%44BAD'>Q4[%3L5.QT^;%T#K#'T4,=4P,78^<""TLAR"09 H0
MIUX@XZQ&)&H? W<>B]!!-;3N<K:-8'K/3R&0\3R,E;V$3S6MHLHOOK&##_9T
M6/V/&_UCM\K_2]89>/BAX,H6AW]+F+[8J=BIV*G8J=BIV*G8:1V3>ES$8 UG
MQ&O* QCCM8E<,"D9!^#N#H[4Y<B>J=O4?#@=WLEG6I"&1[$TW5^!:_1B82C'
MU#7"QFIE6![(D_RC9%&++ D!&8PI)013T'%GU]";M>L;F6Q> +YZ@-\_4E(
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M_R2A%D;Y4^F<;&?.I3H9Y?7I_WS?1&IG][AM 3:,&2/C#(7_^8?=O<W\MQ.
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MMH14.U<_6 "\62=C[WU( H,DYR)O296(&P/(!A\1"1Y+;0.E)'?SIO?9YU8
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M>S AAE5_@-?XTZ'%HO16,522F \GB$":.H9H@15CDC@? WKY#31"O! 8+]D
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MZMK; \;- L:7)<# A1:E+4M$--.(%THBHVR!#%C7C@MCA&:/GK >,'K N#'
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M,F_N\EM]O:M"K"?/MUU*B(=LNSV%<[LW=O$_S]O3VT/Y_A=[6&!C)+4$R3(
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MXHYPCQ.^G:M4V./;#\.WMC<5MRX$67#DE0R($ZT1Z.(665LPR@NMC-.@P'$
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M>4@G>?E$W%4 [ZY(+Z_H'(0WSGF_,SA>P*LCJ$X64QO1>N2/JF'R;=W*8#'
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MOE5;J/E\/TT5A5YV(COTX"O;#T(-!/O+>)'TVD\_#FUJ4YUN;K9)>8O;><Y
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MQ2GP(/R5'"M*I2O*HL"<4ZP%EMA*CJE3!>!7KWYL)VSMO]F+D%6W&PP$=K[
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MCYY0=LV>GTLPP-TPCGHH>TA09G6!E9"B5(7D@&D&-'#A2QX<LP[,I]Y(VA*
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MJXZ@-O@IFDX4__):CX_TR60 ^D;DH]=_[*4/R"\_1U#1%K ?!EAYZJ<9T.X
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MKZ+B_,Y;217-[OLE.445,4ZV]]G@V";9%?]#]15D"XDC@0G^]._JGAEI)"1
M&!LP<RZ.#=),7]9Z^EFKUV5." $:RK\+Z\\?.6WPHE"A^GH\C4<G<P+Y@P5^
M",?,Z#0/Z,>*->8O-!\XML#4YAX\B?#YFJPT;[_Z#M"W\J'RWV-@3$?'O9-^
M0!13DM\*IUKSTL*0IH_J@P;T"\T=1Y\I"YQZ</Q9UQ_D\PO6Y?^M<S5R-XT1
M7Z Q+R=G1;O#U/S^=SUZ($!M19KJCGQVNG.4=2=ZYX4/"1EM/.(A$62(<DA[
M(1E+TDD9-K;Q%EUA3P.R#VH>DV71MHX+H)*Q$JN9G $<QWD+)\,S<*=BY52/
M9,TQG&#O"F4'5>F#V06Z=-FK5:R1U/,SV-3/13Y=?S@Z :E% WL&YLF,Q1>N
MW_LA?ZW6];TLGKT7=CP 5>J?G ]:1L'LV,Z64W_X:33X!,]O>.X5JI@U+-;B
MMCCL>B+UW*O%@)F?G]2+D;EPQ1S[DRL#*41S'#_UXT7%4BTP?PMVP7A0J&N_
MXNXV?#C/O'0S+\TPQI"-N'?G8,#]WWDF* ! <!9.&H)Z=72I';I37EFK/'RC
MMG?K%YT +H U9XOE&/\^C</)[,$O<N7O03_O>NB].X/_5.<OO.7U:1S;UA(T
MF]? 8_BB UDQI0!0J&28<I<[/4C,7."&QX@3I8>[V5^'"2;HSE'X-YW,%9CL
M5"PO/-\#^?.;S_L[ATI&:IW/#3A\=M))CTPR$L$AD#"/DBK%-K8)(<L/Y"QL
MZXD '/]8.9X\%81;C[5*TE)KL4B62^6R"%!<BP (02<"7_%<>2E>'^Q<[GU^
M!9\]POM'A[#=$0X6 4)@<_TCC)&FV"!"DR38!B(EWMAFE"X7AQJ: MC. .99
MA8N$Y(W,=MMI+)ZLP>5F V@=GW^JLO/Y#=E[\Z5\_JR4:6B?:L7Q4_E@3^UE
M,=NO&('K$-HO/7%NPVR;6Z3?JP%/#D8UM.Q,'6NOBLT[.7LUS,=]/_3MN/^<
M&>WG/RY>[QS&I",3)*) 8P)&:QDR7.1BSS[ GA 75,J,=E5:?L-H,\:L(Q1?
M>@9U0O$-CB,!)@]-)$81%8HZ&CB. &@L(_!/DT2*&G;&%P%9E?#7",C\V7-^
M"C^*?\>Q[T^FU+IE^&SU=@H7WHT^9O2O;1VR60ZRS2]BP,Y+8AC5TH*H*0_'
M5V#2.D#+9)A4]%O0G]E9]OK\K+CSX;0&$?P 2W0P:ARGS_AH^X.^?G-(87\"
M3A)YF4M7:Q:1\PY..D6T<TXK[@4<;7SYR=8^T\;Q))NCH]EBUWZCLN)SSB=W
MV3:9;W7#\(C\\P<W&:W%<:Y^KM).>A=@!=_]9&>,6:$(\<H!E N2?2$,SG7I
ML3.)LHH,$M"ESE7U#77G+[Y_<<B9UR(RC7S""G&' P*Z3I#QUJO$ W68WL95
M9<^F(-RK\)>8>;]$]H <#6NWTE%6LW!>/*D@_?VA'T<[N_"[WI_R133S6S"*
M(I6OZCF]&DYEL"UXY59O9Q@:N;Q\QI)X]#=03,>TM=9)1#D%BJE%[AD,@IF2
M\C&7N8%-RI)(;I#$;)=DB;F,=MR+P^QS6T4/1BEE= ,H7Y GD/?E#ZTE<.9C
MJPWHYH6;]:5G$Z0PK '4V4&YZO@BT262&;#4 D"HXA&(B/8@G3@81CA7MA3\
M^1*)O16.5@%X'806P?U(]RX.$VR%= (#WQ JEYX$ZAN] 3FVFJ@88$_<;02W
M!:'S@KI +JZ&LZU--[;_QXW_L3W_V&ILP#R!4?A[H,+SQM6"_+2 #P[D/<#)
M\W$,KX=O<S1'UBCXP/YH.&[^^4OVS/_9!'@<1'\\[/_?>9P<Y'"1 QCH+X.1
M__C\Y(_!$1Z]2XS[@(QBV?22">E(+"(V$.\#Q9G^]FJ)B6$GXT#@C%.#C<=6
M<X.3\4YE[YQ1!+AT!),B@E*?P@:>C<_CQG8CNK5XS(E<32PYK3JKGHXJZ/AI
M' ?E4N/GBWXX.VY"AEM?K.,_\>PKUDU&@_.SU5]I18'Z$IWP0/S9\ 6=;/UY
M/*VG<&J/P!0!%O 1V02#_<D.+NSE9.,?\RH+^KJPAHO37SG)E+[:)"OL"/G>
MJBC=3^< (^/\*1B3?31CZ1V/,T;]5Q^41]$H,,,<##[BK)&*14^D)TI)20\5
MF#TEN@P.X1<9WH9GD__YA]U>MI-7$;46U@I#%Q"X@IUH?-3P>B&%S(F]%BR<
M?#08(6@H?="6?^]&7=S^GSH&ME&;$CT-*S^PIY/X4_.7GT-_<CJPES_UAV7]
MRI<6PZ3A8*BERY@M*DT6L+JB0OWX6O:VBNPM1'17OU-T2VJ^\M=PTJW\W76/
M)61+$7JGQU[_.Z;-UQFLN-5C;ZA:<6,A#7/EHTNR8BHT_#;9(7I!8Z^$,!;<
M:IN#<PD"MUR/!YZDN=4DVW&:L_C35C3"3RM;=;4RK-:HSOBX]SRSO_N:\&T*
MRWQ'"T?,.DIR?Y4^GT(=G"9><'(&)+]*=NC]\,>[W1^[8O!=E>1%I\GO<5P
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MG$?O"!R>L*6@GKZRP#WR47+8<J:#4IUZ?M_JV9G-#Z"&;$X-G<+>)&D03<+
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MV@'TWW^.EPF2\,"2UP%SP9VA(0J7? J,&6,ZV_BQ ].'G;9M;!R<*R0D9##
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MK>,B"9K]6K2#O [ROC_(^Y8NO"_%O,Z%]R68UW;A)1E2=N-CG #SL&"Y>J-
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M9W>,1Q$YD*./J,3<_&0'%_9RLO&/>;]%?]B,B-.J7]CBFJU<F92^VLI4_A.
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M$#6> $!P1[3?V)8W]C:\8XOMIM1:UV#[QJK6W#%)C6#>&NZTU);2&*/UP8M
MO.X:ACX.&G/Y>N<0-L@ _GE$O?*(8Q>0%A&C*(PC@6B7+- 8=:OZ\*L:;'^3
M)MG*D$2""D)+PAV-!OXOR>2MMBG9<!-SZ)IDWUMHU/[.(3< U=+@G,1#$+=8
M(XN)0(KYZ)P7EGE^+TVRNUNAQR8-"QB# 6,HG#&E43KQA"/.HD%PE&LD!,%
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MZF9&D*LNG_-EB%X_TW+LB%[O<6.7S$=02D9/694UP\P'5Y75EE5145X0"KU
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M5KFL1 X0>RM]OV70G:+=*=J=HMV(# B>CP,75ELAA%'*,O@K*2\9CZ OXZZ
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M082[!P:W5VB)6F!O$'G$:JX)_IZN1H5K'+XX.!&.9AF#K2)ANA+>0("N!*]
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MO!I@H@P6_/;I;S50[?%X9V9!:7R ,9T8YIGC+%72<#"SFH-;YCFM2(I!Z$Q
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M"+CU6*L$=VDM%A!U2.7NJOVH+,JS@4/N.0+K$4,6'9,R)Q'.!&$4&T1HD@2
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MN+XJ ,XJ'H-PVH//@8-AA'/PA>?[(4\,MH745#A;XNP./,?)08*]D$Y@Y)4
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M"==(L7RCZ]WR5GKV/;_YYQG*O.D%+/?EJ051W\5J4'#;-7-B<2PX]UB(D40
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M+?8*R89KQ)(?L=4OQ3F?<A=OMC-B^U]+)-P?*+;BR<7V-%.#CH55OCMAW;Z
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MTU>/!S#,B$&KXTNF1MNN@:KU2NZ6@KKRO%^RQXUIDR>G1,S$-I<%J=Q" P%
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MH5PK.)[EQ6/JB]VM^H$B8.R-@\##<(RX(V#MK9)(..&#MTY[EP\-YZC(?X_
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MKCE[A"V>'S$]C]5]D$#.L;I3N9_'2>?0Z@[/5;(YG1''_QV*XWN30=)HGAP
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ME.(2&XHT#A;Q@#4R/D04C66,6IQDR(338IF3FY5M)3"7P%P"\_O+BY3 _$S
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MX;O;PWDPR='C<Q,+C3O/Y6E?-"HIL>4IV%(?][&QT6 26&[+3,'">R:1"2*
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M]-6'VSU.Y6FDCQ.ZNCC!Z'%[;>8??J7==?[5?E5QKH- VPW>VW44J2SS7 =
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M'-.GC&JF:1K8O,5V IN!#B:$,BN\)_DI&>+I&.+FM'UQ28D/*MPP5 ,K'<W
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M!;\26E>"UF_EJA6;.J$=^*%J,!V,,2.R5-]EH4HB4)>!8[M1&(DV/D3NQY*
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MP:4&1]@7FI\//8VSGQEGED7S$#+,"MSMQL.X8,@?H_ *!9TO86$YJ#WZ$Z>
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MSNNMI2W(+4&A<GH>U4S*_C.*4VX-EQ51D:A'@YE8K\,W2ZLE\5 LFD4_FSO
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M:"(B1),V)Z6F:CEH**_O^E9"RCY"RAGX5IV;4=:ARN$HI;%/_=$38LM.F3*
MQ*UV_6OMO*V<U<[_KI_O@4%3>#YY.HG&Z34^M @8?DQH&DH@V4,@06$8LFN:
M#I4SFOYDJ421^U#DO/FQ#MAQ5%4.:N?U;WN$'A(A]A ASA,?1J(<*0<T93<2
M'B;PD$=&Q#\+S8V_ZXU&O?U9^:NJ?#X^.:DU\LCF:?5CM0AR;K":Z?,FZ[B
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MMB=[UAU:SR2=O@R25)8K$3;)UBAOL@1$ JE]Y*B5XP'DZ!T1WV 9GI)G0]D
M2SE@6H6Q SICRB!(Z>TH[V/8B9/@0+J5U:ZD5E8"J54T.[W>)F3<1^6SW.)'
M,C?=/%^WJR3I=X^'7NSW^S+,NB[G+!T%F?WTJN3A$"BB>#Y]G]XNN>,)8GH^
ML>^(AS]7,W&^"RIZ_COIM\^VQ7]Z5GMZ,Q)(&B&6!Q;,H_OF9LSFX^B9YQ3,
MX8V8YV#LA"QQ1W[CXM)W/3ZGP@VB#.Z,+9!J4?AA8-L,LTO+JCA5H>J5U?>=
MM.M#CF!$0_QH) =1[NPH=A*-<Z!K'@4J*;#KP=9KLF>]+=%X'Y7:B@397,!O
M<4"]I#_O=]K;88N#T%^;7\*8-,;\I@[[@UJ^8U$119YWR3HEQ]9R4;?=[Z22
M2];EHBA 'V-D2)3B2/R!I8HE0KA66&9AQ*9S,K MP<S9)1>+(+5AIQ*I_/AZ
MUNKT.ZE0W]H"*F(@67Q"HM4*\#(2B!WXJQI]/P]&WXV7XK'T? -G6\ISMR6^
M 13VD4,&)AA_+E/),B-%TVNA2C:4(KL&@-8^ >TU'6=+ ),)-0J<H>#M*U7R
M5[B2_5$-IM;NZ/9[A;33DG(?S8W\)=_<LE@/ME[6GO0[*=M23]2#L5"&VI&#
M^)X[)KI8.1Q*SO3&\2C,N)I9L.DH>@XX[7>J2>AE!S.,W$H,;81C[R,[#+T9
M%<E;[!538?.ZZX_8]YUTEH($M7SOW0B@'>A1\0*0'HC^"#WK5:+-/IZ8>>M;
M[5:$'HA> I[W.]6(=)!LX?IB,47+MRF?@-P'HC#@WH'K4AG8^L*Y]<)L>RN4
MK#*2EMR]=K^3"N_KR W'73 VGG?QZ(8:7AJ?(0('WDA0+(J1JUL2[@-Y0^F&
M"1JF*7QJA4EP51-$MCFBGE<Z_4XJ%%_ *XG8>X"%$:"A<C\4(D8"DWUDFDL^
MGS,OO&:&20B@/%*GPMUL'02MPM3#2R&I$'D,35W42<([T*7RM>EB.%K%"?ZO
M(HWV4772+/(6$E76 ZZ7I_U^)YV=HB7KP=U0BM[Q+1S?@V6]@T'G_AP.'ME:
M!N$2F5[#)YM-54&M;?'$I@CH^>:DWTW%NHOX)GG11^)D!$@9(59!<#*9 I=
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ME6RV"Y%K!=A5Y4/ THC0-!2>^\B&X8:\H Z ]1YL4E;#S^JI5^_/.NEKH9%
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M?/5.F/,SG(P8'+(3O"3I!8\_8(B"VPS+O-Z"'8>P<STOFT+=D>PH[8JY\%U
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MJGF!WK4=X$TU_2)U>TSG6'E>,/OM9KX@^.[YC?-,U?V\_-SIDMT;Z[PO=Z%
M]_3WQK<5],#KE:.JW,CHXJ1[4J8NR5+#VA6*.Y#/O@C<JPM?Y8S+BT&77 AJ
MR[$+8MU50-0^X1%Q^(05.-Z6VM2.<BJ(51@8T_1HK*<\(VA71*7<#K63[)8[
M?Y![BI+?1GOTXF?]7/+;USZ5!_0^H]BEH;TT%EA%2R_J])UJG]2%(%@.#,O4
M#(HJGZ=;UHY^Q/ )P[9D0E)&C]JGDZ<%) IFR_.DLAJ1!M!8\9==X"LQE]!K
M.^:@^DRX?'M#JI;NI:J] U-/6NL%-_IV-E[MSL>?CF%]77-&Y^33#_\/4$L#
M!!0    ( #&"6%*_&"\DK2L  .K6 0 5    <V=M;RTR,#(P,3(S,5]C86PN
M>&ULW7U9EUNYD>:[?X6F^G5@85]\;/=);9XZ1U722*IVSQ,/EH"2+B:IYB(I
M_>LG0#)W,I,+<'E57E+))2\^1'P (@*!P%__\_O%Z-E7F,Z&D_'??F)_IC\]
M@W&<I.'X\]]^^NW3&V)_^L^__^E/?_U?A/SWBP]OG[V:Q,4%C.?/7D[!SR$]
M^S:<GS_[9X+9[\_R='+Q[)^3Z>_#KYZ0OR__Z.7DR^5T^/E\_HQ3SNY_.OV+
MEXI&T(PHKP61VB;BP3/B+*62@K+*I__]^2\"@A#.E?=9PJ]Q0[SFBB2=$E<
M5ANY?.AH./[]+^5'\#-XAIT;SY8O__;3^7S^Y2_/GW_[]NW/W\-T].?)]/-S
M3JEX?O7MG]9?__[@^]_$\MO,.?=\^>GU5V?#35_$Q[+G__W+VX_Q'"X\&8YG
M<S^.I8'9\"^SY9MO)]'/ES)_$M>SK=\HK\C5UTAYBS!.!/OS]UGZZ>]_>O9L
M)8[I9 0?(#\K__[VX><[3<[\^+._F/PY3BZ>E\^?OYP@&Q#I\B_GEU_@;S_-
MAA=?1G#UWOD4,K[W^6*"+7+*^*J]_UC]X?.;9J,?Q<5HV<NW^'K]YZ61O1'
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M3#R?8'HQ'*_MIN6UX /&< ZDU!-I@R;2E?++AF$GP5G*C-))BK;3S4-0>U[
M_ >;9(Y44AUKY,5B.$J?)A\7P_D2PFR@/*."V4B$!P1BM",!HB$T4BH3#]0S
MOY,Y\N#1NZC;_3&FAPJRK5E9^5[V?W&P%J6[]R\R1:D,!#-46T\)UZG<59D\
ML9E%@BZ^U";Q:'V3'<3]8.X4O:-_L+FCH2;;LNW>S:@#P*D-HC>E^ <*(:=
MO%26Z*@Y6Y8_2(UN*GX:W$[,.O7Q@$Z8=8S6&O)I?87J*\@PG<+FJU0'U":F
MR^5[SI2S=+3<O2LBNOG.HTN8A4YM"L4=!G<GSIWZY$![SE77; >SVGM_609'
MB8BOYN*W0Q^&HY5XC(]:L\")MM&B4><5":E YRDY"HE3W60OXS"X.['PQ*<*
MNIOXJBFV(0E?7WP932X!UIE$MQ$&+BBZ$KCNTZ6IR7"84"E(DHQ)$T5VLM4U
M+CN#W(EP)T[0:4^X2DIL2+--]]Y>P;P<&!U+*EHFU,NR^:=1+A2'AM$FTQRD
M3ZPCA^%1G#N1[<0)->W)5D^5=>(/#Q&^G8P_E]#(NL+;.C1R>U0H*@Q/7)'L
M2UUIY]"OH=:3Y+*5GK&<[Y=SVA*A.*#QG5BD_Q@LZD1!#:>MI=58:@(N2[?.
M;R,4D*B4W!.O*(J#"T.\D9$D=(L+>/QOD\V7?4#N1+4_6#B]F1);EE!\-_WL
MQ^L=9S].'XM(IY>3_''X>3S,PUB.#:Z,RF7ARM$P%NW> ;9;1<##&JI0);!"
M#X^NL7@0ALZE?7*I]TGZGXH#U9WLU\V=2O*;>GL:N=\^0IHGTXMU\M[<#T>=
M*>,Q#*?2T,YR.8W:/L!7&"]@5E;?C^6J,?@\C._]=#Y>GF=\.1FAV3-97>]Y
M]GD*JUJM?ED]:767W6H1OOS'%)\_ZUCA;="?BBH=Z.)4)(MH3*$)M?RS5:%?
M_.-[9;=6>+N;NO=#=3I2'"R[/A1.'B2&=KA5C!@'L91L3<3;N+J?21KEC.9-
M8H(5:_$=)K);CSM#/V8ZO42M_I<?+6 07+ B)4.T\HI(XR5Q/ >2F=!&\B!U
MFU,WC\/JT^&4[CCWX!*P>JJK%F9XT/5[(&]<U8&-/K*0!$DE B+E\M91X"0D
MK21WNF2(M:#6[A#[=)[E=#1KI-*6(8<W?CA=#H)?P,\6J_M7#EFL-SZGPO+Z
M-+ZCK9]-31SN<#[RM$;B:.(N;FKHVK;9].'ZJH?;L^Q7M%X*-O202A[T34$U
M-'6N<^NO]PP.]S).AK610KN7<R6C<I58<8VZG+,:30KP@94&)S9:3DN7 F=1
M:.+*N6DI?18Q<.Y=DQ5L*Z(:QN##"7Y3U[G40B2OB96Y1+%M*;"5'0%#A0,&
MT<HF*6H[(^R3B5B'09O,O_K*JG?^]&H O[D_@%]!F-^J0PDY*Q\<6J=A:9M0
M2KQ@G%!JT(*(*G/9)!=M5X!]L@+;,*F)JKJV[RI'=?=MHM&JV5U,]M$U^_5L
M/KPHZ3?7W\)U_,$BC.Q<7*S*B32R>P[%T=JFJ2*?X^]9N[L4^%(">$-QY .4
MLN.3:]RX=D ?.A+<X>[37L_O3(A-7*S=FKX>. ^_OMWP/WQ.:0^J,Z55D]R1
MWM$R^^F^SW8+PP-38EUXH)P$G<T'ACHM$G4DQE+Q/AHT234%HJ6E0 -:,C8\
MI=7C(!R5E[=/J_^83F:SFPM1RPG'%T5%4.XY]2XJ6DQS-,1#R043Q''+"=IL
M5!@1LKI?#;B"'!Y#U(O;/SHDUYULOI.HM4ZFZ!'0RWG;&^B)9FJ,\>@QV4RD
M"([X$ T!+5/,"62"W)J1=Q#UP?_Z 0EYN%:[)^1 NA18&264,T<0$B<V)$FB
MPS<M"YH;4YUT?;@EY$<@UE[:J18_VAS>NK_):;5EWE%%M"[E)"17Q 7\S7$O
M;%"19]WD=,5.Z(X>/QM:B'%QL5B>A'ET 1)9LNRY(SD7E5$72+!:$>^R\C8(
M%]-NAP".@M$+8Z(=H1Z,J&[T56]^W@?OW?4D\BA=.=<'7.N27)"(E<82I97-
MD*.W0C3A5^],@Y[2ZW!U-9[!-P6OE4U:E&+#67"#UHF5)  8HC@U7&5G0FY2
M[K;J;E*7]_RV(5I;Q37;6;J[27''0'KA9\-R1T5.U/A,'%HRZ(V9\IL2A"<F
M7>; 5)M;$?<%VE@P.RY%/##%&>4D&.R5U,(39Z0AR4?.@*9@M#Z!M'Y BZ,I
M49_:Q&NO_*X&](YKG/,I<\,3<98'(KD'-*&\(.!2EH$'2D.3]-TJZ/MDR?P0
MM#U<]]UG.*A@<RP"$:G4__:J9$0&24#'3),4@HLFR3(U,QRZLFY.2KXJ&FR9
M^+#G'M'V':%P>57J8.%'5Q?%=K;!=ABN[O?8*LBO5A+BKDS-!HF9G23,ES+O
M5DOB:! X)RH11/2LT0UGA\TUM06QU@2^*A4\2KEK^'_@I]>NRP EH[)GQ1DJ
M=42]S,1+J4GBFEJ<2E1.G1@)^\'N53)C"R;N-S%7U7)'YL -YK,\ARE"_G0^
MG2P^G[\9?EVBO_&O!R*R#$F4NNS,EXOL&*XVO/2!@O6>^MRF_$:U'O39FCTI
M7^OJ_O261N6DR^,;[<Q&Z"XQ\Q?_K\GTJAC5;'W(>G8^_%*@71^^/AN-AN5"
MN(/RT_9MHH*4C^I5US(]///OL(:ZEV^37, ],52>3"JVWKT^>CN]7%5^*(?]
M/X^+*[XH5T]>%WGH3%\[ NE>=8=(J/.A=@7F&QK0'X>?+_S9*$V'\?SE9/IE
M7;>CNY&W.Y@3#,0#)752C;XZ^W@:[=TT?&)-;9' T5HYBV@9SH:K B<?5Y^^
MF9;V#Q'U(T^K(+]=L=85RO96#[>B]FN@MNCVZU%#BE4VD YKJ"DQNS-[MF.X
MCOZ6PA8ER#O!&6;\^>H2D1;RWJW)II(_H-?'5^@JQ4M?^-&R_7. ^3%UM;8]
MJT8UK)UP-A/'$74B'W]B0]&TJ?:XI;$C2OD]_L2& NIT0'V,Y^B%C&"2<3SC
M'PW+S0W+H^1H2?UC,DG?AJ-1?2GNTVQ#41_<^W;ZN-Y@O'N;AM]TFT8#O1S0
M?$O]'"N-6GNL#QI[N:YK%0 \Y4H1;90C,K- O,,?P" H'FDP[2Y%WXCHZ-3<
MM5>%3%Z,KY]_>=7?;(1+WF=2.D8DF%2*25BBM65<>HBQ32K5X[!ZM0M:A2L/
M$F_KJ:7.(8%U-Z^KMH[3*_@*H\GRJM_U!52S@6=19F5-*2T3B%1*$R<-]IMY
MD+ZDX:3=KNC>J;E>;2Y6I4$CD5?;X;Z^SN#.E1;7])34*I6#(T99061BF3BJ
M!/&Z)$@%ZG5H4@[K<5B]2FYK,FM45$N]9(A53]]/)QEFLZ5'_P9NNJLR2&=+
M,2HC\(<PE@2I#&%2)IF"R8HUN6[Y<5B[4*6K^[;:4*6B6NK-*LO;"[=V5VNE
M@TFY7)6"W774$R]#()'%8%&T+-RO%%%I5GD4UBY4Z>JVK$:S2CVU-,U3F5Q<
M#.=7Y>5+4B9.A# ^]%:3QQY7([=D5[3'U^'9WM(1=8R>?&A;&;6I6+2]O=KI
M38>UU%:FW87<'P%Q4QQV,5],X9?A>'BQN'CO+Y??7NZ?W\JW?A=&P\_^R#IS
M#=&T55A5654*G;Q%:P)@BR%Z!>W5 @:4E=Q;RPC3Z+U*7BY=!ZU(E%XEE:+.
MT"22LBO 8XV97=OY%07_Z1N,OL(OJ*OSV<!F*20MMX>SS-#^0A%Y<(JHD&U*
M*"QM["D%<Q]PGX(Q3=AWWQ[J1+/5C.I=T9;LXT_?)H,,0)T1DG#O7$E^UL1R
M$1"D$,PJYQKY[GOB[%/LIU>L.T2/IR$;L@<&3#-&+7J6M%Q0@MYF)J$,$8<T
M"5Z#3*S)&?.]D?8I>M0_PNVMRY-0[LUD,1UP:SVU$8ACAB+*<AM]S!2=5E",
M Q72\%,SK@#M4PRJ=X3;6Y.GX=OP:SF"EI@$$8D(UI9""H8$E7&0Y)23T5S!
M_3V1$_ -@?8ID-4_ONVKR<[YMCQ0=@U5,B6XYIPHJLLE )J1P$0Y 4D5\D4R
MG4]*NCMH=V%>5U?%]XIYA^NT]4[?P+-24Y(A&.8TD:6XK0/M2%8,O9Q<-J>;
MK*);\#3>T P^6^&\)5E37&FLH+CFH&6CP#(:3 @F=MG;'J9!U.#)GMN9^RBE
M]7BX??4=I=0S%<N]>A%[S!4)$!.)AH+PAEDJFG@T3R+KD\O<(5T.5,V)MJJ.
MC.D.[J7]G#H"CGAZ'0._+Z^NH^ LQ1RCRX2%&(@,$KF)%@3)SE$C% ^6-RD(
MU8LH^&_C-)PM$STAO?X>\:MG%^75@-F4#$[M)-K$B111$Y>9("'KF)TV+$"3
MI)"#T/9I%6["N[VLURHZ;6Z]0C;:!E_L=H?=M\")E:I8$IDZQB$RWF6"6I]6
MYDXH5$,O)UJ@BSE1\M:715Y^\>B@#?WHUA)SZT^;;$GOWW[;!?A(>1R=2_!Q
M/HF_GT]&.$AFI5@+CJ8#!+[A*17$]A2V!IT_/*5GZ[.:"*)) L_#9BKG[>S7
M0!/!=9>E\[#M:V-[^=&[Y06&9W$^_'I4R<B#VFDBVWW[UU+$'V VGPXCFE'+
M+_TV'LZ;BOKI]MJ*?,_^UA']"[0^<#F[*&<IEKTY6*@/GU1+7$]@;"2((]>1
M;<]K)I1VZ\F#IC:_NSZ0<^38/*BQ9D+=NZ>-)-YB%=^KD682[G@U?]C^S47$
MO^%'"&%]@3':][=N,'Z-8IU< MQ:%X_P;EI!::>ENE)JI,M_+L,#D,Z^HG/]
M&78%_?']^_>+:3POC_M0GE!=L[6!-=-S4PD>K?4K>KV ,>3A_/W('V2N;'I,
M!8D^B:Y%_RLO#'NVT$9JW2T)/X_QUW)KQF&&WNT_KR"*K6AJ]O-PL_;A0^KV
MN8D!>^OYUX[6*WP'I['HQ^G-9(HSWKA,@9-QB=!-\LUM*K?^]O 151= 78G7
MEDBEO<-5*Z75-]/)Q2K6NL 59QTSQ\7H 9K7W^=3/YFFX1C[\_,<+F:;:W<-
M# ]@/'BB _Z05DGB0M!$>Q9+20G.VV3M-.S3L5M$!T"[XLL <K0I44%4TJ4\
M/"1BH]1$Q&BY88(*U:0ZRA&8^[1;V1>FW]^=ZHH2U;8Y#P"\GN@&7@E!M>4D
M<5ON [6"^&0=H0*HXHXZ1YO<$G,XY#YMEOZ!&'P((5INP6Y:J-=6,B)O9IP\
MUD0C\V/G7E4R,-;YDV\ AXH??9S[.9R-TUO\NQ$VO8[NK4$-8@X\49^)!RV)
ME-H1;S(G('CB4@AM39L+>?< >7P-M-MM/91!<,X9S2+A.1N401#$@2NWW')M
MD_)>LR:%1Y[ U:>EO!FG'A9&JZ>K:NOO&M03W19&I21S)#YH2V26!@7 $TE6
M,QH@JN":7#Z\$[H^K:I=DZFBWFI3:KTJ/P1%34PV1T1!4T0[4WCB(_<D<TVS
M8-92VB1Q] E<?3HEV_F<5$-7U0CT"C(@K+1;]Q6S@:&]23PMI>&H\22@O4>"
M@,1LULK+)F[ 7B@KB^3:VKHG"R:I#K8D(69>RN0)2RQ. 20HZW#@&RZ3Z4 6
M6^#U:=5OQ['[0ZR!ZJJ/M#O=WX901Q]$=.A>9<Z(#"$2JQ(098/E3!FI19,(
MW#X@^V0+=$^QZFJL/Z6O%IIMV""@PQY!$QU*$C4KEDM2@BB#L(RD-/(FIR=V
M@]<G"^$$\U<]U56.'FZ83(W5VB5!*%?EO+' KF89B<E64I$I ]\PNMW8RW]"
MURZ <PP8L=J@\QBI(#:F1!3C+J,;H$-N<HCS\+!''T+YQW'H<5>_HL).9&/+
M*%6@WA$+2J-QDH%89C6N&2@$ \%8:!)&.L+&[D-TO2ZIVJFLJV#X]1TFKX89
M^P+CB'#GWP#&&P/)95/[IJ\+)/3E]:<?L/-UPN=M0%4.N'<@N:HY )M"42SX
MH!S)'*T/*8Q#UP9?,LFU!FTMFI\_T))\(TZ(DW$<CH9+!6]I[6S^J#H&3@BE
MI="$J:C0/I,&33,<NT;G;)R/D<8F?GO57OP(B_H^+-R\,WD*E=>WE^]V8;/?
MN+RA(TLEJ">,!HG+563$2Y.(!R$\1!N=BQWR<AO.'V'E;\"\*FIKS:W[;N-R
M^5DO8O.A'PVX1^<0?-FC<"B8K".Q3NIB(66=;+).-*GW=2#>/@4!.N1:5376
MN=?I-;9>CMG!%LC_&$U"&1=7U^6]G7PKPR.MOKZN[>"T<YYI2PP-I10 M<0K
MYPCU'.UR1A.C]BEKLAJ:/M7-K,FMTZBK#LNVH/UU4FSE!78(H:Y%M/KJQW,_
MA0?G,P;&\B"SPYG(Q[*[SU*YYXJ3P(7+$F0 \Z3;4A-0GVIF5N?:*936>B'%
M-UZB]S^<SZZN51LPZASP9(CBG..<"X;8*"*AVB07 K DFX3Z=D:X9WE,\L.P
MK*VN6E/IY3G.L<C\JX@2?F%UEVPY%K;2SV@T^59JHPPX""5MSH3;5.+ZTI/@
M$LZXS($-++,(7;H >T#?A7SF!YSA3J3<UJ1<W=65_K68K4KN#,!G097E! V'
M3*3*BGBM);'(&.6" >]RA\R[CV\7>MD_'KV.4E/G@>:RFOOQY>S!8*@<.WZJ
MG5;AX+WZ5RG">]76-:!;-^L-5);2"X<K7**N%+;'&44*(&C[)\MT8$PV2;I^
M#%2MO;*[3[VZ=/ULG.Y?R7[_]4 HR%$P0530.,_FDJR712(N&\,M$TJS)L'O
MHY'W*:9;C7?;-M:ZT6_U+=R[L$M9PN'X\]ET6LR U10=7%!&(3Q'2V:Y-PB/
M0JG_;M&)D=P(TS0M\$F$?0K@=DRS8_75@DXK5O\*\T$RS"F@0(3%%5[*5*)Z
M#HA*B45.?6"N:7+M;3#5._B/Z62&]@MGB7G%4*4@2C%0]/%=E(0'YZ01(0)K
M8F9NAM/'"?=@1CPR @[50#NZ;W"/4F 44'W$FRC*:,<165+@:4)3U_(0DNR&
M&H<YM[RKR$I[HARIG,9K[@"<A" S)<G37&XU<02]:D8LS=YQ9G2@3?-6F]F[
M-^J4VF7%DB(YAD@DU8ZX4/9W,J/9<4F5;)K]O7TE>'*2[(S\AU+B2?KOJX#J
M?-]H#&5J($6E258"1[A2EE@667DI0[:>:]DD-+B[K]</2[(!,X[61[MU=+6F
M1Y\T3OR61)Y8.906"-JND1COBM4,V0E_*JNJ0B=OJL#CTU_ZZ?0R3Z;?_#3-
M!CYK*Z(P!!6IRNU::+Q'*TE2UB0T:TP*32,@.V#LM9&Y/W^>G#XK::O=F+G>
M+[H#[GKO2%,NE&4*IPCT F7T:.HX$XFS3BBF5+D9J!-*/8ZSIW-O,UI5U%I3
M:EV]M]X<N+W#?39.Z[V"V>8M\)>3V7R@!?76@T+;O9Q0L-81[\$0':6F AC@
MNM45_X[M3)_RMSHB::?Z;\?DN[;/0"1T+SUC1(-"_P^X)T[B]$US\#SA[*U=
MDS("3^#J4PY7%_PZ0BOMJ/)^.L$E?WY9BI+.D>.E8/^7$EL=4$3!>&"$IW(
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MW3["FM[VJ 9">-+N73LGY4?P,_C[G_X_4$L#!!0    ( #&"6%+*X@MACI4
M (IE!@ 5    <V=M;RTR,#(P,3(S,5]D968N>&UL[+UI<ULYDC;Z?7Y%W9JO
M%UW8EX[I><-VV=V.L4L.VS7]WD\,+ F)4Q2I(2F7W;_^)@Y)+5RD0_* E$5W
M5,L6)9_S(/,!D GD\A__Y^OEX*<O,)[T1\.__<S^0G_^"89QE/K#\[_]_/OG
M-\3^_'_^\]_^[3_^'T+^[\N/[W[Z=12O+V$X_>G5&/P4TD]_]J<7/_TSP>2/
MG_)X=/G3/T?C/_I?/"'_V?RC5Z.K;^/^^<7T)TXY6_[I^*]>*AI!,Z*\%D1J
MFX@'SXBSE$H*RBJ?_M_SOPH(0CA7/F<)?XT;XC57).F4N *PVLCFH8/^\(^_
MEB_!3^ G'-QPTGS[MY\OIM.KO_[RRY]__OF7KV$\^,MH?/X+IU3\LOCMG^>_
M_G7E]_\4S6\SY]POS4]O?G727_>+^%CVR_]]_^Y3O(!+3_K#R=0/X^T+\/5I
M>O,/[Z)1O\Q^B+\ZZ?]UTOS[=Z/HIXUZ'AW"3QM_HWQ'%K]&RD>$<2+87[Y.
MTL__^6\__323G!_'\6@ 'R'_-/_K[Q_?KB+M#Z>_I/[E+_/?^<4/!HBX><+T
MVQ7\[>=)__)J (O/+L:0-Z)?#+F 4@7.OY>G_;(WI@L$,H[7 0A^"L-"\ XQ
MKGOZ_IAOGD429'\]F':(>/79G>(=7?I^EP)>>70':)L'D4NX###N$NJ]Y][!
MN0"YC+ \<N*'Y_YR])<XNORE0?=J]*4-JLGYY0A?S2GCL]G[[[-_>.>UJ-_^
ML%^6C'?X[?Q?EW=L#0"^3F&8(/W\4S_][>>^"(%Z;JRA$&6 Z*75V:8L/7[@
M'>^M0-E2 L/):-!/95]YZ0=ER?QT 3"=[":530_K0E*M@"Y)S\AD6(8LM$F2
M.^9"LB:H#)&9:*CKM8+<C40_^#%NXA<P[4??8NG>0KSWGUQ1U@\,84GPRMML
MF(W)@9:**TL%4TXPH8.D$M1FP6\<S,Y:^#3%K\6 FHSR&6XAS<Z^-\$W/+5;
MZ;>!OB1Y[I07SL1HDY92@3?99*V"X-G;2'5ONT%T(O57H\NK,5R4S>4+O!M-
M.A7^ZL/KZ>"1@2RI I2/FBJ0D4J)5G-05$>(3K.L;,QFHRH>'%(G&ODT'<4_
M+D:#A&[(Z_^][D^_=:F2-4^OIY/'AK*D%!NM \X%+D)<,FX<PSU5>4XCI=1*
MNE$I:]Y3QK08U6 4[[UV4%R(T<WF/O !!LVGO>L).??^JG?S<!0#O,6_3GHV
MY,!]%"3R' GN\93@7A\(SF8I<->*1NBU%E-C+64_"8W)-'_#+T59O\!@.EE\
MTJB/4#;W0OY],Y29PG8?'%+X<C1L9/;I I?TR=O)Y!I23W*=0TJ1Y)PY>I6&
M$W0O#<F@G-=.Z9A4C1%NP'-_F+?,?#%>#'ANR>YHZA;_O%.M3T?=RWFF4QS'
MSS^-QDCOO_U,]U7_ZF1Y.XR#ZW+&\6$T;B0\G8[[X7KJPP ^CWX;#>-H.$5!
MXA//WPZG@$.9]J2U3">JB*+1$QDB$"N4(^"<<2Y:D5VN,Q^Z@/_=D^L(6ESE
M(NN$B[-I\>OUN&"'<7^49M.E^?K23R"531=WW,8$ZO'D/!I,FC#% Y%62N*D
M=R1PHUS2+C,JJQ%O.ZS/@V45];-**5Z)4O_M!]>P 3$51E'N-%$Z.")!1.(8
M9T2):)Q2009Q2$8] /6Y$JHK[:SR251=HEZC*3[Z!M#\TH?K<;Q ^!_099[T
MT,, $T(D/C @TDA+K.82.<!8I#YXE\/!EZG->)\KLSK5TRJ]9,WE:B/JGLZ4
MBX K:T@B$Y2-(4XP1]#["X+&Y!RCAUZQ-J)]KM3J4$>KQ%)5UZW?X,_F1Y,>
MXT)K@0MKUJSLUAH-0,LUD9+3E)D3*?F#+U,W\)XK=?;1PBI7=,U%Z!:D3CYD
MC@R.#@2"= Y]!<D(YRXPH01/AAUZT7GV3-E#!ZM$,?L2Y47ZG^O)M#EU^SQZ
MD5(C8C_XX/OI[?"5O^I/_:#A=E@VXSX".JF3_A0^P?A+/\)L=!\ACLYGBFH&
MVI-90$(O 9=*KG WUIYX$PR)4C&3>>0HU!H<JSVP[YZ>3TKSJ\RVNS*[G)RW
M&MR+.!L&_N0L;SA-299:;<$24"")C-X2YR.:EAF\9<FG%9M_]>"^2T#?+>N.
MII559KE]U\SUJ-X.XQAPJKQ!$;Z\GJ"T)A.<-:$_G'F])G'% M,$&$7K4=)
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M*MB?^X'73E"MF$7C*0K<,40D07M&5 FQ<C0D@*=.N!U,]M$PXA-OKZ>&Z<8
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M^!P)5E=-%6*IEP7Q*X3IK3!>7([&TS('7HTFT^:>MS0XC0XR)5DS2B37CKA
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M'O[LU+FO #L,ZFKP?,C]?\'X[_WQ*$Y'L5 -WB#$ 0[XR^@++" R3P7-7I#
MO",RX9;FM>9(P<!+N2AI:+N5N]W[GIW:*XBYPUC/.Q!?N;./;PQ?A) )7$LL
M  $O.>*QB83 !,F.!Y6XIL'Z+=1^[^'/5,>["[##6H"+[I"CW%]L&EZXQ 7Z
MK]SCJ&PH/0)UR<\/43G$DI=[UVSNJ7GSU&>GPIU%MK%&7I=A#UM>Q'1\ ]WA
MVP]^#;;KG335*64O03$K9&+&4:I%^<!*+8,UV]Z-/83C"5R8"=QBG"HI#)R5
MB/4 Q EN2TO K,HT"N;97IA]P*T9($W>X)IS>R$R&D]ZBIF<HP)B<CD)5-&4
M[5D1ZZS+GH,TRR6+NI'*1D3?Z675-NQ:/MOO1CN=-S283_S%Z!>=?+^][P\
M?S2$#_Y;$<_K0?^\7V[(1A\A0O\+])P!PT5B!!QJ7EHKB-/6(@VDDMYER45N
MM1_OCN&$:'1(;77>WN#QZ]>FWUG/9&X2#YY([0V1&<W,8"-ZE=PG"(F6?CSM
M*-7RC2='H!J:Z-JAWP3R'0(;3N -(#P/RB<?2#("G1+(@GBC!+(YI^!%9)#U
M7D2Y?=</BNPE_:Y]_$WP7D^F_<M2D/DC]"_#]7@RBZDL&;%0:IY.>B;Z% +N
MJS*61M'!4X).%"7 T;&U(7O<;O?BS*,0?E"IAJXJ-"!82.6?_>G%8L^]V6M[
M00B>7$(T:*$1F9Q#49A$5'0Q2V9\TI4R>1Y =4+<ZEY+'?8'6"9^T< =B5Q>
M]B?E(A:7T0^E(O-H>):;TJ4+]V#6XXRCX9]T0 IH5;;?$(DK_$_H)J#KKB-+
M8MNU:B<D)T2KPVNNPY+_:];;Q0DC2@EW[NE9?EM45VY6X^A\IL5>HD$$*C0)
M02-:;S6QACFB=+9"@67"M*QEO.VK3YA8%7338;W_V]5U@KC^/AJEV]HB,/DT
M&J1Y+?EFBO2"!- </0,'I90\(-]QMXXDJ4A]X,FHY>9S76V&;>"=$,LJZJW#
M%@ W$8Z^1#=^FH[B'[]=%XGB-Q=^#).WD\DUI+?#.QYICP='H[1 @HN)2"XY
M<=EIDC.*AS+MF:]R?+D-R!-D6C4==ECZ?PW6YH #)=)@[<5@M5,Q$TI+U3Y<
M68F+WA(F)37)9..]K,RM>X!.FT>[ZZ;+LOUK@*$,)GU\;+-XSL]4T]D]ACN:
M&7.XCBK&2J2UL"@"8PA5$<> [D@VO#*3'D=YVO3J6(M==@%X\,#DO?_:O[R^
M7#[EGXU@%N;/>; *$C'41B(=H-L!GI,<LQ=<6HF&Y%Z'6X]"."%F'5!7:RA6
MYW!]L8.C-YNN461^? [324^:Y!1GC/B42QH<I<0ZY0DX$RD3V1K?LLG25N_]
M0:;.M+*&075.X-=C_00#B%-(/6YU-LY98CPM>7& F[F)F@ 8I;(%2&R_X_>'
MW_^#49UK:0VS]@OWNW_XMC@C62"^C3Q:F@T\TJB43\2*4K;4.$^\I&5>6.IS
M",')K6^-MWC_"3.KEI;6,*O+ _D%YAFT&??+S3>,^Z/4\PF$2<J1Z-#7D"*A
M8+*7A)>83$\S7TDZW8I.:U_Z@T/=Z&,-<3H[4K]W'[ 0WQPC$YR!%Y$(4RZ;
ME!+$,62XHM(Q(42R;I<E:-/[3ILNG6AA#5/V;)'[L#^P?M\M\5E7 Q^AAUZ
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MO$0$[ETT9&?DVKXFTA87G4DLJ6(*%PDA#"G]\M+ZQ(S2UL ^,6-$W?I2[/H
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M!N\$)2Y/R,9[25?M5=CC;N'FMKV-[-8W[T63AVNB9L5C9EH&RZ*U?M6CDTN
M$@85CAGO3?:8S;'*TC\E\IZ>%D^E7OW;&1WM>%,W^=>K>:[OI4,VF !93$HP
M;6K8?%::.>>+U#XEBUT":A[ =/I7NY,19MY'<1VNYG9 NWZ(&@"NYPO?@^A.
M\^+73)?#.'* (H[/%BFRB[2M6R]3K;@=6$ ?F1 %:>E \K9+6^@3L.21%\,3
MD62$_#N0HS8VH@]^?C/+/^&?>#;_LJKNOS8NKRZ3@S,\"@"6HJN[J,J,< D&
M6B>N0S'1=GE)'(#M^"Y"0VW>3[%KJHH.UOX_<(8+.".$;_(YB7IYL8 :!/4M
M2 0N$65@1A0"Z3VR(&5A:&7"I#(JT#WX,@C=2V),>W7LW&&:OP7=-^ER7GT8
MSM[.RGQQOA92XSN\AP;I=7<W>&(;=W;:1@W6:F^XTEGR((0LJ7"%"5W08L>=
MW4/#=2Y:\7C?,Q&,#H(7VK_0DT\IB8N!6T9: Y>-]V"[7,\=#KU9]82'W)IW
M\]F?JW:_J[&7'^<7<';W]]6U>3>_^-]X<>OT3%QP2B 49G,.3',>68C@6+88
MB"U1.]\EUK/;C)Y@NGU;9N^LU7!2;G2P%[I-;.WI_S)?7/VH_CTQ,4IZ+K@F
MQBJDV3K#@@7-M%+"YP@ZJ2Z^S'&G^7UY/!T6]2RS<]#]UU7WVOK3-^>UIO$D
M.1V4-89%FVIB,<\L !AF.,1@/7ICPM-]&;LWG^^KX 2\Z)"ULK=4UP%.RW_0
M7[Q8OIVMY_@?N,JWRV_^),?H$ZY^^1,Y7K_ =/$O.+O$"2B>O56)UK0F?\L'
M7>MFDC(@\D+PM.O3>_O(\WQUR^,I\ZAASY:;Z:Z2T);+2\P_7=8:KFO<ZV[E
M.[,2EY-82O'2!1:+H]4N::&'8!+S#ND'=1_079R%/?&^/AH?0:\-2\+?MKY:
M8_[GC+ZW&^;5<OKY;URD*?UL00?9A PLZ7/A+*=L:"69P, Y123BWIO,;03S
MV&U/ QROAFK'UEG#&L /YUQ_J'OV<F/K_GEY,3VO832W6[<+GKNH"D-'*T1#
M4BPZ#RP%G[04!FGA#"+<H4A>%^6.JK>&=>;:)Q8;Y:Q6W##,M7:[U)S1U#(K
M2O"@DY.%=[FG:#:#8X4TG?HP/HG&GTKDTK?5D%4VR0>DU:9JT1LG7)6CH!5(
MOQ'*>(3O9?@;$^'!,OQC%/)<*I@/F=/W,OSCR_"/XLHQ2IGOH^CG0N(4;/2<
M'#"A:[9WJ3$:]7[-92E\E!RS.\T;YY,A[Z@R_$^.NV/TVR=BZX%*W#1VEI;$
M(R(JIK-+S&,M7"-MTDGYK#>=Z>_UT[LH?E3]]#%:V_E,>X00G>7R\GQ]7?I/
M^E69+ZZ\M.GLTXV;-B];6@\LFP?R' RE6[A/6R%M! 49(P1()R/J>L7L8@DE
M*I2T"]I2Y,Z@H(-!G3YT2!6K%%?U7A-J[3;)0&?%($,4Y,0EOME!^*6$#NV-
MX$:S=]3_8;K\SU\6B&]KFUO:E#[ !4Y<U$:AH_TL6]I_? 06LH_,AR2]=#PZ
MV>=5H/?,GN#)TY;IS9[!NG"E5S&C^/@$XY )UD#9>B9_Q,6YF' !W@:I:L%U
MDKM+GH$2D0F%=#H+0R=2OXI97:;T.NE_>G:<PE4=L["O9_;3],]I)O-BO;!!
MFN*B8B1_31.TD04?/.-HHTU%1>&.63"NW<Q>YRIX,EQY2D%##TWP7_,S^LS9
M].+K:HH:15C=.\@2ZDVM%\SS:%@ H26M?&YTGT>:_G/[OB!.S)<> 4'-GBB\
MC1QKCAD$YVDBJ<Y!6@9"&65D@M"I ?MK?)T\A-0GT?BI7R>_[9EE!6J@TX99
MKPW3P2.+GL0)5LFHHLDZ#;D4>&T]_T8I?&O/OS&"[]@E;@B,%]KS;Y0&=K2+
MVT=\';4I;0E%1U_[ABJFB8QTA#K%?,S"&AV"QB&)PT]#BX-Z_K50XABIM>[Y
M1Y*Z;5UGHI"JMGT-'&H7V/I2IVUF/!=TZ!)8.R2T?EC/O[LCGZ[GWRC9SUL(
MKF4/H'O-!UU(608CF#".W#I9$HO!T;F@9=0:)1>#;L">4]?&O36XM^ Z7 []
MA 47BYW6P'],+SZ_G>7JP%_"V3W#@(R%^N#YOFS]3-VF-(\@G!"DPEC(3$7.
MHC..@53T U7ST;&'2]!Y7J_3D'N*I.EP1[0NG[R"?%>>MU/ZD1R3!:2+Y>YY
M7#W\#YE)S["T=E,Y33#:DV+:9EKE:6G2(X&XW8P2I]TDA\"PUA#0T7H6<_$,
M0TY61.&L[?+F_M0)_T@ VROA^QAV]$R4OPU6N>Y^X9)UI=0>VN"8)K&P&$-A
MWCOCI0G)V2Y!<#L1G:"2\8G4O"MI_2 =G3#D;2,K:6@<U1^__WZ=X937Z4VM
M ^!: ^L5#M=5@!O!<=%;0;N?,")%+9$'K0QR:Z(2%A#UCN"XUA!/'BI'#FU6
MTCI&UC]Y!38!B[5]E.2))Q%1J]*EZ]]K")6#D&UVH)F#Z&J_9F0>16'*.RZE
MU2*H+J[P]U"Y0YE^_%"Y,5QY7J%R"3Q:M((A1\%T"9QYGA*C+3=D1"6@]*NB
M\CU4KAG]3\^.9QDJ5SNS96.!)5]H89.UP:(I@B4.,F) +[%++:WOH7)/^A X
MF"O/-%3.%=#26\M4"9EI0=R-7&16A)0R9:>->3Z1HR\@5.[)+8@#^/*D0^52
MDDYP#LS4,T[7FPQ(JK"DA,L\6(6R3[?D5Q@J=Q"I3Z+Q4X?*7<_^.HUU=7=<
M<H+DZ"3BW)%MEI2EM5<LDR 4TO\5K;JD>MT%\?S?74?18-Y('1U,Y8T,YR%H
M>CYT/H7*&?NK9X>>#Y#M$31N@A$J>6:L(^N4F,R\*9%Q="*+>N_/NUP5/H$R
M$]T4/4*D+>/Q'JRQ=M,77F0?M6*1#DTZ1!597N2ILV*YU4&E0  ?>X\8,M#Q
MS>9#E#"H2MT>$FP<JW<;-HHNV>"U9*E6B="<2Q8X-RPZJZU(5KE!UV^O+>Q]
MGU-[?\$W=.8W@Q:'P'BA8>^C-+ C8GH?\74,>R]>>^1<LVR,9MI;P4(A1T<*
M\H5+SD(-*JWW-+0X*.R]A1+'2*UKV+L7&;4,A6F1R'3@!EFPT;$,#J'0*:3R
M$!/J.86]CY+]SK#W,8+K&O:N.'+OR>YS6&/ <Z3I&# ,=>V-%HQ6?D@;].<4
M]KZW!O<6W%%:RUU;;S_@C#YW4>VV?4)NMGWF\ "91\%MA+-D2QK)KG;:+GHE
M:,^=);45-+X8/7D$YJ&2:]R1;^0(7>2];R\^F[S/R9%]Z*V.6H!V67$ZMWPV
MI>BP314#)S=*2^M>DA_A;USNHX*[__GA\MT)9D-XHF3G@K?6YZ(+!Q^*1ZN%
M$J4HG=UD!ZQ]);,R]@^5S]5'FDII&[ -6?%(XM%":B!WTHL20"7R*#DY*R%X
M,DL?A+BOQ/ZX/#^'Q==Y(>\9EQ?3!+/:%@NGGV;5TYK/JF\U+[_.E\L?D+B,
M=_[;_3>$M@"::JJU0#:TK)P$VC7H> R*UH$*7M5^] 8@>V4X3KJ)YF"&7&UP
M-% W#CPT1!\M#Y[49C5&84ES.LI2JWIK.J*U\1R4+=[5<B!;]3AP>GMKZNJZ
MA @S+047.$MT*EW\A3C;.G*E$^;:1[BV*+XDF_GKS6_K:VT;W?8!U98-1Q#<
M9L"R",*D(E.P2:-Q7I'[6P2= $'(G-+DJ"(\G'%U0X+9U^5U-@']^LURB8=$
MO^\U3B=>C)K>AJJ=]P:5"(4<6VT4;1/)AZRY<#D[E=QV58^8Z+[:N_?I7Z<0
M:ZS&%)<_ -FQM=<@XFW?\M7(AYI7^X[:5+--IK[I*5C',0 X'FOC$0-H0RQ<
MF!QJH9]O]+SO^ <\$-T9_=>;T(IH1<@H+<.2+-,F:@8@$\N8?"32"IO48[K=
M^?56N>TW0GJ'%Q,NA0(/EA6H&7#6:19U09; RTB&5.%]FIEN W/$2YPF&MR5
M![ZW@#N$KE]CNIGLG951X15)+I*2R,#R52EVRWSFA1$XVE%C<A:[/%L_@NNE
M4*&%V#N6N?@6V,1X[7/$PF(VN3:C4\R;*)E3A6=I4RZA2\&Z[7!>"@<.$'++
ME\^-.:X?<KD67HM8ZURDR,B1-BQ&9UD4MD"PB$'HL0?64>(AVZKL<.$\E1#%
M;=;.ZJ50) 2A:3)D(M?N+]XS0)J6@!PP"0WD*/58V[L '3L(HH&*YQU$W6%S
MWVKPKH-YAB#K&9:X&]II0A3;J'  +PZ0_W$98KS@+G/%I"!PVI3,(#LZK#C]
ML_B4</- >)[,>"2D\=C$&"/V#H1X?_$9%^_FLW1)!LOL8NV]7#U-<_*[DXR>
M92\<TSPXYH,%6ES:>W &?>B2H?H IN,'1;92W;R/W(]2U^/.X=GX07O@EYM>
M6>W[@*TT(8_&29>=3CX$9VPH9+;S&(,R93)PC-973]EE92#;6@'&,)V*9L$A
M.9@HHN':1LOY6$N^V=5336=;[Z%G9_._ZDK:O"OY\7.-J7D[>W,^OYQ5_]C$
M)$HMXFK)/W92LUAR8<AYCCP(\I^Z7$N,!?H4?-0QFM_<@+HJIN-UULT5VWLR
M_5<%9>JS[8^P6'REA58#E9?7K[P3'X57Y/LQ:Q/)QZO 0M3(,+D,0HC@1>];
MC:%8GSN=>JNG[U788Y#K\U_M9ED-@+.)0F6#MHEAJ?<XA6S"F(IE@E9!$4IX
MR;O81?L"?D7<VE]1'>H&C,!]%8TRT:H4(10P92W)RF-AWDE:$AZTY!R\<UWN
M:L9#?46DVD<Y#7/N5_._!Y?^Y4?Z\_3B&Z@?<(DTZ.>KL(4)DE#0&\%TS+0"
MM!3, RAR421*8PV0/S'(-MQO_.=*DF.)_#Y+]#%9\NUNF8(+B9.?:963M20J
M>;+"*2:4=%&0/ZM=Z<&5%W%6'5?\]WEC#CVL_CE;8)I_FDW_>X7_*AYJ>2.@
MWY&<V?J,18"O*[2]26EQB7GB#,_&!<E0UA+JH=:5R"4S*4QTY!\;%;M<'1Z
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MO]'>TE11,=?5UU'3O*8*@$  0*MQS<'%E8P! )Q=O#STU2\C;QG?1D(' #*
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M-M \Z.OH(/0;]#0?%1^&SY[O"5\WW_XY_G-&Y^Z?JSVWQ,_.K\D?P/^&?U:
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MRP#<=]5$K8#IX'XGC)DA_-64II,[^[2;^WC-ANA8N'9O>:-L%G_7A$Q+>FV
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MVZ8]L.R*K]21WZ(HHED_^L$,'5<5*WLHD\=^6*C1*]['T5J3NT_BLJM'AG:
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M+<FA/KAX"9:#[4G6ER%$]\S#-O$$'+W'>*(+MTCU'035G$D2YY5\>;?2L(
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M/Y;RRN4<[,AWGVHN;J&8**P_1T3XT/OS%^*W9#@!4F='Q?V,""B*$(&O8T2
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MQ,T^O8IU%8;[AU]-%JWW#,/B-QS%;VZ^7F[H,Q959AO^+D[15TFF-.">T#A
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M[?F7+<6L(MDLG7*ZT(\X/\3QYUYW>_"E8NC["YV?(GVH^',F.,L;61+: 0P
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M+FA4<S/V:F-ALWU-[O)]/;60I0^]_'DC1C9?:KEK(QW2G'7GE'L IL!6)*_
M:Y#='EY>NV(0J?#T,/"T(7"[.:]I,"Q3;W4F=JM<Q3'S6/+Q='[_% .7%(/=
M6,_*AWN+.XS L#,V -M/SL!QI9H$>-I= 9W#@'"EK'C0")F<ZC?UM /<3)3N
M]AL9^SZ3 'H+Q/)U %T#4F^Q10F-&@$[X&GGNXZF<1U.-7N($^XEO;)X2AZ"
M*E!'Q)5DE,((@#%!P=-0@D;01-8$&52,IKV&P)L8F)AN MG@&,M$>AH3+L\
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MS,K6J_ZQD3%8_$>_N^W=V21#O"DKLFIQF2X^\:=8S0WD4V>IL,5GA"R-F>*
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M*<C([3^-"B7"R)1K!02 .]?X"GD#=1A$G4R""[0139N&<1J.0L'"@N06,PF
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M(J7*RM<R%W%1+A$$(96"KR*@E\=%MP N5L>]GF""B5=4E1IQ5T=P)N^40 :
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M5#[14&3+1H*V%XFL,[R-3E6]PX@<'(4#RQ*2<^PCK2!B]HC9A#TTO!AJ0=U
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M)+G<[C#B1\&]^&(_7%Z=WNJU@T5R)$TT::PN413/ZS@;[VW2KV*EJX>:L)W
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M%TSO"@8@E(4H(O7[W=DD@\IP(1EB7A%P738Q&(NX%:L.B,<,PDGQ*$,$>6"
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ML!9_(Y3+:[N'A-!>$PY:GB%PWX.#FE@42AA%M;Q*KL@V4GZ?M(KO'3%M:9'
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M--U'PV4X;<_%^!.8?GH]1^>XI*"J%VFTE_SERWXVA<X+KP\-I>>A.Z]QK\^
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M_F@_DI#2-\(I"(?V\=FWYP4Z0!['M*17-C]T.'BK,WC'N??OY(8AXYM>4;Z
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M:_FTD&7I]ON('*)L1L^E,NE9L2W-HY^GP,*[4^!(S\]X!]%W@_:$&KOI:2+
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MNV,4I7FN3?KMB+U?=D!2)9CR/;;GX8VL+'\@4J^PJ'#1.IS]$KF&IH69_RE
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ME1'5C[D!/4TY.Z^S4351UC77>#3],>4D7Q&:WE6&$8RU *-0Z8V^WP#;!M8
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M *$LXA2?J'(F%QJQI=C]HGQV<Y24U9IV(C=IAVZOO'EA8Y:TYEVT4B23E.'
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MT0K=,C0^GN'?W#(B>9G5*Q]WTR=F'IYJ(;STNQ72OP0+UZ3/NV@8HZ?!'K3
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MF35])Q>F\=\-;/H.NE18;J[4U4-P[\-]DDTBYO;NRK6O5MV04.!J-F(?9<.
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M&4XG9H.6N6#[XQ=X=J!-@+N+6N'%1WPTU+': #C[N^IC3\YU39&;4!-+ML,
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M.G^U]R0[^^RUYQ7U>%VZ3A\FMH-1U^[6?/746=<F)W)C]\Z+*F@+>)*K#MH
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M1I5F54*IZ@D!\WB 1TP!18*=#)9,/#CQP%>E)_+@^5N5>[0$WP74-?"R$!I
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M&=KDXUJ5+6"\[P@XLU:U]Q)]VE0]U_+^!9E3@Q*?N,/!6?(7A;!OZ^HY>XZ
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M)X"(UD$%?SWMJC?@'4= F,S-FU%>=:=9"EUD'B@*N(Y[R%B"!N),%XY1#U,
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M,'N@9%?)?EMYW2]'U:7/@\BN12!?;+"V:5-@1&7Q2/G;EDV'\OE??<N[(-S
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M5W]DYV?'7=>)#PO)I[S;>1TWSY(OB)G(RCX:MG0X-48>(-#O\46JG=^1">0
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MZ_&^Q_+&I5*)V9'IS -]PD-V>0$^NPO/V=4('HG<43:^8M!(6$,O("9:IV8
MM\JUY(UH_.4L7,1]Y:*5?8&H;"'VT>JPL-B"'LS+1K&#!]_LR% 6U"Y5CBRK
ME0\H!8CV)XWB"AG&;1NXJ8 38'CY7\9TU\L?M&]Q/G"_X)"ZR*!2+ Z#61"F
M<LV9T=\=3-N:4,UM6'G55F8(U>'-)1OJ5=K5=R%@XY3;6^6C1SXZ'^+!)!RV
M=*#'NE8]6),>>Z?MSATA8Z7'(#9HJO&34J1*K+P>/^'^ZP<=NTQ?*!VIX7JE
M_%I\12U3HPN#YZB9]%">OS,E^$AG-@J,HY %?7>#0I7V+8+1:R?R9XW/1PX\
MS3\P_OXBO?602PS9<FV_0';5_5\0,?Q*T<KT1Y8IO=XHATF;BFUT0T;7GG7V
M(BN_:AP23G"6Z$WR5)KF!O>3-MP<NFN_>]P!S1ZR5AGY(-QO(.'K(,JT+[\^
M*%B>D$'9)V,B?:3.8J3;3S*@YW98DH[N(^;N6Q5C[SD/B=IP6J@C[*:FD%$.
M?<4$5X?5FN??F=6$R@GQ.)_X=O*0K_:X2I7F5RJJ8[I0G]UAMTSCUDTK+QR7
MDX6Z1LK9Z;&.TO7^H"\S+\R(GA>P;*OC.;A0R.G[^B+LDJ-]H@M:B6)U3VZ^
MW$#BZL'1PFX?6K5?VUEI$,$LHT_;6ITJ^C:RL7_=D0KDV= "C,O]L7<]Q>#X
M]$X\I1NK^*DV%B45ZQTH^\S"6"IJUY%"[D^GUT1I%!1)NS9NQ/7E'3G%&W5+
M9)*ST/4GR>G_'LX/-ND%=*?.^CH\=+0^R)":5'/Y$K,(_$EB4_W%Q,X35]K.
M$@471!WO&\V_ 1YO4R=I\-+\X-@MPXSY6+WA)N29CK4YDO"R^#>_Z%V(M__M
MLK2AYB#&+>-%4(3+OS*;#Y+A)5&/#3Y;S,J$=&1<,9[X2@!++3W;8G_R5<_"
MD.RK[H4AP&HIZE'E9[,IUJWZ^>$A?$"U\Q>M9C@:PG[CQM&69[5KOQ(0NM][
MO?XE)L0_ZL^#BW!;J>>?N-0 CH]UH@1>&$:$MZU9FMEJ.#16>\0JAMXP@\<X
M:K2)+;APB[UNY]H<K:7)Q[%:)0G X9HL6<$Y:C8_@BB\( J6^G6'L[4WBBHR
M>BT-ARP+^TUG=3-RWV#^C27KQ])E4B67OE+MJQ/<Z<&16X:_=_%V;<X6UEV2
MK":7C!+',M3#](#9?,5TE^EEHR1[7&E;GH"QXGJ]<MP*UNRW-_,S1U@S=;.O
M3"["\;#.S1Z'LV,UQ7+(<A<[0Y9F$>*_-.,E0[%&F.)^1';XN_%*8//7EXQ@
M7%)D]INA3N\LWL*Z,&>]9/GWDRO^T@?+W^9ST&F%+*=!?ZG:&UIV4)&PK2:/
M[DGZ$BS$8*/PSNEB5ZW+BB?:CY\]@$S8RJORN7[7)GC'NOQ+T*7ZQX]_F?@H
MG^&5>'NM^@SW+98-<NX831//L ;(QG/9_<<;90P;T$JW;V>[R*.!]U9O4&V:
MS)K@]66@"E_W_"7%%B!(*(!XD\CRERYL9-EI(-E]&79P0A='FY:,^3LDXM]
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M\\=#[(MQ'"Q/JD[2;2SM_8#:P',*\P,.D6YO8YP/\CN[Y["M\(<<HE543A5
MT)Z(!Y<9B>86\8.  \TMQZ:A28Y-B\O,DD.PX':!A@8V>Q/-[8$?"^E&\%6:
MP= !2)JBU( ^%1%D33&@J8*RMN3W-S1;9J$SJ<TXK@XYA_CMIFMI0%&-V/J2
MBK(1R]&]T4% ,"]<BVX"6',(#5#YV3)CBWTP@"Z]]?Z/L%H" R>E)"C17#*(
M)&[<FA^!XX% 591FJH(8)GKP>#"')FG5M=AK)-%Y TT*/$@KFS3Q!'&(B<L6
M.M@L''\Z+9W*H?H:6W5K U#WA4&-R+;(R-$DB1;#T;"PZFIO2*-REIBNI@E
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M&!K<&B#/M>8WAS<AGMJ8M<9C\,CM#)7PW?%M SB^B"KL20:K#F.(.9;XB?N
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MU(KT)=:6'U4>QT6MJ4R]/!=V=C]\U/19\B9!*28J+\&J;A'/0+XFQ-P_K\T
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MS<T3R7,X5T-UHM%8H<AD(4K=X'A][P2/O/<TUMTX"T$SY2[_CB^Z+,IDGV=
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M6Q(+^-_J?^- RW7/62C]\@6^UZ(W[YYS+N:XP=M)A%2(!/P  D%(T#FX;Q?
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MNZX!?0DW[E>RU9_R6;O"$R82]I"&I;?1\M@^?\.AP#(F6SWWEHX7"N-/X,!
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MQI\3)[F%5+-60+COBDK=\PTMS8A.+_W.WK>6*V<_"JWTPZQWOZM\!T2SCX)
M6-7O;<I_(0B.=U<-4S9AU(1+>"]MYJF?>5]H>5.#B)#<RGNF:9+0[C\%(R$P
M@L=\O-M;)X"NYV_BJ&5()\@O:2E/8)8(,(]Y.3C3D;K 3&6MQL'!Y"'P)?%+
MD8MZ?<7>YP82;P"ZNV-JU_[;0[4G-\K6TLVSW*5F(?!H69F(6)G2AW1[,RQ!
M,P9^.Y'ZK5)HW/;\-Q).L UPMD^N'EN)-&>T;QU.EY9DP*T2<S:7^0S>>+D
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MEK<KE>RIK?J!V40U<[.B!\X.[I$<Y!DL/F;'?T9[^J8KZ[U \]#YD;?IT@J
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M&QNS<'7-7TKH&ZL+4]..ZAP;]?0X" B@"R\U2L.<H-'I5 "8:'MQ-W+?*-"
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M[_@OU=,27(,K\P7L&A.KAGFHP])$UG8"Y<'0^A8D'+G%]@@4DQ72\A%]")A
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ME+Y]S8@B1(6T5DYA0D'CKB@2*S1:M"&@M"?399_"7,(O,0Y+"$T8?LV9E14
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M]+>XF#7A(;BV6U8R%^R*GIVT2KM??3,EH=9ZCK>?Y7'/)_\KNM"E:O :54Q
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M>NQTGKF3$:;F:W!KA.E2 W/C,BD<3X<BR'_SF@F58_9ET8M?$!HA$T]CXDC
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MK['H.:58<9,+I/:P=WJ(BQ'40:739NB67NZ6CPG76INL3+J8(/4=1S,+#Z
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MF;QD5Z_$HBT( Y$D-1]C8BX7O/EZ$[8%\P@?^%.*+\L@7L/5+&NHQ>O0+O!
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MBGUKI3BFBH.TR-G)O73@."=-M%E>&=T:K)L40*[+ YT(+T:7C<-%"MN"R_1
M[BLMMS:9&Q^QCVM"OC1CK(&'5>63J)6\YL=1#@HQ@E::F58K:)!3CUD45[K=
MZZ@?NY*(2+MA7&XW6WVHJZGG;!GI-7]R=#M&*E/VYGHV9\?PT<2->.:>M\:W
M68?'>?I#$XT)!H/5T.>O*;P#U?4@%I_N\&O&J.0GL5*'18BIK/"E#V3IGM4?
M[<ZI%SG+2WIM$3"K^T 7DG@W2HYV"]L1TL+E.#Y6DZYSU;+-P@Y^5E"&=#><
M&A9CNN>G"]\HJ*1Q3,-V/A+Z_;J%8=QUFMX#TJ-Z5TI=;+2R,+:RYKKYW.5L
M>VIN0_W0]TU?\X?D-E;Q(TQJ>'">@.XHIL_3I'OU0E*T,T;K=9+DBNW=.U<Q
M,1OVTZ?6'R=S]IA:305->3B%[3?&7]7"#T=8UBUO!JGAN/? FHW2NCZ\PH>K
M*6JC/(UGG*U>U",$9?WN$5E=L]%JJ7BO.SS&6HL_X1XP^SJ(/_^NH*-B3WW&
M+K\32B2J2'ZK>:$QR^A?)W5;[+&-(OX>\VS'15$E?JDQ2:5;.8*IH<[;KDG/
MU[Y&('2M'H86(4*]"K4'Q2DHD)':L\6^27<-P%-<$[I=!+OLZY)A%2$DUZ-O
M:!L)JAABW"S,8\=S+;530(*DC&BTA=M;9>O==X\GFC6<[-P\+S3K:ILEO2SY
M$YDQMX'5"WC.\8J_:P;FBK[10LO28:8CWR#8ES^%!>?]*O;RMP;*8?JH7&8V
MFQ+=S=K4X1NCF?QP3[TN/MV^CF$7G2FZAMAUQ5@5JU;P$PCSE^N *"YYBCBH
M9HT".OGJ<'0$8VMKBIX.OOG@8@7G#Q<2*=)V$F"[##Q; J+&X8DD[[@*^0S-
M;P:S2:3E>M&IT; 6Y:,P41*X/4X3[[IE7F]W\I3=;B;"-;7UGQV&7)PO1.5/
M)%:Z7U)R#7_8,Y!=2+\'X- :HV-LCI[&A+3R94\/Q<:)&IQGUHFZWHH\.^4?
MA]&&FL*%<=96KP$6<<C4A;M6*^\X?5U"[S*&EFL%.$-$CX^$$&OL?$\4U>.J
MKLN76B-.,<V^!@.CA6_)[D=39?W)YLG4AT>.ODJTE KLP<<+4L?0WES>H-F2
M^6]4;SM!@:NF"6BDBTITL5X\E_3#+M1EQ@FD$UIGLQ]M+FJ7M4Y%HAGO2*O*
M;WK\2JT1Q5+AG<Z>,MUD"M/;\-R#'?M#BWI+T""J:9.XZBN!CG*)>R#8*.MA
M?G_H6$_JYAWNNN#1U5[I)EY-5?M5)#?,=RVK=MS=?-X:-0>S[Y+5BMN-W5##
M/CT^*!Q5G,L]6&I=5X(R&T[LMFJ]Y-]*'MM]F&UWQ!P?WH%_BRS!B)Y[@&YY
M_ZY)ZA[(?'I8S-C=2ED-4PQE2"R0Y7%\-]#SXP,)H2"E!'6NND&RB7?V+]Z^
M&?92'\9<Q#BTM%E<J!NF8!*4T F(=/;1!-N_6X^5=NHMC\IKF1%CU//TY9F=
M9K4K#<Q+(IRKT5&<D">"GYU1>)3= WK'FHGEGB:SDJV@GI:"""E6VRRIN2:)
M?A1G(9C&>73(E68-G-2>G2.SI2+4).IN^4/<3V1J;E.4<\$^%]V768(ZW;ON
MR\S'#B$^2HYP+I"WW^_F01*Z9OGHY_U] Q)G@AONE#9:[53H$^6N6(S=+O+N
M\]71\"3VX$'S7RXGN&/E)")FI\-NWC*!KE#F^3M2AN:IJ!^9[#E3C-P\84@
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MMQNF?&5]1TQ[&2$JT+.RDCXT4JFUESZCW&BA37"72ZJ8AXEU-/WG/PT/Y7=
M7#NE N'V"H&(12-;\@Y<U>1DU^4YVO?U>P#_IDIW/)>Y2CE:E5GA#?O[[8_/
M]Y5*]YQ*T\5&+=Z%25$D'+;?(9^4);:+"0N5#3/J.')\,WF9<J?G/W</U-SL
M^X\=TC9WJU$<GF?KCF]/V*MN/>H/H!(D6 T01"&[:OS.C)]5P$;V^QXP"H5(
M$@I,N_@J^60UM*$@,GWDLSY_\P<[!-5++,*-#_S2;7+*8PL5U;<@;.-'TG).
MJG\MLPC^:10^W)9$D*9FHWPD9S+TIM;U1'S3AV((P@39EOQOT#8-B'MP2,O"
M+1I%OWUO;M3_);$E< ]TWP.LL^B9BS)>7_($E_:-).*-8V]O[HRVO+3W1A%.
MEVD7GWS<W0R2%2M7C9BZU?AOZI K[@&;RUE?0[12J]-=_I<N2&8=.!1ACA(4
M 5C>?0$^RJWTXY)RKUOJ.O5I#L&OX.*CO*/?5]>5+J9:B1%DJS"Q<6=YEYRL
M,)8^T7_>'BVZN/BY.\.U9, WMZZ?X6=\I,G2*_;"$^)&Z;C+A[<U,0RC?;DF
M*T3=[GJS7XP1XK97<+9GJEM>&<*OQJTYR\N!D,LPJ/&K6B0:^$9AAPQ0J_A'
MV<PTTZX-.A#LMIKX$RYJXW=D-/K*5)2_FE@-UZH]B>*/Z2CBNR!>QH$1>+BO
M?H[\N>/]+FUJ=GSMV+6X*^'I1-CD&.P84:B6T5*U>#'/G)=8J+=/9D8\H]1(
MFNAX3O7C.K!'KSP.E&\!+LPK>YBK<_YIR_X1QL*<Z_5+^S(]6Z<RV7/XU>SG
M?=VM;(ZP#(/:AQ+:DS_%#A, KF#[NGZX/HZ-GVM=(\7TY^?YZ,U%9&E6[Y#S
MMS5<"TRFH3=YO2<"O&>_W<D(=H7BB<J/92(CRAG9M0_:N"=]J-?V_0A &U\K
M##N!=(I[8+UK[BY^?/93\0I"WBCJ9(&%3N&7*"6X$,Y[2"96:E>Z^\KH=ZUI
MDDO$27YCAJ/-T- K/ZU$'C'BBH7@;K#5[\/P!R?-*^3#/PT&+<+UHV?D8+X)
M6[.>[L'K&;6!EU#$/<!1:N]9WNV^3'1\=A4_CE*P0."U)2.*=GZ%;(AE4ZY0
M8*UJL/3+4">U*F[/9F;PU4"N$D@T<<MQG45 ,D&X2J^K]7GK<53Q5D\#-'7-
M$QW25W F=GZH:Y]M5PP:6Y[KWY+DVE3*K[@@W(C=&2P&68"-DYZ9^2_'M1O2
M^V';R"BVVM7R*U5OYRB-\4]6E,N\ZNQM-M#UPUNBT!:1#]Q(Z*MZ<"A.T6K_
MEUT_/>4I.YXT,1NH'(0-^L%@0FX[F'H[0B.Y#V84PG:C VDJI3J4"68$0O&+
M7M$$1MU$?4N#9KI.44RD5+:V!C42?SG+P->NV0KQ3G0LMC7Y4:BVH_&)%D:8
MKY_Q2035856!;VN9I:\E>>_UR4#_3\=7@'ZJF^A^"1US;!_@+ N5XZ_-^_YE
M(E*SH*DOVS+)YSW,X8MMS;X!<<<L"]:4NXN1P<](.F%"661,;)P!WQ'-QB,4
M1)!G2H?WQZ*#/-"+!3&![O NIX68C,SR5\>UQ65[=UPPXK#J:(Q[P'YA6; J
M=/Y*V(G")CH16W @:$2\5.W89SX]Y0=BH2-.3][.)Z%2?V$^%+G2W'& Q'>]
M.H]S-KE'X=2HX7"Z0V(,+DO/=+*T9&04=K4B7SJJ&K@F$V3O%C2Q.DL#KG,B
M*]":'U($<"+S,[PWH6)<N^6P1]>*S0UUT9+OVFL:];R:^QDND50%U^GO@2#?
M\=$2/RP?20BY0XBW0E2FVX>Z@'4LNQ>?OXV8"Y/;HS/&=[FOQX1]GE2M'&^S
M6GFF5&P@:8XY[\SJK @A7+"E>.2=$=_&[#,!$DZ209<F9.[H5(H7-CBRJ-'U
MRQC9@J87YN\:BL H-X_"#P^S:^I.&2>6T=^[R\<+^V_P"5QG(Z)L<A]*42[U
M\&9TAR=>QP%77+H'0'-+_';7]4MIBZ:DY6+'FR5:*Q0^()!S4V;ZKYX75\5>
M'Z)_S:)1S >"UB&!1Z?W0!U?$IH22QLD(SU1.'K-:.KE;*RBXJY$2RM1S>[8
M!9;D&F.P:Y.P?,JMH8!I<Y 2<)+#"DN/_,F^BHVC,I_B\C"GX-P#G;0>Y7-[
M*DHVP#P%;>J[CWN5ZX[]M 6$O9XIA@V3=[02$*BP\F0SAYU-_@\#U:UY0<JO
MF$&HB/8-I/2F%AMAB&1--Y7X.WNQ^?+/469!;QD6&2X[<9J: "BED!H\.KG7
M2#FG &SY,=IWTOU.CZ/EBA(GZ".]'J*O<W9F/CV3*J4$ [0TG(-G\B3@'BA%
MV3"S%%A*9W'H2$[(R$<@<1SZJ#"46Y(+^BJ>\9C=S/52'*[_Z!>$SM>7?Y[/
M]4?P%H/:; .AG1C]6'7?1=J;Q.#+]=NESK,QB_P']T!6(TM-CG=QS2^CP\WV
MT5JE+2FY%%EQVKR\IZE[BM\<"$<2%4?M.';+E\%\<3#J3MVMK%HA^RJ"1';W
M' ?RON:K1P-(8IVY4S=^D$BRN\-!]>GLVH:JIQ:1ZSZ1[5SKR%L"-! 70Q<8
MA]JXCR1C<$DSK9.=UT?V;^VLOQB8$.T"U\VKJV<]H!WX\>BU/"(X/Y3NU>XN
MG?DWRLC*13-O"CSN(ZU1EKF-JTAL)1 ]78->5<T9R/WW2L6.+O&7Z@R\N91A
M['-VB.9\CX1J_E@A$-VMF>9EV6FF[6.WOO-<.4:F$/6M(:%,DD []6MQYG.A
M"3SGR-_;ZTR]P9:*PB!$SCV@_-?/NE[_QYX.6FUE\;P2?XQP^U'UE=+P7$Z/
M1J17B!1GLJYM;&I COE@/AA]C9E9?:;DI"WB(RL5'>SK1"G=4OXN72$-C&ZE
MVP\[P_^\7 K!#5$Z*$6J*:Z'N17@+)DYQV!G)&WOAL&.0@SQ$GO2F3X/7Y"[
MBKEMM(:G2_O*KL/*B]9"GP>_"'TC'4:HC@U0HKJ,*RH,9\BF3'\F"GK%T^HW
MFS+E1J!B(#.0P7JC#[L'X!?=X%*A9?W?(%:[K\A=[\1G^&_/^VY0--WC"B#?
M O49H\\,Y#O%\6K HAJDAO*%C%&2$]I+X2R!*S1W7I1%\,C"#78%L#:%#/.F
MR(T"2U/&6T])W<];B_,&QME?/VQ5N7'@&.H@LGZ[5@ZR#.6A$U>,/J[WQ="V
M,GM#?E[N>VS+!LZ3*#3H._WP11[;:2QC]W(V]TO)3YB;YJB\5[H=,UZ:!H';
MTR?*)!OK<5$U?9YM:X8Q$.$8TYJC<[Y>-IJ-,F][T= #@'&^YD9G#2S^U(K+
M:+F5,CK1@8K+_%M@S>L;+E^ =\L(LU0ZVLVEQ/J8/;MP6="+0_L&MAU+0)4D
M.*K85>,35RH=UZ()GHROYIU=\PO]\&A;]=CNO"5FHQ_N]5%E3Q&=.BQLOUET
M/8VX6SE[7C^KBK*>_<G2;KT'7$!LN@T%MM@>]V8AIE=]EF6M/&3>O9FN9?+-
MKO<8:=05:N_I[6]UIQ?IE]MCLW*%<MYR?*=&Q[*;R3/L=_D&4HXK.#XZ;@4U
M,_[EO1]F>&8X!\GY7*(E%S\$X#C*9)9M514J3,8GY9CEE&E,\Y+[TLHV33GH
MF;?D</"4[A2ABP^T"C? XOO"1"0\B@WYC]AS.>I$7L!5#AZC08PT;MZ,V]](
M'>\;3+A.WB5Z6,"ZT7NW>M]LKY#<V$#D!>UY%B[9[&,@R8Q,L/HN6N2 )P=2
M=I^+#_)=A,:V(Z,MQWF5V-4_3._KNL*77XP-YW1[97Z4/#(2WB5+>'-J& GQ
MM7]79JK=S]H-H'E?6?5K!E15Z5$16MMQ5QU3Q1?H>!Y_D9?!=*J;%X D_KR!
M&=8K/E9Z5  B$C>OP9,ET0O]Q)5^UW5S/4L(L^S.PJ)LYLY;NM0MRPET4AE2
MMN_" ]L#!3>^+%NPN>\SQ5"J+W#'J27FE_).C:,]^P+GTI,B+/E*94N%'7Q[
M.MS0:KRN%?\C92F8ELIDCA%"7D38*;>S+S0W=%WI>B>@+8G0 3(V><.;)9%/
M'_MZPG2X22TAZ59O8?(GX0YV**MM+'/CJRX6S "Q^%$EW#<VBV$VV\ZS/--3
M862*;?DV*F@_Z[7H/6P94[VCNL$18>/E_# C_]RQ+D1(NU.*7KBS1?WDAS7A
M3T+5-N-FR).?=V1XIQ'BW?!EUN,#H<@JK&ZD%U'#T1M^5TM%VXKL(L<+Y3$J
MW^(VT[>@_WJ3EFH)PC"DFF#$7:4>LI-*5P9+*7W/&,E32#$R?$QA)5A*\>P^
MYDYKT<\,]F8CKP<+Y:&C3UJ^@9'\$5I*6=;I^@4=Q;VLF_63#ALUC3*?K5*S
M>]<Q(["?T%80+OZMZ8PD_;MW8C;7F/9==B*%P ZX5A83)B)C;<\OBJB0)VHP
M.*APT:T@47S7,A1<<.ITEHCCUCHZ+<X2LP03 +G%%RE'^S9A2I;.V)X!& !?
MXYP>Z9I:%Q'D$A9E0!8W.U7B2C]^:?VKK9NW=1 MEE0%\Y;!KKOG"S4"#$OR
M#+ZU =K@8]'=%2(?.9KQA2XANY7XHKUW_(04/8\/.!EK5Y]&]TVD'>^ [LC&
M:29C^VE G%M+A8/O[TJANW-/+^,-@_E!+6"JH<URM@/U\+6R[/QW;<<)GN[K
M\L'1^/+XO1D7XZA^7"S-$VZWPKI?1(,[&UB:C$76I]QI%\TT+MXF\,D2&I 8
MQW^6H)8[S2!$D!E@BG_Q02.MJ:]CL(GDPZ:M1RZ6;B%Z+2I@'^1B(*=>9#7+
MD;RPQ5 DHW[H+448O/JP:%SPK.KZN<<WQ/\,)4R83SSF'MAW+YWO='*,BZB3
MKHB-;12(#O_(]>"(,$+.E\Z4:@\AP:7EHI2GHZN9T1 C+I!N><IGBWZ16 6P
M%E00 I7107C8^.;U3C(DNFTO]J;&D*HVP0Z\K_%LMD2)5<T^Y)RP5*'I_1Y8
M&O&1$G-S66SF+4D!!PDWS6;N:RI[AKPEUESUS>*]_'3(TG$6*7^8-KUOB#15
MQG%.4O*#?/"<\M.A4HTO04XNH2;[B'C,FGK.94E4$T0A%UJ;XF-I013)A/O\
MH-VGVV^]9L%:*#X])G_8MU"?OJ::I5&68A7I3FQI3U[/"LH6^X2 F685Z3(9
MUA9*5F+( Y/*"S9V-5*89&"X5/[*\.T97^#=KT7NN;A=(Y;0[C>Y.AKIH>D'
M+W959<_XJ->@\%+'W8>ZPUS>4^YUM#Q)"MEHQNFI@FJYMH6-^]:P^LCG#><L
M-73V"57;KKQ>M3QF:'3 ,OKM&\4F-#,BC/341(#V^CM5QO9IJ8+,^XKI@_1)
M]:J DZ5>LI?KV/G'/)F&$>N>/;Q[1[<^G[-?LA3Z?;T67K!!B"S(:JJ/8 L%
M[L@H^T8J&:H4_3:\89FAF3IKH*\_GNX.)_@IMYD\%-=Y*/*]?Q5_(!7[<XOT
MR"'YOD!9:8J/&HVKV(_)0@6Z?&+7>Z"8*Y-AA;6.H8QQ;3:B#?($X>OAAP]M
MJC>VL1F5\3E%,)DBM.P,.:\5$!XJ,Q\IYY=W*ZK[<Y>\+CCSZ:35 Q#PHP/9
MDH2(,9@"B\;ISZ'?C+&R^P87G\\#'1Q#/+R/H<0J3!VR&UK@G#TCU\/RO(XU
M]>FD]36FN8L6S0D<W!V3-8J'1MZF[-%!J%CZVF%G351A<.WA/EGW<Q;'_!C?
M[XFC7M\\95SUB1B$_01^9#@+LJ%,J^QZ&JRQ[1\1-S4K)E9>F;-CGU[<C^^?
MS0$:'4<'@^WRM8>]_(3T%CIS-Q(D@Y6%DT]!K1RCA<NR:($^PEY%)998KR*_
MW'QS0GSU+>982__9RCIC=\.1NXQK9\[I*^,@XQ19$0CM%PNA[/%&"^:PI:D(
ME*^NB%9\-XLK1<WL1]5P-&JD>TS[)1/=N<5\[MR<93 !+C@LOM86YYF0SCQA
M.<'@$G0ZG;5RM@R(!VKYFA;,[RE?UKJ@$_A"QLJGJ*2$3@9F56K >M=6978;
M))YYK_=6E&V&1"2SEFZXFY2>>8(V[+"TV9;".8VMT:\'TWV:SXT@>P*[4RUI
M6C;.;5VPN<11+ <W1'JIE/I$#8NOD7S U7B=%-<A55_]#99>F46J05(EJ#A[
MBSJ:2MAFY4LX!&%V#TA/?$4#CLT_H(M_HOGH-K2KF^#^%21NI81F+4:!B'<I
MY^+>O6I.MU7##KM^;29V8P;6HLVR]M+8:GF/31NW)  C:&A9WZ%^C B28,Y.
M+5P-U*5B/CZ:+\NNGU3SK/_PJ+RPG&6\YDU$#J\OTO'ARR.>^-8FHZ7M"^$0
M5>'9<L/*;.H2&=_2Q9/,D&][3-DE$U"SR@D[N[RO@W2<S-P5_71/-YIM8 R3
M7<05NT*^57O>0^VV->&,%M[V?8)B@1FY#HCB[EI#O..#J]KL. IM=:E]VKA@
ME7/>33$DO2]N^_< WK-$K8O#B7>G#.MD<6E%8,P/OD!Y3/J+>,9A]0M+=@U3
M.]Z,L,,V6[NGN#A&52%?Q,27V#*Z!$M]B=?LFF=-E6"H)8UV%YZY$=F^[NG9
M2_):IGE[N'N:)E:]$]BS^K>3&N='V+OI]).Z@]HU.NLBQ:Z>"U4L;JJB4JZ]
MS0PU874)&;-#^M&>O\;"M+=#S8.GUYWBS051U/:'?!@+]ZAP8$'IV+/;-E\L
MJ,R#%S"]"A21Q*&6F[2S:"W>;@IR/M$RKG!VO"W=OW[9;J:MHK*H+PFR/UV2
M^]I%LGCRKD-#II A<_*<A4UWR "4J&+P6KL@E@&3"_O)#PSU_YDO#:+"7W"]
MRXS_3*IMAKLK+P5H54R65#<Y5.W6NL,='^D-U(6:ZJ?G TCOR333>;D+,3!4
M?+1 C2=:P[0DO3>6)!=%+HBZKH19/+U%ST#Y,*NY[#[Z ^M?[:L!Z+]HX*7O
M+,.V")*7U1,82;4B UEPE&5T=<GZU:-;6(KOZ)ENQ+.E"L@1U>$$S8Q.]7IF
M>):S[MR*S>,\I=);PI&2[ZL:TSG.G4?MH_I7 J2E#+/"7_CF'($K2X3,@ULS
M><^(^,8-%3G9.M]DR:)1<"/%C;F=%?2&YF*I7;\')9C< W<?[T;2'=[[WECF
M4WIK[#%58GMYO#3:F3<L^N6FP#=QUG>!U8W!L)*WZJ14/<G*<TD?V]D[/[W5
MESS666#6A^R$G J>+F*J)!8I'?3%1/B(9^L-B\Q<246H+KZ436.+T=40E7PF
MB#8V-7-EF $RAI/+DUNQ"=X#,F&$VI?[)_Y1UM-:;:VUDSR71^6YSQ;T,F-U
MGC!:^\<Z"F:_U>+9@+K_8N6AI)9/RIWD*287)#%.7_Y-R[CWFI#5VSQ(]UMC
MA*;F+ICK(';31(6VG(*H]]VJTP&S*+GNY(U$;E_!SL6CK8DW;WX1)M)14)$\
M$J2*]PZV]^=7D2U<OA:.MW,=Q" /#STH*87F-=J=]F/*17([.W?C?#_Q$LLK
M59'B(K=;^FOO/.#?W&W[Z[\RHJOO 100>'/!J>!]VP[<_Z?>;=Z9RO[*#[A"
M3MDP2#4-5.0ZO2#$)J-:.6&;?J36^'EB2>PL3D#E;+L07LX$(^Y;$ 91X6"!
M>H\C_%V<Y1A\WT2]NXHQE%QS(+1>9IN:O]!IX*)ZZ\2!CG?%=->BY&Q#UL!H
MT!9TC4DE*8>1@GLDMB2^FM::"?/K3?Z\>3=SS<PY,FBEPGEF:W]K0X?8[BEG
M.%U34!,<);9'VTS5$F.V^C5L.LPX!5\/ZNK0?26_$574M^80:6NF&:V?_J%%
M<Y7U1S3B&>_POE DO*FXO] &OZ5G*I\5NC"&-(9CK%F:P"? FY-L,M2@3Z90
M6S+XF2I2T.7-2W$ZL%\GTPVW'<0)+:1\K;G9D:Z%SB[.0U']A,"5LDWH[.DE
MR=S2KI;*,FA2UL$)WUZ6UJXD?]]P^GA]K1/QV6R\669S82__2QZRM?ZU:=6U
MJVC%1..NAM*2Y:^M) UM.>TO8N9-AVVK5!E_VR67R? Q0IC:P*@[ARGD8FSX
M/K1$=JRGPRKN]C^&/&X5KB'6U<SE2ROHAE]H3I!LADE\ED9#(;M%+7]Z^^,C
M/J7]\(TII%Y\#625U!+ .3STVO=8N#)ZR!=5GP'"$L=TRD*E EEW<Q^9J3AZ
MQGY!YYA=^S&O!6\4'CK%@TQ9VP!!,%9_05DRZ^63HG L_?HQB5"\$\H\,=N.
M#G(LLG?C(>;J7\03D[I"O94M8^G]2(6KP S=4;*&%X_'Z\JVC$/&>^D->FS=
M5DB:]2S7.5 ]/7J6B=,.JYO(^Z+.^2#0I2G44^*Z-]R36R3[LA _:KV^G._=
MA952I"/"6L3'43896-9DU2>OZW0-1GZQLVXA9:<Z:S_S7,6]G"VV]GMR1C[(
MHD3@PUW[>?D0?YOM6X0NZ2_!A9K0)ZM1PNYBV9W=FR-.$=M9ODH:(X1Z\J[>
M1H$^IQ PR%XC)F^)N1CS68DL=;YXI+T6]:H?9<^:I^[('5'E-#0T:FU>:EX2
MNYDJ9 %&2CBGYII&+G'&%Z@H1.6P7FP^=D>S0T7_Z4OK>./$9B,:,T:>[\!E
M.,+?\.L3<U1%B0W<Y9_-YI#O(GH0<!J[::7THW?TE*;Q7IIW(7/)?0B;M6AH
M)"9(-^:D)I*#;_95PV74,K]?]#U@6/?QEGY9/.X>")"[L+@9F6GUO<T2P_.S
MTAM<-\):N ?R7C?5D-!2#'SR*T6^;G<[IX!O[S"/PE#'*XYG\MV;4\"RYJ3W
M@#GZ7?R(M0]MMI&YC$A4S<X=V30O&^GS65N[K,1^ETW?3 S:5WN.3W9O]I.F
M/I+ON?,)\37D15[9%PO--ZW?B6[2X:3,;=-<X^X:'O'%Y"]Z\JTH5D0J:[^E
MC? P/Q?;V,AP,=PB52B4.!M/9^=K!@G4S*IQ2]_FL66VRAN1[$!!Y)1MME4F
M>ZT'(:F^Z%=:G#!)32&/GK.9&XA87,GO#K;@"8K>O>+J3Q^;UV^+UIKU?GR:
M\&G+];@',#8F9SO<#2E@T]]T/T<[0NE,(,YV\ISS ]X%M&6B+OL98GF/W2@R
M"2L;%C#?TZ-L7 A1\O<:S2>X-[J5T2=+;G9^$;.P*'<.U7DNY9*@ 62H&?*"
M5P5;B6PR_B_2WCNJR>B+$HVB(M*D22<H( K2>Q>0)M)+Z*&(" A([T1 0+J
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M._FII]C3_<RU2A?QU^U-&J$X*T',9MG<;OI)*S'RT//*B>Q(RI\V'65*1()
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M<3+S##+3_ORB5R2WQ.%<]/+5[^XTSN^?C*F/@<4L^.03#^Q;?K= \N<>+MQ
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MW?TJI+Q-<(?YL^M._(,OP!(1.L(]U[>")U)88$ON,%!OK)EX5=T)W+XYLJJ
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M# MALK2[18O/M82VI6/C@P*LGR%G4(#=B=X7$40-MOVL;[8_:JD!2&CM.@"
M(=U[K,4'>E=-*, <\#HA!XP!K95<K0YUY+B#4)M$ <21@R1\Y)]X$T_8%U^;
MG_>7*6&@D3%^&W@'#/)P=C^84JPKJS] YA?/:XM;Y2BL>)X]Z]+T-O[<6_M"
ML2;:!:W8T4NTLJG^X$HVUT7O#5Q:-M;584%\1.WU['PF/POE<UVI+CYU]H.0
MEHMJ_Y,(?(N$JCBS-,FB?CQ?\<IXJ2\%'VL9O+23%QHO'$H,#4=A:D85?D^S
M\ ?+\J):6HR[&:G*S;7^N&K@?WE\Y8SS$=>55D)?5\CP?M[4>I.G"Z, \!7)
MZ:?@S52D,*MQ\-@LIX!BV"E6ZODF"A"!*?KK,R!N11BI72;%+@GP: @%H";T
M]-E$NJ( T+:JGXV2=0F^?Q/"='EWZ.H(!>CVL_S9H^H+M?EV4XD. :]<%'^)
MG<F(,&V/)5W2__F<#1AQ4.*UV5Z7%:=4I[6NV8O^75?""S+_EP97.#H2KQB$
M] 0>/KZI:P_"S)>.ME" *((KBZ:,5$BD'=W/!VE^-N53%:X"4Z&25W1:U5<7
MX+77-W7O?E[F;(\ WL_G:&X<>R@7^5H!GOF;..=Q19@19> R>(5\HGES# 5X
MS(@800$P)F^\6S3U' _85;_-=%J.\_H#\+>%3?^TH,X)H;LF^F.!,$:IIBJ(
M40IVD78D7SX4;7AB_P^MU08(&S-Q5 Q_X17QVSON$I1Y7;\ H_D#C^*$GSVZ
MO\\.+%69V8L*!O2VKVKG2"F\]T1V,OZ".B7N[R !?U-^RE,<:$&[)HGV)Q B
M$!(0F_-C%* G",FSI"CY+T'=(OO/K.KYZZR*^V_R+?,/](@JQ*E' EC^NB^(
M_$VSK9Y0H2FG(*4?5\V'A=(\ES385P7_!S!-VZ/^)MK4DV)_D^$1_Q1KW,AZ
M8%;MYCS;-$,2MV$Y=X269"*"VV@S(CUNI6'._"PCF)73YU\1GO[_^/_C_\&!
MBYKY/U!+ P04    "  Q@EA2^3?(=)!!  #$:P  %    '-G;6\M,C R,#$R
M,S%?9S,N:G!G[;P%7%5+USB\D6[ID))N)*51D1+IYA#2')#N\BB(2@L(2$MW
M<^A0*2GI[I#NSG/^AWN?N#[O??OYWN][O[\+U^_,S-Y[5LR:-6O-GBU\'#X/
MW'XBJR +("$A 9Z(/P"^</M(QA-L"0!*2@ [   8  J2&' +4<)#5)Z\!0,H
MB#(2HJR;E'SS"U !P.W^#2H '=&&@ZA+ C>-&[\]^PM^P2_X!;_@%_R"_TM!
MP\0);$JG86UA[6UB#@"H[Y%_BR>($7%#]GN4OY7KHB)_*R,+\0) 5-3?RW^/
M+3 2;OK[%5O\@E_P"W[!+_@%_W<#WST^7M%[?*+W!.AX!47Y$/]X_[0-$84
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MYAJ'I*E\H4;23$UY!8*BW'?AJ3X>ZWU0 !Q!:6VE .LGXSN'6%_RQ)R Q>&
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M#&6<3Z0.[NG"@7H>F#]'[C\]T, S4U=/8:R=@0-<=$%QT[?FX4"J=WBUFX2
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M&@X4*U[E>_\2]\_0_P%*"K!A#:37%&FTZ>CP\X'+STGG%\RU4)=/EQVE<.
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M!N""2)M37"[/2/\AWMN<J=KJH?G:)(-I1*ZBFQ@K(,R8A-\P.]R8;O+M>X>
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M\OGD'E#.DKY(AL '0@]:?IL6A&M S"IMYJ7?"HB)BXB/XA/X9?S_T%";>_A
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M+CA GQ('!XS*;EXN-H1YU*.&*98):ZE%J3SCF!"P%1HZ$N-0P#/"(+BS@2[
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MOWL+]])\E3XIDY"G"@V7(?DA-'GZ;L=LX.CZCEK54(8#;M'E8B\YNKHLB2=
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M@0*V$]ZDN3&Z,R\^AAZ:(-,KW-G)H>W1@I[%CHG:)W,G9B06=->O<]),V'_
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M?47S0S..?AC9.A:?D5Z*;+@[ESUU.(X? VU)+N0B!L)<P8L'?32JX1(TD$<
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M\MZ_OZU/CS=$ R\^3M[[)H*\K<2F5-&^HR)T",$F\KQ^[Y#SA;HQ*YNZ[ O
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MC=JBW[H &/WB!T?-UZS]:LK(:81)BYV']9?S%9T]Z)>\E5.ELM(.AUNESLV
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M N\^6\P"?MOZZ_Q>0J&!C'=X1TZ]\4*C$%66M<!A]P@ "EP\ @HH)6_>JM.
MEE7<+/4B_M9L-C^8#G,HVCUF&5BAU][^;24&_RA$K!Y;:[*RV@[^D9327_MR
M58!NWX5&UCT";I\N/P)VY\IBZX &ZTF<JD4%;3.CL?7_YNXKVV=L99LE:MO"
M?0N0K5>E)"NW,)$&N3I7Z]'-SJP+R%7;?<DL[:Z,O!_\\O1-#P.-3%9/G</2
MROEVDZ%/(  S8JJA4<S%>#+7PCQ9711?.7TC=;&F<6_465"3 >3=+_/-F+3
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MU8+2I=UR9/61='/B>I?N-9UT!I@Y'NM<KT]Z[J?%[^.["_XQXB8-8G9.RWI
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M=V)J*]T%Q+4I2SA/=<+:6P[2!M.%S]0I/YP?>B32XZ/, \G&-'^=N=\NWY-
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M0S=''(J'R37OSKN&%!*M4%Q7N64XSM_MEXBQX2@:/>O7Y?XZ1%3O-6Y[*#/
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M'KU>4QDXXG^/?Z(BEFR5$(0P=Y+Q-#-%LE177>./9C>XIY[W\U<\X)BE!VI
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MCLZ=-\*$1[IN''D;"&@>2U)N&CM09"7T2&@S6+S<7:KZ9C31:$)AI/R!M#A
MTP2[? 9ZHZ,R[[+AA(N$:M;+L:3CYW@<JDT.SD 3]','-K=QJ?8)H,LQ339W
MN?MTM=85V<B#L:0'0.Y\#2\]PH XU^9TO24IT^<I.A/(4?^J^XK_XJM:?S>.
M3X_?0UH4#/T5-WW2 J OG7S5 <ITX#7JQL3*&>@J0@;O6W_]#?+F\$_?$*>L
MV-?O(J*NOR_A1L>T/96<&R$Q_T0.)-5'U,I H\#UU&]2.8:M[3UH76A%6G;7
MAC?N_FIS?T9G]FI1=*GK;M_E'PSJ.)FV[NW I/:V>AJ2^MCK^N2&G5X\IXB!
MWI?$JL%E>F&SSZ2JB#0ARH^!S"W_U*\HO :C)7.^H<7;EZ%Y2"_'G?>9O/TX
M.@6#R]RN/[4N9YM8XF=JN_'@9*AX[:*/^J;JB4 O\:0]E7J\ /PQ0]6F-P<>
M)<XGY""G(M<UUN!D*]CS"/F"^O)2C<LDY7QV.E&HF<Q30T 6LP8B['%"?T<A
M"O"!(,RU B?VBA109T6LC,V+RIM7U5S#0$?A!Q\(+JWH"2]MPAUT.LF-J!ZZ
MIZ/=>FR5EF<&1'<G>5[3++N4=>5*6S,2Z*<1BHI?)=\=)M\D/3_-4N0#:)\"
MP?EPH<9C9$RF5=FDN))/J6RB>-,&XY<H5M'NW6MY<M=-H2QG(+NT2<8#_[@F
M)J"BA7QYP#V:<=T'F7\G)CVKIQLYT%FMR6-V54+BXXY:!J^\L_-%W\-/9-:Y
M%2@WR6_AV];F;',+!_*;G9,3S[:TI/.=:Y*+UE0=E8T*NV$@ LS_,!4\7JM$
M;#_P&\'RK1^:D*\Y*?K)M$?^33&Z51-JM_,G!O--JWJ+;PLK?Z7F#$2U#E@7
M A;S2^%XSKD0CNV0LEZUH3=.>[3[$>:F$C.:B>%O9A(:^W2)''NH(.@%CS0J
M\C"4'<EO-3>ADPD,<=\7XC2E/2*<)DRW+3W_965*+$N5PZ>=B"'$B&>@1C2]
M%5REE2,J( _N^#3U6?IS^]#[EE*,0IWAGYN=<36\]V1_7*G'L+9$7WTSC@4!
M'O.;Q@HTK5;049OAC#'^X%YI%E?E84N=:ZETC3?N.R^(I8XN\-X@\Y ,3[_3
M?!3;0T<B[Q*= W*!"NV2T<U:-6+W0Y.X-U<[;ER->LK-2/4*&W;Z TL_2S(9
M<'?L9UBGQ?5SP5^3'(ZI"_EOF\;BGGUNEMA_(V!B\RZ3ZZJ:1N..&!>" =@G
MYITT#@']+4B&0:DYAO.>R9M\^D'45N=1RV+7CO;M>_HT]]CT);P=0$W:+J%G
M(%ZH/3H2>Z4<R,\#^!JM.,F=IK@!G"KVFO;ESY>R7R#*Y&%(Q=='-(_LR=R$
M_A:A[2 H-YEY_0S$#$X^V;X\+60*S[H=,==I#?Y:96K[FNUU\XW7>ZM10I-(
M9A++*(*&N+# &"6Z72@JU<^A^/7 D["U^T-ZH)/+_TG$>U,F?]]EYO1TTJV:
M"F)%&_W3XQW>C3,0IU^LO$=%9P)55*O3=ZR:A*DXFV"$'DW'7,EV$$F'L$V^
MW%@$[YIJGQS%SP!RQ\LZ0TNF+7*0F"/ T9.V)E9RURYI"RMJ/RM&K-@4(QCW
M-\OA 5^#40C3K\*#LABA?GMGLE*L*7/0G(SKHRHV=D&,.^S*&>@U.A1[_32>
MY$2PMAJ#2'J]GC3JB\;YKC/)_0Y[)M/K784\L%2<A[:.E2/%D+UD12)-BTL0
M5H(@&%XV0V-(< YW>UFA5^']JBXFX4%Q1W[TC/38M%O\+0WJ#P^$K8G1&RE$
MEP8.M5*BT',@9KZ>Q^':FW[>T(ZD0]VZJV6?.^GRJ*V=(@HR73^KV@+:C6>@
M:_6.*_MS7+U$EQ88 ^3>*=HW!W#4)KC'-"^96_2\.%'MEDBPY]'(E->]PLB\
M@N0 )(F\[7,L4E .!&RD%B*,$#9W801<FA7?EN.W-'I</%R%.PKZ\DQO_P(Y
M\W^/<BT@TY+L 3&\&+,%26"L5C 7$+*LKAXMW.MG3?ZZ-"16Q.D>3JL<@7:I
M=POIT*>-25VD#'"9=,2[!)"9$*J$0ESYN.(] -;BB63Z/5Z;&3:[HSWT<VP5
M#[F0UU"]QV^22IZ<*X6U]%\@=Y'EQK*!.3R,4^V H%CQ<WU052"3>)HM\[H<
M1$EA<JF9BA36/6U2:T%N$5]+HSH7N?IK\&P=E7:LZ$@B; 1BYD(1WC5B?:OP
MGR->^9]^79&0H'E8I+Z@NW%R\H0\D$;C@N0!TEK)%P8W_I:?@33KAUY6VWO8
MZQO"]8W<+\Q"1$VS=\Q,0!=403[.P0O<SKR3&4V*[-'ZE3P\E8"G6.9P!7)Q
M6J3CF:B\]%RB8KQ@,,D5W7OB :]ITG>HN 9W8*0R7;NZ&C$1)!]4$\^AROWU
M%^AXWH23V-]TC X@/T2($Z.#%&_">56(06GIV' WW!R;@X@]2XZ-J:24@))?
MX\C\9L.I4.)IC T1&EWOJ!MZ_CP@SS+@79>D.!58_+2;BR56$\85W;J$-VV=
MG5FDFJ729C_[TVB!3CS_=P%\J4XKSW6*#H=>)B/?UN_ER754Q]A41 X&9-S^
MW#T0<64+Y=#/T(YWF3AL*]_IL&8YH/>YQ-O*($!)O&>E0#B8GR&)$S*S2&U.
MHG-N=K**IOWKL)=QF V1"7+(T=M!J -IB#0!WET !WJ(W<%@6!?'%;S%[F#'
M/AZ]AGH:52;'F94^=].M.O]-9&7>- @E +D.3PX5]_L![#*9/X[Q(/%HM%-4
MB*;58&O0[D"(U.K5Q)%Z/VV;-;?3+V,VNLQWE%%^-K'OL*C(8'1)[&AVSWMV
M7Z7O,&LW]WW4WVVYQ-X\;0'YGMQBU7JY))N\65NQ;UJMMU$2%;5B^#]EOGXJ
MFJ-E &;[BL/@:9K1H&A5V!+TV>G$C9TB6:HK2T^^))^NIV(XX&'.\4;PNL'1
M8+0)O3'X5]=05"]/>KZ]YZ[IRJ0BII!;7:WN#*1*"([>IZ&H. -11^?+$'ID
MF9Y.2X,@^[M.=CIU Q[RA?+/,+%=Y#&5&V.[HMQLGGRD)0Q)" ^4/<30"QD/
M_R#2!()#L+WY*UX!#V9:4'NLW$;M-S^H>APOA;MX6/^TE\.6'Y>'_Y+Y0V)?
M.-FA#&[O_NG(2)*,^CPM<PU$L0S>N9$WVG$_CRVX-SBQ6>SO#O*<0?UF'*3@
M">$MN-BH.T*ST9I':"A@-YBJUVMDXU-?8%]1S9#CD;UF7&(&FZP*<_0.8F?S
MA"XG=<?D;QKHFUCP4N'QFP*Y(X!)F['QL>4Y;S]SE"Z<GSIBT2Q,C[-M_;+V
M/M&SQ.,_>+O54U&44-@?@78_Y34>$=DF67M3H.B!D@=\&&)6M=B#;I*X@^LO
MBL\+/91\4^W<^;\(7I'"PGLU];3PO"$=6"/'EWR1W@)1?7R?QY)\MR:-N"Y[
M,S6W:\ 8UE&\.\\7AIZ7RJNPY*^!0M=+81;Q2U]2Q#8VVF<S1-),%=>[C[?2
MF+WIRBNN-4)TJ8BR41J9^D41#%<^^USU-6(WKQMOXV&J(F:-I60Y5'_BB(YP
M>2$!N+02?P2-MR5T0$=ZY%1R6S(8@GE>2P@U;=]*ZL,[^H9D^N-9Q3MOY!D-
M?FPTIDFGKA.N$,_Y.OP^*O9?WI:7/.?M>$.;HQ_[$0F]*$NH<F:DT9^1$@Y_
M-;3ISJ64O!J.^%[E&0>S,NUJ,=*G=!(JIJA)LM=U\G_\P8K5"MU[:VT A ^L
MUUY<<++ G8%";H[NA9+R/W'RA[:M+$><KLSX2,18U2\!SKH7NSV<7"01PMY/
M$JO=:9>LX!R;Q],6O_[N'5HG1*#R^]2[&PA"/NLDV@5ZW8;C1;FB^+N:7V[$
MWJ->R3DOYS_./NZ8%5D5&Q=J[HQ&]>_9S=AX!S3EJ.4M98F,K]7V91@2P(>!
M@EA_XL_*4"=\=1D6\^+@\+/\AW^9FQ%G57-R:9G,(MA"G.H<KO^"Z?[3FV&/
MO5Q;51*&(S,]U^#4'WYA(#+G[_QU2^8J _I%C\0Y?R-B=I9=BI!MJ,O[T."<
M=KF@[,'>TZQ?@G_0(G,]%;68R]A[>-=FOLNH"Y<@8<#T:]FQII$LL_<CQM5'
MA<^.>5BI?XWGZ(?7R7BF=:9I#ZHR[]",_M=M?1-6H@O^, AY"9"#78<7;6E;
M@E]'S;#,TJ3:9\>49[JV?2B5Y %=^""O);2L2T&>K!8+J37* 5"M6$IB?=-)
MK_GZAL^369'!U-E9\O/KQ>>85D%)T='Y@@:\9_E_?6G(>^A5Q:L '[Y6VA7>
MW^0##;O6^VTS*-^6NSVVY47\-(.$@I!%DQ7C0.W%'U-O4CD'-\I$>$:8Z*/2
M+C33>?-_O_^!AC_IS_\^8HA$K4GZ%#RMF:,\QILWV=[/4:0V]_2O[<WH,:S(
MZ?=M[" AE5[.Z)N8>W)-N/S7;"HII]J2W/Z?)>/3^T3C-#M!?^B;Z% L<X(W
MQYS^-X]U<7[X[!!H^*IOX'0X8#)D,ZJP.KR'\B+)SB_]'I+<AZ%7'-?21!V_
M8N/B+*4+TY*J1#2CP<<,7*1DB:B"SIJD$N<[A_DF)3R.''B'XRL:I#,0:V5L
M;[]Y]UA(Y;#S,ZS+Y\\TOQ8-XW2VC6R2T>"55EYYV?==RQ>7]8]&+ZXE6W3^
MA#:UT!WR8%A3+/X<#%=7BUW.;=+*6+X"_ZPO7%LR7+OVL\1W^%/J/HN4ZB#X
MH8[AIS*LK6JX:K]$\I*1B^1L\I+AGT$6]I.Q,] GQ-M4WF#](8RE'.]5N*YI
M^,8D-M"C1\:59^&D1,S(M>OSI2*SS%_FNCYM_XNL*]<]!VN,98B:B7S;D!L+
MM_]E/RD=E[>>-BFGBK,0HP9V -+?,U"PVN@4\)I+V""5DQ*RO^/DIH4ED/.]
MLAT\2_ZLL92PY51\\ZQ]*\]+7/$9&_<GO8-(5!P[Y[QDJ<<IF$-+UXZ9Q\]E
MW3=ZJZ/N7-<_6LZ%2-$J6&@.2O7J6I '!UTT2@EV+;2'/"_B '>=E_5!MB>_
MIWFX0)?[W(A[_PH[\YPT#XRN/K'S"&6E/CV:H1YZM_8I^UW\J[IS@H0F[9+3
MU.!EL4;V_/E)2W$HW(SYMO:HB,#O$2=^<5TG"5Q,L!ZJK631X<1P)/8-H,[*
M:B\DY:E(2QR-#TKVPKG<F-0L@ OJQ_!78:*4XR9Z<NYY.2Q\75;Q9_-HH_=*
ME2*\)4.JA\MF5/0J1A"V?K30H%JS:R&%"#LGCN6.Y#*Y+PZR!A]OLO/,,O'9
MC+^<A_%.K/HX+0<B3.RD*^:==$:W"EY]:5?XWN7&_3<SY56J!"4USU?PKEF"
MY3,C4Q)U?,)Z9J+=\JFGW=A?[Q1!S;\3_G6LI>LT,]XHRV&\V#^*;/&?BMQ-
M]Y^*_%EIPR$#XW=Y 7U19Z&[4%YG!"/DI-UF\IN5T!^.?\:,CG3ZC,H];]IW
MK0<=KDO6M[%^->5);6N.CE]M*BH#>]ZKW(]W?_'.,& @P"K(\IM^C[V;NJ:(
M &NU';5M_&BWPZ_NV8 Q"0LIXY@\.6.I-N?1-<GN,# $4H,VC4G)'9\#C[2.
M59V!&-3+V6W(N]8[A8#CO0TWJ$^^5.&),>;KJIGT?JE-0<M%SN0?E%7H.Z6*
MR1>YHTT(:6%BBER [M.QLE5LOQ]X,5:;ZWL[Y$J@9^6*X6+8/N,GI$(]\'+>
M4JQ=D8M SLTEW1PCM5<3QM*N6UK!7Z]H=&W;LQUEE7H9? T6CXOGU#0BG($B
MHY+$ J4VN9DG-:3V*J;_T+AOB!]=AZ%(O(1B@DG3'.T;M#UW?&MVRI7G*E<;
MKK^E5MD7-4US@R79/8_]Y& QZW0Z-QH]MI,*/Q?VZMB3,U!^ZLLS$'W^//J8
MA>1W_EI%'IXC50:9TZ(1MB<"G">XS+E-EK$Z-SV(;WOM'U#-CG A<F ]+PK'
M=YZ\[7Q !HT13$YID8IGH":U\_21X_6#CW@HS@LM_#\H% 2G(4E7^->O6! /
MR==DYDC.,?5.+A?OQ_USFUUTY1DH5_G?,@=NZ%WD9C0-;N&XDY9GT0YY +-H
M=^/R>B:EGU<=1#%890S:R?D,1]\\S56D=N1E*^.E<[!B'A5Q1W, 4)-HJT'^
M$3X)<VU7-KZN;^KRIM=D&-2M'*<<>Y&R" C1*UI*01%&"<>O-Y#YAXH4QYTD
MVNZ4ULIK[(C^A")ONWY_+Q<&VNGE/<@GVGU$>.#0- BG?^]K150O$E?'>(0'
MMP.WHKV1W?$A%_+YY:M%-V+AJW%6CO.,%^!S!V' */'PR2A9!%[3/,LX@- O
M3S"'!:,OEG7@+T)T_3NO4B$WW]':?!_W8-R8(Z+P[>&0>]"V.2[ Q9C0'@36
M $\I"#95OTWH=T-=>DG;+1Q\ZT:54_[XQZ':4AQK /+^6AK/&>C-J1T.%;E7
MQ[ &90^WJ.-LD:9W?2EWFF+ZA/V2^Y=K-%Q797_00]E)OD3T1@#A<,$K"*/S
M?KW=1)%Q:&]&O6D26]"DO4"_5_CVXG2R<L>K;UX,$EWO=)_8(W1.4Q1O(V0
M9OP_\5:X(/:Y).7RP2(7-/^(6..P<T5[M6W4G\ARG-H"^Q.)J[)H+4+_QB>(
MTCQCR!B,!5Q&3 S#WFJ]X3.S6:#&:6'[46M*(%-]ZU+H+@4D<7&<%Q\]D;9P
MV*(;7)W3C&)&F ]L(=A%OH^%_II<=4ZJVP%=K'Y>)7_#AI)/4*1CZPW%K/0(
MR9MH[N(/I2UC9(4!NCKG3AI5@5#'"UU^-,IS*?TCU;N.ADVO6%N!]A[Q-#V?
M2(.&-$+[[$7B=@N<? L8;Y7S3/O9*7/ &[HOMLGIHL!ZZ%RPOG3'],/4<SKQ
MA8_AL&OUKZ%,ZTEBS0I>C:G"%83^EC,0Q6IWSL2:P539L=^TSA555[I!.WG.
M-R]\_"^^!61PZ-;Z&V*APHH/@-)FN?K ?1TYG8=O%#F'>01N/Y[BCX;DP-_:
M7:&6[7_YB)?A.<*R.JU);$$>&L++[8P5T:0Y^/Z@^<<,(R-F(EKHK0BDE'>B
M-'"?;ZD?O-=6A4>'U+,H"B/8!V^.%=4R.^)1H.=K6+ZRLAFZL9XSD*W8HE!
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M6 QN87R3=43MQ40QM#]Z.>7:GMR\JS?UZ:/W5+0YP3CV:T^)$%]D%_SF(5K
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M9+9]F4"5N;'Z"]_;)0+V7SCO7P_"UH_I<N%P/1[0B^?UWW0)1=U??E15=18
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M<Y.(E(B(E(Z2G)+N_W7!_P#0W"*<NC%)2, )N$%#0$A#@.\$  $  B*"OQ3
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MV[:HUZFOCJ^/PST/P2SL>,#U,_#J]"_/9_%!\E>L#*V(*YC;U^9'K8(IVG@
M+9A9)LB9\4+5\!AC,*48/+0J1#L8X'>9>;V9_A*T.XL7>)V:YFD[6JT_7('1
M0;U>]FDW>HL'E"W=Y;IX5.P6^!SE-)"X:AHRAE$6.HF"V7TX,GGISX$'*#=
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M=J8,9<!9?2/#@O>;=YSQ@*])#D$YOQTIWN,!=..@4!<ZPX>]JE4GU=>R(@O
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M5,@N?!K?WVCP@&D1R\RDRB,1:N,Y,B<M@F,B31)DW)903C4[Q->%(99O;7W
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M>XJ[(E6-(H-=0Q/K,'2%R6OX_-PC07JFYO6YK*G&TW',2[&'"%C\S*;GR66
MSI'CD2^D:XD%Y<0[['2@-;?_ZMV6<:]W$C<6:O3^N),::;MJ_K;YV>IRJ #*
M0Q=EO3CG$#.F(6WOUL[Y]7DQ]4(\XI!BL8DFZ@1X.U!(NO0S-@9. ;IK9/S2
MP \Z9Z3YV./' ,B]Y8G?>CKF4'@(66.M3;%V,C&)U;[75Y$JID'/7*PRY%@$
M2F,)='_XFO.%19+UQF.Y6V=YM<G"$R=E,L]0RU&>B]3JU;7H^^N.30&.OOOK
M\"MY#9#EUU *I41FR7TCDC6)&/"O#^B?T/G3ZSR5T3QIF%(YYQQM0U/94.Z1
M+2]CO3[@[8:@[M0Q>STG\S"S9:H:SOEFZRDV+"#$4 AUO3F?XXA]IZ!+DZ(H
M/*!JDC'K"<KKLI-UQ3Q.!\+92[9LCUG'D6@."(;!Y^C@W;';XP<N4HV?.^ 7
M5C1S(9GKDU-#,@BW-#U)"UT;N:?;QV4>. 9@=(CS]21G7/\##UB\"H;#!X+\
MVQ!M$MI5XV*L6)9S1,JY0LR<XC=N+0V7FEZ"F->%"X WU/Y20$UL,(,#223&
M!)L+8L(0H>ZWA=:$3<DJKRNO2! BEE@K)5(>UO<>>V,[% T($]]E$I@R_L #
MHI<HL#GWIMM6F2JGJS]#7MAI:TUX#<F5VKS+U>J76D&V+D+HUY>1&AF4=UZA
M8Z]>H&/[EP/E8=T^WBDB"Y3'QK.1KVGXG?S(5+Y+XM9@*I>):SZ=Q>8AYA3-
MINM#EJ+OV9_T'9@FWU^6C6JRU.Y=\J%GXI$<YG,4@''-3R?M>MBYM@+1 \BK
M+CA+LRHR4:WM(WKB:1TCX^WFUQ >0&]%G??3@::];D?J]93]1RM"LR.=9AS(
MPTC1_0#]&:\![\:JRC%^-42U0Y?RRD9FL2O!BDV;%.8.RF?UL,,71(]Y/2YK
M[5(8:.0<O';<+>U0VB^:K*_%/L866[HIJ$$YK%_&MPN=Y^JNFQ/:7[V2](5W
M9'$TH+XMGPET3<7!K*3E!=;J,PA,<;H7!G5R[XHJAE%B+ NG;>%M-><(ZD@S
MB>](^PH4,*19OI"/71I(MQ-KS;XNA.2J0V4A6H4S5X!ZIH+V-9H.>$#316WZ
M!7"M)ZI9X4HU>.9ZK!R&M7)AP%.M5$;V^BDLW1D")Q5+?44FG5:?C$OB,1%M
M]2;;/%GP)^F77)WF3#@>HT"MIG&!-EMG=SS@.4Q+O'!-Z33#.DI)=JC-_I8?
M>=W6G%\/NX,UZV\7"-VZ%]=(ZZ/@62 5B,IQ;CAE38@,O<DU;GLEUYW7*$(N
M[O26K%]]//<CP8@41\U4( UZ=A4\)Z+5-($162UGV'DB;REVLVGZ)+^N-IVS
MG[B/FD+]]"Y5#D_-:SR@75V(Q?PG=.VFI5I_G;3EZ?[9+^CEU !N9F[KVY?K
MUX]EQ0*^+2_8UXW9<[ (+QCUCS7>.0O^P#91:1=IR??<&/Y<8T5.:]'G5N8]
MV==>A:SM_C&/+Q+G'VL<.G<%3J"TU1//I+!)7O 8?ZJ6-6J:P)<HCB1K>[\2
M1Z/$!<6J13KO>@/6C>?YH0!7 $?#14)/MW3=>R?,O;7R#ZV,Z"D?E*),A/7D
MF^9G]FZ@C%*(,*6TT@=Z'<M@K?KKT7&L_7L8ML_R&38A R9:,K<=>!>W5$]7
M%TS27/5A@)N?SN?NS, VHJZM-G__W3J<%#U@,-,LM=(6KB<>;!YV$IU7?:6P
M@,*=+NG<BZ!@)9'Z 6"SE5JNTO@@!@T%(E\)14*IRP*MRGR+7XQC>$@K<#\;
M[8T>JOP84WPF^4 LZ%U% J@ZDU8!\KA@\TWX!$25\&X9I:)GF\MXHQ\G;- B
M?AKV0&1XU>1<+LE(3XKY1/* D?9%B0RM5(&V2GT5'@!S#"/' V3S+F8P"M[.
M3K$+>MZET-Q?Q:P.1DE9F95!W<V?[U&>+"@Z?/TFP"EE2:N?(?RU10G3V1SQ
MC%=P<\Z]$MITN/^JC_)TR\_X81,OY;C5WCRRA-)GG1$Q;ZHR/831_J;LP=:4
M]F+^_;N>)4 YU&QJ?D>Z.[*LUVI"+!:L^5%PG?W;I/MWCMQ'W&3C.D4]:R_[
MF6)D@G\G85_ZRLI0:#3GIPEA3CX>N Q.H4]&Z]?J@H=8+K6;4V?J2]YXJN0\
M2>C21SLHU!&B'7"3P,Y');TM76Q;5+^+-^+JBV:<-R@>7L#\1^VY<$=3K-7*
MW_M7'K.+:,S=M#PL3.17E$^6$B,WBDOM6=4W*,KDX!5/ (U<3GI\?@0*9:AB
M#Q4K)0FN\4L#MRB)5ZQLY6=.:)4HC4G499<"*T.&B6B,<_ZH LC).1Q=9QC-
MCX[O/'H"_]G>0]?VA[G*6.RK\[Q=QFEI$-P#"O5B_Y94;6.8_VE5\VG?@S*!
MNM=6O)F1#7(4L:J__=5"NTY/._6\O7>V5-U$B%Z8:ZGY44!I G51YEH9&FC]
M[-Q&SS=6&5W2E?0U3'^01D(W\Q4Q3;K+%&A]+6RQV.34J=V!Z&&HMX>MQ@25
MEIK%Y(JJD!O3;QE<_AXU-?K)B,+X'Q7?:\.ZAQ=EZ_\(O?&5X">!^3-5:E6R
M3\6.@HLT1Y*9_:V/ZE]YAP>7CUX(M%G["F4[PH"^508HTY,HPA[V]KI:+2I7
MNJ#5B4,RS^5;P6P[5<';[7-:'X7A FW=+<L]%B7CIKNZVG<KF("? T_7-%CL
M:^L2N,SN6>\6)N-,]!>MJQDX)2 ;4DO6LOP+VI-Q>, J(R+V.7."^:V=L>JW
MA<GTUO$>B^J^X% +6)AT7<BW*WT$'L!DMC-8#YXUZ@S;FGY%?"/!CPUWXS,>
M0'J6NK'UB^>JWV'7]ZW2N[5/TE _=07_&O?-^_UKOC_?<!:K*R]U'[X%22@4
M.\;[FG>SN& XEWB#.6.'G<O0*SWW#H+ 6-T]XF7V1OWA+)ZZB4#[;[49Q0I;
MD.E',Y%_N/5ZONEDV<,18C1;)VN,803HHE7;&2?+8WZO!Y*XL3J.+Z=>3,/2
MQ[\<CS'S/+[6^X4"TCEG9AQK=NO[SYO.&T6F7UJ-?WW-D51XORCF6/?^6ZI3
MU,(@EMTP3=][R7XA/RLI"UF)W9 J+;PMZ%?D\FXI)_-7[&!'_0A3GFCPE%_4
MY82B')0WR\.1GJO6QJ(;5.-Q9BC/&@C1'L'H/L$#=D3IN=W"N-+!-O3S$IWQ
M>("V3MNE&I'7ZC<_(#BS;>'Z$"/^=X>8LN[ 3'_JKU&\JF0/O[[]SRJ[M][3
M$0$2"129:I;BXF=,>)C>_6O[G/&ACR*&9NQM>8BSER,><-M>/]FHFM)^S9E!
MV[K(J#?8C1/)W0Y8;=S&.)[,M;I@\\&V<I!NH]"V. S-1M>Z*E-S8:DU0*'H
M*7@S$0^HB?N LPHQ5TC<,M<L' "'PB4^6T<#%68= L7*C2^67JL_9LWQ9UDK
M2S9F)E,2C@NO*+</X@ RB77LC"I;E\\>J$$0/E;6FSF%%[6%6PH[[Z7:F>G[
M'%ANO"PEZN2YNVY%<1OZ+;@M?/#1=-0DYD&MFCFI9EZU[/%^_N0DK2G#H:G<
M]GO6Y+I4J\H^G%@6CKR9_27X? P/(-L_0[[N(>?*2%\YDQ*S4JVRS[TCC?OM
MWG!X:*KX><7J?J?;AX"^M+=*.5KN0<*3,T4[6<3C(!9#^34@<V7:4^*!%S'$
MZ7XB1V5CD]MLGLP;9^4R-''YBA(NVA.(S9H*VLVPQ7Y_<;C/BCGQMTYAYF;S
M-0OLYQR#]6V%Q+#4,M)NZLV3\JI@.C1H8M4%L<B*$"\I<UK% Y12J4^K))Y(
MG0LLSS5#5C4^>)'#:,$PC#5+SQJIU=')OECP5AK![Z#77(7[9G5N:R[W7?/Y
M_6UK@L&96T#CHK5:R D/]88+T3/E8HD+:+M,]R1)Z;/[Y^/-1QHTLI^M)4\*
M,HSP )?3\C1OT+BD'NQIPM52MN.R_\J\@1P<&,N[-YS6F78Y:<C:0S4V+[9S
M6I"UY_Y1'9)=I@>^S9\)[E]J6"N!.A!B=-R3"ZOM3 SF7UY-!4;Z7WS\G ^J
MT;*O(3>OWPL"GALX0T=:GLZ]/<VK09X6;HC'COW >.J@(!W@.S]M5)631Q?V
MX\';\;2W04UNZ2/(K6]L<,IF(6YU9FCE?K?..<U;R(HOAF]43,FY)EIJ_\V:
M878:BX0>,ZO275Q8,\EJR^2<>'0)FO>T"KHZW\ %VR2SKO/F3R!(\$\\H:@Y
M-Y'0Y.%5NX GN0W3]&<Z*M@[!G:AMLH.<]6C/-[GXHB;%[V<%]%E^9T3?M&B
M&N<&]&*;"2;*CJXH*<2C'CS K.UU#M.5*%2P3G+J$U"^%#>ZN*"C;1J;U_!M
M2DY#-,$!+F14=Z?H81/4_983RU9Y_F)Z^O8K?@VQ1 ^W)DG16FFK.WE(ZDXP
MO:_0J^1Y1.N]24\E(3:Q06\)8K$4.TE^$NWW?F6]\O>W0V6511.5&);5LMPW
M1Y8(-T?DYJ..A2C:M\R8(WHUJX,T\ "CEF07JB&W57-JM!N7^3Z8T4'SH:%N
M%7OF2V8XUQ>!F.V:P&&;0LV0]"@UN&W\E=%I#GEMSNBEU:JL458X<@3!XE7-
MK.1D:2'0F2F.:JN[FIJ"8"OXW^77ZVH<\'T$B[67+-/X5CU#^ZQ.MTR6K4UX
M-DEVNH5Q9S[L^$I5X@KX42X$6^/I;(MZ7-U*/OH%61:!.#=J;181S?%9BN._
M+7EZDV/(/!9"I$^OI1TVLX"++4RU.+K4S!<K38[VF-\W6^L*D:=/;Q7>HG/O
M00GH0>O$A-]RS  /P'@ O;F<(Y"BE=/<S.\<S/CF2R+3(T=+"XVK31/J\?P
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MJ07DX)]7K,H]AOK*$N &*F#<@4  N4OVYBEL>\=A%51VKY@$P$1N$*H'=4B
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M4C>V$W[V"A8_!#.UZ?Y8BT4M^@MW@@&7^-TD+48<06K?!(N2X!29WWQIG#_
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M4PI GLMKP#%VH8\N (98-DJU(04S Y(+0,V(G%AA?KF#?TK.-U=7\=D!%V6
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MG!2:+:W6(=Y2C$I8,(6*:]VLZ:,B"5?PR#YN3GFBJC#0&[>/B0A7X+/G+R>
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MV!?FO_OG@IC&]?QD\5?_H]ZI^P+@,!PMBPCSDA?^KD#MPRJ-MUY\\R7QY@5
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M.Y5?.N:9?-Q<\YUH_-E/@%#%JNGR 3>G#XN=62TJ^9+1E\HOP^3@3/*PP2+
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M\P4^+<*9J(C>.I@45^]9))^PP+)TDB8H0=BV^3'JB!@%Z6J"1'[_1LEG]0O
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M>+/93\KU:U=@.TE;8B\W9)?)&K^SI)9(. 1E^\/>>2N/G0M#15IOM2:;D%T
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M@L3I\P:BT7]EKZY'5*7^4V91XG^ =-Z/_S!!_4V&@E>24+Y8;GL U1H-8MS
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M_';?,+L6#D.E%0U2FH<R8+A"C?+3^#MU80%M/N8[W2V9F*5P$02MM8=/=W0
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MD818G8%+\)K0?U=R$965G*:30O1E>7DQE7'?PJ=*E'23\J.+^68&A ;MHX+
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MU%8@\#HG?V,6[>3R<CO*S]G4T1G_>#NI(;?6D+Q3@-KZ0SG *#*X_I\OOIO
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MV_:N?&NH9)]IIA,!JM&08^)P,^C:E-?.RPXC_/O6D23HJD9@NJ82N=&3/Z2
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MX*;>QR>R3"'U:4J=B%-)YW+19[2].(!!ZS2Z\I);B17FA< !0G2%+JB_["N
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M34)($=F:\(S3=>I5A*K5./@V)(FI%DI(GU&N\6/NP'UYA7  ?,^BO=)^*NS
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MR?KR+U&<8NFBEZH"?AP(YSIA)*;QM5NW=R:^]^ETJ_40(X*4[GBQG#+;L19
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M&'??&(KN:"__Z>!+6*G74@(<HJM+_6AK915LN#B%9?]2=_<3GT/_';%^$".
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M'+J>7.%PP-=*%YQ?&>+<WGP'SCRSAD.XIL\1L^2:DVS8QYL)#B!@%&MW,<G
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MTU)])#:73Z4=D;OZ$DS;380+A.\<[_)VOGX^D*QPJ;E;M WJZW&T>/8ZATZ
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M<(TBU2IHCZMJ_!IIL>CT6(WZ\L3'7AXE*=&D@?-P[7,367)FGWIQF+O'4RE
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MOV0ZF]0Y28TXSE/5(%C->5U-J=Q>KFU-]JU(!RT*9X\S,;EP'*?(),7&.D1
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M@F#$(\"<9W)^5]Z.1+&>_[R,A5XF_SJMV@IT>,XAK)A??0[]_+.6XW,\T2/
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M:P0]/JB^BEV-[F:3D<'\I@]&6=2P_JQZ;% MQ.UY"TUXERERT-I@1\UZLFQ
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M!SVJ-AT[?(3T?!"S](J_TG%>I7YF%9;BX;+&-\O%++(%*9W+62TUQ"&[DFX
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MX!IA,#:+?)62L!26P'\*IFQO3]\7$C&&#8\O*SO@1PR))4?R4%G-IHLL:)+
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M4;TKZ]QM@EL<1^IDF]BI%$ /=W)R<.;SPK( 7C8.AS[=M6E20D$';L&X_]I
M98P/UML$+&+HW--8&6'X6&C5_]1P<[W&J)HXX?3(AA]KF4/1[8>/,IQNV@WH
M?QTSK 2,*]3BRRV^W^,)=.34E)H(&P#G!PBI30HYK?A[H(0(CKZUX6D\PS0)
M*9N)W67^$/JL#$K"CQ>) DFL9M?N)Y!.E:SX68)IY +4GU8Y8E_I.E:A,\R,
M-4&V:K%)U+29 "@WTP:!^'3$\%7O\]7(:*LLK0L?Z'0/3;/UU X[[69<;3E]
M(VKUI]!G\J$/EYZSG-]'LTS_# 36#\_+SLCP=^7/:C]F!' ()G>=]; 6//Z
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M#/T]*OU+*MC\=;CL%"HD_Q^A@L4_4^$IA0I2_QM40/TG%:Z@RWR7_SHTHT"
M"Q60B. %\9X 7/YHX N:4D&@=9DLXX-;+MR[%IQ]M(1K=A$81PAT("]^&2>K
MPTP'KQ! M?DSJ%SH2Q[G_D>H]0S6!:&W'R$91"2D0+SV!! ._]T)Z-^'+-J#
MZL^6G=F1[!A/H]@D"]X>] _71?[:KX?^&F"[__O>"KNFF[AF[?MG*U[X U!_
MMN)O)ES[P^JA7!'R2_#J&?_:EA@'<B%'RT[J;.D_S:]7]L5 EDF2Y$BMA7^
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M]/&UV"D.DXX?Y]=Z7J,E/&\ \SE$XM_8[5=\A5,$%A DXIS]>1>55;@@GDJ
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M9\!-V$:QN7*;:?W B*;G/'NK$H"^RD/K+ !6@MLDBK0$[[I/8C2(&A^=%;.
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ML!!^OP<+"\/*>I*MV.)G)=3';A&'+JZA H *#) ^HV\X+_</XAA84E!Q.SU
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M\R]T?8'_$F2Y>K.,R3RSDH[FZTFD$P'\YQ)T9$PXCD6) FR]O#* )P8>?L&
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M_%<%E-PMD(K$DN=%ZJ_-V<9C"Q6>7KZ*P=D3M3%\3WIF9YL;-N$2[.H)U9W
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M$OJ0Z>&DA_M>04-M8\Z8711D3!00'W+O,XM(?0/W6+,"V/#'2,U A9I^4^R
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M[!X<>N%3HT:AMOVZM8W6?VCX!/)]P^K:1=H:GBDG78(P4E1Z4BS-E[.@7<P
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M@][]2Y)GEX#W_T*S>'TGB-,WNL/,*8B]K0&U5/%#J^9[<W'D2?*],YN?8@R
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M>46.HSZ4S2CMHB1:LG2"3\%01-587PFH#UVITJ;]8!B%,")D&*782HHS\M=
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MCYMM5;DY/I:9XX8#,KJCM^U![(3TG=]9H]4_DC7$.XS#@C/ZN \+6CD*(DZ
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M!>G@&""-L*FTTII@T&SK."M22Q@AQ2-]2$)(/W5^N^HJ\OM<\\6=_HULZGP
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M7;^7*XI#Y%-MORGDI53W:,ZGF&P@?@V*E7B[FLR\S0S:SSJVDRQ0X<JT]G
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M/E&H&?OQ"X3^V'7\X\S] ZK?&KM6'K?Z6E0P0A+;YXP]19QUW'=G!RX&3)+
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M#]S*G9@9FNV^NL,U2.PQ)ZQR+:(#EK2GB2CIT?5-E[5&X/1^U_KSBS02S[Z
MEE3^O:W*/0M&O[G^(0)3"7WTN$YIT!20\BC@->NB=OCIZW0E-$]LYOK&-&F;
M5]CIQ6(BB3&6P>\#SA)-LAS)^C?('M+K_]\#]N4OP-_D7R"8\R?+6B5A;W!3
M*87SZ(6MH&MQ@7)WW#>"/>W$%&#+YHYQ:I+'%[!A?--@R$D!X4-))O 5CER:
MVW,?Z._ ^.)-QLAA6;- ]4+*^ 'J2 :OB3.;A8PH0Y<68X2;(;B,3K/?B<.M
M^[J??WB&)CR;UEC_N7OAF-^'8%XDZ"WM1WO)*S[7,I\N^2ZTNN#^Z!TSQ>(U
ME"CQR;R%!DY/:[PLT>9<:/+/EZ%]VC"]+1WWMCJ>2B$0/=K!H/? <JOQJP,
M42@:W&W=ZBXP'O8(KPFR2Y.+?=M 0CA?Q$H0M_5FUKN8Y<)SW8HL' 4>7P+2
M/ 34MRI%']P4Y?TH,-OC ;[E*:,@B3OM\G]?4S?SIF9\*48IQDF>4@WU"*5C
M)>G@,?&UJ0J5S:7IAOC/NLXV3O\]!L--E<?_ 9PD2@[X5F'V@V$T>-Y(F$F.
M_;ZPM] JYH&35SM/:G1BY8N&)ULS* ,KYH*@63!5-7&]%L3/?)V.=JJV<NC.
MN5SA-9/WRT@T_7)=C(A0J02"W;XNI>YFH[Q1LQ(?]I$S[WVB\5BF,<U!"(3[
M"2J7UWX@<#W30#ON5;*DIY?GVR^#[M0G$CM3E)C_UFKY/XJL+Q%3Y9OX>N5@
MI/<2,',),,8EM\"Q(^&IGB:++NL07#2M<H&(7Q:PZ\EVG]4<+LBG 3<?$7?4
M<.QZDY7SEZWY+M/V:G/Y%R\UW1S_.^@V+?4C)#UA@"CB +[M!2%H*LCZDV_A
M,9Q#):9EAE@*=EY$-L6XS$C9A^N!7.8_1F@F;(_(=2 [\8%"ZW?H?Y[1' BP
M<-AEB"FA29+I8.DQEEJG0@RV('O_+A",SR1&HLF,/Y2;K"N!C)O4-I4-,EO=
M=#>6OOC3Y1B_6*2VG=B=.NU*34-$.CU:?5R7I#1[@?TC>B1Y+@R4SC?DJ[OP
MSTAY5^_](7'%A$3&]B(E;D++S!1C+U9D)!/=EIDH1'7%TV/ G2WRACCOXESL
M;JKS<*L&8.#.^J9I@H,[17ALRL7JPQ;)F- :[8-+0%7QR[^';807+M(>@KXG
M(X17>(+NH[/<^)P3@T^6J!.%L3<E8D_!\\^AO\:"[A&B7W^A/AJXKQRR9A&T
M^R$@YOB<YKOU T8_<=\W A.CW,/9XX;4)SF.T1N4XI:NP4',6^E2C097602-
MVI/W5,Y,V@;!D=CQJ18NO8CTNP17EQ2RQ-1;']X;MJ&D=6(FU9_U:VZ?""B_
MI8P(L@*!4(MW2)8&T@5Q70*8LA7>BB#OV3]XBR#H[Q$7YMU%K9A$9,-DZJA<
MP0>*.\ST#<,!*C[3J]6EPL3N5 1) !SV!5@C?,\$_T^(BRH,/ZP,+&C;Y>N&
MI&<XD?@(D&S8?9P.(OQ(_?GL;.S8GV>'PH_!02:*TQGC%+\*6]E@HKA+0"?D
M!IH0T.4M8/>>>DC>0W!_08,=* Z$M+\!"!3=C"*A6&.3^:T@W\_3;UZG%81=
M NYW7 )HC+*2F[O&:<X@)SMCUN0!G$N)^5V5@A\6\,HN/S!A-=# ZB;1P?YF
M,8FYOOE.<PJ;\X3T'4;6V>3IWX'!%<7150V;[RM7>SJDH9NG&Q[2+ZG>O5KA
M4GD_KS%5!>,NXBE<YN3:DK(UKHEA<FDPJ";_FHS^+$=$;1!\#U4D@EB_6Z4_
MS)5U^4'Z?:$4,;/.F]?+>X#,L'LS)@OTX67<#7HZ&9Z8.:_SY='[Z8\QI+XH
M/&4[IK5+.-K B2#H^34G_F;@5I2RH7J''R_CN"]\>76MO-@CR*RS^[ NIY+^
M+;JQXO66C(H_PFI>N]R7;7K +'6\33D^3E8X;8HZW5M%<(@M^3Y=#J9PV(U#
ME-4FWCK&RUOF:DOPMFX%;O@X=*J_W R[4U6);1@4OX?Z&1S8XXN(5:#'Z&@9
M-TQX?<LL'T]U+N0L^5BX'5+-=8-3 _FS:ST1:3G^TU#/>OM]UT2VAJX16RTY
M77U@,F>RV7)9,;"95<*Y;'/MQEWT\RR-)=NW$O&4"M]PH3A?)VP4MAF("UK4
M:F(K:W*[*"U./J1;XY%T:1A8_>:?+O!WU\GY:/J%,3X2I7">4;BOP>W6$P"9
M&2TUF.P!P86C5]Z3JXPZW@;E)O7-J.P_Q@]-'EFI[Y:01;>GY.A//,0L==AV
MP@]L>50@RA<810W2=OB$U\U8S<T]X?6 'Q&R#H]DP1=O=V0*;!**M1[[S?C<
M?"]KZ8<IK[[[LW'?56M']7W/]S_.$>',S);U:GFHXUK, *_9AN>M#W-J)Z89
M8D_.6(ZYQ[<ML@<,2L?-^RNYG;UD*5LSN\]8^]*E%)G_K"79GA7SC.@S)U?\
MSM^G4\O<XQ\<'FO(OY=!S\MJFEH^/)[ZMR:#5H".C_^B.4V@%\DYTC!4Y(AP
MN_A,LKP$4+?U(.[Y2CDP"M8,N15-]\ZVH?+O%IT0<RK.:8A^_B9K=)\QMCA@
MM^LUWQHV+X3>!#9\>V?%!>JG.Z7-U?"(Y@*T"4FQDPA,YTX+S#[AR$-69PZ>
MW[2Z1W2P;,EO#]3Y@O6:KY2N%^E'>B%3X"XW-XX%P-=]+84Y= JVE'+K8NZ:
M"=_SEE].;>;>=N]OL.:;S6Z;+]Q=I/1DQ+5U9M!L1JTIW0J%B.[7N_R3\N)J
M1CV-\43UL9T=:UO?W;?JC#\*:3*50"0C-!U-E1>_IFMQO8$*0\Q_2?]L@$2E
MOF\MQ:%ZC%,,;CBOC M+/]B/G$9,T&P5 WOE8&ADJ->0@->BFX>U@BBR6,()
M0!I^Y9E@HV,E!.0)ZBZ!G,#'#MR#YGTRB#O&?;N6!9+(]EWWSB=H\UC;UQ(%
MC/#UG,I;^8>0J?I+P+3':S"NU,OUEFXQXUY$H0;#YZ8U^3-KQ+-VY+(E?%<[
MH0LW.&*HY2<L=!3KHS>QUZW5D$R=.U0KC^4^1/XJ2$$)$M-I@<2'T(JC_;"C
MT1Q?.\V*.X)7%\:>-%>SW*P!< /-<,CK.I> &WV[:=A ?:N+K/'.5*'6>*>*
M?Q$7=_W.<@GPLP3?FMSS]XDZ*C7INDV(FCIAK79P#IJN<YS1$W#!S!Q1@)-\
M4W8@M.=]GTAZ6//"T!0K0?SUA:S!BETC(U<^[_3E8,I+P">3^)N]C#RGL_N*
MIFC#_.NUEP"W(TD&0Y,'T_^MW.&K"\-_> C_.Q]!!?  F=3FX&PVKGR1V<JU
MA0YKKZOXZ\EI;B;8=5^#IJPKCE2.+#+?0_5"6&'BKD3UH#%$=O^XN:]KA]2[
M6</Z"/>:N7&Q)K.0F"L?<]+=<\Y-O&FDBWTJ=2\!\1VQB:]VZIQ?;UX";'68
M]C4(TCES6Y1*!="[(R66W&7S"2,/;%F.]A1C_19W/Q6H^&'@87+7^!XU1F^[
M+43&:_P.&*7'9HRU?@VFWG7&!+-,/7FGQ.&&I"D" .C?4 JL+48:FS!= FI/
M.Z,+(;_K&F=6'H ]'/O9@;'^K]X/FQG)\UP"*$9*N30-\N=S"1F>M"\+0TKE
M2V%G^]'_76"A?8[0YK,;J8<9,1"N9E$<1#OVV#3]]'5CY_2&]^N H5I>P$-O
M5C)W.U*1T$74WVJCA^F4;OB;A/XI=7.,-S>KTJG):?P:M,\7]V[$D,Y7X16<
M$D0QDK/UDM#7FR*  4>R1?O5F7WMXG/>I*7(>GC4?PDXW@TYD8ES:'!@MFU<
MK$CFE]RH[U S%<@[J?/X5C]&?@IS'U[_7%/8RDZPTCOVIXSJALBY]!_F;<5^
M(LEP9U(6F,%NXI@_T?^ _E(*"*PN26F,EQ8;2DP8:5H5#/P@L*6HIO+:$V4C
MZV6Q1-<ZN01DD%0_>F37XN%4FI9Y7E?.>-Q@D6D&^V*LUF.7]#@D]\_>HD=\
M\JQRW5S\1J.%VR7 RPE#<0E0*E&T[@31XFD%*#.7TX1??]V[*G.-%[3Z5 ]K
MD9>+OSLHBTAA&$>>?KQ)VJH&WQ9TD8JPJW/W5Y<A]02.3# BK0]9UHWV]KRX
MV!-[X=2V<?"(]"?I1-V8LDL +2'856Y!A87=^LLA:^\'2L I,B^(DCR*IN]5
MMQE?X/D+@]A3M_YUF3VM2)*QC?GI]WF1&_5%8&442:GTR+TX<T4LM1//-E)H
M90:54QPY@41+H.Y..XJF(>OA%%Q;_AZD*HCT-YN*4N8GQ5KG<T3!XL]"CV\T
M91\AHPP@?/-!D_M8D>!SV+E%O@H^K6=FO(;:=_'=Z!._57VEZ^KH*]P(\8D[
M5E@<V 0EN1B&ILO&L"K,JV[=>Y+TD0Z7S,,#<VO.&YONDUTR63TH9<'DAL(9
MO.RV*[+YWEI'0VC3XA<,-%+--I[^#[-,H!ZZ61_Y(9NUC34Q4R93?Q?0VE)#
MKFXL"=(05<.G:E/-S#V7@ J]X!JM!B_@C?DM*\#DXMIAM2GBRTB3]WI8'/M?
MVH^* AN: F9>108^(15)FOI%I9(>*\YZ2R)]P)O*7A>QF$"*7J9-GHV7AG70
M@ 838FXXM]D?."7)^0<E=MDJQ(U'UAN5M8Z;[0E,THXGU3SZ&:@KT"J;]+Y1
M[_Q YGW*6(!4&U(<FXQ#]+E65AMGW/*4YU40S)BMJ$0VZ%-"C4=.[ A-F)X7
M>"#BJ(UVIID79L59*2*U1J84<^L#BZ7^;Y1]9U23WYMM%!65$E!Z50&1WD5J
M!*0+"$AO(B E5.D0$@7I3;J $)%>0@\U@!0I(M)!0@F]EX0:((3+;]:ZL^Z]
M,_.?N1_R,6N].>^3Y]G[G'WV/OL=A-$PU?L-EBMKM5ISC[-2=_,]N 3PL8EA
MEXY?XH.PF_A-^-2!7[SYVSOC$AORD\(_+.G=?P#*56_$'%6\H]$UOU\L'7?@
M:Q\D[5Z N&DK\(]+][_)MCS;J%!/6T6P*BW?9:H%+I+KSC]?[WS_65@._+T
MWJ*@F_0I.;=)_B9>K.2EK*1O[FQXU(%FHX,E#ZG(\@6FZ&&-1>S1MF'=OI98
MV:MO_3(L +X4_$+^#(01OU%B;FKV9.0(WSIZV^Z1<!=AGFT9]!N&H5W+F(S8
M0_9)6OPV)MGO;N,5&C+::*0%E5M/M%&&K\QXTX;\MO"K\*G6LVR!KAKCXJ.
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MYJFYO&])_,+))2"@YDA+;^GUVW<N56L1:;M$>60FM[Z5;NKR_56#*C<7O4N
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M MI4$W8VIR;X,,Z/TZ*"IH31.( J(.JT8K%G6_>[7ZIZ!8'K?1/%EEU&M[*
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M-H0-RH9_ Y&9/#3C @>Q=Z'+G--\)K:(9;)0$[V_1"RT)> 5QU><_8[+TB4
M??\'B 1"/^^B#+FSY!;1ZNG4E-&]/I%@5L/7YSK5:^1@Q]%X[3F'A\1OXA0[
M!9&/^ M.Z=5BUFG%+&N$\+.\!.C7U[6&&#:Q@Z/VO!)5L$U/NIR57*T,]#2]
MV*;/#2'T$[ %,X(H#H*A/@3=(1ABG;'M+HN:O8F=.FV-*<\3)3L2[M6Q? QN
MX+_=:0LI/K?&;RVZ=0M1X'5>XJQB4*3>'D\1;HX%?J ?3?'3&<2%:#X+[?G/
MF>^COGUE%Y\G9[H%K744%4?;?8W[F96C^#L@\;6G>IFC3]-JBG\!1K&>SNAS
M"PK;\ OEFF^B4W4CRB>-6:$ W;7D''F73RCG[K52 >6=DL>3P_"ODI9L*+Q+
M!;B- JDX(!_/H9,_^.#![-]&_IAG@)0_E-)>Q/OFE/4/P]X-5DB<A.](8KF(
M?'Y0C,E0WCE[[*&$HU?_A^<F'U<0RZ3!96(QA]Q#7PFJWM?QA5H-36&WD&/;
M4SGCXHW7[IO\*J1HU)$1&SI>#[H$F/1Z.A@&A^I$LD=Y&"K)VQLF-LEVFG]J
M%\F6/74[:8F_!%C6T&&/G;8$7=3F8IJ3L0KKX.PQ@H0LLVW]:<(I]5J"E>M6
MNWA%X^G*70DITT2\1AC^;-S?[<Z@A*%MXF/T9F\0P]M2]8>OU)^1?!WUU-2O
MH\GGMM7T< \\*A]<B/^Q1P]YTW )B*2#1]]TJ7:2%%CY\<F;N:GJ&'"^V!)R
M['B1:(L/96V+E+6@J3MCICIN@CTY 5^L[18%2</S@RYR\(H8K='<NNJZL!$T
M%QF+R),7KVX! (%&':OI9]]GI9E/0.J_GMFCE0VZ+GIZYA@NHF0%%IHEW*BM
MYOR"M]P&6%Q=ONE_75',PJ0_:FH@D,WOD9G?\<*0._IXWIQ>Y:K>XY@YJ;#%
MI9T)?2E[FK)$BO1+BSSB"LW*&J<.2'UVO=%=%C\8X+KJ7R>8;;&K&QN#@'4Z
M(K; @868C0!QN'4B(]VRN/5?EN[.MT_=H5\#)E@G.]AO;M(9;G%EHC<]E)!(
MK:<+"ZFJ'/S;*I('B9+ CMS628$\.SM4/8B'5.S:9(LF6QFYD\UGZ:5KR<M,
M/<#.0^&_9_C>GKEB,*$-H8;H9HC1)@&&?&U!N_QS^JB4A\7\9(\"D7)B*+]C
M:&3YRS3_;E+4Z'^4.D\\A'BT+['<' B2P<8O685"Q==!:'F6-A/;&"#2\0"2
M]K0,%O9B4^J&K;N[?T5\FJ6?V4/<C"'70'=.#CX1TPTE;]#B_GFLM/JCBRG&
MPO1.LKOGW[.EOW'./II,D;\2:]O$)ON?1>THYC:!5,04,W![-XC#:,G8UCN;
M\K)AP*H9QRI9WPSG'@$*] >Z>ZK/['FO]3S\N-@X.!7>+2^$>U>_J%^^F>24
MJMM#'O,NYF;82K^8*IO\YJ>I_</E@ S"7-VC9Y"7[C66A J\+T@O-SR5@X+?
MG+V1&2H7G^.IJ:6O::$J7/M_&H&IC>E)BE_3,1I'B,N);NFV9@F4[=@XVJ4J
MTO!^3%27.)U>PM!NP6HQ/\_]Q-=7C%TYSP6SG-_WN]T&B9?)V._=/Z1=A]?1
M]]CA'N=P!XN;1>2-"+ \S?%DMA](USE#'79DMQ;&=1E](W:WW9SN9"+#]QC5
MB6PV);K4Q-FBL5<T+S [].R0Y6W1N2PK5_("FW3)Q7)MU(4.!"L4LHTB66 5
M4A@=$D#&/'K@WP]?M,E>7B9*H'B$'9\7RTOK>28EU[\=5J:Y]R_OPU ,H(P\
MQ,6ZDCHP 5(THO B"9YG%5D@%QBZ"_H+2C(BH2GPE,+-<EPHE<Q"?B$J]T6;
M^&^-K\73'=DJ:@. (%)[:[?"GA7T]$\7:IFHCH^W@MQO:K+PD#M%1$7D7GO]
M!MA1"67WPVCC$^:#R'Y*ORA]FEDZU>-/(@C=*GJV3!G.4>A46@0QQ<HG%9AN
M2A+%L!>I<&_.S^V^'B4*+/JR]O=XI2!B//,?WLL,D6H>&T-JXW_%V]K26(3<
M57U).;8G<"/L>2GJ YE-XBUW,3S\3P,LNHT1)8EU6RC(77)QVN41;W:X4<DO
M]GBKVWI?E9J;W*Q.K%O'Z2=VK\=%<C&\G;F-Q>_6ULO6-F*O).ZO$WU"4>V7
MSE5^23NSDQ<P.K4>)" @HR-8Y?.C2 : %<MGL8_P+J+7;5V+KX_"G5W?2#W;
M2#(WZ@0R.9FV=6@!NXCB0?0:;7 =S>E3K^GQ))UHOH;JE\;%+SV;/=C6$,;U
M^+YY,L13+15V%KRKB[Q4XNQN[O@.FBNE_4EHY[P(8-Z>^]8':3#B\9]]VXS%
M/W/^GP'5FO=J!"G]. /&(SE,Z"E+.A]6=LJ&?(8V HBT:8M"].N6P%&C5Y-(
M!$BITIX:,9'OS8I2CN!\8O_ ]H/?H(W>NCSG",0@_V?Q>E-^=E7!+[6X_8X%
M[E"LVC,O3A8J5<NQ:SEUB<]2&88Y#%Z\HC50 9!4TO[>9*>5I<W;<'?RG1,:
M<JZ=6O%[A&H8FX]CY%14^M[H3*='^5R*H3RLYQ5RG!^QQU_^"%73$&L7MCC;
MV<,K_*NZ<C[X]H.XQF^WMP\S!>2R$,X[.]'D(F%<BM &6M?4_W\+X'\$O@ )
M'/?V>:DCG.02 ':+9+LS_GI#>&NT=..Z$9L9Q0"G35SH./Z/_*[T8BMZL=7P
MBI]\\&/6;,+;@9>,5Z-?XIZ&^P*GA(;KM![5L,_R46J2A%MIY47MM2-YI$71
M 9 S%H:NI9NF,IU6!_+% ](-@R%$[B9<?0?F#OBDMVIN4]JNY?>OQN[5YSK_
MB[+WC&JRB]9%HR H" B(=()2%1!!>HNH] ^0+C4B4D.1WD(0D-X$!!2$B'01
M(M)KZ$&07D(O07I+*"&0$"[?/O>,T^XX^^X?<XSWWUKC76O.^3QSS6(3A+8_
MKF!7NV2%T:[V RP"XR*K8(*P1_RB#D&G,,!EQH$UEW?<4";,R#/C.MF!8DX^
MKO4[(@$)2731N40IT4NYX2.(Z5T/MWT*NPQ)ZP<_5:9B8+[S8<G2/D3K\UX,
M2B<CPGJG]7!K,9K,":8.X.R<8>ISM);LH%6]RR;^ZU%3S$FWC]2G;_5OYG*F
M9]E*"EF&)6Q8B,X!/$!.V!",_R$?JX(VG1Z[N9=1OWQ(Z_NBU7_;%C4>6IGU
M(!FL"57+# G5D%M1!T3MAG!&/EM_J3<W<R=J;GB9)#1)V=LH'17R;'XYV:G"
MZ"#OP(9:J<81<>=Y/RB%G-IFF:MU"+NJ-N5@65B;RKULF_-<4;?5V;I_D/6_
M8AA.UVCJAU;XS$8%<P65THN!,GH<5D>VXOP"T+P+P#7>,7=W&-7T?)?^]*XO
M_V- 0.=]DR&,6H@M6 4V/Z/4B-J91<2$V7HHM_SYQ-[!_R[-XM5J?VS$(1\[
MCZL2.F4'1!_Z%QX )K?[(<\$('EV[8C'YUE054],\KO++58@T0-%ZIQDBH_
M;W%'?>LE#0[HSR-Z5L/Q!QJI$'BU3<02,N8DEPFG()/1RY<Z:V#53)\DF4?H
MX\+-A8B,'YT_G36MBMOK6Q-I,L_T\6Y;'D&5V+:S' SM]B\+!D 5,2_3I]1M
M>KR^NKY8E&0*^OLE#*P40(U!Q*FPSY_.4)6*50O4:3FL0YF.B+T!@U22CYYL
MVG0KM<IE,99J31_;./HX'?;@0+I5,TG>8$6H^'FE$@CC(8CJ-A"/KA&\"QLN
MJ"E(1,%*AQQZVU;+-A0M>\7+5^IKLQ1C^%_\%OV'_27/>\9QLQ331&WQC&^5
M[_.$FZ3TU02=?L3\SV6\E/GNU\1N X9;-L?_[4-E^.**.F0]-!%>BXI482)L
M$%C_&9:^ / 0UGN)SYQ:N:H??S*KX+?ME5M?-45!'1 $5GP?%A2OPDGH[ G*
M*:I:V@9='\+K.@QUW8&I#33/LG397A&(O0G@X@FB 9Q\&37[S<% NAW==M(X
MF=IX 7@/!2\MWMSV*K#0CSUND>VK;!!5P;F2RGI//_YL_]WVN\(,'S51P7^I
ME<FPP0SL0I\K_UA%T2W4_8-/Z?6G/^GIGW 1:0!GVQBA3A#MI3/XTPK$144[
M8NCN:3"=9^ ?;?T"/.UMF7AG%\65@/X"%3Z/A]&1[N"N;N>R8*W+:RNB?60S
M4W_[\U-3.O")R&:\[;+WM(%@'6V2=<^KD<YNSTQ:G:K/0?^,"F:8_Q7@C>7[
M4HEZ=9L95:AA?WDYA;%N8S(_+UG#)S+P!J50#WSZV@Y+\Z+8Y[A4RE<7@%O\
M^-E<88KM80G5(E5)JTZND9R1WKR)RH1PR0?: +> 4)3^=-$8AF61)&##V@"F
MASZIL6HOX3T?6 "MIG>LK!G*#=[@68D[X?@+$PTH,\3JO_.U=M0<&RP.=8]?
M[6#\\G"-YLV#YE]?!6*XG^:F&R!$I;>Z9[KZWGO>*10(AL/)HL-ZF>4R:9C%
MFPL!X.ZX=;?R OL=:6E*;\H6UBC*P\C](1;J^&;6X@6IM "'SI<!NX5W1CO?
MWGG+Z;Y3]I6Z$6NV*+W="B3XXZ@QQ^,+? >AU14T,1> &M]-C@E[<$OMPJ-H
M5^AZ).V0T8"G@O_[XUT=C$U.T0PA8[TM$\TJ5CS_(^,"X!1C+=PATOV!,_3*
M2_P;93HOVX!.H-)HXC_/K82E1I%F(ZTH]<?A!Q/I9L6JI1AFW=EO.TVGN?*^
MWPYP_0S*[.:A3T4*" Q8AT7,>A>R:L EOS-+PMR7*F'WL #DQ974E13TEBX8
MD=A\!5>\G!SA.^]O6(]U0!1MRAS,M8S=2%W3'&;^$/8T"N5ZO&_MN-.?QT!)
M>C@FT#3C:VV58XBWBFC5TEORHM8M#-C10DQL.XQU#;ND'0R3\FE31MLQM[>.
MT$8;8(;-1U.SG;<E1 W4\QAOVYH\:0/XL96O/)CMTN*C6*C7)(&Y7&!O1;)Q
MU%WU-5KN/F6!/X=?#6UY3P73'^,,VR?+1*I#T@:$C1*_'3.C6@7#=]>2%MC^
M"O$.]E\ OEX $J&)N&=Z<-W).N6NS%M_:-5'F339B44M1--QI0&4;X!9][R%
M8AD1HCEMGG>M &4B])54MN]EH??QHREJU4K50GI?J&'MH*[V0>,6LWDO#[N%
M+/?X>!KPXZ3NWR9OL%O?9QQCRJ0S3%KV)F_S@U\^YM176ENCJI,J[#[<TI1?
MHB\X,TN;MW8;DJ[Z&A"GE2\\RBQEQYF=:E:W8I6^H9->+Z:7Q62\I6[H9ZW_
MLA'[5X6E.=I:]\U40'"7S M=?Q?^F<Q, PGZBD\7@ POQ_'4*P-!_AW )'WL
M?$W,CJ@85,.Q1)=[#,4]%17P\EY/ &\4I7";8N"0]&%%J:=,P[+B_-VU5!T'
M.BE/1T7[ME7OX9RO7+X LP70-3'H8]SA4O)[7\2MC49835!MJ$,NI.SYS:KB
MO;59%% R5RU4:7U.-BD_*3"U*WC_>?DWZ^0M&VZ,%3W?PR0K+!DST;2UZ#W:
MRD/8ZL1H1"ZAI:8J>&LSM.Y)6 N;,X[T/>)E4H@81FO79"\OTCGG,HW:CAY!
MV'QV5;A._? ;+*I"_"OCJ5K*AQ;&FZ7"A;*(%W"1M+<6/I>VL_SZ?R3J/5-W
MLGMRXQB1>P%P0<X H JCEIT*?-0XGKP;B\(@W#JM)_+\<)!ZG&AF27P*]:HE
MR"Z_&KZ^!WT61&-NT=#+\TN.O$4NOMI*/>*#N 5]C2/)Q"LU9C25S;EGK+G6
M@IIWD^+RL8 KW8^W#ES++X$)I&M33_EL]D@Q=+IXJ0M^A^1:9</KP>#L)5JW
M^OO\T/=E&/>088@RY,AT@6UW6?.;6I+<^(-O"=< KP#*(I\(=M@3/0)X:1[T
M9.R)3YU5O\IPN5+TON;4GOYFW-9DQ," -_4G,R\PS8CXO[,"-1+^LWIXB<8P
M</HB)])9/VI!X+Q6^E+]:1>W8/38C$R5L ++3=,4:_?&%.TA.;<E:&'2J+_W
M9MRYUL2/-^/5_?TO*][\R@BP$6AXOXP1+: &O]73&&U&X#W.OTB%3F\O=\$X
MXM;)3+2G[D6MR$EQL1&'IEPST<'YD+>2N@!H(!% <JR=O  X@N-!=$P89XVH
M']*T+?><#P2";]AEOK)KVA>Y^N@KX'H%!*]UGD[F@:J?1_L.<1#RM;.MT"J_
MO]?DS\W]7IUB4^HHND9)*?#A,<\/+>HDD5UQ5MCO&=;85@6AKFPW[1 .S'KG
M"0QXB53YK.LJ_\EF.0$VOG#\NDZQJ "\!),.(2)+R#96@AE]N?_WS3&UP-OH
MT0>H^ZP")[N 6X^ 22W"[-C%J&;: M*_X]N-9PC1W3<\OV\M,).'LS7J,[94
M\:9$LPRJ*YW">E=_\M*G;R.I6ZD)H.6A'5H$H>[)&/\O=+/YDEK#Q!['FOFU
M+KB#7Z_ZZ]+^NGD*1$WP4"=P6K83^>\LMZ;D"-F@R,F:O'DUW]LG7I=;."QP
MG/OZYFI!^&-XX^.L=1@S&24+HB.S$E!M9\E=2$9"F>9D]=JHJ-LQ-16=X!3?
M]^MVOZ_\)*6\\T-0W+YR$#F/((D.727W7 "NUS1X2,&O0K*<FL<K\N&_HTY7
M$FLM]BAM6ZU\A_9[Y+LOD>DU[O/45G8H*T%W>9&9(**APC,.JED:>U-5EY,@
M:U#M/CO/]J7Q4P_;*]*Z_ K/+-$(RDD(QB+PS["P1,P:3FQ'Y28D6%>\*Y>S
M6DO\B)A8(-9Y_]6=>[U-#>0E:CEI7&:\DC+U[LU6%JQCE(H@87;%(_EAC7!1
MTJ%9;1:=[/-*V]K7&SL[0/\,BR?:RT^XC@%X>+)_([J;8=;?%%M;BL4?K@"C
MF^]_G=$I#E"G,W&]5QMH6Y>JDS'?!7^<SAO1R;OQK6EH&KB<W*4?A:P&QGB(
MJK!LP6^2[VQGV<67\UP 7D;A.2T+.%,UM7/:F.O=4#QVWN_^701>F03'1719
M@!.5E#'E1LN+72$*P^;=&&[V7LFBJQB3:SJV.L(/^MZV<;T#3)[G(AVX-9;(
MQ=^WR<*$% PHIO7^>+EIC^6 Q6H78UN%N<D]T2EY9?,D^1Y)KRNX11+S"MZ<
M ,%5+8'C:_8Y-L0J%BNJ_(L['!I3#*]/"L-]7'Y<;7@X;3L0#"<Q95J-2WM,
MPS S^"V=3U)#MZRGS0L24RBOW//D(%*E#()F$"[G6:$.+4)X9T)@*4%'>P+A
M&PS9U5LW"(YOB]M>NV:B6FWW_CGEB;S254 :WO;\BP]R.GIY=SU2*L?T\&5=
MP\1#:9GZ9A,S*MWO)5<3WL:\RUT7>O<$D&Q]N_IC]7_2Q.S_6^;,NB\ U1KX
MXEU&HK83DOI5^@Y)ND ]*Z.4WR-->(8]FYVKQ%YU/'RUI6R7@S"V9%*S'HMT
M3X[+FDT_\/FT5ND:)!5324[A.'H$VU>VJ;0(V@F<&@I.A6LIAS#\]"&R295Q
M0A2=)CDA 9/"*P;OOG\%4"^;>C%HXRX \8O5U^K"CIF7]6DWTP(Z,=Q=MN75
M.BQS/]UY;SRT\N2X&3$DAWKB_=*&D\"YLLAJ_>P'5(>06$;[8\^:N@--U=/'
MSY_&W&B[RH928@R7Y:D9+&GR'IBY  0K<%L'\B(\VDYJTOG[\D48QZ_2BZPX
MI*@\#FU_PG<P.;FNC=6--75EXA[F2M;=5%K\Z'LL&P[C)$"6Y\MF"<&:=6//
MPTR=/]S)<G6DTJ(W'Q+*X#\$2Y#_R Y\)4_".95 @4YVS>,/"\9?IS3&9'@G
MM[_?"*79["!6ELGM9:[G#<0V%VHS;5T ^'84A+\UKXS2O!GAQS8;TO5NF62.
M\UPO'GU!W0.OY-18&DI89(/2B,X,JP5YB*T,]=^^(7)/'//K[IG9M.O34J$P
M,"=):>(-=I]T^S'*E*E[M:+.OE927;+TIJ$[, [8U]J[)8+D+%=3V02U+;4[
MZZ*JG'"(VS TF)8D4&HU9;-=I3Q0W?I/OX>=4EQTPP*S,\54UE0USO]=J#,8
ML)TEDUQA"5'P/:[.J'O4,\ U$L76K^[7F+ 4$?;%%Z$)D;/\(0$G7*_0)BY3
MOQ>'J@%CJ&(]["L*6IW'CT@S<YJ>"5K\]N;C[ZZ8\G/Y5/@^\#/5?0RSR);)
M4O$_CR+I? _0,<45M^_ZK[5@!_IUW>[;'JH/A*O@M@_J*;ZZFJ&MRS >@/=I
M9!H)3,;8I/Y=,2&BK=7NH5+)&3D=/^!C9XB/"_V31OSS2)<HRXJWU,@A#_/0
M7Q*5V67Q&%$#/LBGK[(OV-DBS?E.PU:F.$B+IO1AT4\?@W\8JO_JZ=WB9F.Q
MM_V@N@,Y!&+@D>!V$*.2ZK<<HEC%7->?;%EUE-<'9?F539L* S-,P;F^/YT8
MQJN8#EWH?P&@41$.6&]7*# E,V==GN&@:PY?OS,F&WUB]R$$31UW> & U<R1
MN FE(=CDGELNDVT#]H+W6FK8SH_,=\G#?Y/)+<%L,8>JQ+H#Y?L/G6H@<"A)
M I?1L")&KUCNW8&&L3=.<=IWYO/]33E(V#?JT;1G&S*R_O0C] :A2@?7&N9<
M[H2&^-OZ-*6J;3'XVDZ'+46,UEZA:KT#9AY%18@M9%SBGE+^_R/ 0B=V=^T=
M"$1F(#W!UK7MSZ)7NNNZ:/O!--:$U)</JQ-UC+/[HX)#&F:X2#'T-_H9<]/S
MB,$D=>P0"C&MT7T(E1^WQ;VQ8</1I4P*CJV(W595<7C5=2W];7]?!M<QXF>S
M+S:^'<Q,2B;H- OE!WR8#;_KIMTGG_4H*-*!,KD#$:"_O!^E1/VM-7EYB,$Y
MZ$XZWYU@9961N[%3"4Q]7Z_J>SFQGZ:OE+FQ8OS;0Q1F>T"U@FFARY#C,&:-
MRR.UMJ\/?_(H_J^&T)=L/?7=K\&'-L4XL(XU+9Y\GE&]7*+[/1[,\)MFT0KP
M2^^.XCON=X"K&LHBVSFR> C!*'\[95L&1*\D[OQ=@S=+L<3GD\E(^^#J:8#K
M"1?:LI3 VMF(CJD>@%T GHYY^ X\>E0Y7B%FL"?V[.KUI*>R@JK*U[><*/X"
MKRULU )K&'8]0#'E:TW#?,-2AR6SLR)2J9:GK#RO2PSIM?^^U1CW15"/D8)9
M=]#83#+38M@E'S\*92;<%=(I(;,3OLME':GO1\>:^7]B4[QSE^5*NQL*N;D*
M?W_D!K(9]VVR%NQ9-!^W2Q(9>*KH:[YG^.@YA"\L@^8&@+E'US,#5*7?$2)K
M%6U>0_!8AK@9LC\?L58K:*M(I9KC?MLLH^Y/[T0Q[+,=$6CKI@@H%]5>U5#]
M0/]@0$#L*HWZJB;9I_HC8,+JX4C;CLB0[U!8+A=:Y>YT0(^M)WV>![_W;P_*
ML+OU6:!C0TV)U/ZPX80EBB]FWPS,];X\X"]"N.G>'\^1F>-&Y"V%UE'(G><<
M%YC9FWNXO@XI9E=O2'A$4I7^;>-BL&&*G;:$9N![?_8T;'P'4!Q<;4J>?:;5
M-(%T!#-S:I)Z?D&"3UEY87OLJ9>GBC)&QV_-8">DFL2>BV>(BZW4TY[/;W "
MRT/65*\9THLWG*XS&Z<+#/#T%"XF\<SSAS[>N^_>&MYLTNSL4Y?HS[5[>Z>[
M_SZ*?ZU:>N!E3?,F\DH*,CWPZ=;[E:SS>TE469; V!\]U6O'4T?]R-B9U8Y?
MYW7N&@LOQX%#++W65E(_S#]5R?*GI89L\[JPDQ^8-@\%;2>R&1%,PDT<38A_
M4M?TFB<%\\2IL^H\_>1__]#9#AN2_L41^SE88BZP1"H;G6P:0W'RJUB:Y>]L
ME8E/SV"IQQ N5-M+UJ#9?"N+>\39""F'J$$NP<^J;$BTJ>V9P.F9\O$G9WNA
MCR_Q,"*!S#V=^*PKR%6L6MW![$-#QP[X<^P%X%T$V!76/N-Z!W[%MND]%#U3
M>/1CH<GQ#?!;'&DHMA#HZ"%]!B_#?K$A@_^&L*C=-EO7V Q3N_T14/W1(<T7
MP+(>RM$JY;1(19+Q\-!L'%^_6:O@)</CSSWTC7Z7X'LO;46_IYQS:3%:=W6;
MML74]UZ_KOKINH?1^3CW[&FNR&%9SX+LI,I=0NJ^-=H]<?ZX?;?C.;(C):E/
MD:'T;]H_9ZYPH0P%F\F*C^B5O[%*EI@!?XQ_O/V$M-:;<6G(-*5GU^>.\+<I
MZLB.?"6&KL,L8AW>B<"$O-XL=1+T(<F#V>5!N=?6X[]"!C2YA"U][Z.!M_!?
M\)W%.Y$0QQ4PLZ7'A+V!8([= YQ+=,$/!G,&C[UD&-Q0C-K4]W//M[,,5DV-
M8-^ZC?!T9^';R<G<:H+.3O]9)OF5QU8R-;B5Y;JH8TB.N"DA;#E1W+ F)&UZ
M 7('I\-L)_?&D9*+L;UBO05F"54D>&/%4?!J%&H%E[NB7B=S=LKACZ_]-<E.
M"25ZWG/?W7X"++)AQ65$K(2(NMAP3U:?!^N)&NT&V8]:J=5S,3;<8.=)1]2;
MK8OO#"PC;Q(>DVD8$<X@:B'+Y"C:Y<+@M=%]FX-VA[O::]:#M![S[_2!,B(C
M9O@BPCXNWQ@G=M(N?B7 SX-JHX[YI5I)P+?E46M#C.P#\M-8/AJJZZ?UO2"9
M@*^.,TTEO8CT(^#L88<9N$J]#J=C.E;T<[Q:,:+0A0=HQGD)U:+GP^6O=XJ$
M+,TM>_>HBU"TA;)=4E+=(! =(=F08+;LN>RFM_?8L[#S+78K ^^N+J#R9E:5
M1K6=LW[5["??CA:?UNVR;[_J3&Q3##H=KS7=B;K^[;7\FR>@=&@9CA;_E1"/
MV4_D0'5ZA"UP#?O&(VY^#^UX5A&0^K>PL+J"TU6X9*L[S+#@\/"-6]L<&)N&
M_XV61C"0]$>@H<MR2O*X9\OD=)52__QV+Z7$I[=C"YB>>G7=Y[VJ^HHBCW*O
MC2K$.NLQF!(J>EZ&= $FP^E7<&9A,+8  U>W])74%:-<8VN]5Z1X$\F*JQ'A
MYC&BY5&],](D;Z)9P 5@17;'OSP M8R(S*N<%+,YT<$9RYI%R5<[K=0Y9$#\
M^CSL34TIN4IYW=PU <2(MR3A>3 SN3V4%79W"C:(5K@ =/5S6H9&*]"GHBW,
M8NGZ]8-]*76%LO@3'DM,,3LMZ[$\H?N2<"Z$+SHO4A$*T#<DQ&,O ,O^T<#E
M,V1VT?26=Y.+_^1&]QN?V0<)X0EOC7T[]E&\R8VR!HVMZKCBW0GN]1T_F%0
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MB:'B.B)>7%P(V9BUMQ?XT%W@]<'0XPQ'N_'40/X)H/W'OY)=%JWW+;A9S2X
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M,D^$? ^D=OB(#M099%+[N="\T];6O>E>79C?]V3<L;*N#<HB&_YES;P;VGZ
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M]KZ2!7E:KB"N3!RW/.MBI0K1QD,V7^[-/\X Y-9S4R^)+!\^?-#YJFC3P.H
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MF^]7I.8ZXZTAGL!]X.I0*%]4UT2O80+GR[\.>_Y5!H]8.8PJ=F_YH&@H3.>
M3ELO,KQ2)8&-[6%R3J0G^1RPR(=N7JH#R?M;_1O)48 8@QD.8S3U/_=^6/:R
MISDX9-V#XG*<6L02#H$TCC7=S,]%.GM!QLRV;\JA^RQ48+CI7T:,]3F@)\3E
M'&!Y03+Y[:&17U8)__!J"^G4Y;Q-RX1:#9*610:]OLQNL0K//_YL%@]I'==.
M6<GK16:0<T/O:E8[I3G>_NO16O-L]"DWXFDOW9%>^"'?&-*YNFN14G4FUIW
MHJ]+\5FPMQL6YW8;04IDG09'\CQBD[LA-I=6=PHUZY9E7_[.>BNSG=7W[SE
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M,O$IS0".S^_4A'/6[^!WK;X:0I@4U(BBTY1),(,"O5?YO+]'YY2.A6,JG=]
ML<(:?TI*35C9?7OPT8@L-[K:W^68BJ FME-Z!?$V7<'"N_""<H'<]#D6/9Z_
M [JC&1JMG^HRZK0*"DI2G;#"XR0UA^Z+Z#)8]KJ)&]+Q+)GG?_R3^XUVF&Z$
M?<04?@Z@VX]"82\VW0<($:)%F>V%U"&G\B!D?,[Z#"S4^&>)!X$?&5L6.CBT
ME&U=K'96X!YUE??; <&H@()>J&,,0UX+':8P$^*P;J @,,]F(#)=GA"^9U&]
M_S8%'?1J935&4,&61^XU[0;D$\DFGP :M-AN:<](<GU%T]A(SP36ZG: .Z\A
M!0FM)I%8PV88"92F,B7U\]N<-1I=SI/69'WCU!L!D%@H@R= G),^\$K@,_L8
MKY+4)]HNH;A"@25QE^O[(MWV+HV4#MV+"EB.XQ.H2>Y>+E.LS)XX\OB(R=QA
M)BH)=BG>-,.E]AK40^BW+X>-[6FJ?<G7^_'/]=SF_B% :+1CX- @B'G\",B2
M+2)Z.*,FL)_IR="FRR1S.7F1M7]QG"2_;,5(:.9W8S0;/_+B]2/'K@H(1T8F
M%RUG$8#+=M$DD9$XJSI@IQB3\SN510NSKH'R+4[7=PA[BOIR9^\@"'=7C3:1
M$TI\%7P;%[V3AI=?7$@$W9SN6FS7>XV_Q2FUE^[ =\J9T)98,1W?0/=Z/36H
MO%<%$$(,6-+BTR9:8>HUY6T=(S3#I3H%4TL+0=J_&-\XY7'C+1.6&22M-@)A
M>?"WKQ9 OWS3)3;3%5T6R2Z+"U%(*4B')O+.!D6D(4UWU(WTU,87E+XFKN2_
MQ#Y)@U6?KVSZKM>[PSM93Q0G@#4)7,0@DAG!#WN52PL7TAOG4"&:W8;P'#3@
M.K$^I!ZREE^F5GA-.Z>/B--\%O$_BY[]/\8#(2JG!S*&@@D*;H7!BKBA8Q1\
MOJ]T\[W3A2<&IY9M&><!N+.<GLK?E4YME:H6+:AK3'5:4;^;H*F0RE3QS9<_
M+P(%EAR)9939+5ZR8B?0=ADM,!].(J0/1/-0<@EEG.I?D98\SVA2DLU8&^'^
ME4N,N^-PM4*"Z?QVIQ6]V]IT4)E6E[GMOGO?@JM/O"?=:1(['!YZFW0?M]!Q
M#KC>5>#OHJTI;P<8>+)F%DV]_W/.^!R08ED5X*GC7%*;6M\J!I;XE2DMKM&E
MWC-/)C.*CT+<DJ)OIZIX+-'YBM%82MKE*CRW$T X+X;IV/&Y0$OSX:]'0T7\
MQ;JS7/W.'&(/XUJ?RIJP_94:5HRYTEAOQ;B9M:A4MCF5%5$Z=_LU?VN(5Q.W
M40Q)C4"+T^L,U)IJ+"-)C]5S];]E-IN>,;,/FHF652\T_SL( 5 )AKDDG=PD
MZ&GORX-#&# N>^(H%VT6?S--PLUES=UK1)4XJ[8(>2_%M&?HF\*#$2K\;Y/U
MWD/D=B%OSP$,\ N&<8#2F/*QW32&K0O*'GP92"*%(CT('42Q_YBS=+J$8MG"
MJ,85^@\?#.1-T>M]\L&N]5ZN1SU]3Y<\0GJ1]@-> '[+X+YO2<XAW?8*?/+(
M<,CY*SMY5E?2Z1R06%;]JR:V4U3-=^B,V\?NP9OV(X>!L[R!"YF=&MBAH:GQ
MC%>>J$X9;H'TH1C,*N:DTY?<'B.R+,N**+N)=&I]N"?4LBO6S&--(W_JEDIC
MVBRP'JP;(/$63=CSCA.4=8BJ&M>*#NJ>ZL;[SWQ^7O'HWXWCBNT)W;]+O_)[
MU56< _S#DX4/!!?A73]#GXAU6UC^_7LFQH39BGS=A!M*WY[A49YM;9^05^IW
MK[AQ@Y$6%OC'=[?L%2MO2CVB'4YQ2/L4VMLF>+FRG33RO<V":.XXNEU'"/HA
M=Z,4+]S-M&=B^YN)R]&8.OD F'DG49][$6_B9DM4#WX1Y2%]#N@",[B6?-1_
M[@X+\9$8$$=Q<?MTT%P21B-9-N99QA1HBRYT_,U2,Z<6AF[Z1\P=MS/4P0O[
M;=R1>4HT1C8-37/J2ABFTW:K4Q[GG#7XTQ ,I /$1( (H'>RB4963I3'R#2]
ML3:;2VJW8T0_WTT9B."(('T[C7;QZ=4_D3H)L\&T08]3"3?M\#/8W=[,3VY'
M,U8+FWY_J;_8\\1P[[I';^=-KE[H#X^^H3=:ALM8M>YP@:0$!&3.M/^]YTE*
M&;'HT)XZN6M?#%0_;D:NAC8D]0!C0E%KWKKG@+?0FLS.8TCI*=! 1R-+PM)F
MZ]_PCTN\%Z6(T&-]YM<->R?S5$PH&^?)#I$C"K2BAR&(O@]O(_5K\;>>V-,E
MF\V*)[4L[Z6&] %QG(2\1UTO&ZQ&&!;'3UU#X%>7;*,' ^X?9KFLMRC8:M52
MQB9@C[HKJ9J^VAR\)98WA:?M2%@Y^=MVX/RU.VLVSFSCWAM_(K[ZH:FN)LX\
MNPX=0_(+)ZL^W$!+"6R66X;_"<DGD%T.VI)D"C\W__)I+CILW[4]##ZY#\O^
MJYIK:5R=T;[@O8FB(UV-[J2(->+IMS.-3IX@$@<DG67JRFE20<U%A'J<.YC;
M0@/&H%-5+;*K4)_X@E<'HVF7I#/5!EE,A$&\\6#51)?M\L+[YD5I$@^ZM29N
MFEDABH\F+&4;(^2_%GZLNNFC*4SCVGH$6$2C0X*H](3*36S(PRY2H2TNWLN@
M_*3BG+%O>-YS@,@$;-SBD3\%W-DB%H5'H)@4Y)A-DF8*!!V' 39IYFMRUXZ!
MT_#.I')"18C["[#]^+)00EYM4Z\BKOG,RXKJ,W8UMD^W]/+4.4"@^4S4^U/B
M;3&8KD>AE4P!*(>G;._!I?'*LT<4K_\8S/?2]"5 5>H@<]=D*5?T% %F,"N8
MW38\<8$\*H\WZ;P5_V3G[4^JD%J7#1%K2\C;^039WL8U6N+3M#TZZ=ROQ\,2
M5FP$6ZQ5DH+=DI)-F>-98GJ(]],T8[38LL4G2$+R^OH;V6>RU!R;5D]S1Y@?
M @V[]-9\)5$O6NLV_LK:+'\Z&[Y?^K 4UM(XS9V#SO0VU_ H,257J)\#I@;W
M:]FU"WDO3D?MT\JLXV9))'!TER=?)L/K5=II4 /#N$3U[,&)>ID"HT< ]D^P
MP6*[0>,V+_?$J@9_<$8>!SOBW>&*[>K(.X8W_A%O:L'.9& D088JO9-U-<"@
MH?K,Y3??7W?P\C\#DMY=RK\+0UCKQUL?!ZMXGLBY=4J&-72JL9^ ?[4=><@(
MK;72#U354?_<$QZ!USD$\+]8H4X.40F=48U_H)9Q[2?E?:EIL7/J<?4.V@P5
MF&P1A 8U6A+*V0[FZ[WD6>P/+ )S]"7,$TJS^HDV)1H!>4=IJG@1<^VLP>8O
MWO_D'2AN@USBUR+UH\PU<I;J[(,GQK7R'E[EY/-46/YKZ"NXL[C:GM@B>;I6
M6#^0Q_,:/3CWFPZ8Q#KO5%K*\Q#5]>^<YDZ;ZLT6RUSQ'J]R\T=".Z$&-'_[
M-JC 'P,9^L(%QX.-M3+RT)SWS-_<Y/DABB_'?FE4_C,7.?Y>WJC'WEPK8_4X
M2KR4+_4]*N5X6IM^[6NZAG['V'J\:V[2*\+=;SW>1,U@A7&'^IL-*=^T0QZH
M/$K1O#/'E?;GX!0]WRYOM)Z17>$?K81W^*2@Q]M^#KBZO?7]N7V_"T*!#=^P
M$F.G>",H?-C+LI_X&$/(T^8<"'+,@I+N>9OU'\_D:A0]\ *I=C$E[\W>>/>,
M^@J*M=OK/I=DWT-C@P?PM89/Y+4DAJ5W;?25<9^MSP$99W5;W[PUM4Q] ]6^
M_ ^3U;E_Q^3[]__P?:@]H?_Y-6T/A>["C?AN6UT_;$T0ZP0"@YVP[:(N&2TN
M\EQ!=O$_?UR:36PRX#BNAG>COI/7N\7H"7I=2%E"\Q*<W1$C78TIGH.1/"NV
M7(CMR4,(QG1IT/@Y0,MLU';+5(CZQQ'\ST5%KZ6,6O(0ZK!#EN> #@P2RC*S
MQ<;Y[$7#I(W!M91?19[YS_02OXDI?T/_O-B]"SOK<-(K-$B44-H)O!FLA)LQ
M3>HYR\CVOO^YG%_&*R[BAUS3#[O^%>\19[+$O4JG,XN\-.YR.Z?+69K"6O=F
MNLMX55=SPI[:SAY)4BU975@M6Q0-29#@L 2^.L>5Q-:_E"1!8>$Q,W2==0[J
M8'<%IC\3!/"NH),O6!>GE5DW:H?3([W%^Z#HW^:6@F[RFN8/L#%_51OZ'MSF
MP\^=J!4"4P$$]PONB&"/R5\.1R*INUN2QV%2[+X/I#P>2DB.\7<J2X=,TK(O
M%P<R]NU/KVL13G%YC%3S6VA3$)1A,O='<X-*P-5&ZXY0]Z>]='#3@C"0,Z&<
MR+- J.P;)<QT &\%:^#VNX6+>XI?^9#3E+QO/:.93>I,IN6_X2PB<\P[MD20
MP@MV9)7&UR=XF!/"[V2;XK56=,@%:ES*K/& L,O/GBS 0J14 /Z"O1Y_3KK
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MP:Z3E[(< DTC+P]F[T]O/.C$\#C$M]D4^]-VGF5^DAK(=RAVP@>,#RK)<@
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M^,3DU/3,[-P\#+ZVOK&YM;VSBT0=GYR>G:,O+O_"A0? Q_MOY>_BHKS!=8N
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MQ-6>#R-X)\6OHE)RW?RJ*"_ :]]NQ^#YE8$9+<B>Q""EJ=)A+(AU6=:D6?#
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M1=?-BW=YL];GJOY<!-M-BX<9[B:\T)1^\**$^!/1)/;5='/$%?:5I.,X^)I
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M_/R6A%I7IB?R>=I'AR9%'*#,&[*A\Q.YG,!HP1FO=3T5%;NEL[]^B3<Z9ER
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M-SN>]7(J-'9;TLB4ZI945;VO&?.Q<>TT2]!%&Y42IMYN^+VH;/Z0B9V!:*:
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M5[WJQ10*\2VH6T <JO")$X:#4%NH6<-)T6I%YV#.R^_BH'PMBP"$K-H_6NX
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M3X?"_41A!?PR22UV5>F>Q05+3B,$%YEVH#_5;(2]\2X9I9S#]=&<&N)N*CM
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M.8RD*NX.IL*V0(Z>N9W)QCPGRX79^Z^OZJA"FI,G?@B]I)43$H\5MSV#7!#
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M^ B- Z>6"=AL(]KKW&;75)CE%&\GRQ?RD2_R(!FCS\1PP_DP G '*'3Q5Y]
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M;2/" ,W5H+\MX,"(D:A6+*2@ZB>B/\D<%OOT7H-,G?%^NC+4&&Q07"V*Y!:
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MU[:,:[/Q%9,0^GK+2VG51J#7?1]L]Z&SA%*\ML8\TTRUC^(,.FT?]]&4)EN
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MA"4NI^XFW]%=#H7N(KVT1XHJ/>[)"=(MO0K6-!DR6@F7YA?YV3!@?WWZX<)
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M>__:2B4+?\W0*WT;IW).4?MM<9D+;T?;_-T)_=:/3>.+[[)W["9I3E^L342
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M$FP4Q3E"$2L-3M"^0ELZ8]%YM3+?ZLR7&X"'0M^%_-1>J?#4/K;@N#^QJCV
M5[$H;*MEO_.4< MHNGLVG(@*V3SZEF(1P1YY">"[[Y+,HH8PF(<+W_:1RS+8
M\&;KB.X+D ]J8WZSGNWQ*%BV 6G^;B]H._KQQ/KS\C8T_T)J,Q8+,S497GI
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M'$ZQLXLH686/2MUMP"[R:_FDF%\";EP"AD11$SZ6OK6HL:*%]H4JK%HZH8D
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M <-H$ P7KA;?KE$1MC\J%QREW7$)V- ^X\[B>N!9*\AU>SC\Z\C0*N9>[:Y
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M5F&78-Y2917F_8PV)C,F!AQXF*8@A6.."J CZ<_WL[2%\F*MT)&>B"8W#RK
M)@NB[D)O79)\F'#9*I_A-/'P\<N1Y_OKW=[@QF=I:VZEPPYDLP,\H6TN'P<C
M"2$P5DH!X=!4_$7I@:;XS0'=WQ2^E8FFE2YK&?2S19QSN%%=M#D!I5T1[@)L
MK'UK?I24J"AW.$#L;H)J87<FE1CH7OG&#5QP49RT1C1W9Q8&N(K678P)'JB^
M,F[)(>*YQ^"QKH@N()3JG'!S;+/)T+HE85+#UX:!;;78D1O%]SH\68%+Y9U
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MAC\TV<'C7H &%ZHO9W@6'F'J^2^B,N2B/D.=IE?3,W3[&\ZDZ";V+C+KT=D
M(NG*P3O]WC/\6&2LC[+M0F=#:*I'6OJMRNNO93)%(I5"ED"^EGLH(B0-:IB_
M<\=:;F++W!IV,/HR"S11%]>F-GJGY?J#[]CM"??9ZK+\D&<'.HVC2C8A>;]U
MO?QS^I^%"?6)9I33N(O0HA[= T:70<ZM'9\M#Y-U?V'!.VV]#I+#8Q;+$EE$
MG])]LLZ\M\ZDZVM73KJ?.#%I-!09GA/%9JDNV?YD13P DA[!O:(<4%X=?+=
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MP- 3MX-;K5>I /O9"Z*15("S'JUE@^>3\OYL9<:>01H")\=QKQF&(KOJ_H8
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M7M?EB62(99YXIR^@@EMV^1B]Y82-ZC@<<'JYT'_C$3Q M<47B!4;C=J * 1
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M9F$UJ5?M'_F0221M0-,C\PGKSR=GBEZ)=K437K+7H&Z?ZX,(OW@G.-AJXR[
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M6$(D5KA%P'SR=TSW([>H-\O2&:PU\!K/5(NB!-8@7:4R.)<73WR<LDB"VM-
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M4]7/E)6*D)+> BP&.$;.DD(<1/II#!*=^+I^E<U2N304]SN+YL\?%+S5#7<
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M\[='@ &Z,CM%3:?(^J_#N6F?-IC&=I8M,,<D7B[3L5^4AV?T^TP94:T.:-+
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M'KPX]MYE(#<7"H7N,22@6P)\?@/B_MD=E"+G?QQW3V5#SUS6*.&8GHS)3*R
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MZ%D(I&V7"W9$CH)SVX(V[$F../[QPEVUFP[SF Q^, A-5,Z)ET3YL4+7LK&
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M1$P13)06>O)^)P,W998E>G>'F99JATN$E&-X)YM$54(G?[Y#J*-E$^:U$Q3
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MXM 1AZOW S-]&R4WT\"X6EX!7<^XK9=B")P.+JH187R9OL*(T2W1RA/6$LT
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M4,@PDI=HHW0Y:AY$B YI5B71\8O.0NG >\?<4&X.R6EJ,%JOL4ZU5P= FW'
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MP!('7>XF%S\D]K?'_2XVI_BW.]#+XPLS<8_BSCVMQ..A.P!/KP2Z>(GK%(%
MJU;G]T[\[SV?H[5SZE$.\VFS03'?U7KS;M(F#X6HWFFGL_0QVKP G6J^*QY6
M'7JNO&;JI#(SX_EB^Q-2\%+PY0C?Y*7Y#K3,)4KI 52E_"T_UTC2_'*PPI',
MLHCJ'<#WN&$32 XV7M[K/I^:K=BXC)QQ<ND6$LD930#I,'Z;5U:FU';N)"-L
M2G%=F&'E8Z$E2^H\9;!]:4C$IAZL-_ L0N(3[ HG4;JDTE3FH['JR&/C?HE,
M?>O@(\5=PXDE AK5MIZ AT"2D\G,I-WCQ;)3.]4SI>H=B\NY2R&/H6J'J!3&
MNBOCV.,^)9F2P*[9@8>S;L47$3Z#ML.7H\\&QN@%;XNM.6^:QJ4,=E1.ED=7
MUDRX"%L)+0V3*A <HI3E7CGEE'H [I@SOUVZ ZR_K]-<NN4QN -8W0&H#L/^
M?B/KCQN7TRDWHY<-G40X/^X =>V#'F9'8JPQKGB8 ^05,_C.E>7N-3/^FJEK
MW'#]2>G:NOKJRL]94P+-+B6[5"WN ^R7MRRX,^M'T-K85^IJ$AB>BQ.8D+B]
MSK<LAEJO&CTLB4=TP\TMGD4=\M/X"CU8#CXNPNI+6HR:RS&O/UEUS<?2>3]?
MY[IWQD>R&I1YXR]?#=2O]!/#CL!QV&^F[J/B$1.,6=WJK:WT>T(,"YE57B"V
MR4#"61ZQ.H^9Q(-/H388A Y,"7QDL\=/=L\;(R0OK654F_[,-KY:(3P%L%"2
M_LC?ATX"6VUVY14[N:U78EII==5TM3N\+;)L"6N)V5=;GV2OL(\6-[\:U:BY
MM,^F:1B?Q2NOA'UYXQ@\E66 !ONTSM2NHW!2)]MWVM4&;WPO#U-4[WJLQG[\
M/M$T3Z4[,X1+/E0CG,')X.O#+I%E[?!6':KOIR76(&/(]7;#?&);TDVP?*1+
M^5CTW#6*GM1VP"(/U=!\_B<'"\&RB/S]B[87?+C9L_B^^C44TC>]<2V'SA1^
M?0 D[I'P<^^A(;4G-*GA9CN&KSG,+*,KEX.7*J!B!JZG>SN^V,.=IG:?B[]1
M1O Z78BLEMWT"A5!ZMT;^AV,KBY!4\+'4P5W -IPR:WF@\F92:')KQX*(^]U
M*,7-\0^"3Q8S+5$-S;D_.=93KU*5, LZ+(T8EMNCB0X#1\J&]**HE./.D7J"
MRZVLD]$YMA3(#Q0RZI/Z+%9-.>(G1:Q4&HDT8;)9?D$F:AMS73?N(B%F\D/6
M=9 KYZF<M%C7U*RZD-96Z'SE%4V]?)?>1-FE3V0RJ)ZPOM)'OJ(BY%>@B-#)
MAQ=@!EE>&!(H(>MGJ,189,#+>6W4M613-LDJ-0G1V45^T59BW3=YK3:B\@N*
MC#DYX(;KT(ZVS U)%H4K\ZGKWAFY'<Z&(/(A\6Y\/F/ME)JWXD@;@:EVB>_L
MF8%R3<W-;-\=L?L^ON&^ 75"^.OIS.4SDT7B,Z>\:I")#O+*=AR>*XXPCF'O
MV+\_3IY&9Q#:7HJ@EC11()N>K7 _W1C%^0#/04Z%1*BI>=2];=@/>@6!!6E2
MY99?\4>UC[HS).@Z6>[0ZL.5=)4M)J*X@#_SU->"KW"KV )VR$=#UF*M'%7P
M=/&0=_LU84)HNH-V=;Q#3ME\AO&9-OZ6ZO,^FXQ42585( _+ZALZ<8,@$%M#
M^O8=0.V)W5LMZ3)8^0CV9VNVJ*ET!'L_(>6ALEY8]E.*F3RPD$A:CRR*K<#A
M^=39 <4CL'F^HR0. U95V]>^>%^-9/."5\;;:;% R^14U;WU&CN BZ>UJ:SF
MUP.!<JO:H_/%HHF%$>=+K?Z*(EL^TP";9?CIX=YZ->H8\Q:H]K/'L 8MQ#KZ
M 0;/]MR']0RL-]<DOO1TBY5URAGEP:(&#&LV*68'2GP+5&6F06MRCN:G 5AP
M8?Y9 ,"<^TI>Z?9]6;7[IPA*_TFH(M9,Z-O7G:M)<*R*]WL%>VMW *2?J0?6
MHD]9TG=65K:F/:(7IEC@-+ZM[9/F%NF.XBU"PB@^_80-OBXH?DNA].BJF;35
M+*B82T0MKDI)JN>ADT^9LXVS2'H)R'[A[R);]]>YL/EI<G!S&.];'(XS:"RA
MQ+!LK%C$<LGO5""LH<OIPU(#M8D<V:L[P*%65ACK__ $XFJ;?E_7B>&^DL#&
M[_K<-GD.SU)C*  O3C;D0/"B-*D%?9AB?3GL#36[NL5W]Y7^@< %-SYGHYRM
MF#&78%DQ5/0&?:=.TO"Q<E/-L?;)$9=)C>G--[)33QGAMSJ32L,$U,D0(XK=
M8_)I\V/A!K2RB8<?OL^RTX9*S>Z)[X>T9E+G!KSWGKQ9>-AGZLE*:ILL!4BF
M.DTK/+>5';IMN@-,?OQ286GE^^ZS9\MU@VNY*>/L7O-^P/:*]ZJKBCQFE7&X
M44";B]LX:0Y.9N'BL#B:N\NP'"=MK<MHDA)C-]5-K&RY3@7:-9J73W)=M6)=
MVA1KJ;GA:<R>C@XJB#M-P&^S)0*=@TSQ1>*B!-$7F*G8A\)=[81/9+U6@9E8
M*!8#;T,K(5,\+A^@)XV<')&R6M\+/^98ZZ7T941(J/Y2&8%!31K39PHF-"PZ
MB0Q?U4^[7,.R%GE<9<H'RY2\]86J8(9QW^36N(J3DZ.;X6VE!<VY&]4*M1\V
MX=)OIW^^)2MW@FJPV*=NVQ%2CM$?YY6-0\A"W\ZVDAF\3)MN3:0(WU%)IO5&
M\1<;U?'5B93Q[&04^EC3QLB_DS0RF5VPL&.Z;:/)FX4:<[J%1".=0=E(P4'#
M8TK?@MOC MD7!+W^;  BBK;$P_^I);=K+2=)RY*3&QXNB*DD\NDW5DI.4]@%
MT4[#5G#*)9JU_:3;!X0:?3MU6XDP4%/A+ @%@/X33YA+$<K@HD@]G099/B1[
M=^U=&_! J5:I7RR_.?U:M+Z^"NBT5%/Y2 ^)@MP?#'6.8YY,T A>U!BHY<U;
M,@4120^M?+(3\;5 8D)-9ETJ@LF-EG$I%%?4RQ'';-XLV".;/WL;^IB:7F14
MY^>!/&Y2[@ZJ(R%(H6V12;5SD99J3U),0Y2K\K;?R4+'&$O-B>P'-(+AW+#N
M<786>"O/);;0C3IMHQ?2[7)F_B)9]W"43+I/ W/^1WUVF1T:'K!TA*0Z='91
MF+YL+8%])5PD#-D">6?Y\*,5@S+G7.#V"3M+E/?3R)U#@<%=I)4G^2^<[P"&
M.<4'(2'5(.ON1XUJ:I2TV51OR,IGE9)='%L-EV3:U>X 8M>M>7K"^R>AQ089
M9$/30%.;,PK#E?<?:SK6+"F\4C848ILF#8MS,JLI)LV7WZ0/MK9X\T^L-P/T
MTA8C10\,4[(_93>OJ%>KX'FJF7@W-OONC:WBY)9)803Q\$"VYXUJ(Z7%XBJP
MY)>X,:0(0# 9UK&3 L*L=6Z>A:"J$U-3V]RG9>/=*UGJHD@ X0NGK3TEV Z>
MV$B1W2)I#'QR2O(-&QWD*8.G) #@-DT(%DU@&=Y^W1+;;^1NP/RSA&UR5$$A
M*"S\H^12\JTGG/2\7<J9%B>U4I\5K%L;!'B8%-)A.Y9\GJM^Z!AR!\BD%1H_
M-Q4>T_;>$V'[V!1+\CS7\#N7YZ]H[48AWHTES*V4%^M**"H50QZ3=,P_E3N9
M Q7YH7YOGS',)8TH\E(,'2N_*QO2J7)279:RI>G*W\9\F0\@ [_:4X"XB9F:
MNB\^3:84W021M !P-'J$^_FZRF!BY47+/&*3[KXY@5GU(_IER5KO](2WH60*
MWX.)XGYD.AP7.FJ4EY:-$M*RJ].(<HA%-V<XHHQMR:Z/J6I45S6\^3Y-_=AO
M=< ;0;X/R-#;L@\D:Q-V1DN!:^P57[\8IA#J9[Y0^2G%%P+"(N>R>Y$-A^7/
M@@@)!AXG;3R)&2E=).,*BVOF]ME0@MJ=L\3;W2@H;9=J3$F=AI$!< ;HB5_R
M]YF^V%,<@&D0B9?7FPO@F*4Q$+TG,[",2SILAN?XM)XJ3F8^Q -%2I:51SQY
M[;U<SFNXAC/O"$DR,,>N]J*_)KG4R/8Q=W0EN-[B)M2;G?K(T-2^FR>N?^3I
MC+G#U?B3 +?O=+%;>@1M03=[]*LN.0H@R2?I:&.HP)B09(B9-?!PVN2C!HV@
MH3?K8\JI<A%BKR0,!IGNH@W.^DAS<TBK/3(<,JL>DP_!>=KW0G@OP7)2G84B
MLIG3(K%0 U0A,V>B],Y_8J&L"5N6*:*%L#G+6-WI11N:<=NCJ?;35W;EKB/B
M/3:LC]LXPT3[R@_HPK$3;7/4LM.RIT38W>$]!"OBKV"=I&.S(5HMA$1P"ZC'
ML*DK_D>5FQ\J3Z:#G[[S[,/+W01YG-Y\EC%WHS3*<_HZ.2D(?O@)2<36G-&'
MY".Q.9KG"]N-R8PQ-UJ";)^;/$N0L\Y*!X8P/3X7_K$!\0N.XP*;\]690FAZ
MN$413<3HSFK$?!@K?ZND=03[)$._K?K.=0+)1-QQ2VV,H=M%!;M$T#J @D\U
M]TJLP"^GQNDO3L UMP=W )(7]W69P*=Z&EA.,'  O:+AV;U9\%+IT0'?C63B
M;ZPE1UCC_0F=7/8?6$N:#J#;#;[8U3 IRG\XCY+'-/2AUMD3:N<NFW"<#EXW
MFR77>I=EGS8&]1#3FP+A&M@WC686R$%(%E1&^+O+=^'5>C%T%NP[P$+]VL 5
MMSP^PEJCOMG*@\!#G)US<6C)AE>QTQ(8@KDLD+A#'YSF*W$ZA.<(TUC.KNUX
M**[%/QD/%N*?"DY.-6*AN"8;\(O'H$06,R/V3,*>]XE9FTRM'BF#"LDX@]$Z
MJP^;:D&>H;^T"28ZUKF4Y%<$B^RSK^\ KT.33 6O.G,O+%VI/;(+"]*G;I+G
MY.JFRV4FTQ]@(PE?6'9OB;T/PH8PM_KBD(@Q45/-UZ &HUY>C1*=BRR8Q@TN
MAD-4QS\Q W'FDX%KDEH8DP+P02#JD!IY<7FLTX-X$?Q@PEK%^F'4J>T=L%K1
MK^Z)Q0C%NM&=#:/S[YO5J Z3G^H#9U>']1-1E>C>_N1Y0OS,,"E\XY8P4>$0
M+A;&H?OU9T<8\?)2@VB&TZ5T^81V+#TUKUOGSQI@*B#IQD2#2<X;CP/"\C99
M326.5?IZ\&??$Y0M]:214;4"6CZBRNWEW/6)F:WUG2F;3_F\!68TEN]4"O7#
MOS!Y8J91O&7'#QRS?-*ZRI-;42N"P>@!W^8NF4VT3H&7R,D.VVVY@;Z+L#1:
MS=IW?9CP2090#*4XYQJ/56!HBJ$-5H9[&']ZP':YVV=]KA@>S>5QD,<W#._;
M.V"*,M$Z$VGC*_Q!!VE <IE]$I*$W!)_VVEXE5&$#T?_"N#<G\X?#^B89IJ$
MM"ZJ*>\L!;>R*K9,$:+,+B77L4-ZD600LOM1:U?'X+8!R<>GRZZC?5 VQ40I
M\SO PW="^5D*+/5S 1F9)I$F+BFG'ID8BW@A78R>F.P=Q%X[BJD#Q)6PTE!0
MIAG-\I>L3S:0:<IVN= +R)3:#85X]*Y9Z\@9EW!8GZ""@.N^Q/,"T!FN^8_"
M-,R]94CBL@ C3MQW(/?)GBC6.U,%4(,62];MP4B.7,)QI-APYY9EY8]:/K39
M G,#(ZQ1".2Y!,$O5.D7\YY,LG-.%@]RI&S1ZE;BO-H\!CY?!$HR I"2;0.U
MSL4P)KF4H==7L(!$UQEM!EF$9B:)@I5TILI2%D0;K"1;&:_AMOU!$(5]/NG2
M]DM]820L96$XY_JY>R,1I+S(_GQ.P[+(XNRJ5\P275EKHN_T]&R0ZHLF5[RR
MF0T*'QTCQUEN]@"$%H(MHEL;COOR#F#VS8=P:<J"Z7)D;C]B8V[RS1L;O(UD
MXV ==3H29#LB-I+\C4OXC^R&'R:6Z8;B(F9/&&JT0R5M0]VIYD:/5<&:6ON6
MJX;UL(*Q[)1]\+Q:1['I@C$</E@(M:0C7'Y,C_1(.>IR&?_RM-!5KH33(8LG
MS?Q6SGQF2W5X\]*B@*#&I'@:R$Q$?\G^2(/KA7![ELXTLZ75#K(A>^>%?+D5
M+ZS[FUV5;'9#O^7G4M0"6S:9.T#,#<L-6L.?C^#"SDEO@<_I[TNA/*[SKO<A
MOP,XQA:MAR7V-\SJ;5S^3 ^DGN+^+Z'U_G=<1=R_D=)Q':\BP"Q%G__:9$)H
M>W:QW4? @LA_1$/X(&:V&%;[V\67C#"_MZ*]IQ\NO^[\!4"-D/BD5@V\Y/.'
MJ97= 51@NH2-WY!O8= /E%W]YK=+5,-6OO!+^H;/K&L25; *;Y""@[I1-]5$
M'Q7H6*Q FG=D0&"%[<)&'.O75L=6BLF6F>$PK9T&MKE@V \_9<GI?*(]HJ%<
M4,R88L(LA#ZN\V.Y(T8%U\6"KV,MV6M-APN0N[L+H4V;1$[VV,66.0]GTNAN
MBK6V[ANJ-WW!PG$<'2R*=2^$KA1N"F8Z>D_=^?I"'% N+BX\ERB\E&,K''"3
M$[0C=IUWD3W;;:TM2)7;.9"]G38NY!6:A-BL8[,0G+L[(R0*DD6DIG7=(/>P
MK6E).J[=+#5:MJ?'*A_%QE5^#)=EI79?<"5 HOTR.Z"BX.;)ENJE0<Z$7:\*
M<97?HE YBAV-\/.:\ [\Q4S8&_\F5N]^\&3]T"I!SNJ4;Q^5GG\8745=40X4
MHG[ *.=6#MLIRMHU[,[:3)"U$//\IG\XDUIYH= P27QP/A)N7)UX<:0VIU8E
M3TL-=,K<06BLNH]%KHG<\5_!:O@[CMZ8SX(Z"*><.=J9N\-OHA>HG88#8 \U
M/T\3LR,=LVCV)8RIJ5Y=USB23LI[[":-(139O?&VZI+D05U0E'F\8P9EA\Y)
M_DEM(!TW^CLW)$N[FJ?'VC9\GY19VA6?L9H:%CH,Y:[9G4DV"F(J"C7>G[2+
MS--?X.TT_$:-+)C^)YBDS'_6JZ6&H*3J!J4+TB6FAK/*2_K>Y'ML)821]*\S
MXN(7*:<4GOUY+%'#[34FI-B )<#2V*6BN!,CW>YC9V@#!F*$I_*>-Z/VSX]W
M-#"'I&U-#4--H%6Y%*;9MUO@N(3Z<+00^%2O6N\/[^(><<DG^&L;$KRX5;BI
ML-EZ&2EF=;V5B2VY\W*VV)8GX7E&QKJ %W< 8NAW)&/_YF17@D]Z1VQ&*_W7
M1[T.5[@V!>RPTN'^;LTU](J\9Q\CHJ=4U\N.AHM[53<48_$<3<*%]".[ ]Q*
M6JM^D:'7G \/-Q_2G 6Y<DX!C05J?<4>2O$SR(%P5<JE=B0$*+ESU<YDJ"*&
M*G>V'^SM*+:V3&9[Y5L$)V;81-1JV[S)D6HJ\?W GO-AJZ"\>MV4<UC6A+%Z
M4$N"[@[0;<ONY& -Z=8]3(<(ZX.*V_KW=",T4+H;8)X:I((.J<WL<GX4P7H5
MW$IBU"ACECLC2)3# B^<IY]T0"2TZPK],]3*95>9C=KMNR.H1:,H!6BG+(]$
MV^P.L$Q$J:ZF#BWN ,Z^W/267*U4T7;LQ(&AY=RRN2P7Y?94",J?;6<)TW17
MMI%H+]Z032G+P3G['#[)AHZ'9<"!FH,LR_1&MT?L=2?9269ZZ1\19*=2*.".
MC'M *Z;[XI@'U7_K.&.46NH>/@'VK\WM'IS<X*REX/$MO\O\790P82QV+-?-
M[ [PW>^?]3.UM+(6P#ZOEY?NX]^&I/]+9^N_Q8FE]NK<\"""-<&52XY,5U M
M,2HD,(*?G6(R;^-C5A_, #F#H=L:]R-/HS::UL'7$(H@>J]YTJ\RZX"W6(F6
MB=%/B@O7JV>B7E3WY:!FT_!]/UL$KGD*K/%LAEV3)L1>D]X!IC2%K[!W:LYL
MQW#:L\R=5F=VKYUHEZZ&(,(?F49TJW-C1F%:Y\"^'.T86M/3=P\[9HWB;&Q#
M*E%<"4_\85':*?W+U.O.B2 VL0RZ7 6/KJ$X'PN<F>,\NF.N*0+6YU,P8=EY
MBT V*S*#V]/9RK/",Y$@L<%K7)^6 %+:PNRN8JHU^M"GIUA]3HFBM54'S"5:
M)JR+>%ZK4QJ2+4('R?*H2,&HJ I"!5&0-PS,=;A'RJ#ZCEP,Y#F:DLHOP:[%
M\PJ1"QIR5Z+4+ $$66&](C*-P=E,-6!QUS$)<^P?V=><56*=;Z2UR@U\H[(^
M6S'$D)(VF!1G@:S&NUBH<<A#A]PI5R/@4K,?U?.CT-H=MD)G*#G[U1[UL5XU
M5_L&J2'AJM-.M-";+2K8)ID_<KV2/TO&&-DV7TG0*JWT\NXKEBP<6+N:=Q\\
M*5QKD@*Y/HZV-O3KZX-O1$UU.98*\S>C+/$ WQ)0)\:TB\%I[?U_AAY.+O8X
M9XMD39>BSGM_9$T&0I^5)99NW.K8QH_83?V@6_[LX*7RG3.:0U&6\0E/&YI\
M88:R5ID3NF!=7,P/36&VUYW\O5[G=H6:%5^38C(0) _1^>]S-RH$J7%8P!6#
M+,;E7$M9 3CM1R0%\-6Y4B<R;B":K7VY5"I*V(!B66KFS*GH*HOA?'2%10NP
MV?$;R9%AV;>NM'#]*@4R(EV3]P.6@X6?6S GPU<MS/0HD+;4DHFKAA<2I:XT
M@F,QW*.?&*1HM_.4)]3DY:FY.Y^5/GT7,,(FCWPSUU2'XIOE3#Y\G;BS[-S]
M1G70LN@B:ZX?&LIZV^3.NCXU\T$)0/CB$[*^K6)AV?,K'@Y+HY O$C[-WLT\
MC%QVT )7J7,1&N:)J4<[6IW5%)ZD^&NW%]F3)J9YY]ZG0X9\AG52Y"AGPE>5
M-V#.3IV-.8VL_9L9,*E28)XY6UCKV?&)DN&CY'A;=^1AM52&I@<V:@22 ,*<
MA&3WAY>SLR+J0K/2:&0@8OJW/%TG6"7A/W#G)(9SNB2L[4KZ,$]15E".F;=H
ME]HX4R;Y1B]LG.,W@JT3K)L%NACK9L,ZZ\!%<5F!>8X?)KMVG#,1%AK?KY:*
M ?I"\Z5H9--5;[V0Y6>'#V;D#T'E"00KR[J"KUJRI6C%AY"G9WUX)"RU'KJ!
MLN.8?K82Q8;&->8K,76;YI6-P8>FE8.JT*HAB4I6MDE6QM'/9%SF@);=&@W0
MA^R!):+P4:VC8?"6''E9#2QT(8$&3Q>Y("7>_6!C3WZK1#B!CZ!:=%&P-HR^
M[>.3C;"FJJ=RW='?"1HE&;G&>$RH$JIWQZ;M!B";7+R=-W> _>8/Z8&KG/>A
M8FA_]??^3=FL^*>R&?+_)65S>-!R$68:Y)I1/KM)$CK>-SR^M!78DU[XVBJ6
MD2032[BR9+3W^@Q[?TJ$V,G\D*1I"3 *.R#,+"] 2?!5Y/OP&C=F:B/)L"0W
M.W]$<J-$ ]=<I17WL];( YC.1W33%LF7%NUI/,*GS%.])H>7#U"AN())47XL
MP0PG[_A[C08EX+FC27%4S)'5@33CFV]P[5;5E"9;17\28VF[OG1B86DK=;6U
M1]WY /2YD0X0H'('S"L\HU(0R3W,29UAY[!ER<MR+YPS>5DF5VL2/)4DB-%>
M>_DCU>@@?\SQ:,Z9#Z0]*Z[+W.3EVP>&*J8GY4MJO:X4BF97BR;74]R]Q!S8
M.=Y2.GJ\QVHX">P=]\!AB1;$S&%C<V#_]$GE$::,M/*_(R9':P3V*M<]619"
MA_$Q@M?)S(XD5T8^<\AZ5\S;1M8U7<_1QN@U7H#;:!O9K".JZ[!@2]-2/T;#
MCZ2+Q-#MR]6,]%BF75[E4SJZHCSB=_;/LY"7%PVW+D9 8(=8-$X-\5*^V>_"
MGXGR\H\57$7.*"8:[;ZDK]I77@GT$B=R'"$13)STJQ:;NM\!7@L7GF#'K'5K
MM]-6EG,^E#+)$GQF(T[^!&89SC+3/:LI9DW9W3'!@H8I7SY50TD6_1VQ%GY_
MX"[^AFT&WB.'&]V#=B_9_[UG5S^E/39G,RREOV%F:>N2J9^7%=SQ^9\H5/1%
MTG_UCC2(-=T!'E-TMFLCJ/+_#A#Z?[K^$NY86?WW<$C<.T!3;&IR>YU23S(9
M8EH%"G> HD[P,9.6Q-C?>C0]D!;#7S(A=O=)R'T0Z--WT?/)'.E<FJRH.0,^
MX:K)I+5E(WMCTK"H>(N7.(M40NWXA"XOK3@5>;"X\\^0%*Z!>2*%[PN/*&L_
M^8)IM*U#X]H_RRL>VC=<Z=93'''/+%U-]($1?(-#=N)!4=YYHAR<5J+NN+C,
MG#Y!H*4@YF1>GM$T=M@X+ZN7I-,4SP")F*9VS6^3FC.0@Z1,6/"&2:5V2%6J
MA-F [*W3:HB^T&7!0R9%J4![O7SR\\KG5!0QN;G(.@PA-2C=86:*/)CL@C5E
MCZ%W@  6'O[&5?&?T*H>,7/<IES;),]4U*N1L63*D1-JH=+*F+=IT5Y1S0_;
MM(AFJ1Y8U&UA!*J';V.SL=P(P=74"-C$PI.'^OCJ/^$M6RC/'XTD-*<'6@<&
M_FP*_)#_WQ1Q22W;=OHZ4V/CS+)8#4.@Y;4_05T)DXJ=0I/%B_6 1@F5! 1/
MCC1YS#XD"(L22I-'K-U+%+-PA3G5^G"+KY$6;YR.;#*27%P\L 0"<U0+9L5]
M!2(FJ7?I5#9C'5[V8T&R,!:>"5?V"2J$ @,%(UBI-FV>[$BD9R1(D+N'<) D
M.DS#P'D:)DIMN[L2PTENO_1R)*,-EUIP?4<+&FD"ROF1JMOR=U%T?^G?LL0+
M*L'R"FK&;-Q#N,B[RJ8ZABL.'J>9F\0<=/CJ(9-RF_1YW@'LOW5<4Y:[[)P$
M:ZI+X67?S$O@=L+JA.:M54;D3D>QZM;2Z'PI7%M-S#8F\QM9X!GV7"(N'8KD
MQ$F1<SS%RB,RH@KD9)'K\J V--C8\?V1ZF]C@.VO49B:?'^)2[J<CKV9U6Q(
MYV7C15@@83F;B'^OR&S_WY[0]I\DM4TMUDTKCG$:)0A/1^@A\<!KIP?9OD9H
M:B7PJ*=E!?MX@"/9$ZA23J%%9XF_877&KGKOD6O:;,2*SWB'"+JC%/AVU+3V
MV'Z#\?SQ4(2&S^3G*IO G)L"TYO5/[!U8+='X#EF&[&?KL*.=#+R=P"8.;AV
M[A[PI;QAUO)J-53$ 1WT8J7K/_[48"==X\Z[Z2I!N7^. C:91*Q:PUX"!_DX
M3R97[(=\\#]&"?OG5,AJ4,K\;5:PI/XURK_FLARK??I]5ST][P[PSW'X_C$9
M_(AMPO_1)XW_YT(E[)J[P1N,JP;$(0\4&0&7F([32=(:4-S?&EUY"F%J<$08
M_:79R72T#K\3!O[#NK <)D5LNX?]&V;\?_B?\->H4O1_+L?.[+-PPWW#'R0V
M4)SVFV/3J4[=46<-NQN9>:.2H.:V_J+U?MZ_>?"9ED):K$QP^;^'QV6U$VYI
M*IV>\]6"J6Y(GXT5!QP6CQ<+*EVY$<WR11-9^ERU'Q8FZ\OH!A;]\1#O',I9
MV J0\6$KEM;./MCI5MZ]'GV/J"M4_U$@5</4_.W!=>X?+^-W/,=4 %<TWBQ=
MR/SQ+L=W[ \(X_GWH!E_O&Q+3".C</O'F'^\O,JOG%YP\WO,L#]>[O'\VX0R
MXA_H_B6S;?Z/$30JFL1RL\Y]S7)%>,7K&B8@IIVNE"X8I[R>1?'<")%-JHC0
M;K4B$!JN87UB42RWA.NS\U)%64G![5\'MQ-%?("AJ$)QT:B_3OJD*CSM_[BO
M__M\D#:D_BK(YIK;,=QXAW!<WK(C2"C$+OHH&AQ +_>?RS*$AEUDCU7VFZ\-
MZ2'QS11Q,4DLO(^]]V91@?2(YW[G[/['G7C@AMB)<_^_VXGV'G]-;</>)TQ#
MGF7Y&<I*'N!F?=M8!"HJZ(Q4=O2X Z3S\G&#%O4LY@H0<JXNH_%_!HO\?_DZ
M!(?P'9QD@JOHCU1/ O_<6NCAFUDYO.[_3'L'< GK/^2N#Z0V&6YR^;'RE2W\
M)H;]/9G0L 80Q\S^ERZZRT5<F^P0U=JHJ+5?B0.#,539C25_VB06U\XA9X>U
M2_4+S6/ 7O(= !["U9S@EX.PM2&4^.@EP&2[;]0N!M_R3VU=E"4AV!5""EA5
M=X G?@6G:4CNT2I1C$P:;=C\X.K6GW.^XFYHA<_]*I2AR_&8I4""$;,N0&<'
M6KC4^,BMHE1%UG7'FC%4C.C%IFJP@)@R$F62VN&\VUH%Q61.U7YREFE+D;Z6
MDQ0MO:[AM"1@$H]'@ES27+/9'I1C.!@@:*GAQ*94%FH8;A[W*RLSE"MW9N2%
M5!<>BX^H=!0ON6X&>[]RC2^F]&,IK$>^6(,;FLAC]M_@8F(*A_T'S(%\4#NX
M%HKEW./+RP_^]I\B^++LFI^K@E$E5>.J,8^CPE=']'BHQX<7'/V/.]QF)%=5
M/$_,]"\!G$,F"81!F>NO-]&RV\T?TN]^]6$4GBE-]F%I&*$B=V8.!>_@RCIX
MFQU,4G5/JG=:=94//>9C_>7O=8N%67XD,)Y \=G3J@M("&LT='GSQ4Y&D"2T
M><$181^DG/1I(8STJC_#7ADU[5T0W4,Z-R"(T/9/D,Z7-!7GZ*.W_CVK*7O/
M!SW,+FP"J:6:5S'':&=7)W;3A:8'TRTWY@A:W:X5)H%#(H?9/5W4-9PJ!X]F
M?U#AX4"_0LBJ*CS5YE\XE'Q_S-YFK8JQX>*F2>PN8,IE5)S0IWO O[[IJ^#_
M2 0PCW3",O2SQ"4GK>/ 6I4E;S5**;4U576B6=?MVZZ2?<\^/M):[JL=E!&;
M:05AYK,#!5](LKD/5J4,?;CI,K-I<$D$0*Y-TCW/757-GGI+9BZM95 SXR;<
M@"B ACX"WB=F2;D8\2%0-#$RC;VC$]D^-[:9E=,C/E>M_R';)#D:9O #ZK=6
MC]%E?HR"Y6-M^0J;BU?ME$#DC0UUH\R)(8RSU&K*!@PE:OG<'JH1F94X'+\V
MG7N!"T%J8C?XS -"DBDVY/'QP%X\I$:>-J432#1>5^<=0'ABK,PYX3:^?5 S
MQ=)(NY=\NEQQL#7_<UQ_U+/F*S\'8KW@5Y.E=AIOQ-Q9A_4'-ODV9%D5WPLL
M4RWP:C]%+#\\1<%Q,/[&@G44'PMKQMB&XAMIA(3HT B>RG"W$W3HHVW*=U\
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M-M,P9W&B  <M(FR+RW5!KIOD#A'M60CS#][_=M%Y$::[[HN,.%%]@5E/RWY
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M%O5Z?[#*Z%WPB'QU1)>= \\P1T?MVN=O.EKYP0T!]ZKRN&;H&!4V46VPO@Q
M)Z"5E:9T0'<<?^51+@_LBXV NK+HIB-M;;\)JI>J?DY$4%A%#,U1?1PEVKM%
MK5S<A:+;.2=3\W%:_LOX:NSC:57*27%AH"B< V?M9Y+<?\:(_!/&NLE.$5P&
M_<\A/2.@W87_".G!_FL/N+A/NOIZM),8^L5Q?\3^7.3@KO4)4.*#8C2P6SS0
MX@A8;TJJ<:2T!7Q08\6FL5E+;(3C$GVTIZ,G .'()4%/-L"] KPC^I8?&^IC
M,K)K'-9\Q^*X3]0LY(/<7D_?IT76+2!JBY9N?/FCC5C:"2 #3BSYZ0+-"1F#
M55&Z";U3-S[:,U"?\A4@()?/<XTYJ$!+P<6&/LYJ][VBKWTTQ:4\,%%H*^_L
M LDN4DG<.?(&AOF!0G/O*<V9^J6]S25ZWHKE3<]]!:&\_G52T>WH?ZL80#W^
M"2N),T*3JV7^;-NOX573J.)OR2%,FCA:/?T7[6C5CS*H>#PXZ3_B[F1^D55
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MXO)=O.B*X>@-P:E*L-*[AW?E6H+?"FU8-2[@%)_$B2:IU0TNLT_H;FJ\T>[
M^AB&9MTFV0W^5FSUALE)&%N+R>^R=5^.UF(Q%I/%O)=FFXB2?!DFPG98P+/&
M-S040'6*A8MTC"L&O5#.9LZ9!TYDAQJYR3=OCI<PY.+;J2-.AKC/K[6"G\4/
MM*=H]2O\A_,U_ ?A?\!_["3]M2>[Q0UM>O[VDZ=Z"*?3^,^%DE<%F"P>X9]E
MM%C0K_6=YI'XTO<X5%!6=JQI5[^T<DK11A@?[LM/3G1+PI:AJ^*UB8VX)^UZ
M/L6U]!M<2?EKR:R)6Q//LN'4+^.]>3.?,_LZ9$ZT.YL-;!?4JT7?K^WE<0\/
M]]6!R75"M$<X94-HU-4_2,OQK:6@V%?@=:Q1^H:LYM\'+$"U=GOR.*'KHQ.-
M9CC86FD\LE+-QBM4SW1"$_+(6V('B2*=U:)--5^7!!E4)FU_DZ:"\&/8A5IX
M2A:V@PJU9RR"5U^_0U@]I&>]-FT?FS7*$:/^>LN3&+=T8UY[;#,ED"#=<W(V
MAU^*A*QV=KY:UHO:YN&T!O^4QHR%_X9QVWB_U9B[K>VM0NNN%@8W#S"VKYMU
M?\F]<>X74G-O"3KOE15X*F2YNO<,CXBS3_E5X[-+T[MY% ?3$@HE6*@H6Z]9
M8BP6ZS;. W4M^S>94O'ZB8,D W&?$ZBAEH7=LB:NM\3UE1#&/.2&S4%D/XVC
M'V/?"I-E%CO#&")M*TZU.*I.,P?;,?6D"D#WG]RG"$YH,:-QH7!7TPW-L;&9
MDU.0CP E.>Z6N9*\UL"..%%,W<P<$=$ZY] J\@GYKI2K:P%!"LM]5\_5@W)(
M:7&Q$5^8VGD%**F]X[D7+Y1#WXY%AJ+2LXQP//WL#Z%"=8771:?-?RDZ??/C
MFCZ_>K\PIO!BTIK^86?# 5>1,/D%Y_J+<AZ;&V[)X$WTRX*=AL:/_U3([=]I
M_V=XRS]_9OA7:C="_=R7;I!.LPCOM*'03]*ARSPU\%A.[-=-'R5QW<UJP4<Z
M(?4CY*-&E,[AU\T^%8Z?.I6[.WB4T5W6^\B)?H(@Y.LA\GA*ZEL\R$_ER$O^
M:L@9RE]]0DQ\8;)JQM0;M9H:>"3W)P\$Y7&LMAO$G,I\\7F5+L:#)$6+PDW&
MX#U64R-(RV*$W$W\*NKH=;?Y0-Y,R(OW5B&: ?<%D3.>_ZQ'-_4T(>^FNYT$
MAA,=/M$FX;[Q)66=_,8WX^$3_=D6N_^L6?<WK[S_YRYL_FK[/\$E_4<D-/U=
M25!@Q/G&:_4*\$L6E'VM^L)&R;2YAP9XJKOO/,-Q3C>/6L5%8"NP91_AXR:&
M7 &\E)81IDN0&'Y6!!PGTIE(+188$UY) \VHN)6 >B407G/VT3L'Z__JA;3Q
MN]W5#-C=$7!W[LM#R3B:BP.;\W6P.3[7:KX"E\+IZLSQ$-F;I/W^ANU<P>1_
M0M>POW'YOJ+O.\#O*5N"]D,RB@7I"@!CUQ?7N[;8[8@#XY*>/)MZ;E+X+X$>
M?]%UWO"1?\R_RAC_6[K^S:[$=/JGD:Y= ?Q?)/E7L]+0=%HKG&_J\(SIH0X&
M"&*PW#A&'[" 0[MRS&LTP)-=?><%;OB__H_ES?*#$!(]_RG<@#^S]BM3NF1]
M>7&.:C1_XNU/7/4Q6_5K)/[*VY\&["%252%N^.=A_^> -V\O_Q=]2Y:A_D]V
M_9NRBR.?_JP8M2?<E!4M08K?6]S8=A3.J4L*^&&0/6QW<HG?GA@19\C.1/IH
MT05T V0#H2ENT%&W[:Q)%_5+:?._F*&#RQ27?R=U.TOZ2KY'L29\V'Z=$]*O
MSK(S&K$S(T&U>$JJ<-Y6';A#[VDSV+F%\)E,*?[9@7%_-6 .Y^0ZRX&\FOS2
M(>XTPT/7-0LQFI/+/H33'S_3S9"&?J'"6;5PH*278/1:P/M>WQ9''CII>JST
MW>\Q.?>6[U@_,UX\%&2 15;)"K0%'@)U*<6O ._CM!J^P&(4BS6QQGD,WW<$
M47Z9[&H'H(\*\JEZ\8O$O1SP%,7-B$YB.H2N,\IYAC_,_DIB*H^,I.*A@H_H
MY<#+^77*!A]G6:SSI^JH[^:<][T[B=NJ#/#-V_JDIA*@13;4"30AAQNRF^0*
M'NA\TYI8M/D+$E^5)S'DR&"RH\QNZ+@;[C3^C$Q6L_L%3%M/XE3?-[.W%=13
M(X,S)5@W-;7*AJT*F")=8G'ZXU87N(;/]&,H])_9-73=V>CEH,^IH<(76 X\
MO%26-JX>T5:!E7UTE'75D7Q:JXBB5'Y1.;%_)TEK[TY(.RE[JPK-=X2?J.9+
MY8-B;8U%\+"3*@2J*DDUHL#=K(#3:'AL;U%0C&^GZ/W&BT&XL;JUW'=^@U3F
MB)WJ(2]SLO%>.DCK['&MT]R:X[OL*X!YTQ/4RLPK0/RY48&#6@X/Y[< JR3F
MDBA# H/0^QQ1JSLG0.EA*X.AV!ZX<HYN1[(VLQK%_4:!\V&]E%E33:(9*4PG
MEO%IW!C;^ZH2\FX+I!OBK_@Q5@C%'4-FY8SUVF^GRT,>V_%]RQ3 J%TI%Y>C
M:=Y4$WX:+>L2J'$!HPU[\V(519"W(W<%;,NKQ9 !_NH.Z^4PY0E_S5 M&24V
M5_W0H2/?2ENFNM^)[HT-S+@_480"_%WY55#_,[X9WZ0]94:$CS]SQCC2[]*P
M.V=W!=").U7O24(67LS4N':;&@XTBU*W00M-"_ J[KTB?MR+%[*3)UN!#*D[
MN&7XB3PPBFI_WE2W2 Y[6I/7B;,C&30F]J'.@0=U>M^X^YQHH35>3U C; .R
MO-Z+43%*$PBI\[070<DH=R:?K3Z2M,DHP[*P?T&=U$&Y>:MIB[^XAQ \R_!4
M]6XO1VI=XHJD\4@1WHILOU$?1<449;ZB6\Y>,)F0K<.&SC X-^]">*@H-"ZC
M]H@%QU;JZ!&VC\A*J$)5BFIUM:A#KWF1XN"!-KIZ\SBEUE@C1NH7KUQ1')D&
M\U<_" R<ONH/0P]K2%ED8#;+?HXAO/[IAIK,/Y"Z*I"7 '3M"@,QY;H^*\%*
M>BD9;3:UPOE3:SNK+A5AO43B_%KB.-I2.K-2.!B97P1 )N@Q1UH*-C96>9SU
M&Z,%X6JLO=]L&YC=#XYR59E_X/.LTZ9""=2F/\Q> EOLRF)5XV2)XO$% $"L
MNN8YX5 .;04,T51=J?(*);RGBU_5N[!'5H'T)9&4KBGL'8<SZ.N))%4:G$!3
MOT\F"HHSSS6=MA)YZOL]-0LMA,@"[6R[&00@8@YE1LG"?G8E)Y1RT<-TL_YG
M0_7#%'O,(FJ19!O=+QATF:U:$;(H3((_E--RC ::JRH[?#2$B&-)X>R_2[1X
MXWDK3V\BW2_Y?:V$2:CTO7G?>K[AVMTM]IC4:KI:S+QFLY4R.T@R>TO)[?6L
MM$?Q\R&RC41M45G=;@XD'A0&3U6B-",$40#]URA\T$/D9O)3ZECN2[OKV^ZE
MLS/?.?!%A!PQO+("[C_4'72"GYWNMM*^?8IBWG#8IK\,753=:+B!MZ-6"9I[
M7. 3> !"U^B801_8EB\>6*KE_A'"=/;\^!G/]RA[019I(::JP1284;U/VP!7
M97E9T/> 98/<1A$""CP:L(QUKIQ?+V-JG:3,SASL4 &['=TO[5OT;K<I2YI<
M-K$=7 A9P&%-%0H9?UH?0IV2M2:;KU.E21DZ3/.Q2<-@]G;5FH_@ZE%.#475
M\H%ZH3A3?@.NMF2,U$!WL.*IS].2$'O/L,DP]D&8(PN:Q<=Q:-/X<P<CCK!.
MT[TV8DO(F)X[&2^YC-[8TUS41%EQ=_6/UHR;AW%=LAY3@-RI3]$#@@QO FMV
M*T QP>]F.*%<8<TM^&L>F>:=<ZM,QU*[K<@)1#^0A5EZ,!PDH3"#J@7'5^7<
M)([=3ZV?Y3!M+M542C$M6#P-]\G-7HP-K:C%+M Z\6@==H^Z,)5ZS%0ETKDD
MA;S38VD\KB[&W+L#:\4[PG2ACF]\:$V/V0W.L'__4(H2R;DH.W-WY$,ZX@19
M!BI[O>>#70KJ\2H>KH7,-!.I%5L <^H2+CXH5X6!TIC5'M7XN!T7NCNE;_>\
M_[R"HV[B-6LV<^1%)?B]P=+U1<9;L5SVQ%JC.B6;VQNW3RE4 L(7V%"&55DW
M"3JG$L=PJW/P!\VXQ9WL+P2'#,W!GZW[._%C3;#0/]8%"/)F&^W@0:E@;4:!
MK*BT%F2JJ/ZKHKU/0EV/[\3>S,@%#SGF%>"_BFZ[%*B:YWD=/_)Z!PB742VZ
MM(VY!I?G=,J\O/7#BUS_J6L17)+4#-Z ,,)]W5[ W_S!;H[;N"7MM>F9?\K=
M])>Y^SPB.K-HP]/0N3PY(55?A8;8]97-)U.IL1/?.GF7Y!?"P\%M7ZR, QFR
M%Q-9^#@--+EQ)X72,ER43A9D*L:2-N6>?XOI?J\?":+R>RP&42"D@.-.T% =
MT&9ZDY6<A+:_M!+WK*E$\Y^5;'G#1BC5:XBNIG];]]3#.,&H$C_)A+5D!X 4
MW=NG%@)N40E_OJ'V>L5O*IDK+-V2.YAKEC5Q1>B@]>1# ED;2D%Z]/JP5^]C
MZZ=@)(/CWN] _B&\3*Z,%(MB#<XV<&ZG>R=+]"M993RX721_Z)9WE+?-+5F,
MBG0-XB'C09(7>[EFG1$^*L'[;U7@G-;-K>/,,< C?I.A0L98U9@?^QTUC^GG
M1@S0P;7WI#=C(>WS/!&*TH==JHX^F];)YU2/VKX&;TVZ]H@H)5FZY/2Y1V["
MR285N$HR-RS7"DK8EQ ^)-6L4>(MDN-LA?>,X\MR7.BJ,QJA3,LS/TZ"$VK*
M [B=5DCYAM.%'Z4$2?H,:LFN/(UMI:HE9Q-G@((%GV&N:#:WG*EH1<9.XAT_
M5W5LCVST]/.JG,1PF.!IU\+.&>1D0QR9,+G2TKM=T J6FYU(:YHH>^YLG98F
M3@!3]/VSX%BH"8)0@>=HTD]T[CLLXSVV"SZB(052-GG3ZM[>VMU*@VA8/WE=
M(@#*A^.MP*BACDD?'XV:5UNE]_4R'L%B8M_XZ'+C ; <PNQ>U&4<H+^,8T&>
MTFOFE63M)!W7?M))J'@>L"+LIT&&#2MZD9<"I#Z2=<.1+[)9"O'SV7Y>N;4(
MEHG%_(B?A]9@%;M^V#JO(\;\E#$[.;Z()O3^VIK2A*OO\_[:-0Y^V5ZVI3 I
MY@?SM,T?'MO*RZN@Q7J?6"J7[S2,"V@*!1T5U"L:K;AYV;+#./6E^S"*<2>=
M2Y>/;J,Y3X"&"VU;2 Y)[+8WM?M=8YK+X;1>EK2'$FXN*)0F8,"C4-[\.#EE
MZ0$!.8L<"Y"U:XJI!5(C;HDHB<$YK/9M6N&:[>IQEP7IS+BI"IDW]FWN=GH,
MM_:7NYI0SLDK@$5]HC?(@U)8T(TW&RCN88GPA)2O8X]N'9(WZY]2G[%<VEX'
M7#CA=EUP7@$@-M<6&O/RTXB2WE.%D,_7587^(2FP?T_3H]N] L"%'87/5KCW
M98ZJ=Q7 5X#=\Q3$"'@;8M4EB$^R@0[M&S+'NE4-_8P<5:]8T0,<B&GY0W^8
M"9RK6>&NC[%UJ^[B7FA1$9F4)9D%$A*)[90R5 E/4^P'#VTJM(W[%Z0))3B@
M5VHB>1OG9GE$KDKWZOGN%-H'ZA3?,5QHJ5!W+G\TV8P$&?W"JO-%Z/6=U.)>
M2G"!O("1-Z>5@N)>\KX3;2*=! SZ_#8&[W'^ ]HE$<<S,["3%;MT&2R<(I:8
M/]SN490T16A0F"1);.!&:XZ=K;6RR,!L];[::P%#W4;?>UN+#F#YPYY^60AW
M)?'N2?TI9]#&VN.*SRR-^'@E=*P\E*3L2<-?4+JP@QWZG%,#TR&CMP-I,Y^E
M_?+-#T<1V2/5-4W*M]G=*6II\S)_V$'@O38&%3()F6#>"T_)@=HC!@LJ.SD.
M'W&]%-('6V07R[5M@9T#0>Z![04G9CH#6]CG#+(6Z?[#A"0"[U&HS"C]D)PG
MSF"'I-9=HN^2J^NKE;PPOH80$3*5AX-C"!K;,]SN4SGRG"E*"TH+:R49%MD6
M3ZS#6:&U_5!BVN6JJ(QG'XW# #(Y5 =W2-W56(*=XKQ<6C ]3 DD^G,O%N(#
MFU++@G&<[U2=\%X!GK*UPZODK@"IW5[X'E< ,GSRP\Z&*,^U'0>XC GXTC[N
M"B >>\9\#!=@%MZ( -'O[^JWO*CK#5T_"LI32-G .PM)3>NVGAN40GGEM:MB
M7B2=MZKI#%.!C&C)28GC0*C\12"W59(R@3*P-BTH=&EQFV5<;8<'0CCV^=Z/
M \(%PODOM.GSB?/<O<%.V/.\3B%?3B.8QPS&7[YB9O5AA^WF=LX3S@UPHG.A
MNE*6-X1)K2=??.*]Y;;6[CDLAV.?S UKXXMTT5)M$:/R8A9F)J$[]9^?X18X
M+$ M^NCB_EZY-6>-SVK108?8!Y+_EB'^H!FLK..'4T4YBCY1A-,I!';*U+88
M5E.KD"_< '@_6""8;!_(6R>CJ!SBR-/F[WCM#"5^M8+<S7 YX. C_.!;:A*]
M".+XJMCTU@YV7?.M",6RS[R>MFR0Q>54B951T?B@L(V%>-7Y8;Z2G%>V=34V
M?A7Y^EOX-NYRI)I]9OI6B[O,R8IX[%ZO<J6V7RWL.%^)93(2CPI[;;A:\MGD
MVM$ :E5!S(_DN$_EG_SOR4 DW"@PH/,J-7$$DW:'V8[J(L6K9UFA^33[U#[K
MJ[)/&.6LB[/E 4A;$Y#[A&U ;L5=KY#175HE9DYAEHZ.M3*2E?U"ZL ,&5I&
MW+_M1OJSS.JEAJ_\#DZCUASB).M?SM%38^_)5DTH!?]>^KG98&LJV*F']43I
M7H.;!>)=T[&*L?[,?3V-SU&3"P0T@@QL@2-1MP:$0SGI'-T8J0-1T,KGQ[9(
M6,/#\"AI>'HTCG+M72'K7M0#;?,$IN<D[U(2&O=Q0"Z\;<(/VE-#-=[UT007
MP5H5BCX6P =W3TVX$CZ-8F<Z]+D/CDN".:W(9>(4WAE$HYA@S:M2I1PUKNET
MXU0].;LU,.W:Q#^18YV^<Q19\:K#V")2ML:-=^IX=S@/C&^).J_IE/SEM'16
M[MZ 8;C8N[+@@Z^'^?2TBQ^Q=&1HJB"J 8\Q6CXN] P=$7:V2HKC&EW?HZ/%
M&]&01<V8)]+US^YLQ5BX>8" G,'Y/\J;ER)H> 34[XB_2,VH!,N1/W),HV09
M,PXE7(J4P<Y-*YQJGJG3V^F!9DRV7W[.Y!AX;F'S&&T1L<89FGQ8VV80?N);
MJ56[@VQ'(ZO;[87K[E/1'U GIF:F:.L_ @I^6?'O*A K/LM]&:I/J#5MP3UL
MP?2]@"KL])44X*DBQ/U6:!W#!ZK$]*0"' F(J)%+FU9W?=V\=-&/YOL)*H"%
MQ+LV%T2([28*B)C'IPC'3<[6:=KSYE]P<7,X:N[\ =CSQ6O8<PS?UV0Y16-C
M+V7:!5(TBG3458UCJ>OLO&PN@S 22 .PTXM+MXPQ;FFR2?$B';1SMC0*E%>@
M"-9\6@RI8*!;)!H9%-#,7L>+$%FS E3R5GJXB@E<PNWY]GL'U=^D3O2EY<<U
M:3ER\44UC+V(B=$S:8OOD'[RF, 6<+RH6J#=5$TZE $MC[)87&?5X2O)H=)Y
M@H/&=WC:KN"^(!G"^2YW=)W,6,\K^,E]D$M;XVCHH3X<RTMY4ZWBMFVI5L]^
MVZP]X6Z-\'%'_BF-U]=-X_ZR+B:N>0W'2YS*P:SWI/(NP4CJ!K?G_&T!^1N?
MR[QH1 <*EW<._<9J(0K\Z#3BE.\?-R0"<5Q[+E,@#'&Z0IM4"5OW*\LQ/]A+
M4PKR4B=AAG(2//9_6@J3F2AV==&B8\6^G)&/M)?-#J[S4 #+[*)?OF?4X[>8
M?FJZ+L*3?^:YW^7 WVV[257":N;,RZC@;F)=?NTPM/U7@0Y>DCLC<.GZZ]4H
M?&2D*VY_!;B!P*(>H+Q@*BJ.H_)/#]7\JY\L/U]H[:A!YR<2F ZD**.L(*+4
MIZJLE85\E^CN)KBV<>^KPLBYKP!-<;LQ%R>-5X!W=' .T,\4YX$?;O]A;J*X
M _OR%>!$V9OM"I!$(+SS5+@-?(.J#TL%%ZCL89AZSEP!'MBTZ>\O(,.1LD[Z
M;U C SA*B-Y$O_<BMK@YN9,NN*?!%>!KY!6 2/@F>286* 15[N#]O ^ZH&L@
M!/4&DY]@)2U(_DSH2RE)#N>Z(;,+V5P!_+@76$YW?:\ MY4OS&^2P+4'M&=#
M"A3+9MU7@)W,"Y,K@- ST*P,*(3\!N7U6)Q<*V>1Y/MI QQG)KAAI0WS D5A
M-^UGHBB=-FU#5<#W<]+OR0W'RS(K[ ^+S;6A.<D?3K6S$E+@Q*0V3+N9)HW[
MV4R-(I+"%C.GR*A*(GK '!9M;""4KE*FADO/%_I#_?='S0!"]$W^[R">_Z>T
MRB/&AR.O +M1RSHA^TE&=ZV)L:K!5]*60W*MZ=22'"U5W$]Q5<O">+78!2<E
MQR\CQ'UXU:9Y\>3V<@T@K"-K>AZ_'9SJ\T<\DE%W_\CH&OYWPO_[)AR8>V*S
ML]+B3;R;3A2:!\1Q[L0)_%[*0!+U=9;HR)+>)" ^ZE-A4[WW2#VV:\D5H,4]
M9 H:SX3>.@B1D&M"RV.E##XC.KL7V).@J>PBD@#^ [Q.($3YX5]%C?]]E<%O
MMH!Y0WQ'+R[+\C[6\C13"?T7 PSI=2%HC3CNMZFI3H3S&?9/CYGYJ[$TH-9+
M=468=5E*UO2D5@#6JWE"&>M&'3/<]9N!F4/OI8?5Z?GC\2^>$AU?WBM"S"["
M\T2(6(9S^PQ=_PHP*WL%"#%1TENA\B B:MB)!,X<$#4@1!7SB^1H1QI6.4&(
M^6*!<T:)DX3_N%?T.QU)4GG<RKL"H$C470%$$?^X0 $AU ,KQ /NJXZ89ZPK
MP(*FBE(GV5=+A'(H%8'Z+*\_^]W6O];(]VEZ5X#DH2L '*GA9%"+^O-E:8'6
MVKS2H\HPZCWVX*&/GOQ4(Z^>'W5)!3JQ?<._B/WP U8JFMQ[DP=9[H\"LM8J
M"KF62M;$,9Y;;(+N0S4@C,ZLR:<+>FL.'S$_&0+?/E^(-RP\F5&M3630%A1E
M6G0.EH=(DL&($KF<UMHWE%RKJ""/_'YO&&J3X3_8U6_^5?*F?$JRTR"";X=^
M,[;^W_2<GTN["#;@!/TL;\1J^5D\0/I 7LI13-$38.'ZR#0OU.?X54VE7UK8
MIZ7/G^4?'E'7E==B_HRQ,</0UI:>NS;:H^V'HZ3SPN^?K;#_ZNWO"4Z[;JA:
M5AMKU0EUB_K>*'? 7T?T\[7;,?*K$Q+\H%,AXQS9>PN$5)Y9D^KHNMOO*1-A
M$A K()8%]HI)&O7*YSI%)W(E#378]--0L#SP/+N 6!+V.E"I6O:C!OE39"H(
MGYU.>Z 3U9" *$<?*$?D2=#E4&'%JT?K0D003.26-VD?L9W,OY[V("M'=)(U
MU?X()B&#<JA.C3[^BX"POTBHW?NMLK2V@_ 739B: FD+L<3^T3%6_Z^UW\:$
M_4Q6[X#:]$?$TJJ6RI3$/3)3?KK-O;N)]W4]=BHC;*$W2C'I9>R/HFW&Y6&J
M,'W]L:!7!A6R0*OUAQZ+3OD*2*(XU>L=+&FE-1\PWYB24S[[H6 9HS:R768E
M(<M$J0'Q<#VKCF?>.CDJM)A6+GFZ)6.3 G.2]9C@OQ0SE6!N EJE@+/T/IP-
MNP2_,2S9Q4DR(WY=*9Z G&P#K^34VV@9KUO/G9R1F9.F9!K(6W<O:"M@9-.U
MFD(3>_KU!XKP<.$S".2-"1%M:CG!3Z?(6V.>#%< B*\%XAR\= 7H0_=8<B7_
M.2^L7CTH%,[2\>T7>T/UO_;FO\7>=$.:MK116(PJP@M2#<"T^E'2/^0X-'6@
M07KW2288WEO8[?D+ENI6O'>2XIA!FO:J0HIVP6\B?K>:_Q9+L,WA1"V2C%##
M46(@W7 XAB]>@DYT;H$"T;?,X5/MJ++S&(?OM$4O!BEVUJ5SM*9UUAZU$K%-
M/"W#**7T_6HZR@Y#CL66A('!' S*)LCAG/E65![W1FARGB15J(TRNTWA3J\#
M7V>M\:D\7(OV!ZY-D9F]9WU *(&<<EH].#\B5[WK->(/*ME,*W_$)LG7(C!H
M\G)[:G QT'M"=N+L>=57[8DN)]LP;8D!V<=-J<$0"QH?;> '?T?SI9# ZF>-
MK_@"#S2B>YOU6 8<73DVW'SONC$;!Q-J?@H/\S#"N7PN_P4:NJ$4K<O&$)0@
M8\*4+3; /&3X+)FN,>?H;+.RT"V9BL37=YVV\.Q8H0_*0"H_\QQO7X$$U;&D
MZ<-C?Y?4Q3NA["=#+3M;,=8#IVNF(>GC-)_V4\:HB@8K 1'!CNWNWE/.J(DN
M%F9V(-LOFDW[,E_#/K+)T^.]"E;UO\]#<50DUS<BY67S$C*PHA"AI$S_C='0
MO#_B=6.C4K>)'C$3JL+ HB[;\);L*9GT^/RS%>+B=XF1]"-1!9>6^#R6#/U0
M*^&7.\M)^;+W$NZV^"RSE'Z>QWB"EO&Q<7,\HQQ6EF)XMF'A_(,:1C0[7H(>
M]"2:\,X7?G&R*:TCU$0+<7>D"KSGS=42R;%<\<S,6P(YH/X1"T5)\1]N&^I0
M80P++1P7;J7ZA#LZ.KA!YV)<X90ZQGZ*68D-?F13;_IT]HEBAX<])J(JR@(R
MH_:A#XWCT492)&WF%H/4!M^\+FEX-I;NSQE\:M<5D9#R=B'+,J:Y "F&Z%X!
MKE\\MB[A7)31^[O\JE^^.@MXER5X$<N>09M68ODXK#MF\^@:D8MS4HJK*LMC
MYPE(Y][>8<B>8X=QCDT\9VH?WYJ1&[!Z#/S Y.%!8,P#QWV)?8IQ6% PJK4V
M+$03V$0['U P&_'&Z &*P*PS#M^1\Q>=K[^)S?ZV(_QS0HAG$3_IA7XXUB1B
M>YNC^F?CB?RKMS^"=^)!5L#HCE:M&(+VZCLU2\^L2)M0O)J/:Y<RN'G'XG%D
M1FV31B;ERDM'<IF5U2*+)A9'"Z.TVEV[&NV >Q%&N%--;Z+7%*-ME'UD?+Q$
M<GY<N#@ F1*:UX8CIC7;GH0NRTT$WG:E('%ILXM=,L_XD0+48 S1E=2O&C0H
M"5D(%2XN+7OSN9-1=$58IB^IK>)5_D"["1 C14",CB6,^Y,Z@0!V&19/!VZW
MVHC_ 8]335"*@^-1O[8(K(;*H_,!"@4:6.95,%:-]CV_"4QB!=/R J$DH)N3
M^8-F)Z'Y=4$>'F%P@82 $4>.$UY*UOCTQ*0\[*/))-(;>?F!=#)XF>3<)?>K
M\J3S.Z\2E]=Q]]'K6BL_5A^//^>2.IC/;?A@O72.I2%JQU&A>%JC]2R-+'DE
M?,M.R5(=':5 0-O)9)[V$.BA;6P.ZY+"??;.+MBN\RPB-A035Z^U4->2N?@[
M"_M1D-LMU@Y,0^'FV#RN=[FB7NCQY:]05JX :K[(+CRSH736GH*Y8]UHZGBO
M*'N<6]@P%M;"+$\M_/V#A5@\^#<T#R[9>H;Y#28,Q0T)OE! 6J(%W<UPHNM9
MHADTDFMAFS;1*$12:'.ECP3][W><+><V^'%6;JE-'9PB%<532[@NKB0*$T%S
M724V9/O?6"^S' 55$0F7;B(3M(MA"EI:R8I/<G R>LI#7/758]3PCD>XU<W;
MIITI71L7[U*\Q<PPD5M '8M=)7BMD04]IQ=+]O/C/:\]C^BQC)KYP.D!\-]J
MDVJN#'%#7A9$1@Z,NJ IE'PB<>88N!U/QS"Q.^]')*OM[TO<@H^>/CI*D+;W
M(X,MS2%:P!9$W\ 2PLR\7 WO_P*MK:@R6)Z6:U1Z>X=>%,GQ,-_JN73]0/J+
M0:;Q>V$F+@]=, WI$_2IR%*,;:3G:SZ$PFDWF5+]]Q[CQQ 9O$B#56T,+H<(
MM\:X.Y4GH"F*=;VF[/ KW=_JH-C? MX+].[A@OJTRR$.7.&N+2Y\XI&[DNRR
MMWD]Q>39[A&')[KU:LD];QNICG3IXH167Y93!8HE!]]=E>3L5I(=>_Y%\V96
M?+WZNXO?>D%N/-OS%\%+UUD,35)_^%K^I1N>@'4OQTP93<.2"%:_DE>*X!6
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M2YB]G34H/,<W(IZ1.I/66.+A[,F>V9A0R1]PA-O<Z>; -<,WK\D5'](CCUG
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M(%7T43Y8**6D9Y7$4K7U_NGIF'@)Y:V5C3B_5Y:#Y]6G_@9F5.-;>>!@-)6
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MFXKZ8H%N,*Y@."Y6+W-2,;Y9CRTI[/EP#ZJ6,5F2J["Z)EV[/1PY>6N CP!
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MVYR,T#D9PA<]'ZA2.,2 =1O6BJR9(F?[="-)_+4^%.D,C#(-\-H)A\W!OM"
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M<)D024RD[Y87V6;L_&:2A /\%HC\9#3F'MUM]QDQ(BK :[#+]]-8*30S/:Q
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M@8-1XB^CJ*G]L.^M &*OGNYX[&<#J&,T0*S3,0)^]S3D6YL-Y0O4A7O6G!B
M=]Y)U%$@&<#U"<51S_$RXZ<S8:T1Q&_J^GL78F><]<V_&XWF_?)F.D=Q&*]5
MM(?<:L)@&N-^]$S*Y8;&SLOX&N55:ZLM 0PRN>%6L=0AQ$78;#7Q49B/C8^V
M.<%S,T.?-9VU4NL@ /_A@:/4L=<F.JGJSTSR3HP1 R=4-3$S-& Y-[]D80A9
M8@\ZWFQH;&Y**<APEQB5"PQ\;*K!:R*SFFH6PN6'/4&&<'=BHJDB^(K6KLR
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MIC+A[GH*C5VY3]_7T0"U[.(W#3V7L^CH'#&-[.\/TJ)VGT'N5VVT6E%9/6F
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M[*79K[S0*^M51E4]?1OBPH_27UV1>!6NITVO>W>PTQ:<(9T#XQT(MPK]_<K
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ME?2\.$9HJZ>;*HP):+[48TG =BMB0>-R_C:LW'#X5'4;@Y1FS/;CX_J9TH4
M?)DDC,#RD:TIC8C3;K,Y6Y$=;><?YXJ]>FPP5_OQ2Y0!JLGEI;96693XYOXL
M)K-"S'**R@LWJ!Y7;EF0[Z**C4_>MSDNL;C!YE<;7?*\7:('4T!OR4B!\T.O
ML6PMBBL5DDF5GAD\"\&/ZH/5'7F[S ]2]7^'C0^S#,#P][$"03N=L.,M;"R=
MK7X.(SK&94%M<V;Q5)ZY]0IO[X2,*89'WV^6M[^7'QA.UE5474ZB.T%<3:Y(
M-:J7!M0*=<M,N23H$$.X8[PMQ0(DX1$F,HYREP:\'A!/^?VE 4D(@=\H7LVD
MXQZ7AW)W@^Y:BZXE6%3%+*X]S.)79RQ(MU#SK:&COU_XE:TS3(?38"/I"MP%
M#"78]>0*5($3!,&?0X:3Z.=]+JANH3:G6,X=T>K'^EHG\]YSNF"N(EV0,^8]
M,'&,*X8U:(-$S "["S=%U](>Z%R@RKW;QOE*YW5DS!M_.Z&%T#ST(9G1819N
M10,JZRUIP&B_Y\%=*AO=*\O9X<NH[70BRE_+XZ;[*Q?ZJ9&?@T+T,V0>04C
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MV7B$_*4VI+SMX/#S4TCN:) _6Y#,7>R!6<)&A<B_(-NO('G7J:$;;:IM$33
M(C7@#I.AEWB+;V^4L'ZE=[O,GY0?3_4!"+U?UK%L+:R@9M!$7X)0TO[0K#F.
M6EF^_LSVXY5 G/OHHOF%C8N)]^V>=O29+VY V<%HHC\X2(A>D>]590:E[X(+
M!*D!\RG_B^6N#36$:[^R12M7/Z^S#HV+4NCL$?$)V9\81*(VNV..8#ZP9.@7
M-#F7I<.<)*Q, W( 1 [\,>6%GNITD/KNP3)Z6X-P@P['EGVCO46;B[*-N^AS
M&FOE*4V'3T(%F?G" Q*-3>GYN8;JP@C3 "?Q&[V]5%G"?>*7H[_;Z3T??,L7
MNC_I2[LE9=0S=(VD/S1B.E&NG46ZTPB-QG#N^[Q2 U_I\M^L],R:F&SU.U5>
MH#S8SJ7R_4Q'AMB79\]ZLP#R<_IZ8X+B<59;G20#9(?:,N0UA!?SQ:<F.\R2
M(W1($'N#.+=H/:O[\\&7[S(1P9T/TQ*F2O_=55L#$T&,:P3M6-+1OIL&Q&82
M185FE+>?DV B'H(;NS=E70*=WFA]D[X-2,('WQ,<8'2YROWGN$:@6W>JZ>ZN
MK.D !IX>(L=A!&G YH$9#1@)Y&<XNKTH4D<#7MX$@U7\^:M)W-/'^L;EM3Y"
M55W^67$-$=^AK =M.]D!?SSWD,0^$$+@7C[H58V<%0K7NP2_,;*O"O%PO=X0
ML=>=>2#7<<VM/^.">]77@H0 M1^.FZ\ZJ-E3?9"Z7O)[H:U\NDB^QQRI7 :(
M&$[JT&6K5V2FTJ#[+8]6MNW]^=@:)C55A;#])9%BQR7NX6X_[(><BW_X\/J3
M1,7=2#K=?(:;4C+HA<D*UUQ6I6]98F2I&]Y3D'B0J]R6OGTP<-Z,+@Q:2EKZ
MU^7?7U#WS:)4H[M]0&48.4<K"K-UD\X0HYL;P#X,E#=_H>-%L@U2[3Z:BD/H
MD6&C?[F$;L?-#KOK*;\Q,#3&J,M\-",3^X0K4',:R_7;ITG2X#WX%3RR=T@P
MJ+XCV?R4$'YC]#!34';.XWI[O1$A8_;E\G57BP@VZ0_TLSU- _J50+J_?92-
MI)ST7$>#9^I*B]9AE8'=QR=DKL:%Z6D'W1]2U1X2CF&8IW= QM#;+-]A7UC(
M_"0[L'$E![J,[O:O3K,;Q_@7!,6-"M0+:0#F:;["'<?ACVP8(YXV/[N"'AZ2
M"%*A@W34GQKM"G/K4:F&6<1,WL9=]P/?=,F(-(-O WVKKLQ/K[ (D%<1 R''
MRW#(6=-E1,Y')=3LLZ T\U0%:8,>R4S6;06FJK/5*/V"J?U*?4@TI#YJJ@<Y
MH[KR M_V#]0ERO(\+!7*W%,?!'T\V.;1WS6!I"OP C:V<H?A[6*W&&1.[%#9
M!NAI)CC5HDKW3. 5A$I0V9TI,A3'-O'$?SN :%KZ?+,ZZGZPT^,.EJ5G3U^_
M6A+2_)M)SQX]$9!""O208",X%\_65!@OS>==;^"=NZ%9H#;(A^3XL"J1<X69
MEWN5>UN:I!N4370"2TM!Q:X1GR#N;.<2*8$XZD3L[B]SQPCVU>V'WT)NL^RC
M2JV+BHL7;/IEAGM]^:Z.VMT8N?'A!7-^*6>Y1B<CJTX<>892U<9,O@*&$D*7
MJ)G_?EZ-[MJ6-R1,UC6)K[5BXU7_M'6L)1]6\JG\E+"['E"ID_>+Y;4/*(O:
M'J$!'!J&M>"5E0K#P/CG?6H?/82X]SPL2S ;UKG51OF)6Y&Z%K%T#I^#4F_T
M;G72 &=&50J/+!"*[L!$!6#8]A7.#_B<!/.[>JQX34)Q%=YAMY:^""\7.G[Q
M/;A]]M=[2ZT(I#LJ"L6KXUL":G?J:8_4)O%-:Y3/^K<<)K\A41V>RG)@'SUQ
MS-K?(%>#0_3^- ;:D+0WQL@W,E?:\O&8F[6M)(>W,M4V?RK66$)ZO0>D^A55
M'WZR8WJ_Z\:82>;SAB3X(F91@@\)GS&E]G._AQ>NX9+JYIOG!@)<&(_?EW>3
M=TI( !@U'YX[H;AO2&^2I^D>1"A6,XRI'7%A%&Y2[BY9NU"1,/?N]KD[&[ZQ
M)]6 )L';UGY]Z.^-.[5#0G;S)@2-E6.]G=S'X4_OMU83E$).J>E5BF?)YB7=
MGI&T@ZKS<$X;KGW)Z?RR"OF,<82 \K!(^BXA!>R#%CN[Z]LT)M#E7!6%8U>3
M[8Q]3AN[W+?T6JO[+!:@]OZ$GS[DT<@U?L#B_[^3@=P"OTIR!U_@D-NJAZPT
MP,,^K)C:=%B!H0$2@XB=?^W?^S2** )ZG!;>[?F8V/::DN^'&KI$]MS=H;+[
MDBYBR=R4 LU6[\7VC_BD!!69B9K-0D@SGY[H3XB+C<A;U0-[-2R$#I/M@M3S
M-IM(=K(%_MO&D@KZ _9"F3N?EKK-#_X+(]2N3Z:0(^\:AB/#:_S]18F+(K+I
MDV?R[PQ))PO<XTPU^7V&X2^Y(6AT%C?48_NW=7&GMAOI>VKNU0F"]/&^HY^8
M(E0TE*=%E^#8<6%1GDZ+$A4?[,U\C[5NZ6^];==)OMX7^AE$<5Z49G[JB2=1
MV9'T9<-YZ,M..FEG>PY?_%H^S:JRP6)7N3-YZG;:=*QP V0A16UXF&5#E<PG
M<2V;* H^[ OD/DM!\I0\B#R*.XIKHV]5Q 7R[5J"U=98":A;!)EU$)@HO'M\
M*\7KV<V1-FTF^5D6,LMBVT$>]Q 65';ZA*G:B9*6_^4C/'=.>$L)?87Z&$.W
M= _G[+*'YOB6E0)>))1][I3V$M&S91Q%B F4;:- Y:FN31N6SJ3HNBF>_D"Q
M!YZ9PR=L-24-O<U)V'7H0=]G0RKK,ND"-B@21[<1/;J6$Q^']X6+QO9C981)
MU[9*JZP<+EGC N\@6\_T+CP$H+>0[NC#"]@X&D!4\, >&2L''[1#7QW!>KBG
MA;[FLD^F!61_#N+M^68YRY;D__%8BA_Y^IQU: GZ"J4(LSJ'4*2[_<(RY/JI
MVA226%\UHA_+,G-BF>[[B[(P,77Z2 NZQ]A)T%&M(,N"T65NHJ\HT"X)B7&G
MVO2/CSG].D^+I;25)1M7HJ=A,=":J]C:XJUZ?&B[@T3S2; :]W<^1*^:^$Q@
MRZOBZ6Q-GE\XXT.F"5ET-G*I"@L@EWG B@_D.V->=>YM"B]M/)3B=ROV61DK
M=1E23S:(?U<)G<K[EV%MK$/*F#C$V8TRZ;F.P8]NOGU='S6>A#;>-S<(^)H=
M_>#BMCZ$CECM-YYK0SCI?W7)P?GK&>NN1>O$V6N%%2W(@#/YXT]&3H8> Q "
MX%\2/UU1Y^%T7:W,ZJ4!1A6(;\AV"QJPVD65HP'S&C3@5D8Z./7?/@8@C2?
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M28_ALHG#:NG^TTY>^?(#^K;FG8]KPZKI5S6!.9Z2H"^>.(N[I++B^?K9$<.
M40&K5S\-"*7(4P\%^I#MIZ N<SLGX488L/?3;(VM1"3_+")%)A+BUII^X<9F
MK^*I6QOF!X7"I'* 94/^O]^!CC2#U,B3DU5CD42E#>21J2Q2?9_A:)GD@QC$
MU-;5XGNMLV#Q7\C&^)QR+UUJ9.%ZRN^]?G:NKD,+IE\E' T]HWRHI@J8,;)=
M!4IG$1'D/'U[;V7Z_S6HZLN+$+%VXNF3:CE8XNZP1APGJ]7BG<LK39V=2S8"
M!3\*G*V<F_<0$E(SCER0?G>;5-H-A,C*CU4H\S,<EJY@0*G%=RO*?G<G,W'4
MDJRV0G_EM85!8KQX[[OSB?9S'.?#3+PIFZN066DJ6R@A>DGW]9]:9T^?%0S'
M;&F&O;'A$(K3L<ST"?9BK\R;14!$QNJ/2AI!L>/R0<P.'%H45'9MW)\D->!?
M..MQ;L"?0=RPJ]SF^DZ*O2R 8*<GK ;2O=5S";G-E@<Z[\BDM2^>:XLWQ8PM
MQ+Y6D7UT2H@5&C7Q34%W.#E$ =)Z'YPCJ!(=JY*H[(-Y07;M&19SZ^H;3<@X
M[VWEK]9;'\WJA:033_*)>8DSI /;L*I[_V5V0#JC'3M'>8M<SJ$!;AS-%+FQ
M/GQ@_,VLHK<G'TEF/B5=:]AGW1+1_YTJN>592XF!>ZT@9QT[0J!;U;)C5Y:<
MQ^WL)_UEW\='C>"<@I5.!MC(.UUBD>P+.LN*_H!9:H#N2I*5:,"7G!UJ7&(;
M\G\\KS:UB20J."#7[Q<"B GW$*^B^*)9=Z+@R,STK$$&D8@ON1=W_O:G.!9]
M .#VJ/VW2CJ_'/M" ])2\3Z4N-MT#72><$2VGT<(D1W S&5DW&WR6? SBLM!
M:&R2*#2:WTCR=6[<[7L;@=^:75D]M3.$CYOY;S<[FU-9/:5RH"OG'Y(W59*[
M0GF"DU;=&)!+F32 B^R,SR1V@(/+*$CP*/AIZKI52U.6"VK;^0]/%\YHK?,5
MI_#>T,5+3']56G957Q+LJ,-\Y!NOK%--45PJ+WR!F]IO&C6,3^OB1:9R0T*L
M6$C7X<BTKQ)ZH#E^I[/IC5H0ID=/ICK1S: @M;.@5_Y=X&E+9J[?KR2[D&+I
MEVZ&<R/1J1@?+I<#W*E<!@KJ/,<[R8DV:0]#DFW0"8FQ:W52=HT:TW7#^3H7
MQ$.G)C6&Q,O5S<['\ZN5!J8:L7_*<THUUS^&"(4K@%<^(>:P_' _PA$6IQK7
MPE2DNY4K@B]8%,E17LN\42_Y?[#WGE%-15&WZ$%$.A&07H+2!42I2@NH-!&#
MJ%0A*@H"(J @04."=*D" HHT!41%FC0I)O0BTI$.*?2>4$(DA1>_>\>XXW[W
MN^.^GV_<\7[L/QEI9Z^YYIISG[WVT:_4.\<M5Q>2+^KS=\-8:HEVHI_L]9V2
M0)77IZ"L$Z4NX7>M/GNFDU<2TJ^;"1#8I-Y<_$#4>WO"?MYC/9PTZ3O13XXD
M)B4@.ETTN'._KU9\@KY[H-Y]MI,D=..G^7YRB K9:8XL1A)::"R'4J\@7#(Y
M;Q8D=Q=?OO4F_KAY6M>I?ZNZWJ!075@EI--7 ,[GZ5Y?49GL,>SK82.^.&0Z
M(Y@%< -7:H[IRMJP[\9Y!_+N?=/5&2IL;^SZ;J[Z2,S%HNN.N8U)GY<399C!
MZ4@U1K4LTC-5J]0NKO631,)F N*R-S)>W'8?O;11+DK_K8#NR0,MN&)N,HR0
M8]CJH/4*8D,3:C(3VMJUR^M]-<Q0UW7@4=D9<:GR+PZ?-+OXW96C.EJ*>*NR
MO[$O/$"93V*;47S( >QW=#(N2>"R_' @%#01LRD+='N??<ESHP/5F!"F+VV"
M2S8&Q^96YH;O'@)3WN0L*J@=&U.?_OX;//3=C>O;LBG6%_%^;-\;CK\6"(WX
M*X:T>6EVTW[K7]=[.$.(PD\\!*R)'N$!@Y\>/F.)/7EO^\KZDVV+I?1G!BDA
MH4T :$ESCKTE5XC1BQ71AG*N(1]GERT'72&Z.E?*))OP\OY6&^/1^9[<M>QG
MPKK/RN#<I]Z90OY!<0QX5;:#DZJ$K'R\QN]>I=W3K[I.T[@S#ZK'1UO7 0<Y
ML4K,J9DC*$Y!VT""AX GJLN<:KNV =D;Z_5A2ANR]SZ*27#^3+5>WM]ZG:,S
M7?M$X*[OAD06([A_#I:!(MY(FNA@RAK4QLF2M6=D7I$(Q%U_A9(B%R7Z^#OB
MV%FJ1M?O9E3]2B*%RJR7M:2/_<Y,?Y<496_/$AC"][?:V>)=74J?WX>:)+*\
MK0/3$P3F@8;$E3Y9:STC=JN65IB*IP=+AOX'MDV,066_0)0S]K3(?WU68U+.
MA\#%RK+A__<+'CNY#.YHO//[,DZ:$DG.[UQ5Q<\1K;]%K OV.>?O)T#KA+>3
M=[58%B#$RYB_ZF@]IHN]SZ2<FT)495@<EFAJ:"L!F[1J']70^%;K*IR6W]U!
MR+";8,7R0''>Y*A0(V;)#?N ZD93GC(Z#669]M<P! 630C5?KCY*4L6R&HD[
MH0J\C11(Y%P_'[>%R+0*-W]E\ SL'*=1Z(']>!7+=MF&&E/O9U,54&-;KR"[
MTVESN41'4"B*^!XA.62DX%DSM0?CZ">_6#3]F]/RC#MU^N^3=9EG A;>XQ#/
M+\+@*4VRE8>^^52C&>;5\ !H9&P(J45,?$=B;3[ 1@46^P<6> O?<'!I0<4J
M'\\'7D@*_G-&."Q-T'YNB::4.QEG3/7I3\9C!5%M<;;3?G&+Y=ORAE$3$<%N
M@XYT[SU-_)5#H(5&KVH,)@E?A>*3HLK!;,N\6?FK?*RKFDEF+CU\YFS62!F:
M'05:0I.C-!- T?OEW6>J"[Q\[N0X'1\#ZVX6F(P)*)O!/(3H/(P>R#'S)F@H
M0Y"(*%GRJB%C/?\\=MROVM\15&M-7\4VN@,YS[XRK9LO3;B,<>U]"Y:LX,0,
M1^#>"WO:\26&*2P.M4=E2NKEAE@2[#_?9""7_1=W63S_IRVU9:N9%J,/)R0?
MF[%9&#:7+71V(,4:B+!X[7X0K(6\/VF]2Q9LEVF52[;H^A72?,,8/!2]OO]/
MO^"+F/K%@Y'2Z?K2]0'U[.KK-52E;TO#LIB3<J-:8>VOI^%DAVVCO'FDT(KM
MK]<=VQ9KD@^Y-2N:;/120I18YR'CN8QKW.12)KSZU.DB\DR02*.:]38Q>"U8
M8BX_SHSQB^3;QOVWJGO<W]]#^$^BJ6'G[YX]6WW[\0 66ODJ=EOHYR%0VG\(
M?!!GO#D$W&%_=;"18+*R)^3 7 BEG5E+B_1%K3$%W+(9IA RD<&PKL6;TV.=
MH(SD=F/I#%.A[<XF6$(_J8?<0>G+O/9!NS.B$?3)DR$==GY18=:Y)A._J<"=
M75C;-ABU6<'C]Y!U]3F%BN,_!*+BZ:7HDS2W]W39EAPN7EP29_J"](._99NI
MACTZ[?[[R5T,\5WUJ1=S#\::8:$'J<N/G3MRY#(A?)0GLYK43G3=7Z&Q&9&G
M2Y]NF3_?[H]"$:^%V.,Q+W>S6:]0#@&2BG'8K-K0^/+S"!O'@JV=*VY0]9-6
MZ;(&.[T 0H(I!/PH;(< 5R4Y%B:Z,CIK%SD7XT1)$[V)3N)^@K'[_83ZSGGH
MYQJ39*C&(?E0$K29;KND_OA:W<=O"32>6V?NW<[I7>@Z@4+><!G;8'+;T<VQ
MQAO$2VU,RT3\822#,!X-D/#4=M&U($G-!YVUE/.R^OHY7H><]+P4-*L"2T-5
MCG6H7<*!.Y(XX3O7SO3GSQ94MHHUY\R@+0F'P,N./DR,%@M=X[HC0WILW>!6
MGF?]:-J3C$S70A^IA9(V#Q556Z6 N^LWPRFCD0!*"U(U1LO*:$=1)0)]Z:KI
MF$ (+@>R_0##A5D7Q1X8.=%4_BTTSJ/_+31.%:-6[E=3OS#_,HDIA=0HMPZ!
M.TS.'=P>8!^\]<^ _:?]HP=A:!B3BC)1W8D(IAPNU8$<P'R8Q0E;@:5EHYJW
MJ!(!&/KI1$Q!)L,'Y3;*3;5'2*L:@XGI*VZY+SZO'5S) XG1RXW83*EFR'XC
M=:+#*_#-G/$93UL=2- +D7X^3NJ'MX\4J=^U489@/D3@-YHDY5T>I?@JR+L$
MCKJ>N"&;>CJH U?UV)"/JWQ7SGZ7"@N'$&^6A7K@,!N&7U9'=6:AT8WW2THF
MT\"GIC7OK1H<O(($OQRX^C$4<A7B59;$W@FKA$5HE47;NWK$H#4E?$0NG7Y"
M=)[.\_[R]AG_14<'XJTLZ3^[&:V^P J,BP&FO&@1EW2]EOK1H=WM\0^QT[$B
M3Y]7'G?(F4^%9:*(YH= =/TAT,8. \,S%YW[^> "W FL+7:53])W9B[DD"_O
MGG01,6PK0/$B/]NPP%ZBB+>@?XT@8-28%!,:%FIK^T.8(\P*]S5W&X$T8DZG
MGB_CM?, >P6C%<6*-D XT%-I9DAAA!OTZ(IZR:QS-W[N3H78$M6PSI-MFU7K
M15J:WS$1]Q>9^U"*;%#D7M+1%91X(X3 ?2& _O3JF$^)ND_1PMP[@5M^4*3)
MO-_SV!7,?[U&X 07P1NX<E*^D&3;!ZQ$,N8X5<](SVI-NJ7/3K?\?B'5=/(@
M/!/8U5-I,O E,<SH)6A)A QQMI#[ZNC8Y%BL6X*M>>P?M7<^=^Z9C+LZ"ER*
MUY&%XI$AC% N)>;$,VTRKA*['7B@2(^U0QW<"H(9HYI!F'D32M$A<%=?G2XD
MCS@$_M>[V0>L_\D%*['N#F&8V8JK&1WC)HTUV?,VK*? 'W6")7V=OUCM[-ZG
MJY OHD68^*Q&]NEBQ8S8QBD8DRKOWA?- M;!<OSQC34"I^E%K'67))^@ZE/<
M4HW!LJCF$_>O4ZW@+1K(9\3X=?;RQJK^'2'J)=A+"-$*$RN,X4$]@G#1Z^_Z
MNA%$W0?N)[\'#)JT9 Z!GUK^ZC0N3,AGEM0KY9>W+TS&%+Z=RY/,9-@5']C2
MOZ(5G6A2]&RD#*5TD:#OJ5KU(J)*(^#%E^.=C]]NU=N;4,9V_A 5<7T8JC'B
MYH !-[[+"KN:&A$<FRKU3?:=!\K4E"VIE&GNN #Z(O."$)/3$XP.")=L X^\
MC^)OEU;VGN#[#YFN(KYZ5\T-KMGR'!5* W^@>%O&MQ8^'#WK24ZNZ':XE^!F
M'$+^7)(),$(PN$],E*&80FRM.HF),OL5>QK_&N,J';)^!\VX;K]8]B_7H4G,
M7'_V+]>YO>BGF3]LB.K.+:+'BV!_G0:HR+JD5X? \:JR""P?S7Q.[3%4_<K
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M- 1K, [&3^$V&]-R#!3&U&#*24?]>Q_?Y_BNDJ_,AY&Y8W+T0?0%42J3_W;
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MVS9ZC_)1G SXZ<[1VN.F<];"UFS^;JN"F=F%H\K@=V@V)FR]D\:'";4TN4.
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M3S0"4<S;P;5;&Q)%7IEJ/V<3\KU279P>;D(&(C"/0N*)(9T3*<SIMS5A/5T
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MNA$TR^(K":<\#Z[5^CSU^Y6O>OGA0CF[Z_E2YW8[UQ,DWW74EV9Q)TCX&9K
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MG]R[GW1&BG54?LL:S;CA\ZR'D<[%P-02N*BKOT.(4*KZCR UG7V=Z%'=]X"
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M1+.*!!J*NAU[(I"=?-2MR&MDN=-&M!E[-/S<0B41]<1@'_7!A:*,#WPS?'<
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MN'YM#GG;25$\F5E%VX@6$"S!M/K'^2@U![PGC['N(>M,5<1$>S%@E[;(X']
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M)SVR("X-6-\WU\8$I3 $YE(ACE^D76QCA$[&^XX O"@A@*B#GUC+1=",>5=
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M8(^#U^M'8H;ZE^E:)O?%&J8EL=J9G]M5,^X,3USV<,^6,H1^RPU:R>3EWX@
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M0! \I !(I4Z(_]4:]B]_^9^/R&/L%-GSF)1\"B=/5YE6*>"I4:A$(/>3@!2
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M"$7O&8]_N2'9_XA/H?T5W@5;JJUYA^^992Z+;(08?C&<,+X! W!:7XU%OEN
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M.ZJ[V9A;U*XE$$^["J;QREGT/DUY(Q0;5FW36R&1?#%%]GO\5-#$6W?^SE$
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M]OGL !^?L5RM%"#UIM66U/L('UQ!U@:S];F^./3:\GTD/3@I;_VBHC_Z>&/
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M.:E7Q1B63Q :+2=]V>T=8-O?3"VVA =85Q\?-O;FNM<M]I'+BT\VY7SI6Q&
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MWKF16G9Y;'L^U^#RK5^)R8$9ZR@V%#8Q3Z\X> _%CP@/>CL8.;**%(TY=Z3
MHNZ2Z/,(6<,M!T@#ZWHVH8 4/H1D47A($7=_<_,6PFSDI,I6B7M3TX>$1#/9
MS\?O3)DP%781M+"6K ,' &$>UF"\(:B=UG'#<:.B.-Y;-;I5PRT1-9]O_;AD
M,O1=VOH>&8FXOG)]#.'IXZDP[W  "!F["^N_K^C0&R38;ESP+SY=[E_Z2I&C
MM.BO:;LKA;P?70^ J*NTT;PR]BJHV<L^Y;XS$64]PBK=>F:"B;4@OS%%VW8Q
M<BFT# ?"2'SM!\"2#O7=JTB8$"_ER RI9$BP>+35_(UN$Z;?!6^6,)7Z0#<C
M ";Q:R1O@1&%+81PZ'MS&_=.YF10.]WP";LB:.RIIU-I;=3.M1E9TILD@&*)
MFNDF#8*<1]&I]RO.>YL,8-M5".^BA$0/@/QJ.>5NO3WRG39;W % $=H/RE1$
M^!.Z-),7O[82:*^LJBJELZ^@MGY4C>=8_K2.=)-EDHIK?8176']$@.-KS \
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MMN*X.I%[;5'*=4BI0>_,Q7,' %L^72X,?.B[BL'E .  ?E?1I%+(IU'#EP^
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M"N+U*F/O94HSI/DK9X @=P0]#3";4^OH)M\L5)(F&FIT +BG0B_>1<X$^AX
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MMIS(+P'V&ZK+[4-1IFWCZKIOR^^O*4HM+_\,YI0X?30GQ#D,8) CV^)9/QX
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MX_T]ZCB,N?/83$D-DEK(=$9' +?EXG#1<L5Y<$8!W])#C3\1;(\2GW\(O_P
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MRTL67_/.$ZN2\'#@\BKT]"1!O5*2K"HXFK0GKZ#R:?-S+_OL]\39GPX$GT/
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ML^7S&P/A;Q^16LA55T1'(3HD50970.'#+U\A8(IO\,?\9TKMAD&-O8#=V*?
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ME_MXCUD(L% :J"#&-P<Q-? \O^$43=;;M9#BAY.-9Z"#L=LU"MJ/"-+ ^IS
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MU1&!\9L$KQ=W[Z'[F*AFTX6*.16J*ZE90\JK/,,W[\;@2PW0R?G$J_%!),[
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MMDS_0LN?*_-<RJSI>2,, 2#![Q!@?)N))U@.Y@=)$.]0J[3)3U6%!%#8,8<
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M_/7>V^!9 ANI[1H]E\%'B1P,H1YKF'K\1:@@HF.IUU> 8^N+P?B3#%U6 Y
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M4?)I*B7AX/PR^9U]C ]-J-R\T],;C!N/1-Q,C;69:5>[64U_.'^MPV#+>O%
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M*XS]]G2[29L]1W^YZO)ZV:.4BZ6.""GU,]"GPJP7;QU;[NWMY*(< OZ1%EY
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MS/\TE^#"QPS X[+E2 ,%H<3=[DS$G!E.7DR$\/.;3[3N4"'WI-Q]XIQ7;M>
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MS6'^^J[]56]L1SPX9PR[UR#?:?L2E'GHALEO&^G%&.A%I/T\% Q 8"[[(-&
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MWO16![[12E_[':7^^,C+IX[],E.?O,(%OSC=UX6_>'R%-Y\UL*-H^@'@)?0
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M[JD:%ZR%NG8&,G"G.QN3.];61WO";$9&TVTMB[G1B6:Z%*W.UGY'NO=BW_E
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M+*E_5RL!9V]#@6.PM1&TXH0)?]CKYZ7!C>-:3[:^LS:]92"LMG&Y2G2''.J
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M8ORSJ]!I)Q6,$M_IODL"#_FT\(07Q?S7BE"'70/-X'M/PC3;_IS.A6Z@9$K
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M9WD4#B;I-YY%QNC9Y*T%2QO<>.9>J/]@=NBGD77NX>J!+492@([P9)0V;:S
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MO#H&%X::V QORGEY-#XWKMU9#EW[=L:B'[K6/O:.)G\YX1-@K"4DWJ&K&2(
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M*I$==J<2B^J8V#!0@LI:6U;;KV?5P1Q"=FN6:M)?2\OP&4,])R[#(2^8F#Z
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MDY.V2=7'@<SEBDK1VT"TM:"9=,@Q6]E0D\\Y<F,&)U9G/Z1F$TTF82ZX/W+
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M,-*].TG-!TGD^[BE)-1IW8M8::)^J<N'#3'P!+E4F%EQ]=6W)?' JZ<2XC]
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M'B*9 IJ:<9EH=HN>K/%7HF?,&Y]P>PX,Z2S_W%VVM%L6TK&5\)/XJ6!U&U@
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M[Z^'9?SH^\1H@;DC7G)KG*G=>_/ZWLCIQ1!-DC^!,TG7Q5]PK-;N9S.1__.
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M*U!-S'NALJ8)*+3-<L@W'O 7/K-=DG6[1;HMAFC2J;7WF@=S>J99U9-IC@Z
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M2AWX+!U\='*:V\[@-+4:XU^Q0@?8;Q&\'Y9D*HE1###N'#YOGV9)?8=,*KH
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M.T-6H&A@"+@VU_/<6_!^A2WTF:C @,/SSE%\(37AME=9&&6HOX,F_A_^Q68
MYK-"4\Y*%N=#N=&!AZE67.8^=ZOLCTGGA.==.E@\,]L[)B$,['^AL0N]6]-
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MNP^=3]+I:4[$G Q Q],G.U"9K.:^E5^.S2+RS5)?**;A[86?C%^ 2I:/G"]
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M!CF5]0;_YW(6@Z#K[L#%;_1E7$6:8RL4S=[OT\'DLQR,W4W>W@Q4SJE*0D7
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MQA+?V?#4BOJ0"R>V(%;+LN: )):QX5M;8.ZUNFX8RO_I=1.9CETQ14Y Q;-
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M@=6RK3;!D#1Y 6(ADA$LX:[XE\"CRE',AH/$XQ:<:X*LDY[L[TC;K-.!GL9
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M,0(M,/G!;4*38I@M"A^,. 709@C>J82Q\M*%&@%XP&[>\X$8TUU%7/LIH+-
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M D)6\2148:BV)HQN$\SQU.D+;CU_*CCKIX+PE*ZX8VC&B/[]8L^6 I]H[=Y
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M'!F]#NKQ$B]&+^\1Y 3O:)M>]7P9K3J OSPJHRA$2!NP.1Q50W7$P -Q-^5
MO:MU@0ED2-5VL(<)$JLQG,(V^F%Y^2N[Y*Y7X<-?#_>NWTCE>M9ZDUQ/<RSG
MXK$B.7[(]R;AP73E\Y]>;'/W]]8ON@.+HL6D?D+.D*6(8?@!@N))9+L(A&PW
MOI9BCYL<8(C*,YNJVL^]U>R&CE=U*\VXQ)+4ZLD> "\.5=SI8#D%/$'2PO5.
M<I\^QE=G.&,Z>&$#NL;+3GTM#;7V'@J!?@"DZO57W#?./Q-[*'*Y""NX1KL5
M/SRM^:!H,S"+T))<X^CH[T-Y)U#Q,FEM W3Y$QV%"[^2Z8VGI3#^(M'!)KRY
M8$63_<%[H0?R8<^B]9,7+JWPRA5I/UKJDD@K6?Q.^U$0X)&5AX/TM&L01;E3
M,-[SK7T4A9FC+RJ2'?C\]8$8EZF]O;78"P%-IN5!Y8&";P:9FNW?(FP I*SW
M2&_W\&X,B:0_N6.Q,ZPR5M!N=Z>,A:\N] 9JHQ0N0P+#N8F?03M.V%4:.*Q^
MYOGG0UO/#_7,[S4-<A)!SB%I;5G9#".&)72QZT.H]PLW$_V0N+L*\V/=2(&.
M)R!@1R]="UX[CNTMO!$AG/7#4%;$^WK3G?'^X8W;1N@2<1':1_>M7]$>FMZ9
M?MI0P5OS?'OX!>FZKU-S0^:3)-RS9T.&FA'FAT@.=V$1S[#2K2R;M"9H!K-&
M9/:0%XP:[G$P[<S?;TD@LDBXZ8(,(9)X9N%'#4.WEI09*9 L1FCR/O_9XG$X
M0[[ARUOW7E[3?R#U,B]/(,*-6(>VI.K!DQ3B)5"7FS;/ CCZ.9C/VMBU?!-G
M9TCXQ3)8@OYZ[13PL,LO=#Q<44< A#,#QB! N%/ ;A@U4^293(K6S32D\/<(
M%P?R:NQ%!LZ<U5HK"/B=[G2R7XJ(5(M5;I@YF^HOHUC^\I=>7+[F0>'*?/[<
M<1_\[U_MJG5M4]H:B*_<+2$D=\M?Q+ZBI@ZKK =0,7OW+HESJS)0<=7)KGY6
M79(5LDM%\X(KKKBW70NG_Q8C8!KWAY/#LV/Q>*%W5DW]Y<<(V6@+IX/!F^E5
MPB-7'*9H_ERP]H.5Z37-7##*MOR88/Z,R>K+$..BUI7(/7 FXD4?"0IKLCH%
MA ? 9'KC@JX0(S!:'B#:]@^>%^6&1NQ[EB4/WDNZB0W*#A49T7( JFNP,3O8
M(O)-HE0%#-+S]US^N'HD]\#3B4V*>/IVS]?@;)2745FKO<F[D#V&5Z/-'\51
MJ5=HCE^T]%>.=)GK&RMVTL[4S?;FZAHX7MS*,A%^L_ATR4Y2_JY2[#>$7\J=
MV8V.?M,8,'L#B"AYMQFAUE-I1=;%514;<";4U(=OB?KQQMM&->6_S4]\ZB1I
M-MHCS/AU\J0 [ @Z0_D.J?/N&N.";3^<W2/KN9;9C#GYO]MB]18J+6=WJD^^
MR,>%,/N&8N2;'W06,-<!W]C^VGZ=S.R]0/.T[3J&U8/0@S[HG]A2M\CPG3GF
MKYRGN9AKSL>]U1JG=SW ^2N-MK=U^9^8A:2DL;G$B\?#WB)+9YPX'NTN,6CX
M)6)?FS&LK^[RD>3G$ /@>M._LRO@9S+N?6\ <FPGE-C!?+R="S1B>WKM7/1=
M%:_6,=)^HEUW3'3I>"!S\(N004PAW:(,@>NE8K25X8:3;4K8&CII*/^"'#>/
ME7+S^O4T1XX?AO+B5M^<):;Q'U\[&OPLC&G8!G.Z\;LTE!EMN/])JK3,FF#7
M)Y;H;/HLBL0#R.O4YYE,%-[NZ0!1Q< $VF:)8;56\>;53W=O29KSO*9J;U./
MN"-='OO0<+B5_A7]4F^XZ4]S. UU(]XX!:27D62IS?T'^# D/^04\#_\=+!_
M_/^#\ N2#JQ5'P?I*A2 ; ?G5^<\;9'XR>I_=:#MM^R9:L.EWDP F]$CC=E^
M"$YOE<^MBJ1!3.FI*K<>J-;%Q.VQ%4R^?]TCT?#1Z(RKA+%8=8C9[*KZ?N0A
MF#,(M*BN6ECQ6Z"MILEF )S=*M"XQ\#7^4T=92X'1G=$UN<->LO"Y8KFE[L7
MBYN;)M')M[3+NWR!$Z'JDH_*C:[1IIL@?(A* P4"WD19UR0I_KV"1X4]S&5]
M:@L/AM/7H;M\11;?F$-34MEN6 C=X/JCNE4K(R/M[!A>>?7<8;6]-B=14M4"
MPN#&-.3+][R9AF%V[SO#MU3B,&IU-^H%G@<=TR<C=V:_5YA]=O_PL+XMU78I
MP?QEK%=5B:S0W='R=8%]*9&S ")XQP='>[]E_!3@41A9 ,)SMFQT,_=EZ^,(
M=;X8*^U%\:LR]4\[9.I?%%GSG>4KO@GX"4%ZKC+ Z3%%&S8X@Q@5WP/E4<*)
MY$K(MQ'KU_NZ6;)&4A_$<W\J5TD.W)B$'IZH#JW>_=AT0U"U\9/LO5O%1>7O
M <!'TK2_@ 302;,R:/Y!UY\8:FM)D7D/4[# 5>W\= J2+U3&OWKB)QJ7)>[Z
MC1!@R62>KM<%.(.H2B&$X@/[:B*HG0AQ$:XYH; +UW)"DS)Q+R VY_94\GKC
M+3W[XEY^C+T2]_A!^)I1VA!V&6Z"&^NB*'<TMN.!4<I:P8198;UO966Z/M36
MHUKW06;J\$AE?("_C[](^M:]*'->0# 3@(S]>V049:*#^;!F_JAR3V'OJ#!)
M?7UWT5-5T?9K4)6GI8EX-#=K8LNY>-:1+K&>+.??N7E40PTEYKV=(Y_',X2O
MI6-)B-5>2\OC>^=X#=P]9AK1+KGWSXBXQGT_$\C-L-XIC@AWHYS%K<;X&X^:
MWL91,M]Y6$;FY0UK2!?E^MXU"C2GK]71+)B6JXE4EA&0V=8(N7"WJ;XC('UO
M1<9P1B/:NVU"FM?W1<;K[PP;&SO,6"1PE;($:5"8/ZI@[&CP]U;M+.U."X@+
M?%8Y+DA&\=RU%/LAW/!'Q6ZZL ?,\'/VV;(-[(%N0TM4;YH)6SZ3^I7K+)4\
M(A%+EL8Z](CGB%4''GSASC%)#R9 ""/:NQ*J7'N9X&+E5E%#=DO#?,;Z/F3;
MC\4%M+9]VQ 7RCA(6!DRWX2^6X%=97?_4U#VSGV?T]N[I+OVCHT1G0?"Q=Q\
MJ4>V%R$>"I="(_O>([WV8U>8\?H1Z&4_0Z(Y*F=M>F$;TFAX]T/EJP49&,8\
M@"5KZV!PA#?ERIO==)JM!84=K'LQY:L?F=^X1,X?W9I_<<,LE?N7_-Y%I/;:
M1KJ-N["I72XQANID6PX[YDU[U$"T"&WK+8?S4V09/UEN];3:=!@Y.K4C^V)_
MZ2#+R'T]"PM]AU?T'?=E\O &/9!SQ)6ME8U>!ZYQ?U("/$C)(_>YFH(PHYB[
MO[BOJ:D- "> 7-#H _.U<Y+-_IZ6*'29HL#B[B#48LJ\!)D/>K!MD]Z_-ZMX
M"^L3K?6IR%78J?Y-RDO+L%- EQ;2'1+UQW+GSTP@SW'P6'^^+V&W(8^W:JUM
MIJ'B7;HN\]E^>SJ]LS\>I:&'KY)'(<46!+SU8A_=>7'V6V_%DE68WO^=\ .@
M6?ATB*2%>?>TE/XH*X4A;T^JR'2;C*[GO[QG<EU*O+4\?%Y$V-0#0#ZD;ELM
MLAUN+ 9!2TSISDW:MO$@M%]LZ6C[5:S8Y>PQ,[.58:+D>-X:\QS0B.E$/V/D
M :-2M:]]]ZJD7-G$;S7&W&_&:WBPV_*]U,2I?[0^[Y?%IYO.P"?<<$S$*43/
M=!_TPE[<YK;,""GZL;AS+\AO^/7OY-9GHP6^0>^?K\9H<X[7%'V9)"L66ZW<
M]!/J:RSD]!45XV,I/X<J_!:J?AFOL&B,6CX>&)M/&4 P3YB#K-OJC1/H$&I+
M-R[?38N8^YSB$LQ*GFT<UP%1JZDVA<Q)ZA(^1X2\(P*QUM.: E@PDVW296O)
M2==,KW2N>>&U).8!:7.FH2T:L8 @443L5+NJ"39EO@F3W0MBUZ>PXUR*2QST
MT*U:4(N%'Y[.]<_DQ2W6- ^4GJ9(2:>Q7_WQI<>::(OJ.._ILZW>%/E<Z(%5
M8GANU(\<EEGF4$!O8FD,('#7YL]JS//""[82[9]*Y[<:-RF/>T*\,BXVGENB
M/4/3):;](U1;B7K7#8F%AMYS^W=K^4L+%W94-+"!-/FZG2RM83ZOWXM.K?V)
M1R%1!0C5[U[@I_L+C;P-+_ALK69'^PLLT.=:DQ04:)7MR-CC#T,;^T ;$F:2
MJAZ5W&@H53P6Y7KU&2/5X9<E$E-OJ_)D#D5$#-!.I ^@RR*5%P>]=L@R13;V
M-[LP!:SJG,\=OU?0#VIC0L&J[5RP%2!1BFKBT7A3 V*28(M!*$7,OOUM*2RN
MV._IY_SU&#^D/WUOFF'0Y2ZC[OQI!3*G'R$1!XK7%J&,J:]&:]X QCXO9(,5
M[QXO-*:_^_%-JW9A\)Z+V7VC,V^=^-.'F/9H?3<.:_J$6:A)(5GY%/ 1EG)S
M$G[#*7_5>5H6^SE!N]7NO/ECH@]:!KGC+=/]1Q8Y5[IHO%C6K=T)$1@!*>PE
M/'+U4@K3 3%3Z\1>6X3XHK>P%A2S:#I],>W(E'UAS-7[<OV#48Z^9_PW+H22
MU.&]C_;L0*]<RLA< AB>:/^..>_N[S\7*/E(U5+DNV%WH88)PU_Z(FD)Y1'I
M;_RUXFB_A!Q5$GEZ',3:>(*;8NJK[F]*W]!:?_E >_PUZT@)-F/@RSTP(YG]
M&3"B3=N'*D!Q=B"R'B"(IT]!".:[0>##W_W W5IF5&9'9-N2]LKZR>*KX;[#
MQ;F1)?&2?CN+]DO0*8#,$=@;[%5*XB6:WFEL;\HSFZQN.+=7==_\ZBV; VL>
MWXBTS#13[:+V$C K67PA>*Z0V>U=G[-251,!KFV5&EK:O=N/ ?!MA\KD$!.*
MAG&+Z,*$HX[H N:)#7QF>Z:&^TQ 0%KWK!*]!/LNX.,2S6)A'B_J;\,OZT8N
M>*(,HA'R<"L\U<OV B_  7BVFBIC=[68Y_:B9>$_>!/H/Q=<?[J7:J><)-8X
MG>*H\6P^ %D.?@*..P74/? (KD[ %?<3%O83X'K/_A1\\*\P4M]J:3L%*"DG
MN]Z2?\BC<5['S&J73YQHV@E>F"4\C>A41X3A:XP3](G%'B,446]!F/.>5W4#
M@T39JZ]K[=]-ERWGS />V$G7&'^'\^#\"+'XV3#_U?!3 !O5 _3HS*)F%=I%
MW-N%*?VAL;R?&N(2?;0FAQ;-/U;QOW61:_5(!39LHTV)LCP)RI[@^;OV'-#[
MXRH)HQXC-QPW% I(@1KL.=_.'-Q5'#SB.K;W^U/6L\JTG7VPZN' -W[$/._S
MPV[92D\V)10P?#7]&0"D(TV[T3%?2'A+U$*OS@>BX>J%?2"&.7MW!.<$5*'*
M2Z7U2<'*D_HD?K78=APZ+7K)=5WEU]CN [Q&'P1G5O$%C#H%='Y1,&O!L;<;
MD76Q><.N$<:IHO3GA4+EXSO; 4L["?50@91-N9H>!8:YNW6+,%/=IAR_1L/Z
M3?-H?;9S-IO8I,=)]S@O2G>7)P*TZ 'P+_ABPLV&YI.(!D@8A5GGEY6[(M*E
MOE/&WK[KZE*6U] OPY2,[WRF'CB%>0,*4P@JA0ZN, EGP%=N%;#B"Z/D^C-E
M,]SKAIJ,F'92?/6CL"\O1SG[ ]):-5,[2KB&M\',<!Z,G)>6JP4N.:+<\WSJ
M [.V2=%<]#, ;]K+CRBVD_>T/T")"!#><K>+)$:^[<DJN:U7.Q/)H\TZJ6)(
MI^;7Y_'S2H&>9K%=RV!L"<I@O4D@*0B\$T/-3E>)(2C3B&#34,I5!P]MZL5$
M/N+7C/,IM;LM[Q2Q%@N-5W5;?\B46,TP$KGQH_-$N-KI'A&"6G;J38-%GP*Z
M;;CV.LZ?U;+ FD0;EXCQ7KS?&GU%@\!)\PO9M\]$;")\.TEM%^]5]LP'P,+$
M6G!92>7ZGY9YY7(OO4UWG+DN[Z#6G25Z#SNF48=9_>]5!*2A3/8,@INHT&NS
M%/RM"BW$\'!&3.3=VZ!WNBK=*("BV"7'3B&2&4-2#[X .] !:!>'WYC%(,_!
MY$\!=UH@0)MMM\99#AN)NA];YIH5=]:')$WW)E0%/]=<IG9\?5B=0?-)JFS]
MT505_5Y>.22D>NG;6_19'72.7R:]G:_G+BM5L$WCJM)7K29VCFR?(Q4=VYN,
MTFSIO&C" *BT0C_K&20;7.K=R1L;&$2O@73+A&[E;B%34%JCFIACT(.P5!@F
M5)OA)(D,19,*B=(;NQ+KGL'PB'N/&O6\'O#("0Y5BUW_/:@IZ))#<H;]ZLE"
MXNZES+<8-2RK7SOLEX'O^N9![V1<??-R8^TKA2"S_P(2+<SZZ7,\9K7;1NA+
MK[QXLEO]G/EXV."CFVOL08,ES=2'MC@<YUK8K<[Y:ZAO+=U$E=OUL:^11)#X
M\1M@/!CU+C?109A82I(E_CB2HIJF%WW#R/)M]LY?M@NZA#P&MIU0K(Q II"M
M>Z?*'K@>N2N!IB<":WI0H\$]_>W2>.U\U6ST,JBGR2C(/\1/\VGL5T'GY*DE
M^U<H0(PXA\PF]WC];^7"G<9/C5"EK]RG@,=7/L0,T=*H.GDM^20Z<<6AD5$4
M5IS6VBQ"$)<5A29]Z.(8*_WY<5$S%"N:PWGAN__A&V!8^U5*#^(RKH-\(;![
MA6G\ LEX@,(ZQ=/W0+?L;9!4L\NK4<YKWWXD26%!R$%>OD<RU42J>-/[$!_4
MP,&U8':)*?)U;"O,@GGY\NJ=7)2#735GGA]_JEK!S<&''R1\GS&2AC[[4RU#
M UZ!+&Z,%J*#12!S3BJ5!Q&SK=>7?^PNO_Y%[<]#R(:-7E;CAR>AVJ);E.OG
M8;86>(G/><:X$U*)I<7,K@][4Y/SUF20HX/>6L7@]KA>L 'YPFI?R]_6_ 04
M[?,S-ZEA;8;_5D"V6=_E^E1C@:M76R(RKS^8?=]5XS^K*?J&^/8MU/769(-+
MY/D+$!L#11V?U-:P_F?JP??>$G5OX%KO+*C&E;G+73EC\:D^F0/E2M,8]OK)
MT=$;UF"J?8TO;.CH3@F'L-=[TQ.Q?:E$/[OIJJCUID6Y=6[,Q;WXL6L0.1JW
M)?B(8M/K)ZYS,K1]$"!9 5O:!.& >1OBF1;3'>TM^F72^+1N[S](I%;/,+(Q
M)K8>N)"!UAKHZHA>*,C'(KE@\82!D4+]9N-A*,>"QJOU](,]J[G*V^?YS(U8
MUG'E2]BM?49BP&*W,/6Q"VCFF<@/"?#Z7@G0#^,YO'??#2$T 5=\TABLG>U:
MLJ!@_$+@>;3B*8#&C-Z-JGX*9"ZE_A701V(5257\SW2\42FQ9&75@!"Y['EF
MS#U'G.\WS[K77>WM8/Z3\Y-',B8V$QH5 N^]H4_XC*K6.,2 9IVH&:$-:@S:
M4O.SMR<^T&UIR1E)'U7-9V[]=%UVQ%(\8VFF/ZWH)P54:ZLEWSUK4G_?&KJ#
MMBJF.S T!_CI"-\[!;#:HQQ)QBEAA7CJ_HF<W8% ?VD/4V)2I+X=D$?G5]?)
MJX'>T,7FFB>5'42]YQ"B84<3U=#*@IO@A75(CY <[>EU5VU(7M*B'_EZG\?_
M]V]8_>-_&>C\NH2FKNHJ>\I>O620K,=26?(H'&BFQTW V]Q,[>+097'R,."/
M,A<.9<N4X 3<T_M/H;EY"K@QJ6*-*3B^6]^6*^R4CJ$/N/N%4= ?G%-Q^#_^
M#[E__.,?__C'/_[QCW_\XQ__^,<__O&/?_SC'__XQS_^\8]__.,?__C'/_[Q
MCW_\XQ__^)\5T.G\?P%02P,$%     @ ,8)84M,_,,&Z6P$ 3E,. !4   !S
M9VUO+3(P,C Q,C,Q7VQA8BYX;6S4O7EOY#BV)_K_? J^OL!,-6!V::$DJN\R
M<&YU_28KG9-V=4^C\!#@:FLJ'/*59%>Z/_TCM40HPK&0"DI6-=!9=CA$GO.C
M^.,A>99_^Y_?'Y;@611EEJ_^_4_^7[P_ ;%B.<]6=__^IU]N/T'\I__Y'__M
MO_W;_P/A_WGW[3/XD+.G![&JP/M"D$IP\'M6W8._<U'^!F21/X"_Y\5OV3.!
M\#_JA][GCR]%=G=?@< +_-V_%G\E*/*8B'T8D3B$*,8<$D%\F&+/0YZ(<$3X
MQ=U?0T'#,$WUYSY77PL22.(@@CSF/(B$P'&"ZD:7V>JWO^I_*"D%4,JMROK7
M?__3?54]_O7''W___?>_?*?%\B]Y<?=CX'GAC]VW_]1^_?NK[_\>UM_VTS3]
ML?[K^JMEMN^+JEG_Q__S\^<;=B\>",Q694563'=09G\MZP\_YXQ4->8GY0('
MOZ%_@]W7H/X(^@$,_;]\+_F?_N._ =# 4>1+\4U(H/_[R[>K@UVF/^IO_+@2
M=WIDOXHBR_E-18KJ,Z%BJ:2O6ZM>'L6__ZG,'AZ7HOOLOA!R?[/+HMAJ54N9
M:BG]6$OY+X<Z^_$,\1W)6[V6U8%PM;I?7,EX#-,OSL2]5?P@QA>XU\W9(C<O
MU,<5G^K=77=UMNCC2^SJM<@KLIS@M=ATTQ-YJ3_XK'YJN]$-'2'3NI^6NGNB
MBN^56''1L.56TR#C__XG]=/BJ81WA#PNWCV5V4J4Y?O\@6:KFKS+K_DR8R\+
MCJ1,?20@ICB *(Q"2'F 8.H'*0XX\67@+:KUV[T0*_C+32=(W9MI5W^RT+8Z
M,&L+4>9/!=NL=P_+?8N86K_TBH=_7)$'43Z2]@$EKS8-&A7^HY,4]$7]MQ\W
MBIV%ZW)"M)9O !1HQ 2_MO^]5:\C>+?,V6__WT$,<[8EXU+;$7FQ"T_.+.#9
MFJ$U-)*4M-:M;43A%'@_BF55=I] _0GT_-;:^!>#WGY\]2Y<%ITRI& G!JG]
MQH\L5Y;48P6WQDM;GK9:5[GM:]0@K@3Y$\@++@IE+^]1ZM4+?G-/"O%.66A<
M-?TH5F7=]F51J/=#:%OZW<OF*U_)B_[H\G=2\(__]915+U?*>BQJF[N\KNY%
M<7M/5M>/M7@_J2:J\FK5K$ +'#!$?<$@0U+1$ L%3)6!#&D4!"B4/J4LL:&A
MJ02?&ZE]$TKPC.G=35FIR0B>5EE5 J)54Y_]D*U J?4N_VS'=).]"&F4A!RC
M&*9AC"!*A5J*DHBHGTC*@QC',@@7:M-'\S_RJ]!78,27X>:7/]+0FRV9<QS.
MD1?@6A^H-\H<])4&/:T!?0'][[6:@UKU"] H#WK:@UI]4"G]00O !6@@ .I5
M:4!PMY1//6PN#8/)9)_4S)AZ1':-ELG['V8"?1!2%(7:RI'OGS-"LV569:+\
M*<_Y[]ER>;GB5ZM*29S1I;@L2Z'[W?Y]X<4T0C'&D/.$0A0G$F*UFD&1IC&)
M$6&I3Q?][>U)#CQ;)B-R.[FU=\EQ&PD!J46T6Z3.'R6SU6<:Y*=95CI=@%(&
M]+2Y +W!N#P^&-;K@#, 71+\^4)-RMS.,-RE9'<-VW$M%]FBNYVY58\N1$ P
M\^($"D[4+H!)#])8QC!AB4]YZD<T8&:[@-VFYV>EKZ^EM'AFK/<*K^/D=0X&
M8W.0D?+&+'-(TPU9E!U;E(+]Y2Y__E$]TA"%^F&7'UXU-\DT/Z1$-UL/_MU^
MTETQ65P^\4RA>5E5HJQJ&^S3DMPM/()3+PD$9!%E^MJ20RR(@"(,N8C\)*:!
M;W(B<[R;N9V?7+W_] VTHH*>K$ +:SXYC^!Z>JJZ06ODB3L,**N)?!J',Z;U
MD<8GF^2G%>Q/>8-O3WS(VVZWKI\J[22@_2Z4/5!DJS)C?R/+)[&(B1=YU ]@
MBJE4RSA3RSCF$OJ8A"GU&>-!.,FI[BE)YT9#K;P@WP@,2 7$BH-<@L?C9S,3
M#_+(QW8NAV[^YW3KD[B>OO5^K-$8U"K/X%3.=%1F<0QW4M@_QKF;*>;.#MJ,
M.[1;=\J[AWQQR>XS\5QW?RUO'@7+9";X#5F*LI;CYTS]5.4K45[)R]7JB2S_
MGA=+M0_EXHNHZN]=R\\94^HHH8N</[&J_"8(NU\W]EFUORQ_%@]4% L_0A%"
MRGXEL<008>'!-/74HD1]$BE;5D:2FBQ%;R'\W%:GGOIZ.2H[F4&I-6N)[6&-
M <@D(#4*X/<.!K 25?-UW<*RA0(\MEB 0H/1:WE9PV&VY+W)^W5\%9S[6S/R
MPMA_8:XE6(L+:J5 K3W8J ^N)&@  &L$@(*@_;IJH4,!=#" &H=>RPT2X-<&
MB\,^*6__YO!V*U^S\A_V#=K2XJVH!XQ'/7\YW^AZRR%L[# M06U=^4%K6[V)
M3).86V^)=F>!O:D,;W,8L'WW^E.1E^4B]KDG*0XA\@6!*.$88M\/8<I8$J1)
MDOB(3N33<UC*^5T,7'*>:6D5>8G&?:/VY7D#3YXC8QO%D4=9S"#'B"F[.J"0
MLI1 +T5!@J@G?(2G/.(Y<V2G/-RYTZ*^B6?6D?&<YC3GS%'Z YWC['I4Z4^4
MMO,YPCDR%',ZO-DGYA_JV.8(SJX/;(YU-<PJ4'(\9%7M;'6Y4E*MJDR)LF*9
M*#]D)5OFY5,A= A '0&PP&E"(R(XI)Z/(?*8A%@* 0DA* U8$$@N;18%N^[G
MQO<]Z=5F1%-*3WX[QK<<!S,R'P_=D7GZ*+!@(SOX=93HE&&XN2152PDFY<MA
MZ.Q2X<!6AK'<U8JIS7\I/HCFOU>K2\;R)]6W(EFBG9Q67'U2/*D=U\8]:I$(
MM9%ABMZ2*%#;&TX(3.,XAF'(J9=@%$C/*G9EF!AS8[U.9O#8"%W/T+SV.2>-
M\&"YD=Z.!@<.E!D=C@__V*X9K0+@ATZ%/VO[<ST@7WL#TBK2=_]T1Y#G(>F2
M* =*,BEAGH?6+G&>V=HP FT\\VNSM&>M*DN49\\9?R)+3> %856I_=:N9>=O
MVC=S/^0/)%LM*"88(64X\HA(B+ 70A)$'HQ\@N,XD GUK%Q'W(DV-Z)M-(/-
M)4I?-^TWT&D'UNI=U*Z6^NA[[?_=U]&.B!T.N!DYO\TPCDS8;D<0_-HHZ-#2
M=8^Z2W)W*-VDA.\>U=U%8(0>!KAZ?'QX7.8O0MSH@.2O:M+<*X&^JAGP32=7
M*O\N]'^4A,^B('?B8UEE#SK@Z!/)BL;#S$MDZF-,(,64*P,[I!#K6'%!HC!F
M2>2SU.B,V8DT<Z/_3F!(&HF!Z$0&4LD,GK70]5UI?<0,'EN5.7A:J0$$'V^^
M?@6/JLGZ')KGRR4I2NUBV#Q@>"3M9J -G"BF'+ZQ:;]5!=2Z@$X9H+4!C3J@
MTP>T"H&U1D"K=,(?<(0ALO!6F'*H)G(_6 ]9DURAFTO-_"F:(?N]&[)C$]*5
M.X$KC(_Z!YS=R707_J[PV+K!=];HT&.I9_4*M2OW!T$KM77[F12_B4KOXYHU
M_D:PIZ+>PNEC,E%4:LV^+8CVV6PB\_8=#\<R9B01$0QXI#TA:0PI91CZ" FB
M]EV^"*WN;L<2=&Y+[GM2WM<9%=147A\^;Q0%&QUMC[5&&FC3@Z^W'[[1C\;6
M*NHC,:WD[N"UF3(VBH(?ZKN%1E?0*MO&1?]Y_%N&L4?%[3';2+).?! W+N*O
MC^I&[F_8LO-SMLJ+.M&&XE0EX*V69D&1%%3J]+4!#2!*6 )Q&G+U)B :!U1O
MR:S.Y?;V,C?"_Z)>'+U35ILC/?<[6=6,U](:.A<?Q]6,HL]&:V1^'0J4-2L>
M!<(EI>WO:%(^.JKK+ID<__(P)O@J5CK'MF*>.M/.U[RL"E%E1>.+(E9"9@<,
M3.8+7R ,&9$>1%$L((T8@EAX'B$D2M7_;,ABJ"!SXY/U-K*5N=[RV['(X#$Q
M(YHID!Z9B[ZMY>U@+D<RT<X%RR5?#99E4DH[%[%=UCN[O0''VC\+HMO2/5RM
M'I^JYG2@R)AXGQ>%6-9'46V,3^"''@\0AWX0(64UJ7&C+$700V$4X,A+I&]^
M@FW1\=R(KR<ZJ&7OSCZU]* GOL61ILTX&!PPCX3NR&1G#.R0B#@;A"W.AT="
M>J*CX/-?9;N3W@%H'3W4M6EONO/; 5IN'=4.>7Z84;P^W:W[*>L0K+ +-O=)
M$A-/PI"+&*(X]B"6'H54IH+AB MFY_]\I*^Y,7PM&PCMC-EC6)K9JXX0&IFE
M-U=V%PUGE!>@!>PT+UN;I0:8N+0\CW4WJ7%IH/>N_6CRR  3L3%&VY#-]GU.
M8LE#HFT_F480!43MB5'L0^Y'7I"F81!PH[QJASJ8&R$T:::[Z&H+JV,?> ;V
MVYF0C,P #1KKK 4#C+%]L%@876?",Y%QM?W2N+HL/Z+[45-IWW/3F41'I-XR
M?8Y];YB)\UF4I1"?M?MP6TZD%^(5QV'(> A]3RH31XH$8H8I]# )?9EZF*96
M)LZ1ON;&:(V0=A;.,2C-+!Q' (W,;XV4VJK1<HY;'<@ $9?VS;'N)K5O#/3>
MM6],'AEX-U#D3 A>?E)BZEP5]=UEI>\J7Z[EYA9S<W^YB$*!@T2DD"@S""+$
M/)AZ5(>)!JGP_%1B@JPN!6PEF!N?M-)F34*:AXTK0CG0C\1^3 PO!<9$>F1B
MZF1O*KUJZ5O'CT9^C;R=!X_]+<%0])Q>#U@+,>V]P%",7ET(#&YH:(!\XTC_
M1);7=)G=-98X3;E((AQ!/PT%1#Q6I$<XA3Q,HR1&%*>!91S\GE[F1F<](4&^
MEM(VSGT?G&8L=39((S-1'Y_KT_@,"$L_HK_;Z/-]'4T<9'Y$U]>QY,>^/.!X
MY_\54HI"D<?GS^_;G3A#PJ>,21A&.N,UEZ':%A&AH/,Y(9)3'@?&ISNOVY_;
M7%]+")2(%H<8>Y S.-HY#X^1I_46%$,.=O9@8G&N<QXV$QWKF+TN=H<ZAQ4_
M>J:SY['ICG0.R[QUHG/D:\.LE/J(J)=2HW8.Z[EKI:F(J")Z/^:*O*2,()5>
M"A/ID1 3&5"[>(#CW<V-RYHSQYZX=B;+"6S-;!=WB$URCMU/P-.X>(YSTF,&
MBTO;YD2/DQHY9MKO6CN&3PTCDLMGDBUU@Y_R0F^O-OLH[;^^.="XE&KF7J_$
M[7V1/]W=?\J>Q3\$*<I-/&$B"0N2E$/N16J+1(0'B7K[H.0!HW'H)6E@Y2+J
M3+*YT5,CNJX#HB4'^4J %R4PJ!H%@%0:U)]8\I:[H32CN#<9H)'9L(XCVBAR
M =9*0ID74*MY ?J7_]U9A/KFLJ8_'2ZZXN!&#; BT?6IU ?UEXMVQ+7V0 $"
M6D2 AL0=QSH?%Y=T[$ZX29G;.::[).^^ \MM<%$MONF\$NV&1:8)BF.,8$1P
MH&NV>S"500IIXH=1*"@/S,[V=]J=&Q?7HAEN[780.K'-':[WR!1WH_>&994Q
ML@1]UT=WR68.Z'Z$1M03/0I1O^W2QVZ3T^SP]NNQWMD=^// *_I-[J[+%:^]
M'>_SI7J^;.(&+VE9GWDM.,(I2B2&21"IF<D3I'.H!# -) E#3&-.F=5]O6''
M<YNZGZ\NWUU]OKJ]^G@#+K]\ #>WU^__UW]>?_[P\=O-?_\7'/C)OX*/__N7
MJ]M_6%[PFPZ$F94T!KPC,T1/Y-J6:0.I?^U$=7GS;XF.4S< T[ZG]0FP1.25
M@X#M\T,"9K)5]O#T</-$VZ(K3;6+3T*4;24+]DVPW_*5,H*;U-6+2%D/@E ,
MPY@1J"C,5ZP5(QA[(@I1+'B,N'G<C'7_<R.O5H.N:$U7VD8J#;J"-0P4G0Y6
M=2*'CI#!L?VXN(_,:AWD&^F[TE1:_J[@% -K#=H\_^.B;A-E,RKZ4P7;M*-0
M;D;!Z-UWY3DZ',3C,3CVS4X8BC-8Y^V(G.'-3%S!Z'.V$E>5>"@7/@N86GAB
M&'.DEAU?JF4GP@(RGV-!4" #;I71^WR1YK82G5TB!?RJ=0.U<I8)-!P,L)D1
M/NVPC;V!GV;$IJM?\PKD692KV4CUQZA.\PI%9\5H7K?LJBI#?;6E4\T\%87J
MK9_BGU,4<(%3*%@H(2)(PC2.&$0LY5%$>!H*RY1VYIW/C:.;.]I5OH*MK"X+
M+AP9 S-R'0O9D6GT0'&%!NN-\%,55#B-V;AE%([T_\;%$TXC<[ID@D$;PSBM
M2[2MNLP?Q"WYWFOZBZ@6D12^C$-E@,:Q(B^?Q3"-8@RQQU-?2LR86;5RP_[F
MQESKO/99+2^HR'<[OCJ%K^^CD.C3))2R$"+*&4QU$4LO$"DE/O(I#1<K<:<O
M9J=#.&T0[O<[ <8*W.$+PRF@S=8"AZ_GZ#?]+6J-J$#)VJ?Z"UVFW!W?&^+B
MDN)/=3DIJQOJOTODIH_9<3<7V:*]7W_Y^)W=:_OWBWI5%A[B-)4"0TGU(35*
M H@Y2F"$J1=B&7$DC%R8#G4P-W;N9 2=D$!+:<8;!T$\3A0NH!E[?VV'BC$7
MG%)],_G+;O:7@OWE+G_^43W:3'SUP^Y\/]CL)!/\E%+=C#[YO:%;RDJUE.DJ
M6'7R7$4*JO7EDTZG^U.>\]^SY7+!*.4XY!%,">80A1Z%RO9"D' N*0X\3(+8
M;BMYNM.Y3?6-S(#40MMN&PUP5J2I3%N<P##F5-EBZC6E89CJG *>SU.1X,1?
M-,?Y-Q4IJK=!>U> \3!_1]2O3 %> 2KNLE5]G9'+VK=S!/@C#Z%4O>@P9+&"
M7Z0,$KWIX(D4,>&,RC1JX?^X,C2&QP&_ZWX2Z(6N5CD:Z*9')&YA'/UH9$T6
MC;RU-0Q^6,L,.J$/%Q4:<"1BCI';HQ"#?B<^ C%'XO71A\6S UP_FOP3UVH>
M$UW MTY$4?_S):_^(2H=IB"4DOSR09>H7/B<^IA&(8QCKI;>@&.8"NE#Y@4H
MBCD.D&]T_S:@[[FMP(WT8"U^DUFE_5=I )0*8*T#:)2P<#ZP')GCQ#4RWB/S
MU\R@MO#Q& _RB?P[W$)OY]LQ#+RC?AV634[GTS%,URU_CH%-#%@T;L@JEUGK
M-Q\CZ2<A3V$4Z"+K<<(A02F&B4!A&".:1+XP7A+Z+<^-\!O9+&AE"R8#?AZJ
M_-CG)[580P+GMP"P8,VA0$S$B2=>!#N2VZ?K40K;>F Z@MHGYQ;][/W"P&CX
MCL.:<^+/>:G]!Y*44:ICWD-=L21$$*<BAC3&@I*$Q#C&BRJOR-)L)[RG#RO"
M6?<TXMJK9&JR8N6-L/G*-O1]#Y!F.]PSX1F9DC;F2'O;\X,6T.'F]8CZ3H/9
M]W0S;03[83U?A:T?^>K9(5+OFWO\1>S%2,0AA<C7!:53)*':;DH8\!1'(4LX
M8<1FEK_N8FZ3_%;W <[V ]J#I=E$/P^AL3=^_0O<5KQ1@I5V5!\I+*GKY:T"
MD':T/!)JM/O- 9N$7U:%8/G=*ONGX+?D>U?K9]>7YYLHGY::5G1"P*]%EA>-
MK[EZY&M>9O6BM_!2SCB3/I2ICEZ.?0RIB'T8<^YAC%%"S,HVN!9L;EN42\X;
MP8#,B]I_Y+$359^9/VHM;%)1.!](@UW0&PW/R$S6UZKV35E7/EO[+7::@;5J
M0.L&:N7:X*7ZT;5^;S2(%CNY-QK,B3:"6X.J9QOM!C7K!I5W@UJL![6VZ)NI
MV%R?;4]45Y%1(T!_=%_JLK_IMK4CH+2U*QZC_:'YP,4CR?C'[X]-K%=3D*^Y
M5>I,QA AFO PA;X0"43JK8>IX,JDP2()99#&H6]50]B@S[DMH:W(0#0R-Q'S
M>>U$WAGI0QPN3- W,]@=8SKRNM?!V8I;H]FXY'<WT<[->@N W";P/MWMQ"F[
MC7%XG:3;_-&!>>H8*YX$_UKD4I2Z0F@3>-I-A4B' Z' AT@$5!$13R#U8@;C
M *<$2X28;Y44Y7AW<^.@5EI=9F<M;AU/;9E [CC&9G3C#KF1F:8#K2]IG0I@
M!(HQ \5IGK7C/4Z;/,U(^U<9T<R>&AJV0ZM-BK7=Y&O?!%EJ ZP^_TX]Y#'"
M0QB&G$ 4:A>64!)(:!"D*4\\YA&["![3KN=&,YUL8*F$:VJ<D*WTB"4YH]:)
MQ9"8,=$X0(_,2B<24)9U LKU0&CA70:IV +F-E[%N/>)0U=L47D=Q6+=PL"$
M&>Q>\*>EN);OGLILI6CSDOW74];N!]^]]'ZKDP@O$A)Z?AC%4"9"0H1C"5/.
M)/0"$M H\0A-C7PQA@HP-X;KY-?4UFD ^BI<Z,0*O0_:9-FV>2]LQ\F,\,9$
M?V3:<P^\??J*@>@Y359A*\.TJ2D&(O0J$<70=H96=%JG3E<[4UT[)EO=B173
M&0Y0&(=)' 804:1C)F(?8JHVCVD<8^(IZRZ61FGI#/J:&]?U4_[K4Q;6%]:V
MR--AA,VHRQ%N([/4+F3OC2 ;4/?I)!ANJS\=[F[B&E G]7Y=">KT(X,3.RAJ
MJILL,OJDR>BK>AE^)M]U$K0F]5G_C^5747Q\>%SF+T*H'YD^,4FBA">A[\,T
M\3!$/&1JUZC-JYC'*!(<,[OL8PYDFAL+M;+KFRTM'KD38)FI(=6&@&A%KZEI
MK9-U6H.SA]%TNSGIX(R^#ZVU 7V)@=9'ESQHAJS-GKFED[YV!IU6%Z#5RVD>
M!5<@.\ZU<+984^=C<(7CGIP-SIH>$FLP-,O9]6,MC5I&OHE22<<JT:1/_F65
M5>7U4U56:LU7R\N7I]H_W6.!LA0QAJ%@RGYDZJ=4Q@AZBM?],$XP1T91Y9-*
M/3?ZKT4%>:-$;5-]N_FE!/E&;O!#M@*EUOV(O^X;O@;'%X?9#N[8^WFM#WAW
M/$?ENS9'9?N][1R5K>YJE>%@HSUH7IA:?] # #0(S/$%L8ECF>&+,E6,3/TB
M-,E*6?^%(=M)3<O>]Q[;%X;4+TR?1(K-"U/6+\Q3_<+T:655(^'*>6KJD3L>
M\3.5,!-&$TV,[W:DTM2=#]NQZO2&VJ[*E\LZZD*MWZK7SG-,.XIUQVU*#9JM
M&D)B 4\8"@2,N*^O-Q&!Q&,A3!*?<.;[/O6L7+@&23$WL^2+3K6ZT0)DK1K@
MZ5%34N\86FU3;]23Y"$'GPJ=<L1N>SILS,PVI*./Q,@VQ+;\H%/@8N,!77O&
MKJ\+>EJXVW">!:+++>8P02;=5)Z%U>XV\KS&QBB&NOEMDTAVX0=I$ GF0Q;1
M%"*"(TAU)E).*4U#%-GF=[4786[<^3,I?A-574*X[/DQ]+)7NRQKNG=0S/AQ
M7*CGX">RD7RJZJ+'4)NNC.A>*694+_082G:%08^VY+3JBK9G;[6%<R]N?\^[
M7!XB"3D*(NC[Q(,H#4-(DS2!7BS\*)8B(*&=_XAYWW.CO:;:QKX3#RV]FJ"M
M B!P4B-E[W 8NHF, _(4)TJ[U4PV6[ -ODKXT[E'7!4W.0;:!%5,]G8_AW(E
MQW QK$MRM(F!]ET=D+ NX$FYSZ.8<N@CI&RWB*NMKX@E1'$:)B2-$Q9:;7VW
MFY\;05W>W'R\O;&TO;8!,[2K!L,P,H4T@HU2QW2_SDXMGNT>IK5F]FKWRE+9
M_ZUS75F_%CJ;3?6B+Q&KRQ7794P?->4WKI%<8"^15$(>)$*9()C#-/09I#S$
M7$0\E(E1H7+;CN<VO3MI+^I;^FI=N/>Q*>Y]GIOJB3$PM#M&0'9DQC@/U#-<
M4,T0&L?U]$3?;^1R:H;(85=3P^<GKE19__,W45;KFIG^(@@$I6$801Y[,432
MIY!*'D'F)2F.<$)#'$U2LW*/<'-CO6W_@>=&5JMRR:,,X5D;L=$'9L*=VJ#Z
ME!>M"T"KX:DZS-,5JCR"^RQ*5NZ3;PZ[P;.0=5;&\E@?@X/2=6I<W5Z^S+33
M\7JKA!F.)6,8TI00M;>, T@]I&Q3GGBAB-($$RO7W\-=S8V2-Y*"3E23+9<M
MP(9[42>PC;TO'8;8D"CT$V XCD _U-O4T><GM-X3>7[JB8$)+/=EW&Z3Z+VT
M5%5^>!*74DW4?PA2?,J>Q2)AB. T3& <2P21'\001QZ!(D322V+FI[%5;HM!
M4LR-96[O12&(EM R[^6@(3 CF]&!'9F'&ODO=I/W7ZSK(JI]<)4#*I2YEBDK
MK88?:$6 UL1AHLUS@'2:BW.0(-.FZSP'JU<9/<]J;!@I?GHJ5EGU5.BT09^R
M[_JGLKM>#*(X";FRF@+&(")J.TR31-E4$6%AF@0"2ZL#^L-=S8W>UI+61TZR
ME=6.ZHX :\9G;N :F;2VD>K$'.$&\#0:+IGG2&^3TLMIK7<YQ.") 6$]G>/7
MU>H3R8J_D>63N):?"B'JO5Y9WSVH#M=DM4@BC[*$I=!/%+HHH@DDOH@@9]P/
MPR2-TM0HLGM0[W.CD[7'9+8"4FD GK4*VGE5*B7:\)HF3V$]C;JTXB\6 176
M(W2<A$;'?61>6D-^M0):>%!+#ZXET/(WAU]ED]2PCG'Y/ 7D%K$H8T(_44R)
M^R&P"PH9"N'1X [K1J<+TABJ[U:PQ>!&!M[<Z N$J[)\$OS#4[$^&:S[W7_2
MN" \PH)C#*.4>Q!)%$ :>Q&, T8CFJ8H2.WN9ZQ%F-WRHH2ORZVJ!87E#P_Y
MJ@N[TN$2XKLH6%;6?RU?Q7NJ%4F]6RO!ZBN"W[/J_D#TU@58B3HM0$6^6U[M
MV(^QX07.J",WQ35-"1KQ+QINO-A_*=-WLVLV_9_R0HK:RG-X+3,83:>7+_92
M3'O%,ABE5Q<IPUN:,B[_JWKA[]6'7Q4EJ*7@?<TOM>QMM@#M&/TH6":S-KKN
M/E\JH18L)"3QPQ1&2$80<9' E 82XI0%G'EI%!%__ #]H>+/C>,[/70E@CU,
MW^9O452M9&\_RU;ZH^Q9/:.::FJ,E)VJS7<:7:<(VQ[\&AEL4V;]<DRQC)P5
MZ;]^LVH4M'G>X-#&^K=(Z"4'K+$ -W^0MV>*Z/\IWJ(_3!J 1S.>.LA%;YX1
MX-S1'"<UP&"I_@ Y LY%W$VR@+.EL#/*N,@6']7J7+U<<JZF<'FCYK:X+KX6
M^;->N!=I@FF,J=KA,J[,)R_P(28QAS$- L)P@D)A5$/M5$=S,W0:64$KK-H1
M:7&!KJC5"FRVWIS$][A=X1*UD2V X8 9,ZHI&IN-8-GM!$O!_G*7/_^HFF@V
M@>J'W;W?R>8G(3%3)3NZ,?[^L).QIFSK+?G^36C!LV56,]GZX[;82UNAZK+Z
M)%3;9*F%>%*C^+)Y7DFU\(672($PY)&N%,5( "D6!,:24$P01A19.;$XE6YN
M%*2+]A%EHS0R*^ND%1H42EB[LR^WHVAV+/9F8S,VT4FICRF?15=%6H^3EA%L
M*ZK'KM4)K)7:?>8"7#YH+S-WYV>CP.[R:,VM@).>NHV"[>Z!W#B=#&/_;1^@
MSO5G(5/A8QP', RXSFB,$H@1%C#@<10&4<!E@&UH?'\W<^/CC4/<LG&(:[><
ME@XY!S U(]7SD1J9'5]Y#7X]!9(UPQW'P"55'>AI4LXYKNTN>9SX]ED!#J5J
M3D?)=97@TI0&V/<P#%)=-B:,/8@#+X)!%(<LBBCV(MMJ>WNZF1L+=%+JV:_%
M'!3*L NEV>0_'Z"1)_\:FU;"<6KH'<%@A,B%W9[>(FKA@+8'(A8.?7O ==VW
MC-T_Y"O^GBPSF1>KC+2NHRP,/!8A"DD84H@\R6&:QAC&0I DB7V11$8^N4=[
MF=O4[^14K_5:4HMKAX-@&MPMN8!HY,F_#YW3#K@6,%E<HKB :Z*[#JN7RN[R
MX10*1^\(#CX\W5'^*?FW3MQ/?GF8[?-3GO/?L^7R4UZ([&[5<"I[T2F)RF7]
M:OQ$LE5=CU(Q(O<IYE BJNPAF:A=44)BB (91$SZ1/W1QAXR[WIN1-E*W)8^
M9R^@VL@,"/^_3V5=K,?.=+(8"3-S:AQ\1V;93N@+T('<R0UZ@@,M.?A!RWZX
M7(*U[64/F$M[S*+W26TT>U1V[;8!+0RPY=[G2_5SKK>'SZ)W$]F69/DY6XJR
MRE?=IO&;8")[KA/[> %A*$P4L>FP*X2B"&)$%,5%*96QP'$DS(,H!HLQ-Y+K
M"B ]=!*O71"*M<P69L_PX3$P'R<!?63FV])AVQNU&XJU'FO?HF_3#H6%B3K)
MD$QDPXXU-';F[MF('K6'A[<^G<%\-@);%O7YK0V\=*CN1=$KZ=ADE_.$3X(D
MB&"*_!0BAM0B1&,$F0@1"V(I?6:5X6]O+W-;8VHA0;_@Z* 4?OL1-;QQ.!>G
ML2\<K"&ROW X!H'3^X:]'4U[W7!,UU>W#4>_/&SV?Q,5T94#/Q*UAU_=E9=,
M+6%/R@P67-<49%FUB%B:D##F4#"JMM=4,(AE2F'H$8IEX,>QL,JJ=+K+N?%"
M3T+ &Q'M&,$ 93-Z<(O=V$>4K;"@DQ;\T$>R%=CACMD<'9<T8M#KI)QBCL(N
MP5@\Z<+!X5MV=U]=RU]*40>8+A#U8XRQ!ZGZ01&-VO-BE$@%>1"%Q%?FAS1R
M?C7J;6X<L^/N  HM+LPE?%*_U$D"SG)\V,7:T!IQA>#85LFN&\2W#CTE;!-L
M/I9#Q %0QO.+V.WP#=TC#NA^W$OBT$,.S]CJHSQ2!S?7COV+Q/?\$.,0)BC4
MT>.I!S'W$LB5]<)QB"7%WME':KN]SHUAMH\-^K$]U4;R)H+'P>G-JS$XX]SL
M'&3?ZI@,](1N@NS& -7!"=@YX+[)@=?1-]=5))DM6H,.LUXU]O9G5X?T,SJJ
M.OCP,&OQ_;UN^&JU20WZL:RR!V6.WJH&/^0/REA=)#(@(HD8%%A?_J8>@3A0
M_,ZC(.6($Y3:N<69=#H[9J]EUED]>EEM.[$O@!;<SG8T0M[,A'2-Y]A\?AI*
M\&LCM<,C+QN07%J61OU.:F#:(+%K9UH].VXRX2_B>W7[NU@^BY_S575?+CR1
M(HG4WC9B-('(HRFDQ/>5+8H#3_HREM+J/'VH('.C+O5B^N,D$WXU!&9\-06P
M(W.8;4KA.IGP]>H-<@D? O$MT@F_DF66&84/(38TJ?#!]@9LQR_O[@IQI^CV
MDO.Z4#M9?A//8O4D=&S5W:K^;'V/^;.H[G/>?N'C,KO+Z%+<YLV]IMK9^(3Q
MV \@\;T (B(H3+&0ZI^ Q6'B,5\853EU+MG<&/1K7NF$/V0)2!W;V$YMJ9,"
M\3KE!F'WF5*FWC#I='#K#!PZ28=.$T>6V3_5KSHSG*YA7&Z<; S/'-T/O\%I
MP5L-ZLCLO58+;/0"K=R@IUG/QZ/1;?VE3CMPF[=N'S9G#VYGL?GYQ%L-YT1G
M&)MA)9MA+=H1*WK#NG%P>VB&M?N2Z(953?#&Y\W9:<<8V!\]$7':X72G)F/@
MM'6R,DH'$Y?7NVX2C5X_566EEA1E?7QYJB-*O-B/0^D+& 8>ARB((IB2((:,
M81)@1D-*Y*(I(W=3D:(RVPDYE].&/':E'?.*JTG?FF_$U2D/J+C+5OJR5J_L
MC33@AVS59A<_?+<^T9 G(:%41 1BK*L]^RR&*>,IE GUD?"I1QEKA_SCBO]A
M!KR3=?+A%LI$F^5 FVVNWW3H1K;;'%1@;+54/VSTO "-IC.HQ'AJ$&91CO&@
MD'^,FHRG,'96F/%D1V>D=F]RY)6ZVF^E$Z0LGWA=UZVH9:NJ(J-/%:EME2\*
MSWQ5*6Q5HW=7*[5C5K;-NN @(HD48<@A(7X $8M2B"F2,$51@&*$8A$%UFG?
MG8DWMZ. OG;__5]PX"?_"D2MY5\')&]W-XJ&B\.;C<W8*T-/L?\!&M4NP%HY
MT&H'^NKI3=ZV@J#3<)0RE>. [SQ'O#L)I\\?[QS=O;GEW?<R[DU97=!.3;5%
MRJ2D. QA("*L=H<TAA2G 0PQCQ3Y2RR">(P;LDZ N9&YF@9HG)NQ->1N;\2&
M #G'FS"MP_178;OHO<45V%J&65Y][2(T],KK53M#KKK6617*VWQS5J??HJO5
M>_*8561YR10'E_5?KN5^KEW$*"4\2@AD""O2BZ4/"?81C$3,DC!(26#AF.I(
MJ+D184]D??;1.SYO2^BI#V_4 ^0A!Y\*8IPLVNE FMQ733\\8U]5;332=TV]
M^RJME*X UZH%^F-X+0]9MF\P;C875-./WU1W4[UQ5,MA;X8]ZG'4U<+:<23;
M<W&5KV!_(+-61V?W4FXA/WXEY:BO"6^CW**S?1'EN.UAFXB/#X_+_$6(&U$\
M9^Q @2S5\[/J2O#Z7$N)JT3K__U]7E9?\NH?HFKOT/XI^"(*4^%3P2$+F(3(
M3P7$*6*0AQQ%@2<BX5D=+(TFZ=Q6XUKH[3(Q3(D-"M%$=2K^>&JUW%-X\-O-
M+W9[FO'> +/-SRS&=<*;B[WE!]?Z=1<56B'U:05>1 4V.KE/KSXZ_"ZW6>,)
M.^E^;'3,=S=NXW<X8(>WK@RDILKZY_K:=4%C'!** IA*O6F3$D$2DQ &"<-"
M)DBM*.8U#@_W,S?FWQ0C5!_W2G[5PEJ8[D>0-=A%N<%K9$;=5-?34&U^<PB5
MQ<;%#603[46.OF6N]A6G$3FZ53CR^'36_VD=M@QZ@Z\/C-)K\E[7=9!TC7"%
M_/)5W8R%Y_$DQ8F (M9U826/(0UC"F4884RHYR6>$6=:]3HW!JVEM8S$,T+7
MS)9UCMG(+-K*V]8VT]N'6N2ZFD\K-/BA%=MA%ADKF)Q&XQEU/&TXG@T6K^+Q
MK!X>DO^!E/>7.@=U>:_O.Y_)4I]7]++6_%3D9?G+JA!-A(/.Z?I.R+S0]7H6
M3%$1(9)!RGP)41(CF(9>!#T:"QRPU MPN%C5WKC\UC0WQ#D2&4V]M)EZK^0:
M<1HJ9>K9Q_0/8J,6(+UL3G=:,;7U[S0#2_T[K74#%?END_W@K&$UL"'''Z6)
M"%(/B%($U#_T5 ']/%NU,F"C#=#J@$8?S:63C8Q-LHJI1FBJ#!9.YI"SY!8N
MT#V>\>*L'B9,@^$"B>W<&$Y:'+ 8OGO*EOPVOWG*JOKJNUQ$1!(N8@\&C/C:
MHR:!-$I2&,E0,.E'W,=L\2P*FANM;:\ZL)EG_6[&FV:UB+#*8:F$;!*IV40P
MOH;08#$Y"Y:1%XA:-GTUJZ5K?%_.P\."PL_"92):;O"I<F#ROMAQ[$'UC_+F
MZZ>FX\*#$F_QV^%O#7&CV40F7\MUG?6OA6#JB4QM%SZHOR[S1_V%]Z\_4CS[
M*2O*ZOTZCOE&T>TZ/*YL*QF%' D:\0@*9=$K'O05#P94P)@$%$618 DS/Z^=
M1.2Y'5Q<'HH@?]SH#?A&2[#W0VW_2*U\+_"\#C@?&&\^R<MCXM@SMU=B;+>?
MWMMP+<%:8]!3&?04!._W?:CW+;7>8*,XT)IO MO+(07-IGDM;/R&YO9Z3.55
M-!EI.',WFG*DCCLC32+)A*Y*4R*[[<@T:<_#KE#6-<2_YLN,O=R*[]4[!=UO
M"\K].,)80DQUKC"&.:0\YC"D7D"#D <>MHJ).-31W.R-1DY].&5J$9R$TNR*
MQ 5 (Z^^&VPN0",E^+7]KQ87U/(ZC P[!8G+&Y"#?4UZZ7%*X]U[CI/?'[ S
M6C/,K<)7=!L9Z<>4<@9)E J(O$! G% /)J&,&:*!Q(P:;V3V]3 W'MBD.*J%
MM+ "]^)G8,N?B\K(DW\'D"'V\5YD+,S9<Q&:R/HT?77L+,1CRA\UZ/8^.)W]
M=4SN+7/IZ!?/+/K17OR6"Q12@5C$( XB!-5O'&(12^A1C/V4<T12;U%I#S\S
ML^95#U8\MNYGO)>Q<9K.UU&(HI5S8$6/-9"8*'-05X,7/(H@2B,?4A:$D$4*
M5!0%0>I[9B?\3J"<YI#_VCF,9K;A6=",O"YL,/EX"I/A]4YV]1ZEQLFZD[>I
M:[*KX\%:)J^^.(P<=5VEE?9T7C61^3IUOAK9MNCCY6KUI-V<-W\LOXJB\Y=N
MG.T7+ I$C'RD(.4I1-B/%9NFRBH,&!<I"7TOM<J ?[Y(<S,C6XT ZTE=^Y=>
M@(>V8*IH%"C^1[GS+5%T?[/TW',PLF:\-.UXC4QDW5#U!:Z]J#>U;1N-MKY1
M:M=JT"GE/@S%'<0N.=.!5).2K#L4=UG98<L#]NHW]UDA+N_:K90?^-B+< HY
M3@*(DHA"75\*^BF50GT6DM HT__KIN=&J[5PX/(GB\WG-E0&^_'! (S,4ZWN
M=T-VX-L@6&R]!X,QT9Z[ 87<N;J/V:OOT6WV]A/3[:_W2KJUL=[_C;=)S?OQ
MN[[**'46J#9])XF(+]( P21$"421ERH;,L)0(BQ)&D9(F)'6:!+.C?NZ_*QB
M(^B,\K.^'F S4_)-AVUTQG:7G[6GY_SRLQX<A#GE9WTMY!\J/^M!C%WG9SW<
MT0!#M6GA6G;WW-?%-W&GO9+SXF5SI=TD#13\:O6JW"3FE! F(\B#M,[1IVQ;
M@CT8D)"1E$<1#HRR9CB19FY+0J./IO^-9PK(6O%U$IUSRJR>/70&MO:4 S(R
MV;=C<2TWOF?7!=BHT_<QZQ32^:K.*=IZ]A!9[ 2F'*J)-@^;Z;/V \L+4&R&
MS'16N=I]N,+XZ(;E[$ZFV^.XPF-K6^2LT:''[T7V7)>Q76>*_%F0\JFHU^:K
MU>-3M2 RPES($ J1A!#Y(H&4!QRF(8ZQ'_H()5:IH@SZG-O2]K=<C4@MZ;H6
MJNUA^&F<34^[G:(W^G%V)VT_Y6Q/8%!+[/*DVA@>MT?1I[N=^*S9&(?7A\GF
MCPY,F9$_/.2K.EWW5U)<%W6$//\;63[IE!SU?F#A<Y$&/$4P$$*9VA0+F!*?
M0>%Y@4]X'$2>D:^719]S8YU&Y":+W 5X) 5XUN+6QRI<ER OROI^KCYBL3QA
M,1D",T)R#.S(A-1B>M-@J@361E8C,JAEKF_2:JD=9M0PA\AI/@V#;J?-IF&.
MPZM<&A:/#B,EW59MXM\*=K_*_NNIJ_,N.?$8%P0*RCA$S(\@U8FJ(X8"RA@.
M0FGE7W"HH[G1SUI.</GX6.2$-1'\:ZGM".<@O&8LXP*TD:GE%%[@UT9DA[[I
MIU!QR28'^YJ40DYIO,L;)[\_T*>SNA=%9QYEHM39?YML/XLDH:E,>0R)2#R(
M>(P@YBR$-, $2QDGAO??I[N:&V'4DC8YL=O,5<N-V)8^BH?Q3=/ \Y.(P3#@
M3.-+("&40/762H_**.%!:NGSZ03AB9P_:XR7^>H.JB%]& 5A,T9V@]K(G-S
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M6PN1X"0-LHC (E&EY$D@(%&][2A%"!$6DXQ:#&6P7'UNFUY'/]@S "0'0+(
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MTZ7G=O;M4=[:S*H37IM>OB<?_-4Q8.FGLQ"*V08P#M0C*W2/*#L,![$%S._
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MRAVX?3JE>IF' [5I</G51GMG<^X6T./7 HXH3:1I7C!EG^.X@"3' I(T+'B
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MRHS&.MLM.S=%LB_9DA"7*U6M_RH>;1_>L13$L*H9#]Z1M4Y',^@1W:L5:F?
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M2C"^L3?;FKSB.?+^LP=2$WNS"_V\-/.,&H+][2_&V/C<1"XO.NE.88S!Z^W
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M.7KR(I>: ZQTA':\??Q!>5V_EZ?+DNDV2>M5V_*=W:WN*[RJ,=6I(VF,BB)
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MQ[^R*O<NVJ ]Z"M$^;L@.AN'WR[O=$;96A<4K3K.K=M_*NF+X];F&>4IBHB
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MYEB?.48BAE&HCR-EQ'0/S$375 AH1*(PL$R'/3/0U$A!RZE-O^9<\DG+JNW
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M JYSH*22L2YZ5I4](%I][<(X[>!W4R9A*M/BN[?W6[Y&8YQ%7%>FJUE(.O"
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M3VR(SEZ$J?'=3E2PE_5_V?'9@'DPHS6_Z'IF-YU?IZ4'K?C:#/U-:P"*Y5_
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M9[+0 :,WM7M>?1UUE'PB68!8D$%.$YW-I]O(4I%"*EE.4QJFW"XITFC4R:V
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MX1-(SR12BSX#Y]M$ZK:]@.HLT(+/@%8!:!T<!L0/1,]I@+RM#.,&S ]$Z%4
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MP+,XG$SW';]ZO.3>60]V4GGGO]TO%/U RZ?;A3!_F7#X53>S6)7[%=!BQ8.
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MOWQC[G54\F;<N&.-;TS?C2#>&Q@H7WBT]:V&U4+<ZQ?F%_T*-:I(42P98CB
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M)@C,$J+C195&D"6F( M)XH"06 ;$*EZ<B#]3(\-N0K*QN*[LOD$%;&$!.[B
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M):NHTNA9!UOJF*TCCF=#1&"1>F&%A"'RG0]3T \C#6<^!Q)N$X;DXQ<,RJ\
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MQ!M SD8D$\&MTR90HC6@*&CQZ".@1P]>9-QS(:HJ)QV;QX_3 KO:Z?^3I-E
MMN?=U(?IK$L58*37W?;XLIBAT%<EZEM?7HLFX#X9T#4G5.DR-$#XTL=;$"LB
M)$NU2Z'*#M27P'$S.]6KD*KHJ0$;M,/7W0PLH]DRQ25A*6$L* 40[ZW#S5@Y
M;AAHYZI$Y0^3-&YA21T(/(RS8_31 +*N3@7?^\O=PV7JLW Z HE4E*ZPVI*
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M-$HD&J2M,^3F89K&/J@X'<".TD:+P-KN^I""]UYJDH%G9(/ZT@!#$:6MI\*
MLJ9*4/T /6.?2IP:4 =HH44P[6[QV05OK6($/*!\G!+$.4=)D@H<\LB"KM*.
MY#&BQCX>.#6L#M7',YA >BW,U2)O;VWB;X]-K3[PJ4.G5?L0/U!*=5.B<?W
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MIAJPC^_]Y557_C+*9 E7LR+*3+-MGZ3M;])$<*6XTIJXX,J G231_TTHV91
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MQO8UX;N["JR6GF)\AMQEY(Y*1H(I\6*2P?J84S)5#MJ?1N;(0_SJX*RBIAK
MX54'E5>+\["=.+/Q/BXG3D?'L@3BA?9$)J>(Y< )+B1'T?%TZ&=5V1,?)&GD
MH7Z5]L%A--  EOZV6*0_I[,9AC1O42_SS]/2A[EK%7YWE42ODQ:*$B<R(S+Z
M3#Q^(&%E7(WP:,A9E=1B?Q)'GM97!VN5--0 ]MZ>?_7398FMSY887']=K/SL
M+)>.H^^FWR#MY]%Y:9G1E*"I-BA*7:3()(&, I;X"^/KS \Z@-B1)_;5P6-U
MK36 S#?(X7_ZV07\"KXD? JW^T,=*AQ+45@T\N6JODR<>*D#2<AMC"J(Z*J4
M._2F<.1Y?74P6$<_#0!O6SMTMX3S#E.*&N#6)$*I+#,N$_JKH"SA6DA)F5"X
MV&H5@/V0NI%'^]4!W/!Z:0!L^QJ*;;W83"E+)CGBC=%$0K+$,V\(1>=6:P&,
MR2J-KQ\FJ1>LW#.#U4 :: !+&&:72W/+3B,?IJL_7B$-TW7Y;@(F^<# D^@H
MLA(SD* HBHD)[H6+&"E5 =,C-/7+SM)G!J>AE-  GA[L+G?7Y@;G/*<"PQT-
M*"^**\9&%8G(D7(/*5I:I[=J3P+[(>VY'01444\#L/N ZD$"RE[_"WR#V:)C
M:CM);6N9!<I-1,4(*X-YI1,<5U)IOHEA=J):*Q.KE-_WH*T?V)[;J<'02FD
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M^%LS77.&C_$+I(L9G.6=TN>/)24)GZ>Q=&R8=^WW7RUF^*>+S0GAB\]+V"S
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M(.?Z/';+!;=.1:L2T=R:4L"OB/-9$$DMC;2,8/'^B>BY\XAQIBRUBJ!CY-_
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MY3W<K4I-VVK_K[:E;LQ98[(*A!K:R9,2ZR5#*?@8';I7+E<Y4AV2B9$+5H9
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MRN%CT8%DF9B02O0<T'0'5#OJ7AKNI=4!JH!H'S7CAHZU072T_!L T=.Z5&/
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M9H/9#B)C= ]E+:$P'T0N(T3@A\NJKS^6JT&QFTWEB5%%RJ ML,#45=<5G["
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M"%"*&X@V<$CK;OC".KK43E>=?5K,Z3I=_?I$B]46-/7->3U_Z>9()!:L-LP
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M9DQ9>NZ*[*5AXH/4- *1>PD@:L/^$6!H33OQYW.5R_EV$R:PF$QU/^DVIH-
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M $%33"*-%Q1+<\9"F[3?WD<]T[UG#0'?5MK[X]G?X'FV3J2G+BX!XG/)TQJ
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MO^;%'].8M_@\5^N/I'_[I7S(<?YI-OU/.M3:ZU^?]%[GF(TQN,1!N>"(GS$
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MQB]Y_:8I1&>C$>0]6IUK(BM#2-937(,IZA),P%T:[.CS'R"/_NLIZK8=8%Q
MG4#F\P$%,#* /N3?KQ?Q,P7);SXM\GI0\%.2[EXLY?IBB=5>:0J/LW/@(XL@
MC#52NYB4W,4IVPE5.Y]JI'<5@PA^WEH*8R>I*4+^DA?O_LSQ>C7]@Q3RUQM'
MYM'+M,RS5D$JX,XD4*R0!RD0(;CH52K<,8VO>5P[?]MX<&DDX7E+=G>0]/WN
M>CF=Y>7R3?R/Z^E-HNYFZ)Z)I$W:0\1D07$?R'!'#QI%R9$%+*I)?\66\XQ;
MG#O=C3>D6#I%5_U74M"-,M*9DZ[ZP0NO-4$G(6C%P2DKT"1NDVLS0/6UDXT\
MP' (^>^ J<.%,?;=]Y+M5<EY*96%E .=WY4,R)P YC07W%EG^6Y773<W6R/9
MS0=D9 =FYB/]N5_*@U4<:UV1"8MW1H/27H&R,0!:8T%*+KPJ/NB26YB6%T\S
M;KW]]!?8\2+I %</E[N\F:6?YS.\_\E#[FW4IF@NC6'D\5FNZS)(!JB2!"V\
M=:PDYE.3Q_)[GG-<4S8 ,N:G$]/HU]QG8NK[IY$-4?FQ9IT7OQ0ZTMV/-_1)
MB0J#U6"(=V2]+07)@1A*L3/1FB7CT>QV#>[_Y>-BJRD2YB<42P?&;\M-\=/=
MRQV3DDNZ>AR^KJO!6(#(R6 ->0A,>2=MDV<+KQULW#:>TU^U@PIJ;'OW@J/[
M\W55GU_*6N>6&[<W30(7ULJL().W2E0Y#<ZX"%8[++DN3,J[6;F=O[++.LZ!
M8IXWYWD')NP]?EU?!1_G&PH>CE6]>0[XX^S7Z["<IBDNZD1<K[(0L6X'2'6,
M%Q,6O T%7"IT&QBCM6\R!W+ODX[=K=X BZ>16J=-$O_[FGB9%U>;.7-3O'J+
M*_QMAM=$>WYBGG=KDWCM(X=HE-CKV .U2CS_SH<SDI\_7(O*"<Q2 L_DZ2F5
M70TM"I2<O=#T_R8UZ178\YS'&KMO?MV#AJ+"0LSD6C@A.*BDJA>*"J(62F1R
M2 4V:?W:[7CC7K$MD?74RC40UWF:MK4#?%#+ZFX?? (S]Q()(QF[Y#A:&1SD
MK *H:#@$J16$%%B4F=D0F@1E)S9V]U'6M_6H"N9>F40=\(5> PN*W^3(G0H)
MHG?)!J8<$XV[QO8X[7F9PGUPM[V)K)4PS],RWLVQ>/G/'=Y .\CWGL"N'L"
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MNYL;+ Y? Q@4 *9( 1!XR4^FS"@;3]$6K$>> ]3V<%MTB3R>:#!''8'GGN\
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M^1P"\N*@AX7M_Y*/O[[]E[_TOKGYRF!LZU,N9G^_GV.N[F2/5)/\GMRV]'W
M-W+5]^2-R]A7)._#\1*5+PZBX_;9ZRHMA,=WH2;_VUT7APM'D86/2.F>HZ_R
M3\MGP2\67]L_DEKJ\NCSJUR%[\\&X>Q^RK=^D%6F]O9#%SK"2B_L]BY/^X:K
M_!L^-/.?O%W\'U!+ P04    "  Q@EA2!MFPD28&  #<&P  %P   '-G;6\M
M,C R,#$R,S%X97@S,C$N:'1M[5EM;]LV$/Z^7W%UL#8!;+WZ);;3 )[MKL72
M-$A<=/LT4!)E$:5%C:3B>+]^1TIV[&1)O0U=VRW^(,CD\5Z>._)XIY-GDW?C
MV2\74\CT@L/%^Q_.WHRAT7+=#^'8=2>S";R>O3V#MN/Y,),D5TPSD1/NNM/S
M!C0RK8N!ZRZ72V<9.D+.W=FE:UBU72Z$HDZBD\;IB1G!)R7)Z7<GSUHMF(BX
M7-!<0RPIT32!4K%\#A\2JCY"JU53C46QDFR>:0B\P(</0GYDUZ2:UTQS>KKF
M<^)6_T]<*^0D$LGJ]"1AU\"2EPW6:X<T"</ [_2]=MKV^OUN%/2[-,#!3J_?
M^]5')5TDK]8HO>+T96/!\E9&C?Q!.W!ZG4(/ERS1V<#WO.\;NZ1$SI%:BV+0
M+33.I2+7J(9$MM5KQ?V^C)V%0TUO=(MP-L\'UO":TYHZ%ES(P8%G?T,STTK)
M@O'5X,6,+:B"<[J$2[$@^8NF0F>U%)4LK0@5^YVBYBC$_EU6AO60#V<Y71OJ
M!\:TZ4W&(J8A#!Q_UX"]5(_1(U1^(=W'5&J6LIB80%5P44I5$E1#"_"/X;US
MY8P=>'[@=WM#/^QX32 *1HDH, KW,37\BDS=MJVRJ.]U0:2@,PI71$8DIZKU
M[H;3%8QB;68"SPOV].AG-ZK]2:.,'9+^5C))[6FAJ(942)T!R^&RY!3\D+3\
M]F%TM#&;QJ7$0PH5FM[$&<GG=&V[WP_;UMT$F25XZ!R:!<\/CH/ &VX3VR%_
M>-1\.&)(%3%0_#T7-&'$Z0U!+22\);$DM D7DBJ6&#-Q',89HRF:@.9H=DWA
M78HQC=3(X KU) L!LXQ*4E"<CU43WN2QLV/16"P*DJ]NC3%LKTH\9L\HBD-M
MS)%[(5D>LX)P>,5R@J_XMB7+\*L9-8&2. ,42J,5Q-4V0YC1%:K$B9@4)&8:
MZ71&='/MOX@J:W;&%'S,Q9+39$Z?'W2.AU]W'![Z1\:AWG + H.EWQOB@9'G
M)0)U20N,1A YO!)R ;[7^LG$I[5[18F$*LXF-*:+B,J*7^@W33[S+$++C"%T
MVH"S<W !#A"M$7!<3TPLWY[(.UZN5%@[&=*2<W0.JLN-;Y9,9W=WD;(Q1&,C
MIM+(#P\);B"Y'@6_<YAL=M3NSNCTAR:0OG+?!5N^8SFZ9%&A&N-2@N2)B5HS
M67LP)4PB;@5N08-0TTP3S@&7H0;H:9PH$!S5M*O2S59!AHF]$MG=A50EKP 6
M!6[.*@7M;B/G4]!%0FNQL#GU'IB:1'CHU?21D'A^M!!43@I%!^N78<)4P<EJ
MP'(+C5TTO#;A%1->)R[D6=]F^GWGN!.:"XW&ZXI.UNSKNXYC[SJN3N[/]?J.
M'[8?G/8<_\&YQ]CZQTZWV]V+K6M5KM1&\Q4"_+(1-M8+"I(D>,@-@N(&_-W$
MS6FJ[V)2(?_OQZR]3CX_:./)8I\P.IO^/#J?3"]AXL#;T?AR--U$30W)(]9Z
MQM8]$:ICR$08+@(E.$M@;>RW!-]M/C60V93ZF2#[EE#9ZT[QA-/IX>TUZ!X\
M1_\0GS7-6F"G.LGWY_/_=,D$4Z^])L(K&LF2R!4$;7MS\I\<\J43U-7[\Q_A
MM0-GTZ?$] G8;,5EH*)/"0G3])VJL[JF;TK/ZN]37OJ3O'2O/'_*2_^IO.3:
M,NWQBMH//F=);3D.F$:0XSV*[)EI6L0[30L2Q[;(-:T'4_(^TB;9]#Z8QK*9
M(ZBFZE:0"PT)I0LLT5/&\;EI86QU]LQE=M.6P+IZP91:U^ U#^0?F=H_%A*%
MVV\,T0HEI532/#8S2('EN)%B3J3'^VJEK2SN:'';5@RWVXI-J#M ._W'PV5&
M<5#"@B2F*98*20TA277-.4$EU[T"@U/=FT&PCA 967<@S,44B8SF<YJCHGS+
M2(,!1Y$E0:D[O0[;H:M,=6 $"K<13@C),+20A16+R"W1-$V17*,RMN5:-XXL
M>CM-H[WZG) A+A%%CH44U\PTPQ#V1X V'EPRSHWS)*WU-Z(?7Y*6,F<JJ]CO
M&2P(/M/*F)JF4!8X8FRE2C_<H;GS-:@0U>>P@0U@],R#WX?JGHYWNX1$>*4I
M]<-+_MHGI?I9??>R7^!._P!02P,$%     @ ,8)84O@'6,X4 @  JP4  !@
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M^LDBH9EX![;7'?L%*Y$$+'!!D5GK(U(LI"=]=S48+(VHRW(4+ RNV4:'0/T
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M1@@?_ .T+4&N^#D?E>&&M4*U^R8?!L?[?K=KS*\;I!<?OOA_4$L! A0#%
M  @ ,8)84DBVH!]\K@0 R (K !$              ( !     '-G;6\M,C R
M,#$R,S$N:'1M4$L! A0#%     @ ,8)84D.=-;*>'   7$$! !$
M     ( !JZX$ '-G;6\M,C R,#$R,S$N>'-D4$L! A0#%     @ ,8)84K\8
M+R2M*P  ZM8! !4              ( !>,L$ '-G;6\M,C R,#$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( #&"6%+*X@MACI4  (IE!@ 5              "
M 5CW! !S9VUO+3(P,C Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  Q@EA2SI-Q
M'L9K @"G' , %               @ $9C04 <V=M;RTR,#(P,3(S,5]G,2YJ
M<&=02P$"% ,4    "  Q@EA2$/6K?Z^U  !A[@  %               @ $1
M^0< <V=M;RTR,#(P,3(S,5]G,BYJ<&=02P$"% ,4    "  Q@EA2^3?(=)!!
M  #$:P  %               @ 'RK@@ <V=M;RTR,#(P,3(S,5]G,RYJ<&=0
M2P$"% ,4    "  Q@EA23DR_TPGF  ":\@  %               @ &T\ @
M<V=M;RTR,#(P,3(S,5]G-"YJ<&=02P$"% ,4    "  Q@EA2T,\@';S_ 0#$
M'P( %               @ 'OU@D <V=M;RTR,#(P,3(S,5]G-2YJ<&=02P$"
M% ,4    "  Q@EA2/Q0J6A%P 0"ZB0$ %               @ '=U@L <V=M
M;RTR,#(P,3(S,5]G-BYJ<&=02P$"% ,4    "  Q@EA2UQ\YZ!!6 0#,DP$
M%               @ $@1PT <V=M;RTR,#(P,3(S,5]G-RYJ<&=02P$"% ,4
M    "  Q@EA2HT\?[I0C 0 SN0$ %               @ %BG0X <V=M;RTR
M,#(P,3(S,5]G."YJ<&=02P$"% ,4    "  Q@EA2167RCO4( P#--00 %
M            @ $HP0\ <V=M;RTR,#(P,3(S,5]G.2YJ<&=02P$"% ,4
M"  Q@EA2TS\PP;I; 0!.4PX %0              @ %/RA( <V=M;RTR,#(P
M,3(S,5]L86(N>&UL4$L! A0#%     @ ,8)84AU8!4"%T   &J<) !4
M         ( !/"84 '-G;6\M,C R,#$R,S%?<')E+GAM;%!+ 0(4 Q0    (
M #&"6%(T'55%^P<  /HF   7              "  ?3V% !S9VUO+3(P,C Q
M,C,Q>&5X,S$Q+FAT;5!+ 0(4 Q0    ( #&"6%*CG9E'_@<  $TG   7
M          "  23_% !S9VUO+3(P,C Q,C,Q>&5X,S$R+FAT;5!+ 0(4 Q0
M   ( #&"6%(&V;"1)@8  -P;   7              "  5<'%0!S9VUO+3(P
M,C Q,C,Q>&5X,S(Q+FAT;5!+ 0(4 Q0    ( #&"6%+X!UC.% (  *L%   8
M              "  ;(-%0!S9VUO+3(P,C Q,C,Q>&5X>#(Q,2YH=&U02P$"
M% ,4    "  Q@EA2D2\M%:8$  ![$   &               @ '\#Q4 <V=M
M;RTR,#(P,3(S,7AE>'@R,S$N:'1M4$L! A0#%     @ ,8)84G[P<RQ4$0
M4U$  !<              ( !V!05 '-G;6\M,C R,#$R,S%X97AX-#$N:'1M
64$L%!@     5 !4 ? 4  &$F%0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
